PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Baynton, K; Otterlei, M; Bjoras, M; von Kobbe, C; Bohr, VA; Seeberg, E				Baynton, K; Otterlei, M; Bjoras, M; von Kobbe, C; Bohr, VA; Seeberg, E			WRN interacts physically and functionally with the recombination mediator protein RAD52	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; WERNER-SYNDROME PROTEIN; DNA HELICASE ACTIVITY; HOMOLOGOUS RECOMBINATION; HOLLIDAY JUNCTIONS; IN-VITRO; REPLICATION; RPA; TRANSCRIPTION; PATHWAYS	Werner syndrome (WS) is a premature aging disorder that predisposes affected individuals to cancer development. The affected gene, WRN, encodes an RecQ homologue whose precise biological function remains elusive. Altered DNA recombination is a hallmark of WS cells suggesting that WRN plays an important role in these pathways. Here we report a novel physical and functional interaction between WRN and the homologous recombination mediator protein RAD52. Fluorescence resonance energy transfer ( FRET) analyses show that WRN and RAD52 form a complex in vivo that co-localizes in foci associated with arrested replication forks. Biochemical studies demonstrate that RAD52 both inhibits and enhances WRN helicase activity in a DNA structure-dependent manner, whereas WRN increases the efficiency of RAD52-mediated strand annealing between non-duplex DNA and homologous sequences contained within a double-stranded plasmid. These results suggest that coordinated WRN and RAD52 activities are involved in replication fork rescue after DNA damage.	Univ Oslo, Rikshosp, Ctr Mol Biol & Neurosci, N-0027 Oslo, Norway; Univ Oslo, Rikshosp, Inst Med Microbiol, N-0027 Oslo, Norway; Norwegian Univ Sci & Technol, Inst Canc Res & Mol Biol, N-7005 Trondheim, Norway; NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; Norwegian University of Science & Technology (NTNU); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Seeberg, E (corresponding author), Univ Oslo, Rikshosp, Ctr Mol Biol & Neurosci, N-0027 Oslo, Norway.	e.c.seeberg@labmed.uio.no	Bohr, Vilhelm/AAP-5931-2020; Bjørås, Magnar/N-9286-2017	von Kobbe, Cayetano/0000-0003-3895-3790; Otterlei, Marit/0000-0002-5232-1186	NATIONAL INSTITUTE ON AGING [ZIAAG000726, Z01AG000726] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aguilera A, 2002, EMBO J, V21, P195, DOI 10.1093/emboj/21.3.195; BASU AK, 1993, BIOCHEMISTRY-US, V32, P4708, DOI 10.1021/bi00069a004; Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; Brosh RM, 2002, EXP GERONTOL, V37, P491, DOI 10.1016/S0531-5565(01)00227-3; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Essers J, 2002, EMBO J, V21, P2030, DOI 10.1093/emboj/21.8.2030; Fabre F, 2002, P NATL ACAD SCI USA, V99, P16887, DOI 10.1073/pnas.252652399; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Gangloff S, 2000, NAT GENET, V25, P192, DOI 10.1038/76055; Gonzalez-Barrera S, 2002, GENETICS, V162, P603; Goto M, 1997, MECH AGEING DEV, V98, P239, DOI 10.1016/S0047-6374(97)00111-5; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Iyer LM, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-8; James P, 1996, GENETICS, V144, P1425; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Kagawa W, 2002, MOL CELL, V10, P359, DOI 10.1016/S1097-2765(02)00587-7; Kagawa W, 2001, J BIOL CHEM, V276, P35201, DOI 10.1074/jbc.M104938200; Karmakar P, 2002, J BIOL CHEM, V277, P18291, DOI 10.1074/jbc.M111523200; Kuzminov A, 2001, P NATL ACAD SCI USA, V98, P8461, DOI 10.1073/pnas.151260698; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Li BM, 2001, J BIOL CHEM, V276, P9896, DOI 10.1074/jbc.M008575200; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu JM, 2002, BIOCHEM BIOPH RES CO, V297, P1191, DOI 10.1016/S0006-291X(02)02353-7; Liu YL, 2000, EMBO REP, V1, P85, DOI 10.1093/embo-reports/kvd002; Lloyd JA, 2002, J BIOL CHEM, V277, P46172, DOI 10.1074/jbc.M207262200; Lundin C, 2002, MOL CELL BIOL, V22, P5869, DOI 10.1128/MCB.22.16.5869-5878.2002; Machwe A, 2000, NUCLEIC ACIDS RES, V28, P2762, DOI 10.1093/nar/28.14.2762; Martin GM, 1999, J AM GERIATR SOC, V47, P1136, DOI 10.1111/j.1532-5415.1999.tb05240.x; MATYUS L, 1992, J PHOTOCH PHOTOBIO B, V12, P323, DOI 10.1016/1011-1344(92)85039-W; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Nilsen H, 1997, NUCLEIC ACIDS RES, V25, P750, DOI 10.1093/nar/25.4.750; Odagiri N, 2003, DNA REPAIR, V2, P347, DOI 10.1016/S1568-7864(02)00234-3; Onoda F, 2001, MOL GEN GENET, V264, P702, DOI 10.1007/s004380000358; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Opresko PL, 2001, J BIOL CHEM, V276, P44677, DOI 10.1074/jbc.M107548200; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Orren DK, 2002, BIOCHEMISTRY-US, V41, P13483, DOI 10.1021/bi0266986; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Postow L, 2001, J BIOL CHEM, V276, P2790, DOI 10.1074/jbc.M006736200; Prince PR, 2001, GENE DEV, V15, P933, DOI 10.1101/gad.877001; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; SAHNBO K, 2002, ONCOGENE, V21, P503; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Sakamoto S, 2001, GENES CELLS, V6, P421, DOI 10.1046/j.1365-2443.2001.00433.x; SALK D, 1982, HUM GENET, V62, P1, DOI 10.1007/BF00295598; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Sharpless NE, 2001, MOL CELL, V8, P1187, DOI 10.1016/S1097-2765(01)00425-7; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Stasiak AZ, 2000, CURR BIOL, V10, P337, DOI 10.1016/S0960-9822(00)00385-7; Sugiyama T, 2002, J BIOL CHEM, V277, P31663, DOI 10.1074/jbc.M203494200; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; van den Bosch M, 2002, BIOL CHEM, V383, P873; Van Dyck E, 1999, NATURE, V398, P728, DOI 10.1038/43942; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; von Kobbe C, 2002, J CELL SCI, V115, P3901, DOI 10.1242/jcs.00076; Wei C, 2002, NUCLEIC ACIDS RES, V30, P2862, DOI 10.1093/nar/gkf396; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Xue Y, 2002, BIOCHEMISTRY-US, V41, P2901, DOI 10.1021/bi0157161; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Youvan D. C., 1997, BIOTECHNOLOGY, V3, P1	81	96	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36476	36486		10.1074/jbc.M303885200	http://dx.doi.org/10.1074/jbc.M303885200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12750383	hybrid			2022-12-25	WOS:000185318300076
J	Burrows, PC; Severinov, K; Ishihama, A; Buck, M; Wigneshweraraj, SR				Burrows, PC; Severinov, K; Ishihama, A; Buck, M; Wigneshweraraj, SR			Mapping sigma(54)-RNA polymerase interactions at the -24 consensus promoter element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE RNA-POLYMERASE; TURN-HELIX MOTIF; ESCHERICHIA-COLI; TRANSCRIPTION INITIATION; PROKARYOTIC ENHANCER; TERMINAL SEQUENCES; STRUCTURAL BASIS; FLAP DOMAIN; SIGMA 54; DNA	The sigma(54) promoter specificity factor is distinct from sigma(70)-type factors. The sigma(54)-RNA polymerase binds to promoters with conserved sequence elements at -24 and -12 and utilizes specialized enhancer-binding activators to convert, through an ATP-dependent process, closed promoter complexes to open promoter complexes. The interface between sigma(54)-RNA polymerase and promoter DNA is poorly characterized, contrasting with sigma(70). Here, sigma(54) was modified with strategically positioned cleavage reagents to provide physical evidence that the highly conserved RpoN box motif of sigma(54) is close to and may therefore interact with the consensus -24 promoter element. We show that the spatial relationship between the sigma(54)-RNA polymerase and the -24 promoter element remains unchanged during closed to open complex conversion and transcription initiation but changes during the early elongation phase. In contrast, the spatial relationship between sigma(54)-RNA polymerase and the consensus -12 promoter element changes upon conversion of the closed promoter complex to an open one. We provide evidence that some -12 promoter region-sigma(54) interactions are dependent upon either the core RNA polymerase or a fork junction DNA structure at the -12-position, indicating that DNA fork junctions can substitute for core RNAP. We also show the beta-subunit flap domain contributes to different sets of sigma-promoter DNA interactions at sigma(54)- and sigma(70)-dependent promoters.	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England; Rutgers State Univ, Waksman Inst, Piscataway, NJ 08904 USA; Rutgers State Univ, Dept Genet, Piscataway, NJ 08904 USA; Nippon Inst Biol Sci, Tokyo 1980024, Japan	Imperial College London; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Wigneshweraraj, SR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Sir Alexander Fleming Bldg,S Kensington Campus, London SW7 2AZ, England.	s.r.wig@imperial.ac.uk	Severinov, Konstantin/C-8545-2016	Wigneshweraraj, Sivaramesh/0000-0002-1418-4029	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064530] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM64530] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrios H, 1999, NUCLEIC ACIDS RES, V27, P4305, DOI 10.1093/nar/27.22.4305; Bondarenko V, 2002, NUCLEIC ACIDS RES, V30, P636, DOI 10.1093/nar/30.3.636; Bordes P, 2003, P NATL ACAD SCI USA, V100, P2278, DOI 10.1073/pnas.0537525100; Buck M, 2000, J BACTERIOL, V182, P4129, DOI 10.1128/JB.182.15.4129-4136.2000; BUCK M, 1992, NATURE, V358, P422, DOI 10.1038/358422a0; Callaci S, 1999, MOL CELL, V3, P229, DOI 10.1016/S1097-2765(00)80313-5; Campbell EA, 2002, MOL CELL, V9, P527, DOI 10.1016/S1097-2765(02)00470-7; CANNON W, 1993, MOL MICROBIOL, V8, P287, DOI 10.1111/j.1365-2958.1993.tb01573.x; CANNON W, 1995, NUCLEIC ACIDS RES, V23, P351, DOI 10.1093/nar/23.3.351; Cannon W, 2003, J BIOL CHEM, V278, P19815, DOI 10.1074/jbc.M301296200; Cannon W, 2002, NUCLEIC ACIDS RES, V30, P886, DOI 10.1093/nar/30.4.886; Cannon W, 1999, GENE DEV, V13, P357, DOI 10.1101/gad.13.3.357; CANNON W, 1994, MOL MICROBIOL, V11, P227, DOI 10.1111/j.1365-2958.1994.tb00303.x; Cannon W, 2001, J BIOL CHEM, V276, P386, DOI 10.1074/jbc.M007779200; Cannon WV, 2000, NAT STRUCT BIOL, V7, P594; Casaz P, 1999, J MOL BIOL, V292, P229, DOI 10.1006/jmbi.1999.3076; Casaz P, 1997, P NATL ACAD SCI USA, V94, P12145, DOI 10.1073/pnas.94.22.12145; Casaz P, 1999, J MOL BIOL, V285, P507, DOI 10.1006/jmbi.1998.2328; Chaney M, 1999, MOL MICROBIOL, V33, P1200, DOI 10.1046/j.1365-2958.1999.01566.x; Chaney M, 2001, GENE DEV, V15, P2282, DOI 10.1101/gad.205501; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; Gallegos MT, 2000, J MOL BIOL, V297, P849, DOI 10.1006/jmbi.2000.3608; Gallegos MT, 1999, J MOL BIOL, V288, P539, DOI 10.1006/jmbi.1999.2704; Greiner DP, 1997, BIOCONJUGATE CHEM, V8, P44, DOI 10.1021/bc9600731; Guo YL, 2000, GENE DEV, V14, P2242, DOI 10.1101/gad.794800; Guo YL, 1999, EMBO J, V18, P3736, DOI 10.1093/emboj/18.13.3736; Ishihama A, 2000, CHEM COMMUN, P1091, DOI 10.1039/a908392h; Kuznedelov K, 2002, SCIENCE, V295, P855, DOI 10.1126/science.1066303; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Mekler V, 2002, CELL, V108, P599, DOI 10.1016/S0092-8674(02)00667-0; MERRICK M, 1992, J BACTERIOL, V174, P7221, DOI 10.1128/jb.174.22.7221-7226.1992; MERRICK MJ, 1993, MOL MICROBIOL, V10, P903, DOI 10.1111/j.1365-2958.1993.tb00961.x; MORRIS L, 1994, J BIOL CHEM, V269, P11563; Mukhopadhyay J, 2001, CELL, V106, P453, DOI 10.1016/S0092-8674(01)00464-0; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Murakami KS, 2003, CURR OPIN STRUC BIOL, V13, P31, DOI 10.1016/S0959-440X(02)00005-2; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Owens JT, 1998, BIOCHEMISTRY-US, V37, P7670, DOI 10.1021/bi980188n; Paget MSB, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-203; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; Rippe K, 1997, J MOL BIOL, V270, P125, DOI 10.1006/jmbi.1997.1079; SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K; Taylor M, 1996, MOL MICROBIOL, V22, P1045, DOI 10.1046/j.1365-2958.1996.01547.x; TINTUT Y, 1995, J BIOL CHEM, V270, P24392, DOI 10.1074/jbc.270.41.24392; Wang L, 1999, J BACTERIOL, V181, P7558, DOI 10.1128/JB.181.24.7558-7565.1999; Wang L, 2001, J BIOL CHEM, V276, P8979, DOI 10.1074/jbc.M009587200; WEDEL A, 1995, GENE DEV, V9, P2042, DOI 10.1101/gad.9.16.2042; Wigneshweraraj SR, 2000, EMBO J, V19, P3038, DOI 10.1093/emboj/19.12.3038; Wigneshweraraj SR, 2003, J BIOL CHEM, V278, P3455, DOI 10.1074/jbc.M209442200; Wigneshweraraj SR, 2001, NUCLEIC ACIDS RES, V29, P1163, DOI 10.1093/nar/29.5.1163; Wigneshweraraj SR, 2001, J MOL BIOL, V306, P681, DOI 10.1006/jmbi.2000.4393; WONG CN, 1994, J MOL BIOL, V236, P81, DOI 10.1006/jmbi.1994.1120; Wosten MMSM, 1998, FEMS MICROBIOL REV, V22, P127, DOI 10.1016/S0168-6445(98)00011-4; Wyman C, 1997, SCIENCE, V275, P1658, DOI 10.1126/science.275.5306.1658; Xu H, 2001, CURR OPIN MICROBIOL, V4, P138, DOI 10.1016/S1369-5274(00)00179-X; Zhang X, 2002, MOL MICROBIOL, V45, P895, DOI 10.1046/j.1365-2958.2002.03065.x	56	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29728	29743		10.1074/jbc.M303596200	http://dx.doi.org/10.1074/jbc.M303596200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12750380	hybrid			2022-12-25	WOS:000184507000044
J	Donahue, SL; Lundberg, R; Saplis, R; Campbell, C				Donahue, SL; Lundberg, R; Saplis, R; Campbell, C			Deficient regulation of DNA double-strand break repair in Fanconi anemia fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; RAD51 PROTEIN; CHROMOSOME STABILITY; POSITIONAL CLONING; GENE-PRODUCT; GROUP-A; C-GENE; COMPLEMENTATION; INSTABILITY	Fibroblasts from patients with Fanconi anemia ( FA) display genomic instability, hypersensitivity to DNA cross-linking agents, and deficient DNA end joining. Fibroblasts from two FA patients of unidentified complementation group also had significantly increased cellular homologous recombination (HR) activity. Results described herein show that HR activity levels in patient-derived FA fibroblasts of groups A, C, and G were 10-fold greater than those seen in normal fibroblasts. In contrast, HR activity in group D2 fibroblasts was identical to that in normal cells. Western blot analysis revealed that the RAD51 protein was elevated 10-fold above normal levels in group A, C, and G fibroblasts, but was not altered in group D2 fibroblasts. HR activity levels in these former cells could be restored to near-normal levels by electroporation with anti-RAD51 antibody, whereas similar treatment of normal and complementation group D2 fibroblasts had no effect. These findings are consistent with a model in which FA proteins function to coordinate DNA double-strand break repair activity by regulating both recombinational and non-recombinational DNA repair. Interestingly, whereas positive regulation of DNA end joining requires the combined presence of all FA proteins thus far tested, suppression of HR, which is minimally dependent on the FANCA, FANCC, and FANCG proteins, does not require FANCD2.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Campbell, C (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.				NATIONAL INSTITUTE ON AGING [R01AG016678] Funding Source: NIH RePORTER; NIA NIH HHS [AG16678] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Albala JS, 1997, GENOMICS, V46, P476, DOI 10.1006/geno.1997.5062; Alter BP, 1996, AM J HEMATOL, V53, P99, DOI 10.1002/(SICI)1096-8652(199610)53:2<99::AID-AJH7>3.3.CO;2-M; Apostolou S, 1996, NAT GENET, V14, P324, DOI 10.1038/ng1196-324; AUERBACH AD, 1991, CANCER GENET CYTOGEN, V51, P1, DOI 10.1016/0165-4608(91)90002-C; AUERBACH AD, 1976, NATURE, V261, P494, DOI 10.1038/261494a0; Baron S, 2000, J IMMUNOL METHODS, V242, P115, DOI 10.1016/S0022-1759(00)00242-8; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTTURINI A, 1994, BLOOD, V84, P1650, DOI 10.1182/blood.V84.5.1650.bloodjournal8451650; Carreau M, 1999, MUTAT RES-DNA REPAIR, V435, P103, DOI 10.1016/S0921-8777(99)00041-5; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; DAndrea AD, 1997, BLOOD, V90, P1725, DOI 10.1182/blood.V90.5.1725; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, AM J HUM GENET, V67, P1306, DOI 10.1016/S0002-9297(07)62959-0; de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; Digweed M, 2002, ONCOGENE, V21, P4873, DOI 10.1038/sj.onc.1205616; Digweed M, 2002, CARCINOGENESIS, V23, P1121, DOI 10.1093/carcin/23.7.1121; Donahue SL, 2002, J BIOL CHEM, V277, P46243, DOI 10.1074/jbc.M207937200; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Escarceller M, 1997, SOMAT CELL MOLEC GEN, V23, P401, DOI 10.1007/BF02673750; Escarceller M, 1998, J MOL BIOL, V279, P375, DOI 10.1006/jmbi.1998.1784; FINN GK, 1989, MOL CELL BIOL, V9, P4009, DOI 10.1128/MCB.9.9.4009; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; GLANZ A, 1982, J MED GENET, V19, P412, DOI 10.1136/jmg.19.6.412; Godthelp BC, 2002, ONCOGENE, V21, P5002, DOI 10.1038/sj.onc.1205656; Grompe M, 2001, HUM MOL GENET, V10, P2253, DOI 10.1093/hmg/10.20.2253; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; ISHIDA R, 1982, CANCER RES, V42, P4000; Joenje H, 2000, AM J HUM GENET, V67, P759, DOI 10.1086/303067; Joenje H, 1997, AM J HUM GENET, V61, P940, DOI 10.1086/514881; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Kim PM, 2001, NUCLEIC ACIDS RES, V29, P4352, DOI 10.1093/nar/29.21.4352; KOWALCZYKOWSKI SC, 1994, EXPERIENTIA, V50, P204, DOI 10.1007/BF01924003; Laquerbe A, 1999, MUTAT RES-FUND MOL M, V431, P341, DOI 10.1016/S0027-5107(99)00177-3; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; LoTenFoe JR, 1996, NAT GENET, V14, P320, DOI 10.1038/ng1196-320; Lundberg R, 2001, J BIOL CHEM, V276, P9543, DOI 10.1074/jbc.M008634200; Mazin AV, 2000, EMBO J, V19, P1148, DOI 10.1093/emboj/19.5.1148; McHugh PJ, 2001, LANCET ONCOL, V2, P483, DOI 10.1016/S1470-2045(01)00454-5; Medhurst AL, 2001, HUM MOL GENET, V10, P423, DOI 10.1093/hmg/10.4.423; Morrison C, 2000, INT J BIOCHEM CELL B, V32, P817, DOI 10.1016/S1357-2725(00)00033-9; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 2001, CANCER RES, V61, P4842; Nakanishi K, 2002, NAT CELL BIOL, V4, P913, DOI 10.1038/ncb879; PAPADOPOULO D, 1990, P NATL ACAD SCI USA, V87, P8383, DOI 10.1073/pnas.87.21.8383; Pichierri P, 2002, HUM MOL GENET, V11, P2531, DOI 10.1093/hmg/11.21.2531; Pittman DL, 1998, GENOMICS, V49, P103, DOI 10.1006/geno.1998.5226; RAY FA, 1990, J CELL BIOCHEM, V42, P13, DOI 10.1002/jcb.240420103; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SETLOW RB, 1978, NATURE, V271, P713, DOI 10.1038/271713a0; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Takata M, 2000, MOL CELL BIOL, V20, P6476, DOI 10.1128/MCB.20.17.6476-6482.2000; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; Taniguchi T, 2002, BLOOD, V100, P2414, DOI 10.1182/blood-2002-01-0278; TEBBS RS, 1995, P NATL ACAD SCI USA, V92, P6354, DOI 10.1073/pnas.92.14.6354; Thompson LH, 1999, BIOCHIMIE, V81, P87, DOI 10.1016/S0300-9084(99)80042-X; Thyagarajan B, 1997, J BIOL CHEM, V272, P23328, DOI 10.1074/jbc.272.37.23328; Thyagarajan B, 1996, NUCLEIC ACIDS RES, V24, P4084, DOI 10.1093/nar/24.20.4084; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Tsukamoto Y, 1998, GENES CELLS, V3, P135, DOI 10.1046/j.1365-2443.1998.00180.x; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; Wang Y, 2000, GENE DEV, V14, P927; Whitney MA, 1996, BLOOD, V88, P49; Xia SJJ, 1997, MOL CELL BIOL, V17, P7151, DOI 10.1128/MCB.17.12.7151; Youssoufian H, 1996, J CLIN INVEST, V97, P957, DOI 10.1172/JCI118519; YOUSSOUFIAN H, 1998, P NATL ACAD SCI USA, V95, P13085; ZAKRZEWSKI S, 1989, HUM GENET, V56, P81	73	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29487	29495		10.1074/jbc.M213251200	http://dx.doi.org/10.1074/jbc.M213251200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12748186	hybrid			2022-12-25	WOS:000184507000013
J	Ramsauer, VP; Carraway, CAC; Salas, PJI; Carraway, KL				Ramsauer, VP; Carraway, CAC; Salas, PJI; Carraway, KL			Muc4/Sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 to the apical surface in polarized epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; SIALOMUCIN COMPLEX; SIGNALING NETWORK; PROTEIN; LOCALIZATION; HETERODIMERIZATION; OVEREXPRESSION; TRANSDUCTION; EXPRESSION; FAMILY	Muc4/Sialomucin complex (SMC) acts as an intramembrane ligand for the receptor tyrosine kinase ErbB2, inducing a limited phosphorylation of the receptor. Because Muc4/SMC is found at the apical surfaces of polarized epithelial cells and ErbB2 is often basolateral, the question arises as to whether these components become associated in polarized cells. To address this question, we examined the localization of these proteins in polarized human colon carcinoma CACO-2 cells. Dual color immunofluorescence analysis by confocal microscopy demonstrated the basolateral localization of the ErbB2 in these cells; it is primarily co-localized with E-cadherin at adherens junctions. Expression of apical Muc4/SMC in these cells by transient transfection results in the localization of the ErbB2 at the apical surface. Two-color confocal microscopy indicated that ErbB2 is co-localized with Muc4/SMC in the transfected cells but not in untransfected cells in the same culture. The change of localization of ErbB2 was confirmed by cell surface biotinylation of apical and basolateral proteins, followed by streptavidin precipitation and the subsequent detection of ErbB2 by immunoblotting. In contrast, Na+/K+-ATPase maintains its basolateral localization in Muc4/SMC-transfected cells, indicating that the translocation of ErbB2 is not the result of depolarization of the cells. A potential physiological role for the apical localization of ErbB2 is indicated by the fact that ErbB2 phosphorylated at tyrosine 1248 is found predominantly in Muc4/SMC-transfected cells, but not in untransfected cells, and is co-localized with the apical Muc4/SMC. The ability of Muc4/SMC to alter the localization of ErbB2, particularly a phosphorylated form of it, in epithelial cells, suggests that it has an important role in regulating ErbB2 signaling.	Univ Miami, Sch Med, Dept Cell Biol & Anat R124, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami; University of Miami	Carraway, CAC (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat R124, POB 016960, Miami, FL 33101 USA.		Salas, Pedro J./AAS-9455-2021; Palau, Victoria E/F-3520-2012	Palau, Victoria E/0000-0003-2761-7003; Salas, Pedro/0000-0002-7411-1366	NCI NIH HHS [CA 74072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Arango ME, 2001, INVEST OPHTH VIS SCI, V42, P2749; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Carraway CAC, 1999, J BIOL CHEM, V274, P25659, DOI 10.1074/jbc.274.36.25659; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1995, BIOESSAYS, V17, P171, DOI 10.1002/bies.950170212; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CARRAWAY KL, 2001, PROG NUCL ACIDS RES, V171, P149; CROVELLO CS, 2001, CURR OPIN CELL BIOL, V13, P125; DEPOTTER CR, 1989, INT J CANCER, V44, P969, DOI 10.1002/ijc.2910440604; Dillon C, 2002, MOL CELL BIOL, V22, P6553, DOI 10.1128/MCB.22.18.6553-6563.2002; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; GEIGER B, 1992, COLD SPRING HARB SYM, V57, P631, DOI 10.1101/SQB.1992.057.01.069; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Idris N, 2001, J CELL PHYSIOL, V189, P162, DOI 10.1002/jcp.10012; Idris N, 2000, J CELL PHYSIOL, V185, P310, DOI 10.1002/1097-4652(200011)185:2<310::AID-JCP16>3.0.CO;2-W; Jepson S, 2002, ONCOGENE, V21, P7524, DOI 10.1038/sj.onc.1205970; Klapper LN, 2000, ADV CANCER RES, V77, P25; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Komatsu M, 1999, CANCER RES, V59, P2229; Price-Schiavi SA, 1998, J BIOL CHEM, V273, P35228, DOI 10.1074/jbc.273.52.35228; Reese DM, 1997, STEM CELLS, V15, P1, DOI 10.1002/stem.150001; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rossi EA, 1996, J BIOL CHEM, V271, P33476, DOI 10.1074/jbc.271.52.33476; SHENG Z, 1990, J BIOL CHEM, V265, P8505	28	67	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30142	30147		10.1074/jbc.M303220200	http://dx.doi.org/10.1074/jbc.M303220200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12748185	hybrid			2022-12-25	WOS:000184507000092
J	Duan, L; Miura, Y; Dimri, M; Majumder, B; Dodge, IL; Reddi, AL; Ghosh, A; Fernandes, N; Zhou, PC; Mullane-Robinson, K; Rao, N; Donoghue, S; Rogers, RA; Bowtell, D; Naramura, M; Gu, H; Band, V; Band, H				Duan, L; Miura, Y; Dimri, M; Majumder, B; Dodge, IL; Reddi, AL; Ghosh, A; Fernandes, N; Zhou, PC; Mullane-Robinson, K; Rao, N; Donoghue, S; Rogers, RA; Bowtell, D; Naramura, M; Gu, H; Band, V; Band, H			Cbl-mediated ubiquitinylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOWN-REGULATION; EGF RECEPTOR; TYROSINE KINASE; C-CBL; NEGATIVE REGULATION; PLASMA-MEMBRANE; RING FINGER; UBIQUITINATION; DEGRADATION; PROTEINS	Ligand-induced down-regulation controls the signaling potency of the epidermal growth factor receptor (EGFR/ErbB1). Overexpression studies have identified Cbl-mediated ubiquitinylation of EGFR as a mechanism of ligand-induced EGFR down-regulation. However, the role of endogenous Cbl in EGFR down-regulation and the precise step in the endocytic pathway regulated by Cbl remain unclear. Using Cbl(-/-) mouse embryonic fibroblast cell lines, we demonstrate that endogenous Cbl is essential for ligand-induced ubiquitinylation and efficient degradation of EGFR. Further analyses using Chinese hamster ovary cells with a temperature-sensitive defect in ubiquitinylation confirm a crucial role of the ubiquitin machinery in Cbl-mediated EGFR degradation. However, internalization into early endosomes did not require Cbl function or an intact ubiquitin pathway. Confocal immunolocalization studies indicated that Cbl-dependent ubiquitinylation plays a critical role at the early endosome to late endosome/lysosome sorting step of EGFR down-regulation. These findings establish Cbl as the major endogenous ubiquitin ligase responsible for EGFR degradation, and show that the critical role of Cbl-mediated ubiquitinylation is at the level of endosomal sorting, rather than at the level of internalization.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; Peter MacCallum Canc Inst, Trescowthick Res Labs, Parkville, Vic 3050, Australia; NIAID, Immunol Lab, NIH, Rockville, MD 20852 USA; Tufts Univ New England Med Ctr, Div Radiat & Canc Biol, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Dept Radiat Oncol, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Dept Biochem, Boston, MA 02111 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Peter Maccallum Cancer Center; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Tufts Medical Center; Tufts Medical Center; Tufts Medical Center; Tufts University	Band, H (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol Allergy & Immunol, Smith Bldg,Rm 538C,1 Jimmy Fund Way, Boston, MA 02115 USA.		Bowtell, David/H-1007-2016	Bowtell, David/0000-0001-9089-7525; Naramura, Mayumi/0000-0003-3658-0767	NATIONAL CANCER INSTITUTE [R01CA081076, R01CA076118, R01CA099163, R01CA087986, R01CA105489, R01CA070195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007530] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA105489, CA87986, CA 81076, CA 99163, CA 76118, CA 70195] Funding Source: Medline; NIAMS NIH HHS [T32ARO7530] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Andoniou CE, 1996, ONCOGENE, V12, P1981; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; de Melker AA, 2001, J CELL SCI, V114, P2167; Dunn R, 2001, J BIOL CHEM, V276, P25974, DOI 10.1074/jbc.M104113200; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; Ettenberg SA, 2001, J BIOL CHEM, V276, P27677, DOI 10.1074/jbc.M102641200; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; GOLDMAN A, 1988, CELLS LAB MANUAL; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haglund K, 2002, P NATL ACAD SCI USA, V99, P12191, DOI 10.1073/pnas.192462299; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kil SJ, 1999, J BIOL CHEM, V274, P3141, DOI 10.1074/jbc.274.5.3141; Kil SJ, 2000, J CELL PHYSIOL, V185, P47, DOI 10.1002/1097-4652(200010)185:1<47::AID-JCP4>3.3.CO;2-F; KULKA RG, 1988, J BIOL CHEM, V263, P15726; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Lloyd TE, 2002, CELL, V108, P261, DOI 10.1016/S0092-8674(02)00611-6; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Martinu L, 2002, J BIOL CHEM, V277, P50996, DOI 10.1074/jbc.M204869200; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Rao N, 2002, J LEUKOCYTE BIOL, V71, P753; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Rao NV, 2002, P NATL ACAD SCI USA, V99, P3794, DOI 10.1073/pnas.062055999; ROGERS RA, 1993, J CELL SCI, V106, P485; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Strous GJ, 1997, J BIOL CHEM, V272, P40; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; TODARO GJ, 1966, VIROLOGY, V28, P756, DOI 10.1016/0042-6822(66)90261-3; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	58	157	164	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28950	28960		10.1074/jbc.M304474200	http://dx.doi.org/10.1074/jbc.M304474200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12754251	hybrid			2022-12-25	WOS:000184421100075
J	Hennemann, H; Vassen, L; Geisen, C; Eilers, M; Moroy, T				Hennemann, H; Vassen, L; Geisen, C; Eilers, M; Moroy, T			Identification of a novel Kruppel-associated box domain protein, Krim-1, that interacts with c-Myc and inhibits its oncogenic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEINS; TRANSCRIPTIONAL REPRESSION; ACTIVATES TRANSCRIPTION; HISTONE DEACETYLATION; RECRUITMENT SYSTEM; ESSENTIAL COFACTOR; KAP-1 COREPRESSOR; GENE-EXPRESSION; DNA-BINDING; COMPLEX	We have used the Ras recruitment system to screen for proteins that interact with the N-terminally located transactivation domain of c-Myc. The Ras recruitment system is based on the activation of the mitogenic RAS signaling pathway in yeast by the mammalian GTPase Ha-Ras. This screen led to the identification of two novel nuclear proteins termed Krim-1A and Krim-1B that both contain an N-terminal KRAB box domain and 12 or 9 Kruppel C2H2 type zinc fingers at the C terminus, respectively. We found that sequences covering the Myc box II homology region are essential for the interaction with the Krim-1 proteins and that the second N-terminal zinc finger of Krim-1 is essential for Myc binding. Both Krim-1A and -B genes appear to be expressed ubiquitously with highest levels in spleen and lymph nodes. In particular, Krim-1B and, to a lesser extent, Krim-1A are able to decrease E-box-dependent transcriptional transactivation by c-Myc-Max complexes and also the ability of Myc to malignantly transform primary rat embryo fibroblasts, which is consistent with the functional repressive properties of their KRAB domains. The transcriptional corepressor Tif-1beta is a binding partner for Krim-1 and stabilizes the protein. Our findings suggest that Myc-mediated functions can be negatively regulated by Krim-1, potentially in a complex with Tif-1beta.	Univ Klinikum Essen, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany; Univ Marburg, Inst Mol Biol & Tumorforsch, D-35033 Marburg, Germany	University of Duisburg Essen; Philipps University Marburg	Moroy, T (corresponding author), Univ Klinikum Essen, Inst Zellbiol Tumorforsch, Virchowstr 173, D-45122 Essen, Germany.		Moroy, Tarik/D-9923-2011	Eilers, Martin/0000-0002-0376-6533				Abrink M, 2001, P NATL ACAD SCI USA, V98, P1422, DOI 10.1073/pnas.041616998; ADAMS JM, 1992, CANCER SURV, V15, P119; Agata Y, 1999, J BIOL CHEM, V274, P16412, DOI 10.1074/jbc.274.23.16412; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Amati B, 2001, BBA-REV CANCER, V1471, pM135, DOI 10.1016/S0304-419X(01)00020-8; Aronheim A, 1997, NUCLEIC ACIDS RES, V25, P3373, DOI 10.1093/nar/25.16.3373; Aronheim A, 1998, CURR BIOL, V8, P1125, DOI 10.1016/S0960-9822(98)70468-3; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Aronheim A, 2000, METHOD ENZYMOL, V328, P47, DOI 10.1016/S0076-6879(00)28389-4; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Broder YC, 1998, CURR BIOL, V8, P1121, DOI 10.1016/S0960-9822(98)70467-1; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Elser B, 1997, J BIOL CHEM, V272, P27908, DOI 10.1074/jbc.272.44.27908; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Gebelein B, 2001, MOL CELL BIOL, V21, P928, DOI 10.1128/MCB.21.3.928-939.2001; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lechner MS, 2000, MOL CELL BIOL, V20, P6449, DOI 10.1128/MCB.20.17.6449-6465.2000; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Lorenz P, 2001, BIOL CHEM, V382, P637, DOI 10.1515/BC.2001.075; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101; Peng HZ, 2000, J BIOL CHEM, V275, P18000, DOI 10.1074/jbc.M001499200; Peng HZ, 2000, J MOL BIOL, V295, P1139, DOI 10.1006/jmbi.1999.3402; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Satou A, 2001, J BIOL CHEM, V276, P46562, DOI 10.1074/jbc.M104937200; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291	58	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28799	28811		10.1074/jbc.M207196200	http://dx.doi.org/10.1074/jbc.M207196200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12748187	hybrid			2022-12-25	WOS:000184421100058
J	Hung, CC; Ichimura, T; Stevens, JL; Bonventre, JV				Hung, CC; Ichimura, T; Stevens, JL; Bonventre, JV			Protection of renal epithelial cells against oxidative injury by endoplasmic reticulum stress preconditioning is mediated by ERK1/2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; INDUCED FUNCTIONAL INJURY; MAPK KINASE ACTIVATION; CYTOSOLIC-FREE CALCIUM; MOLECULAR CHAPERONES; SIGNALING PATHWAYS; CELLULAR-RESPONSE; CA2+; MECHANISMS; SURVIVAL	We investigated the role of the endoplasmic reticulum ( ER) stress response in intracellular Ca2+ regulation, MAPK activation, and cytoprotection in LLC-PK1 renal epithelial cells in an attempt to identify the mechanisms of protection afforded by ER stress. Cells preconditioned with trans-4,5-dihydroxy-1,2-dithiane, tunicamycin, thapsigargin, or A23187 expressed ER stress proteins and were resistant to subsequent H2O2-induced cell injury. In addition, ER stress preconditioning prevented the increase in intracellular Ca2+ concentration that normally follows H2O2 exposure. Stable transfection of cells with antisense RNA targeted against GRP78 (pkASgrp78 cells) prevented GRP78 induction, disabled the ER stress response, sensitized cells to H2O2-induced injury, and prevented the development of tolerance to H2O2 that normally occurs with preconditioning. ERK and JNK were transiently ( 30 - 60 min) phosphorylated in response to H2O2. ER stress-preconditioned cells had more ERK and less JNK phosphorylation than control cells in response to H2O2 exposure. Preincubation with a specific inhibitor of JNK activation or adenoviral infection with a construct that encodes constitutively active MEK1, the upstream activator of ERKs, also protected cells against H2O2 toxicity. In contrast, the pkASgrp78 cells had less ERK and more JNK phosphorylation upon H2O2 exposure. Expression of constitutively active ERK also conferred protection on native as well as pkASgrp78 cells. These results indicate that GRP78 plays an important role in the ER stress response and cytoprotection. ER stress preconditioning attenuates H2O2-induced cell injury in LLC-PK1 cells by preventing an increase in intracellular Ca2+ concentration, potentiating ERK activation, and decreasing JNK activation. Thus, the ER stress response modulates the balance between ERK and JNK signaling pathways to prevent cell death after oxidative injury. Furthermore, ERK activation is an important downstream effector mechanism for cellular protection by ER stress.	Brigham & Womens Hosp, Div Renal, Med Serv, Boston, MA 02115 USA; Massachusetts Gen Hosp, Med Serv, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Lilly Res Labs, Greenfield, IN 46146 USA; Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Eli Lilly; Harvard University	Ichimura, T (corresponding author), Brigham & Womens Hosp, Div Renal, Med Serv, Med Res Bldg,4th Floor,75 Francis St, Boston, MA 02115 USA.	tichimura@partners.org						Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Benjamin IJ, 1998, CIRC RES, V83, P117, DOI 10.1161/01.RES.83.2.117; Bush KT, 2000, J CLIN INVEST, V106, P621, DOI 10.1172/JCI10968; Bush KT, 1999, AM J PHYSIOL-RENAL, V277, pF211, DOI 10.1152/ajprenal.1999.277.2.F211; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; CHEN Q, 1994, J CELL PHYSIOL, V161, P293, DOI 10.1002/jcp.1041610214; Chen YR, 2000, INT J ONCOL, V16, P651; CHEUNG JY, 1986, AM J PHYSIOL, V251, pF690, DOI 10.1152/ajprenal.1986.251.4.F690; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Choukroun G, 1998, J CLIN INVEST, V102, P1311, DOI 10.1172/JCI3512; Cutrin JC, 2002, FREE RADICAL BIO MED, V33, P1200, DOI 10.1016/S0891-5849(02)01017-1; Di Mari JF, 1999, AM J PHYSIOL-RENAL, V277, pF195, DOI 10.1152/ajprenal.1999.277.2.F195; Dong Z, 1998, AM J PATHOL, V152, P231; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; Ermak G, 2002, MOL IMMUNOL, V38, P713, DOI 10.1016/S0161-5890(01)00108-0; Gitler C, 2002, BIOCHEM BIOPH RES CO, V290, P624, DOI 10.1006/bbrc.2001.6214; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; Ikeyama S, 2002, FASEB J, V16, pA1163, DOI 10.1096/fj.01-0409fje; Jamora C, 1996, P NATL ACAD SCI USA, V93, P7690, DOI 10.1073/pnas.93.15.7690; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kitao Y, 2001, J CLIN INVEST, V108, P1439, DOI 10.1172/JCI200112978; KRIBBEN A, 1994, J CLIN INVEST, V93, P1922, DOI 10.1172/JCI117183; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Kuznetsov G, 1996, P NATL ACAD SCI USA, V93, P8584, DOI 10.1073/pnas.93.16.8584; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Li CY, 2002, AM J PHYSIOL-CELL PH, V282, pC227, DOI 10.1152/ajpcell.00112.2001; Lievremont JP, 1997, J BIOL CHEM, V272, P30873, DOI 10.1074/jbc.272.49.30873; Liu H, 1998, J BIOL CHEM, V273, P12858, DOI 10.1074/jbc.273.21.12858; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Miyake H, 2000, J CELL BIOCHEM, V77, P396, DOI 10.1002/(SICI)1097-4644(20000601)77:3<396::AID-JCB5>3.0.CO;2-5; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Park KM, 2002, J BIOL CHEM, V277, P2040, DOI 10.1074/jbc.M107525200; Park KM, 2001, J BIOL CHEM, V276, P11870, DOI 10.1074/jbc.M007518200; Paschen W, 2001, CELL CALCIUM, V29, P1, DOI 10.1054/ceca.2000.0162; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Reddy RK, 1999, J BIOL CHEM, V274, P28476, DOI 10.1074/jbc.274.40.28476; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Spear E, 2001, TRAFFIC, V2, P515, DOI 10.1034/j.1600-0854.2001.20801.x; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Treiman M, 2002, TRENDS CARDIOVAS MED, V12, P57, DOI 10.1016/S1050-1738(01)00147-5; UEDA N, 1992, AM J PHYSIOL, V263, pF214, DOI 10.1152/ajprenal.1992.263.2.F214; Urano F, 2000, J CELL SCI, V113, P3697; van de Water B, 1999, CHEM RES TOXICOL, V12, P943, DOI 10.1021/tx990054q; Wang H, 2000, FREE RADICAL BIO MED, V28, P1222, DOI 10.1016/S0891-5849(00)00241-0; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Waser M, 1997, J CELL BIOL, V138, P547, DOI 10.1083/jcb.138.3.547; Welch DR, 2000, CANCER RES, V60, P1552; Wyatt SE, 2002, TRANSGENIC RES, V11, P1, DOI 10.1023/A:1013917701701; Yamashita J, 2001, J PHARMACOL EXP THER, V296, P412; Zhan Y, 1997, MOL CELL BIOL, V17, P6755, DOI 10.1128/MCB.17.11.6755	64	170	189	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29317	29326		10.1074/jbc.M302368200	http://dx.doi.org/10.1074/jbc.M302368200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12738790	hybrid			2022-12-25	WOS:000184421100117
J	Barone, MC; Darley-Usmar, VM; Brookes, PS				Barone, MC; Darley-Usmar, VM; Brookes, PS			Reversible inhibition of cytochrome c oxidase by peroxynitrite proceeds through ascorbate-dependent generation of nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIA; SUPEROXIDE; ACID; RESPIRATION; MECHANISMS; MEMBRANES; TRANSPORT; OXYGEN; ENZYME; CELL	Reversible inhibition of cytochrome c oxidase (CcOX) by nitric oxide (NO.) has potential physiological roles in the regulation of mitochondrial respiration, redox signaling, and apoptosis. However peroxynitrite (ONOO-), an oxidant formed from the reaction of NO. and superoxide, appears mostly detrimental to cell function. This occurs both through direct oxidant reactions and by decreasing the availability of NO. for interacting with CcOX. When isolated CcOX respires with ascorbate as a reducing substrate, the conversion of ONOO- to NO. is observed. It is not known whether this can be ascribed to a direct interaction of the enzyme with ONOO-. In this investigation, the role of ascorbate in this system was examined using polarographic methods to measure NO. production and CcOX activity simultaneously in both the purified enzyme and isolated mitochondria. It was found that ascorbate alone accounts for > 90% of the NO. yield from ONOO- in the presence or absence of purified CcOX in turnover. The yield of NO was CcOX-independent but was dependent on ascorbate and ONOO- concentrations and was not affected by metal chelators. Consistent with this, the interaction of ONOO- with CcOX in respiring isolated mitochondria only yielded NO. when ascorbate was also present in the incubation. These observations are discussed in the context of ONOO-/ascorbate reactivity and the interaction of CcOX with reactive nitrogen species.	Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama, Ctr Free Rad Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Brookes, PS (corresponding author), Univ Alabama, Dept Pathol, Rm 329,BMR-2,901 19th St S, Birmingham, AL 35294 USA.		Darley-Usmar, Victor/F-7656-2010	Brookes, Paul/0000-0002-8639-8413; Darley-Usmar, Victor/0000-0001-8921-7086	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013395] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01-AA13395] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Brookes PS, 2000, J BIOL CHEM, V275, P20474, DOI 10.1074/jbc.M001077200; Brookes PS, 2002, METHOD ENZYMOL, V359, P305; Brookes PS, 2002, FREE RADICAL BIO MED, V33, P755, DOI 10.1016/S0891-5849(02)00901-2; Goldstein S, 2001, CHEM RES TOXICOL, V14, P657, DOI 10.1021/tx010066n; Hancock JT, 2001, FREE RADICAL BIO MED, V31, P697, DOI 10.1016/S0891-5849(01)00646-3; Herold S, 2002, BIOCHEMISTRY-US, V41, P13460, DOI 10.1021/bi026046h; Jackson TS, 1998, CIRC RES, V83, P916; Jensen MP, 2002, INORG CHEM, V41, P4788, DOI 10.1021/ic011089s; Kissner R, 2002, J AM CHEM SOC, V124, P234, DOI 10.1021/ja010497s; Li X, 2002, ARCH BIOCHEM BIOPHYS, V403, P103, DOI 10.1016/S0003-9861(02)00205-9; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; Lizasoain I, 1996, BIOCHEM J, V314, P877, DOI 10.1042/bj3140877; May JM, 2000, FREE RADICAL BIO MED, V28, P1421, DOI 10.1016/S0891-5849(00)00269-0; Merenyi G, 1997, CHEM RES TOXICOL, V10, P1216, DOI 10.1021/tx970101j; NISHIKIMI M, 1975, BIOCHEM BIOPH RES CO, V63, P463, DOI 10.1016/0006-291X(75)90710-X; Packer MA, 1996, BIOCHEM MOL BIOL INT, V40, P527; PACKER MA, 1994, FEBS LETT, V345, P237, DOI 10.1016/0014-5793(94)00461-7; Pearce LL, 1999, J BIOL CHEM, V274, P35763, DOI 10.1074/jbc.274.50.35763; Pearce LL, 2002, J BIOL CHEM, V277, P13556, DOI 10.1074/jbc.M109838200; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Radi R, 2002, BIOL CHEM, V383, P401, DOI 10.1515/BC.2002.044; REED JW, 1974, J AM CHEM SOC, V96, P1248, DOI 10.1021/ja00811a062; Rickwood D, 1987, MITOCHONDRIA PRACTIC, P3; Sarti P, 2000, BIOCHEM BIOPH RES CO, V274, P183, DOI 10.1006/bbrc.2000.3117; Sarti P, 2003, FREE RADICAL BIO MED, V34, P509, DOI 10.1016/S0891-5849(02)01326-6; SCARPA M, 1983, J BIOL CHEM, V258, P6695; Schmidt K, 1998, FREE RADICAL BIO MED, V24, P859, DOI 10.1016/S0891-5849(97)00366-3; Sharpe MA, 1998, J BIOL CHEM, V273, P30961, DOI 10.1074/jbc.273.47.30961; Shiva S, 2001, P NATL ACAD SCI USA, V98, P7212, DOI 10.1073/pnas.131128898; SLADE R, 1985, AM REV RESPIR DIS, V131, P742; Torres J, 2000, FEBS LETT, V475, P263, DOI 10.1016/S0014-5793(00)01682-3; WASHKO P, 1989, J BIOL CHEM, V264, P18996; YONETANI T, 1960, J BIOL CHEM, V235, P845	34	19	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27520	27524		10.1074/jbc.M304129200	http://dx.doi.org/10.1074/jbc.M304129200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12743113	hybrid			2022-12-25	WOS:000184242700024
J	Detich, N; Bovenzi, V; Szyf, M				Detich, N; Bovenzi, V; Szyf, M			Valproate induces replication-independent active DNA demethylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE COMPLEX; MESSENGER-RNA EXPRESSION; ADULT-RAT HIPPOCAMPUS; GENE-EXPRESSION; CPG METHYLATION; BINDING FACTORS; MOUSE MODEL; PROMOTER; PROTEINS; REGION	In this report, we demonstrate that valproic acid (VPA), a drug that has been used for decades in the treatment of epilepsy and as a mood stabilizer, triggers replication-independent active demethylation of DNA. Thus, this drug can potentially reverse DNA methylation patterns and erase stable methylation imprints on DNA in non-dividing cells. Recent discoveries support a role for VPA in the regulation of methylated genes; however, the mechanism has been unclear because it is difficult to dissociate active demethylation from the absence of DNA methylation during DNA synthesis. We therefore took advantage of an assay that measures active DNA demethylation independently from other DNA methylation and DNA replication activities in human embryonal kidney 293 cells. We show that VPA induces histone acetylation, DNA demethylation, and expression of an ectopically methylated CMV-GFP plasmid in a dose-dependent manner. In contrast, valpromide, an analogue of VPA that does not induce histone acetylation, does not induce demethylation or expression of CMV-GFP. Furthermore, we illustrate that methylated DNA-binding protein 2/DNA demethylase (MBD2/dMTase) participates in this reaction since antisense knockdown of MBD2/dMTase attenuates VPA-induced demethylation. Taken together, our data support a new mechanism of action for VPA as enhancing intracellular demethylase activity through its effects on histone acetylation and raises the possibility that DNA methylation is reversible independent of DNA replication by commonly prescribed drugs.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada	McGill University	Szyf, M (corresponding author), 3655 Sir William Osler Promenade, Montreal, PQ H3G 1Y6, Canada.							Alonso-Aperte E, 1999, NEUROLOGY, V52, P750, DOI 10.1212/WNL.52.4.750; Asghari V, 1998, MOL BRAIN RES, V58, P95, DOI 10.1016/S0169-328X(98)00107-7; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bruniquel D, 2003, NAT IMMUNOL, V4, P235, DOI 10.1038/ni887; Cervoni N, 2002, J BIOL CHEM, V277, P25026, DOI 10.1074/jbc.M202256200; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; Chen G, 1999, J NEUROCHEM, V72, P1327, DOI 10.1046/j.1471-4159.2000.0721327.x; Chen Y, 2002, NUCLEIC ACIDS RES, V30, P2930, DOI 10.1093/nar/gkf401; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; Detich N, 2002, J BIOL CHEM, V277, P35791, DOI 10.1074/jbc.C200408200; El-Osta A, 2002, BIOCHEM BIOPH RES CO, V295, P575, DOI 10.1016/S0006-291X(02)00682-4; Francis J, 2002, NEUROSCIENCE, V113, P79, DOI 10.1016/S0306-4522(02)00150-1; Goel A, 2003, J BIOL CHEM, V278, P15333, DOI 10.1074/jbc.M300608200; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Hattori M, 2001, CANCER LETT, V169, P155, DOI 10.1016/S0304-3835(01)00499-2; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Jung BP, 2002, NEUROSCIENCE, V115, P515, DOI 10.1016/S0306-4522(02)00383-4; Kino T, 2001, GENES CELLS, V6, P441, DOI 10.1046/j.1365-2443.2001.00432.x; Loscher W, 2002, CNS DRUGS, V16, P669; Lucarelli M, 2001, J BIOL CHEM, V276, P7500, DOI 10.1074/jbc.M008234200; Manev H, 2002, EUR J PHARMACOL, V445, P149, DOI 10.1016/S0014-2999(02)01711-9; MCCLELLAND M, 1994, NUCLEIC ACIDS RES, V22, P3640, DOI 10.1093/nar/22.17.3640; MCWHINNEY C, 1990, NUCLEIC ACIDS RES, V18, P1233, DOI 10.1093/nar/18.5.1233; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Oswald J, 2000, CURR BIOL, V10, P475, DOI 10.1016/S0960-9822(00)00448-6; PAROUSH Z, 1990, CELL, V63, P1229, DOI 10.1016/0092-8674(90)90418-E; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; Ramchandani S, 1999, P NATL ACAD SCI USA, V96, P6107, DOI 10.1073/pnas.96.11.6107; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; ROULEAU J, 1992, J BIOL CHEM, V267, P7368; Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507; Slack A, 2002, J GENE MED, V4, P381, DOI 10.1002/jgm.288; SZYF M, 1985, P NATL ACAD SCI USA, V82, P8090, DOI 10.1073/pnas.82.23.8090; SZYF M, 1991, J BIOL CHEM, V266, P10027; Tremolizzo L, 2002, P NATL ACAD SCI USA, V99, P17095, DOI 10.1073/pnas.262658999; WILKS A, 1984, NUCLEIC ACIDS RES, V12, P1163, DOI 10.1093/nar/12.2.1163	41	271	283	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27586	27592		10.1074/jbc.M303740200	http://dx.doi.org/10.1074/jbc.M303740200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12748177	hybrid			2022-12-25	WOS:000184242700033
J	Dmitrieva, RI; Doris, PA				Dmitrieva, RI; Doris, PA			Ouabain is a potent promoter of growth and activator of ERK1/2 in ouabain-resistant rat renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ADRENOCORTICAL-CELLS; NA+-K+-ATPASE; ALPHA-SUBUNIT; FACTOR RECEPTOR; CARDIOTONIC STEROIDS; CARDIAC-GLYCOSIDES; ENDOGENOUS OUABAIN; SIGNAL TRANSDUCER; PROTEIN-KINASES; NA,K-ATPASE	Endogenous cardiotonic steroids (ECS) are putative ligands of the inhibitory binding site of the membrane sodium pump (Na+,K+-ATPase). There is growing evidence that cardiotonic steroids may promote the growth of cardiac and vascular myocytes, including evidence indicating growth stimulation at concentrations in the same range as circulating ECS concentrations. We investigated four parameters to determine whether ouabain, a proposed ECS, promotes growth of immortalized rat proximal tubule epithelial cells: cell count by hemocytometer; metabolic activity as reflected in the mitochondrial conversion of the tetrazolium salt, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, to its formazan product (MA); DNA synthesis reflected as bromodeoxyuridine incorporation (DNA); and mitosis reflected as histone phosphorylation state detected using anti-phosphohistone 3 antibody (HP). Maximum stimulatory responses were observed at 1 nM ouabain (MA, 20.3% increase, p < 0.01; DNA, 28.4% increase, p < 0.001; HP, maximum response at 0.5 h, 50% increase, p < 0.001). We observed that growth stimulation was associated with stimulation of ERK1/2 phosphorylation (ERKP), and both growth and ERK-P could be blocked by the MEK inhibitor (U0126, 100 nM). Western blot analysis revealed that the only &alpha; isoform of Na+,K+-ATPase that could be detected in these cultures was the highly ouabain-resistant &alpha;1 isoform. Measurement of ouabain inhibition of ion transport in these cultures using Rb-86(+) uptake revealed the predominance of the expected ouabain-resistant isoform (IC50 = 24 &mu;M) and an additional minor (&SIM;15%) ouabain-sensitive inhibition with IC50 &SIM;30 pM. Similar bimodal transport inhibition curves were obtained in freshly dissected rat proximal tubules. These results indicate that renal epithelial cells may be a sensitive target of the ERK1/2-activating and growth-promoting effects of ouabain even in the presence of ouabain-resistant Na+,K+-ATPase.	Univ Texas, Hlth Sci Ctr, Inst Mol Med, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Doris, PA (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Mol Med, 2121 W Holcombe Blvd, Houston, TX 77030 USA.		Dmitrieva, Renata/AAO-2582-2020	Dmitrieva, Renata/0000-0002-3073-7914	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045538] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK45538] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu-Absi NR, 2002, J BIOTECHNOL, V95, P63, DOI 10.1016/S0168-1656(01)00444-8; Aizman O, 2001, P NATL ACAD SCI USA, V98, P13420, DOI 10.1073/pnas.221315298; Aydemir-Koksoy A, 2001, J BIOL CHEM, V276, P46605, DOI 10.1074/jbc.M106178200; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; Blaustein M. P., 1977, AM J PHYSIOL, V1, P165; Blaustein MP, 1996, KIDNEY INT, V49, P1748, DOI 10.1038/ki.1996.260; Capriotti Teri, 2002, Medsurg Nurs, V11, P71; CHEVAL L, 1990, AM J PHYSIOL, V259, pF111, DOI 10.1152/ajprenal.1990.259.1.F111; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; Di Mari JF, 1999, AM J PHYSIOL-RENAL, V277, pF195, DOI 10.1152/ajprenal.1999.277.2.F195; Dmitrieva RI, 2002, EXP BIOL MED, V227, P561, DOI 10.1177/153537020222700803; Dmitrieva RI, 2000, HYPERTENSION, V36, P442, DOI 10.1161/01.HYP.36.3.442; Eichhorn EJ, 2002, PROG CARDIOVASC DIS, V44, P251, DOI 10.1053/pcad.2002.31591; EPSTEIN FH, 1982, AM J PHYSIOL, V243, pF356, DOI 10.1152/ajprenal.1982.243.4.F356; FALLOWS D, 1987, MOL CELL BIOL, V7, P2985, DOI 10.1128/MCB.7.8.2985; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Feld S, 1996, ENDOCR REV, V17, P423, DOI 10.1210/er.17.5.423; FERAILLE E, 1995, PFLUG ARCH EUR J PHY, V430, P205, DOI 10.1007/BF00374651; Flyvbjerg A, 1999, KIDNEY INT, V56, P2048, DOI 10.1046/j.1523-1755.1999.00776.x; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; Gekle M, 2002, AM J PHYSIOL-RENAL, V282, pF669, DOI 10.1152/ajprenal.00159.2001; GUPTA RS, 1986, J CELL PHYSIOL, V127, P197, DOI 10.1002/jcp.1041270202; GURLEY LR, 1975, J BIOL CHEM, V250, P3936; Haas A, 2002, J BIOL CHEM, V277, P18694, DOI 10.1074/jbc.M111357200; Haas M, 2000, J BIOL CHEM, V275, P27832; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hayward AL, 1999, J HYPERTENS, V17, P1081, DOI 10.1097/00004872-199917080-00006; Hirano T, 2000, ANNU REV BIOCHEM, V69, P115, DOI 10.1146/annurev.biochem.69.1.115; Hopfer U, 1996, AM J PHYSIOL-CELL PH, V270, pC1, DOI 10.1152/ajpcell.1996.270.1.C1; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; KENT RB, 1987, SCIENCE, V237, P901, DOI 10.1126/science.3039660; Kjeldsen K, 2002, CARDIOVASC RES, V55, P710, DOI 10.1016/S0008-6363(02)00466-2; Kometiani P, 1998, J BIOL CHEM, V273, P15249, DOI 10.1074/jbc.273.24.15249; Laredo J, 1997, HYPERTENSION, V29, P401, DOI 10.1161/01.HYP.29.1.401; LAREDO J, 1994, ENDOCRINOLOGY, V135, P794, DOI 10.1210/en.135.2.794; Li SQ, 1998, LIFE SCI, V62, P1023, DOI 10.1016/S0024-3205(98)00023-X; LINDZEN M, 2003, J BIOL CHEM; MANUNTA P, 1994, J HYPERTENS, V12, P549; MARSHALL NJ, 1995, GROWTH REGULAT, V5, P69; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Peng M, 1996, J BIOL CHEM, V271, P10372, DOI 10.1074/jbc.271.17.10372; Perrin A, 1997, MOL CELL ENDOCRINOL, V126, P7, DOI 10.1016/S0303-7207(96)03964-0; PORSTMANN T, 1985, J IMMUNOL METHODS, V82, P169, DOI 10.1016/0022-1759(85)90236-4; PRESSLEY TA, 1992, AM J PHYSIOL, V262, pC743, DOI 10.1152/ajpcell.1992.262.3.C743; Schoner W, 2002, EUR J BIOCHEM, V269, P2440, DOI 10.1046/j.1432-1033.2002.02911.x; Schoner W, 2001, CELL MOL BIOL, V47, P273; SERI I, 1990, AM J PHYSIOL, V258, pF52, DOI 10.1152/ajprenal.1990.258.1.F52; Sheridan AM, 2000, CURR OPIN NEPHROL HY, V9, P427, DOI 10.1097/00041552-200007000-00015; SHYJAN AW, 1990, P NATL ACAD SCI USA, V87, P1178, DOI 10.1073/pnas.87.3.1178; URAYAMA O, 1979, J BIOCHEM, V86, P1371, DOI 10.1093/oxfordjournals.jbchem.a132654; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Woost PG, 1996, KIDNEY INT, V50, P125, DOI 10.1038/ki.1996.295; Xie ZJ, 2002, EUR J BIOCHEM, V269, P2434, DOI 10.1046/j.1432-1033.2002.02910.x; Xie ZJ, 2001, CELL MOL BIOL, V47, P383; YUAN CM, 1993, HYPERTENSION, V22, P178, DOI 10.1161/01.HYP.22.2.178; Zhang Z, 2002, AM J PHYSIOL-RENAL, V283, pF302, DOI 10.1152/ajprenal.00038.2002	56	72	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28160	28166		10.1074/jbc.M303768200	http://dx.doi.org/10.1074/jbc.M303768200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12736249	hybrid			2022-12-25	WOS:000184242700104
J	O'Malley, KL; Jong, YJI; Gonchar, Y; Burkhalter, A; Romano, C				O'Malley, KL; Jong, YJI; Gonchar, Y; Burkhalter, A; Romano, C			Activation of metabotropic glutamate receptor mGlu5 on nuclear membranes mediates intranuclear Ca2+ changes in heterologous cell types and neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY UPTAKE; INOSITOL 1,4,5-TRISPHOSPHATE; EXTRACELLULAR CALCIUM; PLASMA-MEMBRANE; RAT; LOCALIZATION; RELEASE; TRANSPORTER; MECHANISMS; EXPRESSION	Nuclear Ca2+ plays a critical role in many cellular functions although its mode (s) of regulation is unclear. This study shows that the metabotropic glutamate receptor, mGlu5, mobilizes nuclear Ca2+ independent of cytosolic Ca2+ regulation. Immunocytochemical, ultrastructural, and subcellular fractionation techniques revealed that the metabotropic glutamate receptor, mGlu5, can be localized to nuclear membranes in heterologous cells as well as midbrain and cortical neurons. Nuclear mGlu5 receptors derived from HEK cells or cortical cell types bound [H-3] quisqualate. When loaded with Oregon Green BAPTA, nuclei isolated from mGlu5-expressing HEK cells responded to the addition of glutamate with rapid, oscillatory [Ca2+] elevations that were blocked by antagonist or EGTA. In contrast, carbachol-activation of endogenous muscarinic receptors led to cytoplasmic but not nuclear Ca2+ responses. Similarly, activation of mGlu5 receptors expressed on neuronal nuclei led to sustained Ca2+ oscillatory responses. These results suggest mGlu5 may mediate intranuclear signaling pathways.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	O'Malley, KL (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, 660 S Euclid, St Louis, MO 63110 USA.	omalleyk@pcg.wustl.edu						Ango F, 2001, NATURE, V411, P962, DOI 10.1038/35082096; BALCAR VJ, 1992, LIFE SCI, V51, P1467, DOI 10.1016/0024-3205(92)90556-5; Berridge MJ, 2001, NOVART FDN SYMP, V239, P52; Bhattacharya M, 1999, J BIOL CHEM, V274, P15719, DOI 10.1074/jbc.274.22.15719; Bkaily G, 2000, J CARDIOVASC PHARM, V36, pS414, DOI 10.1097/00005344-200036051-00121; BONANNO G, 1994, PROG NEUROBIOL, V44, P451, DOI 10.1016/0301-0082(94)90006-X; Bootman MD, 2002, P NATL ACAD SCI USA, V99, P7320, DOI 10.1073/pnas.132254299; Chatterjee TK, 2000, J BIOL CHEM, V275, P29660, DOI 10.1074/jbc.M000330200; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; D'Santos C, 2000, EUR J HISTOCHEM, V44, P51; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; DANBOLT NC, 1994, PROG NEUROBIOL, V44, P377, DOI 10.1016/0301-0082(94)90033-7; Dehnes Y, 1998, J NEUROSCI, V18, P3606; Divecha N, 2000, CELL MOL LIFE SCI, V57, P379, DOI 10.1007/PL00000700; Dunlop J, 1999, BIOCHEM BIOPH RES CO, V265, P101, DOI 10.1006/bbrc.1999.1633; EHRENGRUBER MU, 2000, CURR PROT NEUROSCI; Fagni Laurent, 2002, Sci STKE, V2002, pre8, DOI 10.1126/stke.2002.137.re8; Flint AC, 1999, P NATL ACAD SCI USA, V96, P12144, DOI 10.1073/pnas.96.21.12144; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; Gobeil F, 2002, CIRC RES, V90, P682, DOI 10.1161/01.RES.0000013303.17964.7A; Gonchar Y, 2001, J COMP NEUROL, V431, P182, DOI 10.1002/1096-9861(20010305)431:2<182::AID-CNE1064>3.0.CO;2-K; He Y, 2000, J COMP NEUROL, V418, P255; Hermans E, 2001, BIOCHEM J, V359, P465, DOI 10.1042/0264-6021:3590465; Hoy M, 2002, FEBS LETT, V531, P199, DOI 10.1016/S0014-5793(02)03500-7; Hubert GW, 2001, J NEUROSCI, V21, P1838, DOI 10.1523/JNEUROSCI.21-06-01838.2001; Hughes TE, 2001, J BIOL CHEM, V276, P4227, DOI 10.1074/jbc.M007608200; Humbert JP, 1996, J BIOL CHEM, V271, P478, DOI 10.1074/jbc.271.1.478; IRVINE R, 2000, SCI STKE, V48, P1; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; Kettunen P, 2002, J NEUROSCI, V22, P1868, DOI 10.1523/JNEUROSCI.22-05-01868.2002; Kubo Y, 1998, SCIENCE, V279, P1722, DOI 10.1126/science.279.5357.1722; Kubokawa K, 1996, FEBS LETT, V392, P71, DOI 10.1016/0014-5793(96)00786-7; Lopez-Bendito G, 2002, CEREB CORTEX, V12, P625, DOI 10.1093/cercor/12.6.625; Lotharius J, 2000, J BIOL CHEM, V275, P38581, DOI 10.1074/jbc.M005385200; Lu D, 1998, ENDOCRINOLOGY, V139, P365, DOI 10.1210/en.139.1.365; Lujan R, 1997, J CHEM NEUROANAT, V13, P219, DOI 10.1016/S0891-0618(97)00051-3; Lundstrom K, 1999, J RECEPT SIGNAL TR R, V19, P673, DOI 10.3109/10799899909036679; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; Mellstrom B, 2001, CURR OPIN NEUROBIOL, V11, P312, DOI 10.1016/S0959-4388(00)00213-0; Munir M, 2000, NEUROCHEM INT, V37, P147, DOI 10.1016/S0197-0186(00)00018-8; Nakanishi S, 1998, BRAIN RES REV, V26, P230, DOI 10.1016/S0165-0173(97)00033-7; Nash MS, 2001, J BIOL CHEM, V276, P19286, DOI 10.1074/jbc.M007600200; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; Overstreet LS, 1999, J NEUROSCI, V19, P9663; Petersen OH, 1998, CELL CALCIUM, V23, P87, DOI 10.1016/S0143-4160(98)90106-3; Petersen OH, 2001, TRENDS NEUROSCI, V24, P271, DOI 10.1016/S0166-2236(00)01787-2; Petralia RS, 1997, J CHEM NEUROANAT, V13, P77, DOI 10.1016/S0891-0618(97)00023-9; Power JM, 2002, J NEUROSCI, V22, P3454; Reimer RJ, 2001, CURR OPIN CELL BIOL, V13, P417, DOI 10.1016/S0955-0674(00)00230-1; Rogue Patrick J., 1999, EMBO (European Molecular Biology Organization) Journal, V18, P5147, DOI 10.1093/emboj/18.19.5147; Romano C, 2001, MOL PHARMACOL, V59, P46, DOI 10.1124/mol.59.1.46; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; ROMANO C, 1995, J COMP NEUROL, V355, P455, DOI 10.1002/cne.903550310; Rose CR, 2001, NEURON, V31, P519, DOI 10.1016/S0896-6273(01)00402-0; Schoepp DD, 2001, J PHARMACOL EXP THER, V299, P12; Sluse FE, 1996, ACTA BIOCHIM POL, V43, P349; Tabata T, 2002, MOL CELL NEUROSCI, V20, P56, DOI 10.1006/mcne.2002.1118; Thomas U, 2002, J NEUROCHEM, V81, P407, DOI 10.1046/j.1471-4159.2002.00869.x; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; Ventura C, 1998, J BIOL CHEM, V273, P13383, DOI 10.1074/jbc.273.22.13383; Ventura C, 2001, CRIT REV EUKAR GENE, V11, P243; Watkins JL, 1998, P NATL ACAD SCI USA, V95, P6779, DOI 10.1073/pnas.95.12.6779; Welbourne T, 2001, NEWS PHYSIOL SCI, V16, P157, DOI 10.1152/physiologyonline.2001.16.4.157; Willard FS, 2000, IMMUNOL CELL BIOL, V78, P387, DOI 10.1046/j.1440-1711.2000.00927.x; Williams AJ, 2001, Q REV BIOPHYS, V34, P61, DOI 10.1017/S0033583501003675; Yamamoto S, 1998, MICROSC RES TECHNIQ, V40, P479, DOI 10.1002/(SICI)1097-0029(19980301)40:6<479::AID-JEMT8>3.0.CO;2-K	68	103	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28210	28219		10.1074/jbc.M300792200	http://dx.doi.org/10.1074/jbc.M300792200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12736269	hybrid			2022-12-25	WOS:000184242700110
J	Sano, Y; Inamura, K; Miyake, A; Mochizuki, S; Kitada, C; Yokoi, H; Nozawa, K; Okada, H; Matsushime, H; Furuichi, K				Sano, Y; Inamura, K; Miyake, A; Mochizuki, S; Kitada, C; Yokoi, H; Nozawa, K; Okada, H; Matsushime, H; Furuichi, K			A novel two-pore domain K+ channel, TRESK, is localized in the spinal cord	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; EXPRESSION; CLONING; SHAKER; MEMBER; SEQUENCE; FAMILY; PH	To find a novel human ion channel gene we have executed an extensive search by using a human genome draft sequencing data base. Here we report a novel two-pore domain K+ channel, TRESK ((T) under bar WIK-(r) under bar elated (s) under bar pinal cord (K) under bar (+) channel). TRESK is coded by 385 amino acids and shows low homology (19%) with previously characterized two-pore domain K+ channels. However, the most similar channel is TREK-2 (two-pore domain K+ channel), and TRESK also has two pore-forming domains and four transmembrane domains that are evolutionarily conserved in the two-pore domain K+ channel family. Moreover, we confirmed that TRESK is expressed in the spinal cord. Electrophysiological analysis demonstrated that TRESK induced outward rectification and functioned as a background K+ channel. Pharmacological analysis showed TRESK to be inhibited by previously reported K+ channel inhibitors Ba2+, propafenone, glyburide, lidocaine, quinine, quinidine, and triethanolamine. Functional analysis demonstrated TRESK to be inhibited by unsaturated free fatty acids such as arachidonic acid and docosahexaenoic acid. TRESK is also sensitive to extreme changes in extracellular and intracellular pH. These results indicate that TRESK is a novel two-pore domain K+ channel that may set the resting membrane potential of cells in the spinal cord.	Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Mol Med Labs, Tsukuba, Ibaraki 3058585, Japan	Astellas Pharmaceuticals	Sano, Y (corresponding author), Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Mol Med Labs, 21 Miyukigaoka, Tsukuba, Ibaraki 3058585, Japan.	sano.yorikata@yamanouchi.co.jp						Bang H, 2000, J BIOL CHEM, V275, P17412, DOI 10.1074/jbc.M000445200; BUTLER A, 1989, SCIENCE, V243, P943, DOI 10.1126/science.2493160; Chapman CG, 2000, MOL BRAIN RES, V82, P74; Czempinski K, 1997, EMBO J, V16, P2565, DOI 10.1093/emboj/16.10.2565; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; Girard C, 2001, BIOCHEM BIOPH RES CO, V282, P249, DOI 10.1006/bbrc.2001.4562; Goldstein SAN, 1996, P NATL ACAD SCI USA, V93, P13256, DOI 10.1073/pnas.93.23.13256; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B., 1992, IONIC CHANNELS EXCIT; Kim D, 2001, BIOCHEM BIOPH RES CO, V284, P923, DOI 10.1006/bbrc.2001.5064; Kim Y, 2000, J BIOL CHEM, V275, P9340, DOI 10.1074/jbc.275.13.9340; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lesage F, 2000, AM J PHYSIOL-RENAL, V279, pF793, DOI 10.1152/ajprenal.2000.279.5.F793; Lesage F, 2000, J BIOL CHEM, V275, P28398, DOI 10.1074/jbc.M002822200; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; Maingret F, 2000, EMBO J, V19, P2483, DOI 10.1093/emboj/19.11.2483; Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381; Miyake A, 1999, J BIOL CHEM, V274, P25018, DOI 10.1074/jbc.274.35.25018; Mochizuki S, 1999, AMINO ACIDS, V17, P243, DOI 10.1007/BF01366923; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; Patel AJ, 2000, J BIOL CHEM, V275, P28722, DOI 10.1074/jbc.M003755200; Patel AJ, 2001, CURR OPIN CELL BIOL, V13, P422, DOI 10.1016/S0955-0674(00)00231-3; Rajan S, 2001, J BIOL CHEM, V276, P7302, DOI 10.1074/jbc.M008985200; Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; Salinas M, 1999, J BIOL CHEM, V274, P11751, DOI 10.1074/jbc.274.17.11751; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; TIMPE LC, 1988, NATURE, V331, P143, DOI 10.1038/331143a0; Toborek M, 1999, J NEUROCHEM, V73, P684, DOI 10.1046/j.1471-4159.1999.0730684.x; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8	35	118	121	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27406	27412		10.1074/jbc.M206810200	http://dx.doi.org/10.1074/jbc.M206810200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12754259	hybrid			2022-12-25	WOS:000184242700011
J	Fujimoto, TT; Katsutani, S; Shimomura, T; Fujimura, K				Fujimoto, TT; Katsutani, S; Shimomura, T; Fujimura, K			Thrombospondin-bound integrin-associated protein (CD47) physically and functionally modifies integrin alpha(IIb)beta(3) by its extracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; PLATELET ACTIVATION; CYTOPLASMIC DOMAIN; LIGAND-BINDING; P-SELECTIN; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; AFFINITY MODULATION; TERMINAL PEPTIDE; RECEPTOR	Integrin-associated protein (IAP/CD47) is a receptor for the C-terminal cell binding domain of thrombospondin (TS). A peptide from the C-terminal cell binding domain, KRFYVVMWKK (4N1K) binds to IAP and stimulates the integrin-dependent cell functions, including platelet aggregation. We investigated the mechanism by which TS-bound IAP modulates the affinity of platelet integrin, alpha(IIb)beta(3). Platelet aggregation induced by 4N1K was not completely inhibited by energy depletion with sodium azide and 2-deoxy-D-glucose, although ADP or collagen-induced platelet response was completely inhibited. The binding of ligand-mimetic antibody PAC1 to alpha(IIb)beta(3) was also induced in the energy-depleted platelets. In the transfected Namalwa cells, 4N1K induced activation of the alpha(IIb)beta(3) with mutated beta(3) (Ser-752 to Pro), which is a non-responsive form to inside-out signaling, as well as wild type alpha(IIb)beta(3). The truncated form of IAP with only the extracellular immunoglobulin-like (Ig) domain was sufficient for the activation of alpha(IIb)beta(3) in Chinese hamster ovary cells, although the IAP-mediated intracellular signaling was abolished, which was monitored by the absence of down-regulation of mitogen-activated protein kinase phosphorylation. Furthermore, the soluble recombinant Ig domain of IAP induced PAC1 binding to alpha(IIb)beta(3) on Chinese hamster ovary cells when added with 4N1K. Physical association between the soluble recombinant Ig domain of IAP and purified alpha(IIb)beta(3) was detected in the presence of 4N1K. These data indicate that the extracellular Ig domain of IAP, when bound to TS, interacts with alpha(IIb)beta(3) and can change alpha(IIb)beta(3) in a high affinity state without the requirement of intracellular signaling. This extracellular event would be a novel mechanism of affinity modulation of integrin.	Hiroshima Univ, Grad Sch Biomed Sci, Program Appl Biomed,Dept Hematol & Oncol, Div Clin Pharmacotherapeut,Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Div Clin Pharmacotherapeut,Minami Ku, Hiroshima 7348551, Japan	Hiroshima University; Hiroshima University	Fujimoto, TT (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Program Appl Biomed,Dept Hematol & Oncol, Div Clin Pharmacotherapeut,Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.							Arnaout MA, 2002, CURR OPIN CELL BIOL, V14, P641, DOI 10.1016/S0955-0674(02)00371-X; Azam M, 2001, MOL CELL BIOL, V21, P2213, DOI 10.1128/MCB.21.6.2213-2220.2001; Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; Brittain JE, 2001, BLOOD, V97, P2159, DOI 10.1182/blood.V97.7.2159; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Brown EJ, 2002, CURR OPIN CELL BIOL, V14, P603, DOI 10.1016/S0955-0674(02)00360-5; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; Chung J, 1999, BLOOD, V94, P642, DOI 10.1182/blood.V94.2.642.414k35_642_648; Dorahy DJ, 1997, J BIOL CHEM, V272, P1323, DOI 10.1074/jbc.272.2.1323; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; FUJIMOTO T, 1993, BLOOD, V82, P1758; FUJIMOTO T, 1991, THROMB HAEMOSTASIS, V66, P598; FUJIMOTO T, 1993, J BIOL CHEM, V268, P11394; FUJIMOTO T, 1995, BLOOD, V86, P2174, DOI 10.1182/blood.V86.6.2174.bloodjournal8662174; Fukudome K, 1996, J BIOL CHEM, V271, P17491, DOI 10.1074/jbc.271.29.17491; Furusawa T, 1998, J BIOCHEM-TOKYO, V123, P101; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; Hauser W, 1999, P NATL ACAD SCI USA, V96, P8120, DOI 10.1073/pnas.96.14.8120; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Kashiwagi H, 1997, J CELL BIOL, V137, P1433, DOI 10.1083/jcb.137.6.1433; Kashiwagi H, 1999, BLOOD, V93, P2559, DOI 10.1182/blood.V93.8.2559.408k12_2559_2568; Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795; MCEVER RP, 1983, J BIOL CHEM, V258, P5269; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Phillips DR, 2001, CURR OPIN CELL BIOL, V13, P546, DOI 10.1016/S0955-0674(00)00250-7; Rebres RA, 2001, J BIOL CHEM, V276, P34607, DOI 10.1074/jbc.M106107200; Seiffert M, 2001, BLOOD, V97, P2741, DOI 10.1182/blood.V97.9.2741; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SHATTIL SJ, 1987, BLOOD, V70, P307; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Tulasne D, 2001, BLOOD, V98, P3346, DOI 10.1182/blood.V98.12.3346; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Wang XQ, 1999, J CELL BIOL, V147, P389, DOI 10.1083/jcb.147.2.389; Wang XQ, 1998, MOL BIOL CELL, V9, P865, DOI 10.1091/mbc.9.4.865; Watson SP, 1999, THROMB HAEMOSTASIS, V82, P365; Woodside DG, 2001, THROMB HAEMOSTASIS, V86, P316, DOI 10.1055/s-0037-1616229	44	33	38	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26655	26665		10.1074/jbc.M302194200	http://dx.doi.org/10.1074/jbc.M302194200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12736272	hybrid			2022-12-25	WOS:000184155700048
J	Zhao, CQ; Koide, A; Abrams, J; Deighton-Collins, S; Martinez, A; Schwartz, JA; Koide, S; Skafar, DF				Zhao, CQ; Koide, A; Abrams, J; Deighton-Collins, S; Martinez, A; Schwartz, JA; Koide, S; Skafar, DF			Mutation of Leu-536 in human estrogen receptor-alpha alters the coupling between ligand binding, transcription activation, and receptor conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTORS; PROMOTER-CONTEXT; HORMONE-BINDING; TRANSACTIVATION; DOMAIN; ANTIESTROGEN; COACTIVATOR; TAMOXIFEN; ESTRADIOL; PROTEIN	The estrogen receptor ( ER), of which there are two forms, ERalpha and ERbeta, is a ligand-modulated transcription factor important in both normal biology and as a target for agents to prevent and treat breast cancer. Crystallographic studies of the ERalpha ligand-binding domain suggest that Leu-536 may be involved in hydrophobic interactions at the start of a helix, "helix 12," that is crucial in the agonist-stimulated activity of ERalpha, as well as in the ability of antagonists to block the activity of ERalpha. We found that certain mutations of Leu-536 increased the ligand-independent activity of ERalpha although greatly reducing or eliminating the agonist activity of 17beta-estradiol (E-2) and 4-hydroxytamoxifen (4OHT), on an estrogen response element-driven and an AP-1-driven reporter. The mutations impaired the interaction of the ERalpha ligand-binding domain with the SRC1 receptor-interacting domain in a mammalian two-hybrid system. When tested in the yeast two-hybrid system, mutation of Leu-536 increased the basal reactivity of ERalpha to probes that recognize the agonist-bound conformation but did not significantly alter its reactivity to these probes in the presence of E-2. Most interestingly, mutation of Leu-536 reduced the interaction of the 4OHT-bound ERalpha and increased the reactivity of the raloxifene- or ICI 182,780-bound ERalpha, with probes that recognize the 4OHT-bound ERalpha conformation in a yeast two-hybrid system. These results show that Leu-536 is critical in coupling the binding of ligand to the modulation of the conformation and activity of ERalpha.	Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA; Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	Wayne State University; Barbara Ann Karmanos Cancer Institute; University of Chicago	Skafar, DF (corresponding author), Wayne State Univ, Sch Med, Dept Physiol, 540 E Canfield, Detroit, MI 48201 USA.			Koide, Shohei/0000-0001-5473-4358	NCI NIH HHS [P30-CA14599] Funding Source: Medline; NIDDK NIH HHS [1R01-DK56934-01A1, R01-DK62316] Funding Source: Medline; NIGMS NIH HHS [R29-GM55042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; *CONS C TREATM EST, 1998, OBSTET GYNECOL SUR S, V53, pS1; *CONS C TREATM EST, 1998, OBSTET GYNECOL SUR S, V53, pS2; Eng FCS, 1997, MOL CELL BIOL, V17, P4644, DOI 10.1128/MCB.17.8.4644; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Gangloff M, 2001, J BIOL CHEM, V276, P15059, DOI 10.1074/jbc.M009870200; Gradishar William J, 2003, Curr Treat Options Oncol, V4, P141, DOI 10.1007/s11864-003-0015-x; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Jung DJ, 2001, J BIOL CHEM, V276, P37280, DOI 10.1074/jbc.M106860200; Koide A, 2002, P NATL ACAD SCI USA, V99, P1253, DOI 10.1073/pnas.032665299; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; McInerney EM, 1996, J BIOL CHEM, V271, P24172, DOI 10.1074/jbc.271.39.24172; Montano MM, 1996, MOL ENDOCRINOL, V10, P230, DOI 10.1210/me.10.3.230; Nilsson S, 2000, BREAST CANCER RES, V2, P360, DOI 10.1186/bcr81; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Pearce ST, 2003, J BIOL CHEM, V278, P7630, DOI 10.1074/jbc.M211129200; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Skafar DF, 2000, CELL BIOCHEM BIOPHYS, V33, P53, DOI 10.1385/CBB:33:1:53; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WRENN CK, 1993, J BIOL CHEM, V268, P24089; Yudt MR, 1999, BIOCHEMISTRY-US, V38, P14146, DOI 10.1021/bi9911132; Zhong L, 2002, BIOCHEMISTRY-US, V41, P4209, DOI 10.1021/bi0121095	35	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27278	27286		10.1074/jbc.M303840200	http://dx.doi.org/10.1074/jbc.M303840200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12736255	hybrid			2022-12-25	WOS:000184155700124
J	Cao, JS; Burn, P; Shi, YG				Cao, JS; Burn, P; Shi, YG			Properties of the mouse intestinal Acyl-CoA : monoacylglycerol acyltransferase, MGAT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RAT-LIVER; TRIACYLGLYCEROL SYNTHESIS; DIACYLGLYCEROL ACYLTRANSFERASE; MIXED MICELLES; FATTY-ACIDS; BIOSYNTHESIS; MUCOSA; PURIFICATION; IDENTIFICATION	Acyl-CoA:monoacylglycerol acyltransferase (MGAT) plays an important role in dietary fat absorption by catalyzing a rate-limiting step in the re-synthesis of diacylglycerols in enterocytes. The present study reports further characterization of MGAT2, a newly identified intestinal MGAT (Cao, J., Lockwood, J., Burn, P., and Shi, Y. (2003) J. Biol. Chem. 278, 13860-13866) for its substrate specificity, requirement for lipid cofactors, optimum pH and Mg2+, and other intrinsic properties. MGAT2 enzyme expressed in COS-7 cells displayed a broad range of substrate specificity toward fatty acyl-CoA derivatives and monoacylglycerols, among which the highest activities were observed with oleoyl-CoA and rac-1-monolauroylglycerol, respectively. MGAT2 appeared to acylate monoacylglycerols containing unsaturated fatty acyls in preference to saturated ones. Lipid cofactors that play roles in signal transduction were shown to modulate MGAT2 activities. In contrast to oleic acid and sphingosine that exhibited inhibitory effects, phosphatidylcholine, phosphatidylserine, and phosphatidic acid stimulated MGAT2 activities. Using recombinant murine MGAT2 expressed in Escherichia coli, we demonstrated conclusively that MGAT2 also possessed an intrinsic acyl-CoA: diacylglycerol acyltransferase (DGAT) activity, which could provide an alternative pathway for triacylglycerol synthesis in the absence of DGAT. In contrast to the inhibitory effect on MGAT2 activities, nonionic and zwitterionic detergents led to a striking activation of DGAT activity of the human DGAT1 expressed in mammalian cells, which further distinguished the behaviors of the two enzymes. The elucidation of properties of MGAT2 will facilitate future development of compounds that inhibit dietary fat absorption as a means to treat obesity.	Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Endocrine Res,DC 0545, Indianapolis, IN 46285 USA	Eli Lilly	Shi, YG (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Endocrine Res,DC 0545, Indianapolis, IN 46285 USA.							BARACNIETO M, 1971, NEPHRON, V8, P488, DOI 10.1159/000179952; BHAT BG, 1993, ARCH BIOCHEM BIOPHYS, V300, P663, DOI 10.1006/abbi.1993.1092; BHAT BG, 1995, BIOCHEMISTRY-US, V34, P11237, DOI 10.1021/bi00035a033; BHAT BG, 1994, J BIOL CHEM, V269, P13172; BIERBACH H, 1983, DIGESTION, V28, P138, DOI 10.1159/000198977; Cao JS, 2003, J BIOL CHEM, V278, P13860, DOI 10.1074/jbc.M300139200; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Cheng D, 2003, J BIOL CHEM, V278, P13611, DOI 10.1074/jbc.C300042200; CIANFLONE KM, 1989, J BIOL CHEM, V264, P426; COLEMAN RA, 1984, J BIOL CHEM, V259, P8934; COLEMAN RA, 1992, METHOD ENZYMOL, V209, P98; COLEMAN RA, 1986, J LIPID RES, V27, P158; COLEMAN RA, 1988, BIOCHIM BIOPHYS ACTA, V963, P367, DOI 10.1016/0005-2760(88)90303-7; COLEMAN RA, 1986, J BIOL CHEM, V261, P224; HJELMSTAD RH, 1991, BIOCHEMISTRY-US, V30, P1731, DOI 10.1021/bi00221a001; JAMDAR SC, 1992, ARCH BIOCHEM BIOPHYS, V296, P419, DOI 10.1016/0003-9861(92)90592-K; JOHNSTON JM, 1970, BIOCHIM BIOPHYS ACTA, V218, P124, DOI 10.1016/0005-2760(70)90099-8; JOHNSTON JM, 1977, LIPID METABOLISM MAM, P151; Kamisaka Y, 1996, J BIOCHEM-TOKYO, V119, P520; LEHNER R, 1993, LIPIDS, V28, P29, DOI 10.1007/BF02536356; Lehner R, 1996, PROG LIPID RES, V35, P169, DOI 10.1016/0163-7827(96)00005-7; LEHNER R, 1992, BIOCHIM BIOPHYS ACTA, V1125, P171, DOI 10.1016/0005-2760(92)90042-T; LEHNER R, 1995, J BIOL CHEM, V270, P13630, DOI 10.1074/jbc.270.23.13630; MANGANARO F, 1985, CAN J BIOCHEM CELL B, V63, P341, DOI 10.1139/o85-050; MANLEY ER, 1974, BIOCHEM BIOPH RES CO, V58, P229, DOI 10.1016/0006-291X(74)90916-4; MISHKIN S, 1974, BIOCHEM BIOPH RES CO, V60, P376; MOSTAFA N, 1993, BIOCHIM BIOPHYS ACTA, V1169, P189, DOI 10.1016/0005-2760(93)90205-N; MOSTAFA N, 1993, J COMP PHYSIOL B, V163, P463; NAKAMURA S, 1993, ADV SEC MESS PHOSPH, V28, P171; NEURINGER M, 1988, ANNU REV NUTR, V8, P517, DOI 10.1146/annurev.nu.08.070188.002505; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ODOHERTY PJ, 1974, CAN J BIOCHEM CELL B, V52, P514, DOI 10.1139/o74-076; ODOHERTY PJA, 1975, FEBS LETT, V60, P256, DOI 10.1016/0014-5793(75)80725-3; PALTAUF F, 1971, BIOCHIM BIOPHYS ACTA, V239, P47, DOI 10.1016/0005-2760(71)90191-3; POLHEIM D, 1973, J LIPID RES, V14, P415; RAO GA, 1966, BIOCHIM BIOPHYS ACTA, V125, P465, DOI 10.1016/0005-2760(66)90035-X; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Trimble M E, 1977, Curr Probl Clin Biochem, V8, P362; TRIMBLE ME, 1978, LIFE SCI, V22, P883; XIA T, 1993, AM J PHYSIOL, V265, pR414, DOI 10.1152/ajpregu.1993.265.2.R414; Yen CLE, 2003, J BIOL CHEM, V278, P18532, DOI 10.1074/jbc.M301633200; Yen CLE, 2002, P NATL ACAD SCI USA, V99, P8512, DOI 10.1073/pnas.132274899	43	51	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25657	25663		10.1074/jbc.M302835200	http://dx.doi.org/10.1074/jbc.M302835200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730219	hybrid			2022-12-25	WOS:000183920200049
J	Leonov, AA; Sergiev, PV; Bodganov, AA; Brimacombe, R; Dontsova, OA				Leonov, AA; Sergiev, PV; Bodganov, AA; Brimacombe, R; Dontsova, OA			Affinity purification of ribosomes with a lethal G2655C mutation in 23 S rRNA that affects the translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-G; ESCHERICHIA-COLI; IN-VITRO; CRYOELECTRON MICROSCOPY; ANGSTROM RESOLUTION; CONSERVED LOOP; EF-G; SUBUNIT; BINDING; BASE	A method for preparation of Escherichia coli ribosomes carrying lethal mutations in 23 S rRNA was developed. The method is based on the site-directed incorporation of a streptavidin binding tag into functionally neutral sites of the 23 S rRNA and subsequent affinity chromatography. It was tested with ribosomes mutated at the 23 S rRNA position 2655 (the elongation factor (EF)-G binding site). Ribosomes carrying the lethal G2655C mutation were purified and studied in vitro. It was found in particular that this mutation confers strong inhibition of the translocation process but only moderately affects GTPase activity and binding of EF-G.	Moscow MV Lomonosov State Univ, Dept Chem, Moscow 119899, Russia; Max Planck Inst Mol Genet, D-14195 Berlin, Germany	Lomonosov Moscow State University; Max Planck Society	Sergiev, PV (corresponding author), Moscow MV Lomonosov State Univ, Dept Chem, Moscow 119899, Russia.	petya@genebee.msu.su	Dontsova, Olga/T-6072-2019; Sergiev, Petr V/D-7493-2012	Sergiev, Petr V/0000-0001-8866-1863				Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Asai T, 1999, P NATL ACAD SCI USA, V96, P1971, DOI 10.1073/pnas.96.5.1971; Avdeeva ON, 2002, FEBS LETT, V514, P70, DOI 10.1016/S0014-5793(02)02332-3; Bachler M, 1999, RNA, V5, P1509, DOI 10.1017/S1355838299991574; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BILGIN N, 1994, J MOL BIOL, V235, P813, DOI 10.1006/jmbi.1994.1041; Blaha G, 2000, METHOD ENZYMOL, V317, P292; Cameron DM, 2002, J MOL BIOL, V319, P27, DOI 10.1016/S0022-2836(02)00235-8; Ehrenberg M, 1990, RIBOSOMES PROTEIN SY, P101; GLUKHOVA M A, 1977, Molekulyarnaya Biologiya (Moscow), V11, P1190; Green R, 1999, BIOCHEMISTRY-US, V38, P1772, DOI 10.1021/bi982246a; Green R, 1996, RNA, V2, P1011; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; Khaitovich P, 1999, BIOCHEMISTRY-US, V38, P1780, DOI 10.1021/bi9822473; Macbeth MR, 1999, J MOL BIOL, V285, P567, DOI 10.1006/jmbi.1998.2337; Macbeth MR, 1999, J MOL BIOL, V285, P965, DOI 10.1006/jmbi.1998.2388; Martemyanov KA, 1999, FEBS LETT, V452, P155, DOI 10.1016/S0014-5793(99)00635-3; Matadeen R, 2001, J MOL BIOL, V307, P1341, DOI 10.1006/jmbi.2001.4547; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOINE H, 1994, J MOL BIOL, V243, P402, DOI 10.1006/jmbi.1994.1668; Munishkin A, 1997, P NATL ACAD SCI USA, V94, P12280, DOI 10.1073/pnas.94.23.12280; OCONNOR M, 1992, NUCLEIC ACIDS RES, V20, P4221, DOI 10.1093/nar/20.16.4221; OCONNOR M, 1993, P NATL ACAD SCI USA, V90, P9214, DOI 10.1073/pnas.90.19.9214; OConnor M, 1996, NUCLEIC ACIDS RES, V24, P2701, DOI 10.1093/nar/24.14.2701; Peabody DS, 1996, NUCLEIC ACIDS RES, V24, P2352, DOI 10.1093/nar/24.12.2352; POWERS T, 1990, P NATL ACAD SCI USA, V87, P1042, DOI 10.1073/pnas.87.3.1042; Rodnina MV, 1997, NATURE, V385, P37, DOI 10.1038/385037a0; Rodnina MV, 1999, P NATL ACAD SCI USA, V96, P9586, DOI 10.1073/pnas.96.17.9586; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2; Sergiev PV, 2000, J MOL BIOL, V299, P379, DOI 10.1006/jmbi.2000.3739; Shimizu Y, 2001, NAT BIOTECHNOL, V19, P751, DOI 10.1038/90802; SIGMUND CD, 1988, METHOD ENZYMOL, V164, P673; Srisawat C, 2001, RNA, V7, P632, DOI 10.1017/S135583820100245X; Stark H, 2000, CELL, V100, P301, DOI 10.1016/S0092-8674(00)80666-2; TAPPRICH WE, 1990, EMBO J, V9, P2649, DOI 10.1002/j.1460-2075.1990.tb07447.x; Vila-Sanjurjo A, 1999, J MOL BIOL, V293, P1, DOI 10.1006/jmbi.1999.3160; WATANABE S, 1972, J MOL BIOL, V67, P443, DOI 10.1016/0022-2836(72)90462-7; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006	40	53	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25664	25670		10.1074/jbc.M302873200	http://dx.doi.org/10.1074/jbc.M302873200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730236	hybrid			2022-12-25	WOS:000183920200050
J	Scheele, U; Alves, R; Frank, R; Duwel, M; Kalthoff, C; Ungewickell, E				Scheele, U; Alves, R; Frank, R; Duwel, M; Kalthoff, C; Ungewickell, E			Molecular and functional characterization of clathrin- and AP-2-binding determinants within a disordered domain of auxilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLES; ADAPTER COMPLEX; SECONDARY STRUCTURE; APPENDAGE DOMAIN; SPOT-SYNTHESIS; BOVINE BRAIN; LIGHT-CHAIN; PROTEIN; IDENTIFICATION; ENDOCYTOSIS	Uncoating of clathrin-coated vesicles requires the J-domain protein auxilin for targeting hsc70 to the clathrin coats and for stimulating the hsc70 ATPase activity. This results in the release of hsc70-complexed clathrin triskelia and concomitant dissociation of the coat. To understand the complex role of auxilin in uncoating and clathrin assembly in more detail, we analyzed the molecular organization of its clathrin-binding domain ( amino acids 547 - 813). CD spectroscopy of auxilin fragments revealed that the clathrin-binding domain is almost completely disordered in solution. By systematic mapping using synthetic peptides and by site-directed mutagenesis, we identified short peptide sequences involved in clathrin heavy chain and AP-2 binding and evaluated their significance for the function of auxilin. Some of the binding determinants, including those containing sequences (DPF)-D-674 and (WDW)-W-636, showed dual specificity for both clathrin and AP-2. In contrast, the two DLL motifs within the clathrin-binding domain were exclusively involved in clathrin binding. Surprisingly, they interacted not only with the N-terminal domain of the heavy chain, but also with the distal domain. Moreover, both DLL peptides proved to be essential for clathrin assembly and uncoating. In addition, we found that the motif (726)NWQ is required for efficient clathrin assembly activity. Auxilin shares a number of protein-protein interaction motifs with other endocytic proteins, including AP180. We demonstrate that AP180 and auxilin compete for binding to the alpha-ear domain of AP-2. Like AP180, auxilin also directly interacts with the ear domain of beta-adaptin. On the basis of our data, we propose a refined model for the uncoating mechanism of clathrin-coated vesicles.	Hannover Med Sch, Dept Cell Biol, D-30625 Hannover, Germany; Hannover Med Sch, Dept Biophys Chem, D-30625 Hannover, Germany; German Res Ctr Biotechnol, Res Grp Mol Recognit, D-38124 Braunschweig, Germany	Hannover Medical School; Hannover Medical School; Helmholtz Association; Helmholtz-Center for Infection Research	Ungewickell, E (corresponding author), Hannover Med Sch, Dept Cell Biol, Carl Neuberg Str 1, D-30625 Hannover, Germany.							AHLE S, 1990, J CELL BIOL, V111, P19, DOI 10.1083/jcb.111.1.19; BARZVI D, 1986, J BIOL CHEM, V261, P9614; Brett TJ, 2002, STRUCTURE, V10, P797, DOI 10.1016/S0969-2126(02)00784-0; Chen CY, 2002, EMBO J, V21, P6072, DOI 10.1093/emboj/cdf594; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Doray B, 2001, MOL BIOL CELL, V12, P1925, DOI 10.1091/mbc.12.7.1925; Drake MT, 2001, J BIOL CHEM, V276, P28700, DOI 10.1074/jbc.M104226200; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; Engqvist-Goldstein AEY, 2001, J CELL BIOL, V154, P1209, DOI 10.1083/jcb.200106089; Frank R, 1996, Methods Mol Biol, V66, P149; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Greener T, 2000, J BIOL CHEM, V275, P1365, DOI 10.1074/jbc.275.2.1365; Han CJ, 2000, J BIOMOL NMR, V17, P281, DOI 10.1023/A:1008353226591; Hao WH, 1999, J BIOL CHEM, V274, P22785, DOI 10.1074/jbc.274.32.22785; Holstein SEH, 1996, J CELL BIOL, V135, P925, DOI 10.1083/jcb.135.4.925; Kalthoff C, 2002, J BIOL CHEM, V277, P8209, DOI 10.1074/jbc.M111587200; Korolchuk VI, 2002, TRAFFIC, V3, P428, DOI 10.1034/j.1600-0854.2002.30606.x; Legendre-Guillemin V, 2002, J BIOL CHEM, V277, P19897, DOI 10.1074/jbc.M112310200; LEGENDREGUILLEM.V, 2002, AM SOC CELL BIOL 42; LINDNER R, 1994, CELL BIOL LAB HDB, P525; LIU SH, 1995, CELL, V83, P257, DOI 10.1016/0092-8674(95)90167-1; Ma YC, 2002, J BIOL CHEM, V277, P49267, DOI 10.1074/jbc.M203695200; Mishra SK, 2001, J BIOL CHEM, V276, P46230, DOI 10.1074/jbc.M108177200; Morgan JR, 2001, NEURON, V32, P289, DOI 10.1016/S0896-6273(01)00467-6; Morgan JR, 2000, J NEUROSCI, V20, P8667; Owen DJ, 2000, EMBO J, V19, P4216, DOI 10.1093/emboj/19.16.4216; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Scheele U, 2001, J BIOL CHEM, V276, P36131, DOI 10.1074/jbc.M106511200; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; Sigrist Christian J A, 2002, Brief Bioinform, V3, P265, DOI 10.1093/bib/3.3.265; Slepnev VI, 2000, J BIOL CHEM, V275, P17583, DOI 10.1074/jbc.M910430199; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Umeda A, 2000, EUR J CELL BIOL, V79, P336, DOI 10.1078/S0171-9335(04)70037-0; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; UNGEWICKELL E, 1991, J BIOL CHEM, V266, P12710	35	39	41	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25357	25368		10.1074/jbc.M303738200	http://dx.doi.org/10.1074/jbc.M303738200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12732633	hybrid			2022-12-25	WOS:000183920200014
J	Dewson, G; Snowden, RT; Almond, JB; Dyer, MJS; Cohen, GM				Dewson, G; Snowden, RT; Almond, JB; Dyer, MJS; Cohen, GM			Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells	ONCOGENE			English	Article						Bax; chronic lymphocytic leukemia; proteasome inhibitors	CYTOCHROME-C RELEASE; TRAIL-INDUCED APOPTOSIS; BCL-2 FAMILY MEMBERS; CASPASE ACTIVATION; HUMAN TISSUES; SURVIVAL; KINASE; RESISTANCE; EXPRESSION; PROTEIN	Chemotherapy resistance remains a major clinical problem in patients with B-cell chronic lymphocytic leukemia (B-CLL). Proteasome inhibitors are able to induce apoptosis in chemotherapy-resistant B-CLL cells in vitro. Exposure of B-CLL cells to the proteasome inhibitors, MG132 and lactacystin, resulted in inhibition of proteasomal activity within 30 min of treatment and was accompanied by an increase in the level of ubiquitinated proteins. Proteasome inhibitors did not alter the levels of expression of the proapoptotic Bcl-2 family proteins, Bax and Bid, prior to the onset of apoptosis. Instead, proteasome inhibitors induced a caspase-independent conformational change in Bax (as shown by a conformation-specific Bax antibody) and its translocation to mitochondria, resulting in mitochondrial perturbation, as evidenced by loss of the mitochondrial membrane potential and cytochrome c release. Similar conformational change and subcellular localization of Bax were observed during apoptosis induced with fludarabine, chlorambucil and prednisolone. These data suggest that alteration of Bax conformation and its redistribution to mitochondria are common and early features of B-CLL apoptosis in response to proteasome inhibitors and other chemotherapeutic agents.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; Univ Leicester, Leicester Royal Infirm, Dept Hematol, Leicester LE2 7LX, Leics, England	University of Leicester; University of Leicester	Cohen, GM (corresponding author), Univ Leicester, MRC, Toxicol Unit, Hodgkin Bldg,POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England.	gmc2@le.ac.uk	dewson, grant/C-7646-2013; Cohen, Gerald M/A-1687-2008; Dyer, Martin/F-2691-2014	dewson, grant/0000-0003-4251-8898; Dyer, Martin/0000-0002-5033-2236				Adams J, 2002, CURR OPIN CHEM BIOL, V6, P493, DOI 10.1016/S1367-5931(02)00343-5; Adams J, 2000, ONCOGENE, V19, P6687, DOI 10.1038/sj.onc.1204088; Almond JB, 2002, LEUKEMIA, V16, P433, DOI 10.1038/sj.leu.2402417; Almond JB, 2001, LEUKEMIA, V15, P1388, DOI 10.1038/sj.leu.2402201; An B, 1998, CELL DEATH DIFFER, V5, P1062, DOI 10.1038/sj.cdd.4400436; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Bannerji R, 2000, CURR OPIN ONCOL, V12, P22, DOI 10.1097/00001622-200001000-00004; Barragan M, 2002, BLOOD, V99, P2969, DOI 10.1182/blood.V99.8.2969; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bosanquet AG, 2002, LEUKEMIA, V16, P1035, DOI 10.1038/sj.leu.2402539; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Chandra J, 1998, BLOOD, V92, P4220, DOI 10.1182/blood.V92.11.4220.423k49_4220_4229; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Delic J, 1998, BRIT J CANCER, V77, P1103, DOI 10.1038/bjc.1998.183; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Dewson G, 2001, BLOOD, V98, P2239, DOI 10.1182/blood.V98.7.2239; Dou QP, 1999, DRUG RESIST UPDATE, V2, P215, DOI 10.1054/drup.1999.0095; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hideshima T, 2001, CANCER RES, V61, P3071; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kalil N, 1999, Oncologist, V4, P352; Kitada S, 1998, AM J PATHOL, V152, P51; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; MacFarlane M, 2002, ONCOGENE, V21, P6809, DOI 10.1038/sj.onc.1205853; MacFarlane M, 2000, BIOCHEM J, V348, P93, DOI 10.1042/0264-6021:3480093; Maianski NA, 2002, BLOOD, V99, P672, DOI 10.1182/blood.V99.2.672; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Marshansky V, 2001, J IMMUNOL, V166, P3130, DOI 10.4049/jimmunol.166.5.3130; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; McConkey DJ, 1996, J IMMUNOL, V156, P2624; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Murray RZ, 2000, ANTI-CANCER DRUG, V11, P407, DOI 10.1097/00001813-200007000-00001; Naujokat C, 2000, EUR J HAEMATOL, V65, P221, DOI 10.1034/j.1600-0609.2000.065004221.x; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; Penault-Llorca F, 1998, PATHOL RES PRACT, V194, P457, DOI 10.1016/S0344-0338(98)80114-3; Pepper C, 1999, BRIT J HAEMATOL, V104, P581, DOI 10.1046/j.1365-2141.1999.01210.x; Pepper C, 1998, LEUKEMIA LYMPHOMA, V28, P355, DOI 10.3109/10428199809092690; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; Reed JC, 1998, SEMIN HEMATOL, V35, P3; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tsubuki S, 1996, J BIOCHEM-TOKYO, V119, P572, DOI 10.1093/oxfordjournals.jbchem.a021280; Tsuruta F, 2002, J BIOL CHEM, V277, P14040, DOI 10.1074/jbc.M108975200; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yamaguchi H, 2001, ONCOGENE, V20, P7779, DOI 10.1038/sj.onc.1204984	71	93	94	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2003	22	17					2643	2654		10.1038/sj.onc.1206326	http://dx.doi.org/10.1038/sj.onc.1206326			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730678				2022-12-25	WOS:000182569000012
J	Diamond, TL; Souroullas, G; Weiss, KK; Lee, KY; Bambara, RA; Dewhurst, S; Kim, B				Diamond, TL; Souroullas, G; Weiss, KK; Lee, KY; Bambara, RA; Dewhurst, S; Kim, B			Mechanistic understanding of an altered fidelity simian immunodeficiency virus reverse transcriptase mutation, V148I, identified in a pig-tailed macaque	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-I; KINETIC MECHANISM; REPLICATION FIDELITY; 3TC RESISTANCE; STEADY-STATE; ACTIVE-SITE; O-HELIX; HIV-1; SELECTION; MUTANT	We have recently reported that the reverse transcriptase (RT) of SIVMNE 170 ( 170), which is a representative viral clone of the late symptomatic phase of infection with the parental strain, SIVMNE CL8 ( CL8), has a largely increased fidelity, compared with the CL8 RT. In the present study, we analyzed the mechanistic alterations of the high fidelity 170 RT variant. First, we found that among several 170 RT mutations, only one, V148I, is solely responsible for the fidelity increase over the CL8 RT. This V148I mutation lies near the Gln-151 residue that we recently found is important to the low fidelity of RT and the binding of incoming dNTPs. Second, we compared dNTP binding affinity (K-d) and catalysis (k(pol)) of the CL8 RT and the CL8-V148I RT using pre-steady state kinetic analysis. In this experiment, the high fidelity CL8-V148I RT has largely decreased binding to both correct and incorrect dNTP without altering kpol. The fidelity increase imparted by the V148I mutation is likely because of the major reduction seen in RT binding to dNTPs. This parallels our findings with the Q151N mutant. Third, site-directed mutagenesis targeting amino acid residue 148 has revealed that a valine amino acid at this position is essential to RT infidelity. Based on these findings, we discuss possible structural impacts of residue 148 ( and mutations at this site) on the interaction of RT with incoming dNTPs and infer how alterations in these properties may relate to viral replication and fitness.	Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14672 USA; Univ Rochester, Dept Biochem & Biophys, Rochester, NY 14672 USA; Univ Rochester, Ctr Canc, Rochester, NY 14672 USA	University of Rochester; University of Rochester; University of Rochester	Kim, B (corresponding author), Univ Rochester, Med Ctr, Dept Microbiol & Immunol, 601 Elmwood Ave,Box 672, Rochester, NY 14672 USA.			Souroullas, George P./0000-0003-2196-8662; Dewhurst, Stephen/0000-0001-7729-7920	NIAID NIH HHS [AI07362, AI49781, AI49815, AI49102] Funding Source: Medline; NIGMS NIH HHS [GM49573] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049781, T32AI007362, R21AI049102, T32AI049815] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bebenek K, 1995, METHOD ENZYMOL, V262, P217; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; Cases-Gonzalez CE, 2000, J BIOL CHEM, V275, P19759, DOI 10.1074/jbc.M910361199; COFFIN J, 1996, AIDS S, V10, P75; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Diamond TL, 2001, J BIOL CHEM, V276, P23624, DOI 10.1074/jbc.M102496200; Feng JY, 1999, BIOCHEMISTRY-US, V38, P9440, DOI 10.1021/bi990709m; Furge LL, 1997, BIOCHEMISTRY-US, V36, P6475, DOI 10.1021/bi9627267; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kaushik N, 2000, BIOCHEMISTRY-US, V39, P2912, DOI 10.1021/bi991376w; Kim B, 1997, METHODS, V12, P318, DOI 10.1006/meth.1997.0485; Klarmann GJ, 2000, J BIOL CHEM, V275, P359, DOI 10.1074/jbc.275.1.359; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; Lewis DA, 1999, J BIOL CHEM, V274, P32924, DOI 10.1074/jbc.274.46.32924; Li Y, 1999, P NATL ACAD SCI USA, V96, P9491, DOI 10.1073/pnas.96.17.9491; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; MartinHernandez AM, 1997, NUCLEIC ACIDS RES, V25, P1383, DOI 10.1093/nar/25.7.1383; O'Neil PK, 2002, J BIOL CHEM, V277, P38053, DOI 10.1074/jbc.M204774200; OVERBAUGH J, 1991, J VIROL, V65, P7025, DOI 10.1128/JVI.65.12.7025-7031.1991; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Rezende LF, 1998, NUCLEIC ACIDS RES, V26, P3066, DOI 10.1093/nar/26.12.3066; ROBERTS JD, 1989, MOL CELL BIOL, V9, P469, DOI 10.1128/MCB.9.2.469; Rouzine IM, 2001, MICROBIOL MOL BIOL R, V65, P151, DOI 10.1128/MMBR.65.1.151-185.2001; RUDENSEY LM, 1995, VIROLOGY, V207, P528, DOI 10.1006/viro.1995.1113; Sarafianos SG, 1999, P NATL ACAD SCI USA, V96, P10027, DOI 10.1073/pnas.96.18.10027; Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999; Suzuki M, 2000, J BIOL CHEM, V275, P32728, DOI 10.1074/jbc.M000097200; Suzuki M, 1997, J BIOL CHEM, V272, P11228; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Weiss KK, 2000, BIOCHEMISTRY-US, V39, P10684, DOI 10.1021/bi000788y; Weiss KK, 2002, J BIOL CHEM, V277, P22662, DOI 10.1074/jbc.M200202200; WILLIAMS KJ, 1992, CURR TOP MICROBIOL, V176, P165; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; YU H, 1992, J BIOL CHEM, V267, P10888	38	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29913	29924		10.1074/jbc.M211754200	http://dx.doi.org/10.1074/jbc.M211754200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12740369	hybrid			2022-12-25	WOS:000184507000064
J	Solomon, DA; Wang, Y; Fox, SR; Lambeck, TC; Giesting, S; Lan, Z; Senderowicz, AM; Knudsen, ES				Solomon, DA; Wang, Y; Fox, SR; Lambeck, TC; Giesting, S; Lan, Z; Senderowicz, AM; Knudsen, ES			Cyclin D1 splice variants - Differential effects on localization, RB phosphorylation, and cellular transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; D-DEPENDENT KINASE; RETINOBLASTOMA-PROTEIN; PRB PHOSPHORYLATION; CDK COMPLEXES; HUMAN CANCER; CELLS; POLYMORPHISM; INHIBITION; EXPRESSION	Cyclin D1 is a proto-oncogene that functions by inactivation of the retinoblastoma tumor suppressor protein, RB. A common polymorphism in the cyclin D1 gene is associated with the production of an alternate transcript of cyclin D1, termed cyclin D1b. Both the polymorphism and the variant transcript are associated with increased risk for multiple cancers and the severity of a given cancer; however, the underlying activities of cyclin D1b have not been elucidated relative to the canonical cyclin D1a. Because cyclin D1b does not possess the threonine 286 phosphorylation site required for nuclear export and regulated degradation, it has been hypothesized to encode a stable nuclear protein that would constitutively inactivate the RB pathway. Surprisingly, we find that cyclin D1b protein does not inappropriately accumulate in cells and exhibits stability comparable to cyclin D1a. As expected, the cyclin D1b protein was constitutively localized in the nucleus, whereas cyclin D1a was exported to the cytoplasm in S-phase. Despite enhanced nuclear localization, we find that cyclin D1b is a poor catalyst of RB phosphorylation/inactivation. However, cyclin D1b potently induced cellular transformation in contrast to cyclin D1a. In summary, we demonstrate that cyclin D1b specifically disrupts contact inhibition in a manner distinct from cyclin D1a. These data reveal novel roles for D-type cyclins in tumorigenesis.	Univ Cincinnati, Dept Cell Biol, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA; NIDCR, NIH, Bethesda, MD 20892 USA	University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Knudsen, ES (corresponding author), Univ Cincinnati, Dept Cell Biol, Vontz Ctr Mol Studies, 3125 Eden Ave, Cincinnati, OH 45267 USA.	erik.knudsen@uc.edu			NATIONAL CANCER INSTITUTE [R01CA082525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES011038] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA82525] Funding Source: Medline; NIEHS NIH HHS [UO1-ES011038] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams PD, 1999, MOL CELL BIOL, V19, P1068; Adams PD, 2001, BBA-REV CANCER, V1471, pM123, DOI 10.1016/S0304-419X(01)00019-1; Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Angus SP, 2002, EXP CELL RES, V276, P201, DOI 10.1006/excr.2002.5510; Arnold A, 1995, J INVEST MED, V43, P543; BATES S, 1994, ONCOGENE, V9, P1633; BETTICHER DC, 1995, ONCOGENE, V11, P1005; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fribourg AF, 2000, CELL GROWTH DIFFER, V11, P361; GILLETT C, 1994, CANCER RES, V54, P1812; Gladden AB, 2003, J BIOL CHEM, V278, P9754, DOI 10.1074/jbc.M212088200; Gordon C, 2002, CURR TOP MICROBIOL, V268, P175; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 2000, CURR OPIN CELL BIOL, V12, P685, DOI 10.1016/S0955-0674(00)00152-6; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Holley SL, 2001, AM J PATHOL, V159, P1917, DOI 10.1016/S0002-9440(10)63038-6; Hosokawa Y, 1998, GENE CHROMOSOME CANC, V22, P66, DOI 10.1002/(SICI)1098-2264(199805)22:1<66::AID-GCC9>3.0.CO;2-5; Howe D, 2001, HAEMATOLOGICA, V86, P563; KATO J, 1993, GENE DEV, V7, P331; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen Erik S, 2003, Methods Mol Biol, V218, P3; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kong SM, 2000, CANCER RES, V60, P249; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Leng XH, 2002, MOL CELL BIOL, V22, P2242, DOI 10.1128/MCB.22.7.2242-2254.2002; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; Lukas J, 1996, MOL CELL BIOL, V16, P6917; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; PALMER A, 1994, EUR J CELL BIOL, V64, P163; Palmero I, 1996, CANCER SURV, V27, P351; PETERS G, 1994, J CELL SCI, P89; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Scovassi AI, 1997, EXP CELL RES, V237, P127, DOI 10.1006/excr.1997.3770; Sherr C J, 2000, Harvey Lect, V96, P73; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; Wang LZ, 2002, CARCINOGENESIS, V23, P257, DOI 10.1093/carcin/23.2.257; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	64	185	192	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30339	30347		10.1074/jbc.M303969200	http://dx.doi.org/10.1074/jbc.M303969200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12746453	hybrid			2022-12-25	WOS:000184507000114
J	Diaz-Flores, E; Siliceo, M; Martinez, C; Merida, I				Diaz-Flores, E; Siliceo, M; Martinez, C; Merida, I			Membrane translocation of protein kinase C theta during T lymphocyte activation requires phospholipase C-gamma-generated diacylglycerol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; CELL-ACTIVATION; PKC-THETA; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; PHORBOL ESTER; RECEPTOR; ANTIGEN; TCR; VAV	Protein kinase Ctheta (PKCtheta) is the only PKC isoform recruited to the immunological synapse after T cell receptor stimulation, suggesting that its activation mechanism differs from that of the other isoforms. Previous studies have suggested that this selective PKCtheta recruitment may operate via a Vav-regulated, cytoskeletal- dependent mechanism, independent of the classical phospholipase C/diacylglycerol pathway. Here, we demonstrate that, together with tyrosine phosphorylation of PKCtheta in the regulatory domain, binding of phospholipase C-dependent diacylglycerol is required for PKCtheta recruitment to the T cell synapse. In addition, we demonstrate that diacylglycerol kinase alpha-dependent diacylglycerol phosphorylation provides the negative signal required for PKCtheta inactivation, ensuring fine control of the T cell activation response.	CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Merida, I (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Plaza Murillo 2, E-28049 Madrid, Spain.	imerida@cnb.uam.es	Merida, Isabel/A-9713-2014	Merida, Isabel/0000-0003-2762-6241				AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; Bi K, 2001, NAT IMMUNOL, V2, P556, DOI 10.1038/88765; Cao YJ, 2002, EMBO J, V21, P4809, DOI 10.1093/emboj/cdf499; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DESAI DM, 1990, NATURE, V348, P66, DOI 10.1038/348066a0; Ebinu JO, 2000, BLOOD, V95, P3199; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Irvin BJ, 2000, MOL CELL BIOL, V20, P9149, DOI 10.1128/MCB.20.24.9149-9161.2000; Isakov N, 2002, ANNU REV IMMUNOL, V20, P761, DOI 10.1146/annurev.immunol.20.100301.064807; Jones DR, 2002, FASEB J, V16, P595, DOI 10.1096/fj.01-0762fje; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Liu YH, 2000, J BIOL CHEM, V275, P3603, DOI 10.1074/jbc.275.5.3603; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Sanjuan MA, 2001, J CELL BIOL, V153, P207, DOI 10.1083/jcb.153.1.207; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Villalba M, 2002, J CELL BIOL, V157, P253, DOI 10.1083/jcb.200201097; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; Wang HB, 2002, J BIOL CHEM, V277, P4541, DOI 10.1074/jbc.M107150200; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	37	28	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29208	29215		10.1074/jbc.M303165200	http://dx.doi.org/10.1074/jbc.M303165200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12738795	hybrid			2022-12-25	WOS:000184421100106
J	Hashimoto, M; Imhoff, B; Ali, MM; Kow, YW				Hashimoto, M; Imhoff, B; Ali, MM; Kow, YW			HU protein of Escherichia coli has a role in the repair of closely opposed lesions in DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLY DAMAGED SITES; IONIZING-RADIATION; ENDONUCLEASE-III; CRUCIFORM DNA; STRAND BREAKS; DEOXYINOSINE; NTH; 3-ENDONUCLEASE; RECOMBINATION; RECOGNITION	Closely opposed lesions form a unique class of DNA damage that is generated by ionizing radiation. Improper repair of closely opposed lesions could lead to the formation of double strand breaks that can result in increased lethality and mutagenesis. In vitro processing of closely opposed lesions was studied using double-stranded DNA containing a nick in close proximity opposite to a dihydrouracil. In this study we showed that HU protein, an Escherichia coli DNA-binding protein, has a role in the repair of closely opposed lesions. The repair of dihydrouracil is initiated by E. coli endonuclease III and processed via the base excision repair pathway. HU protein was shown to inhibit the rate of removal of dihydrouracil by endonuclease III only when the DNA substrate contained a nick in close proximity opposite to the dihydrouracil. In contrast, HU protein did not inhibit the subsequent steps of the base excision repair pathway, namely the DNA synthesis and ligation reactions catalyzed by E. coli DNA polymerase and E. coli DNA ligase, respectively. The nick-dependent selective inhibition of endonuclease III activity by HU protein suggests that HU could play a role in reducing the formation of double strand breaks in E. coli.	Emory Univ, Sch Med, Div Canc Biol, Dept Radiat Oncol, Atlanta, GA 30303 USA	Emory University	Kow, YW (corresponding author), Emory Univ, Sch Med, Div Canc Biol, Dept Radiat Oncol, 145 Edgewood Ave, Atlanta, GA 30303 USA.	ykow@emory.edu			NATIONAL CANCER INSTITUTE [R01CA090860, R56CA090860] Funding Source: NIH RePORTER; NCI NIH HHS [CA 90860] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P4444, DOI 10.1021/bi00436a048; Azam TA, 1999, J BIOL CHEM, V274, P33105, DOI 10.1074/jbc.274.46.33105; BONNEFOY E, 1994, J MOL BIOL, V242, P116, DOI 10.1006/jmbi.1994.1563; BOUBRIK F, 1995, P NATL ACAD SCI USA, V92, P3958, DOI 10.1073/pnas.92.9.3958; Bourdat AG, 1999, NUCLEIC ACIDS RES, V27, P1015, DOI 10.1093/nar/27.4.1015; CASTAING B, 1995, J BIOL CHEM, V270, P10291, DOI 10.1074/jbc.270.17.10291; CHAUDHRY MA, 1995, J MOL BIOL, V249, P914; David-Cordonnier MH, 2000, J BIOL CHEM, V275, P11865, DOI 10.1074/jbc.275.16.11865; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; FREIDBERG EC, 1995, DNA REPAIR MUTAGENES; HALL EJ, 1994, RADIOBIOLOGY RADIOBI; HALL EJ, 1993, RADIOLOGY RADIOLOGIS; Harrison L, 1998, NUCLEIC ACIDS RES, V26, P932, DOI 10.1093/nar/26.4.932; Hashimoto M, 2001, J BIOL CHEM, V276, P12827, DOI 10.1074/jbc.M010906200; HODGESGARCIA Y, 1989, J BIOL CHEM, V264, P14621; Jiang DY, 1997, J BACTERIOL, V179, P3773, DOI 10.1128/jb.179.11.3773-3782.1997; Kamashev D, 1999, EMBO J, V18, P5434, DOI 10.1093/emboj/18.19.5434; Kamashev D, 2000, EMBO J, V19, P6527, DOI 10.1093/emboj/19.23.6527; Li SS, 1998, J BACTERIOL, V180, P3750, DOI 10.1128/JB.180.15.3750-3756.1998; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MacNeill SA, 2001, CURR BIOL, V11, pR842, DOI 10.1016/S0960-9822(01)00500-0; McElhinny SAN, 2003, MOL CELL BIOL, V23, P2309, DOI 10.1128/MCB.23.7.2309-2315.2003; Pellegrini O, 2000, BIOCHIMIE, V82, P693, DOI 10.1016/S0300-9084(00)01151-2; Prasad R, 2001, J BIOL CHEM, V276, P32411, DOI 10.1074/jbc.C100292200; Ramadan K, 2003, J MOL BIOL, V328, P63, DOI 10.1016/S0022-2836(03)00265-1; ROUVIEREYANIV J, 1977, COLD SPRING HARB SYM, V42, P439; Sutherland BM, 2000, P NATL ACAD SCI USA, V97, P103, DOI 10.1073/pnas.97.1.103; Sutherland BM, 2000, BIOCHEMISTRY-US, V39, P8026, DOI 10.1021/bi9927989; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; WARD JF, 1981, RADIAT RES, V86, P185, DOI 10.2307/3575500; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; Wilson III D. M., 1998, DNA DAMAGE REPAIR, VI, P29; Yao M, 1997, J BIOL CHEM, V272, P30774, DOI 10.1074/jbc.272.49.30774; YAO M, 1995, J BIOL CHEM, V270, P28609, DOI 10.1074/jbc.270.48.28609; Yao M, 1996, J BIOL CHEM, V271, P30672, DOI 10.1074/jbc.271.48.30672	36	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28501	28507		10.1074/jbc.M303970200	http://dx.doi.org/10.1074/jbc.M303970200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12748168	hybrid			2022-12-25	WOS:000184421100020
J	Schulze, DH; Muqhal, M; Lederer, WJ; Ruknudin, AM				Schulze, DH; Muqhal, M; Lederer, WJ; Ruknudin, AM			Sodium/calcium exchanger (NCX1) macromolecular complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC NA+-CA2+ EXCHANGER; SODIUM-CALCIUM EXCHANGE; PROTEIN-KINASE-A; PHOSPHORYLATION-DEPENDENT REGULATION; NA+/CA2+ EXCHANGER; CYTOPLASMIC PROTONS; CATALYTIC SUBUNIT; SIGNALING COMPLEX; DEVELOPING RABBIT; NA/CA EXCHANGE	The sodium-calcium exchanger, NCX1, is a ubiquitously expressed membrane protein essential in calcium homeostasis for many cells including those in mammalian heart and brain. The function of NCX1 depends on subcellular ("local") factors, the phosphorylation state of NCX1, and the subcellular location of NCX1 within the cell. Here we investigate the molecular organization of NCX1 within the cardiac myocyte. We show that NCX1 is dynamically phosphorylated by protein kinase A ( PKA)dependent phosphorylation in vitro. We also provide evidence that the regulation of this phosphorylation is attributed to the existence of an NCX1 macromolecular complex. Specifically, we show that the macromolecular complex includes both the catalytic and regulatory subunits of PKA. However, only the RI regulatory subunit is found in this macromolecular complex, not RII. Other critical regulatory enzymes are also associated with NCX1, including protein kinase C (PKC) and two serine/ threonine protein phosphatases, PP1 and PP2A. Importantly, the protein kinase A-anchoring protein, mAKAP, is found and its presence in the macromolecular complex suggests that these regulatory enzymes are coordinately positioned to regulate NCX1 as has been found in diverse cells for a number of channel proteins. Dual immunocytochemical staining showed the colocalization of NCX1 protein with mAKAP and PKA-RI proteins in cardiomyocytes. Finally, leucine/isoleucine zipper motifs have been identified as possible sites of interaction. Our finding of an NCX1 macromolecular complex in heart suggests how NCX1 regulation is achieved in heart and other cells. The existence of the NCX1 macromolecular complex may also provide an explanation for recent controversial findings.	Univ Maryland, Dept Microbiol & Immunol, Sch Med, Baltimore, MD 21201 USA; Univ Maryland, Ctr Med Biotechnol, Inst Mol Cardiol, Baltimore, MD 21201 USA; Univ Maryland, Inst Biotechnol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Schulze, DH (corresponding author), Univ Maryland, Dept Microbiol & Immunol, Sch Med, 655 W Baltimore Ave, Baltimore, MD 21201 USA.		Lederer, William/B-1285-2010					Amieux PS, 1997, J BIOL CHEM, V272, P3993, DOI 10.1074/jbc.272.7.3993; Bauman AL, 2002, NAT CELL BIOL, V4, pE203, DOI 10.1038/ncb0802-e203; BEAUGE L, 1991, ANN NY ACAD SCI, V639, P147, DOI 10.1111/j.1749-6632.1991.tb17298.x; Berberian G, 1998, AM J PHYSIOL-CELL PH, V274, pC724, DOI 10.1152/ajpcell.1998.274.3.C724; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Boerth SR, 1996, ANN NY ACAD SCI, V779, P536, DOI 10.1111/j.1749-6632.1996.tb44831.x; BOERTH SR, 1994, CIRC RES, V74, P354, DOI 10.1161/01.RES.74.2.354; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; CARL SL, 1995, J CELL BIOL, V129, P673, DOI 10.1083/jcb.129.3.673; CARONI P, 1983, EUR J BIOCHEM, V132, P451, DOI 10.1111/j.1432-1033.1983.tb07383.x; Chen FH, 1997, J MOL CELL CARDIOL, V29, P2621, DOI 10.1006/jmcc.1997.0475; Cheng GM, 1999, J BIOL CHEM, V274, P12819, DOI 10.1074/jbc.274.18.12819; COLLINS A, 1992, J PHYSIOL-LONDON, V454, P27, DOI 10.1113/jphysiol.1992.sp019253; CONDRESCU M, 1995, J BIOL CHEM, V270, P9137, DOI 10.1074/jbc.270.16.9137; CORBIN JD, 1977, J BIOL CHEM, V252, P3854; Darman RB, 2001, J BIOL CHEM, V276, P34359, DOI 10.1074/jbc.C100368200; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; DIPOLO R, 1987, BIOCHIM BIOPHYS ACTA, V897, P347, DOI 10.1016/0005-2736(87)90432-9; DiPolo R, 1997, FEBS LETT, V401, P6, DOI 10.1016/S0014-5793(96)01416-0; DIPOLO R, 1974, J GEN PHYSIOL, V64, P503, DOI 10.1085/jgp.64.4.503; DIPOLO R, 1994, AM J PHYSIOL, V266, pC1382, DOI 10.1152/ajpcell.1994.266.5.C1382; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; DOERING AE, 1993, J PHYSIOL-LONDON, V466, P481; DOERING AE, 1994, J PHYSIOL-LONDON, V480, P9, DOI 10.1113/jphysiol.1994.sp020336; Dyck C, 1998, J BIOL CHEM, V273, P12981, DOI 10.1074/jbc.273.21.12981; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; FRANK JS, 1992, J CELL BIOL, V117, P337, DOI 10.1083/jcb.117.2.337; HAN XQ, 1995, CIRC RES, V76, P664, DOI 10.1161/01.RES.76.4.664; Haworth RA, 1996, ANN NY ACAD SCI, V779, P464, DOI 10.1111/j.1749-6632.1996.tb44821.x; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1991, NATURE, V352, P715, DOI 10.1038/352715a0; HILGEMANN DW, 1982, J GEN PHYSIOL, V100, P933; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; Iwamoto T, 2000, J BIOL CHEM, V275, P38571, DOI 10.1074/jbc.M003788200; IWAMOTO T, 1995, J BIOL CHEM, V270, P8996, DOI 10.1074/jbc.270.15.8996; Iwamoto T, 1999, FEBS LETT, V446, P264, DOI 10.1016/S0014-5793(99)00218-5; Iwamoto T, 1998, BIOCHEMISTRY-US, V37, P17230, DOI 10.1021/bi981521q; Iwamoto T, 1996, J BIOL CHEM, V271, P13609, DOI 10.1074/jbc.271.23.13609; Kapiloff MS, 1999, J CELL SCI, V112, P2725; KIEVAL RS, 1992, AM J PHYSIOL, V263, pC545, DOI 10.1152/ajpcell.1992.263.2.C545; LI ZP, 1991, J BIOL CHEM, V266, P1014; LI ZP, 1993, J BIOL CHEM, V268, P11489; Linck B, 1998, AM J PHYSIOL-CELL PH, V274, pC415, DOI 10.1152/ajpcell.1998.274.2.C415; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Marx SO, 2002, SCIENCE, V295, P496, DOI 10.1126/science.1066843; Marx SO, 2001, J CELL BIOL, V153, P699, DOI 10.1083/jcb.153.4.699; MATSUOKA S, 1994, J PHYSIOL-LONDON, V476, P443, DOI 10.1113/jphysiol.1994.sp020146; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; MCCARTNEY S, 1995, J BIOL CHEM, V270, P9327, DOI 10.1074/jbc.270.16.9327; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Mughal M, 2003, BIOPHYS J, V84, p151A; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; O'Rourke B, 1999, CIRC RES, V84, P562, DOI 10.1161/01.RES.84.5.562; Perchenet L, 2000, PFLUG ARCH EUR J PHY, V439, P822, DOI 10.1007/s004240051010; Perkins GA, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-17; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; Qiu ZY, 2001, J BIOL CHEM, V276, P194, DOI 10.1074/jbc.M005571200; Reiken S, 2003, J BIOL CHEM, V278, P444, DOI 10.1074/jbc.M207028200; Ruknudin A, 2002, ANN NY ACAD SCI, V976, P209; Ruknudin A, 2000, J PHYSIOL-LONDON, V529, P599, DOI 10.1111/j.1469-7793.2000.00599.x; Saba RI, 2001, BIOCHEMISTRY-US, V40, P3324, DOI 10.1021/bi0010672; Santacruz-Toloza L, 2000, J BIOL CHEM, V275, P182, DOI 10.1074/jbc.275.1.182; Shigekawa M, 1996, ANN NY ACAD SCI, V779, P249, DOI 10.1111/j.1749-6632.1996.tb44791.x; Smith FD, 2002, CURR BIOL, V12, pR32, DOI 10.1016/S0960-9822(01)00646-7; Studer R, 1997, BASIC RES CARDIOL, V92, P53, DOI 10.1007/BF00794068; STUDER R, 1994, CIRC RES, V75, P443, DOI 10.1161/01.RES.75.3.443; Swynghedauw B, 1999, PHYSIOL REV, V79, P215, DOI 10.1152/physrev.1999.79.1.215; Taylor SS, 1999, PHARMACOL THERAPEUT, V82, P133, DOI 10.1016/S0163-7258(99)00007-8; Wei SK, 2003, CIRC RES, V92, P897, DOI 10.1161/01.RES.0000069701.19660.14; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	72	105	113	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28849	28855		10.1074/jbc.M300754200	http://dx.doi.org/10.1074/jbc.M300754200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12754202	hybrid			2022-12-25	WOS:000184421100063
J	Uthaiah, RC; Praefcke, GJK; Howard, JC; Herrmann, C				Uthaiah, RC; Praefcke, GJK; Howard, JC; Herrmann, C			IIGP1, an interferon-gamma-inducible 47-kDa GTPase of the mouse, showing cooperative enzymatic activity and GTP-dependent multimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLATE-BINDING PROTEIN-1; GUANINE-NUCLEOTIDE EXCHANGE; ELONGATION-FACTOR-TS; TRANSITION-STATE ANALOG; INDUCED MXA PROTEIN; ENDOPLASMIC-RETICULUM; KINETIC MECHANISM; STRUCTURAL BASIS; FACTOR-TU; ANTIVIRAL ACTIVITY	IIGP1 belongs to a well defined family of 47-kDa GTPases whose members are present at low resting levels in mouse cells but are strongly induced transcriptionally by interferons and are implicated in cell-autonomous resistance to intracellular pathogens. Recombinant IIGP1 was expressed in Escherichia coli and purified to homogeneity. Here we present a detailed biochemical characterization of IIGP1 using various biochemical and biophysical methods. IIGP1 binds to GTP and GDP with dissociation constants in the micromolar range with at least 10 times higher affinity for GDP than for GTP. IIGP1 hydrolyzes GTP to GDP, and the GTPase activity is concentration-dependent with a GTP turnover rate of 2 min(-1) under saturating protein concentrations. Functional interaction between IIGP1 molecules is shown by nucleotide-dependent oligomerization in vitro. Both cooperative hydrolysis of GTP and GTP-dependent oligomerization are blocked in a mutant form of IIGP1 modified at the C terminus. IIGP1 shares micromolar nucleotide affinities and oligomerization-dependent hydrolytic activity with the 67-kDa GTPase hGBP1 ( induced by type I and type II interferons), with the antiviral Mx proteins ( interferon type I-induced) and with the paradigm of the self-activating large GTPases, the dynamins, with which Mx proteins show homology. The higher relative affinity for GDP and the relatively low GTPase activity distinguish IIGP1, but this study clearly adds IIGP1 and thus the p47 GTPases to the small group of cooperative GTPase families that appear to characterize the development of intracellular resistance during the interferon response to infection. The present analysis provides essential parameters to understand the molecular mechanism by which IIGP1 participates in this complex resistance program.	Univ Cologne, Inst Genet, D-50674 Cologne, Germany; Max Planck Inst Mol Physiol, Dept Biol Struct, D-44227 Dortmund, Germany	University of Cologne; Max Planck Society	Howard, JC (corresponding author), Univ Cologne, Inst Genet, Zulpicher Str 47, D-50674 Cologne, Germany.		Chottekalapanda, Revathy Uthaiah/AAO-9148-2020	Chottekalapanda, Revathy Uthaiah/0000-0002-6479-8264; Praefcke, Gerrit/0000-0001-8818-1499; Howard, Jonathan/0000-0003-2756-5143				Accola MA, 2002, J BIOL CHEM, V277, P21829, DOI 10.1074/jbc.M201641200; Anderson SL, 1999, VIROLOGY, V256, P8, DOI 10.1006/viro.1999.9614; Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; Binns DD, 2000, BIOCHEMISTRY-US, V39, P7188, DOI 10.1021/bi000033r; Binns DD, 1999, J PROTEIN CHEM, V18, P277, DOI 10.1023/A:1021083211267; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Boehm U, 1998, J IMMUNOL, V161, P6715; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Carlow DA, 1998, J IMMUNOL, V161, P2348; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Collazo CM, 2001, J EXP MED, V194, P181, DOI 10.1084/jem.194.2.181; Danino D, 2001, CURR OPIN CELL BIOL, V13, P454, DOI 10.1016/S0955-0674(00)00236-2; ECCLESTON JF, 1984, J BIOL CHEM, V259, P2997; Eccleston JF, 2002, EUR BIOPHYS J BIOPHY, V31, P275, DOI 10.1007/s00249-002-0226-2; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Gromadski KB, 2002, BIOCHEMISTRY-US, V41, P162, DOI 10.1021/bi015712w; Guenzi E, 2001, EMBO J, V20, P5568, DOI 10.1093/emboj/20.20.5568; Haller O, 2002, TRAFFIC, V3, P710, DOI 10.1034/j.1600-0854.2002.31003.x; Halonen SK, 2001, INFECT IMMUN, V69, P5573, DOI 10.1128/IAI.69.9.5573-5576.2001; Herrmann C, 1996, PROG BIOPHYS MOL BIO, V66, P1, DOI 10.1016/S0079-6107(96)00015-6; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; KLEINEKE J, 1979, FEBS LETT, V107, P198, DOI 10.1016/0014-5793(79)80494-9; Kochs G, 2002, J BIOL CHEM, V277, P14172, DOI 10.1074/jbc.M200244200; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; Praefcke GJK, 1999, J MOL BIOL, V292, P321, DOI 10.1006/jmbi.1999.3062; Prakash B, 2000, EMBO J, V19, P4555, DOI 10.1093/emboj/19.17.4555; Prakash B, 2000, NATURE, V403, P567, DOI 10.1038/35000617; RICHTER MF, 1995, J BIOL CHEM, V270, P13512, DOI 10.1074/jbc.270.22.13512; Riemer C, 2000, J VIROL, V74, P10245, DOI 10.1128/JVI.74.21.10245-10248.2000; ROMERO G, 1985, J BIOL CHEM, V260, P6167; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schlichting I, 1999, NAT STRUCT BIOL, V6, P721, DOI 10.1038/11485; SCHWEMMLE M, 1995, J BIOL CHEM, V270, P13518, DOI 10.1074/jbc.270.22.13518; Song BD, 2003, BIOCHEMISTRY-US, V42, P1369, DOI 10.1021/bi027062h; Stickney JT, 2000, MOL BIOL CELL, V11, P2191, DOI 10.1091/mbc.11.7.2191; Taylor GA, 1997, J BIOL CHEM, V272, P10639; Taylor GA, 2000, P NATL ACAD SCI USA, V97, P751, DOI 10.1073/pnas.97.2.751; Taylor GA, 1996, J BIOL CHEM, V271, P20399, DOI 10.1074/jbc.271.34.20399; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Zerrahn J, 2002, J IMMUNOL, V168, P3428, DOI 10.4049/jimmunol.168.7.3428; Zhang BL, 2001, J BIOL CHEM, V276, P8958, DOI 10.1074/jbc.M008720200; Zhang PJ, 2001, NAT CELL BIOL, V3, P922, DOI 10.1038/ncb1001-922	50	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29336	29343		10.1074/jbc.M211973200	http://dx.doi.org/10.1074/jbc.M211973200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12732635	hybrid			2022-12-25	WOS:000184421100119
J	Pircher, PC; Kitto, JL; Petrowski, ML; Tangirala, RK; Bischoff, ED; Schulman, IG; Westin, SK				Pircher, PC; Kitto, JL; Petrowski, ML; Tangirala, RK; Bischoff, ED; Schulman, IG; Westin, SK			Farnesoid X receptor regulates bile acid-amino acid conjugation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTOR; SALT EXPORT PUMP; HUMAN LIVER; FEEDBACK-REGULATION; BINDING PROTEIN; GENE; IDENTIFICATION; BIOSYNTHESIS; FXR; COA	The farnesoid X receptor (FXR; NR1H4) regulates bile acid and lipid homeostasis by acting as an intracellular bile acid-sensing transcription factor. Several identified FXR target genes serve critical roles in the synthesis and transport of bile acids as well as in lipid metabolism. Here we used Affymetrix micro-array and Northern analysis to demonstrate that two enzymes involved in conjugation of bile acids to taurine and glycine, namely bile acid-CoA synthetase (BACS) and bile acid-CoA: amino acid N-acetyltransferase (BAT) are induced by FXR in rat liver. Analysis of the human BACS and BAT genes revealed the presence of functional response elements in the proximal promoter of BACS and in the intronic region between exons 1 and 2 of the BAT gene. The response elements resemble the consensus FXR binding site consisting of two nuclear receptor half-sites organized as an inverted repeat and separated by a single nucleotide (IR-1). These response elements directly bind FXR/retinoid X receptor (RXR) heterodimers and confer the activity of FXR ligands in transient transfection experiments. Further mutational analysis confirms that the IR-1 sequence of the BACS and BAT genes mediate transactivation by FXR/RXR heterodimers. Finally, Fisher rats treated with the synthetic FXR ligand GW4064 clearly show increased transcript levels of both the BACS and BAT mRNA. These studies demonstrate a mechanism by which FXR regulates bile acid amidation, a critical component of the enterohepatic circulation of bile acids.	X Ceptor Therapeut Inc, Dept Biol, San Diego, CA 92121 USA		Westin, SK (corresponding author), X Ceptor Therapeut Inc, Dept Biol, 4757 Nexus Ctr Dr, San Diego, CA 92121 USA.							Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Auwerx J, 1999, CELL, V97, P161; Bahar RJ, 1999, GASTROENTEROL CLIN N, V28, P27, DOI 10.1016/S0889-8553(05)70042-X; Carlton VEH, 2003, NAT GENET, V34, P91, DOI 10.1038/ng1147; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; CZUBA B, 1981, BIOCHEM J, V195, P263, DOI 10.1042/bj1950263; Denson LA, 2001, GASTROENTEROLOGY, V121, P140, DOI 10.1053/gast.2001.25503; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Helledie T, 2002, J BIOL CHEM, V277, P26821, DOI 10.1074/jbc.M111295200; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; Lambert G, 2003, J BIOL CHEM, V278, P2563, DOI 10.1074/jbc.M209525200; Li-Hawkins J, 2002, J CLIN INVEST, V110, P1191, DOI 10.1172/JCI200216309; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127; Noe J, 2002, GASTROENTEROLOGY, V123, P1659, DOI 10.1053/gast.2002.36587; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Russell DW, 1999, CELL, V97, P539, DOI 10.1016/S0092-8674(00)80763-1; SCHERSTE.T, 1967, BIOCHIM BIOPHYS ACTA, V141, P155, DOI 10.1016/0304-4165(67)90254-1; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Solaas K, 2000, J LIPID RES, V41, P1154; Song CS, 2001, J BIOL CHEM, V276, P42549, DOI 10.1074/jbc.M107557200; Steinberg SJ, 2000, J BIOL CHEM, V275, P15605, DOI 10.1074/jbc.C000015200; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; VESSEY DA, 1977, BIOCHEM J, V163, P181, DOI 10.1042/bj1630181; Vlahcevic ZR, 1999, GASTROENTEROL CLIN N, V28, P1, DOI 10.1016/S0889-8553(05)70041-8; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Zhang Y, 2001, J BIOL CHEM, V276, P43018, DOI 10.1074/jbc.M107823200	29	137	141	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27703	27711		10.1074/jbc.M302128200	http://dx.doi.org/10.1074/jbc.M302128200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12754200	hybrid			2022-12-25	WOS:000184242700048
J	Yun, YS; Lee, TH; Nam, GH; Jang, DS; Shin, SJ; Oh, BH; Choi, KY				Yun, YS; Lee, TH; Nam, GH; Jang, DS; Shin, SJ; Oh, BH; Choi, KY			Origin of the different pH activity profile in two homologous ketosteroid isomerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTIDA BIOTYPE-B; DELTA(5)-3-KETOSTEROID ISOMERASE; PSEUDOMONAS-PUTIDA; 3-OXO-DELTA(5)-STEROID ISOMERASE; DELTA-5-3-KETOSTEROID ISOMERASE; 3-OXO-DELTA-5-STEROID ISOMERASE; CATALYTIC MECHANISM; CRYSTAL-STRUCTURE; HYDROGEN-BOND; DEPENDENCE	Two homologous Delta(5)-3-ketosteroid isomerases from Comamonas testosteroni (TI-WT) and Pseudomonas putida biotype B (PI-WT) exhibit different pH activity profiles. TI-WT loses activity below pH 5.0 due to the protonation of the conserved catalytic base, Asp-38, while PI-WT does not. Based on the structural analysis of PI-WT, the critical catalytic base, Asp-38, was found to form a hydrogen bond with the indole ring NH of Trp-116, which is homologously replaced with Phe-116 in TI-WT. To investigate the role of Trp-116, we prepared the F116W mutant of TI-WT (TI-F116W) and the W116F mutant of PI-WT (PI-W116F) and compared kinetic parameters of those mutants at different pH levels. PI-W116F exhibited significantly decreased catalytic activity at acidic pH like TI-WT, whereas TI-F116W maintained catalytic activity at acidic pH like PI-WT and increased the k(cat)/K-m value by 2.5- to 4.7-fold compared with TI-WT at pH 3.8. The crystal structure of TI-F116W clearly showed that the indole ring NH of Trp-116 could form a hydrogen bond with the carboxyl oxygen of Asp-38 like that of PI-WT. The present results demonstrate that the activities of both PI-WT and TI-F116W at low pH were maintained by a tryptophan, which was able not only to lower the pK(a) value of the catalytic base but also to increase the substrate affinity. This is one example of the strategy nature can adopt to evolve the diversity of the catalytic function in the enzymes. Our results provide insight into deciphering the molecular evolution of the enzyme and creating novel enzymes by protein engineering.	Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Natl Res Ctr Prot Folding & Engn, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Natl Creat Res Iniat, Ctr Biomol Recognit, Pohang 790784, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)	Choi, KY (corresponding author), Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea.		Oh, Byung-Ha/C-2061-2011					ALBERT B, MOL BIOL CELL, P89; ALBERT B, MOL BIOL CELL, P507; Batzold F H, 1976, Adv Enzyme Regul, V14, P243, DOI 10.1016/0065-2571(76)90016-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen RD, 2001, TRENDS BIOTECHNOL, V19, P13, DOI 10.1016/S0167-7799(00)01522-5; Cho HS, 1998, BIOCHEMISTRY-US, V37, P8325, DOI 10.1021/bi9801614; Cho HS, 1999, J BIOL CHEM, V274, P32863, DOI 10.1074/jbc.274.46.32863; Choi G, 2000, BIOCHEMISTRY-US, V39, P903, DOI 10.1021/bi991579k; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; COPELAND RA, 1993, METHODS PROTEIN ANAL, P51; Fersht A., 1999, STRUCTURE MECH PROTE, P169; Gerlt JA, 2001, ANNU REV BIOCHEM, V70, P209, DOI 10.1146/annurev.biochem.70.1.209; Ha NC, 2001, CURR OPIN STRUC BIOL, V11, P674, DOI 10.1016/S0959-440X(01)00268-8; HAWKINSON DC, 1994, BIOCHEMISTRY-US, V33, P12172, DOI 10.1021/bi00206a021; HAWKINSON DC, 1991, BIOCHEMISTRY-US, V30, P6956, DOI 10.1021/bi00242a021; IPPOLITO JA, 1990, J MOL BIOL, V215, P457, DOI 10.1016/S0022-2836(05)80364-X; Kim DH, 1999, BIOCHEMISTRY-US, V38, P13810, DOI 10.1021/bi991040m; KIM SW, 1995, J BACTERIOL, V177, P2602, DOI 10.1128/jb.177.9.2602-2605.1995; Kim SW, 1997, BIOCHEMISTRY-US, V36, P14030, DOI 10.1021/bi971546+; Kim SW, 1997, J BACTERIOL, V179, P7742, DOI 10.1128/jb.179.24.7742-7747.1997; KNOWLES JR, 1976, CRC CR REV BIOCH MOL, V4, P165, DOI 10.3109/10409237609105457; LANGSETMO K, 1991, BIOCHEMISTRY-US, V30, P7603, DOI 10.1021/bi00244a032; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Pollack RM, 1999, ARCH BIOCHEM BIOPHYS, V370, P9, DOI 10.1006/abbi.1999.1384; POLLACK RM, 1986, BIOCHEMISTRY-US, V25, P1905, DOI 10.1021/bi00356a011; RUSSELL AJ, 1987, NATURE, V328, P496, DOI 10.1038/328496a0; RUSSELL AJ, 1987, J MOL BIOL, V193, P803, DOI 10.1016/0022-2836(87)90360-3; Samanta U, 2000, PROTEINS, V38, P288, DOI 10.1002/(SICI)1097-0134(20000215)38:3<288::AID-PROT5>3.3.CO;2-Z; SCHWAB JM, 1990, CHEM REV, V90, P1203, DOI 10.1021/cr00105a007; SMITH SB, 1980, J BIOL CHEM, V255, P2685; SPOMER WE, 1971, BIOCHIM BIOPHYS ACTA, V235, P164, DOI 10.1016/0005-2744(71)90044-1; Thornburg LD, 1998, BIOCHEMISTRY-US, V37, P10499, DOI 10.1021/bi980099a; WEINTRAUB H, 1970, EUR J BIOCHEM, V12, P217, DOI 10.1111/j.1432-1033.1970.tb00840.x; Wu ZR, 1997, SCIENCE, V276, P415, DOI 10.1126/science.276.5311.415; XUE L, 1991, BIOCHEMISTRY-US, V30, P4991, DOI 10.1021/bi00234a022	35	11	12	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28229	28236		10.1074/jbc.M302166200	http://dx.doi.org/10.1074/jbc.M302166200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12734184	hybrid			2022-12-25	WOS:000184242700112
J	Yunoue, S; Tokuo, H; Fukunaga, K; Feng, LP; Ozawa, T; Nishi, T; Kikuchi, A; Hattori, S; Kuratsu, J; Saya, H; Araki, N				Yunoue, S; Tokuo, H; Fukunaga, K; Feng, LP; Ozawa, T; Nishi, T; Kikuchi, A; Hattori, S; Kuratsu, J; Saya, H; Araki, N			Neurofibromatosis type I tumor suppressor neurofibromin regulates neuronal differentiation via its GTPase-activating protein function toward Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PC12 CELLS; GENE-PRODUCT; HIPPOCAMPAL-NEURONS; SIGNAL-TRANSDUCTION; LEARNING-DEFICITS; MOUSE MODEL; KINASE; DOMAIN; NF1	Neurofibromin, the neurofibromatosis type 1 (NF1) gene product, contains a central domain homologous to a family of proteins known as Ras-GTPase-activating proteins (Ras-GAPs), which function as negative regulators of Ras. The loss of neurofibromin function has been thought to be implicated in the abnormal regulation of Ras in NF1-related pathogenesis. In this study, we found a novel role of neurofibromin in neuronal differentiation in conjunction with the regulation of Ras activity via its GAP-related domain (GRD) in neuronal cells. In PC12 cells, time-dependent increases in the GAP activity of cellular neurofibromin (NF1-GAP) were detected after NGF stimulation, which were correlated with the down-regulation of Ras activity during neurite elongation. Interestingly, the NF1-GAP increase was due to the induction of alternative splicing of NF1-GRD type I triggered by the NGF-induced Ras activation. Dominant-negative (DN) forms of NF1-GRD type I significantly inhibited the neurite extension of PC12 cells via regulation of the Ras state. NF1-GRD-DN also reduced axonal and dendritic branching/extension of rat embryonic hippocampal neurons. These results demonstrate that the mutual regulation of Ras and NF1-GAP is essential for normal neuronal differentiation and that abnormal regulation in neuronal cells may be implicated in NF1-related learning and memory disturbance.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Neurosurg, Kumamoto 8600811, Japan; Kagoshima Univ, Fac Med, Dept Neurosurg, Kagoshima 8908520, Japan; Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Miyagi 9808577, Japan; Tohoku Univ, Fac Pharmaceut Sci, Sendai, Miyagi 9808577, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Biochem, Hiroshima 7348551, Japan; Univ Tokyo, Inst Med Sci, Div Cellular Genome Proteom, Tokyo, Japan	Kumamoto University; Kumamoto University; Kagoshima University; Tohoku University; Tohoku University; Hiroshima University; University of Tokyo	Araki, N (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan.		Fukunaga, Kohji/AAI-8811-2021; Saya, Hideyuki/J-4325-2013	Fukunaga, Kohji/0000-0001-8526-2824; Tokuo, Hiroshi/0000-0002-7614-7805				Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BERNARDS A, 1995, BBA-REV CANCER, V1242, P43, DOI 10.1016/0304-419X(95)00003-X; BOLLAG G, 1993, EMBO J, V12, P1923, DOI 10.1002/j.1460-2075.1993.tb05841.x; Burchill SA, 1998, J NEUROL SCI, V157, P129, DOI 10.1016/S0022-510X(98)00083-5; Burry RW, 2001, J NEUROSCI RES, V63, P45, DOI 10.1002/1097-4547(20010101)63:1<45::AID-JNR6>3.0.CO;2-Y; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; Costa RM, 2002, NATURE, V415, P526, DOI 10.1038/nature711; Costa RM, 2001, NAT GENET, V27, P399, DOI 10.1038/86898; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DOTTI CG, 1988, J NEUROSCI, V8, P1454; FUKUNAGA K, 1992, J BIOL CHEM, V267, P22527; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Guo HF, 2000, NATURE, V403, P895, DOI 10.1038/35002593; HATTORI S, 1992, ONCOGENE, V7, P481; HOSHINO M, 1988, MOL CELL BIOL, V8, P4169, DOI 10.1128/MCB.8.10.4169; Ingram DA, 2001, J EXP MED, V194, P57, DOI 10.1084/jem.194.1.57; Izawa I, 1996, FEBS LETT, V382, P53, DOI 10.1016/0014-5793(96)00137-8; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; Kita Y, 1998, J CELL SCI, V111, P907; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Li SW, 1997, J BIOL CHEM, V272, P19328, DOI 10.1074/jbc.272.31.19328; Metheny LJ, 1996, EXP CELL RES, V228, P44, DOI 10.1006/excr.1996.0297; NISHI T, 1991, ONCOGENE, V6, P1555; NORDLUND M, 1993, J NEUROSCI, V13, P1588; North K, 2000, AM J MED GENET, V97, P119, DOI 10.1002/1096-8628(200022)97:2<119::AID-AJMG3>3.0.CO;2-3; NUR EKM, 1993, J BIOL CHEM, V268, P22331; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; REY I, 1994, ONCOGENE, V9, P685; Scheffzek K, 1998, EMBO J, V17, P4313, DOI 10.1093/emboj/17.15.4313; Silva AJ, 1997, NAT GENET, V15, P281, DOI 10.1038/ng0397-281; Smith MA, 1997, J BIOL CHEM, V272, P15675, DOI 10.1074/jbc.272.25.15675; STEPHENS K, 1987, Genomics, V1, P353, DOI 10.1016/0888-7543(87)90037-1; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; Tokuo H, 2001, FEBS LETT, V494, P48, DOI 10.1016/S0014-5793(01)02309-2; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	42	72	77	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26958	26969		10.1074/jbc.M209413200	http://dx.doi.org/10.1074/jbc.M209413200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12730209	hybrid			2022-12-25	WOS:000184155700086
J	Gong, X; Xie, T; Yu, L; Hesterberg, M; Scheide, D; Friedrich, T; Yu, CA				Gong, X; Xie, T; Yu, L; Hesterberg, M; Scheide, D; Friedrich, T; Yu, CA			The ubiquinone-binding site in NADH : ubiquinone oxidoreductase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING NADH; MITOCHONDRIAL COMPLEX-I; HEREDITARY OPTIC NEUROPATHY; RESPIRATORY-CHAIN; QUINONE-BINDING; SUBUNIT; REDUCTASE; MEMBRANE; IDENTIFICATION; DOMAIN	An azido-ubiquinone derivative, 3-azido-2-methyl-5-methoxy[ H-3]-6-decyl-1,4-benzoquinone ([H-3] azido-Q), was used to study the ubiquinone/protein interaction and to identify the ubiquinone-binding site in Escherichia coli NADH: ubiquinone oxidoreductase ( complex I). The purified complex I showed no loss of activity after incubation with a 20-fold molar excess of [H-3] azido-Q in the dark. Illumination of the incubated sample with long wavelength UV light for 10 min at 0 degreesC caused a 40% decrease of NADH: ubiquinone oxidoreductase activity. SDS-PAGE of the complex labeled with [H-3] azido-Q followed by analysis of the radioactivity distribution among the subunits revealed that subunit NuoM was heavily labeled, suggesting that this protein houses the Q-binding site. When the [H-3] azido-Q-labeled NuoM was purified from the labeled reductase by means of preparative SDS-PAGE, a 3-azido-2-methyl-5-methoxy-6-decyl-1,4- benzoquinone-linked peptide, with a retention time of 41.4 min, was obtained by high performance liquid chromatography of the protease K digest of the labeled subunit. This peptide had a partial NH2-terminal amino acid sequence of NH2-VMLIAILALV-, which corresponds to amino acid residues 184 - 193 of NuoM. The secondary structure prediction of NuoM using the Toppred hydropathy analysis showed that the Q-binding peptide overlaps with a proposed Q-binding motif located in the middle of the transmembrane helix 5 toward the cytoplasmic side of the membrane. Using the PHDhtm hydropathy plot, the labeled peptide is located in the transmembrane helix 4 toward the periplasmic side of the membrane.	Oklahoma State Univ, Dept Biochem & Mol Biol, Noble Res Ctr 255, Stillwater, OK 74078 USA; Univ Freiburg, Inst Organ Chem & Biochem, D-79104 Freiburg, Germany	Oklahoma State University System; Oklahoma State University - Stillwater; University of Freiburg	Yu, CA (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Noble Res Ctr 255, Stillwater, OK 74078 USA.	cayuq@okstate.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030721, R37GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; Bader MW, 2000, J BIOL CHEM, V275, P26082, DOI 10.1074/jbc.M003850200; Bottcher B, 2002, J BIOL CHEM, V277, P17970, DOI 10.1074/jbc.M112357200; Brandt U, 1997, BBA-BIOENERGETICS, V1318, P79, DOI 10.1016/S0005-2728(96)00141-7; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; Darrouzet E, 1998, FEBS LETT, V431, P34, DOI 10.1016/S0014-5793(98)00719-4; Dupuis A, 2001, J BIOENERG BIOMEMBR, V33, P159, DOI 10.1023/A:1010770600418; EARLEY FGP, 1984, BIOCHEM J, V224, P525, DOI 10.1042/bj2240525; EARLEY FGP, 1987, FEBS LETT, V219, P108, DOI 10.1016/0014-5793(87)81200-0; ESPOSTI MD, 1994, BBA-BIOENERGETICS, V1187, P116, DOI 10.1016/0005-2728(94)90095-7; ESPOSTI MD, 1994, FEBS LETT, V352, P375, DOI 10.1016/0014-5793(94)00971-6; Fisher N, 2000, J MOL BIOL, V296, P1153, DOI 10.1006/jmbi.2000.3509; Friedrich T, 1997, J THEOR BIOL, V187, P529, DOI 10.1006/jtbi.1996.0387; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; FRIEDRICH T, 1994, EUR J BIOCHEM, V219, P691, DOI 10.1111/j.1432-1033.1994.tb19985.x; Friedrich T, 2000, FEBS LETT, V479, P1, DOI 10.1016/S0014-5793(00)01867-6; Friedrich Thorsten, 1996, P205; HOFHAUS G, 1993, EMBO J, V12, P3043, DOI 10.1002/j.1460-2075.1993.tb05973.x; KIKUNO R, 1985, FEBS LETT, V189, P85, DOI 10.1016/0014-5793(85)80847-4; LEE GY, 1995, J BIOL CHEM, V270, P6193, DOI 10.1074/jbc.270.11.6193; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; Lunardi J, 1998, BBA-MOL BASIS DIS, V1407, P114, DOI 10.1016/S0925-4439(98)00036-2; Majander A, 1996, EUR J BIOCHEM, V239, P201, DOI 10.1111/j.1432-1033.1996.0201u.x; MARINETTI TD, 1979, BIOCHEMISTRY-US, V18, P3126, DOI 10.1021/bi00581a033; Nakamaru-Ogiso E, 2003, BIOCHEMISTRY-US, V42, P746, DOI 10.1021/bi0269660; Ohshima M, 1998, BIOCHEMISTRY-US, V37, P6436, DOI 10.1021/bi9800202; Rasmussen T, 2001, BIOCHEMISTRY-US, V40, P6124, DOI 10.1021/bi0026977; Redfearn E. R., 1967, METHOD ENZYMOL, V10, P381, DOI [10.1016/0076-6879(67)10071-2, DOI 10.1016/0076-6879(67)10071-2]; ROST B, 1995, PROTEIN SCI, V4, P521; Sazanov LA, 2000, J MOL BIOL, V302, P455, DOI 10.1006/jmbi.2000.4079; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schuler F, 1999, P NATL ACAD SCI USA, V96, P4149, DOI 10.1073/pnas.96.7.4149; Schuler F, 2001, BBA-BIOENERGETICS, V1506, P79, DOI 10.1016/S0005-2728(01)00183-9; Shenoy SK, 1997, J BIOL CHEM, V272, P17867, DOI 10.1074/jbc.272.28.17867; Spehr V, 1999, BIOCHEMISTRY-US, V38, P16261, DOI 10.1021/bi9919605; VINOGRADOV AD, 1993, J BIOENERG BIOMEMBR, V25, P367, DOI 10.1007/BF00762462; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WEIDNER U, 1993, J MOL BIOL, V233, P109, DOI 10.1006/jmbi.1993.1488; Xie T, 2002, J BIOL CHEM, V277, P1649, DOI 10.1074/jbc.M108697200; Yagi T, 2003, BIOCHEMISTRY-US, V42, P2266, DOI 10.1021/bi027158b; Yang XD, 1998, J BIOL CHEM, V273, P31916, DOI 10.1074/jbc.273.48.31916; YU L, 1985, J BIOL CHEM, V260, P963	43	60	62	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25731	25737		10.1074/jbc.M302361200	http://dx.doi.org/10.1074/jbc.M302361200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730198	hybrid			2022-12-25	WOS:000183920200058
J	Nakajima, H; Toyoshima-Morimoto, F; Taniguchi, E; Nishida, E				Nakajima, H; Toyoshima-Morimoto, F; Taniguchi, E; Nishida, E			Identification of a consensus motif for Plk (Polo-like kinase) phosphorylation reveals Myt1 as a Plk1 substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE-REGULATED KINASE; HUMAN WEE1 KINASE; CELL-CYCLE; SUBCELLULAR-LOCALIZATION; INHIBITORY KINASE; MITOTIC KINASES; PROTEIN-KINASE; CDC2; PLX1; P34(CDC2)	Plk1 ( Polo-like kinase 1), an evolutionarily conserved serine/threonine kinase, is crucially involved in multiple events during the M phase. Here we have identified a consensus phosphorylation sequence for Plk1, by testing the ability of systematically mutated peptides derived from human Cdc25C to serve as a substrate for Plk1. The obtained results show that a hydrophobic amino acid at position +1 carboxyl-terminal of phosphorylated Ser/Thr and an acidic amino acid at position -2 are important for optimal phosphorylation by Plk1. We have then found that Myt1, an inhibitory kinase for MPF, has a number of putative phosphorylation sites for Plk1 in its COOH-terminal portion. While wild-type Myt1 ( Myt1-WT) served as a good substrate for Plk1 in vitro, a mutant Myt1 (Myt1-4A), in which the four putative phosphorylation sites are replaced by alanines, did not. In nocodazole-treated cells, Myt1-WT, but not Myt1-4A, displayed its mobility shift in gel electrophoresis, due to phosphorylation. These results suggest that Plk1 phosphorylates Myt1 during M phase. Thus, this study identifies a novel substrate for Plk1 by determining a consensus phosphorylation sequence by Plk1.	Kyoto Univ, Dept Cell & Dev Biol, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Dept Cell & Dev Biol, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan.	L50174@sakura.kudpc.kyoto-u.ac.jp	Nakajima, Hiroyuki/Z-1243-2019	Nakajima, Hiroyuki/0000-0003-4139-2779; Toyoshima, Fumiko/0000-0002-3698-0034				Abrieu A, 1998, J CELL SCI, V111, P1751; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; BALDIN V, 1995, J CELL SCI, V108, P2425; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Donaldson MM, 2001, J CELL SCI, V114, P2357; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hunt T, 1991, Semin Cell Biol, V2, P213; Kelm O, 2002, J BIOL CHEM, V277, P25247, DOI 10.1074/jbc.M202855200; KORNBLUTH S, 1994, MOL BIOL CELL, V5, P273, DOI 10.1091/mbc.5.3.273; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; Liu F, 1999, MOL CELL BIOL, V19, P5113; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Okumura E, 2002, NAT CELL BIOL, V4, P111, DOI 10.1038/ncb741; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Sutterlin C, 2001, P NATL ACAD SCI USA, V98, P9128, DOI 10.1073/pnas.161283998; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x	42	250	257	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25277	25280		10.1074/jbc.C300126200	http://dx.doi.org/10.1074/jbc.C300126200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12738781	hybrid			2022-12-25	WOS:000183920200002
J	Tian, JH; Das, S; Sheng, ZH				Tian, JH; Das, S; Sheng, ZH			Ca2+- dependent phosphorylation of syntaxin-1A by the death-associated protein (DAP) kinase regulates its interaction with Munc18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; SYNAPTOSOME-ASSOCIATED PROTEIN; SYNAPTIC VESICLE FUSION; II MUTANT MICE; MEMBRANE-FUSION; NEUROTRANSMITTER RELEASE; CORE COMPLEX; 3-DIMENSIONAL STRUCTURE; CALCIUM-DEPENDENCE; CHROMAFFIN CELLS	Syntaxin-1 is a key component of the synaptic vesicle docking/fusion machinery that binds with VAMP/synaptobrevin and SNAP-25 to form the SNARE complex. Modulation of syntaxin binding properties by protein kinases could be critical to control of neurotransmitter release. Using yeast two-hybrid selection with syntaxin-1A as bait, we have isolated a cDNA encoding the C-terminal domain of death-associated protein (DAP) kinase, a calcium/calmodulin-dependent serine/threonine protein kinase. Expression of DAP kinase in adult rat brain is restricted to particular neuronal subpopulations, including the hippocampus and cerebral cortex. Biochemical studies demonstrate that DAP kinase binds to and phosphorylates syntaxin-1 at serine 188. This phosphorylation event occurs both in vitro and in vivo in a Ca2+-dependent manner. Syntaxin-1A phosphorylation by DAP kinase or its S188D mutant, which mimics a state of complete phosphorylation, significantly decreases syntaxin binding to Munc18-1, a syntaxin-binding protein that regulates SNARE complex formation and is required for synaptic vesicle docking. Our results suggest that syntaxin is a DAP kinase substrate and provide a novel signal transduction pathway by which syntaxin function could be regulated in response to intracellular [Ca2+] and synaptic activity.	NINDS, Synapt Funct Unit, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Sheng, ZH (corresponding author), NINDS, Synapt Funct Unit, NIH, Bldg 36,Rm 5A23,36 Convent Dr, Bethesda, MD 20892 USA.		Das, Sunit/J-3903-2015	Das, Sunit/0000-0002-2146-4168	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002946, Z01NS002946] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BENNETT MK, 1993, J NEUROSCI, V13, P1701; Betz A, 1997, J BIOL CHEM, V272, P2520; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CAPOGNA M, 1995, J NEUROSCI, V15, P1249; CHARRIAUTMARLANGUE C, 1991, P NATL ACAD SCI USA, V88, P10232, DOI 10.1073/pnas.88.22.10232; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Chheda MG, 2001, NAT CELL BIOL, V3, P331, DOI 10.1038/35070000; Chi P, 2001, NAT NEUROSCI, V4, P1187, DOI 10.1038/nn756; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Dittman JS, 1998, J NEUROSCI, V18, P6147; Dubois T, 2002, EUR J BIOCHEM, V269, P909, DOI 10.1046/j.0014-2956.2001.02725.x; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; DUNKLEY PR, 1988, BRAIN RES, V441, P59, DOI 10.1016/0006-8993(88)91383-2; Evans GJO, 2001, J BIOL CHEM, V276, P47877, DOI 10.1074/jbc.M108186200; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Foletti DL, 2001, J NEUROSCI, V21, P5473, DOI 10.1523/JNEUROSCI.21-15-05473.2001; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; GINGRICH KJ, 1985, J NEUROPHYSIOL, V53, P652, DOI 10.1152/jn.1985.53.3.652; Gomis A, 1999, J NEUROSCI, V19, P6309; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; Higgins D., 1998, CULTURING NERVE CELL, P37; Hilfiker S, 1999, J PHYSIOL-LONDON, V515, P1, DOI 10.1111/j.1469-7793.1999.001ad.x; Hirling H, 1996, P NATL ACAD SCI USA, V93, P11945, DOI 10.1073/pnas.93.21.11945; Hosaka M, 1999, NEURON, V24, P377, DOI 10.1016/S0896-6273(00)80851-X; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; Jahn R, 2000, NEURON, V27, P201, DOI 10.1016/S0896-6273(00)00029-5; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Jin YJ, 2001, J BIOL CHEM, V276, P39667, DOI 10.1074/jbc.M101886200; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; Lonart G, 1998, J NEUROSCI, V18, P634; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; NICHOLS RA, 1987, J NEUROCHEM, V48, P615, DOI 10.1111/j.1471-4159.1987.tb04137.x; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; NIELANDER HB, 1995, J NEUROCHEM, V65, P1712; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Patterson SL, 2001, NEURON, V32, P123, DOI 10.1016/S0896-6273(01)00443-3; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Poirier MA, 1998, J BIOL CHEM, V273, P11370, DOI 10.1074/jbc.273.18.11370; POPOLI M, 1995, MOL PHARMACOL, V48, P623; Risinger C, 1999, J NEUROCHEM, V72, P614, DOI 10.1046/j.1471-4159.1999.0720614.x; Sakagami H, 1997, MOL BRAIN RES, V52, P249, DOI 10.1016/S0169-328X(97)00268-4; Sankaranarayanan S, 2001, NAT NEUROSCI, V4, P129, DOI 10.1038/83949; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; Shimazaki Y, 1996, J BIOL CHEM, V271, P14548, DOI 10.1074/jbc.271.24.14548; Shohat G, 2001, J BIOL CHEM, V276, P47460, DOI 10.1074/jbc.M105133200; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Smith C, 1998, NEURON, V20, P1243, DOI 10.1016/S0896-6273(00)80504-8; Soderling TR, 2000, CURR OPIN NEUROBIOL, V10, P375, DOI 10.1016/S0959-4388(00)00090-8; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; Turner KM, 1999, TRENDS NEUROSCI, V22, P459, DOI 10.1016/S0166-2236(99)01436-8; Velentza AV, 2001, J BIOL CHEM, V276, P38956, DOI 10.1074/jbc.M104273200; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Wang LY, 1998, NATURE, V394, P384, DOI 10.1038/28645; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WEISSKOPF MG, 1994, SCIENCE, V265, P1876; Yamamoto M, 1999, J NEUROSCI RES, V58, P674, DOI 10.1002/(SICI)1097-4547(19991201)58:5<674::AID-JNR8>3.0.CO;2-3; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Yokoyama CT, 1997, J NEUROSCI, V17, P6929; Zucker RS, 1996, NEURON, V17, P1049, DOI 10.1016/S0896-6273(00)80238-X	79	58	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26265	26274		10.1074/jbc.M300492200	http://dx.doi.org/10.1074/jbc.M300492200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730201	hybrid			2022-12-25	WOS:000183920200126
J	Rebbaa, A; Zheng, X; Chou, PM; Mirkin, BL				Rebbaa, A; Zheng, X; Chou, PM; Mirkin, BL			Caspase inhibition switches doxorubicin-induced apoptosis to senescence	ONCOGENE			English	Article						apoptosis; senescence; P21/WAF1; drug resistance	CYTOCHROME-C RELEASE; PROTEIN EXPRESSION; CANCER CELLS; DEATH; P53; RESISTANCE; SURVIVAL; PATHWAY; P21; CYTOTOXICITY	The inhibition of apoptosis is generally believed to be a major determinant of resistance to chemotherapy. However, recent findings have shown that caspase inhibitors do not protect cancer cells from death by cytotoxic agents, but may switch drug-induced apoptosis to an alternative 'default death'. The primary goals of this study were to determine the major characteristics of the 'default death' and the mechanism by which this switch is activated. For this purpose, we first investigated putative cell death modes induced by doxorubicin. Molecular markers associated with these death modes were utilized to identify the default death resulting from the inhibition of apoptosis. Our findings demonstrated that doxorubicin induced at least three distinct types of cell death, senescence, apoptosis and a type of necrosis, which were concentration dependent. Specific molecular markers such as p21/WAF1, activated caspase-3 and activated Akt were associated with these death modes. The pan-caspase inhibitor (Q-VD-OPH) greatly reduced doxorubicin-induced caspase-3 activation but did not protect cells against drug toxicity. The combination of doxorubicin and Q-VD-OPH caused an increased expression of p21/WAF1 and senescence -associated -beta-galactosidase activity, but did not alter Akt activation. Collectively, these findings suggest that the inhibition of apoptosis may lead to an increased expression of cell cycle inhibitors and cellular senescence.	Childrens Mem Hosp, Childrens Mem Inst Educ & Res, Dept Pediat, Chicago, IL 60614 USA; Childrens Mem Hosp, Childrens Mem Inst Educ & Res, Dept Pathol, Chicago, IL 60614 USA; Northwestern Univ, Feinberg Sch Med, Dept Biol Chem & Mol Pharmacol, Chicago, IL 60611 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine	Rebbaa, A (corresponding author), Childrens Mem Hosp, Childrens Mem Inst Educ & Res, Dept Pediat, M-C 224,2300 Childrens Plaza, Chicago, IL 60614 USA.	arebbaa@childrensmemorial.org						Ahrendt SA, 2000, SURGERY, V128, P520, DOI 10.1067/msy.2000.108052; Borst P, 2001, DRUG RESIST UPDATE, V4, P129, DOI 10.1054/drup.2001.0187; Brognard J, 2001, CANCER RES, V61, P3986; Brown JM, 1999, CANCER RES, V59, P1391; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Emran MA, 2002, CANCER LETT, V182, P53, DOI 10.1016/S0304-3835(02)00062-9; Ferrandina G, 2000, INT J ONCOL, V17, P1231; Friesen C, 1999, LEUKEMIA, V13, P1854, DOI 10.1038/sj.leu.2401333; Friesen C, 1997, LEUKEMIA, V11, P1833, DOI 10.1038/sj.leu.2400827; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; Hartmann A, 2001, J NEUROSCI, V21, P2247, DOI 10.1523/JNEUROSCI.21-07-02247.2001; Jin YH, 2000, J BIOL CHEM, V275, P30256, DOI 10.1074/jbc.M001902200; Kapranos N, 2001, ANTICANCER RES, V21, P521; Kim SO, 2001, J ENDOTOXIN RES, V7, P292, DOI 10.1179/096805101101532873; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Kojima H, 1998, J BIOL CHEM, V273, P16647, DOI 10.1074/jbc.273.27.16647; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Luschen S, 2000, J BIOL CHEM, V275, P24670, DOI 10.1074/jbc.M003280200; Martinsson P, 2001, ANTI-CANCER DRUG, V12, P699, DOI 10.1097/00001813-200109000-00009; Nakashima S, 2000, ANTICANCER RES, V20, P1933; Rebbaa A, 2001, CANCER CHEMOTH PHARM, V48, P423, DOI 10.1007/s002800100375; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; RONINSON IB, 2002, DRUG RESIST UPDATE, V252, P1; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; te Poele RH, 2002, CANCER RES, V62, P1876; Yaginuma H, 2001, MOL CELL NEUROSCI, V18, P168, DOI 10.1006/mcne.2001.1009; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483; Zunino F, 1997, PHARMACOL THERAPEUT, V76, P177, DOI 10.1016/S0163-7258(97)00086-7	33	147	160	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2003	22	18					2805	2811		10.1038/sj.onc.1206366	http://dx.doi.org/10.1038/sj.onc.1206366			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743603				2022-12-25	WOS:000182569300011
J	Usui, K; Saijo, Y; Narumi, K; Koyama, S; Maemondo, M; Kikuchi, T; Tazawa, R; Hagiwara, K; Ishibashi, Y; Ohta, S; Nukiwa, T				Usui, K; Saijo, Y; Narumi, K; Koyama, S; Maemondo, M; Kikuchi, T; Tazawa, R; Hagiwara, K; Ishibashi, Y; Ohta, S; Nukiwa, T			N-terminal deletion augments the cell-death-inducing activity of BAX in adenoviral gene delivery to nonsmall cell lung cancers	ONCOGENE			English	Article						BAX; apoptosis; gene therapy	MITOCHONDRIAL DYSFUNCTION; BACTERIAL DEATH; BCL-2 PROTEIN; CYTOCHROME-C; IN-VIVO; APOPTOSIS; EXPRESSION; THERAPY; OVEREXPRESSION; DIMERIZATION	Therapeutic modalities that overcome the antiapoptotic function of Bcl-2 that is often overexpressed in cancer cells are expected to be a novel strategy for cancer treatment. We previously reported that the leukemic cell death induced by an N-terminally truncated Bax (DeltaN Bax: corresponding to amino acid 112-192 of full-length Bax) was not blocked by Bcl-2 or Bcl-x(L) owing to the lack of the BH3 domain needed to interact with the antiapoptotic Bcl-2 family molecules. In this study, we used the Cre-loxP system that allowed us to propagate adenoviruses expressing DeltaN Bax, and investigated the effects of the DeltaN Bax gene transfer into A549 and NCI-H1299 nonsmall cell lung cancer cell tines. DeltaN Bax showed more cell-death-inducing activity in both cells than did the full-length Bax in vitro. It was found that the DeltaN Bax-induced cell death was not inhibited by the pan-caspase inhibitor z-VAD-fmk, suggesting that DeltaN Bax induces cell death through a caspase-independent mechanism. Intratumoral injection of adenoviruses expressing AN Bax into A549 tumors in Balb/c nude mice showed a significantly stronger suppression of tumor growth (74%) than full-length Bax (25%) compared to the control. Our results suggest that DeltaN Bax may provide a better alternative than currently used cytotoxic genes in cancer gene therapy trials.	Tohoku Univ, Grad Sch Med, Dept Mol Med & Gene Transfer Res, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Resp Oncol & Mol Med, Aoba Ku, Sendai, Miyagi 9808575, Japan; Nippon Med Coll, Inst Gerontol, Dept Biochem & Cell Biol, Nakahara Ku, Kawasaki, Kanagawa 2118533, Japan	Tohoku University; Tohoku University; Nippon Medical School	Saijo, Y (corresponding author), Tohoku Univ, Grad Sch Med, Dept Mol Med & Gene Transfer Res, Aoba Ku, 2-1 Seiryomachi, Sendai, Miyagi 9808575, Japan.	yasoj@idac.tohoku.ac.jp	Tazawa, Ryushi/AAM-6915-2020; Koyama, Shohei/AAU-4113-2021	Tazawa, Ryushi/0000-0002-4580-004X; Koyama, Shohei/0000-0002-6897-9417; Usui, Kazuhiro/0000-0002-4492-9327				Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Aritomi M, 1997, J BIOL CHEM, V272, P27886, DOI 10.1074/jbc.272.44.27886; Asoh S, 1998, J BIOL CHEM, V273, P11384, DOI 10.1074/jbc.273.18.11384; BECK WT, 1997, CANER PRINCIPLES PRA, P333; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Fan LF, 1999, HUM GENE THER, V10, P2273, DOI 10.1089/10430349950016924; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Gu J, 2002, GENE THER, V9, P30, DOI 10.1038/sj.gt.3301619; Gu J, 2000, CANCER RES, V60, P5359; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Huang ZW, 2000, ONCOGENE, V19, P6627, DOI 10.1038/sj.onc.1204087; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; IKEGAKI N, 1994, CANCER RES, V54, P6; Ishibashi Y, 1998, BIOCHEM BIOPH RES CO, V243, P609, DOI 10.1006/bbrc.1998.8145; Joseph B, 2002, ONCOGENE, V21, P65, DOI 10.1038/sj/onc/1205018; Jurgensmeier JM, 1997, MOL BIOL CELL, V8, P325; Kagawa S, 2000, GENE THER, V7, P75, DOI 10.1038/sj.gt.3301048; Kagawa S, 2000, CANCER RES, V60, P1157; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li XY, 2001, CANCER RES, V61, P186; McCormick F, 2001, NAT REV CANCER, V1, P130, DOI 10.1038/35101008; Mohiuddin M, 2001, CANCER GENE THER, V8, P547, DOI 10.1038/sj.cgt.7700332; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tai YT, 1999, CANCER RES, V59, P2121; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Tamm I, 1998, CANCER RES, V58, P5315; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wu CH, 2002, ONCOGENE, V21, P5160, DOI 10.1038/sj.onc.1205639; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yamashita YI, 2002, HUM GENE THER, V13, P275, DOI 10.1089/10430340252769798; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	45	10	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2003	22	17					2655	2663		10.1038/sj.onc.1206331	http://dx.doi.org/10.1038/sj.onc.1206331			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730679	Bronze			2022-12-25	WOS:000182569000013
J	van Golen, CM; Soules, ME; Grauman, AR; Feldman, EL				van Golen, CM; Soules, ME; Grauman, AR; Feldman, EL			N-Myc overexpression leads to decreased beta 1 integrin expression and increased apoptosis in human neuroblastoma cells	ONCOGENE			English	Article						Myc; neuroblastoma; apoptosis; integrin; adhesion	GROWTH-FACTOR-I; CHEMOTHERAPY-INDUCED APOPTOSIS; ADHESION CHARACTERISTICS; RECEPTOR ACTIVATION; MEDIATED SURVIVAL; GENE-EXPRESSION; C-MYC; BCL-2; AMPLIFICATION; DIFFERENTIATION	Neuroblastoma is a childhood tumor thought to arise through improper differentiation of neural crest cells. Increased N-Myc expression in neuroblastoma indicates highly malignant disease and poor patient prognosis. N-myc enhances cell growth, insulin-like growth factor type I receptor (IGF-IR) expression, and tumorigenicity in combination with Bcl-2. Despite these effects, N-Myc overexpression in SHEP neuroblastoma cells (SHEP/N-Myc cells) increases serum-withdrawal and mannitol-induced apoptosis. Although we have previously shown a protective effect of IGF-I in SHEP cells, in SHEP/N-Myc cells IGF-I rescue from mannitol-induced apoptosis is prevented. N-Myc overexpression has little effect on IGF-IR signaling pathways, but results in increased Akt phosphorylation when Bcl-2 is coexpressed. A loss of integrin-mediated adhesion promotes apoptosis in many systems. SHEP/N-Myc cells have dramatically less beta1 integrin expression than control cells, consistent with previous reports. beta1 integrin expression is decreased in more tumorigenic neuroblastoma cells lines, including IMR32 and SH-SY5Y cells. Reintroduction of beta1 integrin into the N-Myc-overexpressing cells prevents mannitol-mediated apoptosis. We speculate that N-Myc repression of beta1 integrin expression leads to a less differentiated phenotype, resulting in increased growth and tumorigenesis if properly supported or apoptosis if deprived of growth sustaining molecules.	Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Feldman, EL (corresponding author), Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA.	efeldman@umich.edu		Feldman, Eva/0000-0002-9162-2694	NCI NIH HHS [CA46592] Funding Source: Medline; NIAMS NIH HHS [AR20557] Funding Source: Medline; NINDS NIH HHS [R01 NS36778, T32 NS07222] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036778, T32NS007222] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amendola R, 1997, JNCI-J NATL CANCER I, V89, P1300, DOI 10.1093/jnci/89.17.1300; Amendola R, 2001, MED PEDIATR ONCOL, V36, P93, DOI 10.1002/1096-911X(20010101)36:1<93::AID-MPO1021>3.0.CO;2-3; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; Bonfoco E, 2000, NEUROSCIENCE, V101, P1145, DOI 10.1016/S0306-4522(00)00429-2; Bordow SB, 1998, J CLIN ONCOL, V16, P3286, DOI 10.1200/JCO.1998.16.10.3286; Bozzo C, 1997, EXP CELL RES, V237, P326, DOI 10.1006/excr.1997.3777; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CASTLE VP, 1993, AM J PATHOL, V143, P1543; Castleberry RP, 1997, PEDIATR CLIN N AM, V44, P919, DOI 10.1016/S0031-3955(05)70537-X; Chambery D, 1999, CANCER RES, V59, P2898; Cheng HL, 2000, J BIOL CHEM, V275, P27197; Cianfarani S, 1997, EUR J PEDIATR, V156, P256, DOI 10.1007/s004310050595; Corvi R, 1997, J NEURO-ONCOL, V31, P25, DOI 10.1023/A:1005721027709; Dabrowska M, 2001, GYNECOL OBSTET INVES, V51, P248, DOI 10.1159/000058059; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; DOLE M, 1994, CANCER RES, V54, P3253; DOLE MG, 1995, CANCER RES, V55, P2576; FAVROT MC, 1991, INT J CANCER, V49, P347, DOI 10.1002/ijc.2910490306; FLICKINGER KS, 1994, EXP CELL RES, V213, P156, DOI 10.1006/excr.1994.1185; Fulda S, 2000, MED PEDIATR ONCOL, V35, P582, DOI 10.1002/1096-911X(20001201)35:6<582::AID-MPO19>3.0.CO;2-2; Galderisi U, 1999, J CELL BIOCHEM, V73, P97, DOI 10.1002/(SICI)1097-4644(19990401)73:1<97::AID-JCB11>3.0.CO;2-M; Gelbard HA, 1997, PEDIATR NEUROL, V16, P93, DOI 10.1016/S0887-8994(96)00258-5; George RE, 2001, MED PEDIATR ONCOL, V36, P169, DOI 10.1002/1096-911X(20010101)36:1<169::AID-MPO1041>3.0.CO;2-U; Gladson CL, 1996, AM J PATHOL, V148, P1423; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gross N, 2000, EXP CELL RES, V260, P396, DOI 10.1006/excr.2000.5007; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; HOEHNER JC, 1995, INT J CANCER, V62, P19, DOI 10.1002/ijc.2910620106; IKEDA H, 1995, J PEDIATR SURG, V30, P805, DOI 10.1016/0022-3468(95)90752-1; Jasty R, 2001, NEOPLASIA, V3, P304, DOI 10.1038/sj.neo.7900171; Judware R, 1997, ONCOGENE, V14, P1341, DOI 10.1038/sj.onc.1200955; Judware R, 1995, ONCOGENE, V11, P2599; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; KOIZUMI H, 1995, VIRCHOWS ARCH, V427, P167; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Leventhal Phillip S., 1999, V17, P425; Leventhal PS, 1997, TRENDS ENDOCRIN MET, V8, P1, DOI 10.1016/S1043-2760(96)00202-0; LEVENTHAL PS, 1995, EXP CELL RES, V221, P179, DOI 10.1006/excr.1995.1365; Liu XD, 1998, CANCER RES, V58, P5432; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; MARTIN DM, 1992, MOL BRAIN RES, V15, P241, DOI 10.1016/0169-328X(92)90114-Q; Mathews CC, 1996, J CELL PHYSIOL, V166, P323; Matthews CC, 1997, NEUROSCIENCE, V79, P525, DOI 10.1016/S0306-4522(96)00611-2; Mejia MC, 1998, ANTICANCER RES, V18, P801; Meyer GE, 2001, ONCOGENE, V20, P7542, DOI 10.1038/sj.onc.1204927; Miller SE, 2001, CELL BIOL INT, V25, P61, DOI 10.1006/cbir.2000.0678; Mooney A, 1999, AM J PATHOL, V155, P599, DOI 10.1016/S0002-9440(10)65155-3; PHILIP T, 1992, AM J PEDIAT HEMATOL, V14, P97; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; REED JC, 1991, CANCER RES, V51, P6529; Rohn JL, 1998, ONCOGENE, V17, P2811, DOI 10.1038/sj.onc.1202393; ROSSINO P, 1991, CELL REGUL, V2, P1021, DOI 10.1091/mbc.2.12.1021; Rossler J, 2001, BIOCHEM BIOPH RES CO, V281, P272, DOI 10.1006/bbrc.2001.4342; Rozzo C, 1997, INT J CANCER, V70, P688, DOI 10.1002/(SICI)1097-0215(19970317)70:6<688::AID-IJC11>3.3.CO;2-V; ROZZO C, 1993, FEBS LETT, V332, P263, DOI 10.1016/0014-5793(93)80646-C; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; Shakibaei M, 1999, BIOCHEM J, V342, P615, DOI 10.1042/0264-6021:3420615; Singleton JR, 1996, CANCER RES, V56, P4522; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Stallmach A, 2001, EUR J IMMUNOL, V31, P1228, DOI 10.1002/1521-4141(200104)31:4<1228::AID-IMMU1228>3.0.CO;2-K; SULLIVAN KA, 1995, AM J PATHOL, V147, P1790; TANABE M, 1995, MED PEDIATR ONCOL, V24, P292, DOI 10.1002/mpo.2950240505; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; van Golen CM, 2001, CELL GROWTH DIFFER, V12, P371; van Golen CM, 2000, CELL DEATH DIFFER, V7, P654, DOI 10.1038/sj.cdd.4400693; Van Golen CM, 2000, J CELL PHYSIOL, V182, P24, DOI 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6; Wewer UM, 1997, AM J PATHOL, V151, P1191	69	33	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2003	22	17					2664	2673		10.1038/sj.onc.1206362	http://dx.doi.org/10.1038/sj.onc.1206362			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730680				2022-12-25	WOS:000182569000014
J	Pelled, D; Lloyd-Evans, E; Riebeling, C; Jeyakumar, M; Platt, FM; Futerman, AH				Pelled, D; Lloyd-Evans, E; Riebeling, C; Jeyakumar, M; Platt, FM; Futerman, AH			Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; ENDOPLASMIC-RETICULUM; LYSOSOMAL STORAGE; TAY-SACHS; IRREVERSIBLE INHIBITION; RYANODINE RECEPTOR; PROTEIN-SYNTHESIS; BRAIN MICROSOMES; RELEASE CHANNEL; NEURONS	Gangliosides are found at high levels in neuronal tissues where they play a variety of important functions. In the gangliosidoses, gangliosides accumulate because of defective activity of the lysosomal proteins responsible for their degradation, usually resulting in a rapidly progressive neurodegenerative disease. However, the molecular mechanism(s) leading from ganglioside accumulation to neurodegeneration is not known. We now examine the effect of ganglioside GM2 accumulation in a mouse model of Sandhoff disease ( one of the GM2 gangliosidoses), the Hexb-/- mouse. Microsomes from Hexb-/- mouse brain showed a significant reduction in the rate of Ca2+-uptake via the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), which was prevented by feeding Hexb-/- mice with N-butyldeoxynojirimycin (NB-DNJ), an inhibitor of glycolipid synthesis that reduces GM2 storage. Changes in SERCA activity were not due to transcriptional regulation but rather because of a decrease in V-max. Moreover, exogenously added GM2 had a similar effect on SERCA activity. The functional significance of these findings was established by the enhanced sensitivity of neurons cultured from embryonic Hexb-/- mice to cell death induced by thapsigargin, a specific SERCA inhibitor, and by the enhanced sensitivity of Hexb-/- microsomes to calcium-induced calcium release. This study suggests a mechanistic link among GM2 accumulation, reduced SERCA activity, and neuronal cell death, which may be of significance for delineating the neuropathophysiology of Sandhoff disease.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	Weizmann Institute of Science; University of Oxford	Futerman, AH (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	tony.futerman@weizmann.ac.il		Riebeling, Christian/0000-0003-1991-0170; Futerman, Anthony/0000-0003-0013-0115; Platt, Frances/0000-0001-7614-0403				Betto R, 1997, BIOCHEM J, V322, P327, DOI 10.1042/bj3220327; Bieberich E, 2001, J BIOL CHEM, V276, P44396, DOI 10.1074/jbc.M107239200; Bodennec J, 2002, FASEB J, V16, P1814, DOI 10.1096/fj.02-0149fje; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Cornea RL, 2000, J BIOL CHEM, V275, P41487, DOI 10.1074/jbc.M008195200; Cox T, 2000, LANCET, V355, P1481, DOI 10.1016/S0140-6736(00)02161-9; DEBER CM, 1986, BIOCHEM BIOPH RES CO, V134, P731, DOI 10.1016/S0006-291X(86)80481-8; DETTBARN C, 1995, BRAIN RES, V669, P79, DOI 10.1016/0006-8993(94)01234-9; Doutheil J, 1999, CELL CALCIUM, V25, P419, DOI 10.1054/ceca.1999.0042; East JM, 2000, MOL MEMBR BIOL, V17, P189, DOI 10.1080/09687680010009646; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FIELDS A, 1995, BRAIN RES, V687, P94, DOI 10.1016/0006-8993(95)00475-6; FRANK KF, 2002, BASIC RES CARDIOL, V97, P172; Garcia-Ruiz C, 2002, J BIOL CHEM, V277, P36443, DOI 10.1074/jbc.M206021200; Gravel R. A., 2001, METABOLIC MOL BASES, V3, P3827; Heyen MV, 2000, MAMM GENOME, V11, P159, DOI 10.1007/s003350010030; Hirschberg K, 1996, J BIOL CHEM, V271, P14876, DOI 10.1074/jbc.271.25.14876; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; Jeyakumar M, 2003, BRAIN, V126, P974, DOI 10.1093/brain/awg089; Jeyakumar M, 2002, NEUROPATH APPL NEURO, V28, P343, DOI 10.1046/j.1365-2990.2002.00422.x; Jeyakumar M, 1999, P NATL ACAD SCI USA, V96, P6388, DOI 10.1073/pnas.96.11.6388; Ji Y, 1999, ANAL BIOCHEM, V269, P236, DOI 10.1006/abio.1999.4059; Kolter T, 1998, J INHERIT METAB DIS, V21, P548, DOI 10.1023/A:1005419122018; Korkotian E, 1999, J BIOL CHEM, V274, P21673, DOI 10.1074/jbc.274.31.21673; Lloyd-Evans E, 2003, J BIOL CHEM, V278, P23594, DOI 10.1074/jbc.M300212200; MacLennan DH, 2000, EUR J BIOCHEM, V267, P5291, DOI 10.1046/j.1432-1327.2000.01566.x; Mahuran DJ, 1999, BBA-MOL BASIS DIS, V1455, P105, DOI 10.1016/S0925-4439(99)00074-5; Mengesdorf T, 2001, BIOCHEM J, V356, P805, DOI 10.1042/0264-6021:3560805; Misquitta CM, 1999, CELL CALCIUM, V25, P277, DOI 10.1054/ceca.1999.0032; Myerowitz R, 2002, HUM MOL GENET, V11, P1343, DOI 10.1093/hmg/11.11.1343; Nguyen HN, 2002, BRAIN RES, V924, P159, DOI 10.1016/S0006-8993(01)03229-2; PALADE P, 1987, J BIOL CHEM, V262, P6149; Paschen W, 2001, J NEUROCHEM, V76, P1916, DOI 10.1046/j.1471-4159.2001.00206.x; PELLED D, 2003, IN PRESS NEUROPATHOL; Platt FM, 1997, SCIENCE, V276, P428, DOI 10.1126/science.276.5311.428; PLATT FM, 1994, J BIOL CHEM, V269, P8362; Platt FM, 1997, J BIOL CHEM, V272, P19365, DOI 10.1074/jbc.272.31.19365; Riebeling C, 2002, BRIT J CANCER, V87, P366, DOI 10.1038/sj.bjc.6600476; Sango K, 2002, NEUROPATH APPL NEURO, V28, P23, DOI 10.1046/j.1365-2990.2002.00366.x; Sango K, 1996, NAT GENET, V14, P348, DOI 10.1038/ng1196-348; SANGO K, 1995, NAT GENET, V11, P170, DOI 10.1038/ng1095-170; Sofer A, 1996, J CELL SCI, V109, P2111; Tang FJ, 2003, J NEUROSCI, V23, P927; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; Turner CP, 2002, EXP NEUROL, V178, P21, DOI 10.1006/exnr.2002.8027; van Echten-Deckert G, 1998, J BIOL CHEM, V273, P1184, DOI 10.1074/jbc.273.2.1184; Wada R, 2000, P NATL ACAD SCI USA, V97, P10954, DOI 10.1073/pnas.97.20.10954; Wang LH, 1996, FEBS LETT, V388, P128, DOI 10.1016/0014-5793(96)00534-0; Wang YL, 1999, FEBS LETT, V457, P144, DOI 10.1016/S0014-5793(99)01024-8; Wei HF, 1998, J NEUROCHEM, V70, P2305; Wells KM, 1998, J BIOL CHEM, V273, P5020, DOI 10.1074/jbc.273.9.5020; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8	53	109	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29496	29501		10.1074/jbc.M302964200	http://dx.doi.org/10.1074/jbc.M302964200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12756243	hybrid			2022-12-25	WOS:000184507000014
J	Yamashita, A; Watanabe, M; Sato, K; Miyashita, T; Nagatsuka, T; Kondo, H; Kawagishi, N; Nakanishi, H; Kamata, R; Sugiura, T; Waku, K				Yamashita, A; Watanabe, M; Sato, K; Miyashita, T; Nagatsuka, T; Kondo, H; Kawagishi, N; Nakanishi, H; Kamata, R; Sugiura, T; Waku, K			Reverse reaction of lysophosphatidylinositol acyltransferase - Functional reconstitution of coenzyme A-dependent transacylation system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; BOVINE TESTIS MEMBRANES; ACYL-COA SYNTHESIS; ARACHIDONIC-ACID; 1-ACYL-SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; SUBSTRATE-SPECIFICITY; MAMMALIAN-CELLS; PHOSPHOLIPIDS; LYSOPHOSPHOLIPIDS; METABOLISM	CoA-dependent transacylation activity in microsomes catalyzes the transfer of fatty acid between phospholipids and lysophospholipids in the presence of CoA without the generation of free fatty acid. We examined the mechanism of the transacylation system using partially purified acyl-CoA:lysophosphatidylinositol (LPI) acyltransferase (LPIAT) from rat liver microsomes to test our hypothesis that both the reverse and forward reactions of acyl-CoA:lysophospholipid acyltransferases are involved in the CoA-dependent transacylation process. The purified LPIAT fraction exhibited ATP-independent acyl-CoA synthetic activity and CoA-dependent LPI generation from PI, suggesting that LPIAT could operate in reverse to form acyl-CoA and LPI. CoA-dependent acylation of LPI by the purified LPIAT fraction required PI as the acyl donor. In addition, the combination of purified LPIAT and recombinant lysophosphatidic acid acyltransferase could reconstitute CoA-dependent transacylation between PI and phosphatidic acid. These results suggest that the CoA-dependent transacylation system consists of the following: 1) acyl-CoA synthesis from phospholipid through the reverse action of acyl-CoA:lysophospholipid acyltransferases; and 2) transfer of fatty acyl moiety from the newly formed acyl-CoA to lysophospholipid through the forward action of acyl-CoA:lysophospholipid acyltransferases.	Teikyo Univ, Fac Pharmaceut Sci, Kanagawa 1990195, Japan	Teikyo University	Yamashita, A (corresponding author), Teikyo Univ, Fac Pharmaceut Sci, Kanagawa 1990195, Japan.			Nakanishi, Hiroki/0000-0002-5108-1598; Yamashita, Atsushi/0000-0002-2544-2134				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CASY P, 1995, SCIENCE, V268, P221; COLARD O, 1984, BIOCHIM BIOPHYS ACTA, V793, P42, DOI 10.1016/0005-2760(84)90051-1; COLEMAN J, 1990, J BIOL CHEM, V265, P17215; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Corda D, 2002, BBA-MOL CELL BIOL L, V1582, P52, DOI 10.1016/S1388-1981(02)00137-3; DARNELL JC, 1991, BIOCHIM BIOPHYS ACTA, V1084, P292, DOI 10.1016/0005-2760(91)90071-O; Faergeman NJ, 1997, BIOCHEM J, V323, P1; FALASCA M, 1994, EUR J BIOCHEM, V221, P383, DOI 10.1111/j.1432-1033.1994.tb18750.x; Fitzsimmons TJ, 1997, J BIOL CHEM, V272, P31435, DOI 10.1074/jbc.272.50.31435; Ghosh S, 1997, FASEB J, V11, P45, DOI 10.1096/fasebj.11.1.9034165; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Hollenback D, 1998, BIOCHEMISTRY-US, V37, P363, DOI 10.1021/bi971749y; IMAMURA S, 1979, J BIOCHEM, V85, P79, DOI 10.1093/oxfordjournals.jbchem.a132334; IRVINE R F, 1992, Current Opinion in Cell Biology, V4, P212, DOI 10.1016/0955-0674(92)90035-B; IRVINE RF, 1979, BIOCHEM BIOPH RES CO, V91, P1399, DOI 10.1016/0006-291X(79)91222-1; ITABE H, 1992, J BIOL CHEM, V267, P15319; KRAMER RM, 1984, J BIOL CHEM, V259, P2403; Kume K, 1997, BIOCHEM BIOPH RES CO, V237, P663, DOI 10.1006/bbrc.1997.7214; Lands W., 1976, ENZYMES BIOL MEMBRAN, V2, P3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; METS SA, 1986, BIOCHEM BIOPH RES CO, V138, P720; NAKAGAWA Y, 1989, PROG LIPID RES, V28, P205, DOI 10.1016/0163-7827(89)90013-1; OKUYAMA H, 1982, METHOD ENZYMOL, V86, P370; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; RAJASEKHARAN R, 1993, BIOCHEMISTRY-US, V32, P12386, DOI 10.1021/bi00097a016; ROBINSON M, 1985, J BIOL CHEM, V260, P7889; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SEUBERT W, 1960, BIOCHEM PREP, V7, P80; SLOTBOOM AJ, 1970, CHEM PHYS LIPIDS, V4, P15, DOI 10.1016/0009-3084(70)90059-9; STYMNE S, 1985, BIOCHIM BIOPHYS ACTA, V837, P239, DOI 10.1016/0005-2760(85)90047-5; SUGIURA T, 1995, J LIPID RES, V36, P440; SUGIURA T, 1995, BBA-LIPID LIPID MET, V1255, P167, DOI 10.1016/0005-2760(94)00237-S; SUGIURA T, 1987, J BIOL CHEM, V262, P1199; SUGIURA T, 1988, J BIOL CHEM, V263, P17490; TROTTER J, 1982, J BIOL CHEM, V257, P1816; WAKU K, 1992, BIOCHIM BIOPHYS ACTA, V1124, P101, DOI 10.1016/0005-2760(92)90085-A; YAMASHITA A, 1995, BIOCHEM J, V312, P301, DOI 10.1042/bj3120301; YAMASHITA A, 1994, BBA-LIPID LIPID MET, V1211, P263, DOI 10.1016/0005-2760(94)90149-X; Yamashita A, 2001, J BIOL CHEM, V276, P26745, DOI 10.1074/jbc.M101795200; Yamashita A, 1997, J BIOCHEM-TOKYO, V122, P1	42	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30382	30393		10.1074/jbc.M303391200	http://dx.doi.org/10.1074/jbc.M303391200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12756241	hybrid			2022-12-25	WOS:000184507000119
J	Cousin, MA; Malladi, CS; Tan, TC; Raymond, CR; Smillie, KJ; Robinson, PJ				Cousin, MA; Malladi, CS; Tan, TC; Raymond, CR; Smillie, KJ; Robinson, PJ			Synapsin I-associated phosphatidylinositol 3-kinase mediates synaptic vesicle delivery to the readily releasable pool	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; EXCHANGE FACTOR MSEC7-1; PHOSPHOINOSITIDE 3-KINASE; NEUROTRANSMITTER RELEASE; NERVE-TERMINALS; HIPPOCAMPAL SYNAPSES; DISTINCT POOLS; PI-3 KINASE; DYNAMIN-I; PHOSPHORYLATION	Maintaining synaptic transmission requires replenishment of docked synaptic vesicles within the readily releasable pool (RRP) from synaptic vesicle clusters in the synapsin-bound reserve pool. We show that synapsin forms a complex with phosphatidylinositol 3-kinase (PI 3-kinase) in intact nerve terminals and that synapsin associated kinase activity increases on depolarization. Disruption of either PI 3-kinase activity or its interaction with synapsin inhibited replenishment of the RRP, but did not affect exocytosis from the RRP. Thus we conclude that a synapsin-associated PI 3-kinase activity plays a role in synaptic vesicle delivery to the RRP. This also suggests that PI 3-kinase contributes to the maintenance of synaptic transmission during periods of high activity, indicating a possible role in synaptic plasticity.	Univ Edinburgh, Membrane Biol Grp, Div Biomed & Clin Lab Sci, Edinburgh EH8 9XD, Midlothian, Scotland; Childrens Med Res Inst, Cell Signalling Unit, Wentworthville, NSW 2145, Australia; Australian Natl Univ, Movement & Memory Lab, Div Neurosci, John Curtin Sch Med Res, Canberra, ACT 2600, Australia	University of Edinburgh; Children's Medical Research Institute - Australia; Australian National University; John Curtin School of Medical Research	Cousin, MA (corresponding author), Univ Edinburgh, Membrane Biol Grp, Div Biomed & Clin Lab Sci, George Sq, Edinburgh EH8 9XD, Midlothian, Scotland.		Robinson, Phillip J/G-4008-2011	Robinson, Phillip J/0000-0002-7878-0313; Smillie, Karen/0000-0003-4369-0470; Tan, Timothy/0000-0003-4449-1457; Cousin, Michael/0000-0002-1762-160X; Malladi, Chandra/0000-0002-5882-8228				Ashery U, 1999, P NATL ACAD SCI USA, V96, P1094, DOI 10.1073/pnas.96.3.1094; Bhargavi V, 1998, BIOCHEM MOL BIOL INT, V46, P241; Bokoch GM, 1996, BIOCHEM J, V315, P775, DOI 10.1042/bj3150775; Cabin DE, 2002, J NEUROSCI, V22, P8797; Chasserot-Golaz S, 1998, J NEUROCHEM, V70, P2347; Chi P, 2001, NAT NEUROSCI, V4, P1187, DOI 10.1038/nn756; Cousin MA, 2001, J NEUROCHEM, V76, P105, DOI 10.1046/j.1471-4159.2001.00049.x; Cremona O, 2001, J CELL SCI, V114, P1041; Cullen PJ, 1999, BIOCHEM SOC T, V27, P683, DOI 10.1042/bst0270683; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Daw MI, 2002, NAT NEUROSCI, V5, P835, DOI 10.1038/nn903; El Bitar F, 1999, CELL TISSUE RES, V298, P233, DOI 10.1007/s004419900081; Feng J, 2002, J NEUROSCI, V22, P4372, DOI 10.1523/JNEUROSCI.22-11-04372.2002; Fischer PM, 2000, J PEPT RES, V55, P163, DOI 10.1034/j.1399-3011.2000.00163.x; Gaidarov I, 2001, MOL CELL, V7, P443, DOI 10.1016/S1097-2765(01)00191-5; Harrison-Findik D, 2001, BBA-MOL CELL RES, V1538, P10, DOI 10.1016/S0167-4889(00)00130-0; Herrero I, 1996, J NEUROCHEM, V67, P2346; Hilfiker S, 1999, PHILOS T ROY SOC B, V354, P269, DOI 10.1098/rstb.1999.0378; Hill KM, 2001, J BIOL CHEM, V276, P16374, DOI 10.1074/jbc.M006985200; Hong SJ, 1999, BRIT J PHARMACOL, V128, P142, DOI 10.1038/sj.bjp.0702754; Kelly A, 2000, NEUROPHARMACOLOGY, V39, P643, DOI 10.1016/S0028-3908(99)00169-0; Kuromi H, 1998, NEURON, V20, P917, DOI 10.1016/S0896-6273(00)80473-0; LI L, 1995, P NATL ACAD SCI USA, V92, P9235, DOI 10.1073/pnas.92.20.9235; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; MCMAHON HT, 1991, J NEUROCHEM, V56, P86, DOI 10.1111/j.1471-4159.1991.tb02566.x; Mozhayeva MG, 2002, J NEUROSCI, V22, P654, DOI 10.1523/JNEUROSCI.22-03-00654.2002; Neeb A, 1999, EUR J CELL BIOL, V78, P533, DOI 10.1016/S0171-9335(99)80018-1; NICHOLLS DG, 1993, EUR J BIOCHEM, V212, P613, DOI 10.1111/j.1432-1033.1993.tb17700.x; Onofri F, 2000, J BIOL CHEM, V275, P29857, DOI 10.1074/jbc.M006018200; Papakonstanti EA, 2002, MOL BIOL CELL, V13, P2946, DOI 10.1091/mbc.02-01-0599; Peterson MR, 1999, CURR BIOL, V9, P159, DOI 10.1016/S0960-9822(99)80071-2; PIERIBONE VA, 1995, NATURE, V375, P493, DOI 10.1038/375493a0; Powell KA, 2000, J BIOL CHEM, V275, P11610, DOI 10.1074/jbc.275.16.11610; Raymond CR, 2002, NEUROSCIENCE, V109, P531, DOI 10.1016/S0306-4522(01)00500-0; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; Sanna PP, 2002, J NEUROSCI, V22, P3359; Schikorski T, 2001, NAT NEUROSCI, V4, P391, DOI 10.1038/86042; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Singh SS, 1996, BIOCHEMISTRY-US, V35, P16544, DOI 10.1021/bi9609634; Suzuki H, 1998, BRIT J PHARMACOL, V125, P1661, DOI 10.1038/sj.bjp.0702243; ter Haar E, 2000, P NATL ACAD SCI USA, V97, P1096, DOI 10.1073/pnas.97.3.1096; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Waters MG, 2000, TRAFFIC, V1, P588, DOI 10.1034/j.1600-0854.2000.010802.x; Yang F, 2001, NAT NEUROSCI, V4, P19, DOI 10.1038/82858	48	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29065	29071		10.1074/jbc.M302386200	http://dx.doi.org/10.1074/jbc.M302386200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12754199	hybrid			2022-12-25	WOS:000184421100089
J	Cui, XL; Rouhani, FN; Hawari, F; Levine, SJ				Cui, XL; Rouhani, FN; Hawari, F; Levine, SJ			An aminopeptidase, ARTS-1, is required for interleukin-6 receptor shedding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE IL-6 RECEPTOR; NECROSIS-FACTOR-ALPHA; SIGNAL TRANSDUCER GP130; METALLOPROTEINASE INHIBITOR; ANTIINFLAMMATORY CYTOKINE; MESSENGER-RNA; CELLS; PROTEIN; ASSOCIATION; KINASES	Aminopeptidase regulator of TNFR1 shedding (ARTS-1) binds to the type I tumor necrosis factor receptor (TNFR1) and promotes receptor shedding. Because hydroxamic acid-based metalloprotease inhibitors prevent shedding of both TNFR1 and the interleukin-6 receptor (IL-6Ralpha), we hypothesized that ARTS-1 might also regulate shedding of IL-6Ralpha, a member of the type I cytokine receptor superfamily that is structurally different from TNFR1. Reciprocal co-immunoprecipitation experiments identified that membrane-associated ARTS-1 directly binds to a 55-kDa IL-6Ralpha, a size consistent with soluble IL-6Ralpha generated by ectodomain cleavage of the membrane-bound receptor. Furthermore, ARTS-1 promoted IL-6Ralpha shedding, as demonstrated by a direct correlation between increased membrane-associated ARTS-1 protein, increased IL-6Ralpha shedding, and decreased membrane-associated IL-6Ralpha in cell lines overexpressing ARTS-1. The absence of basal IL-6Ralpha shedding from arts-1 knock-out cells identified that ARTS-1 was required for constitutive IL-6Ralpha shedding. Furthermore, the mechanism of constitutive IL-6Ralpha shedding requires ARTS-1 catalytic activity. Thus, ARTS-1 promotes the shedding of two cytokine receptor superfamilies, the type I cytokine receptor superfamily (IL-6Ralpha) and the TNF receptor superfamily (TNFR1). We propose that ARTS-1 is a multifunctional aminopeptidase that may modulate inflammatory events by promoting IL-6Ralpha and TNFR1 shedding.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Levine, SJ (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Bldg 10,Rm 6D03,MSC 1590, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002544, ZIAHL002544] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Cui XL, 2002, J CLIN INVEST, V110, P515, DOI 10.1172/JCI200213847; DAEIPOUR M, 1993, J IMMUNOL, V150, P4743; DEVAULT A, 1988, J BIOL CHEM, V263, P4033; GalleaRobache S, 1997, CYTOKINE, V9, P340, DOI 10.1006/cyto.1996.0174; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Hargreaves PG, 1998, BRIT J HAEMATOL, V101, P694, DOI 10.1046/j.1365-2141.1998.00754.x; Hattori A, 1999, J BIOCHEM-TOKYO, V125, P931, DOI 10.1093/oxfordjournals.jbchem.a022371; Hattori A, 2001, J BIOCHEM-TOKYO, V130, P235, DOI 10.1093/oxfordjournals.jbchem.a002977; Hattori A, 2000, J BIOCHEM-TOKYO, V128, P755, DOI 10.1093/oxfordjournals.jbchem.a022812; HORIUCHI S, 1994, EUR J IMMUNOL, V24, P1945, DOI 10.1002/eji.1830240837; Hurst SM, 2001, IMMUNITY, V14, P705, DOI 10.1016/S1074-7613(01)00151-0; Ishihara K, 2002, CYTOKINE GROWTH F R, V13, P357, DOI 10.1016/S1359-6101(02)00027-8; Jones SA, 1998, EUR J IMMUNOL, V28, P3514, DOI 10.1002/(SICI)1521-4141(199811)28:11<3514::AID-IMMU3514>3.3.CO;2-K; Jones SA, 2001, FASEB J, V15, P43, DOI 10.1096/fj.99-1003rev; Kallen KJ, 2002, BBA-MOL CELL RES, V1592, P323, DOI 10.1016/S0167-4889(02)00325-7; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Marin V, 2002, EUR J IMMUNOL, V32, P2965, DOI 10.1002/1521-4141(2002010)32:10<2965::AID-IMMU2965>3.0.CO;2-V; Montero-Julian FA, 2001, CELL MOL BIOL, V47, P583; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; MULLBERG J, 1995, J IMMUNOL, V155, P5198; MULLBERG J, 1994, J IMMUNOL, V152, P958; Muller-Newen G, 1998, J IMMUNOL, V161, P6347; Oh JW, 1996, CYTOKINE, V8, P401, DOI 10.1006/cyto.1996.0055; Peters M, 1996, J EXP MED, V183, P1399, DOI 10.1084/jem.183.4.1399; Rawlings ND, 2002, NUCLEIC ACIDS RES, V30, P343, DOI 10.1093/nar/30.1.343; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schomburg L, 2000, EUR J BIOCHEM, V267, P3198, DOI 10.1046/j.1432-1327.2000.01348.x; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TILG H, 1994, BLOOD, V83, P113; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; Vermes C, 2002, J BIOL CHEM, V277, P16879, DOI 10.1074/jbc.M200546200; WANG J, 1996, ZINC METALLOPROTEASE, P131; WANG JY, 1993, P NATL ACAD SCI USA, V90, P1222, DOI 10.1073/pnas.90.4.1222; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368; Yamamoto N, 2002, HUM MUTAT, V19, P251, DOI 10.1002/humu.10047; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	45	109	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28677	28685		10.1074/jbc.M300456200	http://dx.doi.org/10.1074/jbc.M300456200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12748171	hybrid			2022-12-25	WOS:000184421100042
J	Kim, JS; Chang, JH; Yu, HK; Ahn, JH; Yum, JS; Lee, SK; Jung, KH; Park, DH; Yoon, Y; Byun, SM; Chung, SI				Kim, JS; Chang, JH; Yu, HK; Ahn, JH; Yum, JS; Lee, SK; Jung, KH; Park, DH; Yoon, Y; Byun, SM; Chung, SI			Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ENDOTHELIAL-CELLS; HUMAN LIPOPROTEIN<A>; SIGNALING PATHWAY; HUMAN-PLASMA; IN-VIVO; PLASMINOGEN; ANGIOSTATIN; EXPRESSION; BINDING	Apolipoprotein(a) (apo(a)) contains tandemly repeated kringle domains that are closely related to plasminogen kringle 4, followed by a single kringle 5-like domain and an inactive protease-like domain. Recently, the anti-angiogenic activities of apo(a) have been demonstrated both in vitro and in vivo. However, its effects on tumor angiogenesis and the underlying mechanisms involved have not been fully elucidated. To evaluate the anti-angiogenic and anti-tumor activities of the apo(a) kringle domains and to elucidate their mechanism of action, we expressed the last three kringle domains of apo(a), KIV-9, KIV-10, and KV, in Escherichia coli. The resultant recombinant protein, termed rhLK68, exhibited a dose-dependent inhibition of basic fibroblast growth factor-stimulated human umbilical vein endothelial cell proliferation and migration in vitro and inhibited the neovascularization in chick chorioallantoic membranes in vivo. The ability of rhLK68 to abrogate the activation of extracellular signal-regulated kinases appears to be responsible for rhLK68-mediated anti-angiogenesis. Furthermore, systemic administration of rhLK68 suppressed human lung (A549) and colon (HCT15) tumor growth in nude mice. Immunohistochemical examination and in situ hybridization analysis of the tumors showed a significant decrease in the number of blood vessels and the reduced expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin, indicating that suppression of angiogenesis may have played a significant role in the inhibition of tumor growth. Collectively, these results suggest that a truncated apo(a), rhLK68, is a potent anti-angiogenic and anti-tumor molecule.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Mogam Biotechnol Res Inst, Yongin 449910, Kyonggi Do, South Korea; Kangnung Natl Univ, Dept Oral Pathol, Coll Dent, Kangnung 210702, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Kangnung Wonju National University	Byun, SM (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.	smbyun@mail.kaist.ac.kr						Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Boonmark NW, 1997, J CLIN INVEST, V100, P558, DOI 10.1172/JCI119565; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chenivesse X, 1998, BIOCHEMISTRY-US, V37, P7213, DOI 10.1021/bi9721546; Cristofanilli M, 2002, NAT REV DRUG DISCOV, V1, P415, DOI 10.1038/nrd819; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Edelstein C, 1996, J LIPID RES, V37, P1786; Edelstein C, 1997, J BIOL CHEM, V272, P11079; Edelstein C, 1999, J BIOL CHEM, V274, P10019, DOI 10.1074/jbc.274.15.10019; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; FLESS GM, 1986, J BIOL CHEM, V261, P8712; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Gao GQ, 2002, J BIOL CHEM, V277, P9492, DOI 10.1074/jbc.M108004200; GUEVARA J, 1992, PROTEINS, V12, P188, DOI 10.1002/prot.340120212; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Hajitou A, 2002, FASEB J, V16, P1802, DOI 10.1096/fj.02-0109fje; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hughes SD, 1997, J CLIN INVEST, V100, P1493, DOI 10.1172/JCI119671; Irigoyen JP, 1997, J BIOL CHEM, V272, P1904, DOI 10.1074/jbc.272.3.1904; Joe YA, 1999, INT J CANCER, V82, P694, DOI 10.1002/(SICI)1097-0215(19990827)82:5<694::AID-IJC12>3.0.CO;2-C; Kim JH, 1999, EXP MOL MED, V31, P203, DOI 10.1038/emm.1999.33; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Lao YH, 2001, INT J BIOCHEM CELL B, V33, P357, DOI 10.1016/S1357-2725(01)00023-1; Lee SK, 2002, HISTOCHEM CELL BIOL, V117, P423, DOI 10.1007/s00418-002-0405-3; LOGRASSO PV, 1994, J BIOL CHEM, V269, P21820; Lou XJ, 1998, EXP MOL PATHOL, V65, P53, DOI 10.1006/exmp.1998.2230; Maru Y, 1998, J CELL PHYSIOL, V176, P223, DOI 10.1002/(SICI)1097-4652(199808)176:2<223::AID-JCP1>3.0.CO;2-Q; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; Mooser V, 1996, J CLIN INVEST, V98, P2414, DOI 10.1172/JCI119055; Mooser V, 1996, J CLIN INVEST, V97, P858, DOI 10.1172/JCI118487; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Pendurthi UR, 2002, ARTERIOSCL THROM VAS, V22, P1421, DOI 10.1161/01.ATV.0000030200.59331.3F; Pintucci G, 1999, SURGERY, V126, P422, DOI 10.1067/msy.1999.99169; Pintucci G, 2002, FASEB J, V16, P598, DOI 10.1096/fj.01-0815fje; Redlitz A, 1999, J VASC RES, V36, P28, DOI 10.1159/000025623; Ribatti D, 1998, EUR J CLIN INVEST, V28, P533; Schulter V, 2001, ARTERIOSCL THROM VAS, V21, P433, DOI 10.1161/01.ATV.21.3.433; Tang SQ, 1997, J BIOL CHEM, V272, P28704, DOI 10.1074/jbc.272.45.28704; Trieu VN, 1999, BIOCHEM BIOPH RES CO, V257, P714, DOI 10.1006/bbrc.1999.0519; Tuszynski GP, 2002, MICROVASC RES, V64, P448, DOI 10.1006/mvre.2002.2444; VANDERHOEK YY, 1993, HUM MOL GENET, V2, P361, DOI 10.1093/hmg/2.4.361; Zubilewicz A, 2001, ONCOGENE, V20, P1403, DOI 10.1038/sj.onc.1204231	47	69	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29000	29008		10.1074/jbc.M301042200	http://dx.doi.org/10.1074/jbc.M301042200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12746434	hybrid			2022-12-25	WOS:000184421100081
J	Pellieux, C; Desgeorges, A; Pigeon, CH; Chambaz, C; Yin, H; Hayoz, D; Silacci, P				Pellieux, C; Desgeorges, A; Pigeon, CH; Chambaz, C; Yin, H; Hayoz, D; Silacci, P			Cap G, a gelsolin family protein modulating protective effects of unidirectional shear stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; ENDOTHELIAL-CELLS; PULSATILE FLOW; GENE-EXPRESSION; ACTIN DYNAMICS; MOTILITY; ATHEROSCLEROSIS; GCAP39; CYTOSKELETON; HEMODYNAMICS	Atherosclerosis is a progressive and complex pathophysiological process occurring in large arteries. Although it is of multifactorial origin, the disease develops at preferential sites along the vasculature in regions experiencing specific hemodynamic conditions that are predisposed to endothelial dysfunction. The exact mechanisms allowing endothelial cells to discriminate between plaque-free and plaque-prone flows remain to be explored. To investigate such mechanisms, we performed a proteomic analysis on endothelial cells exposed in vitro to these two-flow patterns. A few spots on the two-dimensional gel had an intensity that was differentially regulated by plaque-free versus plaque-prone flows. One of them was further investigated and identified as macrophage-capping protein (Cap G), a member of the gelsolin protein superfamily. A 2-fold increase of Cap G protein and a 5-fold increase of Cap G mRNA were observed in cells exposed to a plaque-free flow as compared with static cultures. This increase was not observed in cells exposed to plaque-prone flow. Plaque-free flow induced a corresponding increase in nuclear and cytoskeletal-associated Cap G. Finally, overexpression of Cap G in transfection assays increased the motility potential of endothelial cells. These observations together with the known functions of Cap G suggest that Cap G may contribute to the protective effect exerted by plaque-free flow on endothelial cells. On the contrary, in cells exposed to a plaque-prone flow, no induction of Cap G expression could be observed.	CHU Vaudois, Div Hypertens & Vasc Med, CH-1015 Lausanne, Switzerland; Ecole Polytech Fed Lausanne, Lab Hemodynam & Cardiovasc Technol, CH-1015 Lausanne, Switzerland; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Silacci, P (corresponding author), CHU Vaudois, Div Hypertens & Vasc Med, CH-1015 Lausanne, Switzerland.							Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Azuma N, 2001, AM J PHYSIOL-HEART C, V280, pH189, DOI 10.1152/ajpheart.2001.280.1.H189; Carlier MF, 1999, J BIOL CHEM, V274, P33827, DOI 10.1074/jbc.274.48.33827; Carlier MF, 1997, J MOL BIOL, V269, P459, DOI 10.1006/jmbi.1997.1062; Chappell DC, 1998, CIRC RES, V82, P532, DOI 10.1161/01.RES.82.5.532; Chi TH, 2000, SCIENCE, V287, P1937, DOI 10.1126/science.287.5460.1937; CUCINA A, 1995, EUR J VASC ENDOVASC, V9, P86, DOI 10.1016/S1078-5884(05)80230-8; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; Davies PF, 2001, ANN NY ACAD SCI, V947, P7; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; GLAGOV S, 1988, ARCH PATHOL LAB MED, V112, P1018; Harrison VJ, 1998, J CARDIOVASC PHARM, V31, pS38, DOI 10.1097/00005344-199800001-00013; He XJ, 1996, J BIOMECH ENG-T ASME, V118, P74, DOI 10.1115/1.2795948; KU DN, 1985, ARTERIOSCLEROSIS, V5, P293, DOI 10.1161/01.ATV.5.3.293; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; Li S, 1999, J CLIN INVEST, V103, P1141, DOI 10.1172/JCI5367; Lu PJ, 1998, BIOCHEMISTRY-US, V37, P5738, DOI 10.1021/bi972551g; Malek AM, 1996, J CELL SCI, V109, P713; MOORE JE, 1992, J BIOMECH ENG-T ASME, V114, P391, DOI 10.1115/1.2891400; ONODA K, 1993, CELL MOTIL CYTOSKEL, V26, P227, DOI 10.1002/cm.970260306; ONODA K, 1993, J BIOL CHEM, V268, P4106; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; Ramsby ML, 1999, METH MOL B, V112, P53; Silacci P, 2000, NITRIC OXIDE-BIOL CH, V4, P47, DOI 10.1006/niox.2000.0271; SUN HQ, 1995, J CELL BIOL, V129, P147, DOI 10.1083/jcb.129.1.147; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639; Vyalov S, 1996, AM J PATHOL, V149, P2107; Witke W, 2001, J CELL BIOL, V154, P775, DOI 10.1083/jcb.200101113; YIN HL, 1987, BIOESSAYS, V7, P176, DOI 10.1002/bies.950070409; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; YU FX, 1991, J BIOL CHEM, V266, P19269; ZHAO SM, 1995, ARTERIOSCL THROM VAS, V15, P1781, DOI 10.1161/01.ATV.15.10.1781; Ziegler T, 1998, HYPERTENSION, V32, P351, DOI 10.1161/01.HYP.32.2.351; Ziegler T, 1998, ARTERIOSCL THROM VAS, V18, P686, DOI 10.1161/01.ATV.18.5.686	36	57	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29136	29144		10.1074/jbc.M300598200	http://dx.doi.org/10.1074/jbc.M300598200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12754261	hybrid			2022-12-25	WOS:000184421100098
J	Romsicki, Y; Scapin, G; Beaulieu-Audy, V; Patel, S; Becker, JW; Kennedy, BP; Asante-Appiah, E				Romsicki, Y; Scapin, G; Beaulieu-Audy, V; Patel, S; Becker, JW; Kennedy, BP; Asante-Appiah, E			Functional characterization and crystal structure of the C215D mutant of protein-tyrosine phosphatase-1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-TRAPPING MUTANTS; ACTIVE-SITE; MAXIMUM-LIKELIHOOD; CATALYZED REACTION; TRANSITION-STATE; 1B; INTERMEDIATE; SPECIFICITY; INHIBITOR; BINDING	We have characterized the C215D active-site mutant of protein-tyrosine phosphatase-1B (PTP-1B) and solved the crystal structure of the catalytic domain of the apoenzyme to a resolution of 1.6 Angstrom. The mutant enzyme displayed maximal catalytic activity at pH similar to4.5, which is significantly lower than the pH optimum of 6 for wildtype PTP-1B. Although both forms of the enzyme exhibited identical K-m values for hydrolysis of p-nitrophenyl phosphate at pH 4.5 and 6, the k(cat) values of C215D were similar to70- and similar to7000-fold lower than those of wild-type PTP-1B, respectively. Arrhenius plots revealed that the mutant and wild-type enzymes displayed activation energies of 61+/-1 and 18+/-2 kJ/mol, respectively, at their pH optima. Unlike wild-type PTP-1B, C215D-mediated p-nitrophenyl phosphate hydrolysis was inactivated by 1,2-epoxy-3-(p-nitrophenoxy) propane, suggesting a direct involvement of Asp(215) in catalysis. Increasing solvent microviscosity with sucrose (up to 40% (w/v)) caused a significant decrease in k(cat)/K-m of the wild-type enzyme, but did not alter the catalytic efficiency of the mutant protein. Structurally, the apoenzyme was identical to wild-type PTP-1B, aside from the flexible WPD loop region, which was in both "open" and "closed" conformations. At physiological pH, the C215D mutant of PTP-1B should be an effective substrate-trapping mutant that can be used to identify cellular substrates of PTP-1B. In addition, because of its insensitivity to oxidation, this mutant may be used for screening fermentation broth and other natural products to identify inhibitors of PTP-1B.	Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA	Merck & Company; Merck & Company	Asante-Appiah, E (corresponding author), Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, POB 1005, Pointe Claire, PQ H9R 4P8, Canada.		ID, IMCACAT/D-5867-2014					Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Asante-Appiah E, 2001, J BIOL CHEM, V276, P26036, DOI 10.1074/jbc.M011697200; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bubnik Z., 1995, SUGAR TECHNOLOGISTS, V8; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Dillet V, 2000, J PHYS CHEM B, V104, P11321, DOI 10.1021/jp001575l; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HENGGE AC, 1995, BIOCHEMISTRY-US, V34, P13982, DOI 10.1021/bi00043a003; HOPPE E, 1994, EUR J BIOCHEM, V223, P1069, DOI 10.1111/j.1432-1033.1994.tb19085.x; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kennedy BP, 2000, BIOCHEM PHARMACOL, V60, P877, DOI 10.1016/S0006-2952(00)00305-1; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1990, CRYSTALLOGRAPHIC COM; MATHLOUTHI M, 1995, SUCROSE PROPERTIES A; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; ROSE RB, 1993, BIOCHEMISTRY-US, V32, P12498, DOI 10.1021/bi00097a030; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; SALTO R, 1994, J BIOL CHEM, V269, P10691; Scapin G, 2001, PROTEIN SCI, V10, P1596, DOI 10.1110/ps.11001; Skorey KI, 2001, ANAL BIOCHEM, V291, P269, DOI 10.1006/abio.2001.5029; SUGRUE RJ, 1994, PROTEIN EXPRES PURIF, V5, P76, DOI 10.1006/prep.1994.1011; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TANG J, 1971, J BIOL CHEM, V246, P4510; TONKS NK, 1988, J BIOL CHEM, V263, P6731; Ukkola O, 2002, J INTERN MED, V251, P467, DOI 10.1046/j.1365-2796.2002.00992.x; van Huijsduijnen RH, 1998, GENE, V225, P1; Wu L, 1996, BIOCHEMISTRY-US, V35, P5426, DOI 10.1021/bi952885a; Xie LP, 2002, BIOCHEMISTRY-US, V41, P4032, DOI 10.1021/bi015904r; Yu ZH, 1996, J AM CHEM SOC, V118, P5846, DOI 10.1021/ja954069w; Zhang YL, 2000, J BIOL CHEM, V275, P34205, DOI 10.1074/jbc.M004490200; Zhang ZY, 1997, BIOCHEMISTRY-US, V36, P1362, DOI 10.1021/bi9624043; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007; ZHANG ZY, 1992, BIOCHEMISTRY-US, V31, P1701, DOI 10.1021/bi00121a018	47	9	10	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29009	29015		10.1074/jbc.M303817200	http://dx.doi.org/10.1074/jbc.M303817200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12748196	hybrid			2022-12-25	WOS:000184421100082
J	Farkas, L; Malnasi-Csizmadia, A; Nakamura, A; Kohama, K; Nyitray, L				Farkas, L; Malnasi-Csizmadia, A; Nakamura, A; Kohama, K; Nyitray, L			Localization and characterization of the inhibitory Ca2+-binding site of Physarum polycephalum myosin II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESSENTIAL LIGHT-CHAIN; CALCIUM-BINDING; REGULATORY DOMAIN; SCALLOP MYOSIN; CALMODULIN-BINDING; LOWER EUKARYOTE; EF-HANDS; ACTIN; MAGNESIUM; KINETICS	A myosin II is thought to be the driving force of the fast cytoplasmic streaming in the plasmodium of Physarum polycephalum. This regulated myosin, unique among conventional myosins, is inhibited by direct Ca2+ binding. Here we report that Ca2+ binds to the first EF-hand of the essential light chain (ELC) subunit of Physarum myosin. Flow dialysis experiments of wildtype and mutant light chains and the regulatory domain revealed a single binding site that shows moderate specificity for Ca2+. The regulatory light chain, in contrast to regulatory light chains of higher eukaryotes, is unable to bind divalent cations. Although the Ca2+-binding loop of ELC has a canonical sequence, replacement of glutamic acid to alanine in the -z coordinating position only slightly decreased the Ca2+ affinity of the site, suggesting that the Ca2+ coordination is different from classical EF-hands; namely, the specific "closed-to-open" conformational transition does not occur in the ELC in response to Ca2+. Ca2+- and Mg2+-dependent conformational changes in the microenvironment of the binding site were detected by fluorescence experiments. Transient kinetic experiments showed that the displacement of Mg2+ by Ca2+ is faster than the change in direction of cytoplasmic streaming; therefore, we conclude that Ca2+ inhibition could operate in physiological conditions. By comparing the Physarum Ca2+ site with the well studied Ca2+ switch of scallop myosin, we surmise that despite the opposite effect of Ca2+ binding on the motor activity, the two conventional myosins could have a common structural basis for Ca2+ regulation.	Eotvos Lorand Univ, Dept Biochem, H-1117 Budapest, Hungary; Gunma Univ, Sch Med, Dept Pharmacol, Gunma 371, Japan	Eotvos Lorand University; Gunma University	Nyitray, L (corresponding author), Eotvos Lorand Univ, Dept Biochem, Pazmany P Setany 1-C, H-1117 Budapest, Hungary.	nyitray@cerberus.elte.hu	Csizmadia, András Málnási/K-7632-2018; Nyitray, László/AAE-5910-2020	Csizmadia, András Málnási/0000-0002-2430-8398; Nyitray, László/0000-0003-4717-5994				BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BECKINGHAM K, 1991, J BIOL CHEM, V266, P6027; BENNETT AJ, 1986, BIOCHEM J, V233, P173, DOI 10.1042/bj2330173; Brown SE, 1997, J BIOL CHEM, V272, P3389, DOI 10.1074/jbc.272.6.3389; CAMP W. G., 1936, BULL TORREY BOT CLUB, V63, P205, DOI 10.2307/2480903; CHANTLER PD, 1981, BIOCHEMISTRY-US, V20, P210, DOI 10.1021/bi00504a035; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS JH, 1991, J MUSCLE RES CELL M, V12, P3, DOI 10.1007/BF01781170; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; EDSALL JT, 1958, BIOPHYS CHEM, V1, P591; FROMHERZ S, 1995, P NATL ACAD SCI USA, V92, P7652, DOI 10.1073/pnas.92.17.7652; HATANO S, 1966, BIOCHIM BIOPHYS ACTA, V127, P488, DOI 10.1016/0304-4165(66)90402-8; Homma K, 2001, J BIOL CHEM, V276, P34348, DOI 10.1074/jbc.M104785200; Houdusse A, 1996, STRUCTURE, V4, P1475, DOI 10.1016/S0969-2126(96)00154-2; Houdusse A, 2000, BIOPHYS J, V78, p272A; Houdusse A, 1996, STRUCTURE, V4, P21, DOI 10.1016/S0969-2126(96)00006-8; ISHIKAWA R, 1992, J MUSCLE RES CELL M, V13, P321, DOI 10.1007/BF01766460; ISHIKAWA R, 1991, J BIOL CHEM, V266, P21784; JACKSON AP, 1988, BIOCHEM J, V251, P515, DOI 10.1042/bj2510515; KAMIYA N, 1981, ANNU REV PLANT PHYS, V32, P205, DOI 10.1146/annurev.pp.32.060181.001225; KAWASAKI H, 1994, PROTEIN PROFILE, V1, P343; KESSLER D, 1980, CELL MOTIL CYTOSKEL, V1, P63, DOI 10.1002/cm.970010106; KOHAMA K, 1991, J BIOCHEM-TOKYO, V110, P566, DOI 10.1093/oxfordjournals.jbchem.a123620; KOHAMA K, 1986, J BIOCHEM-TOKYO, V99, P1433, DOI 10.1093/oxfordjournals.jbchem.a135613; KOHAMA K, 1985, P JPN ACAD B-PHYS, V61, P501, DOI 10.2183/pjab.61.501; Kohama K., 1987, Advances in Biophysics, V23, P149; KOHAMA K, 1991, J BIOCHEM-TOKYO, V110, P508, DOI 10.1093/oxfordjournals.jbchem.a123611; Kovacs M, 2002, J BIOL CHEM, V277, P28459, DOI 10.1074/jbc.M202180200; KWON H, 1990, P NATL ACAD SCI USA, V87, P4771, DOI 10.1073/pnas.87.12.4771; Malmendal A, 1999, BIOCHEMISTRY-US, V38, P11844, DOI 10.1021/bi9909288; Malmendal A, 1998, J BIOL CHEM, V273, P28994, DOI 10.1074/jbc.273.44.28994; Martin SR, 2002, PROTEIN SCI, V11, P2909, DOI 10.1110/ps.0210402; Nakamura A, 2000, BIOCHEMISTRY-US, V39, P3827, DOI 10.1021/bi991855v; Nakashima K, 1999, BIOCHEMISTRY-US, V38, P98, DOI 10.1021/bi982067t; Nakashima K, 1996, BIOCHEMISTRY-US, V35, P5602, DOI 10.1021/bi952586l; Naraghi M, 1997, CELL CALCIUM, V22, P255, DOI 10.1016/S0143-4160(97)90064-6; QUAST U, 1984, BIOCHEM BIOPH RES CO, V123, P604, DOI 10.1016/0006-291X(84)90272-9; RIDGWAY EB, 1976, J CELL BIOL, V69, P223, DOI 10.1083/jcb.69.1.223; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Stafford WF, 2001, J MOL BIOL, V307, P137, DOI 10.1006/jmbi.2000.4490; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; Szent-Gyorgyi AG, 1999, MOL CELL BIOCHEM, V190, P55, DOI 10.1023/A:1006975705724; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; TRYBUS KM, 1991, CELL MOTIL CYTOSKEL, V18, P81, DOI 10.1002/cm.970180202; Wendt T, 2001, P NATL ACAD SCI USA, V98, P4361, DOI 10.1073/pnas.071051098; WOLENSKI JS, 1995, TRENDS CELL BIOL, V5, P310, DOI 10.1016/S0962-8924(00)89053-4; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; Yokota E, 1999, PLANT PHYSIOL, V119, P231, DOI 10.1104/pp.119.1.231; Yoshimura M, 2001, J BIOL CHEM, V276, P39600, DOI 10.1074/jbc.M105080200; Zhu T, 1998, J BIOL CHEM, V273, P20481, DOI 10.1074/jbc.273.32.20481	53	6	7	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27399	27405		10.1074/jbc.M304220200	http://dx.doi.org/10.1074/jbc.M304220200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12754206	hybrid			2022-12-25	WOS:000184242700010
J	Jono, H; Xu, H; Kai, H; Lim, DJ; Kim, YS; Feng, XH; Li, JD				Jono, H; Xu, H; Kai, H; Lim, DJ; Kim, YS; Feng, XH; Li, JD			Transforming growth factor-beta-Smad signaling pathway negatively regulates nontypeable Haemophilus influenzae-induced MUC5AC mucin transcription via mitogen-activated protein kinase (MAPK) phosphatase-1-dependent inhibition of p38 MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TOLL-LIKE RECEPTOR-2; TGF-BETA; IN-VIVO; EPITHELIAL-CELLS; EXPRESSION; GENE; PATHOGENESIS; SPECIFICITY; DISEASE	In contrast to the extensive studies on the role of transforming growth factor-beta (TGF-beta) in regulating cell proliferation, differentiation, and apoptosis over the past decade, relatively little is known about the exact role of TGF-beta signaling in regulating host response in infectious diseases. Most of the recent studies have suggested that TGF-beta inhibits macrophage activation during infections with pathogens such as Trypanosoma cruzi and Leishmania, thereby favoring virulence. In certain situations, however, there is also evidence that TGF-beta has been correlated with enhanced resistance to microbes such as Candida albicans, thus benefiting the host. Despite these distinct observations that mainly focused on macrophages, little is known about how TGF-beta regulates host primary innate defensive responses, such as up-regulation of mucin, in the airway epithelial cells. Moreover, how the TGF-beta-Smad signaling pathway negatively regulates p38 mitogen-activated protein kinase (MAPK), a key pathway mediating host response to bacteria, still remains largely unknown. Here we show that nontypeable Haemophilus influenzae, a major human bacterial pathogen of otitis media and chronic obstructive pulmonary diseases, strongly induces up-regulation of MUC5AC mucin via activation of the Toll-like receptor 2-MyD88-dependent p38 pathway. Activation of TGF-beta-Smad signaling, however, leads to down-regulation of p38 by inducing MAPK phophatase-1, thereby acting as a negative regulator for MUC5AC induction. These studies may bring new insights into the novel role of TGF-beta signaling in attenuating host primary innate defensive responses and enhance our understanding of the signaling mechanism underlying the cross-talk between TGF-beta-Smad signaling pathway and the p38 MAPK pathway.	House Ear Res Inst, Gonda Dept Cell & Mol Biol, Los Angeles, CA 90057 USA; Univ So Calif, Dept Otolaryngol, Los Angeles, CA 90057 USA; Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Mol Med, Kumamoto 8620973, Japan; Vet Affairs Med Ctr, Gastrointestinal Res Lab, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	House Research Institute; University of Southern California; Kumamoto University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; Baylor College of Medicine; Baylor College of Medicine	Li, JD (corresponding author), House Ear Res Inst, Gonda Dept Cell & Mol Biol, 2100 W 3rd St, Los Angeles, CA 90057 USA.			Li, Jian-Dong/0000-0002-5593-050X	NIAMS NIH HHS [R01 AR053591] Funding Source: Medline; NIGMS NIH HHS [R01 GM063773-01, R01 GM063773] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063773] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRALNETTO M, 1992, SCIENCE, V257, P545, DOI 10.1126/science.1636092; Basbaum C, 1999, AM J RESP CRIT CARE, V160, pS44, DOI 10.1164/ajrccm.160.supplement_1.12; CARRIE S, 1992, ACTA OTO-LARYNGOL, V112, P504, DOI 10.3109/00016489209137432; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS78; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Desbois-Mouthon C, 2000, ENDOCRINOLOGY, V141, P922, DOI 10.1210/en.141.3.922; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Foxwell AR, 1998, MICROBIOL MOL BIOL R, V62, P294, DOI 10.1128/MMBR.62.2.294-308.1998; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Hill CS, 2001, CURR OPIN GENET DEV, V11, P533, DOI 10.1016/S0959-437X(00)00229-X; Horng T, 2001, P NATL ACAD SCI USA, V98, P12654, DOI 10.1073/pnas.231471798; Imasato A, 2002, J BIOL CHEM, V277, P47444, DOI 10.1074/jbc.M208140200; Jono H, 2002, J BIOL CHEM, V277, P45547, DOI 10.1074/jbc.M206883200; Kim WD, 1997, EUR RESPIR J, V10, P1914, DOI 10.1183/09031936.97.10081914; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Lawler S, 1997, J BIOL CHEM, V272, P14850, DOI 10.1074/jbc.272.23.14850; Li DZ, 1998, J BIOL CHEM, V273, P6812, DOI 10.1074/jbc.273.12.6812; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Li JD, 1997, P NATL ACAD SCI USA, V94, P967, DOI 10.1073/pnas.94.3.967; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Murphy T F, 2000, Semin Respir Infect, V15, P41; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Rao VK, 1999, FEMS MICROBIOL REV, V23, P99, DOI 10.1016/S0168-6445(98)00039-4; Reed SG, 1999, MICROBES INFECT, V1, P1313, DOI 10.1016/S1286-4579(99)00252-X; Roberts AB, 2002, CYTOKINE GROWTH F R, V13, P3, DOI 10.1016/S1359-6101(01)00027-2; Rose MC, 2001, AM J RESP CELL MOL, V25, P533, DOI 10.1165/ajrcmb.25.5.f218; Sethi S, 2000, NEW ENGL J MED, V343, P1969; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shuto T, 2002, J BIOL CHEM, V277, P17263, DOI 10.1074/jbc.M112190200; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; SILVA JS, 1991, J EXP MED, V174, P539, DOI 10.1084/jem.174.3.539; SPACCAPELO R, 1995, J IMMUNOL, V155, P1349; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; Wang BN, 2002, J BIOL CHEM, V277, P949, DOI 10.1074/jbc.M107484200; Wu GJ, 2001, GENE, V279, P17, DOI 10.1016/S0378-1119(01)00736-3; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	45	84	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27811	27819		10.1074/jbc.M301773200	http://dx.doi.org/10.1074/jbc.M301773200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12734193	hybrid			2022-12-25	WOS:000184242700062
J	Katafiasz, BJ; Nieman, MT; Wheelock, MJ; Johnson, KR				Katafiasz, BJ; Nieman, MT; Wheelock, MJ; Johnson, KR			Characterization of cadherin-24, a novel alternatively spliced type II cadherin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; TUMOR PROGRESSION; CLASSIC CADHERINS; SIGNAL PEPTIDES; P120 CATENIN; CANCER; IDENTIFICATION; REGION; REGULATOR; CARCINOMA	Cadherins comprise a superfamily of calcium-dependent cell-cell adhesion molecules. Within the superfamily are six subfamilies including type I and type II cadherins. Both type I and type II cadherins are composed of five extracellular repeat domains with conserved calcium-binding motifs, a single pass transmembrane domain, and a highly conserved cytoplasmic domain that interacts with beta-catenin and p120 catenin. In this study, we describe a novel cadherin, cadherin-24. It is a type II cadherin with a 781-codon open reading frame, which encodes a type II cadherin protein complete with five extracellular repeats containing calcium-binding motifs, a transmembrane domain, and a conserved cytoplasmic domain. Cadherin-24 has the unusual feature of being alternatively spliced in extracellular repeat 4. This alternative exon encodes 38 in-frame amino acids, resulting in an 819-amino-acid protein. Sequence analysis suggests the presence of beta-catenin and p120 catenin-binding sequences, and immunoprecipitation experiments confirm the ability of both forms of the novel cadherin to associate with alpha-catenin, beta-catenin, and p120 catenin. In addition, aggregation assays show that both forms of cadherin-24 mediate strong cell-cell adhesion.	Univ Nebraska, Med Ctr, Eppley Canc Ctr, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Coll Dent, Dept Oral Biol, Omaha, NE 68198 USA; Thromgen Inc, Ann Arbor, MI 48104 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Wheelock, MJ (corresponding author), Univ Nebraska, Med Ctr, Eppley Canc Ctr, 987696 Univ Nebraska Med Ctr, Omaha, NE 68198 USA.				NIGMS NIH HHS [GM51188] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Becker KF, 2002, J PATHOL, V197, P567, DOI 10.1002/path.1149; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Chappuis-Flament S, 2001, J CELL BIOL, V154, P231, DOI 10.1083/jcb.200103143; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; FALCONE D, 1991, MOL CELL BIOL, V11, P2656, DOI 10.1128/MCB.11.5.2656; Feltes CM, 2002, CANCER RES, V62, P6688; Fukudome Y, 2000, INT J CANCER, V88, P579, DOI 10.1002/1097-0215(20001115)88:4<579::AID-IJC10>3.0.CO;2-U; Guilford P, 1999, MOL MED TODAY, V5, P172, DOI 10.1016/S1357-4310(99)01461-6; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Hatsuzawa K, 1997, J BIOCHEM-TOKYO, V121, P270; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; JOHNSON KR, 1993, EXP CELL RES, V207, P252, DOI 10.1006/excr.1993.1191; Kawano R, 2002, J BIOL CHEM, V277, P47679, DOI 10.1074/jbc.M205328200; Kido M, 1998, GENOMICS, V48, P186, DOI 10.1006/geno.1997.5152; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis JE, 1997, J CELL BIOL, V136, P919, DOI 10.1083/jcb.136.4.919; Mareel M, 1997, J CELL PHYSIOL, V173, P271, DOI 10.1002/(SICI)1097-4652(199711)173:2<271::AID-JCP34>3.0.CO;2-G; Mbalaviele G, 1998, J CELL BIOL, V141, P1467, DOI 10.1083/jcb.141.6.1467; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; OKAZAKI M, 1994, J BIOL CHEM, V269, P12092; Orsulic S, 1999, J CELL SCI, V112, P1237; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1990, J CELL BIOL, V111, P1645, DOI 10.1083/jcb.111.4.1645; Paul R, 1997, CANCER RES, V57, P2741; Pishvaian MJ, 1999, CANCER RES, V59, P947; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; PYTELA R, 1994, METHOD ENZYMOL, V245, P420; Rudiger M, 1997, BIOTECHNIQUES, V23, P96, DOI 10.2144/97231bm20; Shimoyama Y, 2000, BIOCHEM J, V349, P159, DOI 10.1042/0264-6021:3490159; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; Takeichi M, 1994, Prog Clin Biol Res, V390, P145; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TANIHARA H, 1994, CELL ADHES COMMUN, V2, P15, DOI 10.3109/15419069409014199; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tomschy A, 1996, EMBO J, V15, P3507, DOI 10.1002/j.1460-2075.1996.tb00719.x; WAHL JK, 2003, J BIOL CHEM; Wheelock MJ, 2001, J MAMMARY GLAND BIOL, V6, P275, DOI 10.1023/A:1011319507155; WHEELOCK MJ, 2003, IN PRESS ANN REV CEL, V19	49	13	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27513	27519		10.1074/jbc.M304119200	http://dx.doi.org/10.1074/jbc.M304119200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12734196	hybrid			2022-12-25	WOS:000184242700023
J	Katome, T; Obata, T; Matsushima, R; Masuyama, N; Cantley, LC; Gotoh, Y; Kishi, K; Shiota, H; Ebina, Y				Katome, T; Obata, T; Matsushima, R; Masuyama, N; Cantley, LC; Gotoh, Y; Kishi, K; Shiota, H; Ebina, Y			Use of RNA interference-mediated gene silencing and adenoviral overexpression to elucidate the roles of AKT/protein kinase B isoforms in insulin actions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUT4 TRANSLOCATION; SERINE-THREONINE KINASE; PROTEIN-KINASE; 3T3-L1 ADIPOCYTES; AKT KINASE; GLUCOSE-TRANSPORT; GLUT4-CONTAINING VESICLES; MOLECULAR-CLONING; GLYCOGEN-SYNTHASE; RESPONSE SEQUENCE	Insulin plays a central role in the regulation of glucose homeostasis in part by stimulating glucose uptake and glycogen synthesis. The serine/threonine protein kinase Akt has been proposed to mediate insulin signaling in several processes. However, it is unclear whether Akt is involved in insulin-stimulated glucose uptake and which isoforms of Akt are responsible for each insulin action. We confirmed that expression of a constitutively active Akt, using an adenoviral expression vector, promoted translocation of glucose transporter 4 (GLUT4) to plasma membrane, 2-deoxyglucose (2-DG) uptake, and glycogen synthesis in both Chinese hamster ovary cells and 3T3-L1 adipocytes. Inhibition of Akt either by adenoviral expression of a dominant negative Akt or by the introduction of synthetic 21-mer short interference RNA against Akt markedly reduced insulin-stimulated GLUT4 translocation, 2-DG uptake, and glycogen synthesis. Experiments with isoform-specific short interference RNA revealed that Akt2, and Akt1 to a lesser extent, has an essential role in insulin-stimulated GLUT4 translocation and 2-DG uptake in both cell lines, whereas Akt1 and Akt2 contribute equally to insulin-stimulated glycogen synthesis. These data suggest a prerequisite role of Akt in insulin-stimulated glucose uptake and distinct functions among Akt isoforms.	Univ Tokushima, Div Mol Genet, Inst Enzyme Res, Grad Sch Med, Tokushima 7708503, Japan; Univ Tokushima, Dept Ophthalmol, Grad Sch Med, Tokushima 7708503, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Beth Israel Deaconess Med Ctr, Dept Med, Div Signal Transduct, Boston, MA 02215 USA	Tokushima University; Tokushima University; University of Tokyo; Harvard University; Beth Israel Deaconess Medical Center	Ebina, Y (corresponding author), Univ Tokushima, Div Mol Genet, Inst Enzyme Res, Grad Sch Med, 3-18-15 Kuramoto, Tokushima 7708503, Japan.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041890, R01GM041890] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41890, R01 GM041890] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Coffer PJ, 1998, BIOCHEM J, V335, P1; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Egawa K, 2002, J BIOL CHEM, V277, P38863, DOI 10.1074/jbc.M203132200; Egawa K, 2000, ENDOCRINOLOGY, V141, P1930, DOI 10.1210/en.141.6.1930; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Halse R, 2003, DIABETES, V52, P9, DOI 10.2337/diabetes.52.1.9; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hill MM, 1999, MOL CELL BIOL, V19, P7771; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KANAI F, 1993, J BIOL CHEM, V268, P14523; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Kishi K, 1998, DIABETES, V47, P550, DOI 10.2337/diabetes.47.4.550; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Kunstle G, 2002, MOL CELL BIOL, V22, P1513, DOI 10.1128/MCB.22.5.1513-1525.2002; Kupriyanova TA, 1999, J BIOL CHEM, V274, P1458, DOI 10.1074/jbc.274.3.1458; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Laine J, 2002, J BIOL CHEM, V277, P3743, DOI 10.1074/jbc.M107069200; Laurent D, 2000, AM J PHYSIOL-ENDOC M, V278, pE663, DOI 10.1152/ajpendo.2000.278.4.E663; Liu D, 2000, CURR BIOL, V10, P1233, DOI 10.1016/S0960-9822(00)00733-8; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; Nishikura K, 2001, CELL, V107, P415, DOI 10.1016/S0092-8674(01)00581-5; Noda Satoshi, 2000, Journal of Medical Investigation, V47, P47; Obata T, 1998, J BIOCHEM-TOKYO, V123, P813; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Tsuru M, 2002, AM J PHYSIOL-ENDOC M, V283, pE338, DOI 10.1152/ajpendo.00457.2001; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang LH, 2000, BIOCHEM J, V345, P543, DOI 10.1042/0264-6021:3450543; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8	54	164	178	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28312	28323		10.1074/jbc.M302094200	http://dx.doi.org/10.1074/jbc.M302094200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12734182	hybrid			2022-12-25	WOS:000184242700122
J	Macchi, R; Montesissa, L; Murakami, K; Ishihama, A; de Lorenzo, V; Bertoni, G				Macchi, R; Montesissa, L; Murakami, K; Ishihama, A; de Lorenzo, V; Bertoni, G			Recruitment of sigma(54)-RNA polymerase to the Pu promoter of Pseudomonas putida through integration host factor-mediated positioning switch of alpha subunit carboxyl-terminal domain on an UP-like element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; TOL PLASMID; BACTERIAL PROMOTERS; TRANSCRIPTION ACTIVATION; RECEPTOR PROTEIN; UPSTREAM ELEMENT; MINOR-GROOVE; DNA-BINDING; RRNB P1; SIGMA	The interactions between the sigma(54)-containing RNA polymerase (sigma(54)-RNAP) and the region of the Pseudomonas putida Pu promoter spanning from the enhancer to the binding site for the integration host factor (IHF) were analyzed both by DNase I and hydroxyl radical foot-printing. A short Pu region centered at position -104 was found to be involved in the interaction with sigma(54)-RNAP, both in the absence and in the presence of IHF protein. Deletion or scrambling of the -104 region strongly reduced promoter affinity in vitro and promoter activity in vivo, respectively. The reduction in promoter affinity coincided with the loss of IHF-mediated recruitment of the sigma(54)-RNAP in vitro. The experiments with oriented-alpha sigma(54)-RNAP derivatives containing bound chemical nuclease revealed interchangeable positioning of only one of the two alpha subunit carboxyl-terminal domains (alphaCTDs) both at the -104 region and in the surroundings of position -78. The addition of IHF resulted in perfect position symmetry of the two alphaCTDs. These results indicate that, in the absence of IHF, the sigma(54)-RNAP asymmetrically uses only one alphaCTD subunit to establish productive contacts with upstream sequences of the Pu promoter. In the presence of IHF-induced curvature, the closer proximity of the upstream DNA to the body of the sigma(54)-RNAP can allow the other alphaCTD to be engaged in and thus favor closed complex formation.	Univ Milan, DGBM, I-20133 Milan, Italy; Nippon Inst Biol Sci, Tokyo 1980024, Japan; CSIC, Ctr Nacl Biotecnol, Dept Microbial Biotechnol, E-28049 Madrid, Spain	University of Milan; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Bertoni, G (corresponding author), Univ Milan, DGBM, Via Celoria 26, I-20133 Milan, Italy.	giovanni.bertoni@unimi.it	BERTONI, GIOVANNI/J-3437-2012	BERTONI, GIOVANNI/0000-0001-5761-9494; de Lorenzo, Victor/0000-0002-6041-2731; Murakami, Katsuhiko/0000-0003-2244-0501				Aiyar SE, 1998, P NATL ACAD SCI USA, V95, P14652, DOI 10.1073/pnas.95.25.14652; Belyaeva TA, 1998, J MOL BIOL, V277, P789, DOI 10.1006/jmbi.1998.1666; Belyaeva TA, 1996, NUCLEIC ACIDS RES, V24, P2243, DOI 10.1093/nar/24.12.2243; Bertoni G, 1998, EMBO J, V17, P5120, DOI 10.1093/emboj/17.17.5120; BLATTER EE, 1994, CELL, V78, P889, DOI 10.1016/S0092-8674(94)90682-3; Buck M, 2000, J BACTERIOL, V182, P4129, DOI 10.1128/JB.182.15.4129-4136.2000; BUCK M, 1992, NATURE, V358, P422, DOI 10.1038/358422a0; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; Carmona M, 1999, J BIOL CHEM, V274, P33790, DOI 10.1074/jbc.274.47.33790; Cases I, 1996, MOL MICROBIOL, V19, P7, DOI 10.1046/j.1365-2958.1996.345873.x; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; DELORENZO V, 1991, EMBO J, V10, P1159, DOI 10.1002/j.1460-2075.1991.tb08056.x; Estrem ST, 1999, GENE DEV, V13, P2134, DOI 10.1101/gad.13.16.2134; Estrem ST, 1998, P NATL ACAD SCI USA, V95, P9761, DOI 10.1073/pnas.95.17.9761; Fredrick K, 1997, P NATL ACAD SCI USA, V94, P4982, DOI 10.1073/pnas.94.10.4982; FREDRICK K, 1995, P NATL ACAD SCI USA, V92, P2582, DOI 10.1073/pnas.92.7.2582; Fujita N, 2000, BIOCHEMISTRY-US, V39, P6243, DOI 10.1021/bi000020d; Gralla JD, 2000, NAT STRUCT BIOL, V7, P530, DOI 10.1038/76732; Gralla JD, 1996, ESCHERICHIA COLI SAL, P1232; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; Hochschild A, 1998, CELL, V92, P597, DOI 10.1016/S0092-8674(00)81126-5; Ishihama A, 2000, ANNU REV MICROBIOL, V54, P499, DOI 10.1146/annurev.micro.54.1.499; Jeon YH, 1997, J MOL BIOL, V267, P953, DOI 10.1006/jmbi.1997.0902; KESSLER B, 1992, MOL GEN GENET, V233, P293, DOI 10.1007/BF00587591; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Law EC, 1999, BIOCHEM J, V337, P415, DOI 10.1042/0264-6021:3370415; Maxam A M, 1980, Methods Enzymol, V65, P499; Meng WM, 2001, NUCLEIC ACIDS RES, V29, P4166, DOI 10.1093/nar/29.20.4166; MERRICK MJ, 1993, MOL MICROBIOL, V10, P903, DOI 10.1111/j.1365-2958.1993.tb00961.x; Murakami K, 1997, P NATL ACAD SCI USA, V94, P11274, DOI 10.1073/pnas.94.21.11274; Murakami K, 1997, P NATL ACAD SCI USA, V94, P1709, DOI 10.1073/pnas.94.5.1709; NEWLANDS JT, 1992, NUCLEIC ACIDS RES, V20, P719, DOI 10.1093/nar/20.4.719; PerezMartin J, 1996, J MOL BIOL, V258, P562, DOI 10.1006/jmbi.1996.0269; PEREZMARTIN J, 1994, J BIOL CHEM, V269, P22657; Ramos JL, 1997, ANNU REV MICROBIOL, V51, P341, DOI 10.1146/annurev.micro.51.1.341; RAO L, 1994, J MOL BIOL, V235, P1421, DOI 10.1006/jmbi.1994.1098; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; Ross W, 1998, J BACTERIOL, V180, P5375, DOI 10.1128/JB.180.20.5375-5383.1998; Ross W, 2001, GENE DEV, V15, P491, DOI 10.1101/gad.870001; SAMBROOK J, 2000, MOL CLONING LAB MANU; SHPIGELMAN ES, 1993, COMPUT APPL BIOSCI, V9, P435; Strainic MG, 1998, BIOCHEMISTRY-US, V37, P18074, DOI 10.1021/bi9813431; Xu H, 2001, CURR OPIN MICROBIOL, V4, P138, DOI 10.1016/S1369-5274(00)00179-X; Yasuno K, 2001, J MOL BIOL, V306, P213, DOI 10.1006/jmbi.2000.4369; Zhang X, 2002, MOL MICROBIOL, V45, P895, DOI 10.1046/j.1365-2958.2002.03065.x	46	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27695	27702		10.1074/jbc.M303031200	http://dx.doi.org/10.1074/jbc.M303031200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12754257	hybrid			2022-12-25	WOS:000184242700047
J	Ruan, H; Pownall, HJ; Lodish, HF				Ruan, H; Pownall, HJ; Lodish, HF			Troglitazone antagonizes tumor necrosis factor-alpha-induced reprogramming of adipocyte gene expression by inhibiting the transcriptional regulatory functions of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; INDUCED INSULIN-RESISTANCE; HORMONE-SENSITIVE LIPASE; PPAR-GAMMA; 3T3-L1 ADIPOCYTES; TNF-ALPHA; THIAZOLIDINEDIONES BLOCK; ADIPOSE-TISSUE; IN-VIVO; DIFFERENTIATION	Troglitazone (TGZ), a member of the thiazolidinedione class of anti-diabetic compounds and a peroxisome proliferator activator receptor-gamma (PPAR-gamma) agonist, restores systemic insulin sensitivity and improves the full insulin resistance syndrome in vivo. The mechanisms underlying its in vivo function are not understood. Here we investigated the potential functional interaction between PPAR-gamma and NF-kappaB in adipocytes. We show that TGZ selectively blocked tumor necrosis factor-alpha-induced and NF-kappaB-dependent repression of multiple adipocyte-specific genes and induction of growth phase and other genes. This occurs without interfering with NF-kappaB expression, activation, nuclear translocation, or DNA binding and without suppressing NF-kappaB-dependent survival signals. Notably, the expressions of some tumor necrosis factor-alpha-induced genes in adipocytes were unaffected by PPAR-gamma activation. In reporter gene assays in HeLa cells, ectopic expression of PPAR-gamma abolished induction of a NF-kappaB-responsive reporter gene by the p65 subunit (RelA) of NF-kappaB, and the inhibition was further enhanced in the presence of TGZ. Conversely, overexpression of p65 inhibited induction of a PPAR-gamma-responsive reporter gene by activated PPAR-gamma in a dose-dependent manner. The inhibitory effect was independent of the presence of NF-kappaB-binding sites in the promoter region. Other NF-kappaB family members, p50 and c-Rel as well as the S276A mutant of p65, blocked PPAR-gamma-mediated gene transcription less effectively. Thus, p65 antagonizes the transcriptional regulatory activity of PPAR-gamma in adipocytes, and PPAR-gamma activation can at least partially override the inhibitory effects of p65 on the expression of key adipocyte genes. Our data suggest that inhibition of NF-kappaB activity is a mechanism by which PPAR-gamma agonists improve insulin sensitivity in vivo and that adipocyte NF-kappaB is a potential therapeutic target for obesity-linked type 2 diabetes.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Baylor Coll Med, Sect Atheroclerosis & Lipoprot Res, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Program Cardiovas Studies, Dept Med, Houston, TX 77030 USA; Methodist Hosp, Houston, TX 77030 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Massachusetts Institute of Technology (MIT)	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr,Rm 601, Cambridge, MA 02142 USA.	lodish@wi.mit.edu		Pownall, Henry/0000-0001-8412-506X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056865, R01HL030914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK047618] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-30914, HL-56865] Funding Source: Medline; NIDDK NIH HHS [R37-DK-47618] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boden G, 2001, ENDOCRIN METAB CLIN, V30, P801, DOI 10.1016/S0889-8529(05)70216-4; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Fasshauer M, 2002, BIOCHEM BIOPH RES CO, V290, P1084, DOI 10.1006/bbrc.2001.6307; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Fruebis J, 1997, ARTERIOSCL THROM VAS, V17, P1289, DOI 10.1161/01.ATV.17.7.1289; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Glorian M, 2001, BIOCHIMIE, V83, P933, DOI 10.1016/S0300-9084(01)01343-8; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hauner H, 2002, DIABETES-METAB RES, V18, pS10, DOI 10.1002/dmrr.249; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Lebovitz HE, 2001, RECENT PROG HORM RES, V56, P265, DOI 10.1210/rp.56.1.265; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Liu LS, 1998, DIABETES, V47, P515, DOI 10.2337/diabetes.47.4.515; Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; Marx N, 1999, CIRCULATION, V99, P3125, DOI 10.1161/01.CIR.99.24.3125; Miles PDG, 1997, DIABETES, V46, P1678, DOI 10.2337/diabetes.46.11.1678; Mirzadegan T, 2000, J BIOL CHEM, V275, P25562, DOI 10.1074/jbc.M000692200; Misra P, 2002, J BIOL CHEM, V277, P20011, DOI 10.1074/jbc.M201739200; Moller DE, 2000, TRENDS ENDOCRIN MET, V11, P212, DOI 10.1016/S1043-2760(00)00272-1; Nordt TK, 2000, SEMIN THROMB HEMOST, V26, P495, DOI 10.1055/s-2000-13205; OHSUMI J, 1994, ENDOCRINOLOGY, V135, P2279, DOI 10.1210/en.135.5.2279; Okazaki H, 2002, DIABETES, V51, P3368, DOI 10.2337/diabetes.51.12.3368; Olefsky JM, 2000, TRENDS ENDOCRIN MET, V11, P362, DOI 10.1016/S1043-2760(00)00306-4; OLEFSKY JM, 1995, AM J CLIN NUTR, V61, p980S, DOI 10.1093/ajcn/61.4.980S; Peraldi P, 1997, J CLIN INVEST, V100, P1863, DOI 10.1172/JCI119715; Qi C, 2000, CELL BIOCHEM BIOPHYS, V32, P187, DOI 10.1385/CBB:32:1-3:187; REAVEN GM, 1993, ANNU REV MED, V44, P121, DOI 10.1146/annurev.me.44.020193.001005; RESHEFF L, 1970, J BIOL CHEM, V245, P5979; Ribon V, 1998, P NATL ACAD SCI USA, V95, P14751, DOI 10.1073/pnas.95.25.14751; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Ruan H, 2002, DIABETES, V51, P3176, DOI 10.2337/diabetes.51.11.3176; Ruan H, 2002, DIABETES, V51, P1319, DOI 10.2337/diabetes.51.5.1319; Ruan H, 2001, DIABETES, V50, P233, DOI 10.2337/diabetes.50.2.233; Scherer PE, 1998, NAT BIOTECHNOL, V16, P581, DOI 10.1038/nbt0698-581; Souza SC, 1998, DIABETES, V47, P691, DOI 10.2337/diabetes.47.4.691; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Stein O, 2002, ATHEROSCLEROSIS, V160, P1, DOI 10.1016/S0021-9150(01)00664-5; STEPHENS JM, 1992, J BIOL CHEM, V267, P13580; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; SUMIDA M, 1990, J BIOCHEM-TOKYO, V107, P1; SZALKOWSKI D, 1995, ENDOCRINOLOGY, V136, P1474, DOI 10.1210/en.136.4.1474; Takamura T, 2001, EUR J PHARMACOL, V422, P23, DOI 10.1016/S0014-2999(01)01053-6; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Waltner-Law M, 2000, J BIOL CHEM, V275, P31847, DOI 10.1074/jbc.M003656200; Yamauchi T, 2001, J BIOL CHEM, V276, P41245, DOI 10.1074/jbc.M103241200; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zhang B, 1996, MOL ENDOCRINOL, V10, P1457, DOI 10.1210/me.10.11.1457; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	57	150	163	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28181	28192		10.1074/jbc.M303141200	http://dx.doi.org/10.1074/jbc.M303141200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12732648	hybrid			2022-12-25	WOS:000184242700107
J	Zhang, CL; Kavurma, MM; Lai, A; Khachigian, LM				Zhang, CL; Kavurma, MM; Lai, A; Khachigian, LM			Ets-1 protects vascular smooth muscle cells from undergoing apoptosis by activating p21(WAF1/Cip1) - Ets-1 regulates basal and inducible p21(WAF1/Cip1) transcription via distinct cis-acting elements in the p21(WAF1/Cip1) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; INHIBITOR; SP1; DIFFERENTIATION; PROLIFERATION; INTERACTS; GENE; P53	The cyclin-dependent kinase inhibitor (CKI) p21(WAF1/Cip1) is regulated at the level of transcription by nuclear factors such as the co-activator p300. It is presently unknown whether the Ets family of transcription factors control p21(WAF1/Cip1) gene expression. Ets-1 inhibits apoptosis in vascular smooth muscle cells as determined by both fluorescein isothiocyanate-linked annexin V/propidium iodide staining of cells and fluorescence-activated cell sorting analysis and quantitative cytoplasmic histone-associated internucleosomal DNA fragmentation. p21(WAF1/Cip1) can play a mitogenic and anti-apoptotic role in smooth muscle cells. Using transient transfection and Western blot analysis, we determined that Ets-1 activates p21(WAF1/Cip1) transcription and protein expression. Electrophoretic mobility shift assays revealed that Ets-1 interacts selectively with the (-1350)GGAA(-1347) Ets element in the p21(WAF1/Cip1) promoter. Mutation of this element reduced basal and Ets-1-inducible p21(WAF1/Cip1) promoter-dependent expression. In contrast, the (-1577)GGAT(-1574) motif mediates basal but not Ets-1 activation of the p21(WAF1/Cip1) promoter. Co-immunoprecipitation and co-transfection analysis showed that Ets-1 binds p300 and cooperatively activates p21(WAF1/Cip1) transcription. The phenotypic importance of Ets-1 regulation of p21(WAF1/Cip1) was demonstrated by the capacity of antisense p21(WAF1/Cip1) strategies to block Ets-1-inhibition of apoptosis and inhibit Ets-1-induction of proliferation.	Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia; Prince Wales Hosp, Dept Haematol, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Khachigian, LM (corresponding author), Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia.		Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323; Kavurma, Mary/0000-0001-7353-0932				Billon N, 1996, ONCOGENE, V13, P2047; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; HARPER JW, 1993, CELL, V75, P805; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Kavurma MM, 2002, J BIOL CHEM, V277, P36244, DOI 10.1074/jbc.M200463200; Kintscher U, 2000, ARTERIOSCL THROM VAS, V20, P1216, DOI 10.1161/01.ATV.20.5.1216; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Santiago FS, 1999, AM J PATHOL, V155, P897, DOI 10.1016/S0002-9440(10)65189-9; Taylor LM, 2000, J BIOL CHEM, V275, P16709, DOI 10.1074/jbc.275.22.16709; Teruyama K, 2001, J CELL PHYSIOL, V188, P243, DOI 10.1002/jcp.1112; Verger A, 2002, BIOESSAYS, V24, P362, DOI 10.1002/bies.10068; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Weiss RH, 2000, J BIOL CHEM, V275, P10285, DOI 10.1074/jbc.275.14.10285; Weiss RH, 2000, CELL SIGNAL, V12, P413, DOI 10.1016/S0898-6568(00)00081-4; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371	21	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27903	27909		10.1074/jbc.M304328200	http://dx.doi.org/10.1074/jbc.M304328200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12740370	hybrid			2022-12-25	WOS:000184242700072
J	Davidson, WS; Hilliard, GM				Davidson, WS; Hilliard, GM			The spatial organization of apolipoprotein A-I on the edge of discoidal high density lipoprotein particles - A mass spectrometry study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER-1; TANGIER-DISEASE; STRUCTURAL MODELS; CROSS-LINKING; BELT MODEL; IDENTIFICATION; RECOMBINANTS; ORIENTATION; CHOLESTEROL; MUTATIONS	The three-dimensional structure of human apoA-I on nascent, discoidal HDL particles has been debated extensively over the past 25 years. Recent evidence has demonstrated that the alpha-helical domains of apoA-I are arranged in a belt-like orientation with the long axis of the helices perpendicular to the phospholipid acyl chains on the disc edge. However, experimental information on the spatial relationships between apoA-I molecules on the disc is lacking. To address this issue, we have taken advantage of recent advances in mass spectrometry technology combined with cleavable crosslinking chemistry to derive a set of distance constraints suitable for testing apoA-I structural models. We generated highly homogeneous, reconstituted HDL particles containing two molecules of apoA-I. These were treated with a thiol-cleavable cross-linking agent, which covalently joined Lys residues in close proximity within or between molecules of apoA-I in the disc. The cross-linked discs were then exhaustively trypsinized to generate a discrete population of peptides. The resulting peptides were analyzed by liquid chromatography/mass spectrometry before and after cleavage of the cross-links, and resulting peaks were identified based on the theoretical tryptic cleavage of apoA-I. We identified at least 8 intramolecular and 7 intermolecular cross-links in the particle. The distance constraints are used to analyze three current models of apoA-I structure. The results strongly support the presence of the salt-bridge interactions that were predicted to occur in the "double belt" model of apoA-I, but a helical hairpin model containing the same salt-bridge docking interface is also consistent with the data.	Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Univ Tennessee, Hlth Sci Ctr, Dept Mol Sci, Memphis, TN 38163 USA; Univ Tennessee, Hlth Sci Ctr, Ctr Excellence Genom & Bioinformat, Memphis, TN 38163 USA	University System of Ohio; University of Cincinnati; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Davidson, WS (corresponding author), Univ Cincinnati, Dept Pathol & Lab Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.			Davidson, William/0000-0003-2756-2989	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R43HL063542, R01HL067093, R44HL063542] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL67093, R01 HL63542] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bennett KL, 2000, PROTEIN SCI, V9, P1503, DOI 10.1110/ps.9.8.1503; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BRASSEUR R, 1992, PROTEINS, V13, P246, DOI 10.1002/prot.340130307; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brouillette CG, 2001, BBA-MOL CELL BIOL L, V1531, P4, DOI 10.1016/S1388-1981(01)00081-6; BROUILLETTE CG, 1995, BBA-LIPID LIPID MET, V1256, P103, DOI 10.1016/0005-2760(95)00018-8; DAVIDSON WS, 1995, J BIOL CHEM, V270, P5882, DOI 10.1074/jbc.270.11.5882; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1986, METHOD ENZYMOL, V128, P553; Kapron JT, 1997, PROTEIN SCI, V6, P2120; Koppaka V, 1999, J BIOL CHEM, V274, P14541, DOI 10.1074/jbc.274.21.14541; Li HH, 2002, J BIOL CHEM, V277, P39093, DOI 10.1074/jbc.M206770200; LUNDKATZ S, 1986, BIOCHEMISTRY-US, V25, P1562, DOI 10.1021/bi00355a016; Maiorano JN, 2000, J BIOL CHEM, V275, P17374, DOI 10.1074/jbc.M000044200; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; McGuire KA, 1996, J LIPID RES, V37, P1519; Panagotopulos SE, 2001, J BIOL CHEM, V276, P42965, DOI 10.1074/jbc.M106462200; Phillips JC, 1997, BIOPHYS J, V73, P2337, DOI 10.1016/S0006-3495(97)78264-X; Roberts LM, 1997, BIOCHEMISTRY-US, V36, P7615, DOI 10.1021/bi962952g; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SEGREST JP, 1977, CHEM PHYS LIPIDS, V18, P7, DOI 10.1016/0009-3084(77)90023-8; Segrest JP, 1999, J BIOL CHEM, V274, P31755, DOI 10.1074/jbc.274.45.31755; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; SWANEY JB, 1978, J BIOL CHEM, V253, P7069; TALL AR, 1977, J BIOL CHEM, V252, P4701; Tricerri MA, 2001, BIOCHEMISTRY-US, V40, P5065, DOI 10.1021/bi002815q; WLODAWER A, 1979, FEBS LETT, V104, P231, DOI 10.1016/0014-5793(79)80821-2; Xu SZ, 1997, J LIPID RES, V38, P1289; Young MM, 2000, P NATL ACAD SCI USA, V97, P5802, DOI 10.1073/pnas.090099097	30	88	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27199	27207		10.1074/jbc.M302764200	http://dx.doi.org/10.1074/jbc.M302764200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12724319	hybrid			2022-12-25	WOS:000184155700115
J	Fang, H; Chartier, J; Sodja, C; Desbois, A; Ribecco-Lutkiewicz, M; Walker, PR; Sikorska, M				Fang, H; Chartier, J; Sodja, C; Desbois, A; Ribecco-Lutkiewicz, M; Walker, PR; Sikorska, M			Transcriptional activation of the human brain-derived neurotrophic factor gene promoter III by dopamine signaling in NT2/N neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; NERVE GROWTH-FACTOR; HUMAN CELL-LINE; ALZHEIMERS-DISEASE; SYNAPTIC-TRANSMISSION; PARKINSONS-DISEASE; SUBSTANTIA-NIGRA; DIFFERENTIATED NEURONS; RECEPTOR EXPRESSION; RESPONSIVE ELEMENT	We have identified a functional cAMP-response element (CRE) in the human brain-derived neurotrophic factor (BDNF) gene promoter III and established that it participated in the modulation of BDNF expression in NT2/N neurons via downstream signaling from the D1 class of dopamine (DA) receptors. The up-regulation of BDNF expression, in turn, produced neuroprotective signals through receptor tyrosine kinase B (TrkB) and promoted cell survival under the conditions of oxygen and glucose deprivation. To our knowledge this is the first evidence showing the presence of a functional CRE in the human BDNF gene and the role of DA signaling in establishing transcriptional competence of CRE in post-mitotic NT2/N neurons. This ability of DA to regulate the expression of the BDNF survival factor has a profound significance for the nigrostriatal pathway, because it indicates the existence of a feedback loop between the neutrophin, which promotes both the maturation and survival of dopaminergic neurons, and the neurotransmitter, which the mature neurons ultimately produce and release.	Natl Res Council Canada, Inst Biol Sci, Neurobiol Program, Ottawa, ON K1A 0R6, Canada	National Research Council Canada	Fang, H (corresponding author), Natl Res Council Canada, Inst Biol Sci, Neurobiol Program, M-54,1500 Montreal Rd, Ottawa, ON K1A 0R6, Canada.	hung.fang@nrc.ca						ALTAR CA, 1992, P NATL ACAD SCI USA, V89, P11347, DOI 10.1073/pnas.89.23.11347; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Aoyama M, 2001, CANCER LETT, V164, P51, DOI 10.1016/S0304-3835(00)00715-1; Barbacid M, 1995, ANN NY ACAD SCI, V766, P442, DOI 10.1111/j.1749-6632.1995.tb26693.x; Binder DK, 2001, TRENDS NEUROSCI, V24, P47, DOI 10.1016/S0166-2236(00)01682-9; Cellerino A, 1998, J NEUROSCI, V18, P3351; Connor B, 1998, BRAIN RES REV, V27, P1, DOI 10.1016/S0165-0173(98)00004-6; Guillemain I, 2000, J COMP NEUROL, V422, P380, DOI 10.1002/1096-9861(20000703)422:3<380::AID-CNE5>3.0.CO;2-C; Guillemot F, 1999, EUR J HUM GENET, V7, P487, DOI 10.1038/sj.ejhg.5200321; Guillin O, 2001, NATURE, V411, P86, DOI 10.1038/35075076; Hartley RS, 1999, J COMP NEUROL, V407, P1, DOI 10.1002/(SICI)1096-9861(19990428)407:1<1::AID-CNE1>3.0.CO;2-Z; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; Iacovitti L, 1997, NEUROREPORT, V8, P1471, DOI 10.1097/00001756-199704140-00029; Jankowsky JL, 1999, MOL CELL NEUROSCI, V14, P273, DOI 10.1006/mcne.1999.0792; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KNIPPER M, 1994, EUR J NEUROSCI, V6, P668, DOI 10.1111/j.1460-9568.1994.tb00312.x; KNUSEL B, 1991, P NATL ACAD SCI USA, V88, P961, DOI 10.1073/pnas.88.3.961; Kuppers E, 2001, NEUROREPORT, V12, P1175; Kuppers E, 2000, MOL BRAIN RES, V81, P19, DOI 10.1016/S0169-328X(00)00156-X; KWASTWELFELD J, 1993, CELL MOL BIOL RES, V39, P231; LINDHOLM D, 1994, J NEUROBIOL, V25, P1362, DOI 10.1002/neu.480251105; Lu B, 1999, J NEUROSCI RES, V58, P76, DOI 10.1002/(SICI)1097-4547(19991001)58:1<76::AID-JNR8>3.0.CO;2-0; MAISONPIERRE PC, 1991, GENOMICS, V10, P558, DOI 10.1016/0888-7543(91)90436-I; Martin-Negrier ML, 2000, NEUROSCIENCE, V99, P257, DOI 10.1016/S0306-4522(00)00187-1; Marty S, 1996, NEURON, V16, P565, DOI 10.1016/S0896-6273(00)80075-6; McAllister AK, 1999, P NATL ACAD SCI USA, V96, P13600, DOI 10.1073/pnas.96.24.13600; Messaoudi E, 1998, J NEUROPHYSIOL, V79, P496, DOI 10.1152/jn.1998.79.1.496; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Mogi M, 1999, NEUROSCI LETT, V270, P45, DOI 10.1016/S0304-3940(99)00463-2; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Murer MG, 2001, PROG NEUROBIOL, V63, P71, DOI 10.1016/S0301-0082(00)00014-9; MURRAY KD, 1994, NEUROSCIENCE, V60, P37, DOI 10.1016/0306-4522(94)90202-X; NAKAYAMA M, 1994, MOL BRAIN RES, V21, P206, DOI 10.1016/0169-328X(94)90251-8; NarisawaSaito M, 1996, NEUROREPORT, V7, P2925, DOI 10.1097/00001756-199611250-00024; Neelands TR, 1998, J NEUROSCI, V18, P4993; Parain K, 1999, NEUROREPORT, V10, P557, DOI 10.1097/00001756-199902250-00021; PHILLIPS HS, 1991, NEURON, V7, P695, DOI 10.1016/0896-6273(91)90273-3; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; Plunkett RJ, 1997, NEUROREPORT, V8, P507, DOI 10.1097/00001756-199701200-00026; Sakolsky DJ, 2000, MOL BRAIN RES, V84, P158, DOI 10.1016/S0169-328X(00)00239-4; Schmidt U, 1996, NEUROSCIENCE, V74, P453, DOI 10.1016/0306-4522(96)00201-1; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; SHINTANI A, 1992, BIOCHEM BIOPH RES CO, V182, P325, DOI 10.1016/S0006-291X(05)80148-2; Sodja C, 2002, MOL BRAIN RES, V99, P83, DOI 10.1016/S0169-328X(01)00324-2; Tabuchi A, 2002, J BIOL CHEM, V277, P35920, DOI 10.1074/jbc.M204784200; Tao X, 2002, NEURON, V33, P383, DOI 10.1016/S0896-6273(01)00561-X; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Timmusk T, 1999, J BIOL CHEM, V274, P1078; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; Vallone D, 2000, NEUROSCI BIOBEHAV R, V24, P125, DOI 10.1016/S0149-7634(99)00063-9; YOUNKIN DP, 1993, P NATL ACAD SCI USA, V90, P2174, DOI 10.1073/pnas.90.6.2174; ZELLER M, 1995, INT J DEV NEUROSCI, V13, P437, DOI 10.1016/0736-5748(95)00025-C; Zetterstrom TSC, 1999, NEUROPHARMACOLOGY, V38, P1063, DOI 10.1016/S0028-3908(99)00022-2; Zigova T, 2000, DEV BRAIN RES, V122, P87, DOI 10.1016/S0165-3806(00)00055-9	56	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26401	26409		10.1074/jbc.M211539200	http://dx.doi.org/10.1074/jbc.M211539200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12738784	hybrid			2022-12-25	WOS:000184155700016
J	Wood, JR; Nelson, VL; Ho, C; Jansen, E; Wang, CY; Urbanek, M; McAllister, JM; Mosselman, S; Strauss, JF				Wood, JR; Nelson, VL; Ho, C; Jansen, E; Wang, CY; Urbanek, M; McAllister, JM; Mosselman, S; Strauss, JF			The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PROTEIN STAR; STIMULATING-HORMONE RECEPTOR; TRANSCRIPTION FACTORS GATA-4; BONE MORPHOGENETIC PROTEIN; RETINOIC ACID; 17,20-LYASE ACTIVITY; BINDING PROTEINS; HUMAN P450C17; EXPRESSION; FAMILY	Polycystic ovary syndrome (PCOS) affects 5% of reproductive aged women and is the leading cause of anovulatory infertility. A hallmark of PCOS is excessive theca cell androgen secretion, which is directly linked to the symptoms of PCOS. Our previous studies demonstrated that theca cells from PCOS ovaries maintained in long term culture persistently secrete significantly greater amounts of androgens than normal theca cells, suggesting an intrinsic abnormality. Furthermore, previous studies suggested that ovarian hyperandrogenemia is inherited as an autosomal dominant trait. However, the genes responsible for ovarian hyperandrogenemia of PCOS have not been identified. In this present study, we carried out microarray analysis to define the gene networks involved in excess androgen synthesis by the PCOS theca cells in order to identify candidate PCOS genes. Our analysis revealed that PCOS theca cells have a gene expression profile that is distinct from normal theca cells. Included in the cohort of genes with increased mRNA abundance in PCOS theca cells were aldehyde dehydrogenase 6 and retinol dehydrogenase 2, which play a role in all-trans-retinoic acid biosynthesis and the transcription factor GATA6. We demonstrated that retinoic acid and GATA6 increased the expression of 17alpha-hydroxylase, providing a functional link between altered gene expression and intrinsic abnormalities in PCOS theca cells. Thus, our analyses have 1) defined a stable molecular phenotype of PCOS theca cells, 2) suggested new mechanisms for excess androgen synthesis by PCOS theca cells, and 3) identified new candidate genes that may be involved in the genetic etiology of PCOS.	Univ Penn, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA; Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Northwestern Univ, Feinberg Sch Med, Div Endocrinol Metab & Mol Med, Chicago, IL 60611 USA; NV Organon, Target Discovery Unit, NL-5340 BH Oss, Netherlands; NV Organon, Dept Pharmacol, NL-5340 BH Oss, Netherlands	University of Pennsylvania; Pennsylvania Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Northwestern University; Feinberg School of Medicine; Merck & Company; Merck & Company	Strauss, JF (corresponding author), Univ Penn, Ctr Res Reprod & Womens Hlth, 1349 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	jfs3@mail.med.upenn.edu	Ho, Clement KM/A-6261-2011; Wood, Jennifer R/S-3213-2019	Ho, Clement KM/0000-0003-1469-5467; Wood, Jennifer R/0000-0001-9337-5837; Urbanek, Margrit/0000-0001-6994-7110	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD034449] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007305] Funding Source: NIH RePORTER; NICHD NIH HHS [T32-HD07305, U54-HD34449] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		*AFF INC, 2001, AFF MICR SUIT VERS 5; Auchus RJ, 1998, J BIOL CHEM, V273, P3158, DOI 10.1074/jbc.273.6.3158; AXELROD LR, 1962, J CLIN ENDOCR METAB, V22, P431, DOI 10.1210/jcem-22-4-431; Behrens J, 2000, J CELL SCI, V113, P911; Bell SE, 2001, J CELL SCI, V114, P2755; Ben-Shlomo I, 2002, ENDOCRINOLOGY, V143, P2041, DOI 10.1210/en.143.6.2041; Brewer A, 1999, J BIOL CHEM, V274, P38004, DOI 10.1074/jbc.274.53.38004; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; Bruno MD, 2000, J BIOL CHEM, V275, P1043, DOI 10.1074/jbc.275.2.1043; Chetyrkin SV, 2001, J BIOL CHEM, V276, P22278, DOI 10.1074/jbc.M102076200; Chetyrkin SV, 2001, ARCH BIOCHEM BIOPHYS, V386, P1, DOI 10.1006/abbi.2000.2203; Christenson LK, 1999, J BIOL CHEM, V274, P26591, DOI 10.1074/jbc.274.37.26591; Christenson LK, 2001, J BIOL CHEM, V276, P27392, DOI 10.1074/jbc.M101650200; Christenson LK, 2000, BBA-MOL CELL BIOL L, V1529, P175, DOI 10.1016/S1388-1981(00)00147-5; Constam DB, 1999, J CELL BIOL, V144, P139, DOI 10.1083/jcb.144.1.139; Dale TC, 1998, BIOCHEM J, V329, P209; Dufau ML, 1997, STEROIDS, V62, P128, DOI 10.1016/S0039-128X(96)00171-7; EHRMANN DA, 1995, ENDOCR REV, V16, P322, DOI 10.1210/er.16.3.322; FRANKS S, 1995, NEW ENGL J MED, V333, P853, DOI 10.1056/NEJM199509283331307; GADDYKURTEN D, 1995, RECENT PROG HORM RES, V50, P109; Geller DH, 1999, MOL ENDOCRINOL, V13, P167, DOI 10.1210/me.13.1.167; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GILLINGSMITH C, 1994, J CLIN ENDOCR METAB, V79, P1158, DOI 10.1210/jc.79.4.1158; Gillio-Meina C, 2003, BIOL REPROD, V68, P412, DOI 10.1095/biolreprod.102.009092; Gottesman ME, 2001, BIOESSAYS, V23, P409, DOI 10.1002/bies.1059; Heikinheimo M, 1997, ENDOCRINOLOGY, V138, P3505, DOI 10.1210/en.138.8.3505; Hsieh M, 2002, ENDOCRINOLOGY, V143, P898, DOI 10.1210/en.143.3.898; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Knight PG, 2001, REPRODUCTION, V121, P503, DOI 10.1530/reprod/121.4.503; Knight PG, 1996, FRONT NEUROENDOCRIN, V17, P476, DOI 10.1006/frne.1996.0013; Laitinen MPE, 2000, J CLIN ENDOCR METAB, V85, P3476, DOI 10.1210/jc.85.9.3476; Lee JH, 2002, MOL CELL BIOL, V22, P7658, DOI 10.1128/MCB.22.21.7658-7666.2002; Legro RS, 1998, RECENT PROG HORM RES, V53, P217; LEUNG PCK, 1992, ENDOCR REV, V13, P476, DOI 10.1210/er.13.3.476; Livera G, 2002, REPRODUCTION, V124, P173, DOI 10.1530/rep.0.1240173; Luu-The V, 2001, MOL CELL ENDOCRINOL, V171, P77, DOI 10.1016/S0303-7207(00)00425-1; Minegishi T, 2000, BBA-MOL CELL RES, V1495, P203, DOI 10.1016/S0167-4889(00)00003-3; Minegishi T, 2000, ARCH BIOCHEM BIOPHYS, V373, P203, DOI 10.1006/abbi.1999.1528; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Nagpal S, 1996, J INVEST DERMATOL, V106, P269, DOI 10.1111/1523-1747.ep12340668; Napoli JL, 1996, CLIN IMMUNOL IMMUNOP, V80, pS52, DOI 10.1006/clin.1996.0142; Napoli JL, 2001, MOL CELL ENDOCRINOL, V171, P103, DOI 10.1016/S0303-7207(00)00392-0; Nelson VL, 1999, MOL ENDOCRINOL, V13, P946, DOI 10.1210/me.13.6.946; Nelson VL, 2001, J CLIN ENDOCR METAB, V86, P5925, DOI 10.1210/jc.86.12.5925; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Pandey AV, 2003, J BIOL CHEM, V278, P2837, DOI 10.1074/jbc.M209527200; Pradeep PK, 2002, ENDOCRINOLOGY, V143, P2930, DOI 10.1210/en.143.8.2930; Rexer BN, 2001, CANCER RES, V61, P7065; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Rus V, 2002, CLIN IMMUNOL, V102, P283, DOI 10.1006/clim.2001.5182; *SIL GEN INC, 2002, GEN VERS 4 2; Silverman E, 1999, J BIOL CHEM, V274, P17987, DOI 10.1074/jbc.274.25.17987; Skillington J, 2002, J CELL BIOL, V159, P135, DOI 10.1083/jcb.200204060; Sreekumar R, 2002, DIABETES, V51, P1913, DOI 10.2337/diabetes.51.6.1913; Strauss JF, 1999, RECENT PROG HORM RES, V54, P369; Strauss JF, 1999, MOL ENDOCRINOL, V13, P800, DOI 10.1210/me.13.6.800; Sugawara T, 1996, BIOCHEMISTRY-US, V35, P9052, DOI 10.1021/bi960057r; Tice DA, 2002, J BIOL CHEM, V277, P14329, DOI 10.1074/jbc.M200334200; Urbanek M, 1999, P NATL ACAD SCI USA, V96, P8573, DOI 10.1073/pnas.96.15.8573; Urbanek M, 2000, J PEDIATR ENDOCR MET, V13, P1311; Wickenheisser JK, 2000, J CLIN ENDOCR METAB, V85, P2304, DOI 10.1210/jc.85.6.2304; Wu W, 2000, CURR BIOL, V10, P1611, DOI 10.1016/S0960-9822(00)00868-X; Xing WR, 2002, BIOL REPROD, V67, P204, DOI 10.1095/biolreprod67.1.204; Zawadzki J, 1992, POLYCYSTIC OVARY SYN, P377; ZHANG LH, 1995, P NATL ACAD SCI USA, V92, P10619, DOI 10.1073/pnas.92.23.10619; Zheng WL, 1999, BIOL REPROD, V60, P110, DOI 10.1095/biolreprod60.1.110; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	68	186	202	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26380	26390		10.1074/jbc.M300688200	http://dx.doi.org/10.1074/jbc.M300688200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12734205	hybrid			2022-12-25	WOS:000184155700014
J	Bornstein, G; Bloom, J; Sitry-Shevah, D; Nakayama, K; Pagano, M; Hershko, A				Bornstein, G; Bloom, J; Sitry-Shevah, D; Nakayama, K; Pagano, M; Hershko, A			Role of the SCFSkp2 ubiquitin ligase in the degradation of p21(Cip1) in S phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CELL-CYCLE; MEDIATED PROTEOLYSIS; INHIBITOR P27(KIP1); CDK INHIBITORS; HUMAN CUL-1; PROTEIN; PATHWAY; COMPLEX; P27	The cyclin-dependent kinase inhibitor p21(Cip1) has important roles in the control of cell proliferation, differentiation, senescence, and apoptosis. It has been observed that p21 is a highly unstable protein, but the mechanisms of its degradation remained unknown. We show here that p21 is a good substrate for an SCF (Skp1-Cullin1-F-box protein) ubiquitin ligase complex, which contains the F-box protein Skp2 ( S phase kinase-associated protein 2) and the accessory protein Cks1 ( cyclin kinase subunit 1). A similar ubiquitin ligase complex has been previously shown to be involved in the degradation of a related cyclin-dependent kinase inhibitor, p27(Kip1). The levels of Skp2 oscillate in the cell cycle, reaching a maximum in S phase. The ubiquitylation of p21 in vitro required the supplementation of all components of the SCF complex as well as of Cks1 and Cdk2-cyclin E. The protein kinase Cdk2-cyclin E acts both by the phosphorylation of p21 on Ser-130 and by the formation of a complex with p21, which is required for its presentation to the ubiquitin ligase. As opposed to the case of p27, the phosphorylation of p21 stimulates its ubiquitylation but is not absolutely required for this process. Levels of p21 are higher in Skp2-/- mouse embryo fibroblasts than in wild-type fibroblasts in the S phase, and the rates of the degradation of p21 are slower in cells that lack Skp2. It is suggested that SCFSkp2 participates in the degradation of p21 in the S phase.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Biochem Unit, IL-31096 Haifa, Israel; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 8128582, Japan	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; New York University; New York University; Kyushu University	Hershko, A (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Biochem Unit, POB 9649, IL-31096 Haifa, Israel.			pagano, michele/0000-0003-3210-2442	NATIONAL CANCER INSTITUTE [R01CA076584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057587] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA76584] Funding Source: Medline; NIGMS NIH HHS [R01-GM57587] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; ENDICOTT JA, 1995, EMBO J, V14, P1004, DOI 10.1002/j.1460-2075.1995.tb07081.x; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Rousseau D, 1999, ONCOGENE, V18, P4313, DOI 10.1038/sj.onc.1202686; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sitry D, 2002, J BIOL CHEM, V277, P42233, DOI 10.1074/jbc.M205254200; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WAGE S, 1994, NATURE, V369, P574; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	36	378	392	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25752	25757		10.1074/jbc.M301774200	http://dx.doi.org/10.1074/jbc.M301774200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730199	hybrid			2022-12-25	WOS:000183920200061
J	Hatley, ME; Srinivasan, S; Reilly, KB; Bolick, DT; Hedrick, CC				Hatley, ME; Srinivasan, S; Reilly, KB; Bolick, DT; Hedrick, CC			Increased production of 12/15 lipoxygenase eicosanoids accelerates monocyte/endothelial interactions in diabetic db/db mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MONOCYTE CHEMOATTRACTANT PROTEIN-1; INDUCED GENE-EXPRESSION; VASCULAR ENDOTHELIUM; GROWTH-FACTOR; C-JUN; ATHEROSCLEROTIC LESIONS; CONNECTING SEGMENT-1; PHOSPHOLIPASE A(2); INSULIN-RESISTANCE	Atherosclerosis is a major complication of diabetes. Up to 16 weeks of age, the db/db mouse is insulin-resistant and hyperglycemic and is a good model of Type 2 diabetes. After similar to16 weeks of age, the mice develop pancreatic beta cell failure that can progress to a Type 1 diabetes phenotype. We have previously shown that glucose increases production of endothelial 12/15 lipoxygenase (12/15LO) products in vitro. In young 10-week-old Type 2 diabetic db/db mice, we found significant elevations in levels of urinary 12/15LO products, 12S-hydroxyeicosatetraenoic acid (12S-HETE) and 13S-hydroxyoctadecaenoic acid (13S-HODE) in vivo compared with C57BLKS/J mice. Using isolated primary aortic endothelial cells (ECs) from db/db mice and WEHI78/24 mouse monocyte cells in static adhesion assays, we found increased WEHI monocyte adhesion to db/db ECs (14 +/- 2 monocytes/field for db/db ECs versus 4 +/- 1 monocytes/ field for C57BLKS/J ECs, p < 0.002). Thus, ECs from db/db mice appear to be "pre-activated" to bind monocytes. Analysis of db/db ECs revealed a 2-fold elevation in 12/15LO protein compared with C57BLKS/J EC. To determine that 12/15LO products were responsible for the increased monocyte adhesion observed with db/db ECs, we inhibited expression of murine 12/15LO using either an adenovirus expressing a ribozyme to 12/15LO (AdRZ) or with the 12/15LO inhibitor cinnamyl-3,4-dihydroxy-alpha-cyanocinnamate. Treatment of db/db ECs for 48 h with AdRZ or 4 h with 10 mu M cinnamyl-3,4-dihydroxy-alpha-cyanocinnamate significantly reduced monocyte adhesion to db/db endothelium ( p < 0.009). Thus, inhibition of the murine 12/15LO in db/db mice significantly reduced monocyte/endothelial interactions. We also found that adhesion of monocytes to diabetic db/db ECs was mediated by interactions of alpha(4)beta(1) integrin on monocytes with endothelial vascular cell adhesion molecule 1 and connecting segment 1 fibronectin and interactions of beta(2) integrins with endothelial intercellular adhesion molecule 1. In summary, regulation of the 12/15LO pathway is important for mediating early vascular changes in diabetes. Modulation of the 12/15LO pathway in the vessel wall may provide therapeutic benefit for early vascular inflammatory events in diabetes.	Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Div Endocrinol & Metab, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Hedrick, CC (corresponding author), Univ Virginia, Cardiovasc Res Ctr, POB 801394,415 Lane Rd,MR5 Rm G123, Charlottesville, VA 22908 USA.	cch6n@virginia.edu	Hedrick, Catherine/D-1106-2012; Bolick, David/A-3467-2017		NHLBI NIH HHS [P01 HL55798-06] Funding Source: Medline; NIDDK NIH HHS [DK39721] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL055798] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039721] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKAWA T, 1992, J BIOL CHEM, V267, P12188; ARAKAWA T, 1995, FEBS LETT, V363, P105, DOI 10.1016/0014-5793(95)00293-I; Bayraktutan U, 2002, DIABETES OBES METAB, V4, P224, DOI 10.1046/j.1463-1326.2002.00184.x; Bleich D, 1997, BIOCHEM BIOPH RES CO, V230, P448, DOI 10.1006/bbrc.1996.5981; Bleich D, 1999, J CLIN INVEST, V103, P1431, DOI 10.1172/JCI5241; Boisvert WA, 1998, J CLIN INVEST, V101, P353, DOI 10.1172/JCI1195; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Chen BK, 2000, MOL PHARMACOL, V57, P153; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHO H, 1991, J MED CHEM, V34, P1503, DOI 10.1021/jm00108a039; COLEMAN DL, 1973, DIABETOLOGIA, V9, P287, DOI 10.1007/BF01221856; COLEMAN DL, 1982, DIABETES, V31, P1; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; CRAVEN PA, 1988, DIABETES, V37, P429, DOI 10.2337/diabetes.37.4.429; Cyrus T, 1999, J CLIN INVEST, V103, P1597, DOI 10.1172/JCI5897; Dandona P, 2002, AM J CARDIOL, V90, p27G; Duckworth W C, 2001, Curr Atheroscler Rep, V3, P383, DOI 10.1007/s11883-001-0076-x; Evans JL, 2002, ENDOCR REV, V23, P599, DOI 10.1210/er.2001-0039; FOLCIK VA, 1995, J CLIN INVEST, V96, P504, DOI 10.1172/JCI118062; Funk CD, 2001, TRENDS CARDIOVAS MED, V11, P116; Furuya Y, 1999, EXP CLIN ENDOCR DIAB, V107, P299, DOI 10.1055/s-0029-1212116; George J, 2001, CIRCULATION, V104, P1646, DOI 10.1161/hc3901.095772; GERRITY RG, 1981, AM J PATHOL, V103, P191; Griendling KK, 2000, ARTERIOSCL THROM VAS, V20, P2175, DOI 10.1161/01.ATV.20.10.2175; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; Harats D, 2000, ARTERIOSCL THROM VAS, V20, P2100, DOI 10.1161/01.ATV.20.9.2100; Hedrick CC, 1999, ADV EXP MED BIOL, V469, P455; Honda HM, 1999, ARTERIOSCL THROM VAS, V19, P680, DOI 10.1161/01.ATV.19.3.680; Huggins KW, 2002, AM J PHYSIOL-ENDOC M, V283, pE994, DOI 10.1152/ajpendo.00110.2002; Huo YQ, 2001, J CLIN INVEST, V108, P1307, DOI 10.1172/JCI12877; Huo YQ, 2000, CIRC RES, V87, P153, DOI 10.1161/01.RES.87.2.153; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; Kelavkar U, 1999, ADV EXP MED BIOL, V469, P67; Kobayashi K, 2000, METABOLISM, V49, P22, DOI 10.1016/S0026-0495(00)90588-2; Kuhn H, 1999, ADV EXP MED BIOL, V447, P5; LEY K, 1995, J IMMUNOL, V155, P525; LUSCINSKAS FW, 1994, J CELL BIOL, V125, P1417, DOI 10.1083/jcb.125.6.1417; Maier KG, 2000, AM J PHYSIOL-HEART C, V279, pH863, DOI 10.1152/ajpheart.2000.279.2.H863; McEvoy LM, 1997, J EXP MED, V185, P2069, DOI 10.1084/jem.185.12.2069; MCNALLY AK, 1990, J IMMUNOL, V145, P254; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Patricia MK, 2001, CIRC RES, V88, P659, DOI 10.1161/hh0701.088838; Patricia MK, 1999, ARTERIOSCL THROM VAS, V19, P2615, DOI 10.1161/01.ATV.19.11.2615; Qiao JH, 1997, AM J PATHOL, V150, P1687; RUDERMAN NB, 1992, FASEB J, V6, P2905, DOI 10.1096/fasebj.6.11.1644256; Shi WB, 2000, CIRCULATION, V102, P75, DOI 10.1161/01.CIR.102.1.75; Shi WB, 2000, CIRC RES, V86, P1078, DOI 10.1161/01.RES.86.10.1078; Shih PT, 1999, J CLIN INVEST, V103, P613, DOI 10.1172/JCI5710; Sigari F, 1997, ARTERIOSCL THROM VAS, V17, P3639, DOI 10.1161/01.ATV.17.12.3639; SOWERS JR, 1995, HYPERTENSION, V26, P869, DOI 10.1161/01.HYP.26.6.869; SPECTOR AA, 1988, PROG LIPID RES, V27, P271, DOI 10.1016/0163-7827(88)90009-4; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Srinivasan S, 2003, CIRC RES, V92, P371, DOI 10.1161/01.RES.0000061714.74668.5C; STERN MP, 1995, DIABETES, V44, P369, DOI 10.2337/diabetes.44.4.369; Thulaseedharan N, 1995, Indian Heart J, V47, P471; Tkac I, 1997, ARTERIOSCL THROM VAS, V17, P3633, DOI 10.1161/01.ATV.17.12.3633; TSAO PS, 1994, CIRCULATION, V89, P2176, DOI 10.1161/01.CIR.89.5.2176; UUSITUPA MIJ, 1990, CIRCULATION, V82, P27, DOI 10.1161/01.CIR.82.1.27; WANG LX, 1990, J LIPID RES, V31, P2265; WIJKANDER J, 1995, J BIOL CHEM, V270, P26543, DOI 10.1074/jbc.270.44.26543; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959; YLAHERTTUALA S, 1995, J CLIN INVEST, V95, P2692, DOI 10.1172/JCI117971; Yoshimoto T, 2002, PROSTAG OTH LIPID M, V68-9, P245, DOI 10.1016/S0163-7827(97)00002-7	68	97	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25369	25375		10.1074/jbc.M301175200	http://dx.doi.org/10.1074/jbc.M301175200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12734208	hybrid			2022-12-25	WOS:000183920200015
J	Suzuki, J; Ohnishi, H; Wada, A; Hirayama, T; Ohno, H; Ueda, N; Yasuda, H; Iiri, T; Wada, Y; Futai, M; Mashima, H				Suzuki, J; Ohnishi, H; Wada, A; Hirayama, T; Ohno, H; Ueda, N; Yasuda, H; Iiri, T; Wada, Y; Futai, M; Mashima, H			Involvement of syntaxin 7 in human gastric epithelial cell vacuolation induced by the Helicobacter pylori-produced cytotoxin VacA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATE ENDOSOME-LYSOSOME; PROTEIN; BINDING; FUSION; COMPARTMENTS; VACUOLES; SNARES; LOCALIZATION; ACTIVATION; TOXIN	The Helicobacter pylori-produced cytotoxin VacA induces intracellular vacuolation. The formed vacuole is assumed to be a hybrid of late endosome and lysosome. To elucidate the molecular mechanism of VacA-induced vacuolation, we examined the participation of syntaxin 7 in the human gastric epithelial cell line AGS. Immunocytochemistry revealed that endogenous syntaxin 7 was localized to vacuoles induced by VacA. Northern and Western blotting demonstrated that VacA intoxication increased syntaxin 7 mRNA and protein expression, respectively, in a time-dependent manner. Transient transfection of dominant-negative mutant syntaxin 7, which lacks a carboxyl-terminal transmembrane domain, inhibited VacA-induced vacuolation. In contrast, transient transfection of wild-type syntaxin 7, dominant-negative mutant syntaxin 1a, or dominant-negative mutant syntaxin 4 did not alter VacA-induced vacuolation. Furthermore, under VacA treatment, neutral red dye uptake, a parameter of VacA-induced vacuolation, was inhibited in cells stably transfected with mutant syntaxin 7 but not in cells stably transfected with wild-type syntaxin 7, mutant syntaxin 1a, or mutant syntaxin 4. Sequential immunocytochemical observation confirmed that expression of mutant syntaxin 7 did not affect VacA attachment to or internalization into AGS cells. We suggest that syntaxin 7 is involved in the intracellular vacuolation induced by VacA.	Jichi Med Sch, Dept Gastroenterol, Minami Kawachi, Tochigi 3290498, Japan; Univ Tokyo, Sch Med, Dept Gastroenterol, Tokyo 1138655, Japan; Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 8528523, Japan; Showa Univ, Fujigaoka Hosp, Div Gastroenterol, Kanagawa 2278501, Japan; Univ Tokyo, Sch Med, Dept Endocrinol & Nephrol, Tokyo 1138655, Japan; Osaka Univ, Inst Sci & Ind Res, Div Biol Sci, Osaka 5670047, Japan	Jichi Medical University; University of Tokyo; Nagasaki University; Showa University; University of Tokyo; Osaka University	Ohnishi, H (corresponding author), Jichi Med Sch, Dept Gastroenterol, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.		Mashima, Hirosato/ABE-6412-2020					Breuza L, 2000, AM J PHYSIOL-CELL PH, V279, pC1239, DOI 10.1152/ajpcell.2000.279.4.C1239; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Chen D, 2000, BLOOD, V95, P921, DOI 10.1182/blood.V95.3.921.003k17_921_929; de Bernard M, 2002, CELL MICROBIOL, V4, P11, DOI 10.1046/j.1462-5822.2002.00163.x; Garner JA, 1996, INFECT IMMUN, V64, P4197, DOI 10.1128/IAI.64.10.4197-4203.1996; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; Hay JC, 2001, EXP CELL RES, V271, P10, DOI 10.1006/excr.2001.5368; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; Mashima H, 1999, DIABETES, V48, P304, DOI 10.2337/diabetes.48.2.304; Molinari M, 1997, J BIOL CHEM, V272, P25339, DOI 10.1074/jbc.272.40.25339; Mullock BM, 2000, MOL BIOL CELL, V11, P3137, DOI 10.1091/mbc.11.9.3137; Nakamura N, 2000, J BIOL CHEM, V275, P6523, DOI 10.1074/jbc.275.9.6523; Ohnishi H, 1997, J CLIN INVEST, V100, P3044, DOI 10.1172/JCI119859; Papini E, 1997, EMBO J, V16, P15, DOI 10.1093/emboj/16.1.15; PAPINI E, 1994, P NATL ACAD SCI USA, V91, P9720, DOI 10.1073/pnas.91.21.9720; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Suzuki J, 2001, J CLIN INVEST, V107, P363, DOI 10.1172/JCI10254; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; Wade N, 2001, J BIOL CHEM, V276, P19820, DOI 10.1074/jbc.M010838200; Ward DM, 2000, MOL BIOL CELL, V11, P2327, DOI 10.1091/mbc.11.7.2327; Yahiro K, 1997, BIOCHEM BIOPH RES CO, V238, P629, DOI 10.1006/bbrc.1997.7345; Yahiro K, 1999, J BIOL CHEM, V274, P36693, DOI 10.1074/jbc.274.51.36693	23	32	34	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25585	25590		10.1074/jbc.M212445200	http://dx.doi.org/10.1074/jbc.M212445200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730232	hybrid			2022-12-25	WOS:000183920200040
J	Yahagi, N; Shimano, H; Matsuzaka, T; Najima, Y; Sekiya, M; Nakagawa, Y; Ide, T; Tomita, S; Okazaki, H; Tamura, Y; Iizuka, Y; Ohashi, K; Gotoda, T; Nagai, R; Kimura, S; Ishibashi, S; Osuga, J; Yamada, N				Yahagi, N; Shimano, H; Matsuzaka, T; Najima, Y; Sekiya, M; Nakagawa, Y; Ide, T; Tomita, S; Okazaki, H; Tamura, Y; Iizuka, Y; Ohashi, K; Gotoda, T; Nagai, R; Kimura, S; Ishibashi, S; Osuga, J; Yamada, N			P53 activation in adipocytes of obese mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN-1; NECROSIS-FACTOR-ALPHA; WILD-TYPE P53; INSULIN-RESISTANCE; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; TRANSGENIC MICE; ADIPOSE-TISSUE; FAT-CELLS; EXPRESSION	The tumor suppressor p53 is a transcription factor that activates or represses its target genes after various genotoxic stresses. We have previously shown that sterol regulatory element-binding protein-1 (SREBP-1), a key transcriptional regulator of triglyceride synthesis, and the lipogenic enzymes under its control are markedly suppressed in adipocytes from genetically obese ob/ob mice. Here we demonstrate that p53 and its target genes are highly induced in adipocytes of ob/ob mice in a fed state, leading to the negative regulation of SREBP-1 and thereby lipogenic genes. In fact, disruption of p53 in ob/ob mice completely suppressed the p53-regulated genes to wild-type levels and partially restored expression of lipogenic enzymes. Consistently, reporter gene analysis showed that p53 overexpression suppressed the promoter activity of the SREBP-1c gene and its downstream genes. Thus, the activation of p53 might constitute a negative feedback loop against excess fat accumulation in adipocytes. In conclusion, we discovered a novel role of p53 in the pathophysiology of obesity.	Univ Tsukuba, Inst Clin Med, Dept Internal Med, Tsukuba, Ibaraki 3058575, Japan; Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo 1138655, Japan	University of Tsukuba; University of Tokyo	Shimano, H (corresponding author), Univ Tsukuba, Inst Clin Med, Dept Internal Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.		Yahagi, Naoya/D-2360-2014; Najima, Yuho/W-3858-2019; Shimano, Hitoshi/AAI-5648-2020; Shimano, Hitoshi/V-1761-2019	Yahagi, Naoya/0000-0002-1823-1865; Najima, Yuho/0000-0001-8910-0021; Shimano, Hitoshi/0000-0002-5562-5572				Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Balint E, 1996, CANCER RES, V56, P1648; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Butler M, 2002, DIABETES, V51, P1028, DOI 10.2337/diabetes.51.4.1028; Carvalho E, 2000, MOL CELL BIOCHEM, V206, P7, DOI 10.1023/A:1007009723616; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; HERBERG L, 1977, METABOLISM, V26, P59, DOI 10.1016/0026-0495(77)90128-7; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; INGALLS AM, 1950, J HERED, V41, P317, DOI 10.1093/oxfordjournals.jhered.a106073; Inoguchi T, 2000, DIABETES, V49, P1939, DOI 10.2337/diabetes.49.11.1939; JEOUNG DI, 1995, J BIOL CHEM, V270, P18367, DOI 10.1074/jbc.270.31.18367; Kaneto H, 2001, J BIOL CHEM, V276, P31099, DOI 10.1074/jbc.M104115200; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Loftus TM, 1998, P NATL ACAD SCI USA, V95, P14168, DOI 10.1073/pnas.95.24.14168; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAYER J, 1951, SCIENCE, V113, P746, DOI 10.1126/science.113.2948.746; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Nadler ST, 2000, P NATL ACAD SCI USA, V97, P11371, DOI 10.1073/pnas.97.21.11371; Nakashima N, 2000, J BIOL CHEM, V275, P12889, DOI 10.1074/jbc.275.17.12889; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; PHILLIPS M, 1986, J BIOL CHEM, V261, P821; RODBELL M, 1964, J BIOL CHEM, V239, P375; Rokhlin OW, 2000, ONCOGENE, V19, P1959, DOI 10.1038/sj.onc.1203453; Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shao J, 2000, J ENDOCRINOL, V167, P107, DOI 10.1677/joe.0.1670107; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 2002, VITAM HORM, V65, P167, DOI 10.1016/S0083-6729(02)65064-2; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 2000, TRENDS CARDIOVAS MED, V10, P275, DOI 10.1016/S1050-1738(00)00079-7; Shimano H, 2001, PROG LIPID RES, V40, P439, DOI 10.1016/S0163-7827(01)00010-8; Soukas A, 2000, GENE DEV, V14, P963; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; Yahagi N, 2002, J BIOL CHEM, V277, P19353, DOI 10.1074/jbc.M201584200; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	49	156	161	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25395	25400		10.1074/jbc.M302364200	http://dx.doi.org/10.1074/jbc.M302364200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12734185	hybrid			2022-12-25	WOS:000183920200018
J	Tourneur, L; Mistou, S; Michiels, FM; Devauchelle, V; Renia, L; Feunteun, J; Chiocchia, G				Tourneur, L; Mistou, S; Michiels, FM; Devauchelle, V; Renia, L; Feunteun, J; Chiocchia, G			Loss of FADD protein expression results in a biased Fas-signaling pathway and correlates with the development of tumoral status in thyroid follicular cells	ONCOGENE			English	Article						FADD; Fas ligand; thyroid; tumor	FLICE-INHIBITORY PROTEIN; COLON-CANCER CELLS; IMMUNE EVASION; DEATH PATHWAY; TRANSGENIC EXPRESSION; LYMPHOCYTE APOPTOSIS; LIGAND EXPRESSION; ENTRY SITE; PROLIFERATION; CD95	Downregulation of proapoptotic molecules like Fas or caspase 8, or upregulation of antiapoptotic molecules like FLICE inhibitory protein has been suggested to be a regulatory mechanism set up by tumor cells to block the death signal received via death receptors. In an in-depth study of the Fas/FasL-signaling pathway in thyroid tumor development, we have demonstrated that tumor cells specifically downregulate the multideath receptor adapter Fas-associated death domain (FADD). The regulation of FADD expression occurred only at the protein level. Furthermore, in the absence of FADD, Fas-signaling resulted in accelerated growth of thyrocytes. Since thyrocytes also acquired FasL expression during tumor development, the absence of FADD protein could lead to greater resistance to numerous death receptor-mediated apoptosis, stimulation of their own proliferation through Fas/FasL interaction, and the capacity to counter-attack the infiltrating lymphocytes.	Univ Paris 05, Inst Cochin, Dept Immunol, IFR 116,CNRS,UMR 8104,INSERM,U567, F-75014 Paris, France; Inst Gustave Roussy, Oncol Mol Lab, CNRS, Unite Rech Associee 1158, F-94805 Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Chiocchia, G (corresponding author), Univ Paris 05, Inst Cochin, Dept Immunol, IFR 116,CNRS,UMR 8104,INSERM,U567, 27 Rue Fbg St Jacques, F-75014 Paris, France.		Feunteun, Jean/AAZ-1267-2020; CHIOCCHIA, Gilles R/F-6287-2013; Renia, Laurent/E-2117-2011	CHIOCCHIA, Gilles R/0000-0001-9973-0940; Renia, Laurent/0000-0003-0349-1557; Feunteun, Jean/0000-0003-1212-9189				Baker JR, 1999, J CLIN ENDOCR METAB, V84, P2593, DOI 10.1210/jc.84.8.2593; Batteux F, 2000, J IMMUNOL, V164, P1681, DOI 10.4049/jimmunol.164.4.1681; Bernstein J, 1997, J BIOL CHEM, V272, P9356; Bretz JD, 1999, J BIOL CHEM, V274, P23627, DOI 10.1074/jbc.274.33.23627; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; Desbarats J, 2000, NAT MED, V6, P920, DOI 10.1038/78688; Desbarats J, 1999, P NATL ACAD SCI USA, V96, P8104, DOI 10.1073/pnas.96.14.8104; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Droin N, 2001, ONCOGENE, V20, P260, DOI 10.1038/sj.onc.1204066; Droin N, 2000, CANCER RES, V60, P7039; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; Favre-Felix N, 2000, J IMMUNOL, V164, P5023, DOI 10.4049/jimmunol.164.10.5023; Freiberg RA, 1997, J INVEST DERMATOL, V108, P215, DOI 10.1111/1523-1747.ep12334273; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; Hiromatsu Y, 1999, J CLIN ENDOCR METAB, V84, P2896, DOI 10.1210/jc.84.8.2896; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kim PKM, 1996, J IMMUNOL, V157, P5461; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; MAZIER D, 1985, SCIENCE, V227, P440, DOI 10.1126/science.3880923; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; Miller DL, 1998, FEBS LETT, V434, P417, DOI 10.1016/S0014-5793(98)01025-4; Mitsiades N, 1999, J CLIN ENDOCR METAB, V84, P2924, DOI 10.1210/jc.84.8.2924; MOLLER P, 1994, INT J CANCER, V57, P371, DOI 10.1002/ijc.2910570314; Nagata S, 1996, NAT MED, V2, P1306, DOI 10.1038/nm1296-1306; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Newton K, 2000, EMBO J, V19, P931, DOI 10.1093/emboj/19.5.931; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; OWENSCHAUB LB, 1993, J IMMUNOTHER, V14, P234, DOI 10.1097/00002371-199310000-00011; Pomerance M, 2000, J BIOL CHEM, V275, P40539, DOI 10.1074/jbc.M002097200; Restifo NP, 2000, NAT MED, V6, P493, DOI 10.1038/74955; SAID S, 1994, J ENDOCRINOL INVEST, V17, P371, DOI 10.1007/BF03349004; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; SUAREZ HG, 1991, ONCOGENE, V6, P677; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tourneur U, 2001, J IMMUNOL, V167, P1338, DOI 10.4049/jimmunol.167.3.1338; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	46	47	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2795	2804		10.1038/sj.onc.1206399	http://dx.doi.org/10.1038/sj.onc.1206399			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743602				2022-12-25	WOS:000182569300010
J	Li, ML; Ren, SX; Tilli, MT; Flaws, JA; Lubet, R; Grubbs, CJ; Furth, PA				Li, ML; Ren, SX; Tilli, MT; Flaws, JA; Lubet, R; Grubbs, CJ; Furth, PA			Chemoprevention of mammary carcinogenesis in a transgenic mouse model by alpha-difluoromethylornithine (DFMO) in the diet is associated with decreased cyclin D1 activity	ONCOGENE			English	Article						DFMO; cell proliferation; apoptosis; cyclin D1; transgenic mouse model; mammary cancer progression	CANCER CELL-LINES; TUMOR PROGRESSION; ORNITHINE DECARBOXYLASE; GROWTH-INHIBITION; MICE; APOPTOSIS; PROLIFERATION; EXPRESSION; INDUCTION; PROTEIN	Mechanisms underlying the chemopreventive effect of difluoromethylornithine (DFMO) on the development of mammary cancer were investigated utilizing the whey acidic protein promoter-T antigen transgenic mouse model of breast cancer progression. Mice were exposed to four different doses of DFMO in the diet (3.5, 4.9, 7.0 and 10 g/kg diet). Tumor latency was increased in a dose-dependent manner. DFMO at the highest dose significantly delayed tumor onset (131 days as compared to 109 days in control unexposed mice, P=0.018). Analyses of preneoplastic mammary tissue collected 1 month after DFMO treatment demonstrated that DFMO (10 g/kg diet) significantly increased the ratio of apoptotic to proliferative indices (P = 0.013) and significantly reduced the percentage of cells demonstrating nuclear localized cyclin D1 (P = 0.013). Nuclear localizations of p27, p21 and Stat5a were not affected. Inhibitory effects of DFMO on cell growth and survival were lost as the cells progressed to cancer. In conclusion, the chemopreventive effects of DFMO on mammary cancer progression were mediated by changes in both apoptosis and cell proliferation in preneoplastic cells. Alterations in cyclin D1 activity in preneoplastic cells could represent an early biomarker of chemopreventive action and are consistent with a mechanistic role for cyclin D1 in progression of mammary cancer.	Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20057 USA; Univ Maryland, Program Human Genet, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; NCI, Div Canc Prevent, Rockville, MD 20892 USA; Univ Alabama Birmingham, Birmingham, AL 35294 USA	Georgetown University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Alabama System; University of Alabama Birmingham	Furth, PA (corresponding author), Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Res Bldg,E518,3970 Reservoir Rd NW, Washington, DC 20057 USA.	paf3@georgetown.edu		Flaws, Jodi/0000-0001-5579-9268	NCI NIH HHS [N01-CN-85076-46] Funding Source: Medline; NICHD NIH HHS [HD 38955] Funding Source: Medline; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN085076] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alt JR, 2002, J BIOL CHEM, V277, P8517, DOI 10.1074/jbc.M108867200; Arbeit JM, 1999, CANCER RES, V59, P3610; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Cooper R., 1993, METHODS TOXICOLOGY B, P45; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; FOZARD JR, 1980, EUR J PHARMACOL, V65, P379, DOI 10.1016/0014-2999(80)90342-8; Furth PA, 1999, ONCOGENE, V18, P6589, DOI 10.1038/sj.onc.1203073; Furth PA, 1998, DEV BIOL STAND, V94, P281; Green JE, 2001, CANCER RES, V61, P7449; Gupta S, 2002, ONCOGENE, V21, P3727, DOI 10.1038/sj.onc.1205474; Hursting SD, 2001, J NUTR, V131, p3092S, DOI 10.1093/jn/131.11.3092S; Ioachim EE, 2000, ANTICANCER RES, V20, P4221; Joe AK, 2002, CLIN CANCER RES, V8, P893; Kelloff GJ, 1998, CANCER EPIDEM BIOMAR, V7, P65; KINGSNORTH AN, 1983, CANCER RES, V43, P4035; Li ML, 1996, CELL GROWTH DIFFER, V7, P3; Li ML, 2000, ONCOGENE, V19, P1010, DOI 10.1038/sj.onc.1203271; Masuda M, 2002, JPN J CANCER RES, V93, P329, DOI 10.1111/j.1349-7006.2002.tb02176.x; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; PEGG AE, 1987, BIOCHEM J, V241, P305, DOI 10.1042/bj2410305; Pidgeon GP, 2002, CANCER RES, V62, P2721; RATKO TA, 1990, ANTICANCER RES, V10, P67; REDDY BS, 1990, CANCER RES, V50, P2562; REDDY PRK, 1981, CONTRACEPTION, V24, P215, DOI 10.1016/0010-7824(81)90094-9; REN S, 2000, CONT TOP LAB ANIMAL, V40, P27; Ren SX, 2002, ONCOGENE, V21, P4335, DOI 10.1038/sj.onc.1205484; Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.2307/3433143; Seufferlein T, 2002, BRIT J CANCER, V86, P1188, DOI 10.1038/sj/bjc/6600186; Soler AP, 1998, CANCER RES, V58, P1654; THOMPSON HJ, 1986, CARCINOGENESIS, V7, P2003, DOI 10.1093/carcin/7.12.2003; TZENG YJ, 1993, ONCOGENE, V8, P1965; Yoshidome K, 2000, CANCER RES, V60, P6901; Zhai SP, 2002, ANN PHARMACOTHER, V36, P905; Zhang M, 2000, ONCOGENE, V19, P6053, DOI 10.1038/sj.onc.1204006	34	7	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2003	22	17					2568	2572		10.1038/sj.onc.1206314	http://dx.doi.org/10.1038/sj.onc.1206314			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730671				2022-12-25	WOS:000182569000004
J	Chellaiah, MA; Biswas, RS; Rittling, SR; Denhardt, DT; Hruska, KA				Chellaiah, MA; Biswas, RS; Rittling, SR; Denhardt, DT; Hruska, KA			Rho-dependent Rho kinase activation increases CD44 surface expression and bone resorption in osteoclasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-CELL MIGRATION; EZRIN/RADIXIN/MOESIN ERM PROTEINS; BREAST-CANCER CELLS; IN-VITRO; INTRACELLULAR OSTEOPONTIN; BASOLATERAL LOCALIZATION; EXTRACELLULAR-MATRIX; CYTOPLASMIC DOMAIN; INHIBITOR Y-27632; EPITHELIAL-CELLS	Osteoclasts from osteopontin-efficient mice exhibit decreased CD44 surface expression. Osteopontin (OPN)/alpha(v)beta(3) generated Rho signaling pathway is required for the surface expression of CD44. In this work we show the Rho effector, Rho kinase (ROK-alpha), to be a potent activator of CD44 surface expression. ROK-alpha activation was associated with autophosphorylation, leading to its translocation to the plasma membrane, as well as its association with CD44. ROK-alpha promoted CD44 surface expression through phosphorylation of CD44 and ezrin-radixin-moesin (ERM) proteins and CD44.ERM.actin complex formation. Osteoclasts from OPN-/- mice exhibited an similar to55-60% decrease in basal level ROK-alpha phosphorylation as compared with wild type osteoclasts. Furthermore, Rho(Val-14) transduction was only partially effective in stimulating ROK-alpha/CD44 phosphorylation, as well as CD44 surface expression, in these osteoclasts. Studies on the inhibition of Rho by C3 transferase or ROK-alpha by the specific inhibitor, Y-27632, showed a decrease in the phosphorylation mediated by ROK-alpha and CD44 surface expression. Neutralizing antibodies to alpha(v), beta(3), or CD44 inhibited the migration and bone resorption of wild type osteoclasts. However, only anti-alpha(v) or -beta(3) antibodies blocked OPN-induced phosphorylation of ROK-alpha, CD44, and the ERM proteins. Our results strongly suggest a role for ROK-alpha in alpha(v)beta(3)-mediated Rho signaling, which is required for the phosphorylation events and CD44 surface expression. The functional deficiencies in the Rho effector(s) because of the lack of OPN were associated with decreased CD44 surface expression and hypomotility in the OPN-/- osteoclasts. Finally, we find that cooperativity exists between alpha(v)beta(3) and CD44 for osteoclast motility and bone resorption.	Univ Maryland, Dept Oral & Craniofacial Biol Sci, Baltimore, MD 21201 USA; Rutgers State Univ, Dept Cell Biol & Neurosci, Nelson Labs, Piscataway, NJ 08854 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA	University System of Maryland; University of Maryland Baltimore; Rutgers State University New Brunswick; Washington University (WUSTL)	Chellaiah, MA (corresponding author), Univ Maryland, Dept Oral & Craniofacial Biol Sci, 666 W Baltimore St, Baltimore, MD 21201 USA.	mac001@dental.umaryland.edu			NATIONAL CANCER INSTITUTE [R01CA072740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046292, R56AR046292, R01AR041677, R01AR044434] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK009976] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES006897] Funding Source: NIH RePORTER; NCI NIH HHS [CA72740] Funding Source: Medline; NIAMS NIH HHS [AR46292, AR44434, AR41677] Funding Source: Medline; NIDDK NIH HHS [DK09976] Funding Source: Medline; NIEHS NIH HHS [ES06897] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; Baron R, 1996, REV RHUM, V63, P633; Bauer M, 1999, BLOOD, V94, P1665, DOI 10.1182/blood.V94.5.1665.417k33_1665_1672; Bito H, 2000, NEURON, V26, P431, DOI 10.1016/S0896-6273(00)81175-7; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; Chellaiah M, 2000, J CELL BIOL, V148, P665, DOI 10.1083/jcb.148.4.665; Chellaiah M, 1996, MOL BIOL CELL, V7, P743, DOI 10.1091/mbc.7.5.743; Chellaiah MA, 2003, MOL BIOL CELL, V14, P173, DOI 10.1091/mbc.E02-06-0354; Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993; Chellaiah MA, 2001, J BIOL CHEM, V276, P47434, DOI 10.1074/jbc.M107494200; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Denhardt DT, 1998, J CELL BIOCHEM, P92, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-A; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; DODDS RA, 1995, J BONE MINER RES, V10, P1666; Faccio R, 1998, BIOCHEM BIOPH RES CO, V249, P522, DOI 10.1006/bbrc.1998.9180; Gunthert U, 2000, IMMUNOLOGIST, V8, P106; HaegelKronenberger H, 1997, ADV EXP MED BIOL, V417, P83; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Huang LQ, 1999, J BIOL CHEM, V274, P12803, DOI 10.1074/jbc.274.18.12803; HUGHES DE, 1993, J BONE MINER RES, V8, P527; ISACKE CM, 1994, J CELL SCI, V107, P2353; Isacke CM, 2002, INT J BIOCHEM CELL B, V34, P718, DOI 10.1016/S1357-2725(01)00166-2; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Jamal HH, 1996, EXP CELL RES, V223, P467, DOI 10.1006/excr.1996.0103; KANEHISA J, 1988, BONE, V9, P73, DOI 10.1016/8756-3282(88)90106-8; Katagiri YU, 1999, CANCER RES, V59, P219; Kawaguchi A, 2000, EUR J PHARMACOL, V403, P203, DOI 10.1016/S0014-2999(00)00593-8; Kong QY, 2003, ONCOL REP, V10, P51; LESLEY J, 1982, IMMUNOGENETICS, V15, P313, DOI 10.1007/BF00364339; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LESLEY J, 1998, FRONT BIOSCI, V3, P616; Leung T, 1996, MOL CELL BIOL, V16, P5313; LIAW L, 1994, CIRC RES, V74, P214, DOI 10.1161/01.RES.74.2.214; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MCKEE MD, 1990, ANAT REC, V228, P77, DOI 10.1002/ar.1092280112; Nakamura F, 1995, J BIOL CHEM, V270, P31377, DOI 10.1074/jbc.270.52.31377; Nakamura F, 1996, BIOCHEM BIOPH RES CO, V226, P650, DOI 10.1006/bbrc.1996.1410; Nakamura H, 1996, J BONE MINER RES, V11, P1715; NAKAMURA H, 1995, CELL TISSUE RES, V280, P225, DOI 10.1007/BF00307793; Nakamura N, 2000, GENES CELLS, V5, P571, DOI 10.1046/j.1365-2443.2000.00348.x; Naor D, 1998, CURR TOP MICROBIOL, V231, P143; NAOT D, 1997, ADV CANCER RES, V71, P241; Narumiya S, 2000, METHOD ENZYMOL, V325, P273; NEAME SJ, 1993, J CELL BIOL, V121, P1299, DOI 10.1083/jcb.121.6.1299; NEAME SJ, 1992, EMBO J, V11, P4733, DOI 10.1002/j.1460-2075.1992.tb05578.x; Ohnaka K, 2001, BIOCHEM BIOPH RES CO, V287, P337, DOI 10.1006/bbrc.2001.5597; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Rittling SR, 1998, J BONE MINER RES, V13, P1101, DOI 10.1359/jbmr.1998.13.7.1101; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Senger DR, 1996, BBA-MOL CELL RES, V1314, P13, DOI 10.1016/S0167-4889(96)00067-5; Sheikh H, 1996, J BIOL CHEM, V271, P12185, DOI 10.1074/jbc.271.21.12185; Sodek J, 2000, J BONE MINER RES, V15, P1218; SODEK J, 1992, CHEM BIOL MINERALIZE; Suzuki K, 2002, J BONE MINER RES, V17, P1486, DOI 10.1359/jbmr.2002.17.8.1486; TAKAISHI K, 1995, ONCOGENE, V11, P39; Tsukita S, 1996, Tanpakushitsu Kakusan Koso, V41, P1899; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; UDAGAWA N, 1996, J BONE MINER RES, V11, pS112; URUSHIDANI T, 1989, AM J PHYSIOL, V256, pG1070, DOI 10.1152/ajpgi.1989.256.6.G1070; van Driel M, 1998, LEUKEMIA, V12, P1821, DOI 10.1038/sj.leu.2401179; Van Driel M, 2002, LEUKEMIA, V16, P135, DOI 10.1038/sj.leu.2402336; Vocero-Akbani A, 2001, METHOD ENZYMOL, V332, P36; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Weber GF, 1997, P ASSOC AM PHYSICIAN, V109, P1; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Wettschureck N, 2002, J MOL MED, V80, P629, DOI 10.1007/s00109-002-0370-2; Wozniak M, 2000, J BONE MINER RES, V15, P1731, DOI 10.1359/jbmr.2000.15.9.1731; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Zohar R, 2000, J CELL PHYSIOL, V184, P118, DOI 10.1002/(SICI)1097-4652(200007)184:1<118::AID-JCP13>3.3.CO;2-P; Zohar R, 1997, J CELL PHYSIOL, V170, P88	80	68	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29086	29097		10.1074/jbc.M211074200	http://dx.doi.org/10.1074/jbc.M211074200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12730217	hybrid			2022-12-25	WOS:000184421100092
J	Ariyanayagam, MR; Oza, SL; Mehlert, A; Fairlamb, AH				Ariyanayagam, MR; Oza, SL; Mehlert, A; Fairlamb, AH			Bis(glutathionyl) spermine and other novel trypanothione analogues in Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRITHIDIA-FASCICULATA; ESCHERICHIA-COLI; GLUTATHIONE; REDUCTASE; BIOSYNTHESIS; GLUTATHIONYLSPERMIDINE; PURIFICATION; PEROXIDASE; METABOLISM; CLONING	Trypanosomatids differ from other cells in their ability to conjugate glutathione with the polyamine spermidine to form the antioxidant metabolite trypanothione (N-1, N-8-bis(glutathionyl) spermidine). In Trypanosoma cruzi, trypanothione is synthesized by an unusual trypanothione synthetase/amidase (TcTryS) that forms both glutathionylspermidine and trypanothione. Because T. cruzi is unable to synthesize putrescine and is dependent on uptake of exogenous polyamines by high affinity transporters, synthesis of trypanothione may be circumstantially limited by lack of spermidine. Here, we show that the parasite is able to circumvent the potential shortage of spermidine by conjugating glutathione with other physiological polyamine substrates from exogenous sources (spermine, N-8-acetylspermidine, and N-acetylspermine). Novel thiols were purified from epimastigotes, and structures were determined by matrix-assisted laser desorption ionization time-of-flight analysis to be N-1, N-12-bis(glutathionyl)spermine, N-1-glutathionyl-N-8-acetylspermidine, and N-1-glutathionyl-N-12-acetylspermine, respectively. Structures were confirmed by enzymatic synthesis with recombinant TcTryS, which catalyzes formation of these compounds with kinetic parameters equivalent to or better than those of spermidine. Despite containing similar amounts of spermine and spermidine, the epimastigotes, trypomastigotes, and amastigotes of T. cruzi preferentially synthesized trypanothione. Bis(glutathionyl) spermine disulfide is a physiological substrate of recombinant trypanothione reductase, comparable to trypanothione and homotrypanothione disulfides. The broad substrate specificity of TcTryS could be exploited in the design of polyamine-based inhibitors of trypanothione metabolism.	Univ Dundee, Wellcome Trust Bioctr, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland	University of Dundee	Fairlamb, AH (corresponding author), Univ Dundee, Wellcome Trust Bioctr, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland.	a.h.fairlamb@dundee.ac.uk	Fairlamb, Alan/A-5272-2009	Fairlamb, Alan/0000-0001-5134-0329; Oza, Sandra/0000-0001-9404-7931				Ariyanayagam MR, 1997, MOL BIOCHEM PARASIT, V84, P111, DOI 10.1016/S0166-6851(96)02788-0; Ariyanayagam MR, 2001, MOL BIOCHEM PARASIT, V115, P189, DOI 10.1016/S0166-6851(01)00285-7; Ariyanayagam MR, 1999, MOL BIOCHEM PARASIT, V103, P61, DOI 10.1016/S0166-6851(99)00118-8; Augustyns K, 2001, CURR PHARM DESIGN, V7, P1117, DOI 10.2174/1381612013397564; BOLLINGER JM, 1995, J BIOL CHEM, V270, P14031, DOI 10.1074/jbc.270.23.14031; Bond CS, 1999, STRUCTURE, V7, P81, DOI 10.1016/S0969-2126(99)80011-2; BORGES A, 1995, EUR J BIOCHEM, V228, P745, DOI 10.1111/j.1432-1033.1995.tb20319.x; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; Dormeyer M, 2001, J BIOL CHEM, V276, P10602, DOI 10.1074/jbc.M010352200; Dumas C, 1997, EMBO J, V16, P2590, DOI 10.1093/emboj/16.10.2590; EBONG S, 1993, COMP BIOCHEM PHYS C, V106, P483, DOI 10.1016/0742-8413(93)90167-J; FAIRLAMB AH, 1987, MOL BIOCHEM PARASIT, V24, P185, DOI 10.1016/0166-6851(87)90105-8; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; FAIRLAMB AH, 1986, MOL BIOCHEM PARASIT, V21, P247, DOI 10.1016/0166-6851(86)90130-1; Fairlamb AH, 1999, MEDICINA-BUENOS AIRE, V59, P179; Fairlamb Alan H., 1997, P149; Flohe L, 1999, FREE RADICAL BIO MED, V27, P966, DOI 10.1016/S0891-5849(99)00172-0; Freire-de-Lima CG, 2000, NATURE, V403, P199, DOI 10.1038/35003208; Hamilton CJ, 2002, J CHEM SOC PERK T 1, P1115, DOI 10.1039/b110149h; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HUNTER KJ, 1994, EUR J BIOCHEM, V226, P1019, DOI 10.1111/j.1432-1033.1994.t01-1-01019.x; HUNTER KJ, 1998, POLYAMINE PROTOCOLS, P119; Jiang YQ, 1999, J BIOL CHEM, V274, P3781, DOI 10.1074/jbc.274.6.3781; Krieger S, 2000, MOL MICROBIOL, V35, P542, DOI 10.1046/j.1365-2958.2000.01721.x; LeQuesne SA, 1996, BIOCHEM J, V316, P481; Lueder DV, 1996, J BIOL CHEM, V271, P17485, DOI 10.1074/jbc.271.29.17485; Machado CA, 2001, P NATL ACAD SCI USA, V98, P7396, DOI 10.1073/pnas.121187198; Meister A, 1989, GLUTATHIONE CHEM BIO, P367; Mudumba S, 2002, BIOCHEM PHARMACOL, V63, P2011, DOI 10.1016/S0006-2952(02)00991-7; NEWTON GL, 1995, METHOD ENZYMOL, V251, P148, DOI 10.1016/0076-6879(95)51118-0; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; Oza SL, 2002, BIOCHEM J, V364, P679, DOI 10.1042/BJ20011370; Oza SL, 2002, J BIOL CHEM, V277, P35853, DOI 10.1074/jbc.M204403200; PONASIK JA, 1995, BIOCHEM J, V311, P371, DOI 10.1042/bj3110371; Reckenfelderbaumer N, 2000, J BIOL CHEM, V275, P7547, DOI 10.1074/jbc.275.11.7547; Roberts SC, 2001, MOL BIOCHEM PARASIT, V115, P217, DOI 10.1016/S0166-6851(01)00293-6; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Seiler N., 1987, INHIBITION POLYAMINE, P49; SHAMES SL, 1986, BIOCHEMISTRY-US, V25, P3519, DOI 10.1021/bi00360a007; SHIM H, 1988, J GEN MICROBIOL, V134, P807; SMITH K, 1992, PROTEIN SCI, V1, P874, DOI 10.1002/pro.5560010705; Tetaud E, 1998, MOL BIOCHEM PARASIT, V96, P111, DOI 10.1016/S0166-6851(98)00120-0; Tetaud E, 1998, J BIOL CHEM, V273, P19383, DOI 10.1074/jbc.273.31.19383; Tovar J, 1998, P NATL ACAD SCI USA, V95, P5311, DOI 10.1073/pnas.95.9.5311; VASQUEZ B, 1982, IN VITRO CELL DEV B, V18, P643; Wang ZJ, 1999, BIOCHEM PHARMACOL, V57, P1095, DOI 10.1016/S0006-2952(99)00028-3; WATANABE S, 1991, J BIOL CHEM, V266, P20803; Wilkinson SM, 2002, J BIOL CHEM, V277, P17062, DOI 10.1074/jbc.M111126200; Wilkinson SR, 2002, P NATL ACAD SCI USA, V99, P13453, DOI 10.1073/pnas.202422899; Wilkinson SR, 2002, BIOCHEM J, V364, P787, DOI 10.1042/BJ20020038	53	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27612	27619		10.1074/jbc.M302750200	http://dx.doi.org/10.1074/jbc.M302750200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12750367	hybrid			2022-12-25	WOS:000184242700036
J	Gubbins, MJ; Arthur, DC; Ghetu, AF; Glover, JNM; Frost, LS				Gubbins, MJ; Arthur, DC; Ghetu, AF; Glover, JNM; Frost, LS			Characterizing the structural features of RNA/RNA interactions of the F-plasmid FinOP fertility inhibition system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTISENSE RNA CONTROL; COLE1 ROM PROTEIN; TARGET RNA; BACTERIAL CONJUGATION; MESSENGER-RNA; SECONDARY STRUCTURE; STEM-LOOPS; IN-VITRO; BINDING; REPLICATION	F-like plasmid transfer is mediated by the FinOP (f) under bar ertility (i) under bar nhibition system. Expression of the F positive regulatory protein, TraJ, is controlled by the action of the antisense RNA, FinP, and the RNA-binding protein FinO. FinO binds to and protects FinP from degradation and promotes duplex formation between FinP and traJ mRNA, leading to repression of both traJ expression and conjugative F transfer. FinP antisense RNA secondary structure is composed of two stem-loops separated by a 4-base single-stranded spacer and flanked on each side by single-stranded tails. Here we show that disruption of the expected Watson-Crick base pairing between the loops of FinP stem-loop I and its cognate RNA binding partner, traJ mRNA stem-loop Ic, led to a moderate reduction in the rate of duplex formation in vitro. In vivo, alterations of the anti-ribosome binding site region in the loop of FinP stem-loop I reduced the ability of the mutant FinP to mediate fertility inhibition and to inhibit TraJ expression when expressed in trans at an elevated copy number. Alterations of intermolecular complementarity between the stems of these RNAs reduced the rate of duplex formation. Our results suggest that successful interaction between stem-loop I of FinP and stem-loop Ic of traJ mRNA requires that base pairing must proceed from an initial loop-loop interaction through the top portion of the stems for stable duplex formation to occur.	Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta	Frost, LS (corresponding author), Univ Alberta, Dept Biol Sci, CW-405 Biol Sci Bldg, Edmonton, AB T6G 2E9, Canada.		Frost, Laura/A-2639-2014	Frost, Laura/0000-0002-8433-8230				ACHTMAN M, 1971, J BACTERIOL, V106, P529, DOI 10.1128/JB.106.2.529-538.1971; Asano K, 1998, J BIOL CHEM, V273, P11826, DOI 10.1074/jbc.273.19.11826; Asano K, 1998, EMBO J, V17, P5201, DOI 10.1093/emboj/17.17.5201; Bernacchi S, 2002, J MOL BIOL, V317, P385, DOI 10.1006/jmbi.2002.5429; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Brantl S, 2002, BBA-GENE STRUCT EXPR, V1575, P15, DOI 10.1016/S0167-4781(02)00280-4; CASADABAN MJ, 1976, J MOL BIOL, V104, P557, DOI 10.1016/0022-2836(76)90120-0; CHANDLER M, 1983, J MOL BIOL, V165, P183, DOI 10.1016/S0022-2836(83)80249-6; D'Souza V, 2001, J MOL BIOL, V314, P217, DOI 10.1006/jmbi.2001.5139; DEMPSEY WB, 1987, MOL GEN GENET, V209, P533, DOI 10.1007/BF00331160; EGUCHI Y, 1991, J MOL BIOL, V220, P831, DOI 10.1016/0022-2836(91)90356-B; EGUCHI Y, 1990, CELL, V60, P199, DOI 10.1016/0092-8674(90)90736-X; FINLAY BB, 1986, J BACTERIOL, V167, P754, DOI 10.1128/jb.167.2.754-757.1986; FINNEGAN D, 1973, MOL GEN GENET, V127, P307, DOI 10.1007/BF00267101; FINNEGAN DJ, 1971, MOL GEN GENET, V111, P256, DOI 10.1007/BF00433110; Franch T, 1999, J MOL BIOL, V294, P1115, DOI 10.1006/jmbi.1999.3306; FROST L, 1989, MOL GEN GENET, V218, P152, DOI 10.1007/BF00330578; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; Ghetu AF, 1999, BIOCHEMISTRY-US, V38, P14036, DOI 10.1021/bi9911482; Ghetu AF, 2000, NAT STRUCT BIOL, V7, P565; HJALT TAH, 1995, NUCLEIC ACIDS RES, V23, P580, DOI 10.1093/nar/23.4.580; Jerome LJ, 1999, J MOL BIOL, V285, P1457, DOI 10.1006/jmbi.1998.2404; Jerome LJ, 1999, J BIOL CHEM, V274, P10356, DOI 10.1074/jbc.274.15.10356; Kolb FA, 2000, RNA, V6, P311, DOI 10.1017/S135583820099215X; Kolb FA, 2001, NUCLEIC ACIDS RES, V29, P3145, DOI 10.1093/nar/29.15.3145; Koraimann G, 1996, MOL MICROBIOL, V21, P811, DOI 10.1046/j.1365-2958.1996.361401.x; KORAIMANN G, 1991, MOL MICROBIOL, V5, P77, DOI 10.1111/j.1365-2958.1991.tb01828.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1992, MOL GEN GENET, V235, P131, DOI 10.1007/BF00286190; Majdalani N, 1998, P NATL ACAD SCI USA, V95, P12462, DOI 10.1073/pnas.95.21.12462; Malmgren C, 1997, J BIOL CHEM, V272, P12508, DOI 10.1074/jbc.272.19.12508; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Moller T, 2002, MOL CELL, V9, P23, DOI 10.1016/S1097-2765(01)00436-1; Mullineaux P, 1985, Basic Life Sci, V30, P605; Muriaux D, 1996, J BIOL CHEM, V271, P33686, DOI 10.1074/jbc.271.52.33686; PERSSON C, 1988, EMBO J, V7, P3279, DOI 10.1002/j.1460-2075.1988.tb03195.x; PERSSON C, 1990, EMBO J, V9, P3767, DOI 10.1002/j.1460-2075.1990.tb07590.x; Sambrook J., 2002, MOL CLONING LAB MANU; Sandercock JR, 1998, MOL GEN GENET, V259, P622, DOI 10.1007/s004380050856; SIEMERING KR, 1993, J BACTERIOL, V175, P2895, DOI 10.1128/JB.175.10.2895-2906.1993; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Takahashi K, 2001, J BIOL CHEM, V276, P31274, DOI 10.1074/jbc.M104577200; Takahashi KI, 2000, RNA, V6, P96, DOI 10.1017/S1355838200991635; TOMIZAWA J, 1981, P NATL ACAD SCI-BIOL, V78, P1421, DOI 10.1073/pnas.78.3.1421; TOMIZAWA J, 1984, CELL, V38, P861, DOI 10.1016/0092-8674(84)90281-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANBIESEN T, 1993, MOL MICROBIOL, V10, P35; VANBIESEN T, 1992, MOL MICROBIOL, V6, P771, DOI 10.1111/j.1365-2958.1992.tb01527.x; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433; Wagner EGH, 2002, TRENDS GENET, V18, P223, DOI 10.1016/S0168-9525(02)02658-6; Wagner EGH, 1998, TRENDS BIOCHEM SCI, V23, P451, DOI 10.1016/S0968-0004(98)01322-X; WAGNER EGH, 1987, EMBO J, V6, P515, DOI 10.1002/j.1460-2075.1987.tb04783.x; WAGNER EGH, 1992, EMBO J, V11, P1195, DOI 10.1002/j.1460-2075.1992.tb05160.x; WILLETTS N, 1986, GENET RES, V47, P1, DOI 10.1017/S0016672300024447; WILLETTS N, 1977, J MOL BIOL, V112, P141, DOI 10.1016/S0022-2836(77)80161-7; YOSHIOKA Y, 1987, J BACTERIOL, V169, P619, DOI 10.1128/jb.169.2.619-623.1987; Zhang AX, 2002, MOL CELL, V9, P11, DOI 10.1016/S1097-2765(01)00437-3; ZUKER M, 2003, NUCLEIC ACIDS RES, V31, P1	59	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27663	27671		10.1074/jbc.M303186200	http://dx.doi.org/10.1074/jbc.M303186200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12748195	hybrid			2022-12-25	WOS:000184242700043
J	Morita, T				Morita, T			Structure-based analysis of high pressure adaptation of alpha-actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; DEEP-SEA AMPHIPODS; HYDROSTATIC-PRESSURE; INTRINSIC FLUORESCENCE; CORYPHAENOIDES-ARMATUS; DIVALENT-CATION; BINDING LOOP; FILAMENT; POLYMERIZATION; PROTEINS	Deep-sea fishes occur to depths of several thousand meters, and at these abyssal depths encounter pressures that shallower living fishes cannot tolerate. Tolerance of abyssal pressures by deep-sea fish is likely to depend in part on adaptive modifications of proteins. However, the types of structural modifications to proteins that allow function at high pressure have not been discovered. To elucidate the mechanisms of protein adaptation to high pressure, we cloned the alpha-skeletal actin cDNAs from two abyssal Coryphaenoides species, C. armatus and C. yaquinae, and identified three amino acid substitutions, V54A or L67P, Q137K, and A155S, that distinguish these abyssal actins from orthologs of alpha-actin from non-abyssal Coryphaenoides. These substitutions, Q137K and A155S, prevent the dissociation reactions of ATP and Ca2+ from being influenced by high pressure. In particular, the lysine residue at position 137 results in a much smaller apparent volume change in the Ca2+ dissociation reaction. The V54A or L67P substitution reduces the volume change associated with actin polymerization and has a role in maintaining the DNase I activity of actin at high pressure. Together, these results indicate that a few amino acid substitutions in key functional positions can adaptively alter the pressure sensitivity of a protein.	Natl Res Inst Fisheries Sci, Kanazawa Ku, Kanagawa 2368648, Japan	Japan Fisheries Research & Education Agency (FRA)	Morita, T (corresponding author), Natl Res Inst Fisheries Sci, Kanazawa Ku, Fukuura 2-12-4, Kanagawa 2368648, Japan.							Belmont LD, 1999, P NATL ACAD SCI USA, V96, P29, DOI 10.1073/pnas.96.1.29; BLIKSTAD I, 1978, CELL, V15, P935, DOI 10.1016/0092-8674(78)90277-5; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BUZAN J, 1990, P NATL ACAD SCI USA, V96, P2823; CHEN X, 1993, J CELL BIOL, V123, P1185, DOI 10.1083/jcb.123.5.1185; CHEN X, 1995, J BIOL CHEM, V270, P11406, DOI 10.1074/jbc.270.19.11406; COLLINS JH, 1975, J BIOL CHEM, V250, P5915; ENDO H, 1992, JPN J ICHTHYOL, V38, P433, DOI 10.1007/BF02905607; ESTES JE, 1992, J MUSCLE RES CELL M, V13, P272, DOI 10.1007/BF01766455; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; France SC, 1996, MAR BIOL, V126, P633, DOI 10.1007/BF00351330; FRANCE SC, 1994, MAR BIOL, V118, P67, DOI 10.1007/BF00699220; GEKKO K, 1986, BIOCHEMISTRY-US, V25, P6563, DOI 10.1021/bi00369a034; Gibbs Allen G., 1997, P239; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Iwamoto T., 1974, Occasional Papers of the California Academy of Sciences, VNo. 111, P1; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KHAITLINA SY, 1993, EUR J BIOCHEM, V218, P911, DOI 10.1111/j.1432-1033.1993.tb18447.x; KINOSIAN HJ, 1993, J BIOL CHEM, V268, P8683; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuznetsova IM, 1999, FEBS LETT, V452, P205, DOI 10.1016/S0014-5793(99)00574-8; LEHRER SS, 1972, BIOCHEMISTRY-US, V11, P1211, DOI 10.1021/bi00757a015; Marshall N. B., 1979, DEV DEEP SEA BIOL; Moraczewska J, 1999, BIOPHYS J, V77, P373, DOI 10.1016/S0006-3495(99)76896-7; Morild E, 1981, Adv Protein Chem, V34, P93, DOI 10.1016/S0065-3233(08)60519-7; Morita T, 2000, FISHERIES SCI, V66, P1150, DOI 10.1046/j.1444-2906.2000.00182.x; Morita T, 1999, MOL PHYLOGENET EVOL, V13, P447, DOI 10.1006/mpev.1999.0661; Ohno S., 1970, EVOLUTION GENE DUPLI; ORLOVA A, 1993, J MOL BIOL, V232, P334, DOI 10.1006/jmbi.1993.1393; Otterbein LR, 2001, SCIENCE, V293, P708, DOI 10.1126/science.1059700; PERUTZ MF, 1983, MOL BIOL EVOL, V1, P1; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAUNDERS PM, 1976, DEEP-SEA RES, V23, P109, DOI 10.1016/0011-7471(76)90813-5; Sheterline P., 1999, ACTIN; Siebenaller J.F., 1991, Biochemistry and Molecular Biology of Fishes, V1, P323; Siebenaller Joseph F., 1995, Biochemistry and Molecular Biology of Fishes, V5, P147; SMITH KL, 1978, NATURE, V274, P362, DOI 10.1038/274362a0; SOMERO GN, 1992, ANNU REV PHYSIOL, V54, P557, DOI 10.1146/annurev.ph.54.030192.003013; SOMERO GN, 1990, AM ZOOL, V30, P123; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SWEZEY RR, 1985, BIOCHEMISTRY-US, V24, P852, DOI 10.1021/bi00325a007; SWEZEY RR, 1982, BIOCHEMISTRY-US, V21, P4496, DOI 10.1021/bi00261a047; TOBACMAN LS, 1983, J BIOL CHEM, V258, P8806; WAECHTER F, 1975, EUR J BIOCHEM, V57, P453, DOI 10.1111/j.1432-1033.1975.tb02320.x; Watabe S, 1995, FISHERIES SCI, V61, P998, DOI 10.2331/fishsci.61.998; Yancey PH, 2001, J EXP ZOOL, V289, P172, DOI 10.1002/1097-010X(20010215)289:3<172::AID-JEZ3>3.0.CO;2-J	51	45	47	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28060	28066		10.1074/jbc.M302328200	http://dx.doi.org/10.1074/jbc.M302328200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12740368	hybrid			2022-12-25	WOS:000184242700092
J	Papucci, L; Schiavone, N; Witort, E; Donnini, M; Lapucci, A; Tempestini, A; Formigli, L; Zecchi-Orlandini, S; Orlandini, G; Carella, G; Brancato, R; Capaccioli, S				Papucci, L; Schiavone, N; Witort, E; Donnini, M; Lapucci, A; Tempestini, A; Formigli, L; Zecchi-Orlandini, S; Orlandini, G; Carella, G; Brancato, R; Capaccioli, S			Coenzyme Q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; CELL-DEATH; RESPIRATORY-CHAIN; UBIQUINONE ANALOGS; OXIDATIVE STRESS; PLASMA-MEMBRANE; CYTOCHROME-C; ANTIOXIDANT; ACTIVATION; PHOSPHORYLATION	The permeability transition pore (PTP) is a mitochondrial channel whose opening causes the mitochondrial membrane potential (Deltapsi) collapse that leads to apoptosis. Some ubiquinone analogues have been demonstrated previously to modulate the PTP open-closed transition in isolated mitochondria and thought to act through a common PTP-binding site rather than through oxidation-reduction reactions. We have demonstrated recently both in vitro and in vivo that the ubiquitous free radical scavenger and respiratory chain coenzyme Q(10) (CoQ(10)) prevents keratocyte apoptosis induced by excimer laser irradiation more efficiently than other antioxidants. On this basis, we hypothesized that the antiapoptotic property of CoQ(10) could be independent of its free radical scavenging ability and related to direct inhibition of PTP opening. In this study, we have verified this hypothesis by evaluating the antiapoptotic effects of CoQ(10) in response to apoptotic stimuli, serum starvation, antimycin A, and ceramide, which do not generate free radicals, in comparison to control, free radical-generating UVC irradiation. As hypothesized, CoQ(10) dramatically reduced apoptotic cell death, attenuated ATP decrease, and hindered DNA fragmentation elicited by all apoptotic stimuli. This was accompanied by inhibition of mitochondrial depolarization, cytochrome c release, and caspase 9 activation. Because these events are consequent to mitochondrial PTP opening, we suggest that the antiapoptotic activity of CoQ(10) could be related to its ability to prevent this phenomenon.	Univ Florence, Dept Expt Pathol & Oncol, I-50134 Florence, Italy; Univ Florence, Dept Anat Histol & Forens Med, I-50134 Florence, Italy; Univ Milan, Hosp San Raffaele, Dept Ophthalmol & Visual Sci, I-20132 Milan, Italy	University of Florence; University of Florence; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Capaccioli, S (corresponding author), Univ Florence, Dept Expt Pathol & Oncol, Viale GB Morgagni 50, I-50134 Florence, Italy.	sergio@unifi.it	Lapucci, Andrea/AAA-6645-2019	LAPUCCI, Andrea/0000-0001-9613-7164; Papucci, Laura/0000-0002-8450-7428; Schiavone, Nicola/0000-0002-1592-4244				Alleva R, 2001, FEBS LETT, V503, P46, DOI 10.1016/S0014-5793(01)02694-1; Armstrong JS, 2002, FASEB J, V16, P1263, DOI 10.1096/fj.02-0097fje; Armstrong JS, 2002, CELL DEATH DIFFER, V9, P252, DOI 10.1038/sj.cdd.4400959; Blankenberg FG, 1997, BLOOD, V89, P3778, DOI 10.1182/blood.V89.10.3778.3778_3778_3786; Brancato R, 2000, EUR J OPHTHALMOL, V10, P32, DOI 10.1177/112067210001000106; Brancato R, 2002, J REFRACT SURG, V18, P135; Brigelius-Flohe R, 1999, FASEB J, V13, P1145, DOI 10.1096/fasebj.13.10.1145; CAPACCIOLI S, 1998, VASCULAR SYSTEMS OPT, P81; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chauvin C, 2001, J BIOL CHEM, V276, P41394, DOI 10.1074/jbc.M106417200; Colombaioni L, 2002, NEUROCHEM INT, V40, P327, DOI 10.1016/S0197-0186(01)00090-0; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Curtin JF, 2002, J IMMUNOL METHODS, V265, P49, DOI 10.1016/S0022-1759(02)00070-4; De Giorgi F, 2002, FASEB J, V16, P607, DOI 10.1096/fj.01-0269fje; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; DHANBHOORA CM, 1992, ARCH BIOCHEM BIOPHYS, V293, P130, DOI 10.1016/0003-9861(92)90375-7; Di Bernardo S, 1998, FEBS LETT, V426, P77, DOI 10.1016/S0014-5793(98)00313-5; Di Paola M, 2000, BIOCHEMISTRY-US, V39, P6660, DOI 10.1021/bi9924415; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Fennell DA, 2000, BRIT J HAEMATOL, V111, P52, DOI 10.1046/j.1365-2141.2000.02271.x; Fontaine E, 1999, J BIOENERG BIOMEMBR, V31, P335, DOI 10.1023/A:1005475802350; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; Formigli L, 2000, J CELL PHYSIOL, V182, P41, DOI 10.1002/(SICI)1097-4652(200001)182:1<41::AID-JCP5>3.0.CO;2-7; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; Guidarelli A, 1996, BIOCHEM J, V317, P371, DOI 10.1042/bj3170371; Hannun YA, 1997, ADV EXP MED BIOL, V407, P145; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Jang BC, 2000, J BIOL CHEM, V275, P39507, DOI 10.1074/jbc.M003224200; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Kulisz A, 2002, AM J PHYSIOL-LUNG C, V282, pL1324, DOI 10.1152/ajplung.00326.2001; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Lenaz G, 1998, BIOFACTORS, V8, P195, DOI 10.1002/biof.5520080305; LENAZ G, 1993, CLIN INVESTIGATOR, V71, pS66; Lopez-Lluch G, 1999, BIOFACTORS, V9, P171, DOI 10.1002/biof.5520090212; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; MEYDANI M, 1995, LANCET, V345, P170, DOI 10.1016/S0140-6736(95)90172-8; Navas P, 2002, FREE RADICAL RES, V36, P369, DOI 10.1080/10715760290021207; ODONNELL V, 1994, BIOCHEM J, V304, P707, DOI 10.1042/bj3040707; Okazaki T, 1998, CELL SIGNAL, V10, P685, DOI 10.1016/S0898-6568(98)00035-7; OYAMA Y, 1994, BRAIN RES, V635, P113, DOI 10.1016/0006-8993(94)91429-X; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; RUTIES SA, 1999, J BIOL CHEM, V274, P24799; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Shiozaki EN, 2002, P NATL ACAD SCI USA, V99, P4197, DOI 10.1073/pnas.072544399; Siskind LJ, 2002, J BIOL CHEM, V277, P26796, DOI 10.1074/jbc.M200754200; Siskind LJ, 2000, J BIOL CHEM, V275, P38640, DOI 10.1074/jbc.C000587200; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Tomasetti M, 2001, FASEB J, V15, P1425, DOI 10.1096/fj.00-0694fje; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; VANDELOOSDRECHT AA, 1994, J IMMUNOL METHODS, V174, P311, DOI 10.1016/0022-1759(94)90034-5; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Walter L, 2002, FREE RADICAL RES, V36, P405, DOI 10.1080/10715760290021252; Walter L, 2000, J BIOL CHEM, V275, P29521, DOI 10.1074/jbc.M004128200; Wang JF, 1996, FREE RADICAL BIO MED, V20, P533, DOI 10.1016/0891-5849(95)02085-3; Wang XD, 2001, GENE DEV, V15, P2922; Wilson SE, 1997, J REFRACT SURG, V13, P171; Zhang HJ, 2002, J BIOL CHEM, V277, P20919, DOI 10.1074/jbc.M109801200; Zini R, 1998, LIFE SCI, V63, P357, DOI 10.1016/S0024-3205(98)00284-7	63	235	254	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28220	28228		10.1074/jbc.M302297200	http://dx.doi.org/10.1074/jbc.M302297200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12736273	hybrid			2022-12-25	WOS:000184242700111
J	Asamitsu, K; Tetsuka, T; Kanazawa, S; Okamoto, T				Asamitsu, K; Tetsuka, T; Kanazawa, S; Okamoto, T			RING finger protein AO7 supports NF-kappa B-mediated transcription by interacting with the transactivation domain of the p65 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; IMMUNODEFICIENCY-VIRUS TYPE-1; AMINO-TERMINAL ENHANCER; NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; ACTIVATION; UBIQUITIN; PHOSPHORYLATION; INHIBITION; KINASE	In this study, a novel interactor of the p65 subunit ( RelA) of NF-kappaB has been explored by performing yeast two-hybrid screen using the transactivation domain (TAD) of p65 located in the C terminus as bait. We have isolated a RING finger motif-containing protein, AO7, previously identified as an interacting protein with a ubiquitin-conjugating enzyme, Ubc5B. We confirmed the protein-protein interaction between p65 and AO7 in vitro and in vivo and found that the C-terminal region of AO7 is responsible for the interaction with p65 TAD. AO7 was predominantly localized in the nucleus and activated the NF-kappaB-dependent gene expression upon stimulation with IL-1beta or TNF or overexpression of NF-kappaB-inducing kinase. We found that both the RING finger and the C-terminal regions of AO7 were necessary for the transcriptional activation. When cotransfected with plasmids expressing Gal4-p65 fusion proteins containing various functional domains of p65, we found that p65 TAD was essential for the transcriptional activation mediated by AO7. Furthermore, the p65-mediated transactivation was suppressed by a ubiquitination-defective AO7 mutant in which the essential Cys residue within the RING finger motif was substituted by Ser. These data suggest that AO7 interacts with the p65 TAD and modulates its transcriptional activity.	Nagoya City Univ, Grad Sch Med Sci, Dept Mol & Cellular Biol, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University	Okamoto, T (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Mol & Cellular Biol, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.	tokamoto@med.nagoya-cu.ac.jp		Asamitsu, Kaori/0000-0001-5333-8011				Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Conkright MD, 2001, J BIOL CHEM, V276, P29299, DOI 10.1074/jbc.M103670200; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Imhof MO, 1996, MOL CELL BIOL, V16, P2594; Kajino S, 2000, ONCOGENE, V19, P2233, DOI 10.1038/sj.onc.1203560; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; MOORE PA, 1993, MOL CELL BIOL, V13, P1666, DOI 10.1128/MCB.13.3.1666; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Okamoto T, 1997, CURR TOP CELL REGUL, V35, P149, DOI 10.1016/S0070-2137(97)80006-4; Ostendorff HP, 2002, NATURE, V416, P99, DOI 10.1038/416099a; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Pham AD, 2000, SCIENCE, V289, P2357, DOI 10.1126/science.289.5488.2357; Sakurada S, 1996, INT IMMUNOL, V8, P1483, DOI 10.1093/intimm/8.10.1483; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Sato T, 1998, AIDS RES HUM RETROV, V14, P293, DOI 10.1089/aid.1998.14.293; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Suzuki Y, 1997, GENE, V200, P149, DOI 10.1016/S0378-1119(97)00411-3; Takada N, 2002, J VIROL, V76, P8019, DOI 10.1128/JVI.76.16.8019-8030.2002; Tetsuka T, 2000, J BIOL CHEM, V275, P4383, DOI 10.1074/jbc.275.6.4383; Uranishi H, 2001, J BIOL CHEM, V276, P13395, DOI 10.1074/jbc.M011176200; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Yu X, 2001, MOL CELL BIOL, V21, P4614, DOI 10.1128/MCB.21.14.4614-4625.2001; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	40	29	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26879	26887		10.1074/jbc.M211831200	http://dx.doi.org/10.1074/jbc.M211831200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12748188	hybrid			2022-12-25	WOS:000184155700076
J	Marchesan, D; Rutberg, M; Andersson, L; Asp, L; Larsson, T; Boren, J; Johansson, BR; Olofsson, SO				Marchesan, D; Rutberg, M; Andersson, L; Asp, L; Larsson, T; Boren, J; Johansson, BR; Olofsson, SO			A phospholipase D-dependent process forms lipid droplets containing caveolin, adipocyte differentiation-related protein, and vimentin in a cell-free system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; LOW-DENSITY LIPOPROTEINS; DIET-INDUCED OBESITY; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; GOLGI-COMPLEX; LYSOPHOSPHATIDIC ACID; ENDOPLASMIC-RETICULUM; SECRETORY VESICLES; ADIPOSE CONVERSION; APOLIPOPROTEIN-B	We developed a microsome-based, cell-free system that assembles newly formed triglyceride (TG) into spherical lipid droplets. These droplets were recovered in the d less than or equal to 1.055 g/ml fraction by gradient ultracentrifugation and were similar in size and appearance to those isolated from rat adipocytes and 3T3-L1 cells. Caveolin 1 and 2, vimentin, adipocyte differentiation-related protein, and the 78-kDa glucose regulatory protein were identified on the droplets from the cell-free system. The caveolin was soluble in 1% Triton X-100, as was the caveolin on lipid droplets from 3T3-L1 cells. The lipid droplets from the cell-free system, like those from 3T3-L1 cells, contained TG, diacylglycerol, phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine. The assembly of these TG-containing structures was dependent on the rate of TG biosynthesis and required an activator present in the 160,000 x g supernatant from homogenized rat adipocytes. The activator induced phospholipase D (PLD) activity, and its effect on the release of the TG-containing structures from the microsomes was inhibited by 1-butanol ( but not 2-butanol) or 2,3-diphosphoglycerate. The activator could be replaced by a constitutively active PLD or phosphatidic acid. These results indicate that PLD and the formation of phosphatidic acid are important in the assembly of the TG-containing structures.	Univ Gothenburg, Dept Med Biochem, SE-41345 Gothenburg, Sweden; Univ Gothenburg, Wallenberg Lab Cardiovasc Res, SE-41345 Gothenburg, Sweden; Univ Gothenburg, Swegene Proteom Ctr, SE-41345 Gothenburg, Sweden; Univ Gothenburg, Dept Anat & Cell Biol, SE-41345 Gothenburg, Sweden	University of Gothenburg; University of Gothenburg; University of Gothenburg; University of Gothenburg	Olofsson, SO (corresponding author), Sahlgrenska Univ Hosp S, Wallenberg Lab, SE-41345 Gothenburg, Sweden.			Andersson, Linda/0000-0003-3230-5397				ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; ANDERSSON M, 1994, J LIPID RES, V35, P535; Asp L, 2000, J BIOL CHEM, V275, P26285, DOI 10.1074/jbc.M003520200; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; BJORGELL P, 1981, BIOCHIM BIOPHYS ACTA, V666, P246, DOI 10.1016/0005-2760(81)90114-4; Blomberg A, 2002, METHOD ENZYMOL, V350, P559, DOI 10.1016/S0076-6879(02)50985-X; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CAIN H, 1983, VIRCHOWS ARCH B, V42, P65, DOI 10.1007/BF02890371; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Chung JK, 1997, J BIOL CHEM, V272, P15980, DOI 10.1074/jbc.272.25.15980; Clifford GM, 2000, J BIOL CHEM, V275, P5011, DOI 10.1074/jbc.275.7.5011; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; Du GW, 2000, MOL BIOL CELL, V11, P4359, DOI 10.1091/mbc.11.12.4359; FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X; FROST SC, 1985, J BIOL CHEM, V260, P2646; Fujimoto T, 2001, J CELL BIOL, V152, P1079, DOI 10.1083/jcb.152.5.1079; Gao YS, 2001, J CELL BIOL, V152, P877, DOI 10.1083/jcb.152.5.877; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Heid HW, 1996, BIOCHEM J, V320, P1025, DOI 10.1042/bj3201025; Hodgkin MN, 2000, CURR BIOL, V10, P43, DOI 10.1016/S0960-9822(99)00264-X; Hoer A, 2000, BBA-PROTEIN STRUCT M, V1481, P189, DOI 10.1016/S0167-4838(00)00108-4; Imamura M, 2002, AM J PHYSIOL-ENDOC M, V283, pE775, DOI 10.1152/ajpendo.00040.2002; JARRETT L, 1974, METHOD ENZYMOL, V31, P60; JOHANSSON BR, 1996, NAT IMMUN, V97, P87; Jones D, 1999, BBA-MOL CELL BIOL L, V1439, P229, DOI 10.1016/S1388-1981(99)00097-9; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; Li WP, 2001, J CELL SCI, V114, P1397; Lieber JG, 1996, J CELL SCI, V109, P3047; Liscovitch M, 1999, BBA-MOL CELL BIOL L, V1439, P245, DOI 10.1016/S1388-1981(99)00098-0; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Liu PS, 1999, NAT CELL BIOL, V1, P369, DOI 10.1038/14067; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; LONDOS C, 1995, BIOCHEM SOC T, V23, P611, DOI 10.1042/bst0230611; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Mor-Vaknin N, 2003, NAT CELL BIOL, V5, P59, DOI 10.1038/ncb898; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; Nilsson CL, 2000, ANAL CHEM, V72, P2148, DOI 10.1021/ac9912754; OLEGARD R, 1970, ACTA PAEDIATR SCAND, V59, P637, DOI 10.1111/j.1651-2227.1970.tb17698.x; OLOFSSON SO, 1987, ATHEROSCLEROSIS, V68, P1, DOI 10.1016/0021-9150(87)90088-8; Olofsson SO, 2000, TRENDS CARDIOVAS MED, V10, P338, DOI 10.1016/S1050-1738(01)00071-8; Olofsson SO, 1999, CURR OPIN LIPIDOL, V10, P341, DOI 10.1097/00041433-199908000-00008; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; PERIDES G, 1987, J BIOL CHEM, V262, P13742; PERIDES G, 1986, EUR J CELL BIOL, V42, P268; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; Prattes S, 2000, J CELL SCI, V113, P2977; Razani B, 2002, J BIOL CHEM, V277, P8635, DOI 10.1074/jbc.M110970200; Roth MG, 1999, CHEM PHYS LIPIDS, V98, P141, DOI 10.1016/S0009-3084(99)00026-2; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; Roth MG, 1999, CELL, V97, P149, DOI 10.1016/S0092-8674(00)80723-0; Roth MG, 1999, TRENDS CELL BIOL, V9, P174, DOI 10.1016/S0962-8924(99)01535-4; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Stillemark P, 2000, J BIOL CHEM, V275, P10506, DOI 10.1074/jbc.275.14.10506; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Trigatti BL, 1999, BIOCHEM BIOPH RES CO, V255, P34, DOI 10.1006/bbrc.1998.0123; van Meer G, 2001, J CELL BIOL, V152, pF29, DOI 10.1083/jcb.152.5.F29; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; Wieland F, 1999, CURR OPIN CELL BIOL, V11, P440, DOI 10.1016/S0955-0674(99)80063-5; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200	73	79	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27293	27300		10.1074/jbc.M301430200	http://dx.doi.org/10.1074/jbc.M301430200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12730229	hybrid			2022-12-25	WOS:000184155700126
J	Wang, ZQ; Malone, MH; Thomenius, MJ; Zhong, F; Xu, F; Distelhorst, CW				Wang, ZQ; Malone, MH; Thomenius, MJ; Zhong, F; Xu, F; Distelhorst, CW			Dexamethasone-induced gene 2 (dig2) is a novel pro-survival stress gene induced rapidly by diverse apoptotic signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA; ACTIVATION; INDUCTION; DEATH	Glucocorticoid hormones induce apoptosis in lymphoid cells. This process requires de novo RNA/protein synthesis. Here we report the identification and cloning of a novel dexamethasone-induced gene designated dig2. Using Affymetrix oligonucleotide microarray analysis of similar to 10,000 genes and expressed sequence tags, we found that the expression of dig2 mRNA is significantly induced not only in the murine T cell lymphoma lines S49. A2 and WEHI7.2 but also in normal mouse thymocytes following dexamethasone treatment. This result was confirmed by Northern blot analysis. The induction of dig2 mRNA by dexamethasone appears to be mediated through the glucocorticoid receptor as it is blocked in the presence of RU486, a glucocorticoid receptor antagonist. Furthermore, we demonstrated that dig2 is a novel stress response gene, as its mRNA is induced in response to a variety of cellular stressors including thapsigargin, tunicamycin, and heat shock. In addition, the levels of dig2 mRNA were up-regulated after treatment with the apoptosis-inducing chemotherapeutic drug etoposide. Though the function of dig2 is unknown, dig2 appears to have a pro-survival function, as overexpression of dig2 reduces the sensitivity of WEHI7.2 cells to dexamethasone-induced apoptosis.	Case Western Reserve Univ, Sch Med, Ctr Comprehens Canc, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Comprehens Canc, Dept Pharmacol, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Distelhorst, CW (corresponding author), Case Western Reserve Univ, Sch Med, Div Hematol Oncol, 10900 Euclid Ave, Cleveland, OH 44106 USA.				NCI NIH HHS [T32 CA73515, T32 CA059366, R01 CA79806, R01 CA42755, P30 CA53703] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA073515, R01CA079806, R01CA042755, T32CA059366, S15CA053703] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; Distelhorst CW, 2002, CELL DEATH DIFFER, V9, P6, DOI 10.1038/sj.cdd.4400969; FORBES IJ, 1992, EXP CELL RES, V198, P367, DOI 10.1016/0014-4827(92)90393-M; Gaynon PS, 1999, ADV EXP MED BIOL, V457, P593; HARMON JM, 1979, J CELL PHYSIOL, V98, P267, DOI 10.1002/jcp.1040980203; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Kokame K, 2000, J BIOL CHEM, V275, P32846, DOI 10.1074/jbc.M002063200; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Smets LA, 1999, ADV EXP MED BIOL, V457, P607; Staudt LM, 2000, ANNU REV IMMUNOL, V18, P829, DOI 10.1146/annurev.immunol.18.1.829; WANG Z, 2003, J BIOL CHEM; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	16	122	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27053	27058		10.1074/jbc.M303723200	http://dx.doi.org/10.1074/jbc.M303723200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12736248	hybrid			2022-12-25	WOS:000184155700097
J	Zhang, XA; He, B; Zhou, B; Liu, L				Zhang, XA; He, B; Zhou, B; Liu, L			Requirement of the p130(CAS)-Crk coupling for metastasis suppressor KAI1/CD82-mediated inhibition of cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; TRANSMEMBRANE PROTEIN FAMILY; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; TETRASPANIN CD82; KAI1 EXPRESSION; DOWN-REGULATION; GROWTH-FACTOR; CANCER CELLS; RHO GTPASES	KAI1/CD82 protein is a member of the tetraspanin superfamily and has been rediscovered as a cancer metastasis suppressor. The mechanism of KAI1/CD82-mediated suppression of cancer metastasis remains to be established. In this study, we found that migration of the metastatic prostate cancer cell line Du145 was substantially inhibited when KAI1/CD82 was expressed. The expression of focal adhesion kinase (FAK) and Lyn, a Src family tyrosine kinase and substrate of FAK, was upregulated at both RNA and protein levels upon KAI1/ CD82 expression. The activation of FAK and Lyn, however, remained unchanged in Du145-KAI1/CD82 cells. As a downstream target of FAK-Lyn signaling, the p130(CAS) (Crk-associated substrate) protein was decreased upon the expression of KAI1/ CD82. Consequently, less p130(CAS)-CrkII complex, which functions as a "molecular switch" in cell motility, was formed in Du145-KAI1/CD82 cells. To confirm that the p130(CAS)-CrkII complex is indeed important for the motility inhibition by KAI1/ CD82, overexpression of p130(CAS) in Du145-KAI1/CD82 cells increased the formation of p130(CAS)-CrkII complex and largely reversed the KAI1/ CD82-mediated inhibition of cell motility. Taken together, our studies indicate the following: 1) signaling of FAK-Lyn-p130(CAS)-CrkII pathway is altered in KAI1/CD82-expressing cells, and 2) p130(CAS)-CrkII coupling is required for KAI1/CD82-mediated suppression of cell motility.	Univ Tennessee, Hlth Sci Ctr, Vasc Biol Ctr, Memphis, TN 38163 USA; Univ Tennessee, Hlth Sci Ctr, Dept Med, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Zhang, XA (corresponding author), Univ Tennessee, Hlth Sci Ctr, Vasc Biol Ctr, Coleman H300,956 Court Ave, Memphis, TN 38163 USA.							Abbi S, 2002, HISTOL HISTOPATHOL, V17, P1163, DOI 10.14670/HH-17.1163; Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Adachi M, 1996, CANCER RES, V56, P1751; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Berditchevski F, 2001, J CELL SCI, V114, P4143; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Chung CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X; Delaguillaumie A, 2002, J CELL SCI, V115, P433; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Dong JT, 1996, CANCER RES, V56, P4387; Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Guo XZ, 1996, CANCER RES, V56, P4876; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hammond C, 1998, J IMMUNOL, V161, P3282; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Hibbs ML, 1997, INT J BIOCHEM CELL B, V29, P397, DOI 10.1016/S1357-2725(96)00104-5; Higashiyama M, 1998, CANCER, V83, P466, DOI 10.1002/(SICI)1097-0142(19980801)83:3<466::AID-CNCR15>3.0.CO;2-U; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; Lagaudriere-Gesbert C, 1998, EUR J IMMUNOL, V28, P4332, DOI 10.1002/(SICI)1521-4141(199812)28:12<4332::AID-IMMU4332>3.0.CO;2-8; LEBELBINAY S, 1995, J IMMUNOL, V155, P101; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lombardi DP, 1999, CANCER RES, V59, P5724; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Mannion BA, 1996, J IMMUNOL, V157, P2039; Mareel MM, 1991, MECHANISMS INVASION, P73; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Miyake M, 1999, ONCOGENE, V18, P2397, DOI 10.1038/sj.onc.1202556; Mlinaric-Rascan I, 2001, FEBS LETT, V498, P26, DOI 10.1016/S0014-5793(01)02474-7; NOJIMA Y, 1993, CELL IMMUNOL, V152, P249, DOI 10.1006/cimm.1993.1285; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Odintsova E, 2000, CURR BIOL, V10, P1009, DOI 10.1016/S0960-9822(00)00652-7; Ono M, 1999, CANCER RES, V59, P2335; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Pujades C, 1996, BIOCHEM J, V313, P899, DOI 10.1042/bj3130899; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Rozengurt E, 1997, ESSAYS BIOCHEM, V32, P73; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Scherberich A, 2002, THROMB HAEMOSTASIS, V87, P1043, DOI 10.1055/s-0037-1613130; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Serru V, 1999, BIOCHEM J, V340, P103, DOI 10.1042/0264-6021:3400103; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Stipp CS, 2000, J CELL SCI, V113, P1871; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Takaoka A, 1998, ONCOGENE, V16, P1443, DOI 10.1038/sj.onc.1201648; Takaoka A, 1998, JPN J CANCER RES, V89, P397, DOI 10.1111/j.1349-7006.1998.tb00577.x; Tamura M, 1999, CANCER RES, V59, P442; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Uchida S, 1999, BRIT J CANCER, V79, P1168, DOI 10.1038/sj.bjc.6690186; UDEA T, 1996, AM J PATHOL, V149, P1435; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; White A, 1998, ONCOGENE, V16, P3143, DOI 10.1038/sj.onc.1201852; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; Yang XH, 2001, CANCER RES, V61, P5284; Zhang XA, 2001, MOL BIOL CELL, V12, P351, DOI 10.1091/mbc.12.2.351; Zhang XA, 1999, J BIOL CHEM, V274, P11, DOI 10.1074/jbc.274.1.11; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200; Zheng DQ, 1999, CANCER RES, V59, P1655; Zheng DQ, 2000, J BIOL CHEM, V275, P24565, DOI 10.1074/jbc.M002646200	78	77	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27319	27328		10.1074/jbc.M303039200	http://dx.doi.org/10.1074/jbc.M303039200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12738793	hybrid			2022-12-25	WOS:000184155700129
J	O'Leary, PD; Hughes, RA				O'Leary, PD; Hughes, RA			Design of potent peptide mimetics of brain-derived neurotrophic factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; CRYSTAL-STRUCTURE; AUTOPHOSPHORYLATION SITES; RECEPTOR COMPLEX; PROTEIN HORMONE; TYROSINE KINASE; SENSORY NEURONS; TRKB RECEPTOR; AMINO-ACIDS; HAV MOTIF	Brain-derived neurotrophic factor ( BDNF) has potential for the treatment of human neurodegenerative diseases. However, the general lack of success of neurotrophic factors in clinical trials has led to the suggestion that low molecular weight neurotrophic drugs may be better agents for therapeutic use. Here we describe small, dimeric peptides designed to mimic a pair of solvent-exposed loops important for the binding and activation of the BDNF receptor, trkB. The monomer components that make up the dimers were based on a monocyclic monomeric peptide mimic of a single loop of BDNF ( loop 2) that we had previously shown to be an inhibitor of BDNF-mediated neuronal survival ( O'Leary, P. D., and Hughes, R. A. ( 1998) J. Neurochem. 70, 1712 1721). Bicyclic dimeric peptides behaved as partial agonists with respect to BDNF, promoting the survival of embryonic chick sensory neurons in culture. We reasoned that the potency and/or efficacy of these compounds might be improved by reducing the conformational flexibility about their dimerizing linker. Thus, we designed a highly conformationally constrained tricyclic dimeric peptide and synthesized it using an efficient, quasi-one-pot approach. Although still a partial BDNF-like agonist, the tricyclic dimer was particularly potent in promoting neuronal survival in vitro (EC50 11 pM). The peptides described here, which are greatly reduced in size compared with the parent protein, could serve as useful lead compounds for the development of true neurotrophic drugs and indicate that the structure-based design approach could be used to obtain potent mimetics of other growth factors that dimerize their receptors.	Univ Melbourne, Dept Pharmacol, Melbourne, Vic 3010, Australia	University of Melbourne	Hughes, RA (corresponding author), Univ Melbourne, Dept Pharmacol, Melbourne, Vic 3010, Australia.	rahughes@unimelb.edu.au		O'Leary, Paul/0000-0003-2717-0790				ASKANAS V, 1995, ADV NEUROL, V68, P241; ATHERTON E, 1985, J CHEM SOC PERK T 1, P2065, DOI 10.1039/p19850002065; Ballinger MD, 1998, NAT STRUCT BIOL, V5, P938, DOI 10.1038/2911; Banfield MJ, 2001, STRUCTURE, V9, P1191, DOI 10.1016/S0969-2126(01)00681-5; Butte MJ, 1998, BIOCHEMISTRY-US, V37, P16846, DOI 10.1021/bi981254o; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; Conti AM, 1997, ANN NEUROL, V42, P838, DOI 10.1002/ana.410420604; Coulson EJ, 2000, J BIOL CHEM, V275, P30537, DOI 10.1074/jbc.M005214200; Cwirla SE, 1997, SCIENCE, V276, P1696, DOI 10.1126/science.276.5319.1696; England BP, 2000, P NATL ACAD SCI USA, V97, P6862, DOI 10.1073/pnas.110053997; FOESTL W, 2000, PHARM ACTA HELV, V74, P247; GUITON M, 1994, J BIOL CHEM, V269, P30370; Hallbook F, 1999, CURR OPIN NEUROBIOL, V9, P616, DOI 10.1016/S0959-4388(99)00011-2; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; ILONDO MM, 1994, ENDOCRINOLOGY, V134, P2397, DOI 10.1210/en.134.6.2397; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; KAMBER B, 1980, HELV CHIM ACTA, V63, P899, DOI 10.1002/hlca.19800630418; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kasarskis EJ, 1999, NEUROLOGY, V52, P1427; Lindsay RM, 1996, PHILOS T ROY SOC B, V351, P365, DOI 10.1098/rstb.1996.0030; LINDSAY RM, 1985, J CELL SCI, P115; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Maliartchouk S, 2000, MOL PHARMACOL, V57, P385; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MIDDLEMAS DS, 1994, J BIOL CHEM, V269, P5458; Miller FD, 2001, CELL MOL LIFE SCI, V58, P1045, DOI 10.1007/PL00000919; O'Leary PD, 1998, J NEUROCHEM, V70, P1712; Poduslo JF, 1996, MOL BRAIN RES, V36, P280, DOI 10.1016/0169-328X(95)00250-V; Robinson RC, 1999, PROTEIN SCI, V8, P2589; Segal RA, 1996, J BIOL CHEM, V271, P20175, DOI 10.1074/jbc.271.33.20175; Siegel GJ, 2000, BRAIN RES REV, V33, P199, DOI 10.1016/S0165-0173(00)00030-8; Skaper SD, 1998, MOL CELL NEUROSCI, V12, P179, DOI 10.1006/mcne.1998.0714; Strohmaier C, 1996, EMBO J, V15, P3332, DOI 10.1002/j.1460-2075.1996.tb00698.x; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; TAPLEY P, 1992, ONCOGENE, V7, P371; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; Wiesmann C, 2001, CELL MOL LIFE SCI, V58, P748, DOI 10.1007/PL00000898; Wiesmann C, 1999, NATURE, V401, P184, DOI 10.1038/43705; Williams E, 2000, J BIOL CHEM, V275, P4007, DOI 10.1074/jbc.275.6.4007; Williams EJ, 2000, MOL CELL NEUROSCI, V15, P456, DOI 10.1006/mcne.2000.0847; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; Wrighton NC, 1997, NAT BIOTECHNOL, V15, P1261, DOI 10.1038/nbt1197-1261; Zhang AJ, 2001, BIOORG MED CHEM LETT, V11, P207, DOI 10.1016/S0960-894X(00)00618-1	44	104	118	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25738	25744		10.1074/jbc.M303209200	http://dx.doi.org/10.1074/jbc.M303209200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730196	hybrid			2022-12-25	WOS:000183920200059
J	Goda, T; Ishii, T; Nakajo, N; Sagata, N; Kobayashi, H				Goda, T; Ishii, T; Nakajo, N; Sagata, N; Kobayashi, H			The RRASK motif in Xenopus cyclin B2 is required for the substrate recognition of Cdc25C by the cyclin B-Cdc2 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; ACTIVATION; BINDING; DOMAIN; PHOSPHORYLATION; IDENTIFICATION; SPECIFICITY; SITE	The FLRRXSK sequence is conserved in the second cyclin box fold of B-type cyclins. We show that this conserved sequence in Xenopus cyclin B2, termed the RRASK motif, is required for the substrate recognition by the cyclin B-Cdc2 complex of Cdc25C. Mutations to charged residues of the RRASK motif of cyclin B2 abolished its ability to activate Cdc2 kinase without affecting its capacity to bind to Cdc2. Cdc2 bound to the cyclin B2 RRASK mutant was not dephosphorylated by Cdc25C, and as a result, the complex was inactive. The cyclin B2 RRASK mutants can form a complex with the constitutively active Cdc2, but a resulting active complex did not phosphorylate a preferred substrate Cdc25C in vitro, although it can phosphorylate the nonspecific substrate histone H1. The RRASK mutations prevented the interaction of Cdc25C with the cyclin B2-Cdc2 complex. Consistently, the RRASK mutants neither induced germinal vesicle breakdown in Xenopus oocyte maturation nor activated in vivo Cdc2 kinase during the cell cycle in mitotic extracts. These results suggest that the RRASK motif in Xenopus cyclin B2 plays an important role in defining the substrate specificity of the cyclin B-Cdc2 complex.	Kyushu Univ, Dept Biol Mol, Grad Sch Med Sci, Fukuoka 8128582, Japan; Kyushu Univ, Dept Biol, Grad Sch Sci, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Kobayashi, H (corresponding author), Kyushu Univ, Dept Biol Mol, Grad Sch Med Sci, Fukuoka 8128582, Japan.	khobaya@molbiol.med.kyushu-u.ac.jp						Adams PD, 1999, MOL CELL BIOL, V19, P1068; Adams PD, 1996, MOL CELL BIOL, V16, P6623; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; Calzada A, 2001, NATURE, V412, P355, DOI 10.1038/35085610; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Endicott JA, 1999, CURR OPIN STRUC BIOL, V9, P738, DOI 10.1016/S0959-440X(99)00038-X; Fattaey A, 1997, Prog Cell Cycle Res, V3, P233; Furstenthal L, 2001, J CELL BIOL, V152, P1267, DOI 10.1083/jcb.152.6.1267; GLOZER M, 1991, NATURE, V349, P132; Goda T, 2001, J BIOL CHEM, V276, P15415, DOI 10.1074/jbc.M011101200; Hochegger H, 2001, DEVELOPMENT, V128, P3795; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kelly BL, 1998, P NATL ACAD SCI USA, V95, P2535, DOI 10.1073/pnas.95.5.2535; Kishimoto T, 1997, Prog Cell Cycle Res, V3, P241; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; Liu F, 1999, MOL CELL BIOL, V19, P5113; Miller ME, 2001, J CELL SCI, V114, P1811; Morris MC, 1999, J MOL BIOL, V286, P475, DOI 10.1006/jmbi.1998.2475; Morris MC, 2000, J BIOL CHEM, V275, P28849, DOI 10.1074/jbc.M002942200; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nakajo N, 1999, DEV BIOL, V207, P432, DOI 10.1006/dbio.1998.9178; Nakajo N, 2000, GENE DEV, V14, P328; Nurse P, 1999, BIOL CHEM, V380, P729, DOI 10.1515/BC.1999.093; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Saha P, 1997, MOL CELL BIOL, V17, P4338, DOI 10.1128/MCB.17.8.4338; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; STEWART E, 1994, EMBO J, V13, P584, DOI 10.1002/j.1460-2075.1994.tb06296.x; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Wohlschlegel JA, 2001, MOL CELL BIOL, V21, P4868, DOI 10.1128/MCB.21.15.4868-4874.2001; ZHENG XF, 1993, CELL, V75, P155, DOI 10.1016/S0092-8674(05)80092-3	36	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19032	19037		10.1074/jbc.M300210200	http://dx.doi.org/10.1074/jbc.M300210200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12754270	hybrid			2022-12-25	WOS:000182932200041
J	Deplancke, B; Gaskins, HR				Deplancke, B; Gaskins, HR			Hydrogen sulfide induces serum-independent cell cycle entry in nontransformed rat intestinal epithelial cells	FASEB JOURNAL			English	Article						IEC-18; colorectal cancer; ulcerative colitis; epithelial hyperproliferation; microarray analysis	ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR-BETA; ULCERATIVE-COLITIS; COLORECTAL-CANCER; CARDIAC MYOCYTES; GENE-EXPRESSION; UP-REGULATION; COLON-CANCER; C-JUN; METABOLIC INHIBITION	Hydrogen sulfide (H2S), produced by commensal sulfate-reducing bacteria, is an environmental insult that potentially contributes to chronic intestinal epithelial disorders. We tested the hypothesis that exposure of nontransformed intestinal epithelial cells (IEC-18) to the reducing agent sodium hydrogen sulfide (NaHS) activates molecular pathways that underlie epithelial hyperplasia, a phenotype common to both ulcerative colitis (UC) and colorectal cancer. Exposure of IEC-18 cells to NaHS rapidly increased the NADPH/NADP ratio, reduced the intracellular redox environment, and inhibited mitochondrial respiratory activity. The addition of 0.2-5 mM NaHS for 4 h increased the IEC-18 proliferative cell fraction (P<0.05), as evidenced by analysis of the cell cycle and proliferating cell nuclear antigen expression, while apoptosis occurred only at the highest concentration of NaHS. Thirty minutes of NaHS exposure increased (P<0.05) c-Jun mRNA concentrations, consistent with the observed activation of mitogen activated protein kinases (MAPK). Microarray analysis confirmed an increase (P<0.05) in MAPK-mediated proliferative activity, likely reflecting the reduced redox environment of NaHS-treated cells. These data identify functional pathways by which H2S may initiate epithelial dysregulation and thereby contribute to UC or colorectal cancer. Thus, it becomes crucial to understand how genetic background may affect epithelial responsiveness to this bacterial-derived environmental insult.	Univ Illinois, Div Nutr Sci, Urbana, IL 61801 USA; Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA; Univ Illinois, Dept Vet Pathobiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Gaskins, HR (corresponding author), Univ Illinois, Div Nutr Sci, 1207 W Gregory Dr, Urbana, IL 61801 USA.	hgaskins@uiuc.edu	Deplancke, Bart/B-3250-2008	Deplancke, Bart/0000-0001-9935-843X; Gaskins, H. Rex/0000-0002-1249-535X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK057940] Funding Source: NIH RePORTER; NIDDK NIH HHS [R21 DK057940-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDROW MG, 1995, CANCER RES, V55, P1452; AUSSERER WA, 1994, MOL CELL BIOL, V14, P5032, DOI 10.1128/MCB.14.8.5032; Babidge W, 1998, MOL CELL BIOCHEM, V181, P117, DOI 10.1023/A:1006838231432; Baserga R, 1997, ENDOCRINE, V7, P99, DOI 10.1007/BF02778073; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; CHRISTL SU, 1995, Z GASTROENTEROL, V33, P408; Christl SU, 1996, DIGEST DIS SCI, V41, P2477, DOI 10.1007/BF02100146; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; Dagsgaard C, 2001, J BIOL CHEM, V276, P7593, DOI 10.1074/jbc.M009180200; Das M, 2001, J BIOL CHEM, V276, P15631, DOI 10.1074/jbc.M010690200; De Laurenzi V, 2000, ANN NY ACAD SCI, V926, P90; Deb SP, 2002, FRONT BIOSCI, V7, pD235, DOI 10.2741/deb; DEPLANCKE B, 2003, IN PRESS EXP BIOL ME; DIETRICH DR, 1993, CRIT REV TOXICOL, V23, P77, DOI 10.3109/10408449309104075; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Esco MA, 2001, J CELL SCI, V114, P4033; EVANS CL, 1967, Q J EXP PHYSIOL CMS, V52, P231, DOI 10.1113/expphysiol.1967.sp001909; FLORIN T, 1991, GUT, V32, P766, DOI 10.1136/gut.32.7.766; Furne J, 2001, BIOCHEM PHARMACOL, V62, P255, DOI 10.1016/S0006-2952(01)00657-8; GIBSON GR, 1996, FEMS MICROBIOL ECOL, V86, P101; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; GONZALEZFLECHA B, 1993, J CLIN INVEST, V91, P456, DOI 10.1172/JCI116223; Griffiths EJ, 1998, BIOCHEM PHARMACOL, V56, P173, DOI 10.1016/S0006-2952(98)00016-1; Guo YS, 2001, J BIOL CHEM, V276, P22941, DOI 10.1074/jbc.M101801200; HAGUE A, 1995, INT J CANCER, V60, P400, DOI 10.1002/ijc.2910600322; Hardy RG, 2000, BRIT MED J, V321, P886, DOI 10.1136/bmj.321.7265.886; Heron-Milhavet L, 2002, J BIOL CHEM, V277, P15600, DOI 10.1074/jbc.M111142200; Hoffmann A, 2001, J CELL PHYSIOL, V188, P33, DOI 10.1002/jcp.1092; Ierardi E, 2001, DIGEST DIS SCI, V46, P1083, DOI 10.1023/A:1010774331331; Isaksen MF, 1996, MAR ECOL PROG SER, V137, P187, DOI 10.3354/meps137187; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jung F, 2001, BIOCHEM BIOPH RES CO, V286, P419, DOI 10.1006/bbrc.2001.5406; Kanazawa K, 1996, CANCER-AM CANCER SOC, V77, P1701, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1701::AID-CNCR42>3.3.CO;2-E; Kang HS, 2001, CELL IMMUNOL, V213, P34, DOI 10.1006/cimm.2001.1861; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kirlin WG, 1999, FREE RADICAL BIO MED, V27, P1208, DOI 10.1016/S0891-5849(99)00145-8; Ladoux A, 2000, J BIOL CHEM, V275, P39914, DOI 10.1074/jbc.M006512200; Levitt MD, 1999, J CLIN INVEST, V104, P1107, DOI 10.1172/JCI7712; Liu YC, 1998, FEBS LETT, V441, P200, DOI 10.1016/S0014-5793(98)01549-X; Loftus EV, 2000, GUT, V46, P336, DOI 10.1136/gut.46.3.336; Magee EA, 2000, AM J CLIN NUTR, V72, P1488; Manthey CL, 1998, J LEUKOCYTE BIOL, V64, P409, DOI 10.1002/jlb.64.3.409; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Masys DR, 2001, BIOINFORMATICS, V17, P319, DOI 10.1093/bioinformatics/17.4.319; Matsuda N, 1998, BIOCHEM BIOPH RES CO, V249, P350, DOI 10.1006/bbrc.1998.9151; OBITABOT ET, 1993, J SURG RES, V55, P575, DOI 10.1006/jsre.1993.1187; PANDEY S, 1995, J CELL BIOCHEM, V58, P135, DOI 10.1002/jcb.240580203; Pellizzaro C, 2002, CARCINOGENESIS, V23, P735, DOI 10.1093/carcin/23.5.735; Pitcher MCL, 1995, GUT, V36, pA63; POCHART P, 1992, FEMS MICROBIOL LETT, V98, P225; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; POWELL MA, 1986, SCIENCE, V233, P563, DOI 10.1126/science.233.4763.563; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Qiao L, 1997, BBA-MOL CELL RES, V1359, P222, DOI 10.1016/S0167-4889(97)00102-X; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153; Rhodes JM, 2002, TRENDS MOL MED, V8, P10, DOI 10.1016/S1471-4914(01)02194-3; ROEDIGER WEW, 1984, J CLIN PATHOL, V37, P704, DOI 10.1136/jcp.37.6.704; Roediger WEW, 1997, DIGEST DIS SCI, V42, P1571, DOI 10.1023/A:1018851723920; ROEDIGER WEW, 1993, GASTROENTEROLOGY, V104, P802, DOI 10.1016/0016-5085(93)91016-B; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Schuchmann S, 2000, FREE RADICAL BIO MED, V28, P235, DOI 10.1016/S0891-5849(99)00226-9; Scott PH, 1998, AM J RESP CRIT CARE, V158, P958, DOI 10.1164/ajrccm.158.3.9712130; SEGAL I, 1988, INT J COLORECTAL DIS, V3, P222, DOI 10.1007/BF01660719; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Smith J, 2000, P NATL ACAD SCI USA, V97, P10032, DOI 10.1073/pnas.170209797; Sodhi CP, 2001, DIABETES, V50, P1482, DOI 10.2337/diabetes.50.6.1482; WEBSTER KA, 1994, CIRC RES, V74, P679, DOI 10.1161/01.RES.74.4.679; Welsh DJ, 2001, AM J RESP CRIT CARE, V164, P282, DOI 10.1164/ajrccm.164.2.2008054; WHITAKER JE, 1991, BIOCHEM BIOPH RES CO, V175, P387, DOI 10.1016/0006-291X(91)91576-X; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; YAO A, 1995, J CLIN INVEST, V96, P69, DOI 10.1172/JCI118081	76	148	154	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1310	+		10.1096/fj.02-0883fje	http://dx.doi.org/10.1096/fj.02-0883fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738807				2022-12-25	WOS:000183165000039
J	Johnston, JD; Cagampang, FRA; Stirland, JA; Carr, AJF; White, MRH; Davis, JRE; Loudon, ASI				Johnston, JD; Cagampang, FRA; Stirland, JA; Carr, AJF; White, MRH; Davis, JRE; Loudon, ASI			Evidence for an endogenous per1- and ICER-independent seasonal timer in the hamster pituitary gland	FASEB JOURNAL			English	Article						clock gene; melatonin; pars tuberalis; refractoriness; photoperiod; circadian	OVINE PARS TUBERALIS; DECODING PHOTOPERIODIC TIME; SUPRACHIASMATIC NUCLEUS; PROLACTIN SECRETION; GENE-EXPRESSION; SIBERIAN HAMSTERS; MELATONIN SIGNAL; SYRIAN-HAMSTERS; PINEAL-GLAND; DOPAMINE	Most mammals use changing annual day-length cycles to regulate pineal melatonin secretion and thereby drive many physiological rhythms including reproduction, metabolism, immune function, and pelage. Prolonged exposure to short winter day lengths results in refractoriness, a spontaneous reversion to long-day physiological status. Despite its critical role in the timing of seasonal rhythms, refractoriness remains poorly understood. The aim of this study was therefore to describe cellular and molecular mechanisms driving the seasonal secretion of a key hormone, prolactin, in refractory Syrian hamsters. We used recently developed single cell hybridization and reporter assays to show that this process is initiated by timed reactivation of endocrine signaling from the pars tuberalis (PT) region of the pituitary gland, a well-defined melatonin target site, causing renewed activation of prolactin gene expression. This timed signaling is independent of per1 clock gene expression in the suprachiasmatic nuclei and PT and of melatonin secretion, which continue to track day length. Within the PT, there is also a continued short day-like profile of ICER expression, suggesting that the change in hormone secretion is independent of cAMP signaling. Our data thus identify the PT as a key anatomical structure involved in endogenous seasonal timing mechanisms, which breaks from prevailing day length-induced gene expression.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Liverpool, Sch Biol Sci, Liverpool L69 3BX, Merseyside, England; Univ Manchester, Sch Med, Manchester M13 9PL, Lancs, England	University of Manchester; University of Liverpool; University of Manchester	Loudon, ASI (corresponding author), Univ Manchester, Sch Biol Sci, 3-614 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	andrew.loudon@man.ac.uk	Cagampang, Felino/AAG-5141-2019; Johnston, Jonathan/AAS-6969-2021; Davis, Julian R/G-8943-2014; Jansen, Heiko T./A-5770-2008; Yoong, Elizabeth/AAF-1297-2019; Johnston, Jonathan D/H-6363-2011	Cagampang, Felino/0000-0003-4404-9853; Davis, Julian R/0000-0003-0838-0557; Jansen, Heiko T./0000-0003-0178-396X; Johnston, Jonathan D/0000-0001-8083-9794; Carr, Amanda-Jayne/0000-0002-5469-0030; White, Michael/0000-0002-3617-3232; Loudon, Andrew/0000-0003-3648-445X				BADURA LL, 1994, NEUROENDOCRINOLOGY, V59, P49, DOI 10.1159/000126637; BADURA LL, 1992, J EXP ZOOL, V261, P27, DOI 10.1002/jez.1402610105; BARTNESS TJ, 1993, J PINEAL RES, V15, P161; BITTMAN EL, 1978, SCIENCE, V202, P648, DOI 10.1126/science.568311; Bockers TM, 1997, ENDOCRINOLOGY, V138, P4101, DOI 10.1210/en.138.10.4101; CURLEWIS JD, 1992, REPROD FERT DEVELOP, V4, P1, DOI 10.1071/RD9920001; Freeman DA, 2001, P NATL ACAD SCI USA, V98, P6447, DOI 10.1073/pnas.111140398; Goldman BD, 2001, J BIOL RHYTHM, V16, P283, DOI 10.1177/074873001129001980; Gwinner E., 1986, CIRCANNUAL RHYTHMS, Vfirst; Hazlerigg DG, 2001, J BIOL RHYTHM, V16, P326, DOI 10.1177/074873001129002042; Hazlerigg DG, 1996, J NEUROENDOCRINOL, V8, P489, DOI 10.1046/j.1365-2826.1996.04971.x; HAZLERIGG DG, 1993, ENDOCRINOLOGY, V132, P285, DOI 10.1210/en.132.1.285; Jagota A, 2000, NAT NEUROSCI, V3, P372, DOI 10.1038/73943; LINCOLN GA, 1994, J NEUROENDOCRINOL, V6, P251, DOI 10.1111/j.1365-2826.1994.tb00580.x; Lincoln GA, 2002, J NEUROENDOCRINOL, V14, P36, DOI 10.1046/j.0007-1331.2001.00734.x; LINCOLN GA, 1995, J NEUROENDOCRINOL, V7, P637, DOI 10.1111/j.1365-2826.1995.tb00802.x; Lincoln GA, 2000, BIOL REPROD, V62, P432, DOI 10.1095/biolreprod62.2.432; MAYWOOD ES, 1993, J ENDOCRINOL, V136, P65, DOI 10.1677/joe.0.1360065; MAYWOOD ES, 1995, ENDOCRINOLOGY, V136, P144, DOI 10.1210/en.136.1.144; Messager S, 2001, NEUROREPORT, V12, P579, DOI 10.1097/00001756-200103050-00029; Messager S, 2000, EUR J NEUROSCI, V12, P2865, DOI 10.1046/j.1460-9568.2000.00174.x; Messager S, 1999, P NATL ACAD SCI USA, V96, P9938, DOI 10.1073/pnas.96.17.9938; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Morgan PJ, 2000, J NEUROENDOCRINOL, V12, P287; Morgan PJ, 1998, J NEUROENDOCRINOL, V10, P319, DOI 10.1046/j.1365-2826.1998.00232.x; Morgan PJ, 1996, ENDOCRINOLOGY, V137, P4018, DOI 10.1210/en.137.9.4018; Mrugala M, 2000, AM J PHYSIOL-REG I, V278, pR987, DOI 10.1152/ajpregu.2000.278.4.R987; NICHOLLS TJ, 1988, PHYSIOL REV, V68, P133, DOI 10.1152/physrev.1988.68.1.133; Nuesslein-Hildesheim B, 2000, EUR J NEUROSCI, V12, P2856, DOI 10.1046/j.1460-9568.2000.00173.x; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; ROLLAG MD, 1980, P SOC EXP BIOL MED, V165, P330, DOI 10.3181/00379727-165-40981; Schwartz WJ, 2001, J BIOL RHYTHM, V16, P302, DOI 10.1177/074873001129002024; STEGER RW, 1991, BIOL REPROD, V44, P76, DOI 10.1095/biolreprod44.1.76; Stirland JA, 2001, J NEUROENDOCRINOL, V13, P147, DOI 10.1046/j.1365-2826.2001.00611.x; SUMOVA A, 1995, P NATL ACAD SCI USA, V92, P7754, DOI 10.1073/pnas.92.17.7754; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Takasuka N, 1998, ENDOCRINOLOGY, V139, P1361, DOI 10.1210/en.139.3.1361; von Gall C, 2002, NAT NEUROSCI, V5, P234, DOI 10.1038/nn806; Yagita K, 2000, FEBS LETT, V465, P79, DOI 10.1016/S0014-5793(99)01724-X	39	47	48	0	3428	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					810	815		10.1096/fj.02-0837com	http://dx.doi.org/10.1096/fj.02-0837com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12724339				2022-12-25	WOS:000183165000006
J	Kojima, K; Bonassar, LJ; Roy, AK; Mizuno, H; Cortiella, J; Vacanti, CA				Kojima, K; Bonassar, LJ; Roy, AK; Mizuno, H; Cortiella, J; Vacanti, CA			A composite tissue-engineered trachea using sheep nasal chondrocyte and epithelial cells	FASEB JOURNAL			English	Article						chondrocytes; polyglycolic acid (PGA); hydrogel; tracheal replacement	HUMAN SEPTAL CARTILAGE; AGE-DEPENDENCE; RECONSTRUCTION; BONE	This study evaluates the feasibility of producing a composite engineered tracheal equivalent composed of cylindrical cartilaginous structures with lumens lined with nasal epithelial cells. Chondrocytes and epithelial cells isolated from sheep nasal septum were cultured in Ham's F12 media. After 2 wk, chondrocyte suspensions were seeded onto a matrix of polyglycolic acid. Cell-polymer constructs were wrapped around silicon tubes and cultured in vitro for 1 wk, followed by implanting into subcutaneous pockets on the backs of nude mice. After 6 wk, epithelial cells were suspended in a hydrogel and injected into the embedded cartilaginous cylinders following removal of the silicon tube. Implants were harvested 4 wk later and analyzed. The morphology of implants resembles that of native sheep trachea. H&E staining shows the presence of mature cartilage and formation of a pseudo-stratified columnar epithelium, with a distinct interface between tissue-engineered cartilage and epithelium. Safranin-O staining shows that tissue-engineered cartilage is organized into lobules with round, angular lacunae, each containing a single chondrocyte. Proteoglycan and hydroxyproline contents are similar to native cartilage. This study demonstrates the feasibility of recreating the cartilage and epithelial portion of the trachea using tissue harvested in a single procedure. This has the potential to facilitate an autologous repair of segmental tracheal defects.	Univ Massachusetts, Sch Med, Ctr Tissue Engn, Worcester, MA USA	University of Massachusetts System; University of Massachusetts Worcester	Vacanti, CA (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Anesthesiol,Lab Tissue Engn, 75 Francis St, Boston, MA 02115 USA.	cvacanti@partners.org	Bonassar, Lawrence J/C-2103-2016	Bonassar, Lawrence J/0000-0003-1094-6433				Banis JC, 1996, PLAST RECONSTR SURG, V98, P1046, DOI 10.1097/00006534-199611000-00019; Cavadas PC, 1998, PLAST RECONSTR SURG, V101, P937, DOI 10.1097/00006534-199804040-00008; Enobakhare BO, 1996, ANAL BIOCHEM, V243, P189, DOI 10.1006/abio.1996.0502; KIM YJ, 1988, ANAL BIOCHEM, V174, P168, DOI 10.1016/0003-2697(88)90532-5; Mukaida T, 1998, ANN THORAC SURG, V66, P205, DOI 10.1016/S0003-4975(98)00154-4; NAKANISHI R, 1993, J THORAC CARDIOV SUR, V106, P1081, DOI 10.1016/S0022-5223(19)33981-9; NEVILLE WE, 1982, INT SURG, V67, P229; Okumura N, 1992, ASAIO J, V38, pM555, DOI 10.1097/00002480-199207000-00096; OSADA H, 1994, J CARDIOVASC SURG, V35, P165; Rotter N, 2002, ARCH BIOCHEM BIOPHYS, V403, P132, DOI 10.1016/S0003-9861(02)00263-1; Rotter N, 2002, BIOMATERIALS, V23, P3087, DOI 10.1016/S0142-9612(02)00031-5; Rotter N, 2001, ARCH OTOLARYNGOL, V127, P1248, DOI 10.1001/archotol.127.10.1248; SPANGENBERG KM, 1998, TISSUE ENG, V4, P476; STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009-8981(67)90167-2; Treppo S, 2000, J ORTHOP RES, V18, P739, DOI 10.1002/jor.1100180510; VACANTI CA, 1994, OTOLARYNG CLIN N AM, V27, P263; VACANTI CA, 1994, CLIN PLAST SURG, V21, P445; VACANTI CA, 1994, J PEDIATR SURG, V29, P201, DOI 10.1016/0022-3468(94)90318-2; van Veenendaal MB, 2000, EUR J PEDIATR, V159, P8, DOI 10.1007/s004310050002	19	87	93	1	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					823	828		10.1096/fj.02-0462com	http://dx.doi.org/10.1096/fj.02-0462com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12724341				2022-12-25	WOS:000183165000008
J	Stockl, L; Berting, A; Malkowski, B; Foerste, R; Hofschneider, PH; Hildt, E				Stockl, L; Berting, A; Malkowski, B; Foerste, R; Hofschneider, PH; Hildt, E			Integrity of c-Raf-1/MEK signal transduction cascade is essential for hepatitis B virus gene expression	ONCOGENE			English	Article						hepatitis B virus; transactivation; replication; antivirals	NF-KAPPA-B; PROTEIN-KINASE-C; HBX PROTEIN; X-PROTEIN; TRANSCRIPTIONAL ACTIVATOR; REPLICATION; RAS; IDENTIFICATION; PATHWAYS	The genome of hepatitis B virus (HBV) encodes two transcriptional activators: the HBx protein and the PreS2-activator large surface protein (LHBs). Both proteins trigger activation of c-Raf-1/MEK kinase cascade. In case of HBx this can be mediated by a PKC-independent and Ras-dependent mechanism, in case of LHBs activation is PKC-dependent and does not require Ras. Selective destruction of either LHBs- or of HBx-specific activation does not result in significant decrease of viral production from transfected HepG2 cells. Simultaneous inhibition of LHBs- and HBx-dependent activation by blocking signaling steps common to both activators, using trans dominant negative c-Raf-1- or MEK-specific inhibitors, abolished HBV gene expression. In accordance with this no HBV propagation was observed after transfection of a mutated HBV genome defective for HBx- and PreS2-activator function. A detailed analysis revealed that the observed inhibition of HBV- propagation is because of a significant reduction of HBV-specific RNA resulting in an inhibition of the de novo synthesis of viral compounds (viral proteins and nucleic acid) and not by blocking secretion or assembly of the virus. Based on these results we conclude that transcriptional-activator function, mediated by the c-Raf-1/MEK signaling cascade, is essential for HBV gene expression.	Robert Koch Inst, D-13353 Berlin, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Robert Koch Institute; Max Planck Society	Hildt, E (corresponding author), Robert Koch Inst, Nordufer 20, D-13353 Berlin, Germany.		Małkowski, Bogdan/H-7131-2014; Hildt, Eberhard/A-1040-2015	Małkowski, Bogdan/0000-0001-6092-2283; 				Andrisani OM, 1999, INT J ONCOL, V15, P373; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Bouchard MJ, 2001, SCIENCE, V294, P2376, DOI 10.1126/science.294.5550.2376; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUSS V, 1994, EMBO J, V13, P2273, DOI 10.1002/j.1460-2075.1994.tb06509.x; HEERMANN KH, 1984, J VIROL, V52, P396, DOI 10.1128/JVI.52.2.396-402.1984; Hildt E, 1996, VIROLOGY, V225, P235, DOI 10.1006/viro.1996.0594; HILDT E, 1995, ONCOGENE, V11, P2055; Hildt E, 1998, RECENT RES CANCER, V154, P315; Hildt E, 2002, EMBO J, V21, P525, DOI 10.1093/emboj/21.4.525; Hildt E, 1999, J EXP MED, V189, P1707, DOI 10.1084/jem.189.11.1707; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; Klein NP, 1999, EMBO J, V18, P5019, DOI 10.1093/emboj/18.18.5019; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MURAKAMI S, 1994, VIROLOGY, V199, P243, DOI 10.1006/viro.1994.1119; Oess S, 2000, GENE THER, V7, P750, DOI 10.1038/sj.gt.3301154; Pleschka S, 2001, NAT CELL BIOL, V3, P301, DOI 10.1038/35060098; Sambrook J., 2002, MOL CLONING LAB MANU; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; Su F, 2001, J VIROL, V75, P215, DOI 10.1128/JVI.75.1.215-225.2001; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; Weiss L, 1996, VIROLOGY, V216, P214, DOI 10.1006/viro.1996.0049; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	26	36	41	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2604	2610		10.1038/sj.onc.1206320	http://dx.doi.org/10.1038/sj.onc.1206320			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730674				2022-12-25	WOS:000182569000008
J	Bento, I; Teixeira, VH; Baptista, AM; Soares, CM; Matias, PM; Carrondo, MA				Bento, I; Teixeira, VH; Baptista, AM; Soares, CM; Matias, PM; Carrondo, MA			Redox-Bohr and other cooperativity effects in the nine-heme cytochrome c from Desulfovibrio desulfuricans ATCC 27774 - Crystallographic and modeling studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII FERREDOXIN; RAY CRYSTAL-STRUCTURES; FREE R-VALUE; FREE-ENERGY; VULGARIS HILDENBOROUGH; DIELECTRIC-CONSTANTS; ATCC 27774; ANGSTROM RESOLUTION; PRIMARY SEQUENCE; STRUCTURAL BASIS	The nine-heme cytochrome c is a monomeric multiheme cytochrome found in Desulfovibrio desulfuricans ATCC 27774. The polypeptide chain comprises 296 residues and wraps around nine hemes of type c. It is believed to take part in the periplasmic assembly of proteins involved in the mechanism of hydrogen cycling, receiving electrons from the tetraheme cytochrome c(3). With the purpose of understanding the molecular basis of electron transfer processes in this cytochrome, we have determined the crystal structures of its oxidized and reduced forms at pH 7.5 and performed theoretical calculations of the binding equilibrium of protons and electrons in these structures. This integrated study allowed us to observe that the reduction process induced relevant conformational changes in several residues, as well as protonation changes in some protonatable residues. In particular, the surroundings of hemes I and IV constitute two areas of special interest. In addition, we were able to ascertain the groups involved in the redox-Bohr effect present in this cytochrome and the conformational changes that may underlie the redox-cooperativity effects on different hemes. Furthermore, the thermodynamic simulations provide evidence that the N- and C-terminal domains function in an independent manner, with the hemes belonging to the N- terminal domain showing, in general, a lower redox potential than those found in the C-terminal domain. In this way, electrons captured by the N- terminal domain could easily flow to the C-terminal domain, allowing the former to capture more electrons. A notable exception is heme IX, which has low redox potential and could serve as the exit path for electrons toward other proteins in the electron transfer pathway.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2781901 Oeiras, Portugal	Universidade Nova de Lisboa	Carrondo, MA (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Av Republ,EAN,Apartado 127, P-2781901 Oeiras, Portugal.	carrondo@itqb.unl.pt	Baptista, Antonio M./C-7246-2012; Soares, Claudio M/E-2675-2012; Matias, Pedro M/B-7180-2008; Bento, Isabel/A-5436-2011	Baptista, Antonio M./0000-0002-7044-1210; Soares, Claudio M/0000-0003-1154-556X; Matias, Pedro M/0000-0001-6170-451X; Carrondo, Maria Armenia/0000-0002-1261-1162; Bento, Isabel/0000-0003-3801-4929; Teixeira, Vitor/0000-0002-1536-0573				ANTOSIEWICZ J, 1994, J MOL BIOL, V238, P415, DOI 10.1006/jmbi.1994.1301; Apostolakis J, 1996, J AM CHEM SOC, V118, P3743, DOI 10.1021/ja9535219; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baptista AM, 1999, BIOPHYS J, V76, P2978, DOI 10.1016/S0006-3495(99)77452-7; Baptista AM, 2001, J PHYS CHEM B, V105, P293, DOI 10.1021/jp002763e; BASHFORD D, 1988, J MOL BIOL, V203, P507, DOI 10.1016/0022-2836(88)90016-2; BASHFORD D, 1992, J MOL BIOL, V224, P473, DOI 10.1016/0022-2836(92)91009-E; Bashford D, 1997, LECT NOTES COMPUTER, P233, DOI [10.1007/3-540-63827-X, DOI 10.1007/3-540-63827-X_66]; BENTO I, 2003, IN PRESS PROTEIN STR; Berglund GI, 2002, NATURE, V417, P463, DOI 10.1038/417463a; Bertini I, 1998, J BIOL INORG CHEM, V3, P401, DOI 10.1007/s007750050250; Brennan L, 2000, J MOL BIOL, V298, P61, DOI 10.1006/jmbi.2000.3652; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; BRUNNETT B, 1993, SURVEYS MATH IND, V3, P1; Coelho AV, 1996, PROTEIN SCI, V5, P1189; DAY MW, 1992, PROTEIN SCI, V1, P1494, DOI 10.1002/pro.5560011111; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Drennan CL, 1999, J MOL BIOL, V294, P711, DOI 10.1006/jmbi.1999.3151; Fei MJ, 2000, ACTA CRYSTALLOGR D, V56, P529, DOI 10.1107/S0907444900002213; Fritz G, 2001, BIOCHEMISTRY-US, V40, P1317, DOI 10.1021/bi001480+; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; GUNNER MR, 1991, P NATL ACAD SCI USA, V88, P9151, DOI 10.1073/pnas.88.20.9151; Harada E, 2002, J MOL BIOL, V319, P767, DOI 10.1016/S0022-2836(02)00367-4; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KING G, 1991, J CHEM PHYS, V95, P4366, DOI 10.1063/1.461760; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Louro RO, 1997, J BIOL INORG CHEM, V2, P488, DOI 10.1007/s007750050160; Louro RO, 2001, J BIOL CHEM, V276, P44044, DOI 10.1074/jbc.M107136200; Louro RO, 2001, CHEMBIOCHEM, V2, P831, DOI 10.1002/1439-7633(20011105)2:11<831::AID-CBIC831>3.0.CO;2-W; Ludwig ML, 1997, BIOCHEMISTRY-US, V36, P1259, DOI 10.1021/bi962180o; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MARK AE, 1994, J MOL BIOL, V240, P167, DOI 10.1006/jmbi.1994.1430; Martel PJ, 1999, J BIOL INORG CHEM, V4, P73, DOI 10.1007/s007750050291; Matias PM, 2002, J BIOL CHEM, V277, P47907, DOI 10.1074/jbc.M207465200; Matias PM, 1999, J BIOL INORG CHEM, V4, P478, DOI 10.1007/s007750050334; Matias PM, 1999, STRUCTURE, V7, P119, DOI 10.1016/S0969-2126(99)80019-7; Messias AC, 1998, J MOL BIOL, V281, P719, DOI 10.1006/jmbi.1998.1974; Morales R, 1999, BIOCHEMISTRY-US, V38, P15764, DOI 10.1021/bi991578s; Muegge I, 1997, J PHYS CHEM B, V101, P825, DOI 10.1021/jp962478o; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Norager S, 1999, J MOL BIOL, V290, P881, DOI 10.1006/jmbi.1999.2917; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAPA S, 1979, FEBS LETT, V105, P213, DOI 10.1016/0014-5793(79)80614-6; Pereira PM, 2002, J BIOL INORG CHEM, V7, P815, DOI 10.1007/s00775-002-0364-0; Pochapsky TC, 2001, BIOCHEMISTRY-US, V40, P5602, DOI 10.1021/bi0028845; Popovic DM, 2001, J AM CHEM SOC, V123, P6040, DOI 10.1021/ja003878z; Reis C, 2002, INORG CHIM ACTA, V339, P248, DOI 10.1016/S0020-1693(02)00951-9; Romero A, 1996, EUR J BIOCHEM, V239, P190, DOI 10.1111/j.1432-1033.1996.0190u.x; ROSSI M, 1993, J BACTERIOL, V175, P4699, DOI 10.1128/JB.175.15.4699-4711.1993; ROUSSEL A, 1989, 15 INT UN CRYST ABST, P66; Saraiva LM, 2001, BBA-GENE STRUCT EXPR, V1520, P63, DOI 10.1016/S0167-4781(01)00250-0; Schaefer M, 1997, J PHYS CHEM B, V101, P1663, DOI 10.1021/jp962972s; Schipke CG, 1999, BIOCHEMISTRY-US, V38, P8228, DOI 10.1021/bi983008i; Schneider TR, 2000, ACTA CRYSTALLOGR D, V56, P714, DOI 10.1107/S0907444900003723; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P195, DOI 10.1107/S0907444901019291; Schutz CN, 2001, PROTEINS, V44, P400, DOI 10.1002/prot.1106; Sham YY, 1998, BIOPHYS J, V74, P1744, DOI 10.1016/S0006-3495(98)77885-3; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Simonson T, 1996, J AM CHEM SOC, V118, P8452, DOI 10.1021/ja960884f; Soares CM, 1998, BIOPHYS J, V74, P1708, DOI 10.1016/S0006-3495(98)77882-8; Soares CM, 1997, J BIOL INORG CHEM, V2, P714, DOI 10.1007/s007750050188; STOUT CD, 1993, J BIOL CHEM, V268, P25920; Svensson-Ek M, 2002, J MOL BIOL, V321, P329, DOI 10.1016/S0022-2836(02)00619-8; Teixeira VH, 2002, J BIOL INORG CHEM, V7, P200, DOI 10.1007/s007750100287; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1763, DOI 10.1107/S0907444901013749; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; Ullmann GM, 2000, J PHYS CHEM B, V104, P6293, DOI 10.1021/jp000711j; Umhau S, 2001, BIOCHEMISTRY-US, V40, P1308, DOI 10.1021/bi001479a; WARSHEL A, 1991, ANNU REV BIOPHYS BIO, V20, P267, DOI 10.1146/annurev.biophys.20.1.267; WATT W, 1991, J MOL BIOL, V218, P195, DOI 10.1016/0022-2836(91)90884-9; Weiss MS, 2001, J APPL CRYSTALLOGR, V34, P130, DOI 10.1107/S0021889800018227; Xavier A.V., 1985, FRONTIERS BIOINORGAN; Xavier AV, 2002, FEBS LETT, V532, P261, DOI 10.1016/S0014-5793(02)03692-X; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723	77	22	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36455	36469		10.1074/jbc.M301745200	http://dx.doi.org/10.1074/jbc.M301745200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12750363	hybrid			2022-12-25	WOS:000185318300074
J	Ellerby, HM; Lee, S; Ellerby, LM; Chen, S; Kiyota, T; del Rio, G; Sugihara, G; Sun, Y; Bredesen, DE; Arap, W; Pasqualini, R				Ellerby, HM; Lee, S; Ellerby, LM; Chen, S; Kiyota, T; del Rio, G; Sugihara, G; Sun, Y; Bredesen, DE; Arap, W; Pasqualini, R			An artificially designed pore-forming protein with anti-tumor effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO DESIGN; COILED-COILS; ANTICANCER ACTIVITY; CELL-LINES; PEPTIDES; DOMAIN; ANTIBACTERIAL; ANTIPARALLEL; APOPTOSIS; INSERTION	Protein engineering is an emerging area that has expanded our understanding of protein folding and laid the groundwork for the creation of unprecedented structures with unique functions. We previously designed the first native-like pore-forming protein, small globular protein (SGP). We show here that this artificially engineered protein has membrane-disrupting properties and anti-tumor activity in several cancer animal models. We propose and validate a mechanism for the selectivity of SGP toward cell membranes in tumors. SGP is the prototype for a new class of artificial proteins designed for therapeutic applications.	Buck Inst, Program Canc & Aging, Novato, CA 94945 USA; Fukuoka Univ, Fac Sci, Dept Chem, Jonan Ku, Fukuoka 81480, Japan; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA	Buck Institute for Research on Aging; Fukuoka University; University of Texas System; UTMD Anderson Cancer Center	Ellerby, HM (corresponding author), Buck Inst, Program Canc & Aging, Novato, CA 94945 USA.	mellerby@buckinstitute.org; rpasqual@notes.mdacc.tmc.edu			NATIONAL CANCER INSTITUTE [R01CA084262, P01CA069381] Funding Source: NIH RePORTER; NCI NIH HHS [CA84262, PC001502, CA69381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON M, 1995, EMBO J, V14, P1615, DOI 10.1002/j.1460-2075.1995.tb07150.x; Bayley H, 1999, CURR OPIN BIOTECH, V10, P94, DOI 10.1016/S0958-1669(99)80017-2; Betz SF, 1997, BIOCHEMISTRY-US, V36, P2450, DOI 10.1021/bi961704h; BROTHMAN A, 1997, ENCY CANC, P1303; Bryson JW, 1998, PROTEIN SCI, V7, P1404, DOI 10.1002/pro.5560070617; Corey MJ, 1996, P NATL ACAD SCI USA, V93, P11428, DOI 10.1073/pnas.93.21.11428; Dathe M, 1997, FEBS LETT, V403, P208, DOI 10.1016/S0014-5793(97)00055-0; DEGRADO WF, 1989, SCIENCE, V243, P622, DOI 10.1126/science.2464850; DEKKER N, 1993, NATURE, V362, P852, DOI 10.1038/362852a0; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Farinas E, 1998, PROTEIN SCI, V7, P1939, DOI 10.1002/pro.5560070909; FARKASHIMSLEY H, 1995, P NATL ACAD SCI USA, V92, P6996, DOI 10.1073/pnas.92.15.6996; Gamen S, 1998, J IMMUNOL, V161, P1758; HANDEL TM, 1993, SCIENCE, V261, P879, DOI 10.1126/science.8346440; HECHT MH, 1994, P NATL ACAD SCI USA, V91, P8729, DOI 10.1073/pnas.91.19.8729; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; HERNDIER BG, 1994, AIDS, V8, P575, DOI 10.1097/00002030-199405000-00002; KAMTEKAR S, 1993, SCIENCE, V262, P1680, DOI 10.1126/science.8259512; KONISKY J, 1982, ANNU REV MICROBIOL, V36, P125, DOI 10.1146/annurev.mi.36.100182.001013; Lazar GA, 1997, PROTEIN SCI, V6, P1167, DOI 10.1002/pro.5560060605; Lee S, 1997, BIOCHEMISTRY-US, V36, P3782, DOI 10.1021/bi962451v; Matsumoto E, 2001, BIOPOLYMERS, V56, P96; MEL SF, 1993, BIOCHEMISTRY-US, V32, P2082, DOI 10.1021/bi00059a028; Mingarro I, 1997, TRENDS BIOTECHNOL, V15, P432, DOI 10.1016/S0167-7799(97)01101-3; Monera OD, 1996, J BIOL CHEM, V271, P3995; MOORE AJ, 1994, PEPTIDE RES, V7, P265; OHSAKI Y, 1992, CANCER RES, V52, P3534; Pasqualini R, 1996, NAT MED, V2, P1197, DOI 10.1038/nm1196-1197; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; QUINN TP, 1994, P NATL ACAD SCI USA, V91, P8747, DOI 10.1073/pnas.91.19.8747; REISBACH G, 1982, ANTICANCER RES, V2, P257; Rojas NRL, 1997, PROTEIN SCI, V6, P2512; Tommos C, 1999, BIOCHEMISTRY-US, V38, P9495, DOI 10.1021/bi990609g; Tuchscherer G, 1998, BIOPOLYMERS, V47, P63, DOI 10.1002/(SICI)1097-0282(1998)47:1<63::AID-BIP7>3.0.CO;2-V; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; Walsh STR, 1999, P NATL ACAD SCI USA, V96, P5486, DOI 10.1073/pnas.96.10.5486; Zakharov SD, 1998, P NATL ACAD SCI USA, V95, P4282, DOI 10.1073/pnas.95.8.4282; ZHOU NE, 1992, J BIOL CHEM, V267, P2664	39	21	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35311	35316		10.1074/jbc.M300474200	http://dx.doi.org/10.1074/jbc.M300474200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12750379	hybrid			2022-12-25	WOS:000185164400070
J	Kim, EJ; Helfman, DM				Kim, EJ; Helfman, DM			Characterization of the metastasis-associated protein, S100A4 - Roles of calcium binding and dimerization in cellular localization and interaction with myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; NONMUSCLE MYOSIN; PROGNOSTIC-SIGNIFICANCE; TUMOR-CELLS; HEAVY-CHAIN; MTS1 PROTEIN; IN-VIVO; CA2+-BINDING PROTEINS; CARCINOMA-CELLS; PEL98 PROTEIN	Elevated S100A4 protein expression is associated with metastatic tumor progression and appears to be a strong molecular marker for clinical prognosis. S100A4 is a calcium-binding protein that is known to form homodimers and interacts with several proteins in a calcium-dependent manner. Here we show that S100A4 localizes to lamellipodia structures in a migrating breast cancer-derived cell line and colocalizes with a known S100A4-interacting protein, myosin heavy chain IIA, at the leading edge. We demonstrate that S100A4 mutants that are defective in either their ability to dimerize or in calcium binding are unable to interact with myosin heavy chain IIA. An S100A4 mutant that is deficient for calcium binding retains the ability to form homodimers, suggesting that S100A4 can exist as calcium-free or calcium-bound dimers in vivo. However, a calcium-bound S100A4 monomer only interacts with another calcium-bound monomer and not with an S100A4 mutant that does not bind calcium. Interestingly, despite the calcium dependence for interaction with known protein partners, calcium binding is not necessary for localization to lamellipodia. Both wild type and a mutant that is deficient for calcium binding colocalize with known markers of actively forming leading edges of lamellipodia, Arp3 and neuronal Wiskott-Aldrich syndrome protein. These data suggest that S100A4 localizes to the leading edge in a calcium-independent manner, and identification of the proteins that are involved in localizing S100A4 to the lamellipodial structures may provide novel insight into the mechanism by which S100A4 regulates metastasis.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; SUNY Stony Brook, Grad Program Genet, Stony Brook, NY 11794 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Helfman, DM (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.		Helfman, David M./C-2058-2011		NCI NIH HHS [CA83182] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083182] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertazzi E, 1998, DNA CELL BIOL, V17, P335, DOI 10.1089/dna.1998.17.335; Ambartsumian N, 2001, ONCOGENE, V20, P4685, DOI 10.1038/sj.onc.1204636; Araya E, 2002, J STRUCT BIOL, V137, P176, DOI 10.1006/jsbi.2002.4463; BABU A, 1992, J BIOL CHEM, V267, P15469; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; Belot N, 2002, BBA-PROTEINS PROTEOM, V1600, P74, DOI 10.1016/S1570-9639(02)00447-8; Davies BR, 2002, J PATHOL, V196, P292, DOI 10.1002/path.1051; DAVIES M, 1995, DNA CELL BIOL, V14, P825, DOI 10.1089/dna.1995.14.825; Davies MPA, 1996, ONCOGENE, V13, P1631; Dukhanina EA, 1997, FEBS LETT, V410, P403, DOI 10.1016/S0014-5793(97)00576-0; Dutta K, 2002, BIOCHEMISTRY-US, V41, P4239, DOI 10.1021/bi012061v; Endo H, 2002, J BIOL CHEM, V277, P26396, DOI 10.1074/jbc.M202244200; FORD HL, 1995, ONCOGENE, V11, P2067; Ford HL, 1997, BIOCHEMISTRY-US, V36, P16321, DOI 10.1021/bi971182l; FORD HL, 1995, ONCOGENE, V10, P1597; GIMONA M, 1995, P NATL ACAD SCI USA, V92, P9776, DOI 10.1073/pnas.92.21.9776; Gongoll S, 2002, GASTROENTEROLOGY, V123, P1478, DOI 10.1053/gast.2002.36606; Grigorian M, 1996, INT J CANCER, V67, P831, DOI 10.1002/(SICI)1097-0215(19960917)67:6<831::AID-IJC13>3.0.CO;2-4; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Kimura K, 2000, INT J ONCOL, V16, P1125; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kriajevska M, 1998, J BIOL CHEM, V273, P9852, DOI 10.1074/jbc.273.16.9852; Kriajevska M, 2002, J BIOL CHEM, V277, P5229, DOI 10.1074/jbc.M110976200; Kriajevska M, 2000, BBA-MOL CELL RES, V1498, P252, DOI 10.1016/S0167-4889(00)00100-2; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Landar A, 1998, BIOCHEMISTRY-US, V37, P17429, DOI 10.1021/bi9817921; Li CL, 2002, J CLIN PATHOL-MOL PA, V55, P250, DOI 10.1136/mp.55.4.250; Lloyd BH, 1998, ONCOGENE, V17, P465, DOI 10.1038/sj.onc.1201948; Maelandsmo GM, 1996, CANCER RES, V56, P5490; MANI RS, 1983, BIOCHEMISTRY-US, V22, P1734, DOI 10.1021/bi00276a033; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mueller A, 1999, HISTOCHEM CELL BIOL, V111, P453, DOI 10.1007/s004180050381; Murakami N, 2000, BIOCHEMISTRY-US, V39, P11441, DOI 10.1021/bi000347e; Nakamura T, 2002, INT J ONCOL, V20, P937; Ninomiya I, 2001, INT J ONCOL, V18, P715; Novitskaya V, 2000, J BIOL CHEM, V275, P41278, DOI 10.1074/jbc.M007058200; PEDROCCHI M, 1994, INT J CANCER, V57, P684, DOI 10.1002/ijc.2910570513; Platt-Higgins AM, 2000, INT J CANCER, V89, P198, DOI 10.1002/(SICI)1097-0215(20000320)89:2<198::AID-IJC16>3.0.CO;2-L; POTTS BCM, 1995, NAT STRUCT BIOL, V2, P790, DOI 10.1038/nsb0995-790; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rudland PS, 2000, CANCER RES, V60, P1595; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Schafer DA, 1998, J CELL BIOL, V143, P1919, DOI 10.1083/jcb.143.7.1919; Sturge J, 2002, J CELL SCI, V115, P699; TAKENAGA K, 1994, CELL STRUCT FUNCT, V19, P133, DOI 10.1247/csf.19.133; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; Takenaga K, 1997, ONCOGENE, V14, P331, DOI 10.1038/sj.onc.1200820; TAKENAGA K, 1994, JPN J CANCER RES, V85, P831, DOI 10.1111/j.1349-7006.1994.tb02955.x; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Tarabykina S, 2001, J BIOL CHEM, V276, P24212, DOI 10.1074/jbc.M009477200; Taylor S, 2002, BRIT J CANCER, V86, P409, DOI 10.1038/sj.bjc.6600071; Wang GZ, 2000, J BIOL CHEM, V275, P11141, DOI 10.1074/jbc.275.15.11141; Yonemura Y, 2000, CLIN CANCER RES, V6, P4234	55	91	100	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30063	30073		10.1074/jbc.M304909200	http://dx.doi.org/10.1074/jbc.M304909200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12756252	hybrid			2022-12-25	WOS:000184507000083
J	Ouyang, T; Bai, RY; Bassermann, F; von Klitzing, C; Klumpen, S; Miething, C; Morris, SW; Peschel, C; Duyster, J				Ouyang, T; Bai, RY; Bassermann, F; von Klitzing, C; Klumpen, S; Miething, C; Morris, SW; Peschel, C; Duyster, J			Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE-CELL LYMPHOMA; TYROSINE KINASE; KI-1 LYMPHOMA; ATIC-ALK; PROTEIN; FUSION; GENE; NPM; AKT; NUCLEOPHOSMIN/B23	Anaplastic large-cell lymphoma is a subtype of non-Hodgkin lymphomas characterized by the expression of CD30. More than half of these lymphomas carry a chromosomal translocation t(2;5) leading to expression of the oncogenic tyrosine kinase nucleophosmin-anaplastic lymphoma kinase ( NPM-ALK). NPM-ALK is capable of transforming fibroblasts and lymphocytes in vitro and of causing lymphomas in mice. Previously, we and others demonstrated phospholipase C-gamma and phosphatidylinositol 3-kinase as crucial downstream signaling mediators of NPM-ALK-induced oncogenicity. In this study, we used an ALK fusion protein as bait in a yeast two-hybrid screen identifying NIPA ( nuclear interacting partner of ALK) as a novel downstream target of NPM-ALK. NIPA encodes a 60-kDa protein that is expressed in a broad range of human tissues and contains a classical nuclear translocation signal in its C terminus, which directs its nuclear localization. NIPA interacts with NPM-ALK and other ALK fusions in a tyrosine kinase-dependent manner and is phosphorylated in NPM-ALK-expressing cells on tyrosine and serine residues with serine 354 as a major phosphorylation site. Overexpression of NIPA in Ba/F3 cells was able to protect from apoptosis induced by IL-3 withdrawal. Mutations of the nuclear translocation signal or the Ser-354 phosphorylation site impaired the antiapoptotic function of NIPA. In NPM-ALK-transformed Ba/F3 cells, apoptosis triggered by wortmannin treatment was enhanced by overexpression of putative dominant-negative NIPA mutants. These results implicate an antiapoptotic role for NIPA in NPM-ALK-mediated signaling events.	Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, D-81675 Munich, Germany; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA	Technical University of Munich; University of Munich; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Duyster, J (corresponding author), Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, Ismaningerstr 22, D-81675 Munich, Germany.	justus.duyster@lrz.tum.de	Miething, Cornelius/F-9498-2014	Miething, Cornelius/0000-0003-4699-3805				Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 1998, ONCOGENE, V17, P941, DOI 10.1038/sj.onc.1202024; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CHAN PK, 1995, BBA-GENE STRUCT EXPR, V1262, P37, DOI 10.1016/0167-4781(95)00044-H; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Colleoni GWB, 2000, AM J PATHOL, V156, P781, DOI 10.1016/S0002-9440(10)64945-0; Coutinho S, 2000, BLOOD, V96, P618; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Grangeasse C, 1999, BIOTECHNIQUES, V27, P62, DOI 10.2144/99271bm12; Hernandez L, 1999, BLOOD, V94, P3265; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Jahn T, 2002, ONCOGENE, V21, P4508, DOI 10.1038/sj.onc.1205559; KADIN ME, 1994, J CLIN ONCOL, V12, P884, DOI 10.1200/JCO.1994.12.5.884; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Lamant L, 1999, BLOOD, V93, P3088; Ma ZG, 2000, BLOOD, V95, P2144, DOI 10.1182/blood.V95.6.2144; MASON DY, 1990, BRIT J HAEMATOL, V74, P161; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; Moroianu J, 1999, J CELL BIOCHEM, P76; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Nieborowska-Skorska M, 2001, CANCER RES, V61, P6517; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Slupianek A, 2001, CANCER RES, V61, P2194; STEIN H, 1991, ANN ONCOL, V2, P33, DOI 10.1093/annonc/2.suppl_2.33; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Trinei M, 2000, CANCER RES, V60, P793; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	42	42	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30028	30036		10.1074/jbc.M300883200	http://dx.doi.org/10.1074/jbc.M300883200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12748172	hybrid			2022-12-25	WOS:000184507000078
J	Atreya, CE; Johnson, EF; Williamson, J; Chang, SY; Liang, PH; Anderson, KS				Atreya, CE; Johnson, EF; Williamson, J; Chang, SY; Liang, PH; Anderson, KS			Probing electrostatic channeling in protozoal bifunctional thymidylate synthase-dihydrofolate reductase using site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPTOPHAN SYNTHASE; ESCHERICHIA-COLI; SUPEROXIDE-DISMUTASE; LEISHMANIA-TROPICA; INACTIVE MUTANTS; ACTIVITY ENZYME; LIGAND-BINDING; SUBSTRATE; MECHANISM; ACETYLCHOLINESTERASE	In this study we used site-directed mutagenesis to test the hypothesis that substrate channeling in the bifunctional thymidylate synthase-dihydrofolate reductase enzyme from Leishmania major occurs via electrostatic interactions between the negatively charged dihydrofolate produced at thymidylate synthase and a series of lysine and arginine residues on the surface of the protein. Accordingly, 12 charge reversal or charge neutralization mutants were made, with up to 6 putative channel residues changed at once. The mutants were assessed for impaired channeling using two criteria: a lag in product formation at dihydrofolate reductase and an increase in dihydrofolate accumulation. Surprisingly, none of the mutations produced changes consistent with impaired channeling, so our findings do not support the electrostatic channeling hypothesis. Burst experiments confirmed that the mutants also did not interfere with intermediate formation at thymidylate synthase. One mutant, K282E/R283E, was found to be thymidylate synthase-dead because of an impaired ability to form the covalent enzyme-methylene tetrahydrofolatedeoxyuridate complex prerequisite for chemical catalysis.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan	Yale University; Academia Sinica - Taiwan	Anderson, KS (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.		Liang, Po-Huang/H-6610-2015	Liang, Po-Huang/0000-0003-1207-5256; Williamson, Jessica/0000-0002-5530-8657	NIAID NIH HHS [AI 44630] Funding Source: Medline; NIGMS NIH HHS [GMO7205] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007205] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KS, 1995, J BIOL CHEM, V270, P29936; Anderson KS, 1999, METHOD ENZYMOL, V308, P111; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; ANDERSON KS, 1990, CHEM REV, V90, P1131, DOI 10.1021/cr00105a004; Atreya CE, 2003, J BIOL CHEM, V278, P14092, DOI 10.1074/jbc.M212690200; BLAKLEY RL, 1960, NATURE, V188, P231, DOI 10.1038/188231a0; CARRERAS CW, 1995, ANNU REV BIOCHEM, V64, P721, DOI 10.1146/annurev.bi.64.070195.003445; Elcock AH, 1997, BIOCHEMISTRY-US, V36, P16049, DOI 10.1021/bi971709u; Elcock AH, 1996, J MOL BIOL, V262, P370, DOI 10.1006/jmbi.1996.0520; FINERMOORE J, 1993, J MOL BIOL, V232, P1101, DOI 10.1006/jmbi.1993.1463; GETZOFF ED, 1983, NATURE, V306, P287, DOI 10.1038/306287a0; GETZOFF ED, 1992, NATURE, V358, P347, DOI 10.1038/358347a0; GRUMONT R, 1986, P NATL ACAD SCI USA, V83, P5387, DOI 10.1073/pnas.83.15.5387; GRUMONT R, 1988, BIOCHEMISTRY-US, V27, P3776, DOI 10.1021/bi00410a039; HYDE CC, 1988, J BIOL CHEM, V263, P17857; Johnson EF, 2002, J BIOL CHEM, V277, P43126, DOI 10.1074/jbc.M206523200; KNIGHTON DR, 1994, NAT STRUCT BIOL, V1, P186, DOI 10.1038/nsb0394-186; KOPPENOL WH, 1982, J BIOL CHEM, V257, P4426; Liang PH, 1998, BIOCHEMISTRY-US, V37, P12195, DOI 10.1021/bi9803168; MALEY F, 1995, BIOCHEMISTRY-US, V34, P1469, DOI 10.1021/bi00005a001; MATTHEWS DA, 1990, J MOL BIOL, V214, P923, DOI 10.1016/0022-2836(90)90346-N; MEEK TD, 1985, BIOCHEMISTRY-US, V24, P678, DOI 10.1021/bi00324a021; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; OVADI J, 1991, J THEOR BIOL, V152, P1, DOI 10.1016/S0022-5193(05)80500-4; PERRY KM, 1993, BIOCHEMISTRY-US, V32, P7116, DOI 10.1021/bi00079a007; RIPOLL DR, 1993, P NATL ACAD SCI USA, V90, P5128, DOI 10.1073/pnas.90.11.5128; Saxl RL, 2001, BIOCHEMISTRY-US, V40, P5275, DOI 10.1021/bi002925x; SCHLICHTING I, 1994, J BIOL CHEM, V269, P26591; Spencer HT, 1997, BIOCHEMISTRY-US, V36, P4212, DOI 10.1021/bi961794q; STROUD RM, 1994, NAT STRUCT BIOL, V1, P131, DOI 10.1038/nsb0394-131; TAN RC, 1993, BIOCHEMISTRY-US, V32, P401, DOI 10.1021/bi00053a003; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q	32	12	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28901	28911		10.1074/jbc.M212689200	http://dx.doi.org/10.1074/jbc.M212689200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12754260	hybrid			2022-12-25	WOS:000184421100069
J	Bates, IR; Boggs, JM; Feix, JB; Harauz, G				Bates, IR; Boggs, JM; Feix, JB; Harauz, G			Membrane-anchoring and charge effects in the interaction of myelin basic protein with lipid bilayers studied by site-directed spin labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; ENTEROBACTIN RECEPTOR FEPA; MULTIPLE-SCLEROSIS; POSTTRANSLATIONAL MODIFICATIONS; SELF-ASSOCIATION; SIDE-CHAINS; KINASE-C; BINDING; CONFORMATION; CHOLESTEROL	Myelin basic protein (MBP) maintains the compaction of the myelin sheath in the central nervous system by anchoring the cytoplasmic face of the two apposing bi-layers and may also play a role in signal transduction. Site-directed spin labeling was done at eight matching sites in each of two recombinant murine MBPs, qC1 (charge +19) and qC8 charge (+13), which, respectively, emulate the native form of the protein (C1) and a post-translationally modified form (C8) that is increased in multiple sclerosis. When interacting with large unilamellar vesicles, most spin-labeled sites in qC8 were more mobile than those in qC1. Depth measurement via continuous wave power saturation indicated that the N-terminal and C-terminal sites in qC1 were located below the plane of the phospholipid headgroups. In qC8, the C-terminal domain dissociated from the membrane, suggesting a means by which the exposure of natural C8 to cytosolic enzymes and ligands might increase in vivo in multiple sclerosis. The importance of two Phe-Phe pairs in MBP to its interactions with lipids was investigated by separately mutating each pair to Ala-Ala. The mobility at F42A/F43A and especially F86A/F87A increased significantly. Depth measurements and helical wheel analysis indicated that the Phe-86/Phe-87 region could form a surface-seeking amphipathic alpha-helix.	Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada; Univ Guelph, Biophys Interdepartmental Grp, Guelph, ON N1G 2W1, Canada; Hosp Sick Children, Dept Struct Biol & Biochem, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada; Med Coll Wisconsin, Biophys Res Inst, Milwaukee, WI 53226 USA	University of Guelph; University of Guelph; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Medical College of Wisconsin	Harauz, G (corresponding author), Univ Guelph, Dept Mol Biol & Genet, 50 Stone Rd E, Guelph, ON N1G 2W1, Canada.			Harauz, George/0000-0002-6114-9947				ANTHONY JS, 1971, BIOCHIM BIOPHYS ACTA, V243, P429, DOI 10.1016/0005-2795(71)90011-0; Arbuzova A, 2000, BIOCHEMISTRY-US, V39, P10330, DOI 10.1021/bi001039j; Bates IR, 2002, PROTEIN EXPRES PURIF, V25, P330, DOI 10.1016/S1046-5928(02)00017-7; Bates IR, 2000, PROTEIN EXPRES PURIF, V20, P285, DOI 10.1006/prep.2000.1307; Boggs JM, 1997, BIOCHEMISTRY-US, V36, P5065, DOI 10.1021/bi962649f; BOGGS JM, 1978, J MEMBRANE BIOL, V39, P75, DOI 10.1007/BF01872756; Boggs JM, 1999, BBA-BIOMEMBRANES, V1417, P254, DOI 10.1016/S0005-2736(99)00008-5; Boggs JM, 2000, BIOCHEMISTRY-US, V39, P7799, DOI 10.1021/bi0002129; Cao LG, 1999, BIOCHEMISTRY-US, V38, P6157; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; Columbus L, 2002, TRENDS BIOCHEM SCI, V27, P288, DOI 10.1016/S0968-0004(02)02095-9; Columbus L, 2001, BIOCHEMISTRY-US, V40, P3828, DOI 10.1021/bi002645h; Cordes FS, 2002, J MOL BIOL, V323, P951, DOI 10.1016/S0022-2836(02)01006-9; DALTON LA, 1987, BIOCHEMISTRY-US, V26, P2117, DOI 10.1021/bi00382a009; DEMEL RA, 1973, BIOCHIM BIOPHYS ACTA, V311, P507, DOI 10.1016/0005-2736(73)90126-0; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; DYER CA, 1994, J NEUROSCI RES, V39, P97, DOI 10.1002/jnr.490390112; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; FARAHBAKHSH ZT, 1992, PHOTOCHEM PHOTOBIOL, V56, P1019, DOI 10.1111/j.1751-1097.1992.tb09725.x; Frazier AA, 2002, BIOCHEMISTRY-US, V41, P6282, DOI 10.1021/bi0160821; Hill CM, 2002, J STRUCT BIOL, V139, P13, DOI 10.1016/S1047-8477(02)00513-0; Hill CMD, 2003, MICRON, V34, P25, DOI 10.1016/S0968-4328(02)00058-6; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; INOUYE H, 1988, BIOPHYS J, V53, P247, DOI 10.1016/S0006-3495(88)83086-8; Ishiyama N, 2001, J STRUCT BIOL, V136, P30, DOI 10.1006/jsbi.2001.4421; JO EJ, 1995, BIOCHEMISTRY-US, V34, P13705, DOI 10.1021/bi00041a053; KENIRY MA, 1979, BIOCHIM BIOPHYS ACTA, V578, P381, DOI 10.1016/0005-2795(79)90169-7; Kitamura A, 1999, BIOPHYS J, V76, P1457, DOI 10.1016/S0006-3495(99)77306-6; Klug CS, 1998, BIOCHEMISTRY-US, V37, P9016, DOI 10.1021/bi980144e; Klug CS, 1997, BIOCHEMISTRY-US, V36, P13027, DOI 10.1021/bi971232m; Mayer BJ, 2001, J CELL SCI, V114, P1253; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; MENDZ GL, 1990, BIOCHEMISTRY-US, V29, P2304, DOI 10.1021/bi00461a014; MOSCARELLO MA, 1994, J CLIN INVEST, V94, P146, DOI 10.1172/JCI117300; MOSCARELLO MA, 1997, CELL BIOL PATHOLOGY; Oh KJ, 2000, METH MOL B, V145, P147; Polverini E, 1999, EUR BIOPHYS J BIOPHY, V28, P351, DOI 10.1007/s002490050218; Polverini E, 2003, LANGMUIR, V19, P872, DOI 10.1021/la020801a; POPP CA, 1981, J MAGN RESON, V43, P249, DOI 10.1016/0022-2364(81)90036-6; Pritzker LB, 2000, BIOCHEMISTRY-US, V39, P5374, DOI 10.1021/bi9925569; Qin ZH, 1996, BIOCHEMISTRY-US, V35, P13272, DOI 10.1021/bi961747y; Rauch ME, 2002, J BIOL CHEM, V277, P14068, DOI 10.1074/jbc.M109572200; READHEAD C, 1990, ANN NY ACAD SCI, V605, P280; SMITH R, 1992, J NEUROCHEM, V59, P1589, DOI 10.1111/j.1471-4159.1992.tb10989.x; Stariha RL, 2001, MICROSC RES TECHNIQ, V52, P680, DOI 10.1002/jemt.1052.abs; SUBCZYNSKI WK, 1989, P NATL ACAD SCI USA, V86, P4474, DOI 10.1073/pnas.86.12.4474; SUBCZYNSKI WK, 1994, BIOCHEMISTRY-US, V33, P7670, DOI 10.1021/bi00190a022; SUREWICZ WK, 1986, BIOCHIM BIOPHYS ACTA, V863, P45, DOI 10.1016/0005-2736(86)90385-8; Victor K, 1999, BIOCHEMISTRY-US, V38, P12527, DOI 10.1021/bi990847b; Victor K, 1998, BIOCHEMISTRY-US, V37, P3402, DOI 10.1021/bi9721501; WARREN KG, 1995, P NATL ACAD SCI USA, V92, P11061, DOI 10.1073/pnas.92.24.11061; WOOD DD, 1989, J BIOL CHEM, V264, P5121; WOOD DD, 1997, MOL BIOL MULTIPLE SC, P37; Zand R, 1998, BIOCHEMISTRY-US, V37, P2441, DOI 10.1021/bi972347t	55	70	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29041	29047		10.1074/jbc.M302766200	http://dx.doi.org/10.1074/jbc.M302766200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12748174	hybrid			2022-12-25	WOS:000184421100086
J	Chiara, F; Michieli, P; Pugliese, L; Comoglio, PM				Chiara, F; Michieli, P; Pugliese, L; Comoglio, PM			Mutations in the met oncogene unveil a "dual switch" mechanism controlling tyrosine kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; PAPILLARY RENAL CARCINOMAS; FACTOR SCATTER FACTOR; SOMATIC MUTATIONS; INVASIVE GROWTH; FACTOR-RECEPTOR; C-MET; HUMAN CANCER; PROTOONCOGENE; TRANSFORMATION	The met oncogene, encoding the high affinity hepatocyte growth factor receptor, is the only known gene inherited in human cancer that is invariably associated with somatic duplication of the mutant locus. Intriguingly, mutated Met requires ligand stimulation in order to unleash its transforming potential. Furthermore, individuals bearing a germ line met mutation develop cancer only late in life and with incomplete penetrance. To date, there is no molecular explanation for this unique behavior, which is unusual for a dominant oncogene. Here we investigate the molecular mechanisms underlying met oncogenic conversion by generating antibodies specific for the differently phosphorylated forms of the Met protein. Using these antibodies, we show that activation of wild-type Met is achieved through sequential phosphorylation of Tyr(1235) and Tyr(1234) in the activation loop and that mutagenesis of either tyrosine dramatically impairs kinase function. Surprisingly, oncogenic Met mutants never become phosphorylated on Tyr(1234) despite their high enzymatic activity, and mutagenesis of Tyr(1234) does not affect their biochemical or biological function. By analyzing the enzymatic properties of the mutant proteins in different conditions, we demonstrate that oncogenic mutations do not elicit constitutive kinase activation but simply overcome the requirement for the second phosphorylation step, thus reducing the threshold for activation. In the presence of activating signals, these mutations result therefore in a dynamic imbalance toward the active conformation of the kinase. This explains why mutant met provides an oncogenic predisposition but needs a second activating "hit," provided by sustained ligand stimulation or receptor overexpression, to achieve a fully transformed phenotype.	Univ Turin, Inst Canc Res & Treatment IRCC, Div Mol Oncol, Sch Med, I-10060 Turin, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Michieli, P (corresponding author), Univ Turin, Inst Canc Res & Treatment IRCC, Div Mol Oncol, Sch Med, Strada Prov 142,Km 3-95, I-10060 Turin, Italy.		Michieli, Paolo/A-2588-2011	Michieli, Paolo/0000-0002-3093-8871; Comoglio, Paolo/0000-0002-7056-5328; chiara, federica/0000-0003-2396-3080				Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Birchmeier W, 1997, CIBA F SYMP, V212, P230; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; CREPALDI T, 1994, J BIOL CHEM, V269, P1750; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; Fischer J, 1998, ONCOGENE, V17, P733, DOI 10.1038/sj.onc.1201983; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; Harlow E., 1988, ANTIBODIES LAB MANUA; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; LONGATI P, 1994, ONCOGENE, V9, P49; Matsumoto K, 1997, CIBA F SYMP, V212, P198; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; Michieli P, 1999, ONCOGENE, V18, P5221, DOI 10.1038/sj.onc.1202899; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; Park WS, 1999, CANCER RES, V59, P307; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Ruco LP, 1996, J PATHOL, V180, P266, DOI 10.1002/(SICI)1096-9896(199611)180:3<266::AID-PATH658>3.0.CO;2-Q; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	31	34	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29352	29358		10.1074/jbc.M302404200	http://dx.doi.org/10.1074/jbc.M302404200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12746450	hybrid			2022-12-25	WOS:000184421100121
J	George, CH; Higgs, GV; Mackrill, JJ; Lai, FA				George, CH; Higgs, GV; Mackrill, JJ; Lai, FA			Dysregulated ryanodine receptors mediate cellular toxicity - Restoration of normal phenotype by FKBP12.6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CA2+ RELEASE CHANNELS; CALCIUM-RELEASE; ENDOPLASMIC-RETICULUM; INDUCED APOPTOSIS; SARCOPLASMIC-RETICULUM; INTRACELLULAR CA2+; CELLS; PHOSPHORYLATION; EXPRESSION	Ca2+ homeostasis is a vital cellular control mechanism in which Ca2+ release from intracellular stores plays a central role. Ryanodine receptor (RyR)-mediated Ca2+ release is a key modulator of Ca2+ homeostasis, and the defective regulation of RyR is pathogenic. However, the molecular events underlying RyR-mediated pathology remain undefined. Cells stably expressing recombinant human RyR2 (Chinese hamster ovary cells, CHOhRyR2) had similar resting cytoplasmic Ca2+ levels ([Ca2+](c)) to wild-type CHO cells (CHOWT) but exhibited increased cytoplasmic Ca2+ flux associated with decreased cell viability and proliferation. Intracellular Ca2+ flux increased with human RyR2 (hRyR2) expression levels and determined the extent of phenotypic modulation. Co-expression of FKBP12.6, but not FKBP12, or incubation of cells with ryanodine suppressed intracellular Ca2+ flux and restored normal cell viability and proliferation. Restoration of normal phenotype was independent of the status of resting [Ca2+](c) or ER Ca2+ load. Heparin inhibition of endogenous inositol trisphosphate receptors ( IP3R) had little effect on intracellular Ca2+ handling or viability. However, purinergic stimulation of endogenous IP3R resulted in apoptotic cell death mediated by hRyR2 suggesting functional interaction occurred between IP3R and hRyR2 Ca2+ release channels. These data demonstrate that defective regulation of RyR causes altered cellular phenotype via profound perturbations in intracellular Ca2+ signaling and highlight a key modulatory role of FKBP12.6 in hRyR2 Ca2+ channel function.	Cardiff Univ, Dept Cardiol, Wales Heart Res Inst, Cardiff CF14 4XN, S Glam, Wales; Univ Coll Cork, Dept Biochem, Cork, Ireland	Cardiff University; University College Cork	George, CH (corresponding author), Cardiff Univ, Dept Cardiol, Wales Heart Res Inst, Cardiff CF14 4XN, S Glam, Wales.	georgech@cf.ac.uk		George, Christopher/0000-0001-9852-1135; Lai, Tony/0000-0003-2852-8547				Anger M, 1998, CIRCULATION, V98, P2477, DOI 10.1161/01.CIR.98.22.2477; Armitage P., 2001, STAT METHODS MED RES; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bhat MB, 1999, BIOPHYS J, V77, P808, DOI 10.1016/S0006-3495(99)76933-X; Blackshaw S, 2000, FASEB J, V14, P1375, DOI 10.1096/fj.14.10.1375; Carmody M, 2001, FEBS LETT, V505, P97, DOI 10.1016/S0014-5793(01)02787-9; Chan SL, 2000, J BIOL CHEM, V275, P18195, DOI 10.1074/jbc.M000040200; Currie S, 1999, CARDIOVASC RES, V41, P135, DOI 10.1016/S0008-6363(98)00241-7; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Fern R, 1998, J NEUROSCI, V18, P7232; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; George CH, 2003, BIOPHYS J, V84, p390A; George CH, 2003, BIOCHEM J, V370, P579, DOI 10.1042/BJ20021433; Haak LL, 2001, J NEUROSCI, V21, P3860, DOI 10.1523/JNEUROSCI.21-11-03860.2001; Hajnoczky G, 2000, CELL CALCIUM, V28, P349, DOI 10.1054/ceca.2000.0169; Hallett Maurice B., 1996, Methods (Orlando), V9, P591, DOI 10.1006/meth.1996.0066; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; Jeyakumar LH, 2001, BIOCHEM BIOPH RES CO, V281, P979, DOI 10.1006/bbrc.2001.4444; Kaftan E, 1996, CIRC RES, V78, P990, DOI 10.1161/01.RES.78.6.990; Kitao Y, 2001, J CLIN INVEST, V108, P1439, DOI 10.1172/JCI200112978; Koizumi S, 1999, J BIOL CHEM, V274, P33327, DOI 10.1074/jbc.274.47.33327; Li YX, 2002, CIRC RES, V90, P309, DOI 10.1161/hh0302.105660; Ma TS, 1999, CELL CALCIUM, V26, P25, DOI 10.1054/ceca.1999.0049; Mackrill JJ, 1997, BIOCHEM J, V327, P251, DOI 10.1042/bj3270251; Mackrill JJ, 1999, BIOCHEM J, V337, P345, DOI 10.1042/0264-6021:3370345; Mackrill JJ, 2001, BIOCHEM BIOPH RES CO, V285, P52, DOI 10.1006/bbrc.2001.5125; Marks AR, 2000, CIRC RES, V87, P8, DOI 10.1161/01.RES.87.1.8; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Marx SO, 2001, J CELL BIOL, V153, P699, DOI 10.1083/jcb.153.4.699; Matute-Bello G, 1999, J IMMUNOL, V163, P2217; Miyakawa T, 2001, EMBO J, V20, P1674, DOI 10.1093/emboj/20.7.1674; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; Nguyen HN, 2002, BRAIN RES, V924, P159, DOI 10.1016/S0006-8993(01)03229-2; OKADA CY, 1982, CELL, V29, P33, DOI 10.1016/0092-8674(82)90087-3; Oyadomari S, 2001, P NATL ACAD SCI USA, V98, P10845, DOI 10.1073/pnas.191207498; Pan Z, 2000, J BIOL CHEM, V275, P19978, DOI 10.1074/jbc.M908329199; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; Somlo S, 2001, CURR BIOL, V11, pR356, DOI 10.1016/S0960-9822(01)00193-2; Thibaut S, 2002, APOPTOSIS, V7, P99, DOI 10.1023/A:1014350128251; Timerman AP, 1996, J BIOL CHEM, V271, P20385, DOI 10.1074/jbc.271.34.20385; Tinel H, 1999, EMBO J, V18, P4999, DOI 10.1093/emboj/18.18.4999; Tong JF, 1999, J BIOL CHEM, V274, P693, DOI 10.1074/jbc.274.2.693; Tunwell REA, 1996, BIOCHEM J, V318, P477, DOI 10.1042/bj3180477; Vanden Abeele F, 2002, CANCER CELL, V1, P169; White C, 2002, J PHYSIOL-LONDON, V542, P725, DOI 10.1113/jphysiol.2002.020131; Xin HB, 2002, NATURE, V416, P334, DOI 10.1038/416334a; Xu KL, 2001, NEURON, V31, P957, DOI 10.1016/S0896-6273(01)00432-9; Xu L, 1998, BIOPHYS J, V75, P2302, DOI 10.1016/S0006-3495(98)77674-X; Yano M, 2000, CIRCULATION, V102, P2131, DOI 10.1161/01.CIR.102.17.2131; Yano M, 2003, CIRCULATION, V107, P477, DOI 10.1161/01.CIR.0000044917.74408.BE; ZORZATO F, 1993, MOL PHARMACOL, V44, P1192	56	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28856	28864		10.1074/jbc.M212440200	http://dx.doi.org/10.1074/jbc.M212440200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12754204	hybrid			2022-12-25	WOS:000184421100064
J	Hussain, NK; Yamabhai, M; Bhakar, AL; Metzler, M; Ferguson, SSG; Hayden, MR; McPherson, PS; Kay, BK				Hussain, NK; Yamabhai, M; Bhakar, AL; Metzler, M; Ferguson, SSG; Hayden, MR; McPherson, PS; Kay, BK			A role for epsin N-terminal homology/AP180 N-terminal homology (ENTH/ANTH) domains in tubulin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTH-DOMAIN; CLATHRIN-BINDING; INTERACTING PROTEIN; ENDOCYTIC VESICLES; NEURITE OUTGROWTH; GROWTH; ACTIN; EPS15; IDENTIFICATION; COMPONENTS	The epsin N-terminal homology (ENTH) domain is a protein module of similar to150 amino acids found at the N terminus of a variety of proteins identified in yeast, plants, nematode, frog, and mammals. ENTH domains comprise multiple alpha-helices folded upon each other to form a compact globular structure that has been implicated in interactions with lipids and proteins. In characterizing this evolutionarily conserved domain, we isolated and identified tubulin as an ENTH domain-binding partner. The interaction, which is direct and has a dissociation constant of similar to1 muM, was observed with ENTH domains of proteins present in various species. Tubulin is co-immunoprecipitated from rat brain extracts with the ENTH domain-containing proteins, epsins 1 and 2, and punctate epsin staining is observed along the microtubule cytoskeleton of dissociated cortical neurons. Consistent with a role in microtubule processes, the over-expression of epsin ENTH domain in PC12 cells stimulates neurite outgrowth. These data demonstrate an evolutionarily conserved property of ENTH domains to interact with tubulin and microtubules.	McGill Univ, Dept Neurol & Neurosurg, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; Suranaree Univ Technol, Sch Biotechnol, Inst Agr Technol, Nakhon Ratchasima 30000, Thailand; Univ British Columbia, Ctr Mol Med & Therapeut, Ctr Med Genet, Vancouver, BC V5Z 4H4, Canada; Robarts Res Inst, Cell Biol Res Grp, London, ON N6A 5K8, Canada; Argonne Natl Lab, Biosci Div, Argonne, IL 60439 USA	McGill University; Suranaree University of Technology; University of British Columbia; Western University (University of Western Ontario); United States Department of Energy (DOE); Argonne National Laboratory	McPherson, PS (corresponding author), McGill Univ, Dept Neurol & Neurosurg, Montreal Neurol Inst, 3801 Univ Ave, Montreal, PQ H3A 2B4, Canada.	peter.mcpherson@mcgill.ca	Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419				Aguilar RC, 2002, MOL BIOL CELL, V13, p93A; Bhakar AL, 2002, J NEUROSCI, V22, P8466; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chen H, 1999, J BIOL CHEM, V274, P3257, DOI 10.1074/jbc.274.6.3257; Chopra VS, 2000, MAMM GENOME, V11, P1006, DOI 10.1007/s003350010195; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; De Camilli P, 2002, FEBS LETT, V513, P11, DOI 10.1016/S0014-5793(01)03306-3; Dent EW, 2001, J NEUROSCI, V21, P9757, DOI 10.1523/JNEUROSCI.21-24-09757.2001; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; DRUBIN DG, 1985, J CELL BIOL, V101, P1799, DOI 10.1083/jcb.101.5.1799; Duncan MC, 2003, NAT CELL BIOL, V5, P77, DOI 10.1038/ncb901; Engqvist-Goldstein AEY, 2001, J CELL BIOL, V154, P1209, DOI 10.1083/jcb.200106089; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; GOLTZ JS, 1992, P NATL ACAD SCI USA, V89, P7026, DOI 10.1073/pnas.89.15.7026; Gu YJ, 2000, J BIOL CHEM, V275, P17917, DOI 10.1074/jbc.C000179200; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; Hirst J, 2003, MOL BIOL CELL, V14, P625, DOI 10.1091/mbc.E02-09-0552; Hussain NK, 1999, J BIOL CHEM, V274, P15671, DOI 10.1074/jbc.274.22.15671; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Jones HD, 1998, PLANT CELL, V10, P245, DOI 10.1105/tpc.10.2.245; Kalthoff C, 2002, MOL BIOL CELL, V13, P4060, DOI 10.1091/mbc.E02-03-0171; Kay BK, 1999, PROTEIN SCI, V8, P435; KELLY WG, 1983, J CELL BIOL, V97, P1191, DOI 10.1083/jcb.97.4.1191; Lamarche-Vane N, 1998, J BIOL CHEM, V273, P29172, DOI 10.1074/jbc.273.44.29172; Legendre-Guillemin V, 2002, J BIOL CHEM, V277, P19897, DOI 10.1074/jbc.M112310200; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; LIN CH, 1993, J CELL BIOL, V121, P1369, DOI 10.1083/jcb.121.6.1369; LINDNER R, 1992, J BIOL CHEM, V267, P16567; MANDELKOW EM, 1992, CELL MOTIL CYTOSKEL, V22, P235, DOI 10.1002/cm.970220403; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; Metzler M, 2001, J BIOL CHEM, V276, P39271, DOI 10.1074/jbc.C100401200; Mills IG, 2003, J CELL BIOL, V160, P213, DOI 10.1083/jcb.200208023; Mishra SK, 2001, J BIOL CHEM, V276, P46230, DOI 10.1074/jbc.M108177200; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Novikoff PM, 1996, J CELL SCI, V109, P21; ODA H, 1995, J BIOL CHEM, V270, P15242, DOI 10.1074/jbc.270.25.15242; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; Rosenthal JA, 1999, J BIOL CHEM, V274, P33959, DOI 10.1074/jbc.274.48.33959; Schaefer AW, 2002, J CELL BIOL, V158, P139, DOI 10.1083/jcb.200203038; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; TANAKA E, 1995, J CELL BIOL, V128, P139, DOI 10.1083/jcb.128.1.139; TEICHMANWEINBERG A, 1988, GENE, V72, P297, DOI 10.1016/0378-1119(88)90155-2; Torrisi MR, 1999, MOL BIOL CELL, V10, P417, DOI 10.1091/mbc.10.2.417; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Wasiak S, 2002, J CELL BIOL, V158, P855, DOI 10.1083/jcb.200205078; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383; Williamson T, 1996, P NATL ACAD SCI USA, V93, P15221, DOI 10.1073/pnas.93.26.15221; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401; Yao LB, 1999, J BIOL CHEM, V274, P19752, DOI 10.1074/jbc.274.28.19752; YE W, 1995, J NEUROSCI RES, V41, P15, DOI 10.1002/jnr.490410104; YE WL, 1995, J BIOL CHEM, V270, P10933, DOI 10.1074/jbc.270.18.10933; ZISAPEL N, 1980, J NEUROCHEM, V34, P26, DOI 10.1111/j.1471-4159.1980.tb04617.x	62	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28823	28830		10.1074/jbc.M300995200	http://dx.doi.org/10.1074/jbc.M300995200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12750376	hybrid			2022-12-25	WOS:000184421100060
J	Sakamoto, T; Wang, F; Schmitz, S; Xu, YH; Xu, Q; Molloy, JE; Veigel, C; Sellers, JR				Sakamoto, T; Wang, F; Schmitz, S; Xu, YH; Xu, Q; Molloy, JE; Veigel, C; Sellers, JR			Neck length and processivity of myosin V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; LEVER ARM; MOTOR; MOVEMENT; BINDING; ACTIN; MOLECULES; DOMAIN; HEAD; ROD	Myosin V is an unconventional myosin that transports cargo such as vesicles, melanosomes, or mRNA on actin filaments. It is a two-headed myosin with an unusually long neck that has six IQ motifs complexed with calmodulin. In vitro studies have shown that myosin V moves processively on actin, taking multiple 36-nm steps that coincide with the helical repeat of actin. This allows the molecule to "walk" across the top of an actin filament, a feature necessary for moving large vesicles along an actin filament bound to the cytoskeleton. The extended neck length of the two heads is thought to be critical for taking 36-nm steps for processive movements. To test this hypothesis we have expressed myosin V heavy meromyosin-like fragments containing 6IQ motifs, as well as ones that shorten (2IQ, 4IQ) or lengthen (8IQ) the neck region or alter the spacing between 3rd and 4th IQ motifs. The step size was proportional to neck length for the 2IQ, 4IQ, 6IQ, and 8IQ molecules, but the molecule with the altered spacing took shorter than expected steps. Total internal reflection fluorescence microscopy was used to determine whether the heavy meromyosin IQ molecules were capable of processive movements on actin. At saturating ATP concentrations, all molecules except for the 2IQ mutant moved processively on actin. When the ATP concentration was lowered to 10 muM or less, the 2IQ mutant demonstrated some processive movements but with reduced run lengths compared with the other mutants. Its weak processivity was also confirmed by actin landing assays.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Electron Microscopy Core, NIH, Bethesda, MD 20892 USA; Natl Inst Med Res, Div Phys Biochem, London NW7 1AA, England	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); MRC National Institute for Medical Research	Sellers, JR (corresponding author), NHLBI, Mol Cardiol Lab, NIH, Bldg 10,Rm 8N202, Bethesda, MD 20892 USA.			Molloy, Justin/0000-0002-8307-2450	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL004229, ZIAHL004229] Funding Source: NIH RePORTER; Medical Research Council [MC_U117570592] Funding Source: Medline; MRC [MC_U117570592] Funding Source: UKRI	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; CRAIG R, 1977, J CELL BIOL, V75, P990, DOI 10.1083/jcb.75.3.990; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; Espindola FS, 2000, CELL MOTIL CYTOSKEL, V47, P269, DOI 10.1002/1097-0169(200012)47:4<269::AID-CM2>3.3.CO;2-7; HARRIS DE, 1993, J BIOL CHEM, V268, P14764; HOMSHER E, 1992, AM J PHYSIOL, V262, P714; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Lauzon AM, 2001, BIOPHYS J, V80, P1900, DOI 10.1016/S0006-3495(01)76159-0; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; Peterson S. L. Reck-, 1999, BIOCHIM BIOPHYS ACTA, V1496, P36; Purcell TJ, 2002, P NATL ACAD SCI USA, V99, P14159, DOI 10.1073/pnas.182539599; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; Ruff C, 2001, NAT STRUCT BIOL, V8, P226, DOI 10.1038/84962; Sakamoto T, 2000, BIOCHEM BIOPH RES CO, V272, P586, DOI 10.1006/bbrc.2000.2819; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; Schott DH, 2002, J CELL BIOL, V156, P35, DOI 10.1083/jcb.200110086; Sellers J. R., 1999, MYOSINS; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Tanaka H, 2002, NATURE, V415, P192, DOI 10.1038/415192a; TRYBUS KM, 1987, J CELL BIOL, V105, P3007, DOI 10.1083/jcb.105.6.3007; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; UBER A, 1980, J ULTRASTRUCT RES, V71, P95; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; Veigel C, 1998, BIOPHYS J, V75, P1424, DOI 10.1016/S0006-3495(98)74061-5; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; Wang F, 2000, J BIOL CHEM, V275, P4329, DOI 10.1074/jbc.275.6.4329; Warshaw DM, 2000, J BIOL CHEM, V275, P37167, DOI 10.1074/jbc.M006438200	30	126	128	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29201	29207		10.1074/jbc.M303662200	http://dx.doi.org/10.1074/jbc.M303662200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12740393	hybrid			2022-12-25	WOS:000184421100105
J	Thompson, PA; Tobias, PS; Viriyakosol, S; Kirkland, TN; Kitchens, RL				Thompson, PA; Tobias, PS; Viriyakosol, S; Kirkland, TN; Kitchens, RL			Lipopolysaccharide (LPS)-binding protein inhibits responses to cell-bound LPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; TOLL-LIKE RECEPTOR-4; BINDING-PROTEIN; SOLUBLE CD14; PLASMA-LIPOPROTEINS; CD14-DEFICIENT MICE; INDUCED ACTIVATION; HOST-DEFENSE; MD-2; COMPLEXES	Lipopolysaccharide (LPS)-binding protein (LBP) is an acute phase reactant that may play a dual role in vivo, both potentiating and decreasing cell responses to bacterial LPS. Whereas low concentrations of LBP potentiate cell stimulation by transferring LPS to CD14, high LBP concentrations inhibit cell responses to LPS. One inhibitory mechanism involves the ability of LBP to neutralize LPS by transferring it to plasma lipoproteins, whereas other inhibitory mechanisms, such as the one described here, do not require exogenous lipoproteins. Here we show that LBP can inhibit monocyte responses to LPS that has already bound to membrane-bound CD14 (mCD14) on the cell surface. LBP caused rapid dissociation of LPS from mCD14 as measured by the ability of LBP to inhibit cross-linking of a radioiodinated, photoactivatable LPS derivative to mCD14. Whereas LBP removed up to 75% of the mCD14-bound LPS in 10 min, this was not accompanied by extensive release of the LPS from the cells. The cross-linking data suggest that much of the LPS that remained bound to the cells was associated with LBP. The ability of LBP to inhibit cell responses could not be explained by its effect on LPS internalization, because LBP did not significantly increase the internalization of the cell-bound LPS. In cell-free LPS cross-linking experiments, LBP inhibited the transfer of LPS from soluble CD14 to soluble MD-2. Our data support the hypothesis that LBP can inhibit cell responses to LPS by inhibiting LPS transfer from mCD14 to the Toll-like receptor 4-MD-2 signaling receptor.	Univ Texas, SW Med Ctr, Dept Internal Med, Div Infect Dis, Dallas, TX 75390 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ Calif San Diego, Sch Med, Dept Pathol, Vet Affairs San Diego Healthcare Syst, La Jolla, CA 92161 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Scripps Research Institute; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Kitchens, RL (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Div Infect Dis, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Kirkland, Theo/ADK-9674-2022		NHLBI NIH HHS [HL 23584] Funding Source: Medline; NIAID NIH HHS [AI32021, AI45896] Funding Source: Medline; NIGMS NIH HHS [P01GM37696] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL023584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045896, R01AI032021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bohuslav J, 1998, J CLIN INVEST, V102, P1645, DOI 10.1172/JCI3877; CAVAILLON JM, 1995, TRENDS MICROBIOL, V3, P320, DOI 10.1016/S0966-842X(00)88963-5; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; ELLISON RT, 1991, J CLIN INVEST, V88, P1080, DOI 10.1172/JCI115407; Elsbach P, 1998, CURR OPIN IMMUNOL, V10, P45, DOI 10.1016/S0952-7915(98)80030-7; Fan MH, 2002, SHOCK, V18, P248, DOI 10.1097/00024382-200209000-00008; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; Gutsmann T, 2001, INFECT IMMUN, V69, P6942, DOI 10.1128/IAI.69.11.6942-6950.2001; Hailman E, 1996, J IMMUNOL, V156, P4384; Hajjar AM, 2002, NAT IMMUNOL, V3, P354, DOI 10.1038/ni777; Hamann L, 2002, BIOCHEM BIOPH RES CO, V295, P553, DOI 10.1016/S0006-291X(02)00710-6; HAZIOT A, 1994, J IMMUNOL, V152, P5868; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Jack RS, 1997, NATURE, V389, P742, DOI 10.1038/39622; Kitchens RL, 1999, J BIOL CHEM, V274, P34116, DOI 10.1074/jbc.274.48.34116; Kitchens RL, 1998, J IMMUNOL, V161, P5534; Kitchens RL, 1998, J IMMUNOL, V160, P1920; KITCHENS RL, 1995, J BIOL CHEM, V270, P9904, DOI 10.1074/jbc.270.17.9904; Kitchens RL, 2001, J CLIN INVEST, V108, P485, DOI 10.1172/JCI200113139; Lamping N, 1998, J CLIN INVEST, V101, P2065, DOI 10.1172/JCI2338; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; MUNFORD RS, 1992, J IMMUNOL METHODS, V148, P115, DOI 10.1016/0022-1759(92)90164-O; MUNFORD RS, 1986, SCIENCE, V234, P203, DOI 10.1126/science.3529396; MUNFORD RS, 1981, J CLIN INVEST, V68, P1503, DOI 10.1172/JCI110404; Munford RS, 2001, J ENDOTOXIN RES, V7, P327, DOI 10.1177/09680519010070040501; Muroi M, 2002, INFECT IMMUN, V70, P3546, DOI 10.1128/IAI.70.7.3546-3550.2002; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; SCHUETT C, 1991, Allergie und Immunologie (Leipzig), V37, P159; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Tapping RI, 1997, J BIOL CHEM, V272, P23157, DOI 10.1074/jbc.272.37.23157; TEGHANEMT A, 2003, IN PRESS J ENDOTOXIN; Vesy CJ, 2000, INFECT IMMUN, V68, P2410, DOI 10.1128/IAI.68.5.2410-2417.2000; Viriyakosol S, 2001, J BIOL CHEM, V276, P38044; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; WURFEL MM, 1994, J EXP MED, V180, P1025, DOI 10.1084/jem.180.3.1025; Yang KK, 2002, J IMMUNOL, V169, P4475, DOI 10.4049/jimmunol.169.8.4475; Zweigner J, 2001, BLOOD, V98, P3800, DOI 10.1182/blood.V98.13.3800	42	55	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28367	28371		10.1074/jbc.M302921200	http://dx.doi.org/10.1074/jbc.M302921200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12754215	hybrid			2022-12-25	WOS:000184421100004
J	Yim, L; Martinez-Vicente, M; Villarroya, M; Aguado, C; Knecht, E; Armengod, ME				Yim, L; Martinez-Vicente, M; Villarroya, M; Aguado, C; Knecht, E; Armengod, ME			The GTPase activity and C-terminal cysteine of the Escherichia coli MnmE protein are essential for its tRNA modifying function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL-ANALYSIS; CRYSTAL-STRUCTURE; SPECIFICITY; EXPRESSION; RIBOSOME; MUTANTS; GENE; SITE; IDENTIFICATION; BIOSYNTHESIS	The Escherichia coli MnmE protein is a three-domain protein that exhibits a very high intrinsic GTPase activity and low affinity for GTP and GDP. The middle GTPase domain, when isolated, conserves the high intrinsic GTPase activity of the entire protein, and the C-terminal domain contains the only cysteine residue present in the molecule. MnmE is an evolutionarily conserved protein that, in E. coli, has been shown to control the modification of the uridine at the wobble position of certain tRNAs. Here we examine the biochemical and functional consequences of altering amino acid residues within conserved motifs of the GTPase and C-terminal domains of MnmE. Our results indicate that both domains are essential for the MnmE tRNA modifying function, which requires effective hydrolysis of GTP. Thus, it is shown for the first time that a confirmed defect in the GTP hydrolase activity of MnmE results in the lack of its tRNA modifying function. Moreover, the mutational analysis of the GTPase domain indicates that MnmE is closer to classical GTPases than to GTP-specific metabolic enzymes. Therefore, we propose that MnmE uses a conformational change associated with GTP hydrolysis to promote the tRNA modification reaction, in which the C-terminal Cys may function as a catalytic residue. We demonstrate that point mutations abolishing the tRNA modifying function of MnmE confer synthetic lethality, which stresses the importance of this function in the mRNA decoding process.	Fdn Valenciana Invest Biomed, Genet Mol Lab, Valencia 46010, Spain; Fdn Valenciana Invest Biomed, Lab Biol Celular, Inst Invest Citol, Valencia 46010, Spain		Armengod, ME (corresponding author), Fdn Valenciana Invest Biomed, Genet Mol Lab, Amadeo Saboya 4, Valencia 46010, Spain.	armengod@ochoa.fib.es	Knecht, Erwin/K-2432-2014; Armengod, Maria Eugenia/K-6030-2014; Martinez-Vicente, Marta/K-4312-2014; Knecht, Erwin/A-9366-2014; Villarroya, M Magdalena/K-7621-2014; Armengod, M. Eugenia/A-9609-2014; Aguado, Carmen/K-4354-2014	Knecht, Erwin/0000-0002-7208-3832; Armengod, Maria Eugenia/0000-0003-1512-2687; Martinez-Vicente, Marta/0000-0001-7053-2625; Villarroya, M Magdalena/0000-0003-4542-7430; Aguado, Carmen/0000-0002-3113-4269				BACHMANN BJ, 1996, ESCHERICHIA COLI SAL, P2460; BERLYN MKB, 1996, ESCHERICHIA COLI SAL, P1715; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Bregeon D, 2001, GENE DEV, V15, P2295, DOI 10.1101/gad.207701; Cabedo H, 1999, EMBO J, V18, P7063, DOI 10.1093/emboj/18.24.7063; Colby G, 1998, J BIOL CHEM, V273, P27945, DOI 10.1074/jbc.273.43.27945; CONDON C, 1992, EMBO J, V11, P4175, DOI 10.1002/j.1460-2075.1992.tb05511.x; Curran J. F., 1998, MODIFICATION EDITING, P493; DECOSTER E, 1993, J MOL BIOL, V232, P79, DOI 10.1006/jmbi.1993.1371; Dunten P, 2002, J MOL BIOL, V316, P257, DOI 10.1006/jmbi.2001.5364; ELSEVIERS D, 1984, NUCLEIC ACIDS RES, V12, P3521, DOI 10.1093/nar/12.8.3521; Fourmy D, 1998, J MOL BIOL, V277, P333, DOI 10.1006/jmbi.1997.1551; GARCIA GA, 1998, MODIFICATION EDITING, P135; GUSTAFSSON C, 1993, J BIOL CHEM, V268, P1326; Hagervall TG, 1998, J MOL BIOL, V284, P33, DOI 10.1006/jmbi.1998.2162; HAGERVALL TG, 1987, J BIOL CHEM, V262, P8488; HOENIG M, 1989, J BIOCHEM BIOPH METH, V19, P249, DOI 10.1016/0165-022X(89)90031-6; JOHN J, 1993, J BIOL CHEM, V268, P923; KANG C, 1994, J BIOL CHEM, V269, P24046; KEALEY JT, 1991, BIOCHEMISTRY-US, V30, P9724, DOI 10.1021/bi00104a022; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; Krab IM, 1999, J BIOL CHEM, V274, P11132, DOI 10.1074/jbc.274.16.11132; Kruger MK, 1998, J MOL BIOL, V284, P609, DOI 10.1006/jmbi.1998.2197; Kruger MK, 1998, J MOL BIOL, V284, P621, DOI 10.1006/jmbi.1998.2196; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Leung HCE, 1997, J BIOL CHEM, V272, P13073, DOI 10.1074/jbc.272.20.13073; Li XM, 2002, MOL CELL BIOL, V22, P7701, DOI 10.1128/MCB.22.21.7701-7711.2002; Li XM, 2002, J BIOL CHEM, V277, P27256, DOI 10.1074/jbc.M203267200; Lim VI, 2001, RNA, V7, P942, DOI 10.1017/S135583820100214X; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Masters M, 1996, ESCHERICHIA COLI SAL, P2421; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Mohr D, 2000, EMBO J, V19, P3458, DOI 10.1093/emboj/19.13.3458; Nakayashiki T, 1998, J BACTERIOL, V180, P2931, DOI 10.1128/JB.180.11.2931-2935.1998; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; PERSSON BC, 1992, P NATL ACAD SCI USA, V89, P3995, DOI 10.1073/pnas.89.9.3995; Praefcke GJK, 1999, J MOL BIOL, V292, P321, DOI 10.1006/jmbi.1999.3062; Rodnina MV, 2000, BIOL CHEM, V381, P377, DOI 10.1515/BC.2000.050; Rodnina MV, 2001, TRENDS BIOCHEM SCI, V26, P124, DOI 10.1016/S0968-0004(00)01737-0; Schmidt G, 1996, ONCOGENE, V12, P87; SULLIVAN MA, 1985, J BACTERIOL, V161, P368, DOI 10.1128/JB.161.1.368-376.1985; UJITA S, 1982, METHOD ENZYMOL, V89, P258; Urbonavicius J, 2001, EMBO J, V20, P4863, DOI 10.1093/emboj/20.17.4863; White DJ, 2001, MOL MICROBIOL, V42, P503, DOI 10.1046/j.1365-2958.2001.02659.x; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; Wittinghofer A, 2000, FR MOLEC B, V24, P244; Yarian C, 2002, J BIOL CHEM, V277, P16391, DOI 10.1074/jbc.M200253200; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; ZHONG JM, 1995, J BIOL CHEM, V270, P10002, DOI 10.1074/jbc.270.17.10002	49	45	47	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28378	28387		10.1074/jbc.M301381200	http://dx.doi.org/10.1074/jbc.M301381200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12730230	hybrid			2022-12-25	WOS:000184421100006
J	Cho, KA; Ryu, SJ; Park, JS; Jang, IS; Ahn, JS; Kim, KT; Park, SC				Cho, KA; Ryu, SJ; Park, JS; Jang, IS; Ahn, JS; Kim, KT; Park, SC			Senescent phenotype can be reversed by reduction of caveolin status	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID FIBROBLASTS; EPIDERMAL-GROWTH-FACTOR; MAP KINASE CASCADE; DNA-SYNTHESIS; PLASMA-MEMBRANE; IN-VIVO; CELLULAR SENESCENCE; GENE FAMILY; MDCK CELLS; EXPRESSION	Hyporesponsiveness to growth factors is one of the fundamental characteristics of senescent cells. We previously reported that the up-regulation of caveolin attenuates the growth factor response and the subsequent downstream signal cascades in senescent human diploid fibroblasts. Therefore, in the present experiment, we investigated the modulation of caveolin status in senescent cells to determine the effect of caveolin on mitogenic signaling efficiency and cell cycling. We reduced the level of caveolin-1 in senescent human diploid fibroblasts using its antisense oligonucleotides and small interfering RNA, and this resulted in the restoration of normal growth factor responses such as the increased phosphorylation of Erk, the nuclear translocation of p-Erk, and the subsequent activation of p-Elk upon epidermal growth factor stimulation. Moreover, DNA synthesis and the re-entry of senescent cells into cell cycle were resumed upon epidermal growth factor stimulation concomitantly with decreases in p53 and p21. Taken together, we conclude that the loss of mitogenic signaling in senescent cells is strongly related to their elevated levels of caveolin-1 and that the functional recovery of senescent cells at least in the terms of growth factor responsiveness and cell cycle entry might be achieved simply by lowering the caveolin level.	Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Aging & Apoptosis Res Ctr, Seoul 110799, South Korea; Dankook Univ, Coll Med, Dept Biochem, Cheonan, South Korea	Seoul National University (SNU); Dankook University	Park, SC (corresponding author), Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Aging & Apoptosis Res Ctr, Seoul 110799, South Korea.			Jang, Ik Soon/0000-0003-2092-6372				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Galbiati F, 2001, MOL BIOL CELL, V12, P2229, DOI 10.1091/mbc.12.8.2229; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Hara E, 1996, MOL CELL BIOL, V16, P859; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; ISHIGAMI A, 1993, BIOCHEM BIOPH RES CO, V196, P181, DOI 10.1006/bbrc.1993.2232; Kagawa S, 1999, CELL DEATH DIFFER, V6, P765, DOI 10.1038/sj.cdd.4400549; Ko YG, 1999, J IMMUNOL, V162, P7217; Ko YG, 1998, J CELL BIOCHEM, V71, P524, DOI 10.1002/(SICI)1097-4644(19981215)71:4<524::AID-JCB7>3.3.CO;2-2; Li SW, 1998, FEBS LETT, V434, P127, DOI 10.1016/S0014-5793(98)00945-4; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lim IK, 2000, MECH AGEING DEV, V119, P113, DOI 10.1016/S0047-6374(00)00167-6; Lim IK, 2001, ANN NY ACAD SCI, V928, P176; Lipardi C, 1998, J CELL BIOL, V140, P617, DOI 10.1083/jcb.140.3.617; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LIU Y, 1996, J BIOL CHEM, V16, P3604; MATSUDA T, 1992, J CELL PHYSIOL, V150, P510, DOI 10.1002/jcp.1041500311; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ohkusu-Tsukada K, 1999, J IMMUNOL, V163, P1966; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Park SC, 1999, J GERONTOL A-BIOL, V54, pB78, DOI 10.1093/gerona/54.2.B78; Park WY, 2000, J BIOL CHEM, V275, P20847, DOI 10.1074/jbc.M908162199; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Razani B, 2001, BIOCHEM SOC T, V29, P494, DOI 10.1042/BST0290494; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; ROA VN, 1994, GENE DEV, V8, P1502; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SEVERS NJ, 1988, J CELL SCI, V90, P341; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Tresini M, 2001, EXP CELL RES, V269, P287, DOI 10.1006/excr.2001.5334; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739	47	91	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27789	27795		10.1074/jbc.M208105200	http://dx.doi.org/10.1074/jbc.M208105200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12730243	hybrid			2022-12-25	WOS:000184242700059
J	Chondrogianni, N; Stratford, FLL; Trougakos, IP; Friguet, B; Rivett, AJ; Gonos, ES				Chondrogianni, N; Stratford, FLL; Trougakos, IP; Friguet, B; Rivett, AJ; Gonos, ES			Central role of the proteasome in senescence and survival of human fibroblasts - Induction of a senescence-like phenotype upon its inhibition and resistance to stress upon its activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BJ FIBROBLASTS; CELLULAR SENESCENCE; PROTEIN OXIDATION; OXIDIZED PROTEINS; GENE-EXPRESSION; 26S PROTEASOME; DEGRADATION; BIOMARKER; CALPAIN; DEATH	Normal human fibroblasts undergo a limited number of divisions in culture and progressively they reach a state of irreversible growth arrest, a process termed as replicative senescence. The proteasome is the major cellular proteolytic machinery, the function of which is impaired during replicative senescence. However, the exact causes of its malfunction in these conditions are unknown. Using WI38 fibroblasts as a model for cellular senescence we have observed reduced levels of proteasomal peptidase activities coupled with increased levels of both oxidized and ubiquitinated proteins in senescent cells. We have found the catalytic subunits of the 20 S complex and subunits of the 19 S regulatory complex to be down-regulated in senescent cells. This is accompanied by a decrease in the level of both 20 S and 26 S complexes. Partial inhibition of proteasomes in young cells caused by treatment with specific inhibitors induced a senescence-like phenotype, thus demonstrating the fundamental importance of the proteasome for retaining cellular maintenance and homeostasis. Stable overexpression of beta(1) and beta(5) subunits in WI38 established cell lines was shown to induce elevated expression levels of beta(1) subunit in beta(5) transfectants and vice versa. Transfectants possess increased proteasome activities and most importantly, increased capacity to cope better with various stresses. In summary these data demonstrate the central role of the proteasome during cellular senescence and survival as well as provide insights toward a better understanding of proteasome regulation.	Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, Athens 11635, Greece; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England; Univ Paris 07, Lab Biol & Biochim Cellulaire Vieillissement, F-75005 Paris, France	National Hellenic Research Foundation; University of Bristol; UDICE-French Research Universities; Universite Paris Cite	Gonos, ES (corresponding author), Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, 48 Vas Constantinou Ave, Athens 11635, Greece.	sgonos@eie.gr	Trougakos, Ioannis/R-6149-2018	Trougakos, Ioannis/0000-0002-6179-2772; Friguet, Bertrand/0000-0001-8085-1961				AKIYAMA KY, 1994, SCIENCE, V265, P1231, DOI 10.1126/science.8066462; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Barradas M, 2002, EXP CELL RES, V273, P127, DOI 10.1006/excr.2001.5434; Brooks P, 2000, BIOCHEM J, V352, P611, DOI 10.1042/0264-6021:3520611; Bulteau AL, 2002, ARCH BIOCHEM BIOPHYS, V397, P298, DOI 10.1006/abbi.2001.2663; Bulteau AL, 2000, EXP GERONTOL, V35, P767, DOI 10.1016/S0531-5565(00)00136-4; Campisi J, 2001, EXP GERONTOL, V36, P607, DOI 10.1016/S0531-5565(00)00230-8; Chen QM, 2001, EXP CELL RES, V265, P294, DOI 10.1006/excr.2001.5182; Chondrogianni N, 2002, BIOGERONTOLOGY, V3, P121, DOI 10.1023/A:1015236203379; Chondrogianni N, 2000, EXP GERONTOL, V35, P721, DOI 10.1016/S0531-5565(00)00137-6; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Drexler HCA, 2000, FASEB J, V14, P65, DOI 10.1096/fasebj.14.1.65; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Franco S, 2001, EXP CELL RES, V268, P14, DOI 10.1006/excr.2001.5264; Friguet B, 2000, ANN NY ACAD SCI, V908, P143; Gaczynska M, 2001, MECH AGEING DEV, V122, P235, DOI 10.1016/S0047-6374(00)00246-3; Gaczynska M, 1996, J BIOL CHEM, V271, P17275, DOI 10.1074/jbc.271.29.17275; Glas R, 1998, NATURE, V392, P618, DOI 10.1038/33443; Gonos ES, 2000, EXP GERONTOL, V35, P15, DOI 10.1016/S0531-5565(99)00075-3; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Hara E, 1996, MOL CELL BIOL, V16, P859; Harlow E., 1999, USING ANTIBODIES LAB; HENDIL KB, 1995, BIOCHEM J, V305, P245, DOI 10.1042/bj3050245; Hisamatsu H, 1996, J EXP MED, V183, P1807, DOI 10.1084/jem.183.4.1807; Jervis KM, 2002, EXP GERONTOL, V37, P897, DOI 10.1016/S0531-5565(02)00024-4; Keller JN, 2000, NEUROSCIENCE, V98, P149, DOI 10.1016/S0306-4522(00)00067-1; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Mannhaupt G, 1999, FEBS LETT, V450, P27, DOI 10.1016/S0014-5793(99)00467-6; Merker K, 2000, EXP GERONTOL, V35, P779, DOI 10.1016/S0531-5565(00)00140-6; Merker K, 2000, ARCH BIOCHEM BIOPHYS, V375, P50, DOI 10.1006/abbi.1999.1657; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Owsianik G, 2002, MOL MICROBIOL, V43, P1295, DOI 10.1046/j.1365-2958.2002.02823.x; Petropoulos I, 2000, J GERONTOL A-BIOL, V55, pB220, DOI 10.1093/gerona/55.5.B220; Petropoulou C, 2001, FEBS LETT, V509, P287, DOI 10.1016/S0014-5793(01)03150-7; Petropoulou C, 2000, ANN NY ACAD SCI, V908, P133; RIVETT AJ, 1994, METHOD ENZYMOL, V244, P331; RIVETT AJ, 1993, BIOCHEM J, V291, P1; Rivett AJ, 2002, EXP GERONTOL, V37, P1217, DOI 10.1016/S0531-5565(02)00127-4; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shang F, 1997, EXP EYE RES, V64, P21, DOI 10.1006/exer.1996.0176; Shringarpure R, 2002, FREE RADICAL BIO MED, V32, P1084, DOI 10.1016/S0891-5849(02)00824-9; Sin N, 1999, BIOORG MED CHEM LETT, V9, P2283, DOI 10.1016/S0960-894X(99)00376-5; Sitte N, 2000, FASEB J, V14, P2503, DOI 10.1096/fj.00-0210com; Sitte N, 2000, FASEB J, V14, P2495, DOI 10.1096/fj.00-0209com; Sitte N, 2000, FREE RADICAL BIO MED, V28, P701, DOI 10.1016/S0891-5849(99)00279-8; Tanaka K, 1998, J BIOCHEM-TOKYO, V123, P195; Tresini M, 1998, CANCER RES, V58, P1; Tsubuki S, 1996, J BIOCHEM-TOKYO, V119, P572, DOI 10.1093/oxfordjournals.jbchem.a021280; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wojcik C, 2002, J BIOL CHEM, V277, P6188, DOI 10.1074/jbc.M109996200; Wynford-Thomas D, 1999, J PATHOL, V187, P100; Xie YM, 2001, P NATL ACAD SCI USA, V98, P3056, DOI 10.1073/pnas.071022298	56	247	256	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28026	28037		10.1074/jbc.M301048200	http://dx.doi.org/10.1074/jbc.M301048200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12736271	hybrid			2022-12-25	WOS:000184242700088
J	Dowd, BFX; Forbush, B				Dowd, BFX; Forbush, B			PASK (proline-alanine-rich STE20-related kinase), a regulatory kinase of the Na-K-Cl cotransporter (NKCC1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; NA-K-2CL COTRANSPORT; MOLECULAR-CLONING; CELL-VOLUME; PHOSPHORYLATION; PROTEIN; MODULATION; ACTIVATION; EPITHELIA; TRANSPORT	Although the phosphorylation-dependent activation of the Na-K-Cl cotransporter (NKCC1) has been previously well documented, the identity of the kinase(s) responsible for this regulation has proven elusive. Recently, Piechotta et al. (Piechotta, K., Lu, J., and Delpire, E. (2002) J. Biol. Chem. 277, 50812-50819) reported the binding of PASK (also referred as SPAK (STE20/SPS1-related proline-alanine-rich kinase)) and OSR1 (oxidative stress response kinase) to cation-chloride cotransporters KCC3, NKCC1, and NKCC2. In this report, we show that overexpression of a kinase inactive, dominant negative (DN) PASK mutant drastically reduces both shark (60+/-5%) and human (80+/-3%) NKCC1 activation. Overexpression of wild type PASK causes a small (sNKCC1 22+/-8% p<0.05, hNKCC1 12&PLUSMN;3% p<0.01) but significant increase in shark and human cotransporter activity in HEK cells. Importantly, DNPASK also inhibits the phosphorylation of two threonines, contained in the previously described N-terminal regulatory domain. We additionally show the near complete restoration of NKCC1 activity in the presence of the protein phosphatase type 1 inhibitor calyculin A, demonstrating that DNPASK inhibition results from an alteration in kinase/phosphatase dynamics rather than from a decrease in functional cotransporter expression. Coimmunoprecipitation assays confirm PASK binding to NKCC1 in transfected HEK cells and further suggest that this binding is not a regulated event; neither PASK nor NKCC1 activity affects the association. In cells preloaded with P-32(i), the phosphorylation of PASK, but not DNPASK, coincides with that of NKCC1 and increases 5.5+/-0.36-fold in low [Cl](e). These data conclusively link PASK with the phosphorylation and activation of NKCC1.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University	Dowd, BFX (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06520 USA.							ALTAMIRANO AA, 1995, AM J PHYSIOL-CELL PH, V269, pC878, DOI 10.1152/ajpcell.1995.269.4.C878; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Darman RB, 2002, J BIOL CHEM, V277, P37542, DOI 10.1074/jbc.M206293200; Darman RB, 2001, J BIOL CHEM, V276, P34359, DOI 10.1074/jbc.C100368200; Fillon S, 2001, COMP BIOCHEM PHYS A, V130, P367, DOI 10.1016/S1095-6433(01)00422-6; Flemmer AW, 2002, J BIOL CHEM, V277, P37551, DOI 10.1074/jbc.M206294200; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Isenring P, 1998, J BIOL CHEM, V273, P11295, DOI 10.1074/jbc.273.18.11295; JENNINGS ML, 1990, J GEN PHYSIOL, V95, P1021, DOI 10.1085/jgp.95.6.1021; Johnston AM, 2000, ONCOGENE, V19, P4290, DOI 10.1038/sj.onc.1203784; Klein JD, 1999, AM J PHYSIOL-CELL PH, V277, pC425, DOI 10.1152/ajpcell.1999.277.3.C425; Klein JD, 1995, AM J PHYSIOL-CELL PH, V269, pC1524, DOI 10.1152/ajpcell.1995.269.6.C1524; Kurihara K, 1999, AM J PHYSIOL-CELL PH, V277, pC1184, DOI 10.1152/ajpcell.1999.277.6.C1184; Lee KK, 2002, J BIOL CHEM, V277, P12351, DOI 10.1074/jbc.M108138200; Leiserson WM, 2000, NEURON, V28, P793, DOI 10.1016/S0896-6273(00)00154-9; Lytle C, 1998, AM J PHYSIOL-CELL PH, V274, pC1002, DOI 10.1152/ajpcell.1998.274.4.C1002; LYTLE C, 1992, J BIOL CHEM, V267, P25438; Lytle C, 2002, AM J PHYSIOL-CELL PH, V283, pC1422, DOI 10.1152/ajpcell.00130.2002; Lytle C, 1996, AM J PHYSIOL-CELL PH, V270, pC437, DOI 10.1152/ajpcell.1996.270.2.C437; Matsuo R, 2001, J IMMUNOL METHODS, V247, P141, DOI 10.1016/S0022-1759(00)00313-6; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; Piechotta K, 2002, J BIOL CHEM, V277, P50812, DOI 10.1074/jbc.M208108200; Ushiro H, 1998, ARCH BIOCHEM BIOPHYS, V355, P233, DOI 10.1006/abbi.1998.0736; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201	25	214	216	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27347	27353		10.1074/jbc.M301899200	http://dx.doi.org/10.1074/jbc.M301899200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12740379	hybrid			2022-12-25	WOS:000184242700004
J	Loris, R; Marianovsky, I; Lah, J; Laeremans, T; Engelberg-Kulka, H; Glaser, G; Muyldermans, S; Wyns, L				Loris, R; Marianovsky, I; Lah, J; Laeremans, T; Engelberg-Kulka, H; Glaser, G; Muyldermans, S; Wyns, L			Crystal structure of the intrinsically flexible addiction antidote MazE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; DOMAIN ANTIBODY FRAGMENT; ESCHERICHIA-COLI; DNA-BINDING; PLASMID R1; FUNCTIONAL REGIONS; STABLE MAINTENANCE; STABILITY SYSTEM; PROTEINS; PARD	A specific camel VHH (variable domain of dromedary heavy chain antibody) fragment was used to crystallize the intrinsically flexible addiction antidote MazE. Only 45% of the polypeptide chain is found ordered in the crystal. The MazE monomer consisting of two beta-hairpins connected by a short alpha-helix has no hydrophobic core on its own and represents only one half of a typical protein domain. A complete domain structure is formed by the association of two chains, creating a hydrophobic core between two four-stranded beta-sheets. This hydrophobic core consists exclusively of short aliphatic residues. The folded part of MazE contains a novel DNA binding motif. A model for DNA binding that is consistent with the available biochemical data is presented.	Free Univ Brussels, ULTR, Lab Ultrastruct, B-1050 Brussels, Belgium; Free Univ Brussels VIB, B-1050 Brussels, Belgium; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Cellular Biochem, IL-91120 Jerusalem, Israel	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Loris, R (corresponding author), Free Univ Brussels, ULTR, Lab Ultrastruct, Bldg E,Pleinlaan 2, B-1050 Brussels, Belgium.	reloris@vub.ac.be	Muyldermans, Serge V/C-6418-2016; Muyldermans, Serge/AAC-7374-2019; Loris, Remy/GPG-0894-2022	Muyldermans, Serge V/0000-0002-3678-3575; Muyldermans, Serge/0000-0002-3678-3575; Loris, Remy/0000-0002-8862-3338				Afif H, 2001, MOL MICROBIOL, V41, P73, DOI 10.1046/j.1365-2958.2001.02492.x; Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Armon A, 2001, J MOL BIOL, V307, P447, DOI 10.1006/jmbi.2000.4474; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; BRAVO A, 1987, MOL GEN GENET, V210, P101, DOI 10.1007/BF00337764; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Couturier M, 1998, TRENDS MICROBIOL, V6, P269, DOI 10.1016/S0966-842X(98)01311-0; Dao-Thi MH, 2000, J MOL BIOL, V299, P1373, DOI 10.1006/jmbi.2000.3815; Dao-Thi MH, 2002, J BIOL CHEM, V277, P3733, DOI 10.1074/jbc.M105505200; Decanniere K, 1999, STRUCTURE, V7, P361, DOI 10.1016/S0969-2126(99)80049-5; Engelberg-Kulka H, 1998, P NATL ACAD SCI USA, V95, P15481, DOI 10.1073/pnas.95.26.15481; Engelberg-Kulka H, 1999, ANNU REV MICROBIOL, V53, P43, DOI 10.1146/annurev.micro.53.1.43; ENGELBERGKULKA H, 2001, INN PRESS ASM NEWS; Gazit E, 1999, J BIOL CHEM, V274, P2652, DOI 10.1074/jbc.274.5.2652; Ghahroudi MA, 1997, FEBS LETT, V414, P521, DOI 10.1016/S0014-5793(97)01062-4; Gotfredsen M, 1998, MOL MICROBIOL, V29, P1065, DOI 10.1046/j.1365-2958.1998.00993.x; Hargreaves D, 2002, STRUCTURE, V10, P1425, DOI 10.1016/S0969-2126(02)00856-0; Hazan R, 2001, J BACTERIOL, V183, P2046, DOI 10.1128/JB.183.6.2046-2050.2001; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hunte C, 2002, CURR OPIN STRUC BIOL, V12, P503, DOI 10.1016/S0959-440X(02)00354-8; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JENSEN RB, 1995, MOL MICROBIOL, V17, P205, DOI 10.1111/j.1365-2958.1995.mmi_17020205.x; Kamada K, 2003, MOL CELL, V11, P875, DOI 10.1016/S1097-2765(03)00097-2; Lah J, 2003, J BIOL CHEM, V278, P14101, DOI 10.1074/jbc.M209855200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lauwereys M, 1998, EMBO J, V17, P3512, DOI 10.1093/emboj/17.13.3512; LENHERR H, 1995, P NATL ACAD SCI USA, V92, P3274; Loris R, 1999, J MOL BIOL, V285, P1667, DOI 10.1006/jmbi.1998.2395; Magnuson R, 1998, J BACTERIOL, V180, P6342; Marianovsky I, 2001, J BIOL CHEM, V276, P5975, DOI 10.1074/jbc.M008832200; MASUDA Y, 1994, J BACTERIOL, V176, P5861, DOI 10.1128/JB.176.18.5861-5863.1994; MASUDA YJ, 1993, J BACTERIOL, V175, P6850, DOI 10.1128/jb.175.21.6850-6856.1993; METZGER S, 1988, J BIOL CHEM, V263, P15699; Mittenhuber Gerhard, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P295; MIYATA T, 1979, J MOL EVOL, V12, P219, DOI 10.1007/BF01732340; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Oberer M, 2002, BIOCHEM J, V361, P41, DOI 10.1042/0264-6021:3610041; Oberer M, 1999, BIOL CHEM, V380, P1413, DOI 10.1515/BC.1999.181; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; ROBERTS RC, 1993, J BIOL CHEM, V268, P27109; ROUSSEL A, 1989, SILICON GRAPHIC GEOM, P71; RUIZECHEVARRIA MJ, 1991, MOL MICROBIOL, V5, P2685, DOI 10.1111/j.1365-2958.1991.tb01977.x; RUIZECHEVARRIA MJ, 1995, J MOL BIOL, V247, P568, DOI 10.1006/jmbi.1995.0163; Santos-Sierra S, 2002, FEMS MICROBIOL LETT, V206, P115, DOI 10.1111/j.1574-6968.2002.tb10995.x; SantosSierra S, 1997, FEMS MICROBIOL LETT, V152, P51, DOI 10.1016/S0378-1097(97)00177-8; Sat B, 2001, J BACTERIOL, V183, P2041, DOI 10.1128/JB.183.6.2041-2045.2001; TAM JE, 1989, MOL GEN GENET, V219, P26, DOI 10.1007/BF00261153; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSUCHIMOTO S, 1988, J BACTERIOL, V170, P1461, DOI 10.1128/jb.170.4.1461-1466.1988; VanMelderen L, 1996, J BIOL CHEM, V271, P27730, DOI 10.1074/jbc.271.44.27730; WILLIAMS DR, 1992, J GEN MICROBIOL, V138, P1; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; YARMOLINSKY MB, 1995, SCIENCE, V267, P836, DOI 10.1126/science.7846528	55	108	112	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28252	28257		10.1074/jbc.M302336200	http://dx.doi.org/10.1074/jbc.M302336200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12743116	hybrid			2022-12-25	WOS:000184242700115
J	Minogue, AM; Schmid, AW; Fogarty, MP; Moore, AC; Campbell, VA; Herron, CE; Lynch, MA				Minogue, AM; Schmid, AW; Fogarty, MP; Moore, AC; Campbell, VA; Herron, CE; Lynch, MA			Activation of the c-Jun N-terminal kinase signaling cascade mediates the effect of amyloid-beta on long term potentiation and cell death in hippocampus - A role for interleukin-1 beta?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-INDUCED APOPTOSIS; RAT DENTATE GYRUS; ALZHEIMERS-DISEASE; IN-VIVO; NEURONAL APOPTOSIS; FAS-LIGAND; CORTICAL-NEURONS; PROTEIN-KINASES; CA1 REGION; DNA-DAMAGE	Amyloid-beta (Abeta) is a major constituent of the neuritic plaque found in the brain of Alzheimer's disease patients, and a great deal of evidence suggests that the neuronal loss that is associated with the disease is a consequence of the actions of Abeta. In the past few years, it has become apparent that activation of c-Jun N-terminal kinase (JNK) mediates some of the effects of Abeta on cultured cells; in particular, the evidence suggests that Abeta-triggered JNK activation leads to cell death. In this study, we investigated the effect of intracerebroventricular injection of Abeta((1-40)) on signaling events in the hippocampus and on long term potentiation in Schaffer collateral CA1 pyramidal cell synapses in vivo. We report that Abeta((1-40)) induced activation of JNK in CA1 and that this was coupled with expression of the proapoptotic protein, Bax, cytosolic cytochrome c, poly-(ADPribose) polymerase cleavage, and Fas ligand expression in the hippocampus. These data indicate that Abeta((1-40)) inhibited expression of long term potentiation, and this effect was abrogated by administration of the JNK inhibitor peptide, D-JNKI1. In parallel with these findings, we observed that Abeta-induced changes in caspase-3 activation and TdT-mediated dUTP nick-end labeling staining in neuronal cultured cells were inhibited by D-JNKI1. We present evidence suggesting that interleukin (IL)-1beta plays a significant role in mediating the effects of Abeta((1-40)) because Abeta((1-40)) increased hippocampal IL-1beta and because several effects of Abeta((1-40)) were inhibited by the caspase-1 inhibitor Ac-YVAD-CMK. On the basis of our findings, we propose that Abeta-induced changes in hippocampal plasticity are likely to be dependent upon IL-1beta-triggered activation of JNK.	Univ Dublin Trinity Coll, Trinity Coll Inst Neurosci, Dept Physiol, Dublin 2, Ireland; Univ Coll Dublin, Conway Inst, Dept Human Anat & Physiol, Dublin 2, Ireland	Trinity College Dublin; University College Dublin	Lynch, MA (corresponding author), Univ Dublin Trinity Coll, Trinity Coll Inst Neurosci, Dept Physiol, Dublin 2, Ireland.	lynchma@tcd.ie	Schmid, Adrien/CAG-1527-2022	Lynch, Marina/0000-0002-4631-0499; Schmid, Adrien W./0000-0001-6671-7950				Anderson AJ, 1996, J NEUROSCI, V16, P1710, DOI 10.1523/jneurosci.16-05-01710.1996; ANDERSON AJ, 1994, EXP NEUROL, V125, P286, DOI 10.1006/exnr.1994.1031; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; BlumDegen D, 1995, NEUROSCI LETT, V202, P17, DOI 10.1016/0304-3940(95)12192-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Chapman PF, 1999, NAT NEUROSCI, V2, P271, DOI 10.1038/6374; Chen QS, 2000, J NEUROSCI RES, V60, P65, DOI 10.1002/(SICI)1097-4547(20000401)60:1<65::AID-JNR7>3.0.CO;2-Q; Chen QS, 2002, NEUROBIOL LEARN MEM, V77, P354, DOI 10.1006/nlme.2001.4034; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Cullen WK, 1997, NEUROREPORT, V8, P3213, DOI 10.1097/00001756-199710200-00006; de la Monte SM, 1998, LAB INVEST, V78, P401; delaMonte SM, 1997, J NEUROL SCI, V152, P73, DOI 10.1016/S0022-510X(97)00131-7; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Estus S, 1997, J NEUROSCI, V17, P7736; Fogarty MP, 2003, BIOCHEM J, V371, P789, DOI 10.1042/BJ20021660; Freir DB, 2003, J NEUROPHYSIOL, V89, P3061, DOI 10.1152/jn.00992.2002; Freir DB, 2003, J NEUROPHYSIOL, V89, P2917, DOI 10.1152/jn.00996.2002; Freir DB, 2001, J NEUROPHYSIOL, V85, P708, DOI 10.1152/jn.2001.85.2.708; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; Jang JH, 2002, ANN NY ACAD SCI, V973, P228, DOI 10.1111/j.1749-6632.2002.tb04639.x; Kelly A, 2001, J BIOL CHEM, V276, P45564, DOI 10.1074/jbc.M108757200; Kihiko ME, 1999, J NEUROCHEM, V73, P2609, DOI 10.1046/j.1471-4159.1999.0732609.x; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Lonergan PE, 2002, J BIOL CHEM, V277, P20804, DOI 10.1074/jbc.M202387200; Lynch AM, 2002, EUR J NEUROSCI, V15, P1779, DOI 10.1046/j.1460-9568.2002.02012.x; Marcus DL, 1998, NEUROBIOL AGING, V19, P393, DOI 10.1016/S0197-4580(98)00077-3; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; MATSUYAMA T, 1995, MOL BRAIN RES, V34, P166, DOI 10.1016/0169-328X(95)00162-L; McGahon B, 1996, NEUROSCIENCE, V72, P847, DOI 10.1016/0306-4522(95)00579-X; Mehlhorn G, 2000, INT J DEV NEUROSCI, V18, P423, DOI 10.1016/S0736-5748(00)00012-5; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; Mrak RE, 2001, NEUROBIOL AGING, V22, P903, DOI 10.1016/S0197-4580(01)00287-1; O'Donnell E, 2000, EUR J NEUROSCI, V12, P345, DOI 10.1046/j.1460-9568.2000.00900.x; Paradis E, 1996, J NEUROSCI, V16, P7533; Ray SK, 2000, BRAIN RES, V852, P326, DOI 10.1016/S0006-8993(99)02148-4; Saleshando G, 2000, NEUROSCI LETT, V288, P119, DOI 10.1016/S0304-3940(00)01210-6; Savage MJ, 2002, J NEUROSCI, V22, P3376; Seidl R, 1999, NEUROSCI LETT, V260, P9, DOI 10.1016/S0304-3940(98)00945-8; Selznick LA, 2000, J NEUROPATH EXP NEUR, V59, P271, DOI 10.1093/jnen/59.4.271; Sheng JG, 2000, EXP NEUROL, V163, P388, DOI 10.1006/exnr.2000.7393; Shoji M, 2000, MOL BRAIN RES, V85, P221, DOI 10.1016/S0169-328X(00)00245-X; Stadelmann C, 1999, AM J PATHOL, V155, P1459, DOI 10.1016/S0002-9440(10)65460-0; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; Szczepanik AM, 2001, J NEUROIMMUNOL, V113, P49, DOI 10.1016/S0165-5728(00)00404-5; Vereker E, 2000, J NEUROSCI, V20, P6811, DOI 10.1523/JNEUROSCI.20-18-06811.2000; Vereker E, 2000, J BIOL CHEM, V275, P26252, DOI 10.1074/jbc.M002226200; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang HW, 2002, BRAIN RES, V924, P133, DOI 10.1016/S0006-8993(01)03058-X; Wei WL, 2002, BRAIN, V125, P2036, DOI 10.1093/brain/awf205; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Zhang Y, 2002, J CELL BIOL, V156, P519, DOI 10.1083/jcb.200110119; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x	58	108	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27971	27980		10.1074/jbc.M302530200	http://dx.doi.org/10.1074/jbc.M302530200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12738769	hybrid			2022-12-25	WOS:000184242700081
J	Rane, MJ; Pan, Y; Singh, S; Powell, DW; Wu, R; Cummins, T; Chen, Q; McLeish, KR; Klein, JB				Rane, MJ; Pan, Y; Singh, S; Powell, DW; Wu, R; Cummins, T; Chen, Q; McLeish, KR; Klein, JB			Heat shock protein 27 controls apoptosis by regulating Akt activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; FORKHEAD TRANSCRIPTION FACTOR; C-DEPENDENT ACTIVATION; INTEGRIN-LINKED KINASE; CYTOCHROME-C; PHOSPHOINOSITIDE 3-KINASE; NEUTROPHIL APOPTOSIS; NEGATIVE REGULATOR; MEDIATED APOPTOSIS; CELL-SURVIVAL	Activation of the serine-threonine kinase Akt by cytokines, chemokines, and bacterial products delays constitutive neutrophil apoptosis, resulting in a prolonged inflammatory response. We showed previously that Akt exists in a signaling complex with p38 MAPK, MAPK-activated protein kinase-2 (MAPKAPK-2), and heat shock protein-27 (Hsp27); and Hsp27 dissociates from the complex upon neutrophil activation. To better understand the regulation of this signaling module, the hypothesis that Akt phosphorylation of Hsp27 regulates its interaction with Akt was tested. The present study shows that Akt phosphorylated Hsp27 on Ser-82 in vitro and in intact cells, and phosphorylation of Hsp27 resulted in its dissociation from Akt. Additionally, the interaction between Hsp27 and Akt was necessary for activation of Akt in intact neutrophils. Constitutive neutrophil apoptosis was accelerated by sequestration of Hsp27 from Akt, and this enhanced rate of apoptosis was reversed by introduction of constitutively active recombinant Akt. Our results define a new mechanism by which Hsp27 regulates apoptosis, through control of Akt activity.	Univ Louisville, Dept Med, Louisville, KY 40202 USA; Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; Univ Louisville, Core Proteom Lab, Louisville, KY 40202 USA; Vet Affairs Med Ctr, Louisville, KY 40206 USA	University of Louisville; University of Louisville; University of Louisville; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Rane, MJ (corresponding author), Mol Signalling Grp, Donald E Baxter Biomed Res Bldg,570 S Preston St, Louisville, KY 40202 USA.		Cummins, Timothy D./C-9120-2013; Cummins, Timothy/C-4197-2011; Klein, Jon/B-9833-2013; Powell, David W/E-9288-2013; McLeish, Kenneth R./B-9819-2013	McLeish, Kenneth R./0000-0002-7816-3286	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066358] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66358-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; COX G, 1996, AM J PHYSIOL, V271, P566; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Keel M, 1997, BLOOD, V90, P3356, DOI 10.1182/blood.V90.9.3356; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Klein JB, 2001, CELL SIGNAL, V13, P335, DOI 10.1016/S0898-6568(01)00151-6; Klein JB, 2000, J IMMUNOL, V164, P4286, DOI 10.4049/jimmunol.164.8.4286; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; LEE A, 1993, J LEUKOCYTE BIOL, V54, P283, DOI 10.1002/jlb.54.4.283; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Ozes ON, 1999, NATURE, V401, P82; Pandey P, 2000, ONCOGENE, V19, P1975, DOI 10.1038/sj.onc.1203531; Paul C, 2002, MOL CELL BIOL, V22, P816, DOI 10.1128/MCB.22.3.816-834.2002; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Savill J, 1997, J LEUKOCYTE BIOL, V61, P375, DOI 10.1002/jlb.61.4.375; SAVILL J, 1995, SEMIN CELL BIOL, V6, P385, DOI 10.1016/S1043-4682(05)80009-1; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Sheth K, 2001, J SURG RES, V99, P129, DOI 10.1006/jsre.2000.6100; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tezel G, 2000, J NEUROSCI, V20, P3552, DOI 10.1523/JNEUROSCI.20-10-03552.2000; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; VANSTRIJP JAG, 1989, J CLIN INVEST, V84, P107, DOI 10.1172/JCI114129; WEERSINK AJL, 1990, J IMMUNOL, V145, P318; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737	44	306	330	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27828	27835		10.1074/jbc.M303417200	http://dx.doi.org/10.1074/jbc.M303417200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12740362	hybrid			2022-12-25	WOS:000184242700064
J	Simpson, RJY; Cram, ED; Czolij, R; Matthews, JM; Crossley, M; Mackay, JP				Simpson, RJY; Cram, ED; Czolij, R; Matthews, JM; Crossley, M; Mackay, JP			CCHX zinc finger derivatives retain the ability to bind Zn(II) and mediate orotein-DNA interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMBIGUOUS DISTANCE RESTRAINTS; PROTEIN STRUCTURES; H-1-NMR SPECTRA; DOMAIN; ASSIGNMENT; QUALITY; SPECTROSCOPY; RECOGNITION; RESOLUTION; REFINEMENT	Classical (CCHH) zinc fingers are among the most common protein domains found in eukaryotes. They function as molecular recognition elements that mediate specific contact with DNA, RNA, or other proteins and are composed of a betabetaalpha fold surrounding a single zinc ion that is ligated by two cysteine and two histidine residues. In a number of variant zinc fingers, the final histidine is not conserved, and in other unrelated zinc binding domains, residues such as aspartate can function as zinc ligands. To test whether the final histidine is required for normal folding and the DNA-binding function of classical zinc fingers, we focused on finger 3 of basic Kruppel-like factor. The structure of this domain was determined using NMR spectroscopy and found to constitute a typical classical zinc finger. We generated a panel of substitution mutants at the final histidine in this finger and found that several of the mutants retained some ability to fold in the presence of zinc. Consistent with this result, we showed that mutation of the final histidine had only a modest effect on DNA binding in the context of the full three-finger DNA-binding domain of basic Kruppel-like factor. Further, the zinc binding ability of one of the point mutants was tested and found to be indistinguishable from the wild-type domain. These results suggest that the final zinc chelating histidine is not an essential feature of classical zinc fingers and have implications for zinc finger evolution, regulation, and the design of experiments testing the functional roles of these domains.	Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia	University of Sydney	Mackay, JP (corresponding author), Univ Sydney, Sch Mol & Microbial Biosci, G08, Sydney, NSW 2006, Australia.	j.mackay@mmb.usyd.edu.au	Crossley, Merlin/D-7888-2011; Matthews, Jacqueline/A-7322-2013; Mackay, Joel/D-6834-2011	Crossley, Merlin/0000-0003-2057-3642; Matthews, Jacqueline/0000-0001-8518-3472; Mackay, Joel/0000-0001-7508-8033				Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COOK WJ, 1994, J BIOL CHEM, V269, P9374; Crossley M, 1996, MOL CELL BIOL, V16, P1695; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Demarest SJ, 2002, NATURE, V415, P549, DOI 10.1038/415549a; Folmer RHA, 1997, J BIOMOL NMR, V9, P245, DOI 10.1023/A:1018670623695; Green A, 1998, BIOCHEM J, V333, P85, DOI 10.1042/bj3330085; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HAYES DB, 1995, SEDNTERP 1 05; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kowalski K, 1999, J BIOMOL NMR, V13, P249, DOI 10.1023/A:1008309602929; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Liew CK, 2000, STRUCTURE, V8, P1157, DOI 10.1016/S0969-2126(00)00527-X; Linge JP, 2003, PROTEINS, V50, P496, DOI 10.1002/prot.10299; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; LUDVIGSEN S, 1992, J BIOMOL NMR, V2, P227, DOI 10.1007/BF01875318; Luscombe NM, 2000, GENOME BIOL, V1; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MERKLE DL, 1991, J AM CHEM SOC, V113, P5450, DOI 10.1021/ja00014a045; Nagaoka M, 2002, BIOCHEM BIOPH RES CO, V296, P553, DOI 10.1016/S0006-291X(02)00898-7; Narayan VA, 1997, J BIOL CHEM, V272, P7801, DOI 10.1074/jbc.272.12.7801; NEUHAUS D, 1992, J MOL BIOL, V228, P637, DOI 10.1016/0022-2836(92)90846-C; NILGES M, 1995, J MOL BIOL, V245, P645, DOI 10.1006/jmbi.1994.0053; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Nilges M, 1997, FOLD DES, V2, pS53, DOI 10.1016/S1359-0278(97)00064-3; Pabo CO, 2001, ANNU REV BIOCHEM, V70, P313, DOI 10.1146/annurev.biochem.70.1.313; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELTON JG, 1993, PROTEIN SCI, V2, P543; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; VRIEND G, 1993, J APPL CRYSTALLOGR, V26, P47, DOI 10.1107/S0021889892008240; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Wang BS, 2001, NAT STRUCT BIOL, V8, P589, DOI 10.1038/89617; Wolfe SA, 2001, STRUCTURE, V9, P717, DOI 10.1016/S0969-2126(01)00632-3	44	42	44	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28011	28018		10.1074/jbc.M211146200	http://dx.doi.org/10.1074/jbc.M211146200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12736264	hybrid			2022-12-25	WOS:000184242700086
J	Yamin, G; Glaser, CB; Uversky, VN; Fink, AL				Yamin, G; Glaser, CB; Uversky, VN; Fink, AL			Certain metals trigger fibrillation of methionine-oxidized alpha-synuclein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; IN-VITRO; SULFOXIDE REDUCTASE; ALZHEIMERS-DISEASE; PROTEIN; OXIDATION; FILAMENTS; NITRATION; FIBRILLOGENESIS; OLIGOMERIZATION	The aggregation and fibrillation of alpha-synuclein has been implicated as a key step in the etiology of Parkinson's disease and several other neurodegenerative disorders. In addition, oxidative stress and certain environmental factors, including metals, are believed to play an important role in Parkinson's disease. Previously, we have shown that methionine-oxidized human alpha-synuclein does not fibrillate and also inhibits fibrillation of unmodified alpha-synuclein (Uversky, V. N., Yamin, G., Souillac, P. O., Goers, J., Glaser, C. B., and Fink, A. L. (2002) FEBS Lett. 517, 239-244). Using dynamic light scattering, we show that the inhibition results from stabilization of the monomeric form of Met-oxidized alpha-synuclein. We have now examined the effect of several metals on the structural properties of methionine-oxidized human alpha-synuclein and its propensity to fibrillate. The presence of metals induced partial folding of both oxidized and non-oxidized alpha-synucleins, which are intrinsically unstructured under conditions of neutral pH. Although the fibrillation of alpha-synuclein was completely inhibited by methionine oxidation, the presence of certain metals (Ti3+, Zn2+, Al3+, and Pb2+) overcame this inhibition. These findings indicate that a combination of oxidative stress and environmental metal pollution could play an important role in triggering the fibrillation of alpha-synuclein and thus possibly Parkinson's disease.	Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Fink, AL (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA.		Uversky, Vladimir N./F-4515-2011	Uversky, Vladimir N./0000-0002-4037-5857	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039985] Funding Source: NIH RePORTER; NINDS NIH HHS [NS39985] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Butterfield DA, 2002, PEPTIDES, V23, P1299, DOI 10.1016/S0196-9781(02)00066-9; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; COTTON FA, 1960, J AM CHEM SOC, V82, P2986, DOI 10.1021/ja01497a003; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; Duda JE, 2000, AM J PATHOL, V157, P1439, DOI 10.1016/S0002-9440(10)64781-5; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Good PF, 1998, J NEUROPATH EXP NEUR, V57, P338, DOI 10.1097/00005072-199804000-00006; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JENNER P, 1992, ANN NEUROL S, V32, P82; Krishnan S, 2003, BIOCHEMISTRY-US, V42, P829, DOI 10.1021/bi026528t; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Lewy F.H., 2017, HDB NEUROLOGIE, V3, P920; Manning-Bog AB, 2002, J BIOL CHEM, V277, P1641, DOI 10.1074/jbc.C100560200; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; NAIKI H, 1990, LAB INVEST, V62, P768; Paik SR, 2000, ARCH BIOCHEM BIOPHYS, V378, P269, DOI 10.1006/abbi.2000.1822; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; REDDY PS, 1994, ECOTOX ENVIRON SAFE, V29, P255, DOI 10.1016/0147-6513(94)90002-7; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Sharov VS, 1999, FEBS LETT, V455, P247, DOI 10.1016/S0014-5793(99)00888-1; Sharov VS, 2000, FREE RADICAL BIO MED, V29, P986, DOI 10.1016/S0891-5849(00)00400-7; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; TANNER CM, 1989, TRENDS NEUROSCI, V12, P49, DOI 10.1016/0166-2236(89)90135-5; Tanner CM, 1999, JAMA-J AM MED ASSOC, V281, P341, DOI 10.1001/jama.281.4.341; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; Uversky VN, 2002, NEUROTOXICOLOGY, V23, P527, DOI 10.1016/S0161-813X(02)00067-0; Uversky VN, 2002, FEBS LETT, V517, P239, DOI 10.1016/S0014-5793(02)02638-8; Uversky VN, 2001, J BIOL CHEM, V276, P43495, DOI 10.1074/jbc.C100551200; Uversky VN, 2001, FEBS LETT, V500, P105, DOI 10.1016/S0014-5793(01)02597-2; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696	41	153	157	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27630	27635		10.1074/jbc.M303302200	http://dx.doi.org/10.1074/jbc.M303302200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12754258	hybrid			2022-12-25	WOS:000184242700038
J	Pagani, F; Buratti, E; Stuani, C; Baralle, FE				Pagani, F; Buratti, E; Stuani, C; Baralle, FE			Missense, nonsense, and neutral mutations define juxtaposed regulatory elements of splicing in cystic fibrosis transmembrane regulator exon 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; FIBRONECTIN EDA EXON; MESSENGER-RNA DECAY; OPEN READING FRAME; CONDUCTANCE REGULATOR; SR PROTEINS; INTRONIC ELEMENT; SITE SELECTION; IN-VIVO; HNRNP-H	Exonic sequence variations may induce exon inclusion or exclusion from the mature mRNA by disrupting exonic regulatory elements and/or by affecting a nuclear reading frame scanning mechanism. We have carried out a systematic study of the effect on cystic fibrosis transmembrane regulator exon 9 splicing of natural and site-directed sequence mutations. We have observed that changes in the splicing pattern were not related to the creation of premature termination codons, a fact that indicates the lack of a significant nuclear check of the reading frame in this system. In addition, the splice pattern could not be predicted by available Ser/Arg protein matrices score analysis. An extensive site-directed mutagenesis of the 3' portion of the exon has identified two juxtaposed splicing enhancer and silencer elements. The study of double mutants at these regulatory elements showed a complex regulatory activity. For example, one natural mutation (146C) enhances exon inclusion and overrides all of the downstream silencing mutations except for a C to G transversion (155G). This unusual effect is explained by the creation of a specific binding site for the inhibitory splicing factor hnRNPH. In fact, on the double mutant 146C-155G, the silencing effect is dominant. These results indicate a strict dependence between the two juxtaposed enhancer and silencer sequences and show that many point mutations in these elements cause changes in splicing efficiency by different mechanisms.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Baralle, FE (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.		Buratti, Emanuele/K-4691-2016	Buratti, Emanuele/0000-0002-1356-9074; Pagani, Franco/0000-0002-2678-3459	Telethon [GGP02453] Funding Source: Medline	Telethon(Fondazione Telethon)		Aoufouchi S, 1996, CELL, V85, P415, DOI 10.1016/S0092-8674(00)81119-8; Buratti E, 2001, EMBO J, V20, P1774, DOI 10.1093/emboj/20.7.1774; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Caputi M, 2002, GENE DEV, V16, P1754, DOI 10.1101/gad.997502; CAPUTI M, 1994, NUCLEIC ACIDS RES, V22, P1018, DOI 10.1093/nar/22.6.1018; Caputi M, 2001, J BIOL CHEM, V276, P43850, DOI 10.1074/jbc.M102861200; Cartegni L, 2002, NAT GENET, V30, P377, DOI 10.1038/ng854; CARTER MS, 1995, J BIOL CHEM, V270, P28995, DOI 10.1074/jbc.270.48.28995; Chen CD, 1999, GENE DEV, V13, P593, DOI 10.1101/gad.13.5.593; Cooper TA, 1997, AM J HUM GENET, V61, P259, DOI 10.1086/514856; Cote J, 2001, P NATL ACAD SCI USA, V98, P938, DOI 10.1073/pnas.031564098; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; DELANEY SJ, 1993, NAT GENET, V4, P426, DOI 10.1038/ng0893-426; DIETZ HC, 1994, NAT GENET, V8, P183, DOI 10.1038/ng1094-183; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; Dietz HC, 1997, AM J HUM GENET, V60, P729; Fairbrother WG, 2002, SCIENCE, V297, P1007, DOI 10.1126/science.1073774; Fogel BL, 2000, J BIOL CHEM, V275, P32371, DOI 10.1074/jbc.M005000200; FULMER SB, 1995, P NATL ACAD SCI USA, V92, P6832, DOI 10.1073/pnas.92.15.6832; Gersappe A, 1999, MOL CELL BIOL, V19, P1640; GONTAREK RR, 1993, GENE DEV, V7, P1926, DOI 10.1101/gad.7.10.1926; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Hoffmeyer S, 1998, AM J HUM GENET, V62, P269, DOI 10.1086/301715; Jacquenet S, 2001, J BIOL CHEM, V276, P40464, DOI 10.1074/jbc.M104070200; Li BH, 2002, P NATL ACAD SCI USA, V99, P5277, DOI 10.1073/pnas.082095299; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Liu HX, 2000, MOL CELL BIOL, V20, P1063, DOI 10.1128/MCB.20.3.1063-1071.2000; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307; LOZANO F, 1994, EMBO J, V13, P4617, DOI 10.1002/j.1460-2075.1994.tb06783.x; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; Muro AF, 1999, MOL CELL BIOL, V19, P2657; Niksic M, 1999, HUM MOL GENET, V8, P2339, DOI 10.1093/hmg/8.13.2339; Nissim-Rafinia M, 2000, HUM MOL GENET, V9, P1771, DOI 10.1093/hmg/9.12.1771; Noensie EN, 2001, NAT BIOTECHNOL, V19, P434, DOI 10.1038/88099; Pagani F, 2000, J BIOL CHEM, V275, P21041, DOI 10.1074/jbc.M910165199; Pagani F, 2003, HUM MOL GENET, V12, P1111, DOI 10.1093/hmg/ddg131; Pagani F, 2002, NAT GENET, V30, P426, DOI 10.1038/ng858; Pitts SA, 2001, HUM MOL GENET, V10, P1155, DOI 10.1093/hmg/10.11.1155; QIAN LA, 1993, MOL CELL BIOL, V13, P1686, DOI 10.1128/MCB.13.3.1686; Romao L, 2000, BLOOD, V96, P2895; SHEPPARD DN, 1995, EMBO J, V14, P876, DOI 10.1002/j.1460-2075.1995.tb07069.x; Shiga N, 1997, J CLIN INVEST, V100, P2204, DOI 10.1172/JCI119757; SIEBEL CW, 1992, GENE DEV, V6, P1386, DOI 10.1101/gad.6.8.1386; Van Oene M, 2000, J BIOL CHEM, V275, P19577, DOI 10.1074/jbc.M002186200; Wang J, 2002, SCIENCE, V297, P108, DOI 10.1126/science.1069757; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9	49	112	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26580	26588		10.1074/jbc.M212813200	http://dx.doi.org/10.1074/jbc.M212813200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12732620	hybrid			2022-12-25	WOS:000184155700039
J	Xie, RL; Gupta, S; Miele, A; Shiffman, D; Stein, JL; Stein, GS; van Wijnen, AJ				Xie, RL; Gupta, S; Miele, A; Shiffman, D; Stein, JL; Stein, GS; van Wijnen, AJ			The tumor suppressor interferon regulatory factor 1 interferes with SP1 activation to repress the human CDK2 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H4 GENE-TRANSCRIPTION; CELL-CYCLE REGULATION; CCAAT DISPLACEMENT PROTEIN; DNA-BINDING DOMAIN; FACTOR-I IRF-1; HISTONE GENE; IFN-GAMMA; HINF-D; MOLECULAR CHARACTERIZATION; DEPENDENT KINASES	Cell growth control by interferons (IFNs) involves upregulation of the tumor suppressor interferon regulatory factor 1 (IRF1). To exert its anti-proliferative effects, this factor must ultimately control transcription of several key genes that regulate cell cycle progression. Here we show that the G(1)/S phase-related cyclin-dependent kinase 2 (CDK2) gene is a novel proliferation-related downstream target of IRF1. We find that IRF1, but not IRF2, IRF3, or IRF7, selectively represses CDK2 gene transcription in a dose- and time-dependent manner. We delineate the IRF1-responsive repressor element between nt -68 to -31 of the CDK2 promoter. For comparison, the tumor suppressor p53 represses CDK2 promoter activity independently of IRF1 through sequences upstream of nt -68, and the CDP/cut/Cux1 homeodomain protein represses transcription downstream of -31. Thus, IRF1 repression represents one of three distinct mechanisms to attenuate CDK2 levels. The -68/-31 segment lacks a canonical IRF responsive element but contains a single SP1 binding site. Mutation of this element abrogates SP1-dependent enhancement of CDK2 promoter activity as expected but also abolishes IRF1-mediated repression. Forced elevation of SP1 levels increases endogenous CDK2 levels, whereas IRF1 reduces both endogenous SP1 and CDK2 protein levels. Hence, IRF1 represses CDK2 gene expression by interfering with SP1-dependent transcriptional activation. Our findings establish a causal series of events that functionally connect the anti-proliferative effects of interferons with the IRF1-dependent suppression of the CDK2 gene, which encodes a key regulator of the G(1)/S phase transition.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; CV Therapeut, Palo Alto, CA 94304 USA	University of Massachusetts System; University of Massachusetts Worcester	Stein, GS (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.	gary.stein@umassmed.edu	van Wijnen, Andre J./AAG-3578-2019	van Wijnen, Andre J./0000-0002-4458-0946	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032010] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR049069] Funding Source: Medline; NIGMS NIH HHS [GM32010] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Aziz F, 1998, MOL BIOL REP, V25, P1, DOI 10.1023/A:1006888731301; Birnbaum MJ, 1997, J CELL BIOCHEM, V66, P175, DOI 10.1002/(SICI)1097-4644(19970801)66:2<175::AID-JCB5>3.0.CO;2-N; Botz J, 1996, MOL CELL BIOL, V16, P3401; Catt D, 1999, CELL MOL BIOL, V45, P1149; Chen SH, 2000, FASEB J, V14, P565, DOI 10.1096/fasebj.14.3.565; Coccia EM, 1999, ONCOGENE, V18, P2129, DOI 10.1038/sj.onc.1202536; Coccia EM, 2001, BIOCHEM J, V360, P285, DOI 10.1042/0264-6021:3600285; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; de Borja PF, 2001, EMBO J, V20, P5737; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Escalante CR, 1998, NATURE, V391, P103, DOI 10.1038/34224; Fujii Y, 1999, EMBO J, V18, P5028, DOI 10.1093/emboj/18.18.5028; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Furui J, 1998, STRUCT FOLD DES, V6, P491, DOI 10.1016/S0969-2126(98)00050-1; Futaki M, 1996, LEUKEMIA RES, V20, P601, DOI 10.1016/0145-2126(96)00013-6; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Haidweger E, 2001, J MOL BIOL, V306, P201, DOI 10.1006/jmbi.2000.4406; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Harper JW, 2001, CHEM REV, V101, P2511, DOI 10.1021/cr0001030; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Kirchhoff S, 1998, BIOCHIMIE, V80, P659, DOI 10.1016/S0300-9084(99)80019-4; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; Kirchhoff S, 2000, EUR J BIOCHEM, V267, P6753, DOI 10.1046/j.1432-1327.2000.01750.x; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; LAH TT, 1995, FEBS LETT, V363, P85; LIN RT, 1994, J BIOL CHEM, V269, P17542; Luo W, 1996, J BIOL CHEM, V271, P23445, DOI 10.1074/jbc.271.38.23445; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Masumi A, 2001, J BIOL CHEM, V276, P20973, DOI 10.1074/jbc.M101707200; Masumi A, 1999, MOL CELL BIOL, V19, P1810; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; McAlexander MB, 2001, MOL CELL ENDOCRINOL, V184, P135, DOI 10.1016/S0303-7207(01)00593-7; Mitra P, 2002, MOL BIOL CELL, V13, p436A; Moon NS, 2000, J BIOL CHEM, V275, P31325, DOI 10.1074/jbc.M002912200; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Muller C, 1999, J BIOL CHEM, V274, P11220, DOI 10.1074/jbc.274.16.11220; Nakagawa K, 2002, FEBS LETT, V530, P204, DOI 10.1016/S0014-5793(02)03486-5; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; Nguyen H, 1999, ONCOGENE, V18, P5455, DOI 10.1038/sj.onc.1202924; NGUYEN H, 1995, ONCOGENE, V11, P537; Pagliuca A, 2000, J CELL BIOCHEM, V76, P360, DOI 10.1002/(SICI)1097-4644(20000301)76:3<360::AID-JCB3>3.0.CO;2-1; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; RAMSEYEWING A, 1994, P NATL ACAD SCI USA, V91, P4475, DOI 10.1073/pnas.91.10.4475; Rubinstein YR, 2000, ONCOGENE, V19, P1411, DOI 10.1038/sj.onc.1203435; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Sato M, 2001, CYTOKINE GROWTH F R, V12, P133, DOI 10.1016/S1359-6101(00)00032-0; Schaper F, 1998, BIOCHEM J, V335, P147, DOI 10.1042/bj3350147; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Senger K, 2000, MOL CELL, V6, P931, DOI 10.1016/S1097-2765(05)00081-X; Sharf R, 1997, J BIOL CHEM, V272, P9785; Shiffman D, 1996, J BIOL CHEM, V271, P12199, DOI 10.1074/jbc.271.21.12199; Staal A, 2000, J CELL PHYSIOL, V185, P269, DOI 10.1002/1097-4652(200011)185:2<269::AID-JCP12>3.0.CO;2-L; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; van der Meijden CMJ, 1998, BBA-GENE STRUCT EXPR, V1442, P82, DOI 10.1016/S0167-4781(98)00147-X; van's Gravesande KS, 2002, J IMMUNOL, V168, P4488, DOI 10.4049/jimmunol.168.9.4488; VANWIJNEN AJ, 1992, MOL CELL BIOL, V12, P3273, DOI 10.1128/MCB.12.7.3273; vanWijnen AJ, 1996, P NATL ACAD SCI USA, V93, P11516, DOI 10.1073/pnas.93.21.11516; VANWIJNEN AJ, 1991, J CELL BIOCHEM, V46, P174, DOI 10.1002/jcb.240460211; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; Vaughan PS, 1997, J MOL MED-JMM, V75, P348, DOI 10.1007/s001090050120; Vaughan PS, 1998, J BIOL CHEM, V273, P194, DOI 10.1074/jbc.273.1.194; Vogt B, 1999, J GEN VIROL, V80, P2103, DOI 10.1099/0022-1317-80-8-2103; Xie RL, 2002, CANCER RES, V62, P2510; Xie RL, 2001, J BIOL CHEM, V276, P18624, DOI 10.1074/jbc.M010391200; Yim JH, 1999, J INTERF CYTOK RES, V19, P723, DOI 10.1089/107999099313569; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; Zhang Y, 1997, BBA-GENE STRUCT EXPR, V1353, P307, DOI 10.1016/S0167-4781(97)00063-8	72	52	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26589	26596		10.1074/jbc.M301491200	http://dx.doi.org/10.1074/jbc.M301491200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12732645	hybrid			2022-12-25	WOS:000184155700040
J	Xu, Q; Leung, DYM; Kisich, KO				Xu, Q; Leung, DYM; Kisich, KO			Serine-arginine-rich protein p30 directs alternative splicing of glucocorticoid receptor pre-mRNA to glucocorticoid receptor beta in neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SR PROTEINS; 5'-SPLICE-SITE RECOGNITION; FACTOR ASF/SF2; EXPRESSION; EXON; CELLS; ENHANCER; ASTHMA; SITE; SPLICEOSOME	Glucocorticoid ( GC) insensitivity is a major clinical challenge in the treatment of many inflammatory diseases. It has been shown previously that GC insensitivity, in several inflammatory cell types, is due to an overabundance of the beta isoform of the glucocorticoid receptor (GCRbeta) relative to the ligand binding isoform, GCRalpha. GCRbeta functions as a dominant inhibitor of GCRalpha action. A number of GCR isoforms are created from the same pre-mRNA transcript via alternative splicing, and the factor or factors that control alternative splicing of GCR pre-mRNA are of great importance. In the current study, we have identified the predominant alternative splicing factor present in human neutrophils, which is known to be exceptionally GC-insensitive. The predominant alternative splicing factor in neutrophils is SRp30c, which is one of several highly conserved serine-arginine-rich (SR) proteins that are involved in both constitutive and alternative splicing in eukaryotic cells. Inhibition of SRp30c expression with antisense oligonucleotide strongly inhibited expression of GCRbeta and stimulated expression of GCRalpha. Antisense molecules targeted to other SR proteins had no effect. Our data indicate that SRp30c is necessary for alternative splicing of the GCR pre-mRNA to create mRNA encoding GCRbeta.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Pediat Allergy Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Leung, DYM (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Pediat Allergy Immunol, 1400 Jackson St,Rm K926, Denver, CO 80206 USA.	leungd@njc.org						Bruce SR, 2001, NUCLEIC ACIDS RES, V29, P2292, DOI 10.1093/nar/29.11.2292; Bruni R, 1996, P NATL ACAD SCI USA, V93, P10423, DOI 10.1073/pnas.93.19.10423; Christodoulopoulos P, 2000, J ALLERGY CLIN IMMUN, V106, P479; Cowper AE, 2001, J BIOL CHEM, V276, P48908, DOI 10.1074/jbc.M103967200; Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; Dance GSC, 2002, J BIOL CHEM, V277, P12703, DOI 10.1074/jbc.M111337200; Du KY, 1997, MOL CELL BIOL, V17, P4096, DOI 10.1128/MCB.17.7.4096; Du KY, 1998, J BIOL CHEM, V273, P35208, DOI 10.1074/jbc.273.52.35208; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; Gallego ME, 1997, EMBO J, V16, P1772, DOI 10.1093/emboj/16.7.1772; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; Hamid QA, 1999, AM J RESP CRIT CARE, V159, P1600, DOI 10.1164/ajrccm.159.5.9804131; Hamilos DL, 2001, J ALLERGY CLIN IMMUN, V108, P59; Hauk PJ, 2002, AM J RESP CELL MOL, V27, P361, DOI 10.1165/rcmb.4861; HIMMELSPACH M, 1995, RNA, V1, P794; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; Honda M, 2000, GASTROENTEROLOGY, V118, P859, DOI 10.1016/S0016-5085(00)70172-7; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; JAMISON SF, 1995, NUCLEIC ACIDS RES, V23, P3260, DOI 10.1093/nar/23.16.3260; Kadener S, 2002, P NATL ACAD SCI USA, V99, P8185, DOI 10.1073/pnas.122246099; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Kuo BA, 2002, J CELL BIOCHEM, V86, P45, DOI 10.1002/jcb.10188; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lemaire R, 2002, GENE DEV, V16, P594, DOI 10.1101/gad.939502; Leung DYM, 1997, J EXP MED, V186, P1567, DOI 10.1084/jem.186.9.1567; Leung DYM, 1998, ANN NY ACAD SCI, V840, P735, DOI 10.1111/j.1749-6632.1998.tb09612.x; Leung DYM, 2003, J ALLERGY CLIN IMMUN, V111, P1, DOI 10.1067/mai.2003.62; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Molin M, 2000, J VIROL, V74, P9002, DOI 10.1128/JVI.74.19.9002-9009.2000; Muro AF, 1998, FEBS LETT, V437, P137, DOI 10.1016/S0014-5793(98)01201-0; NEUGEBAUER KM, 1995, J CELL BIOL, V129, P899, DOI 10.1083/jcb.129.4.899; Oakley RH, 1996, J BIOL CHEM, V271, P9550, DOI 10.1074/jbc.271.16.9550; Oakley RH, 1999, J BIOL CHEM, V274, P27857, DOI 10.1074/jbc.274.39.27857; Pollard AJ, 2002, J BIOL CHEM, V277, P15241, DOI 10.1074/jbc.M109046200; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; ROSCIGNO RF, 1995, RNA, V1, P692; Sala A, 1999, J BIOL CHEM, V274, P28264, DOI 10.1074/jbc.274.40.28264; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; Shih SR, 1996, EMBO J, V15, P5415, DOI 10.1002/j.1460-2075.1996.tb00925.x; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Sousa AR, 2000, J ALLERGY CLIN IMMUN, V105, P943, DOI 10.1067/mai.2000.106486; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Strickland I, 2001, J EXP MED, V193, P585, DOI 10.1084/jem.193.5.585; TARN WY, 1995, P NATL ACAD SCI USA, V92, P2504, DOI 10.1073/pnas.92.7.2504; ten Dam GB, 1999, BBA-GENE STRUCT EXPR, V1446, P317, DOI 10.1016/S0167-4781(99)00119-0; TIAN HC, 1995, MOL CELL BIOL, V15, P6291; TUCKER KA, 1987, BLOOD, V70, P372; Young PJ, 2002, HUM MOL GENET, V11, P577, DOI 10.1093/hmg/11.5.577; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	50	49	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27112	27118		10.1074/jbc.M300824200	http://dx.doi.org/10.1074/jbc.M300824200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12738786	hybrid			2022-12-25	WOS:000184155700105
J	Joubert, AM; Byrd, AS; LiCata, VJ				Joubert, AM; Byrd, AS; LiCata, VJ			Global conformations, hydrodynamics, and X-ray scattering properties of Taq and Escherichia coli DNA polymerases in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMUS-AQUATICUS; CRYSTAL-STRUCTURE; NUCLEASE DOMAIN; KLENOW FRAGMENT; PURIFICATION; PROTEINS; SEDIMENTATION; EXPRESSION; PROGRAM	Escherichia coli polymerase 1 (Pol 1) and Thermus aquaticus Taq polymerase are homologous Type I DNA polymerases, each comprised of a polymerase domain, a proofreading domain ( inactive in Taq), and a 5' nuclease domain. "Klenow" and "Klentaq" are the large fragments of Pol 1 and Taq and are functional polymerases lacking the 5' nuclease domain. In the available crystal structures of full-length Taq, the 5' nuclease domain is positioned in two different orientations: in one structure, it is extended out into solution, whereas in the other, it is folded up against the polymerase domain in a more compact structure. Analytical ultracentrifugation experiments report s(20,w) values of 5.05 for Taq, 4.1 for Klentaq, 5.3 for E. coli Pol 1, and 4.6 for Klenow. Measured partial specific volumes are all quite similar, indicating no significant differences in packing density between the mesophilic and thermophilic proteins. Small angle x-ray scattering studies report radii of gyration of 38.3 Angstrom for Taq, 30.7 Angstrom for Klentaq, and 30.5 Angstrom for Klenow. The hydrodynamic and x-ray scattering properties of the polymerases were also calculated directly from the different crystal structures using the programs HYDROPRO (Garcia De La Torre, J., Huertas, M. L., and Carrasco, B. (2000) Biophys J. 78, 719 - 730) and CRYSOL (Svergun, D. I., Barberato, C., and Koch, M. H. J. ( 1995) J. Appl. Crystalogr. 28, 768 - 773), respectively. The combined experimental and computational characterizations indicate that the full-length polymerases in solution are in a conformation where the 5' nuclease domain is extended into solution. Further, the radius of gyration, and hence the global conformation of Taq polymerase, is not altered by the binding of either matched primer template DNA or ddATP.	Louisiana State Univ, Dept Sci Biol, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	LiCata, VJ (corresponding author), Louisiana State Univ, Dept Sci Biol, Baton Rouge, LA 70803 USA.	licata@lsu.edu	Richard, Allison/N-1987-2017	Byrd, Angela/0000-0002-6743-4343				BARNES WM, 1992, GENE, V112, P29, DOI 10.1016/0378-1119(92)90299-5; BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; CHIEN A, 1976, J BACTERIOL, V127, P1550, DOI 10.1128/JB.127.3.1550-1557.1976; Datta K, 2003, J BIOL CHEM, V278, P5694, DOI 10.1074/jbc.M208133200; de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6; EDELSTEIN SJ, 1967, J BIOL CHEM, V242, P306; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; Guinier A., 1939, ANN PHYS-LEIPZIG, DOI DOI 10.1051/ANPHYS/193911120161; Joyce CM, 1995, METHOD ENZYMOL, V262, P3; KALEDIN A S, 1980, Biokhimiya, V45, P644; Karshikoff A, 1998, PROTEIN ENG, V11, P867, DOI 10.1093/protein/11.10.867; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KIRSCHNER MW, 1971, BIOCHEMISTRY-US, V10, P1900, DOI 10.1021/bi00786a027; KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264; Lawyer F C, 1993, PCR Methods Appl, V2, P275; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; Lyamichev V, 1999, P NATL ACAD SCI USA, V96, P6143, DOI 10.1073/pnas.96.11.6143; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MINKLEY EG, 1984, J BIOL CHEM, V259, P386; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1997, PROTEINS, V27, P110; Tanford C, 1961, PHYS CHEM MACROMOLEC, P364; Urs UK, 1999, ACTA CRYSTALLOGR D, V55, P1971; VANHOLDE KE, 1998, PRINCIPLES PHYSICAL, P202; [No title captured]	27	17	17	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25341	25347		10.1074/jbc.M302118200	http://dx.doi.org/10.1074/jbc.M302118200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730189	Green Published, hybrid			2022-12-25	WOS:000183920200012
J	Misra, S; Ghatak, S; Zoltan-Jones, A; Toole, BP				Misra, S; Ghatak, S; Zoltan-Jones, A; Toole, BP			Regulation of multidrug resistance in cancer cells by hyaluronan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-RESISTANCE; EXTRACELLULAR-MATRIX; SOLID TUMORS; SURVIVAL; APOPTOSIS; BINDING; INHIBITION; MECHANISMS; RECEPTORS; REVERSAL	Multidrug resistance in cancer cells is often due to ATP-dependent efflux pumps, but is also linked to alterations in cell survival and apoptotic signaling pathways. We have found previously that perturbation of hyaluronan-tumor cell interaction by treatment with hyaluronan oligosaccharides suppresses the phosphoinositide 3-kinase/Akt cell survival signaling pathway in cancer cells and reduces tumor growth in vivo. Here we find that these oligomers suppress both the MAP kinase and phosphoinositide 3-kinase pathways in multidrug resistant tumor cells and sensitize these cells to a variety of chemotherapeutic drugs. On the other hand, increased hyaluronan production induces resistance in drug-sensitive tumor cells. Likewise, increased expression of emmprin, which is a glycoprotein that is present on the surface of most malignant cancer cells and that stimulates hyaluronan production, also induces increased resistance. Thus, perturbation of hyaluronan signaling may provide a dual therapeutic role, since it has intrinsic suppressive effects on tumor growth as well as sensitizing cancer cells to chemotherapeutic agents.	Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA	Tufts University	Toole, BP (corresponding author), Med Univ S Carolina, Dept Anat & Cell Biol, 173 Ashley Ave, Charleston, SC 29425 USA.				NATIONAL CANCER INSTITUTE [R01CA082867, R01CA073839, R01CA079866] Funding Source: NIH RePORTER; NCI NIH HHS [CA73839, CA79866, CA82867] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Baumgartner G, 1998, CANCER LETT, V131, P85, DOI 10.1016/S0304-3835(98)00204-3; BISWAS C, 1995, CANCER RES, V55, P434; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Damiano JS, 2001, LEUKEMIA, V15, P1232, DOI 10.1038/sj.leu.2402179; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Desoize B, 2000, CRIT REV ONCOL HEMAT, V36, P193, DOI 10.1016/S1040-8428(00)00086-X; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Ghatak S, 2002, J BIOL CHEM, V277, P38013, DOI 10.1074/jbc.M202404200; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; KONGTAWELERT P, 1990, ANAL BIOCHEM, V185, P313, DOI 10.1016/0003-2697(90)90300-X; Lesley J, 2000, J BIOL CHEM, V275, P26967; Li RS, 2001, J CELL PHYSIOL, V186, P371, DOI 10.1002/1097-4652(2000)9999:999<000::AID-JCP1042>3.0.CO;2-8; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Mabuchi S, 2002, J BIOL CHEM, V277, P33490, DOI 10.1074/jbc.M204042200; Makin G, 2001, TRENDS CELL BIOL, V11, pS22, DOI 10.1016/S0962-8924(01)82111-5; Masters SC, 2001, MOL PHARMACOL, V60, P1325, DOI 10.1124/mol.60.6.1325; O'Gorman DM, 2001, LEUKEMIA, V15, P21, DOI 10.1038/sj.leu.2401998; St Croix B, 1998, CANCER LETT, V131, P35, DOI 10.1016/S0304-3835(98)00199-2; StCroix B, 1996, JNCI-J NATL CANCER I, V88, P1285, DOI 10.1093/jnci/88.18.1285; Tamura M, 1999, JNCI-J NATL CANCER I, V91, P1820, DOI 10.1093/jnci/91.21.1820; Tool BP, 2001, SEMIN CELL DEV BIOL, V12, P79, DOI 10.1006/scdb.2000.0244; Toole BP, 2002, AM J PATHOL, V161, P745, DOI 10.1016/S0002-9440(10)64232-0; Toole BP, 2002, GLYCOBIOLOGY, V12, p37R, DOI 10.1093/glycob/12.3.37R; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; UNDERHILL CB, 1983, J BIOL CHEM, V258, P8086; UNDERHILL CB, 1981, EXP CELL RES, V131, P419, DOI 10.1016/0014-4827(81)90248-2; Ward JA, 2003, AM J PATHOL, V162, P1403, DOI 10.1016/S0002-9440(10)64273-3; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Worm J, 2001, J BIOL CHEM, V276, P39990, DOI 10.1074/jbc.M103181200; Zucker S, 2001, AM J PATHOL, V158, P1921, DOI 10.1016/S0002-9440(10)64660-3	32	193	201	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25285	25288		10.1074/jbc.C300173200	http://dx.doi.org/10.1074/jbc.C300173200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12738783	hybrid			2022-12-25	WOS:000183920200004
J	Noguchi, K; Ishii, S; Shimizu, T				Noguchi, K; Ishii, S; Shimizu, T			Identification of p2y(9)/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; ACTIVATING-FACTOR; OVARIAN-CANCER; CELLS; EXPRESSION; RESPONSES; CYCLASE; DENSITY; LPA; CHO	Lysophosphatidic acid (LPA) is a bioactive lipid mediator with diverse physiological and pathological actions on many types of cells. LPA has been widely considered to elicit its biological functions through three types of G protein-coupled receptors, Edg-2 (endothelial cell differentiation gene-2)/LPA(1)/vzg-1 (ventricular zone gene-1), Edg-4/LPA(2), and Edg-7/LPA(3). We identified an orphan G protein-coupled receptor, p2y(9)/GPR23, as the fourth LPA receptor (LPA(4)). Membrane fractions of RH7777 cells transiently expressing p2y(9)/GPR23 displayed a specific binding for 1-oleoyl-LPA with a K-d value of around 45 nM. Competition binding and reporter gene assays showed that p2y(9)/GPR23 preferred structural analogs of LPA with a rank order of 1-oleoyl- > 1-stearoyl- > 1-palmitoyl- > 1-myristoyl- > 1-alkyl- > 1-alkenyl-LPA. In Chinese hamster ovary cells expressing p2y(9)/GPR23, 1-oleoyl- LPA induced an increase in intracellular Ca2+ concentration and stimulated adenylyl cyclase activity. Quantitative real-time PCR demonstrated that mRNA of p2y(9)/GPR23 was significantly abundant in ovary compared with other tissues. Interestingly, p2y(9)/GPR23 shares only 20-24% amino acid identities with Edg-2/LPA1, Edg-4/LPA(2), and Edg-7/LPA(3), and phylogenetic analysis also shows that p2y(9)/GPR23 is far distant from the Edg family. These facts suggest that p2y(9)/GPR23 has evolved from different ancestor sequences from the Edg family.	Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Japan Sci & Technol Corp,CREST,Bunkyo Ku, Tokyo 1130033, Japan	Japan Science & Technology Agency (JST); University of Tokyo	Ishii, S (corresponding author), Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Japan Sci & Technol Corp,CREST,Bunkyo Ku, Tokyo 1130033, Japan.		Shimizu, Takao/AAV-7052-2021					An SZ, 1998, MOL PHARMACOL, V54, P881, DOI 10.1124/mol.54.5.881; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; Aoki J, 2002, J BIOL CHEM, V277, P48737, DOI 10.1074/jbc.M206812200; Baker DL, 2001, ANAL BIOCHEM, V292, P287, DOI 10.1006/abio.2001.5063; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Bandoh K, 2000, FEBS LETT, V478, P159, DOI 10.1016/S0014-5793(00)01827-5; Boeynaems Jean-Marie, 2000, Trends in Pharmacological Sciences, V21, P1, DOI 10.1016/S0165-6147(99)01415-7; Carruthers AM, 1999, BRIT J PHARMACOL, V126, P1221, DOI 10.1038/sj.bjp.0702401; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921-6929.2002; Fang XJ, 2000, ANN NY ACAD SCI, V905, P188; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; Goetzl EJ, 1999, CANCER RES, V59, P4732; Gueguen G, 1999, BIOCHEMISTRY-US, V38, P8440, DOI 10.1021/bi9816756; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hooks SB, 2001, J BIOL CHEM, V276, P4611, DOI 10.1074/jbc.M007782200; Im DS, 2000, MOL PHARMACOL, V57, P753, DOI 10.1124/mol.57.4.753; Janssens R, 1997, BIOCHEM BIOPH RES CO, V236, P106, DOI 10.1006/bbrc.1997.6895; Jaspard B, 1996, BIOCHEMISTRY-US, V35, P1352, DOI 10.1021/bi950938i; Liliom K, 1998, AM J PHYSIOL-CELL PH, V274, pC1065, DOI 10.1152/ajpcell.1998.274.4.C1065; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Michal P, 2001, BRIT J PHARMACOL, V132, P1217, DOI 10.1038/sj.bjp.0703931; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; ODowd BF, 1997, GENE, V187, P75, DOI 10.1016/S0378-1119(96)00722-6; Ogasawara H, 2002, J BIOL CHEM, V277, P18763, DOI 10.1074/jbc.M109447200; OGURA M, 1985, BLOOD, V66, P1384; Pages C, 2001, PROSTAG OTH LIPID M, V64, P1, DOI 10.1016/S0090-6980(01)00110-1; Schneider E, 2002, TRENDS IMMUNOL, V23, P255, DOI 10.1016/S1471-4906(02)02215-9; Sugiura T, 1999, BBA-MOL CELL BIOL L, V1440, P194, DOI 10.1016/S1388-1981(99)00127-4; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TIGYI G, 1992, J BIOL CHEM, V267, P21360; Tokumura A, 2002, BBA-MOL CELL BIOL L, V1582, P18, DOI 10.1016/S1388-1981(02)00133-6; Tokumura A, 2002, BIOCHEM J, V365, P617, DOI 10.1042/BJ20020348; TOKUMURA A, 1995, PROG LIPID RES, V34, P151, DOI 10.1016/0163-7827(95)00001-G; Varga EV, 1998, EUR J PHARMACOL, V348, pR1, DOI 10.1016/S0014-2999(98)00258-1; Xu Y, 1995, CLIN CANCER RES, V1, P1223	40	462	484	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25600	25606		10.1074/jbc.M302648200	http://dx.doi.org/10.1074/jbc.M302648200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12724320	hybrid			2022-12-25	WOS:000183920200042
J	Wang, XQ; Sun, P; Paller, AS				Wang, XQ; Sun, P; Paller, AS			Ganglioside GM3 inhibits matrix metalloproteinase-9 activation and disrupts its association with integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; HUMAN BREAST-CANCER; PROTEIN-KINASE-C; CELLS IN-VITRO; MATRIX METALLOPROTEINASES; FACTOR RECEPTOR; IV COLLAGENASE/GELATINASE; SIGNAL-TRANSDUCTION; COLLAGEN LATTICES; ENDOTHELIAL-CELLS	Gangliosides GM3 and GT1b both inhibit epithelial cell adhesion and migration on fibronectin. GT1b binds to integrin alpha(5)beta(1) and blocks the integrin-fibronectin interaction; GM3 does not interact with integrin, and its effect is poorly understood. We evaluated the effects of endogenous modulation of GM3 expression on epithelial cell motility on several matrices and the mechanism of these effects. Endogenous accumulation of GM3 decreased cell migration on fibronectin, types I, IV, and VII collagen matrices; depletion of GM3 dramatically increased cell migration, regardless of matrix. GM3 overexpression and depletion in vitro correlated inversely with the expression and activity of matrix metalloproteinase-9; consistently, the cell migration stimulated by GM3 depletion is reversed by inhibition of matrix metalloproteinase-9 activity. Accumulation and depletion of GM3 in epithelial cells grown on fibronectin also correlated inversely with epidermal growth factor receptor and mitogen activated protein kinase phosphorylation and with Jun expression. Ganglioside depletion facilitated the co-immunoprecipitation of matrix metalloproteinase-9 and integrin alpha(5)beta(1), while endogenous accumulation of GM3, but not GT1b, blocked the co-immunoprecipitation. These data suggest modulation of epidermal growth factor receptor signaling and dissociation of integrin/matrix metalloproteinase-9 as mechanisms for the GM3-induced effects on matrix metalloproteinase-9 function.	Northwestern Univ, Sch Med, Childrens Mem Inst Educ & Res, Dept Pediat, Chicago, IL 60614 USA; Northwestern Univ, Sch Med, Childrens Mem Inst Educ & Res, Dept Dermatol, Chicago, IL 60614 USA	Northwestern University; Northwestern University	Paller, AS (corresponding author), Childrens Mem Hosp, Div Dermatol 107, 2300 Childrens Plaza, Chicago, IL 60614 USA.	apaller@northwestern.edu		Paller, Amy/0000-0001-6187-6549				ABE A, 1995, J LIPID RES, V36, P611; ALLAN JA, 1995, BIOCHEM J, V309, P299, DOI 10.1042/bj3090299; Alper O, 2001, J NATL CANCER I, V93, P1375, DOI 10.1093/jnci/93.18.1375; Amano S, 2001, EXP CELL RES, V271, P249, DOI 10.1006/excr.2001.5387; Aoudjit F, 1998, J IMMUNOL, V160, P2967; ARNSMEIER SL, 1995, J LIPID RES, V36, P911; Bannikov GA, 2002, J BIOL CHEM, V277, P16022, DOI 10.1074/jbc.M110931200; CHEN LL, 1993, BIOCHEM BIOPH RES CO, V193, P167, DOI 10.1006/bbrc.1993.1605; Cox G, 2000, CLIN CANCER RES, V6, P2349; Dumin JA, 2001, J BIOL CHEM, V276, P29368, DOI 10.1074/jbc.M104179200; Ellerbroek SM, 2001, CANCER RES, V61, P1855; Ellerbroek SM, 2001, J BIOL CHEM, V276, P24833, DOI 10.1074/jbc.M005631200; Ellerbroek SM, 1998, INT J CANCER, V78, P331, DOI 10.1002/(SICI)1097-0215(19981029)78:3<331::AID-IJC13>3.0.CO;2-9; Franchi A, 2002, CANCER-AM CANCER SOC, V95, P1902, DOI 10.1002/cncr.10916; Gocht A, 2000, HISTOCHEM J, V32, P447, DOI 10.1023/A:1004099406623; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Guo HM, 1997, J BIOL CHEM, V272, P24; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Hakomori S, 1996, CANCER RES, V56, P5309; HEIDENHEIM M, 1995, BRIT J DERMATOL, V133, P392, DOI 10.1111/j.1365-2133.1995.tb02666.x; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Hofmann UB, 2000, INT J CANCER, V87, P12, DOI 10.1002/1097-0215(20000701)87:1<12::AID-IJC3>3.0.CO;2-A; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Kadono Y, 1998, CANCER RES, V58, P2240; Kawakami Y, 2002, J BIOL CHEM, V277, P34349, DOI 10.1074/jbc.M200771200; Kawamura S, 2001, INT J CANCER, V94, P343, DOI 10.1002/ijc.1482; Kondapaka SB, 1997, INT J CANCER, V70, P722, DOI 10.1002/(SICI)1097-0215(19970317)70:6<722::AID-IJC15>3.3.CO;2-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li DQ, 2001, EXP EYE RES, V73, P449, DOI 10.1006/exer.2001.1054; Malik N, 1996, J IMMUNOL, V156, P3952; Marquina G, 1996, CANCER RES, V56, P5165; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Medina OP, 2001, CANCER RES, V61, P3978; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nojiri H, 1999, FEBS LETT, V453, P140, DOI 10.1016/S0014-5793(99)00709-7; Nojiri H, 2002, CANCER DETECT PREV, V26, P114, DOI 10.1016/S0361-090X(02)00033-8; O-charoenrat P, 2001, ARCH OTOLARYNGOL, V127, P813; Olson MW, 2000, J BIOL CHEM, V275, P2661, DOI 10.1074/jbc.275.4.2661; Ono M, 2001, BIOCHEMISTRY-US, V40, P6414, DOI 10.1021/bi0101998; PALLER AS, 1995, J INVEST DERMATOL, V105, P237, DOI 10.1111/1523-1747.ep12317572; PALLER AS, 1995, EXP CELL RES, V217, P118, DOI 10.1006/excr.1995.1070; PALLER AS, 1993, J INVEST DERMATOL, V100, P841, DOI 10.1111/1523-1747.ep12476755; PALLER AS, 1992, J INVEST DERMATOL, V98, P226, DOI 10.1111/1523-1747.ep12555896; ROMANIC AM, 1994, J CELL BIOL, V125, P1165, DOI 10.1083/jcb.125.5.1165; Saito S, 2000, TOHOKU J EXP MED, V190, P271, DOI 10.1620/tjem.190.271; Santibanez JF, 2002, BIOCHEM BIOPH RES CO, V296, P267; SASAKI K, 1994, J BIOL CHEM, V269, P15950; Satoh M, 2001, INT J ONCOL, V19, P723; SELTZER JL, 1994, EXP CELL RES, V213, P365, DOI 10.1006/excr.1994.1211; Shi W, 2000, J CELL BIOL, V148, P591, DOI 10.1083/jcb.148.3.591; Silletti S, 2001, P NATL ACAD SCI USA, V98, P119, DOI 10.1073/pnas.011343298; Stricker TP, 2001, J BIOL CHEM, V276, P29375, DOI 10.1074/jbc.M102217200; Sun P, 2002, J INVEST DERMATOL, V119, P107, DOI 10.1046/j.1523-1747.2002.01802.x; Sundareshan P, 1999, PROSTATE, V40, P159, DOI 10.1002/(SICI)1097-0045(19990801)40:3<159::AID-PROS3>3.0.CO;2-W; Sung CC, 1998, EXP CELL RES, V239, P311, DOI 10.1006/excr.1997.3897; Thant AA, 2001, CLIN EXP METASTAS, V18, P423, DOI 10.1023/A:1010921730952; Wada T, 1999, BIOCHEM BIOPH RES CO, V261, P21, DOI 10.1006/bbrc.1999.0973; Wang XQ, 2002, J BIOL CHEM, V277, P47028, DOI 10.1074/jbc.M208257200; Wang XQ, 2002, J BIOL CHEM, V277, P40410, DOI 10.1074/jbc.M207117200; Wang XQ, 2001, J INVEST DERMATOL, V116, P69, DOI 10.1046/j.1523-1747.2001.00222.x; Wang XQ, 2001, GLYCOBIOLOGY, V11, P515, DOI 10.1093/glycob/11.7.515; Wang XQ, 2001, J BIOL CHEM, V276, P44504, DOI 10.1074/jbc.M106563200; Wang XQ, 2001, J BIOL CHEM, V276, P8436, DOI 10.1074/jbc.M006097200; Wang YL, 1999, METHOD ENZYMOL, V306, P281; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; Watanabe R, 2002, CANCER RES, V62, P3850; Xie B, 1998, J BIOL CHEM, V273, P11576, DOI 10.1074/jbc.273.19.11576; YOGEESWARAN G, 1983, ADV CANCER RES, V38, P289, DOI 10.1016/S0065-230X(08)60191-8; ZHENG MZ, 1992, BIOCHEM BIOPH RES CO, V186, P1397, DOI 10.1016/S0006-291X(05)81561-X; ZHENG MZ, 1993, J BIOL CHEM, V268, P2217	71	38	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25591	25599		10.1074/jbc.M302211200	http://dx.doi.org/10.1074/jbc.M302211200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12724312	hybrid			2022-12-25	WOS:000183920200041
J	Cha, MK; Choi, YS; Hong, SK; Kim, WC; No, KT; Kim, IH				Cha, MK; Choi, YS; Hong, SK; Kim, WC; No, KT; Kim, IH			Nuclear thiol peroxidase as a functional alkyl-hydroperoxide reductase necessary for stationary phase growth of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT PROTEIN; OXIDATIVE STRESS; MAMMALIAN PEROXIREDOXIN; CONSERVED CYSTEINE; PROTECTOR PROTEIN; ESCHERICHIA-COLI; BUDDING YEAST; THIOREDOXIN; PURIFICATION; FAMILY	Yeast nucleus-localized thiol peroxidase (nTPx) was characterized as a functional peroxidase. There are two cysteine residues in nTPx. Replacement of Cys-106 or Cys-111 with serine resulted in a complete loss of thioredoxin-linked peroxidase activity. However, when their activities were measured in terms of the ability to inhibit oxidation of glutamine synthetase, C111S showed the same antioxidant activity as the wild type protein. SDS-PAGE gel analysis revealed that only C111S existed as the dimer form. In addition to the identification of Cys-106 as the primary catalytic site, these data suggest the formation of the intradisulfide bond as a part of the catalytic cycle between nTPx and thioredoxin. nTPx preferentially reduced alkyl-hydroperoxides rather than H2O2. Furthermore, a nTPx mutant strain showed higher sensitivity toward alkyl-hydroperoxide than hydrogen peroxide. Also, reduction of the viability of nTPx mutant strain against various oxidants supports an in vivo antioxidant role for nTPx. nTPx transcriptional activity was not significantly detectable in log phase yeast, but the activity was exponentially increased after the diauxic shift. The transcriptional activity was highly induced even in the log phase yeast grown in nonfermentable carbon source. Deletion of Tor1p, Ras1p, and Ras2p resulted in considerable induction when compared with their parent strains, demonstrating the activation of the transcription of nTPx gene at the diauxic shift. Transcription of nTPx gene was induced in response to oxidative stress. Viability of a stationary phase nTPx mutant was considerably reduced compared with the isogenic strain. Collectively, these data demonstrate that nTPx is a thiol peroxidase family acting as alkyl-hydroperoxide reductase in the nucleus during post-diauxic growth.	Paichai Univ, Dept Biochem, Taejon 302735, South Korea; Soongsil Univ, Comp Aided Mol Design Res Ctr, Seoul 156743, South Korea; Yonsei Univ, Dept Bioengn, Seoul 120749, South Korea	Pai Chai University; Soongsil University; Yonsei University	Kim, IH (corresponding author), Paichai Univ, Dept Biochem, 439-6 Doma 2 Dong, Taejon 302735, South Korea.		Kim, Il-Han/W-1401-2019; No, Kyoung Tai/P-1644-2015					Adams A, 1997, METHODS YEAST GENETI; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Bertram PG, 1998, CURR BIOL, V8, P1259, DOI 10.1016/S0960-9822(07)00535-0; BOUCHERIE H, 1985, J BACTERIOL, V161, P385, DOI 10.1128/JB.161.1.385-392.1985; Boy-Marcotte E, 1998, J BACTERIOL, V180, P1044, DOI 10.1128/JB.180.5.1044-1052.1998; Cha MK, 1998, J BIOCHEM MOL BIOL, V31, P409; Cha MK, 1996, J BIOCHEM MOL BIOL, V29, P236; Cha MK, 2000, BIOCHEMISTRY-US, V39, P6944, DOI 10.1021/bi000034j; Cha MK, 1996, J BACTERIOL, V178, P5610, DOI 10.1128/jb.178.19.5610-5614.1996; CHA MK, 1995, J BIOL CHEM, V270, P28635, DOI 10.1074/jbc.270.48.28635; CHAE HJ, 1994, J BIOL CHEM, V269, P27671; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; ENGELBERG D, 1994, CELL, V77, P1025; Estruch F, 2000, FEMS MICROBIOL REV, V24, P469, DOI 10.1016/S0168-6445(00)00035-8; GOUNALAKI N, 1994, EMBO J, V13, P4036, DOI 10.1002/j.1460-2075.1994.tb06720.x; Halliwell B, 1999, FREE RADICAL BIO MED, P105, DOI DOI 10.1093/ACPR0F:0S0/9780198717478.003.0005; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; Jeong W, 2000, J BIOL CHEM, V275, P2924, DOI 10.1074/jbc.275.4.2924; Jeong W, 2000, J BIOCHEM MOL BIOL, V33, P234; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM KW, 1988, J BIOL CHEM, V263, P4704; Knoops B, 1999, J BIOL CHEM, V274, P30451, DOI 10.1074/jbc.274.43.30451; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; KWON SJ, 1994, BIOCHEM BIOPH RES CO, V201, P8, DOI 10.1006/bbrc.1994.1662; Lee J, 1999, J BIOL CHEM, V274, P4537, DOI 10.1074/jbc.274.8.4537; LIM YS, 1993, BIOCHEM BIOPH RES CO, V192, P273, DOI 10.1006/bbrc.1993.1410; LIM YS, 1994, GENE, V140, P279, DOI 10.1016/0378-1119(94)90558-4; LIM YS, 1994, BIOCHEM BIOPH RES CO, V199, P199, DOI 10.1006/bbrc.1994.1214; Park SG, 2000, J BIOL CHEM, V275, P5723, DOI 10.1074/jbc.275.8.5723; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Singer MS, 1998, GENETICS, V150, P613; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993	40	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24636	24643		10.1074/jbc.M302628200	http://dx.doi.org/10.1074/jbc.M302628200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12730197	hybrid			2022-12-25	WOS:000183824800048
J	Gingras, B; Rodier, G; Giasson, E; Coulombe, P; Chassagne, C; Meloche, S				Gingras, B; Rodier, G; Giasson, E; Coulombe, P; Chassagne, C; Meloche, S			Expression of angiotensin type II receptor downregulates Cdk4 synthesis and inhibits cell-cycle progression	ONCOGENE			English	Article						angiotensin receptor; cell proliferation; cell cycle; CDK4	GROWTH-FACTOR-BETA; RETINOBLASTOMA PROTEIN; PHOSPHORYLATION; PROLIFERATION; FIBROBLASTS; ACTIVATION; CLONING	Accumulating evidence suggests that angiotensin II type II (AT(2)) receptor subtype negatively regulates cell proliferation in pathophysiological conditions associated with tissue remodeling. However, the mechanisms through which AT(2) receptor achieves this effect remain poorly understood. In this study, we demonstrate that expression of AT(2) receptor inhibits the proliferation of rat fibroblasts in a ligand-independent manner. The antiproliferative action of AT(2) is dependent on the density of surface receptors. We show that AT(2) receptor expression negatively regulates G1 phase progression in both cycling cells and G0-arrested cells stimulated to re-enter the cell cycle, but has no detectable effect on apoptosis. The delay in cell-cycle progression of AT(2)-expressing cells is associated with downregulation of cyclin E expression, decreased assembly of cyclin E-Cdk2 complexes, and the resulting attenuation of Cdk2 activation. The induction of Cdk4 expression and activity is also markedly attenuated, which likely contributes to the inhibition of cyclin E expression. Ectopic expression of Cdk4 alleviates the proliferation defect of AT2-expressing cells. These findings suggest that the growth-inhibitory effects of the AT(2) receptor are attributable in part to its spontaneous inhibitory action on the cell cycle machinery.	Inst Rech Clin Montreal, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Mol Biol, Montreal, PQ H2W 1R7, Canada; Univ Paris 07, Hop Lariboisiere, Inst Federat Rech Circulat Paris 7, INSERM,U127, Paris, France	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universite de Montreal; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Meloche, S (corresponding author), Inst Rech Clin Montreal, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	melochs@ircm.qc.ca	GIASSON, ELVIO/J-3623-2012	GIASSON, ELVIO/0000-0003-3659-6873; COULOMBE, Philippe/0000-0002-4638-9694; RODIER, Genevieve/0000-0002-9901-639X				Akishita M, 1999, J CLIN INVEST, V103, P63, DOI 10.1172/JCI5182; Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000; Bedecs K, 1997, BIOCHEM J, V325, P449, DOI 10.1042/bj3250449; Blume A, 2001, CURR OPIN NEPHROL HY, V10, P239, DOI 10.1097/00041552-200103000-00013; BOND RA, 1998, DRUGS PHARM SCI, V89, P363; CHAASSAGNE C, 1995, GENOMICS, V25, P601, DOI 10.1016/0888-7543(95)80072-T; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; de Gasparo M, 2000, PHARMACOL REV, V52, P415; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DUDLEY DT, 1993, REGUL PEPTIDES, V44, P199, DOI 10.1016/0167-0115(93)90243-2; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ewen ME, 2000, GENE DEV, V14, P2265, DOI 10.1101/gad.842100; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Goto M, 1997, HYPERTENSION, V30, P358, DOI 10.1161/01.HYP.30.3.358; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Horiuchi M, 1999, HYPERTENSION, V33, P613, DOI 10.1161/01.HYP.33.2.613; Huang XC, 1996, J BIOL CHEM, V271, P15635, DOI 10.1074/jbc.271.26.15635; Hutchinson HG, 1999, CARDIOVASC RES, V41, P689, DOI 10.1016/S0008-6363(98)00267-3; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; Kim S, 2000, PHARMACOL REV, V52, P11; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; LAMBERT C, 1995, CIRC RES, V77, P1001, DOI 10.1161/01.RES.77.5.1001; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Leurs R, 1998, TRENDS BIOCHEM SCI, V23, P418, DOI 10.1016/S0968-0004(98)01287-0; Maric C, 1998, KIDNEY INT, V53, P92, DOI 10.1046/j.1523-1755.1998.00749.x; Masaki H, 1998, J CLIN INVEST, V101, P527, DOI 10.1172/JCI1885; Matsubara H, 1998, CIRC RES, V83, P1182, DOI 10.1161/01.RES.83.12.1182; Meffert S, 1996, MOL CELL ENDOCRINOL, V122, P59, DOI 10.1016/0303-7207(96)03873-7; MELOCHE S, 1986, MOL PHARMACOL, V30, P537; MELOCHE S, 1995, J CELL PHYSIOL, V163, P577, DOI 10.1002/jcp.1041630319; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; Miura SI, 2000, EMBO J, V19, P4026, DOI 10.1093/emboj/19.15.4026; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; NAKAJIMA M, 1995, P NATL ACAD SCI USA, V92, P10663, DOI 10.1073/pnas.92.23.10663; Nouet S, 2000, TRENDS ENDOCRIN MET, V11, P1, DOI 10.1016/S1043-2760(99)00205-2; Ohkubo N, 1997, CIRCULATION, V96, P3954; Reed SI, 1997, CANCER SURV, V29, P7; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; VISWANATHAN M, 1992, PEPTIDES, V13, P783, DOI 10.1016/0196-9781(92)90187-8; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yamada T, 1996, P NATL ACAD SCI USA, V93, P156, DOI 10.1073/pnas.93.1.156; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	53	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2003	22	17					2633	2642		10.1038/sj.onc.1206346	http://dx.doi.org/10.1038/sj.onc.1206346			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730677				2022-12-25	WOS:000182569000011
J	Hopfer, H; Maron, R; Butzmann, U; Helmchen, U; Weiner, HL; Kalluri, R				Hopfer, H; Maron, R; Butzmann, U; Helmchen, U; Weiner, HL; Kalluri, R			The importance of cell-mediated immunity in the course and severity of autoimmune anti-glomerular basement membrane disease in mice	FASEB JOURNAL			English	Article						glomerulonephritis; Goodpasture syndrome; alpha 3(IV) type IV collagen; autoimmunity	IV COLLAGEN; GOODPASTURES-SYNDROME; T-CELLS; GLOMERULONEPHRITIS; SUSCEPTIBILITY; CHAIN; RAT; AUTOANTIBODIES; AUTOANTIGEN; ANTIBODIES	Anti-glomerular basement membrane (GBM) disease is a rapidly progressive glomerulonephritis (GN) resulting from autoimmunity against the Goodpasture antigen alpha3(IV)NC1. In addition to the well-characterized antibody contribution, a T helper 1 (Th1) response has been suspected as the culprit for glomerular injury. We induced anti-GBM disease in DBA/1, C57BL/6, AKR, and NOD mice with recombinant human alpha3(IV) NC1 to investigate the involvement of humoral and cellular autoimmunity. DBA/1 mice had crescentic GN 11 wk postimmunization with alpha3(IV)NC1. C57BL/6 and AKR mice developed a chronic disease course resulting in comparable kidney injury to DBA/1 mice within 6 months. NOD revealed only minor glomerular changes. The rapid course and the severity of the disease in DBA/1 mice can be explained by our immunological findings in their sera and splenocytes: 1) high antibody titers specific for the putative clinically relevant epitope of alpha3(IV)NC1 with Th1-type isotypes, and 2) a strong proliferative response and high amounts of the inflammatory cytokine IFN-gamma, secreted by splenocytes stimulated in vitro with alpha3(IV)NC1, with only low amounts of the anti-inflammatory cytokine IL-10. Our in vivo and in vitro results provide direct evidence that the balance between Th1 and Th2 responses associates with the outcome of anti-GBM disease in mice.	Beth Israel Deaconess Med Ctr, Dept Med, Program Matrix Biol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Univ Hamburg, Dept Pathol, D-20246 Hamburg, Germany	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Hamburg	Kalluri, R (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Program Matrix Biol, 330 Brookline Ave,Dana 514, Boston, MA 02215 USA.	rkalluri@bidmc.harvard.edu	Weiner, Irving D/G-6333-2016; Hopfer, Helmut/T-5954-2019; Kalluri, Raghu/E-2677-2015	Weiner, Irving D/0000-0002-0046-0600; Hopfer, Helmut/0000-0003-1755-2170; Kalluri, Raghu/0000-0002-2190-547X	NIDDK NIH HHS [DK-51711, DK-55001] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051711] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Abbate M, 1998, KIDNEY INT, V54, P1550, DOI 10.1046/j.1523-1755.1998.00153.x; Abrass Christine K., 1997, P291; Batista FD, 1998, IMMUNITY, V8, P751, DOI 10.1016/S1074-7613(00)80580-4; Bolton WK, 1996, KIDNEY INT, V50, P1753, DOI 10.1038/ki.1996.495; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; David M, 2001, J BIOL CHEM, V276, P6370, DOI 10.1074/jbc.M008956200; Fisher M, 1997, KIDNEY INT, V51, P222, DOI 10.1038/ki.1997.27; Hellmark T, 1999, KIDNEY INT, V55, P936, DOI 10.1046/j.1523-1755.1999.055003936.x; Holdsworth SR, 1999, KIDNEY INT, V55, P1198, DOI 10.1046/j.1523-1755.1999.00369.x; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; Kalluri R, 1996, J BIOL CHEM, V271, P9062, DOI 10.1074/jbc.271.15.9062; Kalluri R, 1997, J CLIN INVEST, V100, P2263, DOI 10.1172/JCI119764; Kalluri R, 2000, J BIOL CHEM, V275, P20027, DOI 10.1074/jbc.M904549199; KOHLFELDT E, 1997, FEBS LETT, V414, P557; Lanzavecchia A, 2000, SCIENCE, V290, P92, DOI 10.1126/science.290.5489.92; LERNER RA, 1967, J EXP MED, V126, P989, DOI 10.1084/jem.126.6.989; Luross JA, 2001, IMMUNOLOGY, V103, P407, DOI 10.1046/j.1365-2567.2001.01267.x; Martin RM, 1998, J IMMUNOL METHODS, V212, P187, DOI 10.1016/S0022-1759(98)00015-5; McDevitt HO, 1998, CURR OPIN IMMUNOL, V10, P677, DOI 10.1016/S0952-7915(98)80088-5; Merkel F, 1996, KIDNEY INT, V49, P1127, DOI 10.1038/ki.1996.163; Meyers Catherine M., 1997, P959; Nakamura A, 2000, J EXP MED, V191, P899, DOI 10.1084/jem.191.5.899; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; NISHIKAWA K, 1993, J EXP MED, V177, P667, DOI 10.1084/jem.177.3.667; NISHIKAWA K, 1994, EUR J IMMUNOL, V24, P249; PETTERSSON E, 1984, CLIN IMMUNOL IMMUNOP, V31, P171, DOI 10.1016/0090-1229(84)90237-X; Randolph DA, 1999, SCIENCE, V286, P2159, DOI 10.1126/science.286.5447.2159; Reynolds J, 1998, NEPHROL DIAL TRANSPL, V13, P44, DOI 10.1093/ndt/13.1.44; Reynolds J, 2000, J CLIN INVEST, V105, P643, DOI 10.1172/JCI6710; Reynolds J, 2001, J AM SOC NEPHROL, V12, P61, DOI 10.1681/ASN.V12161; REYNOLDS J, 2000, J AM SOC NEPHROL, V11, P481; Sado Y, 1998, KIDNEY INT, V54, P311; SADO Y, 1986, J CLIN LAB IMMUNOL, V19, P193; Schweitzer AN, 1997, J IMMUNOL, V158, P2713; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; WEBER M, 1988, NEPHRON, V49, P54, DOI 10.1159/000184986; WIESLANDER J, 1985, J BIOL CHEM, V260, P8564; Wu J, 2001, J IMMUNOL, V167, P2388, DOI 10.4049/jimmunol.167.4.2388	39	58	59	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					860	868		10.1096/fj.02-0746com	http://dx.doi.org/10.1096/fj.02-0746com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12724345				2022-12-25	WOS:000183165000012
J	Mackay, A; Jones, C; Dexter, T; Silva, RLA; Bulmer, K; Jones, A; Simpson, P; Harris, RA; Jat, PS; Neville, AM; Reis, LFL; Lakhani, SR; O'Hare, MJ				Mackay, A; Jones, C; Dexter, T; Silva, RLA; Bulmer, K; Jones, A; Simpson, P; Harris, RA; Jat, PS; Neville, AM; Reis, LFL; Lakhani, SR; O'Hare, MJ			cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells	ONCOGENE			English	Article						ERBB2 (HER2/neu); breast cancer; cDNA microarray; expression profiling; tissue array	METASTATIC BREAST-CANCER; GALACTOSIDE-BINDING-PROTEIN; MONOCLONAL-ANTIBODY; PROGNOSTIC-SIGNIFICANCE; MEMBRANE-PROTEIN; GROWTH-FACTOR; CARCINOMA CELLS; P-CADHERIN; PHASE-II; EXPRESSION	To investigate changes in gene expression associated with ERBB2, expression profiting of immortalized human mammary luminal epithelial cells and variants expressing a moderate and high level of ERBB2 has been carried out using cDNA microarrays corresponding to approximately 6000 unique genes/ESTs. A total of 61 significantly up- or downregulated (>2.0-fold) genes were identified and further validated by RT-PCR analysis as well as microarray comparisons with a spontaneously ERBB2-overexpressing breast cancer cell line and ERBB2-positive primary breast tumors. The expression and clinical relevance of proteins predicted to be associated with ERBB2 overexpression in breast cancers were analysed together with their clinical relevance by antibody screening using a tissue array. Differentially regulated genes include those involved in cell-matrix interactions including proline 4-hydroxylase (P4HA2), galectin 1 (LGALS1) and galectin 3 (LGALS3), fibronectin 1 (FN1) and p-cadherin (CDH3), and cell proliferation (CRIP1, IGFBP3) and transformation (S100P, S100A4). A number of genes associated with MYC signalling were also differentially expressed, including NDRG1, USF2 and the epithelial membrane proteins 1 and 3 (EMP1, EMP3). These data represent profiles of the transcriptional changes associated with ERBB2-related pathways in the breast, and identify novel and potentially useful targets for prognosis and therapy.	UCL, LICR UCL Breast Canc Lab, London W1W 7EJ, England; Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Ctr, London SW3 6JB, England; Ludwig Inst Canc Res, Sao Paulo, Brazil; UCL, Ludwig Inst Canc Res, London, England; Royal Marsden Hosp, London SW3 6JJ, England	University of London; University College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Ludwig Institute for Cancer Research; Ludwig Institute for Cancer Research; University of London; University College London; Royal Marsden NHS Foundation Trust	Mackay, A (corresponding author), UCL, LICR UCL Breast Canc Lab, Charles Bell House,Riding House St, London W1W 7EJ, England.	alan.mackay@ucl.ac.uk	Simpson, Peter/F-1225-2010; Lakhani, Sunil R/I-1970-2018; Jones, Chris/ABE-6059-2021; Reis, Luiz F. L./C-4556-2013	Simpson, Peter/0000-0002-4816-8289; Lakhani, Sunil R/0000-0003-4067-2760; Jones, Chris/0000-0001-8118-2296; Reis, Luiz/0000-0002-4040-2456				Andre S, 1999, J CANCER RES CLIN, V125, P461, DOI 10.1007/s004320050303; BALDINI A, 1993, GENOMICS, V15, P216, DOI 10.1006/geno.1993.1039; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Ben-Porath I, 1998, GENOMICS, V49, P443, DOI 10.1006/geno.1998.5238; Ben-Porath I, 1999, MOL CELL BIOL, V19, P3529; Bieche I, 1996, CANCER RES, V56, P3886; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Chen Y, 1997, GENOMICS, V41, P40, DOI 10.1006/geno.1997.4524; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Cuny M, 2000, CANCER RES, V60, P1077; Da Silva IDCG, 2000, INT J ONCOL, V16, P231; De Iorio P, 2001, ANTICANCER RES, V21, P1395; Gamallo C, 2001, MODERN PATHOL, V14, P650, DOI 10.1038/modpathol.3880367; GOLDSTONE SD, 1991, BIOCHEM BIOPH RES CO, V178, P746, DOI 10.1016/0006-291X(91)90171-3; Harris RA, 1999, INT J CANCER, V80, P477, DOI 10.1002/(SICI)1097-0215(19990129)80:3<477::AID-IJC23>3.0.CO;2-W; Hippo Y, 2001, CANCER RES, V61, P889; Houston SJ, 1999, BRIT J CANCER, V79, P1220, DOI 10.1038/sj.bjc.6690196; Hughes RC, 2001, BIOCHIMIE, V83, P667; Ignatoski KMW, 2000, BRIT J CANCER, V82, P666, DOI 10.1054/bjoc.1999.0979; Kauraniemi P, 2001, CANCER RES, V61, P8235; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Liehr T, 1999, GENOMICS, V58, P106, DOI 10.1006/geno.1999.5803; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Mazzucchelli L, 2002, AM J PATHOL, V160, P7, DOI 10.1016/S0002-9440(10)64342-8; Menard S, 2001, ONCOLOGY-BASEL, V61, P67, DOI 10.1159/000055404; Miles DW, 1999, INT J CANCER, V84, P354, DOI 10.1002/(SICI)1097-0215(19990820)84:4<354::AID-IJC4>3.0.CO;2-6; Moon BK, 2001, AM J PATHOL, V159, P1055, DOI 10.1016/S0002-9440(10)61780-4; Paz A, 2001, ONCOGENE, V20, P7486, DOI 10.1038/sj.onc.1204950; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Rocha RL, 1996, J NATL CANCER I, V88, P601, DOI 10.1093/jnci/88.9.601; Ross, 1998, Oncologist, V3, P237; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; Rudland PS, 2000, CANCER RES, V60, P1595; Schiemann S, 1997, ANTICANCER RES, V17, P13; Scorilas A, 1999, BRIT J CANCER, V81, P1385, DOI 10.1038/sj.bjc.6693404; Shen L, 1998, BIOCHEM PHARMACOL, V55, P1711, DOI 10.1016/S0006-2952(98)00045-8; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Soler AP, 1999, CANCER-AM CANCER SOC, V86, P1263, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1263::AID-CNCR23>3.3.CO;2-U; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stoll BA, 1997, BRIT J CANCER, V76, P1652, DOI 10.1038/bjc.1997.612; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; Werbajh SE, 1998, FEBS LETT, V440, P277, DOI 10.1016/S0014-5793(98)01473-2; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yu DH, 2000, BIOESSAYS, V22, P673, DOI 10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A	49	132	144	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2680	2688		10.1038/sj.onc.1206349	http://dx.doi.org/10.1038/sj.onc.1206349			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730682				2022-12-25	WOS:000182569000016
J	Sarma, T; Voyno-Yasenetskaya, T; Hope, TJ; Rasenick, MM				Sarma, T; Voyno-Yasenetskaya, T; Hope, TJ; Rasenick, MM			Heterotrimeric G-proteins associate with microtubules during differentiation in PC12 pheochromocytoma cells	FASEB JOURNAL			English	Article						tubulin; G-protein; NGF; cytoskeleton; growth cone	NERVE GROWTH-FACTOR; ADRENAL GLOMERULOSA CELLS; BETA-ADRENERGIC RECEPTORS; COUPLED RECEPTORS; KINASE ACTIVATION; ALPHA-SUBUNITS; MAP KINASE; PHOSPHORYLATES TUBULIN; SIGNAL-TRANSDUCTION; REGULATORY SUBUNIT	Tubulin modifies G-protein signaling and heterotrimeric G-proteins regulate microtubule assembly. Here we report an interplay among G-protein-coupled receptor and receptor tyrosine kinase (such as nerve growth factor-NGF) signaling systems in PC12 pheochromocytoma cells that resulted in a translocation of G(alphas),G(alphai1), and G(alphao) from cell bodies to cellular processes where they appear to localize with tubulin-containing structures. This relocation appeared to depend on the integrity of microtubules, as it was blocked and reversed by nocodazole. Latrunculin, which promotes actin filament depolymerization, had no effect. Both deconvolution microscopy and immunoprecipitation showed a significant increase of G(alpha) association with microtubules that was coincident with the extension of "neurites." There were distinctions among the G(alpha) subtypes, with G(alphas) showing the most profound NGF-induced colocalization with tubulin. Translocation of G(alpha) was blocked by agents that inhibit the MAP kinases required for neuronal differentiation, suggesting that G-protein relocation is triggered by the intracellular signals for differentiation. Consistent with this, Galpha in Neuro-2A cells, which spontaneously differentiate, showed a similar translocation coincident with differentiation. Thus, diverse signals that promote neuronal differentiation and changes in cell morphology may use specific G-proteins to evoke cytoskeletal rearrangement.	Univ Illinois, Coll Med, Dept Physiol, Chicago, IL USA; Univ Illinois, Coll Med, Dept Biophys, Chicago, IL USA; Univ Illinois, Coll Med, Dept Psychiat, Chicago, IL USA; Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL USA; Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Rasenick, MM (corresponding author), Univ Illinois, Dept Physiol & Biophys, 835 S Wolcott M-C 901, Chicago, IL 60612 USA.	RAZ@uic.edu	voyno-yasenetskaya, tatyana/A-3171-2008		NIAID NIH HHS [AI 47770-04] Funding Source: Medline; NIA NIH HHS [AG 15482] Funding Source: Medline; NIGMS NIH HHS [GM 56159] Funding Source: Medline; NIMH NIH HHS [MH 39595, MH 57391] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047770, R56AI047770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM056159, R01GM056159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057391, R01MH039595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015482] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; Cote M, 1997, ENDOCRINOLOGY, V138, P69, DOI 10.1210/en.138.1.69; Cote M, 1997, ENDOCRINOLOGY, V138, P3299, DOI 10.1210/en.138.8.3299; Cowen DS, 1996, J BIOL CHEM, V271, P22297, DOI 10.1074/jbc.271.37.22297; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Crouch MF, 2000, CELL SIGNAL, V12, P153, DOI 10.1016/S0898-6568(99)00080-7; DEGTYAREV MY, 1994, CELL SIGNAL, V6, P25, DOI 10.1016/0898-6568(94)90058-2; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; Dent EW, 1999, J NEUROSCI, V19, P8894, DOI 10.1523/JNEUROSCI.19-20-08894.1999; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Gallo G, 1999, CURR BIOL, V9, pR490, DOI 10.1016/S0960-9822(99)80304-2; Gao ZH, 1999, J BIOL CHEM, V274, P5972, DOI 10.1074/jbc.274.9.5972; GUNNING PW, 1981, J NEUROSCI, V1, P368; GUNNING PW, 1981, J NEUROSCI, V1, P1085; Haga K, 1998, EUR J BIOCHEM, V255, P363, DOI 10.1046/j.1432-1327.1998.2550363.x; HERMOUET S, 1992, FEBS LETT, V312, P223, DOI 10.1016/0014-5793(92)80940-I; IBARRONDO J, 1995, P NATL ACAD SCI USA, V92, P8413, DOI 10.1073/pnas.92.18.8413; Ip NY, 1995, PROG BRAIN RES, V105, P189; Joneson T, 1998, J BIOL CHEM, V273, P7743, DOI 10.1074/jbc.273.13.7743; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LEWIS JM, 1991, CELL REGUL, V2, P1097, DOI 10.1091/mbc.2.12.1097; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; Murthy KS, 1998, J BIOL CHEM, V273, P4695, DOI 10.1074/jbc.273.8.4695; NIKODIJEVIC B, 1994, CELL MOL NEUROBIOL, V14, P27, DOI 10.1007/BF02088587; Nusse O, 1996, J CELL SCI, V109, P221; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; Popova JS, 1997, J BIOL CHEM, V272, P6760, DOI 10.1074/jbc.272.10.6760; RANSNAS LA, 1989, P NATL ACAD SCI USA, V86, P7900, DOI 10.1073/pnas.86.20.7900; RASENICK MM, 1981, NATURE, V294, P560, DOI 10.1038/294560a0; RASENICK MM, 1984, J NEUROCHEM, V43, P1447, DOI 10.1111/j.1471-4159.1984.tb05407.x; ROYCHOWDHURY S, 1993, BIOCHEMISTRY-US, V32, P4955, DOI 10.1021/bi00069a034; Roychowdhury S, 1999, J BIOL CHEM, V274, P13485, DOI 10.1074/jbc.274.19.13485; Roychowdhury S, 1997, J BIOL CHEM, V272, P31576, DOI 10.1074/jbc.272.50.31576; Saunders C, 2000, MOL PHARMACOL, V57, P44; Saunders C, 1997, J BIOL CHEM, V272, P19035, DOI 10.1074/jbc.272.30.19035; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Short SM, 2000, J BIOL CHEM, V275, P12970, DOI 10.1074/jbc.275.17.12970; Slaughter T, 1997, J NEUROSCI, V17, P5807; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; STOWARD PJ, 1991, HISTOCHEMISTRY THEOR, V3, P1; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG N, 1991, BIOCHEMISTRY-US, V30, P10957, DOI 10.1021/bi00109a021; WANG N, 1990, J BIOL CHEM, V265, P1239; WILSON BS, 1994, ENDOCRINOLOGY, V134, P233, DOI 10.1210/en.134.1.233; Witt-Enderby PA, 2000, CELL MOTIL CYTOSKEL, V46, P28, DOI 10.1002/(SICI)1097-0169(200005)46:1<28::AID-CM4>3.0.CO;2-5; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Wu HC, 1998, J CELL BIOCHEM, V70, P553, DOI 10.1002/(SICI)1097-4644(19980915)70:4<553::AID-JCB11>3.0.CO;2-I; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Yan K, 2001, J NEUROCHEM, V76, P182, DOI 10.1046/j.1471-4159.2001.00013.x; Yan K, 1996, J NEUROCHEM, V66, P1489; Yu JZ, 2002, MOL PHARMACOL, V61, P352, DOI 10.1124/mol.61.2.352; Yu WQ, 1996, J CELL BIOL, V133, P151, DOI 10.1083/jcb.133.1.151; Zhong HY, 1999, BIOCHEM J, V344, P889, DOI 10.1042/0264-6021:3440889	59	35	35	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					848	859		10.1096/fj.02-0730com	http://dx.doi.org/10.1096/fj.02-0730com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12724344				2022-12-25	WOS:000183165000011
J	Park, S; Gakh, O; O'Neill, HA; Mangravita, A; Nichol, H; Ferreira, GC; Isaya, G				Park, S; Gakh, O; O'Neill, HA; Mangravita, A; Nichol, H; Ferreira, GC; Isaya, G			Yeast frataxin sequentially chaperones and stores iron by coupling protein assembly with iron oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE FERROCHELATASE; TRIPLET-REPEAT EXPANSION; FRIEDREICHS-ATAXIA; MITOCHONDRIAL IRON; HEME-SYNTHESIS; CLUSTER BIOSYNTHESIS; FERROXIDASE ACTIVITY; HEART-MITOCHONDRIA; BINDING PROPERTIES; CRYSTAL-STRUCTURE	We have investigated the mechanism of frataxin, a conserved mitochondrial protein involved in iron metabolism and neurodegenerative disease. Previous studies revealed that the yeast frataxin homologue (mYfh1p) is activated by Fe(II) in the presence of O-2 and assembles stepwise into a 48-subunit multimer (alpha(48)) that sequesters > 2000 atoms of iron in 2-4-nm cores structurally similar to ferritin iron cores. Here we show that mYfh1p assembly is driven by two sequential iron oxidation reactions: A ferroxidase reaction catalyzed by mYfh1p induces the first assembly step (alpha --> alpha(3)), followed by a slower autoxidation reaction that promotes the assembly of higher order oligomers yielding alpha(48). Depending on the ionic environment, stepwise assembly is associated with accumulation of 50 - 75 Fe(II)/ subunit. Initially, this Fe( II) is loosely bound to mYfh1p and can be readily mobilized by chelators or made available to the mitochondrial enzyme ferrochelatase to synthesize heme. Transfer of mYfh1p-bound Fe( II) to ferrochelatase occurs in the presence of citrate, a physiologic ferrous iron chelator, suggesting that the transfer involves an intermolecular interaction. If mYfh1p-bound Fe( II) is not transferred to a ligand, iron oxidation, and mineralization proceed to completion, Fe(III) becomes progressively less accessible, and a stable iron-protein complex is formed. Iron oxidation-driven stepwise assembly is a novel mechanism by which yeast frataxin can function as an iron chaperone or an iron store.	Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ Saskatchewan, Coll Med, Dept Anat & Cell Biol, Saskatoon, SK S7N 5E5, Canada	Mayo Clinic; Mayo Clinic; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Saskatchewan	Isaya, G (corresponding author), Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, 200 1st St SW,Stabile 7-52, Rochester, MN 55905 USA.		Ferreira, Gloria C/A-4709-2012	Ferreira, Gloria C/0000-0001-9279-2217	NATIONAL INSTITUTE ON AGING [R01AG015709] Funding Source: NIH RePORTER; NIA NIH HHS [AG15709] Funding Source: Medline; PHS HHS [44748] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adamec J, 2000, AM J HUM GENET, V67, P549, DOI 10.1086/303056; Adinolfi S, 2002, HUM MOL GENET, V11, P1865, DOI 10.1093/hmg/11.16.1865; Aslamkhan AG, 2002, J EXP ZOOL, V292, P507, DOI 10.1002/jez.10068; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Banfield JF, 2000, SCIENCE, V289, P751, DOI 10.1126/science.289.5480.751; Branda SS, 1999, J BIOL CHEM, V274, P22763, DOI 10.1074/jbc.274.32.22763; CAMADRO JM, 1988, J BIOL CHEM, V263, P11675; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Cavadini P, 2002, HUM MOL GENET, V11, P217, DOI 10.1093/hmg/11.3.217; Chasteen ND, 1999, J STRUCT BIOL, V126, P182, DOI 10.1006/jsbi.1999.4118; Chen OS, 2002, P NATL ACAD SCI USA, V99, P16922, DOI 10.1073/pnas.232392299; Chen OS, 2002, P NATL ACAD SCI USA, V99, P12321, DOI 10.1073/pnas.192449599; Cho SJ, 2000, P NATL ACAD SCI USA, V97, P8932, DOI 10.1073/pnas.160270897; Crichton R., 2001, INORGANIC BIOCH IRON, P133; DARNELL J, 1990, MOL CELL BIOL, P583; Dhe-Paganon S, 2000, J BIOL CHEM, V275, P30753, DOI 10.1074/jbc.C000407200; Duby G, 2002, HUM MOL GENET, V11, P2635, DOI 10.1093/hmg/11.21.2635; Ferreira GC, 1999, INT J BIOCHEM CELL B, V31, P995, DOI 10.1016/S1357-2725(99)00066-7; FLATMARK T, 1975, J BIOL CHEM, V250, P6433; Foury F, 1999, FEBS LETT, V456, P281, DOI 10.1016/S0014-5793(99)00961-8; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; Gakh O, 2002, BIOCHEMISTRY-US, V41, P6798, DOI 10.1021/bi025566+; GATTERMANN N, 1993, LEUKEMIA, V7, P2069; Gora M, 1996, J BIOL CHEM, V271, P11810, DOI 10.1074/jbc.271.20.11810; Halliwell B, 1999, FREE RADICAL BIO MED, P48; HARDING AE, 1981, BRAIN, V104, P589, DOI 10.1093/brain/104.3.589; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; JUNG DW, 1995, J BIOL CHEM, V270, P672, DOI 10.1074/jbc.270.2.672; Jung DW, 1996, ARCH BIOCHEM BIOPHYS, V332, P19, DOI 10.1006/abbi.1996.0311; Karlberg T, 2002, BIOCHEMISTRY-US, V41, P13499, DOI 10.1021/bi0260785; Karthikeyan G, 2002, HUM MOL GENET, V11, P1351, DOI 10.1093/hmg/11.11.1351; King DW, 1998, ENVIRON SCI TECHNOL, V32, P2997, DOI 10.1021/es980206o; Lesuisse E, 2003, HUM MOL GENET, V12, P879, DOI 10.1093/hmg/ddg096; LEVI S, 1994, J MOL BIOL, V238, P649, DOI 10.1006/jmbi.1994.1325; MILLERO FJ, 1989, J SOLUTION CHEM, V18, P585, DOI 10.1007/BF00664239; MILLERO FJ, 1995, MAR CHEM, V50, P21, DOI 10.1016/0304-4203(95)00024-L; MINOTTI G, 1987, FREE RADICAL BIO MED, V3, P379, DOI 10.1016/0891-5849(87)90016-5; MONSTED O, 1991, ADV INORG CHEM, V37, P2381; Muhlenhoff U, 2002, J BIOL CHEM, V277, P29810, DOI 10.1074/jbc.M204675200; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; Muhlenhoff U, 2000, BBA-BIOENERGETICS, V1459, P370, DOI 10.1016/S0005-2728(00)00174-2; Musco G, 2000, STRUCTURE, V8, P695, DOI 10.1016/S0969-2126(00)00158-1; Nichol H, 2003, BIOCHEMISTRY-US, V42, P5971, DOI 10.1021/bi027021l; Park S, 2002, J BIOL CHEM, V277, P38589, DOI 10.1074/jbc.M206711200; Patel PI, 2001, AM J HUM GENET, V69, P15, DOI 10.1086/321283; PEHKONEN S, 1995, ANALYST, V120, P2655, DOI 10.1039/an9952002655; Petrat F, 2001, BIOCHEM J, V356, P61, DOI 10.1042/0264-6021:3560061; Ponka P, 1997, BLOOD, V89, P1; PORRA RJ, 1963, BIOCHEM J, V87, P186, DOI 10.1042/bj0870186; PORRA RJ, 1963, BIOCHEM J, V87, P181, DOI 10.1042/bj0870181; PORRA RJ, 1967, BIOCHEM J, V104, P321, DOI 10.1042/bj1040321; REESE RN, 1988, J BIOL CHEM, V263, P4186; Richards TD, 1996, J INORG BIOCHEM, V61, P1, DOI 10.1016/0162-0134(95)00029-1; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Rotig A, 2002, TRENDS MOL MED, V8, P221, DOI 10.1016/S1471-4914(02)02330-4; SCHMID R, 1988, INORG CHEM, V27, P1530, DOI 10.1021/ic00282a005; Shi Z, 2003, ANAL BIOCHEM, V318, P18, DOI 10.1016/S0003-2697(03)00175-1; SKOOG DA, 1980, ANAL CHEM, P253; TANGERAS A, 1985, BIOCHIM BIOPHYS ACTA, V843, P199, DOI 10.1016/0304-4165(85)90140-0; WALDO GS, 1993, BIOCHEMISTRY-US, V32, P13262, DOI 10.1021/bi00211a039; Welch KD, 2002, ARCH BIOCHEM BIOPHYS, V397, P360, DOI 10.1006/abbi.2001.2694; Wilson RB, 1997, NAT GENET, V16, P352, DOI 10.1038/ng0897-352; Wu CK, 2001, NAT STRUCT BIOL, V8, P156, DOI 10.1038/84152; Yang XK, 1999, BIOCHEM J, V338, P615, DOI 10.1042/0264-6021:3380615; Yang XK, 1998, BIOCHEMISTRY-US, V37, P9743, DOI 10.1021/bi973128a; Yoon T, 2003, J AM CHEM SOC, V125, P6078, DOI 10.1021/ja027967i; Zhao GH, 2001, BIOCHEMISTRY-US, V40, P10832, DOI 10.1021/bi011052j	67	136	142	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31340	31351		10.1074/jbc.M303158200	http://dx.doi.org/10.1074/jbc.M303158200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12732649	hybrid			2022-12-25	WOS:000184658800116
J	Kamali-Moghaddam, M; Geiduschek, EP				Kamali-Moghaddam, M; Geiduschek, EP			Thermoirreversible and thermoreversible promoter opening by two Escherichia coli RNA polymerase holoenzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN-COMPLEX-FORMATION; BACTERIOPHAGE-T4 LATE PROMOTER; THERMAL-ENERGY REQUIREMENT; LAMBDA-PR PROMOTER; SIGMA FACTOR ASIA; LAC UV5 PROMOTER; TRANSCRIPTION INITIATION; CONFORMATIONAL-CHANGES; RECOGNITION PROTEIN; ANGSTROM RESOLUTION	Promoter opening, in which the complementary DNA strands separate around the transcriptional start site, is generally thermoreversible. An exceptional case of thermoirreversible opening of the T4 late promoter has been analyzed by KMnO4 footprinting and transcription. T4 late promoters, which consist of an 8-base pair (bp) TATA box "-10" element, are recognized by the small, phage-encoded, highly diverged sigma-family initiation subunit gp55. The T4 late promoter only opens above 15-20degreesC, but once it has been formed remains open and transcriptionally active for days at -0.5degreesC. The low temperature-trapped open complex and its isothermally formed state are shown to be structurally distinctive. Two "extended -10" sigma(70) promoters, which, like the T4 late promoter, lack "-35" sites, have been subjected to a comparative analysis: the T4 middle promoter P-rIIB2 opens and closes thermoreversibly under conditions of basal and MotA- and AsiA-activated transcription. The open galP1 promoter complex, whose transcription bubble is very AT-rich, also closes reversibly upon shift to -0.5degreesC, but more slowly than does the rIIB(2) promoter. Formation of a trapped-open low temperature state of the promoter complex appears to be a singular property of gp55-RNA polymerase holoenzyme.	Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Geiduschek, EP (corresponding author), Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA.							Brodolin K, 2001, J MOL BIOL, V307, P25, DOI 10.1006/jmbi.2000.4483; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; Buckle M, 1999, J MOL BIOL, V285, P955, DOI 10.1006/jmbi.1998.2391; BUCKLE M, 1991, METHOD ENZYMOL, V208, P236; BURNS H, 1994, NUCLEIC ACIDS RES, V22, P3840, DOI 10.1093/nar/22.19.3840; Burns HD, 1996, BIOCHEM J, V317, P305, DOI 10.1042/bj3170305; Burns HD, 1999, NUCLEIC ACIDS RES, V27, P2051, DOI 10.1093/nar/27.9.2051; Campbell EA, 2002, MOL CELL, V9, P527, DOI 10.1016/S1097-2765(02)00470-7; CHAN B, 1990, BIOCHEM J, V270, P141, DOI 10.1042/bj2700141; CHRISTENSEN AC, 1982, NATURE, V299, P369, DOI 10.1038/299369a0; Cicero MP, 2001, J BACTERIOL, V183, P2289, DOI 10.1128/JB.183.7.2289-2297.2001; COWING DW, 1989, J MOL BIOL, V210, P521, DOI 10.1016/0022-2836(89)90128-9; Craig ML, 1998, J MOL BIOL, V283, P741, DOI 10.1006/jmbi.1998.2129; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; Eichenberger P, 1997, P NATL ACAD SCI USA, V94, P9022, DOI 10.1073/pnas.94.17.9022; ELLIOTT T, 1984, CELL, V36, P211, DOI 10.1016/0092-8674(84)90091-6; Gaal T, 1997, SCIENCE, V278, P2092, DOI 10.1126/science.278.5346.2092; GEIDUSCHEK EP, 1997, NUCL ACIDS MOL BIOL, V11, P135; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; GRIMES E, 1991, NUCLEIC ACIDS RES, V19, P6113, DOI 10.1093/nar/19.22.6113; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Hernandez VJ, 1996, J BIOL CHEM, V271, P18775, DOI 10.1074/jbc.271.31.18775; Hsu LM, 2002, BBA-GENE STRUCT EXPR, V1577, P191, DOI 10.1016/S0167-4781(02)00452-9; JIN DJ, 1994, J MOL BIOL, V236, P72, DOI 10.1006/jmbi.1994.1119; Kolesky S, 1999, J MOL BIOL, V291, P267, DOI 10.1006/jmbi.1999.2953; Kolesky SE, 2002, J MOL BIOL, V321, P767, DOI 10.1016/S0022-2836(02)00732-5; Leonetti JP, 1998, EMBO J, V17, P1467, DOI 10.1093/emboj/17.5.1467; Li M, 1997, P NATL ACAD SCI USA, V94, P3691, DOI 10.1073/pnas.94.8.3691; Li N, 2002, MOL MICROBIOL, V43, P1079, DOI 10.1046/j.1365-2958.2002.02809.x; Li XY, 1998, J BIOL CHEM, V273, P23558, DOI 10.1074/jbc.273.36.23558; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; Minakhin L, 2003, J MOL BIOL, V326, P679, DOI 10.1016/S0022-2836(02)01442-0; Minton AP, 2001, J BIOL CHEM, V276, P10577, DOI 10.1074/jbc.R100005200; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Naryshkin N, 2000, CELL, V101, P601, DOI 10.1016/S0092-8674(00)80872-7; OUHAMMOUCH M, 1995, P NATL ACAD SCI USA, V92, P1451, DOI 10.1073/pnas.92.5.1451; Pande S, 2002, J BACTERIOL, V184, P3957, DOI 10.1128/JB.184.14.3957-3964.2002; PFEFFER SR, 1977, J BIOL CHEM, V252, P5403; RECORD J, 1996, ESCHERICHIA COLI SAL, P792; Rhodius VA, 1998, CURR OPIN MICROBIOL, V1, P152, DOI 10.1016/S1369-5274(98)80005-2; ROE JH, 1985, J MOL BIOL, V184, P441, DOI 10.1016/0022-2836(85)90293-1; ROE JH, 1984, J MOL BIOL, V176, P495, DOI 10.1016/0022-2836(84)90174-8; Saecker RM, 2002, J MOL BIOL, V319, P649, DOI 10.1016/S0022-2836(02)00293-0; Sanders GM, 1997, EMBO J, V16, P3124, DOI 10.1093/emboj/16.11.3124; Severinov K, 1997, P NATL ACAD SCI USA, V94, P13481, DOI 10.1073/pnas.94.25.13481; SPASSKY A, 1985, BIOCHEMISTRY-US, V24, P2723, DOI 10.1021/bi00332a019; TINKER RL, 1994, CELL, V77, P225, DOI 10.1016/0092-8674(94)90315-8; Tsodikov OV, 1998, J MOL BIOL, V283, P757, DOI 10.1006/jmbi.1998.2130; Urbauer JL, 2002, P NATL ACAD SCI USA, V99, P1831, DOI 10.1073/pnas.032464699; Urbauer JL, 2001, J BIOL CHEM, V276, P41128, DOI 10.1074/jbc.M106400200; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; Wong K, 1998, J MOL BIOL, V284, P195, DOI 10.1006/jmbi.1998.2166; Wong K, 2003, J BIOL CHEM, V278, P7073, DOI 10.1074/jbc.M211447200	55	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29701	29709		10.1074/jbc.M304604200	http://dx.doi.org/10.1074/jbc.M304604200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12754208	hybrid			2022-12-25	WOS:000184507000041
J	Schmidt, C; Li, B; Bloodworth, L; Erlenbach, I; Zeng, FY; Wess, J				Schmidt, C; Li, B; Bloodworth, L; Erlenbach, I; Zeng, FY; Wess, J			Random mutagenesis of the M-3 muscarinic acetylcholine receptor expressed in yeast - Identification of point mutations that "silence" a constitutively active mutant M-3 receptor and greatly impair receptor/G protein coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3RD CYTOPLASMIC LOOP; TRANSMEMBRANE SEGMENTS; LIGAND-BINDING; C5A RECEPTOR; ACTIVATION; RHODOPSIN; MECHANISMS; SITE; LOCALIZATION; CONSTRUCTION	The M-3 muscarinic receptor is a prototypical member of the class I family of G protein-coupled receptors (GPCRs). To facilitate studies on the structural mechanisms governing M-3 receptor activation, we generated an M-3 receptor-expressing yeast strain (Saccharomyces cerevisiae) that requires agonist-dependent M-3 receptor activation for cell growth. By using receptor random mutagenesis followed by a genetic screen in yeast, we initially identified a point mutation at the cytoplasmic end of transmembrane domain (TM) VI (Q490L) that led to robust agonist-independent M-3 receptor signaling in both yeast and mammalian cells. To explore further the molecular mechanisms by which point mutations can render GPCRs constitutively active, we subjected a region of the Q490L mutant M-3 receptor that included TM V-VII to random mutagenesis. We then applied a yeast genetic screen to identify second-site mutations that could suppress the activating effects of the Q490L mutation and restore wild-type receptor-like function to the Q490L mutant receptor. This analysis led to the identification of 12 point mutations that allowed the Q490L mutant receptor to function in a fashion similar to the wild-type receptor. These amino acid substitutions mapped to two distinct regions of the M-3 receptor, the exofacial segments of TM V and VI and the cytoplasmic ends of TM V-VII. Strikingly, in the absence of the activating Q490L mutation, all recovered point mutations severely reduced the efficiency of receptor/G protein coupling, indicating that the targeted residues play important roles in receptor activation and/or receptor/G protein coupling. This strategy should be generally applicable to identify sites in GPCRs that are critically involved in receptor function.	NIDDK, Mol Signalling Sect, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wess, J (corresponding author), NIDDK, Mol Signalling Sect, Bioorgan Chem Lab, NIH, Bldg 8A,Rm B1A-05,Ctr Dr MSC 0810, Bethesda, MD 20892 USA.	jwess@helix.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK032003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdulaev NG, 1998, P NATL ACAD SCI USA, V95, P12854, DOI 10.1073/pnas.95.22.12854; AGATEP R, 1998, TECHNICAL TIPS ONLIN, V1, P51; Altenbach C, 1999, BIOCHEMISTRY-US, V38, P7931, DOI 10.1021/bi9900121; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; Burstein ES, 1996, J BIOL CHEM, V271, P2882, DOI 10.1074/jbc.271.6.2882; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Erlenbach I, 2001, J BIOL CHEM, V276, P29382, DOI 10.1074/jbc.M103203200; Erlenbach I, 2001, J NEUROCHEM, V77, P1327, DOI 10.1046/j.1471-4159.2001.00344.x; FROMANT M, 1995, ANAL BIOCHEM, V224, P347, DOI 10.1006/abio.1995.1050; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Geva A, 2000, J BIOL CHEM, V275, P35393, DOI 10.1074/jbc.M005602200; Higuchi R., 1989, PCR TECHNOLOGY, P61; Horn F, 2001, NUCLEIC ACIDS RES, V29, P346, DOI 10.1093/nar/29.1.346; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Konopka JB, 1996, P NATL ACAD SCI USA, V93, P6764, DOI 10.1073/pnas.93.13.6764; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Lu ZL, 2001, J BIOL CHEM, V276, P34098, DOI 10.1074/jbc.M104217200; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Maggio R, 1996, J BIOL CHEM, V271, P31055, DOI 10.1074/jbc.271.49.31055; Martin NP, 2002, J MOL BIOL, V317, P765, DOI 10.1006/jmbi.2002.5444; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parnot C, 2002, TRENDS ENDOCRIN MET, V13, P336, DOI 10.1016/S1043-2760(02)00628-8; Pausch Mark H., 1998, P196; Pauwels PJ, 1998, MOL NEUROBIOL, V17, P109, DOI 10.1007/BF02802027; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Price LA, 1996, MOL PHARMACOL, V50, P829; PRICE LA, 1995, MOL CELL BIOL, V15, P6188; Scheer A, 1997, J RECEPT SIGNAL TR R, V17, P57, DOI 10.3109/10799899709036594; SCHONEBERG T, 1995, J BIOL CHEM, V270, P18000; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Shi L, 2002, ANNU REV PHARMACOL, V42, P437, DOI 10.1146/annurev.pharmtox.42.091101.144224; Sommers CM, 1997, J MOL BIOL, V266, P559, DOI 10.1006/jmbi.1996.0816; SOMMERS CM, 1999, REC BIOCH M, P141; STEFAN CJ, 1994, MOL CELL BIOL, V14, P3339, DOI 10.1128/MCB.14.5.3339; WATSON S, 1994, G PROTEIN LINKED REC, P1; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Yang K, 1996, BIOCHEMISTRY-US, V35, P14040, DOI 10.1021/bi962113u; Yu HB, 1999, BIOCHEMISTRY-US, V38, P12028, DOI 10.1021/bi990948+; Zeng FY, 1999, J NEUROCHEM, V72, P2404, DOI 10.1046/j.1471-4159.1999.0722404.x	55	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30248	30260		10.1074/jbc.M304991200	http://dx.doi.org/10.1074/jbc.M304991200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12750375	hybrid			2022-12-25	WOS:000184507000105
J	Melen, K; Fagerlund, R; Franke, J; Kohler, M; Kinnunen, L; Julkunen, I				Melen, K; Fagerlund, R; Franke, J; Kohler, M; Kinnunen, L; Julkunen, I			Importin alpha nuclear localization signal binding sites for STAT1, STAT2, and influenza a virus nucleoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KARYOPHERIN-ALPHA; PROTEIN IMPORT; T-ANTIGEN; CRYSTALLOGRAPHIC ANALYSIS; TRANSCRIPTION FACTOR; HUMAN HOMOLOG; IFN-GAMMA; TRANSPORT; RECOGNITION; EXPRESSION	Proteins actively transported into the nucleus via the classical nuclear import pathway contain nuclear localization signals (NLSs), which are recognized by the family of importin alpha molecules. Importin alpha contains 10 armadillo (arm) repeats, of which the N-terminal arm repeats 2-4 have been considered as the "major" NLS binding site. Interferon-activated, dimerized signal transducers and activators of transcription (STAT1 and STAT2) directly bind to importin alpha5 via a dimeric non-classical NLS. Here we show by site-directed mutagenesis that the very C-terminal arm repeats 8 and 9 of importin alpha5 form a unique binding site for STAT1 homodimers and STAT1-STAT2 heterodimers. Influenza A virus nucleoprotein also contains a nonclassical NLS that is recognized by the C-terminal NLS binding site of importin alpha5, comprising arm repeats 7-9. Binding of influenza A virus nucleoprotein to importin alpha3 also occurs via the C-terminal arm repeats. Simian virus 40 large T antigen instead binds to the major N-terminal arm repeats of importin alpha3, indicating that one importin alpha molecule is able to use either its N- or C-terminal arm repeats for binding various NLS containing proteins.	Natl Publ Hlth Inst, Dept Microbiol, Lab Infect Dis Immunol, FIN-00300 Helsinki, Finland; Max Delbruck Ctr, HELIOS Clin, Franz Volhard Clin, Med Fac Charite, D-13122 Berlin, Germany; Natl Publ Hlth Inst, Diabet & Genet Epidemiol Unit, Dept Epidemiol & Hlth Promot, FIN-00300 Helsinki, Finland	Finland National Institute for Health & Welfare; Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Finland National Institute for Health & Welfare	Melen, K (corresponding author), Natl Publ Hlth Inst, Dept Microbiol, Lab Infect Dis Immunol, Mannerheimintie 166, FIN-00300 Helsinki, Finland.		Kinnunen, Leena/B-7059-2012	Kinnunen, Leena/0000-0001-8739-4812				Bild AH, 2002, EMBO J, V21, P3255, DOI 10.1093/emboj/cdf351; Cantalupo P, 1999, METHOD ENZYMOL, V306, P297; CANTELL K, 1986, METHOD ENZYMOL, V119, P54; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; Fagerlund R, 2002, J BIOL CHEM, V277, P30072, DOI 10.1074/jbc.M202943200; Fischer N, 1997, J BIOL CHEM, V272, P3999, DOI 10.1074/jbc.272.7.3999; Fontes MRM, 2000, J MOL BIOL, V297, P1183, DOI 10.1006/jmbi.2000.3642; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; Goodwin DJ, 2001, J BIOL CHEM, V276, P19905, DOI 10.1074/jbc.M009513200; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Harreman MT, 2003, J BIOL CHEM, V278, P5854, DOI 10.1074/jbc.M210951200; Herold A, 1998, J CELL BIOL, V143, P309, DOI 10.1083/jcb.143.2.309; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Kohler M, 1997, FEBS LETT, V417, P104, DOI 10.1016/S0014-5793(97)01265-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; McBride KM, 2002, EMBO J, V21, P1754, DOI 10.1093/emboj/21.7.1754; Melen K, 2001, J BIOL CHEM, V276, P16447, DOI 10.1074/jbc.M008821200; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Milocco LH, 1999, MOL CELL BIOL, V19, P2913; Miyamoto Y, 1997, J BIOL CHEM, V272, P26375, DOI 10.1074/jbc.272.42.26375; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P7059, DOI 10.1073/pnas.93.14.7059; Nachury MV, 1998, P NATL ACAD SCI USA, V95, P582, DOI 10.1073/pnas.95.2.582; Nadler SG, 1997, J BIOL CHEM, V272, P4310, DOI 10.1074/jbc.272.7.4310; Neumann G, 1997, J VIROL, V71, P9690, DOI 10.1128/JVI.71.12.9690-9700.1997; Olson VA, 2002, J VIROL, V76, P9505, DOI 10.1128/JVI.76.18.9505-9515.2002; ONEILL RE, 1995, VIROLOGY, V206, P116, DOI 10.1016/S0042-6822(95)80026-3; Ribbeck K, 2002, EMBO J, V21, P2664, DOI 10.1093/emboj/21.11.2664; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; RONNI T, 1995, J IMMUNOL, V154, P2764; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Seki T, 1997, BIOCHEM BIOPH RES CO, V234, P48, DOI 10.1006/bbrc.1997.6535; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Strehlow I, 1998, J BIOL CHEM, V273, P28049, DOI 10.1074/jbc.273.43.28049; Subramaniam PS, 2000, J CELL SCI, V113, P2771; Summers M., 1986, TEX AGR EXP STN B, V1555, P1; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; Wang P, 1997, J VIROL, V71, P1850, DOI 10.1128/JVI.71.3.1850-1856.1997; Weber F, 1998, VIROLOGY, V250, P9, DOI 10.1006/viro.1998.9329; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x	52	143	156	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28193	28200		10.1074/jbc.M303571200	http://dx.doi.org/10.1074/jbc.M303571200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12740372	hybrid			2022-12-25	WOS:000184242700108
J	Voloshin, ON; Vanevski, F; Khil, PP; Camerini-Otero, RD				Voloshin, ON; Vanevski, F; Khil, PP; Camerini-Otero, RD			Characterization of the DNA damage-inducible helicase DinG from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; SINGLE-STRANDED-DNA; RNA HELICASE; SACCHAROMYCES-CEREVISIAE; XERODERMA-PIGMENTOSUM; HOMOLOGOUS RECOMBINATION; DEPENDENT ATPASE; COUPLING FACTOR; LEXA REPRESSOR; GENE ENCODES	The dinG promoter was first isolated in a genetic screen scoring for damage-inducible loci in Escherichia coli (Lewis, L. K., Jenkins, M. E., and Mount, D. W. (1992) J. Bacteriol. 174, 3377-3385). Sequence analysis suggests that the dinG gene encodes a putative helicase related to a group of eukaryotic helicases that includes mammalian XPD (Koonin, E. V. (1993) Nucleic Acids Res. 21, 1497), an enzyme involved in transcription-coupled nucleotide excision repair and basal transcription. We have characterized the dinG gene product from E. coli using genetic and biochemical approaches. Deletion of dinG has no severe phenotype, indicating that it is nonessential for cell viability. Both dinG deletion and overexpression of the DinG protein from a multicopy plasmid result in a slight reduction of UV resistance. DinG, purified as a fusion protein from E. coli cells, behaves as a monomer in solution, as judged from gel filtration experiments. DinG is an ATP-hydrolyzing enzyme; single-stranded (ss) DNA stimulates the ATPase activity 15-fold. Kinetic data yield a Hill coefficient of 1, consistent with one ATP-hydrolyzing site per DinG molecule. DinG possesses a DNA helicase activity; it translocates along ssDNA in a 5' --> 3' direction, as revealed in experiments with substrates containing non-natural 5'-5' and 3'-3' linkages. The ATP-dependent DNA helicase activity of DinG requires divalent cations (Mg2+, Ca2+, and Mn2+) but is not observed in the presence of Zn2+. The DinG helicase does not discriminate between ribonucleotide and deoxyribonucleotide triphosphates, and it unwinds duplex DNA with similar efficiency in the presence of ATP or dATP. We discuss the possible involvement of the DinG helicase in DNA replication and repair processes.	NIDDK, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Camerini-Otero, RD (corresponding author), Bldg 5,Rm 205A,5 Mem Dr,MSC 0538, Bethesda, MD 20892 USA.			Khil, Pavel/0000-0002-4903-8777	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK052008] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASAI T, 1993, EMBO J, V12, P3287, DOI 10.1002/j.1460-2075.1993.tb05998.x; BAILLY V, 1991, P NATL ACAD SCI USA, V88, P9712, DOI 10.1073/pnas.88.21.9712; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BONURA T, 1975, J BACTERIOL, V121, P511, DOI 10.1128/JB.121.2.511-517.1975; Cabrera JE, 2001, J BACTERIOL, V183, P6126, DOI 10.1128/JB.183.20.6126-6134.2001; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; Diges CM, 2001, EMBO J, V20, P5503, DOI 10.1093/emboj/20.19.5503; Fernandez de Henestrosa AR, 2000, MOL MICROBIOL, V35, P1560, DOI 10.1046/j.1365-2958.2000.01826.x; GORBALENYA AE, 1991, FEBS LETT, V291, P277, DOI 10.1016/0014-5793(91)81301-N; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Henn A, 2001, P NATL ACAD SCI USA, V98, P5007, DOI 10.1073/pnas.071372498; IGGO R, 1990, NUCLEIC ACIDS RES, V18, P5413, DOI 10.1093/nar/18.18.5413; KALMAN M, 1991, NEW BIOL, V3, P886; Kaplan DL, 2000, J MOL BIOL, V301, P285, DOI 10.1006/jmbi.2000.3965; KOGOMA T, 1983, EMBO J, V2, P463, DOI 10.1002/j.1460-2075.1983.tb01445.x; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; KOGOMA T, 1979, MOL GEN GENET, V176, P1, DOI 10.1007/BF00334288; Koonin EV, 1996, PROTEIN SCI, V5, P178; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P1497, DOI 10.1093/nar/21.6.1497; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; LARK KG, 1979, COLD SPRING HARB SYM, V43, P537, DOI 10.1101/SQB.1979.043.01.059; Lehmann AR, 2001, GENE DEV, V15, P15, DOI 10.1101/gad.859501; LEWIS LK, 1992, J BACTERIOL, V174, P3377, DOI 10.1128/jb.174.10.3377-3385.1992; LEWIS LK, 1992, J BACTERIOL, V174, P5110, DOI 10.1128/JB.174.15.5110-5116.1992; Liou GG, 2002, J BIOL CHEM, V277, P41157, DOI 10.1074/jbc.M206618200; Mechanic LE, 1999, J BIOL CHEM, V274, P12488, DOI 10.1074/jbc.274.18.12488; MORIYA H, 1995, NUCLEIC ACIDS RES, V23, P595, DOI 10.1093/nar/23.4.595; OHMORI H, 1994, JPN J GENET, V69, P1, DOI 10.1266/jjg.69.1; OHMORI H, 1995, J BACTERIOL, V177, P156, DOI 10.1128/jb.177.1.156-165.1995; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; REUVEN NB, 1995, J BACTERIOL, V177, P5393, DOI 10.1128/jb.177.19.5393-5400.1995; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; SELBY CP, 1995, J BIOL CHEM, V270, P4890, DOI 10.1074/jbc.270.9.4890; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; Swagemakers SMA, 1998, J BIOL CHEM, V273, P28292, DOI 10.1074/jbc.273.43.28292; Taylor EM, 1997, P NATL ACAD SCI USA, V94, P8658, DOI 10.1073/pnas.94.16.8658; Theis K, 2000, MUTAT RES-DNA REPAIR, V460, P277, DOI 10.1016/S0921-8777(00)00032-X; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; Van Dyk TK, 2001, J BACTERIOL, V183, P5496, DOI 10.1128/JB.183.19.5496-5505.2001; Voloshin ON, 2000, J MOL BIOL, V303, P709, DOI 10.1006/jmbi.2000.4163; Voloshin ON, 1996, SCIENCE, V272, P868, DOI 10.1126/science.272.5263.868; Voloshin ON, 2001, GENE DEV, V15, P415, DOI 10.1101/gad.862901; Waksman G, 2000, NAT STRUCT BIOL, V7, P20, DOI 10.1038/71215; Yasuda T, 1998, EMBO J, V17, P3207, DOI 10.1093/emboj/17.11.3207; Yasuda T, 1996, J BACTERIOL, V178, P3854, DOI 10.1128/jb.178.13.3854-3859.1996; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597	52	60	63	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28284	28293		10.1074/jbc.M301188200	http://dx.doi.org/10.1074/jbc.M301188200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12748189	hybrid			2022-12-25	WOS:000184242700119
J	Bhattacharyya, A; Pathak, S; Basak, C; Law, S; Kundu, M; Basu, J				Bhattacharyya, A; Pathak, S; Basak, C; Law, S; Kundu, M; Basu, J			Execution of macrophage apoptosis by Mycobacterium avium through apoptosis signal-regulating kinase 1/p38 mitogen-activated protein kinase signaling and caspase 8 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; INITIATOR CASPASE; FAS LIGAND; DEATH; TUBERCULOSIS; PHAGOSOME; MITOCHONDRIA; INHIBITION; INDUCTION; NECROSIS	acrophage apoptosis is an important component of the innate immune defense machinery (against pathogenic mycobacteria) responsible for limiting bacillary viability. However, little is known about the mechanism of how apoptosis is executed in mycobacteria-infected macrophages. Apoptosis signal-regulating kinase 1 (ASK1) was activated in Mycobacterium avium-treated macrophages and in turn activated p38 mitogen-activated protein ( MAP) kinase. M. avium-induced macrophage cell death could be blocked in cells transfected with a catalytically inactive mutant of ASK1 or with dominant negative p38 MAP kinase arguing in favor of a central role of ASK1/p38 MAP kinase signaling in apoptosis of macrophages challenged with M. avium. ASK1/p38 MAP kinase signaling was linked to the activation of caspase 8. At the same time, M. avium triggered caspase 8 activation, and cell death occurred in a Fas-associated death domain (FADD)-dependent manner. The death signal induced upon caspase 8 activation linked to mitochondrial death signaling through the formation of truncated Bid (t-Bid), its translocation to the mitochondria and release of cytochrome c. Caspase 8 inhibitor (z-IETD-FMK) could block the release of cytochrome c as well as the activation of caspases 9 and 3. The final steps of apoptosis probably involved caspases 9 and 3, since inhibitors of both caspases could block cell death. Of foremost interest in the present study was the finding that ASK1/p38 signaling was essential for caspase 8 activation linked to M. avium-induced death signaling. This work provides the first elucidation of a signaling pathway in which ASK1 plays a central role in innate immunity.	Bose Inst, Dept Chem, Kolkata 700009, W Bengal, India	Department of Science & Technology (India); Bose Institute	Kundu, M (corresponding author), Bose Inst, Dept Chem, 93-1 Acharya Prafulla,Chandra Rd, Kolkata 700009, W Bengal, India.	mani18@hotmail.com; joyoti@vsnl.com	Bhattacharyya, Asima/J-7423-2012; PATHAK, SHRESH/I-6938-2012	Bhattacharyya, Asima/0000-0001-7292-6644; Law, Sujata/0000-0002-2115-7440; PATHAK, SHRESH/0000-0001-5275-1816				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bermudez LE, 1999, CLIN EXP IMMUNOL, V116, P94; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; CROWLE AJ, 1991, INFECT IMMUN, V59, P1823, DOI 10.1128/IAI.59.5.1823-1831.1991; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; ELLNER JJ, 1991, J INFECT DIS, V163, P1326, DOI 10.1093/infdis/163.6.1326; Fratazzi C, 1997, J IMMUNOL, V158, P4320; FREHEL C, 1991, INFECT IMMUN, V59, P2207, DOI 10.1128/IAI.59.6.2207-2214.1991; Gilot D, 2002, J BIOL CHEM, V277, P49220, DOI 10.1074/jbc.M207325200; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hasan Z, 1997, MOL MICROBIOL, V24, P545, DOI 10.1046/j.1365-2958.1997.3591731.x; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; HAWKINS CC, 1986, ANN INTERN MED, V105, P184, DOI 10.7326/0003-4819-105-2-184; Hayashi T, 1997, INFECT IMMUN, V65, P5262, DOI 10.1128/IAI.65.12.5262-5271.1997; Higuchi H, 2003, J BIOL CHEM, V278, P454, DOI 10.1074/jbc.M209387200; Huang SS, 1999, J BIOL CHEM, V274, P27754, DOI 10.1074/jbc.274.39.27754; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; INDERLIED CB, 1993, CLIN MICROBIOL REV, V6, P266, DOI 10.1128/CMR.6.3.266-310.1993; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Kuehnel MP, 2001, CELL MICROBIOL, V3, P551, DOI 10.1046/j.1462-5822.2001.00139.x; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li HL, 1999, CURR OPIN CELL BIOL, V11, P261, DOI 10.1016/S0955-0674(99)80035-0; Li LM, 1998, CELL, V93, pU17; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Maiti D, 2001, J BIOL CHEM, V276, P329, DOI 10.1074/jbc.M002650200; Matsuzawa A, 2001, J BIOCHEM-TOKYO, V130, P1; MCDONOUGH KA, 1993, INFECT IMMUN, V61, P2763, DOI 10.1128/IAI.61.7.2763-2773.1993; MOLLOY A, 1994, J EXP MED, V180, P1499, DOI 10.1084/jem.180.4.1499; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Oddo M, 1998, J IMMUNOL, V160, P5448; Pais TF, 2000, J IMMUNOL, V164, P389, DOI 10.4049/jimmunol.164.1.389; RALPH P, 1975, J IMMUNOL, V114, P898; Raoul C, 2002, NEURON, V35, P1067, DOI 10.1016/S0896-6273(02)00905-4; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; SturgillKoszycki S, 1996, EMBO J, V15, P6960, DOI 10.1002/j.1460-2075.1996.tb01088.x; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Via LE, 1997, J BIOL CHEM, V272, P13326, DOI 10.1074/jbc.272.20.13326; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198	58	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26517	26525		10.1074/jbc.M300852200	http://dx.doi.org/10.1074/jbc.M300852200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12724324	hybrid			2022-12-25	WOS:000184155700031
J	Fujita, T; Kobayashi, Y; Wada, O; Tateishi, Y; Kitada, L; Yamamoto, Y; Takashima, H; Murayama, A; Yano, T; Baba, T; Kato, S; Kawabe, Y; Yanagisawa, J				Fujita, T; Kobayashi, Y; Wada, O; Tateishi, Y; Kitada, L; Yamamoto, Y; Takashima, H; Murayama, A; Yano, T; Baba, T; Kato, S; Kawabe, Y; Yanagisawa, J			Full activation of estrogen receptor alpha activation function-1 induces proliferation of breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; LIGAND-BINDING DOMAIN; GROWTH-FACTOR-BETA; NUCLEAR RECEPTOR; TRANSCRIPTIONAL ACTIVATION; HISTONE ACETYLTRANSFERASE; SIGNALING PATHWAYS; N-COR; TRANSACTIVATION DOMAINS; COACTIVATOR COMPLEX	The effects of estrogen and anti-estrogen are mediated through the estrogen receptors (ER) alpha and beta, which function as ligand-induced transcriptional factors. Recently, one of the phthalate esters, n-butylbenzyl phthalate (BBP), has been shown to induce estrogen receptor-mediated responses. By using the truncated types of ER mutants, we revealed that activation function-1 (AF-1) activity was necessary for the BBP-dependent transactivation function of ERalpha. AF-1 is also known to be responsible for the partial agonistic activity of tamoxifen. Whereas tamoxifen exhibits an anti-estrogenic effect on proliferation of the MCF-7 breast cancer cell line, BBP showed an estrogenic effect on MCF-7 to stimulate proliferation. In vivo and in vitro binding assays revealed that whereas 4-hydroxytamoxifen (OHT) induced binding of ERalpha to both an AF-1 coactivator complex (p68/p72 and p300) and corepressor complexes (N-CoR/SMRT), BBP selectively enhanced the binding to the AF-1 coactivators. We also showed that the transcriptional activity of OHT-bound ERalpha was modulated by the ratio between the AF-1 coactivator and corepressor complexes. Expression of a dominant-negative type of N-CoR inhibited the interaction between OHT-bound ERalpha and NCoR/SMRT and enhanced the transcriptional activity of OHT-bound ERalpha. Furthermore, the cell growth of MCF-7 stably expressing the dominant-negative type of N-CoR was enhanced by the addition of OHT. These results indicated that fully activated AF-1 induces the stimulation of breast cancer growth and that the ratio between AF-1 coactivators and corepressors plays a key role to prevent proliferation of tumor by tamoxifen.	Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan; Univ Tokyo, Fac Med, Dept Obstet & Gynecol, Bunkyo Ku, Tokyo 1138655, Japan; Taiho Pharmaceut Co Ltd, Canc Res Lab, Hanno Res Ctr, Hanno, Saitama 3578527, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130034, Japan; Japan Sci & Technol, CREST, Kawaguchi, Saitama 3320012, Japan; Japan Sci & Technol, SORST, Kawaguchi, Saitama 3320012, Japan	University of Tsukuba; University of Tokyo; Taiho Pharmaceutical; University of Tokyo; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Yanagisawa, J (corresponding author), Univ Tsukuba, Inst Appl Biochem, 1-1-1 Tenno Dai, Tsukuba, Ibaraki 3058572, Japan.	junny-tky@umin.ac.jp						Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; Cohen RN, 1998, MOL ENDOCRINOL, V12, P1567, DOI 10.1210/me.12.10.1567; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Endoh H, 1999, MOL CELL BIOL, V19, P5363; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Glass CK, 2000, GENE DEV, V14, P121; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1992, J STEROID BIOCHEM, V41, P217, DOI 10.1016/0960-0760(92)90347-L; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang EY, 2000, GENE DEV, V14, P45; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; JOBLING S, 1995, ENVIRON HEALTH PERSP, V103, P582, DOI 10.2307/3432434; Jordan VC, 2001, J NATL CANCER I, V93, P1449, DOI 10.1093/jnci/93.19.1449; Jordan VC, 1998, SCI AM, V279, P60, DOI 10.1038/scientificamerican1098-60; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LEES JA, 1989, J STEROID BIOCHEM, V34, P33, DOI 10.1016/0022-4731(89)90063-0; Lemon BD, 1999, CURR OPIN GENET DEV, V9, P499, DOI 10.1016/S0959-437X(99)00010-6; Levenson AS, 1999, EUR J CANCER, V35, P1628, DOI 10.1016/S0959-8049(99)00183-5; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Lopez GN, 1999, MOL ENDOCRINOL, V13, P897, DOI 10.1210/me.13.6.897; MCDONNELL DP, 1995, ANN NY ACAD SCI, V761, P121, DOI 10.1111/j.1749-6632.1995.tb31374.x; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; MORROW M, 1993, ARCH SURG-CHICAGO, V128, P1187; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; ONATE SA, 1995, SCIENCE, V270, P1354; Parker MG, 1998, BIOCHEM SOC SYMP, P45; Picard K, 2001, TOXICOL APPL PHARM, V172, P108, DOI 10.1006/taap.2001.9141; Pritchard Kathleen I., 2000, Cancer, V88, P3065, DOI 10.1002/1097-0142(20000615)88:12+<3065::AID-CNCR25>3.0.CO;2-P; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; RIBEIRO RCJ, 1995, ANNU REV MED, V46, P443, DOI 10.1146/annurev.med.46.1.443; Sakamoto T, 2002, MOL CELL ENDOCRINOL, V192, P93, DOI 10.1016/S0303-7207(02)00086-2; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Sonnenschein C, 1998, J STEROID BIOCHEM, V65, P143, DOI 10.1016/S0960-0760(98)00027-2; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; TONETTI DA, 1995, ANTI-CANCER DRUG, V6, P498, DOI 10.1097/00001813-199508000-00002; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; VANLEEUWEN FE, 1994, LANCET, V343, P448, DOI 10.1016/S0140-6736(94)92692-1; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; WOLF DM, 1994, BREAST CANCER RES TR, V31, P129, DOI 10.1007/BF00689683; WOLF DM, 1994, BREAST CANCER RES TR, V31, P117, DOI 10.1007/BF00689682; WOLF DM, 1993, BREAST CANCER RES TR, V27, P27, DOI 10.1007/BF00683191; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Yamamoto Y, 2001, J BIOL CHEM, V276, P42684, DOI 10.1074/jbc.M107844200; Yanagi Y, 1999, J BIOL CHEM, V274, P12971, DOI 10.1074/jbc.274.19.12971; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zacharewski TR, 1998, TOXICOL SCI, V46, P282, DOI 10.1006/toxs.1998.2505; Zamir I, 1996, MOL CELL BIOL, V16, P5458; Zhang X, 1998, MOL ENDOCRINOL, V12, P513, DOI 10.1210/me.12.4.513; Zou AH, 1999, MOL ENDOCRINOL, V13, P418, DOI 10.1210/me.13.3.418	86	72	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26704	26714		10.1074/jbc.M301031200	http://dx.doi.org/10.1074/jbc.M301031200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12738788	hybrid			2022-12-25	WOS:000184155700053
J	St Onge, RP; Besley, BDA; Pelley, JL; Davey, S				St Onge, RP; Besley, BDA; Pelley, JL; Davey, S			A role for the phosphorylation of hRad9 in checkpoint signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; CELL-CYCLE CHECKPOINT; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; PROTEIN-KINASE; BREAST-CANCER; HUMAN RAD17; FACTOR-C; COMPLEXES; ATM	The integrity of the human genome is preserved by signal transduction pathways called checkpoints, which delay progression through the cell cycle when DNA damage is present. Three checkpoint proteins, hRad9, hRad1, and hHus1, form a proliferating cell nuclear antigen-like, heterotrimeric complex that has been proposed to function in the initial detection of DNA structural abnormalities. hRad9 is highly modified by phosphorylation, in a constitutive manner and in response to both DNA damage and cell cycle position. Here we present evidence that Thr(292) of hRad9 is subject to Cdc2-dependent phosphorylation in mitosis. Furthermore, our data are also consistent with four other hRad9 phosphorylation sites (Ser(277), Ser(328), Ser(336), and Thr(355)) being regulated in part by Cdc2. We also identify Ser(387) as a novel site of hRad9 constitutive phosphorylation and show that phosphorylation at Ser387 is a prerequisite for one form of DNA damage-induced hyperphosphorylation of hRad9. Characterization of nonphosphorylatable mutants has revealed that hRad9 phosphorylation plays a critical role in checkpoint signaling. Overexpression of these mutants blocks the interaction between hRad9 and the DNA damage-responsive protein TopBP1 and impairs the cellular response to DNA damage during S phase.	Queens Univ, Canc Res Inst, Div Canc Biol & Genet, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Oncol, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada	Davey, S (corresponding author), Queens Univ, Canc Res Inst, Div Canc Biol & Genet, Kingston, ON K7L 3N6, Canada.							Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; Griffith JD, 2002, J BIOL CHEM, V277, P15233, DOI 10.1074/jbc.C200129200; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; KASTAN MB, 1991, CANCER RES, V51, P6304; Kim JY, 2002, ASIAN AUSTRAL J ANIM, V15, P570, DOI 10.5713/ajas.2002.570; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Makiniemi M, 2001, J BIOL CHEM, V276, P30399, DOI 10.1074/jbc.M102245200; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Marchetti MA, 2002, P NATL ACAD SCI USA, V99, P7472, DOI 10.1073/pnas.112702399; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Post S, 2001, P NATL ACAD SCI USA, V98, P13102, DOI 10.1073/pnas.231364598; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Roos-Mattjus P, 2002, J BIOL CHEM, V277, P43809, DOI 10.1074/jbc.M207272200; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; St Onge RP, 2001, J BIOL CHEM, V276, P41898, DOI 10.1074/jbc.M105152200; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Wang H, 2002, GENETICS, V160, P1295; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	42	74	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26620	26628		10.1074/jbc.M303134200	http://dx.doi.org/10.1074/jbc.M303134200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12734188	hybrid			2022-12-25	WOS:000184155700044
J	Wu, M; Xu, LG; Zhai, ZH; Shu, HB				Wu, M; Xu, LG; Zhai, ZH; Shu, HB			SINK is a p65-interacting negative regulator of NF-kappa B-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR FAMILY; TNF RECEPTOR; SIGNALING COMPLEX; MEMBER TALL-1; CELL-DEATH; IKK-GAMMA; ACTIVATION; PROTEIN; KINASE; IDENTIFICATION	The transcription factor NF-kappaB plays important roles in inflammation and cell survival. In this study, we identified SINK, an NF-kappaB-inducible protein. Overexpression of SINK inhibited NF-kappaB-dependent transcription induced by tumor necrosis factor (TNF) stimulation or its downstream signaling proteins but did not inhibit NF-kappaB translocation to the nucleus and binding to DNA. Co-immunoprecipitation and in vitro kinase assays indicated that SINK specifically interacted with the NF-kappaB transactivator p65 and inhibited p65 phosphorylation by the catalytic subunit of protein kinase A, which has previously been shown to regulate NF-kappaB activation. Consistent with its role in inhibition of NF-kappaB-dependent transcription, SINK also sensitized cells to apoptosis induced by TNF and TRAIL (TNF-related apoptosis-inducing ligand). Taken together, these data suggest that SINK is critically involved in a novel negative feedback control pathway of NF-kappaB-induced gene expression.	Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Dept Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Ctr Canc, Denver, CO 80206 USA; Peking Univ, Coll Life Sci, Dept Cell Biol & Genet, Beijing 100871, Peoples R China	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Peking University	Shu, HB (corresponding author), Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Dept Immunol, 1400 Jackson St,K516C, Denver, CO 80206 USA.	shuh@njc.org	Wu, Min/AAE-5066-2021	Wu, Min/0000-0003-1372-4764; Xu, Liangguo/0000-0003-1991-2889	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049992] Funding Source: NIH RePORTER; NIAID NIH HHS [AI49992] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Chen DY, 2002, J BIOL CHEM, V277, P15985, DOI 10.1074/jbc.M108675200; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gross JA, 2000, NATURE, V404, P995, DOI 10.1038/35010115; Grosshans J, 2000, CELL, V101, P523, DOI 10.1016/S0092-8674(00)80862-4; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hong X, 2001, FEBS LETT, V499, P133, DOI 10.1016/S0014-5793(01)02535-2; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Marsters SA, 2000, CURR BIOL, V10, P785, DOI 10.1016/S0960-9822(00)00566-2; Mata J, 2000, CELL, V101, P511, DOI 10.1016/S0092-8674(00)80861-2; Mayumi-Matsuda K, 1999, BIOCHEM BIOPH RES CO, V258, P260, DOI 10.1006/bbrc.1999.0576; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Moore PA, 1999, SCIENCE, V285, P260, DOI 10.1126/science.285.5425.260; Mukhopadhyay A, 1999, J BIOL CHEM, V274, P15978, DOI 10.1074/jbc.274.23.15978; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Rolink AG, 2002, CURR OPIN IMMUNOL, V14, P266, DOI 10.1016/S0952-7915(02)00332-1; Rorth P, 2000, MOL CELL, V6, P23; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Seher TC, 2000, CURR BIOL, V10, P623, DOI 10.1016/S0960-9822(00)00502-9; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Shu HB, 2000, P NATL ACAD SCI USA, V97, P9156, DOI 10.1073/pnas.160213497; Shu HB, 1999, J LEUKOCYTE BIOL, V65, P680, DOI 10.1002/jlb.65.5.680; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Thompson JS, 2000, J EXP MED, V192, P129, DOI 10.1084/jem.192.1.129; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Xia XZ, 2000, J EXP MED, V192, P137, DOI 10.1084/jem.192.1.137; Xu LG, 2002, J LEUKOCYTE BIOL, V72, P410; Yan MH, 2000, NAT IMMUNOL, V1, P37, DOI 10.1038/76889; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	48	96	104	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27072	27079		10.1074/jbc.M209814200	http://dx.doi.org/10.1074/jbc.M209814200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12736262	hybrid			2022-12-25	WOS:000184155700100
J	Jin, JP; Brotto, MA; Hossain, MM; Huang, QQ; Brotto, LS; Nosek, TM; Morton, DH; Crawford, TO				Jin, JP; Brotto, MA; Hossain, MM; Huang, QQ; Brotto, LS; Nosek, TM; Morton, DH; Crawford, TO			Truncation by Glu(180) nonsense mutation results in complete loss of slow skeletal muscle troponin T in a lethal nemaline myopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; MYOSIN HEAVY-CHAIN; THIN FILAMENT; CONFORMATIONAL MODULATION; STRUCTURAL ORGANIZATION; STRIATED-MUSCLE; GENE; CONTRACTION; EXPRESSION; ISOFORMS	A lethal form of nemaline myopathy, named "Amish Nemaline Myopathy" (ANM), is linked to a nonsense mutation at codon Glu(180) in the slow skeletal muscle troponin T (TnT) gene. We found that neither the intact nor the truncated slow TnT protein was present in the muscle of patients with ANM. The complete loss of slow TnT is consistent with the observed recessive pattern of inheritance of the disease and indicates a critical role of the COOH-terminal T2 domain in the integration of TnT into myofibrils. Expression of slow and fast isoforms of TnT is fiber-type specific. The lack of slow TnT results in selective atrophy of type 1 fibers. Slow TnT confers a higher Ca2+ sensitivity than does fast TnT in single fiber contractility assays. Despite the lack of slow TnT, individuals with ANM have normal muscle power at birth. The postnatal onset and infantile progression of ANM correspond to a down-regulation of cardiac and embryonic splice variants of fast TnT in normal developing human skeletal muscle, suggesting that the fetal TnT isoforms complement slow TnT. These results lay the foundation for understanding the molecular pathophysiology and the potential targeted therapy of ANM.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Clin Special Children, Strasburg, PA 17579 USA; Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21287 USA	Case Western Reserve University; Johns Hopkins University; Johns Hopkins University	Jin, JP (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA.		Crawford, Thomas/E-6307-2012	Jin, JP/0000-0001-9932-1063; Nosek, Thomas/0000-0001-6466-9035	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048816] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 048816] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AUSUBEL FM, 2001, CURRENT PROTOCOLS MO; Baldwin KM, 2001, J APPL PHYSIOL, V90, P345, DOI 10.1152/jappl.2001.90.1.345; Barton PJR, 1999, GENOMICS, V57, P102, DOI 10.1006/geno.1998.5702; BREITBART RE, 1986, J MOL BIOL, V188, P313, DOI 10.1016/0022-2836(86)90157-9; Brotto MAP, 1996, J APPL PHYSIOL, V81, P731, DOI 10.1152/jappl.1996.81.2.731; Brotto MD, 2001, PFLUG ARCH EUR J PHY, V442, P738, DOI 10.1007/s004240100587; CRAWFORD TO, 2003, NEUROMUSCULAR DISORD, P145; Donner K, 2002, NEUROMUSCULAR DISORD, V12, P151, DOI 10.1016/S0960-8966(01)00252-8; Dubowitz V, 1985, MUSCLE BIOPSY PRACTI, P19; Fitts RH, 2001, J EXP BIOL, V204, P3201; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; Huang QQ, 1999, J PHYSIOL-LONDON, V520, P231, DOI 10.1111/j.1469-7793.1999.00231.x; Huang QQ, 1999, GENE, V229, P1, DOI 10.1016/S0378-1119(99)00051-7; Huang QQ, 1999, J MOL EVOL, V49, P780, DOI 10.1007/PL00006600; Jin JP, 2000, AM J PHYSIOL-CELL PH, V279, pC1067, DOI 10.1152/ajpcell.2000.279.4.C1067; Jin JP, 1998, GENE, V214, P121, DOI 10.1016/S0378-1119(98)00214-5; JIN JP, 1992, J MOL BIOL, V227, P1269, DOI 10.1016/0022-2836(92)90540-Z; JIN JP, 1990, HYBRIDOMA, V9, P597, DOI 10.1089/hyb.1990.9.597; Jin JP, 2001, BIOCHEMISTRY-US, V40, P2623, DOI 10.1021/bi002423j; Jin JP, 1996, GENE, V168, P217, DOI 10.1016/0378-1119(95)00803-9; Jin JP, 1996, BIOCHEM BIOPH RES CO, V225, P883, DOI 10.1006/bbrc.1996.1267; Johnston JJ, 2000, AM J HUM GENET, V67, P814, DOI 10.1086/303089; Knollmann BC, 2001, TRENDS CARDIOVAS MED, V11, P206, DOI 10.1016/S1050-1738(01)00115-3; LAING NG, 1995, NAT GENET, V9, P75, DOI 10.1038/ng0195-75; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; Lehrer SS, 1998, J MOL BIOL, V277, P1081, DOI 10.1006/jmbi.1998.1654; Lin JJC, 1984, MONOCLONAL ANTIBODIE, P119; MAQUAT LE, 1995, RNA, V1, P453; MAYHEW TM, 1992, J NEUROCYTOL, V21, P313, DOI 10.1007/BF01191700; Myers CD, 1996, J CELL BIOL, V132, P1061, DOI 10.1083/jcb.132.6.1061; North KN, 1997, J MED GENET, V34, P705, DOI 10.1136/jmg.34.9.705; Nowak KJ, 1999, NAT GENET, V23, P208, DOI 10.1038/13837; Ogut O, 1999, AM J PHYSIOL-CELL PH, V276, pC1162, DOI 10.1152/ajpcell.1999.276.5.C1162; Ogut O, 1998, J BIOL CHEM, V273, P27858, DOI 10.1074/jbc.273.43.27858; Ogut O, 2003, J BIOL CHEM, V278, P3089, DOI 10.1074/jbc.M205853200; Pelin K, 1999, P NATL ACAD SCI USA, V96, P2305, DOI 10.1073/pnas.96.5.2305; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Wang J, 1998, BIOCHEMISTRY-US, V37, P14519, DOI 10.1021/bi9812322; Wang J, 1997, GENE, V193, P105, DOI 10.1016/S0378-1119(97)00100-5; Watkins H, 1996, J CLIN INVEST, V98, P2456, DOI 10.1172/JCI119063	42	63	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26159	26165		10.1074/jbc.M303469200	http://dx.doi.org/10.1074/jbc.M303469200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12732643	hybrid			2022-12-25	WOS:000183920200114
J	Tran, QK; Black, DJ; Persechini, A				Tran, QK; Black, DJ; Persechini, A			Intracellular coupling via limiting calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE CA2+-ATPASE; NITRIC-OXIDE SYNTHASE; CA2+; PHOSPHORYLATION; MECHANISMS; PUMP; CA2+-CALMODULIN; MODULATION; ATPASE	Measurements of cellular Ca2+-calmodulin concentrations have suggested that competition for limiting calmodulin may couple calmodulin-dependent activities. Here we have directly tested this hypothesis. We have found that in endothelial cells the amount of calmodulin bound to nitric-oxide synthase and the catalytic activity of the enzyme both are increased similar to3-fold upon changes in the phosphorylation status of the enzyme. Quantitative immunoblotting indicates that the synthase can bind up to 25% of the total cellular calmodulin. Consistent with this, simultaneous determinations of the free Ca2+ and Ca2+-calmodulin concentrations in these cells performed using indo-1 and a fluorescent calmodulin biosensor (K-d = 2 nM) indicate that increased binding of calmodulin to the synthase is associated with substantial reductions in the Ca2+-calmodulin concentrations produced and an increase in the [Ca2+](50) for formation of the calmodulin-biosensor complex. The physiological significance of these effects is confirmed by a corresponding 40% reduction in calmodulin-dependent plasma membrane Ca2+ pump activity. An identical reduction in pump activity is produced by expression of a high affinity (K-d = 0.3 nM) calmodulin biosensor, and treatment to increase calmodulin binding to the synthase then has no further effect. This suggests that the observed reduction in pump activity is due specifically to reduced calmodulin availability. Increases in synthase activity thus appear to be coupled to decreases in the activities of other calmodulin targets through reductions in the size of a limiting pool of available calmodulin. This exemplifies what is likely to be a ubiquitous mechanism for coupling among diverse calmodulin-dependent activities.	Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Persechini, A (corresponding author), Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Rm 412,Biol Sci Bldg,5007 Rochill Rd, Kansas City, MO 64110 USA.	persechinia@umkc.edu		Tran, Kim/0000-0003-1881-1357	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053863] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 53863] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aramburu J, 2000, CURR TOP CELL REGUL, V36, P237; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Bruce JIE, 2002, J BIOL CHEM, V277, P48172, DOI 10.1074/jbc.M208393200; Caride AJ, 1999, J BIOL CHEM, V274, P35227, DOI 10.1074/jbc.274.49.35227; CARONI P, 1981, J BIOL CHEM, V256, P9371; Dean WL, 1997, J BIOL CHEM, V272, P15113, DOI 10.1074/jbc.272.24.15113; Fleming I, 2003, AM J PHYSIOL-REG I, V284, pR1, DOI 10.1152/ajpregu.00323.2002; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Gu C, 1999, J BIOL CHEM, V274, P8012, DOI 10.1074/jbc.274.12.8012; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; JARRETT HW, 1977, BIOCHEM BIOPH RES CO, V77, P1210, DOI 10.1016/S0006-291X(77)80108-3; Levitan IB, 1999, NEURON, V22, P645, DOI 10.1016/S0896-6273(00)80722-9; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; Persechini A, 2002, TRENDS CARDIOVAS MED, V12, P32, DOI 10.1016/S1050-1738(01)00144-X; Persechini A, 1996, J BIOL CHEM, V271, P62, DOI 10.1074/jbc.271.1.62; Persechini A, 1999, J BIOL CHEM, V274, P6827, DOI 10.1074/jbc.274.11.6827; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; Sedova M, 1999, CELL CALCIUM, V25, P333, DOI 10.1054/ceca.1999.0036; SMALLWOOD JI, 1988, J BIOL CHEM, V263, P2195; Teruel MN, 2000, CURR BIOL, V10, P86, DOI 10.1016/S0960-9822(00)00295-5; VINCENZI FF, 1980, FED PROC, V39, P2427; Wang X, 2002, CELL CALCIUM, V31, P265, DOI 10.1016/S0143-4160(02)00075-1	24	78	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24247	24250		10.1074/jbc.C300165200	http://dx.doi.org/10.1074/jbc.C300165200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12738782	hybrid			2022-12-25	WOS:000183824800002
J	Hribal, ML; Perego, L; Lovari, S; Andreozzi, F; Menghini, R; Perego, C; Finzi, G; Usellini, L; Placidi, C; Capella, C; Guzzi, V; Lauro, D; Bertuzzi, F; Davalli, A; Pozza, G; Pontiroli, A; Federici, M; Lauro, R; Brunetti, A; Folli, F; Sesti, G				Hribal, ML; Perego, L; Lovari, S; Andreozzi, F; Menghini, R; Perego, C; Finzi, G; Usellini, L; Placidi, C; Capella, C; Guzzi, V; Lauro, D; Bertuzzi, F; Davalli, A; Pozza, G; Pontiroli, A; Federici, M; Lauro, R; Brunetti, A; Folli, F; Sesti, G			Chronic hyperglycemia impairs insulin secretion by affecting insulin receptor expression, splicing, and signaling in RIN beta-cell line and human islets of Langerhans	FASEB JOURNAL			English	Article						glucose toxicity; diabetes; pancreatic islets	HUMAN PANCREATIC-ISLETS; P70 S6 KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; GENE-TRANSCRIPTION; PROLONGED EXPOSURE; PROTEIN-SYNTHESIS; CAUSES APOPTOSIS; GLUCOSE; PHOSPHORYLATION; DIFFERENTIATION	0Recent evidence suggests that insulin signaling through the insulin receptor A type (Ex11-), regulates insulin gene transcription. Because chronic hyperglycemia negatively affects insulin receptor function and regulates alternative splicing of the insulin receptor, we inquired whether chronic exposure of pancreatic beta-cells to high glucose results in alterations in insulin signaling due to changes in insulin receptor expression and relative abundance of its spliced isoforms. Our results demonstrate that the insulin receptor is localized in insulin secretory vescicles in human pancreatic beta-cells. Furthermore, we find that alterations in insulin expression and secretion caused by chronic exposure to high glucose are paralleled by decreased insulin receptor expression and increased relative abundance of the Ex11+ isoform in both human islets and RIN beta-cells. PDX-1 and HMGI(Y) transcription factors are down-regulated by high glucose. These changes are associated with defects in insulin signaling involving insulin receptor-associated PI 3-kinase/Akt/PHAS-I pathway in RIN beta-cells. Re-expression in RIN beta-cells chronically exposed to high glucose of the Ex11-, but not the Ex11+, isoform restored insulin mRNA expression. These data suggest that changes in early steps of insulin receptor signaling may play a role in determining beta-cell dysfunction caused by chronic hyperglycemia.	Univ Catanzaro Magna Graecia, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; Univ Roma Tor Vergata, Dept Internal Med, Mol Med Lab, Rome, Italy; HS Raffaele, Dept Med, Unit Endocrinol & Metab Dis, Milan, Italy; Univ Milan, Dept Internal Med, I-20122 Milan, Italy; CNR, Ctr Studio Farmacol Cellulare & Mol, I-20133 Milan, Italy; Univ Insubria, Dept Surg Pathol, Varese, Italy; HS Raffaele, Dept Surg, Milan, Italy; HS Raffaele, Dept Med, Milan, Italy; Univ Vita Salute San Raffaele, Milan, Italy	Magna Graecia University of Catanzaro; University of Rome Tor Vergata; University of Milan; Consiglio Nazionale delle Ricerche (CNR); University of Insubria; Vita-Salute San Raffaele University	Folli, F (corresponding author), Univ Catanzaro Magna Graecia, Dipartimento Med Sperimentale & Clin, Via Campanella 115, I-88100 Catanzaro, Italy.	folli.franco@hsr.it; sesti@unicz.it	Lauro, Davide/K-4683-2018; pontiroli, antonio e/AAI-5575-2020; Federici, Massimo/G-9940-2012; Sesti, Giorgio/B-1509-2012; Brunetti, Antonio/K-7756-2016; menghini, rossella/I-3485-2012; Perego, Carla/L-6147-2015; folli, franco/J-2795-2018; Andreozzi, Francesco/J-4073-2018	Federici, Massimo/0000-0003-4989-5194; menghini, rossella/0000-0001-8397-2355; Perego, Carla/0000-0003-3027-1779; folli, franco/0000-0001-9824-5222; Lovari, Sarah/0000-0003-3065-4227; Andreozzi, Francesco/0000-0001-9375-1513; Lauro, Davide/0000-0002-8597-4415; Sesti, Giorgio/0000-0002-1618-7688; Brunetti, Antonio/0000-0003-1533-8779	Telethon [GGP04245, E.0739, E.1309] Funding Source: Medline	Telethon(Fondazione Telethon)		Boden G, 1996, AM J PHYSIOL-ENDOC M, V270, pE251, DOI 10.1152/ajpendo.1996.270.2.E251; Bogdanovic E, 2001, DIABETES, V50, pA267; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BRUNETTI A, 1989, J CLIN INVEST, V83, P192, DOI 10.1172/JCI113858; Brunetti A, 2001, FASEB J, V15, P492, DOI 10.1096/fj.00-0190com; BRUNETTI A, 1993, J CLIN INVEST, V92, P1288, DOI 10.1172/JCI116702; EIZIRIK DL, 1992, J CLIN INVEST, V90, P1263, DOI 10.1172/JCI115989; Federici M, 2001, FASEB J, V15, P22; Federici M, 2001, DIABETES, V50, P1290, DOI 10.2337/diabetes.50.6.1290; FOLLI F, 1992, J BIOL CHEM, V267, P22171; FORSAYETH JR, 1987, J BIOL CHEM, V262, P4134; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; FREIDENBERG GR, 1987, J CLIN INVEST, V79, P240, DOI 10.1172/JCI112789; Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Jackerott M, 2001, DIABETES, V50, pS146, DOI 10.2337/diabetes.50.2007.S146; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; KAN M, 1995, DIABETES, V44, P1081, DOI 10.2337/diabetes.44.9.1081; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kulkarni RN, 1999, J CLIN INVEST, V104, pR69, DOI 10.1172/JCI8339; Kurowski TG, 1999, DIABETES, V48, P658, DOI 10.2337/diabetes.48.3.658; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Ling ZD, 1996, J CLIN INVEST, V98, P2805, DOI 10.1172/JCI119108; Marshak S, 1999, DIABETES, V48, P1230, DOI 10.2337/diabetes.48.6.1230; MCCLAIN DA, 1991, MOL ENDOCRINOL, V5, P734, DOI 10.1210/mend-5-5-734; Moran A, 1997, J CLIN INVEST, V99, P534, DOI 10.1172/JCI119190; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; NORGREN S, 1994, P NATL ACAD SCI USA, V91, P1465, DOI 10.1073/pnas.91.4.1465; NORGREN S, 1994, BIOCHEM BIOPH RES CO, V199, P277, DOI 10.1006/bbrc.1994.1225; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Poitout V, 1996, J CLIN INVEST, V97, P1041, DOI 10.1172/JCI118496; Porzio O, 1999, J CLIN INVEST, V104, P357, DOI 10.1172/JCI5870; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; Senn JJ, 2002, DIABETES, V51, P3391, DOI 10.2337/diabetes.51.12.3391; SESTI G, 1995, DIABETOLOGIA, V38, P445, DOI 10.1007/BF00410282; SESTI G, 1994, ACTA DIABETOL, V31, P59, DOI 10.1007/BF00570536; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1127, DOI 10.1210/me.9.9.1127; Song XM, 1999, AM J PHYSIOL-REG I, V277, pR1690, DOI 10.1152/ajpregu.1999.277.6.R1690; Takano A, 2001, DIABETES, V50, P1891, DOI 10.2337/diabetes.50.8.1891; Terauchi Y, 1995, J BIOL CHEM, V270, P30253, DOI 10.1074/jbc.270.51.30253; THORENS B, 1992, J CLIN INVEST, V90, P77, DOI 10.1172/JCI115858; TOOZE J, 1991, CELL BIOPHYS, V19, P117, DOI 10.1007/BF02989885; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485; YAMAGUCHI Y, 1991, ENDOCRINOLOGY, V129, P2058, DOI 10.1210/endo-129-4-2058	50	51	59	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1340	+		10.1096/fj.02-0685fje	http://dx.doi.org/10.1096/fj.02-0685fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738810				2022-12-25	WOS:000183165000040
J	Tezapsidis, N; Merz, PA; Merz, G; Hong, H				Tezapsidis, N; Merz, PA; Merz, G; Hong, H			Microtubular interactions of presenilin direct kinesis of A beta peptide and its precursors	FASEB JOURNAL			English	Article						Alzheimer's disease; amyloid precursor protein; cytoskeleton; trafficking	RECEPTOR-RELATED PROTEIN; ALZHEIMERS-DISEASE; AMYLOID PRECURSOR; GAMMA-SECRETASE; FULL-LENGTH; ENDOCYTIC PATHWAY; APOLIPOPROTEIN-E; CELLS; SURFACE; BINDING	In our previous study we demonstrated that presenilin 1 (PS1) interacts with cytoplasmic linker protein 170/Restin (CLIP-170/Restin). Herein we show that disruption of the interaction of these proteins within neuronal cell-lines (SY5Y and N2a) can be accomplished by the transfection of vectors that drive the expression of peptide fragments corresponding to their binding domains (BDPs). Interestingly, the disruption of the PS1/CLIP-170 complex is associated with both decreased secretion of endogenous Abeta and decreased uptake of exogenous Abeta from the medium. BDP-expressing cells were also more resistant to surges of Abeta secretion induced by thapsigargin and ionomycin (that elevate intracellular calcium concentrations) and mutations in PS1 linked to familial Alzheimer's disease. Uptake of Abeta by SY5Y cells was amplified when preincubated with ApoE and was mediated through lipoprotein receptor-related protein (LRP). BDP-expressing cells or cells treated with PS1 anti-sense oligonucleotides were less capable of taking up Abeta from the medium compared with controls, indicating that the PS1/CLIP-170 interaction is involved and that PS1 cannot be substituted. In this study, we also mapped the minimum binding domains (mBDPs) of PS1 and CLIP-70 to regions corresponding to the N-terminal end of the large cytoplasmic loop of PS1 and the metal binding motif-containing C-terminal end of CLIP-170. Further, our data obtained from experiments involving in vitro taxol-polymerization of tubulin and confocal immmunofluorescence suggest that PS1, via CLIP-170, may serve as an anchor to the microtubules for specific subcellular fractions containing amyloidogenic fragments. Interestingly, Notch is absent from this population of microtubule binding subcellular fractions and its cleavage was unaffected in cells transfected with the PS1-based BDP. This raises the possibility that the interaction of PS1 with CLIP-170 could provide the conceptual basis for anti-amyloidogenic therapeutic strategies with improved specificity. However, this approach may be hampered by a low efficiency, because it may also block Abeta clearance from the interstitial space of the CNS.	Columbia Univ, Coll Phys & Surg, Dept Pathol, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA; New York State Inst Basic Res Dev Disabil, Dept Virol, Staten Isl, NY 10314 USA; New York State Inst Basic Res Dev Disabil, Lab Digital Microscopy, Staten Isl, NY 10314 USA	Columbia University; Institute for Basic Research in Developmental Disabilities; Institute for Basic Research in Developmental Disabilities	Tezapsidis, N (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol, Taub Inst Res Alzheimers Dis & Aging Brain, P&S 15-408,630 W 168th St, New York, NY 10032 USA.	nt2024@columbia.edu						Armogida M, 2001, NAT CELL BIOL, V3, P1030, DOI 10.1038/ncb1101-1030; BEELER TJ, 1979, J BIOL CHEM, V254, P6229; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; Dujardin DL, 2002, CURR OPIN CELL BIOL, V14, P44, DOI 10.1016/S0955-0674(01)00292-7; Efthimiopoulos S, 1996, P NATL ACAD SCI USA, V93, P8046, DOI 10.1073/pnas.93.15.8046; Figueiredo-Pereira ME, 1999, J NEUROCHEM, V72, P1417, DOI 10.1046/j.1471-4159.1999.721417.x; FRACKOWIAK J, 1995, BRAIN RES, V676, P225, DOI 10.1016/0006-8993(94)01465-T; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hashimoto Y, 2000, J NEUROSCI, V20, P8401, DOI 10.1523/JNEUROSCI.20-22-08401.2000; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; Hoogenraad CC, 2000, J CELL SCI, V113, P2285; Johnsingh AA, 2000, FEBS LETT, V465, P53, DOI 10.1016/S0014-5793(99)01664-6; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kopan R, 2002, NEURON, V33, P321, DOI 10.1016/S0896-6273(02)00585-8; Lah JJ, 2000, MOL CELL NEUROSCI, V16, P111, DOI 10.1006/mcne.2000.0861; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; Pigino G, 2001, J NEUROSCI, V21, P834, DOI 10.1523/JNEUROSCI.21-03-00834.2001; Poirier J, 2000, ANN NY ACAD SCI, V924, P81; QUERFURTH HW, 1994, BIOCHEMISTRY-US, V33, P4550, DOI 10.1021/bi00181a016; Rand MD, 2000, MOL CELL BIOL, V20, P1825, DOI 10.1128/MCB.20.5.1825-1835.2000; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; RICKARD JE, 1991, J BIOL CHEM, V266, P17597; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Saura CA, 2000, J BIOL CHEM, V275, P17136, DOI 10.1074/jbc.M909624199; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; Tarsounas M, 2001, DEV BIOL, V236, P400, DOI 10.1006/dbio.2001.0286; Tezapsidis N, 1998, BIOCHEMISTRY-US, V37, P1274, DOI 10.1021/bi9714159; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; VASSILACOPOULOU D, 1995, J NEUROCHEM, V64, P2140; Xia XF, 2002, P NATL ACAD SCI USA, V99, P8760, DOI 10.1073/pnas.132045399; Yamauchi K, 2002, ANN CLIN LAB SCI, V32, P65; Yamazaki T, 1996, J CELL SCI, V109, P999	41	18	20	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1322	+		10.1096/fj.02-0980fje	http://dx.doi.org/10.1096/fj.02-0980fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738804				2022-12-25	WOS:000183165000032
J	Chinopoulos, C; Starkov, AA; Fiskum, G				Chinopoulos, C; Starkov, AA; Fiskum, G			Cyclosporin A-insensitive permeability transition in brain mitochondria - Inhibition by 2-aminoethoxydiphenyl borate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2&-INDUCED MEMBRANE TRANSITION; CALCIUM SIGNAL TRANSMISSION; CYTOCHROME-C RELEASE; OPERATED CA2+ ENTRY; CELL-DEATH; HEART-MITOCHONDRIA; CNS MITOCHONDRIA; STORE DEPLETION; INNER MEMBRANE; RAT-BRAIN	The mitochondrial permeability transition pore (PTP) may operate as a physiological Ca2+ release mechanism and also contribute to mitochondrialdeenergization and release of proapoptotic proteins after pathological stress, e.g. ischemia/reperfusion. Brain mitochondria exhibit unique PTP characteristics, including relative resistance to inhibition by cyclosporin A. In this study, we report that 2-aminoethoxydiphenyl borate blocks Ca2+-induced Ca2+ release in isolated, non-synaptosomal rat brain mitochondria in the presence of physiological concentrations of ATP and Mg2+. Ca2+ release was not mediated by the mitochondrial Na+/Ca2+ exchanger or by reversal of the uniporter responsible for energy-dependent Ca2+ uptake. Loss of mitochondrial Ca2+ was accompanied by release of cytochrome c and pyridine nucleotides, indicating an increase in permeability of both the inner and outer mitochondrial membranes. Under these conditions, Ca2+-induced opening of the PTP was not blocked by cyclosporin A, antioxidants, or inhibitors of phospholipase A(2) or nitric-oxide synthase but was abolished by pretreatment with bongkrekic acid. These findings indicate that in the presence of adenine nucleotides and Mg2+, Ca2+-induced PTP in non-synaptosomal brain mitochondria exhibits a unique pattern of sensitivity to inhibitors and is particularly responsive to 2-aminoethoxydiphenyl borate.	Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; Cornell Univ, Weill Med Coll, Dept Neurol, New York, NY 10021 USA	University System of Maryland; University of Maryland Baltimore; Cornell University	Fiskum, G (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, 685 W baltimore St,MSTF 5-34, Baltimore, MD 21201 USA.	gfisk001@umaryland.edu	Starkov, Anatoly/B-2688-2012; Chinopoulos, Christos/A-5175-2008	Starkov, Anatoly/0000-0002-1334-4828; Chinopoulos, Christos/0000-0003-0183-4149				Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; ANTONENKO YN, 1991, J MEMBRANE BIOL, V124, P151, DOI 10.1007/BF01870459; Appaix F, 2002, BBA-BIOENERGETICS, V1556, P155, DOI 10.1016/S0005-2728(02)00358-4; Berman SB, 2000, EXP NEUROL, V164, P415, DOI 10.1006/exnr.2000.7438; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; BERS DM, 1994, METHOD CELL BIOL, V40, P3; Bilmen JG, 2002, EUR J BIOCHEM, V269, P3678, DOI 10.1046/j.1432-1033.2002.03060.x; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; Broekemeier KM, 2002, BIOCHEMISTRY-US, V41, P7771, DOI 10.1021/bi020157z; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Brustovetsky N, 2000, J NEUROSCI, V20, P103, DOI 10.1523/JNEUROSCI.20-01-00103.2000; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; Custodio JBA, 1998, TOXICOL APPL PHARM, V152, P10, DOI 10.1006/taap.1998.8510; De Giorgi F, 2000, CELL CALCIUM, V28, P365, DOI 10.1054/ceca.2000.0177; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; Dobryndeva Y, 2001, MOL PHARMACOL, V60, P541; Dykens JA, 2001, METHOD CELL BIOL, V65, P285, DOI 10.1016/S0091-679X(01)65018-0; EKHOLM A, 1993, BRAIN RES, V604, P185, DOI 10.1016/0006-8993(93)90367-V; EVTODIENKO YV, 1994, CELL CALCIUM, V15, P143, DOI 10.1016/0143-4160(94)90053-1; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Gilabert JA, 2000, EMBO J, V19, P6401, DOI 10.1093/emboj/19.23.6401; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gunter TE, 2000, CELL CALCIUM, V28, P285, DOI 10.1054/ceca.2000.0168; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Hansson MJ, 2003, BRAIN RES, V960, P99, DOI 10.1016/S0006-8993(02)03798-8; Harks EGA, 2003, FASEB J, V17, P941, DOI 10.1096/fj.02-0786fje; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HAWORTH RA, 1980, J MEMBRANE BIOL, V54, P231, DOI 10.1007/BF01870239; He LH, 2002, FEBS LETT, V512, P1, DOI 10.1016/S0014-5793(01)03314-2; Horn TFW, 2002, FASEB J, V16, P1611, DOI 10.1096/fj.02-0126com; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; Hoth M, 2000, P NATL ACAD SCI USA, V97, P10607, DOI 10.1073/pnas.180143997; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; Huser J, 1998, BIOPHYS J, V74, P2129, DOI 10.1016/S0006-3495(98)77920-2; ICHAS F, 1994, FEBS LETT, V348, P211, DOI 10.1016/0014-5793(94)00615-6; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; KLINGENBERG M, 1985, METHOD ENZYMAT AN, P251; Kobayashi T, 2003, BRAIN RES, V960, P62, DOI 10.1016/S0006-8993(02)03767-8; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kristian T, 2002, J NEUROCHEM, V83, P1297, DOI 10.1046/j.1471-4159.2002.01238.x; Kushnareva YE, 2000, ARCH BIOCHEM BIOPHYS, V376, P377, DOI 10.1006/abbi.2000.1730; LAPIDUS RG, 1992, FEBS LETT, V313, P314, DOI 10.1016/0014-5793(92)81217-A; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Lemasters JJ, 1997, MOL CELL BIOCHEM, V174, P159, DOI 10.1023/A:1006827601337; Ma HT, 2002, J BIOL CHEM, V277, P6915, DOI 10.1074/jbc.M107755200; Ma HT, 2001, J BIOL CHEM, V276, P18888, DOI 10.1074/jbc.M100944200; Malkevitch NV, 1997, FEBS LETT, V412, P173, DOI 10.1016/S0014-5793(97)00666-2; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Minamikawa T, 1999, EXP CELL RES, V246, P26, DOI 10.1006/excr.1998.4290; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montero M, 2001, MOL BIOL CELL, V12, P63, DOI 10.1091/mbc.12.1.63; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; NOVGORODOV SA, 1992, J BIOL CHEM, V267, P16274; NOVGORODOV SA, 1994, ARCH BIOCHEM BIOPHYS, V311, P219, DOI 10.1006/abbi.1994.1230; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; RILEY WW, 1985, J BIOL CHEM, V260, P2416; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; Schindl R, 2002, J BIOL CHEM, V277, P26950, DOI 10.1074/jbc.M203700200; Simpson PB, 1996, J BIOL CHEM, V271, P33493, DOI 10.1074/jbc.271.52.33493; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Skulachev VP, 1996, FEBS LETT, V397, P7, DOI 10.1016/0014-5793(96)00989-1; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; Starkov AA, 2002, J NEUROCHEM, V83, P220, DOI 10.1046/j.1471-4159.2002.01153.x; Stout AK, 1999, NEUROSCIENCE, V89, P91, DOI 10.1016/S0306-4522(98)00441-2; Szalai G, 2000, J BIOL CHEM, V275, P15305, DOI 10.1074/jbc.275.20.15305; TJIOE S, 1970, BIOCHIM BIOPHYS ACTA, V216, P270, DOI 10.1016/0005-2728(70)90218-5; VALLE VGR, 1986, BIOCHEM BIOPH RES CO, V135, P189, DOI 10.1016/0006-291X(86)90961-7; van Rossum DB, 2000, J BIOL CHEM, V275, P28562, DOI 10.1074/jbc.M003147200; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Wang Y, 2002, CELL CALCIUM, V32, P209, DOI 10.1016/S0143416002001562; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	82	112	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27382	27389		10.1074/jbc.M303808200	http://dx.doi.org/10.1074/jbc.M303808200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12750371	hybrid, Green Accepted			2022-12-25	WOS:000184242700008
J	Delgado, M				Delgado, M			Inhibition of interferon (IFN) gamma-induced Jak-STAT1 activation in microglia by vasoactive intestinal peptide - Inhibitory effect on CD40, IFN-induced protein-10, and inducible nitric-oxide synthase expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; IP-10 MESSENGER-RNA; REGULATORY FACTOR-I; POLYPEPTIDE INHIBIT; RESPONSE ELEMENT; T-CELLS; CHEMOKINE RECEPTORS	Interferon (IFN)-gamma is one of the most important microglia stimulators in vivo participating in inflammation and Th1 activation/differentiation. IFN-gamma-mediated signaling involves the activation of the Jak/STAT1 pathway. The neuropeptides vasoactive intestinal peptide (VIP) and the pituitary adenylate cyclase activating polypeptide (PACAP) are two potent microglia-deactivating factors that inhibit the production of proinflammatory mediators in vitro and in vivo. The present study investigated the molecular mechanisms involved in the VIP/PACAP regulation of several IFN-gamma-induced microglia-derived factors, including IFN-gamma-inducible protein-10 (IP-10), inducible nitric-oxide synthase (iNOS), and CD40. The results indicate that VIP/PACAP inhibit Jak1-2 and STAT1 phosphorylation, and the binding of activated STAT1 to the IFN-gamma activated site motif in the IFN regulatory factor-1 and CD40 promoter and to the IFN-stimulated response element motif of the IP-10 promoter. Through its effect in the IFN-gamma-induced Jak/STAT1 pathway, VIP and PACAP are able to control the gene expression of IP-10, CD40, and iNOS, three microglia-derived mediators that play an essential role in several pathologies, i.e. inflammation and autoimmune disorders. The effects of VIP/PACAP are mediated through the specific receptor VPAC1 and the cAMP/protein kinase A transduction pathway. Because IFN-gamma is a major stimulator of innate and adaptive immune responses in vivo, the down-regulation of IFN-gamma-induced gene expression by VIP and PACAP could represent a significant element in the regulation of the inflammatory response in the central nervous system by endogenous neuropeptides.	CSIC, Inst Parasitol & Biomed Lopez Neyra, Granada 18001, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)	Delgado, M (corresponding author), CSIC, Inst Parasitol & Biomed Lopez Neyra, Calle Ventanilla 11, Granada 18001, Spain.	mdelgado@ipb.csic.es	Delgado, Mario/P-1524-2016	Delgado, Mario/0000-0003-1893-5982				ALLEVA DG, 1994, J IMMUNOL, V153, P1674; Aloisi F, 1999, J IMMUNOL, V162, P1384; Annunziato F, 1999, J LEUKOCYTE BIOL, V65, P691, DOI 10.1002/jlb.65.5.691; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; Becher B, 2000, J NEUROIMMUNOL, V102, P44, DOI 10.1016/S0165-5728(99)00152-6; Becher B, 2001, J EXP MED, V193, P967, DOI 10.1084/jem.193.8.967; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Boorsma DM, 1999, CYTOKINE, V11, P469, DOI 10.1006/cyto.1998.0463; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; Carson MJ, 1998, GLIA, V22, P72, DOI 10.1002/(SICI)1098-1136(199801)22:1<72::AID-GLIA7>3.0.CO;2-A; Chabot S, 1999, J IMMUNOL, V162, P6819; CHAO CC, 1993, J IMMUNOL, V151, P1473; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Delgado M, 1999, J IMMUNOL, V162, P4685; Delgado M, 2003, FASEB J, V17, P944, DOI 10.1096/fj.02-0799fje; Delgado M, 2003, J LEUKOCYTE BIOL, V73, P155, DOI 10.1189/jlb.0702372; Delgado M, 1999, J IMMUNOL, V162, P1200; Delgado M, 2002, BIOCHEM BIOPH RES CO, V293, P771, DOI 10.1016/S0006-291X(02)00283-8; Delgado M, 2002, BIOCHEM BIOPH RES CO, V297, P1181, DOI 10.1016/S0006-291X(02)02305-7; Delgado M, 2002, J MOL MED, V80, P16, DOI 10.1007/s00109-001-0291-5; Delgado M, 2002, GLIA, V39, P148, DOI 10.1002/glia.10098; Delgado M, 2003, TRENDS IMMUNOL, V24, P221, DOI 10.1016/S1471-4906(03)00069-3; Delgado M, 2000, J IMMUNOL, V165, P3051, DOI 10.4049/jimmunol.165.6.3051; DELGADO M, 2003, IN PRESS FASEB J; DICKSON DW, 1991, LAB INVEST, V64, P135; Fife BT, 2001, J IMMUNOL, V166, P7617, DOI 10.4049/jimmunol.166.12.7617; Ganea D, 2002, CRIT REV ORAL BIOL M, V13, P229, DOI 10.1177/154411130201300303; GATTASS CR, 1994, J EXP MED, V179, P1373, DOI 10.1084/jem.179.4.1373; Gerritse K, 1996, P NATL ACAD SCI USA, V93, P2499, DOI 10.1073/pnas.93.6.2499; Gisselbrecht S, 1999, EUR CYTOKINE NETW, V10, P463; Goetzl EJ, 1998, ANN NY ACAD SCI, V840, P540, DOI 10.1111/j.1749-6632.1998.tb09593.x; Gomariz RP, 2001, CURR PHARM DESIGN, V7, P89, DOI 10.2174/1381612013398374; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Gourlet P, 1997, PEPTIDES, V18, P1539, DOI 10.1016/S0196-9781(97)00228-3; Gourlet P, 1997, PEPTIDES, V18, P1555, DOI 10.1016/S0196-9781(97)00230-1; GOURLET P, 1995, EUR J PHARMACOL, V287, P7, DOI 10.1016/0014-2999(95)00467-5; Gozes I, 2001, TRENDS NEUROSCI, V24, P700, DOI 10.1016/S0166-2236(00)01931-7; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Grewal IS, 1996, SCIENCE, V273, P1864, DOI 10.1126/science.273.5283.1864; Grimm MC, 1996, INFLAMM BOWEL DIS, V2, P88, DOI 10.1002/ibd.3780020204; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Hua LWL, 2000, GLIA, V30, P74, DOI 10.1002/(SICI)1098-1136(200003)30:1<74::AID-GLIA8>3.0.CO;2-C; Issazadeh S, 1998, J IMMUNOL, V161, P1104; Ivashkiv LB, 1996, J IMMUNOL, V157, P1415; Jiang XJ, 2002, J NEUROIMMUNOL, V133, P81, DOI 10.1016/S0165-5728(02)00365-X; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; Kanda N, 2002, J INVEST DERMATOL, V119, P1080, DOI 10.1046/j.1523-1747.2002.19510.x; Kawada N, 1997, BIOCHEM BIOPH RES CO, V233, P464, DOI 10.1006/bbrc.1997.6481; Kim WK, 2000, J NEUROSCI, V20, P3622, DOI 10.1523/JNEUROSCI.20-10-03622.2000; Kim WK, 2002, J NEUROIMMUNOL, V126, P16, DOI 10.1016/S0165-5728(02)00059-0; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kuroda E, 2001, J IMMUNOL, V166, P1650, DOI 10.4049/jimmunol.166.3.1650; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; Lee EH, 1998, INFECT IMMUN, V66, P2514, DOI 10.1128/IAI.66.6.2514-2520.1998; Liberatore GT, 1999, NAT MED, V5, P1403; LOOK DC, 1994, J BIOL CHEM, V269, P8952; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; Lucas DM, 1998, J IMMUNOL, V160, P4337; LUSTER AD, 1987, J EXP MED, V166, P1084, DOI 10.1084/jem.166.4.1084; Ma XJ, 1997, J BIOL CHEM, V272, P10389; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Nazar ASMI, 1997, J NEUROIMMUNOL, V77, P116, DOI 10.1016/S0165-5728(97)00070-2; Nguyen VT, 2000, J BIOL CHEM, V275, P23674, DOI 10.1074/jbc.M002482200; Nguyen VT, 1998, EUR J IMMUNOL, V28, P2537, DOI 10.1002/(SICI)1521-4141(199808)28:08<2537::AID-IMMU2537>3.0.CO;2-1; Nguyen VT, 2002, J BIOL CHEM, V277, P13796, DOI 10.1074/jbc.M111906200; OHMORI Y, 1995, J IMMUNOL, V154, P5235; OHMORI Y, 1993, J BIOL CHEM, V268, P6677; Patel DD, 2001, CLIN IMMUNOL, V98, P39, DOI 10.1006/clim.2000.4957; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Pozo D, 2000, IMMUNOL TODAY, V21, P7, DOI 10.1016/S0167-5699(99)01525-X; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Ren LQ, 1998, MOL BRAIN RES, V59, P256, DOI 10.1016/S0169-328X(98)00170-3; Said SI, 1996, J CLIN INVEST, V97, P2163, DOI 10.1172/JCI118655; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schonbeck U, 2001, CELL MOL LIFE SCI, V58, P4, DOI 10.1007/PL00000776; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sengupta TK, 1996, P NATL ACAD SCI USA, V93, P9499, DOI 10.1073/pnas.93.18.9499; Serafini B, 2000, AM J PATHOL, V157, P1991, DOI 10.1016/S0002-9440(10)64838-9; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Sorensen TL, 1999, J CLIN INVEST, V103, P807, DOI 10.1172/JCI5150; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; VANGURI P, 1994, J IMMUNOL, V152, P1411; VANGURI P, 1990, J BIOL CHEM, V265, P15049; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	89	64	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27620	27629		10.1074/jbc.M303199200	http://dx.doi.org/10.1074/jbc.M303199200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12754213	hybrid			2022-12-25	WOS:000184242700037
J	Konrad, RJ; Gold, G; Lee, TN; Workman, R; Broderick, CL; Knierman, MD				Konrad, RJ; Gold, G; Lee, TN; Workman, R; Broderick, CL; Knierman, MD			Glucose stimulates the tyrosine phosphorylation of Crk-associated substrate in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAYS; GROWTH-FACTOR; V-CRK; C-SRC; P130(CAS); ACTIVATION; ADHESION; PAXILLIN; P130CAS; FAK	Several years ago, we demonstrated that glucose induced tyrosine phosphorylation of a 125-kDa protein (p125) in pancreatic beta-cells (Konrad, R. J., Dean, R. M., Young, R. A., Bilings, P. C., and Wolf, B. A. ( 1996) J. Biol. Chem. 271, 24179-24186). Glucose induced p125 tyrosine phosphorylation in beta-TC3 insulinoma cells, beta-HC9 cells, and in freshly isolated rat islets, whereas increased tyrosine phosphorylation was not observed with other fuel secretagogues. Initial efforts to identify p125 were unsuccessful, so a new approach was taken. The protein was purified from betaTC6, F7 cells via an immunodepletion method. After electrophoresis and colloidal Coomassie Blue staining, the area of the gel corresponding to p125 was excised and subjected to tryptic digestion. Afterward, mass spectrometry was performed and the presence of Crk-associated substrate (Cas) was detected. Commercially available antibodies against Cas were obtained and tested directly in beta-cells, confirming glucose-induced tyrosine phosphorylation of Cas. Further experiments demonstrated that in beta-cells the glucose-induced increase in Cas tyrosine phosphorylation occurs immediately and is not accompanied by increased focal adhesion kinase tyrosine phosphorylation. Finally, it is also demonstrated via Western blotting that Cas is present in normal isolated rat islets. Together, these results show that the identity of the previously described p125 beta-cell protein is Cas and that Cas undergoes rapid glucose-induced tyrosine phosphorylation in beta-cells.	Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA	Eli Lilly	Konrad, RJ (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Bldg 88-358C, Indianapolis, IN 46285 USA.			Knierman, Michael/0000-0001-7427-2269				Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Bruce-Staskal PJ, 2001, EXP CELL RES, V264, P296, DOI 10.1006/excr.2000.5137; Calcerrada MC, 1999, BRAIN RES, V835, P275, DOI 10.1016/S0006-8993(99)01612-1; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Casamassima A, 1997, J BIOL CHEM, V272, P9363; Donaldson JC, 2000, EXP CELL RES, V256, P168, DOI 10.1006/excr.2000.4822; Etienne S, 1998, J IMMUNOL, V161, P5755; Ferris HA, 1999, BIOCHEMISTRY-US, V38, P1497, DOI 10.1021/bi981903w; Freitas F, 2002, BONE, V30, P99, DOI 10.1016/S8756-3282(01)00625-1; Garcia-Guzman M, 1999, J BIOL CHEM, V274, P5762, DOI 10.1074/jbc.274.9.5762; Gotoh T, 2000, J BIOL CHEM, V275, P30118, DOI 10.1074/jbc.M003074200; Keogh RJ, 2002, BIOCHEM BIOPH RES CO, V290, P1470, DOI 10.1006/bbrc.2002.6350; Konrad RJ, 1996, J BIOL CHEM, V271, P24179, DOI 10.1074/jbc.271.39.24179; Lakkakorpi PT, 1999, J BIOL CHEM, V274, P4900, DOI 10.1074/jbc.274.8.4900; Leopoldt D, 2001, J CELL PHYSIOL, V188, P106, DOI 10.1002/jcp.1102; Li EG, 2000, J BIOL CHEM, V275, P14729, DOI 10.1074/jbc.275.19.14729; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nakamura I, 1998, J BIOL CHEM, V273, P11144, DOI 10.1074/jbc.273.18.11144; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Okuda M, 1999, J BIOL CHEM, V274, P26803, DOI 10.1074/jbc.274.38.26803; Panetti TS, 2002, FRONT BIOSCI-LANDMRK, V7, pD143, DOI 10.2741/panetti; Pellicena P, 2001, J BIOL CHEM, V276, P28190, DOI 10.1074/jbc.M100055200; Rock MT, 1997, J BIOL CHEM, V272, P33377, DOI 10.1074/jbc.272.52.33377; Rosado JA, 2000, ARCH BIOCHEM BIOPHYS, V377, P85, DOI 10.1006/abbi.2000.1761; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Ruest PJ, 2001, MOL CELL BIOL, V21, P7641, DOI 10.1128/MCB.21.22.7641-7652.2001; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259	32	4	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28116	28122		10.1074/jbc.M212899200	http://dx.doi.org/10.1074/jbc.M212899200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12746446	hybrid			2022-12-25	WOS:000184242700098
J	Liedtke, C; Groger, N; Manns, MP; Trautwein, C				Liedtke, C; Groger, N; Manns, MP; Trautwein, C			The human caspase-8 promoter sustains basal activity through SP1 and ETS-like transcription factors and can be up-regulated by a p53-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING COMPLEX; P53 MUTATIONS; APOPTOSIS; LIVER; CD95; GENE; EXPRESSION; ACTIVATION; DEATH; BINDING	Caspase-8, also known as MACH/FLICE/Mch5, is the most upstream-located cysteine-aspartyl-protease (caspase) in a caspase cascade involved in apoptosis triggered by members of the tumor necrosis factor receptor superfamily or other stimuli such as chemotherapeutic agents. Regulation of caspase-8 expression on a post-translational level has been studied in detail, whereas only little information is available on its control by gene transcription. We identified and cloned the human caspase-8 promoter, determined the transcriptional start site of the caspase-8 gene, and examined the regulatory mechanisms of the promoter with respect to its basal activity as well as to its inducibility upon apoptotic stimuli in human hepatoma cells. We identified two minimal sequences essential for basal transcription of caspase-8 and demonstrate that a single SP1 and an ETS-like binding motif mediate this effect. We further show that the caspase-8 promoter is inducible and demonstrate that adenoviral infection increases caspase-8 mRNA levels. However, the increase in caspase-8 gene transcription after adenoviral infection absolutely depends on the p53 status of the hepatoma cell line, implying that caspase-8 is a target gene of p53. We show that delivery of exogenous p53 alone is sufficient to induce the caspase-8 promoter even in p53-deficient Hep3B hepatoma cells. Subsequent promoter deletion analysis in combination with luciferase reporter assays identified a p53-responsive element downstream of the transcriptional start site. We demonstrate that this p53-responsive sequence overlaps with the ETS-like binding site and suggest that an additional p53-inducible, yet unknown factor interacts with this region of the caspase-8 promoter. In summary, our study contributes to the understanding of the transcriptional regulation of the caspase-8 gene by basal (SP1- and ETS-dependent) and inducible (p53-dependent) mechanisms.	Hannover Med Sch, Abt Gastroenterol Hepatol & Endokrinol, D-30625 Hannover, Germany	Hannover Medical School	Trautwein, C (corresponding author), Hannover Med Sch, Abt Gastroenterol Hepatol & Endokrinol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	trautwein.christian@mh-hannover.de	Liedtke, Christian/DTV-1874-2022	Liedtke, Christian/0000-0003-4681-7887				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Grenet J, 1999, GENE, V226, P225, DOI 10.1016/S0378-1119(98)00565-4; Gupta S, 2001, J BIOL CHEM, V276, P10585, DOI 10.1074/jbc.C100025200; Kanzler S, 2000, SEMIN CANCER BIOL, V10, P173, DOI 10.1006/scbi.2000.0318; Kavurma MM, 2002, J BIOL CHEM, V277, P36244, DOI 10.1074/jbc.M200463200; Kischkel FC, 1998, CYTOGENET CELL GENET, V82, P95, DOI 10.1159/000015073; Kubicka S, 1997, HEPATOLOGY, V25, P867, DOI 10.1002/hep.510250414; Kubicka S, 1999, J BIOL CHEM, V274, P32137, DOI 10.1074/jbc.274.45.32137; Kuhnel F, 2000, J BIOL CHEM, V275, P6421, DOI 10.1074/jbc.275.9.6421; Liu WF, 2002, J BIOL CHEM, V277, P8273, DOI 10.1074/jbc.M110768200; MacLachan TK, 2002, P NATL ACAD SCI USA, V99, P9492, DOI 10.1073/pnas.132241599; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mullauer L, 2001, MUTAT RES-REV MUTAT, V488, P211, DOI 10.1016/S1383-5742(01)00057-6; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1998, EUR CYTOKINE NETW, V9, P685; Mundt B, 2002, FASEB J, V16, P94, DOI 10.1096/fj.02-0537fje; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; Nishimura Y, 1997, INT IMMUNOL, V9, P307, DOI 10.1093/intimm/9.2.307; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rozenfeld-Granot G, 2002, ONCOGENE, V21, P1469, DOI 10.1038/sj.onc.1205218; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmitt CA, 1999, J PATHOL, V187, P127; Schuchmann M, 2001, EUR J GASTROEN HEPAT, V13, P785, DOI 10.1097/00042737-200107000-00005; Shivapurkar N, 2002, CANCER BIOL THER, V1, P65, DOI 10.4161/cbt.1.1.45; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Takita J, 2000, MED PEDIATR ONCOL, V35, P541, DOI 10.1002/1096-911X(20001201)35:6<541::AID-MPO9>3.0.CO;2-T; Tannapfel A, 2001, ONCOGENE, V20, P7104, DOI 10.1038/sj.onc.1204902; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Trautwein C, 1998, J CLIN INVEST, V101, P1960, DOI 10.1172/JCI504; Volkmann M, 2001, J MOL MED-JMM, V79, P594, DOI 10.1007/s001090100244; Weis L, 1997, MOL CELL BIOL, V17, P2973, DOI 10.1128/MCB.17.6.2973; Yang XZ, 2003, CANCER RES, V63, P1122; Zender L, 2002, GASTROENTEROLOGY, V123, P608, DOI 10.1053/gast.2002.34756; Zuzak TJ, 2002, EUR J CANCER, V38, P83, DOI 10.1016/S0959-8049(01)00355-0	41	66	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27593	27604		10.1074/jbc.M304077200	http://dx.doi.org/10.1074/jbc.M304077200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12748179	hybrid			2022-12-25	WOS:000184242700034
J	Pitts, KE; Dobbin, PS; Reyes-Ramirez, F; Thomson, AJ; Richardson, DJ; Seward, HE				Pitts, KE; Dobbin, PS; Reyes-Ramirez, F; Thomson, AJ; Richardson, DJ; Seward, HE			Characterization of the Shewanella oneidensis MR-1 decaheme cytochrome MtrA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTREFACIENS MR-1; OUTER-MEMBRANE; FUMARATE REDUCTASE; SPECTROSCOPIC CHARACTERIZATION; FRIGIDIMARINA NCIMB400; ANAEROBIC RESPIRATION; ESCHERICHIA-COLI; METAL REDUCTION; IRON; FLAVOCYTOCHROME	Shewanella oneidensis MR-1 has the metabolic capacity to grow anaerobically using Fe(III) as a terminal electron acceptor. Growth under these conditions results in the de novo synthesis of a number of periplasmic c-type cytochromes, many of which are multiheme in nature and are thought to be involved in the Fe(III) respiratory process. To begin a biochemical study of these complex cytochromes, the mtrA gene that encodes an approximate 32-kDa periplasmic decaheme cytochrome has been heterologously expressed in Escherichia coli. Co-expression of mtrA with a plasmid that contains cytochrome c maturation genes leads to the assembly of a correctly targeted holoprotein, which covalently binds ten hemes. The recombinant MtrA protein has been characterized by magnetic circular dichroism, which shows that all ten hemes have bis-histidine axial ligation. EPR spectroscopy detected only eight of these hemes, all of which are low spin and provides evidence for a spin-coupled pair of hemes in the oxidized state. Redox titrations of MtrA have been carried out with optical- and EPR-monitored methods, and the hemes are shown to reduce over the potential range -100 to -400 mV. In intact cells of E. coli, MtrA is shown to obtain electrons from the host electron transport chain and pass these onto host oxidoreductases or a range of soluble Fe(III) species. This demonstrates the promiscuous nature of this decaheme cytochrome and its potential to serve as a soluble Fe( III) reductase in intact cells.	Univ E Anglia, Sch Biol Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Sch Chem Sci, Norwich NR4 7TJ, Norfolk, England; Univ Essex, Dept Biol Sci, Colchester CO4 3SQ, Essex, England	University of East Anglia; University of East Anglia; University of Essex	Seward, HE (corresponding author), Univ E Anglia, Sch Biol Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England.		Reyes-Ramirez, Francisca/L-3314-2014; Richardson, David J/E-2275-2011; Richardson, David/N-5129-2014	Reyes-Ramirez, Francisca/0000-0002-5120-8931; Richardson, David/0000-0002-7751-1058				AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; Bamford V, 1999, NAT STRUCT BIOL, V6, P1104; Bamford VA, 2002, BIOCHEMISTRY-US, V41, P2921, DOI 10.1021/bi015765d; Beliaev AS, 1998, J BACTERIOL, V180, P6292; Beliaev AS, 2001, MOL MICROBIOL, V39, P722, DOI 10.1046/j.1365-2958.2001.02257.x; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; CARTRON M, 2002, BIOCHEM J, V328, P425; DOBBIN P, 1996, BIOMETALS, V8, P291; Dobbin PS, 1996, MICROBIOL-UK, V142, P765, DOI 10.1099/00221287-142-4-765; Dobbin PS, 1999, BIOCHEM J, V342, P439, DOI 10.1042/0264-6021:3420439; Field SJ, 2000, J BIOL CHEM, V275, P8515, DOI 10.1074/jbc.275.12.8515; GADSBY PMA, 1990, J AM CHEM SOC, V112, P5003, DOI 10.1021/ja00169a002; GORDON E, 2001, FEBS LETT, V489, P8; Heidelberg JF, 2002, NAT BIOTECHNOL, V20, P1118, DOI 10.1038/nbt749; Hendrich MP, 2001, J AM CHEM SOC, V123, P2997, DOI 10.1021/ja002982d; HUSSAIN H, 1994, MOL MICROBIOL, V12, P153, DOI 10.1111/j.1365-2958.1994.tb01004.x; Leys D, 2002, J BIOL CHEM, V277, P35703, DOI 10.1074/jbc.M203866200; Leys D, 1999, NAT STRUCT BIOL, V6, P1113; LOVLEY DR, 1993, ANNU REV MICROBIOL, V47, P263, DOI 10.1146/annurev.mi.47.100193.001403; LOVLEY DR, 1995, ADV AGRON, V54, P175, DOI 10.1016/S0065-2113(08)60900-1; LOVLEY DR, 1988, APPL ENVIRON MICROB, V54, P1472, DOI 10.1128/AEM.54.6.1472-1480.1988; LOVLEY DR, 1993, MAR GEOL, V113, P41, DOI 10.1016/0025-3227(93)90148-O; MCKNIGHT J, 1993, EUR J BIOCHEM, V213, P683, DOI 10.1111/j.1432-1033.1993.tb17808.x; MOORE G, 1990, SPRINGER SERIES MOL, P316; MYERS CR, 1992, J BACTERIOL, V174, P3429, DOI 10.1128/JB.174.11.3429-3438.1992; MYERS CR, 1993, FEMS MICROBIOL LETT, V108, P15; Myers CR, 1997, J BACTERIOL, V179, P1143, DOI 10.1128/jb.179.4.1143-1152.1997; MYERS CR, 1990, J BACTERIOL, V172, P6232, DOI 10.1128/jb.172.11.6232-6238.1990; NEALSON KH, 1994, ANNU REV MICROBIOL, V48, P311, DOI 10.1146/annurev.mi.48.100194.001523; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Richardson DJ, 2000, MICROBIOL-SGM, V146, P551, DOI 10.1099/00221287-146-3-551; Roldan MD, 1998, J BIOL CHEM, V273, P28785, DOI 10.1074/jbc.273.44.28785; Taylor P, 1999, NAT STRUCT BIOL, V6, P1108; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; WOOLDRIDGE KG, 1993, FEMS MICROBIOL REV, V12, P325, DOI 10.1016/0168-6445(93)90011-W	36	165	174	3	74	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27758	27765		10.1074/jbc.M302582200	http://dx.doi.org/10.1074/jbc.M302582200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12732647	hybrid			2022-12-25	WOS:000184242700055
J	Wimmerova, M; Mitchell, E; Sanchez, JF; Gautier, C; Imberty, A				Wimmerova, M; Mitchell, E; Sanchez, JF; Gautier, C; Imberty, A			Crystal structure of fungal lectin - Six-bladed beta-propeller fold and novel fucose recognition mode for Aleuria aurantia lectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCLEROTIUM-ROLFSII; BINDING LECTIN; PROTEIN; MUSHROOM; CRYSTALLIZATION; PURIFICATION; SPECIFICITY; NEURAMINIDASE; AGGLUTININ; COMPLEXES	Aleuria aurantia lectin is a fungal protein composed of two identical 312-amino acid subunits that specifically recognizes fucosylated glycans. The crystal structure of the lectin complexed with fucose reveals that each monomer consists of a six-bladed beta-propeller fold and of a small antiparallel two-stranded beta-sheet that plays a role in dimerization. Five fucose residues were located in binding pockets between the adjacent propeller blades. Due to repeats in the amino acid sequence, there are strong similarities between the sites. Oxygen atoms O-3, O-4, and O-5 of fucose are involved in hydrogen bonds with side chains of amino acids conserved in all repeats, whereas O-1 and O-2 interact with a large number of water molecules. The nonpolar face of each fucose residue is stacked against the aromatic ring of a Trp or Tyr amino acid, and the methyl group is located in a highly hydrophobic pocket. Depending on the precise binding site geometry, the alpha- or beta-anomer of the fucose ligand is observed bound in the crystal. Surface plasmon resonance experiments conducted on a series of oligosaccharides confirm the broad specificity of the lectin, with a slight preference for alphaFuc1-2Gal disaccharide. This multivalent carbohydrate recognition fold is a new prototype of lectins that is proposed to be involved in the host recognition strategy of several pathogenic organisms including not only the fungi Aspergillus but also the phytopathogenic bacterium Ralstonia solanacearum.	Univ Grenoble 1, CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble 09, France; Masaryk Univ, Natl Ctr Biomol Res, CS-61137 Brno, Czech Republic; Masaryk Univ, Dept Biochem, CS-61137 Brno, Czech Republic; European Synchrotron Radiat Facil, Expt Div, F-38043 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Masaryk University Brno; Masaryk University Brno; European Synchrotron Radiation Facility (ESRF)	Imberty, A (corresponding author), Univ Grenoble 1, CNRS, Ctr Rech Macromol Vegetales, BP 53, F-38041 Grenoble 09, France.	imberty@cermav.cnrs.fr	Wimmerova, Michaela/A-4114-2010; Imberty, Anne/P-6451-2018	Wimmerova, Michaela/0000-0002-7108-4198; Imberty, Anne/0000-0001-6825-9527				Audette GF, 2002, CAN J CHEM, V80, P1010, DOI 10.1139/V02-134; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beisel HG, 1999, EMBO J, V18, P2313, DOI 10.1093/emboj/18.9.2313; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bianchet MA, 2002, NAT STRUCT BIOL, V9, P628, DOI 10.1038/nsb817; Bouchara JP, 1997, INFECT IMMUN, V65, P2717, DOI 10.1128/IAI.65.7.2717-2724.1997; BRASSART D, 1991, INFECT IMMUN, V59, P1605, DOI 10.1128/IAI.59.5.1605-1613.1991; Chattopadhyay TK, 1999, ACTA CRYSTALLOGR D, V55, P1589, DOI 10.1107/S0907444999007945; Cowtan KD, 1999, PROG BIOPHYS MOL BIO, V72, P245, DOI 10.1016/S0079-6107(99)00008-5; Crennell SJ, 1996, J MOL BIOL, V259, P264, DOI 10.1006/jmbi.1996.0318; DEBRAY H, 1989, CARBOHYD RES, V185, P15, DOI 10.1016/0008-6215(89)84017-0; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dupont B, 2000, MED MYCOL, V38, P215, DOI 10.1080/mmy.38.s1.215.224; ELAD Y, 1983, J BACTERIOL, V154, P1431, DOI 10.1128/JB.154.3.1431-1435.1983; Fujihashi M, 2003, ACTA CRYSTALLOGR D, V59, P378, DOI 10.1107/S0907444902022175; FUKUMORI F, 1990, J BIOCHEM-TOKYO, V107, P190, DOI 10.1093/oxfordjournals.jbchem.a123024; FUKUMORI F, 1989, FEBS LETT, V250, P153, DOI 10.1016/0014-5793(89)80709-4; Fulop V, 1999, CURR OPIN STRUC BIOL, V9, P715, DOI 10.1016/S0959-440X(99)00035-4; GASKELL A, 1995, STRUCTURE, V3, P1197, DOI 10.1016/S0969-2126(01)00255-6; GIOLLANT M, 1993, PLANT PHYSIOL, V101, P513, DOI 10.1104/pp.101.2.513; Haselhorst T, 2001, J AM CHEM SOC, V123, P10705, DOI 10.1021/ja011156h; HIRANO S, 1987, J BIOCHEM-TOKYO, V102, P445, DOI 10.1093/oxfordjournals.jbchem.a122073; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; INBAR J, 1994, MICROBIOL-SGM, V140, P651, DOI 10.1099/00221287-140-3-651; Ishida H, 2002, BIOSCI BIOTECH BIOCH, V66, P1002, DOI 10.1271/bbb.66.1002; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; Jawad Z, 2002, STRUCTURE, V10, P447, DOI 10.1016/S0969-2126(02)00750-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOCHIBE N, 1980, BIOCHEMISTRY-US, V19, P2841, DOI 10.1021/bi00554a004; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leonidas DD, 2003, ACTA CRYSTALLOGR D, V59, P363, DOI 10.1107/S0907444902021121; Lis H, 1998, CHEM REV, V98, P637, DOI 10.1021/cr940413g; Luo Y, 1999, J MOL BIOL, V285, P323, DOI 10.1006/jmbi.1998.2345; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mitchell E, 2002, NAT STRUCT BIOL, V9, P918, DOI 10.1038/nsb865; NAGATA Y, 1991, BIOCHIM BIOPHYS ACTA, V1076, P187, DOI 10.1016/0167-4838(91)90264-Z; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NORDBRINGHERTZ B, 1979, NATURE, V281, P477, DOI 10.1038/281477a0; Nurizzo D, 2002, NAT STRUCT BIOL, V9, P665, DOI 10.1038/nsb835; Ogawa S, 2001, BIOSCI BIOTECH BIOCH, V65, P686, DOI 10.1271/bbb.65.686; OGURI S, 1994, BIOSCI BIOTECH BIOCH, V58, P502, DOI 10.1271/bbb.58.502; Oubrie A, 1999, J MOL BIOL, V289, P319, DOI 10.1006/jmbi.1999.2766; Paoli M, 2001, PROG BIOPHYS MOL BIO, V76, P103, DOI 10.1016/S0079-6107(01)00007-4; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Sudakevitz D, 2002, J BIOCHEM, V132, P353, DOI 10.1093/oxfordjournals.jbchem.a003230; Tronchin G, 2002, INFECT IMMUN, V70, P6891, DOI 10.1128/IAI.70.12.6891-6895.2002; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; Waldherr-Teschner M., 1992, Advances in Scientific Visualization, P58; Weimar T, 2000, J CARBOHYD CHEM, V19, P1083, DOI 10.1080/07328300008544136; WEIMAR T, 1994, ANGEW CHEM INT EDIT, V33, P88, DOI 10.1002/anie.199400881	51	142	148	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27059	27067		10.1074/jbc.M302642200	http://dx.doi.org/10.1074/jbc.M302642200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12732625	hybrid			2022-12-25	WOS:000184155700098
J	Silva, J; Beckedorf, A; Bieberich, E				Silva, J; Beckedorf, A; Bieberich, E			Osteoblast-derived oxysterol is a migration-inducing factor for human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; ARACHIDONIC-ACID RELEASE; BINDING-PROTEIN; PHOSPHOINOSITIDE 3-KINASE; CHOLESTEROL-METABOLISM; CHEMOKINE RECEPTORS; KINASE PATHWAY; FAMILY; METASTASIS; EXPRESSION	Bone metastasis is the major reason for death caused by breast cancer. We used human breast cancer (MCF-7) cells that are poorly metastatic but show highly inducible migration to determine bone-derived factors that induce migration of initially non-disseminating breast cancer cells. We have found that a lipid fraction from human osteoblast-like MG63 cell-conditioned medium (MG63CM) contains a migration-inducing factor for MCF-7 cells. In this fraction, we have identified oxysterol ( OS) as a lipid mediator for tumor cell migration. In MCF-7 cells, insulin-like growth factor 1 elevates the expression of OS-binding protein-related protein 7. Binding of OS to OS-binding protein or OS-binding protein-related protein is known to trigger elevation of sphingomyelin, a sphingolipid that organizes lipid microdomains in the cell membrane. In MCF-7 cells, OS increases the intracellular concentration of sphingomyelin and other phospholipids and induces the translocation of the small GTPase p21Ras to GM1- and cholesterol-rich membrane areas. The induction of migration by MG63CM is prevented by incubation of MG63 cells with mevinolin, a statin-type cholesterol biosynthesis inhibitor that depletes the conditioned medium of OS. Osteoblast-derived OS may, thus, be a yet unrecognized lipid mediator for bone metastasis of breast cancer and a new target for anti-metastasis chemotherapy with statins.	Med Coll Georgia, Inst Mol Med & Genet, 1120 15th St,Rm CB-2803, Augusta, GA 30909 USA; Med Coll Georgia, Dept Med, Augusta, GA 30909 USA; Univ Munster, Inst Med Phys & Biophys, D-48149 Munster, Germany	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University of Munster	Bieberich, E (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, 1120 15th St,Rm CB-2803, Augusta, GA 30909 USA.			Silva, PhD, MPA, EdS, EdD, MB(ASCP)CM, Jeane/0000-0003-3368-3963	NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH061934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011853] Funding Source: NIH RePORTER; NIMH NIH HHS [MH61934-04] Funding Source: Medline; NINDS NIH HHS [NS11853] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bieberich E, 2002, CANCER LETT, V181, P55, DOI 10.1016/S0304-3835(02)00049-6; Bradlow HL, 1995, MOL CELL ENDOCRINOL, V115, P221, DOI 10.1016/0303-7207(95)03684-9; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Careri M, 1998, J CHROMATOGR A, V794, P253, DOI 10.1016/S0021-9673(97)00764-4; CASTANHO MARB, 1992, J BIOL CHEM, V267, P204; Dasgupta S, 2001, J LIPID RES, V42, P301; Denoyelle C, 2001, CARCINOGENESIS, V22, P1139, DOI 10.1093/carcin/22.8.1139; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Fournier MV, 1999, CANCER RES, V59, P3748; Gabbitas B, 1997, J CELL PHYSIOL, V172, P253, DOI 10.1002/(SICI)1097-4652(199708)172:2<253::AID-JCP12>3.0.CO;2-A; Guvakova MA, 2002, J CELL SCI, V115, P4149, DOI 10.1242/jcs.00104; Holthuis JCM, 2001, PHYSIOL REV, V81, P1689, DOI 10.1152/physrev.2001.81.4.1689; Jaumot M, 2002, J BIOL CHEM, V277, P272, DOI 10.1074/jbc.M108423200; Jiang WG, 2002, CRIT REV ONCOL HEMAT, V43, P13, DOI 10.1016/S1040-8428(01)00181-0; Jo M, 2002, J BIOL CHEM, V277, P12479, DOI 10.1074/jbc.M111147200; Kasimir-Bauer S, 2002, INT J ONCOL, V20, P1027; Keely PJ, 2001, METHODS ENZYMOL, V333, P256; Lacroix M, 1996, BREAST CANCER RES TR, V38, P209, DOI 10.1007/BF01806675; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lagace TA, 1997, BIOCHEM J, V326, P205, DOI 10.1042/bj3260205; Lagace TA, 1999, J LIPID RES, V40, P109; LAHOUA Z, 1991, CELL SIGNAL, V3, P559, DOI 10.1016/0898-6568(91)90032-P; LAHOUA Z, 1988, BIOCHIM BIOPHYS ACTA, V958, P396, DOI 10.1016/0005-2760(88)90225-1; Laitinen S, 2002, J LIPID RES, V43, P245; Laitinen S, 1999, J LIPID RES, V40, P2204; Lehto M, 2003, BBA-MOL CELL BIOL L, V1631, P1, DOI 10.1016/S1388-1981(02)00364-5; Lehto M, 2001, J LIPID RES, V42, P1203; London E, 2002, CURR OPIN STRUC BIOL, V12, P480, DOI 10.1016/S0959-440X(02)00351-2; Lou ZK, 2001, J IMMUNOL, V167, P5749, DOI 10.4049/jimmunol.167.10.5749; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Murphy PM, 2001, NEW ENGL J MED, V345, P833, DOI 10.1056/NEJM200109133451113; NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298; Onuffer JJ, 2002, TRENDS PHARMACOL SCI, V23, P459, DOI 10.1016/S0165-6147(02)02064-3; Pennisi PA, 2002, CANCER RES, V62, P6529; Puglianiello A, 2000, J ENDOCRINOL, V165, P123, DOI 10.1677/joe.0.1650123; Ridgway ND, 2000, BBA-MOL CELL BIOL L, V1484, P129, DOI 10.1016/S1388-1981(00)00006-8; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; Rizzo MA, 2001, J BIOL CHEM, V276, P34928, DOI 10.1074/jbc.M105918200; Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361; Shan H, 2003, STEROIDS, V68, P221, DOI 10.1016/S0039-128X(02)00185-X; Sloan EK, 2002, CELL MOL LIFE SCI, V59, P1491, DOI 10.1007/s00018-002-8524-5; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; van Meer G, 2002, J BIOL CHEM, V277, P25855, DOI 10.1074/jbc.R200010200; van Meer G, 2001, J CELL BIOL, V152, pF29, DOI 10.1083/jcb.152.5.F29; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VARANI J, 1978, AM J PATHOL, V90, P159; Wittmann T, 2001, J CELL SCI, V114, P3795; Wohlfeil ER, 1997, BBA-LIPID LIPID MET, V1345, P109, DOI 10.1016/S0005-2760(96)00170-1; Wyles JP, 2002, J BIOL CHEM, V277, P29908, DOI 10.1074/jbc.M201191200; Xu YQ, 2001, J BIOL CHEM, V276, P18407, DOI 10.1074/jbc.M101204200	53	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25376	25385		10.1074/jbc.M301233200	http://dx.doi.org/10.1074/jbc.M301233200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12734199	hybrid			2022-12-25	WOS:000183920200016
J	Xu, B; Chibber, R; Ruggerio, D; Kohner, E; Ritter, J; Ferro, A				Xu, B; Chibber, R; Ruggerio, D; Kohner, E; Ritter, J; Ferro, A			Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products	FASEB JOURNAL			English	Article						diabetes mellitus; vasodilation; endothelial function; AGE proteins	OXIDATIVE STRESS; CELL BIOLOGY; IN-VITRO; RECEPTOR; GLYCOSYLATION; PROTEINS; N-EPSILON-(CARBOXYMETHYL)LYSINE; DYSFUNCTION; VASODILATATION; GLYCOXIDATION	Endothelial damage is believed to play a key role in the development of both micro- and macrovascular disease in diabetes, and advanced glycation end products (AGEs) may contribute importantly to this. To determine whether glucose-derived AGEs can cause endothelial dysfunction, we examined the effects of albumin AGE-modified by glucose (AGE-Glu) both in vivo, after injection into rabbit femoral artery, and in vitro on rabbit aortic rings and cultured human umbilical vein endothelial cells (HUVEC). Exposure of blood vessels to AGE-Glu, in vivo and in vitro, inhibited endothelium-dependent vasorelaxation, whereas unmodified albumin did not. In isolated rabbit aorta, this effect was reversible after AGE-Glu washout, and the response to the endothelium-independent vasodilator sodium nitroprusside was unaffected by AGE-Glu. In HUVEC, AGE-Glu inhibited endothelial nitric oxide synthase activity, and this was associated with a decrease in serine phosphorylation of this enzyme. Longer term (72 h) incubation decreased HUVEC viability. Use of specific antibodies demonstrated that these effects were mediated by N-epsilon-(carboxymethyl)lysine (CML), an important AGE found in vivo, and by the AGE-R1 receptor. Furthermore, these effects all occurred at CML concentrations similar to those found in the plasma of diabetic patients. These results suggest an important role of AGE in the pathogenesis of diabetic vasculopathy.	Kings Coll London, Dept Clin Pharmacol, Div Cardiovasc, GKT Sch Med,Ctr Cardiovasc Biol & Med, London SE1 7EH, England; Diabet Microangiopathy Res Unit, Villeurbanne, France	University of London; King's College London	Ferro, A (corresponding author), Kings Coll London, Dept Clin Pharmacol, Div Cardiovasc, GKT Sch Med,Ctr Cardiovasc Biol & Med, St Thomas Hosp Campus,Lambeth Palace Rd, London SE1 7EH, England.	albert.ferro@kcl.ac.uk		Ferro, Albert/0000-0002-5486-9145				AGGARWAL M, 1992, CLIN RES, V40, pA179; AMEZCUA JL, 1988, BRIT J PHARMACOL, V95, P830, DOI 10.1111/j.1476-5381.1988.tb11711.x; ARAKI N, 1995, EUR J BIOCHEM, V230, P408, DOI 10.1111/j.1432-1033.1995.0408h.x; Baynes JW, 2000, FREE RADICAL BIO MED, V28, P1708, DOI 10.1016/S0891-5849(00)00228-8; Berg TJ, 1998, DIABETES CARE, V21, P1997, DOI 10.2337/diacare.21.11.1997; BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; BUCALA R, 1991, J CLIN INVEST, V87, P432, DOI 10.1172/JCI115014; Busse R, 1998, J VASC RES, V35, P73, DOI 10.1159/000025568; CALVER A, 1992, J CLIN INVEST, V90, P2548, DOI 10.1172/JCI116149; CAYATTE AJ, 1994, ARTERIOSCLER THROMB, V14, P753, DOI 10.1161/01.ATV.14.5.753; Chakravarthy U, 1998, DIABETES, V47, P945, DOI 10.2337/diabetes.47.6.945; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Chibber R, 1997, DIABETOLOGIA, V40, P156, DOI 10.1007/s001250050657; COHEN RA, 1993, CIRCULATION, V87, P67; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; ELLIOTT TG, 1993, CLIN SCI, V85, P687, DOI 10.1042/cs0850687; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; FERRO A, 1999, BRIT J PHARMACOL, V126, P1842; Fontana L, 1999, BRIT J PHARMACOL, V126, P730, DOI 10.1038/sj.bjp.0702331; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; Gardner PR, 1996, ARCH BIOCHEM BIOPHYS, V325, P20, DOI 10.1006/abbi.1996.0003; Giugliano D, 1996, DIABETES CARE, V19, P257, DOI 10.2337/diacare.19.3.257; Guo Zhijian, 2002, Zhonghua Yi Xue Za Zhi, V82, P1328; Horie K, 1997, J CLIN INVEST, V100, P2995, DOI 10.1172/JCI119853; IGNARRO LJ, 1988, J PHARMACOL EXP THER, V246, P218; Jensen J S, 1997, J Cardiovasc Risk, V4, P121; Kilhovd BK, 1999, DIABETES CARE, V22, P1543, DOI 10.2337/diacare.22.9.1543; Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; Li YM, 1996, P NATL ACAD SCI USA, V93, P11047, DOI 10.1073/pnas.93.20.11047; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; MCVEIGH GE, 1992, DIABETOLOGIA, V35, P771; Miura J, 2003, J DIABETES COMPLICAT, V17, P16, DOI 10.1016/S1056-8727(02)00183-6; Nishikawa T, 2000, KIDNEY INT, V58, pS26, DOI 10.1046/j.1523-1755.2000.07705.x; Ohgami N, 2001, J BIOL CHEM, V276, P13348, DOI 10.1074/jbc.M011613200; Ohgami N, 2001, J BIOL CHEM, V276, P3195, DOI 10.1074/jbc.M006545200; Onorato JM, 1998, ANN NY ACAD SCI, V854, P277, DOI 10.1111/j.1749-6632.1998.tb09909.x; POSTON L, 1995, CLIN SCI, V88, P245, DOI 10.1042/cs0880245; Pricci F, 2000, KIDNEY INT, V58, pS31, DOI 10.1046/j.1523-1755.2000.07706.x; REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021; REES DD, 1989, BRIT J PHARMACOL, V96, P418, DOI 10.1111/j.1476-5381.1989.tb11833.x; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1145, DOI 10.1152/ajpheart.1986.250.6.H1145; Sakata N, 1999, ATHEROSCLEROSIS, V142, P67, DOI 10.1016/S0021-9150(98)00192-0; SALTER M, 1991, FEBS LETT, V291, P145, DOI 10.1016/0014-5793(91)81123-P; Schmidt AM, 2000, BBA-MOL CELL RES, V1498, P99, DOI 10.1016/S0167-4889(00)00087-2; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SESSA WC, 1994, CIRC RES, V74, P349, DOI 10.1161/01.RES.74.2.349; SHUKLA SD, 1992, THROMB RES, V66, P239, DOI 10.1016/0049-3848(92)90194-F; Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591; Sobrevia L, 1997, EXP PHYSIOL, V82, P423, DOI 10.1113/expphysiol.1997.sp004038; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Stitt AW, 1999, BIOCHEM BIOPH RES CO, V256, P549, DOI 10.1006/bbrc.1999.0291; THORNALLEY PJ, 1995, CONTRIB NEPHROL, V112, P24; Thornalley PJ, 1998, CELL MOL BIOL, V44, P1013; TSAO PS, 1994, ARTERIOSCLER THROMB, V14, P1529, DOI 10.1161/01.ATV.14.10.1529; Wautier J L, 1998, Vasc Med, V3, P131, DOI 10.1191/135886398672565440; XU B, 1993, ACTA PHARM SINIC, V14, P229; Yamagishi S, 1996, FEBS LETT, V384, P103, DOI 10.1016/0014-5793(96)00279-7	62	156	172	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1289	+		10.1096/fj.02-0490fje	http://dx.doi.org/10.1096/fj.02-0490fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738813				2022-12-25	WOS:000183165000034
J	Assadi-Porter, FM; Abildgaard, F; Blad, H; Markley, JL				Assadi-Porter, FM; Abildgaard, F; Blad, H; Markley, JL			Correlation of the sweetness of variants of the protein brazzein with patterns of hydrogen bonds detected by NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE CHORDA TYMPANI; TASTING PROTEIN; SCALAR COUPLINGS; IMPROVED SENSITIVITY; ANGSTROM RESOLUTION; BACKBONE DYNAMICS; THAUMATIN; MONELLIN; (3H)J(NC'); SPECTRA	In sequence-function investigations, approaches are needed for rapidly screening protein variants for possible changes in conformation. Recent NMR methods permit direct detection of hydrogen bonds through measurements of scalar couplings that traverse hydrogen bonds (transhydrogen bond couplings). We have applied this approach to screen a series of five single site mutants of the sweet protein brazzein with altered sweetness for possible changes in backbone hydrogen bonding with respect to wild-type. Long range, three-dimensional data correlating connectivities among backbone H-1(N), N-15, and C-13' atoms were collected from the six brazzein proteins labeled uniformly with carbon-13 and nitrogen-15. In wild-type brazzein, this approach identified 17 backbone hydrogen bonds. In the mutants, altered magnitudes of the couplings identified hydrogen bonds that were strengthened or weakened; missing couplings identified hydrogen bonds that were broken, and new couplings indicated the presence of new hydrogen bonds. Within the series of brazzein mutants investigated, a pattern was observed between sweetness and the integrity of particular hydrogen bonds. All three "sweet" variants exhibited the same pattern of hydrogen bonds, whereas all three "non-sweet" variants lacked one hydrogen bond at the middle of the alpha-helix, where it is kinked, and one hydrogen bond in the middle of beta-strands II and III, where they are twisted. Two of the non-sweet variants lack the hydrogen bond connecting the N and C termini. These variants showed greater mobility in the Nand C-terminal regions than wild-type brazzein.	Univ Wisconsin, Dept Biochem, Natl Magnet Resonance Facil, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Assadi-Porter, FM (corresponding author), Univ Wisconsin, Dept Biochem, Natl Magnet Resonance Facil, Madison, WI 53706 USA.	fariba@nmrfam.wisc.edu			NCRR NIH HHS [RR02301] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002301] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Alexandrescu AT, 2001, PROTEIN SCI, V10, P1856, DOI 10.1110/ps.14301; Assadi-Porter FM, 2000, ARCH BIOCHEM BIOPHYS, V376, P259, DOI 10.1006/abbi.2000.1726; Assadi-Porter FM, 2000, ARCH BIOCHEM BIOPHYS, V376, P252, DOI 10.1006/abbi.2000.1725; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BAX A, 1991, J MAGN RESON, V91, P174, DOI 10.1016/0022-2364(91)90422-P; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; Bonvin AMJJ, 2001, J BIOMOL NMR, V21, P221, DOI 10.1023/A:1012935005256; Caldwell J, 1999, J CHEM SOC PAKISTAN, V21, P268; Caldwell JE, 1998, NAT STRUCT BIOL, V5, P427, DOI 10.1038/nsb0698-427; Caldwell JE, 1998, J BIOMOL NMR, V11, P231, DOI 10.1023/A:1008262104643; CALDWELL JE, 1998, THESIS U WISCONSIN M, P49; CHYLLA RA, 1995, J BIOMOL NMR, V5, P245; Cole AM, 2001, J IMMUNOL, V167, P623, DOI 10.4049/jimmunol.167.2.623; Cordier F, 1999, J AM CHEM SOC, V121, P1601, DOI 10.1021/ja983945d; Cornilescu G, 1999, J AM CHEM SOC, V121, P6275, DOI 10.1021/ja9909024; Cornilescu G, 1999, J AM CHEM SOC, V121, P2949, DOI 10.1021/ja9902221; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FARROW NA, 1994, J BIOMOL NMR, V4, P727, DOI 10.1007/BF00404280; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; HELLEKANT G, 1991, ACS SYM SER, V450, P290; Hellekant G, 1997, PHYSIOL BEHAV, V61, P829, DOI 10.1016/S0031-9384(96)00562-8; Hellekant G, 1997, J NEUROPHYSIOL, V77, P978, DOI 10.1152/jn.1997.77.2.978; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; Izawa H, 1996, BIOPOLYMERS, V39, P95, DOI 10.1002/(SICI)1097-0282(199607)39:1<95::AID-BIP10>3.0.CO;2-B; Kaneko R, 2001, CHEM SENSES, V26, P167, DOI 10.1093/chemse/26.2.167; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; KO TP, 1994, ACTA CRYSTALLOGR D, V50, P813, DOI 10.1107/S0907444994005512; KOHMURA M, 1994, BIOSCI BIOTECH BIOCH, V58, P1522, DOI 10.1271/bbb.58.1522; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Li XD, 2002, P NATL ACAD SCI USA, V99, P4692, DOI 10.1073/pnas.072090199; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Markley JL, 1998, EUR J BIOCHEM, V256, P1, DOI 10.1046/j.1432-1327.1998.2560001.x; MING D, 1994, FEBS LETT, V355, P106, DOI 10.1016/0014-5793(94)01184-2; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Niccolai N, 2001, PROTEIN SCI, V10, P1498, DOI 10.1110/ps.30101; OGATA CM, 1992, J MOL BIOL, V228, P893, DOI 10.1016/0022-2836(92)90873-I; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; SHASLLENBERGER RS, 1967, NATURE, V216, P480; SOMOZA JR, 1993, J MOL BIOL, V234, P390, DOI 10.1006/jmbi.1993.1594; SOMOZA JR, 1995, CHEM SENSES, V20, P61, DOI 10.1093/chemse/20.1.61; Talluri S, 1996, J MAGN RESON SER B, V112, P200, DOI 10.1006/jmrb.1996.0132; Temussi PA, 2002, FEBS LETT, V526, P1, DOI 10.1016/S0014-5793(02)03155-1; Wales TE, 2001, J AM CHEM SOC, V123, P7709, DOI 10.1021/ja010775n; Wang YX, 1999, J BIOMOL NMR, V14, P181, DOI 10.1023/A:1008346517302; Xie HF, 2001, BIOCHEMISTRY-US, V40, P5700, DOI 10.1021/bi010034z; Zhao Q, 2002, BIOCHEMISTRY-US, V41, P12284, DOI 10.1021/bi025702a	51	28	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31331	31339		10.1074/jbc.M302663200	http://dx.doi.org/10.1074/jbc.M302663200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12732626	hybrid			2022-12-25	WOS:000184658800115
J	Grav, HJ; Tronstad, KJ; Gudbrandsen, OA; Berge, K; Fladmark, KE; Martinsen, TC; Waldum, H; Wergedahl, H; Berge, RK				Grav, HJ; Tronstad, KJ; Gudbrandsen, OA; Berge, K; Fladmark, KE; Martinsen, TC; Waldum, H; Wergedahl, H; Berge, RK			Changed energy state and increased mitochondrial beta-oxidation rate in liver of rats associated with lowered proton electrochemical potential and stimulated uncoupling protein 2 (UCP-2) expression - Evidence for peroxisome proliferator-activated receptor-alpha independent induction of UCP-2 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; CARNITINE PALMITOYLTRANSFERASE-II; ADIPOSE-TISSUE MITOCHONDRIA; TETRADECYLTHIOACETIC ACID; GENE-EXPRESSION; INNER MEMBRANE; DOCOSAHEXAENOIC ACID; EICOSAPENTAENOIC ACID; IN-VITRO; CELLS	Lowering of plasma triglyceride levels by hypolipidemic agents is caused by a shift in the liver cellular metabolism, which become poised toward peroxisome proliferator-activated receptor (PPAR) alpha-regulated fatty acid catabolism in mitochondria. After dietary treatment of rats with the hypolipidemic, modified fatty acid, tetradecylthioacetic acid (TTA), the energy state parameters of the liver were altered at the tissue, cell, and mitochondrial levels. Thus, the hepatic phosphate potential, energy charge, and respiratory control coefficients were lowered, whereas rates of oxygen uptake, oxidation of pyridine nucleotide redox pairs, beta-oxidation, and ketogenesis were elevated. Moderate uncoupling of mitochondria from TTA-treated rats was confirmed, as the proton electrochemical potential (Deltap) was 15% lower than controls. The change affected the Deltapsi component only, leaving the DeltapH component unaltered, suggesting that TTA causes induction of electrogenic ion transport rather than electrophoretic fatty acid activity. TTA treatment induced expression of hepatic uncoupling protein 2 (UCP-2) in rats as well as in wild type and PPARalpha-deficient mice, accompanied by a decreased double bond index of the mitochondrial membrane lipids. However, changes of mitochondrial fatty acid composition did not seem to be related to the effects on mitochondrial energy conductance. As TTA activates PPARdelta, we discuss how this subtype might compensate for deficiency of PPARalpha. The overall changes recorded were moderate, making it likely that liver metabolism can maintain its function within the confines of its physiological regulatory framework where challenged by a hypolipemic agent such as TTA, as well as others.	Haukeland Hosp, Inst Med, Sect Med Biochem, N-5021 Bergen, Norway; Univ Oslo, Inst Nutr Res, N-0316 Oslo, Norway; Univ Bergen, Dept Anat & Cell Biol, N-5009 Bergen, Norway; Norwegian Univ Sci & Technol, Dept Intraabdominal Dis, N-7491 Trondheim, Norway	University of Bergen; Haukeland University Hospital; University of Oslo; University of Bergen; Norwegian University of Science & Technology (NTNU)	Berge, RK (corresponding author), Haukeland Hosp, Inst Med, Sect Med Biochem, N-5021 Bergen, Norway.	rolf.berge@med.uib.no		Waldum, Helge/0000-0002-3137-0843; Gudbrandsen, Oddrun/0000-0001-5268-692X; Wergedahl, Hege/0000-0003-4614-1960; Tronstad, Karl Johan/0000-0003-3496-3123				AARSLAND A, 1990, BIOCHIM BIOPHYS ACTA, V1033, P176, DOI 10.1016/0304-4165(90)90009-L; Armstrong MB, 2001, AM J PHYSIOL-ENDOC M, V281, pE1197, DOI 10.1152/ajpendo.2001.281.6.E1197; ASIEDU DK, 1995, BIOCHEM PHARMACOL, V49, P1013, DOI 10.1016/0006-2952(94)00460-4; Berge K, 2001, CARCINOGENESIS, V22, P1747, DOI 10.1093/carcin/22.11.1747; Berge RK, 1999, BIOCHEM J, V343, P191, DOI 10.1042/0264-6021:3430191; BERGE RK, 1994, PHARMACOL THERAPEUT, V61, P345, DOI 10.1016/0163-7258(94)90016-7; Berge RK, 2002, CURR OPIN LIPIDOL, V13, P295, DOI 10.1097/00041433-200206000-00010; BERGE RK, 1984, EUR J BIOCHEM, V141, P637, DOI 10.1111/j.1432-1033.1984.tb08239.x; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; Bjorndal B, 2002, J LIPID RES, V43, P1630, DOI 10.1194/jlr.M100406-JLR200; BRAND MD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P128, DOI 10.1016/0005-2728(90)90232-S; BREMER J, 1972, BIOCHIM BIOPHYS ACTA, V280, P515, DOI 10.1016/0005-2760(72)90131-2; Bremer J, 2001, PROG LIPID RES, V40, P231, DOI 10.1016/S0163-7827(01)00004-2; Brookes PS, 1998, COMP BIOCHEM PHYS B, V119, P325, DOI 10.1016/S0305-0491(97)00357-X; Brookes PS, 1997, BBA-BIOMEMBRANES, V1330, P157, DOI 10.1016/S0005-2736(97)00160-0; BROWN GC, 1991, BIOCHIM BIOPHYS ACTA, V1059, P55, DOI 10.1016/S0005-2728(05)80187-2; CHRISTIANSEN R, 1976, FEBS LETT, V62, P313, DOI 10.1016/0014-5793(76)80083-X; Dawson A., 1987, MITOCHONDRIA PRACTIC, P35; Elholm M, 2001, IUBMB LIFE, V51, P99, DOI 10.1080/15216540152122094; Fleischer S, 1979, Methods Enzymol, V55, P32; Froyland L, 1997, J LIPID RES, V38, P1522; GRAV HJ, 1970, EUR J BIOCHEM, V12, P11, DOI 10.1111/j.1432-1033.1970.tb00815.x; GRAV HJ, 1994, J CHROMATOGR B, V658, P1, DOI 10.1016/0378-4347(94)00224-X; Hermesh O, 1998, J BIOL CHEM, V273, P3937, DOI 10.1074/jbc.273.7.3937; HOHORST HJ, 1959, BIOCHEM Z, V332, P18; HOVIK R, 1990, BIOCHEM J, V270, P167, DOI 10.1042/bj2700167; JACOBSEN SEW, 1994, J EXP MED, V179, P1665, DOI 10.1084/jem.179.5.1665; Jezek P, 1998, BBA-BIOENERGETICS, V1365, P319, DOI 10.1016/S0005-2728(98)00084-X; Kelly LJ, 1998, ENDOCRINOLOGY, V139, P4920, DOI 10.1210/en.139.12.4920; Krebs H. A., 1969, ENERGY LEVEL METABOL, P329; KRYVI H, 1990, J STRUCT BIOL, V103, P257, DOI 10.1016/1047-8477(90)90044-D; Kuiper KKJ, 2001, ATHEROSCLEROSIS, V158, P269, DOI 10.1016/S0021-9150(01)00417-8; LANOUE KF, 1973, J BIOL CHEM, V248, P7171; Larrouy D, 1997, BIOCHEM BIOPH RES CO, V235, P760, DOI 10.1006/bbrc.1997.6852; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LENARTOWICZ E, 1978, J BIOL CHEM, V253, P5990; Madsen L, 1999, LIPIDS, V34, P951, DOI 10.1007/s11745-999-0445-x; Madsen L, 1999, BIOCHEM PHARMACOL, V57, P1011, DOI 10.1016/S0006-2952(99)00004-0; Madsen L, 2002, J LIPID RES, V43, P742; Madsen L, 1997, J LIPID RES, V38, P554; Muna ZA, 2002, BIOCHEM PHARMACOL, V63, P1127, DOI 10.1016/S0006-2952(01)00934-0; Muna ZA, 2000, FREE RADICAL BIO MED, V28, P1068, DOI 10.1016/S0891-5849(00)00196-9; Muoio DM, 2002, J BIOL CHEM, V277, P26089, DOI 10.1074/jbc.M203997200; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; NICHOLLS DG, 1974, EUR J BIOCHEM, V49, P573, DOI 10.1111/j.1432-1033.1974.tb03861.x; NICHOLLS DG, 1992, BIOENERGETICS, V2, P93; Porter RK, 1996, AM J PHYSIOL-REG I, V271, pR1550, DOI 10.1152/ajpregu.1996.271.6.R1550; Porter RK, 2001, BBA-BIOENERGETICS, V1504, P120, DOI 10.1016/S0005-2728(00)00246-2; Raspe E, 1999, J LIPID RES, V40, P2099; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; ROTTENBERG H, 1990, BIOCHIM BIOPHYS ACTA, V1018, P1, DOI 10.1016/0005-2728(90)90103-B; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Sies H., 1982, METABOLIC COMPARTMEN, P205; SKORVE J, 1995, LIPIDS, V30, P987, DOI 10.1007/BF02536282; Skrede S, 1997, BBA-LIPID LIPID MET, V1344, P115, DOI 10.1016/S0005-2760(96)00138-5; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; STOCCHI V, 1987, ANAL BIOCHEM, V167, P181, DOI 10.1016/0003-2697(87)90150-3; Tran TN, 2001, BBA-MOL CELL BIOL L, V1533, P255, DOI 10.1016/S1388-1981(01)00159-7; VEECH RL, 1979, J BIOL CHEM, V254, P6538; WARHURST IW, 1983, THESIS U E ANGLIA NO; Westergaard M, 2001, J INVEST DERMATOL, V116, P702, DOI 10.1046/j.1523-1747.2001.01329.x; Williamson J R, 1979, Methods Enzymol, V55, P200; Willumsen N, 1996, LIPIDS, V31, P579, DOI 10.1007/BF02523828; Willumsen N, 1997, J LIPID MEDIAT CELL, V17, P115, DOI 10.1016/S0929-7855(97)00024-2; WOITCZAK L, 1993, BIOCHIM BIOPHYS ACTA, V1183, P41, DOI 10.1016/0005-2728(93)90004-Y; Wojtczak L, 1998, ARCH BIOCHEM BIOPHYS, V357, P76, DOI 10.1006/abbi.1998.0777	67	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30525	30533		10.1074/jbc.M303382200	http://dx.doi.org/10.1074/jbc.M303382200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12756242	hybrid			2022-12-25	WOS:000184658800016
J	Monte, M; Benetti, R; Buscemi, G; Sandy, P; Del Sal, G; Schneider, C				Monte, M; Benetti, R; Buscemi, G; Sandy, P; Del Sal, G; Schneider, C			The cell cycle-regulated protein human GTSE-1 controls DNA damage-induced apoptosis by affecting p53 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; G(2) CHECKPOINT; ARREST; MDM2; GENE; 14-3-3-SIGMA; MECHANISMS; PHOSPHORYLATION; UBIQUITINATION; ACETYLATION	GTSE-1 (G(2) and S phase-expressed-1) protein is specifically expressed during S and G(2) phases of the cell cycle. It is mainly localized to the microtubules and when overexpressed delays the G(2) to M transition. Here we report that human GTSE-1 (hGTSE-1) protein can negatively regulate p53 transactivation function, protein levels, and p53-dependent apoptosis. We identified a physical interaction between the C-terminal regulatory domain of p53 and the C-terminal region of hGTSE-1 that is necessary and sufficient to down-regulate p53 activity. Furthermore, we provide evidence that hGTSE-1 is able to control p53 function in a cell cycle-dependent fashion. hGTSE-1 knock-down by small interfering RNA resulted in a S/G(2)-specific increase of p53 levels as well as cell sensitization to DNA damage-induced apoptosis during these phases of the cell cycle. Altogether, this work suggests a physiological role of hGTSE-1 in apoptosis control after DNA damage during S and G(2) phases through regulation of p53 function.	LNCIB, I-34012 Trieste, Italy; Ist Nazl Tumori, Dipartimento Oncol Sperimentale, I-20133 Milan, Italy; Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, I-34100 Trieste, Italy; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Trieste; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine	Schneider, C (corresponding author), LNCIB, Area Sci Pk,Padriciano 99, I-34012 Trieste, Italy.		Buscemi, Giacomo/ABI-1170-2020	Buscemi, Giacomo/0000-0002-8404-7142; Monte, Martin/0000-0002-5068-563X; BENETTI, Roberta/0000-0001-8863-0821; DEL SAL, GIANNINO/0000-0003-2185-6003				Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Benetti R, 2001, EMBO J, V20, P2702, DOI 10.1093/emboj/20.11.2702; Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Collavin L, 2000, FEBS LETT, V481, P57, DOI 10.1016/S0014-5793(00)01969-4; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Monte M, 2000, GENE, V254, P229, DOI 10.1016/S0378-1119(00)00260-2; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141	28	69	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30356	30364		10.1074/jbc.M302902200	http://dx.doi.org/10.1074/jbc.M302902200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12750368	hybrid			2022-12-25	WOS:000184507000116
J	Holinstat, M; Mehta, D; Kozasa, T; Minshall, RD; Malik, AB				Holinstat, M; Mehta, D; Kozasa, T; Minshall, RD; Malik, AB			Protein kinase C alpha-induced p115RhoGEF phosphorylation signals endothelial cytoskeletal rearrangement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-INDUCED INCREASE; FOCAL ADHESION KINASE; BARRIER FUNCTION; P115 RHOGEF; LYSOPHOSPHATIDIC ACID; EXCHANGE FACTORS; RHO/RHO-KINASE; SHAPE CHANGE; ACTIVATION; RECEPTOR	Heterotrimeric G-proteins of the Galpha(12/13) family activate Rho GTPase through the guanine nucleotide exchange factor p115RhoGEF. Because Rho activation is also dependent on protein kinase Calpha (PKCalpha), we addressed the possibility that PKCalpha can also induce Rho activation secondary to the phosphorylation of p115RhoGEF. Studies were made using human umbilical vein endothelial cells in which we addressed the mechanisms of PKCalpha-induced Rho activation and its consequences on actin cytoskeletal changes. We observed that PKCalpha associated with p115RhoGEF within 1 min of thrombin stimulation and p115RhoGEF phosphorylation was dependent on PKCalpha. Inhibition of PKCalpha-dependent p115RhoGEF phosphorylation prevented the thrombin-induced Rho activation, indicating that the response occurred downstream of PKCalpha phosphorylation of p115RhoGEF. The regulator of G-protein signaling domain of p115RhoGEF, a GTPase activating protein for G(12/13), also prevented thrombin-induced Rho activation, indicating the parallel requirement of G(12/13) in signaling Rho activation via p115RhoGEF. These data demonstrate a pathway of Rho activation involving PKCalpha dependent phosphorylation of p115RhoGEF. Thus, Rho activation in endothelial cells and the subsequent actin cytoskeletal re-arrangement require the cooperative interaction of both G(12/13) and PKCalpha pathways that converge at p115RhoGEF.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Anesthesiol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Mehta, D (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave,M-C 868, Chicago, IL 60612 USA.	dmehta@uic.edu		Malik, Asrar/0000-0002-8205-7128	NHLBI NIH HHS [HL71794, T32-HL07239, HL46350, HL45638] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071794, R01HL046350, R01HL045638] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aepfelbacher M, 2001, CELL MICROBIOL, V3, P649, DOI 10.1046/j.1462-5822.2001.00145.x; Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335; Amerongen GPV, 2001, ARTERIOSCL THROM VAS, V21, P300, DOI 10.1161/01.ATV.21.3.300; An SZ, 1998, J CELL BIOCHEM, P147; Barr AJ, 1997, J BIOL CHEM, V272, P2223; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; Chen Z, 2001, NAT STRUCT BIOL, V8, P805, DOI 10.1038/nsb0901-805; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 2000, METHOD ENZYMOL, V325, P61; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hehner SP, 2000, J BIOL CHEM, V275, P18160, DOI 10.1074/jbc.275.24.18160; HUNG DT, 1992, J BIOL CHEM, V267, P20831; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Kozasa T, 2001, LIFE SCI, V68, P2309, DOI 10.1016/S0024-3205(01)01020-7; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Lum H, 1996, CAN J PHYSIOL PHARM, V74, P787, DOI 10.1139/cjpp-74-7-787; LUM H, 1993, J CELL BIOL, V120, P1491, DOI 10.1083/jcb.120.6.1491; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mehta D, 2002, J PHYSIOL-LONDON, V539, P779, DOI 10.1113/jphysiol.2001.013289; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sandoval R, 2001, AM J PHYSIOL-LUNG C, V280, pL239, DOI 10.1152/ajplung.2001.280.2.L239; Suzuki N, 2003, P NATL ACAD SCI USA, V100, P733, DOI 10.1073/pnas.0234057100; Tamas P, 2001, CELL SIGNAL, V13, P475, DOI 10.1016/S0898-6568(01)00172-3; TIRUPPATHI C, 1992, AM J PHYSIOL, V263, pL595, DOI 10.1152/ajplung.1992.263.5.L595; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Wells C, 2002, METHOD ENZYMOL, V345, P371; Wells CD, 2002, J BIOL CHEM, V277, P1174, DOI 10.1074/jbc.M105274200; Wells CD, 2001, J BIOL CHEM, V276, P28897, DOI 10.1074/jbc.M102913200; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343	38	123	130	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28793	28798		10.1074/jbc.M303900200	http://dx.doi.org/10.1074/jbc.M303900200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12754211	hybrid			2022-12-25	WOS:000184421100057
J	Ma, J; Zhang, T; Diermayr, VN; Tan, ALC; Cao, XM				Ma, J; Zhang, T; Diermayr, VN; Tan, ALC; Cao, XM			A novel sequence in the coiled-coil domain of Stat3 essential for its nuclear translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED RECEPTOR-BINDING; EPIDERMAL-GROWTH-FACTOR; NUCLEOCYTOPLASMIC TRANSPORT; TRANSCRIPTIONAL ACTIVATION; TYROSINE PHOSPHORYLATION; IMPORT; PROTEIN; FAMILY; SIGNALS; COMPLEX	Stat3 is activated by cytokines and growth factors via specific tyrosine phosphorylation, dimerization, and nuclear translocation. However, the mechanism involved in its nuclear translocation is unclear. In this study, by systematic deletion and site-directed mutagenesis we identified Arg-214/215 in the alpha-helix 2 region of the coiled-coil domain of Stat3 as a novel sequence element essential for its nuclear translocation, stimulated by epidermal growth factor as well as by interleukin-6. Furthermore, we identified Arg-414/417 in the DNA binding domain as also required for the nuclear localization of Stat3. This sequence element corresponds to Lys-410/413 of Stat1, a reported sequence for Stat1 nuclear translocation. On the other hand, Leu-411 of Stat3, corresponding to Leu-407 of Stat1, a necessary residue for Stat1 nuclear transport, is not essential for Stat3 nuclear import. The mutant of Arg-214/215 or Arg-414/417 was shown to be tyrosyl-phosphorylated normally but failed to enter the nucleus in response to epidermal growth factor or interleukin-6. The defect, however, can be rescued by the wild-type Stat3 but cannot be compensated by these two mutants. Mutations on Arg-414/417, but not Arg-214/215, destroy the DNA binding activity of Stat3. Our data for the first time identified a sequence element located in the coiled-coil domain that is involved in the ligand-induced nuclear translocation of Stat3. This novel sequence together with a conserved sequence element in the DNA binding domain coordinates to mediate the nuclear translocation of Stat3.	Natl Univ Singapore, Dept Biochem, Singapore 117609, Singapore	National University of Singapore	Cao, XM (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.	mcbcaoxm@imcb.nus.edu.sg						ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Bhattacharya S, 2003, J CLIN INVEST, V111, P553, DOI 10.1172/JCI200315372; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Fagerlund R, 2002, J BIOL CHEM, V277, P30072, DOI 10.1074/jbc.M202943200; FELDHERR CM, 1990, ELECTRON MICROSC REV, V3, P73, DOI 10.1016/0892-0354(90)90014-J; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; Herrington J, 1999, J BIOL CHEM, V274, P5138, DOI 10.1074/jbc.274.8.5138; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; McBride KM, 2002, EMBO J, V21, P1754, DOI 10.1093/emboj/21.7.1754; Melen K, 2001, J BIOL CHEM, V276, P16447, DOI 10.1074/jbc.M008821200; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Meyer T, 2002, EXP CELL RES, V272, P45, DOI 10.1006/excr.2001.5405; Milocco LH, 1999, MOL CELL BIOL, V19, P2913; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; REICHELT R, 1990, J CELL BIOL, V110, P883, DOI 10.1083/jcb.110.4.883; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Thiel S, 1998, FEBS LETT, V441, P231, DOI 10.1016/S0014-5793(98)01559-2; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Zhang T, 2002, J BIOL CHEM, V277, P17556, DOI 10.1074/jbc.M105525200; Zhang T, 2000, MOL CELL BIOL, V20, P7132, DOI 10.1128/MCB.20.19.7132-7139.2000; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	49	79	82	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29252	29260		10.1074/jbc.M304196200	http://dx.doi.org/10.1074/jbc.M304196200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12746441	hybrid			2022-12-25	WOS:000184421100110
J	Rosenfeld, SS; Xing, J; Chen, LQ; Sweeney, HL				Rosenfeld, SS; Xing, J; Chen, LQ; Sweeney, HL			Myosin IIB is unconventionally conventional	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE; DIFFERENTIAL EXPRESSION; NEURITE OUTGROWTH; KINETIC MECHANISM; ISOFORMS; ACTIN; ADP; LOCALIZATION; CONTRACTION; TENSION	Members of the myosin II class of molecular motors have been referred to as "conventional," a term used to describe their ability to form thick filaments, their low duty ratio, the ability of individual motor-containing "heads" to operate independently of each other, and their rate-limiting phosphate release. These features ensure that those motors that have completed their power stroke dissociate rapidly enough to prevent them from interfering with those motors that are beginning theirs. However, in this study, we demonstrate that myosin IIB, a cytoplasmic myosin II particularly enriched in the central nervous system and cardiac tissue, has a number of features that it shares instead with "unconventional" myosin isoforms, including myosins V and VI. These include a high duty ratio, rate-limiting ADP release, and high ADP affinity. These features imply that myosin IIB serves a set of physiologic needs different from those served by its more conventional myosin II counterparts, and this work provides a plausible basis for explaining the physiologic role of this unconventionally conventional myosin.	Univ Alabama, Dept Neurol, Birmingham, AL 35294 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Pennsylvania	Rosenfeld, SS (corresponding author), Univ Alabama, Dept Neurol, UAb Stn, Birmingham, AL 35294 USA.		Sweeney, H Lee/F-1862-2010		NIAMS NIH HHS [AR35661] Funding Source: Medline; NINDS NIH HHS [NS34856] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035661] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034856] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAORTO DM, 1992, J CELL BIOL, V117, P357, DOI 10.1083/jcb.117.2.357; Bhatia-Dey N, 1998, MECH DEVELOP, V78, P33, DOI 10.1016/S0925-4773(98)00136-1; Bridgman PC, 2001, J NEUROSCI, V21, P6159, DOI 10.1523/JNEUROSCI.21-16-06159.2001; Coluccio LR, 1999, J BIOL CHEM, V274, P21575, DOI 10.1074/jbc.274.31.21575; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Gillespie GY, 1999, CANCER RES, V59, P2076; Hodge T, 2000, J CELL SCI, V113, P3353; Holmes KC, 2000, PHILOS T R SOC B, V355, P419, DOI 10.1098/rstb.2000.0583; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; MAUPIN P, 1994, J CELL SCI, V107, P3077; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; Pato MD, 1996, J BIOL CHEM, V271, P2689, DOI 10.1074/jbc.271.5.2689; ROCHLIN MW, 1995, J CELL SCI, V108, P3661; Rosenfeld SS, 2000, J BIOL CHEM, V275, P25418, DOI 10.1074/jbc.M002685200; ROSENFELD SS, 1984, J BIOL CHEM, V259, P1908; ROTH K, 1991, MAGNET RESON MED, V22, P505, DOI 10.1002/mrm.1910220258; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Svitkina TM, 1997, J CELL BIOL, V139, P397, DOI 10.1083/jcb.139.2.397; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; Tullio AN, 1997, P NATL ACAD SCI USA, V94, P12407, DOI 10.1073/pnas.94.23.12407; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; VERKHOVSKY AB, 1993, J CELL BIOL, V123, P637, DOI 10.1083/jcb.123.3.637; Wylie SR, 1998, P NATL ACAD SCI USA, V95, P12967, DOI 10.1073/pnas.95.22.12967; Wylie SR, 2001, NAT CELL BIOL, V3, P88, DOI 10.1038/35050613; XIAO M, 2003, IN PRESS NAT STRUCT	30	90	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27449	27455		10.1074/jbc.M302555200	http://dx.doi.org/10.1074/jbc.M302555200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12740390	hybrid			2022-12-25	WOS:000184242700016
J	Bohnsack, RN; Haas, AL				Bohnsack, RN; Haas, AL			Conservation in the mechanism of nedd8 activation by the human AppBp1-Uba3 heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; KAPPA-B-ALPHA; UBIQUITIN ACTIVATION; CONJUGATING ENZYMES; CRYSTAL-STRUCTURE; CELL-CYCLE; PATHWAY; COMPLEX; LIGASES; SYSTEM	Human Nedd8-activating enzyme AppBp1-Uba3 was purified to apparent homogeneity from erythrocytes. In the presence of [2,8-H-3] ATP and I-125-Nedd8, heterodimer rapidly forms a stable stoichiometric ternary complex composed of tightly bound Nedd8 [H-3] adenylate and Uba3-I-125-Nedd8 thiol ester. Isotope exchange kinetics show that the heterodimer follows a pseudo-ordered mechanism with ATP the leading and Nedd8 the trailing substrate. Human AppBp1-Uba3 follows hyperbolic kinetics for HsUbc12 transthiolation with I-125-Nedd8 (k(cat) = 3.5 +/- 0.2 s(-1)), yielding K-m values for ATP (103 +/- 12 muM), I-125-Nedd8 (0.95 +/- 0.18 muM), and HsUbc12 (43 +/- 13 nM) similar to those for ubiquitin activation by Uba1. Wild type I-125-ubiquitin fails to support AppBp1-Uba3 catalyzed activation or HsUbc12 transthiolation. However, modest inhibition of I-125-Nedd8 ternary complex formation by unlabeled ubiquitin suggests a K-d > 300 muM for ubiquitin. Alanine 72 of Nedd8 is a critical specificity determinant for AppBp1-Uba3 binding because I-125-UbR72L undergoes heterodimer-catalyzed hyperbolic HsUbc12 transthiolation and yields K-m = 20 +/- 9 muM and k(cat) = 0.9 +/- 0.3 s(-1). These observations demonstrate remarkable conservation in the mechanism of AppBp1-Uba3 that mirrors its sequence conservation with the Uba1 ubiquitin-activating enzyme.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Haas, AL (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.				NIGMS NIH HHS [GM34009] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034009] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; BURCH TJ, 1994, BIOCHEMISTRY-US, V33, P7300, DOI 10.1021/bi00189a035; Chen YZ, 2000, J BIOL CHEM, V275, P8929, DOI 10.1074/jbc.275.12.8929; Chow NW, 1996, J BIOL CHEM, V271, P11339, DOI 10.1074/jbc.271.19.11339; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; del Pozo JC, 1999, P NATL ACAD SCI USA, V96, P15342, DOI 10.1073/pnas.96.26.15342; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dittmar GAG, 2002, SCIENCE, V295, P2442, DOI 10.1126/science.1069989; ECKER DJ, 1987, J BIOL CHEM, V262, P3524; Furukawa M, 2002, J BIOL CHEM, V277, P15758, DOI 10.1074/jbc.M108565200; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1983, BIOCHEMISTRY-US, V22, P4388, DOI 10.1021/bi00288a007; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1985, PREP BIOCHEM, V15, P49; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; Haas AL, 1997, FASEB J, V11, P1257; HAAS AL, 1988, J BIOL CHEM, V263, P13258; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Lake MW, 2001, NATURE, V414, P325, DOI 10.1038/35104586; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Larsen CN, 2002, J PROTEOME RES, V1, P411, DOI 10.1021/pr025522n; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; LOEB KR, 1992, J BIOL CHEM, V267, P7806; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; PICKART CM, 1994, J BIOL CHEM, V269, P7115; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PICKART CM, 1988, J BIOL CHEM, V263, P12028; Raasi S, 2001, J BIOL CHEM, V276, P35334, DOI 10.1074/jbc.M105139200; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P42; SEGAL IH, 1975, ENZYME KINETICS; Siepmann TJ, 2003, J BIOL CHEM, V278, P9448, DOI 10.1074/jbc.M211240200; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Walden H, 2003, NATURE, V422, P330, DOI 10.1038/nature01456; Whitby FG, 1998, J BIOL CHEM, V273, P34983, DOI 10.1074/jbc.273.52.34983; Wu K, 2000, J BIOL CHEM, V275, P32317, DOI 10.1074/jbc.M004847200; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362	47	94	97	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26823	26830		10.1074/jbc.M303177200	http://dx.doi.org/10.1074/jbc.M303177200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12740388	hybrid			2022-12-25	WOS:000184155700069
J	Tsuda, M; Takahashi, S; Takahashi, Y; Asahara, H				Tsuda, M; Takahashi, S; Takahashi, Y; Asahara, H			Transcriptional co-activators CREB-binding protein and p300 regulate chondrocyte-specific gene expression via association with Sox9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; RUBINSTEIN-TAYBI SYNDROME; MESENCHYMAL STEM-CELLS; HISTONE ACETYLTRANSFERASE; BETA-CATENIN; CARTILAGE FORMATION; STRUCTURAL BASIS; IN-VITRO; CBP; ACTIVATION	Chondrocytes are critical components for the precise patterning of a developing skeletal framework and articular joint formation. Sox9 is a key transcription factor that is essential for chondrocyte differentiation and chondrocyte-specific gene expressions; however, the precise transcriptional activation mechanism of Sox9 is not fully understood. Here we demonstrate that Sox9 utilizes a cAMP-response element-binding protein ( CREB)-binding protein (CBP)/p300 to exert its effects. Sox9 associates with CBP/p300 in the chondrosarcoma cell line SW1353 via its carboxyl termini activation domain in a cell type-specific manner. In promoter assays, CBP/p300 enhances Col2a1, which encodes cartilage-specific type II collagen gene promoter activity via Sox9. Chromatin immunoprecipitation shows that p300 is bound to the Col2a1 promoter region. Furthermore, the CBP/Sox9 complex disrupter peptide suppresses Col2a1 gene expression and chondrogenesis from mesenchymal stem cells. These data demonstrate that CBP and p300 function as co-activators of Sox9 for cartilage tissue-specific gene expression and chondrocyte differentiation.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Tokyo Univ Pharm & Life Sci, Sch Life Sci, Lab Environm Mol Physiol, Tokyo 1920392, Japan; Japan Sci & Technol Corp, PRESTO, Kawaguchi 3320012, Japan	Scripps Research Institute; Tokyo University of Pharmacy & Life Sciences; Japan Science & Technology Agency (JST)	Asahara, H (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd,MEM161, La Jolla, CA 92037 USA.							Aigner T, 2002, CELL MOL LIFE SCI, V59, P5, DOI 10.1007/s00018-002-8400-3; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Asahara H, 1999, MOL CELL BIOL, V19, P8219; Asahara H, 2002, MOL CELL BIOL, V22, P2974, DOI 10.1128/MCB.22.9.2974-2983.2002; Asahara H, 2001, MOL CELL BIOL, V21, P7892, DOI 10.1128/MCB.21.23.7892-7900.2001; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bi WM, 2001, P NATL ACAD SCI USA, V98, P6698, DOI 10.1073/pnas.111092198; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; CANCEDDA R, 1995, INT REV CYTOL, V159, P265, DOI 10.1016/S0074-7696(08)62109-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; de Crombrugghe B, 2000, MATRIX BIOL, V19, P389, DOI 10.1016/S0945-053X(00)00094-9; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Goodman RH, 2000, GENE DEV, V14, P1553; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Jones KA, 2000, GENE DEV, V14, P1992; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Pittenger MF, 2000, CURR TOP MICROBIOL, V251, P3; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Sekiya I, 2002, P NATL ACAD SCI USA, V99, P4397, DOI 10.1073/pnas.052716199; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tanaka K, 2000, MOL CELL BIOL, V20, P4428, DOI 10.1128/MCB.20.12.4428-4435.2000; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F	43	172	179	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27224	27229		10.1074/jbc.M303471200	http://dx.doi.org/10.1074/jbc.M303471200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12732631	hybrid			2022-12-25	WOS:000184155700118
J	Im, HJ; Pacione, C; Chubinskaya, S; van Wijnen, AJ; Sun, YB; Loeser, RF				Im, HJ; Pacione, C; Chubinskaya, S; van Wijnen, AJ; Sun, YB; Loeser, RF			Inhibitory effects of insulin-like growth factor-1 and osteogenic protein-1 on fibronectin fragment- and interleukin-1 beta-stimulated matrix metalloproteinase-13 expression in human chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR CHONDROCYTES; BONE MORPHOGENETIC PROTEIN; MESSENGER-RNA EXPRESSION; GENE-EXPRESSION; COLLAGENASE-3 MATRIX-METALLOPROTEINASE-13; OSTEOARTHRITIC CARTILAGE; CELL-CULTURES; REPAIR; DIFFERENTIATION; PROLIFERATION	Matrix metalloproteinase-13 (collagenase-3), a member of the family of matrix metalloproteinases ( MMPs), plays a major pathological role in the cartilage destruction of arthritis. A dramatic up-regulation of MMP-13 by inflammatory cytokines such as interleukin (IL)-1beta or by fibronectin fragments has been observed in chondrocytes. In this study, we investigated the inhibitory effects of insulin-like growth factor-1 (IGF-1) and osteogenic protein-1 (OP-1) on the expression of MMP-13, which was induced by fibronectin fragment or IL-1beta in human immortalized or human primary chondrocytes. IGF-1 and OP-1 each significantly reduced the basal level as well as fibronectin fragment- or IL-1beta-stimulated transcription of the MMP-13 gene in a dose-dependent fashion with the corresponding decreases in the protein level of MMP-13. The most prominent suppressive effect was observed by the combination of IGF-1 and OP-1, which decreased the basal promoter activity by 60% and almost completely abrogated the fibronectin fragment-stimulated MMP-13 promoter activity. OP-1 was found to enhance mRNA levels of IGF-1 and the IGF-1 receptor, the latter of which appeared to be responsible for the combined effect of IGF-1 and OP-1. The suppressive effect of IGF-1 and OP-1 on MMP-13 expression was due in part to down-regulation of the expression of pro-inflammatory cytokines and the activity of their intermediate molecules, including NF-kappaB and AP-1 factors. We propose that IGF-1 and OP-1 could be key physiological regulators of MMP-13 gene expression and that the combination of IGF-1 and OP-1 may be useful in controlling the excess catabolic activity in arthritis.	Rush Med Coll, Rush Presbyterian St Lukes Med Ctr, Dept Biochem, Rheumatol Sect, Chicago, IL 60612 USA; Rush Med Coll, Rush Presbyterian St Lukes Med Ctr, Dept Internal Med, Rheumatol Sect, Chicago, IL 60612 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Miami, Sch Med, Dept Med, Miami, FL 33101 USA	Rush University; Rush University; University of Massachusetts System; University of Massachusetts Worcester; University of Miami	Loeser, RF (corresponding author), Rush Med Coll, Rush Presbyterian St Lukes Med Ctr, Dept Biochem, Rheumatol Sect, 1725 W Harrison,Suite 1017, Chicago, IL 60612 USA.		van Wijnen, Andre J./AAG-3578-2019	van Wijnen, Andre J./0000-0002-4458-0946	NIAMS NIH HHS [R01 AR049069, R01 AR053220-04, R01 AR053220, R37 AR049003, R01 AR049003, AR49003] Funding Source: Medline; NIA NIH HHS [AG16697, AG47654, R01 AG016697] Funding Source: Medline; BLRD VA [I01 BX002647] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053220, R01AR049069, R37AR049003, R01AR049003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016697] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002647] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); BLRD VA; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Veterans Affairs(US Department of Veterans Affairs)		Billinghurst RC, 1997, J CLIN INVEST, V99, P1534, DOI 10.1172/JCI119316; Bondeson J, 2000, J RHEUMATOL, V27, P2078; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; Chubinskaya S, 2000, J HISTOCHEM CYTOCHEM, V48, P239, DOI 10.1177/002215540004800209; D'Alonzo RC, 2002, J BIOL CHEM, V277, P816, DOI 10.1074/jbc.M107082200; Dahlberg L, 2000, ARTHRITIS RHEUM, V43, P673, DOI 10.1002/1529-0131(200003)43:3<673::AID-ANR25>3.0.CO;2-8; Delany AM, 1996, ENDOCRINOLOGY, V137, P4665, DOI 10.1210/en.137.11.4665; Forsyth CB, 2002, ARTHRITIS RHEUM, V46, P2368, DOI 10.1002/art.10502; Fortier LA, 2002, J BONE JOINT SURG BR, V84B, P276, DOI 10.1302/0301-620X.84B2.11167; Gazzerro E, 1999, ENDOCRINOLOGY, V140, P562, DOI 10.1210/en.140.2.562; Goldring MB, 2000, ARTHRITIS RHEUM-US, V43, P1916, DOI 10.1002/1529-0131(200009)43:9<1916::AID-ANR2>3.0.CO;2-I; Gould SE, 2002, KIDNEY INT, V61, P51, DOI 10.1046/j.1523-1755.2002.00103.x; Haaijman A, 2000, GROWTH FACTORS, V17, P177, DOI 10.3109/08977190009001067; Homandberg GA, 1997, BIOCHEM J, V321, P751, DOI 10.1042/bj3210751; Hui W, 2001, ANN RHEUM DIS, V60, P254, DOI 10.1136/ard.60.3.254; Ito Y, 2001, J BONE MINER METAB, V19, P188, DOI 10.1007/s007740170041; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; Koepp HE, 1999, INFLAMM RES, V48, P199, DOI 10.1007/s000110050446; Kuhn K, 2001, ARTHRITIS RHEUM-US, V44, P1644, DOI 10.1002/1529-0131(200107)44:7<1644::AID-ART287>3.0.CO;2-S; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Leeman MF, 2002, CRIT REV BIOCHEM MOL, V37, P149, DOI 10.1080/10409230290771483; Liacini A, 2002, MATRIX BIOL, V21, P251, DOI 10.1016/S0945-053X(02)00007-0; Madry H, 2001, GENE THER, V8, P1443, DOI 10.1038/sj.gt.3301535; Mengshol JA, 2001, NUCLEIC ACIDS RES, V29, P4361, DOI 10.1093/nar/29.21.4361; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; REDDI AH, 1993, J BONE MINER RES, V8, P499; SAMPATH TK, 1992, J BIOL CHEM, V267, P20352; Shlopov BV, 2000, ARTHRITIS RHEUM-US, V43, P195, DOI 10.1002/1529-0131(200001)43:1<195::AID-ANR24>3.0.CO;2-G; Spies M, 2001, GENE THER, V8, P1409, DOI 10.1038/sj.gt.3301543; Stanton H, 2002, BIOCHEM J, V364, P181, DOI 10.1042/bj3640181; Tardif G, 1997, BIOCHEM J, V323, P13, DOI 10.1042/bj3230013; Tsuzaki M, 2003, J ORTHOP RES, V21, P256, DOI 10.1016/S0736-0266(02)00141-9; Varghese S, 1997, ENDOCRINOLOGY, V138, P1035, DOI 10.1210/en.138.3.1035; VUKICEVIC S, 1989, P NATL ACAD SCI USA, V86, P8793, DOI 10.1073/pnas.86.22.8793; Wozney JM, 1998, CLIN ORTHOP RELAT R, P26; Yamashita H, 1996, BONE, V19, P569, DOI 10.1016/S8756-3282(96)00259-1; Yasuda T, 2002, ARTHRITIS RHEUM, V46, P138, DOI 10.1002/1529-0131(200201)46:1<138::AID-ART10051>3.0.CO;2-K; Yeh LCC, 1998, J CELL PHYSIOL, V175, P78, DOI 10.1002/(SICI)1097-4652(199804)175:1<78::AID-JCP9>3.0.CO;2-9; Yeh LCC, 1997, ENDOCRINOLOGY, V138, P4181, DOI 10.1210/en.138.10.4181; Yeh LCC, 1996, ENDOCRINOLOGY, V137, P1921, DOI 10.1210/en.137.5.1921	40	114	121	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25386	25394		10.1074/jbc.M302048200	http://dx.doi.org/10.1074/jbc.M302048200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12734180	hybrid, Green Accepted			2022-12-25	WOS:000183920200017
J	Kim, I; Chu, XY; Kim, S; Provoda, CJ; Lee, KD; Amidon, GL				Kim, I; Chu, XY; Kim, S; Provoda, CJ; Lee, KD; Amidon, GL			Identification of a human valacyclovirase - Biphenyl hydrolase-like protein as valacyclovir hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-VALYL ESTER; ACYCLOVIR PRODRUG VALACICLOVIR; MULTIPLE SEQUENCE ALIGNMENT; METABOLIC DISPOSITION; PEPTIDE TRANSPORTER; PHARMACOKINETICS; CPT-11; CARBOXYLESTERASE; VALGANCICLOVIR; ABSORPTION	Valacyclovir is the 5'-valyl ester prodrug of acyclovir, an effective anti-herpetic drug. Systemic availability of acyclovir in humans is three to five times higher when administered orally as the prodrug. The increased bioavailability of valacyclovir is attributed to carrier-mediated intestinal absorption, via the hPEPT1 peptide transporter, followed by the rapid and complete conversion to acyclovir. The one or more human enzymes responsible for in vivo activation of the prodrug to the active drug and its conversion sites, however, have not been identified. In this report, we describe the purification, identification, and characterization of a human enzyme that activates valacyclovir to acyclovir. A protein with significant hydrolytic activity toward valacyclovir, the 5'-glycyl ester of acyclovir, and the 5'-valyl ester of zidovudine (AZT), was purified from Caco-2 cells derived from human intestine. Using a non-redundant data base search, the N-terminal 19-amino acid sequence of the purified 27-kDa, basic protein revealed a perfect match within the N terminus of a serine hydrolase, Biphenyl hydrolase-like (BPHL, gi: 4757862) protein, previously cloned from human breast carcinoma. Recombinant BPHL exhibited significant hydrolytic activity for both valacyclovir and valganciclovir with specificity constants (k(cat)/K-m), 420 and 53.2 mM(-1).s(-1), respectively. We conclude that BPHL may be an important enzyme activating valacyclovir and valganciclovir in humans and an important new target for prodrug design.	Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Amidon, GL (corresponding author), Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, 428 Church St, Ann Arbor, MI 48109 USA.	glamidon@umich.edu			NIGMS NIH HHS [GM 37188] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037188] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Balimane PV, 1998, BIOCHEM BIOPH RES CO, V250, P246, DOI 10.1006/bbrc.1998.9298; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE TC, 1994, DRUG METAB DISPOS, V22, P60; BURNETTE TC, 1995, J BIOL CHEM, V270, P15827, DOI 10.1074/jbc.270.26.15827; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Curran M, 2001, DRUGS, V61, P1145, DOI 10.2165/00003495-200161080-00013; DEMIRANDA P, 1994, DRUG METAB DISPOS, V22, P55; Ganapathy ME, 1998, BIOCHEM BIOPH RES CO, V246, P470, DOI 10.1006/bbrc.1998.8628; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Han HK, 2000, AAPS PHARMSCI, V2; Han HK, 1998, PHARMACEUT RES, V15, P1154, DOI 10.1023/A:1011919319810; Humerickhouse R, 2000, CANCER RES, V60, P1189; KIM I, 2002, AAPS PHARMSCI, V4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Perry CM, 1996, DRUGS, V52, P754, DOI 10.2165/00003495-199652050-00009; Pescovitz MD, 2000, ANTIMICROB AGENTS CH, V44, P2811, DOI 10.1128/AAC.44.10.2811-2815.2000; Puente XS, 1998, GENOMICS, V51, P459, DOI 10.1006/geno.1998.5351; PUENTE XS, 1995, J BIOL CHEM, V270, P12926, DOI 10.1074/jbc.270.21.12926; Puente XS, 1997, BIOCHEM J, V322, P947, DOI 10.1042/bj3220947; *ROCH LAB INC, 2001, VALCYTE COMPL PROD I; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Satoh T, 2002, DRUG METAB DISPOS, V30, P488, DOI 10.1124/dmd.30.5.488; SATOH T, 1994, BIOL PHARM BULL, V17, P662; Sinko PJ, 1998, BIOPHARM DRUG DISPOS, V19, P209, DOI 10.1002/(SICI)1099-081X(199805)19:4<209::AID-BDD93>3.0.CO;2-O; Smiley ML, 1996, ADV EXP MED BIOL, V394, P33; SOULLAWTON J, 1995, ANTIMICROB AGENTS CH, V39, P2759, DOI 10.1128/AAC.39.12.2759; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wadkins RM, 2001, MOL PHARMACOL, V60, P355, DOI 10.1124/mol.60.2.355; WELLER S, 1993, CLIN PHARMACOL THER, V54, P595, DOI 10.1038/clpt.1993.196	30	78	82	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25348	25356		10.1074/jbc.M302055200	http://dx.doi.org/10.1074/jbc.M302055200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12732646	hybrid			2022-12-25	WOS:000183920200013
J	Djavaheri-Mergny, M; Wietzerbin, J; Besancon, F				Djavaheri-Mergny, M; Wietzerbin, J; Besancon, F			2-methoxyestradiol induces apoptosis in Ewing sarcoma cells through mitochondrial hydrogen peroxide production	ONCOGENE			English	Article						Ewing tumor; apoptosis; 2-methoxyestradiol; reactive oxygen species; mitochondria	N-TERMINAL KINASE; ENDOGENOUS ESTROGEN METABOLITE; CANCER-CELLS; GLUTATHIONE-PEROXIDASE; SIGNALING PATHWAY; INHIBITS ANGIOGENESIS; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; PROSTATE-CANCER; TUMOR-GROWTH	The Ewing sarcoma is the second most common bone tumor in children and young adults. Despite the advances in therapy, the 5-year survival rate for patients with metastatic disease is poor, indicating the need for alternative treatments. Here, we report that 2-methoxy-estradiol (2-Me), a natural estrogen metabolite, induced a caspase-dependent apoptosis of Ewing sarcoma-derived cells independently of their p53 status. 2-Me-induced apoptosis occurred through the mitochondrial death pathway as evidenced by reduction of the mitochondrial transmembrane potential, cytochrome c release and caspase-9 activation. Treatment of cells with 2-Me resulted in generation of intracellular H2O2, which occurred earlier than caspase-9 activation. The H2O2-reducing agent Ebselen and the lipid peroxidation inhibitor vitamin E decreased both 2-Me-induced caspase-9 activation and cell death, thus providing evidence for a role of H2O2 and lipid peroxides in the initiation of this process. Rotenone, an inhibitor of the mitochondrial respiratory chain, abolished both apoptosis and H2O2 production, thereby identifying mitochondria as the source of H2O2. Moreover, we observed that treatment of cells with 2-Me or H2O2 induced activation of the c-Jun N-terminal kinase (JNK). Overexpression of a dominant-negative mutant of JNK1 reduced 2-Me-induced apoptosis indicating that JNK participates in this process. Altogether, our results provide evidence that 2-Me triggers apoptosis of Ewing sarcoma cells through induction of a mitochondria redox-dependent mechanism and suggest that this compound or other agents that selectively increase the level of reactive oxygen species may prove useful to the development of novel strategies for treatment of Ewing tumors.	Inst Curie, Sect Rech, INSERM, U365, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Djavaheri-Mergny, M (corresponding author), Inst Curie, Sect Rech, INSERM, U365, 26 Rue Ulm, F-75248 Paris 05, France.		Djavaheri-Mergny, Mojgan/L-3890-2019; Djavaheri-Mergny, Mojgan/N-6315-2017	Djavaheri-Mergny, Mojgan/0000-0003-4893-6505; Djavaheri-Mergny, Mojgan/0000-0003-4893-6505				Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Attalla H, 1998, BIOCHEM BIOPH RES CO, V247, P616, DOI 10.1006/bbrc.1998.8870; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Cai JY, 1999, J BIOENERG BIOMEMBR, V31, P327, DOI 10.1023/A:1005423818280; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Curtin JF, 2002, J IMMUNOL METHODS, V265, P49, DOI 10.1016/S0022-1759(02)00070-4; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; DeSilva DR, 1998, J IMMUNOL, V160, P4175; Djavaheri-Mergny M, 2001, FREE RADICAL RES, V34, P583, DOI 10.1080/10715760100300481; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.3.CO;2-P; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; Gupta S, 2001, LIFE SCI, V69, P2957, DOI 10.1016/S0024-3205(01)01404-7; HALLIWELL B, 1984, LANCET, V2, P1095; Hamel E, 1996, BIOCHEMISTRY-US, V35, P1304, DOI 10.1021/bi951559s; Hashimoto M, 2002, J BIOL CHEM, V277, P11465, DOI 10.1074/jbc.M111428200; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Javelaud D, 2001, ONCOGENE, V20, P4365, DOI 10.1038/sj.onc.1204570; Kotamraju S, 2000, J BIOL CHEM, V275, P33585, DOI 10.1074/jbc.M003890200; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar Heinrich, 1998, Current Opinion in Oncology, V10, P334, DOI 10.1097/00001622-199807000-00010; Kumar AP, 2001, MOL CARCINOGEN, V31, P111, DOI 10.1002/mc.1046; Kushner BH, 2001, J CLIN ONCOL, V19, P870, DOI 10.1200/JCO.2001.19.3.870; LEDENEV AN, 1986, BIOCHEM INT, V13, P391; Lin HL, 2000, CANCER-AM CANCER SOC, V89, P983, DOI 10.1002/1097-0142(20000901)89:5<983::AID-CNCR7>3.3.CO;2-7; Mukhopadhyay T, 1997, ONCOGENE, V14, P379, DOI 10.1038/sj.onc.1200835; Nakamura Y, 2002, J BIOL CHEM, V277, P2687, DOI 10.1074/jbc.M109641200; Nomura K, 2001, BIOL SIGNAL RECEPT, V10, P81; Oberlin O, 2001, BRIT J CANCER, V85, P1646, DOI 10.1054/bjoc.2001.2150; Ollinger Karin, 2002, Subcell Biochem, V36, P151; Petrosillo G, 2001, FEBS LETT, V509, P435, DOI 10.1016/S0014-5793(01)03206-9; Pinkerton CR, 2001, EUR J CANCER, V37, P1338, DOI 10.1016/S0959-8049(01)00131-9; Pribluda VS, 2000, CANCER METAST REV, V19, P173, DOI 10.1023/A:1026543018478; Qadan LR, 2001, BIOCHEM BIOPH RES CO, V285, P1259, DOI 10.1006/bbrc.2001.5320; Qanungo S, 2002, ONCOGENE, V21, P4149, DOI 10.1038/sj.onc.1205508; Ramachandran A, 2002, BIOL CHEM, V383, P693, DOI 10.1515/BC.2002.071; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Reed JC, 2002, MOL CELL, V9, P1, DOI 10.1016/S1097-2765(02)00437-9; Sartorius U, 2001, CHEMBIOCHEM, V2, P20, DOI 10.1002/1439-7633(20010105)2:1<20::AID-CBIC20>3.3.CO;2-O; Schumacher G, 2001, J CANCER RES CLIN, V127, P405, DOI 10.1007/s004320000233; SIES H, 1994, METHOD ENZYMOL, V234, P476; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Sitailo LA, 2002, J BIOL CHEM, V277, P19346, DOI 10.1074/jbc.M200401200; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Szibor M, 2001, ANTIOXID REDOX SIGN, V3, P515, DOI 10.1089/15230860152409149; Tang DG, 2002, BIOL CHEM, V383, P425, DOI 10.1515/BC.2002.046; YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5; Yue TL, 1997, MOL PHARMACOL, V51, P951, DOI 10.1124/mol.51.6.951; Zhao R, 2002, P NATL ACAD SCI USA, V99, P8579, DOI 10.1073/pnas.122061399; Zhao YF, 2001, ANTIOXID REDOX SIGN, V3, P375, DOI 10.1089/15230860152409022	56	69	73	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2558	2567		10.1038/sj.onc.1206356	http://dx.doi.org/10.1038/sj.onc.1206356			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730670				2022-12-25	WOS:000182569000003
J	Ramjeesingh, R; Leung, R; Siu, CH				Ramjeesingh, R; Leung, R; Siu, CH			Interleukin-8 secreted by endothelial cells induces chemotaxis of melanoma cells through the chemokine receptor CXCR1	FASEB JOURNAL			English	Article						chemokines; under-agarose assay; transendothelial migration; antibody inhibition	TRANSENDOTHELIAL MIGRATION; CANCER-CELLS; IN-VITRO; MALIGNANT-MELANOMA; AMINO-ACID; EXPRESSION; IL-8; METASTASIS; GROWTH; MATRIX	There is increasing evidence that both cell adhesion molecules and soluble factors are involved in tumor metastasis. We have found that endothelial cells secrete chemoattractants that can induce melanoma cell chemotaxis. Protein separation on an ion-exchange column shows the association of IL-8 with fractions that contain the chemoattractant activity. This activity is completely lost from the conditioned medium after immunoprecipitation with anti-IL-8 antibodies, indicating that IL-8 is the major melanoma chemoattractant secreted by endothelial cells. IL-8(77), the predominant endothelial IL-8 isoform that contains 77 amino acids, is found to be twice as potent as the more common 72-amino acid isoform IL-8(72). Antibody inhibition studies indicate that the chemotactic response of melanoma cells is mediated by the CXC-chemokine receptor CXCR1 and not by the more promiscuous CXCR2. When stimulated by tumor necrosis factor alpha, the nonresponsive WM35 melanoma cells synthesize a higher level of CXCR1 and become chemotactic toward interleukin (IL)-8. Pretreatment of cells with pertussis toxin nullifies their chemotactic response, suggesting the involvement of G proteins. Antibodies against either IL-8 or CXCR1 inhibit melanoma transendothelial migration in a coculture assay by 30%. These results are consistent with a role for IL-8-induced chemotaxis in the transendothelial migration of melanoma cells.	Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1L6, Canada	University of Toronto; University of Toronto	Siu, CH (corresponding author), Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.	chi.hung.siu@utoronto.ca	Ramjeesingh, Ravi/AAB-3374-2022	Ramjeesingh, Ravi/0000-0001-5584-3505				ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059; AlonsoVarona A, 1996, B CANCER, V83, P27; AUERBACH R, 1985, MICROVASC RES, V29, P401, DOI 10.1016/0026-2862(85)90028-7; AYALON O, 1994, J CELL BIOL, V126, P247, DOI 10.1083/jcb.126.1.247; AZNAVOORIAN S, 1990, J CELL BIOL, V110, P1427, DOI 10.1083/jcb.110.4.1427; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Baggiolini M, 2001, J INTERN MED, V250, P91, DOI 10.1046/j.1365-2796.2001.00867.x; Belien ATJ, 1999, J CELL BIOL, V144, P373, DOI 10.1083/jcb.144.2.373; BERENS ME, 1994, CLIN EXP METASTAS, V12, P405, DOI 10.1007/BF01755884; CHUNTHARAPAI A, 1995, J IMMUNOL, V155, P2587; Damaj BB, 1996, J BIOL CHEM, V271, P12783, DOI 10.1074/jbc.271.22.12783; De Larco JE, 2001, CANCER RES, V61, P2857; DEJANA E, 1995, FASEB J, V9, P910, DOI 10.1096/fasebj.9.10.7615160; GESSER B, 1995, BIOCHEM BIOPH RES CO, V210, P660, DOI 10.1006/bbrc.1995.1711; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; HAMMOND MEW, 1995, J IMMUNOL, V155, P1428; HERLYN M, 1985, CANCER RES, V45, P5670; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Holtkamp GM, 1998, CLIN EXP IMMUNOL, V112, P34; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; Inoue K, 2000, CANCER RES, V60, P2290; Kim SJ, 2001, NEOPLASIA, V3, P33, DOI 10.1038/sj.neo.7900124; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; LEE J, 1992, J BIOL CHEM, V267, P16283; Lewalle JM, 1997, EXP CELL RES, V237, P347, DOI 10.1006/excr.1997.3799; Liotta L A, 1986, Prog Clin Biol Res, V212, P17; Luca M, 1997, AM J PATHOL, V151, P1105; Meier F., 1998, FRONT BIOSCI J VIS L, V3, P1005, DOI [10.2741/a341, DOI 10.2741/A341]; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murakami T, 2002, CANCER RES, V62, P7328; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NELSON RD, 1975, J IMMUNOL, V115, P1650; NICOLSON GL, 1982, J HISTOCHEM CYTOCHEM, V30, P214, DOI 10.1177/30.3.7061823; NOURSHARGH S, 1992, J IMMUNOL, V148, P106; OPAS M, 1985, EXP CELL BIOL, V53, P241; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; PAULI BU, 1990, CANCER METAST REV, V9, P175, DOI 10.1007/BF00046359; REPESH LA, 1989, INVAS METAST, V9, P192; Robledo MM, 2001, J BIOL CHEM, V276, P45098, DOI 10.1074/jbc.M106912200; Rofstad EK, 2000, CANCER RES, V60, P4932; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; RUSCIANO D, 1992, BIOESSAYS, V14, P185, DOI 10.1002/bies.950140309; SAMANTA AK, 1990, J BIOL CHEM, V265, P183; Sandig M, 1997, CELL MOTIL CYTOSKEL, V38, P351, DOI 10.1002/(SICI)1097-0169(1997)38:4<351::AID-CM5>3.3.CO;2-Z; SCHADENDORF D, 1993, J IMMUNOL, V151, P2667; Scherbarth S, 1997, CANCER RES, V57, P4105; Schraufstatter IU, 2001, AM J PHYSIOL-LUNG C, V280, pL1094, DOI 10.1152/ajplung.2001.280.6.L1094; Singh RK, 2000, HISTOL HISTOPATHOL, V15, P843, DOI 10.14670/HH-15.843; SINGH RK, 1994, CANCER RES, V54, P3242; STRACKE ML, 1988, BIOCHEM BIOPH RES CO, V153, P1076, DOI 10.1016/S0006-291X(88)81338-X; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; Voura EB, 1998, MICROSC RES TECHNIQ, V43, P265, DOI 10.1002/(SICI)1097-0029(19981101)43:3<265::AID-JEMT9>3.0.CO;2-Z; Voura EB, 2001, MOL BIOL CELL, V12, P2699, DOI 10.1091/mbc.12.9.2699; Voura EB, 2001, CLIN EXP METASTAS, V18, P527, DOI 10.1023/A:1011884807746; Voura EB, 1998, CELL TISSUE RES, V293, P375, DOI 10.1007/s004410051129; WALZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755, DOI 10.1016/0006-291X(87)90432-3; WANG JM, 1990, BIOCHEM BIOPH RES CO, V169, P165, DOI 10.1016/0006-291X(90)91449-3; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; Wu LJ, 1996, J BIOL CHEM, V271, P31202, DOI 10.1074/jbc.271.49.31202; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; Youngs SJ, 1997, INT J CANCER, V71, P257, DOI 10.1002/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D	63	64	67	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1292	+		10.1096/fj.02-0560fje	http://dx.doi.org/10.1096/fj.02-0560fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738812				2022-12-25	WOS:000183165000029
J	Ishii, R; Nureki, O; Yokoyama, S				Ishii, R; Nureki, O; Yokoyama, S			Crystal structure of the tRNA processing enzyme RNase PH from Aquifex aeolicus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; POLYNUCLEOTIDE PHOSPHORYLASE; MESSENGER-RNA; DEGRADATION; MATURATION; END; REPLACEMENT; REFINEMENT; PROTEINS; EXOSOME	RNase PH is one of the exoribonucleases that catalyze the 3' end processing of tRNA in bacteria. RNase PH removes nucleotides following the CCA sequence of tRNA precursors by phosphorolysis and generates mature tRNAs with amino acid acceptor activity. In this study, we determined the crystal structure of Aquifex aeolicus RNase PH bound with a phosphate, a co-substrate, in the active site at 2.3-Angstrom resolution. RNase PH has the typical alpha/beta fold, which forms a hexameric ring structure as a trimer of dimers. This ring structure resembles that of the polynucleotide phosphorylase core domain homotrimer, another phosphorolytic exoribonuclease. Four amino acid residues, Arg-86, Gly-124, Thr-125, and Arg-126, of RNase PH are involved in the phosphate-binding site. Mutational analyses of these residues showed their importance in the phosphorolysis reaction. A docking model with the tRNA acceptor stem suggests how RNase PH accommodates substrate RNAs.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan; RIKEN, Harima Inst SPring 8, Cellular Signaling Lab, Mikazuki, Hyogo 6795148, Japan; Japan Sci & Technol Corp, PRESTO, Kawaguchi, Saitama 3320012, Japan	University of Tokyo; RIKEN; RIKEN; Japan Science & Technology Agency (JST)	Yokoyama, S (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Ishii, Ryohei/0000-0003-2486-1393				Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Butler JS, 2002, TRENDS CELL BIOL, V12, P90, DOI 10.1016/S0962-8924(01)02225-5; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; Coburn GA, 1999, PROG NUCLEIC ACID RE, V62, P55; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DEUTSCHER MP, 1984, CRC CR REV BIOCH MOL, V17, P45, DOI 10.3109/10409238409110269; DEUTSCHER MP, 1988, P NATL ACAD SCI USA, V85, P4710, DOI 10.1073/pnas.85.13.4710; Deutscher Murray P., 1995, P51; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; Frank DN, 1998, ANNU REV BIOCHEM, V67, P153, DOI 10.1146/annurev.biochem.67.1.153; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Jarrige AC, 2002, J MOL BIOL, V321, P397, DOI 10.1016/S0022-2836(02)00645-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELLY KO, 1992, J BIOL CHEM, V267, P17153; Koonin EV, 2001, GENOME RES, V11, P240, DOI 10.1101/gr.162001; Li ZW, 1998, P NATL ACAD SCI USA, V95, P2856, DOI 10.1073/pnas.95.6.2856; Li ZW, 1996, CELL, V86, P503, DOI 10.1016/S0092-8674(00)80123-3; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; Morl M, 2001, EMBO REP, V2, P17, DOI 10.1093/embo-reports/kve006; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; OST KA, 1990, BIOCHIMIE, V72, P813, DOI 10.1016/0300-9084(90)90190-R; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; RAMAKRISHNAN V, 1992, NATURE, V358, P768, DOI 10.1038/358768a0; Schierling K, 2002, J MOL BIOL, V316, P895, DOI 10.1006/jmbi.2001.5395; Schiffer S, 2002, EMBO J, V21, P2769, DOI 10.1093/emboj/21.11.2769; Schurer H, 2001, BIOL CHEM, V382, P1147, DOI 10.1515/BC.2001.144; Shi HJ, 2000, RNA, V6, P1091, DOI 10.1017/S1355838200000364; Symmons MF, 2000, STRUCTURE, V8, P1215, DOI 10.1016/S0969-2126(00)00521-9; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Zhou T, 2000, STRUCTURE, V8, P1247, DOI 10.1016/S0969-2126(00)00533-5; Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017	34	36	38	3	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32397	32404		10.1074/jbc.M300639200	http://dx.doi.org/10.1074/jbc.M300639200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12746447	hybrid			2022-12-25	WOS:000184782100119
J	Goudelock, DM; Jiang, KC; Pereira, E; Russell, B; Sanchez, Y				Goudelock, DM; Jiang, KC; Pereira, E; Russell, B; Sanchez, Y			Regulatory interactions between the checkpoint kinase Chk1 and the proteins of the DNA-dependent protein kinase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAMAGE-INDUCED PHOSPHORYLATION; CELL-CYCLE CHECKPOINTS; HUMAN P53; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; INDUCED APOPTOSIS; MRE11 COMPLEX; FISSION YEAST; ATM KINASE; PATHWAY	Checkpoints are biochemical pathways that provide cells a mechanism to detect DNA damage and respond by arresting the cell cycle to allow DNA repair. The conserved checkpoint kinase, Chk1, regulates mitotic progression in response to DNA damage by blocking the activation of Cdk1/cyclin B. In this study, we investigate the regulatory interaction between Chk1 and members of the Atm family of kinases and the functional role of the C-terminal non-catalytic domains of Chk1. Chk1 stimulates the kinase activity of DNA-PK ( protein kinase) complexes, which leads to increased phosphorylation of p53 on Ser-15 and Ser-37. In addition, Chk1 stimulates DNA-PK-dependent end-joining reactions in vitro. We also show that Chk1 protein complexes bind to single-stranded DNA and DNA ends. These results indicate a connection between components that regulate the checkpoint pathways and DNA-PK complex proteins, which have a role in the repair of double strand breaks.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Sanchez, Y (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.				NCI NIH HHS [R01 CA84463] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084463] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Haber JE, 1999, NATURE, V398, P665, DOI 10.1038/19423; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Jackson SP, 1996, CURR OPIN GENET DEV, V6, P19, DOI 10.1016/S0959-437X(96)90005-2; Jhappan C, 2000, MOL CELL BIOL, V20, P4075, DOI 10.1128/MCB.20.11.4075-4083.2000; Jiang KC, 2003, J BIOL CHEM, V278, P25207, DOI 10.1074/jbc.M300070200; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Liu QH, 2000, GENE DEV, V14, P1448; Lustig AJ, 1999, NAT GENET, V23, P130, DOI 10.1038/13755; MEYN MS, 1995, CANCER RES, V55, P5991; Mori N, 2001, ONCOGENE, V20, P3609, DOI 10.1038/sj.onc.1204497; Muller C, 1998, NUCLEIC ACIDS RES, V26, P1382, DOI 10.1093/nar/26.6.1382; Ochem AE, 1997, J BIOL CHEM, V272, P29919, DOI 10.1074/jbc.272.47.29919; Park JS, 1999, J BIOL CHEM, V274, P32520, DOI 10.1074/jbc.274.45.32520; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Usui T, 2001, MOL CELL, V7, P1255, DOI 10.1016/S1097-2765(01)00270-2; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Weinert T, 1998, CURR OPIN GENET DEV, V8, P185, DOI 10.1016/S0959-437X(98)80140-8; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303; Yu LJ, 1998, J BIOL CHEM, V273, P33455, DOI 10.1074/jbc.273.50.33455; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	57	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29940	29947		10.1074/jbc.M301765200	http://dx.doi.org/10.1074/jbc.M301765200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12756247	hybrid			2022-12-25	WOS:000184507000067
J	Ogawa, K; Chen, FF; Kim, YJ; Chen, Y				Ogawa, K; Chen, FF; Kim, YJ; Chen, Y			Transcriptional regulation of tristetraprolin by transforming growth factor-beta in human T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TGF-BETA; DNA-BINDING; MESSENGER-RNA; TARGETED DISRUPTION; TRANSGENIC MICE; SMAD PROTEINS; MAD PROTEINS; TNF-ALPHA; PROMOTER	Transforming growth factor-beta (TGF-beta) is a pleiotropic cytokine that plays a critical role in modulating immune response and inflammation. We employed the Affymetrix cDNA microarray system to detect genes whose expression is regulated by TGF-beta1 in a human T cell line HuT78. Tristetraprolin (TTP), a protein involved in the degradation of tumor necrosis factor-alpha (TNF-alpha) mRNA, was found to be up-regulated by TGF-beta. This up-regulation was confirmed by reverse transcriptase-PCR analysis that revealed a rapid and transient induction of TTP mRNA by TGF-beta1 in HuT78 cells, primary human T cells, and THP-1 macrophage-monocyte cells. In addition, de novo protein synthesis was not required for this induction, suggesting that TTP is regulated by TGF-beta at the transcriptional level. To delineate the transcriptional regulation of the TTP gene, a 2.7-kb human TTP promoter region (-2682 to +56 bp relative to the transcription initiation site) was isolated. We found that this promoter was stimulated by TGF-beta1 or a constitutively active TGF-beta type I receptor via TGF-beta-specific Smad proteins. Furthermore, a series of TTP promoter deletion constructs were used to localize the Smad-responsive region to the -583 to -263 bp portion of the promoter. In this region, the TTP promoter contained a stretch of putative Smad-binding elements that had a synergistic effect in mediating Smad activation of the promoter. These putative Smad-binding element-containing sequences were also able to bind Smad3 and Smad4 proteins purified in vitro. As TGF-beta- and TTP-deficient mice exhibit overlapping phenotypes manifested by multifocal inflammation and autoimmunity, our findings that TTP transcription is under the control of TGF-beta signaling would indicate a potential role of TTP in mediating the immune suppressive action of TGF-beta in vivo.	Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA; Inst Phys & Chem Res, Lab Cellular Biochem, Wako, Saitama 3510198, Japan	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute; RIKEN	Chen, Y (corresponding author), Indiana Univ, Sch Med, Dept Med & Mol Genet, 975 W Walnut St,Ib130, Indianapolis, IN 46202 USA.				NIDDK NIH HHS [R01 DK55991] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055991] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1996, P NATL ACAD SCI USA, V93, P12992, DOI 10.1073/pnas.93.23.12992; CHENG J, 1992, GENE DEV, V6, P1444, DOI 10.1101/gad.6.8.1444; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; ESPEVIK T, 1987, J EXP MED, V166, P571, DOI 10.1084/jem.166.2.571; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; GADDYKURTEN D, 1995, RECENT PROG HORM RES, V50, P109; GOOTENBERG JE, 1981, J EXP MED, V154, P1403, DOI 10.1084/jem.154.5.1403; Gorelik L, 2002, NAT REV IMMUNOL, V2, P46, DOI 10.1038/nri704; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HEXIMER SP, 1993, DNA CELL BIOL, V12, P73, DOI 10.1089/dna.1993.12.73; HOLTER W, 1994, INT IMMUNOL, V6, P469; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAI WS, 1995, J BIOL CHEM, V270, P25266, DOI 10.1074/jbc.270.42.25266; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Li W, 2001, BIOCHEM BIOPH RES CO, V286, P1163, DOI 10.1006/bbrc.2001.5529; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mostert V, 2001, EUR J BIOCHEM, V268, P6176, DOI 10.1046/j.0014-2956.2001.02565.x; Moustakas A, 2001, J CELL SCI, V114, P4359; Nagarajan RP, 1999, J BIOL CHEM, V274, P31229, DOI 10.1074/jbc.274.44.31229; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Ogawa K, 2000, J IMMUNOL, V165, P2997, DOI 10.4049/jimmunol.165.6.2997; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; VARNUM BC, 1989, ONCOGENE, V4, P119; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	47	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30373	30381		10.1074/jbc.M304856200	http://dx.doi.org/10.1074/jbc.M304856200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12754205	hybrid			2022-12-25	WOS:000184507000118
J	Mohammad-Panah, R; Harrison, R; Dhani, S; Ackerley, C; Huan, LJ; Wang, YC; Bear, CE				Mohammad-Panah, R; Harrison, R; Dhani, S; Ackerley, C; Huan, LJ; Wang, YC; Bear, CE			The chloride channel ClC-4 contributes to endosomal acidification and trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; DENTS-DISEASE; CELL-LINE; ENDOCYTOSIS; MEMBRANE; MOUSE; CIC-5; MODEL; MICE; INTERNALIZATION	Mutations in the gene coding for the chloride channel ClC-5 cause Dent's disease, a disease associated with proteinuria and renal stones. Studies in ClC-5 knockout mice suggest that this phenotype is related to defective endocytosis of low molecular weight proteins and membrane proteins by the renal proximal tubule. In this study, confocal micrographs of proximal tubules and cultured epithelial cells revealed that the related protein ClC-4 is expressed in endosomal membranes suggesting that this channel may also contribute to the function of this organelle. In support of this hypothesis, specific disruption of endogenous ClC-4 expression by transfection of ClC-4 antisense cDNA acidified endosomal pH and altered transferrin trafficking in cultured epithelial cells to the same extent as the specific disruption of ClC-5. Both channels can be co-immunoprecipitated, arguing that they may partially contribute to endosomal function as a channel complex. These studies prompt future investigation of the role of ClC-4 in renal function in health and in Dent's disease. Future studies will assess whether the severity of Dent's disease relates not only to the impact of particular mutations on ClC-5 but also on the consequences of those mutations on the functional expression of ClC-4.	Hosp Sick Children, Programme Struct Biol & Biochem, Res Inst, Toronto, ON M5X 1G8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Bear, CE (corresponding author), Hosp Sick Children, Programme Struct Biol & Biochem, Res Inst, Toronto, ON M5X 1G8, Canada.	bear@sickkids.on.ca						ALAWQATI Q, 1995, CURR OPIN CELL BIOL, V7, P504, DOI 10.1016/0955-0674(95)80006-9; BARASCH J, 1988, J CELL BIOL, V107, P2137, DOI 10.1083/jcb.107.6.2137; BIRN H, 1993, AM J PHYSIOL, V264, pF239, DOI 10.1152/ajprenal.1993.264.2.F239; Devuyst O, 1999, HUM MOL GENET, V8, P247, DOI 10.1093/hmg/8.2.247; Dowland LK, 2000, J BIOL CHEM, V275, P37765, DOI 10.1074/jbc.M004840200; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Forgac M, 1999, J BIOENERG BIOMEMBR, V31, P57, DOI 10.1023/A:1005496530380; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; Gentzsch M, 2003, J BIOL CHEM, V278, P6440, DOI 10.1074/jbc.M211050200; Grabe M, 2001, J GEN PHYSIOL, V117, P329, DOI 10.1085/jgp.117.4.329; Gunther W, 2003, PFLUG ARCH EUR J PHY, V445, P456, DOI 10.1007/s00424-002-0950-6; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; Gyomorey K, 2000, PEDIATR RES, V48, P731; Hackam DJ, 1997, J BIOL CHEM, V272, P29810, DOI 10.1074/jbc.272.47.29810; Hao MM, 2000, J BIOL CHEM, V275, P15279, DOI 10.1074/jbc.275.20.15279; Haug K, 2003, NAT GENET, V33, P527, DOI 10.1038/ng1121; Jankowski A, 2002, J BIOL CHEM, V277, P6059, DOI 10.1074/jbc.M110059200; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; JENTSCH TJ, 1995, SOC GEN PHY, V50, P149; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; Li XH, 2002, AM J PHYSIOL-CELL PH, V282, pC1483, DOI 10.1152/ajpcell.00504.2001; Lin SX, 2002, MOL BIOL CELL, V13, P96, DOI 10.1091/mbc.01-05-0224; Lloyd SE, 1997, HUM MOL GENET, V6, P1233, DOI 10.1093/hmg/6.8.1233; LORENZ C, 1994, HUM MOL GENET, V3, P941, DOI 10.1093/hmg/3.6.941; Marshansky V, 2002, CURR OPIN NEPHROL HY, V11, P527, DOI 10.1097/00041552-200209000-00009; Mindell JA, 2001, NATURE, V409, P219, DOI 10.1038/35051631; Mohammad-Panah R, 2001, J BIOL CHEM, V276, P8306, DOI 10.1074/jbc.M006764200; Mohammad-Panah R, 2002, J BIOL CHEM, V277, P566, DOI 10.1074/jbc.M106968200; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Mukhopadhyay A, 1997, J CELL BIOL, V136, P1227, DOI 10.1083/jcb.136.6.1227; Obermuller N, 2001, AM J PHYSIOL-RENAL, V280, pF244, DOI 10.1152/ajprenal.2001.280.2.F244; Piwon N, 2000, NATURE, V408, P369, DOI 10.1038/35042597; Presley JF, 1997, J BIOL CHEM, V272, P13929, DOI 10.1074/jbc.272.21.13929; Roberts RL, 2000, J LEUKOCYTE BIOL, V68, P627; RUGARLI EI, 1995, NAT GENET, V10, P466, DOI 10.1038/ng0895-466; Sasaki Y, 2001, BIOCHEM BIOPH RES CO, V282, P212, DOI 10.1006/bbrc.2001.4557; Schwake M, 2001, J BIOL CHEM, V276, P12049, DOI 10.1074/jbc.M010642200; Sheff D, 2002, J CELL BIOL, V156, P797, DOI 10.1083/jcb.20111048; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; Waldegger S, 2000, J AM SOC NEPHROL, V11, P1331, DOI 10.1681/ASN.V1171331; Wang LW, 2000, J PHYSIOL-LONDON, V524, P63, DOI 10.1111/j.1469-7793.2000.t01-1-00063.x; Wang SS, 2000, HUM MOL GENET, V9, P2937, DOI 10.1093/hmg/9.20.2937; Woodman PG, 2000, TRAFFIC, V1, P695, DOI 10.1034/j.1600-0854.2000.010902.x; Yu ASL, 2001, CURR OPIN NEPHROL HY, V10, P415, DOI 10.1097/00041552-200105000-00019	48	79	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29267	29277		10.1074/jbc.M304357200	http://dx.doi.org/10.1074/jbc.M304357200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12746443	hybrid			2022-12-25	WOS:000184421100112
J	Itagaki, K; Hauser, CJ				Itagaki, K; Hauser, CJ			Sphingosine 1-phosphate, a diffusible calcium influx factor mediating store-operated calcium entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SMOOTH-MUSCLE-CELLS; HUMAN NEUTROPHILS; CA2+ INFLUX; FUNCTIONAL-CHARACTERIZATION; LYSOPHOSPHATIDIC ACID; MOLECULAR-CLONING; MAMMALIAN-CELLS; HL-60 CELLS; KINASE	Store-operated calcium entry (SOCE) is a fundamental mechanism of calcium signaling. The mechanisms linking store depletion to SOCE remain controversial, hypothetically involving both diffusible messengers and conformational coupling of stores to channels. Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid that can signal via cell surface G-protein-coupled receptors, but S1P can also act as a second messenger, mobilizing calcium directly via unknown mechanisms. We show here that S1P opens calcium entry channels in human neutrophils (PMNs) and HL60 cells without prior store depletion, independent of G-proteins and of phospholipase C. S1P-mediated entry has the typical divalent cation permeability profile and inhibitor profile of SOCE in PMNs, is fully inhibited by 1 muM Gd3+, and is independent of [Ca2+](i). Depletion of PMN calcium stores by thapsigargin induces S1P synthesis. Inhibition of S1P synthesis by dimethylsphingosine blocks thapsigargin-, ionomycin-, and platelet-activating factor-mediated SOCE despite normal store depletion. We propose that S1P is a "calcium influx factor," linking calcium store depletion to downstream SOCE.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Div Trauma, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Hauser, CJ (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Div Trauma, G-524,185 S Orange Ave, Newark, NJ 07103 USA.		Itagaki, Kiyoshi/M-5501-2015; Hauser, Carl J./Y-1189-2019	Itagaki, Kiyoshi/0000-0002-6033-1122; Hauser, Carl/0000-0003-3167-1846	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059179] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM059179, GM-59179] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aas V, 2001, CELL COMMUN ADHES, V8, P125, DOI 10.3109/15419060109080712; Alemany R, 1999, J BIOL CHEM, V274, P3994, DOI 10.1074/jbc.274.7.3994; Birchwood CJ, 2001, J BIOL CHEM, V276, P11712, DOI 10.1074/jbc.M010221200; Csutora P, 1999, P NATL ACAD SCI USA, V96, P121, DOI 10.1073/pnas.96.1.121; Edsall LC, 1997, J NEUROSCI, V17, P6952; Essler M, 2002, CELL SIGNAL, V14, P607, DOI 10.1016/S0898-6568(02)00013-X; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; GALLAGHER R, 1979, BLOOD, V54, P713; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Halaszovich CR, 2000, J BIOL CHEM, V275, P37423, DOI 10.1074/jbc.M007010200; Hauser CJ, 2001, J LEUKOCYTE BIOL, V69, P63; He R, 2003, BLOOD, V101, P1572, DOI 10.1182/blood-2002-05-1431; Heringdorf DM, 1999, FEBS LETT, V461, P217, DOI 10.1016/S0014-5793(99)01463-5; Heringdorf DMZ, 1998, EMBO J, V17, P2830, DOI 10.1093/emboj/17.10.2830; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Itagaki K, 2002, J IMMUNOL, V168, P4063, DOI 10.4049/jimmunol.168.8.4063; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kuriyama H, 1998, PHYSIOL REV, V78, P811, DOI 10.1152/physrev.1998.78.3.811; Le Stunff H, 2002, J CELL BIOL, V158, P1039, DOI 10.1083/jcb.200203123; Le Stunff H, 2002, BBA-MOL CELL BIOL L, V1582, P8, DOI 10.1016/S1388-1981(02)00132-4; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu XB, 2001, J BIOL CHEM, V276, P29891, DOI 10.1074/jbc.M103283200; Luo D, 2001, J BIOL CHEM, V276, P5613, DOI 10.1074/jbc.M007524200; M'Rabet L, 1999, J BIOL CHEM, V274, P21847, DOI 10.1074/jbc.274.31.21847; MacKinnon AC, 2002, J IMMUNOL, V169, P6394, DOI 10.4049/jimmunol.169.11.6394; Mathes C, 1998, J BIOL CHEM, V273, P25020, DOI 10.1074/jbc.273.39.25020; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P105, DOI 10.1113/jphysiol.1989.sp017830; Murata N, 2000, BIOCHEM J, V352, P809, DOI 10.1042/0264-6021:3520809; Olivera A, 2001, PROSTAG OTH LIPID M, V64, P123, DOI 10.1016/S0090-6980(01)00108-3; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Putney JW, 2001, J CELL SCI, V114, P2223; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Shi LC, 1996, J NEUROCHEM, V67, P1478; Siehler S, 2002, BBA-MOL CELL BIOL L, V1582, P94, DOI 10.1016/S1388-1981(02)00142-7; Slimane TA, 2002, FEBS LETT, V529, P54, DOI 10.1016/S0014-5793(02)03183-6; Spiegel S, 2000, BBA-MOL CELL BIOL L, V1484, P107, DOI 10.1016/S1388-1981(00)00010-X; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; STUDZINSKI GP, 1991, CANCER RES, V51, P3451; Su ZC, 2001, AM J PHYSIOL-CELL PH, V280, pC1284, DOI 10.1152/ajpcell.2001.280.5.C1284; Tiffany HL, 2001, J BIOL CHEM, V276, P23645, DOI 10.1074/jbc.M101031200; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Trepakova ES, 2000, J BIOL CHEM, V275, P26158, DOI 10.1074/jbc.M004666200; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; VANVELDHOVEN PP, 1989, J LIPID RES, V30, P611; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Young KW, 2000, J BIOL CHEM, V275, P38532, DOI 10.1074/jbc.M006631200; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	50	96	101	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27540	27547		10.1074/jbc.M301763200	http://dx.doi.org/10.1074/jbc.M301763200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12746430	Green Accepted, hybrid			2022-12-25	WOS:000184242700027
J	Javanbakht, H; Halwani, R; Cen, S; Saadatmand, J; Musier-Forsyth, K; Gottlinger, H; Kleiman, L				Javanbakht, H; Halwani, R; Cen, S; Saadatmand, J; Musier-Forsyth, K; Gottlinger, H; Kleiman, L			The interaction between HIV-1 Gag and human lysyl-tRNA synthetase during viral assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PRIMER TRANSFER-RNAS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; TERMINAL DOMAIN; CAPSID PROTEIN; WILD-TYPE; PARTICLES; BINDING; PR160GAG-POL	Human lysyl-tRNA synthetase (LysRS) is a tRNA-binding protein that is selectively packaged into HIV-1 along with its cognate tRNA(Lys) isoacceptors. Evidence exists that Gag alone is sufficient for the incorporation of LysRS into virions. Herein, using both in vitro and in vivo methods, we begin to map regions in Gag and LysRS that are required for this interaction. In vitro reactions between wild-type and truncated HIV-1 Gag and human LysRS were monitored using GST-tagged molecules and glutathione-agarose chromatography. Gag/LysRS interaction in vivo was detected in 293FT cells cotransfected with plasmids coding for wild-type or mutant HIV-1 Gag and LysRS, either by monitoring Gag.LysRS complexes immunoprecipitated from cell lysate with anti-LysRS or by measuring the ability of LysRS to be packaged into budded Gag viral-like particles. Based on these studies, we conclude that the Gag/LysRS interaction depends upon Gag sequences within the C-terminal domain of capsid (the last 54 amino acids) and amino acids 208-259 of LysRS. The latter domain includes the class II amino-acyl-tRNA synthetase consensus sequence known as motif 1. Both regions have been implicated in homodimerization of capsid and LysRS, respectively. Sequences falling outside these amino acid stretches can be deleted from either molecule without affecting the Gag/LysRS interaction, further supporting the observation that LysRS is incorporated into Gag viral-like particles independent of its ability to bind tRNA(Lys).	Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; Jewish Gen Hosp, McGill AIDS Ctr, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA; Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA	Lady Davis Institute; McGill University; McGill University; McGill University; McGill University; University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Dana-Farber Cancer Institute	Kleiman, L (corresponding author), Jewish Gen Hosp, Lady Davis Inst Med Res, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.		Halwani, Rabih/AAN-1568-2021	Halwani, Rabih/0000-0002-6516-7771; Gottlinger, Heinrich/0000-0003-4124-5824				Accola MA, 2000, J VIROL, V74, P5395, DOI 10.1128/JVI.74.12.5395-5402.2000; BERKOWITZ R, 1996, MORPHOGENESIS MATURA, V214, P177; Berthet-Colominas C, 1999, EMBO J, V18, P1124, DOI 10.1093/emboj/18.5.1124; Burniston MT, 1999, J VIROL, V73, P8527, DOI 10.1128/JVI.73.10.8527-8540.1999; CAMPBELL S, 1995, J VIROL, V69, P6487, DOI 10.1128/JVI.69.10.6487-6497.1995; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; Cen S, 2002, J VIROL, V76, P13111, DOI 10.1128/JVI.76.24.13111-13115.2002; Cen S, 2001, J VIROL, V75, P5043, DOI 10.1128/JVI.75.11.5043-5048.2001; Craven RC, 1996, CURR TOP MICROBIOL, V214, P65; Cusack S, 1996, EMBO J, V15, P6321, DOI 10.1002/j.1460-2075.1996.tb01022.x; ERIANI G, 1990, NUCLEIC ACIDS RES, V18, P7109, DOI 10.1093/nar/18.23.7109; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; ERIANI G, 1993, P NATL ACAD SCI USA, V90, P10816, DOI 10.1073/pnas.90.22.10816; Francin M, 2003, J BIOL CHEM, V278, P1472, DOI 10.1074/jbc.M208802200; Francin M, 2002, J BIOL CHEM, V277, P1762, DOI 10.1074/jbc.M109759200; Gabor J, 2002, J VIROL, V76, P9096, DOI 10.1128/JVI.76.18.9096-9102.2002; Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849; Garnier L, 1998, J VIROL, V72, P4667, DOI 10.1128/JVI.72.6.4667-4677.1998; Geigenmuller U, 1996, J VIROL, V70, P667; HUANG Y, 1994, J VIROL, V68, P7676, DOI 10.1128/JVI.68.12.7676-7683.1994; Javanbakht H, 2002, J BIOL CHEM, V277, P17389, DOI 10.1074/jbc.M112479200; JIANG M, 1993, J VIROL, V67, P3246, DOI 10.1128/JVI.67.6.3246-3253.1993; KRAUSSLICH HG, 1995, J VIROL, V69, P3407; Li S, 2000, NATURE, V407, P409, DOI 10.1038/35030177; MAK J, 1994, J VIROL, V68, P2065, DOI 10.1128/JVI.68.4.2065-2072.1994; Mak J, 1997, J VIROL, V71, P8087, DOI 10.1128/JVI.71.11.8087-8095.1997; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; Morikawa Y, 2000, J VIROL, V74, P16, DOI 10.1128/JVI.74.1.16-23.2000; ONESTI S, 1995, STRUCTURE, V3, P163, DOI 10.1016/S0969-2126(01)00147-2; PARK J, 1992, J VIROL, V66, P6304, DOI 10.1128/JVI.66.11.6304-6313.1992; SAKS ME, 1994, SCIENCE, V263, P191, DOI 10.1126/science.7506844; Sandefur S, 1998, J VIROL, V72, P2723, DOI 10.1128/JVI.72.4.2723-2732.1998; Shiba K, 1997, J BIOL CHEM, V272, P22809, DOI 10.1074/jbc.272.36.22809; SMITH AJ, 1990, J VIROL, V64, P2743, DOI 10.1128/JVI.64.6.2743-2750.1990; SMITH AJ, 1993, J VIROL, V67, P2266, DOI 10.1128/JVI.67.4.2266-2275.1993; SRINIVASAKUMAR N, 1995, J VIROL, V69, P6106, DOI 10.1128/JVI.69.10.6106-6114.1995; Stello T, 1999, NUCLEIC ACIDS RES, V27, P4823, DOI 10.1093/nar/27.24.4823; Swanstrom R., 1997, P263	38	79	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27644	27651		10.1074/jbc.M301840200	http://dx.doi.org/10.1074/jbc.M301840200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12756246	hybrid			2022-12-25	WOS:000184242700040
J	Kahya, N; Scherfeld, D; Bacia, K; Poolman, B; Schwille, P				Kahya, N; Scherfeld, D; Bacia, K; Poolman, B; Schwille, P			Probing lipid mobility of raft-exhibiting model membranes by fluorescence correlation spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; FC-EPSILON-RI; SIGNAL-TRANSDUCTION; CELL-MEMBRANE; BIOLOGICAL-MEMBRANES; DOMAIN FORMATION; GANGLIOSIDE GM1; CHOLESTEROL; MICROSCOPY; SPHINGOMYELIN	Confocal fluorescence microscopy and fluorescence correlation spectroscopy (FCS) have been employed to investigate the lipid spatial and dynamic organization in giant unilamellar vesicles (GUVs) prepared from ternary mixtures of dioleoyl-phosphatidylcholine/sphingomyelin/ cholesterol. For a certain range of cholesterol concentration, formation of domains with raft-like properties was observed. Strikingly, the lipophilic probe 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI-C-18) was excluded from sphingomyelin-enriched regions, where the raft marker ganglioside GM1 was localized. Cholesterol was shown to promote lipid segregation in dioleoyl-phosphatidylcholine-enriched, liquid-disordered, and sphingomyelin-enriched, liquid-ordered phases. Most importantly, the lipid mobility in sphingomyelin-enriched regions significantly increased by increasing the cholesterol concentration. These results pinpoint the key role, played by cholesterol in tuning lipid dynamics in membranes. At cholesterol concentrations > 50 mol%, domains vanished and the lipid diffusion slowed down upon further addition of cholesterol. By taking the molecular diffusion coefficients as a fingerprint of membrane phase compositions, FCS is proven to evaluate domain lipid compositions. Moreover, FCS data from ternary and binary mixtures have been used to build a ternary phase diagram, which shows areas of phase coexistence, transition points, and, importantly, how lipid dynamics varies between and within phase regions.	Univ Groningen, Membrane Enzymol Grp, NL-9747 AG Groningen, Netherlands; Max Planck Inst Biophys Chem, Expt Biophys Grp, D-37077 Gottingen, Germany	University of Groningen; Max Planck Society	Poolman, B (corresponding author), Univ Groningen, Membrane Enzymol Grp, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Poolman, Bert/D-1882-2012; Schwille, Petra/A-4983-2010					Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; ANGELOVA MI, 1986, FARADAY DISCUSS, V81, P303; Bagatolli LA, 2000, BIOPHYS J, V78, P290, DOI 10.1016/S0006-3495(00)76592-1; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 2001, P NATL ACAD SCI USA, V98, P10517, DOI 10.1073/pnas.191386898; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Brown RE, 1998, J CELL SCI, V111, P1; Dietrich C, 2001, P NATL ACAD SCI USA, V98, P10642, DOI 10.1073/pnas.191168698; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; DIMITROV DS, 1988, BIOELECTROCH BIOENER, V19, P323, DOI 10.1016/0302-4598(88)80013-8; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; Feigenson GW, 2001, BIOPHYS J, V80, P2775, DOI 10.1016/S0006-3495(01)76245-5; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; Fridriksson EK, 1999, BIOCHEMISTRY-US, V38, P8056, DOI 10.1021/bi9828324; Fujiwara T, 2002, J CELL BIOL, V157, P1071, DOI 10.1083/jcb.200202050; GERMAIN RN, 1997, CURR BIOL, V7, P640; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Heerklotz H, 2002, BIOPHYS J, V83, P2693, DOI 10.1016/S0006-3495(02)75278-8; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; KOPPEL DE, 1974, PHYS REV A, V10, P1938, DOI 10.1103/PhysRevA.10.1938; Korlach J, 1999, P NATL ACAD SCI USA, V96, P8461, DOI 10.1073/pnas.96.15.8461; MAGDE D, 1972, PHYS REV LETT, V29, P705, DOI 10.1103/PhysRevLett.29.705; Mathivet L, 1996, BIOPHYS J, V70, P1112, DOI 10.1016/S0006-3495(96)79693-5; McConnell HM, 2003, ANNU REV BIOPH BIOM, V32, P469, DOI 10.1146/annurev.biophys.32.110601.141704; Menger FM, 1998, ACCOUNTS CHEM RES, V31, P789, DOI 10.1021/ar970103v; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; Samsonov AV, 2001, BIOPHYS J, V81, P1486, DOI 10.1016/S0006-3495(01)75803-1; SANKARAM MB, 1990, BIOCHEMISTRY-US, V29, P10670, DOI 10.1021/bi00499a014; SCHMIDT CF, 1978, NATURE, V271, P775, DOI 10.1038/271775a0; Schutz GJ, 2000, EMBO J, V19, P892, DOI 10.1093/emboj/19.5.892; Schwille P, 2001, CELL BIOCHEM BIOPHYS, V34, P383, DOI 10.1385/CBB:34:3:383; Schwille P, 1999, CYTOMETRY, V36, P176, DOI 10.1002/(SICI)1097-0320(19990701)36:3<176::AID-CYTO5>3.0.CO;2-F; Sevinsky JR, 1996, J CELL BIOL, V133, P293, DOI 10.1083/jcb.133.2.293; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; Silvius JR, 1996, BIOCHEMISTRY-US, V35, P15198, DOI 10.1021/bi9615506; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; SPINK CH, 1990, BIOCHIM BIOPHYS ACTA, V1023, P25, DOI 10.1016/0005-2736(90)90005-9; Stang E, 1997, MOL BIOL CELL, V8, P47, DOI 10.1091/mbc.8.1.47; Stulnig TM, 1997, J BIOL CHEM, V272, P19242, DOI 10.1074/jbc.272.31.19242; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Wilson BS, 2000, J CELL BIOL, V149, P1131, DOI 10.1083/jcb.149.5.1131; Yuan CB, 2000, BIOPHYS J, V79, P2768, DOI 10.1016/S0006-3495(00)76516-7; Yuan CB, 2002, BIOPHYS J, V82, P2526, DOI 10.1016/S0006-3495(02)75596-3	52	410	416	2	90	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28109	28115		10.1074/jbc.M302969200	http://dx.doi.org/10.1074/jbc.M302969200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12736276	hybrid, Green Published			2022-12-25	WOS:000184242700097
J	Rottensteiner, H; Wabnegger, L; Erdmann, R; Hamilton, B; Ruis, H; Hartig, A; Gurvitz, A				Rottensteiner, H; Wabnegger, L; Erdmann, R; Hamilton, B; Ruis, H; Hartig, A; Gurvitz, A			Saccharomyces cerevisiae PIP2 mediating oleic acid induction and peroxisome proliferation is regulated by Adr1p and Pip2p-Oaf1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPSTREAM ACTIVATING SEQUENCE; REPRESSIBLE ALCOHOL-DEHYDROGENASE; YEAST SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTORS PIP2P; BETA-OXIDATION; FATTY-ACIDS; 2,4-DIENOYL-COA REDUCTASE; GLYCEROL KINASE; PROTEIN IMPORT; MESSENGER-RNA	Saccharomyces cerevisiae genes involved in fatty acid degradation contain in their promoters oleate response elements (OREs) and type 1 upstream activation sequences (UAS1s) that bind Pip2p-Oaf1p and Adr1p, respectively. The promoter of the PIP2 gene was found to contain a potential UAS1 that consists of a tandem array of CYCCRR half-sites in an overlapping arrangement with a previously characterized ORE. Electrophoretic mobility shift analysis demonstrated that Adr1p bound to UAS1(PIP2), and Northern analysis in combination with a lacZ reporter gene confirmed that Adr1p influenced the transcription of PIP2. Immunoprecipitation showed that, in adr1Delta mutant cells grown on oleic acid, Pip2p was less abundant compared with the corresponding wild-type. In addition, the amount of Pip2p-Oaf1p that bound to a target ORE in vitro was reduced in mutant extracts compared with the wild-type. Transcription of the oleic acid-inducible genes SPS19 and CTA1, which rely on both Pip2p-Oaf1p and Adr1p for their regulation, was reduced in adr1Delta mutant cells. However, by ectopically restoring levels of Pip2p in adr1Delta cells grown on oleic acid medium, transcription of both genes increased 2-fold compared with the control. This partial suppression of the adr1Delta mutant phenotype was additionally manifested by moderate utilization of oleic acid. Hence, both the expression as well as the action of the two transcription factors, Adr1p and Pip2p-Oaf1p, are interconnected, which allows for an elaborate control of fatty acid-inducible genes.	Univ Vienna, Max F Perutz Labs, Univ Dept,Vienna Bioctr, Dept Biochem & Mol Cell Biol, A-1030 Vienna, Austria; Ruhr Univ Bochum, Inst Physiol Chem, D-44780 Bochum, Germany; Ludwig Boltzmann Forschungsstelle Biochem, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Ruhr University Bochum; Ludwig Boltzmann Institute	Gurvitz, A (corresponding author), Univ Vienna, Max F Perutz Labs, Univ Dept,Vienna Bioctr, Dept Biochem & Mol Cell Biol, Dr Bohr Gasse 9, A-1030 Vienna, Austria.			Hartig, Andreas/0000-0003-3334-2763				Baumgartner U, 1999, J BIOL CHEM, V274, P22208, DOI 10.1074/jbc.274.32.22208; BEERS RF, 1952, J BIOL CHEM, V195, P133; BEMIS LT, 1988, MOL CELL BIOL, V8, P2125, DOI 10.1128/MCB.8.5.2125; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; CHENG C, 1994, MOL CELL BIOL, V14, P3842, DOI 10.1128/MCB.14.6.3842; CIRIACY M, 1975, MOL GEN GENET, V138, P157, DOI 10.1007/BF02428119; DENIS CL, 1987, MOL GEN GENET, V208, P101, DOI 10.1007/BF00330429; DENIS CL, 1981, J MOL BIOL, V148, P355, DOI 10.1016/0022-2836(81)90181-9; EINERHAND AWC, 1993, EUR J BIOCHEM, V214, P323, DOI 10.1111/j.1432-1033.1993.tb17927.x; EISEN A, 1988, MOL CELL BIOL, V8, P4552, DOI 10.1128/MCB.8.10.4552; Epstein CB, 2001, MOL BIOL CELL, V12, P297, DOI 10.1091/mbc.12.2.297; FILIPITS M, 1993, GENE, V132, P49, DOI 10.1016/0378-1119(93)90513-3; Geisbrecht BV, 1999, BIOCHEM BIOPH RES CO, V260, P28, DOI 10.1006/bbrc.1999.0860; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Grauslund M, 1999, NUCLEIC ACIDS RES, V27, P4391, DOI 10.1093/nar/27.22.4391; Gurvitz A, 2001, J BIOL CHEM, V276, P31825, DOI 10.1074/jbc.M105989200; Gurvitz A, 1997, MOL MICROBIOL, V26, P675, DOI 10.1046/j.1365-2958.1997.5931969.x; Gurvitz A, 1997, J BIOL CHEM, V272, P22140, DOI 10.1074/jbc.272.35.22140; Gurvitz A, 1999, J BIOL CHEM, V274, P24514, DOI 10.1074/jbc.274.35.24514; Gurvitz A, 1999, MOL GEN GENET, V262, P481; Gurvitz Aner, 2000, Molecular Cell Biology Research Communications, V4, P81, DOI 10.1006/mcbr.2000.0261; Hagerman Ruth A., 2001, Molecular Cell Biology Research Communications, V4, P299, DOI 10.1006/mcbr.2001.0294; Haurie V, 2001, J BIOL CHEM, V276, P76, DOI 10.1074/jbc.M008752200; HEDGES D, 1995, MOL CELL BIOL, V15, P1915; Henke B, 1998, J BIOL CHEM, V273, P3702, DOI 10.1074/jbc.273.6.3702; Igual JC, 1996, MOL GEN GENET, V252, P446, DOI 10.1007/s004380050249; JONES EW, 1977, GENETICS, V85, P23; Karpichev IV, 1997, MOL CELL BIOL, V17, P69, DOI 10.1128/MCB.17.1.69; Karpichev IV, 1998, MOL CELL BIOL, V18, P6560, DOI 10.1128/MCB.18.11.6560; Koerkamp MG, 2002, MOL BIOL CELL, V13, P2783, DOI 10.1091/mbc.E02-02-0075; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luo Y, 1996, J BIOL CHEM, V271, P12068, DOI 10.1074/jbc.271.20.12068; Miller JH., 1972, EXPT MOL GENETICS; PAVLIK P, 1993, CURR GENET, V24, P21, DOI 10.1007/BF00324660; RICHTER K, 1980, J BIOL CHEM, V255, P8019; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Rottensteiner H, 1997, EUR J BIOCHEM, V247, P776, DOI 10.1111/j.1432-1033.1997.00776.x; Rottensteiner H, 1996, EMBO J, V15, P2924, DOI 10.1002/j.1460-2075.1996.tb00655.x; Rottensteiner H, 2003, EUR J BIOCHEM, V270, P2013, DOI 10.1046/j.1432-1033.2003.03575.x; Sambrook J., 2002, MOL CLONING LAB MANU; SIMON M, 1991, MOL CELL BIOL, V11, P699, DOI 10.1128/MCB.11.2.699; SIMON M, 1992, YEAST, V8, P303, DOI 10.1002/yea.320080407; SIMON MM, 1995, MOL GEN GENET, V249, P289, DOI 10.1007/BF00290529; Smith JJ, 2002, J CELL BIOL, V158, P259, DOI 10.1083/jcb.200204059; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Stein K, 2002, MOL CELL BIOL, V22, P6056, DOI 10.1128/MCB.22.17.6056-6069.2002; van Roermund CWT, 1998, EMBO J, V17, P677, DOI 10.1093/emboj/17.3.677; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; Walther K, 2001, MICROBIOL-SGM, V147, P2037, DOI 10.1099/00221287-147-8-2037; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; Young ET, 2002, J BIOL CHEM, V277, P38095, DOI 10.1074/jbc.M206158200; YOUNG ET, 2003, J BIOL CHEM	54	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27605	27611		10.1074/jbc.M304097200	http://dx.doi.org/10.1074/jbc.M304097200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12748191	hybrid			2022-12-25	WOS:000184242700035
J	Stelzl, U; Zengel, JM; Tovbina, M; Walker, M; Nierhaus, KH; Lindahl, L; Patel, DJ				Stelzl, U; Zengel, JM; Tovbina, M; Walker, M; Nierhaus, KH; Lindahl, L; Patel, DJ			RNA-structural mimicry in Escherichia coli ribosomal protein L4-dependent regulation of the S10 operon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L4-MEDIATED ATTENUATION CONTROL; TRANSCRIPTION TERMINATION; MESSENGER-RNA; BINDING-SITES; SECONDARY STRUCTURE; AUTOGENOUS CONTROL; LEADER; NUSA; L4; DETERMINANTS	Ribosomal protein L4 regulates the 11-gene S10 operon in Escherichia coli by acting, in concert with transcription factor NusA, to cause premature transcription termination at a Rho-independent termination site in the leader sequence. This process presumably involves L4 interaction with the leader mRNA. Here, we report direct, specific, and independent binding of ribosomal protein L4 to the S10 mRNA leader in vitro. Most of the binding energy is contributed by a small hairpin structure within the leader region, but a 64-nucleotide sequence is required for the bona fide interaction. Binding to the S10 leader mRNA is competed by the 23 S rRNA L4 binding site. Although the secondary structures of the mRNA and rRNA binding sites appear different, phosphorothioate footprinting of the L4-RNA complexes reveals close structural similarity in three dimensions. Mutational analysis of the mRNA binding site is compatible with the structural model. In vitro binding of L4 induces structural changes of the S10 leader RNA, providing a first clue for how protein L4 may provoke transcription termination.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Univ Maryland Baltimore Cty, Dept Biol Sci, Baltimore, MD 21250 USA	Memorial Sloan Kettering Cancer Center; University System of Maryland; University of Maryland Baltimore County	Stelzl, U (corresponding author), Max Delbruck Ctr Mol Med, AG Ribosomen, Robert Rossle Str 10, D-13092 Berlin, Germany.	u.stelzl@mdc-berlin.de	Stelzl, Ulrich/J-9506-2015	Stelzl, Ulrich/0000-0003-2500-3585	NCI NIH HHS [CA46778, P30 CA008748] Funding Source: Medline; NIGMS NIH HHS [GM54876] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748, R01CA046778] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054876] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen T, 1999, J BACTERIOL, V181, P6124, DOI 10.1128/JB.181.19.6124-6132.1999; Artsimovitch I, 1998, GENE DEV, V12, P3110, DOI 10.1101/gad.12.19.3110; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Diedrich G, 1997, PROTEIN EXPRES PURIF, V10, P42, DOI 10.1006/prep.1996.0702; DRAPER DE, 1989, TRENDS BIOCHEM SCI, V14, P335, DOI 10.1016/0968-0004(89)90167-9; DRAPER DE, 1988, METHOD ENZYMOL, V164, P203; FREEDMAN LP, 1987, P NATL ACAD SCI USA, V84, P6516, DOI 10.1073/pnas.84.18.6516; Gerstner RB, 2001, BIOCHEMISTRY-US, V40, P7165, DOI 10.1021/bi010026i; Gusarov I, 2001, CELL, V107, P437, DOI 10.1016/S0092-8674(01)00582-7; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; Henkin TM, 2000, CURR OPIN MICROBIOL, V3, P149, DOI 10.1016/S1369-5274(00)00067-9; Keener J, 1996, ESCHERICHIA COLI SAL, V2, P1417; Klein DJ, 2001, EMBO J, V20, P4214, DOI 10.1093/emboj/20.15.4214; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Landick R, 2001, CELL, V105, P567, DOI 10.1016/S0092-8674(01)00381-6; Leontis NB, 2001, RNA, V7, P499, DOI 10.1017/S1355838201002515; Li X, 1997, J BACTERIOL, V179, P7046, DOI 10.1128/jb.179.22.7046-7054.1997; Li X, 1996, RNA, V2, P24; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; LINDAHL L, 1983, CELL, V33, P241, DOI 10.1016/0092-8674(83)90353-7; OSSWALD M, 1990, NUCLEIC ACIDS RES, V18, P6755; Pfeiffer T, 1995, GENE, V167, P141, DOI 10.1016/0378-1119(95)00698-2; PHILIPPE C, 1990, J MOL BIOL, V211, P415, DOI 10.1016/0022-2836(90)90362-P; Robert F, 2001, NUCLEIC ACIDS RES, V29, P677, DOI 10.1093/nar/29.3.677; Schlax PJ, 2001, J BIOL CHEM, V276, P38494, DOI 10.1074/jbc.M106934200; Serganov AA, 1996, RNA, V2, P1124; SHA YZ, 1995, J MOL BIOL, V245, P486, DOI 10.1006/jmbi.1994.0040; SHA YZ, 1995, J MOL BIOL, V245, P474, DOI 10.1006/jmbi.1994.0039; SHEN P, 1988, NUCLEIC ACIDS RES, V16, P8905, DOI 10.1093/nar/16.18.8905; Stelzl U, 2000, METHOD ENZYMOL, V318, P251; Stelzl U, 2000, P NATL ACAD SCI USA, V97, P4597, DOI 10.1073/pnas.090009297; Stelzl U, 2001, RNA, V7, P598, DOI 10.1017/S1355838201002059; Strobel SA, 1999, CURR OPIN STRUC BIOL, V9, P346, DOI 10.1016/S0959-440X(99)80046-3; Torres M, 2001, EMBO J, V20, P3811, DOI 10.1093/emboj/20.14.3811; Torres-Larios A, 2002, NAT STRUCT BIOL, V9, P343, DOI 10.1038/nsb789; Toulokhonov I, 2001, SCIENCE, V292, P730, DOI 10.1126/science.1057738; Verma S, 1998, ANNU REV BIOCHEM, V67, P99, DOI 10.1146/annurev.biochem.67.1.99; Worbs M, 2000, EMBO J, V19, P807, DOI 10.1093/emboj/19.5.807; Worbs M, 2002, BIOCHIMIE, V84, P731, DOI 10.1016/S0300-9084(02)01410-4; YATES JL, 1980, CELL, V21, P517, DOI 10.1016/0092-8674(80)90489-4; ZENGEL JM, 1990, P NATL ACAD SCI USA, V87, P2675, DOI 10.1073/pnas.87.7.2675; ZENGEL JM, 1980, CELL, V21, P523, DOI 10.1016/0092-8674(80)90490-0; Zengel JM, 1996, J BACTERIOL, V178, P2383, DOI 10.1128/jb.178.8.2383-2387.1996; ZENGEL JM, 1993, NUCLEIC ACIDS RES, V21, P2429, DOI 10.1093/nar/21.10.2429; ZENGEL JM, 1990, J MOL BIOL, V213, P67, DOI 10.1016/S0022-2836(05)80122-6; ZENGEL JM, 1994, PROG NUCLEIC ACID RE, V47, P331, DOI 10.1016/S0079-6603(08)60256-1; Zengel JM, 2002, RNA, V8, P572, DOI 10.1017/S1355838202026237; ZENGEL JM, 1992, GENE DEV, V6, P2655, DOI 10.1101/gad.6.12b.2655	49	30	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28237	28245		10.1074/jbc.M302651200	http://dx.doi.org/10.1074/jbc.M302651200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12738792	hybrid, Green Accepted			2022-12-25	WOS:000184242700113
J	Brazer, SCW; Singh, BB; Liu, XB; Swaim, W; Ambudkar, IS				Brazer, SCW; Singh, BB; Liu, XB; Swaim, W; Ambudkar, IS			Caveolin-1 contributes to assembly of store-operated Ca2+ influx channels by regulating plasma membrane localization of TRPC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID RAFTS; SIGNAL-TRANSDUCTION; CATION CHANNEL; C-TERMINUS; PROTEIN; COMPLEX; EXPRESSION; SUBUNIT; DOMAINS; CELLS	TRPC1, a component of store-operated Ca2+ entry (SOCE) channels, is assembled in a complex with caveolin-1 (Cav1) and key Ca2+ signaling proteins. This study examines the role of Cav1 in the function of TRPC1. TRPC1 and Cav1 were colocalized in the plasma membrane region of human submandibular gland and Madin-Darby canine kidney cells. Full-length Cav1 bound to both the N and C termini of TRPC1. Amino acids 271 - 349, which includes a Cav1 binding motif ( amino acids 322 - 349), was identified as the Cav1 binding domain in the TRPC1 N terminus. Deletion of amino acids 271 - 349 or 322 - 349 prevented plasma membrane localization of TRPC1. Importantly, TRPC1Delta271-349 induced a dominant suppression of SOCE and was associated with wild-type TRPC1. Although the role of the C-terminal Cav1 binding domain is not known, its deletion did not affect localization of TRPC1 (Singh, B. B., Liu, X., and Ambudkar, I. S. ( 2000) J. Biol. Chem. 275, 36483 36486). Further, expression of a truncated Cav1 ( Cav1Delta51-169), but not full-length Cav1, similarly disrupted plasma membrane localization of endogenously and exogenously expressed TRPC1 in human submandibular gland and Madin-Darby canine kidney cells. Cav1Delta51-169 also suppressed thapsigargin- and carbachol-stimulated Ca2+ influx and increased the detergent solubility of TRPC1, although plasma membrane lipid raft domains were not disrupted. These data demonstrate that plasma membrane localization of TRPC1 depends on an interaction between its N terminus and Cav1. Thus, our data suggest that Cav1 has an important role in the assembly of SOCE channel(s).	NIDCR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, Dept Hlth & Human Serv,NIH, Bethesda, MD 20892 USA; NIDCR, Cellular Imaging Core, Dept Hlth & Human Serv, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Ambudkar, IS (corresponding author), NIDCR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, Dept Hlth & Human Serv,NIH, Bldg 10,Rm 1N-113, Bethesda, MD 20892 USA.	indu.ambudkar@nih.gov		Singh, Brij/0000-0003-0535-5997	NIDCR NIH HHS [R01 DE017102-07, R01 DE017102-05, R01 DE017102-04, R01 DE017102-03, R01 DE017102-02, R01 DE017102-01A1, R01 DE017102-06A1, R01 DE017102] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE017102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000438] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Antoniotti S, 2002, FEBS LETT, V510, P189, DOI 10.1016/S0014-5793(01)03256-2; Brough GH, 2001, FASEB J, V15, P1727, DOI 10.1096/fj.01-0108com; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Engelke M, 2002, FEBS LETT, V523, P193, DOI 10.1016/S0014-5793(02)02971-X; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Harteneck C, 2002, FASEB J, V16, P1668, DOI 10.1096/fj.02-0192fje; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Isshiki M, 1999, CELL CALCIUM, V26, P201, DOI 10.1054/ceca.1999.0073; Isshiki M, 2002, J BIOL CHEM, V277, P43389, DOI 10.1074/jbc.M205411200; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Karlsson M, 2001, FASEB J, V15, P249, DOI 10.1096/fj.01-0646fje; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Kunzelmann-Marche C, 2002, J BIOL CHEM, V277, P19876, DOI 10.1074/jbc.M200324200; Li HS, 2000, J CELL BIOL, V150, P1411, DOI 10.1083/jcb.150.6.1411; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Liu XB, 2003, J BIOL CHEM, V278, P11337, DOI 10.1074/jbc.M213271200; Lockwich T, 2001, J BIOL CHEM, V276, P42401, DOI 10.1074/jbc.M106956200; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Montell C., 2001, SCI STKE; Mori Y, 2002, J EXP MED, V195, P673, DOI 10.1084/jem.20011758; Parton RG, 2001, SCIENCE, V293, P2404, DOI 10.1126/science.1065677; Putney JW, 2001, J CELL SCI, V114, P2223; Razani B, 2000, J CELL SCI, V113, P2103; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Singh BB, 2001, FASEB J, V15, P1652, DOI 10.1096/fj.00-0749fje; Singh BB, 2000, J BIOL CHEM, V275, P36483, DOI 10.1074/jbc.C000529200; Suh PG, 2001, BIOCHEM BIOPH RES CO, V288, P1, DOI 10.1006/bbrc.2001.5710; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Torihashi S, 2002, J BIOL CHEM, V277, P19191, DOI 10.1074/jbc.M201728200; Trevino CL, 2001, FEBS LETT, V509, P119, DOI 10.1016/S0014-5793(01)03134-9; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Wang WC, 1999, AM J PHYSIOL-CELL PH, V276, pC969, DOI 10.1152/ajpcell.1999.276.4.C969; Xu SZ, 2001, CIRC RES, V88, P84, DOI 10.1161/01.RES.88.1.84; Xu XZS, 2000, NEURON, V26, P647, DOI 10.1016/S0896-6273(00)81201-5; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3	43	168	175	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27208	27215		10.1074/jbc.M301118200	http://dx.doi.org/10.1074/jbc.M301118200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12732636	Green Accepted, hybrid			2022-12-25	WOS:000184155700116
J	Hendriks, EF; Abdul-Razak; Matthews, KR				Hendriks, EF; Abdul-Razak; Matthews, KR			tbCPSF30 depletion by RNA interference disrupts polycistronic RNA processing in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; POLYADENYLATION SPECIFICITY FACTOR; CAENORHABDITIS-ELEGANS; INDUCIBLE EXPRESSION; MAMMALIAN CLEAVAGE; SITE SELECTION; IN-VITRO; PROTEIN; YEAST; TRISTETRAPROLIN	Gene expression in eukaryotes requires the post-transcriptional cleavage of mRNA precursors into mature mRNAs. In Trypanosoma brucei, mRNA processing is of particular importance, since most transcripts are derived from polycistronic transcription units. This organization dictates that regulated gene expression is promoter-independent and governed at the posttranscriptional level. We have identified tbCPSF30, a protein containing five CCCH zinc finger motifs, which is a homologue of the cleavage and polyadenylation specificity factor ( CPSF) 30-kDa subunit, a component of the machinery required for 3'-end formation in yeast and mammals. Using gene silencing of tbCPSF30 by RNA interference, we demonstrate that this gene is essential in bloodstream and procyclic forms of T. brucei. Interestingly, tbCPSF30-specific RNA interference results in the accumulation of an aberrant tbCPSF30 mRNA species concomitant with depletion of tbCPSF30 protein. tbCPSF30 protein depletion is accompanied by the accumulation of unprocessed tubulin RNAs, implicating tbCPSF30 in polycistronic RNA processing. By genome data base mining, we also identify several other putative components of the T. brucei cleavage and polyadenylation machinery, indicating their conservation throughout eukaryotic evolution. This study is the first to identify and characterize a core component of the T. brucei CPSF and show its involvement in polycistronic RNA processing.	Univ Manchester, Sch Biol Sci, Div Biochem, Manchester M13 9PT, Lancs, England	University of Manchester	Matthews, KR (corresponding author), Univ Manchester, Sch Biol Sci, Div Biochem, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.			Matthews FRS FMedSci FRSE, Professor Keith/0000-0003-0309-9184				AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bai CY, 1996, MOL CELL BIOL, V16, P6661; Bai CY, 1998, NUCLEIC ACIDS RES, V26, P1597, DOI 10.1093/nar/26.7.1597; Barabino SML, 2000, EMBO J, V19, P3778, DOI 10.1093/emboj/19.14.3778; Barabino SML, 1997, GENE DEV, V11, P1703, DOI 10.1101/gad.11.13.1703; Biebinger S, 1997, MOL BIOCHEM PARASIT, V85, P99, DOI 10.1016/S0166-6851(96)02815-0; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Clayton CE, 2002, EMBO J, V21, P1881, DOI 10.1093/emboj/21.8.1881; Dichtl B, 2001, EMBO J, V20, P3197, DOI 10.1093/emboj/20.12.3197; Evans D, 2001, GENE DEV, V15, P2562, DOI 10.1101/gad.920501; Gaiano N, 1996, NATURE, V383, P829, DOI 10.1038/383829a0; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hendriks EF, 2001, EMBO J, V20, P6700, DOI 10.1093/emboj/20.23.6700; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Kennerdell JR, 2002, GENE DEV, V16, P1884, DOI 10.1101/gad.990802; Kuersten S, 1997, RNA, V3, P269; LaCount DJ, 2002, J BIOL CHEM, V277, P17580, DOI 10.1074/jbc.M200873200; Lai WS, 1999, MOL CELL BIOL, V19, P4311; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; Li YZ, 2001, RNA, V7, P920, DOI 10.1017/S1355838201010226; Mair G, 2000, RNA, V6, P163, DOI 10.1017/S135583820099229X; MATTHEWS KR, 1994, GENE DEV, V8, P491, DOI 10.1101/gad.8.4.491; MUHICH ML, 1988, MOL CELL BIOL, V8, P3837, DOI 10.1128/MCB.8.9.3837; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; NIWA M, 1992, NATURE, V360, P277, DOI 10.1038/360277a0; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; NIWA M, 1991, GENE DEV, V5, P2086, DOI 10.1101/gad.5.11.2086; NIWA M, 1991, GENE EXPRESSION, V1, P5; PALFI Z, 1991, P NATL ACAD SCI USA, V88, P9097, DOI 10.1073/pnas.88.20.9097; Preker PJ, 1997, EMBO J, V16, P4727, DOI 10.1093/emboj/16.15.4727; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; Tasker M, 2001, MOL MICROBIOL, V39, P272, DOI 10.1046/j.1365-2958.2001.02252.x; Tasker M, 2000, MOL BIOL CELL, V11, P1905, DOI 10.1091/mbc.11.5.1905; THOMAS J, 1990, NUCLEIC ACIDS RES, V18, P2633, DOI 10.1093/nar/18.9.2633; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; ULLU E, 1993, MOL CELL BIOL, V13, P720, DOI 10.1128/MCB.13.1.720; Veraldi KL, 2000, RNA, V6, P768, DOI 10.1017/S135583820099246X; Vo LTA, 2001, MOL CELL BIOL, V21, P8346, DOI 10.1128/MCB.21.24.8346-8356.2001; Wahle E, 1999, FEMS MICROBIOL REV, V23, P277, DOI 10.1016/S0168-6445(99)00008-X; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Zarudnaya MI, 2002, IUBMB LIFE, V54, P27, DOI 10.1080/15216540213821; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999; Zhao J, 1999, MOL CELL BIOL, V19, P7733	45	31	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26870	26878		10.1074/jbc.M302405200	http://dx.doi.org/10.1074/jbc.M302405200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12746436	hybrid			2022-12-25	WOS:000184155700075
J	Hossain, A; Saunders, GF				Hossain, A; Saunders, GF			Synergistic cooperation between the beta-catenin signaling pathway and steroidogenic factor 1 in the activation of the mullerian inhibiting substance type II receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRODUCTIVE-TRACT; SEXUAL DEVELOPMENT; HORMONE-RECEPTOR; DUCT REGRESSION; EXPRESSION; CELLS; PHOSPHORYLATION; APOPTOSIS; POLARITY; WNT-7A	Mullerian inhibiting substance type II receptor (MISRII) is a member of the transforming growth factor-beta superfamily. Mutations in mullerian inhibiting substance (MIS) or MISRII cause male sexual abnormalities, persistent mullerian duct syndrome, and pseudohermaphroditism. The spatial and temporal regulation of MIS and MISRII is important for its biological action. Male Wnt7a mutant mice do not undergo regression of mullerian ducts. Here we showed that the canonical Wnt signaling pathway regulated MISRII. The promoter MISRII was activated by beta-catenin expression, and this activation was dependent on TCF4-binding sites. The nuclear receptor superfamily member steroidogenic factor 1 (SF1) synergistically activated the MISRII promoter with beta-catenin. APC, a negative regulator of Wnt signaling, decreased SF1-mediated activation of the MISRII promoter in the colon carcinoma cell line SW480. We also showed a direct physical interaction between beta-catenin and SF1 by co-immunoprecipitation. Thus, our findings suggest that MISRII is a developmental target of Wnt7a signaling for mullerian duct regression during sexual differentiation.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Saunders, GF (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Box 117,1515 Holcombe Blvd, Houston, TX 77030 USA.	gsaunders@odin.mdacc.tmc.edu			NATIONAL CANCER INSTITUTE [P30CA016672, P01CA034936] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672, CA 34936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allard S, 2000, DEVELOPMENT, V127, P3349; Arango NA, 1999, CELL, V99, P409, DOI 10.1016/S0092-8674(00)81527-5; BAARENDS WM, 1995, ENDOCRINOLOGY, V136, P5614, DOI 10.1210/en.136.12.5614; BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; de Santa Barbara P, 1998, J BIOL CHEM, V273, P29654; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Hossain A, 2001, J BIOL CHEM, V276, P16817, DOI 10.1074/jbc.M009056200; IMBEAUD S, 1995, NAT GENET, V11, P382, DOI 10.1038/ng1295-382; Jamin SP, 2002, NAT GENET, V32, P408, DOI 10.1038/ng1003; Josso N, 2001, MOL CELL ENDOCRINOL, V179, P25, DOI 10.1016/S0303-7207(01)00467-1; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Kozopas KM, 1998, GENE DEV, V12, P1155, DOI 10.1101/gad.12.8.1155; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Mishina Y, 1996, GENE DEV, V10, P2577, DOI 10.1101/gad.10.20.2577; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; Parr BA, 1998, NATURE, V395, P707, DOI 10.1038/27221; Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200; Polakis P, 2000, GENE DEV, V14, P1837; Roberts LM, 1999, DEV BIOL, V208, P110, DOI 10.1006/dbio.1998.9190; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Teixeira J, 1996, ENDOCRINOLOGY, V137, P160, DOI 10.1210/en.137.1.160; Teixeira J, 1999, P NATL ACAD SCI USA, V96, P13831, DOI 10.1073/pnas.96.24.13831; Teng CS, 2001, CELL TISSUE RES, V306, P27, DOI 10.1007/s004410100426; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068	31	48	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26511	26516		10.1074/jbc.M300804200	http://dx.doi.org/10.1074/jbc.M300804200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12724325	hybrid			2022-12-25	WOS:000184155700030
J	Pfoestl, A; Hofinger, A; Kosma, P; Messner, P				Pfoestl, A; Hofinger, A; Kosma, P; Messner, P			Biosynthesis of dTDP-3-acetamido-3,6-dideoxy-alpha-D-galactose in Aneurinibacillus thermoaerophilus L420-91(T)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-LAYER GLYCOPROTEIN; STREPTOMYCES-FRADIAE GENOME; THYMIDINE-LINKED SUGARS; L-RHAMNOSE BIOSYNTHESIS; O-ANTIGEN BIOSYNTHESIS; ESCHERICHIA-COLI; ENZYMATIC-SYNTHESIS; LIPOPOLYSACCHARIDE BIOSYNTHESIS; XANTHOMONAS-CAMPESTRIS; SALMONELLA-ENTERICA	The glycan chain of the S-layer protein of Aneurinibacillus thermoaerophilus L420-91(T) (DSM 10154) consists of D-rhamnose and 3-acetamido-3,6-dideoxy-D-galactose (D-Fucp3NAc). Thymidine diphosphate-activated D-Fucp3NAc serves as precursor for the assembly of structural polysaccharides in Gram-positive and Gram-negative organisms. The biosynthesis of dTDP-3-acetamido-3,6-dideoxy-alpha-D-galactose (dTDP-D-Fucp3NAc) involves five enzymes. The first two steps of the reaction are catalyzed by enzymes that are part of the well studied dTDP-L-rhamnose biosynthetic pathway, namely D-glucose-1-phosphate thymidyltransferase (RmlA) and dTDP-D-glucose-4,6-dehydratase (RmlB). The enzymes catalyzing the last three synthesis reactions have not been characterized biochemically so far. These steps include an isomerase, a transaminase, and a transacetylase. We identified all five genes involved by chromosome walking in the Gram-positive organism A. thermoaerophilus L420-91T and overexpressed the three new enzymes heterologously in Escherichia coli. The activities of these enzymes were monitored by reverse phase high performance liquid chromatography, and the intermediate products formed were characterized by H-1 and C-13 nuclear magnetic resonance spectroscopy analysis. Alignment of the newly identified proteins with known sequences revealed that the elucidated pathway in this Gram-positive organism may also be valid in the biosynthesis of the O-antigen of lipopolysaccharides of Gram-negative organisms. The key enzyme in the biosynthesis of dTDP-D-Fucp3NAc has been identified as an isomerase, which converts the 4-keto educt into the 3-keto product, with concomitant epimerization at C-4 to produce a 6-deoxy-D-xylo configuration. This is the first report of the functional characterization of the biosynthesis of dTDP-D-Fucp3NAc and description of a novel type of isomerase capable of synthesizing dTDP-6-deoxy-D-xylohex-3-ulose from dTDP-6-deoxy-D-xylohex-4-ulose.	Univ Bodenkultur Wien, Zentrum Ultrastrukturforsch, A-1180 Vienna, Austria; Univ Bodenkultur Wien, Ludwig Boltzmann Inst Mol Nanotechnol, A-1180 Vienna, Austria; Univ Bodenkultur Wien, Inst Chem, A-1190 Vienna, Austria	University of Natural Resources & Life Sciences, Vienna; Ludwig Boltzmann Institute; University of Natural Resources & Life Sciences, Vienna; University of Natural Resources & Life Sciences, Vienna	Messner, P (corresponding author), Univ Bodenkultur Wien, Zentrum Ultrastrukturforsch, Gregor Mendel Str 33, A-1180 Vienna, Austria.	paul.messner@boku.ac.at	Kosma, Paul/Y-7443-2019; Messner, Paul/Q-5345-2017	Kosma, Paul/0000-0001-5342-7161; Messner, Paul/0000-0002-3246-5801				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASHWELL G, 1965, J BIOL CHEM, V240, P4549; Bock AK, 1999, J BACTERIOL, V181, P1861, DOI 10.1128/JB.181.6.1861-1867.1999; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen HW, 1999, J AM CHEM SOC, V121, P7166, DOI 10.1021/ja991213v; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Eads JC, 1999, BIOCHEMISTRY-US, V38, P9840, DOI 10.1021/bi990018q; Gandecha AR, 1997, GENE, V184, P197, DOI 10.1016/S0378-1119(96)00595-1; Giraud MF, 2000, CURR OPIN STRUC BIOL, V10, P687, DOI 10.1016/S0959-440X(00)00145-7; GLASER L, 1961, J BIOL CHEM, V236, P1795; Graninger M, 2002, APPL ENVIRON MICROB, V68, P3708, DOI 10.1128/AEM.68.8.3708-3715.2002; Graninger M, 1999, J BIOL CHEM, V274, P25069, DOI 10.1074/jbc.274.35.25069; Gronow S, 2001, J ENDOTOXIN RES, V7, P3, DOI 10.1179/096805101101532468; HARTMANN E, 1993, J BACTERIOL, V175, P4515, DOI 10.1128/JB.175.14.4515-4519.1993; HASELEY SR, 1995, EUR J BIOCHEM, V233, P899, DOI 10.1111/j.1432-1033.1995.899_3.x; Haseley SR, 1997, EUR J BIOCHEM, V247, P815, DOI 10.1111/j.1432-1033.1997.00815.x; HERMANSSON K, 1993, CARBOHYD RES, V248, P199, DOI 10.1016/0008-6215(93)84127-R; Heyndrickx M, 1997, INT J SYST BACTERIOL, V47, P808, DOI 10.1099/00207713-47-3-808; JIANG XM, 1991, MOL MICROBIOL, V5, P695, DOI 10.1111/j.1365-2958.1991.tb00741.x; Kneidinger B, 2001, BIOTECHNIQUES, V30, P248, DOI 10.2144/01302bm01; Kneidinger B, 2001, J BIOL CHEM, V276, P5577, DOI 10.1074/jbc.M010027200; Knirel' Iu A, 1994, Biokhimiia, V59, P1784; KORNFELD S, 1961, J BIOL CHEM, V236, P1791; KOSMA P, 1995, GLYCOCONJUGATE J, V12, P99, DOI 10.1007/BF00731875; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Marolda CL, 1999, MICROBIOL-UK, V145, P2485, DOI 10.1099/00221287-145-9-2485; MATSUHASHI M, 1964, J BIOL CHEM, V239, P2454; MeierStauffer K, 1996, INT J SYST BACTERIOL, V46, P532, DOI 10.1099/00207713-46-2-532; MERSONDAVIES LA, 1994, MOL MICROBIOL, V13, P349, DOI 10.1111/j.1365-2958.1994.tb00428.x; Nakano Y, 2000, J BIOL CHEM, V275, P6806, DOI 10.1074/jbc.275.10.6806; Naundorf A, 1996, CARBOHYD RES, V285, P141, DOI 10.1016/S0008-6215(96)90180-9; Olsen LR, 2001, BIOCHEMISTRY-US, V40, P1913, DOI 10.1021/bi002503n; Perelle S, 2002, J APPL MICROBIOL, V93, P758, DOI 10.1046/j.1365-2672.2002.01743.x; Quiros LM, 1998, MOL MICROBIOL, V28, P1177, DOI 10.1046/j.1365-2958.1998.00880.x; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rocchetta HL, 1999, MICROBIOL MOL BIOL R, V63, P523, DOI 10.1128/MMBR.63.3.523-553.1999; Sambrook J., 2001, MOL CLONING; Sara M, 2000, J BACTERIOL, V182, P859, DOI 10.1128/JB.182.4.859-868.2000; Schaffer C, 1996, MICROB DRUG RESIST, V2, P17, DOI 10.1089/mdr.1996.2.17; Schaffer C, 1999, GLYCOBIOLOGY, V9, P407, DOI 10.1093/glycob/9.4.407; Schaffer C, 2001, BIOCHIMIE, V83, P591, DOI 10.1016/S0300-9084(01)01299-8; SHIBAEV VN, 1986, ADV CARBOHYD CHEM BI, V44, P277; Stein A, 1998, GLYCOCONJUGATE J, V15, P139, DOI 10.1023/A:1006912121278; STUTZMANENGWALL KJ, 1992, J BACTERIOL, V174, P144, DOI 10.1128/jb.174.1.144-154.1992; Summers RG, 1997, MICROBIOL-UK, V143, P3251, DOI 10.1099/00221287-143-10-3251; SUMPER M, 1995, GLYCOPROTEINS, P455; Tonetti M, 1996, J BIOL CHEM, V271, P27274, DOI 10.1074/jbc.271.44.27274; VAARA M, 1992, FEMS MICROBIOL LETT, V97, P249, DOI 10.1016/0378-1097(92)90344-N; Valvano MA, 2002, MICROBIOL-SGM, V148, P1979, DOI 10.1099/00221287-148-7-1979; VOLK WA, 1963, BIOCHEM BIOPH RES CO, V12, P116, DOI 10.1016/0006-291X(63)90245-6; Vorholter FJ, 2001, MOL GENET GENOMICS, V266, P79, DOI 10.1007/s004380100521; Yoshida Y, 1999, J BIOL CHEM, V274, P16933, DOI 10.1074/jbc.274.24.16933	52	67	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26410	26417		10.1074/jbc.M300858200	http://dx.doi.org/10.1074/jbc.M300858200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12740380	hybrid			2022-12-25	WOS:000184155700017
J	Santoro, F; Greenstone, HL; Insinga, A; Liszewski, MK; Atkinson, JP; Lusso, P; Berger, EA				Santoro, F; Greenstone, HL; Insinga, A; Liszewski, MK; Atkinson, JP; Lusso, P; Berger, EA			Interaction of glycoprotein H of human herpesvirus 6 with the cellular receptor CD46	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX-VIRUS GLYCOPROTEIN; COFACTOR PROTEIN MCP; HUMAN-HERPESVIRUS 6; HLA CLASS-II; MEASLES-VIRUS; NEUTRALIZING EPITOPE; VARIANT-A; MONOCLONAL-ANTIBODIES; FUNCTIONAL DOMAINS; SEQUENCE ANALYSES	Human herpesvirus 6 (HHV-6) employs the complement regulator CD46 (membrane cofactor protein) as a receptor for fusion and entry into target cells. Like other known herpesviruses, HHV-6 encodes multiple glycoproteins, several of which have been implicated in the entry process. In this report, we present evidence that glycoprotein H (gH) is the viral component responsible for binding to CD46. Antibodies to CD46 co-immunoprecipitated an similar to110-kDa protein band specifically associated with HHV-6-infected cells. This protein was identified as gH by selective depletion with an anti-gH monoclonal antibody, as well as by immunoblot analysis with a rabbit hyperimmune serum directed against a gH synthetic peptide. In reciprocal experiments, a monoclonal antibody against HHV-6 gH was found to co-immunoprecipitate CD46. Studies using monoclonal antibodies directed against specific CD46 domains, as well as engineered constructs lacking defined CD46 regions, demonstrated a close correspondence between the CD46 domains involved in the interaction with gH and those previously shown to be critical for HHV-6 fusion (i.e. short consensus repeats 2 and 3).	NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; Ist Sci San Raffaele, Dept Biol & tech Res, Unit Human Virol, I-20132 Milan, Italy; Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63110 USA; Univ Cagliari, Sch Med, Dept Med Sci, I-09100 Cagliari, Italy	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Washington University (WUSTL); University of Cagliari	Berger, EA (corresponding author), NIAID, Viral Dis Lab, NIH, Bldg 4,Rm 237, Bethesda, MD 20892 USA.	edward_berger@nih.gov	Insinga, Alessandra/AAR-9551-2020	Atkinson, John/0000-0002-2514-3441; Insinga, Alessandra/0000-0002-6060-8339	NIAID NIH HHS [R01 AI37618] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000733, R01AI037618] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson RA, 1999, J GEN VIROL, V80, P1485, DOI 10.1099/0022-1317-80-6-1485; BALACHANDRAN N, 1989, J VIROL, V63, P2835, DOI 10.1128/JVI.63.6.2835-2840.1989; Campadelli-Fiume G, 2000, REV MED VIROL, V10, P305, DOI 10.1002/1099-1654(200009/10)10:5<305::AID-RMV286>3.0.CO;2-T; Carfi A, 2001, MOL CELL, V8, P169, DOI 10.1016/S1097-2765(01)00298-2; Chakrabarti S, 1997, BIOTECHNIQUES, V23, P1094, DOI 10.2144/97236st07; CHO SW, 1991, CLIN EXP IMMUNOL, V83, P257; Christiansen D, 2000, J GEN VIROL, V81, P911, DOI 10.1099/0022-1317-81-4-911; Dockrell DH, 2003, J MED MICROBIOL, V52, P5, DOI 10.1099/jmm.0.05074-0; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FOATOMASI L, 1991, J VIROL, V65, P4124; GOMPELS UA, 1993, J GEN VIROL, V74, P613, DOI 10.1099/0022-1317-74-4-613; GOMPELS UA, 1991, J VIROL, V65, P2393, DOI 10.1128/JVI.65.5.2393-2401.1991; Greenstone HL, 2002, J BIOL CHEM, V277, P39112, DOI 10.1074/jbc.M206488200; Haan KM, 2000, J VIROL, V74, P2451, DOI 10.1128/JVI.74.5.2451-2454.2000; Haan KM, 2001, VIROLOGY, V290, P106, DOI 10.1006/viro.2001.1141; Hourcade D, 2000, IMMUNOPHARMACOLOGY, V49, P103, DOI 10.1016/S0162-3109(00)80296-9; HUTCHINSON L, 1992, J VIROL, V66, P2240, DOI 10.1128/JVI.66.4.2240-2250.1992; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; Kemper C, 2003, NATURE, V421, P388, DOI 10.1038/nature01315; Krummenacher C, 1998, J VIROL, V72, P7064, DOI 10.1128/JVI.72.9.7064-7074.1998; Li QX, 1997, J VIROL, V71, P4657, DOI 10.1128/JVI.71.6.4657-4662.1997; LISZEWSKI MK, 1994, J BIOL CHEM, V269, P10776; LIU DX, 1993, J GEN VIROL, V74, P1847, DOI 10.1099/0022-1317-74-9-1847; LIU DX, 1993, VIROLOGY, V197, P12, DOI 10.1006/viro.1993.1562; MANCHESTER M, 1995, P NATL ACAD SCI USA, V92, P2303, DOI 10.1073/pnas.92.6.2303; Maresova L, 2001, J VIROL, V75, P9483, DOI 10.1128/JVI.75.19.9483-9492.2001; Mori Y, 2003, J VIROL, V77, P4992, DOI 10.1128/JVI.77.8.4992-4999.2003; Mori Y, 2003, J VIROL, V77, P2452, DOI 10.1128/JVI.77.4.2452-2458.2003; Mori Y, 2002, J VIROL, V76, P6750, DOI 10.1128/JVI.76.13.6750-6761.2002; Muggeridge MI, 2000, J GEN VIROL, V81, P2017, DOI 10.1099/0022-1317-81-8-2017; NEMEROW GR, 1987, J VIROL, V61, P1416, DOI 10.1128/JVI.61.5.1416-1420.1987; NUSSBAUM O, 1995, J VIROL, V69, P3341, DOI 10.1128/JVI.69.6.3341-3349.1995; Parren PWHI, 1999, AIDS, V13, pS137; Pertel PE, 2002, J VIROL, V76, P4390, DOI 10.1128/JVI.76.9.4390-4400.2002; Pertel PE, 2001, VIROLOGY, V279, P313, DOI 10.1006/viro.2000.0713; PESANDO JM, 1987, HUM IMMUNOL, V19, P235, DOI 10.1016/0198-8859(87)90041-3; PFEIFFER B, 1995, J VIROL, V69, P3490, DOI 10.1128/JVI.69.6.3490-3500.1995; PFEIFFER B, 1993, J VIROL, V67, P4611, DOI 10.1128/JVI.67.8.4611-4620.1993; PURCELL DFJ, 1989, IMMUNOL CELL BIOL, V67, P279, DOI 10.1038/icb.1989.42; QIAN G, 1993, VIROLOGY, V194, P380, DOI 10.1006/viro.1993.1272; ROOP C, 1993, J VIROL, V67, P2285, DOI 10.1128/JVI.67.4.2285-2297.1993; Santoro F, 1999, CELL, V99, P817, DOI 10.1016/S0092-8674(00)81678-5; Schmidt J, 2001, J VIROL, V75, P10054, DOI 10.1128/JVI.75.21.10054-10064.2001; Schroder C, 1997, J VIROL, V71, P25; SEYA T, 1990, J IMMUNOL, V145, P238; Spear PG, 2000, VIROLOGY, V275, P1, DOI 10.1006/viro.2000.0529; Takeda K, 1997, J GEN VIROL, V78, P2171, DOI 10.1099/0022-1317-78-9-2171; Takeda K, 1996, VIROLOGY, V222, P176, DOI 10.1006/viro.1996.0408; TANNER J, 1987, CELL, V50, P203, DOI 10.1016/0092-8674(87)90216-9; Turner A, 1998, J VIROL, V72, P873, DOI 10.1128/JVI.72.1.873-875.1998; Westra DF, 1997, J VIROL, V71, P2285, DOI 10.1128/JVI.71.3.2285-2291.1997; Whitbeck JC, 1997, J VIROL, V71, P6083, DOI 10.1128/JVI.71.8.6083-6093.1997; Willis SH, 1998, J VIROL, V72, P5937, DOI 10.1128/JVI.72.7.5937-5947.1998	53	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25964	25969		10.1074/jbc.M302373200	http://dx.doi.org/10.1074/jbc.M302373200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12724329	hybrid			2022-12-25	WOS:000183920200090
J	Yang, TZ; Ta, TA; Pessah, IN; Allen, PD				Yang, TZ; Ta, TA; Pessah, IN; Allen, PD			Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNEL; CENTRAL CORE DISEASE; GENOTYPE-PHENOTYPE CORRELATION; MUSCLE SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE; INCREASED SENSITIVITY; CAFFEINE; CELLS; 4-CHLORO-M-CRESOL; SUSCEPTIBILITY	Malignant hyperthermia (MH) is a potentially fatal pharmacogenetic disorder of skeletal muscle that segregates with > 60 mutations within the MHS-1 locus on chromosome 19 coding for ryanodine receptor type 1 (RyR1). Although some (MH)RyR1s have been shown to enhance sensitivity to caffeine and halothane when expressed in non-muscle cells, their influence on EC coupling can only be studied in skeletal myotubes. We therefore expressed (WT)RyR1, six of the most common human (MH)RyR1s (R163C, G341R, R614C, R2163C, V2168M, and R2458H), and a newly identified C-terminal mutation (T4826I) in dyspedic myotubes to study their functional defects and how they influence EC coupling. Myotubes expressing any (MH)RyR1 were significantly more sensitive to stimulation by caffeine and 4-CmC than those expressing (WT)RyR1. The hypersensitivity of MH myotubes extended to K+ depolarization. MH myotubes responded to direct channel activators with maximum Ca2+ amplitudes consistently smaller than WT myotubes, whereas the amplitude of their responses to depolarization were consistently larger than WT myotubes. The magnitudes of responses attainable from myotubes expressing MHRyR1s are therefore related to the nature of the stimulus rather than size of the Ca2+ store. The functional changes of (MH)RyR1s were directly analyzed using [H-3] ryanodine binding analysis of isolated myotube membranes. Although none of the MHRyR1s examined significantly altered EC50 for Ca2+ activation, many failed to be completely inhibited by a low Ca2+ (less than or equal to100 nM), and all were significantly more responsive to caffeine than (WT)RyR1 at Ca2+ concentrations that approximate those in resting myotubes. All seven mutations had diminished sensitivity to inhibition by Ca2+ and Mg2+. Using a homologous expression system, our study demonstrates for the first time that these 7 MH mutations are all both necessary and sufficient to induce MH-related phenotypes. Decreased sensitivity to Ca2+ and Mg2+ inhibition and inability of MHRyR1s to be fully inactivated at [Ca2+](i) typical of normal myotubes at rest are key defects that contribute to the initiation of MH episodes.	Brigham & Womens Hosp, Boston, MA 02115 USA; Univ Calif Davis, Dept Mol Biosci, Davis, CA 95616 USA	Harvard University; Brigham & Women's Hospital; University of California System; University of California Davis	Yang, TZ (corresponding author), Brigham & Womens Hosp, 20 Shattuck St SR 158, Boston, MA 02115 USA.		Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X				Balog EM, 2001, BIOPHYS J, V81, P2050, DOI 10.1016/S0006-3495(01)75854-7; Baur CP, 2000, ANESTH ANALG, V90, P200, DOI 10.1097/00000539-200001000-00040; Brinkmeier H, 1999, BRIT J ANAESTH, V83, P855, DOI 10.1093/bja/83.6.855; Brown RL, 2000, HUM MOL GENET, V9, P1515, DOI 10.1093/hmg/9.10.1515; BUCK E, 1992, J BIOL CHEM, V267, P23560; Dietze B, 2000, J PHYSIOL-LONDON, V526, P507, DOI 10.1111/j.1469-7793.2000.t01-1-00507.x; Du GG, 2001, P NATL ACAD SCI USA, V98, P13625, DOI 10.1073/pnas.241516898; Fessenden JD, 2001, P NATL ACAD SCI USA, V98, P2865, DOI 10.1073/pnas.041608898; FILL M, 1990, BIOPHYS J, V57, P471, DOI 10.1016/S0006-3495(90)82563-7; Fraefel C, 1996, J VIROL, V70, P7190, DOI 10.1128/JVI.70.10.7190-7197.1996; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; Gallant EM, 1996, MUSCLE NERVE, V19, P68, DOI 10.1002/(SICI)1097-4598(199601)19:1<68::AID-MUS9>3.3.CO;2-0; GALLANT EM, 1992, AM J PHYSIOL, V262, P422; GILLARD EF, 1991, GENOMICS, V11, P751, DOI 10.1016/0888-7543(91)90084-R; Girard T, 2002, BRIT J ANAESTH, V89, P571, DOI 10.1093/bja/aef237; Girard T, 2001, J BIOL CHEM, V276, P48077, DOI 10.1074/jbc.M107134200; GROUP EM, 1984, BRIT J ANAESTH, V56, P1267; HerrmannFrank A, 1996, BIOCHEM PHARMACOL, V52, P149, DOI 10.1016/0006-2952(96)00175-X; HODGKIN AL, 1960, J PHYSIOL-LONDON, V153, P386, DOI 10.1113/jphysiol.1960.sp006541; Jiang DW, 2002, CIRC RES, V91, P218, DOI 10.1161/01.RES.0000028455.36940.5E; Kabbara AA, 1999, CELL CALCIUM, V25, P227, DOI 10.1054/ceca.1999.0023; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; Laver DR, 1997, BIOPHYS J, V73, P1913, DOI 10.1016/S0006-3495(97)78222-5; Lopez JR, 2000, ANESTHESIOLOGY, V92, P1799, DOI 10.1097/00000542-200006000-00040; Manning BM, 1998, AM J HUM GENET, V62, P599, DOI 10.1086/301748; Masumiya H, 2001, J BIOL CHEM, V276, P39727, DOI 10.1074/jbc.M106557200; McCarthy TV, 2000, HUM MUTAT, V15, P410, DOI 10.1002/(SICI)1098-1004(200005)15:5<410::AID-HUMU2>3.0.CO;2-D; MICKELSON JR, 1988, J BIOL CHEM, V263, P9310; MICKELSON JR, 1986, BIOCHIM BIOPHYS ACTA, V862, P318, DOI 10.1016/0005-2736(86)90234-8; MICKELSON JR, 1990, ARCH BIOCHEM BIOPHYS, V278, P251, DOI 10.1016/0003-9861(90)90255-W; Monnier N, 2001, HUM MOL GENET, V10, P2581, DOI 10.1093/hmg/10.22.2581; Monnier N, 2000, HUM MOL GENET, V9, P2599, DOI 10.1093/hmg/9.18.2599; Moore RA, 1998, J CELL BIOL, V140, P843, DOI 10.1083/jcb.140.4.843; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; OBRIEN PJ, 1986, CAN J VET RES, V50, P318; OTSU K, 1994, J BIOL CHEM, V269, P9413; Owen VJ, 1997, AM J PHYSIOL-CELL PH, V272, pC203, DOI 10.1152/ajpcell.1997.272.1.C203; Oyamada H, 2002, JPN J PHARMACOL, V88, P159, DOI 10.1254/jjp.88.159; Pessah IN, 1997, AM J PHYSIOL-CELL PH, V272, pC601, DOI 10.1152/ajpcell.1997.272.2.C601; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; PESSAH IN, 1991, MOL PHARMACOL, V39, P679; Richter M, 1997, J BIOL CHEM, V272, P5256, DOI 10.1074/jbc.272.8.5256; Sambuughin N, 2001, NEUROMUSCULAR DISORD, V11, P530, DOI 10.1016/S0960-8966(01)00202-4; SHOMER NH, 1993, AM J PHYSIOL, V264, pC125, DOI 10.1152/ajpcell.1993.264.1.C125; Tong JF, 1999, J BIOL CHEM, V274, P693, DOI 10.1074/jbc.274.2.693; Tong JF, 1997, J BIOL CHEM, V272, P26332, DOI 10.1074/jbc.272.42.26332; TREVES S, 1994, BIOCHEM J, V301, P661, DOI 10.1042/bj3010661; Wang Y, 2000, AM J PHYSIOL-CELL PH, V278, pC619, DOI 10.1152/ajpcell.2000.278.3.C619; Wehner M, 2002, CLIN GENET, V62, P135, DOI 10.1034/j.1399-0004.2002.620206.x; ZIMANYI I, 1992, MOL PHARMACOL, V42, P1049; ZORZATO F, 1993, MOL PHARMACOL, V44, P1192	51	91	94	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25722	25730		10.1074/jbc.M302165200	http://dx.doi.org/10.1074/jbc.M302165200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12732639	hybrid			2022-12-25	WOS:000183920200057
J	Merle, P; Barraud, L; Lefrancois, L; Chevallier, M; Guerret, S; Maisonnas, M; Bordes, I; Savre-Train, I; Trepo, C; Vitvitski-Trepo, L				Merle, P; Barraud, L; Lefrancois, L; Chevallier, M; Guerret, S; Maisonnas, M; Bordes, I; Savre-Train, I; Trepo, C; Vitvitski-Trepo, L			Long-term high-dose interferon-alpha therapy delays Hepadnavirus-related hepatocarcinogenesis in X/myc transgenic mice	ONCOGENE			English	Article						hepatocellular carcinoma; interferon; c-myc; proliferation	HEPATITIS-B-VIRUS; TELOMERASE REVERSE-TRANSCRIPTASE; C-MYC; HEPATOCELLULAR-CARCINOMA; NUCLEOTIDE-SEQUENCE; EXPRESSION; GENE; ACTIVATION; GROWTH; CANCER	The role of interferon-alpha (IFN-alpha) remains unclear in prevention of virus-induced hepatocellular carcinoma in humans. We have investigated it herewith in the X/myc transgenic mouse model of Hepadnavirus-related hepatocarcinogenesis because of upregulation of c-myc oncogene in the liver. We have demonstrated that IFN-alpha can downregulate dose-dependently hepatocyte proliferation and c-myc overexpression at early premalignant stages, while it does not affect either hepatocyte apoptosis or telomerase activity at these steps. However, continuous and long-term administration of IFN-alpha dose-dependently delays tumor onset in dysplastic livers and increases overall survival of animals, more efficiently whether started before the onset of dysplasia. The present study therefore highlights that early preventive administration of IFN-alpha can slow down evolution towards hepatocellular carcinoma via repression of c-myc and hepatocyte proliferation at premalignant steps in experimental c-myc-induced hepatocarcinogenesis. However, the transient effect observed in this study emphasizes a need to clarify the possible mechanisms of acquired resistance and subsequent therapeutic escape. Our experimental model may be a pertinent toot to explore antioncogenic properties of IFN-alpha in human cirrhotic livers showing c-myc upregulation.	INSERM, U271, F-69424 Lyon 03, France; Labs Marcel Merieux, Dept Anat Pathol, F-69365 Lyon 07, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Trepo, C (corresponding author), INSERM, U271, 151 Cours Albert Thomas, F-69003 Lyon, France.	trepo@lyon151.inserm.fr						BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; CHAOUCHI N, 1994, CLIN IMMUNOL IMMUNOP, V73, P197, DOI 10.1006/clin.1994.1188; Cheng J, 2000, CANCER GENE THER, V7, P407, DOI 10.1038/sj.cgt.7700127; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Ebinuma H, 1999, INT J ONCOL, V15, P991; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; Einhorn S, 1996, J INTERF CYTOK RES, V16, P275, DOI 10.1089/jir.1996.16.275; ETIEMBLE J, 1994, ONCOGENE, V9, P727; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FARSHID M, 1993, J MED VIROL, V39, P177; Fausto N, 1999, SEMIN LIVER DIS, V19, P243, DOI 10.1055/s-2007-1007114; FERRANTINI M, 1994, J IMMUNOL, V153, P4604; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GALIBERT F, 1982, J VIROL, V41, P51, DOI 10.1128/JVI.41.1.51-65.1982; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; HIMENO Y, 1988, LIVER, V8, P208; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; IKEDA K, 1993, HEPATOLOGY, V18, P47, DOI 10.1016/0270-9139(93)90505-H; Ikeda K, 1998, CANCER-AM CANCER SOC, V82, P827, DOI 10.1002/(SICI)1097-0142(19980301)82:5<827::AID-CNCR5>3.0.CO;2-G; Kawate S, 1999, ONCOLOGY-BASEL, V57, P157, DOI 10.1159/000012024; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kojima H, 1997, GASTROENTEROLOGY, V112, P493, DOI 10.1053/gast.1997.v112.pm9024303; Komine F, 2000, J HEPATOL, V32, P235, DOI 10.1016/S0168-8278(00)80068-9; Kondoh N, 2001, INT J ONCOL, V18, P1271; Kumada T, 1997, HEPATOLOGY, V25, P87, DOI 10.1053/jhep.1997.v25.pm0008985270; Liu P, 1997, HEPATOLOGY, V25, P874, DOI 10.1002/hep.510250415; Llovet JM, 2000, HEPATOLOGY, V31, P54, DOI 10.1002/hep.510310111; Lundberg AS, 1999, EUR J CANCER, V35, P1886, DOI 10.1016/S0959-8049(99)00292-0; Merle P, 2001, J HEPATOL, V34, P562, DOI 10.1016/S0168-8278(00)00054-4; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Nishiguchi S, 2001, LANCET, V357, P196, DOI 10.1016/S0140-6736(00)03595-9; Qin XQ, 1998, P NATL ACAD SCI USA, V95, P14411, DOI 10.1073/pnas.95.24.14411; Shen LL, 1998, HEPATO-GASTROENTEROL, V45, P1753; SHOUVAL D, 1983, J CLIN INVEST, V72, P707, DOI 10.1172/JCI111020; SU TS, 1985, BIOCHEM BIOPH RES CO, V132, P264, DOI 10.1016/0006-291X(85)91017-4; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; VORAVUD N, 1989, HUM PATHOL, V20, P1163, DOI 10.1016/S0046-8177(89)80006-1; WADLER S, 1990, CANCER RES, V50, P3473; Wang L, 2000, HEPATOLOGY, V32, P43, DOI 10.1053/jhep.2000.8525; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2000, BLOOD, V96, P4313, DOI 10.1182/blood.V96.13.4313.h8004313_4313_4318; Yano H, 1999, HEPATOLOGY, V29, P1708, DOI 10.1002/hep.510290624; Yuen MF, 2001, CANCER, V91, P106, DOI 10.1002/1097-0142(20010101)91:1<106::AID-CNCR14>3.0.CO;2-2; ZHANG XK, 1990, ONCOGENE, V5, P909	47	16	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2003	22	18					2762	2771		10.1038/sj.onc.1206375	http://dx.doi.org/10.1038/sj.onc.1206375			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743599				2022-12-25	WOS:000182569300007
J	Sakao, E; Ishihara, A; Horikawa, K; Akiyama, M; Arai, M; Kato, M; Seki, N; Fukunaga, K; Shimizu-Yabe, A; Iwase, K; Ohtsuka, S; Sato, T; Kohno, Y; Shibata, S; Takiguchi, M				Sakao, E; Ishihara, A; Horikawa, K; Akiyama, M; Arai, M; Kato, M; Seki, N; Fukunaga, K; Shimizu-Yabe, A; Iwase, K; Ohtsuka, S; Sato, T; Kohno, Y; Shibata, S; Takiguchi, M			Two-peaked synchronization in day/night expression rhythms of the fibrinogen gene cluster in the mouse liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCADIAN CLOCK; CHROMOSOMAL LOCALIZATION; PERIPHERAL-TISSUES; PLASMA-FIBRINOGEN; THYROID-HORMONE; TRANSCRIPTION; PROTEINS; AGGREGATION; MECHANISM; PLATELETS	Genes expressed with day/night rhythms in the mouse liver were searched for by microarray analysis using an in-house array harboring mouse liver cDNAs. The rhythmic expression with a single peak and trough level was confirmed by RNA blot analysis for 3beta-Hsd and Gabarapl1 genes exhibiting a peak in the light phase and Spot14, Hspa8, Hspa5, and Hsp84-1 genes showing a peak in the dark phase. On the other hand, mRNA levels for all of the three fibrinogen subunits, Aalpha, Bbeta and gamma, exhibited two peaks each in the light and dark phases in a synchronized manner. This two-peaked rhythmic pattern of fibrinogen genes as well as the single peak-trough pattern of other genes was diminished or almost completely lost in the liver of Clock mutant mice, suggesting that the two-peaked expression is also under the control of oscillation-generating genes. In constant darkness, the first peak of the expression rhythm of fibrinogen genes was almost intact, but the second peak disappeared. Therefore, although the first peak in the subjective day is a component of the innate circadian rhythm, the second peak seems to require light stimuli. Fasting in constant darkness caused shifts of time phases of the circadian rhythms. Protein levels of the fibrinogen subunits in whole blood also exhibited circadian rhythms. In the mouse and human loci of the fibrinogen gene cluster, a number of sequence elements resembling circadian transcription factor-binding sites were found. The fibrinogen gene locus provides a unique system for the study of two-peaked day/night rhythms of gene expression in a synchronized form.	Chiba Univ, Grad Sch Med, Dept Biochem & Genet, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Pediat, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Funct Genom, Chiba 2608670, Japan; Waseda Univ, Sch Human Sci, Dept Pharmacol & Brain Sci, Tokorozawa, Saitama 3591192, Japan; Tohoku Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sendai, Miyagi 9808578, Japan	Chiba University; Chiba University; Chiba University; Waseda University; Tohoku University	Takiguchi, M (corresponding author), Chiba Univ, Grad Sch Med, Dept Biochem & Genet, Inohana 1-8-1, Chiba 2608670, Japan.	mtak@med.m.chiba-u.ac.jp	Kato, Masaki/B-5846-2018; Fukunaga, Kohji/AAI-8811-2021	Kato, Masaki/0000-0002-5184-1841; Fukunaga, Kohji/0000-0001-8526-2824				Akhtar RA, 2002, CURR BIOL, V12, P540, DOI 10.1016/S0960-9822(02)00759-5; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Braverman N, 2000, GENOMICS, V63, P181, DOI 10.1006/geno.1999.6080; Brown SB, 1997, J BIOL CHEM, V272, P2163, DOI 10.1074/jbc.272.4.2163; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Compe E, 2001, BIOCHEM J, V358, P175, DOI 10.1042/0264-6021:3580175; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fonjallaz P, 1996, EMBO J, V15, P351, DOI 10.1002/j.1460-2075.1996.tb00365.x; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Fuller GM, 2001, ANN NY ACAD SCI, V936, P469; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Hara R, 2001, GENES CELLS, V6, P269, DOI 10.1046/j.1365-2443.2001.00419.x; HAUS E, 1990, CHRONOBIOL INT, V7, P203, DOI 10.3109/07420529009056976; HECKEL JL, 1990, CELL, V62, P447, DOI 10.1016/0092-8674(90)90010-C; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Kanabrocki EL, 1999, CLIN APPL THROMB-HEM, V5, P37, DOI 10.1177/107602969900500108; KANT JA, 1985, P NATL ACAD SCI USA, V82, P2344, DOI 10.1073/pnas.82.8.2344; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kita Y, 2002, PHARMACOGENETICS, V12, P55, DOI 10.1097/00008571-200201000-00008; Kornmann B, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.11.e51; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Le Minh N, 2001, EMBO J, V20, P7128, DOI 10.1093/emboj/20.24.7128; MARINO MW, 1986, CYTOGENET CELL GENET, V42, P36, DOI 10.1159/000132248; Mitsui S, 2001, GENE DEV, V15, P995, DOI 10.1101/gad.873501; Mosesson MW, 2001, ANN NY ACAD SCI, V936, P11; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; PETRALITO A, 1982, CHRONOBIOLOGIA, V9, P195; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Ripperger JA, 2001, CURR OPIN CELL BIOL, V13, P357, DOI 10.1016/S0955-0674(00)00220-9; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; Schwarz M, 2000, J CLIN INVEST, V106, P1175, DOI 10.1172/JCI10902; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Stokkan KA, 2001, SCIENCE, V291, P490, DOI 10.1126/science.291.5503.490; Storch KF, 2002, NATURE, V417, P78, DOI 10.1038/nature744; Sun DS, 1996, GENOMICS, V36, P54, DOI 10.1006/geno.1996.0425; Ueda HR, 2002, NATURE, V418, P534, DOI 10.1038/nature00906; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Xin YR, 2001, GENOMICS, V74, P408, DOI 10.1006/geno.2001.6555; Yoshikawa T, 2000, BIOCHEM BIOPH RES CO, V275, P532, DOI 10.1006/bbrc.2000.3330	46	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30450	30457		10.1074/jbc.M304809200	http://dx.doi.org/10.1074/jbc.M304809200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12750384	hybrid			2022-12-25	WOS:000184658800008
J	Boren, J; Lee, WNP; Bassilian, S; Centelles, JJ; Lim, S; Ahmed, S; Boros, LG; Cascante, M				Boren, J; Lee, WNP; Bassilian, S; Centelles, JJ; Lim, S; Ahmed, S; Boros, LG; Cascante, M			The stable isotope-based dynamic metabolic profile of butyrate-induced HT29 cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-BUTYRATE; MASS ISOTOPOMER; LEUKEMIA-CELLS; COLONOCYTES; ACTIVATION; APOPTOSIS; PATHWAYS; CULTURE; COLON; LINE	Stable isotope-based dynamic metabolic profiling is applied in this paper to elucidate the mechanism by which butyrate induces cell differentiation in HT29 cells. We utilized butyrate-sensitive ( HT29) cells incubated with [1,2-C-13(2)] glucose or [1,2-C-13(2)] butyrate as single tracers to observe the changes in metabolic fluxes in these cells. In HT29 cells, increasing concentrations of butyrate inhibited glucose uptake, glucose oxidation, and nucleic acid ribose synthesis in a dose-dependent fashion. Glucose carbon utilization for de novo fatty acid synthesis and tricarboxylic acid cycle flux was replaced by butyrate. We also demonstrated that these changes are not present in butyrate-resistant pancreatic adenocarcinoma MIA cells. The results suggest that the mechanism by which colon carcinoma cells acquire a differentiated phenotype is through a replacement of glucose for butyrate as the main carbon source for macromolecule biosynthesis and energy production. This provides a better understanding of cell differentiation through metabolic adaptive changes in response to butyrate in HT29 cells, demonstrating that variations in metabolic pathway substrate flow are powerful regulators of tumor cell proliferation and differentiation.	Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Parc Cient Barcelona,Ctr Rec Quim Teor, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; Univ Calif Los Angeles, Sch Med, Harbor UCLA Res & Educ Inst, Torrance, CA 90502 USA	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Cascante, M (corresponding author), Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Parc Cient Barcelona,Ctr Rec Quim Teor, Dept Biochem & Mol Biol, Marti & Franques 1, E-08028 Barcelona, Spain.	marta@bq.ub.es	CASCANTE, MARTA/AFK-5991-2022; CASCANTE, MARTA/AAG-4355-2022; Boren, Joan/A-8515-2012; Centelles, Josep J./K-2972-2014	CASCANTE, MARTA/0000-0002-2062-4633; CASCANTE, MARTA/0000-0002-2062-4633; Centelles, Josep J./0000-0002-6289-9678	NCI NIH HHS [P01-CA42710] Funding Source: Medline; NCRR NIH HHS [M01-RR00425] Funding Source: Medline; NIDDK NIH HHS [DK56090-A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042710] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056090] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad MS, 2000, GUT, V46, P493, DOI 10.1136/gut.46.4.493; AUGERON C, 1984, CANCER RES, V44, P3961; BERGMEYER HV, 1974, METHOD ENZYMAT AN, P860; Cascante M, 2002, NAT BIOTECHNOL, V20, P243, DOI 10.1038/nbt0302-243; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Della Ragione F, 2001, FEBS LETT, V499, P199, DOI 10.1016/S0014-5793(01)02539-X; Ding QM, 2001, BIOCHEM BIOPH RES CO, V284, P282, DOI 10.1006/bbrc.2001.4969; Emenaker NJ, 2001, DIGEST DIS SCI, V46, P96, DOI 10.1023/A:1005661809250; Iacomino G, 2001, BIOCHEM BIOPH RES CO, V285, P1280, DOI 10.1006/bbrc.2001.5323; Kasho VN, 1996, ALIMENT PHARM THERAP, V10, P985, DOI 10.1046/j.1365-2036.1996.99271000.x; KATZ J, 1989, J BIOL CHEM, V264, P12994; Lee WNP, 1996, ADV EXP MED BIOL, V399, P95; Lee WNP, 1996, DEV NEUROSCI-BASEL, V18, P469, DOI 10.1159/000111442; Lee WNP, 1998, AM J PHYSIOL-ENDOC M, V274, pE843, DOI 10.1152/ajpendo.1998.274.5.E843; Madigan MC, 1999, ONCOL RES, V11, P331; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Miller TL, 1996, APPL ENVIRON MICROB, V62, P1589, DOI 10.1128/AEM.62.5.1589-1592.1996; ROEDIGER WEW, 1982, GASTROENTEROLOGY, V83, P424; Rosato RR, 2001, INT J ONCOL, V19, P181; SOERGEL KH, 1994, CLIN INVESTIGATOR, V72, P742; Witt O, 2000, BLOOD, V95, P2391, DOI 10.1182/blood.V95.7.2391.007k21_2391_2396; Witt O, 2001, CANCER LETT, V171, P173, DOI 10.1016/S0304-3835(01)00628-0; Yin L, 2001, J BIOL CHEM, V276, P44641, DOI 10.1074/jbc.M105170200	23	70	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28395	28402		10.1074/jbc.M302932200	http://dx.doi.org/10.1074/jbc.M302932200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12750369	hybrid			2022-12-25	WOS:000184421100008
J	Golodne, DM; Monteiro, RQ; Graca-Souza, AV; Silva-Neto, MAC; Atella, GC				Golodne, DM; Monteiro, RQ; Graca-Souza, AV; Silva-Neto, MAC; Atella, GC			Lysophosphatidylcholine acts as an anti-hemostatic molecule in the saliva of the blood-sucking bug Rhodnius prolixus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; AORTIC ENDOTHELIAL-CELLS; LOW-DENSITY-LIPOPROTEIN; MOSQUITO AEDES-AEGYPTI; AMBLYOMMA-AMERICANUM; PLATELET-AGGREGATION; GENE-EXPRESSION; CULTURED HUMAN; PURIFICATION; MECHANISMS	Blood-sucking arthropods possess a variety of anti-hemostatic factors in their salivary glands to maintain blood fluidity during feeding. In this work we demonstrate the anti-hemostatic properties of lysophosphatidylcholine (lysoPC) isolated from the salivary glands of Rhodnius prolixus. First, we examined salivary glands of fourth and fifth instar nymphs for their phospholipid composition. The lumen displayed an accumulation of its phospholipid content, mainly phosphatidylcholine and lysoPC, with a 6-fold increase for the latter. To determine the presence of phospholipids in the saliva, fourth instar nymphs were fed with a P-32-enriched blood meal. After 28 days their saliva was collected and subjected to lipid extraction, thin-layer chromatography, and autoradiography. The results showed the presence in the saliva of the same phospholipids present in the lumen. We then examined possible biological roles of these phospholipids when compared with other known effects of lysoPC. The luminal lipid extract and purified lysoPC from the lumen and saliva were tested for inhibition of washed rabbit platelets' aggregation induced by alpha-thrombin and platelet-activating factor. Both the luminal lipid extract and salivary lysoPC showed an increasing inhibition of aggregation, which correlated with the response of the platelets to standard lysoPC (up to 13 mug/ml). Next, salivary lysoPC was incubated with porcine arterial endothelial cells for 24 h. After incubation, culture medium was assayed for nitric oxide and showed increased nitric oxide production, similar to control cells exposed to standard lysoPC (up to 20 mug/ml). Together these data demonstrate the presence of lysoPC in the saliva of Rhodnius prolixus and its potential anti-hemostatic activities.	Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	Atella, GC (corresponding author), Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Ciencias Biomed, Dept Bioquim Med, POB 68041,Cidade Univ,Ilha Fundao,Ave Bauhinia 40, BR-21941590 Rio De Janeiro, Brazil.		Monteiro, Robson/GRX-0672-2022; DE QUEIROZ MONTEIRO, ROBSON/B-8007-2014; Silva-Neto, Mario A C/C-1211-2013; Atella, Georgia/AAK-7897-2020; de Queiroz Monteiro, Robson/M-7097-2019	Monteiro, Robson/0000-0002-5260-2332; Silva-Neto, Mario A C/0000-0003-2273-194X; 				BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bowman AS, 1996, PARASITOL TODAY, V12, P388, DOI 10.1016/0169-4758(96)10061-2; CHAMPAGNE DE, 1994, P NATL ACAD SCI USA, V91, P138, DOI 10.1073/pnas.91.1.138; Chisolm GM, 2000, FREE RADICAL BIO MED, V28, P1697, DOI 10.1016/S0891-5849(00)00227-6; Chisolm GM, 2000, FREE RADICAL BIO MED, V28, P1815, DOI 10.1016/S0891-5849(00)00344-0; Cieslik K, 2001, J BIOL CHEM, V276, P1211, DOI 10.1074/jbc.M005305200; Cieslik K, 1998, J BIOL CHEM, V273, P14885, DOI 10.1074/jbc.273.24.14885; COOKE JP, 1994, ARTERIOSCLER THROMB, V14, P653, DOI 10.1161/01.ATV.14.5.653; Engelmann B, 1999, ARTERIOSCL THROM VAS, V19, P47, DOI 10.1161/01.ATV.19.1.47; Francischetti IMB, 2000, J BIOL CHEM, V275, P12639, DOI 10.1074/jbc.275.17.12639; Francischetti IMB, 2002, J EXP BIOL, V205, P2429; Gewaltig MT, 2002, CARDIOVASC RES, V55, P250, DOI 10.1016/S0008-6363(02)00327-9; Golodne DM, 2001, INSECT BIOCHEM MOLEC, V31, P563, DOI 10.1016/S0965-1748(00)00161-2; HIRATA K, 1995, CIRC RES, V76, P958, DOI 10.1161/01.RES.76.6.958; Inoue N, 2001, ATHEROSCLEROSIS, V155, P45, DOI 10.1016/S0021-9150(00)00530-X; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; LAW JH, 1992, ANNU REV BIOCHEM, V61, P87, DOI 10.1146/annurev.bi.61.070192.000511; LERNER EA, 1991, J BIOL CHEM, V266, P11234; Li HG, 2002, NITRIC OXIDE-BIOL CH, V7, P132, DOI 10.1016/S1089-8603(02)00127-1; Libby P, 2000, J INTERN MED, V247, P349, DOI 10.1046/j.1365-2796.2000.00654.x; Montfort WR, 2000, BBA-PROTEIN STRUCT M, V1482, P110, DOI 10.1016/S0167-4838(00)00165-5; PARTHASARATHY S, 1985, P NATL ACAD SCI USA, V82, P3000, DOI 10.1073/pnas.82.9.3000; RIBEIRO JMC, 1993, SCIENCE, V260, P539, DOI 10.1126/science.8386393; RIBEIRO JMC, 1981, J EXP BIOL, V94, P219; RIBEIRO JMC, 1992, EXP PARASITOL, V74, P112, DOI 10.1016/0014-4894(92)90145-Z; RIBEIRO JMC, 1995, INFECT AGENT DIS, V4, P143; Rong JX, 2002, ARTERIOSCL THROM VAS, V22, P1617, DOI 10.1161/01.ATV.0000035408.93749.71; Ruiz JI, 1997, J LIPID RES, V38, P1482; SHIPLEY MM, 1993, ARCH INSECT BIOCHEM, V23, P37, DOI 10.1002/arch.940230106; SilvaNeto MAC, 1996, J BIOL CHEM, V271, P30227, DOI 10.1074/jbc.271.47.30227; Stark KR, 1996, PARASITOL TODAY, V12, P430, DOI 10.1016/0169-4758(96)10064-8; Valenzuela JG, 2002, INSECT BIOCHEM MOLEC, V32, P1101, DOI 10.1016/S0965-1748(02)00047-4; Yuan YP, 1996, J BIOL CHEM, V271, P27090, DOI 10.1074/jbc.271.43.27090; YUAN YP, 1995, BLOOD, V86, P4166, DOI 10.1182/blood.V86.11.4166.bloodjournal86114166; ZEMBOWICZ A, 1995, J BIOL CHEM, V270, P17006, DOI 10.1074/jbc.270.28.17006; ZINGALI RB, 1993, BIOCHEMISTRY-US, V32, P10794, DOI 10.1021/bi00091a034	38	28	29	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27766	27771		10.1074/jbc.M212421200	http://dx.doi.org/10.1074/jbc.M212421200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12740385	hybrid			2022-12-25	WOS:000184242700056
J	Kasri, NN; Sienaert, I; Parys, JB; Callewaert, G; Missiaen, L; Jeromin, A; De Smedt, H				Kasri, NN; Sienaert, I; Parys, JB; Callewaert, G; Missiaen, L; Jeromin, A; De Smedt, H			A novel Ca2+-induced Ca2+ release mechanism in A7r5 cells regulated by calmodulin-like proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CALCIUM-RELEASE; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; SMOOTH-MUSCLE CELLS; ADRENAL CHROMAFFIN CELLS; ENDOPLASMIC-RETICULUM; CYTOSOLIC CA2+; RYANODINE RECEPTORS; BINDING-SITES; CA2+-DEPENDENT INACTIVATION; TRISPHOSPHATE RECEPTORS	Intracellular Ca2+ release is involved in setting up Ca2+ signals in all eukaryotic cells. Here we report that an increase in free Ca2+ concentration triggered the release of up to 41 +/- 3% of the intracellular Ca2+ stores in permeabilized A7r5 (embryonic rat aorta) cells with an EC50 of 700 nM. This type of Ca2+-induced Ca2+ release (CICR) was neither mediated by inositol 1,4,5-trisphosphate receptors nor by ryanodine receptors, because it was not blocked by heparin, 2-aminoethoxydiphenyl borate, xestospongin C, ruthenium red, or ryanodine. ATP dose-dependently stimulated the CICR mechanism, whereas 10 mM MgCl2 abolished it. CICR was not affected by exogenously added calmodulin (CaM), but CaM1234, a Ca2+-insensitive CaM mutant, strongly inhibited the CICR mechanism. Other proteins of the CaM-like neuronal Ca2+-sensor protein family such as Ca2+-binding protein 1 and neuronal Ca2+ sensor-1 were equally potent for inhibiting the CICR. Removal of endogenous CaM, using a CaM-binding peptide derived from the ryanodine receptor type-1 (amino acids 3614-3643) prevented subsequent activation of the CICR mechanism. A similar CICR mechanism was also found in 16HBE14o- (human bronchial mucosa) cells. We conclude that A7r5 and 16HBE14o- cells express a novel type of CICR mechanism that is silent in normal resting conditions due to inhibition by CaM but becomes activated by a Ca2+-dependent dissociation of CaM. This CICR mechanism, which may be regulated by members of the family of neuronal Ca2+-sensor proteins, may provide an additional route for Ca2+ release that could allow amplification of small Ca2+ signals.	Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA	KU Leuven; Baylor College of Medicine	Kasri, NN (corresponding author), Katholieke Univ Leuven, Fysiol Lab, Campus Gasthuisberg O-N,Herestr 49, B-3000 Louvain, Belgium.	nael.nadifkasri@med.kuleuven.ac.be; humbert.desmedt@med.kuleuven.ac.be	Nadif Kasri, Nael/E-2270-2012	Nadif Kasri, Nael/0000-0002-7448-9289; Parys, Jan/0000-0002-3591-4967				Albrecht MA, 2001, J GEN PHYSIOL, V118, P83, DOI 10.1085/jgp.118.1.83; Bak J, 1999, CURR BIOL, V9, P751, DOI 10.1016/S0960-9822(99)80335-2; Bennett DL, 1996, J BIOL CHEM, V271, P6356, DOI 10.1074/jbc.271.11.6356; Berridge MJ, 2001, NOVART FDN SYMP, V239, P52; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOOTMAN MD, 1995, BIOCHEM J, V306, P445, DOI 10.1042/bj3060445; Cahalan MD, 2002, NAT CELL BIOL, V4, pE56, DOI 10.1038/ncb0302-e56; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; Genazzani AA, 1996, BIOCHEM J, V315, P721, DOI 10.1042/bj3150721; Haeseleer F, 2002, BIOCHEM BIOPH RES CO, V290, P615, DOI 10.1006/bbrc.2001.6228; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; Kasri NN, 2002, BBA-PROTEINS PROTEOM, V1600, P19; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Lemmens R, 2001, J BIOL CHEM, V276, P9971, DOI 10.1074/jbc.M009463200; Liu M, 2003, J BIOL CHEM, V278, P5462, DOI 10.1074/jbc.M209111200; Lomax RB, 2002, J BIOL CHEM, V277, P26479, DOI 10.1074/jbc.M201845200; LYNN S, 1995, FEBS LETT, V367, P23, DOI 10.1016/0014-5793(95)00499-Y; Marengo JJ, 1996, FEBS LETT, V383, P59, DOI 10.1016/0014-5793(96)00222-0; MARTIN SR, 1992, EUR J BIOCHEM, V205, P1107, DOI 10.1111/j.1432-1033.1992.tb16879.x; McFerran BW, 1999, J BIOL CHEM, V274, P30258, DOI 10.1074/jbc.274.42.30258; Missiaen L, 1997, BIOCHEM J, V323, P123, DOI 10.1042/bj3230123; MISSIAEN L, 1994, J BIOL CHEM, V269, P7238; MISSIAEN L, 1992, J BIOL CHEM, V267, P22961; Missiaen L, 2002, J BIOL CHEM, V277, P6898, DOI 10.1074/jbc.M110939200; Missiaen L, 1996, J BIOL CHEM, V271, P12287, DOI 10.1074/jbc.271.21.12287; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MISSIAEN L, 1990, J PHYSIOL-LONDON, V427, P171, DOI 10.1113/jphysiol.1990.sp018166; Nakamura T, 1999, NEURON, V24, P727, DOI 10.1016/S0896-6273(00)81125-3; Nishiyama M, 2000, NATURE, V408, P584, DOI 10.1038/35046067; Parys JB, 2000, CALCIUM: THE MOLECULAR BASIS OF CALCIUM ACTION IN BIOLOGY AND MEDICINE, P179; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 1999, P NATL ACAD SCI USA, V96, P14669, DOI 10.1073/pnas.96.26.14669; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Rodney GG, 2001, J BIOL CHEM, V276, P2069, DOI 10.1074/jbc.M008891200; Scott K, 1997, CELL, V91, P375, DOI 10.1016/S0092-8674(00)80421-3; Sharma G, 2001, P NATL ACAD SCI USA, V98, P4148, DOI 10.1073/pnas.071540198; Sienaert I, 2002, BIOCHEM J, V365, P269, DOI 10.1042/BJ20020144; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Somlo S, 2001, CURR BIOL, V11, pR356, DOI 10.1016/S0960-9822(01)00193-2; STAROVASNIK MA, 1992, PROTEIN SCI, V1, P245; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; TANG YH, 1994, BIOPHYS J, V67, P2223, DOI 10.1016/S0006-3495(94)80707-6; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; Taylor CW, 2002, CELL CALCIUM, V32, P321, DOI 10.1016/S0143416002001859; Taylor CW, 1998, BBA-MOL CELL BIOL L, V1436, P19, DOI 10.1016/S0005-2760(98)00122-2; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; Trost C, 1999, FEBS LETT, V451, P257, DOI 10.1016/S0014-5793(99)00588-8; Turner H, 2003, BIOCHEM J, V371, P341, DOI 10.1042/BJ20021381; Verkhratsky A, 2002, EUR J PHARMACOL, V447, P141, DOI 10.1016/S0014-2999(02)01838-1; Wang SQ, 2001, NATURE, V410, P592, DOI 10.1038/35069083; Warr CG, 1996, BIOCHEM J, V314, P497, DOI 10.1042/bj3140497; Weiss JL, 2000, J BIOL CHEM, V275, P40082, DOI 10.1074/jbc.M008603200; Wissing F, 2002, BIOCHEM J, V361, P605, DOI 10.1042/0264-6021:3610605; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Xiong LW, 2002, J BIOL CHEM, V277, P40862, DOI 10.1074/jbc.M206763200; Zhao XH, 2001, J BIOL CHEM, V276, P40183, DOI 10.1074/jbc.M104048200; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	67	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27548	27555		10.1074/jbc.M302026200	http://dx.doi.org/10.1074/jbc.M302026200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12746431	hybrid			2022-12-25	WOS:000184242700028
J	Kim, MS; Shin, J; Lee, WT; Lee, HS; Oh, BH				Kim, MS; Shin, J; Lee, WT; Lee, HS; Oh, BH			Crystal structures of RbsD leading to the identification of cytoplasmic sugar-binding proteins with a novel folding architecture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; ELECTRON-DENSITY MAPS; ESCHERICHIA-COLI; L-FUCOSE; RIBOSE; RIBOKINASE; FORMS; PURIFICATION; TRANSPORT; REGULON	RbsD is the only protein whose biochemical function is unknown among the six gene products of the rbs operon involved in the active transport of ribose. FucU, a paralogue of RbsD conserved from bacteria to human, is also the only protein whose function is unknown among the seven gene products of the L-fucose regulon. Here we report the crystal structures of Bacillus subtilis RbsD, which reveals a novel decameric toroidal assembly of the protein. Nuclear magnetic resonance and other studies on RbsD reveal that the intersubunit cleft of the protein binds specific forms of D-ribose, but it does not have an enzyme activity toward the sugar. Likewise, FucU binds L-fucose but lacks an enzyme activity toward this sugar. We conclude that RbsD and FucU are cytoplasmic sugar-binding proteins, a novel class of proteins whose functional role may lie in helping influx of the sugar substrates.	Pohang Univ Sci & Technol, Ctr Biomol Recognit, Pohang 790784, Kyungbuk, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Dept Life Sci, Pohang 790784, Kyungbuk, South Korea; Pohang Accelerator Lab, Pohang 790784, Kyungbuk, South Korea; Yonsei Univ, Dept Biochem, Coll Sci, Seoul 120749, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Yonsei University	Oh, BH (corresponding author), Pohang Univ Sci & Technol, Ctr Biomol Recognit, Pohang 790784, Kyungbuk, South Korea.		LEE, WEON TAE/AAQ-9088-2021; Oh, Byung-Ha/C-2061-2011	Lee, Weontae/0000-0003-2347-1262				ANDERSON A, 1969, BIOCHIM BIOPHYS ACTA, V177, P163, DOI 10.1016/0304-4165(69)90081-6; Andersson CE, 2002, J MOL BIOL, V315, P409, DOI 10.1006/jmbi.2001.5248; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Bjorkman AJ, 1998, J MOL BIOL, V279, P651, DOI 10.1006/jmbi.1998.1785; BJORKMAN AJ, 1994, J BIOL CHEM, V269, P30206; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUCKEL SD, 1986, J BIOL CHEM, V261, P7659; CHEN YM, 1987, MOL GEN GENET, V210, P331, DOI 10.1007/BF00325702; Drew KN, 1998, CARBOHYD RES, V307, P199, DOI 10.1016/S0008-6215(98)00040-8; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Flowers H M, 1981, Adv Carbohydr Chem Biochem, V39, P279; FURLONG CE, 1982, METHOD ENZYMOL, V90, P467; GUNN FJ, 1995, MOL MICROBIOL, V15, P771, DOI 10.1111/j.1365-2958.1995.tb02384.x; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim MS, 2001, ACTA CRYSTALLOGR D, V57, P728, DOI 10.1107/S0907444901003109; McClelland M, 2001, NATURE, V413, P852, DOI 10.1038/35101614; Oh H, 1999, J BIOL CHEM, V274, P14006, DOI 10.1074/jbc.274.20.14006; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park SH, 1998, J BIOL CHEM, V273, P5685, DOI 10.1074/jbc.273.10.5685; Sigrell JA, 1998, STRUCTURE, V6, P183, DOI 10.1016/S0969-2126(98)00020-3; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; WILLIS RC, 1974, J BIOL CHEM, V249, P6926; ZHU Y, 1988, J BACTERIOL, V170, P2352, DOI 10.1128/jb.170.5.2352-2358.1988	27	18	21	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28173	28180		10.1074/jbc.M304523200	http://dx.doi.org/10.1074/jbc.M304523200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12738765	hybrid			2022-12-25	WOS:000184242700106
J	Singh, LS; Bukys, MA; Beck, DO; Kalafatis, M				Singh, LS; Bukys, MA; Beck, DO; Kalafatis, M			Amino acids Glu(323), Tyr(324), Glu(330), and Val(331) of factor Va heavy chain are essential for expression of cofactor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; COAGULATION FACTOR-V; PEPTIDE CHLOROMETHYL KETONES; XA-BINDING SITE; PROTHROMBINASE COMPLEX; CATALYZED ACTIVATION; SUBSTRATE RECOGNITION; PHOSPHOLIPID-VESICLES; SERINE PROTEINASES; COMPLETE CDNA	We have recently demonstrated that amino acid region 323-331 of factor Va heavy chain (9 amino acids, AP4') contains a binding site for factor Xa (Kalafatis, M., and Beck, D. O. (2002) Biochemistry 41, 12715-12728). To ascertain which amino acids within this region are important for the effector and receptor properties of the cofactor with respect to factor Xa, we have synthesized three overlapping peptides (5 amino acids each) spanning the amino acid region 323-331 and tested them for their effect on prothrombinase complex assembly and function. Peptide containing amino acids (323)EYFIA(327) alone was found to increase the catalytic efficiency of factor Xa but had no effect on the fluorescent anisotropy of active site-labeled factor Xa (human factor Xa labeled in the active site with Oregon Green 488; [OG(488)]-EGR-hXa). In contrast, peptide containing the sequence (327)AAEEV(331) was found to interact with [OG(488)]-EGR-hXa with half-maximal saturation reached at similar to150 muM, but it was unable to produce a cofactor effect on factor Xa. Peptide (325)FIAAE(329) inhibited prothrombinase activity and was able to partially decrease the fluorescent anisotropy of [OG(488)]-EGR-hXa but could not increase the catalytic efficiency of factor Xa with respect to prothrombin. A control peptide with the sequence FFFIA did not increase the catalytic efficiency of factor Xa, whereas a peptide with the sequence AAEMI was impaired in its capability to interact with [OG(488)]-EGR-hXa. Two mutant recombinant factor Va molecules (Glu(323) --> Phe/Tyr(324) --> Phe, factor Va(FF); Glu(330) --> Met/Val(331) --> Ile, factor Va(MI)) showed impaired cofactor activity when used at limiting cofactor concentration, whereas the quadruple mutant (Glu(323) --> Phe/Tyr(324) --> Phe and Glu(330) --> Met/Val(331) --> Ile, factor VaFF/MI) had no cofactor activity under similar experimental conditions. Our data demonstrate that amino acid residues Glu(323), Tyr(324), Glu(330), and Val(331) of factor Va heavy chain are critical for expression of factor Va cofactor activity.	Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, Cleveland, OH 44195 USA	University System of Ohio; Cleveland State University; Cleveland Clinic Foundation	Kalafatis, M (corresponding author), Cleveland State Univ, Dept Chem, Sci Bldg,2351 Euclid Ave, Cleveland, OH 44115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034575, R37HL034575] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL34575] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANNAMALAI AE, 1987, BLOOD, V70, P139; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bianchini EP, 2002, J BIOL CHEM, V277, P20527, DOI 10.1074/jbc.M201139200; Blostein MD, 2000, J BIOL CHEM, V275, P38120, DOI 10.1074/jbc.M007174200; BOCK PE, 1993, METHOD ENZYMOL, V222, P478; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; Boskovic DS, 2001, J BIOL CHEM, V276, P28686, DOI 10.1074/jbc.M101813200; Brufatto N, 2003, J BIOL CHEM, V278, P6755, DOI 10.1074/jbc.M206413200; CRIPE LD, 1992, BIOCHEMISTRY-US, V31, P3777, DOI 10.1021/bi00130a007; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; Gomori G, 1942, J LAB CLIN MED, V27, P955; Grimm DR, 2001, CELL MOL LIFE SCI, V58, P148, DOI 10.1007/PL00000775; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; Heeb MJ, 1996, PROTEIN SCI, V5, P1883, DOI 10.1002/pro.5560050914; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; Kalafatis M, 1996, BLOOD, V87, P4695, DOI 10.1182/blood.V87.11.4695.bloodjournal87114695; KALAFATIS M, 1993, J BIOL CHEM, V268, P27246; Kalafatis M, 2002, BIOCHEMISTRY-US, V41, P12715, DOI 10.1021/bi026208+; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P6538, DOI 10.1021/bi00187a022; KALAFATIS M, 1995, J BIOL CHEM, V270, P4053, DOI 10.1074/jbc.270.8.4053; Kalafatis M, 2001, J BIOL CHEM, V276, P18614, DOI 10.1074/jbc.M007134200; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; Kalafatis M, 1997, CRIT REV EUKAR GENE, V7, P241, DOI 10.1615/CritRevEukarGeneExpr.v7.i3.40; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KANE WH, 1981, J BIOL CHEM, V256, P1002; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; Kojima Y, 1998, J BIOL CHEM, V273, P14900, DOI 10.1074/jbc.273.24.14900; Kolfschoten MV, 2002, BLOOD COAGUL FIBRIN, V13, P207, DOI 10.1097/00001721-200204000-00006; KRISHNASWAMY S, 1989, J BIOL CHEM, V264, P3160; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P3319, DOI 10.1021/bi9623993; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mann KG, 2003, BLOOD, V101, P20, DOI 10.1182/blood-2002-01-0290; Mann KG, 1997, J BIOL CHEM, V272, P20678, DOI 10.1074/jbc.272.33.20678; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1982, J BIOL CHEM, V257, P1443; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NESHEIM ME, 1980, METHOD ENZYMOL, V80, P243; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; Steen M, 2002, J BIOL CHEM, V277, P50022, DOI 10.1074/jbc.M205609200; Steen M, 2002, J BIOL CHEM, V277, P38424, DOI 10.1074/jbc.M204972200; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUCKER MM, 1983, J BIOL CHEM, V258, P1210; vantVeer C, 1997, J BIOL CHEM, V272, P20721, DOI 10.1074/jbc.272.33.20721; vantVeer C, 1997, J BIOL CHEM, V272, P7983, DOI 10.1074/jbc.272.12.7983; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; WALKER RK, 1994, J BIOL CHEM, V269, P27441; Wilkens M, 2002, J BIOL CHEM, V277, P9366, DOI 10.1074/jbc.M110848200; WILLIAMS EB, 1993, METHOD ENZYMOL, V222, P503; Yamazaki T, 2002, BLOOD, V100, P2515, DOI 10.1182/blood.V100.7.2515; Yang TL, 1998, BLOOD, V91, P4593, DOI 10.1182/blood.V91.12.4593.412a02_4593_4599	60	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28335	28345		10.1074/jbc.M300233200	http://dx.doi.org/10.1074/jbc.M300233200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12738785	Green Published, hybrid			2022-12-25	WOS:000184242700124
J	Zhao, M; Qiao, M; Oyajobi, BO; Mundy, GR; Chen, D				Zhao, M; Qiao, M; Oyajobi, BO; Mundy, GR; Chen, D			E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha 1/Runx2 degradation and plays a specific role in osteoblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-FORMATION; PROTEIN LIGASE; IN-VITRO; CBFA1; PATHWAY; CELLS; GENE; EXPRESSION; INDUCTION; FAMILY	Osteoblast differentiation and bone formation is stimulated by bone morphogenetic protein (BMP)-2 and its downstream signaling molecules Smad1 and -5 and the osteoblast-specific transcription factor core-binding factor alpha1 (Cbfa1). Proteolytic degradation of Smad1 and Cbfa1 is proteasome-dependent, and intracellular concentrations of Smad1 and Cbfa1 are enhanced by inhibition of the 26 S proteasome. Smad1 degradation is mediated by the E3 ubiquitin ligase Smurf1 (Smad ubiquitin regulatory factor 1), but the specific E3 ligase responsible for Cbfa1 degradation has not been identified. Because Cbfa1 interacts with Smad1, whose degradation is mediated by Smurf1, we examined the effect of Smurf1 on Cbfa1 degradation in osteoblast precursor cells. Smurf1 interacts directly with Cbfa1 and mediates Cbfa1 degradation in a ubiquitin- and proteasome-dependent manner. Because Smurf1 controls the intracellular concentrations of several key molecules in the bone formation cascade, we examined the effect of a mutant form of Smurf1 in osteoblasts and found that expression of mutant Smurf1 markedly enhanced osteoblast differentiation. Smurf1 therefore appears to be an important regulatory factor in osteoblast differentiation and a potential molecular target for identification of bone anabolic agents.	Univ Texas, Hlth Sci Ctr, Dept Cell & Struct Biol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Chen, D (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Cell & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.			Oyajobi, Babatunde/0000-0002-1064-3072	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR048920] Funding Source: NIH RePORTER; NIAMS NIH HHS [R03 AR048920, AR048920] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295; Chen D, 1997, CALCIFIED TISSUE INT, V60, P283, DOI 10.1007/s002239900230; Chikazu D, 2002, J BONE MINER RES, V17, P1430, DOI 10.1359/jbmr.2002.17.8.1430; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Krishnan V, 2003, MOL ENDOCRINOL, V17, P423, DOI 10.1210/me.2002-0225; Leboy PS, 2001, J BONE JOINT SURG AM, V83A, pS15; Murray EJB, 1998, EXP CELL RES, V242, P460, DOI 10.1006/excr.1998.4090; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Podos SD, 2001, DEV CELL, V1, P567, DOI 10.1016/S1534-5807(01)00057-0; Rotin D, 1998, CURR TOP MICROBIOL, V228, P115; Tintut Y, 1999, J BIOL CHEM, V274, P28875, DOI 10.1074/jbc.274.41.28875; WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	22	230	252	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27939	27944		10.1074/jbc.M304132200	http://dx.doi.org/10.1074/jbc.M304132200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12738770	hybrid			2022-12-25	WOS:000184242700077
J	Liang, YY; Lin, X; Liang, M; Brunicardi, FC; ten Dijke, P; Chen, ZH; Choi, KW; Feng, XH				Liang, YY; Lin, X; Liang, M; Brunicardi, FC; ten Dijke, P; Chen, ZH; Choi, KW; Feng, XH			dSmurf selectively degrades decapentaplegic-activated MAD, and its overexpression disrupts imaginal disc development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E3 UBIQUITIN LIGASE; TGF-BETA; DROSOPHILA; DEGRADATION; RECEPTOR; SMURF2; SMAD2; P15(INK4B); TARGETS; PATTERN	MAD plays an important role in decapentaplegic (DPP) signaling throughout Drosophila development. Despite a recent study describing the restriction of DPP signaling via putative ubiquitin E3 ligase dSmurf (1), the molecular mechanisms of how dSmurf affects DPP signaling remain unexplored. Toward this goal we demonstrated the degradation of phosphorylated MAD by dSmurf. dSmurf selectively interacted with MAD, but not Medea and Dad, and the MAD-dSmurf interaction was induced by constitutively active DPP type I receptor thickveins. Wild type dSmurf, but not its C1029A mutant, mediated ubiquitination-dependent degradation of MAD. Silencing of dSmurf using RNA interference stabilized MAD protein in Drosophila S2 cells. Targeted expression of dSmurf in various tissues abolished phosphorylated MAD and disrupted patterning and growth. In contrast, similar overexpression of inactive dSmurf(C1029A) showed no significant effects on development. We conclude that dSmurf specifically targets phosphorylated MAD to proteasome-dependent degradation and regulates DPP signaling during development.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Netherlands Cancer Institute	Feng, XH (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza,Rm 137D, Houston, TX 77030 USA.		Choi, Kwang-Wook/C-1707-2011; Dijke, Peter ten/AAG-4660-2021	Choi, Kwang-Wook/0000-0002-8997-3065; Dijke, Peter ten/0000-0002-7234-342X	NATIONAL CANCER INSTITUTE [R01CA095731] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063773] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA95731] Funding Source: Medline; NEI NIH HHS [R01 EY11110] Funding Source: Medline; NIGMS NIH HHS [R01 GM63773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arora K, 2001, DEV CELL, V1, P441, DOI 10.1016/S1534-5807(01)00067-3; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brummel T, 1999, GENE DEV, V13, P98, DOI 10.1101/gad.13.1.98; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; Cho KO, 1998, NATURE, V396, P272, DOI 10.1038/24394; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; Padgett R W, 2001, Dev Cell, V1, P343, DOI 10.1016/S1534-5807(01)00048-X; Podos SD, 2001, DEV CELL, V1, P567, DOI 10.1016/S1534-5807(01)00057-0; Raftery LA, 1999, DEV BIOL, V210, P251, DOI 10.1006/dbio.1999.9282; Robertson G, 2001, UASGCP REP, V2001, P43; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	23	37	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26307	26310		10.1074/jbc.C300028200	http://dx.doi.org/10.1074/jbc.C300028200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12754252	hybrid			2022-12-25	WOS:000184155700002
J	Chirita, CN; Necula, M; Kuret, J				Chirita, CN; Necula, M; Kuret, J			Anionic micelles and vesicles induce tau fibrillization in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; PAIRED HELICAL FILAMENTS; BETA-AMYLOID PEPTIDE; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; FATTY-ACIDS; SULFATED GLYCOSAMINOGLYCANS; TERMINAL DOMAIN; BINDING	Alzheimer's disease is defined in part by the intraneuronal accumulation of filaments comprised of the microtubule-associated protein tau. In vitro, fibrillization of recombinant tau can be induced by treatment with various agents, including phosphotransferases, polyanionic compounds, and fatty acids. Here we characterize the structural features required for the fatty acid class of tau fibrillization inducer using recombinant full-length tau protein, arachidonic acid, and a series of straight chain anionic, cationic, and nonionic detergents. Induction of measurable tau fibrillization required an alkyl chain length of at least 12 carbons and a negative charge consisting of carboxylate, sulfonate, or sulfate moieties. All detergents and fatty acids were micellar at active concentrations, due to a profound, tau-dependent depression of their critical micelle concentrations. Anionic surfaces larger than detergent micelles, such as those supplied by phosphatidylserine vesicles, also induced tau fibrillization with resultant filaments originating from their surface. These data suggest that anionic surfaces presented as micelles or vesicles can serve to nucleate tau fibrillization, that this mechanism underlies the activity of fatty acid inducers, and that anionic membranes may serve this function in vivo.	Ohio State Univ, Coll Med & Publ Hlth, Dept Mol & Cellular Biochem, Ctr Biotechnol, Columbus, OH 43210 USA; Ohio State Univ, Coll Med & Publ Hlth, Biophys Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Kuret, J (corresponding author), Ohio State Univ, Coll Med & Publ Hlth, Dept Mol & Cellular Biochem, Ctr Biotechnol, 1060 Carmack Rd, Columbus, OH 43210 USA.				NATIONAL INSTITUTE ON AGING [R01AG014452] Funding Source: NIH RePORTER; NIA NIH HHS [AG14452] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ackmann M, 2000, J BIOL CHEM, V275, P30335, DOI 10.1074/jbc.M002590200; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Bales BL, 2001, J PHYS CHEM B, V105, P6798, DOI 10.1021/jp004576m; Barghorn S, 2002, BIOCHEMISTRY-US, V41, P14885, DOI 10.1021/bi026469j; BAUDIER J, 1987, J BIOL CHEM, V262, P17577; Bondareff W, 1998, J NEUROSCI RES, V52, P498, DOI 10.1002/(SICI)1097-4547(19980601)52:5<498::AID-JNR2>3.0.CO;2-7; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRITO RMM, 1986, ANAL BIOCHEM, V152, P250, DOI 10.1016/0003-2697(86)90406-9; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; ChooSmith LP, 1997, J BIOL CHEM, V272, P22987, DOI 10.1074/jbc.272.37.22987; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; Cole NB, 2002, J BIOL CHEM, V277, P6344, DOI 10.1074/jbc.M108414200; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; CORRIN ML, 1947, J AM CHEM SOC, V69, P683, DOI 10.1021/ja01195a065; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Farooqui AA, 1997, NEUROCHEM RES, V22, P523, DOI 10.1023/A:1027380331807; Feany MB, 1996, ANN NEUROL, V40, P139, DOI 10.1002/ana.410400204; Friedhoff P, 1998, BIOCHEMISTRY-US, V37, P10223, DOI 10.1021/bi980537d; Gamblin TC, 2000, BIOCHEMISTRY-US, V39, P6136, DOI 10.1021/bi000201f; Ghoshal N, 2002, EXP NEUROL, V177, P475, DOI 10.1006/exnr.2002.8014; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GomezIsla T, 1996, J NEUROSCI, V16, P4491; GRAY EG, 1987, NEUROPATH APPL NEURO, V13, P91, DOI 10.1111/j.1365-2990.1987.tb00174.x; GUNNARSSON G, 1980, J PHYS CHEM-US, V84, P3114, DOI 10.1021/j100460a029; Hasegawa M, 1997, J BIOL CHEM, V272, P33118, DOI 10.1074/jbc.272.52.33118; Huibers PDT, 1997, J COLLOID INTERF SCI, V187, P113, DOI 10.1006/jcis.1996.4680; Kampers T, 1996, FEBS LETT, V399, P344, DOI 10.1016/S0014-5793(96)01386-5; KHATOON S, 1992, J NEUROCHEM, V59, P750, DOI 10.1111/j.1471-4159.1992.tb09432.x; KING MD, 1987, BIOCHEMISTRY-US, V26, P1224, DOI 10.1021/bi00379a004; King ME, 1999, BIOCHEMISTRY-US, V38, P14851, DOI 10.1021/bi9911839; King ME, 2000, J NEUROCHEM, V74, P1749, DOI 10.1046/j.1471-4159.2000.0741749.x; Koyama Y, 1996, BIOCONJUGATE CHEM, V7, P298, DOI 10.1021/bc9600123; Lee HJ, 2002, J BIOL CHEM, V277, P671, DOI 10.1074/jbc.M107045200; Lins L, 2002, PROTEIN ENG, V15, P513, DOI 10.1093/protein/15.6.513; Martinez-Senac MD, 1999, EUR J BIOCHEM, V265, P744, DOI 10.1046/j.1432-1327.1999.00775.x; Perez M, 1996, J NEUROCHEM, V67, P1183; Perez-Canadillas JM, 2001, CURR OPIN STRUC BIOL, V11, P53, DOI 10.1016/S0959-440X(00)00164-0; Perrin RJ, 2001, J BIOL CHEM, V276, P41958, DOI 10.1074/jbc.M105022200; Pillot T, 1997, J MOL BIOL, V274, P381, DOI 10.1006/jmbi.1997.1382; Pillot T, 1996, J BIOL CHEM, V271, P28757, DOI 10.1074/jbc.271.46.28757; Ranganathan R, 2000, J PHYS CHEM B, V104, P2260, DOI 10.1021/jp993917x; RAY A, 1971, NATURE, V231, P313, DOI 10.1038/231313a0; Sato S, 2002, J BIOL CHEM, V277, P42060, DOI 10.1074/jbc.M202241200; Schlegel RA, 2001, CELL DEATH DIFFER, V8, P551, DOI 10.1038/sj.cdd.4400817; Schroeder F, 1998, CHEM PHYS LIPIDS, V92, P1, DOI 10.1016/S0009-3084(98)00003-6; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Sharon R, 2001, P NATL ACAD SCI USA, V98, P9110, DOI 10.1073/pnas.171300598; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; SUN GY, 1985, PHOSPHOLIPIDS NERVOU, P79; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; TESSARI M, 1993, BIOPOLYMERS, V33, P1877, DOI 10.1002/bip.360331213; TROJANOWSKI JQ, 1995, NEUROBIOL AGING, V16, P335, DOI 10.1016/0197-4580(94)00176-2; Uversky VN, 2001, J BIOL CHEM, V276, P43495, DOI 10.1074/jbc.C100551200; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; von Bergen M, 2001, J BIOL CHEM, V276, P48165, DOI 10.1074/jbc.M105196200; VONECHE V, 1992, P NATL ACAD SCI USA, V89, P3810, DOI 10.1073/pnas.89.9.3810; Wells K, 1995, NEUROCHEM RES, V20, P1329, DOI 10.1007/BF00992508; Wilson DM, 1997, AM J PATHOL, V150, P2181; Yen S, 2002, NEUROBIOL AGING, V23, pS490	60	181	187	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25644	25650		10.1074/jbc.M301663200	http://dx.doi.org/10.1074/jbc.M301663200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730214	hybrid			2022-12-25	WOS:000183920200047
J	Connelly, MA; de la Llera-Moya, M; Peng, YN; Drazul-Schrader, D; Rothblat, GH; Williams, DL				Connelly, MA; de la Llera-Moya, M; Peng, YN; Drazul-Schrader, D; Rothblat, GH; Williams, DL			Separation of lipid transport functions by mutations in the extracellular domain of scavenger receptor class B, type I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CHOLESTERYL ESTER HYDROLASE; APOLIPOPROTEIN-A-I; SR-BI; SELECTIVE UPTAKE; EXTRALYSOSOMAL HYDROLYSIS; MEDIATED ENDOCYTOSIS; HDL; CELLS; EXPRESSION	Scavenger receptor class B, type I (SR-BI) shows a variety of effects on cellular cholesterol metabolism, including increased selective uptake of high density lipoprotein (HDL) cholesteryl ester, stimulation of free cholesterol (FC) efflux from cells to HDL and phospholipid vesicles, and changes in the distribution of plasma membrane FC as evidenced by increased susceptibility to exogenous cholesterol oxidase. Previous studies showed that these multiple effects require the extracellular domain of SR-BI, but not the transmembrane and cytoplasmic domains. To test whether 1) the extracellular domain of SR-BI mediates multiple activities by virtue of discrete functional subdomains, or 2) the multiple activities are, in fact, secondary to and driven by changes in cholesterol flux, the extracellular domain of SR-BI was subjected to insertional mutagenesis by strategically placing an epitope tag into nine sites. These experiments identified four classes of mutants with disruptions at different levels of function. Class 4 mutants showed a clear separation of function between HDL binding, HDL cholesteryl ester uptake, and HDL-dependent FC efflux on one hand and FC efflux to small unilamellar vesicles and an increased cholesterol oxidase-sensitive pool of membrane FC on the other. Selective disruption of the latter two functions provides evidence for multiple functional subdomains in the extracellular receptor domain. Furthermore, these findings uncover a difference in the SR-BI-mediated efflux pathways for FC transfer to HDL acceptors versus phospholipid vesicles. The loss of the cholesterol oxidase-sensitive FC pool and FC efflux to small unilamellar vesicle acceptors in Class 4 mutants suggests that these activities may be mechanistically related.	SUNY Stony Brook, Dept Pharmacol Sci, Univ Med Ctr, Stony Brook, NY 11794 USA; Childrens Hosp Philadelphia, Dept Pediat, Div Gastroenterol & Nutr, Philadelphia, PA 19104 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Williams, DL (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Univ Med Ctr, Stony Brook, NY 11794 USA.	dave@pharm.sunysb.edu	Eckhardt, Erik/G-1567-2010		NHLBI NIH HHS [HL63768] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063768] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; Berrios M, 1999, METHOD ENZYMOL, V307, P55; Braun A, 2002, CIRC RES, V90, P270, DOI 10.1161/hh0302.104462; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CALVO D, 1993, J BIOL CHEM, V268, P18929; Connelly MA, 2003, J LIPID RES, V44, P331, DOI 10.1194/jlr.M200186-JLR200; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; Connelly MA, 2001, BIOCHEMISTRY-US, V40, P5249, DOI 10.1021/bi002825r; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; DELAMATRE JG, 1993, J CELL PHYSIOL, V157, P164, DOI 10.1002/jcp.1041570121; Francone OL, 1997, J LIPID RES, V38, P813; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; GWYNNE JT, 1980, J BIOL CHEM, V255, P875; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Holm TM, 2002, BLOOD, V99, P1817, DOI 10.1182/blood.V99.5.1817; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; Kellner-Weibel G, 2000, BIOCHEMISTRY-US, V39, P221, DOI 10.1021/bi991666c; Kozarsky KF, 2000, ARTERIOSCL THROM VAS, V20, P721, DOI 10.1161/01.ATV.20.3.721; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Liu T, 2002, J BIOL CHEM, V277, P21576, DOI 10.1074/jbc.M112103200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mardones P, 2001, J LIPID RES, V42, P170; Miettinen HE, 2001, J CLIN INVEST, V108, P1717, DOI 10.1172/JCI13288; OBERT S, 1994, MOL CELL BIOL, V14, P1333, DOI 10.1128/MCB.14.2.1333; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; Rigotti A, 1997, CURR OPIN LIPIDOL, V8, P181, DOI 10.1097/00041433-199706000-00009; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; Rothblat GH, 1999, J LIPID RES, V40, P781; SHIMADA A, 1994, BBA-LIPID LIPID MET, V1215, P126, DOI 10.1016/0005-2760(94)90101-5; Silver DL, 2001, CURR OPIN LIPIDOL, V12, P497, DOI 10.1097/00041433-200110000-00004; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SPARROW CP, 1990, BIOCHIM BIOPHYS ACTA, V1043, P203, DOI 10.1016/0005-2760(90)90297-B; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; STEIN Y, 1983, BIOCHIM BIOPHYS ACTA, V752, P98, DOI 10.1016/0005-2760(83)90237-0; Temel RE, 2003, J BIOL CHEM, V278, P4792, DOI 10.1074/jbc.M208160200; Temel RE, 2002, J BIOL CHEM, V277, P26565, DOI 10.1074/jbc.M203014200; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Ueda Y, 2000, J BIOL CHEM, V275, P20368, DOI 10.1074/jbc.M000730200; Vinals M, 2003, J BIOL CHEM, V278, P5325, DOI 10.1074/jbc.M211073200; Williams DL, 2002, J LIPID RES, V43, P544; Williams DL, 1999, CURR OPIN LIPIDOL, V10, P329, DOI 10.1097/00041433-199908000-00007; Yancey PG, 2000, J BIOL CHEM, V275, P36596, DOI 10.1074/jbc.M006924200	55	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25773	25782		10.1074/jbc.M302820200	http://dx.doi.org/10.1074/jbc.M302820200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730208	hybrid			2022-12-25	WOS:000183920200064
J	Oinuma, I; Katoh, H; Harada, A; Negishi, M				Oinuma, I; Katoh, H; Harada, A; Negishi, M			Direct interaction of Rnd1 with plexin-B1 regulates PDZ-RhoGEF-mediated Rho activation by plexin-B1 and induces cell contraction in COS-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTORS; ACTIVE RAC; AXON GUIDANCE; G-PROTEINS; FAMILY; GROWTH; SEMAPHORINS; RECEPTORS; GTPASES; KINASE	Plexins are receptors for the axon guidance molecule semaphorins, and several lines of evidence suggest that Rho family small GTPases are implicated in the downstream signaling of Plexins. Recent studies have demonstrated that Plexin-B1 activates RhoA and induces growth cone collapse through Rho-specific guanine nucleotide exchange factor PDZ-RhoGEF. Here we show that Rnd1, a member of Rho family GTPases, directly interacted with the cytoplasmic domain of Plexin-B1. In COS-7 cells, coexpression of Rnd1 and Plexin-B1 induced cell contraction in response to semaphorin 4D (Sema4D), a ligand for Plexin-B1, whereas expression of Plexin-B1 alone or coexpression of Rnd1 and a Rnd1 interaction-defective mutant of Plexin-B1 did not. The Sema4D-induced contraction in Plexin-B1/Rnd1-expressing COS-7 cells was suppressed by dominant negative RhoA, a Rho-associated kinase inhibitor, a dominant negative form of PDZ-RhoGEF, or deletion of the carboxyl-terminal PDZ-RhoGEF-binding region of Plexin-B1, indicating that the PDZ-RhoGEF/RhoA/Rho-associated kinase pathway is involved in this morphological effect. We also found that Rnd1 promoted the interaction between Plexin-B1 and PDZ-RhoGEF and thereby dramatically potentiated the Plexin-B1-mediated RhoA activation. We propose that Rnd1 plays an important role in the regulation of Plexin-B1 signaling, leading to Rho activation during axon guidance and cell migration.	Kyoto Univ, Grad Sch Biostudies, Mol Neurobiol Lab, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Negishi, M (corresponding author), Kyoto Univ, Grad Sch Biostudies, Mol Neurobiol Lab, Sakyo Ku, Kyoto 6068502, Japan.			Katoh, Hironori/0000-0002-8191-8117				Aoki J, 2000, BIOCHEM BIOPH RES CO, V278, P604, DOI 10.1006/bbrc.2000.3842; Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; Christensen CRL, 1998, CANCER RES, V58, P1238; Driessens MHE, 2002, FEBS LETT, V529, P168, DOI 10.1016/S0014-5793(02)03323-9; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Foster R, 1996, MOL CELL BIOL, V16, P2689; Fujita H, 2002, J BIOL CHEM, V277, P45428, DOI 10.1074/jbc.M208090200; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Goshima Y, 2002, J CLIN INVEST, V109, P993, DOI 10.1172/JCI200215467; Guasch RM, 1998, MOL CELL BIOL, V18, P4761, DOI 10.1128/MCB.18.8.4761; Hansen SH, 2000, MOL CELL BIOL, V20, P9364, DOI 10.1128/MCB.20.24.9364-9375.2000; Hirotani M, 2002, BIOCHEM BIOPH RES CO, V297, P32, DOI 10.1016/S0006-291X(02)02122-8; Hu HL, 2001, NEURON, V32, P39, DOI 10.1016/S0896-6273(01)00453-6; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; Katoh H, 2002, MOL CELL BIOL, V22, P2952, DOI 10.1128/MCB.22.9.2952-2964.2002; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kumanogoh A, 2000, IMMUNITY, V13, P621, DOI 10.1016/S1074-7613(00)00062-5; Liu BP, 2001, CURR OPIN CELL BIOL, V13, P619, DOI 10.1016/S0955-0674(00)00260-X; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MANSER E, 1995, METHOD ENZYMOL, V256, P215; Mitsui N, 2002, EMBO J, V21, P3274, DOI 10.1093/emboj/cdf328; Nakamura F, 2000, J NEUROBIOL, V44, P219, DOI 10.1002/1097-4695(200008)44:2<219::AID-NEU11>3.0.CO;2-W; Negishi M, 2002, J BIOCHEM, V132, P157, DOI 10.1093/oxfordjournals.jbchem.a003205; Nishi M, 1999, MOL BRAIN RES, V67, P74, DOI 10.1016/S0169-328X(99)00039-X; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; Raper JA, 2000, CURR OPIN NEUROBIOL, V10, P88, DOI 10.1016/S0959-4388(99)00057-4; Ren XD, 2000, METHOD ENZYMOL, V325, P264; RHOM B, 2000, FEBS LETT, V486, P68; Spriggs MK, 1999, CURR OPIN IMMUNOL, V11, P387, DOI 10.1016/S0952-7915(99)80065-X; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Takahashi T, 2001, NEURON, V29, P429, DOI 10.1016/S0896-6273(01)00216-1; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Vikis HG, 2000, P NATL ACAD SCI USA, V97, P12457, DOI 10.1073/pnas.220421797; Vikis HG, 2002, GENE DEV, V16, P836, DOI 10.1101/gad.966402; Wunnenberg-Stapleton K, 1999, DEVELOPMENT, V126, P5339; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200; Zanata SM, 2002, J NEUROSCI, V22, P471, DOI 10.1523/JNEUROSCI.22-02-00471.2002; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	42	90	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25671	25677		10.1074/jbc.M303047200	http://dx.doi.org/10.1074/jbc.M303047200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730235	hybrid			2022-12-25	WOS:000183920200051
J	Prunier, C; Pessah, M; Ferrand, N; Seo, SR; Howe, P; Atfi, A				Prunier, C; Pessah, M; Ferrand, N; Seo, SR; Howe, P; Atfi, A			The oncoprotein ski acts as an antagonist of transforming growth factor-beta signaling by suppressing Smad2 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSION; COREPRESSOR TGIF; BINDING PROTEIN; CO-REPRESSOR; V-SKI; ONCOGENE; RECEPTOR; TRANSDUCTION; COMPONENT; MUTATIONS	The phosphorylation of Smad2 and Smad3 by the transforming growth factor (TGF)-beta-activated receptor kinases and their subsequent heterodimerization with Smad4 and translocation to the nucleus form the basis for a model how Smad proteins work to transmit TGF-beta signals. The transcriptional activity of Smad2-Smad4 or Smad3-Smad4 complexes can be limited by the corepressor Ski, which is believed to interact with Smad complexes on TGF-beta-responsive promoters and represses their ability to activate TGF-beta target genes by assembling on DNA a repressor complex containing histone deacetylase. Here we show that Ski can block TGF-beta signaling by interfering with the phosphorylation of Smad2 and Smad3 by the activated TGF-beta type I receptor. Furthermore, we demonstrate that overexpression of Ski induces the assembly of Smad2-Smad4 and Smad3-Smad4 complexes independent of TGF-beta signaling. The ability of Ski to engage Smad proteins in nonproductive complexes provides new insights into the molecular mechanism used by Ski for disabling TGF-beta signaling.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France; Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Cleveland Clinic Foundation	Atfi, A (corresponding author), Hop St Antoine, INSERM, U482, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.		Frottier, Celine Prunier/G-8259-2017	Frottier, Celine Prunier/0000-0002-7784-0273				Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Kim RH, 2000, GENE DEV, V14, P1605; Kokura K, 2003, J BIOL CHEM, V278, P20133, DOI 10.1074/jbc.M210855200; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Melhuish TA, 2000, J BIOL CHEM, V275, P39762, DOI 10.1074/jbc.C000416200; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; Nicol R, 1998, J BIOL CHEM, V273, P3588, DOI 10.1074/jbc.273.6.3588; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Pessah M, 2002, J BIOL CHEM, V277, P29094, DOI 10.1074/jbc.M202831200; Pessah M, 2001, P NATL ACAD SCI USA, V98, P6198, DOI 10.1073/pnas.101579798; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Prunier C, 2001, MOL CELL BIOL, V21, P3302, DOI 10.1128/MCB.21.10.3302-3313.2001; Reed JA, 2001, CANCER RES, V61, P8074; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wotton D, 2001, CELL GROWTH DIFFER, V12, P457; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0	41	50	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26249	26257		10.1074/jbc.M304459200	http://dx.doi.org/10.1074/jbc.M304459200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12732634	hybrid			2022-12-25	WOS:000183920200124
J	Habib, GM; Shi, ZZ; Cuevas, AA; Lieberman, MW				Habib, GM; Shi, ZZ; Cuevas, AA; Lieberman, MW			Identification of two additional members of the membrane-bound dipeptidase family	FASEB JOURNAL			English	Article						MBD gene family; leukotriene D4; glutathione; asthma	GAMMA-GLUTAMYL-TRANSPEPTIDASE; RENAL DIPEPTIDASE; LEUKOTRIENE D-4; PHOSPHOLIPASE-C; METABOLISM; GENE; PURIFICATION; INHIBITORS; ENZYMES; ASTHMA	We have cloned two mouse cDNAs encoding previously unidentified membrane-bound dipeptidases [membrane-bound dipeptidase-2 (MBD-2) and membrane-bound dipeptidase-3 (MBD-3)] from membrane-bound dipeptidase-1 (MBD-1) deficient mice (Habib, G.M., Shi, ZZ., Cuevas, A.A., Guo, Q., Matzuk, M.M., and Lieberman, M.W. (1998) Proc. Natl. Acad. Sci. USA 95, 4859-4863). These enzymes are closely related to MBD-1 (EC 3.4.13.19), which is known to cleave leukotriene D-4 (LTD4) and cystinyl-bis-glycine. MBD-2 cDNA is 56% identical to MBD-1 with a predicted amino acid identity of 33%. The MBD-3 and MBD-1 cDNAs share a 55% nucleotide identity and a 39% predicted amino acid sequence identity. All three genes are tightly linked on the same chromosome. Expression of MBD-2 and MBD-3 in Cos cells indicated that both are membrane-bound through a glycosylphosphatidyl-inositol linkage. MBD-2 cleaves leukotriene D-4 (LTD4) but not cystinyl-bis-glycine, while MBD-3 cleaves cystinyl-bisglycine but not LTD4. MBD-1 is expressed at highest levels in kidney, lung, and heart and is absent in spleen, while MBD-2 is expressed at highest levels in lung, heart, and testis and at somewhat lower levels in spleen. Of the tissues examined, MBD-3 expression was detected only in testis. Our identification of a second enzyme capable of cleaving LTD4 raises the possibility that clearance of LTD4 during asthma and in related inflammatory conditions may be mediated by more than one enzyme.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Lieberman, MW (corresponding author), Baylor Coll Med, Dept Pathol, 1 Baylor Plaza, Houston, TX 77030 USA.	mikel@bcm.tmc.edu						CAMPBELL BJ, 1984, J BIOL CHEM, V259, P4586; Carter BZ, 1998, J BIOL CHEM, V273, P28277, DOI 10.1074/jbc.273.43.28277; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENZLINGER C, 1986, J BIOL CHEM, V261, P5601; Devillier P, 1999, PHARMACOL RES, V40, P3, DOI 10.1006/phrs.1998.0458; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; Habib GM, 1996, J BIOL CHEM, V271, P16273, DOI 10.1074/jbc.271.27.16273; Habib GM, 1999, ADV EXP MED BIOL, V469, P295; Habib GM, 1998, P NATL ACAD SCI USA, V95, P4859, DOI 10.1073/pnas.95.9.4859; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; HOOPER NM, 1987, BIOCHEM J, V244, P465, DOI 10.1042/bj2440465; Horwitz RJ, 1998, AM J RESP CRIT CARE, V157, P1363, DOI 10.1164/ajrccm.157.5.9706059; HUBER M, 1987, EUR J BIOCHEM, V167, P73, DOI 10.1111/j.1432-1033.1987.tb13305.x; KENNY AJ, 1987, MAMMALIAN ECTOENZYME, P329; KOZAK EM, 1982, J BIOL CHEM, V257, P6322; KROPP H, 1982, ANTIMICROB AGENTS CH, V22, P62, DOI 10.1128/AAC.22.1.62; LIEBERMAN MW, 1995, AM J PATHOL, V147, P1175; LITTLEWOOD GM, 1989, BIOCHEM J, V257, P361, DOI 10.1042/bj2570361; Meister A., 1995, METABOLIC BASIS INHE, P1461; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH S, 1993, BIOCHIM BIOPHYS ACTA, V1163, P234, DOI 10.1016/0167-4838(93)90157-M	21	40	44	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1313	+		10.1096/fj.02-0899fje	http://dx.doi.org/10.1096/fj.02-0899fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738806				2022-12-25	WOS:000183165000033
J	Nevin, ST; Cromer, BA; Haddrill, JL; Morton, CJ; Parker, MW; Lynch, JW				Nevin, ST; Cromer, BA; Haddrill, JL; Morton, CJ; Parker, MW; Lynch, JW			Insights into the structural basis for zinc inhibition of the glycine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZN2+ BINDING-SITE; GATED ION CHANNELS; NICOTINIC RECEPTORS; BETA-SUBUNIT; HISTIDINE RESIDUE; DOMAIN; MODULATION; SENSITIVITY; SYNAPSES; GABA	Histidines 107 and 109 in the glycine receptor ( GlyR) alpha(1) subunit have previously been identified as determinants of the inhibitory zinc-binding site. Based on modeling of the GlyR alpha(1) subunit extracellular domain by homology to the acetylcholine-binding protein crystal structure, we hypothesized that inhibitory zinc is bound within the vestibule lumen at subunit interfaces, where it is ligated by His(107) from one subunit and His(109) from an adjacent subunit. This was tested by co-expressing alpha(1) subunits containing the H107A mutation with alpha(1) subunits containing the H109A mutation. Although sensitivity to zinc inhibition is markedly reduced when either mutation is individually incorporated into all five subunits, the GlyRs formed by the co-expression of H107A mutant subunits with H109A mutant subunits exhibited an inhibitory zinc sensitivity similar to that of the wild type alpha(1) homomeric GlyR. This constitutes strong evidence that inhibitory zinc is coordinated at the interface between adjacent alpha(1) subunits. No evidence was found for beta subunit involvement in the coordination of inhibitory zinc, indicating that a maximum of two zinc-binding sites per alpha(1)beta receptor is sufficient for maximal zinc inhibition. Our data also show that two zinc-binding sites are sufficient for significant inhibition of alpha(1) homomers. The binding of zinc at the interface between adjacent alpha(1) subunits could restrict intersubunit movements, providing a feasible mechanism for the inhibition of channel activation by zinc.	Univ Queensland, Dept Physiol & Pharmacol, Sch Biomed Sci, Brisbane, Qld 4072, Australia; St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia	University of Queensland; St. Vincent's Institute of Medical Research	Lynch, JW (corresponding author), Univ Queensland, Dept Physiol & Pharmacol, Sch Biomed Sci, Brisbane, Qld 4072, Australia.	j.lynch@mailbox.uq.edu.au	Nevin, Simon/B-2663-2014; Morton, Craig/GON-8638-2022; Lynch, Joseph/C-8636-2009; Parker, Michael W/F-9069-2013; Cromer, Brett/AAQ-6533-2020	Morton, Craig/0000-0001-5452-5193; Parker, Michael W/0000-0002-3101-1138; Cromer, Brett/0000-0003-0743-1535				ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056; Birinyi A, 2001, J COMP NEUROL, V433, P208, DOI 10.1002/cne.1136; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CALVO DJ, 1994, P NATL ACAD SCI USA, V91, P12725, DOI 10.1073/pnas.91.26.12725; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; Cromer BA, 2002, TRENDS BIOCHEM SCI, V27, P280, DOI 10.1016/S0968-0004(02)02092-3; Davies PA, 2003, J BIOL CHEM, V278, P712, DOI 10.1074/jbc.M208814200; DRAGUHN A, 1990, NEURON, V5, P781, DOI 10.1016/0896-6273(90)90337-F; Dunne EL, 2002, BRIT J PHARMACOL, V137, P29, DOI 10.1038/sj.bjp.0704835; Fisher JL, 2002, NEUROPHARMACOLOGY, V42, P922, DOI 10.1016/S0028-3908(02)00050-3; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; GILL CH, 1995, BRIT J PHARMACOL, V114, P1211, DOI 10.1111/j.1476-5381.1995.tb13335.x; Gisselmann G, 2002, NAT NEUROSCI, V5, P11, DOI 10.1038/nn787; Grutter T, 2001, TRENDS BIOCHEM SCI, V26, P459, DOI 10.1016/S0968-0004(01)01921-1; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Han NLR, 2001, J NEUROCHEM, V79, P636, DOI 10.1046/j.1471-4159.2001.00601.x; Handford CA, 1996, MOL BRAIN RES, V35, P211; Harvey RJ, 1999, J PHYSIOL-LONDON, V520, P53, DOI 10.1111/j.1469-7793.1999.00053.x; Horenstein J, 1998, MOL PHARMACOL, V53, P870; Hosie AM, 2003, NAT NEUROSCI, V6, P362, DOI 10.1038/nn1030; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; Laube B, 2000, J PHYSIOL-LONDON, V522, P215, DOI 10.1111/j.1469-7793.2000.t01-1-00215.x; LAUBE B, 1995, J PHYSIOL-LONDON, V483, P613, DOI 10.1113/jphysiol.1995.sp020610; Laube B, 2002, TRENDS PHARMACOL SCI, V23, P519, DOI 10.1016/S0165-6147(02)02138-7; Le Novere N, 2002, P NATL ACAD SCI USA, V99, P3210, DOI 10.1073/pnas.042699699; Legendre P, 2001, CELL MOL LIFE SCI, V58, P760, DOI 10.1007/PL00000899; Lesburg CA, 1997, BIOCHEMISTRY-US, V36, P15780, DOI 10.1021/bi971296x; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Lynch JW, 1998, J NEUROCHEM, V71, P2159; Palma E, 1998, P NATL ACAD SCI USA, V95, P10246, DOI 10.1073/pnas.95.17.10246; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Shan Q, 2001, J NEUROCHEM, V76, P1109, DOI 10.1046/j.1471-4159.2001.00124.x; SMART TG, 1994, PROG NEUROBIOL, V42, P393, DOI 10.1016/0301-0082(94)90082-5; Suwa H, 2001, J NEUROPHYSIOL, V85, P912, DOI 10.1152/jn.2001.85.2.912; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; Vogt K, 2000, NEURON, V26, P187, DOI 10.1016/S0896-6273(00)81149-6; WANG TL, 1995, J NEUROSCI, V15, P7684; Wooltorton JRA, 1997, J PHYSIOL-LONDON, V505, P633, DOI 10.1111/j.1469-7793.1997.633ba.x	43	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28985	28992		10.1074/jbc.M300097200	http://dx.doi.org/10.1074/jbc.M300097200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12740384	hybrid			2022-12-25	WOS:000184421100079
J	Zhang, B; Hirahashi, J; Cullere, X; Mayadas, TN				Zhang, B; Hirahashi, J; Cullere, X; Mayadas, TN			Elucidation of molecular events leading to neutrophil apoptosis following phagocytosis - Cross-talk between caspase 8, reactive oxygen species, and MAPK/ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; NF-KAPPA-B; CHRONIC GRANULOMATOUS-DISEASE; SIGNAL-REGULATED KINASE; PROGRAMMED CELL-DEATH; COLONY-STIMULATING FACTOR; NITRIC-OXIDE SYNTHASE; NADPH OXIDASE; RESPIRATORY BURST	Phagocytosis of complement-opsonized targets is a primary function of neutrophils at sites of inflammation, and the clearance of neutrophils that have phagocytosed microbes is important for the resolution of inflammation. Our previous work suggests that phagocytosis leads to rapid neutrophil apoptosis that is inhibited by antibody to the beta(2) integrin, Mac-1, and requires NADPH oxidase-derived reactive oxygen species (ROS) generated during phagocytosis. Here we report that phagocytosis- induced cell death (PICD) does not occur in Mac-1-deficient murine neutrophils, suggesting that PICD proceeds through a bona fide Mac-1-dependent pathway. A sustained, intracellular oxidative burst is associated with PICD. Furthermore, PICD does not require traditional death receptors, Fas, or tumor necrosis factor (TNF) receptor. TNF but not Fas synergizes with phagocytosis to enhance significantly PICD by increasing the oxidative burst, and this is Mac-1-dependent. Phagocytosis-induced ROS promote cleavage/ activation of caspases 8 and 3, key players in most extrinsic ("death receptor") mediated pathways of apoptosis, and caspases 8 and 3 but not caspase 9/mitochondria, are required for PICD. This suggests that ROS target the extrinsic versus the intrinsic ("stress stimulus") apoptotic pathway. Phagocytosis also triggers a competing MAPK/ERK-dependent survival pathway that provides resistance to PICD likely by downregulating caspase 8 activation. The anti-apoptotic factor granulocyte-macrophage colony-stimulating factor (GM-CSF) significantly enhances ROS generation associated with phagocytosis. Despite this, it completely suppresses PICD by sustaining ERK activation and inhibiting caspase 8 activation in phagocytosing neutrophils. Together, these studies suggest that Mac-1-mediated phagocytosis promotes apoptosis through a caspase 8/3-dependent pathway that is modulated by NADPH oxidase-generated ROS and MAPK/ERK. Moreover, TNF and GM-CSF, likely encountered by phagocytosing neutrophils at inflammatory sites, exploit pro( ROS) and anti-apoptotic ( ERK) signals triggered by phagocytosis to promote or suppress PICD, respectively, and thus modulate the fate of phagocytosing neutrophils.	Brigham & Womens Hosp, Dept Pathol, Div Vasc Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Mayadas, TN (corresponding author), Brigham & Womens Hosp, Dept Pathol, Div Vasc Res, Boston, MA 02115 USA.				NHLBI NIH HHS [P01-HL36028] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036028] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1998, TRENDS CARDIOVAS MED, V8, P59, DOI 10.1016/S1050-1738(97)00133-3; Akgul C, 2001, FEBS LETT, V487, P318, DOI 10.1016/S0014-5793(00)02324-3; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Baran J, 2001, INFECT IMMUN, V69, P1287, DOI 10.1128/IAI.69.3.1287-1297.2001; BAZZONI F, 1991, J LEUKOCYTE BIOL, V50, P223, DOI 10.1002/jlb.50.3.223; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BICKNELL S, 1994, AM J RESP CELL MOL, V10, P16, DOI 10.1165/ajrcmb.10.1.8292377; Blouin E, 1999, EUR J IMMUNOL, V29, P3419, DOI 10.1002/(SICI)1521-4141(199911)29:11<3419::AID-IMMU3419>3.3.CO;2-T; BRACH MA, 1992, BLOOD, V80, P2920; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Cai JY, 1999, J BIOENERG BIOMEMBR, V31, P327, DOI 10.1023/A:1005423818280; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Cimino F, 1997, CURR TOP CELL REGUL, V35, P123, DOI 10.1016/S0070-2137(97)80005-2; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Colamussi ML, 1999, BLOOD, V93, P2395, DOI 10.1182/blood.V93.7.2395.407a22_2395_2403; COLOTTA F, 1992, BLOOD, V80, P2012; Condliffe AM, 1996, IMMUNOLOGY, V89, P105, DOI 10.1046/j.1365-2567.1996.d01-711.x; Coxon A, 1999, J EXP MED, V190, P923, DOI 10.1084/jem.190.7.923; Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2; CROSS AR, 1990, FREE RADICAL BIO MED, V8, P71, DOI 10.1016/0891-5849(90)90147-B; Dahlgren C, 1999, J IMMUNOL METHODS, V232, P3, DOI 10.1016/S0022-1759(99)00146-5; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; DeLeo FR, 1998, J CLIN INVEST, V101, P455, DOI 10.1172/JCI949; Doussiere J, 1999, BIOCHEMISTRY-US, V38, P3694, DOI 10.1021/bi9823481; DRANSFIELD I, 1994, J IMMUNOL, V153, P1254; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; ELLIS JA, 1988, BIOCHEM J, V251, P887, DOI 10.1042/bj2510887; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Fukazawa H, 2002, MOL CANCER THER, V1, P303; Gamberale R, 1998, J IMMUNOL, V161, P3666; Gardai S, 2002, J BIOL CHEM, V277, P5236, DOI 10.1074/jbc.M110005200; Ginis I, 1997, AM J PHYSIOL-CELL PH, V272, pC295, DOI 10.1152/ajpcell.1997.272.1.C295; GRAHAM IL, 1989, J IMMUNOL, V142, P2352; GUTHRIE LA, 1984, J EXP MED, V160, P1656, DOI 10.1084/jem.160.6.1656; Hansen LL, 1999, J BIOL CHEM, V274, P25078, DOI 10.1074/jbc.274.35.25078; Henderson LM, 1996, BBA-BIOENERGETICS, V1273, P87, DOI 10.1016/0005-2728(95)00140-9; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; Ibata-Ombetta S, 2001, J LEUKOCYTE BIOL, V70, P149; JONES OTG, 1991, BIOCHEM SOC T, V19, P70, DOI 10.1042/bst0190070; KEENEY SE, 1993, J LEUKOCYTE BIOL, V54, P97, DOI 10.1002/jlb.54.2.97; Kobayashi SD, 2003, J LEUKOCYTE BIOL, V73, P315, DOI 10.1189/jlb.1002481; Kobayashi SD, 2002, P NATL ACAD SCI USA, V99, P6901, DOI 10.1073/pnas.092148299; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; Lofgren R, 1999, BBA-MOL CELL RES, V1452, P46, DOI 10.1016/S0167-4889(99)00112-3; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; Maccarrone M, 2001, FEBS LETT, V507, P30, DOI 10.1016/S0014-5793(01)02949-0; Matsuda T, 1999, SHOCK, V12, P365; McLeish KR, 1998, J LEUKOCYTE BIOL, V64, P835, DOI 10.1002/jlb.64.6.835; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; NATHAN DG, 1969, J CLIN INVEST, V48, P1895, DOI 10.1172/JCI106156; NEWBURGER PE, 1983, BLOOD, V61, P1247; NEWBURGER PE, 1986, BLOOD, V68, P914; OEZ S, 1993, ANN HEMATOL, V66, P21, DOI 10.1007/BF01737685; Prasad KVS, 1997, P NATL ACAD SCI USA, V94, P6346, DOI 10.1073/pnas.94.12.6346; Pryde JG, 2000, J BIOL CHEM, V275, P33574, DOI 10.1074/jbc.M001008200; Renshaw SA, 2000, J LEUKOCYTE BIOL, V67, P662, DOI 10.1002/jlb.67.5.662; ROSS GD, 1993, CLIN EXP IMMUNOL, V92, P181; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; SAVILL J, 1994, IMMUNOPHARMACOLOGY N, P295; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Scheel-Toellner D, 2002, EUR J IMMUNOL, V32, P486, DOI 10.1002/1521-4141(200202)32:2<486::AID-IMMU486>3.0.CO;2-U; Schonhoff CM, 2001, J NEUROCHEM, V78, P631, DOI 10.1046/j.1471-4159.2001.00432.x; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Seely AJE, 1998, ARCH SURG-CHICAGO, V133, P1305, DOI 10.1001/archsurg.133.12.1305; Serrander L, 1999, BBA-MOL CELL RES, V1452, P133, DOI 10.1016/S0167-4889(99)00123-8; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Soderstrom TS, 2002, J IMMUNOL, V169, P2851, DOI 10.4049/jimmunol.169.6.2851; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; Sweeney JF, 1997, J LEUKOCYTE BIOL, V62, P517, DOI 10.1002/jlb.62.4.517; Tortorella C, 1998, J CLIN IMMUNOL, V18, P321, DOI 10.1023/A:1023286831246; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; TSUCHIDA H, 1995, J IMMUNOL, V154, P2403; van den Berg JM, 2001, J LEUKOCYTE BIOL, V69, P467; Walzog B, 1997, FASEB J, V11, P1177, DOI 10.1096/fasebj.11.13.9367353; Ward C, 1999, TRENDS PHARMACOL SCI, V20, P503, DOI 10.1016/S0165-6147(99)01391-7; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; Ward RA, 2000, J BIOL CHEM, V275, P36713, DOI 10.1074/jbc.M003017200; Watson RWG, 1996, J IMMUNOL, V156, P3986; Watson RWG, 1999, FEBS LETT, V453, P67, DOI 10.1016/S0014-5793(99)00688-2; Watson RWG, 1997, J IMMUNOL, V158, P945; Whitlock BB, 2000, J CELL BIOL, V151, P1305, DOI 10.1083/jcb.151.6.1305; William R, 1997, BLOOD, V89, P4175, DOI 10.1182/blood.V89.11.4175	89	196	200	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28443	28454		10.1074/jbc.M210727200	http://dx.doi.org/10.1074/jbc.M210727200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12736263	hybrid			2022-12-25	WOS:000184421100014
J	Hong, YH; Varanasi, US; Yang, WB; Leff, T				Hong, YH; Varanasi, US; Yang, WB; Leff, T			AMP-activated protein kinase regulates HNF4 alpha transcriptional activity by inhibiting dimer formation and decreasing protein stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE NUCLEAR FACTOR-4; GENE-EXPRESSION; GLUCOSE-TRANSPORT; FATTY-ACID; INSULIN-SECRETION; RAT HEPATOCYTES; SKELETAL-MUSCLE; GAMMA-SUBUNIT; BETA-SUBUNIT; DNA-BINDING	AMP-activated protein kinase (AMPK) is the central component of a cellular signaling system that regulates multiple metabolic enzymes and pathways in response to reduced intracellular energy levels. The transcription factor hepatic nuclear factor 4alpha (HNF4alpha) is an orphan nuclear receptor that regulates the expression of genes involved in energy metabolism in the liver, intestine, and endocrine pancreas. Inheritance of a single null allele of HNF4alpha causes diabetes in humans. Here we demonstrate that AMPK directly phosphorylates HNF4alpha and represses its transcriptional activity. AMPK-mediated phosphorylation of HNF4alpha on serine 304 had a 2-fold effect, reducing the ability of the transcription factor to form homodimers and bind DNA and increasing its degradation rate in vivo. These results demonstrate that HNF4alpha is a downstream target of AMPK and raise the possibility that one of the effects of AMPK activation is reduced expression of HNF4alpha target genes.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Ctr Integrat Metab & Endocrine Res, Detroit, MI 48201 USA; Pfizer Inc, Global Res & Dev, Dept Mol Sci, Ann Arbor, MI 48105 USA	Wayne State University; Wayne State University; Pfizer	Leff, T (corresponding author), Wayne State Univ, Sch Med, Dept Pathol CIMER, 540 E CAnfield, Detroit, MI 48201 USA.	tleff@med.wayne.edu	Leff, Todd/U-9084-2018	Leff, Todd/0000-0001-6923-3900				Bergeron R, 1999, AM J PHYSIOL-ENDOC M, V276, pE938, DOI 10.1152/ajpendo.1999.276.5.E938; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; FIGUEIREDO MS, 1995, J BIOL CHEM, V270, P11828, DOI 10.1074/jbc.270.20.11828; Foretz M, 1998, J BIOL CHEM, V273, P14767, DOI 10.1074/jbc.273.24.14767; Gao G, 1996, J BIOL CHEM, V271, P8675, DOI 10.1074/jbc.271.15.8675; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; HENIN N, 1995, FASEB J, V9, P541, DOI 10.1096/fasebj.9.7.7737463; Herman WH, 1997, DIABETES, V46, P1749, DOI 10.2337/diabetes.46.11.1749; Hubert A, 2000, FEBS LETT, V481, P209, DOI 10.1016/S0014-5793(00)02006-8; Ilag LL, 2000, DIABETES, V49, P961, DOI 10.2337/diabetes.49.6.961; Inoue Y, 2002, J BIOL CHEM, V277, P25257, DOI 10.1074/jbc.M203126200; Ishihara H, 2000, IUBMB LIFE, V49, P391; Iwasaki N, 1998, DIABETES CARE, V21, P2144, DOI 10.2337/diacare.21.12.2144; Jiang GQ, 1997, ARCH BIOCHEM BIOPHYS, V340, P1, DOI 10.1006/abbi.1997.9914; Kawaguchi T, 2002, J BIOL CHEM, V277, P3829, DOI 10.1074/jbc.M107895200; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; Leclerc I, 2001, DIABETES, V50, P1515, DOI 10.2337/diabetes.50.7.1515; Lindner T, 1997, J CLIN INVEST, V100, P1400, DOI 10.1172/JCI119660; Lo WS, 2001, SCIENCE, V293, P1142, DOI 10.1126/science.1062322; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107, DOI 10.1152/ajpendo.1997.273.6.E1107; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Musi N, 2001, DIABETES, V50, P921, DOI 10.2337/diabetes.50.5.921; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; Reddy S, 1999, J BIOL CHEM, V274, P33050, DOI 10.1074/jbc.274.46.33050; Ryffel GU, 2001, J MOL ENDOCRINOL, V27, P11, DOI 10.1677/jme.0.0270011; Salt I, 1998, BIOCHEM J, V334, P177, DOI 10.1042/bj3340177; Salt IP, 1998, BIOCHEM J, V335, P533, DOI 10.1042/bj3350533; Shih DQ, 2000, DIABETES, V49, P832, DOI 10.2337/diabetes.49.5.832; Sladek FM, 1998, DIABETES, V47, P985, DOI 10.2337/diabetes.47.6.985; Sladek R, 2000, ADV PHARMACOL, V47, P23; Stapleton D, 1997, FEBS LETT, V409, P452, DOI 10.1016/S0014-5793(97)00569-3; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4; Thornton C, 1998, J BIOL CHEM, V273, P12443, DOI 10.1074/jbc.273.20.12443; Turnley AM, 1999, J NEUROCHEM, V72, P1707, DOI 10.1046/j.1471-4159.1999.721707.x; Viollet B, 1997, MOL CELL BIOL, V17, P4208, DOI 10.1128/MCB.17.8.4208; Wang HY, 2000, J BIOL CHEM, V275, P35953, DOI 10.1074/jbc.M006612200; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4; WOODS A, 1994, J BIOL CHEM, V269, P19509; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yang WB, 2001, J BIOL CHEM, V276, P38341, DOI 10.1074/jbc.C100316200; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	53	160	166	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27495	27501		10.1074/jbc.M304112200	http://dx.doi.org/10.1074/jbc.M304112200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12740371	hybrid			2022-12-25	WOS:000184242700021
J	Rutherford, JC; Jaron, S; Winge, DR				Rutherford, JC; Jaron, S; Winge, DR			Aft1p and Aft2p mediate iron-responsive gene expression in yeast through related promoter elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRATAXIN-DEFICIENT STRAIN; SACCHAROMYCES-CEREVISIAE; SUBCELLULAR-LOCALIZATION; REGULATORY NETWORKS; TRANSCRIPTION; BIOSYNTHESIS; TRANSPORTERS; RESISTANCE; ACTIVATOR; PATHWAYS	The transcription factors Aft1p and Aft2p from Saccharomyces cerevisiae regulate the expression of genes that are involved in iron homeostasis. In vitro studies have shown that both transcription factors bind to an iron-responsive element (FeRE) that is present in the upstream region of genes in the iron regulon. We have used DNA microarrays to distinguish the genes that are activated by Aft1p and Aft2p and to establish for the first time that each factor gives rise to a unique transcriptional profile due to the differential expression of individual iron-regulated genes. We also show that both Aft1p and Aft2p mediate the in vivo expression of FET3 and FIT3 through a consensus FeRE. In addition, both proteins regulate MRS4 via a variant FeRE with Aft2p being the stronger activator from this particular element. Like other paralogous pairs of transcription factors within S. cerevisiae, Aft1p and Aft2p are able to interact with the same promoter elements while maintaining specificity of gene activation.	Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA.		Winge, Dennis/G-3611-2010		NCI NIH HHS [CA 61286] Funding Source: Medline; NIEHS NIH HHS [ES03817] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061286] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES003817, R01ES003817] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUSUBEL FM, 1997, CURRENT PROTOCOLS MO, V2; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; Blaiseau PL, 2001, J BIOL CHEM, V276, P34221, DOI 10.1074/jbc.M104987200; Casas C, 1997, YEAST, V13, P621, DOI 10.1002/(SICI)1097-0061(19970615)13:7<621::AID-YEA121>3.0.CO;2-U; Chen OS, 2002, P NATL ACAD SCI USA, V99, P12321, DOI 10.1073/pnas.192449599; Cohen BA, 2002, MOL BIOL CELL, V13, P1608, DOI 10.1091/mbc.01-10-0472; Dancis A, 1998, J PEDIATR-US, V132, pS24, DOI 10.1016/S0022-3476(98)70524-4; DOHRMANN PR, 1992, GENE DEV, V6, P93, DOI 10.1101/gad.6.1.93; Dohrmann PR, 1996, MOL CELL BIOL, V16, P1746; Doolin MT, 2001, MOL MICROBIOL, V40, P422, DOI 10.1046/j.1365-2958.2001.02388.x; Fernandes L, 1997, MOL CELL BIOL, V17, P6982, DOI 10.1128/MCB.17.12.6982; Foury F, 2002, J BIOL CHEM, V277, P24475, DOI 10.1074/jbc.M111789200; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; Kumar A, 2002, GENE DEV, V16, P707, DOI 10.1101/gad.970902; Lascaris RF, 2000, NUCLEIC ACIDS RES, V28, P1390, DOI 10.1093/nar/28.6.1390; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Li LT, 2001, J BIOL CHEM, V276, P5036, DOI 10.1074/jbc.M008969200; Mamnun YM, 2002, MOL MICROBIOL, V46, P1429, DOI 10.1046/j.1365-2958.2002.03262.x; MARTINS L, 1997, J BIOL CHEM, V273, P23716; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; Portnoy ME, 2002, BIOCHEM J, V362, P119, DOI 10.1042/bj3620119; Protchenko O, 2001, J BIOL CHEM, V276, P49244, DOI 10.1074/jbc.M109220200; Rutherford JC, 2001, P NATL ACAD SCI USA, V98, P14322, DOI 10.1073/pnas.261381198; Stadler JA, 2002, J BIOL CHEM, V277, P39649, DOI 10.1074/jbc.M203924200; TOONE WM, 1995, EMBO J, V14, P5824, DOI 10.1002/j.1460-2075.1995.tb00270.x; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Yun CW, 2000, J BIOL CHEM, V275, P16354, DOI 10.1074/jbc.M001456200; Yun CW, 2000, J BIOL CHEM, V275, P10709, DOI 10.1074/jbc.275.14.10709	31	156	169	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27636	27643		10.1074/jbc.M300076200	http://dx.doi.org/10.1074/jbc.M300076200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12756250	hybrid			2022-12-25	WOS:000184242700039
J	Sablina, AA; Chumakov, PM; Kopnin, BP				Sablina, AA; Chumakov, PM; Kopnin, BP			Tumor suppressor p53 and its homologue p73 alpha affect cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53-REGULATED GENE-EXPRESSION; GROWTH-FACTOR RECEPTOR; TARGET GENES; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; PHOSPHOINOSITIDE 3-KINASE; RHO-GTPASES; DNA-DAMAGE; P73; IDENTIFICATION	The p53 tumor suppressor plays a central role in the negative control of growth and survival of abnormal cells. Previously we demonstrated that in addition to these functions, p53 expression affects cell morphology and lamellar activity of the cell edge (Alexandrova, A., Ivanov, A., Chumakov, P. M., Kopnin, P. B., and Vasiliev, J. M. (2000) Oncogene 19, 5826-5830). In the present work we studied the effects of p53 and its homologue p73alpha on cell migration. We found that loss of p53 function correlated with decreased cell migration that was analyzed by in vitro wound closure test and Boyden chamber assay. The decreased motility of p53-deficient cells was observed in different cell contexts: human foreskin fibroblasts (BJ), human colon and lung carcinoma cell lines (HCT116 and H1299, respectively), as well as mouse normal fibroblasts from lung and spleen, peritoneal macrophages, and keratinocytes. On the other hand, overexpression of the p53 family member p73alpha stimulated cell migration. Changes in cell migration correlated directly with transcription activation induced by p53 or p73alpha. Noteworthy, p53 modulated cell motility in the absence of stress. The effect of p53 and p73alpha on cell migration was mediated through the activity of the phosphatidylinositol 3-kinase/Rac1 pathway. This p53/p73 function was mainly associated with some modulation of intracellular signaling rather than with stimulation of production of secreted motogenic factors. The identified novel activity of the p53 family members might be involved in regulation of embryogenesis, wound healing, or inflammatory response.	Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Russian Canc Res Ctr, Inst Carcinogenesis, Moscow 115478, Russia; VA Engelhardt Mol Biol Inst, Moscow 119991, Russia	Cleveland Clinic Foundation; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Chumakov, PM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Sablina, Anna/B-2217-2017; Sablina, Anna/P-2818-2019; Kopnin, Boris/R-8240-2019	Sablina, Anna/0000-0001-9526-4014; Sablina, Anna/0000-0001-9526-4014; Kopnin, Boris/0000-0003-3100-2212; Chumakov, Peter/0000-0002-8078-2908				Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Alexandrova A, 2000, ONCOGENE, V19, P5826, DOI 10.1038/sj.onc.1203944; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BUCKBINDER L, 1994, P NATL ACAD SCI USA, V91, P10640, DOI 10.1073/pnas.91.22.10640; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cantrell DA, 2001, J CELL SCI, V114, P1439; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; Comer KA, 1998, ONCOGENE, V16, P1299, DOI 10.1038/sj.onc.1201645; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Gadea G, 2002, EMBO J, V21, P2373, DOI 10.1093/emboj/21.10.2373; Guo FK, 2003, J BIOL CHEM, V278, P14414, DOI 10.1074/jbc.M300341200; Hardie WD, 1999, PEDIATR DEVEL PATHOL, V2, P415, DOI 10.1007/s100249900144; Hausmann R, 1998, INT J LEGAL MED, V111, P169, DOI 10.1007/s004140050142; Iotsova V, 1996, CELL GROWTH DIFFER, V7, P629; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kane CD, 2000, WOUND REPAIR REGEN, V8, P45, DOI 10.1046/j.1524-475x.2000.00045.x; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Metcalfe AMJ, 1997, NUCLEIC ACIDS RES, V25, P983, DOI 10.1093/nar/25.5.983; Mograbi B, 1997, EUR CYTOKINE NETW, V8, P73; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Prives C, 1999, J PATHOL, V187, P112; Pugacheva EN, 2002, ONCOGENE, V21, P4595, DOI 10.1038/sj.onc.1205704; Ridley AJ, 2001, J CELL SCI, V114, P2713; Sablina AA, 1998, J CELL SCI, V111, P977; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Seol DW, 1999, J BIOL CHEM, V274, P3565, DOI 10.1074/jbc.274.6.3565; Shiraishi K, 2000, CANCER RES, V60, P3722; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Toschi E, 2000, J INVEST DERMATOL, V114, P1188, DOI 10.1046/j.1523-1747.2000.00000.x; Vikhanskaya F, 2001, ONCOGENE, V20, P7293, DOI 10.1038/sj.onc.1204896; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yoon H, 2002, P NATL ACAD SCI USA, V99, P15632, DOI 10.1073/pnas.242597299; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhao RB, 2000, GENE DEV, V14, P981; Zhu JH, 1998, CANCER RES, V58, P5061	51	43	48	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27362	27371		10.1074/jbc.M300547200	http://dx.doi.org/10.1074/jbc.M300547200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12750388	hybrid			2022-12-25	WOS:000184242700006
J	Friedman, AD; Nimbalkar, D; Quelle, FW				Friedman, AD; Nimbalkar, D; Quelle, FW			Erythropoietin receptors associate with a ubiquitin ligase, p33(RUL), and require its activity for erythropoietin-induced proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASE; CELL-CYCLE ARREST; HEMATOPOIETIC-CELLS; PROTEASOME PATHWAY; STAT5 ACTIVATION; NITRIC-OXIDE; RING FINGER; C-ALPHA	The proliferation and survival of hematopoietic cells is strictly regulated by cytokine growth factors that act through receptors of the Type I cytokine receptor family, including erythropoietin (Epo) and its receptor, EpoR. Mitogenic signaling by these receptors depends on activation of Jak tyrosine kinases. However, other required components of this pathway have not been fully identified. In a screen for proteins that interact with EpoR and Jak2, we identified a novel member of the U-box family of ubiquitin ligases. This receptor-associated ubiquitin ligase, RUL, co-precipitated with EpoR from mammalian cells and mediated ubiquitination of EpoR. Also, endogenously expressed RUL was rapidly and transiently phosphorylated on serine after cytokine treatment of factor-dependent hematopoietic cells. Expression of ubiquitin ligase-deficient mutants of RUL inhibited Epo-induced expression of c-myc and bcl-2, two immediate-early genes normally associated with Epo-induced cell growth. Consistent with that finding, expression of mutant RUL also inhibited Epo-dependent proliferation and survival of factor-dependent cells. Together, these observations suggest that RUL is a required component of mitogenic signaling by EpoR. We also show that RUL is phosphorylated in response to growth factors that act through non-cytokine receptors, suggesting that RUL may function as a common regulator of mitogenesis.	Univ Iowa, Carver Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA; Univ Iowa, Carver Coll Med, Grad Program Immunol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Quelle, FW (corresponding author), Univ Iowa, Carver Coll Med, Dept Pharmacol, 2-210 Bowen Sci Bldg, Iowa City, IA 52242 USA.	frederick-quelle@uiowa.edu		Quelle, Frederick/0000-0002-1184-6170	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25295] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 2000, CURR BIOL, V10, pR132, DOI 10.1016/S0960-9822(00)00398-5; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bunting KD, 2002, BLOOD, V99, P479, DOI 10.1182/blood.V99.2.479; Chen CM, 2001, J BIOL CHEM, V276, P38518, DOI 10.1074/jbc.M105702200; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; Dedio J, 2001, FASEB J, V15, P79, DOI 10.1096/fj.00-0078com; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Eapen AK, 2001, MOL CELL BIOL, V21, P6113, DOI 10.1128/MCB.21.18.6113-6121.2001; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; Guthridge MA, 2000, MOL CELL, V6, P99, DOI 10.1016/S1097-2765(00)00011-3; Haslauer M, 1999, BLOOD, V94, P114, DOI 10.1182/blood.V94.1.114.413k21_114_126; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Henry MK, 2001, BLOOD, V98, P834, DOI 10.1182/blood.V98.3.834; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hilton DJ, 1999, CELL MOL LIFE SCI, V55, P1568, DOI 10.1007/s000180050396; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Konig P, 2002, GASTROENTEROLOGY, V123, P314, DOI 10.1053/gast.2002.34212; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; MIURA O, 1994, BLOOD, V84, P1501; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIZUNO K, 1993, BIOCHEM BIOPH RES CO, V194, P178, DOI 10.1006/bbrc.1993.1801; Nakamura T, 2002, J BIOL CHEM, V277, P6254, DOI 10.1074/jbc.M109878200; Nimbalkar D, 2003, CANCER RES, V63, P1034; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Ouaaz F, 1995, RES IMMUNOL, V146, P678, DOI 10.1016/0923-2494(96)84916-9; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Pringa E, 2001, J BIOL CHEM, V276, P19617, DOI 10.1074/jbc.M100192200; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Quelle FW, 1998, GENE DEV, V12, P1099, DOI 10.1101/gad.12.8.1099; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Verdier F, 2000, J BIOL CHEM, V275, P18375, DOI 10.1074/jbc.275.24.18375; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; von Lindern M, 2000, J BIOL CHEM, V275, P34719, DOI 10.1074/jbc.M007042200; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Yen CH, 2000, J IMMUNOL, V165, P6372, DOI 10.4049/jimmunol.165.11.6372; Zang HS, 2001, EMBO J, V20, P3156, DOI 10.1093/emboj/20.12.3156; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	55	18	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26851	26861		10.1074/jbc.M210039200	http://dx.doi.org/10.1074/jbc.M210039200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12746455	hybrid			2022-12-25	WOS:000184155700073
J	Gao, X; Wu, L; O'Neil, RG				Gao, X; Wu, L; O'Neil, RG			Temperature-modulated diversity of TRPV4 channel gating - Activation by physical stresses and phorbol ester derivatives through protein kinase C-dependent and -independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICAL COLLECTING DUCT; HEAT-EVOKED ACTIVATION; PROXIMAL TUBULE CELLS; RECEPTOR-LIKE PROTEIN; VANILLOID RECEPTOR; CALCIUM-CHANNEL; CATION CHANNEL; ION-CHANNEL; FAMILY; TRANSLOCATION	The TRPV4 calcium-permeable channel was cloned from mouse kidney M-1 cells, and the effect of temperature modulation on channel gating/activation by physical and chemical signals was evaluated. A TRPV4 cDNA construct with a C-terminal V5 epitope was stably transfected into human embryonic kidney (HEK) 293 and Chinese hamster ovary cells resulting in high levels of expression at the plasma membrane. Channel activation was assessed from changes in calcium influx (fura-2 fluorescence measurements) or whole cell currents ( patch clamp analysis). At room temperature ( 22 - 24 degreesC), exposure of TRPV4-transfected cells to hypotonic medium ( 225 mOsm/liter) or a non-protein kinase C (PKC)- activating phorbol ester derivative, 4alpha-phorbol 12,13-decanoate ( 100 nM), induces modest channel activation, whereas phorbol 12-myristate 13-acetate ( 100 nM), a PKC-activating phorbol ester, and shear stress ( 3 - 20 dyne/cm(2)) had minimal or no effect on channel activation. In contrast, at elevated temperatures ( 37 degreesC) the channel was rapidly activated by all stimuli. Inhibition of PKC by calphostin C (50 nM) or staurosporine (500 nM) abolished phorbol 12-myristate 13-acetate-induced activation of the channel without affecting the response to other stimuli. Ruthenium red ( 1 muM) effectively blocked the channel activity by all stimuli. It is concluded that temperature is a critical modulator of TRPV4 channel gating, leading to activation of the channel by a diverse range of microenvironmental chemical and physical signals utilizing a least two transduction pathways, one PKC-dependent and one PKC-independent. The convergence of multiple signals and transduction pathways on the same channel indicate that the channel functions as a molecular integrator of microenvironmental chemical and physical signals.	Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	O'Neil, RG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, 6431 Fannin, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040545] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 40545] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AnkorinaStark I, 1997, CELL CALCIUM, V21, P163, DOI 10.1016/S0143-4160(97)90040-3; Asai T, 1996, AM J PHYSIOL-HEART C, V270, pH620, DOI 10.1152/ajpheart.1996.270.2.H620; BERKOVA Z, 2003, CELL CALCIUM, V360, P1; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Colbert HA, 1997, J NEUROSCI, V17, P8259; Delany NS, 2001, PHYSIOL GENOMICS, V4, P165, DOI 10.1152/physiolgenomics.2001.4.3.165; GOA X, 2003, FASEB J, V17, pA1229; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guler AD, 2002, J NEUROSCI, V22, P6408; Gunthorpe MJ, 2002, TRENDS PHARMACOL SCI, V23, P183, DOI 10.1016/S0165-6147(02)01999-5; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hoenderop JGJ, 2002, BBA-PROTEINS PROTEOM, V1600, P6, DOI 10.1016/S1570-9639(02)00438-7; IKEDA M, 1994, KIDNEY INT, V45, P811, DOI 10.1038/ki.1994.107; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; KAWAHARA K, 1992, BIOCHEM BIOPH RES CO, V184, P198, DOI 10.1016/0006-291X(92)91178-S; Kazanietz MG, 2000, BIOCHEM PHARMACOL, V60, P1417, DOI 10.1016/S0006-2952(00)00470-6; KORBMACHER C, 1993, AM J PHYSIOL, V265, pC349, DOI 10.1152/ajpcell.1993.265.2.C349; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Liu X, 2003, FEBS LETT, V538, P101, DOI 10.1016/S0014-5793(03)00150-9; MCCARTY NA, 1991, J MEMBRANE BIOL, V123, P161, DOI 10.1007/BF01998086; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Nakamura J, 2001, CELL SIGNAL, V13, P199, DOI 10.1016/S0898-6568(01)00136-X; Nishizuka Y, 2001, ALCOHOL CLIN EXP RES, V25, p3S, DOI 10.1111/j.1530-0277.2001.tb02367.x; ONeil RG, 1997, AM J PHYSIOL-RENAL, V273, pF120, DOI 10.1152/ajprenal.1997.273.1.F120; Peier AM, 2002, SCIENCE, V296, P2046, DOI 10.1126/science.1073140; Praetorius HA, 2001, J MEMBRANE BIOL, V184, P71, DOI 10.1007/s00232-001-0075-4; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Suga S, 2001, BMC Pharmacol, V1, P3, DOI 10.1186/1471-2210-1-3; Tinel Hanna, 1997, Pfluegers Archiv European Journal of Physiology, V433, P245; Tobin DM, 2002, NEURON, V35, P307, DOI 10.1016/S0896-6273(02)00757-2; Vennekens R, 2002, CELL CALCIUM, V31, P253, DOI 10.1016/S0143-4160(02)00055-6; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; Wissenbach U, 2000, FEBS LETT, V485, P127, DOI 10.1016/S0014-5793(00)02212-2; Woda CB, 2002, AM J PHYSIOL-RENAL, V283, pF437, DOI 10.1152/ajprenal.00316.2001; Woll E, 1996, NEPHRON, V74, P150, DOI 10.1159/000189295; Xu HX, 2002, NATURE, V418, P181, DOI 10.1038/nature00882; Zhang MIN, 1996, AM J PHYSIOL-CELL PH, V271, pC1757, DOI 10.1152/ajpcell.1996.271.5.C1757; Zhang MIN, 2001, CELL CALCIUM, V29, P263, DOI 10.1054/ceca.2000.0189	44	228	246	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27129	27137		10.1074/jbc.M302517200	http://dx.doi.org/10.1074/jbc.M302517200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12738791	hybrid			2022-12-25	WOS:000184155700107
J	Jaburek, M; Garlid, KD				Jaburek, M; Garlid, KD			Reconstitution of recombinant uncoupling proteins - UCP1,-2, and-3 have similar affinities for ATP and are unaffected by coenzyme Q(10)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; TRANSPORT PROTEIN; INSULIN-SECRETION; SKELETAL-MUSCLE; BACTERIAL EXPRESSION; ENERGY-METABOLISM; ESCHERICHIA-COLI; PROTON TRANSPORT; FATTY-ACIDS; BETA-CELLS	The successful development of recombinant expression and reconstitution protocols has enabled a detailed study of the transport properties and regulation of the uncoupling proteins (UCP). We optimized conditions of isolation and refolding of bacterially expressed uncoupling proteins and reexamined the transport properties and regulation of bacterially expressed UCP1, - 2, and - 3 reconstituted in liposomes. We show for the first time that ATP inhibits UCP1, - 2, and - 3 with similar affinities. The K-i values for ATP inhibition were 50 muM (UCP1), 70 muM (UCP2), and 120 muM (UCP3) at pH 7.2. These affinities for ATP are similar to those obtained with native UCP1 isolated from brown adipose tissue mitochondria (K-i = 65 muM at pH 7.2). The V-max values for proton transport were also similar among the UCPs, ranging from 8 to 20 mumol.min(-1).mg(-1), depending on experimental conditions. We also examined the effect of coenzyme Q on fatty acid-catalyzed proton flux in liposomes containing recombinant UCP1, - 2, and - 3. We found that coenzyme Q had no effect on the fatty acid-dependent proton transport catalyzed by any of the UCPs nor did it affect nucleotide regulation of the UCPs. We conclude that coenzyme Q is not a cofactor of UCP-mediated proton transport.	Portland State Univ, Dept Biol, Portland, OR 97207 USA	Portland State University	Garlid, KD (corresponding author), Portland State Univ, Dept Biol, POB 751, Portland, OR 97207 USA.		Jabůrek, Martin/H-1114-2019; Jaburek, Martin/B-9652-2012	Jabůrek, Martin/0000-0002-4357-1116; Garlid, Keith/0000-0002-6777-1235	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056273] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56273] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Bernal-Mizrachi C, 2002, ARTERIOSCL THROM VAS, V22, P961, DOI 10.1161/01.ATV.0000019404.65403.71; Bienengraeber M, 1998, BIOCHEMISTRY-US, V37, P3, DOI 10.1021/bi972463w; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Cadenas S, 2002, J BIOL CHEM, V277, P2773, DOI 10.1074/jbc.M109736200; Chan CB, 2001, DIABETES, V50, P1302, DOI 10.2337/diabetes.50.6.1302; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Cline GW, 2001, J BIOL CHEM, V276, P20240, DOI 10.1074/jbc.M102540200; Couplan E, 2002, J BIOL CHEM, V277, P26268, DOI 10.1074/jbc.M202535200; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Echtay KS, 2001, P NATL ACAD SCI USA, V98, P1416, DOI 10.1073/pnas.98.4.1416; Echtay KS, 1999, FEBS LETT, V450, P8, DOI 10.1016/S0014-5793(99)00460-3; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Garlid KD, 1995, METHOD ENZYMOL, V260, P331, DOI 10.1016/0076-6879(95)60149-X; Garlid KD, 2001, BIOCHEM SOC T, V29, P803, DOI 10.1042/BST0290803; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Hamilton JA, 1999, DIABETES, V48, P2255, DOI 10.2337/diabetes.48.12.2255; Heimpel S, 2001, J BIOL CHEM, V276, P11499, DOI 10.1074/jbc.M010586200; Jaburek M, 2001, J BIOL CHEM, V276, P31897, DOI 10.1074/jbc.M103507200; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; JABUREK M, 2002, BIOPHYS J, V80; Jekabsons MB, 2002, BIOCHEM J, V366, P565, DOI 10.1042/BJ20020469; JEZEK P, 1994, J BIOL CHEM, V269, P26184; JEZEK P, 1990, J BIOL CHEM, V265, P19296; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KAPLAN RS, 1995, J BIOL CHEM, V270, P4108, DOI 10.1074/jbc.270.8.4108; Lameloise N, 2001, DIABETES, V50, P803, DOI 10.2337/diabetes.50.4.803; Lee FYJ, 1999, AM J PHYSIOL-CELL PH, V276, pC386, DOI 10.1152/ajpcell.1999.276.2.C386; Li LX, 2001, BIOCHEM BIOPH RES CO, V282, P273, DOI 10.1006/bbrc.2001.4577; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; OROSZ DE, 1993, ANAL BIOCHEM, V210, P7, DOI 10.1006/abio.1993.1143; RIDLEY RG, 1986, NUCLEIC ACIDS RES, V14, P4025, DOI 10.1093/nar/14.10.4025; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; SUNDIN U, 1987, AM J PHYSIOL, V252, pR822, DOI 10.1152/ajpregu.1987.252.5.R822; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; WOHLRAB H, 1994, BIOCHEMISTRY-US, V33, P9371, DOI 10.1021/bi00198a001; XU Y, 1995, BIOCHEM BIOPH RES CO, V207, P783, DOI 10.1006/bbrc.1995.1255; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	41	94	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25825	25831		10.1074/jbc.M302126200	http://dx.doi.org/10.1074/jbc.M302126200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12734183	hybrid			2022-12-25	WOS:000183920200070
J	Leimkuhler, S; Freuer, A; Araujo, JAS; Rajagopalan, KV; Mendel, RR				Leimkuhler, S; Freuer, A; Araujo, JAS; Rajagopalan, KV; Mendel, RR			Mechanistic studies of human molybdopterin synthase reaction and characterization of mutants identified in group B patients of molybdenum cofactor deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NITRATE REDUCTASE; CRYSTAL-STRUCTURE; READING FRAMES; BIOSYNTHESIS; INVOLVEMENT; GEPHYRIN; GENE; ACTIVATION; PRECURSOR	Biosynthesis of the molybdenum cofactor involves the initial formation of precursor Z, its subsequent conversion to molybdopterin (MPT) by MPT synthase, and attachment of molybdenum to the dithiolene moiety of MPT. The sulfur used for the formation of the dithiolene group of MPT exists in the form of a thiocarboxylate group at the C terminus of the smaller subunit of MPT synthase. Human MPT synthase contains the MOCS2A and MOCS2B proteins that display homology to the Escherichia coli proteins MoaD and MoaE, respectively. MOCS2A and MOCS2B were purified after heterologous expression in E. coli, and the separately purified subunits readily assemble into a functional MPT synthase tetramer. The rate of conversion of precursor Z to MPT by the human enzyme is slower than that of the eubacterial homologue. To obtain insights into the molecular mechanism leading to human molybdenum cofactor deficiency, site-specific mutations identified in patients showing symptoms of molybdenum cofactor deficiency were generated. Characterization of a V7F substitution in MOCS2A, identified in a patient with an unusual mild form of the disease, showed that the mutation weakens the interaction between MOCS2A and MOCS2B, whereas a MOCS2B-E168K mutation identified in a severely affected patient attenuates binding of precursor Z.	Tech Univ Carolo Wilhelmina Braunschweig, Dept Plant Biol, D-38023 Braunschweig, Germany; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Braunschweig University of Technology; Duke University	Leimkuhler, S (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Dept Plant Biol, D-38023 Braunschweig, Germany.			Leimkuhler, Silke/0000-0003-3238-2122				Feng GP, 1998, SCIENCE, V282, P1321, DOI 10.1126/science.282.5392.1321; GLASER JH, 1972, MOL GEN GENET, V116, P1, DOI 10.1007/BF00334254; Gray TA, 2000, RNA, V6, P928, DOI 10.1017/S1355838200000182; Gutzke G, 2001, J BIOL CHEM, V276, P36268, DOI 10.1074/jbc.M105321200; Hanzelmann P, 2002, J BIOL CHEM, V277, P18303, DOI 10.1074/jbc.M200947200; Johnson J.L, 1995, METABOLIC MOL BASES, V7th edition., P2271, DOI [10.1016/0168-9525(96)81407-7, DOI 10.1016/0168-9525(96)81407-7]; JOHNSON JL, 1989, J CLIN INVEST, V83, P897, DOI 10.1172/JCI113974; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; Johnson JL, 2001, AM J MED GENET, V104, P169, DOI 10.1002/1096-8628(20011122)104:2<169::AID-AJMG1603>3.0.CO;2-8; Johnson JL., 2001, METABOLIC MOL BASES, P3163; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; Kinsland C, 1998, PROTEIN SCI, V7, P1839, DOI 10.1002/pro.5560070821; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lake MW, 2000, J BIOL CHEM, V275, P40211, DOI 10.1074/jbc.M007406200; Leimkuhler S, 2001, J BIOL CHEM, V276, P34695, DOI 10.1074/jbc.M102787200; Leimkuhler S, 2001, J BIOL CHEM, V276, P22024, DOI 10.1074/jbc.M102072200; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; Reiss J, 2000, HUM GENET, V106, P157, DOI 10.1007/s004390051023; Reiss J, 1999, AM J HUM GENET, V64, P706, DOI 10.1086/302296; Reiss J, 2001, AM J HUM GENET, V68, P208, DOI 10.1086/316941; Rudolph MJ, 2003, J BIOL CHEM, V278, P14514, DOI 10.1074/jbc.M300449200; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P42; Stallmeyer B, 1999, AM J HUM GENET, V64, P698, DOI 10.1086/302295; Stallmeyer B, 1999, P NATL ACAD SCI USA, V96, P1333, DOI 10.1073/pnas.96.4.1333; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982; Temple CA, 2000, ARCH BIOCHEM BIOPHYS, V383, P281, DOI 10.1006/abbi.2000.2089; Wuebbens MM, 2003, J BIOL CHEM, V278, P14523, DOI 10.1074/jbc.M300453200; WUEBBENS MM, 1995, J BIOL CHEM, V270, P1082, DOI 10.1074/jbc.270.3.1082	28	48	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26127	26134		10.1074/jbc.M303092200	http://dx.doi.org/10.1074/jbc.M303092200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12732628	hybrid			2022-12-25	WOS:000183920200111
J	Masumi, A; Yamakawa, Y; Fukazawa, H; Ozato, K; Komuro, K				Masumi, A; Yamakawa, Y; Fukazawa, H; Ozato, K; Komuro, K			Interferon regulatory factor-2 regulates cell growth through its acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL COACTIVATORS P300; ADENOVIRAL ONCOPROTEIN E1A; CREB-BINDING PROTEIN/P300; HIV-1 TAT; HISTONE ACETYLTRANSFERASES; IN-VIVO; P300-MEDIATED ACETYLATION; FACTOR GATA-1; FACTOR IRF-2; DNA-BINDING	We have previously shown that interferon regulatory factor-2 (IRF-2) is acetylated by p300 and PCAF in vivo and in vitro. In this study we identified, by mass spectrometry, two lysine residues in the DNA binding domain (DBD), Lys-75 and Lys-78, to be the major acetylation sites in IRF-2. Although acetylation of IRF-2 did not alter DNA binding activity in vitro, mutation of Lys-75 diminished the IRF-2-dependent activation of histone H4 promoter activity. Acetylation of IRF-2 and IRF-2-stimulated H4 promoter activity were inhibited by the adenovirus E1A, indicating the involvement of p300/ CBP. Mutation of Lys-78, a residue conserved throughout the IRF family members, led to the abrogation of DNA binding activity independently of acetylation. H4 is transcribed only in rapidly growing cells and its promoter activity is dependent on cell growth. Consistent with a role for acetylated IRF-2 in cell growth control, IRF-2 was acetylated only in growing NIH 3T3 cells, but not in growth-arrested counterparts. Chromatin immunoprecipitation assays showed that IRF-2 interacted with p300 and bound to the endogenous H4 promoter only in growing cells, although the levels of total IRF-2 were comparable in both growing and growth-arrested cells. These results indicate that IRF-2 is acetylated in a cell growth-dependent manner, which enables it to contribute to transcription of cell growth-regulated promoters.	Natl Inst Infect Dis, Dept Safety Res Biol, Musashimurayama, Tokyo, Japan; Natl Inst Infect Dis, Dept Biochem & Cell Biol, Musashimurayama, Tokyo, Japan; Natl Inst Infect Dis, Dept Bioact Mol, Musashimurayama, Tokyo, Japan; NICHD, Lab Mol Growth & Regulat, NIH, Bethesda, MD 20892 USA	National Institute of Infectious Diseases (NIID); National Institute of Infectious Diseases (NIID); National Institute of Infectious Diseases (NIID); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Masumi, A (corresponding author), Natl Inst Infect Dis, Dept Safety Res Biol, 4-7-1 Gakuen, Musashimurayama, Tokyo, Japan.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001310] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001310] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Bannister AJ, 2000, CELL MOL LIFE SCI, V57, P1184, DOI 10.1007/PL00000758; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; Bergel M, 2000, J BIOL CHEM, V275, P11514, DOI 10.1074/jbc.275.15.11514; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Caillaud A, 2002, J BIOL CHEM, V277, P49417, DOI 10.1074/jbc.M207484200; Deng LW, 2000, VIROLOGY, V277, P278, DOI 10.1006/viro.2000.0593; Escalante CR, 1998, NATURE, V391, P103, DOI 10.1038/34224; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Herrera JE, 1999, MOL CELL BIOL, V19, P3466; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Ito T, 2000, GENE DEV, V14, P1899; Jesse TL, 1998, J CELL BIOL, V140, P1265, DOI 10.1083/jcb.140.5.1265; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kumar BRP, 2001, J BIOL CHEM, V276, P16804, DOI 10.1074/jbc.M100934200; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Li M, 2000, MOL CELL BIOL, V20, P8254, DOI 10.1128/MCB.20.21.8254-8263.2000; Liu L, 1999, MOL CELL BIOL, V19, P1202; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Luo W, 1996, J BIOL CHEM, V271, P23445, DOI 10.1074/jbc.271.38.23445; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Masumi A, 2001, J BIOL CHEM, V276, P20973, DOI 10.1074/jbc.M101707200; Masumi A, 1999, MOL CELL BIOL, V19, P1810; Mizuguchi G, 2001, J BIOL CHEM, V276, P14773, DOI 10.1074/jbc.M100125200; Nakatani Y, 2001, GENES CELLS, V6, P79, DOI 10.1046/j.1365-2443.2001.00411.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ott M, 1999, CURR BIOL, V9, P1489, DOI 10.1016/S0960-9822(00)80120-7; Paulson M, 2002, NAT CELL BIOL, V4, P140, DOI 10.1038/ncb747; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Sewack GF, 2001, MOL CELL BIOL, V21, P1404, DOI 10.1128/MCB.21.4.1404-1415.2001; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Suhara W, 2002, J BIOL CHEM, V277, P22304, DOI 10.1074/jbc.M200192200; Tamura T, 2000, IMMUNITY, V13, P155, DOI 10.1016/S1074-7613(00)00016-9; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; Vaughan PS, 1998, J BIOL CHEM, V273, P194, DOI 10.1074/jbc.273.1.194; Wang IM, 1996, MOL CELL BIOL, V16, P6313; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Weissman JD, 1998, P NATL ACAD SCI USA, V95, P11601, DOI 10.1073/pnas.95.20.11601; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	55	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25401	25407		10.1074/jbc.M213037200	http://dx.doi.org/10.1074/jbc.M213037200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12738767	hybrid			2022-12-25	WOS:000183920200019
J	Qi, C; Surapureddi, S; Zhu, YJ; Yu, ST; Kashireddy, P; Rao, MS; Reddy, JK				Qi, C; Surapureddi, S; Zhu, YJ; Yu, ST; Kashireddy, P; Rao, MS; Reddy, JK			Transcriptional coactivator PRIP, the peroxisome proliferator-activated receptor gamma (PPAR gamma)-interacting protein, is required for PPAR gamma- mediated adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; BINDING PROTEIN; EMBRYONIC-DEVELOPMENT; INTERACTING PROTEIN; TRAP220 COMPONENT; GENE-EXPRESSION; COMPLEX; ALPHA; IDENTIFICATION; COREGULATORS	Nuclear receptor coactivator PRIP ( peroxisome proliferators-activated receptor ( PPARgamma)-interacting protein) appears to serve as a linker between cAMP response element-binding protein-binding protein (CBP/ p300) anchored and PBP (PPARgamma-binding protein)-anchored coactivator complexes involved in the transcriptional activity of nuclear receptors. Disruption of PRIP and PBP genes results in embryonic lethality between embryonic day 11.5 and 12.5 (postcoitum), indicating that PRIP and PBP are essential and nonredundant coactivators. Both PRIP and PBP were initially identified as PPARgamma coactivators, suggesting a role for these molecules in PPARgamma-induced adipogenesis. PBP-/- mouse embryonic fibroblasts fail to exhibit PPARgamma-stimulated adipogenesis indicating that PBP is a downstream regulator of PPARgamma-mediated adipogenesis. We now show that PRIP-/- mouse embryonic fibroblasts are also refractory to PPARgamma-stimulated adipogenesis and fail to express adipogenic marker aP2, a PPARgamma-responsive gene. Chromatin immunoprecipitation assays reveal reduced association in PRIP-/- cells of PIMT (PRIP-binding protein) and PBP with aP2 gene promoter, suggesting that PRIP is required for the linking of CBP/p300-anchored cofactor complex with PBP-anchored mediator complex. These data indicate that PRIP, like PBP, is a downstream regulator of PPARgamma-mediated adipogenesis and that both these coactivators are required for the successful completion of adipogenic program.	Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Reddy, JK (corresponding author), Northwestern Univ, Dept Pathol, Feinberg Sch Med, 303 E Chicago Ave, Chicago, IL 60611 USA.				NATIONAL CANCER INSTITUTE [R01CA064239, R01CA084472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K08ES000356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023750, R01GM023750] Funding Source: NIH RePORTER; NCI NIH HHS [CA64239, CA84472] Funding Source: Medline; NIEHS NIH HHS [K08 ES00356] Funding Source: Medline; NIGMS NIH HHS [GM23750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonson P, 2003, MOL CELL BIOL, V23, P1260, DOI 10.1128/MCB.23.4.1260-1268.2003; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; Ge K, 2002, NATURE, V417, P563, DOI 10.1038/417563a; Glass CK, 2000, GENE DEV, V14, P121; Hihi AK, 2002, CELL MOL LIFE SCI, V59, P790, DOI 10.1007/s00018-002-8467-x; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Kuang SQ, 2002, J BIOL CHEM, V277, P45356, DOI 10.1074/jbc.C200509200; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Mahajan MA, 2000, MOL CELL BIOL, V20, P5048, DOI 10.1128/MCB.20.14.5048-5063.2000; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Misra P, 2002, J BIOL CHEM, V277, P20011, DOI 10.1074/jbc.M201739200; Mueller E, 2002, J BIOL CHEM, V277, P41925, DOI 10.1074/jbc.M206950200; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Reddy JK, 2001, ANNU REV NUTR, V21, P193, DOI 10.1146/annurev.nutr.21.1.193; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Surapureddi S, 2002, P NATL ACAD SCI USA, V99, P11836, DOI 10.1073/pnas.182426699; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 2000, J BIOL CHEM, V275, P13510, DOI 10.1074/jbc.275.18.13510; Zhu YJ, 2000, J BIOL CHEM, V275, P14779, DOI 10.1074/jbc.C000121200; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921; Zhu YJ, 2003, J BIOL CHEM, V278, P1986, DOI 10.1074/jbc.C200634200; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500; Zhu YJ, 2001, P NATL ACAD SCI USA, V98, P10380, DOI 10.1073/pnas.181347498	29	50	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25281	25284		10.1074/jbc.C300175200	http://dx.doi.org/10.1074/jbc.C300175200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12754253	hybrid			2022-12-25	WOS:000183920200003
J	Roshal, M; Kim, B; Zhu, YH; Nghiem, P; Planelles, V				Roshal, M; Kim, B; Zhu, YH; Nghiem, P; Planelles, V			Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CELL-CYCLE ARREST; YEAST SCHIZOSACCHAROMYCES-POMBE; EARLY EMBRYONIC LETHALITY; LENTIVIRAL VECTORS; GENOTOXIC STRESS; CHECKPOINT GENE; VPR ARRESTS; G2 ARREST; REPLICATION	DNA damage is a universal inducer of cell cycle arrest at the G(2) phase. Infection by the human immunodeficiency virus type 1 ( HIV-1) also blocks cellular proliferation at the G(2) phase. The HIV-1 accessory gene vpr encodes a conserved 96-amino acid protein (Vpr) that is necessary and sufficient for the HIV-1-induced block of cellular proliferation. In the present study, we examined a recently identified DNA damage-signaling protein, the ATM- and Rad3-related protein, ATR, for its potential role in the induction of G(2) arrest by Vpr. We show that inhibition of ATR by pharmacological inhibitors, by expression of the dominant-negative form of ATR, or by RNA interference inhibits Vpr-induced cell cycle arrest. As with DNA damage, activation of ATR by Vpr results in phosphorylation of Chk1. This study provides conclusive evidence of activation of the ATR-initiated DNA damage-signaling pathway by a viral gene product. These observations are important toward understanding how HIV infection promotes cell cycle disruption, cell death, and ultimately, CD4+ lymphocyte depletion.	Univ Utah, Sch Med, Dept Pathol, Div Cellular Biol & Immunol, Salt Lake City, UT 84132 USA; Univ Rochester, Ctr Canc, Dept Microbiol & Immunol, Rochester, NY 14642 USA; DNAX Res Inc, Palo Alto, CA 94304 USA; Harvard Univ, Howard Hughes Med Inst, Dept Chem & Chem Biol, Cambridge, MA 02138 USA	Utah System of Higher Education; University of Utah; University of Rochester; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Harvard University; Howard Hughes Medical Institute	Planelles, V (corresponding author), Univ Utah, Sch Med, Dept Pathol, Div Cellular Biol & Immunol, 30 N 1900 E,SOM 5C210, Salt Lake City, UT 84132 USA.	vicente.planelles@path.utah.edu	Nghiem, Paul T/A-9210-2011	Nghiem, Paul T/0000-0003-2784-963X	NIAID NIH HHS [T32AI49815, R21AI054188, R01AI49057] Funding Source: Medline; NINR NIH HHS [NR01AI49781] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI049815, R01AI049057, R21AI054188] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akkina RK, 1996, J VIROL, V70, P2581, DOI 10.1128/JVI.70.4.2581-2585.1996; An DS, 1999, J VIROL, V73, P7671, DOI 10.1128/JVI.73.9.7671-7677.1999; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bartz SR, 1996, J VIROL, V70, P2324, DOI 10.1128/JVI.70.4.2324-2331.1996; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Brown EJ, 2000, GENE DEV, V14, P397; Busby EC, 2000, CANCER RES, V60, P2108; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Davy CE, 2002, J VIROL, V76, P9806, DOI 10.1128/JVI.76.19.9806-9818.2002; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; de Noronha CMC, 2001, SCIENCE, V294, P1105, DOI 10.1126/science.1063957; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elder RT, 2001, VIROLOGY, V287, P359, DOI 10.1006/viro.2001.1007; Elder RT, 2000, VIRUS RES, V68, P161, DOI 10.1016/S0168-1702(00)00167-2; Forget J, 1998, J MOL BIOL, V284, P915, DOI 10.1006/jmbi.1998.2206; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Hrimech M, 1999, J VIROL, V73, P4101, DOI 10.1128/JVI.73.5.4101-4109.1999; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Jordan M. A., 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P1, DOI 10.2174/1568011023354290; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; Luo Y, 2001, ANTICANCER RES, V21, P23; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Masuda M, 2000, J VIROL, V74, P2636, DOI 10.1128/JVI.74.6.2636-2646.2000; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; Nghiem P, 2002, J BIOL CHEM, V277, P4428, DOI 10.1074/jbc.M106113200; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; Planelles V, 1996, J VIROL, V70, P2516, DOI 10.1128/JVI.70.4.2516-2524.1996; Poggioli GJ, 2000, J VIROL, V74, P9562, DOI 10.1128/JVI.74.20.9562-9570.2000; Poon B, 1997, J VIROL, V71, P3961, DOI 10.1128/JVI.71.5.3961-3971.1997; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; Roos-Mattjus P, 2002, J BIOL CHEM, V277, P43809, DOI 10.1074/jbc.M207272200; Shostak LD, 1999, EXP CELL RES, V251, P156, DOI 10.1006/excr.1999.4568; Smith GCM, 1999, BIOCHEM SOC SYMP, P91; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Vanitharani R, 2001, VIROLOGY, V289, P334, DOI 10.1006/viro.2001.1153; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walworth NC, 2000, CURR OPIN CELL BIOL, V12, P697, DOI 10.1016/S0955-0674(00)00154-X; Westphal CH, 1997, CURR BIOL, V7, pR789, DOI 10.1016/S0960-9822(06)00406-4; Wrzesinski S, 2000, AIDS RES HUM RETROV, V16, P1771, DOI 10.1089/08892220050193290; Zhang SG, 1998, GENE, V212, P157, DOI 10.1016/S0378-1119(98)00178-4; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhu YH, 2001, MOL THER, V4, P375, DOI 10.1006/mthe.2001.0469; Zhu YH, 2001, J VIROL, V75, P3791, DOI 10.1128/JVI.75.8.3791-3801.2001; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	57	168	177	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25879	25886		10.1074/jbc.M303948200	http://dx.doi.org/10.1074/jbc.M303948200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12738771	hybrid			2022-12-25	WOS:000183920200078
J	Wang, YH; Tsay, YG; Tan, BCM; Lo, WY; Lee, SC				Wang, YH; Tsay, YG; Tan, BCM; Lo, WY; Lee, SC			Identification and characterization of a novel p300-mediated p53 acetylation site, lysine 305	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; TERMINAL DOMAIN; NUCLEAR IMPORT; MDM2; PHOSPHORYLATION; TRANSCRIPTION; KINASE; DEGRADATION; ACTIVATION; APOPTOSIS	Post-translational modifications serve as important regulatory elements in modulating the transcriptional activity of the tumor suppressor protein p53. We have previously reported a tandem mass spectrometry-based method (viz. selected ion tracing analysis) that can be applied to the identification of phosphopeptides as well as exact mapping of the phosphorylated residues within. In this study, we describe the application of the same strategy for the identification of p300 acetyltransferase-mediated acetylation sites on p53. Consistent with the previous finding, lysines 370, 372, 373, 381, and 382 were detected by this modified selected ion tracing method as the target sites of p300 in vitro. Moreover, two novel acetylation sites, Lys-292 and Lys-305, were also found. Immunoblotting using anti-acetyl-Lys-305 antibody confirmed this discovery and demonstrated that Lys-305 could be acetylated by p300 both in vitro and in vivo. We also show that an alanine or glutamine substitution at Lys-305 (K305A or K305Q) suppressed the transcriptional activity of p53, whereas an arginine mutation (K305R) increased the transcriptional activity. Thus, p300 may further regulate the transcriptional activity of p53 through a novel acetylation site, Lys-305.	Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei 10018, Taiwan; Natl Taiwan Univ, Coll Med, Inst Clin Med, Taipei 10018, Taiwan; Acad Sinica, Inst Biol Chem, Taipei, Taiwan	National Taiwan University; National Taiwan University; Academia Sinica - Taiwan	Lee, SC (corresponding author), Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei 10018, Taiwan.		Tsay, Yeou-Guang/HGE-2076-2022; Wang, Yan-Hsiung/ABD-4004-2020	Wang, Yan-Hsiung/0000-0001-8161-7472; Tan, Bertrand/0000-0002-2218-7115				Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Blaydes JP, 2001, J BIOL CHEM, V276, P4699, DOI 10.1074/jbc.M003485200; Chiu CM, 2002, J BIOL CHEM, V277, P39102, DOI 10.1074/jbc.M205915200; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DESAINTES C, 1995, ONCOGENE, V10, P2155; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Harwood FG, 1996, ONCOGENE, V12, P2057; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Kim IS, 2000, J BIOL CHEM, V275, P23139, DOI 10.1074/jbc.M909256199; Kishi H, 2001, J BIOL CHEM, V276, P39115, DOI 10.1074/jbc.M105134200; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Miau LH, 1997, MOL CELL BIOL, V17, P230, DOI 10.1128/MCB.17.1.230; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Sambrook J., 2002, MOL CLONING LAB MANU; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Tsay YG, 2000, ANAL BIOCHEM, V287, P55, DOI 10.1006/abio.2000.4837; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; WANG L, 1995, J BIOL CHEM, V270, P23159, DOI 10.1074/jbc.270.39.23159; Zhou P, 1999, EMBO J, V18, P1182, DOI 10.1093/emboj/18.5.1182	36	69	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25568	25576		10.1074/jbc.M212574200	http://dx.doi.org/10.1074/jbc.M212574200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12724314	hybrid			2022-12-25	WOS:000183920200038
J	Wu, CL; Wu, F; Pan, JL; Morser, J; Wu, QY				Wu, CL; Wu, F; Pan, JL; Morser, J; Wu, QY			Furin-mediated processing of pro-C-type natriuretic peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SERINE-PROTEASE; PORCINE BRAIN; HEART; INHIBITION; ACTIVATION; DISEASE; FAMILY; CORIN; CNP	C-type natriuretic peptide (CNP) is a member of the natriuretic peptide family that is involved in a variety of homeostatic processes. Here we characterize the processing essential for the conversion of the precursor, human pro-CNP, to the biologically active hormone. In human embryonic kidney 293 and chondrosarcoma SW 1353 cells, recombinant pro-CNP was converted into a mature peptide intracellularly as detected by Western analysis. Expression of recombinant human corin, a proatrial natriuretic peptide convertase, did not enhance the processing of pro-CNP in these cells. The processing of pro-CNP was inhibited in the presence of an inhibitor of the endoprotease furin but was not affected by inhibitors of matrix metalloproteinases and tumor necrosis factor-alpha convertase. In furin-deficient human colon adenocarcinoma LoVo cells, no conversion of recombinant pro-CNP to CNP was detected. Expression of recombinant human furin in LoVo cells restored the ability of these cells to process pro-CNP. Furthermore, incubation of purified recombinant human furin with LoVo cell lysate containing pro-CNP led to the conversion of the precursor to a mature peptide. The furin-processed CNP was shown to be biologically active in a cell-based cGMP assay. These results demonstrate that furin is a critical enzyme for the processing of human pro-CNP.	Berlex Biosci, Dept Cardiovasc Res, Richmond, CA 94804 USA; Jiangsu Inst Hematol, Suzhou 215006, Jiangsu, Peoples R China		Wu, QY (corresponding author), 26 Hilltop Dr, Richmond, CA 94804 USA.			Wu, Qingyu/0000-0003-0561-9315				Abbey SE, 2002, J BIOL CHEM, V277, P42423, DOI 10.1074/jbc.M206686200; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; Bodo I, 2001, BLOOD, V98, P2973, DOI 10.1182/blood.V98.10.2973; BROWN J, 1992, AM J PHYSIOL, V263, pH1318; CHRISMAN TD, 1993, J BIOL CHEM, V268, P3698; Chusho H, 2001, P NATL ACAD SCI USA, V98, P4016, DOI 10.1073/pnas.071389098; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; DEBOLD AJ, 1985, SCIENCE, V230, P767, DOI 10.1126/science.2932797; Do H, 2002, J BIOL CHEM, V277, P29737, DOI 10.1074/jbc.M202369200; FURUYA M, 1991, BIOCHEM BIOPH RES CO, V177, P927, DOI 10.1016/0006-291X(91)90627-J; GARTEN W, 1989, VIROLOGY, V172, P25, DOI 10.1016/0042-6822(89)90103-7; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; Hutchinson HG, 1997, CARDIOVASC RES, V35, P158, DOI 10.1016/S0008-6363(97)00086-2; INAGAMI T, 1989, J BIOL CHEM, V264, P3043; KOLLER KJ, 1992, CIRCULATION, V86, P1081, DOI 10.1161/01.CIR.86.4.1081; KOMATSU Y, 1991, ENDOCRINOLOGY, V129, P1104, DOI 10.1210/endo-129-2-1104; Levin ER, 1998, NEW ENGL J MED, V339, P321; MINAMINO N, 1991, BIOCHEM BIOPH RES CO, V179, P535, DOI 10.1016/0006-291X(91)91404-Z; MINAMINO N, 1990, BIOCHEM BIOPH RES CO, V170, P973, DOI 10.1016/0006-291X(90)92187-5; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Park HI, 2002, J BIOL CHEM, V277, P35168, DOI 10.1074/jbc.M205071200; Prickett TCR, 2001, BIOCHEM BIOPH RES CO, V286, P513, DOI 10.1006/bbrc.2001.5419; QU Q, 2003, CURR TOP DEV BIOL, V54, P167; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; SHINOMIYA M, 1994, BIOCHEM BIOPH RES CO, V205, P1051, DOI 10.1006/bbrc.1994.2772; Stein B, 1998, AM HEART J, V135, P914, DOI 10.1016/S0002-8703(98)70054-7; STEINER DF, 1992, J BIOL CHEM, V267, P23435; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUGA S, 1992, J CLIN INVEST, V90, P1145, DOI 10.1172/JCI115933; TAKAHASHI S, 1995, J BIOL CHEM, V270, P26565, DOI 10.1074/jbc.270.44.26565; TAWARAGI Y, 1991, BIOCHEM BIOPH RES CO, V175, P645, DOI 10.1016/0006-291X(91)91614-I; Ueno H, 1997, CIRCULATION, V96, P2272; VOLLMAR AM, 1993, ENDOCRINOLOGY, V132, P1872, DOI 10.1210/en.132.4.1872; Wilkins MR, 1997, LANCET, V349, P1307, DOI 10.1016/S0140-6736(96)07424-7; Wu F, 2002, J BIOL CHEM, V277, P16900, DOI 10.1074/jbc.M201503200; Yan W, 1999, J BIOL CHEM, V274, P14926, DOI 10.1074/jbc.274.21.14926; Yan W, 2000, P NATL ACAD SCI USA, V97, P8525, DOI 10.1073/pnas.150149097; YANDLE TG, 1993, PEPTIDES, V14, P713, DOI 10.1016/0196-9781(93)90102-M; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	40	153	166	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25847	25852		10.1074/jbc.M301223200	http://dx.doi.org/10.1074/jbc.M301223200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12736257	hybrid			2022-12-25	WOS:000183920200073
J	Hundal, RS; Gomez-Munoz, A; Kong, JY; Salh, BS; Marotta, A; Duronio, V; Steinbrecher, UP				Hundal, RS; Gomez-Munoz, A; Kong, JY; Salh, BS; Marotta, A; Duronio, V; Steinbrecher, UP			Oxidized low density lipoprotein inhibits macrophage apoptosis by blocking ceramide generation, thereby maintaining protein kinase B activation and Bcl-X-L levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; COLONY-STIMULATING FACTOR; HUMAN ENDOTHELIAL-CELLS; MOUSE PERITONEAL-MACROPHAGES; SMOOTH-MUSCLE CELLS; FACTOR-KAPPA-B; LYSOSOMAL SPHINGOMYELINASE; ATHEROSCLEROTIC PLAQUES; MONOCYTE-MACROPHAGES; INDUCE APOPTOSIS	Macrophages play a central role in the development and progression of atherosclerotic lesions. It is well known that oxidized low density lipoprotein (ox-LDL) promotes the recruitment of monocytes (which differentiate to macrophages) into the intima. We reported recently that ox-LDL blocks apoptosis in bone marrow-derived macrophages deprived of macrophage colony-stimulating factor (M-CSF) by a mechanism involving protein kinase B (PKB) (Hundal, R., Salh, B., Schrader, J., Gomez-Munoz, A., Duronio, V., and Steinbrecher, U. (2001) J. Lipid Res. 42, 1483-1491). The aims of the present study were 1) to define the apoptotic pathway involved in the pro-survival effect of ox-LDL; 2) to determine which PKB target mediated this effect; and 3) to identify mechanisms responsible for PKB activation by ox-LDL. Apoptosis following M-CSF withdrawal was accompanied by activation of the caspase 9-caspase 3 cascade and cytochrome c release from mitochondria, but the caspase 8 pathway was unaffected. M-CSF withdrawal resulted in a marked and selective reduction in Bcl-X-L protein and mRNA levels, and this decrease was prevented by ox-LDL. The ability of ox-LDL to preserve Bcl-X-L levels was blocked by NFkappaB antagonists, thereby implicating IkappaB kinase as a key PKB target. M-CSF deprivation resulted in activation of acid sphingomyelinase and an increase in ceramide levels. Desipramine ( a sphingomyelinase inhibitor) prevented the increase in ceramide and inhibited apoptosis after M-CSF deprivation. Ox-LDL completely blocked the increase in acid sphingomyelinase activity as well as the increase in ceramide after M-CSF deprivation. Pretreatment of macrophages with C-2-ceramide reversed the effect of ox-LDL on PKB and macrophage survival. These results indicate that ox-LDL prevents apoptosis in M-CSF-deprived macrophages at least in part by inhibiting acid sphingomyelinase. This in turn prevents ceramide-induced down-regulation of PKB, the activity of which is required to maintain production of Bcl-X-L.	Univ British Columbia, Dept Med, Div Gastroenterol, Vancouver, BC V5Z 3P1, Canada; Univ Basque Country, Dept Biochem & Mol Biol, Bilbao 48080, Spain	University of British Columbia; University of Basque Country	Steinbrecher, UP (corresponding author), Univ British Columbia, Dept Med, Div Gastroenterol, 100-2647 Willow St, Vancouver, BC V5Z 3P1, Canada.			Kong, Jennifer/0000-0003-4571-3330; GOMEZ MUNOZ, ANTONIO/0000-0002-2539-016X				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Asmis R, 1998, EUR J BIOCHEM, V255, P147, DOI 10.1046/j.1432-1327.1998.2550147.x; Bachem MG, 1999, CLIN CHEM LAB MED, V37, P319, DOI 10.1515/CCLM.1999.054; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; Bielawska A, 2001, ANAL BIOCHEM, V298, P141, DOI 10.1006/abio.2001.5342; Biwa T, 1998, J BIOL CHEM, V273, P28305, DOI 10.1074/jbc.273.43.28305; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BROWN DL, 1995, CIRCULATION, V91, P2125, DOI 10.1161/01.CIR.91.8.2125; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Dimmeler S, 1997, CIRCULATION, V95, P1760; Escargueil-Blanc I, 1998, J BIOL CHEM, V273, P27389, DOI 10.1074/jbc.273.42.27389; EscargueilBlanc I, 1997, ARTERIOSCL THROM VAS, V17, P331, DOI 10.1161/01.ATV.17.2.331; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Farber A, 1999, J SURG RES, V85, P323, DOI 10.1006/jsre.1999.5663; GALIS ZS, 1995, ANN NY ACAD SCI, V748, P501; GALIS ZS, 1995, FASEB J, V9, P974, DOI 10.1096/fasebj.9.10.7615167; GALIS ZS, 1995, P NATL ACAD SCI USA, V92, P402, DOI 10.1073/pnas.92.2.402; Galle J, 1999, KIDNEY INT, V55, P1450, DOI 10.1046/j.1523-1755.1999.00351.x; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hamilton JA, 1999, ARTERIOSCL THROM VAS, V19, P98, DOI 10.1161/01.ATV.19.1.98; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Harada-Shiba M, 1998, J BIOL CHEM, V273, P9681, DOI 10.1074/jbc.273.16.9681; Hardwick SJ, 1996, J PATHOL, V179, P294; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Higuchi M, 1996, J IMMUNOL, V157, P297; HOPPE G, 1994, J CLIN INVEST, V94, P1506, DOI 10.1172/JCI117490; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Hundal RS, 2001, J LIPID RES, V42, P1483; HURWITZ R, 1994, BIOL CHEM H-S, V375, P447, DOI 10.1515/bchm3.1994.375.7.447; Jaworowski A, 1999, J BIOL CHEM, V274, P15127, DOI 10.1074/jbc.274.21.15127; KATSUDA S, 1993, AM J PATHOL, V142, P1787; Kelley TW, 1999, J BIOL CHEM, V274, P26393, DOI 10.1074/jbc.274.37.26393; Kinscherf R, 1998, FASEB J, V12, P461, DOI 10.1096/fasebj.12.6.461; Kockx MM, 1998, ARTERIOSCL THROM VAS, V18, P1519, DOI 10.1161/01.ATV.18.10.1519; Kockx MM, 1998, CIRC RES, V83, P378, DOI 10.1161/01.RES.83.4.378; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; LI D, 1998, AM J PHYSIOL, V275, P568; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu B, 2000, METHOD ENZYMOL, V311, P164; LOUGHEED M, 1991, J BIOL CHEM, V266, P14519; MAOR I, 1995, ARTERIOSCL THROM VAS, V15, P1378, DOI 10.1161/01.ATV.15.9.1378; Martens JS, 1999, J BIOL CHEM, V274, P10903, DOI 10.1074/jbc.274.16.10903; Martens JS, 1998, J BIOL CHEM, V273, P4915, DOI 10.1074/jbc.273.9.4915; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nishio E, 1996, BIOCHEM BIOPH RES CO, V223, P413, DOI 10.1006/bbrc.1996.0907; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; ONeil J, 1997, FREE RADICAL BIO MED, V23, P215, DOI 10.1016/S0891-5849(96)00612-0; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; REID VC, 1993, FEBS LETT, V332, P218, DOI 10.1016/0014-5793(93)80635-8; REKHTER MD, 1995, AM J PATHOL, V147, P668; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SAKAI M, 1994, J BIOL CHEM, V269, P31430; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; SAMBRANO GR, 1994, P NATL ACAD SCI USA, V91, P3265, DOI 10.1073/pnas.91.8.3265; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; Sata M, 1998, J CLIN INVEST, V102, P1682, DOI 10.1172/JCI3531; Shiratsuchi A, 1998, BIOCHEM BIOPH RES CO, V246, P549, DOI 10.1006/bbrc.1998.8663; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; Sukhova GK, 1999, CIRCULATION, V99, P2503, DOI 10.1161/01.CIR.99.19.2503; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; YUI S, 1993, ARTERIOSCLER THROMB, V13, P331, DOI 10.1161/01.ATV.13.3.331; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	70	84	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24399	24408		10.1074/jbc.M209179200	http://dx.doi.org/10.1074/jbc.M209179200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12750385	hybrid			2022-12-25	WOS:000183824800021
J	Baba, M; Hirai, S; Yamada-Okabe, H; Hamada, K; Tabuchi, H; Kobayashi, K; Kondo, K; Yoshida, M; Yamashita, A; Kishida, T; Nakaigawa, N; Nagashima, Y; Kubota, Y; Yao, M; Ohno, S				Baba, M; Hirai, S; Yamada-Okabe, H; Hamada, K; Tabuchi, H; Kobayashi, K; Kondo, K; Yoshida, M; Yamashita, A; Kishida, T; Nakaigawa, N; Nagashima, Y; Kubota, Y; Yao, M; Ohno, S			Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through Hypoxia-inducible factor	ONCOGENE			English	Article						VHL; tumor suppressor; contact inhibition; renal cell carcinoma; cyclinDl; HIF	TUMOR-SUPPRESSOR GENE; TRANSFORMING-GROWTH-FACTOR; RENAL-CARCINOMA CELLS; UBIQUITIN LIGASE; HIF-ALPHA; G1 PHASE; VHL; CYCLE; COMPLEX; FIBROBLASTS	Loss of the von Hippel-Lindau gene (VHL) expression causes deregulation of contact inhibition of cell growth, which might be one of the bases of the tumor suppressor function of VHL. Here we show that this function of the VHL gene product (pVHL) depends on cell autonomous events. To identify the target gene of pVHL, which is directly involved in the contact inhibition, we compared the gene expression profile between VHL-deficient renal carcinoma 786-O cells and those infected with an adenovirus vector encoding VHL. In addition to known pVHL-regulated genes, such as vascular endothelial growth factor and carbonic anhydrase, we found cyclinD1 as a new target of pVHL at a high cell density. In VHL-expressing cells (VHL (+) cells), the cyclinD1 mRNA expression level diminishes at a high cell density, while it remains at a relatively high level in VHL-deficient cells (VHL (-) cells). The cyclinD1 expression level was also abnormally high in VHL (-) cells at a high cell density. Consequently, the phosporylation level of the retinoblastoma (Rb) protein remained high in these cells, whereas there was no phosporylated Rb in VHL (+) cells under the contact inhibition. The abnormal expression of cyctinD1 at a high cell density was observed even in VHL (+) cells under the hypoxic state. Moreover, ectopic expression of a HIF mutant resistant to pVHL-mediated proteolysis causes the abnormal cyclinD1 expression in VHL (+) cells. Taken together, these observations indicate that VHL is required for the downregulation of cyclinD1 at a high cell density through HIF.	Yokohama City Univ, Sch Med, Dept Mol Biol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Urol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Pathol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Chugai Res Ctr, Pharmacol Res Dept 4, Kamakura, Kanagawa 2473590, Japan	Yokohama City University; Yokohama City University; Yokohama City University; Chugai Pharmaceutical Co., Ltd.	Hirai, S (corresponding author), Yokohama City Univ, Sch Med, Dept Mol Biol, Kanazawa Ku, 3-9 Fuko Ura, Yokohama, Kanagawa 2360004, Japan.		Baba, Masaya/ABE-4893-2020; Ohno, Shigeo/B-1768-2010; Baba, Masaya/L-7490-2013; Nagashima, Yoji/AAA-2591-2021	Ohno, Shigeo/0000-0002-1294-5269; Baba, Masaya/0000-0002-5308-6683; 				Baba M, 2001, ONCOGENE, V20, P2727, DOI 10.1038/sj.onc.1204397; Bindra RS, 2002, CANCER RES, V62, P3014; de Paulsen N, 2001, P NATL ACAD SCI USA, V98, P1387, DOI 10.1073/pnas.031587498; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; Iizuka N, 2002, CANCER RES, V62, P3939; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Izumi Y, 1997, J BIOL CHEM, V272, P7381, DOI 10.1074/jbc.272.11.7381; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jacobsen K, 2002, ONCOGENE, V21, P3058, DOI 10.1038/sj.onc.1205423; JIANG W, 1993, ONCOGENE, V8, P3447; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Knebelmann B, 1998, CANCER RES, V58, P226; Kondo K, 2001, EXP CELL RES, V264, P117, DOI 10.1006/excr.2000.5139; Kondo K, 2002, GENE CHROMOSOME CANC, V34, P58, DOI 10.1002/gcc.10054; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; PAPADIMITRIOU E, 1993, J IMMUNOL METHODS, V162, P41, DOI 10.1016/0022-1759(93)90405-V; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Sellers WR, 1996, BBA-REV CANCER, V1288, pM1, DOI 10.1016/0304-419X(96)00014-5; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHUIN T, 1994, CANCER RES, V54, P2852; Siemeister G, 1996, CANCER RES, V56, P2299; Vinals F, 1999, MOL CELL BIOL, V19, P2763; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; Yao M, 2002, JNCI-J NATL CANCER I, V94, P1569; Zatyka M, 2002, CANCER RES, V62, P3803	43	77	80	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2728	2738		10.1038/sj.onc.1206373	http://dx.doi.org/10.1038/sj.onc.1206373			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743597				2022-12-25	WOS:000182569300004
J	Kamsteeg, M; Rutherford, T; Sapi, E; Hanczaruk, B; Shahabi, S; Flick, M; Brown, D; Mor, G				Kamsteeg, M; Rutherford, T; Sapi, E; Hanczaruk, B; Shahabi, S; Flick, M; Brown, D; Mor, G			Phenoxodiol - an isoflavone analog - induces apoptosis in chemoresistant ovarian cancer cells	ONCOGENE			English	Article						phenoxodiol; apoptosis; XIAP; ovarian cancer; Fas	FAS/FAS-LIGAND SYSTEM; FAS-MEDIATED APOPTOSIS; CD95-MEDIATED APOPTOSIS; SIGNALING COMPLEX; TUMOR-CELLS; C-FLIP; DEATH; EXPRESSION; ESTROGEN; INHIBITION	Interference with the innate apoptotic activity is a hallmark of neoplastic transformation and tumor formation. In this study we characterize the cytotoxic effect of phenoxodiol, a synthetic anticancer drug analog of genestein, and demonstrate the mechanism of action by which phenoxodiol affects the components of the Fas apoptotic pathway on ovarian cancer cells. Primary ovarian cancer cells, isolated from ascitic fluids of ovarian cancer patients, resistant to conventional chemotherapy, undergo apoptosis following phenoxodiol treatment. This effect is dependent upon the activation of the caspase system, inhibiting XIAP, an inhibitor of apoptosis, and disrupting FLICE inhibitory protein (FLIP) expression through the Akt signal transduction pathway. We suggest that phenoxodiol is an efficient inducer of cell death in ovarian cancer cells and sensitizes the cancer cells to Fas-mediated apoptosis. We identified FLIP and XIAP signalling pathways as key factors regulating the survival of ovarian cancer cells. These findings demonstrate a novel nontoxic drug that controls FLIP/XIAP function and has the potential to eliminate tumor cells through Fas-mediated apoptosis.	Yale Univ, Sch Med, Dept Obstet & Gynecol, New Haven, CT 06520 USA	Yale University	Mor, G (corresponding author), Yale Univ, Sch Med, Dept Obstet & Gynecol, 333 Cedar St, New Haven, CT 06520 USA.		Kamsteeg, M./L-4422-2015		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037137] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA092435] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA92435-01] Funding Source: Medline; NICHD NIH HHS [R01 HD37137-01A2] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aschkenazi S, 2002, BIOL REPROD, V66, P1853, DOI 10.1095/biolreprod66.6.1853; Baldwin RL, 1999, GYNECOL ONCOL, V74, P265, DOI 10.1006/gyno.1999.5448; BERCHUCK A, 1994, J SOC GYNECOL INVEST, V1, P181, DOI 10.1177/107155769400100302; Constantinou AI, 2002, ANTICANCER RES, V22, P2581; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; FLICK M, UNPUB; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; GREENE MH, 1984, SEMIN ONCOL, V11, P209; Gutierrez LS, 1999, BREAST CANCER RES TR, V54, P245, DOI 10.1023/A:1006102601215; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HUGHES FM, 1991, ENDOCRINOLOGY, V129, P2415, DOI 10.1210/endo-129-5-2415; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Lamartiniere CA, 1998, P SOC EXP BIOL MED, V217, P358, DOI 10.3181/00379727-217-44245; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Mor G, 2002, BIOCHEM PHARMACOL, V64, P1305, DOI 10.1016/S0006-2952(02)01267-4; Mor G, 2001, AM J REPROD IMMUNOL, V46, P298, DOI 10.1034/j.1600-0897.2001.d01-16.x; Mori T, 1997, HORM RES, V48, P11, DOI 10.1159/000191295; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; ODWYER PJ, 1994, CANCER RES, V54, P724; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Peter M E, 1999, Results Probl Cell Differ, V23, P25; Quirk SM, 1997, ENDOCRINOLOGY, V138, P4558, DOI 10.1210/en.138.11.4558; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Rohn JL, 1998, ONCOGENE, V17, P2811, DOI 10.1038/sj.onc.1202393; Roughton SA, 1999, BIOL REPROD, V60, P797, DOI 10.1095/biolreprod60.4.797; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sapi E, 2002, J SOC GYNECOL INVEST, V9, P243, DOI 10.1016/S1071-5576(02)00162-4; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Song J, 2000, J CLIN INVEST, V106, P1209, DOI 10.1172/JCI10411; Song J, 2002, MOL HUM REPROD, V8, P447, DOI 10.1093/molehr/8.5.447; Song RXD, 2001, J NATL CANCER I, V93, P1714, DOI 10.1093/jnci/93.22.1714; Suhara T, 2001, CIRC RES, V89, P13, DOI 10.1161/hh1301.092506; Tilly J L, 1996, Rev Reprod, V1, P162, DOI 10.1530/revreprod/1.3.162; Tilly JL, 2001, NAT REV MOL CELL BIO, V2, P838, DOI 10.1038/35099086; Weber G, 2000, EUR J GYNAECOL ONCOL, V21, P231; Xerri L, 1997, J CLIN PATHOL-MOL PA, V50, P87, DOI 10.1136/mp.50.2.87	42	160	174	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2611	2620		10.1038/sj.onc.1206422	http://dx.doi.org/10.1038/sj.onc.1206422			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730675				2022-12-25	WOS:000182569000009
J	Phlippen, N; Hoffmann, K; Fischer, R; Wolf, K; Zimmermann, M				Phlippen, N; Hoffmann, K; Fischer, R; Wolf, K; Zimmermann, M			The glutathione synthetase of Schizosaccharomyces pombe is synthesized as a homodimer but retains full activity when present as a heterotetramer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR PERMUTATION; FISSION YEAST; ARABIDOPSIS-THALIANA; PROTEIN; GENE; PURIFICATION; CLONING; GSH2; COMPLEMENTATION; PHYTOCHELATINS	Glutathione synthetase was overexpressed as a histidine-tagged protein in Schizosaccharomyces pombe and purified by two-step affinity chromatography. The recovered enzyme occurred in two different forms: a homodimeric protein consisting of two identical 56-kDa subunits and a heterotetrameric protein composed of two 32-kDa and two 24-kDa subfragments. Both forms are encoded by the GSH2 gene. The 56-Da protein corresponds to the complete GSH2 open reading frame, while the subfragments are produced following the cleavage of this larger protein by a metalloprotease. A stable homodimer was obtained by site-directed mutagenesis to remove the protease cleavage site, and this showed normal activity. A structural model of the fission yeast glutathione synthetase was produced, based on the x-ray coordinates of the human enzyme. According to this model the interacting domains of the proteolytic subfragments are strongly entangled. The subfragments were therefore coexpressed as independent proteins. These subfragments assembled correctly to yield functional heterotetramers with equivalent activity to the wild type enzyme. Furthermore, a permuted version of the protein was created. This also showed normal levels of glutathione synthetase activity. These data provide novel insight into the mechanisms of protein folding and the structure and evolution of the glutathione synthetase family.	Univ Aachen, Inst Biol Microbiol & Genet 4, D-52056 Aachen, Germany; Univ Aachen, Inst Biol Mol Biotechnol 7, D-52056 Aachen, Germany	RWTH Aachen University; RWTH Aachen University	Zimmermann, M (corresponding author), Univ Aachen, Inst Biol Microbiol & Genet 4, Worringer Weg, D-52056 Aachen, Germany.	Martin.Zimmermann@rwthaachen.de	Hoffmann, Kurt/P-2539-2014	Hoffmann, Kurt/0000-0002-7991-423X				Al-Lahham A, 1999, YEAST, V15, P385, DOI 10.1002/(SICI)1097-0061(19990330)15:5<385::AID-YEA382>3.0.CO;2-6; Anderson ME, 1998, CHEM-BIOL INTERACT, V112, P1; Ausubel FM, 1991, CURRENT PROTOCOLS MO; Basharov MA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P1380, DOI 10.1023/A:1002800822475; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cheltsov AV, 2001, J BIOL CHEM, V276, P19141, DOI 10.1074/jbc.M100329200; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; FAN C, 1995, P NATL ACAD SCI USA, V92, P1172, DOI 10.1073/pnas.92.4.1172; FIGUEIREDO E, 1994, BIOCHEM J, V300, P15, DOI 10.1042/bj3000015; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; GRILL E, 1985, SCIENCE, V230, P674, DOI 10.1126/science.230.4726.674; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HOCHSTENBACH F, 1997, FISSION YEAST HDB; HUANG CS, 1995, P NATL ACAD SCI USA, V92, P1232, DOI 10.1073/pnas.92.4.1232; Inoue Y, 1998, BBA-GENE STRUCT EXPR, V1395, P315, DOI 10.1016/S0167-4781(97)00199-1; Iwakura M, 2000, NAT STRUCT BIOL, V7, P580, DOI 10.1038/76811; Jeltsch A, 1999, J MOL EVOL, V49, P161, DOI 10.1007/PL00006529; JENO P, 1995, ANAL BIOCHEM, V224, P75, DOI 10.1006/abio.1995.1010; Jung J, 2001, PROTEIN SCI, V10, P1881, DOI 10.1110/ps.05801; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee J, 1997, J BIOL CHEM, V272, P23042, DOI 10.1074/jbc.272.37.23042; Lindqvist Y, 1997, CURR OPIN STRUC BIOL, V7, P422, DOI 10.1016/S0959-440X(97)80061-9; LUGER K, 1989, SCIENCE, V243, P206, DOI 10.1126/science.2643160; Lund PA, 2001, ADV MICROB PHYSIOL, V44, P93, DOI 10.1016/S0065-2911(01)44012-4; MAJERUS PW, 1971, J CLIN INVEST, V50, P1637, DOI 10.1172/JCI106652; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MEISTER A, 1985, METHOD ENZYMOL, V113, P393; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MOOZ ED, 1967, BIOCHEMISTRY-US, V6, P1722, DOI 10.1021/bi00858a022; MUTOH N, 1991, BIOCHEM BIOPH RES CO, V181, P430, DOI 10.1016/S0006-291X(05)81437-8; NAKAGAWA CW, 1993, BIOCHEM CELL BIOL, V71, P447, DOI 10.1139/o93-066; Nakamura T, 1999, J BIOL CHEM, V274, P19041, DOI 10.1074/jbc.274.27.19041; Nasim A., 1989, MOL BIOL FISSION YEA; Nok AJ, 2001, J BIOCHEM MOL TOXIC, V15, P215, DOI 10.1002/jbt.19.abs; Penninckx M, 2000, ENZYME MICROB TECH, V26, P737, DOI 10.1016/S0141-0229(00)00165-4; Polekhina G, 1999, EMBO J, V18, P3204, DOI 10.1093/emboj/18.12.3204; Ponting CP, 2002, ANNU REV BIOPH BIOM, V31, P45, DOI 10.1146/annurev.biophys.31.082901.134314; Russell RB, 1998, CURR OPIN STRUC BIOL, V8, P364, DOI 10.1016/S0959-440X(98)80071-7; Sabeur K, 2001, REPRODUCTION, V122, P139, DOI 10.1530/reprod/122.1.139; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sookkheo B, 2000, PROTEIN EXPRES PURIF, V20, P142, DOI 10.1006/prep.2000.1282; Ullmann P, 1996, EUR J BIOCHEM, V236, P662, DOI 10.1111/j.1432-1033.1996.00662.x; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Wang CL, 1997, BIOCHEM J, V326, P563, DOI 10.1042/bj3260563; Wang CL, 1996, PLANT MOL BIOL, V31, P1093, DOI 10.1007/BF00040827; WUNDERLICH C, 1999, THESIS AACHEN U AACH; YAMAGUCHI H, 1993, J MOL BIOL, V229, P1083, DOI 10.1006/jmbi.1993.1106	48	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40152	40161		10.1074/jbc.M303102200	http://dx.doi.org/10.1074/jbc.M303102200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12734194	hybrid			2022-12-25	WOS:000185713800108
J	Cowart, LA; Okamoto, Y; Pinto, FR; Gandy, JL; Almeida, JS; Hannun, YA				Cowart, LA; Okamoto, Y; Pinto, FR; Gandy, JL; Almeida, JS; Hannun, YA			Roles for sphingolipid biosynthesis in mediation of specific programs of the heat stress response determined through gene expression profiling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; TOR-SIGNALING PATHWAY; SACCHAROMYCES-CEREVISIAE; ENVIRONMENTAL-CHANGES; TRANSCRIPTION FACTORS; BUDDING YEAST; KINASE PHO85; G(1) ARREST; CELL-GROWTH; RNA GENE	Previous studies have demonstrated roles for de novo production of sphingolipids in Saccharomyces cerevisiae in the regulation of the transient cell cycle arrest and nutrient permease degradation associated with the heat stress response, suggesting multiple functions for yeast sphingolipids in this response. We, therefore, sought to determine the generalized involvement of sphingolipids in the heat stress response by using microarray hybridization of RNA isolated from heat-stressed cultures of the mutant strain lcb1-100, which is unable to produce sphingolipids in response to heat. Approximately 70 genes showed differential regulation during the first 15 min of heat stress in the lcb1-100 strain compared with the wild type strain, indicating a requirement for de novo sphingolipid biosynthesis for proper regulation of these genes during heat stress. Grouping these genes into functional categories revealed several pathways, including some in which sphingolipids were previously suspected to play a role, such as stress response pathways and cell cycle regulation. Hierarchical clustering analysis revealed sphingolipid involvement in regulation of tRNA synthesis and metabolic genes and transporters. Additionally, the microarray results demonstrated novel sphingolipid involvement in transcriptional regulation of pathways of translation and cell wall organization and biogenesis. Our results demonstrate a broad-reaching effect of sphingolipids in the yeast heat stress response and suggest that the mechanism of sphingolipid involvement in several cellular pathways occurs via sphingolipid-mediated regulation of message levels.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29403 USA; Med Univ S Carolina, Dept Epidemiol & Biometry, Charleston, SC 29403 USA; Univ Nova Lisboa, Inst Tecnol Quim & Biol, Biomath Grp, P-2780156 Oeiras, Portugal	Medical University of South Carolina; Medical University of South Carolina; Universidade Nova de Lisboa	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 114 Doughty St,Rm 611-STB, Charleston, SC 29403 USA.		Almeida, Jonas/C-9093-2009; Pinto, Francisco/A-7443-2008	Almeida, Jonas/0000-0002-7883-7922; Pinto, Francisco/0000-0002-4217-0054	NCI NIH HHS [R24CA095841] Funding Source: Medline; NCRR NIH HHS [P20RR016434] Funding Source: Medline; NIGMS NIH HHS [GM 63265] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA095841] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016434] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063265] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Boer VM, 2003, J BIOL CHEM, V278, P3265, DOI 10.1074/jbc.M209759200; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; CHAO R, 1992, J BIOL CHEM, V267, P23459; Chung N, 2000, J BIOL CHEM, V275, P17229, DOI 10.1074/jbc.C000229200; Chung NJ, 2001, J BIOL CHEM, V276, P35614, DOI 10.1074/jbc.M105653200; COSTIGAN C, 1994, MOL CELL BIOL, V14, P2391, DOI 10.1128/MCB.14.4.2391; Dickson RC, 1997, J BIOL CHEM, V272, P29620, DOI 10.1074/jbc.272.47.29620; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; ESPINOZA FH, 1994, SCIENCE, V266, P1388, DOI 10.1126/science.7973730; Estruch F, 2000, FEMS MICROBIOL REV, V24, P469, DOI 10.1016/S0168-6445(00)00035-8; Feoktistova A, 2001, GENETICS, V158, P1397; Gallego C, 1997, EMBO J, V16, P7196, DOI 10.1093/emboj/16.23.7196; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gaynor EC, 1999, MOL BIOL CELL, V10, P627, DOI 10.1091/mbc.10.3.627; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Holmes WB, 2002, J BIOL CHEM, V277, P20205, DOI 10.1074/jbc.M201242200; Hong SP, 1999, J BIOL CHEM, V274, P10523, DOI 10.1074/jbc.274.15.10523; Huang DQ, 2002, MOL CELL BIOL, V22, P5076, DOI 10.1128/MCB.22.14.5076-5088.2002; Irniger S, 1997, J CELL SCI, V110, P1523; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Jenkins GM, 2001, J BIOL CHEM, V276, P8574, DOI 10.1074/jbc.M007425200; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; JOHNSON AR, 1992, APPL MULTIVARIATE ST; Lopez S, 2001, MOL CELL BIOL, V21, P3096, DOI 10.1128/MCB.21.9.3096-3104.2001; Martin MP, 2001, MOL CELL BIOL, V21, P6429, DOI 10.1128/MCB.21.19.6429-6439.2001; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Messenguy F, 2000, J BACTERIOL, V182, P3158, DOI 10.1128/JB.182.11.3158-3164.2000; MESSENGUY F, 1983, EMBO J, V2, P1249, DOI 10.1002/j.1460-2075.1983.tb01577.x; MESSENGUY F, 1969, FEBS LETT, V3, P47, DOI 10.1016/0014-5793(69)80093-1; Moreira JMA, 1999, EMBO J, V18, P2836, DOI 10.1093/emboj/18.10.2836; Moreira JMA, 1998, EMBO J, V17, P6028, DOI 10.1093/emboj/17.20.6028; Moreira JMA, 2000, EMBO J, V19, P6804, DOI 10.1093/emboj/19.24.6804; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; Nadon R, 2002, TRENDS GENET, V18, P265, DOI 10.1016/S0168-9525(02)02665-3; NAGIEC MM, 1994, P NATL ACAD SCI USA, V91, P7899, DOI 10.1073/pnas.91.17.7899; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Packeiser AN, 1999, YEAST, V15, P1485, DOI 10.1002/(SICI)1097-0061(199910)15:14<1485::AID-YEA477>3.0.CO;2-4; Pinson B, 2000, NUCLEIC ACIDS RES, V28, P4665, DOI 10.1093/nar/28.23.4665; PIPER P, 1997, YEAST STRESS RESPONS; Powers T, 1999, MOL BIOL CELL, V10, P987, DOI 10.1091/mbc.10.4.987; Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576; Sawai H, 2000, J BIOL CHEM, V275, P39793, DOI 10.1074/jbc.M007721200; Sawai H, 1999, CHEM PHYS LIPIDS, V102, P141, DOI 10.1016/S0009-3084(99)00082-1; SETHY I, 1995, J BIOL CHEM, V270, P28463; Sutterlin C, 1997, J CELL SCI, V110, P2703; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; Umebayashi K, 2001, J BIOL CHEM, V276, P41444, DOI 10.1074/jbc.M105829200; Wells GB, 1998, J BIOL CHEM, V273, P7235, DOI 10.1074/jbc.273.13.7235; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Yeong FM, 2001, MOL CELL BIOL, V21, P5071, DOI 10.1128/MCB.21.15.5071-5081.2001; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	53	42	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30328	30338		10.1074/jbc.M300656200	http://dx.doi.org/10.1074/jbc.M300656200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12740364	hybrid			2022-12-25	WOS:000184507000113
J	Zhang, JL; Zhou, B; Zheng, CF; Zhang, ZY				Zhang, JL; Zhou, B; Zheng, CF; Zhang, ZY			A bipartite mechanism for ERK2 recognition by its cognate regulators and substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; OF-FUNCTION MUTATION; MAP KINASE; DOCKING SITES; CATALYTIC ACTIVATION; DUAL PHOSPHORYLATION; TYROSINE PHOSPHATASE; ENZYMATIC-ACTIVITY; IN-VIVO; BINDING	Mitogen-activated protein ( MAP) kinases control gene expression in response to extracellular stimuli and exhibit exquisite specificity for their cognate regulators and substrates. We performed a structure-based mutational analysis of ERK2 to identify surface areas that are important for recognition of its interacting proteins. We show that binding and activation of MKP3 by ERK2 involve two distinct protein-protein interaction sites in ERK2. Thus, the common docking ( CD) site composed of Glu-79, Tyr-126, Arg-133, Asp-160, Tyr-314, Asp-316, and Asp-319 are important for high affinity MKP3 binding but not essential for ERK2-induced MKP3 activation. MKP3 activation requires residues Tyr-111, Thr-116, Leu-119, Lys-149, Arg-189, Trp-190, Glu-218, Arg-223, Lys-229, and His-230 in the ERK2 substrate-binding region, located distal to the common docking site. Interestingly, many of the residues important for MKP3 recognition are also used for Elk1 binding and phosphorylation. In addition to the shared residues, there are also residues that are unique to each target recognition. There is evidence indicating that the CD site and the substrate-binding region defined here are also utilized for MEK1 recognition, and indeed, we demonstrate that the binding of MKP3, Elk1, and MEK1 to ERK2 is mutually exclusive. Taken together, our data suggest that the efficiency and fidelity of ERK2 signaling is achieved by a bipartite recognition process. In this model, one part of the ERK2-binding proteins ( e. g. the kinase interaction motif sequence) docks to the CD site located on the back side of the ERK2 catalytic pocket for high affinity association, whereas the interaction of the substrate-binding region with another structural element ( e. g. the FXFP motif in MKP3 and Elk1) may not only stabilize binding but also provide contacts crucial for modulating the activity and/or specificity of ERK2 target molecules.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Biomyx Technol, San Diego, CA 92121 USA	Yeshiva University; Albert Einstein College of Medicine	Zhang, ZY (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	zyzhang@aecom.yu.edu			NATIONAL CANCER INSTITUTE [R01CA069202] Funding Source: NIH RePORTER; NCI NIH HHS [CA69202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1991, J BIOL CHEM, V266, P4220; Bardwell AJ, 2003, BIOCHEM J, V370, P1077, DOI 10.1042/BJ20021806; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BRILL JA, 1994, MOL BIOL CELL, V5, P297, DOI 10.1091/mbc.5.3.297; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Emrick MA, 2001, J BIOL CHEM, V276, P46469, DOI 10.1074/jbc.M107708200; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Farooq A, 2001, MOL CELL, V7, P387, DOI 10.1016/S1097-2765(01)00186-1; Fjeld CC, 2000, J BIOL CHEM, V275, P6749, DOI 10.1074/jbc.275.10.6749; Galanis A, 2001, J BIOL CHEM, V276, P965, DOI 10.1074/jbc.M007697200; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Gum RJ, 1999, BIOCHEM BIOPH RES CO, V266, P284, DOI 10.1006/bbrc.1999.1787; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Jiang Y, 1997, J BIOL CHEM, V272, P11096; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Karim FD, 1999, MOL CELL, V3, P741, DOI 10.1016/S1097-2765(01)80006-X; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Lim YM, 1999, GENETICS, V153, P763; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Prowse CN, 2001, J BIOL CHEM, V276, P99, DOI 10.1074/jbc.M008137200; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Robinson FL, 2002, J BIOL CHEM, V277, P14844, DOI 10.1074/jbc.M107776200; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Stewart AE, 1999, NAT STRUCT BIOL, V6, P174; Tanoue T, 2002, J BIOL CHEM, V277, P22942, DOI 10.1074/jbc.M202096200; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; Wang ZX, 2002, BIOCHEMISTRY-US, V41, P7849, DOI 10.1021/bi025776m; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; Zhao Y, 2001, J BIOL CHEM, V276, P32382, DOI 10.1074/jbc.M103369200; Zhou B, 2001, J BIOL CHEM, V276, P6506, DOI 10.1074/jbc.M009753200; Zhou B, 1999, J BIOL CHEM, V274, P35526, DOI 10.1074/jbc.274.50.35526; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200; Zhou B, 2002, J BIOL CHEM, V277, P13889, DOI 10.1074/jbc.M200377200	49	83	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29901	29912		10.1074/jbc.M303909200	http://dx.doi.org/10.1074/jbc.M303909200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12754209	hybrid			2022-12-25	WOS:000184507000063
J	Chung, JH; Lester, RL; Dickson, RC				Chung, JH; Lester, RL; Dickson, RC			Sphingolipid requirement for generation of a functional V-1 component of the vacuolar ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; FATTY-ACID ELONGATION; CHAIN BASE PHOSPHATES; YEAST V-ATPASE; SACCHAROMYCES-CEREVISIAE; H+-ATPASE; GENE DISRUPTION; PLASMA-MEMBRANE; COATED VESICLE; 14-KDA SUBUNIT	There has been no previous indication that vacuolar ATPases (V-ATPases) require sphingolipids for function. Here we show, by using Saccharomyces cerevisiae sur4Delta and fen1Delta cells, that sphingolipids with a C26 acyl group are required for generating V-1 domains with ATPase activity. Sphingolipids in sur4Delta cells contain C22 and C24 acyl groups instead of C26 acyl groups whereas about 30% of the sphingolipids in fen1Delta cells have C26 acyl groups and the rest have C22 and C24 acyl groups. sur4Delta cells have several phenotypes (vacuolar membrane ATPase, Vma(-)) that indicate a defect in the V-ATPase, and vacuoles purified from sur4Delta cells have little to no ATPase activity. These phenotypes are less pronounced in fen1Delta cells, consistent with the idea that the C26 acyl group in sphingolipids is necessary for V-ATPase activity. Other results show that the two V-ATPase domains, V-1 and V-0, are assembled and delivered to the vacuolar membrane in sur4Delta cells similar to wild-type cells. In vitro assembly studies show that V1 from sur4Delta cells associates with wild-type V-0 but the complex lacks V-ATPase activity, indicating that V-1 is defective. Reciprocal experiments with V-0 from sur4Delta cells show that it is normal. We conclude that sphingolipids with a C26 acyl group are required for generating fully functional V-1 domains.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Kentucky, Coll Med, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Dickson, RC (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, 800 Rose St, Lexington, KY 40536 USA.	bobd@uky.edu			NIGMS NIH HHS [GM41302] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041302] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe M, 2001, J BIOL CHEM, V276, P26923, DOI 10.1074/jbc.M102179200; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Brachmann CB, 1998, YEAST, V14, P115; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Dickson RC, 1999, BBA-MOL CELL BIOL L, V1438, P305, DOI 10.1016/S1388-1981(99)00068-2; Dickson RC, 2002, BBA-MOL CELL BIOL L, V1583, P13, DOI 10.1016/S1388-1981(02)00210-X; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; DOWNING DT, 1992, J LIPID RES, V33, P301; Ferguson-Yankey SR, 2002, YEAST, V19, P573, DOI 10.1002/yea.861; Forgac M, 2000, J EXP BIOL, V203, P71; FOURY F, 1990, J BIOL CHEM, V265, P18554; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; Graham LA, 2000, J EXP BIOL, V203, P61; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HECHTBERGER P, 1994, EUR J BIOCHEM, V225, P641, DOI 10.1111/j.1432-1033.1994.00641.x; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HO MN, 1993, J BIOL CHEM, V268, P18286; Kane PM, 1999, J BIOL CHEM, V274, P17275, DOI 10.1074/jbc.274.24.17275; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kane PM, 2000, J EXP BIOL, V203, P81; KANE PM, 1992, J BIOL CHEM, V267, P447; Kohlwein SD, 2001, MOL CELL BIOL, V21, P109, DOI 10.1128/MCB.21.1.109-125.2001; Kunz J, 2000, J BIOL CHEM, V275, P37011, DOI 10.1074/jbc.M007296200; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; LESTER RL, 1993, J BIOL CHEM, V268, P845; Lester RL, 2001, ANAL BIOCHEM, V298, P283, DOI 10.1006/abio.2001.5368; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; OHYA Y, 1991, J BIOL CHEM, V266, P13971; Oluwatosin YE, 1998, MOL CELL BIOL, V18, P1534, DOI 10.1128/MCB.18.3.1534; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; Parra KJ, 1996, J BIOL CHEM, V271, P19592, DOI 10.1074/jbc.271.32.19592; PATTON JL, 1991, J BACTERIOL, V173, P3101, DOI 10.1128/JB.173.10.3101-3108.1991; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; REVARDEL E, 1995, BBA-GENE STRUCT EXPR, V1263, P261, DOI 10.1016/0167-4781(95)00124-Y; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Smardon AM, 2002, J BIOL CHEM, V277, P13831, DOI 10.1074/jbc.M200682200; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUNEJA SK, 1991, J NEUROCHEM, V57, P140, DOI 10.1111/j.1471-4159.1991.tb02108.x; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Tvrdik P, 2000, J CELL BIOL, V149, P707, DOI 10.1083/jcb.149.3.707; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; WEISMAN LS, 1987, J CELL BIOL, V105, P1539, DOI 10.1083/jcb.105.4.1539; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737	51	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28872	28881		10.1074/jbc.M300943200	http://dx.doi.org/10.1074/jbc.M300943200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12746460	hybrid			2022-12-25	WOS:000184421100066
J	Gao, L; Zackert, WE; Hasford, JJ; Danekis, ME; Milne, GL; Remmert, C; Reese, J; Yin, HY; Tai, HH; Dey, SK; Porter, NA; Morrow, JD				Gao, L; Zackert, WE; Hasford, JJ; Danekis, ME; Milne, GL; Remmert, C; Reese, J; Yin, HY; Tai, HH; Dey, SK; Porter, NA; Morrow, JD			Formation of prostaglandins E-2 and D-2 via the isoprostane pathway - A mechanism for the generation of bioactive prostaglandins independent of cyclooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMED IN-VIVO; PRODUCTS; HUMANS; NONCYCLOOXYGENASE; F-2-ISOPROSTANE; IDENTIFICATION; CHROMATOGRAPHY; ENDOPEROXIDES; THROMBOXANE; EICOSANOIDS	It has heretofore been assumed that the cyclooxygenases (COXs) are solely responsible for peostaglandin ( PG) synthesis in vivo. An important structural feature of PGH(2) formed by COX is the trans-configuration of side chains relative to the prostane ring. Previously, we reported that a series of PG-like compounds termed isoprostanes (IsoPs) are formed in vivo in humans from the free radical-catalyzed peroxidation of arachidonate independent of COX. A major difference between these compounds and PGs is that IsoPs are formed from endoperoxide intermediates, the vast majority of which contain side chains that are cis relative to the prostane ring. In addition, unlike the formation of eicosanoids from COX, IsoPs are formed as racemic mixtures because they are generated nonenzymatically. IsoPs containing E- and D-type prostane rings (E-2/D-2-IsoPs) are one class of IsoPs formed, and we have reported previously that one of the major IsoPs generated is 15-E-2t-IsoP (8-iso-PGE(2)). Unlike PGE(2), 15-E(2t)IsoP is significantly more unstable in buffered solutions in vitro and undergoes epimerization to PGE(2). Analogously, the D-ring IsoP (15-D-2c-IsoP) would be predicted to rearrange to PGD(2). We now report that compounds identical in all respects to PGE(2) and PGD(2) and their respective enantiomers are generated in vivo via the IsoP pathway, presumably by epimerization of racemic 15-E(2t)IsoP and 15-D-2c-IsoP, respectively. Racemic PGE(2) and PGD(2) were present esterified in phospholipids derived from liver tissue from rats exposed to oxidant stress at levels of 24 +/- 16 and 37 +/- 12 ng/g of tissue, respectively. In addition, racemic PGs, particularly PGD(2), were present unesterified in urine from normal animals and humans and represented up to 10% of the total PG detected. Levels of racemic PGD(2) increased 35-fold after treatment of rats with carbon tetrachloride to induce oxidant stress. In this setting, PGD(2) and its enantiomer generated by the IsoP pathway represented similar to30% of the total PGD(2) present in urine. These findings strongly support the contention that a second pathway exists for the formation of bioactive PGs in vivo that is independent of COX.	Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pediat, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA; Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Kentucky	Morrow, JD (corresponding author), Vanderbilt Univ, Dept Med, 526 RRB,23rd & Pierce Ave, Nashville, TN 37232 USA.		Milne, Ginger/D-7648-2014	Milne, Ginger/0000-0003-3890-151X; Reese, Jeff/0000-0001-8751-6146	NCI NIH HHS [CA77839] Funding Source: Medline; NHLBI NIH HHS [HL46296] Funding Source: Medline; NICHD NIH HHS [HD12304] Funding Source: Medline; NIDDK NIH HHS [DK48831] Funding Source: Medline; NIGMS NIH HHS [GM42056] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD012304, R37HD012304] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM042056, R01GM042056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIPPI H, 1990, BRIT J CLIN PHARMACO, V29, P305, DOI 10.1111/j.1365-2125.1990.tb03640.x; Chen Y, 1999, J BIOL CHEM, V274, P10863, DOI 10.1074/jbc.274.16.10863; DANIEL VC, 1994, J CHROMATOGR B, V653, P117, DOI 10.1016/0378-4347(93)E0432-P; DANIELS EG, 1968, J AM CHEM SOC, V90, P5894, DOI 10.1021/ja01023a041; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; FITZGERALD GA, 1983, J CLIN INVEST, V71, P676, DOI 10.1172/JCI110814; FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713; Gilman A.G., 2001, GOODMAN GILMANS PHAR; Hou X, 2001, AM J PHYSIOL-REG I, V281, pR391, DOI 10.1152/ajpregu.2001.281.2.R391; Janssen LJ, 2001, AM J PHYSIOL-LUNG C, V280, pL1067, DOI 10.1152/ajplung.2001.280.6.L1067; LONGMIRE AW, 1994, PROSTAGLANDINS, V48, P247, DOI 10.1016/0090-6980(94)90011-6; MARINO JP, 1987, J ORG CHEM, V52, P4898, DOI 10.1021/jo00231a014; Marnett LJ, 2000, CURR OPIN CHEM BIOL, V4, P545, DOI 10.1016/S1367-5931(00)00130-7; Marnett LJ, 1999, J BIOL CHEM, V274, P22903, DOI 10.1074/jbc.274.33.22903; Morrow JD, 1999, DRUG METAB REV, V31, P117, DOI 10.1081/DMR-100101910; MORROW JD, 1994, BBA-LIPID LIPID MET, V1210, P244, DOI 10.1016/0005-2760(94)90128-7; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1994, J BIOL CHEM, V269, P4317; MORROW JD, 1992, PROSTAGLANDINS, V44, P155, DOI 10.1016/0090-6980(92)90077-7; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; Morrow JD, 1998, J LIPID RES, V39, P1589; OCONNOR DE, 1984, J AM CHEM SOC, V106, P3577, DOI 10.1021/ja00324a028; RANE A, 1978, CLIN PHARMACOL THER, V23, P658; Reese J, 2000, P NATL ACAD SCI USA, V97, P9759, DOI 10.1073/pnas.97.17.9759; Roberts LJ, 1996, J BIOL CHEM, V271, P20617, DOI 10.1074/jbc.271.34.20617; Roth GJ, 1997, SYNLETT, P618; Schneider C, 2000, ANAL BIOCHEM, V287, P186, DOI 10.1006/abio.2000.4847; Taber DF, 1998, J ORG CHEM, V63, P6607, DOI 10.1021/jo980763t; Taber DF, 2000, TETRAHEDRON, V56, P5991, DOI 10.1016/S0040-4020(00)00531-7; Yin HY, 2002, J AM CHEM SOC, V124, P7745, DOI 10.1021/ja0201092	31	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28479	28489		10.1074/jbc.M303984200	http://dx.doi.org/10.1074/jbc.M303984200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12746435	hybrid			2022-12-25	WOS:000184421100018
J	Tudzynski, B; Mihlan, M; Rojas, MC; Linnemannstons, P; Gaskin, P; Hedden, P				Tudzynski, B; Mihlan, M; Rojas, MC; Linnemannstons, P; Gaskin, P; Hedden, P			Characterization of the final two genes of the gibberellin biosynthesis gene cluster of Gibberella fujikuroi - des and P450-3 encode GA(4) desaturase and the 13-hydroxylase, respectively	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENT-KAURENE SYNTHASE; REGULATORY GENE; TRANSFORMATION; CLONING; SEEDS; 3-BETA-HYDROXYLASE; SPECIFICITY; METABOLISM; PATHWAY; ENZYME	Recently, six genes of the gibberellin (GA) biosynthesis gene cluster in Gibberella fujikuroi were cloned and the functions of five of these genes were determined. Here we describe the function of the sixth gene, P450-3, and the cloning and functional analysis of a seventh gene, orf3, located at the left border of the gene cluster. We have thereby defined the complete GA biosynthesis gene cluster in this fungus. The predicted amino acid sequence of orf3 revealed no close homology to known proteins. High performance liquid chromatography and gas chromatography-mass spectrometry analyses of the culture fluid of knock-out mutants identified GA(1) and GA(4), rather than GA(3) and GA(7), as the major C-19-GA products, suggesting that orf3 encodes the GA(4) 1,2-desaturase. This was confirmed by transformation of the SG139 mutant, which lacks the GA biosynthesis gene cluster, with the desaturase gene renamed des. The transformants converted GA(4) to GA(7), and also metabolized GA(9) (3-deoxyGA(4)) to GA(120) (1,2-didehydroGA(9)), but the 2alpha-hydroxylated compound GA(40) was the major product in this case. We demonstrate also by gene disruption that P450-3, one of the four cytochrome P450 monooxygenase genes in the GA gene cluster, encodes the 13-hydroxylase, which catalyzes the conversion of GA(7) to GA(3), in the last step of the pathway. This enzyme also catalyzes the 13-hydroxylation of GA(4) to GA(1). Disruption of the des gene in an UV-induced P450-3 mutant produced a double mutant lacking both desaturase and 13-hydroxylase activities that accumulated high amounts of the commercially important GA(4). The des and P450-3 genes differ in their regulation by nitrogen metabolite repression. In common with the other five GA biosynthesis genes, expression of the desaturase gene is repressed by high amounts of nitrogen in the culture medium, whereas P450-3 is the only gene in the cluster not repressed by nitrogen.	Univ Munster, Inst Bot, D-48149 Munster, Germany; Univ Chile, Fac Ciencias, Dept Quim, Lab Bioorgan, Santiago, Chile; Rothamsted Res Long Ashton, Bristol BS41 9AF, Avon, England	University of Munster; Universidad de Chile; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Tudzynski, B (corresponding author), Univ Munster, Inst Bot, Schlossgarten 3, D-48149 Munster, Germany.	Bettina.Tudzynski@uni-muenster.de	ROJAS, MARIA CECILIA/D-8730-2014	ROJAS, MARIA CECILIA/0000-0002-6034-9779	Biotechnology and Biological Sciences Research Council [BBS/E/C/00004161] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ALBONE KS, 1990, PLANT PHYSIOL, V94, P132, DOI 10.1104/pp.94.1.132; Alexander NJ, 1999, MOL GEN GENET, V261, P977, DOI 10.1007/s004380051046; BARENDSE GWM, 1980, J CHROMATOGR, V198, P449, DOI 10.1016/S0021-9673(00)80514-2; Barrero AF, 1999, PHYTOCHEMISTRY, V50, P1133, DOI 10.1016/S0031-9422(98)00699-2; BIRCH AJ, 1958, P CHEM SOC LONDON, P192; Brown DW, 1996, P NATL ACAD SCI USA, V93, P1418, DOI 10.1073/pnas.93.4.1418; COQUE JJR, 1995, J BACTERIOL, V177, P2230, DOI 10.1128/jb.177.8.2230-2235.1995; DESJARDINS AE, 1992, J IND MICROBIOL, V9, P201, DOI 10.1007/BF01569624; EVANS R, 1970, J CHEM SOC C, P2601, DOI 10.1039/j39700002601; Gaskin P., 1992, GC MS GIBBERELLINS R; GEISSMAN TA, 1966, PHYTOCHEMISTRY, V5, P933, DOI 10.1016/S0031-9422(00)82790-9; Hedden P, 1997, PHYSIOL PLANTARUM, V101, P709, DOI 10.1111/j.1399-3054.1997.tb01055.x; Hedden P, 2001, J PLANT GROWTH REGUL, V20, P319, DOI 10.1007/s003440010037; Hedden P, 2000, TRENDS PLANT SCI, V5, P523, DOI 10.1016/S1360-1385(00)01790-8; HEDDEN P, 1994, MECH PLANT GROWTH IM, P173; HOHN TM, 1995, MOL APPROACHES FOOD, P239; Homann V, 1996, CURR GENET, V30, P232, DOI 10.1007/s002940050126; Kawaide H, 1997, J BIOL CHEM, V272, P21706, DOI 10.1074/jbc.272.35.21706; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; Linnemannstons P, 1999, APPL ENVIRON MICROB, V65, P2558; MacMillan J, 2001, J PLANT GROWTH REGUL, V20, P387, DOI 10.1007/s003440010038; MacMillan J, 1997, NAT PROD REP, V14, P221, DOI 10.1039/np9971400221; Mende K, 1997, MOL GEN GENET, V255, P96, DOI 10.1007/s004380050477; Mihlan M, 2003, MOL MICROBIOL, V47, P975, DOI 10.1046/j.1365-2958.2003.03326.x; Nakayama M, 2001, PHYTOCHEMISTRY, V57, P749, DOI 10.1016/S0031-9422(01)00154-6; PUNT PJ, 1987, GENE, V56, P117, DOI 10.1016/0378-1119(87)90164-8; Rojas MC, 2001, P NATL ACAD SCI USA, V98, P5838, DOI 10.1073/pnas.091096298; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH VA, 1990, PLANT PHYSIOL, V94, P1390, DOI 10.1104/pp.94.3.1390; Spray CR, 1996, P NATL ACAD SCI USA, V93, P10515, DOI 10.1073/pnas.93.19.10515; Toyomasu T, 2000, BIOSCI BIOTECH BIOCH, V64, P660, DOI 10.1271/bbb.64.660; Tudzynski B, 1996, MICROBIOL-SGM, V142, P533, DOI 10.1099/13500872-142-3-533; Tudzynski B, 1999, MOL GEN GENET, V261, P106, DOI 10.1007/s004380050950; Tudzynski B, 2002, J BIOL CHEM, V277, P21246, DOI 10.1074/jbc.M201651200; Tudzynski B, 1998, CURR GENET, V34, P234, DOI 10.1007/s002940050392; Tudzynski B, 2001, APPL ENVIRON MICROB, V67, P3514, DOI 10.1128/AEM.67.8.3514-3522.2001; Tudzynski B, 1998, FUNGAL GENET BIOL, V25, P157, DOI 10.1006/fgbi.1998.1095; Voss T, 2001, CURR GENET, V39, P377, DOI 10.1007/s002940100218; Williams J, 1998, PLANT PHYSIOL, V117, P559, DOI 10.1104/pp.117.2.559; Woitek S, 1997, CURR GENET, V31, P38, DOI 10.1007/s002940050174; Yamaguchi S, 2000, PLANT CELL PHYSIOL, V41, P251, DOI 10.1093/pcp/41.3.251	41	80	101	4	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28635	28643		10.1074/jbc.M301927200	http://dx.doi.org/10.1074/jbc.M301927200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12750377	hybrid			2022-12-25	WOS:000184421100037
J	Connelly, L; Jacobs, AT; Palacios-Callender, M; Moncada, S; Hobbs, AJ				Connelly, L; Jacobs, AT; Palacios-Callender, M; Moncada, S; Hobbs, AJ			Macrophage endothelial nitric-oxide synthase autoregulates cellular activation and pro-inflammatory protein expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; SOLUBLE GUANYLYL CYCLASE; KAPPA-B ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; MITOCHONDRIAL RESPIRATION; J774 MACROPHAGES; TNF-ALPHA; CELLS; INDUCTION; INHIBITION	Expression of inducible nitric-oxide (NO) synthase (iNOS) and "high-output" production of NO by macrophages mediates many cytotoxic actions of these immune cells. However, macrophages have also been shown to express a constitutive NOS isoform, the function of which remains obscure. Herein, bone marrow-derived macrophages (BMDMOs) from wild-type and endothelial NOS (eNOS) knock-out (KO) mice have been used to assess the role of this constitutive NOS isoform in the regulation of macrophage activation. BMDMOs from eNOS KO animals exhibited reduced nuclear factor-kappaB activity, iNOS expression, and NO production after exposure to lipopolysaccharide (LPS) as compared with cells derived from wild-type mice. Soluble guanylate cyclase (sGC) was identified in BMDMOs at a mRNA and protein level, and activation of cells with LPS resulted in accumulation of cyclic GMP. Moreover, the novel non-NO-based sGC activator, BAY 41-2272, enhanced BMDMO activation in response to LPS, and the sGC inhibitor 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one attenuated activation. These observations provide the first demonstration of a pathophysiological role for macrophage eNOS in regulating cellular activation and suggest that NO derived from this constitutive NOS isoform, in part via activation of sGC, is likely to play a pivotal role in the initiation of an inflammatory response.	UCL, Wolfson Inst Biomed Res, London WC1E 6AE, England; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	University of London; University College London; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Hobbs, AJ (corresponding author), UCL, Wolfson Inst Biomed Res, Cruciform Bldg,Gower St, London WC1E 6AE, England.	a.hobbs@ucl.ac.uk	Connelly, Linda/GVS-4612-2022; Palacios-Callender, Miriam/GQP-1574-2022	Palacios-Callender, Miriam/0000-0002-3521-0927; Hobbs, Adrian/0000-0002-3589-7108				Baltrons MA, 1999, J NEUROCHEM, V73, P2149; Bellamy TC, 2000, P NATL ACAD SCI USA, V97, P2928, DOI 10.1073/pnas.97.6.2928; BRANDI ML, 1995, P NATL ACAD SCI USA, V92, P2954, DOI 10.1073/pnas.92.7.2954; BROWN GC, 1995, FEBS LETT, V369, P136, DOI 10.1016/0014-5793(95)00763-Y; Chauhan SD, 2003, FASEB J, V17, P773, DOI 10.1096/fj.02-0668fje; Chen CC, 1999, MOL PHARMACOL, V55, P481; Choi SH, 1999, NEUROSCI LETT, V276, P29, DOI 10.1016/S0304-3940(99)00783-1; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; COLASANTI M, 1995, J BIOL CHEM, V270, P26731, DOI 10.1074/jbc.270.45.26731; Connelly L, 2001, J IMMUNOL, V166, P3873, DOI 10.4049/jimmunol.166.6.3873; DEAKIN AM, 1995, CYTOKINE, V7, P408, DOI 10.1006/cyto.1995.0056; Diaz-Guerra MJM, 1999, J IMMUNOL, V162, P6184; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; DIMMELER S, 1992, J BIOL CHEM, V267, P16771; Ehrt S, 2001, J EXP MED, V194, P1123, DOI 10.1084/jem.194.8.1123; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; HECKER M, 1992, J CARDIOVASC PHARM, V20, pS139, DOI 10.1097/00005344-199204002-00039; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HIRSCH S, 1981, J EXP MED, V154, P713, DOI 10.1084/jem.154.3.713; Iwase K, 2000, J BIOL CHEM, V275, P11929, DOI 10.1074/jbc.275.16.11929; Kalra D, 2000, CIRCULATION, V102, P1302, DOI 10.1161/01.CIR.102.11.1302; KASTEN TP, 1994, P NATL ACAD SCI USA, V91, P3569, DOI 10.1073/pnas.91.9.3569; Kawanaka H, 2002, HEPATOLOGY, V35, P393, DOI 10.1053/jhep.2002.30958; Korhonen R, 2001, INFLAMMATION, V25, P223, DOI 10.1023/A:1010971703271; Korhonen R, 2001, BIOCHEM J, V354, P351, DOI 10.1042/0264-6021:3540351; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; Lizasoain I, 1996, BIOCHEM J, V314, P877, DOI 10.1042/bj3140877; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Miles PR, 1998, AM J PHYSIOL-LUNG C, V274, pL360, DOI 10.1152/ajplung.1998.274.3.L360; MUNDER PG, 1971, FEBS LETT, V15, P191, DOI 10.1016/0014-5793(71)80309-5; Mustafa SB, 1999, AM J PHYSIOL-GASTR L, V277, pG351, DOI 10.1152/ajpgi.1999.277.2.G351; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; Park SJ, 2002, CELL BIOL TOXICOL, V18, P121, DOI 10.1023/A:1015384201785; Park SK, 1997, BIOCHEM J, V322, P609, DOI 10.1042/bj3220609; Patel R, 1999, J IMMUNOL, V162, P4191; Peng HB, 1998, J IMMUNOL, V161, P1970; Perez-Sala D, 2001, AM J PHYSIOL-RENAL, V280, pF466, DOI 10.1152/ajprenal.2001.280.3.F466; RADDASSI K, 1994, CELL IMMUNOL, V153, P443, DOI 10.1006/cimm.1994.1041; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; REILING N, 1994, EUR J IMMUNOL, V24, P1941, DOI 10.1002/eji.1830240836; Roman V, 1997, IMMUNOLOGY, V91, P643, DOI 10.1046/j.1365-2567.1997.d01-2263.x; SCHMIDT HHHW, 1992, MOL PHARMACOL, V41, P615; Schwartz D, 1997, J CLIN INVEST, V100, P439, DOI 10.1172/JCI119551; Stasch JP, 2001, NATURE, V410, P212, DOI 10.1038/35065611; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; Togashi H, 1997, P NATL ACAD SCI USA, V94, P2676, DOI 10.1073/pnas.94.6.2676; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Umansky V, 1998, EUR J IMMUNOL, V28, P2276, DOI 10.1002/(SICI)1521-4141(199808)28:08<2276::AID-IMMU2276>3.0.CO;2-H; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1994, J LEUKOCYTE BIOL, V56, P576, DOI 10.1002/jlb.56.5.576; Yamashita T, 2000, CIRCULATION, V101, P931, DOI 10.1161/01.CIR.101.8.931; Yun HY, 1998, P NATL ACAD SCI USA, V95, P5773, DOI 10.1073/pnas.95.10.5773	57	125	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26480	26487		10.1074/jbc.M302238200	http://dx.doi.org/10.1074/jbc.M302238200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12740377	hybrid			2022-12-25	WOS:000184155700026
J	Dai, CS; Li, YJ; Yang, JW; Liu, YH				Dai, CS; Li, YJ; Yang, JW; Liu, YH			Hepatocyte growth factor preserves beta cell mass and mitigates hyperglycemia in streptozotocin-induced diabetic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-CELLS; ISLET TRANSPLANTATION; PANCREATIC-ISLETS; DEATH; EXPRESSION; GENE; SURVIVAL; OVEREXPRESSION; PROLIFERATION; STRATEGIES	Type I diabetes is an autoimmune disease that results in destructive depletion of the insulin-producing beta cells in the islets of Langerhans in pancreas. With the knowledge that hepatocyte growth factor (HGF) is a potent survival factor for a wide variety of cells, we hypothesized that supplementation of HGF may provide a novel strategy for protecting pancreatic beta cells from destructive death and for preserving insulin production. In this study, we demonstrate that expression of the exogenous HGF gene preserved insulin excretion and mitigated hyperglycemia of diabetic mice induced by streptozotocin. Blood glucose levels were significantly reduced in mice receiving a single intravenous injection of naked HGF gene at various time points after streptozotocin administration. Consistently, HGF concomitantly increased serum insulin levels in diabetic mice. Immunohistochemical staining revealed a marked preservation of insulin-producing beta cells by HGF in the pancreatic islets of the diabetic mice. This beneficial effect of HGF was apparently mediated by both protection of beta cells from death and promotion of their proliferation. Delivery of HGF gene in vivo induced prosurvival Akt kinase activation and Bcl-xL expression in the pancreatic islets of diabetic mice. These findings suggest that supplementation of HGF to prevent beta cells from destructive depletion and to promote their proliferation might be an effective strategy for ameliorating type I diabetes.	Univ Pittsburgh, Sch Med, Dept Pathol, Div Cellular & Mol Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Liu, YH (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Div Cellular & Mol Pathol, S-405 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15261 USA.	liuy@msx.upmc.edu		Liu, Youhua/0000-0002-4740-805X	NIDDK NIH HHS [DK54922, DK64005, DK61408] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064005, R01DK054922, R01DK061408] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPASAMY R, 1993, LAB INVEST, V68, P270; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cheung AT, 2000, SCIENCE, V290, P1959, DOI 10.1126/science.290.5498.1959; Dai CS, 2003, J BIOL CHEM, V278, P12537, DOI 10.1074/jbc.M300777200; Dai CS, 2002, J AM SOC NEPHROL, V13, P411, DOI 10.1681/ASN.V132411; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davalli AM, 1996, DIABETES, V45, P1161, DOI 10.2337/diabetes.45.9.1161; EIZIRIK DL, 1991, BIOCHEM PHARMACOL, V42, P2275, DOI 10.1016/0006-2952(91)90230-3; Federici M, 2001, DIABETES, V50, P1290, DOI 10.2337/diabetes.50.6.1290; Garcia-Ocana A, 2003, J BIOL CHEM, V278, P343, DOI 10.1074/jbc.M207848200; Garcia-Ocana A, 2001, DIABETES, V50, P2752, DOI 10.2337/diabetes.50.12.2752; Garcia-Ocana A, 2001, J CLIN ENDOCR METAB, V86, P984, DOI 10.1210/jc.86.3.984; Garcia-Ocana A, 2000, J BIOL CHEM, V275, P1226, DOI 10.1074/jbc.275.2.1226; Harris MI, 1998, DIABETES CARE, V21, pC11, DOI 10.2337/diacare.21.3.C11; HAYEK A, 1995, DIABETES, V44, P1458, DOI 10.2337/diabetes.44.12.1458; Lee HC, 2000, NATURE, V408, P483, DOI 10.1038/35044106; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; LIU ML, 1994, AM J PATHOL, V144, P129; Liu YH, 1999, AM J PHYSIOL-RENAL, V277, pF624, DOI 10.1152/ajprenal.1999.277.4.F624; Liu YH, 1998, EXP CELL RES, V242, P174, DOI 10.1006/excr.1998.4107; Liu YH, 2002, CURR OPIN NEPHROL HY, V11, P23, DOI 10.1097/00041552-200201000-00004; Lumelsky N, 2001, SCIENCE, V292, P1389, DOI 10.1126/science.1058866; Marx J, 2002, SCIENCE, V296, P686, DOI 10.1126/science.296.5568.686; Mathis D, 2001, NATURE, V414, P792, DOI 10.1038/414792a; Nakagami H, 2002, DIABETES, V51, P2604, DOI 10.2337/diabetes.51.8.2604; Nakano M, 2000, TRANSPLANTATION, V69, P214, DOI 10.1097/00007890-200001270-00004; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Otonkoski T, 1996, ENDOCRINOLOGY, V137, P3131, DOI 10.1210/en.137.7.3131; OTONKOSKI T, 1994, DIABETES, V43, P947, DOI 10.2337/diabetes.43.7.947; Peck AB, 2001, ANN MED, V33, P186, DOI 10.3109/07853890109002076; Ryan EA, 2001, DIABETES, V50, P710, DOI 10.2337/diabetes.50.4.710; Sandler S, 2000, UPSALA J MED SCI, V105, P17, DOI 10.1517/03009734000000053; Shapiro A M, 2001, Lancet, V358 Suppl, pS21, DOI 10.1016/S0140-6736(01)07034-9; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Shifrin AL, 2001, GENE THER, V8, P1480, DOI 10.1038/sj.gt.3301544; Soria B, 2001, DIABETOLOGIA, V44, P407, DOI 10.1007/s001250051636; Yang J, 2001, GENE THER, V8, P1470, DOI 10.1038/sj.gt.3301545; Yang JW, 2002, J CLIN INVEST, V110, P1525, DOI 10.1172/JC1200216219; Yang JW, 2002, J AM SOC NEPHROL, V13, P96, DOI 10.1681/ASN.V13196; Yang JW, 2001, HEPATOLOGY, V33, P848, DOI 10.1053/jhep.2001.23438; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; Zhang XH, 2003, AM J PHYSIOL-RENAL, V284, pF82, DOI 10.1152/ajprenal.00200.2002; ZIONCHECK TF, 1994, ENDOCRINOLOGY, V134, P1879, DOI 10.1210/en.134.4.1879	44	67	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27080	27087		10.1074/jbc.M211947200	http://dx.doi.org/10.1074/jbc.M211947200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12746445	hybrid			2022-12-25	WOS:000184155700101
J	Eide, T; Tasken, KA; Carlson, C; Williams, G; Jahnsen, T; Tasken, K; Collas, P				Eide, T; Tasken, KA; Carlson, C; Williams, G; Jahnsen, T; Tasken, K; Collas, P			Protein kinase A-anchoring protein AKAP95 interacts with MCM2, a regulator of DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; CHROMOSOME CONDENSATION; NUCLEAR-PROTEIN; S-PHASE; INITIATION; SUBUNIT; CHROMATIN; COMPLEX; HA95; CLONING	Protein kinase A (PKA)-anchoring protein AKAP95 is localized to the nucleus in interphase, where it primarily associates with the nuclear matrix. A yeast two-hybrid screen for AKAP95 interaction partners identified the minichromosome maintenance (MCM) 2 protein, a component of the pre-replication complex. AKAP95-MCM2 interaction was mapped to residues 1 - 195 of AKAP95 and corroborated by glutathione S-transferase precipitation and immunoprecipitation from chromatin. Disruption of AKAP95-MCM2 interaction with an AKAP95-(1- 195) peptide within HeLa cell nuclei abolishes initiation of DNA replication in G(1) phase and the elongation phase of replication in vitro without affecting global nuclear organization or import. Disruption of the C-terminal zinc finger of AKAP95 reduces efficiency of replication initiation. Disruption of the PKA-binding domain does not impair replication in G(1)- or S-phase nuclei, whereas a PKA inhibitor affects the initiation but not the elongation phase of replication. Depleting AKAP95 from nuclei partially depletes MCM2 and abolishes replication. Recombinant AKAP95 restores intranuclear MCM2 and replication in a dose-dependent manner. Our results suggest a role of AKAP95 in DNA replication by providing a scaffold for MCM2.	Univ Oslo, Dept Med Biochem, N-0317 Oslo, Norway; Univ Cambridge, Dept Pathol, Div Mol & Cellular Pathol, Cambridge CB2 1QP, England	University of Oslo; University of Cambridge	Tasken, K (corresponding author), Univ Oslo, Dept Med Biochem, POB 1112 Blindern, N-0317 Oslo, Norway.			Tasken, Kjetil/0000-0003-2841-4697				Akileswaran L, 2001, J BIOL CHEM, V276, P17448, DOI 10.1074/jbc.M101171200; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Bomar J, 2002, J CELL SCI, V115, P2931; Buendia B, 1997, EXP CELL RES, V230, P133, DOI 10.1006/excr.1996.3395; CARR DW, 1991, J BIOL CHEM, V266, P14188; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; Collas P, 1999, J CELL BIOL, V147, P1167, DOI 10.1083/jcb.147.6.1167; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; Costanzo V, 1999, CURR BIOL, V9, P903, DOI 10.1016/S0960-9822(99)80395-9; Eide T, 2002, EMBO REP, V3, P426, DOI 10.1093/embo-reports/kvf089; Eide T, 1998, EXP CELL RES, V238, P305, DOI 10.1006/excr.1997.3855; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; Furusawa M, 2002, J BIOL CHEM, V277, P50885, DOI 10.1074/jbc.M206387200; Han I, 2002, MOL CELL BIOL, V22, P2136, DOI 10.1128/MCB.22.7.2136-2146.2002; Iborra FJ, 2002, CURR OPIN CELL BIOL, V14, P780, DOI 10.1016/S0955-0674(02)00386-1; Ishimi Y, 1998, J BIOL CHEM, V273, P8369, DOI 10.1074/jbc.273.14.8369; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Labib K, 2001, CURR OPIN GENET DEV, V11, P64, DOI 10.1016/S0959-437X(00)00158-1; Lei M, 2001, J CELL SCI, V114, P1447; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; MAINE GT, 1984, GENETICS, V106, P365; Martins S, 2003, J CELL BIOL, V160, P177, DOI 10.1083/jcb.200210026; Martins SB, 2000, J CELL SCI, V113, P3703; Munshi R, 1998, EXP CELL RES, V240, P321, DOI 10.1006/excr.1998.4019; Orstavik S, 2000, BIOL CELL, V92, P27, DOI 10.1016/S0248-4900(00)88761-4; Pasero P, 1999, GENE DEV, V13, P2159, DOI 10.1101/gad.13.16.2159; SOLBERG R, 1994, EXP CELL RES, V214, P595, DOI 10.1006/excr.1994.1297; Steen RL, 2000, J CELL BIOL, V149, P531, DOI 10.1083/jcb.149.3.531; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334	35	42	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26750	26756		10.1074/jbc.M300765200	http://dx.doi.org/10.1074/jbc.M300765200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12740381	hybrid			2022-12-25	WOS:000184155700059
J	Grambihler, A; Higuchi, H; Bronk, SF; Gores, GJ				Grambihler, A; Higuchi, H; Bronk, SF; Gores, GJ			CFLIP-L inhibits p38 MAPK activation - An additional anti-apoptotic mechanism in bile acid-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEIN; CULTURED RAT HEPATOCYTES; SIGNAL-TRANSDUCTION; CELL-DEATH; GENE-EXPRESSION; CASPASE HOMOLOG; HEPATOMA-CELLS; LIVER-DISEASE; KINASE; FAS	In cholestasis, toxic bile acids accumulate within the liver inducing hepatocyte apoptosis, which exacerbates liver injury. Although bile acids activate both death receptors and mitogen-activated kinase ( MAPK) pathways, the mechanistic link between death receptor signaling and MAPK activation in bile acid apoptosis remains unclear. The aim of this study was to ascertain if MAPKs contribute to bile acid cytotoxicity. Although deoxycholate induced apoptosis and activated all three classic mediators of the MAPK pathways including JNK 1/2, p38, and p42/44, only p38 MAPK inhibition attenuated apoptosis. Suppressing FADD expression with siRNA or employing a caspase inhibitor, zVAD-fmk, did not block p38 MAPK activation suggesting its activation was not death receptor-dependent. Unexpectedly, expression of cFLIP-L in a stably transfected cell line blocked apoptosis and p38 MAPK phosphorylation. Based on these data we postulated a direct effect of cFLIP on p38 MAPK activation. The nonphosphorylated but not the phosphorylated/active form of p38 MAPK co-immunoprecipitated with cFLIP-L. In reverse immunoprecipitation experiments, cFLIP-L long but not cFLIP-S co-immunoprecipitate with p38 MAPK. In conclusion, these data suggest that cFLIP-L exerts its antiapoptotic activity, in part, by inhibiting p38 MAPK activation, an additional anti-apoptotic effect for this protein.	Mayo Med Sch Clin & Fdn, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA	Mayo Clinic	Gores, GJ (corresponding author), Mayo Med Sch Clin & Fdn, Div Gastroenterol & Hepatol, 200 1st SW, Rochester, MN 55905 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041876, R37DK041876, R29DK041876] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41876] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bartke T, 2001, ONCOGENE, V20, P571, DOI 10.1038/sj.onc.1204124; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Bortul R, 2003, LEUKEMIA, V17, P379, DOI 10.1038/sj.leu.2402793; Burns TF, 2001, J BIOL CHEM, V276, P37879; Cahill MA, 1996, ONCOGENE, V13, P2087; Canbay A, 2002, GASTROENTEROLOGY, V123, P1323, DOI 10.1053/gast.2002.35953; Cardier JE, 2002, MICROVASC RES, V63, P10, DOI 10.1006/mvre.2001.2360; De Vree JML, 2000, GASTROENTEROLOGY, V119, P1720, DOI 10.1053/gast.2000.20222; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Graf D, 2002, GASTROENTEROLOGY, V122, P1411, DOI 10.1053/gast.2002.32976; GREIM H, 1972, GASTROENTEROLOGY, V63, P846; Gumpricht E, 2002, J BIOL CHEM, V277, P25823, DOI 10.1074/jbc.M112305200; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Higuchi H, 2002, J PHARMACOL EXP THER, V303, P461, DOI 10.1124/jpet.102.040030; Higuchi H, 2001, J BIOL CHEM, V276, P38610, DOI 10.1074/jbc.M105300200; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Kurz AK, 2001, GASTROENTEROLOGY, V121, P407, DOI 10.1053/gast.2001.26262; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Miyoshi H, 1999, GASTROENTEROLOGY, V117, P669, DOI 10.1016/S0016-5085(99)70461-0; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Newton K, 2001, CURR BIOL, V11, P273, DOI 10.1016/S0960-9822(01)00067-7; Qiao D, 2001, CARCINOGENESIS, V22, P35, DOI 10.1093/carcin/22.1.35; Qiao L, 2002, HEPATOLOGY, V35, P779, DOI 10.1053/jhep.2002.32533; Qiao L, 2001, MOL BIOL CELL, V12, P2629, DOI 10.1091/mbc.12.9.2629; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Rodrigues CMP, 1998, J CLIN INVEST, V101, P2790, DOI 10.1172/JCI1325; Rust C, 2000, AM J MED, V108, P567, DOI 10.1016/S0002-9343(00)00370-3; Saldeen J, 2001, BIOCHEM PHARMACOL, V61, P1561, DOI 10.1016/S0006-2952(01)00605-0; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Schliess F, 1997, GASTROENTEROLOGY, V113, P1306, DOI 10.1053/gast.1997.v113.pm9322526; Schlottmann K, 2000, CANCER RES, V60, P4270; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shima Y, 1999, HEPATOLOGY, V30, P1215, DOI 10.1002/hep.510300503; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Strasser A, 1999, INT J BIOCHEM CELL B, V31, P533, DOI 10.1016/S1357-2725(99)00003-5; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Thompson R, 2000, SEMIN LIVER DIS, V20, P365, DOI 10.1055/s-2000-9384; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Webster CRL, 1998, HEPATOLOGY, V27, P1324, DOI 10.1002/hep.510270519; Webster CRL, 2001, HEPATOLOGY, V33, P608, DOI 10.1053/jhep.2001.22756; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	63	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26831	26837		10.1074/jbc.M303229200	http://dx.doi.org/10.1074/jbc.M303229200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12746452	hybrid			2022-12-25	WOS:000184155700070
J	Strotmann, R; Schultz, G; Plant, TD				Strotmann, R; Schultz, G; Plant, TD			Ca2+-dependent potentiation of the nonselective cation channel TRPV4 is mediated by a C-terminal calmodulin binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; HEAT-EVOKED ACTIVATION; CA2+ CHANNEL; ION-CHANNEL; INTRACELLULAR CA2+; CAPSAICIN-RECEPTOR; MOLECULAR-CLONING; FAMILY; PROTEIN; ECAC1	Most Ca2+-permeable ion channels are inhibited by increases in the intracellular Ca2+ concentration ([Ca2+](i)), thus preventing potentially deleterious rises in [Ca2+](i). In this study, we demonstrate that currents through the osmo-, heat- and phorbol ester-sensitive, Ca2+-permeable nonselective cation channel TRPV4 are potentiated by intracellular Ca2+. Spontaneous TRPV4 currents and currents stimulated by hypotonic solutions or phorbol esters were reduced strongly at all potentials in the absence of extracellular Ca2+. The other permeant divalent cations Ba2+ and Sr2+ were less effective than Ca2+ in supporting channel activity. An intracellular site of Ca2+ action was supported by the parallel decrease in spontaneous currents and [Ca2+](i) on removal of extracellular Ca2+ and the ability of Ca2+ release from intracellular stores to restore TRPV4 activity in the absence of extracellular Ca2+. During TRPV4 activation by hypotonic solutions or phorbol esters, Ca2+ entry through the channel increased the rate and extent of channel activation. Currents were also potentiated by ionomycin in the presence of extracellular Ca2+. Ca2+-dependent potentiation of TRPV4 was often followed by inhibition. By mutagenesis, we localized the structural determinant of Ca2+-dependent potentiation to an intracellular, C-terminal calmodulin binding domain. This domain binds calmodulin in a Ca2+-dependent manner. TRPV4 mutants that did not bind calmodulin lacked Ca2+-dependent potentiation. We conclude that TRPV4 activity is tightly controlled by intracellular Ca2+. Ca2+ entry increases both the rate and extent of channel activation by a calmodulin-dependent mechanism. Excessive increases in [Ca2+](i) via TRPV4 are prevented by a Ca2+-dependent negative feedback mechanism.	Free Univ Berlin, Univ Klinikum Benjamin Franklin, Inst Pharmakol, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Plant, TD (corresponding author), Free Univ Berlin, Univ Klinikum Benjamin Franklin, Inst Pharmakol, Thielallee 67-73, D-14195 Berlin, Germany.	tplant@zedat.fu-berlin.de						Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; CHAO SH, 1984, MOL PHARMACOL, V26, P75; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Docherty RJ, 1996, PFLUG ARCH EUR J PHY, V431, P828, DOI 10.1007/BF02332166; Guler AD, 2002, J NEUROSCI, V22, P6408; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; Ikeda M, 2002, CURR OPIN NEPHROL HY, V11, P539, DOI 10.1097/00041552-200209000-00010; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; Kasri NN, 2002, BBA-PROTEINS PROTEOM, V1600, P19; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; McHugh D, 2003, J BIOL CHEM, V278, P11002, DOI 10.1074/jbc.M210810200; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C., 2001, SCI STKE; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; Nilius B, 2003, PFLUG ARCH EUR J PHY, V445, P584, DOI 10.1007/s00424-002-0923-9; Nilius B, 2002, J BIOL CHEM, V277, P30852, DOI 10.1074/jbc.M202418200; Nilius B, 2001, CELL CALCIUM, V29, P417, DOI 10.1054/ceca.2001.0201; Nilius B, 2001, PFLUG ARCH EUR J PHY, V443, P227, DOI 10.1007/s004240100676; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Peier AM, 2002, SCIENCE, V296, P2046, DOI 10.1126/science.1073140; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Trost C, 2001, BIOCHEM J, V355, P663, DOI 10.1042/bj3550663; Voets T, 2002, J BIOL CHEM, V277, P33704, DOI 10.1074/jbc.M204828200; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; Wissenbach U, 2000, FEBS LETT, V485, P127, DOI 10.1016/S0014-5793(00)02212-2; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Xu HX, 2002, NATURE, V418, P181, DOI 10.1038/nature00882; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698	41	155	164	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26541	26549		10.1074/jbc.M302590200	http://dx.doi.org/10.1074/jbc.M302590200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12724311	hybrid			2022-12-25	WOS:000184155700034
J	Hu, LYA; Chen, W; Martin, NP; Whalen, EJ; Premont, RT; Lefkowitz, RJ				Hu, LYA; Chen, W; Martin, NP; Whalen, EJ; Premont, RT; Lefkowitz, RJ			GIPC interacts with the beta(1)-adrenergic receptor and regulates beta(1)-adrenergic receptor-mediated ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; DOMAIN-CONTAINING PROTEIN; BETA(2)-ADRENERGIC RECEPTOR; CARDIAC MYOCYTES; PDZ DOMAIN; BETA-1-ADRENERGIC RECEPTOR; BETA-ARRESTINS; C-TERMINUS; KINASE-A; HEPTAHELICAL RECEPTORS	beta(1)-adrenergic receptors, expressed at high levels in the human heart, have a carboxyl-terminal ESKV motif that can directly interact with PDZ domain-containing proteins. Using the beta(1)-adrenergic receptor carboxyl terminus as bait, we identified the novel beta(1)-adrenergic receptor-binding partner GIPC in a yeast two-hybrid screen of a human heart cDNA library. Here we demonstrate that the PDZ domain-containing protein, GIPC, co-immunoprecipitates with the beta(1)-adrenergic receptor in COS-7 cells. Essential for this interaction is the Ser residue of the beta(1)-adrenergic receptor carboxyl-terminal ESKV motif. Our data also demonstrate that beta(1)-adrenergic receptor stimulation activates the mitogen-activated protein kinase, ERK1/2. beta(1)-adrenergic receptor-mediated ERK1/2 activation was inhibited by pertussis toxin, implicating G(i), and was substantially decreased by the expression of GIPC. Expression of GIPC had no observable effect on beta(1)-adrenergic receptor sequestration or receptor-mediated cAMP accumulation. This GIPC effect was specific for the beta(1)-adrenergic receptor and was dependent on an intact PDZ binding motif. These data suggest that GIPC can regulate beta(1)-adrenergic receptor-stimulated, G(i)-mediated, ERK activation while having no effect on receptor internalization or G(s)-mediated cAMP signaling.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Box 3821, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021	Martin, Negin/0000-0003-3166-8989; Premont, Richard/0000-0002-8053-5026; Chen, Wei/0000-0002-9934-4000	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Awan A, 2002, BIOCHEM BIOPH RES CO, V290, P1030, DOI 10.1006/bbrc.2001.6288; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; Booth RA, 2002, J BIOL CHEM, V277, P6719, DOI 10.1074/jbc.M108033200; BRODDE OE, 1993, PHARMACOL THERAPEUT, V60, P405, DOI 10.1016/0163-7258(93)90030-H; BRODDE OE, 1991, PHARMACOL REV, V43, P203; Brzostowski JA, 2001, TRENDS BIOCHEM SCI, V26, P291, DOI 10.1016/S0968-0004(01)01804-7; Cai HB, 1999, J NEUROSCI, V19, P6519; Chesley A, 2000, CIRC RES, V87, P1172, DOI 10.1161/01.RES.87.12.1172; Communal C, 2000, J BIOL CHEM, V275, P19395, DOI 10.1074/jbc.M910471199; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Devic E, 2001, MOL PHARMACOL, V60, P577; El Mourabit H, 2002, MATRIX BIOL, V21, P207, DOI 10.1016/S0945-053X(01)00198-6; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hu LA, 2002, J BIOL CHEM, V277, P1607, DOI 10.1074/jbc.M107297200; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Kang PM, 2000, CIRC RES, V86, P1107; Kilts JD, 2000, CIRC RES, V87, P705, DOI 10.1161/01.RES.87.8.705; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; Lefkowitz RJ, 2000, NAT CELL BIOL, V2, pE133, DOI 10.1038/35017152; Lou XJ, 2001, MOL BIOL CELL, V12, P615, DOI 10.1091/mbc.12.3.615; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 2002, CAN J PHYSIOL PHARM, V80, P375, DOI 10.1139/Y02-045; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; McDonald PH, 2001, CELL SIGNAL, V13, P683, DOI 10.1016/S0898-6568(01)00203-0; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Steinberg SF, 1999, CIRC RES, V85, P1101; Tan C, 2001, DEVELOPMENT, V128, P3665; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; Tani TT, 2001, J BIOL CHEM, V276, P36535, DOI 10.1074/jbc.M105785200; Wang LH, 1999, J BIOL CHEM, V274, P14137, DOI 10.1074/jbc.274.20.14137; Xiang Y, 2002, J BIOL CHEM, V277, P33783, DOI 10.1074/jbc.M204136200; Xiao RP, 1999, CIRC RES, V85, P1092; Xiao RP, 1999, CIRC RES, V84, P43; XIAO RP, 2001, SCI STKE; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200; Zamah AM, 2002, J BIOL CHEM, V277, P31249, DOI 10.1074/jbc.M202753200; Zheng M, 2000, J BIOL CHEM, V275, P40635, DOI 10.1074/jbc.M006325200; Zhu WZ, 2001, P NATL ACAD SCI USA, V98, P1607, DOI 10.1073/pnas.98.4.1607	48	80	83	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26295	26301		10.1074/jbc.M212352200	http://dx.doi.org/10.1074/jbc.M212352200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12724327	hybrid			2022-12-25	WOS:000183920200129
J	Heck, DE; Vetrano, AM; Mariano, TM; Laskin, JD				Heck, DE; Vetrano, AM; Mariano, TM; Laskin, JD			UVB light stimulates production of reactive oxygen species - Unexpected role for catalase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPRESSES NITRIC-OXIDE; DNA-DAMAGE; MECHANISMS; CELL; PHOTOCARCINOGENESIS; SKIN; CARCINOGENESIS; KERATINOCYTES; MACROPHAGES; GENERATION	In keratinocytes, UVB light stimulates the production of reactive oxygen species ( ROS). Lysates of these cells were found to possess a non- dialyzable, trypsin- and heat- sensitive material capable of generating ROS in response to UVB light. Using ion exchange, metal affinity, and size exclusion chromatography, a 240- kDa protein was isolated with ROS generating activity. The protein exhibited strong absorption in the 320 - 360 nm range with additional soret peaks around 400 - 410 nm, suggesting the presence of heme. Sequencing using liquid chromatography- ion trap mass spectrometry identified the protein as catalase. Using purified catalases from a variety of species, the ROS generating activity was found to be temperature- and O-2- dependent, stimulated by inhibitors of the catalatic activity of catalase, including 3- aminotriazole and azide, and inhibited by cyanide. A marked increase in the production of ROS was observed in UVB- treated cells overexpressing catalase and decreased generation of oxidants was found in UVB- treated keratinocytes with reduced levels of catalase. Our data indicate that catalase plays a direct role in generating oxidants in response to UVB light. The finding that catalase mediates the production of ROS following UVB treatment is both novel and highly divergent from the well known antioxidant functions of the enzyme. We hypothesize that, through the actions of catalase, high energy DNA damaging UVB light is absorbed by the enzyme and converted to reactive chemical intermediates that can be detoxified by cellular antioxidant enzymes. Accumulation of excessive ROS, generated through the action of catalase, may lead to oxidative stress, DNA damage, and the development of skin cancer.	Rutgers State Univ, Dept Pharmacol & Toxicol, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Environm & Community Med, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Heck, DE (corresponding author), Rutgers State Univ, Dept Pharmacol & Toxicol, 170 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	heck@eohsi.rutgers.edu			NCI NIH HHS [CA93798] Funding Source: Medline; NIEHS NIH HHS [ES05022, ES06897] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093798, R55CA093798] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES006897] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alam M, 2001, NEW ENGL J MED, V344, P975, DOI 10.1056/NEJM200103293441306; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bauer V, 1999, GEN PHYSIOL BIOPHYS, V18, P7; Beyer W F Jr, 1988, Basic Life Sci, V49, P651; BORS W, 1982, SUPEROXIDE DISMUTASE, V2, P31; Cadenas E, 1997, BIOFACTORS, V6, P391, DOI 10.1002/biof.5520060404; Cadet J, 2001, CURR PROBL DERMATOL, V29, P62; CAMHI SL, 1995, NEW HORIZ, V3, P70; CHANCE B, 1969, ANN NY ACAD SCI, V168, P354, DOI 10.1111/j.1749-6632.1969.tb43122.x; CHANCE B, 1971, BIOCHEM J, V122, P225, DOI 10.1042/bj1220225; Cleaver JE, 2002, FRONT BIOSCI-LANDMRK, V7, pD1024, DOI 10.2741/cleaver; de Gruijl FR, 2001, J PHOTOCH PHOTOBIO B, V63, P19, DOI 10.1016/S1011-1344(01)00199-3; Decraene D, 2001, J PHOTOCH PHOTOBIO B, V63, P78, DOI 10.1016/S1011-1344(01)00204-4; DEISSEROTH A, 1970, PHYSIOL REV, V50, P319, DOI 10.1152/physrev.1970.50.3.319; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Engelsing K, 2001, MECH TIME-DEPEND MAT, V5, P27, DOI 10.1023/A:1009858702188; Fu YC, 2000, J TOXICOL ENV HEAL A, V61, P177, DOI 10.1080/00984100050131323; Gocke E, 2001, J Environ Pathol Toxicol Oncol, V20, P285; HANDLER JA, 1997, COMPREHENSIVE TOXICO, V3, P217; Harris DL, 2001, CURR OPIN CHEM BIOL, V5, P724, DOI 10.1016/S1367-5931(01)00272-1; HECK DE, 1992, J BIOL CHEM, V267, P21277; Hensley K, 2000, FREE RADICAL BIO MED, V28, P1456, DOI 10.1016/S0891-5849(00)00252-5; Jackson AL, 2001, MUTAT RES-FUND MOL M, V477, P7, DOI 10.1016/S0027-5107(01)00091-4; Kalko SG, 2001, J AM CHEM SOC, V123, P9665, DOI 10.1021/ja010512t; Ko TP, 2000, ACTA CRYSTALLOGR D, V56, P241, DOI 10.1107/S0907444999015930; Kovacic P, 2001, CURR MED CHEM, V8, P773, DOI 10.2174/0929867013373084; Lands WEM, 1998, ALCOHOL, V15, P147, DOI 10.1016/S0741-8329(97)00110-9; Lardinois OM, 1996, BBA-PROTEIN STRUCT M, V1298, P180, DOI 10.1016/S0167-4838(96)00130-6; Lee HC, 2000, J BIOMED SCI, V7, P2, DOI 10.1007/BF02255913; Loft S, 1996, J MOL MED, V74, P297, DOI 10.1007/BF00207507; Mates JM, 2000, TOXICOLOGY, V153, P83, DOI 10.1016/S0300-483X(00)00306-1; Matsumura Y, 2002, FRONT BIOSCI-LANDMRK, V7, pD765, DOI 10.2741/matsumur; MONKS TJ, 1990, TOXICOL APPL PHARM, V106, P1, DOI 10.1016/0041-008X(90)90100-9; OSHINO N, 1973, BIOCHEM J, V131, P555, DOI 10.1042/bj1310555; Putnam CD, 2000, J MOL BIOL, V296, P295, DOI 10.1006/jmbi.1999.3458; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; SPITZ DR, 1998, RADIAT RES, V114, P114; Strange RC, 2001, MUTAT RES-FUND MOL M, V482, P21, DOI 10.1016/S0027-5107(01)00206-8; Sur R, 2002, BIOCHEM PHARMACOL, V64, P1469, DOI 10.1016/S0006-2952(02)01419-3; Thiele JJ, 2001, CURR PROBL DERMATOL, V29, P26; Thurman R G, 1975, Adv Exp Med Biol, V59, P163; THURMAN RG, 1989, DRUG METAB REV, V20, P679, DOI 10.3109/03602538909103570; Ullrich SE, 2002, FRONT BIOSCI-LANDMRK, V7, pD684, DOI 10.2741/ullrich; Vink AA, 2001, J PHOTOCH PHOTOBIO B, V65, P101, DOI 10.1016/S1011-1344(01)00245-7; Weinberger B, 1998, AM J RESP CRIT CARE, V158, P931, DOI 10.1164/ajrccm.158.3.9708014; Yang Q, 1998, PROTEIN EXPRES PURIF, V12, P277, DOI 10.1006/prep.1997.0827	47	269	274	1	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22432	22436		10.1074/jbc.C300048200	http://dx.doi.org/10.1074/jbc.C300048200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12730222	hybrid			2022-12-25	WOS:000183503900036
J	Muller, YL; Yueh, YG; Yaworsky, PJ; Salbaum, JM; Kappen, C				Muller, YL; Yueh, YG; Yaworsky, PJ; Salbaum, JM; Kappen, C			Caudal dysgenesis in islet-1 transgenic mice	FASEB JOURNAL			English	Article						maternal diabetes; pancreas; embryopathy	INSULIN GENE-TRANSCRIPTION; DOMINANT SACRAL AGENESIS; HOMEOBOX GENE; DIABETIC EMBRYOPATHY; SONIC-HEDGEHOG; NEURAL-TUBE; BIRTH-WEIGHT; PAX-3 GENE; PAIRED BOX; EXPRESSION	Maternal diabetes during pregnancy is responsible for the occurrence of diabetic embryopathy, a spectrum of birth defects that includes heart abnormalities, neural tube defects, and caudal dysgenesis syndromes. Here, we report that mice transgenic for the homeodomain transcription factor Isl-1 develop profound caudal growth defects that resemble human sacral/caudal agenesis. Isl-1 is normally expressed in the pancreas and is required for pancreas development and endocrine cell differentiation. Aberrant regulation of this pancreatic transcription factor causes increased mesodermal cell death, and the severity of defects is dependent on transgene dosage. Together with the finding that mutation of the pancreatic transcription factor HLXB9 causes sacral agenesis, our results implicate pancreatic transcription factors in the pathogenesis of birth defects associated with diabetes.	Mayo Clin Scottsdale, Samuel C Johnson Med Res Ctr, Scottsdale, AZ USA; Neurosci Inst, San Diego, CA USA	Mayo Clinic; Mayo Clinic Phoenix	Kappen, C (corresponding author), Univ Nebraska, Med Ctr, Munroe Meyer Inst, Ctr Human Mol Genet, 600 S 42nd St, Omaha, NE 68198 USA.	ckappen@unmc.edu	Yueh, Yir Gloria/U-1699-2019		NCRR NIH HHS [P20 RR018788] Funding Source: Medline; NICHD NIH HHS [R01 HD037804] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037804] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018788] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Alles A J, 1993, Birth Defects Orig Artic Ser, V29, P83; Arber S, 1999, NEURON, V23, P659, DOI 10.1016/S0896-6273(01)80026-X; BAKER L, 1993, J DIABETES COMPLICAT, V7, P204, DOI 10.1016/1056-8727(93)90046-2; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BIEBERICH CJ, 1990, P NATL ACAD SCI USA, V87, P8462, DOI 10.1073/pnas.87.21.8462; Bohring A, 1999, AM J MED GENET, V87, P99, DOI 10.1002/(SICI)1096-8628(19991119)87:2<99::AID-AJMG1>3.0.CO;2-Q; Briscoe J, 1999, SEMIN CELL DEV BIOL, V10, P353, DOI 10.1006/scdb.1999.0295; BUCHANAN TA, 1994, ANNU REV MED, V45, P245; Casson IF, 1997, BRIT MED J, V315, P275, DOI 10.1136/bmj.315.7103.275; Cederberg J, 2001, PEDIATR RES, V49, P755, DOI 10.1203/00006450-200106000-00007; Chang TI, 1999, SEMIN REPROD ENDOCR, V17, P153, DOI 10.1055/s-2007-1016222; Dabelea D, 2001, J PEDIATR ENDOCR MET, V14, P1085; Dias MS, 1998, PEDIATR NEUROSURG, V28, P223, DOI 10.1159/000028655; DUHAMEL B, 1961, ARCH DIS CHILD, V36, P152, DOI 10.1136/adc.36.186.152; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Edlund H, 2001, DIABETES, V50, pS5, DOI 10.2337/diabetes.50.2007.S5; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; FREINKEL N, 1988, HORM METAB RES, V20, P463, DOI 10.1055/s-2007-1010861; Gardner DP, 1996, TRANSGENIC RES, V5, P37, DOI 10.1007/BF01979920; GAUSE A, 1987, EUR J IMMUNOL, V17, P981, DOI 10.1002/eji.1830170714; Goto Motoko P., 1994, Current Opinion in Pediatrics, V6, P486, DOI 10.1097/00008480-199408000-00023; GOULDING M, 1993, GENOMICS, V17, P355, DOI 10.1006/geno.1993.1332; Greene MF, 2001, TERATOLOGY, V63, P116, DOI 10.1002/tera.1021; Habener JF, 1998, P ASSOC AM PHYSICIAN, V110, P12; Hagan DM, 2000, AM J HUM GENET, V66, P1504, DOI 10.1086/302899; Harrison KA, 1999, NAT GENET, V23, P71, DOI 10.1038/12674; Hattersley AT, 1999, LANCET, V353, P1789, DOI 10.1016/S0140-6736(98)07546-1; HOTH CF, 1993, AM J HUM GENET, V52, P455; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; KAPPEN C, 1999, GENETIC MANIPULATION, P69; KUCERA J, 1971, J REPROD MED, V7, P73; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Li H, 1999, NAT GENET, V23, P67; Lynch SA, 2000, J MED GENET, V37, P561, DOI 10.1136/jmg.37.8.561; LYNCH SA, 1995, NAT GENET, V11, P93, DOI 10.1038/ng0995-93; Lyons Jones K., 1988, SMITHS RECOGNIZABLE; MANSOURI A, 1994, J CELL SCI, P35; Marshak S, 1996, P NATL ACAD SCI USA, V93, P15057, DOI 10.1073/pnas.93.26.15057; MARTINEZFRIAS ML, 1994, AM J MED GENET, V51, P108, DOI 10.1002/ajmg.1320510206; Meigs JB, 2000, DIABETES, V49, P2201, DOI 10.2337/diabetes.49.12.2201; MILLS JL, 1982, TERATOLOGY, V25, P385, DOI 10.1002/tera.1420250316; *NAT DIAB DAT GROU, 1995, NIH PUBL; Olson LK, 1998, MOL ENDOCRINOL, V12, P207, DOI 10.1210/me.12.2.207; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; Phelan SA, 1997, DIABETES, V46, P1189, DOI 10.2337/diabetes.46.7.1189; Roduit R, 2000, J BIOL CHEM, V275, P35799, DOI 10.1074/jbc.M006001200; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Ross AJ, 1998, NAT GENET, V20, P358, DOI 10.1038/3828; Rundle CH, 1998, BBA-GENE STRUCT EXPR, V1398, P164, DOI 10.1016/S0167-4781(98)00046-3; Salbaum JM, 1998, MECH DEVELOP, V71, P201, DOI 10.1016/S0925-4773(98)00005-7; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1127, DOI 10.1210/me.9.9.1127; Shashikant CS, 1995, DEVELOPMENT, V121, P4339; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; TASSABEHJI M, 1993, NAT GENET, V3, P26, DOI 10.1038/ng0193-26; Terauchi Y, 2000, DIABETES, V49, P82, DOI 10.2337/diabetes.49.1.82; Thaler J, 1999, NEURON, V23, P675, DOI 10.1016/S0896-6273(01)80027-1; Van Assche EA, 1998, J PERINAT MED, V26, P337; WALLIN J, 1994, DEVELOPMENT, V120, P1109; Weir GC, 1997, ACTA DIABETOL, V34, P177, DOI 10.1007/s005920050071; Yaworsky PJ, 1997, J BIOL CHEM, V272, P25112, DOI 10.1074/jbc.272.40.25112; Yueh YG, 1998, P NATL ACAD SCI USA, V95, P9956, DOI 10.1073/pnas.95.17.9956	66	10	11	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1349	+		10.1096/fj.02-0856fje	http://dx.doi.org/10.1096/fj.02-0856fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738808	Green Accepted			2022-12-25	WOS:000183165000028
J	Dutkiewicz, R; Schilke, B; Knieszner, H; Walter, W; Craig, EA; Marszalek, J				Dutkiewicz, R; Schilke, B; Knieszner, H; Walter, W; Craig, EA; Marszalek, J			Ssq1, a mitochondrial Hsp70 involved in iron-sulfur (Fe/S) center biogenesis - Similarities to and differences from its bacterial counterpart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE SYSTEM; ASSEMBLY PROTEIN ISCU; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; DNAK CHAPERONE; ATPASE CYCLE; GRPE; CLUSTERS; HOMOLOG; MUTANT	The results of in vivo and in organellar experiments indicate that the Hsp70 Ssq1 and the J-protein Jac1 function together to assist in the biogenesis of iron-sulfur (Fe/S) centers in the mitochondrial matrix. Here we present biochemical evidence supporting this idea. Isu, the proposed scaffold on which Fe/S centers are assembled, is a substrate for both Jac1 and Ssq1. Jac1 and Isu1 cooperatively stimulate the ATPase activity of Ssq1. In addition, Jac1 facilitates the interaction of Ssq1 with Isu1 in the presence of ATP. These findings are consistent with the role in Fe/S biogenesis previously proposed for the bacterial Hsp70 Hsc66 and J-protein Hsc20 that interact with the bacterial Isu homologue IscU. However, unlike the bacterial Hsp70, we found that Ssq1 has a high affinity for nucleotide, and shares a nucleotide exchange factor, Mge1, with a second mitochondrial Hsp70, Ssc1. Thus, whereas the bacterial and mitochondrial chaperone systems share critical features, they possess significant biochemical differences as well.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Gdansk, Dept Mol & Cellular Biol, Fac Biotechnol, PL-80822 Gdansk, Poland	University of Wisconsin System; University of Wisconsin Madison; Fahrenheit Universities; University of Gdansk	Craig, EA (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.	ecraig@wisc.edu	Marszalek, Jaroslaw/F-5824-2011; Dutkiewicz, Rafal/ABE-6979-2020; Dutkiewicz, Rafal/F-5956-2011	Dutkiewicz, Rafal/0000-0003-4150-0450; Marszalek, Jaroslaw/0000-0002-6978-1189	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013790] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027870] Funding Source: NIH RePORTER; NCRR NIH HHS [S10 RR13790] Funding Source: Medline; NIGMS NIH HHS [R01GM27870] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; Brehmer D, 2001, NAT STRUCT BIOL, V8, P427, DOI 10.1038/87588; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; CRAIG E, 1999, MOL CHAPERONES FOLDI, P139; Craig EA, 1999, BIOL CHEM, V380, P1167, DOI 10.1515/BC.1999.148; Craig EA, 2002, CELL MOL LIFE SCI, V59, P1658, DOI 10.1007/PL00012493; Dekker PJT, 1997, J MOL BIOL, V270, P321, DOI 10.1006/jmbi.1997.1131; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; Hesterkamp T, 1998, EMBO J, V17, P4818, DOI 10.1093/emboj/17.16.4818; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Horst M, 1997, EMBO J, V16, P1842, DOI 10.1093/emboj/16.8.1842; Huynen MA, 2001, HUM MOL GENET, V10, P2463, DOI 10.1093/hmg/10.21.2463; KAWULA TH, 1994, J BACTERIOL, V176, P610, DOI 10.1128/jb.176.3.610-619.1994; Kim R, 2001, J BIOL CHEM, V276, P17524, DOI 10.1074/jbc.M010695200; Knight SAB, 1998, J BIOL CHEM, V273, P18389, DOI 10.1074/jbc.273.29.18389; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; LIBEREK K, 1992, P NATL ACAD SCI USA, V89, P3516, DOI 10.1073/pnas.89.8.3516; Lill R, 1999, BIOL CHEM, V380, P1157, DOI 10.1515/BC.1999.147; Lutz T, 2001, J MOL BIOL, V307, P815, DOI 10.1006/jmbi.2001.4527; Miao BJ, 1997, J MOL BIOL, V265, P541, DOI 10.1006/jmbi.1996.0762; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Schilke B, 1996, J CELL BIOL, V134, P603, DOI 10.1083/jcb.134.3.603; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; Schmidt S, 2001, J MOL BIOL, V313, P13, DOI 10.1006/jmbi.2001.5013; SEATON BL, 1994, P NATL ACAD SCI USA, V91, P2066, DOI 10.1073/pnas.91.6.2066; SIKORSKI RS, 1989, GENETICS, V122, P19; Silberg JJ, 1998, J BACTERIOL, V180, P6617, DOI 10.1128/JB.180.24.6617-6624.1998; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Silberg JJ, 2000, J BIOL CHEM, V275, P7779, DOI 10.1074/jbc.275.11.7779; Tokumoto U, 2002, J BIOCHEM, V131, P713, DOI 10.1093/oxfordjournals.jbchem.a003156; Vickery LE, 1997, PROTEIN SCI, V6, P1047, DOI 10.1002/pro.5560060511; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; Voisine C, 2000, MOL CELL BIOL, V20, P3677, DOI 10.1128/MCB.20.10.3677-3684.2000; Voisine C, 2001, P NATL ACAD SCI USA, V98, P1483, DOI 10.1073/pnas.98.4.1483; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437	43	103	109	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29719	29727		10.1074/jbc.M303527200	http://dx.doi.org/10.1074/jbc.M303527200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12756240	hybrid			2022-12-25	WOS:000184507000043
J	Fisher, RD; Wang, B; Alam, SL; Higginson, DS; Robinson, H; Sundquist, WI; Hill, CP				Fisher, RD; Wang, B; Alam, SL; Higginson, DS; Robinson, H; Sundquist, WI; Hill, CP			Structure and ubiquitin binding of the ubiquitin-interacting motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASE SUBUNIT; UBA DOMAINS; PROTEINS; SURFACE; HRS; RECOGNITION; COMPONENTS; REGULATOR; COMPLEX; TSG101	Ubiquitylation is used to target proteins into a large number of different biological processes including proteasomal degradation, endocytosis, virus budding, and vacuolar protein sorting (Vps). Ubiquitylated proteins are typically recognized using one of several different conserved ubiquitin binding modules. Here, we report the crystal structure and ubiquitin binding properties of one such module, the ubiquitin-interacting motif (UIM). We found that UIM peptides from several proteins involved in endocytosis and vacuolar protein sorting including Hrs, Vps27p, Stam1, and Eps15 bound specifically, but with modest affinity (K-d = 0.1 - 1 mM), to free ubiquitin. Full affinity ubiquitin binding required the presence of conserved acidic patches at the N and C terminus of the UIM, as well as highly conserved central alanine and serine residues. NMR chemical shift perturbation mapping experiments demonstrated that all of these UIM peptides bind to the I44 surface of ubiquitin. The 1.45 Angstrom resolution crystal structure of the second yeast Vps27p UIM (Vps27p-2) revealed that the ubiquitin-interacting motif forms an amphipathic helix. Although Vps27p-2 is monomeric in solution, the motif unexpectedly crystallized as an antiparallel four-helix bundle, and the potential biological implications of UIM oligomerization are therefore discussed.	Univ Utah, Dept Biochem, Sch Med, Salt Lake City, UT 84132 USA; Brookhaven Natl Lab, Dept Biol 463, Upton, NY 11973 USA	Utah System of Higher Education; University of Utah; United States Department of Energy (DOE); Brookhaven National Laboratory	Sundquist, WI (corresponding author), Univ Utah, Dept Biochem, Sch Med, Salt Lake City, UT 84132 USA.	wes@biochem.utah.edu; chris@biochem.utah.edu	Higginson, Daniel/X-8619-2018; Higginson, Daniel/AAW-4021-2020	Higginson, Daniel/0000-0002-6686-7454; Higginson, Daniel/0000-0002-6686-7454				AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Bache KG, 2003, J BIOL CHEM, V278, P12513, DOI 10.1074/jbc.M210843200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Bean AJ, 2000, J BIOL CHEM, V275, P15271, DOI 10.1074/jbc.275.20.15271; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Carbone R, 1997, CANCER RES, V57, P5498; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chen L, 2001, EMBO REP, V2, P933, DOI 10.1093/embo-reports/kve203; Confalonieri S, 2000, J CELL BIOL, V150, P905, DOI 10.1083/jcb.150.4.905; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Donaldson KM, 2003, CURR BIOL, V13, P258, DOI 10.1016/S0960-9822(03)00043-5; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Koonin EV, 1997, NAT GENET, V16, P330, DOI 10.1038/ng0897-330; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; McRorie D. K., 1993, SELF ASS SYSTEMS ANA; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Myszka DG, 1998, TRENDS BIOCHEM SCI, V23, P149, DOI 10.1016/S0968-0004(98)01183-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pelham HRB, 2001, TRENDS CELL BIOL, V11, P99, DOI 10.1016/S0962-8924(01)01929-8; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Ponting CP, 1997, J MOL MED-JMM, V75, P467; Ponting CP, 2000, BIOCHEM J, V351, P527, DOI 10.1042/0264-6021:3510527; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; Pornillos O, 2002, TRENDS CELL BIOL, V12, P569, DOI 10.1016/S0962-8924(02)02402-9; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Rosenthal JA, 1999, J BIOL CHEM, V274, P33959, DOI 10.1074/jbc.274.48.33959; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shekhtman A, 2002, BIOCHEM BIOPH RES CO, V296, P1222, DOI 10.1016/S0006-291X(02)02006-5; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; Strack B, 2002, J VIROL, V76, P5472, DOI 10.1128/JVI.76.11.5472-5479.2002; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Urbanowski JL, 2001, TRAFFIC, V2, P622, DOI 10.1034/j.1600-0854.2001.20905.x; vanDelft S, 1997, J BIOL CHEM, V272, P14013, DOI 10.1074/jbc.272.22.14013; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Yoo SH, 1997, J MOL BIOL, V269, P780, DOI 10.1006/jmbi.1997.1051; You JX, 1999, BIOTECHNIQUES, V27, P950, DOI 10.2144/99275st01; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461	67	156	159	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28976	28984		10.1074/jbc.M302596200	http://dx.doi.org/10.1074/jbc.M302596200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12750381	hybrid			2022-12-25	WOS:000184421100078
J	Kim, DW; Kempf, H; Chen, RE; Lassar, AB				Kim, DW; Kempf, H; Chen, RE; Lassar, AB			Characterization of Nkx3.2 DNA binding specificity and its requirement for somitic chondrogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMAD TRANSCRIPTIONAL COREPRESSOR; SONIC-HEDGEHOG; HOMEOBOX GENES; CARTILAGE FORMATION; HOMEODOMAIN FACTOR; ACTS DOWNSTREAM; AXIAL SKELETON; COLLAGEN GENE; II COLLAGEN; SOX9	We have previously shown that Nkx3.2, a member of the NK class of homeoproteins, functions as a transcriptional repressor to promote somitic chondrogenesis. However, it has not been addressed whether Nkx3.2 can bind to DNA in a sequence-specific manner and whether DNA binding by Nkx3.2 is required for its biological activity. In this work, we employed a DNA binding site selection assay, which identified TAAGTG as a high affinity Nkx3.2 binding sequence. Sequence-specific binding of Nkx3.2 to the TAAGTG motif in vitro was confirmed by electrophoretic mobility shift assays, and mutagenesis of this sequence revealed that HRAGTG (where H represents A, C, or T, and R represents A or G) comprises the consensus DNA binding site for Nkx3.2. Consistent with these findings, the expression of a reporter gene containing reiterated Nkx3.2 binding sites was repressed in vivo by Nkx3.2 co-expression. In addition, we have generated a DNA nonbinding point mutant of Nkx3.2 (Nkx3.2-N200Q), which contains an asparagine to glutamine missense mutation in the homeodomain. Interestingly, despite being defective in DNA binding, Nkx3.2-N200Q still retains its intrinsic transcriptional repressor function. Finally, we demonstrate that unlike wild-type Nkx3.2, Nkx3.2-N200Q is unable to activate the chondrocyte differentiation program in somitic mesoderm, indicating that DNA binding by Nkx3.2 is critical for this factor to induce somitic chondrogenesis.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Lassar, AB (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.		Kempf, Herve/F-1171-2011	Kempf, Herve/0000-0003-1818-2327				Akazawa H, 2000, GENES CELLS, V5, P499, DOI 10.1046/j.1365-2443.2000.00339.x; Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; Amendt BA, 1999, J BIOL CHEM, V274, P11635, DOI 10.1074/jbc.274.17.11635; Bi WM, 2001, P NATL ACAD SCI USA, V98, P6698, DOI 10.1073/pnas.111092198; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWELL TK, 1995, METHOD ENZYMOL, V254, P604; BOTFIELD MC, 1994, BIOCHEMISTRY-US, V33, P6177, DOI 10.1021/bi00186a017; Britto JM, 2000, BIOESSAYS, V22, P499, DOI 10.1002/(SICI)1521-1878(200006)22:6<499::AID-BIES1>3.0.CO;2-F; CATRON KM, 1993, MOL CELL BIOL, V13, P2354, DOI 10.1128/MCB.13.4.2354; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Choi CY, 1999, J BIOL CHEM, V274, P31543, DOI 10.1074/jbc.274.44.31543; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; Denisenko ON, 1997, MOL CELL BIOL, V17, P4707, DOI 10.1128/MCB.17.8.4707; Dockter JL, 2000, CURR TOP DEV BIOL, V48, P77; Fraenkel E, 1998, NAT STRUCT BIOL, V5, P692, DOI 10.1038/1382; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; Harfe BD, 1998, DEVELOPMENT, V125, P421; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Hirsinger E, 2000, INT REV CYTOL, V198, P1; Hirsinger E, 1997, DEVELOPMENT, V124, P4605; Huang RJ, 2000, DEVELOPMENT, V127, P527; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; Kawakami Y, 1996, DEVELOPMENT, V122, P3557; KIM YS, 1989, P NATL ACAD SCI USA, V86, P7716, DOI 10.1073/pnas.86.20.7716; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Lettice LA, 1999, P NATL ACAD SCI USA, V96, P9695, DOI 10.1073/pnas.96.17.9695; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; Murtaugh LC, 2001, DEV CELL, V1, P411, DOI 10.1016/S1534-5807(01)00039-9; Murtaugh LC, 1999, GENE DEV, V13, P225, DOI 10.1101/gad.13.2.225; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; POMERANTZ JL, 1994, BIOCHEMISTRY-US, V33, P10851, DOI 10.1021/bi00202a001; Reshef R, 1998, GENE DEV, V12, P290, DOI 10.1101/gad.12.3.290; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sekiya I, 2000, J BIOL CHEM, V275, P10738, DOI 10.1074/jbc.275.15.10738; Smits P, 2001, DEV CELL, V1, P277, DOI 10.1016/S1534-5807(01)00003-X; Steadman DJ, 2000, NUCLEIC ACIDS RES, V28, P2389, DOI 10.1093/nar/28.12.2389; Stockdale FE, 2000, DEV DYNAM, V219, P304, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1057>3.0.CO;2-5; Teillet MA, 1998, DEVELOPMENT, V125, P2019; Tonegawa A, 1997, DEVELOPMENT, V124, P1975; Tribioli C, 1999, DEVELOPMENT, V126, P5699; Tribioli C, 1997, MECH DEVELOP, V65, P145, DOI 10.1016/S0925-4773(97)00067-1; Wotton D, 1999, J BIOL CHEM, V274, P37105, DOI 10.1074/jbc.274.52.37105; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Zeng L, 2002, GENE DEV, V16, P1990, DOI 10.1101/gad.1008002	57	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27532	27539		10.1074/jbc.M301461200	http://dx.doi.org/10.1074/jbc.M301461200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12746429	hybrid			2022-12-25	WOS:000184242700026
J	Wu, J; Howe, DL; Woodard, RW				Wu, J; Howe, DL; Woodard, RW			Thermotoga maritima 3-deoxy-d-arabino-heptulosonate 7-phosphate (DAHP) synthase - The ancestral eubacterial DAHP synthase?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DEOXY-D-MANNO-OCTULOSONATE 8-PHOSPHATE SYNTHASE; ESCHERICHIA-COLI; AQUIFEX-AEOLICUS; NEISSERIA-GONORRHOEAE; REGULATORY ENZYMES; BACILLUS SUBTILIS; METAL; PURIFICATION; SYNTHETASE; KINETICS	The gene encoding the 3-deoxy-D-arabino-heptulosonate 7-phosphate (DAHP) synthase from the thermophilic microorganism Thermotoga maritima was cloned, and the enzyme was overexpressed in Escherichia coli. The purified DAHP synthase displays a homotetrameric structure and exhibits maximal activity at 90 degreesC. The enzyme is extremely thermostable, with 50% of its initial activity retained after incubation for similar to5 h at 80 degreesC, 21 h at 70 degreesC, and 86 h at 60 degreesC. The enzyme appears to follow Michaelis-Menten kinetics with K-m for phosphoenolpyruvate = 9.5-13 muM, K-m for D-erythrose 4-phosphate = 57.3-350.1 muM, and k(cat) = 2.3-7.6 s(-1) between 50 degreesC and 70 degreesC. Metal analysis indicates that DAHP synthase as isolated contains Zn2+, and the enzyme is inactivated by treatment with EDTA. The apo-enzyme is partially reactivated by a variety of divalent metals including Zn2+, Cd-2+, Mn2+, Cu2+, Co2+, and Ni2+. These observations suggest that T. maritima DAHP synthase is a metalloenzyme. The activity of T. maritima DAHP synthase is inhibited by two of the three aromatic amino acids (L-Phe and L-Tyr) formed in the Shikimate pathway. This report is the first description of a thermophilic eubacterial DAHP synthase.	Univ Michigan, Coll Pharm, Dept Med Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Woodard, RW (corresponding author), Univ Michigan, Coll Pharm, Dept Med Chem, 428 Church St, Ann Arbor, MI 48109 USA.			Woodard, Ronald/0000-0002-7472-3653	NIGMS NIH HHS [GM 53069] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053069] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHENBACHRICHTER L, 1987, SYST APPL MICROBIOL, V9, P34, DOI 10.1016/S0723-2020(87)80053-X; Akowski JP, 1997, BIOCHEMISTRY-US, V36, P15817, DOI 10.1021/bi971135t; Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056; BAASOV T, 1989, J BACTERIOL, V171, P6155, DOI 10.1128/jb.171.11.6155-6160.1989; Birck MR, 2001, J MOL EVOL, V52, P205, DOI 10.1007/s002390010149; Bocchetta M, 2000, J MOL EVOL, V50, P366, DOI 10.1007/s002399910040; BROWN KD, 1966, BIOCHIM BIOPHYS ACTA, V118, P157, DOI 10.1016/S0926-6593(66)80153-4; CHEN CC, 1993, FEMS MICROBIOL LETT, V107, P223, DOI 10.1111/j.1574-6968.1993.tb06034.x; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; DELEO AB, 1973, J BIOL CHEM, V248, P2344; Duewel HS, 2001, J BIOL CHEM, V276, P8393, DOI 10.1074/jbc.M007884200; Duewel HS, 2000, J BIOL CHEM, V275, P22824, DOI 10.1074/jbc.M000133200; Gosset G, 2001, J BACTERIOL, V183, P4061, DOI 10.1128/JB.183.13.4061-4070.2001; Howe DL, 2000, J BIOL CHEM, V275, P40258, DOI 10.1074/jbc.M003585200; HUBER R, 1986, ARCH MICROBIOL, V144, P324, DOI 10.1007/BF00409880; JENSEN RA, 1966, J BIOL CHEM, V241, P3365; JENSEN RA, 1966, J BIOL CHEM, V241, P3373; Jensen RA, 2002, J MOL EVOL, V54, P416, DOI 10.1007/s00239-001-0031-z; Jordan PA, 2001, BIOCHEMISTRY-US, V40, P8387, DOI 10.1021/bi010238f; Krosky DJ, 2002, BBA-PROTEIN STRUCT M, V1594, P297, DOI 10.1016/S0167-4838(01)00319-3; NIMMO GA, 1981, BIOCHEM J, V199, P657, DOI 10.1042/bj1990657; Park OK, 1999, J BACTERIOL, V181, P1636, DOI 10.1128/JB.181.5.1636-1642.1999; RAY JM, 1991, J BACTERIOL, V173, P1894, DOI 10.1128/jb.173.6.1894-1901.1991; SCHONER R, 1976, J BIOL CHEM, V251, P5440; Sheflyan GY, 1998, J AM CHEM SOC, V120, P11027, DOI 10.1021/ja9816281; Shumilin IA, 1999, STRUCTURE, V7, P865, DOI 10.1016/S0969-2126(99)80109-9; Shumilin IA, 2002, J MOL BIOL, V320, P1147, DOI 10.1016/S0022-2836(02)00545-4; STEPHENS CM, 1991, J BIOL CHEM, V266, P20810; Subramaniam PS, 1998, J BACTERIOL, V180, P119, DOI 10.1128/JB.180.1.119-127.1998; Sundaram AK, 2001, ORG LETT, V3, P21, DOI 10.1021/ol0066126; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wagner T, 2000, J MOL BIOL, V301, P389, DOI 10.1006/jmbi.2000.3957; WALSH CT, 1996, CURR BIOL, V3, P93; Wang J, 2001, BIOCHEMISTRY-US, V40, P15676, DOI 10.1021/bi015568e	34	30	52	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27525	27531		10.1074/jbc.M304631200	http://dx.doi.org/10.1074/jbc.M304631200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12743122	hybrid			2022-12-25	WOS:000184242700025
J	Dyall, SD; Agius, SC; Lousa, CD; Trezeguet, V; Tokatlidis, K				Dyall, SD; Agius, SC; Lousa, CD; Trezeguet, V; Tokatlidis, K			The dynamic dimerization of the yeast ADP/ATP carrier in the inner mitochondrial membrane is affected by conserved cysteine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-ATP CARRIER; BEEF-HEART MITOCHONDRIA; ABC TRANSPORTERS; SACCHAROMYCES-CEREVISIAE; PROTEIN IMPORT; OXOGLUTARATE CARRIER; INTERMEMBRANE SPACE; MEDIATES INSERTION; OUTER-MEMBRANE; TOM COMPLEX	The ADP/ATP carrier (AAC) that facilitates the translocation of ATP made in mitochondria is inserted at the inner mitochondrial membrane by the TIM10-TIM22 protein import system. Here we addressed the state of the AAC precursor during insertion ( stage IV of import) and identified residues of the carrier important for dimerization. By a combination of (i) import of a mix of His-tagged and untagged versions of AAC either S-35-labeled or unlabeled, (ii) import of a tandem covalent dimer AAC into wild-type mitochondria, and (iii) import of monomeric AAC into mitochondria expressing only the tandem covalent dimer AAC, we found that the stage IV intermediate is a monomer, and this stage is probably the rate-limiting step of insertion in the membrane. Subsequent dimerization occurs extremely rapidly ( within less than a minute). The incoming monomer dimerizes with monomeric endogenous AAC suggesting that the AAC dimer is very dynamic. Conserved Cys residues were found not to affect insertion significantly, but they are crucial for the dimerization process to obtain a functional carrier.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Inst Biochim & Genet Cellulaires, Lab Physiol Mol & Cellulaire, F-33077 Bordeaux, France; Univ Crete, Dept Chem, Iraklion 71409, Crete, Greece; Fdn Res & Technol, Inst Mol Biol & Biotechnol, Iraklion 71409, Crete, Greece	University of Manchester; University of Crete	Tokatlidis, K (corresponding author), Univ Manchester, Sch Biol Sci, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.			Agius, Stephanie/0000-0001-6561-1898; De Marcos Lousa, Carine/0000-0002-5041-6261; Trezeguet, Veronique/0000-0003-2487-7571; Tokatlidis, Kostas/0000-0001-6295-8183	MRC [G0000153] Funding Source: UKRI; Medical Research Council [G0000153] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adam A, 1999, EMBO J, V18, P313, DOI 10.1093/emboj/18.2.313; BEYER K, 1985, BIOCHEMISTRY-US, V24, P3821, DOI 10.1021/bi00336a001; Beyer K, 1996, BIOCHEMISTRY-US, V35, P15784, DOI 10.1021/bi9610055; Bisaccia F, 1996, BBA-PROTEIN STRUCT M, V1292, P281, DOI 10.1016/0167-4838(95)00215-4; BLOCK MR, 1984, BIOCHIM BIOPHYS ACTA, V767, P369, DOI 10.1016/0005-2728(84)90207-X; BLOCK MR, 1982, BIOCHEM BIOPH RES CO, V109, P471, DOI 10.1016/0006-291X(82)91745-4; BOULAY F, 1984, BIOCHEMISTRY-US, V23, P4807, DOI 10.1021/bi00315a042; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; ElMoualij B, 1997, YEAST, V13, P573, DOI 10.1002/(SICI)1097-0061(199705)13:6<573::AID-YEA107>3.0.CO;2-I; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; GAWAZ M, 1990, J BIOL CHEM, V265, P14202; HACKENBERG H, 1980, BIOCHEMISTRY-US, V19, P548, DOI 10.1021/bi00544a024; Hashimoto M, 1999, BIOCHEMISTRY-US, V38, P1050, DOI 10.1021/bi9822978; Hatanaka T, 1999, BIOCHEM BIOPH RES CO, V262, P726, DOI 10.1006/bbrc.1999.1283; Hatanaka T, 2001, BIOCHEM BIOPH RES CO, V286, P936, DOI 10.1006/bbrc.2001.5498; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Higgins CF, 2001, SCIENCE, V293, P1782, DOI 10.1126/science.1065588; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HOFFMANN B, 1994, J BIOL CHEM, V269, P1940; Huang SG, 2001, ARCH BIOCHEM BIOPHYS, V394, P67, DOI 10.1006/abbi.2001.2520; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199; Jones PM, 2000, EUR J BIOCHEM, V267, P5298, DOI 10.1046/j.1432-1327.2000.01628.x; Kerscher O, 2000, MOL BIOL CELL, V11, P103, DOI 10.1091/mbc.11.1.103; Kerscher O, 1997, J CELL BIOL, V139, P1663, DOI 10.1083/jcb.139.7.1663; Klingenberg M, 1976, ENZYMES BIOLOGICAL M, V3, P383; Koehler CM, 2000, MOL CELL BIOL, V20, P1187, DOI 10.1128/MCB.20.4.1187-1193.2000; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Kovermann P, 2002, MOL CELL, V9, P363, DOI 10.1016/S1097-2765(02)00446-X; Kubrich M, 1998, J BIOL CHEM, V273, P16374, DOI 10.1074/jbc.273.26.16374; Luciano P, 2001, EMBO J, V20, P4099, DOI 10.1093/emboj/20.15.4099; MAJIMA E, 1995, J BIOL CHEM, V270, P29548, DOI 10.1074/jbc.270.49.29548; NELSON DR, 1993, J MOL BIOL, V230, P1171, DOI 10.1006/jmbi.1993.1234; NELSON DR, 1993, J MOL BIOL, V230, P1159, DOI 10.1006/jmbi.1993.1233; Nelson DR, 1996, BBA-BIOENERGETICS, V1275, P133, DOI 10.1016/0005-2728(96)00063-1; Palmisano A, 1998, BIOCHEM J, V333, P151, DOI 10.1042/bj3330151; PFANNER N, 1987, J BIOL CHEM, V262, P7528; Popot JL, 2000, ANNU REV BIOCHEM, V69, P881, DOI 10.1146/annurev.biochem.69.1.881; Rehling P, 2003, SCIENCE, V299, P1747, DOI 10.1126/science.1080945; RICCIO P, 1975, FEBS LETT, V56, P133, DOI 10.1016/0014-5793(75)80127-X; Ryan MT, 1999, J BIOL CHEM, V274, P20619, DOI 10.1074/jbc.274.29.20619; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schroers A, 1998, J BIOL CHEM, V273, P14269, DOI 10.1074/jbc.273.23.14269; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; SMAGULA C, 1988, J BIOL CHEM, V263, P6783; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; Tokatlidis K, 2000, METHOD ENZYMOL, V327, P305, DOI 10.1016/S0076-6879(00)27286-8; Trezeguet V, 2000, BBA-BIOENERGETICS, V1457, P81, DOI 10.1016/S0005-2728(99)00115-2; Truscott KN, 2002, MOL CELL BIOL, V22, P7780, DOI 10.1128/MCB.22.22.7780-7789.2002; Vial S, 2002, J BIOL CHEM, V277, P36100, DOI 10.1074/jbc.M202310200; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x; Wiedemann N, 2001, EMBO J, V20, P951, DOI 10.1093/emboj/20.5.951; Winkler HH, 1999, TRENDS BIOCHEM SCI, V24, P64, DOI 10.1016/S0968-0004(98)01334-6	57	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26757	26764		10.1074/jbc.M302700200	http://dx.doi.org/10.1074/jbc.M302700200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12740376	hybrid			2022-12-25	WOS:000184155700060
J	Hemmerlin, A; Hoeffler, JF; Meyer, O; Tritsch, D; Kagan, IA; Grosdemange-Billiard, C; Rohmer, M; Bach, TJ				Hemmerlin, A; Hoeffler, JF; Meyer, O; Tritsch, D; Kagan, IA; Grosdemange-Billiard, C; Rohmer, M; Bach, TJ			Cross-talk between the cytosolic mevalonate and the plastidial methylerythritol phosphate pathways in Tobacco Bright Yellow-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1-DEOXY-D-XYLULOSE 5-PHOSPHATE REDUCTOISOMERASE; COENZYME-A REDUCTASE; HMG-COA REDUCTASE; ISOPRENOID BIOSYNTHESIS; ISOPENTENYL DIPHOSPHATE; ESCHERICHIA-COLI; INDEPENDENT BIOSYNTHESIS; COMPETITIVE INHIBITOR; FRUIT-DEVELOPMENT; HIGHER-PLANTS	In plants, two pathways are utilized for the synthesis of isopentenyl diphosphate, the universal precursor for isoprenoid biosynthesis. The key enzyme of the cytoplasmic mevalonic acid (MVA) pathway is 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR). Treatment of Tobacco Bright Yellow-2 (TBY-2) cells by the HMGR-specific inhibitor mevinolin led to growth reduction and induction of apparent HMGR activity, in parallel to an increase in protein representing two HMGR isozymes. Maximum induction was observed at 24 h. 1-Deoxy-D-xylulose (DX), the dephosphorylated first precursor of the plastidial 2-C-methyl-D-erythritol4-phosphate ( MEP) pathway, complemented growth inhibition by mevinolin in the low millimolar concentration range. Furthermore, DX partially re-established feedback repression of mevinolin-induced HMGR activity. Incorporation studies with [1,1,1,4-H-2(4)]DX showed that sterols, normally derived from MVA, in the presence of mevinolin are synthesized via the MEP pathway. Fosmidomycin, an inhibitor of 1-deoxy-D-xylulose-5-phosphate reductoisomerase, the second enzyme of the MEP pathway, was utilized to study the reverse complementation. Growth inhibition by fosmidomycin of TBY-2 cells could be partially overcome by MVA. Chemical complementation was further substantiated by incorporation of [2-C-13] MVA into plastoquinone, representative of plastidial isoprenoids. Best rates of incorporation of exogenous stably labeled precursors were observed in the presence of both inhibitors, thereby avoiding internal isotope dilution.	CNRS, UPR 2357, Inst Biol Mol Plantes, F-67038 Strasbourg, France; Univ Strasbourg, CNRS, Inst Le Bel, F-67070 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Bach, TJ (corresponding author), CNRS, UPR 2357, Inst Biol Mol Plantes, 28 Rue Goethe, F-67038 Strasbourg, France.	Thomas.Bach@bota-ulp.u-strasbg.fr		Hemmerlin, Andrea/0000-0002-3383-7355				Adam KP, 1998, ARCH BIOCHEM BIOPHYS, V354, P181, DOI 10.1006/abbi.1998.0666; ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; Anderson MD, 1998, PLANT PHYSIOL, V118, P1127, DOI 10.1104/pp.118.4.1127; Arigoni D, 1997, P NATL ACAD SCI USA, V94, P10600, DOI 10.1073/pnas.94.20.10600; Bach T.J., 1991, PHYSL BIOCH STEROLS, P29; BACH TJ, 1987, PLANT PHYSIOL BIOCH, V25, P163; BACH TJ, 1986, EUR J BIOCHEM, V154, P103, DOI 10.1111/j.1432-1033.1986.tb09364.x; BACH TJ, 1990, RECENT ADV PHYTOCHEM, V24, P1; BACH TJ, 1983, PHYSIOL PLANTARUM, V59, P50, DOI 10.1111/j.1399-3054.1983.tb06570.x; BACH TJ, 1995, LIPIDS, V30, P191, DOI 10.1007/BF02537822; CHAPPELL J, 1995, PLANT PHYSIOL, V107, P1, DOI 10.1145/224057.224059; CHAPPELL J, 1995, PLANT PHYSIOL, V109, P1337, DOI 10.1104/pp.109.4.1337; Charon L, 2000, BIOCHEM J, V346, P737, DOI 10.1042/0264-6021:3460737; Che P, 2002, PLANT PHYSIOL, V129, P625, DOI 10.1104/pp.001842; Crane YM, 2002, J PLANT PHYSIOL, V159, P1301, DOI 10.1078/0176-1617-00874; CROWELL DN, 1992, PLANT PHYSIOL, V100, P2090, DOI 10.1104/pp.100.4.2090; De-Eknamkul W, 2003, PHYTOCHEMISTRY, V62, P389, DOI 10.1016/S0031-9422(02)00555-1; Dewick PM, 2002, NAT PROD REP, V19, P181, DOI 10.1039/b002685i; Disch A, 1998, BIOCHEM J, V331, P615, DOI 10.1042/bj3310615; Duvold T, 1997, TETRAHEDRON LETT, V38, P6181, DOI 10.1016/S0040-4039(97)01392-0; Eisenreich W, 1998, CHEM BIOL, V5, pR221, DOI 10.1016/S1074-5521(98)90002-3; Giner JL, 1998, TETRAHEDRON LETT, V39, P8021, DOI 10.1016/S0040-4039(98)01791-2; Ginger ML, 2001, J BIOL CHEM, V276, P11674, DOI 10.1074/jbc.M006850200; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRUMBACH KH, 1979, Z NATURFORSCH C, V34, P941; GRUMBACH KH, 1980, Z NATURFORSCH C, V35, P645; Hartmann MA, 1998, TRENDS PLANT SCI, V3, P170, DOI 10.1016/S1360-1385(98)01233-3; Hartmann MA, 2001, TETRAHEDRON LETT, V42, P655, DOI 10.1016/S0040-4039(00)02031-1; Hemmerlin A, 1998, PLANT J, V14, P65, DOI 10.1046/j.1365-313X.1998.00095.x; Hemmerlin A, 1999, ACTA BOT GALLICA, V146, P85, DOI 10.1080/12538078.1999.10515804; Hemmerlin A, 2000, PLANT PHYSIOL, V123, P1257, DOI 10.1104/pp.123.4.1257; Hoeffler JF, 2002, BIOCHEM J, V366, P573, DOI 10.1042/BJ20020337; Jux A, 2001, ANGEW CHEM INT EDIT, V40, P2091, DOI 10.1002/1521-3773(20010601)40:11<2091::AID-ANIE2091>3.0.CO;2-5; Kasahara H, 2002, J BIOL CHEM, V277, P45188, DOI 10.1074/jbc.M208659200; Kessler A, 2002, ANNU REV PLANT BIOL, V53, P299, DOI 10.1146/annurev.arplant.53.100301.135207; KITA T, 1980, J CLIN INVEST, V66, P1094, DOI 10.1172/JCI109938; KREUZ K, 1984, EUR J BIOCHEM, V141, P531, DOI 10.1111/j.1432-1033.1984.tb08225.x; Kuzuyama T, 1998, TETRAHEDRON LETT, V39, P7913, DOI 10.1016/S0040-4039(98)01755-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lichtenthaler HK, 1999, ANNU REV PLANT PHYS, V50, P47, DOI 10.1146/annurev.arplant.50.1.47; Lichtenthaler HK, 1997, FEBS LETT, V400, P271, DOI 10.1016/S0014-5793(96)01404-4; Lois LM, 2000, PLANT J, V22, P503, DOI 10.1046/j.1365-313x.2000.00764.x; Lois LM, 1998, P NATL ACAD SCI USA, V95, P2105, DOI 10.1073/pnas.95.5.2105; Luan F, 2002, PHYTOCHEMISTRY, V60, P451, DOI 10.1016/S0031-9422(02)00147-4; LUTKEBRINKHAUS F, 1987, PLANTA, V171, P406, DOI 10.1007/BF00398686; Mandel MA, 1996, PLANT J, V9, P649, DOI 10.1046/j.1365-313X.1996.9050649.x; MERCER EI, 1962, BIOCHEM J, V85, pP13; MURACA RF, 1967, J AM CHEM SOC, V89, P1505, DOI 10.1021/ja00982a038; Nagata N, 2002, PLANTA, V216, P345, DOI 10.1007/s00425-002-0871-9; NAGATA T, 1992, INT REV CYTOL, V132, P1, DOI 10.1016/S0074-7696(08)62452-3; Nakanishi, 1999, COMPREHENSIVE NATURA, P15; NARITA JO, 1989, PLANT CELL, V1, P181, DOI 10.1105/tpc.1.2.181; Piel J, 1998, ANGEW CHEM INT EDIT, V37, P2478, DOI 10.1002/(SICI)1521-3773(19981002)37:18<2478::AID-ANIE2478>3.0.CO;2-Q; Rodriguez-Concepcion M, 2001, PLANT J, V27, P213, DOI 10.1046/j.1365-313x.2001.01089.x; Rohmer M., 1999, COMPR NAT PROD CHEM, V2, P45, DOI 10.1016/B978-0-08-091283-7.00036-9; Sacchettini JC, 1997, SCIENCE, V277, P1788, DOI 10.1126/science.277.5333.1788; SCHALLER H, 1995, PLANT PHYSIOL, V109, P761, DOI 10.1104/pp.109.3.761; SCHINDLER S, 1985, Z NATURFORSCH C, V40, P208; Schwarz M, 1994, THESIS EIDGENOSSISCH; Schwender J, 1996, BIOCHEM J, V316, P73, DOI 10.1042/bj3160073; SETO H, 1996, TETRAHEDRON LETT, V31, P6025; SHIGI Y, 1989, J ANTIMICROB CHEMOTH, V24, P131, DOI 10.1093/jac/24.2.131; Shindia AA, 1997, FOLIA MICROBIOL, V42, P477, DOI 10.1007/BF02826557; SOLER E, 1993, PLANTA, V191, P324, DOI 10.1007/BF00195689; Steliopoulos P, 2002, PHYTOCHEMISTRY, V60, P13, DOI 10.1016/S0031-9422(02)00068-7; STERMER BA, 1994, J LIPID RES, V35, P1133; VOLLACK KU, 1994, J PLANT PHYSIOL, V143, P479, DOI 10.1016/S0176-1617(11)81810-9; WEISSENBORN DL, 1995, PHYSIOL PLANTARUM, V93, P393, DOI 10.1111/j.1399-3054.1995.tb02244.x; Wentzinger LF, 2002, PLANT PHYSIOL, V130, P334, DOI 10.1104/pp.004655	69	328	350	0	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26666	26676		10.1074/jbc.M302526200	http://dx.doi.org/10.1074/jbc.M302526200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12736259	hybrid			2022-12-25	WOS:000184155700049
J	Tamarit, J; Belli, G; Cabiscol, E; Herrero, E; Ros, J				Tamarit, J; Belli, G; Cabiscol, E; Herrero, E; Ros, J			Biochemical characterization of yeast mitochondrial Grx5 monothiol glutaredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBONIC-ANHYDRASE-III; SULFUR CLUSTER BIOSYNTHESIS; SITE-DIRECTED MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; S-THIOLATION; FUNCTIONAL-CHARACTERIZATION; OXIDATIVE STRESS; MIXED DISULFIDE; HOMOLOGY DOMAIN	Grx5 is a yeast mitochondrial protein involved in iron-sulfur biogenesis that belongs to a recently described family of monothiolic glutaredoxin-like proteins. No member of this family has been biochemically characterized previously. Grx5 contains a conserved cysteine residue (Cys-60) and a non-conserved one (Cys-117). In this work, we have purified wild type and mutant C60S and C117S proteins and characterized their biochemical properties. A redox potential of - 175 mV was calculated for wild type Grx5. The pK(a) values obtained by titration of mutant proteins with iodoacetamide at different pHs were 5.0 for Cys-60 and 8.2 for Cys-117. When Grx5 was incubated with glutathione disulfide, a transient mixed disulfide was formed between glutathione and the cystein 60 of the protein because of its low pK(a). Binding of glutathione to Cys-60 promoted a decrease in the Cys-117 pK(a) value that triggered the formation of a disulfide bond between both cysteine residues of the protein, indicating that Cys-117 plays an essential role in the catalytic mechanism of Grx5. The disulfide bond in Grx5 could be reduced by GSH but at a rate at least 20 times slower than that observed for the reduction of glutaredoxin 1 from E. coli, a dithiolic glutaredoxin. This slow reduction rate could suggest that GSH may not be the physiologic reducing agent of Grx5. The fact that wild type Grx5 efficiently reduced a glutathiolated protein used as a substrate indicated that Grx5 may act as a thiol reductase inside the mitochondria.	Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Lleida, Spain	Universitat de Lleida	Ros, J (corresponding author), Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Rovira Roure 44, Lleida, Spain.		Ros, Joaquim/A-7507-2010; belli, gemma/A-7424-2011; Tamarit, Jordi/C-6316-2008; Cabiscol, Elisa/A-4584-2009; Herrero, Enrique/B-5592-2009; Bellí, Gemma/AAD-5325-2019; ROS, Joaquim/ABG-7487-2020	belli, gemma/0000-0002-4161-3204; Tamarit, Jordi/0000-0003-3227-6928; Cabiscol, Elisa/0000-0003-2795-7999; Herrero, Enrique/0000-0002-6763-111X; Bellí, Gemma/0000-0002-4161-3204; ROS, Joaquim/0000-0003-0901-8648				Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; Belli G, 2002, J BIOL CHEM, V277, P37590, DOI 10.1074/jbc.M201688200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; CABISCOL E, 1994, J BIOL CHEM, V269, P6592; Cabiscol E, 1996, P NATL ACAD SCI USA, V93, P4170, DOI 10.1073/pnas.93.9.4170; CHAI YC, 1991, ARCH BIOCHEM BIOPHYS, V284, P270, DOI 10.1016/0003-9861(91)90295-T; Chen OS, 2002, P NATL ACAD SCI USA, V99, P12321, DOI 10.1073/pnas.192449599; Collinson EJ, 2002, J BIOL CHEM, V277, P16712, DOI 10.1074/jbc.M111686200; Foloppe N, 2001, J MOL BIOL, V310, P449, DOI 10.1006/jmbi.2001.4767; GAN ZR, 1990, ARCH BIOCHEM BIOPHYS, V282, P110, DOI 10.1016/0003-9861(90)90093-E; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; Herrero E, 2002, METHOD ENZYMOL, V348, P136, DOI 10.1016/S0076-6879(02)48633-8; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; Kato S, 2002, P NATL ACAD SCI USA, V99, P5948, DOI 10.1073/pnas.082123599; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; Lange H, 2001, EMBO REP, V2, P715, DOI 10.1093/embo-reports/kve161; LII CK, 1994, ARCH BIOCHEM BIOPHYS, V308, P231, DOI 10.1006/abbi.1994.1033; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Luikenhuis S, 1998, MOL BIOL CELL, V9, P1081, DOI 10.1091/mbc.9.5.1081; Lundstrom-Ljung J, 1999, FEBS LETT, V443, P85, DOI 10.1016/S0014-5793(98)01698-6; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P6088, DOI 10.1021/bi00239a002; NIKKOLA M, 1991, J BIOL CHEM, V266, P16105; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; Pedrajas JR, 2002, BIOCHEM J, V364, P617, DOI 10.1042/BJ20020570; Pedrajas JR, 1999, J BIOL CHEM, V274, P6366, DOI 10.1074/jbc.274.10.6366; Rahlfs S, 2001, J BIOL CHEM, V276, P37133, DOI 10.1074/jbc.M105524200; Reckenfelderbaumer N, 2002, J BIOL CHEM, V277, P17548, DOI 10.1074/jbc.M112115200; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Shenton D, 2002, J BIOL CHEM, V277, P16853, DOI 10.1074/jbc.M200559200; Smith AD, 2001, J AM CHEM SOC, V123, P11103, DOI 10.1021/ja016757n; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Washburn MP, 1999, BIOCHEMISTRY-US, V38, P268, DOI 10.1021/bi980480v; Weiner Michael P., 1995, P613; Witte S, 2000, J BIOL CHEM, V275, P1902, DOI 10.1074/jbc.275.3.1902; YANG YF, 1991, J BIOL CHEM, V266, P12759	42	103	106	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25745	25751		10.1074/jbc.M303477200	http://dx.doi.org/10.1074/jbc.M303477200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730244	Green Published, hybrid			2022-12-25	WOS:000183920200060
J	Ejima, K; Layne, MD; Carvajal, IM; Kritek, PA; Baron, RM; Chen, YH; vom Saal, J; Levy, BD; Yet, SF; Perrella, MA				Ejima, K; Layne, MD; Carvajal, IM; Kritek, PA; Baron, RM; Chen, YH; vom Saal, J; Levy, BD; Yet, SF; Perrella, MA			Cyclooxygenase-2 deficient mice are resistant to endotoxin-induced inflammation and death	FASEB JOURNAL			English	Article						sepsis; nitric oxide synthase-2; heme oxygenase-1; NF-kappa B; AP-1	NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; SMOOTH-MUSCLE-CELLS; HEME OXYGENASE-1; INDUCED MORTALITY; PROTECTS MICE; INTERLEUKIN-10; SEPSIS; INDUCTION	Sepsis is a systemic inflammatory response to a blood-borne infection that is associated with an extremely high rate of morbidity and mortality. The present study investigates the role of cyclooxygenase (COX)-2 in host responses to bacterial endotoxemia. After administration of Escherichia coli lipopolysaccharide, 50% of wild-type mice die within 96 h. COX-2 deficient mice displayed a dramatic improvement in survival with reduced leukocyte infiltration into critical organs (kidneys and lungs) and a blunted and delayed induction of the cytokine inducible genes nitric oxide synthase 2 and heme oxygenase-1. Translocation and activation of transcription factors important for signaling events during an inflammatory response, such as nuclear factor (NF)-kappaB, were also markedly reduced. While the absence of COX-2 did not alter the induction of several pro-inflammatory cytokines in tissue macrophages, induction of the anti-inflammatory cytokine IL-10 was exaggerated. Administration of IL-10 to wild-type mice reduced NF-kappaB activation. Taken together, our data suggest that COX-2 deficient mice are resistant to many of the detrimental consequences of endotoxemia. These beneficial effects occur, in part, by a compensatory increase in IL-10 that counterbalances the pro-inflammatory host response to endotoxemia.	Brigham & Womens Hosp, Dept Internal Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Kaohsiung Med Univ, Dept Internal Med, Div Infect Dis, Kaohsiung, Taiwan	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Kaohsiung Medical University	Perrella, MA (corresponding author), Brigham & Womens Hosp, Dept Internal Med, 75 Francis St, Boston, MA 02115 USA.	mperrella@rics.bwh.harvard.edu	Yet, Shaw-Fang/B-1067-2010	Chen, Yen-hsu/0000-0002-8667-4844; Yet, Shaw-Fang/0000-0001-9097-3962; Layne, Matthew/0000-0003-0007-4870				Alcaraz MJ, 2001, BBA-GEN SUBJECTS, V1526, P13, DOI 10.1016/S0304-4165(01)00112-X; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Bohrer H, 1997, J CLIN INVEST, V100, P972, DOI 10.1172/JCI119648; Bone RC, 1997, CHEST, V112, P235, DOI 10.1378/chest.112.1.235; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; FINK MP, 1989, J APPL PHYSIOL, V67, P1950, DOI 10.1152/jappl.1989.67.5.1950; Fink MP, 2001, AM J PHYSIOL-LUNG C, V281, pL534, DOI 10.1152/ajplung.2001.281.3.L534; FLETCHER JR, 1993, ANN SURG, V217, P668, DOI 10.1097/00000658-199306000-00008; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GERARD C, 1993, J EXP MED, V177, P547, DOI 10.1084/jem.177.2.547; Hamilton LC, 1998, BRIT J PHARMACOL, V125, P335, DOI 10.1038/sj.bjp.0702077; HOWARD M, 1993, J EXP MED, V177, P1205, DOI 10.1084/jem.177.4.1205; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Langenbach R, 1999, ANN NY ACAD SCI, V889, P52, DOI 10.1111/j.1749-6632.1999.tb08723.x; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MONCADA S, 1992, J LAB CLIN MED, V120, P187; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; NORTHOVER BJ, 1962, J PATHOL BACTERIOL, V83, P463, DOI 10.1002/path.1700830217; Parrillo J E, 1993, N Engl J Med, V328, P1471; Pellacani A, 1998, CIRC RES, V83, P396, DOI 10.1161/01.RES.83.4.396; Perrella MA, 1996, J BIOL CHEM, V271, P13776, DOI 10.1074/jbc.271.23.13776; Perrella MA, 1996, P NATL ACAD SCI USA, V93, P2054, DOI 10.1073/pnas.93.5.2054; Perrow C., 1994, TECHNOLOGY STUDIES, V1, P1; Pinsky MR, 2001, CONTRIB NEPHROL, V132, P354; RANA B, 1994, MOL CELL BIOL, V14, P5858, DOI 10.1128/MCB.14.9.5858; Reddy RC, 2001, AM J PHYSIOL-LUNG C, V281, pL537, DOI 10.1152/ajplung.2001.281.3.L537; Santucci L, 1996, GASTROENTEROLOGY, V111, P736, DOI 10.1053/gast.1996.v111.pm8780580; SCHREIBER BM, 1988, ATHEROSCLEROSIS, V69, P69, DOI 10.1016/0021-9150(88)90290-0; Song GY, 1999, SURGERY, V126, P378, DOI 10.1016/S0039-6060(99)70180-7; STONE R, 1994, SCIENCE, V264, P365, DOI 10.1126/science.8153620; Tabary O, 2003, AM J PATHOL, V162, P293, DOI 10.1016/S0002-9440(10)63820-5; VANDERPOLL T, 1995, J IMMUNOL, V155, P5397; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; Wiesel P, 2000, CIRCULATION, V102, P3015, DOI 10.1161/01.cir.102.24.3015; Wiesel P, 2000, J BIOL CHEM, V275, P24840, DOI 10.1074/jbc.M000835200; Yamano S, 2001, J GENE MED, V3, P450, DOI 10.1002/jgm.213; Yet SF, 2002, METHOD ENZYMOL, V353, P163; Yet SF, 2001, CIRC RES, V89, P168, DOI 10.1161/hh1401.093314; Yet SF, 1997, J BIOL CHEM, V272, P4295, DOI 10.1074/jbc.272.7.4295	47	102	104	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1325	+		10.1096/fj.02-1078fje	http://dx.doi.org/10.1096/fj.02-1078fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738799				2022-12-25	WOS:000183165000038
J	Meilhac, O; Ho-Tin-Noe, B; Houard, X; Philippe, M; Michel, JB; Angles-Cano, E				Meilhac, O; Ho-Tin-Noe, B; Houard, X; Philippe, M; Michel, JB; Angles-Cano, E			Pericellular plasmin induces smooth muscle cell anoikis	FASEB JOURNAL			English	Article						plasminogen activators; extracellular matrix; metalloproteinases; fibronectin	ACTIVATOR INHIBITOR TYPE-1; VARICOSE-VEINS; UROKINASE; BINDING; DEGRADATION; MECHANISM; APOPTOSIS; FIBRIN; FIBRONECTIN; CLEAVAGE	Smooth muscle cell (SMC) rarefaction is involved in the development of several vascular pathologies. We suggest that the plasminogen activation system is a potential extracellular signal that can induce pericellular proteolysis and apoptosis of vascular SMCs. Using primary cultures of arterial SMCs, we show that plasmin generated from plasminogen on the cell surface induces cell retraction and fibronectin fragmentation, leading to detachment and morphological/biochemical changes characteristic of apoptosis (also called anoikis). The generation of cell-bound plasmin mediated by tissue-type plasminogen activator (t-PA), constitutively expressed by VSMCs, requires binding of plasminogen to the cell surface and is inhibited by epsilon-aminocaproic acid (IC50=0.9+/-0.2 mM), a competitor of plasminogen binding to membrane glycoproteins. Conversely, addition of alpha(2)-antiplasmin, which blocks free plasmin in the cell supernatant, could not fully prevent anoikis. Finally, an MMP inhibitor failed to prevent VSMC anoikis, arguing for a direct involvement of plasmin in this phenomenon. Indeed, similar changes are induced by plasmin directly added to VSMCs or to arterial rings, ex-vivo. We show for the first time that pathological anoikis can be triggered by a process that requires functional assembly of the plasminogen activation system on the surface of VSMCs.	CHU Bichat Claude Bernard, INSERM, U460, F-75877 Paris 18, France; Coll France, INSERM, U36, F-75231 Paris 05, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France	Meilhac, O (corresponding author), CHU Bichat Claude Bernard, INSERM, U460, Bat 13,46 Rue Henri Huchard, F-75877 Paris 18, France.	u460@bichat.inserm.fr	Ho-Tin-Noé, Benoit/U-8059-2018; Michel, Jean-Baptiste/AAH-9336-2020; Meilhac, Olivier/N-4385-2017; ANGLES-CANO, Eduardo/ABA-1739-2020; ANGLES-CANO, Eduardo/G-2311-2012	Ho-Tin-Noé, Benoit/0000-0002-7428-1760; ANGLES-CANO, Eduardo/0000-0001-7891-3975; ANGLES-CANO, Eduardo/0000-0001-7891-3975; Meilhac, Olivier/0000-0002-3740-7539				ANGLESCANO E, 1987, THROMB HAEMOSTASIS, V58, P843; ANGLESCANO E, 1992, BIOCHIM BIOPHYS ACTA, V1156, P34, DOI 10.1016/0304-4165(92)90092-9; ANGLESCANO E, 1994, CHEM PHYS LIPIDS, V67-8, P353, DOI 10.1016/0009-3084(94)90157-0; ANIDJAR S, 1990, CIRCULATION, V82, P973, DOI 10.1161/01.CIR.82.3.973; Badier-Commander C, 2000, J PATHOL, V192, P105, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH670>3.0.CO;2-1; Badier-Commander C, 2001, J PATHOL, V193, P398, DOI 10.1002/path.819; BARICOS WH, 1995, KIDNEY INT, V47, P1039, DOI 10.1038/ki.1995.150; BATTLE T, 1994, TISSUE CELL, V26, P943, DOI 10.1016/0040-8166(94)90043-4; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; CHAIN D, 1991, FEBS LETT, V285, P251, DOI 10.1016/0014-5793(91)80810-P; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; CLOWES AW, 1990, CIRC RES, V67, P61, DOI 10.1161/01.RES.67.1.61; Davis GE, 2001, J CELL SCI, V114, P917; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Di Matola T, 2000, J CLIN ENDOCR METAB, V85, P1188, DOI 10.1210/jc.85.3.1188; EHRLICH MI, 1981, J LAB CLIN MED, V98, P263; Ellis V, 1997, BLOOD, V90, P2312, DOI 10.1182/blood.V90.6.2312.2312_2312_2322; FLEURY V, 1991, BIOCHEMISTRY-US, V30, P7630, DOI 10.1021/bi00244a035; FLEURY V, 1993, J BIOL CHEM, V268, P18554; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; GAUSSEM P, 1993, J BIOL CHEM, V268, P12150; Gonzalez W, 2000, HYPERTENSION, V36, P103, DOI 10.1161/01.HYP.36.1.103; HERRON GS, 1991, ARTERIOSCLER THROMB, V11, P1667, DOI 10.1161/01.ATV.11.6.1667; HOLDERBAUM D, 1986, J CELL PHYSIOL, V126, P216, DOI 10.1002/jcp.1041260210; Ikari Y, 2001, J BIOL CHEM, V276, P11798, DOI 10.1074/jbc.M008503200; Isik FF, 1998, J CELL PHYSIOL, V175, P149, DOI 10.1002/(SICI)1097-4652(199805)175:2<149::AID-JCP4>3.0.CO;2-O; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Kapila YL, 1999, J BIOL CHEM, V274, P30906, DOI 10.1074/jbc.274.43.30906; Kockx MM, 2000, J PATHOL, V190, P267, DOI 10.1002/(SICI)1096-9896(200002)190:3<267::AID-PATH523>3.0.CO;2-A; Lau HKF, 1999, CARDIOVASC RES, V43, P1049, DOI 10.1016/S0008-6363(99)00136-4; Lijnen HR, 2001, FRONT BIOSCI, V6, pD239, DOI 10.2741/Lijnen; LIOTTA LA, 1981, THROMB RES, V21, P663, DOI 10.1016/0049-3848(81)90268-1; LopezCandales A, 1997, AM J PATHOL, V150, P993; LUPU F, 1995, ARTERIOSCL THROM VAS, V15, P1444, DOI 10.1161/01.ATV.15.9.1444; Luttun A, 2002, ARTERIOSCL THROM VAS, V22, P499, DOI 10.1161/hq0302.104529; Madden HL, 2000, AM J RESP CRIT CARE, V162, P1553, DOI 10.1164/ajrccm.162.4.2001015; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; Michel JB, 2001, ARTERIOSCL THROM VAS, V21, P1389; Montes R, 1996, BRIT J HAEMATOL, V92, P979, DOI 10.1046/j.1365-2141.1996.416951.x; Nayeem N, 1999, J CELL SCI, V112, P4739; Ryniers F, 2002, BIOL CHEM, V383, P159, DOI 10.1515/BC.2002.016; Salame MY, 2000, ATHEROSCLEROSIS, V152, P19, DOI 10.1016/S0021-9150(99)00441-4; Shireman PK, 1996, J VASC SURG, V24, P719, DOI 10.1016/S0741-5214(96)70003-4; Sinniger V, 1999, J BIOL CHEM, V274, P12414, DOI 10.1074/jbc.274.18.12414; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; Takeda K, 2001, ARTERIOSCL THROM VAS, V21, P868, DOI 10.1161/01.ATV.21.5.868; Ugwu F, 2001, THROMB RES, V102, P61, DOI 10.1016/S0049-3848(01)00218-3; VANLEEUWEN RTJ, 1994, CIRCULATION, V90, P362, DOI 10.1161/01.CIR.90.1.362; Walsh K, 2000, CIRC RES, V87, P184, DOI 10.1161/01.RES.87.3.184; WEISS RE, 1981, BIOCHEM J, V197, P529, DOI 10.1042/bj1970529; WIMAN B, 1973, EUR J BIOCHEM, V36, P25, DOI 10.1111/j.1432-1033.1973.tb02880.x	53	84	88	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1301	+		10.1096/fj.02-0687fje	http://dx.doi.org/10.1096/fj.02-0687fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738809				2022-12-25	WOS:000183165000035
J	Sucharov, CC; Mariner, P; Long, C; Bristow, M; Leinwand, L				Sucharov, CC; Mariner, P; Long, C; Bristow, M; Leinwand, L			Yin Yang 1 is increased in human heart failure and represses the activity of the human alpha-myosin heavy chain promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR YY1; GENE-EXPRESSION; DILATED CARDIOMYOPATHY; HYPERTROPHY; ADAPTATIONS; MODULATION; EXERCISE; ENHANCER; HOMOLOG; MICE	Yin Yang 1 (YY1) is a transcription factor that can repress or activate transcription of the genes with which it interacts. In this report we show that YY1 is a negative regulator of the alpha-myosin heavy chain (alphaMyHC) gene, which, with betaMyHC are the molecular motors of the heart. alphaMyHC mRNA and protein levels are down-regulated in hypertrophy and heart failure, and this is thought to be detrimental for cardiac contractility. We show that YY1 specifically interacts with the alphaMyHC promoter and that overexpression of YY1 in cardiac cells represses the activity of the alphaMyHC promoter. We also show that the 170-200-amino acid region of YY1, important for its interaction with histone acetyl transferases and histone deacetylases, is important for its repressive activity and that YY1 deleted in this region is an activator of the alphaMyHC promoter. Moreover, we show that YY1 levels and DNA binding activity are increased in failing human left ventricles and in a mouse model of hypertrophic cardiomyopathy, where alphaMyHC levels are decreased. These results suggest that YY1 is a negative regulator of alphaMyHC gene expression.	Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA; Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Cardiol, Denver, CO 80262 USA; Denver Hlth Med Ctr, Dept Med, Denver, CO 80204 USA	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Denver Health Medical Center	Leinwand, L (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, CB 347, Boulder, CO 80309 USA.	Leslie.Leinwand@colorado.edu	bristow, michael r/G-7850-2011	Long, Carlin/0000-0001-7251-2847; LEINWAND, LESLIE/0000-0003-1470-4810				Abraham WT, 2002, MOL MED, V8, P750, DOI 10.1007/BF03402039; Allen DL, 2001, J APPL PHYSIOL, V90, P1900, DOI 10.1152/jappl.2001.90.5.1900; ARCHISON L, 2003, EMBO J, V22, P1347; Bhalla SS, 2001, J BIOL CHEM, V276, P11439, DOI 10.1074/jbc.M100208200; Chen CY, 1997, MOL ENDOCRINOL, V11, P812, DOI 10.1210/me.11.6.812; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Freeman K, 2001, AM J PHYSIOL-HEART C, V280, pH151, DOI 10.1152/ajpheart.2001.280.1.H151; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; Gupta M, 1998, MOL CELL BIOL, V18, P7243, DOI 10.1128/MCB.18.12.7243; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; Herron TJ, 2002, CIRC RES, V90, P1150, DOI 10.1161/01.RES.0000022879.57270.11; HYDEDERUYSCHER RP, 1995, NUCLEIC ACIDS RES, V23, P4457, DOI 10.1093/nar/23.21.4457; Jin HK, 2000, AM J PHYSIOL-HEART C, V279, pH2994, DOI 10.1152/ajpheart.2000.279.6.H2994; KAPLAN ML, 1994, AM J PHYSIOL, V267, pH1167, DOI 10.1152/ajpheart.1994.267.3.H1167; KITSIS RN, 1991, P NATL ACAD SCI USA, V88, P4138, DOI 10.1073/pnas.88.10.4138; LEE JS, 1995, NUCLEIC ACIDS RES, V23, P925, DOI 10.1093/nar/23.6.925; LEE JS, 1995, GENE DEV, V9, P925; Long C S, 2001, Heart Fail Rev, V6, P81; Lowes BD, 2002, NEW ENGL J MED, V346, P1357, DOI 10.1056/NEJMoa012630; Lowes BD, 1997, J CLIN INVEST, V100, P2315, DOI 10.1172/JCI119770; MALHOTRA A, 1984, EUR HEART J, V5, P61, DOI 10.1093/eurheartj/5.suppl_F.61; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Menard C, 1999, J BIOL CHEM, V274, P29063, DOI 10.1074/jbc.274.41.29063; Miyata S, 2000, CIRC RES, V86, P386, DOI 10.1161/01.RES.86.4.386; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P19512; Molkentin JD, 1996, J MOL CELL CARDIOL, V28, P1211, DOI 10.1006/jmcc.1996.0112; Morkin E, 2000, MICROSC RES TECHNIQ, V50, P522, DOI 10.1002/1097-0029(20000915)50:6<522::AID-JEMT9>3.0.CO;2-U; Nakao K, 1997, J CLIN INVEST, V100, P2362, DOI 10.1172/JCI119776; Patten M, 2000, J MOL CELL CARDIOL, V32, P1341, DOI 10.1006/jmcc.2000.1169; RINDT H, 1995, TRANSGENIC RES, V4, P397, DOI 10.1007/BF01973758; Sucharov C, 1995, GENE EXPRESSION, V5, P93; SWYNGHEDAUW B, 1986, PHYSIOL REV, V66, P710, DOI 10.1152/physrev.1986.66.3.710; TARDIFF JC, 2000, AM J PHYSIOL, V278, P1742; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; VANBILSEN M, 1993, CARDIOVASC RES, V27, P1140; Vikstrom KL, 1996, MOL MED, V2, P556, DOI 10.1007/BF03401640; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YANG WM, 1997, J BIOL CHEM, V272, P12845; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001	40	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31233	31239		10.1074/jbc.M301917200	http://dx.doi.org/10.1074/jbc.M301917200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12754214	hybrid			2022-12-25	WOS:000184658800102
J	Amorino, GP; Mikkelsen, RB; Valerie, K; Schmidt-Ullrich, RK				Amorino, GP; Mikkelsen, RB; Valerie, K; Schmidt-Ullrich, RK			Dominant-negative cAMP-responsive element-binding protein inhibits proliferating cell nuclear antigen and DNA repair, leading to increased cellular radiosensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; GROWTH-FACTOR RECEPTOR; HUMAN-MELANOMA CELLS; IONIZING-RADIATION; CARCINOMA-CELLS; POLYMERASE-BETA; MAP KINASE; GENE; EXPRESSION; ACTIVATION	Selective inhibition of the epidermal growth factor receptor or mitogen-activated protein kinase ( MAPK) results in radiosensitization of cancer cells. One potential mechanism involves cAMP-responsive element-binding protein, which is activated by radiation via the epidermal growth factor receptor/MAPK pathway and which regulates synthesis of proliferating cell nuclear antigen ( PCNA), a protein involved in repair of ionizing radiation-induced DNA damage. To test for a role of CREB in cellular radiosensitivity, CHO cells were transfected with plasmids expressing dominant-negative CREB mutants (CR133 or KCREB), and various endpoints were measured 48 h later. Basal levels of PCNACAT reporter construct activity were reduced by 60 and 40% following expression of CR133 and KCREB, respectively; similar decreases were observed in PCNA protein levels. Pulsed-field gel electrophoresis measurements showed that CR133 inhibited the repair of radiation-induced DNA double-strand breaks, and this effect was reversed by over-expression of PCNA; dominant-negative CREB also significantly inhibited split-dose recovery. Clonogenic assays were used to determine surviving fraction; the dose enhancement ratios for dominant-negative CREB-expressing cells compared with control ( vector alone) were 1.5 and 1.3 for CR133 and KCREB, respectively. Importantly, co-transfection of mutant CREB and a construct constitutively expressing PCNA protein restored radiosensitivity of CHO cells back to wild-type levels. Moreover, cells expressing either CREB mutant showed no significant cell cycle redistribution. These data demonstrate that genetic disruption of CREB results in radiosensitization, and that this effect can be explained by a mechanism involving decreased PCNA expression and inhibition of DNA repair.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA	Virginia Commonwealth University	Schmidt-Ullrich, RK (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, POB 980058,401 Coll St, Richmond, VA 23298 USA.		Valerie, Kristoffer/AAL-8299-2021		NATIONAL CANCER INSTITUTE [P01CA072955, R01CA065896] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA72955, R01 CA65896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amorino GP, 2002, MOL BIOL CELL, V13, P2233, DOI 10.1091/mbc.01-12-0572; Atlas E, 2001, ONCOGENE, V20, P7110, DOI 10.1038/sj.onc.1204890; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; Balajee AS, 2001, NUCLEIC ACIDS RES, V29, P1341, DOI 10.1093/nar/29.6.1341; Boothman DA, 1996, MUTAT RES-FUND MOL M, V358, P143, DOI 10.1016/S0027-5107(96)00115-7; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Bradbury CM, 2001, CANCER RES, V61, P7689; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Chang YC, 2002, ANN NY ACAD SCI, V973, P384, DOI 10.1111/j.1749-6632.2002.tb04670.x; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; FEUERSTEIN N, 1995, J BIOL CHEM, V270, P9454, DOI 10.1074/jbc.270.16.9454; HALL EJ, 2000, RADIOBIOLOGY RADIOLO, P74; Henderson DS, 1998, MUTAGENESIS, V13, P57; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; HUANG DY, 1994, MOL CELL BIOL, V14, P4233, DOI 10.1128/MCB.14.6.4233; Ikebuchi M, 1998, RADIAT RES, V150, P416, DOI 10.2307/3579660; JACKSON P, 1994, BIOCHEM BIOPH RES CO, V203, P133, DOI 10.1006/bbrc.1994.2159; Jung M, 2001, SEMIN RADIAT ONCOL, V11, P346, DOI 10.1053/srao.2001.26034; Karmakar P, 2001, MUTAGENESIS, V16, P225, DOI 10.1093/mutage/16.3.225; Lammering G, 2001, INT J RADIAT ONCOL, V51, P775, DOI 10.1016/S0360-3016(01)01714-X; Lammering G, 2001, J NATL CANCER I, V93, P921, DOI 10.1093/jnci/93.12.921; Lee BH, 1997, P NATL ACAD SCI USA, V94, P4481, DOI 10.1073/pnas.94.9.4481; LIU YC, 1989, BIOCHEMISTRY-US, V28, P2967, DOI 10.1021/bi00433a034; Miura M, 2000, RADIAT RES, V153, P773, DOI 10.1667/0033-7587(2000)153[0773:BRTIRI]2.0.CO;2; Nevaldine B, 1997, RADIAT RES, V147, P535, DOI 10.2307/3579619; NIAS AHW, 1990, INTRO RADIOBIOLOGY, P102; Paunesku T, 2001, INT J RADIAT BIOL, V77, P1007, DOI 10.1080/09553000110069335; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; Reardon DB, 1999, ONCOGENE, V18, P4756, DOI 10.1038/sj.onc.1202849; SAHIJDAK WM, 1994, RADIAT RES, V138, pS47, DOI 10.2307/3578760; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; Utsumi H, 2001, RADIAT RES, V155, P680, DOI 10.1667/0033-7587(2001)155[0680:RFRODD]2.0.CO;2; VALERIE K, 1988, NATURE, V333, P78, DOI 10.1038/333078a0; Vens C, 2002, NUCLEIC ACIDS RES, V30, P2995, DOI 10.1093/nar/gkf403; Wenz F, 1998, RADIAT RES, V149, P32, DOI 10.2307/3579679; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Xu J, 1999, MOL CELL BIOL, V19, P12; Yacoub A, 2001, INT J RADIAT BIOL, V77, P1067, DOI 10.1080/09553000110069317; Yang XP, 1997, J BIOMED SCI, V4, P279, DOI 10.1007/BF02258351; Yang YM, 1996, ONCOGENE, V12, P2223; ZUBER M, 1989, MOL CELL BIOL, V9, P57, DOI 10.1128/MCB.9.1.57	41	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29394	29399		10.1074/jbc.M304012200	http://dx.doi.org/10.1074/jbc.M304012200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12734192	hybrid			2022-12-25	WOS:000184507000003
J	Genth, H; Gerhard, R; Maeda, A; Amano, M; Kaibuchi, K; Aktories, K; Just, I				Genth, H; Gerhard, R; Maeda, A; Amano, M; Kaibuchi, K; Aktories, K; Just, I			Entrapment of rho ADP-ribosylated by Clostridium botulinum C3 exoenzyme in the Rho-guanine nucleotide dissociation inhibitor-1 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; NECROTIZING FACTOR-I; REGULATORY PROTEIN; PHOSPHOLIPASE-D; CHIMERIC TOXIN; FAMILY GTPASES; CELL-ADHESION; ACTIVATION; GDI; TRANSLOCATION	RhoA, -B, and -C are ADP-ribosylated by Clostridium botulinum exoenzyme C3 to induce redistribution of the actin filaments in intact cells, a finding that has led to the notion that the ADP-ribosylation blocks coupling of Rho to the downstream effectors. ADP-ribosylation, however, does not alter nucleotide binding, intrinsic, and GTPase-activating protein-stimulated GTPase activity. ADP-ribosylated Rho is even capable of activating the effector protein ROK in a recombinant system. Treatment of cells with a cell-permeable chimeric C3 toxin led to complete localization of modified Rho to the cytosolic fraction based on the complexation of ADP-ribosylated Rho with the guanine-nucleotide dissociation inhibitor-1 (GDI-1). The modified complex turned out to be resistant to phosphatidylinositol 4,5-bisphosphateand GTPgammaS-induced release of Rho from GDI-1. Thus, ADP-ribosylation leads to entrapment of Rho in the GDI-1 complex. The increased stability of the GDI complex prevented binding of Rho to membrane-associated players of the GTPase cycle such as the activating guanine nucleotide exchange factors and effector proteins.	Hannover Med Sch, Inst Toxikol, D-30625 Hannover, Germany; Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, D-79098 Freiburg, Germany; Nagoya Univ, Dept Cell Pharmacol, Grad Sch Med, Nagoya, Aichi 4668550, Japan	Hannover Medical School; University of Freiburg; Nagoya University	Genth, H (corresponding author), Hannover Med Sch, Inst Toxikol, Carl Neuberg Str 1, D-30625 Hannover, Germany.		Aktories, Klaus/CAJ-5682-2022; Genth, Harald/HHS-0118-2022; Amano, Mutsuki/M-4820-2014	Aktories, Klaus/0000-0002-5397-0436; Amano, Mutsuki/0000-0002-0662-1524				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Adra CN, 1997, P NATL ACAD SCI USA, V94, P4279, DOI 10.1073/pnas.94.9.4279; AKTORIES K, 1997, BACTERIAL TOXINS TOO, P93; Aktories K, 1997, BACTERIAL TOXINS TOO, P61; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; AULLO P, 1993, EMBO J, V12, P921, DOI 10.1002/j.1460-2075.1993.tb05733.x; Barth H, 1999, J BIOL CHEM, V274, P27407, DOI 10.1074/jbc.274.39.27407; Barth H, 1998, INFECT IMMUN, V66, P1364, DOI 10.1128/IAI.66.4.1364-1369.1998; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; Boquet P, 1998, CURR OPIN MICROBIOL, V1, P66, DOI 10.1016/S1369-5274(98)80144-6; BOURMEYSTER N, 1992, BIOCHEMISTRY-US, V31, P12863, DOI 10.1021/bi00166a022; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; Fensome A, 1998, J BIOL CHEM, V273, P13157, DOI 10.1074/jbc.273.21.13157; FIORENTINI C, 1995, INFECT IMMUN, V63, P3936, DOI 10.1128/IAI.63.10.3936-3944.1995; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Fujihara H, 1997, MOL BIOL CELL, V8, P2437, DOI 10.1091/mbc.8.12.2437; Fujisawa K, 1998, J BIOL CHEM, V273, P18943, DOI 10.1074/jbc.273.30.18943; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; Genth H, 2003, BIOCHEM BIOPH RES CO, V302, P127, DOI 10.1016/S0006-291X(03)00112-8; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANCOCK JF, 1993, EMBO J, V12, P1915, DOI 10.1002/j.1460-2075.1993.tb05840.x; Henning SW, 1998, CURR OPIN IMMUNOL, V10, P322, DOI 10.1016/S0952-7915(98)80171-4; ISOMURA M, 1991, ONCOGENE, V6, P119; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Longenecker K, 1999, ACTA CRYSTALLOGR D, V55, P1503, DOI 10.1107/S090744499900801X; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; NOBES CD, 1997, BACTERIAL TOXINS TOO, P71; OHISHI I, 1987, INFECT IMMUN, V55, P1461, DOI 10.1128/IAI.55.6.1461-1465.1987; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; SASAKI T, 1993, J BIOL CHEM, V268, P23959; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Sehr P, 1998, BIOCHEMISTRY-US, V37, P5296, DOI 10.1021/bi972592c; SEKINE A, 1989, J BIOL CHEM, V264, P8602; STASIA MJ, 1991, BIOCHEM BIOPH RES CO, V180, P615, DOI 10.1016/S0006-291X(05)81110-6; Sterpetti P, 1999, MOL CELL BIOL, V19, P1334; Takahashi K, 1998, ONCOGENE, V16, P3279, DOI 10.1038/sj.onc.1201874; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TAKAISHI K, 1995, ONCOGENE, V11, P39; VAN AL, 1997, GENE DEV, V11, P2295; Zalcman G, 1996, J BIOL CHEM, V271, P30366, DOI 10.1074/jbc.271.48.30366	51	78	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28523	28527		10.1074/jbc.M301915200	http://dx.doi.org/10.1074/jbc.M301915200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12750364	hybrid			2022-12-25	WOS:000184421100023
J	Nagaoka, K; Nojima, H; Watanabe, F; Chang, KT; Christenson, RK; Sakai, S; Imakawa, K				Nagaoka, K; Nojima, H; Watanabe, F; Chang, KT; Christenson, RK; Sakai, S; Imakawa, K			Regulation of blastocyst migration, apposition, and initial adhesion by a chemokine, interferon gamma-inducible protein 10 kDa (IP-10), during early gestation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR EXPRESSION; INTEGRIN EXPRESSION; CELL-LINE; IMPLANTATION; UTERUS; PREGNANCY; ESTABLISHMENT; OSTEOPONTIN; ENDOMETRIUM; RECOGNITION	For a pregnancy to be established, initial apposition and adhesion of the blastocyst to maternal endometrium must occur in a coordinated manner; however, a key factor(s) that mediates the trophoblast cell migration and attachment to the apical surface of the endometrium has not been identified. In this study, we examined the effect of an endometrial chemokine, interferon-gamma inducible protein 10 kDa (IP-10), on conceptus migration to the endometrial epithelium. We first studied endometrial IP-10 mRNA expression, which was localized in the subepithelial stromal region, and detected the protein in the uterine flushing media during early pregnancy. Expression of IP-10 mRNA by the endometrium of cyclic animals was stimulated by the addition of a conceptus factor interferon-tau (IFN-tau). Immunofluorescent analysis revealed that IP-10 receptor, CXCR3, was localized in the trophoblast cells, to which biotinylated-recombinant caprine IP-10 (rcIP-10) bound. Chemotaxis assay indicated that rcIP-10 stimulated the migration of trophoblast cells, and the effects of rcIP-10 were neutralized by the pretreatment with an anti-IP-10 antibody. Adhesive activity of trophoblast cells to fibronectin was promoted by rcIP-10, and the effect was inhibited by the use of anti-IP-10 antibody. Further adhesion experiments demonstrated that binding of trophoblast cells to fibronectin was completely inhibited by a peptide of the Arg-Gly-Asp(RGD) sequence, which binds to integrins alpha(5)beta(1), alpha(V)beta(1), alpha(V)beta(3), and alpha(V)beta(5), whereas non-binding peptide containing Arg-Gly-Glu(RGE) had minimal effects. More importantly, rcIP-10 promoted the adhesion of trophoblast cells to primary cells isolated from endometrial epithelium. Furthermore, rcIP-10 stimulated the expression of integrin alpha(5), alpha(V), and beta(3) subunit mRNA in trophoblast cells. These findings suggest that endometrial IP-10 regulates the establishment of apical interactions between trophoblast and epithelial cells during early gestation.	Univ Tokyo, Fac Agr, Lab Anim Breeding, Bunkyo Ku, Tokyo 1138657, Japan; Higeta Shoyu Co Ltd, R&D Dept, Chiba 2888680, Japan; Korea Res Inst Biosci & Biotechnol, Taejon 305333, South Korea; ARS, Meat Anim Res Ctr, USDA, Clay Ctr, NE 68933 USA	University of Tokyo; Korea Research Institute of Bioscience & Biotechnology (KRIBB); United States Department of Agriculture (USDA)	Imakawa, K (corresponding author), Univ Tokyo, Fac Agr, Lab Anim Breeding, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	akaz@mail.ecc.u-tokyo.ac.jp	Nagaoka, Kentaro/C-2019-2013; Imakawa, Kazuhiko/AAD-3211-2022	Nagaoka, Kentaro/0000-0003-1038-1380; 				ARMANT DR, 1986, P NATL ACAD SCI USA, V83, P6751, DOI 10.1073/pnas.83.18.6751; Asselin E, 2001, BIOL REPROD, V64, P992, DOI 10.1095/biolreprod64.3.992; Athanassakis I, 2000, HUM IMMUNOL, V61, P651, DOI 10.1016/S0198-8859(00)00128-2; Athanassakis I, 2001, J REPROD IMMUNOL, V50, P105, DOI 10.1016/S0165-0378(01)00062-6; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bowen JA, 1996, BIOL REPROD, V55, P1098, DOI 10.1095/biolreprod55.5.1098; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; Caballero-Campo P, 2002, MOL HUM REPROD, V8, P375, DOI 10.1093/molehr/8.4.375; CAMPBELL S, 1995, HUM REPROD, V10, P1571, DOI 10.1093/HUMREP/10.6.1571; Cella M, 1999, NAT MED, V5, P919, DOI 10.1038/11360; Chantakru S, 2001, J REPROD IMMUNOL, V49, P33, DOI 10.1016/S0165-0378(00)00076-0; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; Douglas GC, 2001, J REPROD IMMUNOL, V49, P97, DOI 10.1016/S0165-0378(00)00083-8; Farber JM, 1997, J LEUKOCYTE BIOL, V61, P246, DOI 10.1002/jlb.61.3.246; Genbacev OD, 2003, SCIENCE, V299, P405, DOI 10.1126/science.1079546; Homey B, 2002, NAT REV IMMUNOL, V2, P175, DOI 10.1038/nri748; Illera MJ, 2000, BIOL REPROD, V62, P1285, DOI 10.1095/biolreprod62.5.1285; IMAKAWA K, 1995, ENDOCRINE, V3, P511, DOI 10.1007/BF02738826; IMAKAWA K, 1987, NATURE, V330, P377, DOI 10.1038/330377a0; Inngjerdingen M, 2001, BLOOD, V97, P367, DOI 10.1182/blood.V97.2.367; Johnson GA, 1999, BIOL REPROD, V61, P892, DOI 10.1095/biolreprod61.4.892; Johnson GA, 2001, BIOL REPROD, V65, P820, DOI 10.1095/biolreprod65.3.820; Kimber SJ, 2000, SEMIN CELL DEV BIOL, V11, P77, DOI 10.1006/scdb.2000.0154; KOYAMA H, 1986, J VET MED B, V33, P586, DOI 10.1111/j.1439-0450.1986.tb00073.x; Loetscher M, 1998, EUR J IMMUNOL, V28, P3696, DOI 10.1002/(SICI)1521-4141(199811)28:11<3696::AID-IMMU3696>3.0.CO;2-W; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MacIntyre DM, 2002, BIOL REPROD, V66, P1430, DOI 10.1095/biolreprod66.5.1430; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; MACLAREN LA, 1995, BIOL REPROD, V53, P153, DOI 10.1095/biolreprod53.1.153; Miyazaki H, 2002, PLACENTA, V23, P613, DOI 10.1053/plac.2002.0846; Moussa M, 2001, AM J REPROD IMMUNOL, V46, P309, DOI 10.1034/j.1600-0897.2001.d01-17.x; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nagaoka K, 2003, BIOL REPROD, V68, P1413, DOI 10.1095/biolreprod.102.008912; Red-Horse K, 2001, AM J PATHOL, V159, P2199, DOI 10.1016/S0002-9440(10)63071-4; ROBERTS RM, 1992, P SOC EXP BIOL MED, V200, P7, DOI 10.3181/00379727-200-43387A; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SUTHERLAND AE, 1993, DEVELOPMENT, V119, P1175; Takahashi Hitomi, 2001, Journal of Reproduction and Development, V47, P181, DOI 10.1262/jrd.47.181; Tan JQ, 2000, J IMMUNOL, V165, P1548, DOI 10.4049/jimmunol.165.3.1548; Teixeira MG, 1997, ENDOCRINE, V6, P31, DOI 10.1007/BF02738799; Wood GW, 1997, MOL REPROD DEV, V46, P62, DOI 10.1002/(SICI)1098-2795(199701)46:1<62::AID-MRD10>3.0.CO;2-5; Wood GW, 1999, CYTOKINE, V11, P1038, DOI 10.1006/cyto.1999.0513; WOODING FBP, 1992, PLACENTA, V13, P101, DOI 10.1016/0143-4004(92)90025-O	44	69	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29048	29056		10.1074/jbc.M300470200	http://dx.doi.org/10.1074/jbc.M300470200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12756249	hybrid			2022-12-25	WOS:000184421100087
J	Biagini, GA; Bray, PG; Spiller, DG; White, MRH; Ward, SA				Biagini, GA; Bray, PG; Spiller, DG; White, MRH; Ward, SA			The digestive food vacuole of the malaria parasite is a dynamic intracellular Ca2+ store	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM; H+-PYROPHOSPHATASE; ANTIMALARIALS; RESISTANCE; ATPASE	The acidic food vacuole of Plasmodium falciparum has been the subject of intense scientific investigation in the 40 years since its role in the digestion of host hemoglobin was first suggested. This proposed role has important implications for the complex host-parasite inter-relationship and also for the mode of action of several of the most effective antimalarial drugs. In addition, adaptive changes in the physiology of this organelle are implicated in drug resistance. Here we show that in addition to these functions, the digestive food vacuole of the malaria parasite is a dynamic internal store for free Ca2+, a role hitherto unsuspected. With the aid of live-cell laser scanning confocal imaging, spatio-temporal studies revealed that maintenance of elevated free Ca2+ in the digestive food vacuole (relative to cytosolic levels) is achieved by a thapsigargin (and cyclopiazonic acid)-sensitive Ca2+-pump in cooperation with a H+-dependent Ca2+ transporter. Redistribution of free cytosolic and vacuolar Ca2+ during parasite growth also suggests that vacuolar Ca2+ plays an essential role in parasite morphogenesis. These data imply that the digestive food vacuole of the malaria parasite is functionally akin to the vacuole of plants (tonoplast) and the small electron-dense granules of some parasites (acidocalcisomes) whereby H+-coupled Ca2+ transport is involved in ion transport, Ca2+ homeostasis, and signal transduction. These findings have significant implications for parasite development, antimalarial drug action, and mechanisms of drug resistance.	Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; Univ Liverpool, Sch Biol Sci, Ctr Cell Imaging, Liverpool L69 7ZB, Merseyside, England	Liverpool School of Tropical Medicine; University of Liverpool; University of Liverpool	Biagini, GA (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Pembroke Pl, Liverpool L3 5QA, Merseyside, England.	Biagini@liv.ac.uk; Saward@liv.ac.uk	Spiller, David G/I-3645-2012; Biagini, Giancarlo A/F-3449-2011; Ward, Steve/G-6003-2015	Biagini, Giancarlo A/0000-0001-6356-6595; Ward, Steve/0000-0003-2331-3192; White, Michael/0000-0002-3617-3232; Spiller, David Geoffrey/0000-0003-2502-6787				Alleva LM, 2001, MOL BIOCHEM PARASIT, V117, P121, DOI 10.1016/S0166-6851(01)00338-3; Bray PG, 2002, MOL BIOCHEM PARASIT, V119, P301, DOI 10.1016/S0166-6851(01)00403-0; Coombs GH, 2001, TRENDS PARASITOL, V17, P532, DOI 10.1016/S1471-4922(01)02037-2; Docampo R, 1999, PARASITOL TODAY, V15, P443, DOI 10.1016/S0169-4758(99)01531-8; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Garcia CRS, 1998, EUR J CELL BIOL, V76, P133, DOI 10.1016/S0171-9335(98)80026-5; Garcia CRS, 1996, EUR J CELL BIOL, V71, P409; GOEGER DE, 1989, BIOCHEM PHARMACOL, V38, P3995, DOI 10.1016/0006-2952(89)90679-5; Hirschi K, 2001, TRENDS PLANT SCI, V6, P100, DOI 10.1016/S1360-1385(00)01863-X; Krishna S, 2001, J BIOL CHEM, V276, P10782, DOI 10.1074/jbc.M010554200; Loria P, 1999, BIOCHEM J, V339, P363, DOI 10.1042/0264-6021:3390363; Maravall M, 2000, BIOPHYS J, V78, P2655, DOI 10.1016/S0006-3495(00)76809-3; Marchesini N, 2000, BIOCHEM J, V347, P243, DOI 10.1042/0264-6021:3470243; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; RUDZINSKA MA, 1960, J PROTOZOOL, V7, P24; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; Saliba KJ, 2003, J BIOL CHEM, V278, P5605, DOI 10.1074/jbc.M208648200; Spiller DG, 2002, TRENDS PARASITOL, V18, P441, DOI 10.1016/S1471-4922(02)02365-6; Sze H, 1999, PLANT CELL, V11, P677, DOI 10.1105/tpc.11.4.677; Taylor CW, 1998, TRENDS PHARMACOL SCI, V19, P370, DOI 10.1016/S0165-6147(98)01243-7; Thomas D, 2000, CELL CALCIUM, V28, P213, DOI 10.1054/ceca.2000.0152; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Warhurst DC, 2002, LANCET, V360, P1527, DOI 10.1016/S0140-6736(02)11577-7; WASSERMAN M, 1982, AM J TROP MED HYG, V31, P711, DOI 10.4269/ajtmh.1982.31.711; Winstanley P, 2001, Lancet Infect Dis, V1, P242, DOI 10.1016/S1473-3099(01)00119-0; World Health Organization, 2002, ROLL BACK MAL	27	61	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27910	27915		10.1074/jbc.M304193200	http://dx.doi.org/10.1074/jbc.M304193200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12740366	hybrid			2022-12-25	WOS:000184242700073
J	Ikeda, W; Kakunaga, S; Itoh, S; Shingai, T; Takekuni, K; Satoh, K; Inoue, Y; Hamaguchi, A; Morimoto, K; Takeuchi, M; Imai, T; Takai, Y				Ikeda, W; Kakunaga, S; Itoh, S; Shingai, T; Takekuni, K; Satoh, K; Inoue, Y; Hamaguchi, A; Morimoto, K; Takeuchi, M; Imai, T; Takai, Y			Tage4/nectin-like molecule-5 heterophilically trans-interacts with cell adhesion molecule nectin-3 and enhances cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPRESSOR TSLC1 GENE; IMMUNOGLOBULIN SUPERFAMILY; CONTACT INHIBITION; POLIOVIRUS RECEPTOR; PROTEIN; MEMBER; AFADIN; EXPRESSION; BINDING; JUNCTIONS	Malignant transformation of cells causes disruption of cell-cell adhesion, enhancement of cell motility, and invasion into surrounding tissues. Nectins have both homophilic and heterophilic cell-cell adhesion activities and organize adherens junctions in cooperation with cadherins. We examined here whether Tage4, which was originally identified to be a gene overexpressed in colon carcinoma and has a domain structure similar to those of nectins, is involved in cell adhesion and/or migration. Tage4 heterophilically trans-interacted with nectin-3, but not homophilically with Tage4. Expression of Tage4 was markedly elevated in NIH3T3 cells transformed by an oncogenic Ki-Ras (V12Ras-NIH3T3 cells) as compared with that of wild-type NIH3T3 cells. trans-Interaction of Tage4 with nectin-3 enhanced motility of V12Ras-NIH3T3 cells. Tage4 did not bind afadin, a nectin- and actin filament-binding protein that connects nectins to the actin cytoskeleton and cadherins through catenins. Thus, Tage4 heterophilically trans-interacts with nectin-3 and regulates cell migration. Tage4 is tentatively re-named here nectin-like molecule-5 (necl-5) on the basis of its function and domain structure similar to those of nectins.	Osaka Univ, Fac Med, Grad Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; KAN Res Inst Inc, Shimogyo Ku, Kyoto 6008815, Japan	Osaka University; KAN Research Institute	Takai, Y (corresponding author), Osaka Univ, Fac Med, Grad Sch Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Ikeda, Wataru/V-8531-2019	Ikeda, Wataru/0000-0002-6907-9058; Itoh, Shinsuke/0000-0001-9567-8188				ABERCROMBIE M, 1979, NATURE, V281, P259, DOI 10.1038/281259a0; ABERCROMBIE M, 1970, IN VITRO CELL DEV B, V6, P128; Baury B, 2001, GENE, V265, P185, DOI 10.1016/S0378-1119(01)00343-2; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chadeneau C, 1996, INT J CANCER, V68, P817; CHADENEAU C, 1994, J BIOL CHEM, V269, P15601; FUJIOKA H, 1992, J BIOL CHEM, V267, P926; Fukami T, 2002, GENE, V295, P7, DOI 10.1016/S0378-1119(02)00835-1; Fukuhara H, 2001, ONCOGENE, V20, P5401, DOI 10.1038/sj.onc.1204696; Gomyo H, 1999, GENOMICS, V62, P139, DOI 10.1006/geno.1999.6001; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Honda T, 2003, GENES CELLS, V8, P51, DOI 10.1046/j.1365-2443.2003.00616.x; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; James P, 1996, GENETICS, V144, P1425; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; KOIKE S, 1992, J VIROL, V66, P7059, DOI 10.1128/JVI.66.12.7059-7066.1992; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; MARTZ E, 1972, J CELL PHYSIOL, V79, P189, DOI 10.1002/jcp.1040790205; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Sakisaka T, 2001, J VIROL, V75, P4734, DOI 10.1128/JVI.75.10.4734-4743.2001; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Urase K, 2001, NEUROREPORT, V12, P3217, DOI 10.1097/00001756-200110290-00015; Wakayama T, 2001, MOL REPROD DEV, V60, P158, DOI 10.1002/mrd.1072	34	109	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28167	28172		10.1074/jbc.M303586200	http://dx.doi.org/10.1074/jbc.M303586200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12740392	hybrid			2022-12-25	WOS:000184242700105
J	Parschat, K; Hauer, B; Kappl, R; Kraft, R; Huttermann, J; Fetzner, S				Parschat, K; Hauer, B; Kappl, R; Kraft, R; Huttermann, J; Fetzner, S			Gene cluster of Arthrobacter ilicis Ru61a involved in the degradation of quinaldine to anthranilate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MOLYBDENUM-CONTAINING HYDROXYLASE; XANTHINE-OXIDASE FAMILY; CARBON-MONOXIDE DEHYDROGENASE; SITE-DIRECTED MUTAGENESIS; COMPLETE GENOME SEQUENCE; HOST-RANGE CLONING; PSEUDOMONAS-PUTIDA; ALDEHYDE OXIDOREDUCTASE; MICROBIAL-METABOLISM; QUINOLINE 2-OXIDOREDUCTASE	A genetic analysis of the anthranilate pathway of quinaldine degradation was performed. A 23-kb region of DNA from Arthrobacter ilicis Ru61a was cloned into the cosmid pVK100. Although Escherichia coli clones containing the recombinant cosmid did not transform quinaldine, cosmids harboring the 23-kb region, or a 10.8-kb stretch of this region, conferred to Pseudomonas putida KT2440 the ability to cometabolically convert quinaldine to anthranilate. The 10.8-kb fragment thus contains the genes coding for quinaldine 4-oxidase (Qox), 1H-4-oxoquinaldine 3-monooxygenase, 1H-3-hydroxy-4-oxoquinaldine 2,4-dioxygenase, and N-acetylanthranilate amidase. The qoxLMS genes coding for the molybdopterin cytosine dinucleotide- (MCD-), FeSI-, FeSII-, and FAD-containing Qox were inserted into the expression vector pJB653, generating pKP1. Qox is the first MCD-containing enzyme to be synthesized in a catalytically fully competent form by a heterologous host, P. putida KT2440 pKP1; the catalytic properties and the UV-visible and EPR spectra of Qox purified from P. putida KT2440 pKP1 were essentially like those of wild-type Qox. This provides a starting point for the construction of protein variants of Qox by site-directed mutagenesis. Downstream of the qoxLMS genes, a putative gene whose deduced amino acid sequence showed 37% similarity to the cofactor-inserting chaperone XdhC was located. Additional open reading frames identified on the 23-kb segment may encode further enzymes (a glutamyl tRNA synthetase, an esterase, two short-chain dehydrogenases/reductases, an ATPase belonging to the AAA family, a 2-hydroxyhepta-2,4-diene-1,7-dioate isomerase/5-oxopent-3-ene-1,2,5-tricarboxylate decarboxylase-like protein, and an enzyme of the mandelate racemase group) and hypothetical proteins involved in transcriptional regulation, and metabolite transport.	Carl von Ossietzky Univ Oldenburg, Inst Chem & Biol Meeres, AG Mikrobiol, D-26111 Oldenburg, Germany; Univ Munster, Inst Mol Mikrobiol & Biotechnol, D-48149 Munster, Germany; BASF AG, D-67056 Ludwigshafen, Germany; Univ Saarland, Fachrichtung Biophys & Phys Grundlagen Med, D-66421 Homburg, Germany	Carl von Ossietzky Universitat Oldenburg; University of Munster; BASF; Saarland University	Fetzner, S (corresponding author), Carl von Ossietzky Univ Oldenburg, Inst Chem & Biol Meeres, AG Mikrobiol, D-26111 Oldenburg, Germany.	fetzner@uni-muenster.de		Fetzner, Susanne/0000-0002-7228-1871; Kappl, Reinhard/0000-0003-0223-6642				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andrade SLA, 2000, EUR J BIOCHEM, V267, P2054, DOI 10.1046/j.1432-1327.2000.01209.x; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P469, DOI 10.1016/S0968-0004(98)01293-6; Attwood TK, 1998, NUCLEIC ACIDS RES, V26, P304, DOI 10.1093/nar/26.1.304; Babbitt PC, 1996, BIOCHEMISTRY-US, V35, P16489, DOI 10.1021/bi9616413; BAGDASARIAN M, 1981, GENE, V16, P237, DOI 10.1016/0378-1119(81)90080-9; Baitsch D, 2001, J BACTERIOL, V183, P5262, DOI 10.1128/JB.183.18.5262-5267.2001; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; Betz A, 2000, J BASIC MICROB, V40, P7, DOI 10.1002/(SICI)1521-4028(200002)40:1<7::AID-JOBM7>3.0.CO;2-5; BILOUS PT, 1988, MOL MICROBIOL, V2, P785, DOI 10.1111/j.1365-2958.1988.tb00090.x; BLACK GW, 1990, FEMS MICROBIOL LETT, V70, P249, DOI 10.1016/S0378-1097(05)80003-5; Blase M, 1996, J BIOL CHEM, V271, P23068; Blatny JM, 1997, APPL ENVIRON MICROB, V63, P370, DOI 10.1128/AEM.63.2.370-379.1997; *BOEHR MANNH GMBH, 1995, DIG SYST US GUID FIL; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; Canne C, 1997, BIOCHEMISTRY-US, V36, P9780, DOI 10.1021/bi970581d; Canne C, 1999, BIOCHEMISTRY-US, V38, P14077, DOI 10.1021/bi991089s; Chaiyen PC, 1997, P NATL ACAD SCI USA, V94, P7233, DOI 10.1073/pnas.94.14.7233; Clark TJ, 2002, MICROBIOL-SGM, V148, P1213, DOI 10.1099/00221287-148-4-1213; Collier LS, 1997, J BACTERIOL, V179, P5943, DOI 10.1128/jb.179.18.5943-5946.1997; Coughlan M. P., 1980, Molybdenum and molybdenum-containing enzymes, P119; DEBEYER A, 1993, BIOL CHEM H-S, V374, P101, DOI 10.1515/bchm3.1993.374.1-6.101; DEMBEK G, 1989, FEBS LETT, V246, P113, DOI 10.1016/0014-5793(89)80264-9; Diaz E, 2000, CURR OPIN BIOTECH, V11, P467, DOI 10.1016/S0958-1669(00)00126-9; Dobbek H, 1999, P NATL ACAD SCI USA, V96, P8884, DOI 10.1073/pnas.96.16.8884; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; Eaton RW, 1997, J BACTERIOL, V179, P3171, DOI 10.1128/jb.179.10.3171-3180.1997; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; Fetzner S, 1998, APPL MICROBIOL BIOT, V49, P237, DOI 10.1007/s002530051164; Fetzner S, 2002, APPL MICROBIOL BIOT, V60, P243, DOI 10.1007/s00253-002-1123-4; Fetzner S, 2000, NATURWISSENSCHAFTEN, V87, P59, DOI 10.1007/s001140050011; Fischer F, 1999, J BACTERIOL, V181, P5725, DOI 10.1128/JB.181.18.5725-5733.1999; Fischer F, 2000, FEMS MICROBIOL LETT, V190, P21, DOI 10.1111/j.1574-6968.2000.tb09256.x; Fraaije MW, 1998, TRENDS BIOCHEM SCI, V23, P206, DOI 10.1016/S0968-0004(98)01210-9; Freist W, 1997, BIOL CHEM, V378, P1313; Frerichs-Deeken U, 2003, EUR J BIOCHEM, V270, P1567, DOI 10.1046/j.1432-1033.2003.03526.x; GARRETT RM, 1994, J BIOL CHEM, V269, P272; Gerlt JA, 2001, ANNU REV BIOCHEM, V70, P209, DOI 10.1146/annurev.biochem.70.1.209; Glatigny A, 1998, J MOL BIOL, V278, P431, DOI 10.1006/jmbi.1998.1707; Hames BD., 1990, GEL ELECTROPHORESIS, P1; HARWOOD CS, 1994, J BACTERIOL, V176, P6479, DOI 10.1128/JB.176.21.6479-6488.1994; Hasson MS, 1998, P NATL ACAD SCI USA, V95, P10396, DOI 10.1073/pnas.95.18.10396; HERZBERG O, 1987, SCIENCE, V236, P694, DOI 10.1126/science.3107125; HETTRICH D, 1991, BIOL CHEM H-S, V372, P513, DOI 10.1515/bchm3.1991.372.2.513; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Hille R, 1998, FEMS MICROBIOL REV, V22, P489; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; Hille R, 2002, MET IONS BIOL SYST, V39, P187; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hopwood D. A., 1985, GENETIC MANIPULATION; HUGHES RK, 1992, BIOCHEM J, V285, P507, DOI 10.1042/bj2850507; HUND HK, 1990, BIOL CHEM H-S, V371, P1005, DOI 10.1515/bchm3.1990.371.2.1005; Israel I, 2002, FEMS MICROBIOL LETT, V210, P123; IWASAKI K, 1994, BIOSCI BIOTECH BIOCH, V58, P851, DOI 10.1271/bbb.58.851; JONES D, 1986, BERGEYS MANUAL SYSTE, V2, P1261; Kallberg Y, 2002, EUR J BIOCHEM, V269, P4409, DOI 10.1046/j.1432-1033.2002.03130.x; Kappl R, 2002, MET IONS BIOL SYST, V39, P481; KELLY JA, 1985, J BIOL CHEM, V260, P6449; KISKER C, 1995, J MOL BIOL, V247, P260, DOI 10.1006/jmbi.1994.0138; KNAUF VC, 1982, PLASMID, V8, P45, DOI 10.1016/0147-619X(82)90040-3; Kojic M, 2002, J BACTERIOL, V184, P2324, DOI 10.1128/JB.184.8.2324-2330.2002; KOONIN EV, 1993, J MOL BIOL, V229, P1165, DOI 10.1006/jmbi.1993.1115; KOWALCHUK GA, 1994, GENE, V146, P23, DOI 10.1016/0378-1119(94)90829-X; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMANN M, 1994, J BIOL CHEM, V269, P11254; Leimkuhler S, 1999, J BACTERIOL, V181, P2745; Lucas CE, 1997, J BACTERIOL, V179, P4123, DOI 10.1128/jb.179.13.4123-4128.1997; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; Mendel RR, 2002, MET IONS BIOL SYST, V39, P317; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; Nakada Y, 2001, J BACTERIOL, V183, P6517, DOI 10.1128/JB.183.22.6517-6524.2001; Nelson KE, 2002, ENVIRON MICROBIOL, V4, P799, DOI 10.1046/j.1462-2920.2002.00366.x; Neuwald AF, 1999, GENOME RES, V9, P27; NISHIZAWA M, 1995, APPL ENVIRON MICROB, V61, P3208, DOI 10.1128/AEM.61.9.3208-3215.1995; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Parke D, 2000, J BACTERIOL, V182, P257, DOI 10.1128/JB.182.2.257-263.2000; Pau RN, 2002, MET IONS BIOL SYST, V39, P31; PEARSON DM, 1994, BBA-BIOENERGETICS, V1188, P432, DOI 10.1016/0005-2728(94)90066-3; PERONA JJ, 1993, BIOCHEMISTRY-US, V32, P8758, DOI 10.1021/bi00085a006; Pollock VV, 1997, J BIOL CHEM, V272, P3355, DOI 10.1074/jbc.272.6.3355; Rebelo J, 2000, J MOL BIOL, V297, P135, DOI 10.1006/jmbi.2000.3552; Rebelo JM, 2001, J BIOL INORG CHEM, V6, P791, DOI 10.1007/s007750100255; REZNIKOFF WS, 1985, ANNU REV GENET, V19, P355, DOI 10.1146/annurev.genet.19.1.355; ROGER P, 1990, BIOL CHEM H-S, V371, P511, DOI 10.1515/bchm3.1990.371.1.511; Romao MJ, 1997, PROG BIOPHYS MOL BIO, V68, P121, DOI 10.1016/S0079-6107(97)00022-9; Romao MJ, 1998, STRUCT BOND, V90, P69; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; Romine MF, 1999, J BACTERIOL, V181, P1585, DOI 10.1128/JB.181.5.1585-1602.1999; ROPER DI, 1993, EUR J BIOCHEM, V217, P575, DOI 10.1111/j.1432-1033.1993.tb18279.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schenk S, 1998, J MOL BIOL, V284, P1323, DOI 10.1006/jmbi.1998.2227; SCHUBEL U, 1995, J BACTERIOL, V177, P2197, DOI 10.1128/jb.177.8.2197-2203.1995; Schultz AC, 2001, J BACTERIOL, V183, P3293, DOI 10.1128/JB.183.11.3293-3302.2001; Schumacher MA, 2002, EMBO J, V21, P1210, DOI 10.1093/emboj/21.5.1210; Stephan I, 1996, EUR J BIOCHEM, V236, P155, DOI 10.1111/j.1432-1033.1996.00155.x; Temple CA, 2000, J BIOL CHEM, V275, P40202, DOI 10.1074/jbc.M007407200; Truglio JJ, 2002, STRUCTURE, V10, P115, DOI 10.1016/S0969-2126(01)00697-9; TSHISUAKA B, 1993, BIOCHEMISTRY-US, V32, P12928, DOI 10.1021/bi00210a047; VANDERMEER JR, 1992, MICROBIOL REV, V56, P677, DOI 10.1128/MMBR.56.4.677-694.1992; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; Williams PA, 1997, J BACTERIOL, V179, P5935, DOI 10.1128/jb.179.18.5935-5942.1997; Wyndham R. Campbell, 1994, Biodegradation, V5, P323, DOI 10.1007/BF00696468; Zor T, 1996, ANAL BIOCHEM, V236, P302, DOI 10.1006/abio.1996.0171	106	27	28	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27483	27494		10.1074/jbc.M301330200	http://dx.doi.org/10.1074/jbc.M301330200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12730200	hybrid			2022-12-25	WOS:000184242700020
J	Tuzi, S; Uekama, N; Okada, M; Yamaguchi, S; Saito, H; Yagisawa, H				Tuzi, S; Uekama, N; Okada, M; Yamaguchi, S; Saito, H; Yagisawa, H			Structure and dynamics of the phospholipase C-delta 1 pleckstrin homology domain located at the lipid bilayer surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE ALPHA-HELICES; SOLID-STATE NMR; C-13 NMR; HIGH-AFFINITY; TRANSGLUTAMINASE-II; BINDING; BACTERIORHODOPSIN; MEMBRANE; CONFORMATION; C-DELTA-1	Despite the importance of signal transduction pathways at membrane surfaces, there have been few means of investigating their molecular mechanisms based on the structural information of membrane-bound proteins. We applied solid state NMR as a novel method to obtain structural information about the phospholipase C-delta1 (PLC-delta1) pleckstrin homology (PH) domain at the lipid bilayer surface. NMR spectra of the alanine residues in the vicinity of the beta5/beta6 loop in the PH domain revealed changes in local conformations due to the membrane localization of the protein. We propose that these conformational changes originate from a hydrophobic interaction between the amphipathic alpha-helix located in the beta5/beta6 loop and the hydrophobic layer of the membrane and contribute to the membrane binding affinity, interdomain interactions and intermolecular interactions of PLC-delta1.	Himeji Inst Technol, Dept Life Sci, Kamigori, Hyogo 6781297, Japan	University of Hyogo	Tuzi, S (corresponding author), Himeji Inst Technol, Dept Life Sci, Harima Sci Garden City,Kouto 3 Chome, Kamigori, Hyogo 6781297, Japan.		Okada, Masashi/AAC-2171-2021; Yagisawa, Hitoshi/C-9305-2012	Yagisawa, Hitoshi/0000-0002-5365-4513				Baek KJ, 2001, J BIOL CHEM, V276, P5591, DOI 10.1074/jbc.M008252200; Bottomley MJ, 1998, BBA-MOL CELL BIOL L, V1436, P165, DOI 10.1016/S0005-2760(98)00141-6; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Hirata M, 1998, JPN J PHARMACOL, V76, P255, DOI 10.1254/jjp.76.255; Hristova K, 1999, J MOL BIOL, V290, P99, DOI 10.1006/jmbi.1999.2840; Kang SK, 2002, BIOCHEM BIOPH RES CO, V293, P383, DOI 10.1016/S0006-291X(02)00197-3; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 1998, CURR TOP MICROBIOL, V228, P39; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; RAMIREZ F, 1991, PROTEINS, V9, P229, DOI 10.1002/prot.340090402; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; ROTHWELL WP, 1981, J CHEM PHYS, V74, P2721, DOI 10.1063/1.441433; Saito H, 2000, BBA-BIOENERGETICS, V1460, P39, DOI 10.1016/S0005-2728(00)00128-6; Saito H, 1998, ANNU REP NMR SPECTRO, V36, P79, DOI 10.1016/S0066-4103(08)60006-X; SAITO H, 1986, MAGN RESON CHEM, V24, P835, DOI 10.1002/mrc.1260241002; Saituo H., 1989, ANNU REP NMR SPECTRO, V21, P209, DOI DOI 10.1016/S0066-4103(08)60124-6; Tanio M, 1999, BIOPHYS J, V77, P431, DOI 10.1016/S0006-3495(99)76901-8; Tanio M, 1999, BIOPHYS J, V77, P1577, DOI 10.1016/S0006-3495(99)77005-0; Tuzi S, 1999, BIOPHYS J, V76, P1523, DOI 10.1016/S0006-3495(99)77311-X; TUZI S, 1994, BIOCHEMISTRY-US, V33, P15046, DOI 10.1021/bi00254a013; Tuzi S, 2001, BIOPHYS J, V81, P425, DOI 10.1016/S0006-3495(01)75710-4; White SH, 2001, J BIOL CHEM, V276, P32395, DOI 10.1074/jbc.R100008200; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; Yagisawa H, 1998, J BIOL CHEM, V273, P417, DOI 10.1074/jbc.273.1.417	27	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28019	28025		10.1074/jbc.M300101200	http://dx.doi.org/10.1074/jbc.M300101200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12736268	hybrid			2022-12-25	WOS:000184242700087
J	Letley, DP; Rhead, JL; Twells, RJ; Dove, B; Atherton, JC				Letley, DP; Rhead, JL; Twells, RJ; Dove, B; Atherton, JC			Determinants of non-toxicity in the gastric pathogen Helicobacter pylori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLATING CYTOTOXIN GENE; TOXIN VACA; HELA-CELLS; CAMPYLOBACTER-PYLORI; PEPTIC-ULCERATION; CAGA GENOTYPES; DIVERSITY; DISEASES; PROTEIN; STRAINS	The Helicobacter pylori vacuolating cytotoxin gene, vacA, is naturally polymorphic, the two most diverse regions being the signal region ( which can be type s1 or s2) and the mid region (m1 or m2). Previous work has shown which features of vacA make peptic ulcer and gastric cancer-associated type s1/m1 and s1/m2 strains toxic. vacA s2/m2 strains are associated with lower peptic ulcer and gastric cancer risk and are non-toxic. We now define the features of vacA that determine the non-toxicity of these strains. To do this, we deleted parts of vacA and constructed isogenic hybrid strains in which regions of vacA were exchanged between toxigenic and non-toxigenic strains. We showed that a naturally occurring 12-amino acid hydrophilic N-terminal extension found on s2 VacA blocks vacuolating activity as its removal (to make the strain s1-like) confers activity. The mid region of s2/m2 vacA does not cause the non-vacuolating phenotype, but if VacA is unblocked, it confers cell line specificity of vacuolation as in natural s1/m2 strains. Chromosomal replacement of vacA in a non-toxigenic strain with vacA from a toxigenic strain confers full vacuolating activity proving that this activity is entirely controlled by elements within vacA. This work defines why H. pylori strains with different vacA allelic structures have differing toxicity and provides a rational basis for vacA typing schemes.	Univ Nottingham, Queens Med Ctr, Div Gastroenterol, Nottingham NG7 2UH, England; Univ Nottingham, Queens Med Ctr, Inst Infect Immun & Inflammat, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham	Letley, DP (corresponding author), Univ Nottingham, Queens Med Ctr, Div Gastroenterol, C Floor,W Block,Clifton Blvd, Nottingham NG7 2UH, England.			/0000-0001-6180-0042				Achtman M, 1999, MOL MICROBIOL, V32, P459, DOI 10.1046/j.1365-2958.1999.01382.x; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; ATHERTON JC, 1995, J BIOL CHEM, V270, P17771, DOI 10.1074/jbc.270.30.17771; Atherton JC, 1999, J CLIN MICROBIOL, V37, P2979, DOI 10.1128/JCM.37.9.2979-2982.1999; Atherton JC, 1999, CURR MICROBIOL, V39, P211, DOI 10.1007/s002849900447; Atherton JC, 1997, GASTROENTEROLOGY, V112, P92, DOI 10.1016/S0016-5085(97)70223-3; ATHERTON JC, 2001, HELICOBACTER PYLORI, P97; Atherton John C., 1997, P133; Basso D, 1998, GUT, V43, P182, DOI 10.1136/gut.43.2.182; COVER TL, 1993, INFECT IMMUN, V61, P1427, DOI 10.1128/IAI.61.4.1427-1431.1993; COVER TL, 1992, J BIOL CHEM, V267, P10570; COVER TL, 1994, J BIOL CHEM, V269, P10566; COVER TL, 1990, INFECT IMMUN, V58, P603, DOI 10.1128/IAI.58.3.603-610.1990; CRABTREE JE, 1991, LANCET, V338, P332, DOI 10.1016/0140-6736(91)90477-7; de Bernard M, 2000, EMBO J, V19, P48, DOI 10.1093/emboj/19.1.48; de Bernard M, 1998, INFECT IMMUN, V66, P6014, DOI 10.1128/IAI.66.12.6014-6016.1998; FIGURA N, 1989, J CLIN MICROBIOL, V27, P225, DOI 10.1128/JCM.27.1.225-226.1989; Forsyth MH, 1998, INFECT IMMUN, V66, P3088, DOI 10.1128/IAI.66.7.3088-3094.1998; Garner JA, 1996, INFECT IMMUN, V64, P4197, DOI 10.1128/IAI.64.10.4197-4203.1996; Gerhard M, 1999, P NATL ACAD SCI USA, V96, P12778, DOI 10.1073/pnas.96.22.12778; Han SR, 1998, CLIN DIAGN LAB IMMUN, V5, P139, DOI 10.1128/CDLI.5.2.139-145.1998; Ji XH, 2000, INFECT IMMUN, V68, P3754, DOI 10.1128/IAI.68.6.3754-3757.2000; Ji XH, 2002, FEMS MICROBIOL LETT, V206, P253, DOI 10.1016/S0378-1097(01)00543-2; Kuck D, 2001, INFECT IMMUN, V69, P5080, DOI 10.1128/IAI.69.8.5080-5087.2001; Letley DP, 1999, J CLIN MICROBIOL, V37, P1203, DOI 10.1128/JCM.37.4.1203-1205.1999; Letley DP, 2000, J BACTERIOL, V182, P3278, DOI 10.1128/JB.182.11.3278-3280.2000; LEUNK RD, 1988, J MED MICROBIOL, V26, P93, DOI 10.1099/00222615-26-2-93; Lupetti P, 1996, J CELL BIOL, V133, P801, DOI 10.1083/jcb.133.4.801; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; Martinez TA, 2001, REV MED CHILE, V129, P1147; McClain MS, 2001, J BACTERIOL, V183, P6499, DOI 10.1128/JB.183.22.6499-6508.2001; McClain MS, 2001, INFECT IMMUN, V69, P1181, DOI 10.1128/IAI.69.2.1181-1184.2001; Miehlke S, 2000, INT J CANCER, V87, P322, DOI 10.1002/1097-0215(20000801)87:3&lt;322::AID-IJC3&gt;3.0.CO;2-M; Molinari M, 1998, J EXP MED, V187, P135, DOI 10.1084/jem.187.1.135; Molinari M, 1997, J BIOL CHEM, V272, P25339, DOI 10.1074/jbc.272.40.25339; Morales-Espinosa R, 1999, J CLIN MICROBIOL, V37, P3001, DOI 10.1128/JCM.37.9.3001-3004.1999; Ogura K, 2000, J EXP MED, V192, P1601, DOI 10.1084/jem.192.11.1601; Pagliaccia C, 1998, P NATL ACAD SCI USA, V95, P10212, DOI 10.1073/pnas.95.17.10212; Papini E, 1996, J MED MICROBIOL, V45, P84, DOI 10.1099/00222615-45-2-84; PAPINI E, 1993, FEMS MICROBIOL LETT, V113, P155, DOI 10.1016/0378-1097(93)90262-Z; PAPINI E, 1993, MOL MICROBIOL, V7, P323, DOI 10.1111/j.1365-2958.1993.tb01123.x; PAPINI E, 1994, P NATL ACAD SCI USA, V91, P9720, DOI 10.1073/pnas.91.21.9720; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PEREZPEREZ GI, 1987, INFECT IMMUN, V55, P1256, DOI 10.1128/IAI.55.5.1256-1263.1987; PHADNIS SH, 1994, INFECT IMMUN, V62, P1557, DOI 10.1128/IAI.62.5.1557-1565.1994; Ricci V, 1997, J PATHOL, V183, P453; Rudi J, 1998, J CLIN MICROBIOL, V36, P944, DOI 10.1128/JCM.36.4.944-948.1998; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; Strobel S, 1998, J CLIN MICROBIOL, V36, P1285, DOI 10.1128/JCM.36.5.1285-1289.1998; Suerbaum S, 1998, P NATL ACAD SCI USA, V95, P12619, DOI 10.1073/pnas.95.21.12619; Szabo I, 1999, EMBO J, V18, P5517, DOI 10.1093/emboj/18.20.5517; TEE W, 1995, J CLIN MICROBIOL, V33, P1203, DOI 10.1128/JCM.33.5.1203-1205.1995; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Tombola F, 1999, FEBS LETT, V460, P221, DOI 10.1016/S0014-5793(99)01348-4; van Doorn LJ, 1998, J CLIN MICROBIOL, V36, P1271, DOI 10.1128/JCM.36.5.1271-1276.1998; Velayudhan J, 2000, MOL MICROBIOL, V37, P274, DOI 10.1046/j.1365-2958.2000.01987.x; Vinion-Dubiel AD, 1999, J BIOL CHEM, V274, P37736, DOI 10.1074/jbc.274.53.37736; Wang HJ, 1998, BIOCHEM BIOPH RES CO, V250, P397, DOI 10.1006/bbrc.1998.9228; Wang HJ, 2000, BIOCHEM BIOPH RES CO, V278, P449, DOI 10.1006/bbrc.2000.3820; WARREN JR, 1983, LANCET, V1, P1273; Weel JFL, 1996, J INFECT DIS, V173, P1171, DOI 10.1093/infdis/173.5.1171; Ye D, 1999, J BIOL CHEM, V274, P9277, DOI 10.1074/jbc.274.14.9277	64	74	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26734	26741		10.1074/jbc.M304071200	http://dx.doi.org/10.1074/jbc.M304071200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12738773	hybrid			2022-12-25	WOS:000184155700057
J	Lyons, AJ; Robertson, HD				Lyons, AJ; Robertson, HD			Detection of tRNA-like structure through RNase P cleavage of viral internal ribosome entry site RNAs near the AUG start triplet	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; STEM-LOOP; TRANSLATION; SEQUENCE; ELEMENT; RIBONUCLEASE; INITIATION; CONTAINS; SUBUNIT; BINDING	The 9600-base RNA genome of hepatitis C virus (HCV) has an internal ribosome entry site (IRES) in its first 370 bases, including the AUG start triplet at bases 342 - 344. Structural elements of this and other IRES domains substitute for a 5' terminal cap structure in protein synthesis. Recent work (Nadal, A., Martell, M., Lytle, J. R., Lyons, A. J., Robertson, H. D., Cabot, B., Esteban, J. I., Esteban, R., Guardia, J., and Gomez, J. ( 2002) J. Biol. Chem. 277, 30606 - 30613) has demonstrated that the host pre-tRNA processing enzyme, RNase P, can cleave the HCV RNA genome at a site in the IRES near the AUG initiator triplet. Although this step is unlikely to be part of the HCV life cycle, such a reaction could indicate the presence of a tRNA-like structure in this IRES. Because susceptibility to cleavage by mammalian RNase P is a strong indicator of tRNA-like structure, we have conducted the studies reported here to test whether such tRNA mimicry is unique to HCV or is a general property of IRES structure. We have assayed IRES domains of several viral RNA genomes: two pestiviruses related to HCV, classical swine fever virus and bovine viral diarrhea virus; and two unrelated viruses, encephalomyocarditis virus and cricket paralysis virus. We have found similarly placed RNase P cleavage sites in these IRESs. Thus a tRNA-like domain could be a general structural feature of IRESs, the first IRES structure to be identified with a functional correlate. Such tRNA-like features could be recognized by pre-existing ribosomal tRNA-binding sites as part of the IRES initiation cycle.	Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA	Cornell University	Robertson, HD (corresponding author), Cornell Univ, Weill Med Coll, Dept Biochem, Room E-012A,1300 York Ave, New York, NY 10021 USA.	hdrober@mail.med.cornell.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056424] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-56424] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTMAN S, 1995, BIO-TECHNOL, V13, P327, DOI 10.1038/nbt0495-327; Altman S., 1989, ADV ENZYMOL RAMB, V62, P1; BARRELL BG, 1971, PROCEDURES NUCL ACID, P751; Baumstark T, 2001, RNA, V7, P1652; BERNSTEIN J, 1995, J BIOL CHEM, V270, P10559, DOI 10.1074/jbc.270.18.10559; BRANCH AD, 1982, SCIENCE, V217, P1147, DOI 10.1126/science.217.4565.1147; BRANCH AD, 1989, METHOD ENZYMOL, V180, P130; Carter MS, 2000, COLD SPRING HARBOR M, V39, P615; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; DEMOERLOOZE L, 1993, J GEN VIROL, V74, P1433, DOI 10.1099/0022-1317-74-7-1433; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; HOUGHTON M, 1996, FIELDS VIROLOGY, P1035; Jackson RJ, 2000, COLD SPRING HARBOR M, V39, P127; Jackson RJ, 1997, CURR OPIN GENET DEV, V7, P233, DOI 10.1016/S0959-437X(97)80133-5; Jan E, 2001, COLD SPRING HARB SYM, V66, P285, DOI 10.1101/sqb.2001.66.285; Jarrous N, 2001, METHOD ENZYMOL, V342, P93, DOI 10.1016/S0076-6879(01)42538-9; JOSHI S, 1982, NUCLEIC ACIDS RES, V10, P1947, DOI 10.1093/nar/10.6.1947; Jubin R, 2000, J VIROL, V74, P10430, DOI 10.1128/JVI.74.22.10430-10437.2000; KAHLE D, 1993, BIOCHIMIE, V75, P955, DOI 10.1016/0300-9084(93)90145-I; Klinck R, 2000, RNA, V6, P1423, DOI 10.1017/S1355838200000935; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; KUFEL J, 1994, J MOL BIOL, V244, P511, DOI 10.1006/jmbi.1994.1749; Lyons AJ, 2001, NUCLEIC ACIDS RES, V29, P2535, DOI 10.1093/nar/29.12.2535; Lytle JR, 2002, RNA, V8, P1045, DOI 10.1017/S1355838202029965; Lytle JR, 2001, J VIROL, V75, P7629, DOI 10.1128/JVI.75.16.7629-7636.2001; Martin LR, 2000, J VIROL, V74, P3074, DOI 10.1128/JVI.74.7.3074-3081.2000; Merrick WC, 2000, COLD SPRING HARBOR M, V39, P89; Nadal A, 2002, J BIOL CHEM, V277, P30606, DOI 10.1074/jbc.M203595200; NADAL A, 2000, VIRAL HEPATITIS, P93; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Ridpath JF, 1997, VIRUS RES, V50, P237, DOI 10.1016/S0168-1702(97)00064-6; Rijnbrand R, 2001, RNA, V7, P585, DOI 10.1017/S1355838201000589; ROBERTSON HD, 1972, J BIOL CHEM, V247, P5243; SEIDMAN JG, 1975, P NATL ACAD SCI USA, V72, P1491, DOI 10.1073/pnas.72.4.1491; Spahn CMT, 2001, SCIENCE, V291, P1959, DOI 10.1126/science.1058409; WANG CY, 1995, RNA, V1, P526	37	39	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26844	26850		10.1074/jbc.M304052200	http://dx.doi.org/10.1074/jbc.M304052200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12746454	hybrid			2022-12-25	WOS:000184155700072
J	Mittra, B; Sinha, KM; Hines, JC; Ray, DS				Mittra, B; Sinha, KM; Hines, JC; Ray, DS			Presence of multiple mRNA cycling sequence element-binding proteins in Crithidia fasciculata	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; TRYPANOSOMA-BRUCEI; 3'-UNTRANSLATED REGION; GENE-EXPRESSION; AU-RICH; CRUZI; CIS; STABILITY; REPLICATION; KINETOPLAST	A consensus sequence present in the 5'- or 3'-untranslated regions of several Crithidia fasciculata messenger RNAs encoding proteins involved in DNA metabolism has been shown to be necessary for the periodic accumulation of these mRNAs during the cell cycle. A protein complex termed cycling sequence-binding protein (CSBP) has two subunits, CSBPA and CSBPB, and binds the consensus sequence with high specificity. The binding activity of CSBP was shown to vary during the cell cycle in parallel with the levels of putative target mRNAs. Although disruption of the CSBPA gene resulted in loss of both CSBPA and CSBPB, the putative target message levels still continued to vary during the cell cycle. The presence of an additional and distinct binding activity was revealed in these CSBPA null mutant cells. This activity, termed CSBP II, was also expressed in wild-type Crithidia cells. CSBP II has higher binding specificity for the cycling sequence element than the earlier described CSBP complex. Three polypeptides associated with purified CSBP II show specific binding to the cycling sequence. These proteins may represent a family of sequence-specific RNA-binding proteins involved in post-transcriptional regulation.	Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Ray, DS (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, 301A Paul D Boyer Hall,611 Charles Young Dr E, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM053254, R01GM053254] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53254] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bates EJ, 2000, NUCLEIC ACIDS RES, V28, P1211, DOI 10.1093/nar/28.5.1211; BERBEROF M, 1995, EMBO J, V14, P2925, DOI 10.1002/j.1460-2075.1995.tb07292.x; Brooks DR, 2000, FEMS MICROBIOL LETT, V186, P287, DOI 10.1111/j.1574-6968.2000.tb09119.x; Brown LM, 1997, NUCLEIC ACIDS RES, V25, P3281, DOI 10.1093/nar/25.16.3281; COSGROVE WB, 1970, J PROTOZOOL, V17, P172, DOI 10.1111/j.1550-7408.1970.tb02350.x; Coughlin BC, 2000, J BIOL CHEM, V275, P12051, DOI 10.1074/jbc.275.16.12051; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; D'Orso I, 2001, J BIOL CHEM, V276, P15783, DOI 10.1074/jbc.M010959200; D'Orso I, 2001, J BIOL CHEM, V276, P34801, DOI 10.1074/jbc.M102120200; Di Noia JM, 2000, J BIOL CHEM, V275, P10218, DOI 10.1074/jbc.275.14.10218; Furger A, 1997, MOL CELL BIOL, V17, P4372, DOI 10.1128/MCB.17.8.4372; Hotchkiss TL, 1999, MOL BIOCHEM PARASIT, V98, P117, DOI 10.1016/S0166-6851(98)00156-X; JEFFERIES D, 1991, MOL CELL BIOL, V11, P338, DOI 10.1128/MCB.11.1.338; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mahmood R, 1999, MOL CELL BIOL, V19, P6174; Mahmood R, 2001, MOL CELL BIOL, V21, P4453, DOI 10.1128/MCB.21.14.4453-4459.2001; Mahmood R, 1998, J BIOL CHEM, V273, P23729, DOI 10.1074/jbc.273.37.23729; Maranon C, 2000, BBA-GENE STRUCT EXPR, V1490, P1, DOI 10.1016/S0167-4781(99)00228-6; PASION SG, 1994, J CELL SCI, V107, P3515; Pasion SG, 1996, MOL CELL BIOL, V16, P6724; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; Wilson K, 1999, EXP PARASITOL, V91, P222, DOI 10.1006/expr.1998.4366	24	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26564	26571		10.1074/jbc.M304322200	http://dx.doi.org/10.1074/jbc.M304322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12730192	hybrid			2022-12-25	WOS:000184155700037
J	Mochizuki, H; Yoshida, K; Gotoh, M; Sugioka, S; Kikuchi, N; Kwon, YD; Tawada, A; Maeyama, K; Inaba, N; Hiruma, T; Kimata, K; Narimatsu, H				Mochizuki, H; Yoshida, K; Gotoh, M; Sugioka, S; Kikuchi, N; Kwon, YD; Tawada, A; Maeyama, K; Inaba, N; Hiruma, T; Kimata, K; Narimatsu, H			Characterization of a heparan sulfate 3-O-sulfotransferase-5, an enzyme synthesizing a tetrasulfated disaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; HERPES-SIMPLEX VIRUS; ANTITHROMBIN-BINDING SEQUENCE; FLAVOBACTERIUM-HEPARINUM; MOLECULAR-CLONING; SUBSTRATE-SPECIFICITY; N-SULFOTRANSFERASE; HUMAN CDNAS; PROTEOGLYCANS	Heparan sulfate D-glucosaminyl 3-O-sulfotransferases (3-OSTs) catalyze the transfer of sulfate from 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to position 3 of the glucosamine residue of heparan sulfate and heparin. A sixth member of the human 3-OST family, named 3-OST-5, was recently reported (Xia, G., Chen, J., Tiwari, V., Ju, W., Li, J.- P., Malmstrom, A., Shukla, D., and Liu, J. ( 2002) J. Biol. Chem. 277, 37912 - 37919). In the present study, we cloned putative catalytic domain of the human 3-OST-5 and expressed it in insect cells as a soluble enzyme. Recombinant 3-OST-5 only exhibited sulfotransferase activity toward heparan sulfate and heparin. When incubated heparan sulfate with [S-35] PAPS, the highest incorporation of S-35 was observed, and digestion of the product with a mixture of heparin lyases yielded two major S-35-labeled disaccharides, which were determined as DeltaHexA-GlcN(NS, 3S, 6S) and DeltaHexA(2S)-GlcN( NS, 3S) by further digestion with 2-sulfatase and degradation with mercuric acetate. However, when used heparin as acceptor, we identified a highly sulfated disaccharide unit as a major product. This had a structure of DeltaHexA( 2S)- GlcN( NS, 3S, 6S). Quantitative real-time PCR analysis revealed that 3-OST-5 was highly expressed in fetal brain, followed by adult brain and spinal cord, and at very low or undetectable levels in the other tissues. Finally, we detected a tetrasulfated disaccharide unit in bovine intestinal heparan sulfate. To our knowledge, this is the first report to describe not only the natural occurrence of tetrasulfated disaccharide unit but also the enzymatic formation of this novel structure.	Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Glycogene Funct Team, Tsukuba, Ibaraki 3058568, Japan; Seikagaku Corp, Cent Res Labs, Tokyo 2070021, Japan; Mizutani Fdn Glycosci, Chuo Ku, Tokyo 1030023, Japan; Amersham Biosci KK, Shinjuku Ku, Tokyo 1690073, Japan; Mitsui Knowledge Ind Co Ltd, Nakano Ku, Tokyo 1648721, Japan; JGS Japan Genome Solut Inc, Tokyo 1920031, Japan; Fujirebio Inc, Fundamental Res Dept, Frontier Res Div, Tokyo 1920031, Japan; Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Seikagaku Corporation; H.U. Group Holdings Inc; Aichi Medical University	Narimatsu, H (corresponding author), Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Glycogene Funct Team, Cent 2,1-1-1 Umezono, Tsukuba, Ibaraki 3058568, Japan.		Narimatsu, Hisashi/M-4757-2018	Narimatsu, Hisashi/0000-0002-8402-133X				Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; Aikawa J, 2001, J BIOL CHEM, V276, P5876, DOI 10.1074/jbc.M009606200; ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Carey DJ, 1997, BIOCHEM J, V327, P1; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; Chuang WL, 2001, J CHROMATOGR A, V932, P65, DOI 10.1016/S0021-9673(01)01241-9; CONRAD HE, 1973, ANAL BIOCHEM, V51, P486, DOI 10.1016/0003-2697(73)90505-8; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DESAI UR, 1993, ARCH BIOCHEM BIOPHYS, V306, P461, DOI 10.1006/abbi.1993.1538; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FOLKMAN J, 1988, AM J PATHOL, V130, P393; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; Habuchi O, 2000, BBA-GEN SUBJECTS, V1474, P115, DOI 10.1016/S0304-4165(00)00016-7; Iwai T, 2002, J BIOL CHEM, V277, P12802, DOI 10.1074/jbc.M112457200; KARIYA Y, 1992, COMP BIOCHEM PHYS B, V103, P473, DOI 10.1016/0305-0491(92)90323-J; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kutyavin IV, 2000, NUCLEIC ACIDS RES, V28, P655, DOI 10.1093/nar/28.2.655; Lander AD, 1996, PERSPECT DEV NEUROBI, V3, P347; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Liu J, 2002, J BIOL CHEM, V277, P33456, DOI 10.1074/jbc.M202034200; LIU J, 2000, HDB GLYCOSYLTRANSFER, P475; Liu JA, 1999, J BIOL CHEM, V274, P38155, DOI 10.1074/jbc.274.53.38155; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; LUDWIGS U, 1987, BIOCHEM J, V245, P795, DOI 10.1042/bj2450795; LYON M, 1994, J BIOL CHEM, V269, P11216; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; NADER HB, 1990, J BIOL CHEM, V265, P16807; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; Rhomberg AJ, 1998, P NATL ACAD SCI USA, V95, P12232, DOI 10.1073/pnas.95.21.12232; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Rostand KS, 1997, INFECT IMMUN, V65, P1; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; SILVA ME, 1975, J BIOL CHEM, V250, P6841; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; Xia GQ, 2002, J BIOL CHEM, V277, P37912, DOI 10.1074/jbc.M204209200; YAMADA SH, 1993, J BIOL CHEM, V268, P4780; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451	50	46	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26780	26787		10.1074/jbc.M301861200	http://dx.doi.org/10.1074/jbc.M301861200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12740361	hybrid			2022-12-25	WOS:000184155700063
J	Tabuchi, A; Yoshioka, A; Higashi, T; Shirakawa, R; Nishioka, H; Kita, T; Horiuchi, H				Tabuchi, A; Yoshioka, A; Higashi, T; Shirakawa, R; Nishioka, H; Kita, T; Horiuchi, H			Direct demonstration of involvement of protein kinase C alpha in the Ca2+-induced platelet aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE GRANULE SECRETION; CA-2+ MOBILIZATION; MODULATION; ACTIVATION; MECHANISMS; RECEPTORS; CALCIUM; ALPHA(IIB)BETA(3); PHOSPHORYLATION; IDENTIFICATION	Platelets play critical roles in hemostasis and thrombosis through their aggregation following activation of integrin alpha(IIb)beta(3). However, the molecular mechanism of the integrin activation inside platelets remains largely unknown. Pharmacological experiments have demonstrated that protein kinase C (PKC) plays an important role in platelet aggregation. Because PKC inhibitors can have multiple substrates and given that non-PKC-phorbol ester-binding signaling molecules have been demonstrated to play important roles, the precise involvement of PKC in cellular functions requires re-evaluation. Here, we have established an assay for analyzing the Ca2+-induced aggregation of permeabilized platelets. The aggregation of platelets was inhibited by the addition of the arginine-glycine-aspartate-serine peptide, an integrin-binding peptide inhibitor of alpha(IIb)beta(3), suggesting that the aggregation was mediated by the integrin. The aggregation was also dependent on exogenous ATP and platelet cytosol, indicating the existence of essential cytosolic factors required for the aggregation. To examine the role of PKC in the aggregation assay, we immunodepleted PKCalpha and beta from the cytosol. The PKC-depleted cytosol lost the aggregation-supporting activity, which was recovered by the addition of purified PKCalpha. Furthermore, the addition of purified PKCalpha in the absence of cytosol did not support the aggregation, whereas the cytosol containing less PKC supported it efficiently, suggesting that additional factors besides PKC would also be required. Thus, we directly demonstrated that PKCalpha is involved in the regulation of Ca2+-induced platelet aggregation.	Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Horiuchi, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Kyoto 6068507, Japan.	horiuchi@kuhp.kyoto-u.ac.jp	Higashi, Tomohito/AHE-7942-2022	Higashi, Tomohito/0000-0001-5616-1477				AUTHI KS, 1988, BIOCHEM J, V255, P885, DOI 10.1042/bj2550885; Basani RB, 2001, J BIOL CHEM, V276, P13975, DOI 10.1074/jbc.M011511200; BOTTECCHIA D, 1976, HAEMOSTASIS, V5, P176; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brass L. F, 2000, HEMATOLOGY BASIC PRI, P1753; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Flaumenhaft R, 1999, J CELL PHYSIOL, V179, P1; GERRARD JM, 1989, BLOOD, V74, P2405; GIROLAMI A, 1976, ACTA HAEMATOL-BASEL, V56, P151, DOI 10.1159/000207932; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; Hers I, 2000, ARTERIOSCL THROM VAS, V20, P1651, DOI 10.1161/01.ATV.20.6.1651; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; KAIBUCHI K, 1983, J BIOL CHEM, V258, P6701; Kazanietz MG, 2000, BIOCHEM PHARMACOL, V60, P1417, DOI 10.1016/S0006-2952(00)00470-6; Kinlough-Rathbone RL, 1999, THROMB RES, V95, P315, DOI 10.1016/S0049-3848(99)00051-1; KNIGHT DE, 1982, NATURE, V296, P256, DOI 10.1038/296256a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOVITS J, 1995, NEW ENGL J MED, V332, P1553, DOI 10.1056/NEJM199506083322306; Lemons PP, 1997, BLOOD, V90, P1490, DOI 10.1182/blood.V90.4.1490.1490_1490_1500; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; Nishioka H, 2001, BIOCHEM BIOPH RES CO, V280, P970, DOI 10.1006/bbrc.2001.4237; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Palmer M, 1998, EMBO J, V17, P1598, DOI 10.1093/emboj/17.6.1598; PHILLIPS DR, 1977, J CLIN INVEST, V60, P535, DOI 10.1172/JCI108805; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PLOW EF, 2000, HEMATOLOGY BASIC PRI, P1741; Rhee JS, 2002, CELL, V108, P121, DOI 10.1016/S0092-8674(01)00635-3; Santos MT, 2000, CIRCULATION, V102, P1924, DOI 10.1161/01.CIR.102.16.1924; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; Shirakawa R, 2000, J BIOL CHEM, V275, P33844, DOI 10.1074/jbc.M002834200; SIESS W, 1988, BIOCHEM J, V255, P309; Sloan DC, 1997, BIOCHEM J, V328, P13; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; SWARTZ KJ, 1993, NEURON, V11, P305, DOI 10.1016/0896-6273(93)90186-U; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; Wang HB, 2002, J BIOL CHEM, V277, P4541, DOI 10.1074/jbc.M107150200; Yoshioka A, 2001, ANN NY ACAD SCI, V947, P403; Yoshioka A, 2001, J BIOL CHEM, V276, P39379, DOI 10.1074/jbc.M102933200	43	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26374	26379		10.1074/jbc.M212407200	http://dx.doi.org/10.1074/jbc.M212407200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12724315	hybrid, Green Submitted			2022-12-25	WOS:000184155700013
J	White, PW; Titolo, S; Brault, K; Thauvette, L; Pelletier, A; Welchner, E; Bourgon, L; Doyon, L; Ogilvie, WW; Yoakim, C; Cordingley, MG; Archambault, J				White, PW; Titolo, S; Brault, K; Thauvette, L; Pelletier, A; Welchner, E; Bourgon, L; Doyon, L; Ogilvie, WW; Yoakim, C; Cordingley, MG; Archambault, J			Inhibition of human papillomavirus DNA replication by small molecule antagonists of the E1-E2 protein interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE T-ANTIGEN; 11 E1 HELICASE; BOVINE PAPILLOMAVIRUS; E2 PROTEINS; TRANSCRIPTION FACTOR; TRANSACTIVATION DOMAIN; COMPLEX-FORMATION; BINDING DOMAIN; TYPE-16 E1; IN-VITRO	Human papillomavirus (HPV) DNA replication is initiated by recruitment of the E1 helicase by the E2 protein to the viral origin. Screening of our corporate compound collection with an assay measuring the cooperative binding of E1 and E2 to the origin identified a class of small molecule inhibitors of the protein interaction between E1 and E2. Isothermal titration calorimetry and changes in protein fluorescence showed that the inhibitors bind to the transactivation domain of E2, the region that interacts with E1. These compounds inhibit E2 of the low risk HPV types 6 and 11 but not those of high risk HPV types or of cottontail rabbit papillomavirus. Functional evidence that the transactivation domain is the target of inhibition was obtained by swapping this domain between a sensitive ( HPV11) and a resistant ( cottontail rabbit papillomavirus) E2 type and by identifying an amino acid substitution, E100A, that increases inhibition by similar to10-fold. This class of inhibitors was found to antagonize specifically the E1-E2 interaction in vivo and to inhibit HPV DNA replication in transiently transfected cells. These results highlight the potential of the E1-E2 interaction as a small molecule antiviral target.	Boehringer Ingelheim Ltd, Dept Biol Sci, Laval, PQ H7S 2G5, Canada; Boehringer Ingelheim Ltd, Dept Chem, Laval, PQ H7S 2G5, Canada	Boehringer Ingelheim; Boehringer Ingelheim	Archambault, J (corresponding author), Boehringer Ingelheim Ltd, Dept Biol Sci, 2100 Cunard St, Laval, PQ H7S 2G5, Canada.			Archambault, Jacques/0000-0001-8107-3428				Antson AA, 2000, NATURE, V403, P805, DOI 10.1038/35001638; ARGOS P, 1988, PROTEIN ENG, V2, P101, DOI 10.1093/protein/2.2.101; BENSON JD, 1995, J VIROL, V69, P4364, DOI 10.1128/JVI.69.7.4364-4372.1995; Berg M, 1997, J VIROL, V71, P3853, DOI 10.1128/JVI.71.5.3853-3863.1997; Beutner Karl R., 1997, American Journal of Medicine, V102, P28; Beutner KR, 1998, ANTIMICROB AGENTS CH, V42, P789, DOI 10.1128/AAC.42.4.789; BROWN DR, 1993, J CLIN MICROBIOL, V31, P2667, DOI 10.1128/JCM.31.10.2667-2673.1993; Chow Louise T., 1997, P267; CHOW LT, 1994, INTERVIROLOGY, V37, P150, DOI 10.1159/000150373; Cochran AG, 2001, CURR OPIN CHEM BIOL, V5, P654, DOI 10.1016/S1367-5931(01)00262-9; Cochran AG, 2000, CHEM BIOL, V7, pR85, DOI 10.1016/S1074-5521(00)00106-X; Cooper CS, 1998, VIROLOGY, V241, P312, DOI 10.1006/viro.1997.8941; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; DARVEAU A, 1994, METHODS NEUROSCI, V26, P77; Eftink MR, 1997, METHOD ENZYMOL, V278, P221; Ferguson MK, 1996, J VIROL, V70, P4193, DOI 10.1128/JVI.70.7.4193-4199.1996; Fouts ET, 1999, J BIOL CHEM, V274, P4447, DOI 10.1074/jbc.274.7.4447; Gadek TR, 2003, BIOCHEM PHARMACOL, V65, P1, DOI 10.1016/S0006-2952(02)01479-X; GISSMANN L, 1983, P NATL ACAD SCI-BIOL, V80, P560, DOI 10.1073/pnas.80.2.560; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HOWLEY PM, 1996, FIELDS VIROLOGY, P2045; HUBBARD SJ, 1994, PROTEIN SCI, V3, P2194, DOI 10.1002/pro.5560031205; JANIN J, 1990, J BIOL CHEM, V265, P16027; Kasukawa H, 1998, J VIROL, V72, P8166, DOI 10.1128/JVI.72.10.8166-8173.1998; Kovelman R, 1996, J VIROL, V70, P7549, DOI 10.1128/JVI.70.11.7549-7560.1996; LUSKY M, 1994, P NATL ACAD SCI USA, V91, P8895, DOI 10.1073/pnas.91.19.8895; Masterson PJ, 1998, J VIROL, V72, P7407, DOI 10.1128/JVI.72.9.7407-7419.1998; MCBRIDE AA, 1997, HUMAN PAPILLOMAVIRUS, P54; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; Phelps WC, 1998, ANTIVIR CHEM CHEMOTH, V9, P359, DOI 10.1177/095632029800900501; Sakai H, 1996, J VIROL, V70, P1602, DOI 10.1128/JVI.70.3.1602-1611.1996; Sanders CM, 2001, J BIOL CHEM, V276, P23689, DOI 10.1074/jbc.M101861200; Sanders CM, 1998, EMBO J, V17, P7044, DOI 10.1093/emboj/17.23.7044; SARAFI TR, 1995, VIROLOGY, V211, P385, DOI 10.1006/viro.1995.1421; Sedman J, 1998, J VIROL, V72, P6893, DOI 10.1128/JVI.72.8.6893-6897.1998; Sedman J, 1995, EMBO J, V14, P6218, DOI 10.1002/j.1460-2075.1995.tb00312.x; Sedman T, 1997, J VIROL, V71, P2887, DOI 10.1128/JVI.71.4.2887-2896.1997; SEO YS, 1993, P NATL ACAD SCI USA, V90, P2865, DOI 10.1073/pnas.90.7.2865; SHAH KV, 1996, FIELDS VIROLOGY, P2077; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; Stubenrauch F, 1999, SEMIN CANCER BIOL, V9, P379, DOI 10.1006/scbi.1999.0141; SVERDRUP F, 1997, HUMAN PAPILLOMAVIRUS, P37; Titolo S, 2003, J VIROL, V77, P5178, DOI 10.1128/JVI.77.9.5178-5191.2003; Titolo S, 1999, J VIROL, V73, P5282, DOI 10.1128/JVI.73.7.5282-5293.1999; Titolo S, 2000, J VIROL, V74, P7349, DOI 10.1128/JVI.74.16.7349-7361.2000; UDENFRIEND S, 1987, ANAL BIOCHEM, V161, P494, DOI 10.1016/0003-2697(87)90479-9; Way JC, 2000, CURR OPIN CHEM BIOL, V4, P40, DOI 10.1016/S1367-5931(99)00049-6; White PW, 2001, J BIOL CHEM, V276, P22426, DOI 10.1074/jbc.M101932200; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0; Yasugi T, 1997, J VIROL, V71, P891, DOI 10.1128/JVI.71.2.891-899.1997; Zou NX, 1998, J VIROL, V72, P3436, DOI 10.1128/JVI.72.4.3436-3441.1998; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427; Zutshi R, 1998, CURR OPIN CHEM BIOL, V2, P62, DOI 10.1016/S1367-5931(98)80036-7	53	56	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26765	26772		10.1074/jbc.M303608200	http://dx.doi.org/10.1074/jbc.M303608200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12730224	hybrid			2022-12-25	WOS:000184155700061
J	Zhong, P; Gu, ZL; Wang, X; Jiang, HB; Feng, J; Yan, Z				Zhong, P; Gu, ZL; Wang, X; Jiang, HB; Feng, J; Yan, Z			Impaired modulation of GABAergic transmission by muscarinic receptors in a mouse transgenic model of Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; PREFRONTAL CORTICAL-NEURONS; ACETYLCHOLINE-RECEPTOR; KINASE-C; WORKING-MEMORY; BETA-PROTEIN; HUMAN-BRAIN; SIGNAL-TRANSDUCTION; PYRAMIDAL NEURONS; CORTEX	It has long been recognized that muscarinic acetylcholine receptors (mAChRs) are crucial for the control of cognitive processes, and drugs that activate mAChRs are helpful in ameliorating cognitive deficits of Alzheimer's disease ( AD). On the other hand, GABAergic transmission in prefrontal cortex (PFC) plays a key role in "working memory" via controlling the timing of neuronal activity during cognitive operations. To test whether the muscarinic and gamma-aminobutyric acid ( GABA) system are interconnected in normal cognition and dementia, we examined the muscarinic regulation of GABAergic transmission in PFC of an animal model of AD. Transgenic mice overexpressing a mutant gene for beta-amyloid precursor protein (APP) show behavioral and histopathological abnormalities resembling AD and, therefore, were used as an AD model. Application of the mAChR agonist carbachol significantly increased the spontaneous inhibitory postsynaptic current (sIPSC) frequency and amplitude in PFC pyramidal neurons from wild-type animals. In contrast, carbachol failed to increase the sIPSC amplitude in APP transgenic mice, whereas the carbachol-induced increase of the sIPSC frequency was not significantly changed in these mutants. Similar results were obtained in rat PFC slices pretreated with the beta-amyloid peptide (Abeta). Inhibiting protein kinase C (PKC) blocked the carbachol enhancement of sIPSC amplitudes, implicating the PKC dependence of this mAChR effect. In APP transgenic mice, carbachol failed to activate PKC despite the apparently normal expression of mAChRs. These results show that the muscarinic regulation of GABA transmission is impaired in the AD model, probably due to the Abeta-mediated interference of mAChR activation of PKC.	SUNY Buffalo, Sch Med & Biomed Sci, Dept Physiol & Biophys, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Yan, Z (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, Dept Physiol & Biophys, 124 Sherman Hall, Buffalo, NY 14214 USA.	zhenyan@buffalo.edu	Wang, Xun/F-5444-2015	Wang, Xun/0000-0002-4637-7626	NIA NIH HHS [AG21923] Funding Source: Medline; NIMH NIH HHS [MH63128] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021923] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARAUJO DM, 1988, J NEUROCHEM, V50, P1914, DOI 10.1111/j.1471-4159.1988.tb02497.x; Auld DS, 1998, TRENDS NEUROSCI, V21, P43, DOI 10.1016/S0166-2236(97)01144-2; Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BROWN DA, 1980, NATURE, V283, P673, DOI 10.1038/283673a0; Brown J.H., 1996, GOODMAN GILMANS PHAR, V9th, P141; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; Cai X, 2002, J PHYSIOL-LONDON, V540, P743; Chapman PF, 1999, NAT NEUROSCI, V2, P271, DOI 10.1038/6374; Constantinidis C, 2002, NAT NEUROSCI, V5, P175, DOI 10.1038/nn799; Cowburn RF, 1996, NEURODEGENERATION, V5, P483, DOI 10.1006/neur.1996.0067; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; DURKIN TP, 1994, NEUROSCIENCE, V62, P681, DOI 10.1016/0306-4522(94)90469-3; Egorov AV, 2002, NATURE, V420, P173, DOI 10.1038/nature01171; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; Feng J, 2001, J NEUROSCI, V21, P6502, DOI 10.1523/JNEUROSCI.21-17-06502.2001; Fernandez I, 2001, NEURON, V32, P1057, DOI 10.1016/S0896-6273(01)00548-7; Fisher A, 2000, ANN NY ACAD SCI, V920, P315; Fransen E, 2002, J NEUROSCI, V22, P1081, DOI 10.1523/JNEUROSCI.22-03-01081.2002; Fraser DD, 1996, J NEUROSCI, V16, P4113; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GIACOBINI E, 1990, J NEUROSCI RES, V27, P548, DOI 10.1002/jnr.490270416; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; GREENWOOD AF, 1995, NEUROSCIENCE, V69, P125, DOI 10.1016/0306-4522(95)00220-D; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HajDahmane S, 1996, J NEUROSCI, V16, P3848; Hasselmo ME, 1999, TRENDS COGN SCI, V3, P351, DOI 10.1016/S1364-6613(99)01365-0; Hoshi M, 1997, J BIOL CHEM, V272, P2038, DOI 10.1074/jbc.272.4.2038; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Irizarry MC, 1997, J NEUROSCI, V17, P7053; Kar S, 1996, J NEUROSCI, V16, P1034; Kawaguchi Y, 1997, J NEUROPHYSIOL, V78, P1743, DOI 10.1152/jn.1997.78.3.1743; Kelly JF, 1996, P NATL ACAD SCI USA, V93, P6753, DOI 10.1073/pnas.93.13.6753; Klink R, 1997, J NEUROPHYSIOL, V77, P1829, DOI 10.1152/jn.1997.77.4.1829; Kondo S, 2001, NEUROSCIENCE, V107, P551, DOI 10.1016/S0306-4522(01)00388-8; Lazarov O, 2002, J NEUROSCI, V22, P9785; LEVEY AI, 1991, J NEUROSCI, V11, P3218; Ma XH, 2003, J NEUROSCI, V23, P1159, DOI 10.1523/JNEUROSCI.23-04-01159.2003; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MCCORMICK DA, 1985, P NATL ACAD SCI USA, V82, P6344, DOI 10.1073/pnas.82.18.6344; McDonald DR, 1998, J NEUROSCI, V18, P4451; Miller EK, 1999, NEURON, V22, P15, DOI 10.1016/S0896-6273(00)80673-X; MOSS SJ, 1995, NATURE, V377, P344, DOI 10.1038/377344a0; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; PERRY EK, 1995, NEUROSCIENCE, V64, P385, DOI 10.1016/0306-4522(94)00410-7; Rao SG, 2000, J NEUROSCI, V20, P485, DOI 10.1523/JNEUROSCI.20-01-00485.2000; SAWAGUCHI T, 1988, BEHAV BRAIN RES, V31, P193, DOI 10.1016/0166-4328(88)90023-X; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SITARAM N, 1978, SCIENCE, V201, P274, DOI 10.1126/science.351808; Stewart AE, 1999, J NEUROPHYSIOL, V81, P72, DOI 10.1152/jn.1999.81.1.72; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; Weinstock M, 1995, NEURODEGENERATION, V4, P349, DOI 10.1006/neur.1995.0042; WHISHAW IQ, 1987, BEHAV NEUROSCI, V101, P603, DOI 10.1037/0735-7044.101.5.603; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; WHITEHOUSE PJ, 1993, ACTA NEUROL SCAND, V88, P42; WINKLER J, 1995, NATURE, V375, P484, DOI 10.1038/375484a0; Xiang ZX, 1998, SCIENCE, V281, P985, DOI 10.1126/science.281.5379.985; Yan Z, 1996, J NEUROSCI, V16, P2592; Yan Z, 2001, NEUROSCIENCE, V103, P1017, DOI 10.1016/S0306-4522(01)00039-2; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Yoshihara M, 2002, NEURON, V36, P897, DOI 10.1016/S0896-6273(02)01065-6; Zhou FM, 1999, J NEUROPHYSIOL, V82, P2989, DOI 10.1152/jn.1999.82.6.2989	68	64	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26888	26896		10.1074/jbc.M302789200	http://dx.doi.org/10.1074/jbc.M302789200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12746438	hybrid			2022-12-25	WOS:000184155700077
J	Perrot, V; Rechler, MM				Perrot, V; Rechler, MM			Characterization of insulin inhibition of transactivation by a C-terminal fragment of the forkhead transcription factor Foxo1 in rat hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; GENE-EXPRESSION; FACTOR FKHR; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORT; CAENORHABDITIS-ELEGANS; PHOSPHORYLATION SITES; RESPONSE SEQUENCE; NUCLEAR EXCLUSION; FAMILY-MEMBER	The transcription factor Foxo1 controls the expression of genes involved in fundamental cellular processes. In keeping with its important physiological roles, Foxo1 activity is negatively regulated in response to growth factors and cytokines that activate a phosphatidylinositol 3-kinase (PI 3-kinase) protein kinase B (PKB)/Akt pathway. PKB/Akt-mediated phosphorylation of Foxo1 has been shown to result in the inhibition of target gene transcription and to trigger the export of Foxo1 from the nucleus, which is generally believed to explain the subsequent decrease of transcription. In the present study, using a chimeric protein in which a C-terminal fragment of Foxo1 (amino acids 208-652) containing the transactivation domain is fused to the yeast Gal4 DNA binding domain, we present evidence showing that insulin can directly regulate transactivation by Foxo1 in H4IIE rat hepatoma cells. Insulin inhibition of Foxo1-(208-652)-stimulated transactivation is mediated by PI 3-kinase but in contrast to full-length Foxo1, does not require either of the two PKB/Akt phosphorylation sites (Ser(253) and Ser(316)) present in the protein fragment. Using mutational and deletion studies, we identify two potential phosphorylation sites, Ser(319) and Ser(499), as well as a 15-amino acid region located between residues 350 and 364 that are critical for insulin inhibition of transactivation by Foxo1-(208-652). We conclude that the transcriptional activity of Foxo1 is regulated at different levels by insulin: transactivation, as well as DNA binding and nuclear exclusion. These different regulatory mechanisms allow the precise control of transcription of Foxo1 target genes by insulin.	NIDDK, Growth & Dev Sect, Diabet Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Perrot, V (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bldg 30,Rm 207,9000 Rockville Pike, Bethesda, MD 20892 USA.	vperrot@nidcr.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK055006] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Band CJ, 1997, J BIOL CHEM, V272, P138; Bandyopadhyay G, 2002, J CLIN ENDOCR METAB, V87, P716, DOI 10.1210/jc.87.2.716; Barthel A, 2001, BIOCHEM BIOPH RES CO, V285, P897, DOI 10.1006/bbrc.2001.5261; Ben Shushan E, 1999, DNA CELL BIOL, V18, P471, DOI 10.1089/104454999315196; BENNICELLI JL, 1995, ONCOGENE, V11, P119; Biggs WH, 2001, MAMM GENOME, V12, P416, DOI 10.1007/s003350020002; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; Farese RV, 2002, AM J PHYSIOL-ENDOC M, V283, pE1, DOI 10.1152/ajpendo.00045.2002; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Jackson JG, 2000, ONCOGENE, V19, P4574, DOI 10.1038/sj.onc.1203825; Kaestner KH, 2000, GENE DEV, V14, P142; Kashii Y, 2000, BLOOD, V96, P941, DOI 10.1182/blood.V96.3.941.015k14_941_949; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Komeili A, 2000, CURR OPIN CELL BIOL, V12, P355, DOI 10.1016/S0955-0674(00)00100-9; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; Leenders H, 2000, EUR J IMMUNOL, V30, P2980, DOI 10.1002/1521-4141(200010)30:10<2980::AID-IMMU2980>3.0.CO;2-9; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Nakae J, 2001, BIOCHEMISTRY-US, V40, P11768, DOI 10.1021/bi015532m; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; O'Brien RM, 2001, BIOCHEM SOC T, V29, P552, DOI 10.1042/BST0290552; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; OOI GT, 1993, J BIOL CHEM, V268, P16664; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; Patel S, 2002, J BIOL CHEM, V277, P9889, DOI 10.1074/jbc.M109870200; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; Suh DS, 1996, MOL ENDOCRINOL, V10, P1227, DOI 10.1210/me.10.10.1227; Suhara T, 2002, MOL CELL BIOL, V22, P680, DOI 10.1128/MCB.22.2.680-691.2002; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tanaka M, 2001, J BIOL CHEM, V276, P15082, DOI 10.1074/jbc.M007958200; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Tomizawa M, 2000, J BIOL CHEM, V275, P7289, DOI 10.1074/jbc.275.10.7289; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Uddin S, 2000, BIOCHEM BIOPH RES CO, V275, P16, DOI 10.1006/bbrc.2000.3266; Yellaturu CR, 2002, J BIOL CHEM, V277, P40148, DOI 10.1074/jbc.M206376200; Zhang XH, 2002, J BIOL CHEM, V277, P45276, DOI 10.1074/jbc.M208063200; Zheng WH, 2002, J NEUROCHEM, V80, P1049, DOI 10.1046/j.0022-3042.2002.00783.x	81	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26111	26119		10.1074/jbc.M212750200	http://dx.doi.org/10.1074/jbc.M212750200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12724332	hybrid			2022-12-25	WOS:000183920200109
J	Zhu, J; Watanabe, I; Gomez, B; Thornhill, WB				Zhu, J; Watanabe, I; Gomez, B; Thornhill, WB			Heteromeric Kv1 potassium channel expression - Amino acid determinants involved in processing and trafficking to the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT COMPOSITION; MAMMALIAN BRAIN; BETA-SUBUNITS; K+ CHANNELS; DIVERSITY; GLYCOSYLATION; ANTIBODIES	Kv1.4 and Kv1.1 potassium channels are expressed in brain as mature glycoproteins that are trans-Golgi glycosylated. When expressed in cell lines these homomers had very different trans-Golgi glycosylation efficiencies and cell surface expression levels with Kv1.4 > Kv1.1 for both parameters (Zhu, J., Watanabe, I., Gomez, B., and Thornhill, W. B. (2001) J. Biol. Chem. 276, 39419-39427). This previous study identified determinants in the outer pore region of Kv1.4 and Kv1.1 that positively and negatively, respectively, affected these events when expressed as homomers. Here we investigated which subunit exhibited positive or negative effects on these processes when expressed as heteromers. Kv1.4/Kv1.1 heteromers, by coexpression or expression as tandem-linked heteromers, were expressed on the cell surface at similar to20-fold lower levels versus Kv1.4 homomers but they were trans-Golgi glycosylated. The lower Kv1.4/Kv1.1 expression level was not rescued by Kvbeta 2.1 subunits. Thus Kv1.1 inhibited high cell surface expression and partially retained the heteromer in the endoplasmic reticulum, whereas Kv1.4 stimulated trans-Golgi glycosylation. The subunit determinants and cellular events responsible for these differences were investigated. In a Kv1.4/Kv1.1 heteromer, the Kv1.1 pore was a major negative determinant, and it inhibited high cell surface expression because it induced high partial endoplasmic reticulum retention and it decreased protein stability. Other Kv1.1 regions also inhibited high surface expression of heteromers. The Kv1.1 C terminus induced partial Golgi retention and contributed to a decreased protein stability, whereas the Kv1.1 N terminus contributed to only a decreased protein stability. Thus a neuron may regulate its cell surface K+ channel protein levels by different Kv1 subfamily homomeric and heteromeric combinations that affect intracellular retention characteristics and protein stability.	Fordham Univ, Dept Biol Sci, Bronx, NY 10458 USA	Fordham University	Thornhill, WB (corresponding author), Fordham Univ, Dept Biol Sci, Bronx, NY 10458 USA.	thornhill@fordham.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029633] Funding Source: NIH RePORTER; NINDS NIH HHS [NS29633] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashcroft FM, 2000, ION CHANNELS DIS; BekeleArcuri Z, 1996, NEUROPHARMACOLOGY, V35, P851, DOI 10.1016/0028-3908(96)00128-1; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; Coleman SK, 1999, J NEUROCHEM, V73, P849, DOI 10.1046/j.1471-4159.1999.0730849.x; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; Deutsch C, 2002, ANNU REV PHYSIOL, V64, P19, DOI 10.1146/annurev.physiol.64.081501.155934; Dolly JO, 1996, J BIOENERG BIOMEMBR, V28, P231, DOI 10.1007/BF02110698; Helms LMH, 1997, BIOCHEMISTRY-US, V36, P3737, DOI 10.1021/bi962351p; HILLE B, 2000, IONIC CHANNELS EXCIT; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; Li DQ, 2000, J BIOL CHEM, V275, P11597, DOI 10.1074/jbc.275.16.11597; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Manganas LN, 2001, P NATL ACAD SCI USA, V98, P14055, DOI 10.1073/pnas.241403898; Manganas LN, 2000, J BIOL CHEM, V275, P29685, DOI 10.1074/jbc.M005010200; Papazian DM, 1999, NEURON, V23, P7, DOI 10.1016/S0896-6273(00)80746-1; REHM H, 1989, FEBS LETT, V247, P28, DOI 10.1016/0014-5793(89)81233-5; Rhodes KJ, 1997, J NEUROSCI, V17, P8246; ROSENBERG RL, 1992, NATURE, V360, P166, DOI 10.1038/360166a0; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SCOTT VES, 1994, BIOCHEMISTRY-US, V33, P1617, DOI 10.1021/bi00173a001; Shamotienko O, 1999, BIOCHEMISTRY-US, V38, P16766, DOI 10.1021/bi991039n; Shi G, 1999, J MEMBRANE BIOL, V168, P265, DOI 10.1007/s002329900515; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; Thornhill WB, 1996, J BIOL CHEM, V271, P19093, DOI 10.1074/jbc.271.32.19093; Trimmer JS, 1998, CURR OPIN NEUROBIOL, V8, P370, DOI 10.1016/S0959-4388(98)80063-9; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; Zhu J, 2001, J BIOL CHEM, V276, P39419, DOI 10.1074/jbc.M107399200	29	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25558	25567		10.1074/jbc.M207984200	http://dx.doi.org/10.1074/jbc.M207984200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730233	hybrid			2022-12-25	WOS:000183920200037
J	Bianco, R; Shin, I; Ritter, CA; Yakes, FM; Basso, A; Rosen, N; Tsurutani, J; Dennis, PA; Mills, GB; Arteaga, CL				Bianco, R; Shin, I; Ritter, CA; Yakes, FM; Basso, A; Rosen, N; Tsurutani, J; Dennis, PA; Mills, GB; Arteaga, CL			Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors	ONCOGENE			English	Article						epidermal growth factor receptor; ZD1839; PTEN; tyrosine kinase inhibitors; Akt	GROWTH-FACTOR RECEPTOR; BREAST-CANCER; PHOSPHATIDYLINOSITOL 3-KINASE; ZD1839 IRESSA; CELLULAR-SURVIVAL; REGULATED KINASES; CYCLE PROGRESSION; UP-REGULATION; AKT; GENE	We have examined the possible mechanisms of resistance to the epidermal growth factor receptor (EGFR) inhibitors in tumor cells with variable levels of EGFR. ZD1839 (Iressa) is a small-molecular-weight, ATP-mimetic that specifically inhibits the EGFR tyrosine kinase. A431 cell growth was markedly inhibited by ZD1839 (IC(50)less than or equal to0.1 muM) whereas the MDA-468 cells were relatively resistant (IC50>2 muM). Low doses of ZD1839 delayed cell cycle progression and induced apoptosis in A431 cells but not in MDA-468 cells. In both cell tines, 0.1 muM ZD1839 eliminated EGFR phosphorylation. However, the basal activity of the phosphatidytinositol-3 kinase (PI3 K) target Akt was eliminated in A431 but not in MDA-468 cells, implying that their Akt activity is independent of EGFR signals. A431 cells express PTEN/MMAC1/TEP, a phosphatase that can dephosphorylate position D3 of phosphatidytinositol-3,4,5 trisphosphate, the site that recruits the plecstrin-homology domain of Akt to the cell membrane. On the contrary, MDA-468 cells lack the phosphatase and tensin homolog (PTEN), potentially setting Akt activity at a high threshold that is unresponsive to EGFR inhibition alone. Therefore, we reintroduced (PTEN) by retroviral infection in MDA-468 cells. In MDA-468/PTEN but not in vector controls, treatment with ZD1839 inhibited P-Akt levels, induced relocalization of the Forkbead factor FKHRL1 to the cell nucleus, and increased FKHRL1-dependent transcriptional activity. ZD1839 induced a greater degree of apoptosis and cell cycle delay in PTEN-reconstituted than in control cells. These data suggest that loss of PTEN, by permitting a high level of Akt activity independent of receptor tyrosine kinase inputs, can temporally dissociate the inhibition of the EGFR with that of Akt induced by EGFR inhibitors. Thus, in EGFR-expressing tumor cells with concomitant amplification(s) of PI3K-Akt signaling, combined blockade of the EGFR tyrosine kinase and Akt should be considered as a therapeutic approach.	Vanderbilt Univ, Sch Med, Dept Med, Div Oncol, Nashville, TN 37232 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Cell Biol & Genet, New York, NY 10021 USA; NCI, Ctr Canc Res, Bethesda, MD 20892 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA; Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA	Vanderbilt University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; UTMD Anderson Cancer Center; Vanderbilt University; Vanderbilt University	Arteaga, CL (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Div Oncol, 2220 Pierce Ave,777 Preston Res Bldg, Nashville, TN 37232 USA.	carlos.arteaga@vanderbilt.edu	Rosen, Neal/ABF-2677-2020		NATIONAL CANCER INSTITUTE [R01CA080195, P30CA068485, Z01SC010292] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485, R01 CA80195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albanell J, 2001, CANCER RES, V61, P6500; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Arteaga CL, 2001, J CLIN ONCOL, V19, p32S; Baselga J, 2002, J CLIN ONCOL, V20, P4292, DOI 10.1200/JCO.2002.03.100; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Brognard J, 2001, CANCER RES, V61, P3986; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Chakravarti A, 2002, CANCER RES, V62, P200; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; Fan Z, 1997, CLIN CANCER RES, V3, P1943; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; Forgacs E, 1998, ONCOGENE, V17, P1557, DOI 10.1038/sj.onc.1202070; Fry MJ, 2001, BREAST CANCER RES, V3, P304, DOI 10.1186/bcr312; Goldstein NI, 1995, CLIN CANCER RES, V1, P1311; Grignani F, 1998, CANCER RES, V58, P14; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Hermanto U, 2001, ONCOGENE, V20, P7551, DOI 10.1038/sj.onc.1204964; Kohno T, 1998, GENE CHROMOSOME CANC, V22, P152, DOI 10.1002/(SICI)1098-2264(199806)22:2<152::AID-GCC10>3.0.CO;2-S; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lenferink AEG, 2000, P NATL ACAD SCI USA, V97, P9609, DOI 10.1073/pnas.160564197; Lenferink AEG, 2001, CANCER RES, V61, P6583; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Moasser MM, 2001, CANCER RES, V61, P7184; Moulder SL, 2001, CANCER RES, V61, P8887; Moyer JD, 1997, CANCER RES, V57, P4838; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Nelson JM, 2001, J BIOL CHEM, V276, P14842, DOI 10.1074/jbc.M008786200; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Simpson SJ, 2000, ADV STUD BEHAV, V29, P1, DOI 10.1016/S0065-3454(08)60102-3; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Sun M, 2001, CANCER RES, V61, P5985; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Teng DHF, 1997, CANCER RES, V57, P5221; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Wakeling AE, 2002, CANCER RES, V62, P5749; Yakes FM, 2002, CANCER RES, V62, P4132; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	58	384	417	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2003	22	18					2812	2822		10.1038/sj.onc.1206388	http://dx.doi.org/10.1038/sj.onc.1206388			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743604				2022-12-25	WOS:000182569300012
J	Bowers, AJ; Scully, S; Boylan, JF				Bowers, AJ; Scully, S; Boylan, JF			SKIP3, a novel Drosophila tribbles ortholog, is overexpressed in human tumors and is regulated by hypoxia	ONCOGENE			English	Article						SKIP3; ATF4; hypoxia; tumor; gene expression	ACTIVATING TRANSCRIPTION FACTOR-4; LEUCINE-ZIPPER PROTEINS; CAMP RESPONSE ELEMENT; DNA-BINDING; GENE; ATF4; IDENTIFICATION; MORPHOGENESIS; EXPRESSION; INTERACT	Regions of hypoxia are a hallmark of solid tumors. Tumor cells modulate the regulation of specific genes allowing adaptation and survival in the harsh hypoxic environment. We have identified SKIP3, a novel human kinase-like gene, which is overexpressed in multiple human tumors and is regulated by hypoxia. SKIP3 is an ortholog of the Drosophila tribbles, rat NIPK, dog C5FW, and human C8FW genes. Drosophila tribbles is involved in slowing cell-cycle progression during Drosophila development, but little is known regarding the function or tissue distribution of the vertebrate orthologs. We show that the normal tissue expression of SKIP3 is confined to human liver, while multiple primary human lung, colon, and breast tumors express high levels of SKIP3 transcript. Endogenous SKIP3 protein accumulates within 48 h under hypoxic growth conditions in HT-29 and PC-3 cells, with upregulation of the SKIP3 mRNA transcript by 72 h. We identified activating transcription factor 4 (ATF4) as a SKIP3-binding partner using the yeast-two-hybrid assay. Coexpression of SKIP3 and ATF4 showed that SKIP3 is associated with the proteolysis of ATF4, which can be blocked using a proteosome inhibitor. These results indicate that SKIP3 may be an important participant in tumor cell growth.	Amgen Inc, Dept Canc Biol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Pathol, Thousand Oaks, CA 91320 USA	Amgen; Amgen	Boylan, JF (corresponding author), Amgen Inc, Dept Canc Biol, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.		Bowers, Alex J./C-1557-2013	Bowers, Alex J./0000-0002-5140-6428				AUSSERER WA, 1994, MOL CELL BIOL, V14, P5032, DOI 10.1128/MCB.14.8.5032; Butscher WG, 1998, J BIOL CHEM, V273, P552, DOI 10.1074/jbc.273.1.552; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; ESTES SD, 1995, EXP CELL RES, V220, P47, DOI 10.1006/excr.1995.1290; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Gachon F, 2001, FEBS LETT, V502, P57, DOI 10.1016/S0014-5793(01)02646-1; Grosshans J, 2000, CELL, V101, P523, DOI 10.1016/S0092-8674(00)80862-4; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; Hewes RS, 2000, GENETICS, V155, P1711; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; Kato Y, 1999, MOL CELL ENDOCRINOL, V154, P151, DOI 10.1016/S0303-7207(99)00078-7; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Lal A, 2001, JNCI-J NATL CANCER I, V93, P1337, DOI 10.1093/jnci/93.17.1337; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Liang GS, 1997, J BIOL CHEM, V272, P24088, DOI 10.1074/jbc.272.38.24088; Masuoka HC, 2002, BLOOD, V99, P736, DOI 10.1182/blood.V99.3.736; Mata J, 2000, CELL, V101, P511, DOI 10.1016/S0092-8674(00)80861-2; Mayumi-Matsuda K, 1999, BIOCHEM BIOPH RES CO, V258, P260, DOI 10.1006/bbrc.1999.0576; NISHIZAWA M, 1992, FEBS LETT, V299, P36, DOI 10.1016/0014-5793(92)80094-W; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Reddy TR, 1997, ONCOGENE, V14, P2785, DOI 10.1038/sj.onc.1201119; Rorth P, 2000, MOL CELL, V6, P23; Saramaki OR, 2001, CANCER GENET CYTOGEN, V128, P31, DOI 10.1016/S0165-4608(01)00396-X; Seher TC, 2000, CURR BIOL, V10, P623, DOI 10.1016/S0960-9822(00)00502-9; Semenza GL, 2000, GENE DEV, V14, P1983; Tang KQ, 2000, BIOCHEMISTRY-US, V39, P3185, DOI 10.1021/bi992664v; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; Wadle A, 2001, ONCOGENE, V20, P5920, DOI 10.1038/sj.onc.1204797; WILCOX JN, 1993, J HISTOCHEM CYTOCHEM, V41, P1725, DOI 10.1177/41.12.8245419; Wilkin F, 1997, EUR J BIOCHEM, V248, P660, DOI 10.1111/j.1432-1033.1997.t01-1-00660.x; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997; YAO KS, 1995, J NATL CANCER I, V87, P117, DOI 10.1093/jnci/87.2.117	38	120	128	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2823	2835		10.1038/sj.onc.1206367	http://dx.doi.org/10.1038/sj.onc.1206367			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743605				2022-12-25	WOS:000182569300013
J	Gery, S; Yin, D; Xie, D; Black, KL; Koeffler, HP				Gery, S; Yin, D; Xie, D; Black, KL; Koeffler, HP			TMEFF1 and brain tumors	ONCOGENE			English	Article						brain cancer; epidermal growth factor and follistatin	EPIDERMAL GROWTH-FACTOR; PROSTATE-CANCER; FOLLISTATIN; CELLS	TMEFF1 is a novel transmembrane protein, containing two follisatin domains and an epidermal growth factor-like region. These structural domains suggest a role for TMEFF1 in growth factor signaling. TMEFF1 fused to enhanced green fluorescent protein revealed that TMEFF1 is expressed on the cell membrane. Northern analysis of normal human tissue showed that TMEFF1 is predominantly expressed in the brain. Study of cancer cell lines from different tissues including the brain, demonstrated moderate to low levels of TMEFF1 in most of these transformed cell lines. Furthermore, quantitative real-time RT-PCR analysis of 54 brain tumors showed that most of these tumors (96%) had lower levels of TMEFF1 expression than normal brain tissue. Interestingly, ectopic expression of TMEFF1 in brain cancer cells resulted in their growth inhibition. These data suggest that TMEFF1 may behave as a tumor suppressor gene in brain cancers.	Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Maxine Dunitz Neurosurg Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center	Gery, S (corresponding author), Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA.			Black, Keith/0000-0002-0546-4934				Eib DW, 1996, J NEUROCHEM, V67, P1047; Eib DW, 1998, CYTOGENET CELL GENET, V81, P180, DOI 10.1159/000015023; EIB DW, 2000, MECH DEVELOP, V97, P67; ENGLER DA, 1990, FEBS LETT, V271, P47, DOI 10.1016/0014-5793(90)80368-S; Gery S, 2002, ONCOGENE, V21, P4739, DOI 10.1038/sj.onc.1205142; Glynne-Jones E, 2001, INT J CANCER, V94, P178, DOI 10.1002/ijc.1450; Horie M, 2000, GENOMICS, V67, P146, DOI 10.1006/geno.2000.6228; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; Patel K, 1998, INT J BIOCHEM CELL B, V30, P1087, DOI 10.1016/S1357-2725(98)00064-8; PATTHY L, 1993, TRENDS NEUROSCI, V16, P76, DOI 10.1016/0166-2236(93)90021-D; Westermark Bengt, 1995, Current Opinion in Oncology, V7, P220, DOI 10.1097/00001622-199505000-00005	11	21	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2723	2727		10.1038/sj.onc.1206351	http://dx.doi.org/10.1038/sj.onc.1206351			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743596				2022-12-25	WOS:000182569300003
J	Czipri, M; Otto, JM; Cs-Szabo, G; Kamath, RV; Vermes, C; Firneisz, G; Kolman, KJ; Watanabe, H; Li, YF; Roughley, PJ; Yamada, Y; Olsen, BR; Glant, TT				Czipri, M; Otto, JM; Cs-Szabo, G; Kamath, RV; Vermes, C; Firneisz, G; Kolman, KJ; Watanabe, H; Li, YF; Roughley, PJ; Yamada, Y; Olsen, BR; Glant, TT			Genetic rescue of chondrodysplasia and the perinatal lethal effect of cartilage link protein deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR-CARTILAGE; N-TERMINAL PEPTIDE; TUMOR-NECROSIS-FACTOR; AMINO-ACID-SEQUENCES; HYALURONIC-ACID; MESSENGER-RNA; CHROMOSOMAL LOCALIZATION; CDNA CLONES; SULFATE PROTEOGLYCAN; RAT CHONDROSARCOMA	The targeted disruption of cartilage link protein gene (Crtl1) in homozygous mice resulted in a severe chondrodysplasia and perinatal lethality. This raised the question of whether the abnormalities seen in Crtl1 null mice are all caused by the absence of link protein in cartilage or whether the deficiency of the protein in other tissues and organs contributed to the phenotype. To address this question we have generated transgenic mice overexpressing cartilage link protein under the control of a cartilage-specific promoter, and then these transgenic mice were used for a genetic rescue of abnormalities in Crtl1 null mice. While the overexpression of cartilage link protein resulted in no abnormal phenotype, the cartilage-specific transgene expression of link protein could completely prevent the perinatal mortality of link protein-deficient mice and, depending on the level of the link protein expression, rescue skeletal abnormalities. Although link protein was originally isolated from cartilage, we found and determined Crtl1 transcripts and corresponding proteins in every organ tested from mouse embryos to aging animals. We also identified three additional members of the link protein family, all co-localized with hyaluronic acid-binding proteoglycans in the mouse genome. The ubiquitous presence of link protein suggests a general and systemic function of link protein in the organization of extracellular matrix in a number of tissues, possibly interacting with other proteoglycans, such as versican, brevican, and neurocan.	Rush Univ, Rush Presbyterian St Lukes Med Ctr, Dept Biochem, Sect Biochem & Mol Biol, Chicago, IL 60612 USA; Rush Univ, Rush Presbyterian St Lukes Med Ctr, Dept Orthoped Surg, Sect Biochem & Mol Biol, Chicago, IL 60612 USA; Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Shriners Hosp Crippled Children, Genet Unit, Montreal, PQ H3G 1A6, Canada; McGill Univ, Dept Surg, Montreal, PQ H3G 1A6, Canada; NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20982 USA	Rush University; Rush University; Aichi Medical University; Harvard University; Harvard Medical School; McGill University; McGill University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Glant, TT (corresponding author), Rush Univ, Rush Presbyterian St Lukes Med Ctr, Dept Biochem, Sect Biochem & Mol Biol, 1653 W Congress Pkwy, Chicago, IL 60612 USA.		Firneisz, Gabor/AAC-9654-2021	Firneisz, Gabor/0000-0002-9123-8131; Watanabe, Hideto/0000-0001-5291-0696	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR047135, R01AR040310] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000483] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR47135, AR40310] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arikawa-Hirasawa E, 1999, NAT GENET, V23, P354, DOI 10.1038/15537; BAKER JR, 1979, J BIOL CHEM, V254, P2387; BINETTE F, 1994, J BIOL CHEM, V269, P19116; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; CsSzabo G, 1997, ARTHRITIS RHEUM, V40, P1037, DOI 10.1002/art.1780400607; Day AJ, 1999, BIOCHEM SOC T, V27, P115, DOI 10.1042/bst0270115; DEAK F, 1986, P NATL ACAD SCI USA, V83, P3766, DOI 10.1073/pnas.83.11.3766; DEAK F, 1991, NUCLEIC ACIDS RES, V19, P4983, DOI 10.1093/nar/19.18.4983; Deak F, 1999, CYTOGENET CELL GENET, V87, P75, DOI 10.1159/000015395; DOEGE K, 1986, P NATL ACAD SCI USA, V83, P3761, DOI 10.1073/pnas.83.11.3761; DUDHIA J, 1989, J MOL BIOL, V206, P749, DOI 10.1016/0022-2836(89)90581-0; DUDHIA J, 1994, BIOCHEM J, V303, P329, DOI 10.1042/bj3030329; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Fulop C, 1997, GENE, V202, P95, DOI 10.1016/S0378-1119(97)00459-9; GARDELL S, 1980, BIOCHEM BIOPH RES CO, V95, P1823, DOI 10.1016/S0006-291X(80)80111-2; Glant TT, 2002, ARTHRITIS RHEUM-US, V46, P2207, DOI 10.1002/art.10555; GLANT TT, 1986, BIOCHEM J, V236, P71, DOI 10.1042/bj2360071; HARDINGHAM TE, 1979, BIOCHEM J, V177, P237, DOI 10.1042/bj1770237; HASCALL VC, 1974, J BIOL CHEM, V249, P4232; HECHT JT, 1992, AM J MED GENET, V44, P420, DOI 10.1002/ajmg.1320440406; HERING TM, 1995, COMP BIOCHEM PHYS B, V112, P197, DOI 10.1016/0305-0491(95)00073-9; Hirakawa S, 2000, BIOCHEM BIOPH RES CO, V276, P982, DOI 10.1006/bbrc.2000.3583; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Horton WA, 1996, ANN NY ACAD SCI, V785, P150, DOI 10.1111/j.1749-6632.1996.tb56253.x; JACENKO O, 1995, J RHEUMATOL, V22, P39; Kerlavage A, 2002, NUCLEIC ACIDS RES, V30, P129, DOI 10.1093/nar/30.1.129; KIMMEL CA, 1981, STAIN TECHNOL, V56, P271, DOI 10.3109/10520298109067325; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; Lesley J, 2002, J BIOL CHEM, V277, P26600, DOI 10.1074/jbc.M201068200; Liu HX, 1999, BBA-GEN SUBJECTS, V1428, P191, DOI 10.1016/S0304-4165(99)00074-4; Liu HX, 2000, ARCH BIOCHEM BIOPHYS, V378, P116, DOI 10.1006/abbi.2000.1758; LOHMANDER LS, 1980, J BIOL CHEM, V255, P6084; LOUGHLIN J, 1994, HUM GENET, V94, P698; MARTIN H, 1993, EUR J BIOCHEM, V212, P87, DOI 10.1111/j.1432-1033.1993.tb17636.x; McKenna LA, 1998, ARTHRITIS RHEUM, V41, P157, DOI 10.1002/1529-0131(199801)41:1<157::AID-ART19>3.0.CO;2-J; MORGELIN M, 1988, BIOCHEM J, V253, P175; Muller G, 1996, CONNECT TISSUE RES, V33, P243, DOI 10.3109/03008209609028881; NEAME PJ, 1993, EXPERIENTIA, V49, P393, DOI 10.1007/BF01923584; NEAME PJ, 1986, J BIOL CHEM, V261, P3519; OBYRNE EM, 1990, ARTHRITIS RHEUM, V33, P1023, DOI 10.1002/art.1780330715; Oohashi T, 2002, MOL CELL NEUROSCI, V19, P43, DOI 10.1006/mcne.2001.1061; OSBORNELAWRENCE SL, 1990, GENOMICS, V8, P562, DOI 10.1016/0888-7543(90)90044-U; PIERSCHBACHER M, 1983, P NATL ACAD SCI-BIOL, V80, P1224, DOI 10.1073/pnas.80.5.1224; RAUCH U, 1995, GENOMICS, V28, P405, DOI 10.1006/geno.1995.1168; RHODES C, 1991, NUCLEIC ACIDS RES, V19, P1933, DOI 10.1093/nar/19.8.1933; RIPELLINO JA, 1989, J CELL BIOL, V108, P1899, DOI 10.1083/jcb.108.5.1899; Roebuck KA, 2001, J BONE MINER RES, V16, P501, DOI 10.1359/jbmr.2001.16.3.501; Roughley PJ, 1996, BIOCHEM J, V318, P779, DOI 10.1042/bj3180779; Sambrook J., 2002, MOL CLONING LAB MANU; SHINOMURA T, 1995, J BIOL CHEM, V270, P10328, DOI 10.1074/jbc.270.17.10328; Spicer AP, 2003, J BIOL CHEM, V278, P21083, DOI 10.1074/jbc.M213100200; STIRPE NS, 1990, DEV BIOL, V137, P419, DOI 10.1016/0012-1606(90)90266-L; Sun GW, 2002, MOL REPROD DEV, V63, P223, DOI 10.1002/mrd.90008; Sun GW, 1999, J HISTOCHEM CYTOCHEM, V47, P1433, DOI 10.1177/002215549904701109; VINTINER GM, 1993, J MED GENET, V30, P773, DOI 10.1136/jmg.30.9.773; WALCZ E, 1994, GENOMICS, V22, P364, DOI 10.1006/geno.1994.1396; WATANABE H, 1994, NAT GENET, V7, P154, DOI 10.1038/ng0694-154; Watanabe H, 1999, NAT GENET, V21, P225, DOI 10.1038/6016; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; WIGHT TN, 1991, CELL BIOL EXTRACELLU, P45, DOI DOI 10.1007/978-1-4615-3770-0_3; YAMADA H, 1994, J BIOL CHEM, V269, P10119; YAMADA Y, 1990, ANN NY ACAD SCI, V580, P81, DOI 10.1111/j.1749-6632.1990.tb17920.x; Yamauchi S, 1997, J DENT RES, V76, P1730, DOI 10.1177/00220345970760110301	63	33	36	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39214	39223		10.1074/jbc.M303329200	http://dx.doi.org/10.1074/jbc.M303329200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12732630	hybrid			2022-12-25	WOS:000185575100136
J	Armengaud, J; Fernandez, B; Chaumont, V; Rollin-Genetet, F; Finet, S; Marchetti, C; Myllykallio, H; Vidaud, C; Pellequer, JL; Gribaldo, S; Forterre, P; Gans, P				Armengaud, J; Fernandez, B; Chaumont, V; Rollin-Genetet, F; Finet, S; Marchetti, C; Myllykallio, H; Vidaud, C; Pellequer, JL; Gribaldo, S; Forterre, P; Gans, P			Identification, purification, and characterization of an eukaryotic-like phosphopantetheine adenylyltransferase (coenzyme A biosynthetic pathway) in the hyperthermophilic archaeon Pyrococcus abyssi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL METHIONINE; ESCHERICHIA-COLI; PANTOTHENATE KINASE; CRYSTAL-STRUCTURE; MOLECULAR CHARACTERIZATION; PROTEINS; PHOSPHATE; ENZYME; GENE; DEPHOSPHOCOENZYME	Although coenzymeA (CoA) is essential in numerous metabolic pathways in all living cells, molecular characterization of the CoA biosynthetic pathway in Archaea remains undocumented. Archaeal genomes contain detectable homologues for only three of the five steps of the CoA biosynthetic pathway characterized in Eukarya and Bacteria. In case of phosphopantetheine adenylyltransferase (PPAT) (EC 2.7.7.3), the putative archaeal enzyme exhibits significant sequence similarity only with its eukaryotic homologs, an unusual situation for a protein involved in a central metabolic pathway. We have overexpressed in Escherichia coli, purified, and characterized this putative PPAT from the hyperthermophilic archaeon Pyrococcus abyssi (PAB0944). Matrix-assisted laser desorption ionization-time of flight mass spectrometry and high performance liquid chromatography measurements are consistent with the presence of a dephospho-CoA (dPCoA) molecule tightly bound to the polypeptide. The protein indeed catalyzes the synthesis of dPCoA from 4'-phosphopantetheine and ATP, as well as the reverse reaction. The presence of dPCoA stabilizes PAB0944, as it induces a shift from 76 to 82 degreesC of the apparent T-m measured by differential scanning micro-calorimetry. Potassium glutamate was found to stabilize the protein at 400 mM. The enzyme behaves as a monomeric protein. Although only distantly related, secondary structure prediction indicates that archaeal and eukaryal PPAT belong to the same nucleotidyltransferase superfamily of bacterial PPAT. The existence of operational proteins highly conserved between Archaea and Eukarya involved in a central metabolic pathway challenge evolutionary scenarios in which eukaryal operational proteins are strictly of bacterial origin.	CEA VALRHO, DSV DIEP, SBTN, Serv Biochim Postgenom & Toxicol Nucl, F-30207 Bagnols Sur Ceze, France; European Synchrotron Radiat Facil, F-38043 Grenoble, France; Univ Paris 11, Inst Genet & Microbiol, UMR CNRS 8621, F-91405 Orsay, France; Univ Grenoble 1, Inst Biol Struct, CEA, CNRS UJF,UMR 5075,Lab Resonance Magnet Nucl, F-38027 Grenoble, France	CEA; European Synchrotron Radiation Facility (ESRF); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA	Armengaud, J (corresponding author), CEA VALRHO, DSV DIEP, SBTN, Serv Biochim Postgenom & Toxicol Nucl, BP 17171, F-30207 Bagnols Sur Ceze, France.	armengaud@cea.fr	gribaldo, simonetta/AAW-4377-2020; Pellequer, Jean-Luc/L-6855-2013; VIDAUD, Claude/AGX-9878-2022; Myllykallio, Hannu/Y-5462-2019	gribaldo, simonetta/0000-0002-7662-021X; Pellequer, Jean-Luc/0000-0002-8944-2715; ARMENGAUD, Jean/0000-0003-1589-445X; Myllykallio, Hannu/0000-0002-0541-1197				Aghajanian S, 2002, BIOCHEM J, V365, P13, DOI 10.1042/BJ20020569; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BORK P, 1995, PROTEINS, V22, P259, DOI 10.1002/prot.340220306; CHEN SWW, 2003, IN PRESS CURR MED CH; DALBOGE H, 1990, FEBS LETT, V266, P1, DOI 10.1016/0014-5793(90)90001-B; Daugherty M, 2002, J BIOL CHEM, V277, P21431, DOI 10.1074/jbc.M201708200; Geerlof A, 1999, J BIOL CHEM, V274, P27105, DOI 10.1074/jbc.274.38.27105; Guinier A., 1955, SMALL ANGLE SCATTERI; Hethke C, 1999, GENETICS, V152, P1325; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; Izard T, 1999, EMBO J, V18, P2021, DOI 10.1093/emboj/18.8.2021; Izard T, 1999, ACTA CRYSTALLOGR D, V55, P1226, DOI 10.1107/S0907444999004394; Izard T, 2002, J MOL BIOL, V315, P487, DOI 10.1006/jmbi.2001.5272; Jain R, 1999, P NATL ACAD SCI USA, V96, P3801, DOI 10.1073/pnas.96.7.3801; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kupke T, 2000, J BIOL CHEM, V275, P31838, DOI 10.1074/jbc.M004273200; Kupke T, 2002, J BIOL CHEM, V277, P36137, DOI 10.1074/jbc.M206188200; Lamosa P, 2000, APPL ENVIRON MICROB, V66, P1974, DOI 10.1128/AEM.66.5.1974-1979.2000; MARTIN DP, 1993, BIOCHEM BIOPH RES CO, V192, P1155, DOI 10.1006/bbrc.1993.1537; Matte-Tailliez O, 2000, TRENDS GENET, V16, P533, DOI 10.1016/S0168-9525(00)02137-5; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mishra PK, 2001, J BACTERIOL, V183, P2774, DOI 10.1128/JB.183.9.2774-2778.2001; Narayanan T, 2001, NUCL INSTRUM METH A, V467, P1005, DOI 10.1016/S0168-9002(01)00553-8; O'Toole N, 2003, PROTEIN SCI, V12, P327, DOI 10.1110/ps.0227803; Obmolova G, 2001, J STRUCT BIOL, V136, P119, DOI 10.1006/jsbi.2001.4428; ROSSMANN MG, 1975, ENZYMES, V11; SCHOLZ S, 1992, FEBS LETT, V306, P239, DOI 10.1016/0014-5793(92)81008-A; SONG WJ, 1994, J BIOL CHEM, V269, P27051; SONG WJ, 1992, J BACTERIOL, V174, P6411, DOI 10.1128/JB.174.20.6411-6417.1992; Strauss E, 2001, J BIOL CHEM, V276, P13513, DOI 10.1074/jbc.C100033200; Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001; WORRALL DM, 1983, BIOCHEM J, V215, P153, DOI 10.1042/bj2150153; Yun M, 2000, J BIOL CHEM, V275, P28093; Zhyvoloup A, 2002, J BIOL CHEM, V277, P22107, DOI 10.1074/jbc.C200195200	35	26	27	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31078	31087		10.1074/jbc.M301891200	http://dx.doi.org/10.1074/jbc.M301891200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12756245	Green Published, hybrid			2022-12-25	WOS:000184658800084
J	Tzima, E; Kiosses, WB; del Pozo, MA; Schwartz, MA				Tzima, E; Kiosses, WB; del Pozo, MA; Schwartz, MA			Localized Cdc42 activation, detected using a novel assay, mediates microtubule organizing center positioning in endothelial cells in response to fluid shear stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVING CELLS; RHO; RAC; MIGRATION; POLARITY; GTPASES; ORIENTATION; INTEGRINS; ADHESION; KINASE	Fluid flow regulates morphology, physiology, and pathophysiology of vascular endothelial cells (reviewed in Ref. 1). The small GTPase Cdc42 mediates polarity in several systems including migrating cells and early embryos, which involve reorientation of the microtubule organizing center (MTOC) and Golgi apparatus toward the direction of movement. Here, we show that Cdc42 is activated by fluid shear stress and that activation is a consequence of integrins binding to extracellular matrix. A novel fluorescence energy transfer assay to visualize Cdc42 activation in single cells shows that Cdc42 activity is polarized in the direction of flow. Localized activation of Cdc42 as well as the activity of Par6 and protein kinase Czeta direct the reorientation of the MTOC to a position on the downstream side of the nucleus relative to the direction of flow. Thus, shear-stimulated integrin dynamics induce polarized Cdc42 activity, which induces MTOC localization through the Par6-protein kinase Czeta complex.	Scripps Res Inst, Dept Cell Biol, Div Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schwartz, MA (corresponding author), Univ Virginia, Mellon Prostate Canc Res Ctr, Cardiovasc Res Ctr, Dept Microbiol, 415 Lane Rd, Charlottesville, VA 22908 USA.		del Pozo, Miguel Angel/L-2861-2014; Tzima, Ellie/L-9256-2017	del Pozo, Miguel Angel/0000-0001-9077-391X; Tzima, Ellie/0000-0002-3437-0902; schwartz, martin/0000-0002-2071-1243	NHLBI NIH HHS [P01HL48728] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Chamberlain CE, 2000, METHOD ENZYMOL, V325, P389; CLARKE MSF, 1992, J CELL SCI, V102, P533; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; DAVIES PF, 1994, J CLIN INVEST, V93, P2031, DOI 10.1172/JCI117197; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Gao L, 2002, CURR BIOL, V12, P221, DOI 10.1016/S0960-9822(01)00663-7; GOTLIEB AI, 1981, AM J PATHOL, V103, P271; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; IVES CL, 1986, IN VITRO CELL DEV B, V22, P500; Jalali S, 2001, P NATL ACAD SCI USA, V98, P1042, DOI 10.1073/pnas.031562998; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Kiosses WB, 1997, ARTERY, V22, P251; Kiosses WB, 1997, ARTERIOSCL THROM VAS, V17, P2891, DOI 10.1161/01.ATV.17.11.2891; KOONCE MP, 1984, J CELL BIOL, V98, P1999, DOI 10.1083/jcb.98.6.1999; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; LEVESQUE MJ, 1985, J BIOMECH ENG-T ASME, V107, P341, DOI 10.1115/1.3138567; Li S, 1999, J CLIN INVEST, V103, P1141, DOI 10.1172/JCI5367; MALECH HL, 1977, J CELL BIOL, V75, P666, DOI 10.1083/jcb.75.3.666; Malek AM, 1996, J CELL SCI, V109, P713; Meller N, 2002, NAT CELL BIOL, V4, P639, DOI 10.1038/ncb835; NEREM RM, 1990, TOXICOL PATHOL, V18, P572; NHIEU TV, 1999, EMBO J, V18, P3249; OAKLEY C, 1993, J CELL SCI, V106, P343; Palazzo AF, 2001, CURR BIOL, V11, P1536, DOI 10.1016/S0960-9822(01)00475-4; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; ROGERS KA, 1985, P NATL ACAD SCI USA, V82, P3272, DOI 10.1073/pnas.82.10.3272; Tzima E, 2002, EMBO J, V21, P6791, DOI 10.1093/emboj/cdf688; Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639	37	143	150	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31020	31023		10.1074/jbc.M301179200	http://dx.doi.org/10.1074/jbc.M301179200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12754216	hybrid			2022-12-25	WOS:000184658800077
J	Chang, SY; Ko, TP; Liang, PH; Wang, AHJ				Chang, SY; Ko, TP; Liang, PH; Wang, AHJ			Catalytic mechanism revealed by the crystal structure of undecaprenyl pyrophosphate synthase in complex with sulfate, magnesium, and triton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL DIPHOSPHATE SYNTHASE; CIS-PRENYLTRANSFERASE; SIGNIFICANT RESIDUES; MOLECULAR-CLONING; SUBSTRATE-BINDING; EXPRESSION; IDENTIFICATION; PURIFICATION; MOLSCRIPT; PROGRAM	Undecaprenyl pyrophosphate synthase (UPPs) catalyzes chain elongation of farnesyl pyrophosphate (FPP) to undecaprenyl pyrophosphate (UPP) via condensation with eight isopentenyl pyrophosphates (IPP). UPPs from Escherichia coli is a dimer, and each subunit consists of 253 amino acid residues. The chain length of the product is modulated by a hydrophobic active site tunnel. In this paper, the crystal structure of E. coli UPPs was refined to 1.73 Angstrom resolution, which showed bound sulfate and magnesium ions as well as Triton X-100 molecules. The amino acid residues 72 - 82, which encompass an essential catalytic loop not seen in the previous apoenzyme structure ( Ko, T.- P., Chen, Y. K., Robinson, H., Tsai, P. C., Gao, Y.- G., Chen, A. P.- C., Wang, A. H.- J., and Liang, P.- H. ( 2001) J. Biol. Chem. 276, 47474 - 47482), also became visible in one subunit. The sulfate ions suggest locations of the pyrophosphate groups of FPP and IPP in the active site. The Mg2+ is chelated by His- 199 and Glu-213 from different subunits and possibly plays a structural rather than catalytic role. However, the metal ion is near the IPP-binding site, and double mutation of His- 199 and Glu-213 to alanines showed a remarkable increase of K-m value for IPP. Inside the tunnel, one Triton surrounds the top portion of the tunnel, and the other occupies the bottom part. These two Triton molecules may mimic the hydrocarbon moiety of the UPP product in the active site. Kinetic analysis indicated that a high concentration (> 1%) of Triton inhibits the enzyme activity.	Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Wang, AHJ (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan.	ahjwang@gate.sinica.edu.tw	Liang, Po-Huang/H-6610-2015	Liang, Po-Huang/0000-0003-1207-5256				ALLEN CM, 1985, METHOD ENZYMOL, V110, P281; Apfel CM, 1999, J BACTERIOL, V181, P483, DOI 10.1128/JB.181.2.483-492.1999; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN AJ, 1994, PROTEIN SCI, V3, P600; Chen YH, 2002, J BIOL CHEM, V277, P7369, DOI 10.1074/jbc.M110014200; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fujihashi M, 2001, P NATL ACAD SCI USA, V98, P4337, DOI 10.1073/pnas.071514398; Fujikura K, 2000, J BIOCHEM, V128, P917, DOI 10.1093/oxfordjournals.jbchem.a022842; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kharel Y, 2001, J BIOL CHEM, V276, P28459, DOI 10.1074/jbc.M102057200; Ko TP, 2001, J BIOL CHEM, V276, P47474, DOI 10.1074/jbc.M106747200; KOYAMA T, 1995, BIOCHEM BIOPH RES CO, V212, P681, DOI 10.1006/bbrc.1995.2022; Koyama T, 1996, BIOCHEMISTRY-US, V35, P9533, DOI 10.1021/bi960137v; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Liang PH, 2002, EUR J BIOCHEM, V269, P3339, DOI 10.1046/j.1432-1033.2002.03014.x; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ogura K, 1998, CHEM REV, V98, P1263, DOI 10.1021/cr9600464; Ogura K, 1997, Subcell Biochem, V28, P57; Oh SK, 2000, J BIOL CHEM, V275, P18482, DOI 10.1074/jbc.M002000200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan JJ, 2000, BIOCHEMISTRY-US, V39, P10936, DOI 10.1021/bi000992l; Pan JJ, 2000, BIOCHEMISTRY-US, V39, P13856, DOI 10.1021/bi001226h; POULTER CD, 1976, BIOCHEMISTRY-US, V15, P1079, DOI 10.1021/bi00650a019; ROBYT J, 1998, ESSENTIALS CARBOHYDR, P305; Sato M, 1999, MOL CELL BIOL, V19, P471; Shimizu N, 1998, J BIOL CHEM, V273, P19476, DOI 10.1074/jbc.273.31.19476; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Wang KC, 2000, BBA-MOL CELL BIOL L, V1529, P33, DOI 10.1016/S1388-1981(00)00136-0	31	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29298	29307		10.1074/jbc.M302687200	http://dx.doi.org/10.1074/jbc.M302687200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12756244	hybrid			2022-12-25	WOS:000184421100115
J	Katz, BZ; Romer, L; Miyamoto, S; Volberg, T; Matsumoto, K; Cukierman, E; Geiger, B; Yamada, KM				Katz, BZ; Romer, L; Miyamoto, S; Volberg, T; Matsumoto, K; Cukierman, E; Geiger, B; Yamada, KM			Targeting membrane-localized focal adhesion kinase to focal adhesions - Roles of tyrosine phosphorylation and Src family kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; EXTRACELLULAR-MATRIX; INTEGRIN FUNCTION; BINDING-SITE; IN-VIVO; FAK; CYTOSKELETAL; FIBRONECTIN; INHIBITION; ACTIVATION	In the present study, we examined regulation of activated focal adhesion kinase localization in focal adhesions. By using focal adhesion kinase fused to an inert transmembrane anchor, we found that the focal contact targeting region within focal adhesion kinase was preserved in the membrane-targeted fusion protein. However, upon tyrosine phosphorylation, full-length focal adhesion kinase became excluded from focal adhesions. This negative regulation of localization could be abolished by mutating key amino acid residues of focal adhesion kinase shown previously to be involved in adhesion-mediated signal transduction. Hyper-phosphorylation of endogenous focal adhesion kinase induced by pervanadate resulted in a similar reduction of localization at focal adhesions. We also show here that Src family kinases are essential for the phosphorylation-dependent exclusion of focal adhesion kinase from focal adhesions. We propose here a molecular model for the tyrosine phosphorylation-dependent regulation of focal adhesion kinase organization involving Src kinases and an inhibitory phosphorylation of the C-terminal (Tyr-925) tyrosine residue.	Tel Aviv Med Ctr & Sch Med, Inst Hematol, IL-64239 Tel Aviv, Israel; NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Dept Anesthesiol, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21224 USA; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Weizmann Institute of Science	Katz, BZ (corresponding author), Tel Aviv Med Ctr & Sch Med, Inst Hematol, 6 Weizman St, IL-64239 Tel Aviv, Israel.		cukierman, edna/AAU-8932-2020	cukierman, edna/0000-0002-1452-9576; Yamada, Kenneth/0000-0003-1512-6805	FIC NIH HHS [F06TW02341] Funding Source: Medline; NHLBI NIH HHS [HL03299] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F06TW002341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000524] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; CHAN PY, 1994, J BIOL CHEM, V269, P20567; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Davidson D, 2001, EMBO J, V20, P3414, DOI 10.1093/emboj/20.13.3414; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hayashi I, 2002, NAT STRUCT BIOL, V9, P101, DOI 10.1038/nsb755; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Ilic D, 2001, AM J PATHOL, V159, P93, DOI 10.1016/S0002-9440(10)61677-X; Johnson RP, 2000, J BIOL CHEM, V275, P95, DOI 10.1074/jbc.275.1.95; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Miyamoto S, 1998, ANN NY ACAD SCI, V857, P119, DOI 10.1111/j.1749-6632.1998.tb10112.x; Nakamura K, 2001, ONCOGENE, V20, P2626, DOI 10.1038/sj.onc.1204359; Ruest PJ, 2001, MOL CELL BIOL, V21, P7641, DOI 10.1128/MCB.21.22.7641-7652.2001; SAMBROOK J, 1989, MOLC LONING LAB MANU; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Volberg T, 2001, J CELL SCI, V114, P2279; Vuori K, 1998, J MEMBRANE BIOL, V165, P191, DOI 10.1007/s002329900433; Zamir E, 2001, J CELL SCI, V114, P3583; Zamir E, 1999, J CELL SCI, V112, P1655; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021	37	73	74	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29115	29120		10.1074/jbc.M212396200	http://dx.doi.org/10.1074/jbc.M212396200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12754219	hybrid			2022-12-25	WOS:000184421100095
J	Sen Gupta, S; Ton, VK; Beaudry, V; Rulli, S; Cunningham, K; Rao, R				Sen Gupta, S; Ton, VK; Beaudry, V; Rulli, S; Cunningham, K; Rao, R			Antifungal activity of amiodarone is mediated by disruption of calcium homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SECRETORY PATHWAY; SACCHAROMYCES-CEREVISIAE; H+/CA2+ EXCHANGE; GENETIC-ANALYSIS; CA2+; CALCINEURIN; HOMOLOG; DRUG; PMR1; DESETHYLAMIODARONE	The antiarrhythmic drug amiodarone was recently demonstrated to have novel broad range fungicidal activity. We provide evidence that amiodarone toxicity is mediated by disruption of Ca2+ homeostasis in Saccharomyces cerevisiae. In mutants lacking calcineurin and various Ca2+ transporters, including pumps (Pmr1 and Pmc1), channels (Cch1/Mid1 and Yvc1), and exchangers (Vcx1), amiodarone sensitivity correlates with cytoplasmic calcium overload. Measurements of cytosolic Ca2+ by aequorin luminescence demonstrate a biphasic response to amiodarone. An immediate and extensive calcium influx was observed that was dose-dependent and correlated with drug sensitivity. The second phase consisted of a sustained release of calcium from the vacuole via the calcium channel Yvc1 and was independent of extracellular Ca2+ entry. To uncover additional cellular pathways involved in amiodarone sensitivity, we conducted a genome-wide screen of nearly 5000 single-gene yeast deletion mutants. 36 yeast strains with amiodarone hypersensitivity were identified, including mutants in transporters (pmr1, pdr5, and vacuolar H+-ATPase), ergosterol biosynthesis (erg3, erg6, and erg24), intracellular trafficking (vps45 and rcy1), and signaling (ypk1 and ptc1). Of three mutants examined (vps45, vma3, and rcy1), all were found to have defective calcium homeostasis, supporting a correlation with amiodarone hypersensitivity. We show that low doses of amiodarone and an azole ( miconazole, fluconazole) are strongly synergistic and exhibit potent fungicidal effects in combination. Our findings point to the potentially effective application of amiodarone as a novel antimycotic, particularly in combination with conventional antifungals.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Rao, R (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.	rrao@jhmi.edu		Sengupta, Soma/0000-0003-4577-1397	NIGMS NIH HHS [GM62142] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062142] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich H, 1999, EMBO J, V18, P6005, DOI 10.1093/emboj/18.21.6005; ALLEN DG, 1977, SCIENCE, V195, P996, DOI 10.1126/science.841325; Andjelic S, 1997, J IMMUNOL, V158, P2527; Bargout R, 2000, AM J PHYSIOL-LUNG C, V278, pL1039, DOI 10.1152/ajplung.2000.278.5.L1039; Baritussio A, 2001, AM J PHYSIOL-LUNG C, V281, pL1189, DOI 10.1152/ajplung.2001.281.5.L1189; Bauer BE, 1999, BBA-BIOMEMBRANES, V1461, P217, DOI 10.1016/S0005-2736(99)00160-1; Bonilla M, 2002, EMBO J, V21, P2343, DOI 10.1093/emboj/21.10.2343; Courchesne WE, 2003, MOL MICROBIOL, V47, P223, DOI 10.1046/j.1365-2958.2003.03291.x; Courchesne WE, 2002, J PHARMACOL EXP THER, V300, P195, DOI 10.1124/jpet.300.1.195; Cruz MC, 2002, EMBO J, V21, P546, DOI 10.1093/emboj/21.4.546; Cruz MC, 2001, ANTIMICROB AGENTS CH, V45, P3162, DOI 10.1128/AAC.45.11.3162-3170.2001; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; Cyert MS, 2001, ANNU REV GENET, V35, P647, DOI 10.1146/annurev.genet.35.102401.091302; Denis V, 2002, J CELL BIOL, V156, P29, DOI 10.1083/jcb.200111004; DEZIEL MR, 1989, ARCH BIOCHEM BIOPHYS, V274, P463, DOI 10.1016/0003-9861(89)90459-1; Di Matola T, 2000, J CLIN ENDOCR METAB, V85, P4323, DOI 10.1210/jc.85.11.4323; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; Edlind T, 2002, MOL MICROBIOL, V46, P257, DOI 10.1046/j.1365-2958.2002.03165.x; EIDE DJ, 1993, MOL GEN GENET, V241, P447, DOI 10.1007/BF00284699; FONZI WA, 1993, GENETICS, V134, P717; Foti M, 2001, MOL BIOL CELL, V12, P2396, DOI 10.1091/mbc.12.8.2396; Fox DS, 2002, BIOESSAYS, V24, P894, DOI 10.1002/bies.10157; Gage MJ, 2001, MOL MICROBIOL, V41, P775, DOI 10.1046/j.1365-2958.2001.02554.x; HAGELUKEN A, 1995, MOL PHARMACOL, V47, P234; Himmel HM, 2000, N-S ARCH PHARMACOL, V362, P489, DOI 10.1007/s002100000301; HONEGGER UE, 1993, BIOCHEM PHARMACOL, V45, P349, DOI 10.1016/0006-2952(93)90070-D; Kodama I, 1999, AM J CARDIOL, V84, p20R; KODAVANTI PRS, 1992, N-S ARCH PHARMACOL, V345, P213, DOI 10.1007/BF00165739; Kontoyiannis DP, 2000, ANTIMICROB AGENTS CH, V44, P2915, DOI 10.1128/AAC.44.10.2915-2918.2000; KURZWEILOVA H, 1993, FOLIA MICROBIOL, V38, P524, DOI 10.1007/BF02814408; Lecourieux D, 2002, PLANT CELL, V14, P2627, DOI 10.1105/tpc.005579; Locke EG, 2000, MOL CELL BIOL, V20, P6686, DOI 10.1128/MCB.20.18.6686-6694.2000; Lupetti A, 2002, TRENDS MOL MED, V8, P76, DOI 10.1016/S1471-4914(02)02280-3; Mandal D, 2000, J BIOL CHEM, V275, P23933, DOI 10.1074/jbc.M002619200; Marchi V, 1999, FEBS LETT, V454, P181, DOI 10.1016/S0014-5793(99)00803-0; Matsumoto TK, 2002, J BIOL CHEM, V277, P33075, DOI 10.1074/jbc.M205037200; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; Miseta A, 1999, FEBS LETT, V451, P132, DOI 10.1016/S0014-5793(99)00519-0; MOIR D, 1982, GENETICS, V100, P547; Muller EM, 2001, GENETICS, V159, P1527; Paidhungat M, 1997, MOL CELL BIOL, V17, P6339, DOI 10.1128/MCB.17.11.6339; Palmer CP, 2001, P NATL ACAD SCI USA, V98, P7801, DOI 10.1073/pnas.141036198; POWIS G, 1990, TOXICOL APPL PHARM, V103, P156, DOI 10.1016/0041-008X(90)90271-U; Pozos TC, 1996, MOL CELL BIOL, V16, P3730; Roling EE, 2002, DIAGN MICR INFEC DIS, V43, P13, DOI 10.1016/S0732-8893(02)00361-9; Sitcheran R, 2000, GENETICS, V156, P963; Sorin A, 1997, J BIOL CHEM, V272, P9895; Stevenson William G, 2002, Cardiol Rev, V10, P8, DOI 10.1097/00045415-200201000-00004; Tkacz JS, 2001, CURR OPIN MICROBIOL, V4, P540, DOI 10.1016/S1369-5274(00)00248-4; Ton VK, 2002, J BIOL CHEM, V277, P6422, DOI 10.1074/jbc.M110612200; VIG PJS, 1991, NEUROTOXICOLOGY, V12, P595; VIG PJS, 1991, PHARMACOL TOXICOL, V68, P26, DOI 10.1111/j.1600-0773.1991.tb01203.x; Warmka J, 2001, MOL CELL BIOL, V21, P51, DOI 10.1128/MCB.21.1.51-60.2001; Wei Y, 2000, J BIOL CHEM, V275, P23927, DOI 10.1074/jbc.M002618200; Wiederkehr A, 2000, J CELL BIOL, V149, P397, DOI 10.1083/jcb.149.2.397	56	123	131	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28831	28839		10.1074/jbc.M303300200	http://dx.doi.org/10.1074/jbc.M303300200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12754197	hybrid			2022-12-25	WOS:000184421100061
J	Lee, PSW; Chang, CB; Liu, D; Derynck, R				Lee, PSW; Chang, CB; Liu, D; Derynck, R			Sumoylation of Smad4, the common Smad mediator of transforming growth factor-beta family signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR SMAD4/DPC4; UBIQUITIN-RELATED MODIFIER; SUMO E3 LIGASE; TRANSCRIPTIONAL ACTIVATION; COVALENT MODIFICATION; ANDROGEN RECEPTOR; I RECEPTORS; C-JUN; PROTEINS; PATHWAY	Transforming growth factor-beta (TGF-beta) and TGF-beta-related factors regulate cell growth, differentiation, and apoptosis, and play key roles in normal development and tumorigenesis. TGF-beta family-induced changes in gene expression are mediated by serine/threonine kinase receptors at the cell surface and Smads as intracellular effectors. Receptor-activated Smads combine with a common Smad4 to translocate into the nucleus where they cooperate with other transcription factors to activate or repress transcription. The activities of the receptor-activated Smads are controlled by post-translational modifications such as phosphorylation and ubiquitylation. Here we show that Smad4 is modified by sumoylation. Sumoylation of Smad4 was enhanced by the conjugating enzyme Ubc9 and members of the PIAS family of SUMO ligases. A major sumoylation site in Smad4 was localized to Lys-159 in its linker segment with an additional site at Lys-113 in the MH-1 domain. Increased sumoylation in the presence of the PIASy E3 ligase correlated with targeting of Smad4 to subnuclear speckles that contain SUMO-1 and PIASy. Replacement of lysines 159 and 113 by arginines or increased sumoylation enhanced the stability of Smad4, and transcription in mammalian cells and Xenopus embryos. These observations suggest a role for Smad4 sumoylation in the regulation of TGF-beta signaling through Smads.	Univ Calif San Francisco, Dept Growth & Dev, Cell Biol Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Cell Biol Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Program Dev Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Growth & Dev, Program Dev Biol, San Francisco, CA 94143 USA; Univ Alabama Birmingham, Dept Cell Biol, Mol & Cellular Biol Program, Birmingham, AL 35294 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Alabama System; University of Alabama Birmingham	Derynck, R (corresponding author), Univ Calif San Francisco, Dept Growth & Dev, Cell Biol Program, San Francisco, CA 94143 USA.	derynck@itsa.ucsf.edu			NCI NIH HHS [CA63101] Funding Source: Medline; NHLBI NIH HHS [HL62301] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063101] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Bai RY, 2002, NAT CELL BIOL, V4, P181, DOI 10.1038/ncb753; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Blanchette F, 2001, J BIOL CHEM, V276, P33986, DOI 10.1074/jbc.M100093200; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; Chang CB, 1997, DEVELOPMENT, V124, P827; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Dundr M, 2001, BIOCHEM J, V356, P297, DOI 10.1042/0264-6021:3560297; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Lin X, 2003, J BIOL CHEM, V278, P18714, DOI 10.1074/jbc.M302243200; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Masuyama N, 1999, J BIOL CHEM, V274, P12163, DOI 10.1074/jbc.274.17.12163; Maurice D, 2001, J BIOL CHEM, V276, P43175, DOI 10.1074/jbc.M105895200; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Moustakas A, 2001, J CELL SCI, V114, P4359; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Parekh RB, 1997, CURR OPIN BIOTECH, V8, P718, DOI 10.1016/S0958-1669(97)80126-7; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pawson T, 1999, CELL, V97, P675, DOI 10.1016/S0092-8674(00)80779-5; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schul W, 1998, J CELL BIOCHEM, V70, P159, DOI 10.1002/(SICI)1097-4644(19980801)70:2<159::AID-JCB2>3.0.CO;2-N; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Subramanian L, 2003, J BIOL CHEM, V278, P9134, DOI 10.1074/jbc.M210440200; Wicks SJ, 2000, MOL CELL BIOL, V20, P8103, DOI 10.1128/MCB.20.21.8103-8111.2000; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Yakmovych I, 2001, FASEB J, V15, P553; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	77	118	135	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27853	27863		10.1074/jbc.M301755200	http://dx.doi.org/10.1074/jbc.M301755200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12740389	hybrid			2022-12-25	WOS:000184242700067
J	van den Burg, HA; Westerink, N; Francoijs, KJ; Roth, R; Woestenenk, E; Boeren, S; de Wit, PJGM; Joosten, MHAJ; Vervoort, J				van den Burg, HA; Westerink, N; Francoijs, KJ; Roth, R; Woestenenk, E; Boeren, S; de Wit, PJGM; Joosten, MHAJ; Vervoort, J			Natural disulfide bond-disrupted mutants of AVR4 of the tomato pathogen Cladosporium fulvum are sensitive to proteolysis, circumvent Cf-4-mediated resistance, but retain their chitin binding ability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVIRULENCE GENE; ELICITOR PROTEINS; DEFENSE RESPONSES; CYSTEINE RESIDUES; CYSTINE KNOT; RECOGNITION; INVERTEBRATES; EXPRESSION; VIRULENCE; EFFICIENT	The extracellular AVR4 elicitor of the pathogenic fungus Cladosporium fulvum induces defense responses in the tomato genotype Cf-4. Here, the four disulfide bonds of AVR4 were identified as Cys-11-41, Cys-21-27, Cys-35-80, and Cys-57-72 by partial reduction with Tris-(2-carboxyethyl)-phosphine hydrochloride, subsequent cyanylation, and base-catalyzed chain cleavage. The resulting peptide fragments were analyzed by mass spectrometry. Sequence homology and the disulfide bond pattern revealed that AVR4 contains an invertebrate (inv) chitin-binding domain (ChBD). Binding of AVR4 to chitin was confirmed experimentally. The three disulfide bonds encompassing the inv ChBD motif are also required for protein stability of AVR4. Independent disruption of each of the three conserved disulfide bonds in AVR4 resulted in a protease-sensitive protein, whereas the fourth disulfide bond appeared not to be required for protein stability. Most strains of C. fulvum virulent on Cf-4 tomato contain Cys to Tyr substitutions in AVR4 involving two (Cys-11-41, Cys-35-80) of the three disulfide bonds present in the inv ChBD motif. These natural Cys to Tyr mutant AVR4 proteins did retain their chitin binding ability and when bound to chitin were less sensitive to proteases. Thus, the widely applied tomato Cf-4 resistance gene is circumvented by C. fulvum by amino acid substitutions affecting two disulfide bonds in AVR4 resulting in the absence of the corresponding AVR4 isoforms in apoplastic fluid. However, these natural isoforms of AVR4 appear to have retained their intrinsic function, i.e. binding to chitin present in the cell wall of C. fulvum, most likely to protect it against the deleterious effects of plant chitinases.	Univ Wageningen & Res Ctr, Biochem Lab, NL-6703 HA Wageningen, Netherlands; Univ Wageningen & Res Ctr, Phytopathol Lab, NL-6709 PD Wageningen, Netherlands	Wageningen University & Research; Wageningen University & Research	Vervoort, J (corresponding author), Univ Wageningen & Res Ctr, Biochem Lab, Dreijenlaan 3, NL-6703 HA Wageningen, Netherlands.	Jacques.vervoort@wur.nl	de Wit, Pierre J. G.M./CAI-9966-2022; Joosten, Matthieu/AAB-5150-2022; de Wit, Pierre/A-1998-2013; Joosten, Matthieu/AAB-5131-2022	de Wit, Pierre/0000-0002-4208-288X; Joosten, Matthieu/0000-0002-6243-4547; van den Burg, Harrold/0000-0003-4142-374X				Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Bonas U, 2002, CURR OPIN MICROBIOL, V5, P44, DOI 10.1016/S1369-5274(02)00284-9; CHAPMAN S, 1992, PLANT J, V2, P549; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; Darling RJ, 2000, J BIOL CHEM, V275, P15413, DOI 10.1074/jbc.275.20.15413; DAY PR, 1957, NATURE, V179, P1141, DOI 10.1038/1791141b0; De Jong CF, 2000, PHYSIOL MOL PLANT P, V56, P169, DOI 10.1006/pmpp.2000.0263; DEGANI Y, 1974, BIOCHEMISTRY-US, V13, P1, DOI 10.1021/bi00698a001; DEWIT PJGM, 1979, PHYSIOL PLANT PATHOL, V15, P257, DOI 10.1016/0048-4059(79)90077-8; DEWIT PJGM, 1982, PHYSIOL PLANT PATHOL, V21, P1, DOI 10.1016/0048-4059(82)90002-9; Durrant WE, 2000, PLANT CELL, V12, P963, DOI 10.1105/tpc.12.6.963; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; Harrison PM, 1996, J MOL BIOL, V264, P603, DOI 10.1006/jmbi.1996.0664; JOOSTEN MHAJ, 1994, NATURE, V367, P384, DOI 10.1038/367384a0; Joosten MHAJ, 1997, PLANT CELL, V9, P367; Joosten MHAJ, 1999, ANNU REV PHYTOPATHOL, V37, P335, DOI 10.1146/annurev.phyto.37.1.335; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; Kawabata S, 1996, J BIOCHEM-TOKYO, V120, P1253; Kjemtrup S, 2000, CURR OPIN MICROBIOL, V3, P73, DOI 10.1016/S1369-5274(99)00054-5; Kussmann M, 1997, J MASS SPECTROM, V32, P593; Luderer R, 2002, MOL MICROBIOL, V45, P875, DOI 10.1046/j.1365-2958.2002.03060.x; Luderer R, 2002, MOL PLANT PATHOL, V3, P91, DOI 10.1046/j.1464-6722.2001.00095.x; Mas JM, 1998, J MOL BIOL, V284, P541, DOI 10.1006/jmbi.1998.2194; Primus JL, 1999, J BIOL INORG CHEM, V4, P274, DOI 10.1007/s007750050313; Rivas S, 2002, PLANT J, V29, P783, DOI 10.1046/j.1365-313X.2002.01254.x; Romeis T, 1999, PLANT CELL, V11, P273, DOI 10.1105/tpc.11.2.273; Romeis T, 2001, EMBO J, V20, P5556, DOI 10.1093/emboj/20.20.5556; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; Sanchez R, 1998, P NATL ACAD SCI USA, V95, P13597, DOI 10.1073/pnas.95.23.13597; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shen ZC, 1999, J MOL EVOL, V48, P341, DOI 10.1007/PL00006478; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Suetake T, 2000, J BIOL CHEM, V275, P17929, DOI 10.1074/jbc.C000184200; Tjoelker LW, 2000, J BIOL CHEM, V275, P514, DOI 10.1074/jbc.275.1.514; van den Burg HA, 2001, J BIOMOL NMR, V20, P251, DOI 10.1023/A:1011206701288; van den Hooven HW, 2001, BIOCHEMISTRY-US, V40, P3458, DOI 10.1021/bi0023089; VANDERACKERVEKE.GF, 1993, PLANT PHYSIOL, V130, P91; VANKAN JAL, 1991, MOL PLANT MICROBE IN, V4, P52, DOI 10.1094/MPMI-4-052; White FF, 2000, CURR OPIN PLANT BIOL, V3, P291, DOI 10.1016/S1369-5266(00)00082-0; Wit P. J. G. M. de, 1977, Netherlands Journal of Plant Pathology, V83, P109, DOI 10.1007/BF01981556; Wu J, 1998, ANAL BIOCHEM, V258, P268, DOI 10.1006/abio.1998.2596; Wu J, 1997, PROTEIN SCI, V6, P391; Zhu HY, 1999, PROTEIN SCI, V8, P326	47	84	85	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27340	27346		10.1074/jbc.M212196200	http://dx.doi.org/10.1074/jbc.M212196200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12736265	hybrid			2022-12-25	WOS:000184242700003
J	Faour, WH; Mancini, A; He, QW; Di Battista, JA				Faour, WH; Mancini, A; He, QW; Di Battista, JA			T-cell-derived interleukin-17 regulates the level and stability of cyclooxygenase-2 (COX-2) mRNA through restricted activation of the p38 mitogen-activated protein kinase cascade - Role of distal sequences in the 3 '-untranslated region of COX-2 mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE-2 GENE-EXPRESSION; HUMAN SYNOVIAL FIBROBLASTS; NITRIC-OXIDE PRODUCTION; NF-KAPPA-B; RHEUMATOID-ARTHRITIS; TNF-ALPHA; POSTTRANSCRIPTIONAL CONTROL; MOLECULAR CHARACTERIZATION; TRANSLATION INITIATION; NEUTROPHIL RECRUITMENT	Although interleukin-17 (IL-17) is the pre-eminent T-cell-derived pro-inflammatory cytokine, its cellular mechanism of action remains poorly understood. We explored novel signaling pathways mediating IL-17 induction of the cyclooxygenase-2 (COX-2) gene in human chondrocytes, synovial fibroblasts, and macrophages. In preliminary work, recombinant human ( rh) IL-17 stimulated a rapid ( 5 - 15 min), substantial (> 8-fold), and sustained (> 24 h) increase in COX-2 mRNA, protein, and prostaglandin E-2 release. Screening experiments with cell-permeable kinase inhibitors ( e. g. SB202190 and p38 inhibitor), Western analysis using specific anti-phosphoantibodies to a variety of mitogen-activated protein kinase cascade intermediates, co-transfection studies using chimeric cytomegalovirus-driven constructs of GAL4 DNA-binding domains fused to the transactivation domains of transcription factors together with Gal-4 binding element-luciferase reporters, ectopic overexpression of activated protein kinase expression plasmids (e.g. MKK3/6), or transfection experiments with wild-type and mutant COX-2 promoter constructs revealed that rhIL-17 induction of the COX-2 gene was mediated exclusively by the stress-activated protein kinase 2/p38 cascade. A rhIL-17-dependent transcriptional pulse (1.76 +/- 0.11-fold induction) was initiated by ATF-2/CREB-1 transactivation through the ATF/CRE enhancer site in the proximal promoter. However, steadystate levels of rhIL-17-induced COX-2 mRNA declined rapidly (< 2 h) to control levels under wash-out conditions. Adding rhIL-17 to transcriptionally arrested cells stabilized COX-2 mRNA for up to 6 h, a process compromised by SB202190. Deletion analysis using transfected chimeric luciferase-COX-2 mRNA 3'-untranslated region reporter constructs revealed that rhIL-17 increased reporter gene mRNA stability and protein synthesis via distal regions ( - 545 to - 1414 bases) of the 3'-untranslated region. This response was mediated entirely by the stress-activated protein kinase 2/p38 cascade. As such, IL-17 can exert direct transcriptional and post-transcriptional control over target proinflammatory cytokines and oncogenes.	Univ Montreal, Program Mol Biol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 1A1, Canada	Universite de Montreal; McGill University; McGill University	Di Battista, JA (corresponding author), McGill Univ, Royal Victoria Hosp, Ctr Hlth, Div Clin Immunol & Rheumatol, 687 Pine Ave W,Rm M-11-22, Montreal, PQ H3A 1A1, Canada.		faour, wissam/J-3419-2019	faour, wissam/0000-0002-0746-3687				Aggarwal S, 2002, J LEUKOCYTE BIOL, V71, P1; Alaaeddine N, 1997, J RHEUMATOL, V24, P1985; Albanesi C, 1999, J IMMUNOL, V162, P494; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; Attur MG, 1997, ARTHRITIS RHEUM, V40, P1050, DOI 10.1002/art.1780400609; Awane M, 1999, J IMMUNOL, V162, P5337; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Cai LP, 2001, CYTOKINE, V16, P10, DOI 10.1006/cyto.2001.0939; Cai XY, 1998, IMMUNOL LETT, V62, P51, DOI 10.1016/S0165-2478(98)00027-3; Chabaud M, 1998, J IMMUNOL, V161, P409; Chabaud M, 2000, CYTOKINE, V12, P1092, DOI 10.1006/cyto.2000.0681; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; Dayer JM, 1999, ARTHRITIS RES, V1, P17, DOI 10.1186/ar5; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; Di Battista JA, 1999, ARTHRITIS RHEUM, V42, P157, DOI 10.1002/1529-0131(199901)42:1<157::AID-ANR19>3.0.CO;2-P; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Faour WH, 2001, J BIOL CHEM, V276, P31720, DOI 10.1074/jbc.M104036200; Firestein GS, 1996, ARTHRITIS RHEUM, V39, P1781, DOI 10.1002/art.1780391103; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Fraser CS, 1999, BIOCHEM J, V342, P519, DOI 10.1042/0264-6021:3420519; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; Gou Q, 1998, BIOCHEM BIOPH RES CO, V242, P508, DOI 10.1006/bbrc.1997.7994; HE QW, 2001, OSTEOARTHRITIS CAR B, V9, pS9; He W, 2002, J RHEUMATOL, V29, P546; Jovanovic DV, 1998, J IMMUNOL, V160, P3513; Jovanovic DV, 2000, ARTHRITIS RHEUM-US, V43, P1134, DOI 10.1002/1529-0131(200005)43:5<1134::AID-ANR24>3.0.CO;2-#; Kalajdzic T, 2002, ARTHRITIS RHEUM, V46, P494, DOI 10.1002/art.10055; Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Laan M, 2001, BRIT J PHARMACOL, V133, P200, DOI 10.1038/sj.bjp.0704063; Laan M, 1999, J IMMUNOL, V162, P2347; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Lee J, 2001, J BIOL CHEM, V276, P1660, DOI 10.1074/jbc.M008289200; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Li HZ, 2000, P NATL ACAD SCI USA, V97, P773, DOI 10.1073/pnas.97.2.773; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Morley SJ, 2002, J BIOL CHEM, V277, P32855, DOI 10.1074/jbc.C200376200; Newton R, 1998, J BIOL CHEM, V273, P32312, DOI 10.1074/jbc.273.48.32312; Newton R, 1997, BIOCHEM BIOPH RES CO, V234, P85, DOI 10.1006/bbrc.1997.6586; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; ROUVIER E, 1993, J IMMUNOL, V150, P5445; RYSECK RP, 1992, CELL GROWTH DIFFER, V3, P443; Sawaoka H, 2003, J BIOL CHEM, V278, P13928, DOI 10.1074/jbc.M300016200; Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x; Schwandner R, 2000, J EXP MED, V191, P1233, DOI 10.1084/jem.191.7.1233; Shalom-Barak T, 1998, J BIOL CHEM, V273, P27467, DOI 10.1074/jbc.273.42.27467; Shi YG, 2000, J BIOL CHEM, V275, P19167, DOI 10.1074/jbc.M910228199; Shin HCK, 1999, CYTOKINE, V11, P257, DOI 10.1006/cyto.1998.0433; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Subramaniam SV, 1999, BIOCHEM BIOPH RES CO, V262, P14, DOI 10.1006/bbrc.1999.1156; van Bezooijen RL, 2001, BONE, V28, P378, DOI 10.1016/S8756-3282(00)00457-9; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Weyand CM, 1997, J MOL MED-JMM, V75, P772, DOI 10.1007/s001090050167; Witowski J, 2000, J IMMUNOL, V165, P5814, DOI 10.4049/jimmunol.165.10.5814; Wu KK, 1996, J LAB CLIN MED, V128, P242, DOI 10.1016/S0022-2143(96)90023-2; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Yamamura Y, 2001, J IMMUNOL, V166, P2270, DOI 10.4049/jimmunol.166.4.2270; Yao ZB, 1997, CYTOKINE, V9, P794, DOI 10.1006/cyto.1997.0240; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; YOO ZB, 1995, J IMMUNOL, V155, P5483; Ziolkowska N, 2000, J IMMUNOL, V164, P2832, DOI 10.4049/jimmunol.164.5.2832	69	73	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26897	26907		10.1074/jbc.M212790200	http://dx.doi.org/10.1074/jbc.M212790200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12746433	hybrid			2022-12-25	WOS:000184155700078
J	Ozkurt, IC; Tetradis, S				Ozkurt, IC; Tetradis, S			Parathyroid hormone-induced E4BP4/NFIL3 down-regulates transcription in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; GENE-EXPRESSION; 1-34 INFUSION; BZIP FAMILY; E4BP4; BONE; CELLS; REPRESSOR; RECEPTOR; ACTIVATION	Parathyroid hormone (PTH), a major regulator of bone metabolism, activates the PTHR1 receptor on the osteoblast plasma membrane to initiate signaling and induce transcription of primary response genes. Subsequently, primary genes with transcriptional activity regulate expression of downstream PTH targets. We have identified the adenovirus E4 promoter-binding protein/nuclear factor regulated by IL-3 (E4bp4) as a PTH-induced primary gene in osteoblasts. E4BP4 is a basic leucine zipper ( bZIP) transcription factor that represses or activates transcription in non-osteoblastic cells. We report here that PTH rapidly and transiently induced E4bp4 mRNA in osteoblastic cells and that this induction did not require protein synthesis. PTH also induced E4BP4 protein synthesis and E4BP4 binding to a consensus but not to a mutant E4BP4 response element (EBPRE). E4BP4 overexpression inhibited an EBPRE-containing promoter-reporter construct, whereas PTH treatment attenuated activity of the same construct in primary mouse osteoblasts. Finally, E4BP4 overexpression inhibited PTH-induced activity of a cyclooxygenase-2 promoter-reporter construct. Our data suggest a role for E4BP4 in attenuation of PTH target gene transcription in osteoblasts.	Univ Calif Los Angeles, Sch Dent, Div Diagnost & Surg Sci, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Tetradis, S (corresponding author), Univ Calif Los Angeles, Sch Dent, Div Diagnost & Surg Sci, Rm 53-068 CHS, Los Angeles, CA 90095 USA.	sotirist@dent.ucla.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013316] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01-DE13316] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Castano E, 2000, P NATL ACAD SCI USA, V97, P7184, DOI 10.1073/pnas.140202297; Chen HL, 2002, J BIOL CHEM, V277, P19374, DOI 10.1074/jbc.M108913200; Chen WJ, 1995, BBA-GENE STRUCT EXPR, V1264, P388, DOI 10.1016/0167-4781(95)00182-4; Chu CC, 1998, MOL IMMUNOL, V35, P487, DOI 10.1016/S0161-5890(98)00031-5; CLOHISY JC, 1992, MOL ENDOCRINOL, V6, P1834, DOI 10.1210/me.6.11.1834; COWELL IG, 1994, NUCLEIC ACIDS RES, V22, P59, DOI 10.1093/nar/22.1.59; Cowell IG, 1996, NUCLEIC ACIDS RES, V24, P3607, DOI 10.1093/nar/24.18.3607; Cowell IG, 2002, BIOESSAYS, V24, P1023, DOI 10.1002/bies.10176; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; Doi M, 2001, P NATL ACAD SCI USA, V98, P8089, DOI 10.1073/pnas.141090998; FUJIMORI A, 1992, ENDOCRINOLOGY, V130, P29, DOI 10.1210/en.130.1.29; FUKAYAMA S, 1994, ENDOCRINOLOGY, V134, P1851, DOI 10.1210/en.134.4.1851; FUKUMOTO S, 1992, J CELL PHYSIOL, V152, P346, DOI 10.1002/jcp.1041520216; GRAY JG, 1993, MOL CELL BIOL, V13, P6678, DOI 10.1128/MCB.13.11.6678; HAAS NB, 1995, MOL CELL BIOL, V15, P1923; Hulme DJ, 2000, HUM GENET, V106, P594, DOI 10.1007/s004390050030; Ikushima S, 1997, P NATL ACAD SCI USA, V94, P2609, DOI 10.1073/pnas.94.6.2609; Ishida H, 2000, J VIROL, V74, P1241, DOI 10.1128/JVI.74.3.1241-1251.2000; JEROME CP, 1991, CALCIFIED TISSUE INT, V49, P398, DOI 10.1007/BF02555850; JEROME CP, 1992, BONE MINER, V19, P117, DOI 10.1016/0169-6009(92)90920-9; Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; Kim S, 1997, P NATL ACAD SCI USA, V94, P820, DOI 10.1073/pnas.94.3.820; KREAM BE, 1993, MOL ENDOCRINOL, V7, P399, DOI 10.1210/me.7.3.399; Kuribara R, 1999, MOL CELL BIOL, V19, P2754; Lai CK, 1999, J VIROL, V73, P3197, DOI 10.1128/JVI.73.4.3197-3209.1999; Mitsui S, 2001, GENE DEV, V15, P995, DOI 10.1101/gad.873501; Nishimura Y, 2001, J BIOL CHEM, V276, P19921, DOI 10.1074/jbc.M010332200; ONYIA JE, 1995, BONE, V17, P479, DOI 10.1016/8756-3282(95)00332-2; PARTRIDGE NC, 1994, J CELL BIOCHEM, V55, P321, DOI 10.1002/jcb.240550308; Qin L, 2003, J BIOL CHEM, V278, P19723, DOI 10.1074/jbc.M212226200; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rubin MR, 2002, OSTEOPOROSIS INT, V13, P267, DOI 10.1007/s001980200026; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; SCOTT DK, 1992, MOL ENDOCRINOL, V6, P2153, DOI 10.1210/me.6.12.2153; Strewler GJ, 2001, J CLIN INVEST, V107, P271, DOI 10.1172/JCI11777; Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378-1119(01)00798-3; Tetradis S, 1997, ENDOCRINOLOGY, V138, P3594, DOI 10.1210/en.138.9.3594; Tetradis S, 2001, BIOCHEM BIOPH RES CO, V281, P913, DOI 10.1006/bbrc.2001.4459; Tetradis S, 1998, J BONE MINER RES, V13, P1846, DOI 10.1359/jbmr.1998.13.12.1846; Tetradis S, 2001, ENDOCRINOLOGY, V142, P663, DOI 10.1210/en.142.2.663; Tomaras GD, 1999, J LEUKOCYTE BIOL, V66, P183, DOI 10.1002/jlb.66.1.183; Unoki M, 2001, ONCOGENE, V20, P4457, DOI 10.1038/sj.onc.1204608; Wallace AD, 1997, BIOCHEM BIOPH RES CO, V232, P403, DOI 10.1006/bbrc.1997.6206; Yu YL, 2002, J BIOL CHEM, V277, P27144, DOI 10.1074/jbc.M200924200; ZHANG W, 1995, MOL CELL BIOL, V15, P6055	47	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26803	26809		10.1074/jbc.M212652200	http://dx.doi.org/10.1074/jbc.M212652200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12743120	hybrid			2022-12-25	WOS:000184155700066
J	Andrau, D; Dumanchin-Njock, C; Ayral, E; Vizzavona, J; Farzan, M; Boisbrun, M; Fulcrand, P; Hernandez, JF; Martinez, J; Lefranc-Jullien, S; Checler, F				Andrau, D; Dumanchin-Njock, C; Ayral, E; Vizzavona, J; Farzan, M; Boisbrun, M; Fulcrand, P; Hernandez, JF; Martinez, J; Lefranc-Jullien, S; Checler, F			BACE1- and BACE2-expressing human cells - Characterization of beta-amyloid precursor protein-derived catabolites, design of a novel fluorimetric assay, and identification of new in vitro inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; GAMMA-SECRETASE; A-BETA; STEREOSPECIFIC SYNTHESIS; THYMOCYTE DEVELOPMENT; INTRACELLULAR DOMAIN; ALPHA-SECRETASE; CATHEPSIN-D; HUMAN BRAIN; CLEAVAGE	We have set up stably transfected HEK293 cells overexpressing the beta\-secretases BACE1 and BACE2 either alone or in combination with wild-type beta-amyloid precursor protein (betaAPP). The characterization of the betaAPP-derived catabolites indicates that cells expressing BACEs produce less genuine Abeta1 - 40/42 but higher amounts of secreted sAPPbeta and N-terminal-truncated Abeta species. This was accompanied by a concomitant modulation of the C-terminal counterpart products C89 and C79 for BACE1 and BACE2, respectively. These cells were used to set up a novel BACE assay based on two quenched fluorimetric substrates mimicking the wild-type (JMV2235) and Swedish-mutated (JMV2236) betaAPP sequences targeted by BACE activities. We show that BACEs activities are enhanced by the Swedish mutation and maximal at pH 4.5. The specificity of this double assay for genuine beta-secretase activity was demonstrated by means of cathepsin D, a "false positive" BACE candidate. Thus, cathepsin D was unable to cleave preferentially the JMV2236-mutated substrate. The selectivity of the assay was also emphasized by the lack of JMV cleavage triggered by other "secretases" candidates such as ADAM10 ( A disintegrin and metalloprotease 10), tumor necrosis alpha-converting enzyme, and presenilins 1 and 2. Finally, the assay was used to screen for putative in vitro BACE inhibitors. We identified a series of statine-derived sequences that dose-dependently inhibited BACE1 and BACE2 activities with IC50 in the micromolar range, some of which displaying selectivity for either BACE1 or BACE2.	Inst Pharmacol Mol & Cellulaire, CNRS, UMR 6097, F-06560 Valbonne, France; Lab Amino Acides Peptides & Prot, CNRS, UMR 5810, F-34093 Montpellier, France; Harvard Univ, Sch Med, Boston, MA 02115 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); Harvard University; Harvard Medical School	Checler, F (corresponding author), Inst Pharmacol Mol & Cellulaire, CNRS, UMR 6097, 660 Route Lucioles, F-06560 Valbonne, France.	checler@ipmc.cnrs.fr	Martinez, Jean/R-9421-2019; Checler, Frederic/C-1241-2009	Martinez, Jean/0000-0002-9267-4621; Checler, Frederic/0000-0003-2098-1750; Farzan, Michael/0000-0002-2990-5319				Acquati F, 2000, FEBS LETT, V468, P59, DOI 10.1016/S0014-5793(00)01192-3; Ancolio K, 1999, P NATL ACAD SCI USA, V96, P4119, DOI 10.1073/pnas.96.7.4119; Ancolio K, 1997, J NEUROCHEM, V69, P2494, DOI 10.1046/j.1471-4159.1997.69062494.x; BARANY G, 1987, INT J PEPT PROT RES, V30, P705; Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; BORCH RF, 1971, J AM CHEM SOC, V93, P2897, DOI 10.1021/ja00741a013; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Checler F, 1999, IUBMB LIFE, V48, P33, DOI 10.1080/152165499307396; CHECLER F, 1995, J NEUROCHEM, V65, P1431; Checler F, 2001, J NEUROCHEM, V76, P1621, DOI 10.1046/j.1471-4159.2001.00244.x; Chevallier N, 1997, BRIT J PHARMACOL, V121, P556, DOI 10.1038/sj.bjp.0701151; Chevallier N, 1997, BRAIN RES, V750, P11, DOI 10.1016/S0006-8993(96)01330-3; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Citron Martin, 2001, Expert Opin Ther Targets, V5, P341, DOI 10.1517/14728222.5.3.341; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; Doerfler P, 2001, P NATL ACAD SCI USA, V98, P9312, DOI 10.1073/pnas.161102498; Ehehalt R, 2002, BIOCHEM BIOPH RES CO, V293, P30, DOI 10.1016/S0006-291X(02)00169-9; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; FEHRENTZ JA, 1994, TETRAHEDRON LETT, V35, P1557, DOI 10.1016/S0040-4039(00)76757-8; FELSENSTEIN KM, 1994, NAT GENET, V6, P251, DOI 10.1038/ng0394-251; Fluhrer R, 2002, J NEUROCHEM, V81, P1011, DOI 10.1046/j.1471-4159.2002.00908.x; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Hadland BK, 2001, P NATL ACAD SCI USA, V98, P7487, DOI 10.1073/pnas.131202798; HARBESON SL, 1994, J MED CHEM, V37, P2918, DOI 10.1021/jm00044a013; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hirata IY, 1995, LETT PEPT SCI, V1, P299, DOI DOI 10.1007/BF00119771; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Huse JT, 2002, J BIOL CHEM, V277, P16278, DOI 10.1074/jbc.M111141200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; JOUIN P, 1987, J CHEM SOC PERK T 1, P1177, DOI 10.1039/p19870001177; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kim SH, 1996, J NEUROCHEM, V67, P1172; LADROR US, 1994, J BIOL CHEM, V269, P18422; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Liu KN, 2002, BIOCHEMISTRY-US, V41, P3128, DOI 10.1021/bi015800g; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Motonaga K, 2002, NEUROSCI LETT, V326, P64, DOI 10.1016/S0304-3940(02)00287-2; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; NISHIZAWA R, 1977, J MED CHEM, V20, P510, DOI 10.1021/jm00214a010; Octave JN, 1995, REV NEUROSCIENCE, V6, P287; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; Qian S, 1998, NEURON, V20, P611, DOI 10.1016/S0896-6273(00)80999-X; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Roggo Silvio, 2002, Current Topics in Medicinal Chemistry, V2, P359, DOI 10.2174/1568026024607490; SAUNDERS AJ, 1999, SCIENCE, V286, P1254; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Sisodia SS, 2001, TRENDS NEUROSCI, V24, pS2, DOI 10.1016/S0166-2236(00)01987-1; Skovronsky DM, 2000, TRENDS PHARMACOL SCI, V21, P161, DOI 10.1016/S0165-6147(00)01467-X; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; Tanahashi H, 2001, NEUROSCI LETT, V307, P9, DOI 10.1016/S0304-3940(01)01912-7; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; Van Broeckhoven C, 1995, NAT GENET, V11, P230; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vassar R, 2001, J MOL NEUROSCI, V17, P157, DOI 10.1385/JMN:17:2:157; Vincent B, 2001, J BIOL CHEM, V276, P37743; Wolfe MS, 2001, J NEUROCHEM, V76, P1615, DOI 10.1046/j.1471-4159.2001.00245.x; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia W, 2001, Curr Neurol Neurosci Rep, V1, P422, DOI 10.1007/s11910-001-0101-z; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3	71	64	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25859	25866		10.1074/jbc.M302622200	http://dx.doi.org/10.1074/jbc.M302622200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12736275	hybrid			2022-12-25	WOS:000183920200075
J	Bottone, FG; Martinez, JM; Collins, JB; Afshari, CA; Eling, TE				Bottone, FG; Martinez, JM; Collins, JB; Afshari, CA; Eling, TE			Gene modulation by the cyclooxygenase inhibitor, sulindac sulfide, in human colorectal carcinoma cells - Possible link to apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COLON-CANCER CELLS; FAMILIAL ADENOMATOUS POLYPOSIS; NSAID-ACTIVATED GENE; TARGET GENES; ADENOCARCINOMA CELLS; INDUCE APOPTOSIS; DNA-DAMAGE; EXPRESSION; GROWTH	The mechanisms underlying the anti-tumorigenic properties of cyclooxygenase inhibitors are not well understood. One novel hypothesis is alterations in gene expression. To test this hypothesis sulindac sulfide, which is used to treat familial adenomatous polyposis, was selected to detect gene modulation in human colorectal cells at physiological concentrations with microarray analysis. At micromolar concentrations, sulindac sulfide stimulated apoptosis and inhibited the growth of colorectal cancer cells on soft agar. Sulindac sulfide ( 10 muM) altered the expression of 65 genes in SW-480 colorectal cancer cells, which express cyclooxygenase-1 but little cyclooxygenase-2. A more detailed study of 11 genes revealed that their expression was altered in a time- and dose-dependent manner as measured by real-time RT-PCR. Northern analysis confirmed the expression of 9 of these genes, and Western analysis supported the conclusion that sulindac sulfide altered the expression of these proteins. Cyclooxygenase-deficient HCT-116 cells were more responsive to sulindac sulfide-induced gene expression than SW-480 cells. However, this response was diminished in HCT-116 cells overexpressing cyclooxygenase-1 compared with normal HCT-116 cells suggesting the presence of cyclooxygenase attenuates this response. However, prostaglandin E-2, the main product of cyclooxygenase, only suppressed the sulindac sulfide-induced expression of two genes, with little known biological function while it modulated the expression of two more. The most likely explanation for this finding is the metabolism of sulindac sulfide to inactive metabolites by the peroxidase activity of cyclooxygenase. In conclusion, this is the first report showing sulindac sulfide, independent of cyclooxygenase, altered the expression of several genes possibly linked to its anti-tumorigenic and pro-apoptotic activity.	NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Lab Computat Biol & Risk Anal, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Natl Ctr Toxicogenom, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Eling, TE (corresponding author), NIEHS, Mol Carcinogenesis Lab, NIH, POB 12233,Mail Drop E4-09,111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES023026, ZIAES050144, Z01ES050143, Z01ES050144, ZIAES023026, Z01ES023027, Z01ES010016, ZIAES010016] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akashi H, 2000, INT J CANCER, V88, P873, DOI 10.1002/1097-0215(20001215)88:6<873::AID-IJC6>3.0.CO;2-B; *AM SOC HLTH SYST, 2003, AHFS DRUG INF, P1997; Baek SJ, 2002, J PHARMACOL EXP THER, V301, P1126, DOI 10.1124/jpet.301.3.1126; Baek SJ, 2001, J BIOL CHEM, V276, P33384, DOI 10.1074/jbc.M101814200; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; Bauvy C, 2001, EXP CELL RES, V268, P139, DOI 10.1006/excr.2001.5285; Bonnesen C, 2001, CANCER RES, V61, P6120; Boolbol SK, 1996, CANCER RES, V56, P2556; Bottone FG, 2002, J NUTR, V132, P773, DOI 10.1093/jn/132.4.773; Bushdid PB, 2001, DEV BIOL, V237, P107, DOI 10.1006/dbio.2001.0356; Bushel PR, 2001, BIOINFORMATICS, V17, P564, DOI 10.1093/bioinformatics/17.6.564; Cai Y, 2000, BLOOD, V96, P2140, DOI 10.1182/blood.V96.6.2140.h8002140_2140_2148; Chinery R, 1998, CANCER RES, V58, P2323; Derisi Joseph L., 1999, Current Opinion in Oncology, V11, P76, DOI 10.1097/00001622-199901000-00015; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; EGAN RW, 1980, J BIOL CHEM, V255, P323; EGAN RW, 1979, J BIOL CHEM, V254, P3295; Fan FY, 2002, ONCOGENE, V21, P7488, DOI 10.1038/sj.onc.1205896; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Ganan Y, 1998, DEV BIOL, V196, P33, DOI 10.1006/dbio.1997.8843; Goldberg Y, 1996, ONCOGENE, V12, P893; Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje; Gwyn K, 2002, AM J GASTROENTEROL, V97, P13, DOI 10.1111/j.1572-0241.2002.05435.x; Hawcroft G, 2002, CARCINOGENESIS, V23, P107, DOI 10.1093/carcin/23.1.107; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; Hewitt RE, 2000, J PATHOL, V192, P446; Hinz B, 2002, J PHARMACOL EXP THER, V300, P367, DOI 10.1124/jpet.300.2.367; Huang Y, 2001, CANCER RES, V61, P6918; Iizaka M, 2002, BIOCHEM BIOPH RES CO, V292, P498, DOI 10.1006/bbrc.2002.6648; Janne PA, 2000, NEW ENGL J MED, V342, P1960, DOI 10.1056/NEJM200006293422606; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kim KS, 2002, GASTROENTEROLOGY, V122, P1388, DOI 10.1053/gast.2002.32972; LaTulippe E, 2002, CANCER RES, V62, P4499; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; Lim JTE, 1999, BIOCHEM PHARMACOL, V58, P1097, DOI 10.1016/S0006-2952(99)00200-2; Mashima T, 2001, J CELL PHYSIOL, V188, P352, DOI 10.1002/jcp.1130; Piazza GA, 1997, CANCER RES, V57, P2452; Picariello L, 1998, EUR J PHARMACOL, V360, P105, DOI 10.1016/S0014-2999(98)00665-7; Rajeevan MS, 2001, J MOL DIAGN, V3, P26, DOI 10.1016/S1525-1578(10)60646-0; Ravi R, 2002, CANCER RES, V62, P1583; Richter M, 2001, CARCINOGENESIS, V22, P17, DOI 10.1093/carcin/22.1.17; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Shirin H, 2001, CANCER RES, V61, P725; Sun YJ, 2002, CANCER RES, V62, P6323; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; Taketo MM, 1998, J NATL CANCER I, V90, P1529, DOI 10.1093/jnci/90.20.1529; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Vogt T, 2001, MELANOMA RES, V11, P587, DOI 10.1097/00008390-200112000-00005; Wick M, 2002, MOL PHARMACOL, V62, P1207, DOI 10.1124/mol.62.5.1207; Williams Christopher S., 1999, Neoplasia (New York), V1, P170, DOI 10.1038/sj.neo.7900024; WINDE G, 1993, INT J COLORECTAL DIS, V8, P13, DOI 10.1007/BF00341270; Yamazaki R, 2002, FEBS LETT, V531, P278, DOI 10.1016/S0014-5793(02)03535-4; Yuan CJ, 2000, CANCER RES, V60, P1084; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451; Zhang ZH, 2001, ONCOGENE, V20, P4450, DOI 10.1038/sj.onc.1204588; Zhu JX, 2002, JNCI-J NATL CANCER I, V94, P1745	58	58	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25790	25801		10.1074/jbc.M301002200	http://dx.doi.org/10.1074/jbc.M301002200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12734198	hybrid			2022-12-25	WOS:000183920200066
J	Fitch, MJ; Donato, JJ; Tye, BK				Fitch, MJ; Donato, JJ; Tye, BK			Mcm7, a subunit of the presumptive MCM helicase, modulates its own expression in conjunction with Mcm1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; DNA-REPLICATION; BUDDING YEAST; MINICHROMOSOME MAINTENANCE; TERNARY COMPLEX; T-ANTIGEN; MADS-BOX; DEPENDENT TRANSCRIPTION; AUTO-REGULATION	The Saccharomyces cerevisiae Mcm7 protein is a subunit of the presumed heteromeric MCM helicase that melts origin DNA and unwinds replication forks. Previous work showed that Mcm1 binds constitutively to the MCM7 promoter and regulates MCM7 expression. Here, we identify Mcm7 as a novel cofactor of Mcm1 in the regulation of MCM7 expression. Transcription of MCM7 is increased in the mcm7-1 mutant and decreased in the mcm1-1 mutant, suggesting that Mcm7 modulates its own expression in conjunction with Mcm1. Indeed, Mcm7 stimulates Mcm1 binding to the early cell cycle box upstream of the promoters of MCM7 as well as CDC6 and MCM5. Whereas Mcm1 binds these promoters constitutively, Mcm7 is recruited during late M phase, consistent with Mcm7 playing a direct role in modulating the periodic expression of early cell cycle genes. The multiple roles of Mcm7 in replication initiation, replication elongation, and autoregulation parallel those of the oncoprotein, the large T-antigen of the SV40 virus.	Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Cornell University	Tye, BK (corresponding author), Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA.	bt16@cornell.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034190, T32GM007273] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07273, GM34190] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; ALTHOEFER H, 1995, MOL CELL BIOL, V15, P5917; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BRADLEY MK, 1982, CELL, V28, P125, DOI 10.1016/0092-8674(82)90382-8; BRAUN RE, 1985, CELL, V40, P159, DOI 10.1016/0092-8674(85)90319-8; Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; Chang VK, 2003, J BIOL CHEM, V278, P6093, DOI 10.1074/jbc.M209827200; Cheng IH, 2002, J BIOL CHEM, V277, P41706, DOI 10.1074/jbc.M205793200; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; CHRIST C, 1991, GENE DEV, V5, P751, DOI 10.1101/gad.5.5.751; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; DaFonseca CJ, 2001, P NATL ACAD SCI USA, V98, P3034, DOI 10.1073/pnas.061487598; DALTON S, 1995, P NATL ACAD SCI USA, V92, P2514, DOI 10.1073/pnas.92.7.2514; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Haase SB, 1997, METHOD ENZYMOL, V283, P322; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; JARVIS EE, 1989, GENE DEV, V3, P936, DOI 10.1101/gad.3.7.936; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lei M, 1996, MOL CELL BIOL, V16, P5081; Lei M, 2001, J CELL SCI, V114, P1447; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; MAHER M, 1995, MOL CELL BIOL, V15, P3129; Mai B, 2002, MOL CELL BIOL, V22, P430, DOI 10.1128/MCB.22.2.430-441.2002; MAINE GT, 1984, GENETICS, V106, P365; Maru Y, 1996, J BIOL CHEM, V271, P15353, DOI 10.1074/jbc.271.26.15353; McInerny CJ, 1997, GENE DEV, V11, P1277, DOI 10.1101/gad.11.10.1277; MUELLER CGF, 1991, EMBO J, V10, P4219, DOI 10.1002/j.1460-2075.1991.tb05000.x; NASMYTH K, 1985, CELL, V42, P225, DOI 10.1016/S0092-8674(85)80118-5; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; NURRISH SJ, 1995, MOL CELL BIOL, V15, P4076; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; Pereverzeva I, 2000, MOL CELL BIOL, V20, P3667, DOI 10.1128/MCB.20.10.3667-3676.2000; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Platt A, 1998, EMBO J, V17, P4086, DOI 10.1093/emboj/17.14.4086; Pramila T, 2002, GENE DEV, V16, P3034, DOI 10.1101/gad.1034302; PRIMIG M, 1991, EMBO J, V10, P4209, DOI 10.1002/j.1460-2075.1991.tb04999.x; Raghuraman MK, 2001, SCIENCE, V294, P115, DOI 10.1126/science.294.5540.115; REED SI, 1976, P NATL ACAD SCI USA, V73, P3083, DOI 10.1073/pnas.73.9.3083; Riechmann JL, 1997, BIOL CHEM, V378, P1079; RIO DC, 1983, CELL, V32, P1227, DOI 10.1016/0092-8674(83)90305-7; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Simon I, 2001, CELL, V106, P697, DOI 10.1016/S0092-8674(01)00494-9; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Takei Y, 2001, EMBO REP, V2, P119, DOI 10.1093/embo-reports/kve026; Tan S, 1998, NATURE, V391, P660, DOI 10.1038/35563; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; TREISMAN R, 1995, NATURE, V376, P468, DOI 10.1038/376468a0; Tye BK, 2000, J BIOL CHEM, V275, P34833, DOI 10.1074/jbc.R000018200; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Wang Y, 2000, FEBS LETT, V484, P17, DOI 10.1016/S0014-5793(00)02117-7; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; Wyrick JJ, 2001, SCIENCE, V294, P2357, DOI 10.1126/science.1066101; Yankulov K, 1999, MOL CELL BIOL, V19, P6154; Young MR, 1997, MOL BIOL CELL, V8, P1587, DOI 10.1091/mbc.8.8.1587	66	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25408	25416		10.1074/jbc.M300699200	http://dx.doi.org/10.1074/jbc.M300699200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12738768	hybrid			2022-12-25	WOS:000183920200020
J	McRobert, EA; Gallicchio, M; Jerums, G; Cooper, ME; Bach, LA				McRobert, EA; Gallicchio, M; Jerums, G; Cooper, ME; Bach, LA			The amino-terminal domains of the ezrin, radixin, and moesin (ERM) proteins bind advanced glycation end products, an interaction that may play a role in the development of diabetic complications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; TYROSINE PHOSPHORYLATION; IN-VITRO; RECEPTOR; GLYCOSYLATION; FAMILY; CELLS; IDENTIFICATION; MORPHOGENESIS; INVOLVEMENT	The presence of advanced glycation end products (AGEs) formed because of hyperglycemia in diabetic patients has been strongly linked to the development of diabetic complications and disturbances in cellular function. In this report, we describe the isolation and identification of novel AGE-binding proteins from diabetic rat kidneys. The proteins were purified by cation exchange and AGE-modified bovine serum albumin (AGE-BSA) affinity chromatography. NH2-terminal and internal sequencing identified the proteins as the NH2-terminal domains of ezrin, radixin, and moesin (ERM proteins). Using BIAcore biosensor analysis, human N-ezrin-(1-324) bound to immobilized AGE-BSA with a K-D of 5.3 +/- 2.1 x 10(-7) M, whereas full-length ezrin-(1-586) and C-ezrin-(323 - 586) did not bind. Other glycated proteins such as AGE-RNase, N-epsilon-carboxymethyllysine (CML)- BSA, and glycated human serum albumin isolated from hyperglycemic diabetic sera competed with the immobilized AGE-BSA for binding to N-ezrin, but non-glycated BSA and RNase did not. Thus N-ezrin binds to AGEs in a glycation- and concentration-dependent manner. Phosphorylated ezrin plays a crucial role in cell shape changes, cell attachment, and cell adhesion. The effect of AGE-BSA on ezrin function was studied in a tubulogenesis model in which LLC-PK1 cell tubule formation is dependent on phosphorylated ezrin. Addition of AGE-BSA completely inhibited the ability of the cells to produce tubules. Furthermore, in vitro tyrosine phosphorylation of N-ezrin and ezrin was also inhibited by AGE-BSA. These proteins represent a novel family of intracellular binding molecules for glycated proteins and provide a potential new target for therapeutic intervention in the prevention or treatment of diabetic complications.	Univ Melbourne, Austin & Repatriat Med Ctr, Dept Med, Heidelberg, Vic 3084, Australia; Alfred Hosp, Baker Med Res Inst, Prahran, Vic 3181, Australia	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Baker Heart and Diabetes Institute; Florey Institute of Neuroscience & Mental Health	Bach, LA (corresponding author), Univ Melbourne, Austin & Repatriat Med Ctr, Dept Med, Studley Rd, Heidelberg, Vic 3084, Australia.	l.bach@unimelb.edu.au	Cooper, Mark E/E-8680-2010; Cooper, Mark/AAC-5326-2020	Cooper, Mark E/0000-0002-5953-642X; Bach, Leon/0000-0002-9062-1518				ARAKI N, 1995, EUR J BIOCHEM, V230, P408, DOI 10.1111/j.1432-1033.1995.0408h.x; BEISSWENGER PJ, 1995, DIABETES, V44, P824, DOI 10.2337/diabetes.44.7.824; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; BROWNLEE M, 1994, DIABETES, V43, P836, DOI 10.2337/diab.43.6.836; Cayot P, 1997, ANAL BIOCHEM, V249, P184, DOI 10.1006/abio.1997.2161; CHEN J, 1995, P NATL ACAD SCI USA, V92, P7495, DOI 10.1073/pnas.92.16.7495; Chen ZC, 2001, CANCER-AM CANCER SOC, V92, P3068, DOI 10.1002/1097-0142(20011215)92:12<3068::AID-CNCR10149>3.0.CO;2-5; Cortes P, 2000, KIDNEY INT, V58, P2452, DOI 10.1046/j.1523-1755.2000.00428.x; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Forbes JM, 2001, DIABETOLOGIA, V44, P108, DOI 10.1007/s001250051587; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; GIARDINO I, 1994, J CLIN INVEST, V94, P110, DOI 10.1172/JCI117296; Granes F, 2000, J CELL SCI, V113, P1267; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Ishikawa H, 2001, J MOL BIOL, V310, P973, DOI 10.1006/jmbi.2001.4818; Jandeleit-Dahm K, 2000, CIRC RES, V87, P1133, DOI 10.1161/01.RES.87.12.1133; KIHARA M, 1991, P NATL ACAD SCI USA, V88, P6107, DOI 10.1073/pnas.88.14.6107; KIM EK, 1992, AM J OPHTHALMOL, V114, P329, DOI 10.1016/S0002-9394(14)71800-8; KRIEG J, 1992, J BIOL CHEM, V267, P19258; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; Massry SG, 1997, MINER ELECTROL METAB, V23, P253; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Mifsud SA, 2001, DIABETOLOGIA, V44, P878; Minkoff C, 1999, CURR OPIN NEPHROL HY, V8, P603, DOI 10.1097/00041552-199909000-00012; Nakamura F, 1999, MOL BIOL CELL, V10, P2669, DOI 10.1091/mbc.10.8.2669; NEEPER M, 1992, J BIOL CHEM, V267, P14998; Neumann GM, 1999, J BIOL CHEM, V274, P14587, DOI 10.1074/jbc.274.21.14587; Oldfield MD, 2001, J CLIN INVEST, V108, P1853; Orlando RA, 2001, J AM SOC NEPHROL, V12, P1589, DOI 10.1681/ASN.V1281589; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; Roy C, 1997, J BIOL CHEM, V272, P20088, DOI 10.1074/jbc.272.32.20088; Sakurai H, 1997, AM J PHYSIOL-RENAL, V272, pF139, DOI 10.1152/ajprenal.1997.272.1.F139; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; Shcherbina A, 1999, FEBS LETT, V443, P31, DOI 10.1016/S0014-5793(98)01674-3; SHUSTER CB, 1995, J CELL BIOL, V128, P837, DOI 10.1083/jcb.128.5.837; Somlo S, 2000, NAT GENET, V24, P333, DOI 10.1038/74139; Symonian M, 1998, KIDNEY INT, V54, P1206, DOI 10.1046/j.1523-1755.1998.00109.x; Takeda T, 2001, J CLIN INVEST, V108, P289, DOI 10.1172/JCI12539; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; Thornalley PJ, 1998, CELL MOL BIOL, V44, P1013; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Ulrich P, 2001, RECENT PROG HORM RES, V56, P1, DOI 10.1210/rp.56.1.1; VLASSARA H, 1994, P NATL ACAD SCI USA, V91, P11704, DOI 10.1073/pnas.91.24.11704; VLASSARA H, 1995, MOL MED, V1, P634, DOI 10.1007/BF03401604; Wade JB, 2001, AM J PHYSIOL-CELL PH, V280, pC192, DOI 10.1152/ajpcell.2001.280.1.C192; YANG Z, 1991, J EXP MED, V174, P515, DOI 10.1084/jem.174.3.515; YAO XB, 1993, AM J PHYSIOL, V265, pC36, DOI 10.1152/ajpcell.1993.265.1.C36; Youssef S, 1999, KIDNEY INT, V55, P907, DOI 10.1046/j.1523-1755.1999.055003907.x; ZHOU XP, 1995, LAB INVEST, V73, P372	56	49	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25783	25789		10.1074/jbc.M210433200	http://dx.doi.org/10.1074/jbc.M210433200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12734202	hybrid			2022-12-25	WOS:000183920200065
J	Nadesalingam, J; Bernal, AL; Dodds, AW; Willis, AC; Mahoney, DJ; Day, AJ; Reid, KBM; Palaniyar, N				Nadesalingam, J; Bernal, AL; Dodds, AW; Willis, AC; Mahoney, DJ; Day, AJ; Reid, KBM; Palaniyar, N			Identification and characterization of a novel interaction between pulmonary surfactant protein D and decorin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCAN; HOMEOSTASIS IN-VIVO; GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; BRONCHOALVEOLAR LAVAGE; ASPERGILLUS-FUMIGATUS; EXTRACELLULAR-MATRIX; BINDING-PROTEIN; AMNIOTIC-FLUID; HUMAN TISSUES	Surfactant-associated protein D (SP-D) is a collectin that is present in lung surfactant and mucosal surfaces. Although SP-D regulates diverse functions, only a few proteins are known to bind to this collectin. Here we describe the co-purification of decorin, a novel SP-D-binding protein, from amniotic fluid. The human decorin that co-purified with SP-D is a 130-150-kDa proteoglycan, which has a 46-kDa protein core and similar to90-kDa dermatan sulfate chain. Both native and recombinant decorin can bind to SP-D that is already bound to maltose-agarose matrix, and these SP-D-decorin complexes are dissociated at high salt (0.5-1.0 M NaCl) conditions, releasing the decorin. We further show that SP-D and decorin interact with each other (k(d) = 4 nM) by two mechanisms. First, the direct binding and competition experiments show that the carbohydrate recognition domain (CRD) of SP-D binds in a calcium dependent-manner to the sulfated N-acetyl galactosamine moiety of the glycosaminoglycan chain. Second, complement component C1q, a complement protein that is known to interact with decorin core protein via its collagen-like region, partially blocks the interaction between decorin and native SP-D. This protein, however, does not block the interaction between decorin and SP-D(n/CRD), a recombinant fragment that lacks the N-terminal and collagen-like regions. Furthermore, the core protein, obtained by chondroitin ABC lyase treatment of decorin, binds SP-D, but not SP-D(n/CRD). These findings suggest that decorin core protein binds the collagen-like region of the SP-D. Concentrations of decorin and SP-D are negatively correlated to each other, in amniotic fluid, implying a functional relevance for SP-D-decorin interaction, in vivo. Collectively, our results show that carbohydrate recognition domains of SP-D interact with the dermatan sulfate moiety of decorin via lectin activity and that the core protein of decorin binds the collagen-like region of SP-D in vitro, and these interactions may be operative in vivo.	Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England	University of Oxford; University of Oxford	Palaniyar, N (corresponding author), Univ Oxford, Dept Biochem, MRC, Immunochem Unit, S Parks Rd, Oxford OX1 3QU, England.		Day, Anthony/O-1658-2015	Day, Anthony/0000-0002-1415-3134; Palaniyar, Nades/0000-0002-2170-8548; Dodds, Alister William/0000-0003-3396-1257				Allen MJ, 2001, INFECT IMMUN, V69, P2037, DOI 10.1128/IAI.69.4.2037-2044.2001; Asakura S, 1996, AM J RESP CRIT CARE, V154, P1525, DOI 10.1164/ajrccm.154.5.8912775; Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; Chiba H, 2002, J BIOL CHEM, V277, P20379, DOI 10.1074/jbc.M201089200; Clark H, 2002, J IMMUNOL, V169, P2892, DOI 10.4049/jimmunol.169.6.2892; CROUCH E, 1994, J BIOL CHEM, V269, P17311; CROUCH E, 1991, AM J RESP CELL MOL, V5, P13, DOI 10.1165/ajrcmb/5.1.13; Crouch E, 2000, IMMUNOL REV, V173, P52, DOI 10.1034/j.1600-065X.2000.917311.x; Delorme MA, 1998, THROMB RES, V90, P147, DOI 10.1016/S0049-3848(98)00035-8; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; HASSELL JR, 1986, ANNU REV BIOCHEM, V55, P539, DOI 10.1146/annurev.bi.55.070186.002543; Hocking AM, 1996, J BIOL CHEM, V271, P19571, DOI 10.1074/jbc.271.32.19571; Holmskov U, 1997, J BIOL CHEM, V272, P13743, DOI 10.1074/jbc.272.21.13743; HONDA Y, 1995, AM J RESP CRIT CARE, V152, P1860, DOI 10.1164/ajrccm.152.6.8520747; Imai K, 1997, BIOCHEM J, V322, P809, DOI 10.1042/bj3220809; KHALIL N, 1991, AM J RESP CELL MOL, V5, P155, DOI 10.1165/ajrcmb/5.2.155; Kolb M, 2001, AM J PHYSIOL-LUNG C, V280, pL1327, DOI 10.1152/ajplung.2001.280.6.L1327; Kolb M, 2001, AM J RESP CRIT CARE, V163, P770, DOI 10.1164/ajrccm.163.3.2006084; Korfhagen TR, 1998, J BIOL CHEM, V273, P28438, DOI 10.1074/jbc.273.43.28438; Koslowski R, 2001, EUR RESPIR J, V18, P347, DOI 10.1183/09031936.01.00085601; KRUMDIECK R, 1992, J IMMUNOL, V149, P3695; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; Lausen M, 1999, J BIOL CHEM, V274, P32234, DOI 10.1074/jbc.274.45.32234; Lu J, 1993, Behring Inst Mitt, P6; LU JH, 1992, BIOCHEM J, V284, P795, DOI 10.1042/bj2840795; Madan T, 2001, J CLIN INVEST, V107, P467, DOI 10.1172/JCI10124; Madsen J, 2000, J IMMUNOL, V164, P5866, DOI 10.4049/jimmunol.164.11.5866; Mahoney DJ, 2001, J BIOL CHEM, V276, P22764, DOI 10.1074/jbc.M100666200; MANISCALCO WM, 1994, AM J PHYSIOL, V266, pL672, DOI 10.1152/ajplung.1994.266.6.L672; Mason RJ, 1998, EUR RESPIR J, V12, P1147, DOI 10.1183/09031936.98.12051147; Matsushima N, 2000, PROTEINS, V38, P210, DOI 10.1002/(SICI)1097-0134(20000201)38:2<210::AID-PROT9>3.0.CO;2-1; MIYAMURA K, 1994, BBA-LIPID LIPID MET, V1210, P303, DOI 10.1016/0005-2760(94)90233-X; OGASAWARA Y, 1992, J BIOL CHEM, V267, P21244; OOSTING RS, 1994, AM J PHYSIOL, V267, pL165, DOI 10.1152/ajplung.1994.267.2.L165; Palaniyar N, 2002, IMMUNOBIOLOGY, V205, P575, DOI 10.1078/0171-2985-00156; Palaniyar N, 2002, J BIOL CHEM, V277, P26971, DOI 10.1074/jbc.M110080200; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PERSSON A, 1990, J BIOL CHEM, V265, P5755; PULKKINEN L, 1992, CYTOGENET CELL GENET, V60, P107, DOI 10.1159/000133314; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; REID KB, 1982, METHOD ENZYMOL, V82, P16; Sano H, 2000, J BIOL CHEM, V275, P22442, DOI 10.1074/jbc.M001107200; SAWHNEY RS, 1991, J BIOL CHEM, V266, P9231; SCHLUMBERGER W, 1989, EUR J CELL BIOL, V50, P100; Schonherr E, 1998, ARCH BIOCHEM BIOPHYS, V355, P241, DOI 10.1006/abbi.1998.0720; Schonherr E, 2001, J CELL PHYSIOL, V187, P37, DOI 10.1002/1097-4652(2001)9999:9999<::AID-JCP1048>3.0.CO;2-W; Seidler DG, 2002, J BIOL CHEM, V277, P42409, DOI 10.1074/jbc.M208442200; Strong P, 1998, J IMMUNOL METHODS, V220, P139, DOI 10.1016/S0022-1759(98)00160-4; Tenni R, 2002, EUR J BIOCHEM, V269, P1428, DOI 10.1046/j.1432-1033.2002.02784.x; Trask BC, 2001, J BIOL CHEM, V276, P37846; van de Wetering JK, 2001, J INFECT DIS, V184, P1143, DOI 10.1086/323746; Vuk-Pavlovic Z, 2001, AM J RESP CELL MOL, V24, P475, DOI 10.1165/ajrcmb.24.4.3504; Wang YQ, 2002, AM J PHYSIOL-LUNG C, V282, pL484, DOI 10.1152/ajplung.00160.2001; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997; WESTERGRENTHORSSON G, 1993, J CLIN INVEST, V92, P632, DOI 10.1172/JCI116631; Xaus J, 2001, BLOOD, V98, P2124, DOI 10.1182/blood.V98.7.2124; Yoshida M, 2001, J IMMUNOL, V166, P7514, DOI 10.4049/jimmunol.166.12.7514; Zhang LQ, 2001, J BIOL CHEM, V276, P19214, DOI 10.1074/jbc.M010191200; Zhao JS, 1999, AM J PHYSIOL-LUNG C, V277, pL412, DOI 10.1152/ajplung.1999.277.2.L412	61	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25678	25687		10.1074/jbc.M210186200	http://dx.doi.org/10.1074/jbc.M210186200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730206	hybrid			2022-12-25	WOS:000183920200052
J	Davis, J; Wagner, MR; Zhang, WB; Xu, F; Van Nostrand, WE				Davis, J; Wagner, MR; Zhang, WB; Xu, F; Van Nostrand, WE			Amyloid beta-protein stimulates the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYOCARDIAL-INFARCTION; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; MATRIX METALLOPROTEINASES; PATHOLOGICAL PROPERTIES; CEREBRAL-HEMORRHAGE; SECRETASE ACTIVITY; PEPTIDE ANALOGS; IV COLLAGENASE; HUMAN BRAIN	The accumulation of fibrillar amyloid-beta protein (Abeta) in cerebral blood vessels, a condition known as cerebral amyloid angiopathy (CAA), is a key pathological feature of Alzheimer's disease and certain related disorders and is intimately associated with cerebrovascular cell death both in vivo and in vitro. Moreover, severe CAA leads to loss of vessel wall integrity and cerebral hemorrhage. Although the basis for these latter pathological consequences in CAA remains unresolved alterations in local proteolytic mechanisms may be involved. Here we show that pathogenic forms of Abeta stimulate the expression of plasminogen activator activity in cultured human cerebrovascular smooth muscle (HCSM) cells, an in vitro model of CAA. RNase protection assays and plasminogen zymography showed that urokinase-type plasminogen activator (uPA) was responsible for this activity. There was preferential accumulation of uPA on the HCSM cell surface that was mediated through a concomitant increase in expression of the uPA receptor. In the presence of plasminogen there was robust degradation of Abeta that was added to the HCSM cells resulting in restoration of cell viability. This suggests that increased expression of uPA may initially serve as a protective mechanism leading to localized degradation and clearance of the pathogenic stimulus Abeta. On the other hand, chronic expression of uPA and plasminogen activation led to a profound loss of HCSM cell attachment. This suggests that a similar prolonged effect in vivo in the cerebral vessel wall may contribute to loss of integrity and cerebral hemorrhage in CAA.	SUNY Stony Brook, Hlth Sci Ctr, Dept Med, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Van Nostrand, WE (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Med, T-15-081, Stony Brook, NY 11794 USA.				NHLBI NIH HHS [HL49566] Funding Source: Medline; NINDS NIH HHS [NS35781] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035781] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Asahina M, 2001, CLIN NEUROPATHOL, V20, P60; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BURDICK D, 1992, J BIOL CHEM, V267, P546; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; CORIA F, 1989, J NEUROPATH EXP NEUR, V48, P368, DOI 10.1097/00005072-198905000-00207; Davis J, 1999, AMYLOID, V6, P157, DOI 10.3109/13506129909007321; Davis J, 1996, P NATL ACAD SCI USA, V93, P2996, DOI 10.1073/pnas.93.7.2996; DAVISSALINAS J, 1995, J NEUROCHEM, V65, P931; DAVISSALINAS J, 1995, J BIOL CHEM, V270, P20887, DOI 10.1074/jbc.270.36.20887; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; Gurwitz JH, 1998, ANN INTERN MED, V129, P597, DOI 10.7326/0003-4819-129-8-199810150-00002; Heymans S, 1999, NAT MED, V5, P1135, DOI 10.1038/13459; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; ITOH Y, 1993, J NEUROL SCI, V116, P135, DOI 10.1016/0022-510X(93)90317-R; JUNG SS, 2003, IN PRESS J N EUROCHE; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KAWAI M, 1993, BRAIN RES, V623, P142, DOI 10.1016/0006-8993(93)90021-E; KESKIOJA J, 1992, EXP CELL RES, V202, P471, DOI 10.1016/0014-4827(92)90101-D; KINGSTON IB, 1995, NAT MED, V1, P138; Ledesma MD, 2000, EMBO REP, V1, P530; Li DWC, 2001, EXP CELL RES, V266, P279, DOI 10.1006/excr.2001.5223; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Melchor JP, 2000, J NEUROCHEM, V74, P2209, DOI 10.1046/j.1471-4159.2000.0742209.x; Mok SS, 2002, EUR J BIOCHEM, V269, P3014, DOI 10.1046/j.1432-1033.2002.02976.x; Nuydens R, 1998, J NEUROCHEM, V70, P1124; OKADA Y, 1992, J BIOL CHEM, V267, P21712; Peng T, 1999, J NEUROSCI RES, V57, P680; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; Sakalihasan N, 1996, J VASC SURG, V24, P127, DOI 10.1016/S0741-5214(96)70153-2; SCHNEIDERMAN J, 1995, J CLIN INVEST, V96, P639, DOI 10.1172/JCI118079; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; SLOAN MA, 1995, NEUROLOGY, V45, P649, DOI 10.1212/WNL.45.4.649; STERN RA, 1990, FEBS LETT, V264, P43; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; Tohgi H, 1999, ACTA NEUROPATHOL, V98, P111, DOI 10.1007/s004010051058; Tsirka SE, 1997, J NEUROSCI, V17, P543; Tucker HM, 2000, J NEUROCHEM, V75, P2172, DOI 10.1046/j.1471-4159.2000.0752172.x; Tucker HM, 2002, J NEUROSCI RES, V70, P249, DOI 10.1002/jnr.10417; Tucker HM, 2000, J NEUROSCI, V20, P3937; Van Nostrand WE, 1999, BIOCHEMISTRY-US, V38, P11570, DOI 10.1021/bi990610f; Van Nostrand WE, 2001, J BIOL CHEM, V276, P32860, DOI 10.1074/jbc.M104135200; VanNostrand WE, 1996, ANN NY ACAD SCI, V777, P297; VANNOSTRAND WE, 1994, AMYLOID, V1, P1, DOI 10.3109/13506129409148618; VANNOSTRAND WE, 1997, J NEUROCHEM, V69, P216; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walker DG, 2002, BRAIN RES, V926, P69, DOI 10.1016/S0006-8993(01)03298-X; WANG R, 1991, J BIOL CHEM, V266, P16960; WATTENDORFF AR, 1995, J NEUROL NEUROSUR PS, V59, P699; Weller RO, 2002, ANN NY ACAD SCI, V977, P162, DOI 10.1111/j.1749-6632.2002.tb04812.x; Weller RO, 1998, AM J PATHOL, V153, P725, DOI 10.1016/S0002-9440(10)65616-7; Winkler DT, 2002, ANN NEUROL, V51, P790, DOI 10.1002/ana.10210; WISNIEWSKI HM, 1994, AMYLOID, V1, P8, DOI 10.3109/13506129409148619; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yamada M, 2000, NEUROPATHOLOGY, V20, P8, DOI 10.1046/j.1440-1789.2000.00268.x; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107	61	50	51	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19054	19061		10.1074/jbc.M301398200	http://dx.doi.org/10.1074/jbc.M301398200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12754271	hybrid			2022-12-25	WOS:000182932200045
J	Brady, AE; Wang, Q; Colbran, RJ; Allen, PB; Greengard, P; Limbird, LE				Brady, AE; Wang, Q; Colbran, RJ; Allen, PB; Greengard, P; Limbird, LE			Spinophilin stabilizes cell surface expression of alpha(2B)-adrenergic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3RD INTRACELLULAR LOOP; FILAMENT-BINDING PROTEIN; CANINE KIDNEY-CELLS; ALPHA(2)-ADRENERGIC RECEPTORS; ADRENERGIC-RECEPTORS; ALPHA(2A)-ADRENERGIC RECEPTOR; BASOLATERAL MEMBRANE; NEURABIN; LOCALIZATION; MODULATION	The third intracellular (3i) loops of the alpha(2A)- and alpha(2B)-adrenergic receptor (AR) subtypes are critical for retention of these receptors at the basolateral surface of polarized Madin-Darby canine kidney (MDCKII) cells at steady state. The third intracellular loops of the alpha(2A), alpha(2B), and alpha(2C)-AR subtypes interact with spinophilin, a multidomain protein that, like the three alpha(2)-AR subtypes, is enriched at the basolateral surface of MDCKII cells. The present studies provide evidence that alpha(2)-AR interaction with spinophilin contributes to cell surface stabilization of the receptor. We exploited the unique targeting profile of the alpha(2B)-AR subtype in MDCKII cells: random delivery to apical and basolateral surfaces with rapid (t(1/2)less than or equal to60 min) apical versus slower (t(1/2)=10-12 h) basolateral turnover. Apical delivery of a spinophilin subdomain containing the alpha(2)-AR-interacting region (Sp151-483) by fusion with apically targeted p75(NTR) extended the half-life of alpha(2B)-AR at the apical surface to similar to3.6 h and eliminated the rapid phase (0-60 min) of alpha(2B)-AR turnover on that surface. Furthermore, we examined alpha(2B)-AR turnover at the surface of mouse embryo fibroblasts derived from wild type (Sp(+/+)) or spinophilin knock-out (Sp(-/-)) mice. Two independent experimental approaches demonstrated that agonist-evoked internalization of HA-alpha(2B)-AR was accelerated in mouse embryo fibroblasts derived from Sp(-/-) mice. These findings are consistent with the interpretation that endogenous spinophilin contributes to the stabilization of alpha(2B)-AR and presumably all three alpha(2)-AR subtypes at the surface of target cells and may act as a scaffold that could link alpha(2)-ARs to proteins interacting with spinophilin via other domains.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Ctr Mol Neurosci, Nashville, TN 37232 USA; Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06508 USA; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA	Vanderbilt University; Vanderbilt University; Yale University; Rockefeller University	Limbird, LE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, 464 Robinson Res Bldg, Nashville, TN 37232 USA.	lee.limbird@vanderbilt.edu	Colbran, Roger/AAU-7708-2021	Colbran, Roger/0000-0001-7401-8244; Wang, Qin/0000-0002-1079-5914	NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404, P60DK020593, R01DK043879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA010044] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485] Funding Source: Medline; NCRR NIH HHS [1S10RR15682-1] Funding Source: Medline; NIDA NIH HHS [DA10044] Funding Source: Medline; NIDDK NIH HHS [DK43879, DK58404, DK20593] Funding Source: Medline; NIGMS NIH HHS [GM07628-20, GM07628-21, GM07628-19] Funding Source: Medline; NIMH NIH HHS [MH40899] Funding Source: Medline; NINDS NIH HHS [NS37508] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; CLARK JD, 1990, AM J PHYSIOL, V259, pF977, DOI 10.1152/ajprenal.1990.259.6.F977; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Edwards SW, 1999, J BIOL CHEM, V274, P16331, DOI 10.1074/jbc.274.23.16331; Feng J, 2000, P NATL ACAD SCI USA, V97, P9287, DOI 10.1073/pnas.97.16.9287; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; KEEFER JR, 1994, J BIOL CHEM, V269, P16425; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KUROSE H, 1994, J BIOL CHEM, V269, P10093; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; Li M, 2000, MOL PHARMACOL, V57, P446, DOI 10.1124/mol.57.3.446; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; Lin RW, 2001, P NATL ACAD SCI USA, V98, P5258, DOI 10.1073/pnas.011538198; MacMillan LB, 1999, J BIOL CHEM, V274, P35845, DOI 10.1074/jbc.274.50.35845; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Prezeau L, 1999, J BIOL CHEM, V274, P13462, DOI 10.1074/jbc.274.19.13462; Richman JG, 1998, AM J PHYSIOL-CELL PH, V274, pC654, DOI 10.1152/ajpcell.1998.274.3.C654; Richman JG, 2001, J BIOL CHEM, V276, P15003, DOI 10.1074/jbc.M011679200; ROSS EM, 1988, COLD SPRING HARB SYM, V53, P499, DOI 10.1101/SQB.1988.053.01.057; RUFFOLO RR, 1994, PHARMACOL THERAPEUT, V61, P1, DOI 10.1016/0163-7258(94)90058-2; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Saunders C, 1996, J BIOL CHEM, V271, P995, DOI 10.1074/jbc.271.2.995; Saunders C, 1998, J BIOL CHEM, V273, P24196, DOI 10.1074/jbc.273.37.24196; Saunders C, 2000, MOL PHARMACOL, V57, P44; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; Smith FD, 1999, J BIOL CHEM, V274, P19894, DOI 10.1074/jbc.274.28.19894; SUMMERS RJ, 1984, FED PROC, V43, P2917; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; Wang Q, 2002, J BIOL CHEM, V277, P50589, DOI 10.1074/jbc.M208503200; WILSON AL, 1991, MOL PHARMACOL, V39, P481; Wilson MH, 2000, BIOCHEMISTRY-US, V39, P693, DOI 10.1021/bi9920275; Wozniak M, 1996, J BIOL CHEM, V271, P5017	34	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32405	32412		10.1074/jbc.M304195200	http://dx.doi.org/10.1074/jbc.M304195200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12738775	hybrid			2022-12-25	WOS:000184782100120
J	Bourguignon, LYW; Singleton, PA; Zhu, HB; Diedrich, F				Bourguignon, LYW; Singleton, PA; Zhu, HB; Diedrich, F			Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (Macrophage-Colony stimulating factor) production and breast tumor progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANKYRIN-BINDING DOMAIN; DOCKING PROTEIN GAB1; CELL-MIGRATION; GROWTH-FACTOR; PHOSPHOINOSITIDE 3-KINASE; M-CSF; OSTEOCLAST DIFFERENTIATION; OSTEOPROTEGERIN-LIGAND; SURVIVAL PATHWAY; FOCAL ADHESIONS	In this study we have examined CD44 ( a hyaluronan ( HA) receptor) interaction with a RhoA-specific guanine nucleotide exchange factor ( p115RhoGEF) in human metastatic breast tumor cells (MDA-MB-231 cell line). Immunoprecipitation and immunoblot analyses indicate that both CD44 and p115RhoGEF are expressed in MDA-MB-231 cells and that these two proteins are physically associated as a complex in vivo. The binding of HA to MDA-MB-231 cells stimulates p115RhoGEF-mediated RhoA signaling and Rho kinase (ROK) activity, which, in turn, increases serine/threonine phosphorylation of the adaptor protein, Gab-1 (Grb2-associated binder-1). Phosphorylated Gab-1 promotes PI 3-kinase recruitment to CD44v3. Subsequently, PI 3-kinase is activated (in particular, alpha, beta, gamma forms but not the delta form of the p110 catalytic subunit), AKT signaling occurs, the cytokine (macrophage-colony stimulating factor (M-CSF)) is produced, and tumor cell-specific phenotypes ( e. g. tumor cell growth, survival and invasion) are up-regulated. Our results also demonstrate that HA/CD44-mediated oncogenic events ( e. g. AKT activation, M-CSF production and breast tumor cell-specific phenotypes) can be effectively blocked by a PI 3-kinase inhibitor (LY294002). Finally, we have found that overexpression of a dominant-negative form of ROK ( by transfection of MBA-MD-231 cells with the Rho-binding domain cDNA of ROK) not only inhibits HA/CD44-mediated RhoA-ROK activation and Gab-1 phosphorylation but also downregulates oncogenic signaling events ( e. g. Gab-1.PI 3-kinase-CD44v3 association, PI 3-kinase-mediated AKT activation, and M-CSF production) and tumor cell behaviors ( e. g. cell growth, survival, and invasion). Taken together, these findings strongly suggest that CD44 interaction with p115RhoGEF and ROK plays a pivotal role in promoting Gab-1 phosphorylation leading to Gab-1 . PI 3-kinase membrane localization, AKT signaling, and cytokine (M-CSF) production during HA-mediated breast cancer progression.	Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, Endocrine Unit 111N, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Bourguignon, LYW (corresponding author), Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, 4150 Clement St, San Francisco, CA 94121 USA.							Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Amano T, 2001, BIOCHEM J, V354, P149, DOI 10.1042/0264-6021:3540149; Bates RC, 2001, CANCER RES, V61, P5275; Begum N, 2002, J BIOL CHEM, V277, P6214, DOI 10.1074/jbc.M110508200; Bourguignon LYW, 2000, J CELL BIOL, V150, P177, DOI 10.1083/jcb.150.1.177; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bourguignon LYW, 2002, J BIOL CHEM, V277, P39703, DOI 10.1074/jbc.M204320200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; Bourguignon LYW, 1996, CURR TOP MEMBR, V43, P293; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Bourguignon LYW, 2001, J MAMMARY GLAND BIOL, V6, P287, DOI 10.1023/A:1011371523994; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; BOURGUIGNON LYW, 1998, FRONT BIOSCI, V3, P637; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; DALL P, 1995, INT J CANCER, V60, P471, DOI 10.1002/ijc.2910600408; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fixe P, 1998, CYTOKINE, V10, P32, DOI 10.1006/cyto.1997.0249; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fukata Y, 1999, J CELL BIOL, V145, P347, DOI 10.1083/jcb.145.2.347; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Ghatak S, 2002, J BIOL CHEM, V277, P38013, DOI 10.1074/jbc.M202404200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hemmings BA, 1997, SCIENCE, V275, P1899, DOI 10.1126/science.275.5308.1899; HIRAO M, 1996, J CELL BIOL, V135, P36; HOGADOMADRUGA M, 1996, NATURE, V8, P560; IIDA N, 1995, J CELL PHYSIOL, V162, P127, DOI 10.1002/jcp.1041620115; KACINSKI BM, 1995, ANN MED, V27, P79, DOI 10.3109/07853899509031941; KALISH ED, 1999, FRONT BIOSCI, V4, P1; Kamikura DM, 2000, MOL CELL BIOL, V20, P3482, DOI 10.1128/MCB.20.10.3482-3496.2000; Kaneko T, 2000, BIOCHEM BIOPH RES CO, V273, P110, DOI 10.1006/bbrc.2000.2901; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; KAUFMANN M, 1995, LANCET, V345, P615, DOI 10.1016/S0140-6736(95)90521-9; Kawano Y, 2000, J BIOL CHEM, V275, P29628, DOI 10.1074/jbc.M002440200; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Krugmann S, 1999, J BIOL CHEM, V274, P17152, DOI 10.1074/jbc.274.24.17152; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Leung T, 1996, MOL CELL BIOL, V16, P5313; LIAO HX, 1995, J IMMUNOL, V155, P3938; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; LOKESHWAR VB, 1991, J BIOL CHEM, V266, P17983; Lokeshwar VB, 1996, J BIOL CHEM, V271, P23853, DOI 10.1074/jbc.271.39.23853; Lories RJU, 2001, CLIN RHEUMATOL, V20, P3, DOI 10.1007/s100670170095; Mancino AT, 2001, J SURG RES, V100, P18, DOI 10.1006/jsre.2001.6204; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rohrschneider LR, 1997, MOL REPROD DEV, V46, P96; Roymans D, 2001, EUR J BIOCHEM, V268, P487, DOI 10.1046/j.1432-1327.2001.01936.x; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Sawyer C, 2003, CANCER RES, V63, P1667; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Shinohara M, 2001, J BIOL CHEM, V276, P18941, DOI 10.1074/jbc.M100909200; Singleton PA, 2002, CELL MOTIL CYTOSKEL, V53, P293, DOI 10.1002/cm.10078; Sohara Y, 2001, MOL BIOL CELL, V12, P1859, DOI 10.1091/mbc.12.6.1859; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Sy Man-Sun, 1997, Current Opinion in Oncology, V9, P108; Taya S, 2001, J CELL BIOL, V155, P809, DOI 10.1083/jcb.200106139; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Yoshioka K, 1999, CANCER RES, V59, P2004; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589; Zhu D, 2000, J CELL PHYSIOL, V183, P182, DOI 10.1002/(SICI)1097-4652(200005)183:2<182::AID-JCP5>3.0.CO;2-O; Zhu D, 1998, CELL MOTIL CYTOSKEL, V39, P209, DOI 10.1002/(SICI)1097-0169(1998)39:3<209::AID-CM4>3.0.CO;2-#	79	203	209	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29420	29434		10.1074/jbc.M301885200	http://dx.doi.org/10.1074/jbc.M301885200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12748184	hybrid			2022-12-25	WOS:000184507000006
J	Ma, HL; Inesi, G; Toyoshima, C				Ma, HL; Inesi, G; Toyoshima, C			Substrate-induced conformational fit and headpiece closure in the Ca2+ ATPase (SERCA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; CALCIUM-PUMP; ADENOSINE-TRIPHOSPHATASE; BINDING-SITE; PHOSPHORYLATION; DOMAIN; MG2+; IDENTIFICATION; INTERMEDIATE; NUCLEOTIDE	Protection of the Ca2+ ATPase (SERCA) from proteinase K digestion has been observed following the addition of Ca2+, Mg2+, and nucleotide and interpreted as a substrate-dependent conformational change ( 1). The protected digestion site is located on the loop connecting the A domain and the M3 transmembrane helix. We studied by mutational analysis the protective effect of AMP-PCP, an ATP analog that is not utilized for enzyme phosphorylation. We found that the nucleotide protective effect is interfered with by single mutations of Arg560 and Glu-439 in the N domain and Lys-352, Lys-684, Thr-353, Asp-703, and Asp-707 in the P domain. This is consistent with a transition from the open to the compact configuration of the ATPase headpiece and approximation of the N and P domains by interactions with the nucleotide adenosine and phosphate moieties, respectively. The A domain-M3 loop is consequently involved. Protection by nucleotide substrate increased following the mutations of Asp-351 ( the residue undergoing phosphorylation by ATP) and neighboring Asn-706 to Ala, underlying the importance of side chain specificity in positioning the nucleotide terminal phosphate and limiting the stability of the substrate-enzyme complex. Protection is not observed when AMP-PCP is added in the absence of Ca2+ or following mutations ( E771Q or N796A) that interfere with Ca2+ binding. Therefore, nucleotide binds to the Ca2+-activated enzyme in the open headpiece conformation and the consequent approximation of the N and P domains occurs while the transmembrane domain is still in the Ca2+-bound conformation. Mg2+ is not required for the protective effect of nucleotide, even though it is specifically required for the subsequent catalytic reactions.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 113, Japan	University System of Maryland; University of Maryland Baltimore; University of Tokyo	Inesi, G (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.	ginesi@umaryland.edu	Toyoshima, Chikashi/R-4153-2019	Toyoshima, Chikashi/0000-0001-9640-0778	NHLBI NIH HHS [HL27867] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; Champeil P, 1998, J BIOL CHEM, V273, P6619, DOI 10.1074/jbc.273.12.6619; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; Hua SM, 2002, BIOCHEMISTRY-US, V41, P2264, DOI 10.1021/bi015684h; Hua SM, 2002, BIOCHEMISTRY-US, V41, P11405, DOI 10.1021/bi026181u; KARIN NJ, 1989, MOL CELL BIOL, V9, P1978, DOI 10.1128/MCB.9.5.1978; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; Lahiri SD, 2002, BIOCHEMISTRY-US, V41, P8351, DOI 10.1021/bi0202373; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; McIntosh DB, 1999, J BIOL CHEM, V274, P25227, DOI 10.1074/jbc.274.36.25227; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MURPHY AJ, 1977, ARCH BIOCHEM BIOPHYS, V180, P114, DOI 10.1016/0003-9861(77)90014-5; Pedersen PA, 2000, J BIOL CHEM, V275, P37588, DOI 10.1074/jbc.M005610200; REINSTEIN J, 1993, BIOCHEMISTRY-US, V32, P6632, DOI 10.1021/bi00077a016; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8; YAMAGATA K, 1993, J BIOL CHEM, V268, P20930; YAMAMOTO H, 1988, J BIOCHEM-TOKYO, V103, P452, DOI 10.1093/oxfordjournals.jbchem.a122291; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959; Zhang ZS, 2000, BIOCHEMISTRY-US, V39, P8758, DOI 10.1021/bi000185m	26	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28938	28943		10.1074/jbc.M304120200	http://dx.doi.org/10.1074/jbc.M304120200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12750373	hybrid			2022-12-25	WOS:000184421100073
J	Gregory, CA; Singh, H; Perry, AS; Prockop, DJ				Gregory, CA; Singh, H; Perry, AS; Prockop, DJ			The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROMAL CELLS; WNT/BETA-CATENIN; GENE-EXPRESSION; BETA-CATENIN; C-FOS; RECEPTOR; ADHESION; PATHWAY; IDENTIFICATION; DENSITY	Adult human mesenchymal stem cells from bone marrow stroma (hMSCs) differentiate into numerous mesenchymal tissue lineages and are attractive candidates for cell and gene therapy. When early passage hMSCs are plated or replated at low density, the cultures display a lag phase of 3 - 5 days, a phase of rapid exponential growth, and then enter a stationary phase without the cultures reaching confluence. We found that as the cultures leave the lag phase, they secrete high levels of dickkopf-1 (Dkk-1), an inhibitor of the canonical Wnt signaling pathway. The addition of recombinant Dkk-1 toward the end of the lag period increased proliferation and decreased the cellular concentration of beta-catenin. The addition of antibodies to Dkk-1 in the early log phase decreased proliferation. Also, expression of Dkk-1 in hMSCs decreased during cell cycle arrest induced by serum starvation. The results indicated that high levels of Dkk-1 allow the cells to reenter the cell cycle by inhibiting the canonical Wnt/beta-catenin signaling pathway. Since antibodies to Dkk-1 also increased the lag phase of an osteosarcoma line that expressed the gene, Dkk-1 may have a similar role in some other cell systems.	Tulane Univ, Hlth Sci Ctr, Ctr Gene Therapy, New Orleans, LA 70112 USA	Tulane University	Prockop, DJ (corresponding author), Tulane Univ, Hlth Sci Ctr, Ctr Gene Therapy, 1430 Tulnae Ave, New Orleans, LA 70112 USA.	dprocko@tulane.edu		Gregory, Carl/0000-0001-6444-5541	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048323, R21AR047796] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 47796, AR 48323] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahmad M, 1998, J BIOL CHEM, V273, P4616, DOI 10.1074/jbc.273.8.4616; ASHTON BA, 1980, CLIN ORTHOP RELAT R, P294; Austin TW, 1997, BLOOD, V89, P3624, DOI 10.1182/blood.V89.10.3624.3624_3624_3635; Baek SH, 2003, P NATL ACAD SCI USA, V100, P3245, DOI 10.1073/pnas.0330217100; BALABAN N, 1990, EXP CELL RES, V191, P219, DOI 10.1016/0014-4827(90)90008-X; BENNETT JH, 1991, J CELL SCI, V99, P131; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097-4644(199702)64:2<278::AID-JCB11>3.0.CO;2-F; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097; Colter DC, 2001, P NATL ACAD SCI USA, V98, P7841, DOI 10.1073/pnas.141221698; COLTER DC, 2001, THESIS TULANE U NEW; DiGirolamo CM, 1999, BRIT J HAEMATOL, V107, P275, DOI 10.1046/j.1365-2141.1999.01715.x; Fedi P, 1999, J BIOL CHEM, V274, P19465, DOI 10.1074/jbc.274.27.19465; Feuerbach D, 1997, FEBS LETT, V402, P21, DOI 10.1016/S0014-5793(96)01495-0; Fischer L, 2002, J BIOL CHEM, V277, P30870, DOI 10.1074/jbc.M109330200; FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Gregory CA, 2001, ANAL BIOCHEM, V296, P114, DOI 10.1006/abio.2001.5237; GREGORY CA, 1999, THESIS U MANCHESTER; Grotewold L, 2002, EMBO J, V21, P966, DOI 10.1093/emboj/21.5.966; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; Hartmann C, 2000, DEVELOPMENT, V127, P3141; Houghton A, 1998, BONE, V22, P7, DOI 10.1016/S8756-3282(97)00229-9; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Katoh M, 2002, INT J MOL MED, V10, P683; Kikuchi A, 2000, BIOCHEM BIOPH RES CO, V268, P243, DOI 10.1006/bbrc.1999.1860; Ko K, 2000, AM J PHYSIOL-CELL PH, V279, pC147, DOI 10.1152/ajpcell.2000.279.1.C147; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Kotton DN, 2001, DEVELOPMENT, V128, P5181; Kuhl M, 2001, MECH DEVELOP, V106, P61, DOI 10.1016/S0925-4773(01)00416-6; Li L, 2002, J BIOL CHEM, V277, P5977, DOI 10.1074/jbc.M111131200; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Liu T, 2002, J BIOL CHEM, V277, P30887, DOI 10.1074/jbc.M203852200; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Lutz C, 2002, J BIOL CHEM, V277, P43143, DOI 10.1074/jbc.M204426200; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; MCCABE LR, 1995, EXP CELL RES, V218, P255, DOI 10.1006/excr.1995.1154; Murphy LLS, 2002, J IMMUNOL, V169, P3717, DOI 10.4049/jimmunol.169.7.3717; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Nakamura T, 2001, BBA-GENE STRUCT EXPR, V1518, P63, DOI 10.1016/S0167-4781(01)00168-3; Packard M, 2002, CELL, V111, P319, DOI 10.1016/S0092-8674(02)01047-4; Pandur P, 2002, BIOESSAYS, V24, P881, DOI 10.1002/bies.10164; Pandur P, 2002, NATURE, V418, P636, DOI 10.1038/nature00921; Petropoulos H, 2002, J BIOL CHEM, V277, P15393, DOI 10.1074/jbc.M112141200; PIERSMA AH, 1985, EXP HEMATOL, V13, P237; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Rost B, 1997, J MOL BIOL, V270, P471, DOI 10.1006/jmbi.1997.1101; Sekiya I, 2002, P NATL ACAD SCI USA, V99, P4397, DOI 10.1073/pnas.052716199; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Spees JL, 2002, CELL STRESS CHAPERON, V7, P97, DOI 10.1379/1466-1268(2002)007<0097:TAASIT>2.0.CO;2; TANAKA Y, 1995, J BONE MINER RES, V10, P1462; Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; Wilkins MR, 1997, J THEOR BIOL, V186, P7, DOI 10.1006/jtbi.1996.0346; Wu W, 2000, CURR BIOL, V10, P1611, DOI 10.1016/S0960-9822(00)00868-X; Yamane T, 2001, J IMMUNOL, V167, P765, DOI 10.4049/jimmunol.167.2.765; Zorn AM, 2001, CURR BIOL, V11, pR592, DOI 10.1016/S0960-9822(01)00360-8	63	225	248	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28067	28078		10.1074/jbc.M300373200	http://dx.doi.org/10.1074/jbc.M300373200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12740383	hybrid			2022-12-25	WOS:000184242700093
J	Jutabha, P; Kanai, Y; Hosoyamada, M; Chairoungdua, A; Kim, DK; Iribe, Y; Babu, E; Kim, JY; Anzai, N; Chatsudthipong, V; Endou, H				Jutabha, P; Kanai, Y; Hosoyamada, M; Chairoungdua, A; Kim, DK; Iribe, Y; Babu, E; Kim, JY; Anzai, N; Chatsudthipong, V; Endou, H			Identification of a novel voltage-driven organic anion transporter present at apical membrane of renal proximal tubule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; AFFINITY GLUTAMATE TRANSPORTER; P-AMINOHIPPURATE TRANSPORT; RESISTANCE PROTEIN MRP2; XENOPUS-LAEVIS OOCYTES; BRUSH-BORDER MEMBRANE; RAT-KIDNEY; FUNCTIONAL-CHARACTERIZATION; EXPRESSION CLONING; SUBSTRATE SELECTIVITY	A novel transport protein with the properties of voltage-driven organic anion transport was isolated from pig kidney cortex by expression cloning in Xenopus laevis oocytes. A cDNA library was constructed from size-fractionated poly(A)(+) RNA and screened for p-aminohippurate (PAH) transport in high potassium medium. A 1856-base pair cDNA encoding a 467-amino acid peptide designated as OAT(V)1 (voltage-driven organic anion transporter 1) was isolated. The predicted amino acid sequence of OAT(V)1 exhibited 60-65% identity to those of human, rat, rabbit, and mouse sodium-dependent phosphate cotransporter type 1 (NPT1), although OAT(V)1 did not transport phosphate. The homology of this transporter to known members of the organic anion transporter family (OAT family) was about 25-30%. OAT(V)1-mediated PAH transport was affected by the changes in membrane potential. The transport was Na+-independent and enhanced at high concentrations of extracellular potassium and low concentrations of extracellular chloride. Under the voltage clamp condition, extracellularly applied PAH induced outward currents in oocytes expressing OAT(V)1. The current showed steep voltage dependence, consistent with the voltage-driven transport of PAH by OAT(V)1. The PAH transport was inhibited by various organic anions but not by organic cations, indicating the multispecific nature of OAT(V)1 for anionic compounds. This transport protein is localized at the apical membrane of renal proximal tubule, consistent with the proposed localization of a voltage-driven organic anion transporter. Therefore, it is proposed that OAT(V)1 plays an important role to excrete drugs, xenobiotics, and their metabolites driven by membrane voltage through the apical membrane of the tubular epithelial urine.	Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, Tokyo 1818611, Japan; Chosun Univ, Coll Dent, Dept Oral Physiol, Gwangju 501759, South Korea; Mahidol Univ, Fac Sci, Dept Physiol, Bangkok 10400, Thailand	Kyorin University; Chosun University; Mahidol University	Endou, H (corresponding author), Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, 6-20-2 Shinkawa, Tokyo 1818611, Japan.		Jutabha, Promsuk/AFF-4363-2022; Jutabha, Promsuk/AAE-9872-2022; ANZAI, NAOHIKO/K-9492-2017	ANZAI, NAOHIKO/0000-0003-0605-0458				Apiwattanakul N, 1999, MOL PHARMACOL, V55, P847; ARONSON PS, 1989, ANNU REV PHYSIOL, V51, P419; BLOMSTEDT JW, 1980, J CLIN INVEST, V65, P931, DOI 10.1172/JCI109748; BURCKHARDT BC, 1992, PFLUG ARCH EUR J PHY, V420, P83, DOI 10.1007/BF00378645; BURCKHARDT BC, 1992, PFLUG ARCH EUR J PHY, V420, P78, DOI 10.1007/BF00378644; BURG MB, 1969, AM J PHYSIOL, V217, P1064, DOI 10.1152/ajplegacy.1969.217.4.1064; Cha SH, 2000, J BIOL CHEM, V275, P4507, DOI 10.1074/jbc.275.6.4507; Cha SH, 2001, MOL PHARMACOL, V59, P1277, DOI 10.1124/mol.59.5.1277; Chairoungdua A, 1999, J BIOL CHEM, V274, P28845, DOI 10.1074/jbc.274.41.28845; Dantzler WH, 2002, BBA-BIOMEMBRANES, V1566, P169, DOI 10.1016/S0005-2736(02)00599-0; Fukasawa Y, 2000, J BIOL CHEM, V275, P9690, DOI 10.1074/jbc.275.13.9690; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; GUGGINO SE, 1983, AM J PHYSIOL, V244, pF612, DOI 10.1152/ajprenal.1983.244.6.F612; Habu Y, 2002, PHARMACEUT RES, V19, P1822, DOI 10.1023/A:1021437306990; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hisano S, 1996, BRAIN RES, V710, P299, DOI 10.1016/0006-8993(95)01442-X; Hosoyamada M, 1999, AM J PHYSIOL-RENAL, V276, pF122, DOI 10.1152/ajprenal.1999.276.1.F122; Humphreys BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1232, DOI 10.1152/ajpcell.1997.272.4.C1232; KAHN AM, 1983, AM J PHYSIOL, V244, pF56, DOI 10.1152/ajprenal.1983.244.1.F56; KAHN AM, 1983, AM J PHYSIOL, V245, pF151, DOI 10.1152/ajprenal.1983.245.2.F151; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Kanai Y, 2000, J BIOL CHEM, V275, P20787, DOI 10.1074/jbc.M000634200; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; KANAI Y, 1994, J BIOL CHEM, V269, P20599; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Kim DK, 2001, J BIOL CHEM, V276, P17221, DOI 10.1074/jbc.M009462200; Kojima R, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134848; Krick W, 2000, PFLUG ARCH EUR J PHY, V441, P125, DOI 10.1007/s004240000378; Leier I, 2000, KIDNEY INT, V57, P1636, DOI 10.1046/j.1523-1755.2000.00007.x; MARTINEZ F, 1990, AM J PHYSIOL, V258, pF1145, DOI 10.1152/ajprenal.1990.258.5.F1145; MIYAMOTO KI, 1995, BIOCHEM J, V305, P81, DOI 10.1042/bj3050081; Moller J. V., 1983, PHARMACOL REV, V34, P315; PRITCHARD JB, 1988, AM J PHYSIOL, V255, pF597, DOI 10.1152/ajprenal.1988.255.4.F597; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; Romero MF, 1998, METHOD ENZYMOL, V296, P17; SCHMITT C, 1993, PFLUG ARCH EUR J PHY, V423, P280, DOI 10.1007/BF00374407; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Segel IH, 1975, ENZYME KINETICS BEHA; Sekine T, 2000, PFLUG ARCH EUR J PHY, V440, P337, DOI 10.1007/s004240000297; Sekine T, 1998, AM J PHYSIOL-RENAL, V275, pF298, DOI 10.1152/ajprenal.1998.275.2.F298; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; SHIMADA H, 1987, AM J PHYSIOL, V253, pF795, DOI 10.1152/ajprenal.1987.253.5.F795; Sweet DH, 2003, AM J PHYSIOL-RENAL, V284, pF763, DOI 10.1152/ajprenal.00405.2002; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; Taketani Y, 1998, J BIOL CHEM, V273, P14575, DOI 10.1074/jbc.273.23.14575; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; Tojo A, 1999, J AM SOC NEPHROL, V10, P464; Uchino H, 2000, BIOCHEM BIOPH RES CO, V270, P254, DOI 10.1006/bbrc.2000.2407; Ullrich KJ, 1997, J MEMBRANE BIOL, V158, P95, DOI 10.1007/s002329900247; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; Van Aubel RAMH, 2000, AM J PHYSIOL-RENAL, V279, pF713, DOI 10.1152/ajprenal.2000.279.4.F713; WERNER D, 1990, J PHARMACOL EXP THER, V252, P792	52	90	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27930	27938		10.1074/jbc.M303210200	http://dx.doi.org/10.1074/jbc.M303210200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12740363	hybrid			2022-12-25	WOS:000184242700076
J	Kotecha, SA; Jackson, MF; Al-Mahrouki, A; Roder, JC; Orser, BA; MacDonald, JF				Kotecha, SA; Jackson, MF; Al-Mahrouki, A; Roder, JC; Orser, BA; MacDonald, JF			Co-stimulation of mGluR5 and N-methyl-D-aspartate receptors is required for potentiation of excitatory synaptic transmission in hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; LONG-TERM POTENTIATION; PROTEIN-COUPLED RECEPTORS; NMDA RECEPTORS; AMPA RECEPTORS; TYROSINE KINASE; CA2+ RELEASE; ION-CHANNEL; RAT-BRAIN; ACTIVATION	In the central nervous system, excitatory synaptic transmission is mediated by the neurotransmitter glutamate and its receptors. Interestingly, stimulation of group I metabotropic glutamate receptors (mGluRs) can either enhance or depress synaptic transmission at CA1 hippocampal synapses. Here we report that co-activation of mGluR5, a member of the group I mGluR family, and N-methyl-D-aspartate receptors (NMDARs) potentiates NMDAR currents and induces a long lasting enhancement of excitatory synaptic transmission in primary cultured hippocampal neurons. Unexpectedly, activation of mGluR5 alone fails to enhance evoked NMDAR currents and synaptic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor (AMPAR) AMPAR currents. The observed potentiation requires an mGluR5-induced, inositol 1,4,5-trisphosphate receptor-mediated mobilization of intracellular Ca2+, which acts in concert with a protein kinase C, calcium-activated tyrosine kinase cascade to induce a long lasting enhancement of NMDAR and AMPAR currents.	Univ Toronto, Mt Sinai Hosp, Fac Med, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Mt Sinai Hosp, Fac Med, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Mt Sinai Hosp, Fac Med, Dept Immunol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Mt Sinai Hosp, Fac Med, Dept Anesthesiol, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	MacDonald, JF (corresponding author), Univ Toronto, Dept Physiol, Med Sci Bldg,,1 Kings Coll, Toronto, ON M5S 1A8, Canada.	j.macdonald@utoronto.ca	Roder, John/G-6468-2013; Jackson, Mike/H-5573-2012	Jackson, Mike/0000-0002-4730-201X	NHLBI NIH HHS [T32 HL007572] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alagarsamy S, 2001, CURR OPIN NEUROBIOL, V11, P357, DOI 10.1016/S0959-4388(00)00219-1; Ali DW, 2001, CURR OPIN NEUROBIOL, V11, P336, DOI 10.1016/S0959-4388(00)00216-6; Ango F, 2000, J NEUROSCI, V20, P8710; Ango F, 2001, NATURE, V411, P962, DOI 10.1038/35082096; Anwyl R, 1999, BRAIN RES REV, V29, P83, DOI 10.1016/S0165-0173(98)00050-2; BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bortolotto ZA, 1999, CURR OPIN NEUROBIOL, V9, P299, DOI 10.1016/S0959-4388(99)80044-0; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; COLLINGRIDGE GL, 1995, TRENDS NEUROSCI, V18, P54, DOI 10.1016/0166-2236(95)93868-X; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Constantine-Paton M, 2000, NEUROBIOL DIS, V7, P515, DOI 10.1006/nbdi.2000.0344; Contractor A, 1998, P NATL ACAD SCI USA, V95, P8969, DOI 10.1073/pnas.95.15.8969; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Doherty AJ, 1997, NEUROPHARMACOLOGY, V36, P265, DOI 10.1016/S0028-3908(97)00001-4; Ferraguti F, 1998, J COMP NEUROL, V400, P391; Fitzjohn SM, 2001, NEUROPHARMACOLOGY, V41, P693, DOI 10.1016/S0028-3908(01)00128-9; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Gasparini F, 1999, NEUROPHARMACOLOGY, V38, P1493, DOI 10.1016/S0028-3908(99)00082-9; Grosshans DR, 2001, J NEUROCHEM, V76, P737, DOI 10.1046/j.1471-4159.2001.00034.x; Hannan AJ, 2001, NAT NEUROSCI, V4, P282, DOI 10.1038/85132; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; HEMMINGS HCJ, 1997, REGULATORY PROTEIN M, P147; Huang YQ, 2001, NEURON, V29, P485, DOI 10.1016/S0896-6273(01)00220-3; Huber KM, 2001, J NEUROPHYSIOL, V86, P321, DOI 10.1152/jn.2001.86.1.321; Huber KM, 2000, SCIENCE, V288, P1254, DOI 10.1126/science.288.5469.1254; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Jia ZP, 1998, LEARN MEMORY, V5, P331; Kemp N, 2001, PROG NEUROBIOL, V65, P339, DOI 10.1016/S0301-0082(01)00013-2; Koizumi S, 1999, NEURON, V22, P125, DOI 10.1016/S0896-6273(00)80684-4; Kotecha SA, 2002, NEURON, V35, P1111, DOI 10.1016/S0896-6273(02)00859-0; Krupp JJ, 1999, J NEUROSCI, V19, P1165; Lee HK, 1998, NEURON, V21, P1151, DOI 10.1016/S0896-6273(00)80632-7; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; Lu WY, 2000, J NEUROSCI, V20, P4452, DOI 10.1523/JNEUROSCI.20-12-04452.2000; Lu WY, 1999, NAT NEUROSCI, V2, P331, DOI 10.1038/7243; Lu WY, 2001, NEURON, V29, P243, DOI 10.1016/S0896-6273(01)00194-5; Lu YM, 1998, SCIENCE, V279, P1363, DOI 10.1126/science.279.5355.1363; Lu YM, 1997, J NEUROSCI, V17, P5196; Lujan R, 1996, EUR J NEUROSCI, V8, P1488, DOI 10.1111/j.1460-9568.1996.tb01611.x; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Luscher C, 2001, TRENDS NEUROSCI, V24, P665, DOI 10.1016/S0166-2236(00)01959-7; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MACDONALD JF, 1989, J PHYSIOL-LONDON, V414, P17, DOI 10.1113/jphysiol.1989.sp017674; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Marino MJ, 2001, J NEUROSCI, V21, P7001, DOI 10.1523/JNEUROSCI.21-18-07001.2001; Miyamoto S, 2000, BRIT J PHARMACOL, V130, P650, DOI 10.1038/sj.bjp.0703358; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; Movsesyan VA, 2001, J PHARMACOL EXP THER, V296, P41; Musleh W, 1997, P NATL ACAD SCI USA, V94, P9451, DOI 10.1073/pnas.94.17.9451; O'Leary DM, 2000, BRIT J PHARMACOL, V131, P1429, DOI 10.1038/sj.bjp.0703715; Peavy RD, 2001, J NEUROSCI, V21, P9619, DOI 10.1523/JNEUROSCI.21-24-09619.2001; Pickard L, 2001, NEUROPHARMACOLOGY, V41, P700, DOI 10.1016/S0028-3908(01)00127-7; Rae MG, 2000, J NEUROSCI, V20, P8628; ROMANO C, 1995, J COMP NEUROL, V355, P455, DOI 10.1002/cne.903550310; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Shmigol A, 1996, NEUROSCIENCE, V73, P1061, DOI 10.1016/0306-4522(96)00108-X; Snyder EM, 2001, NAT NEUROSCI, V4, P1079, DOI 10.1038/nn746; Soderling TR, 2000, TRENDS NEUROSCI, V23, P75, DOI 10.1016/S0166-2236(99)01490-3; Sosa R, 2002, J NEUROCHEM, V81, P973, DOI 10.1046/j.1471-4159.2002.00883.x; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WANG LY, 1995, J PHYSIOL-LONDON, V486, P83, DOI 10.1113/jphysiol.1995.sp020792; WANG LY, 1994, NATURE, V369, P230, DOI 10.1038/369230a0; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Wang YT, 2000, NEURON, V25, P635, DOI 10.1016/S0896-6273(00)81066-1; Wilsch VW, 1998, J NEUROSCI, V18, P6071; Xiong ZG, 1999, CAN J PHYSIOL PHARM, V77, P715, DOI 10.1139/cjpp-77-9-715	70	91	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27742	27749		10.1074/jbc.M301946200	http://dx.doi.org/10.1074/jbc.M301946200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12740378	hybrid			2022-12-25	WOS:000184242700053
J	Sun, Y; Yao, J; Kim, TW; Tall, AR				Sun, Y; Yao, J; Kim, TW; Tall, AR			Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; STEAROYL-COA DESATURASE; A REDUCTASE INHIBITORS; ALZHEIMERS-DISEASE; CHOLESTEROL EFFLUX; OXYSTEROL RECEPTORS; PLASMA-MEMBRANE; LIPID RAFTS; TRANSPORTER; BINDING	A hallmark of Alzheimer's disease is the deposition of plaques of amyloid beta peptide (Abeta) in the brain. Abeta is thought to be formed from the amyloid precursor protein (APP) in cholesterol-enriched membrane rafts, and cellular cholesterol depletion decreases Abeta formation. The liver X receptors (LXR) play a key role in regulating genes that control cellular cholesterol efflux and membrane composition and are widely expressed in cells of the central nervous system. We show that treatment of APP-expressing cells with LXR activators reduces the formation of Abeta. LXR activation resulted in increased levels of the ATP-binding cassette transporter A1 (ABCA1) and stearoyl CoA desaturase, and expression of these genes individually decreased formation of Abeta. Expression of ABCA1 led to both decreased beta-cleavage product of APP(Sw) (i.e. C99 peptide) and reduced gamma-secretase-cleavage of C99 peptide. Remarkably, these effects of ABCA1 on APP processing were independent of cellular lipid efflux. LXR and ABCA1-induced changes in membrane lipid organization had favorable effects on processing of APP, suggesting a new approach to the treatment of Alzheimer's disease.	Columbia Univ Coll Phys & Surg, Dept Med, Div Mol Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA	Columbia University; Columbia University	Tall, AR (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, Div Mol Med, New York, NY 10032 USA.		Tall, Alan/AAT-8528-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022682, P01HL054591, R37HL022682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018026] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 54591, HL 22682] Funding Source: Medline; NIA NIH HHS [AG18026] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Coons JC, 2002, ANN PHARMACOTHER, V36, P326; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Costet P, 2000, J BIOL CHEM, V275, P28240; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Fukumoto H, 2002, J BIOL CHEM, V277, P48508, DOI 10.1074/jbc.M209085200; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Koldamova RP, 2003, J BIOL CHEM, V278, P13244, DOI 10.1074/jbc.M300044200; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; Ntambi JM, 1999, J LIPID RES, V40, P1549; Parkin ET, 1999, J NEUROCHEM, V72, P1534, DOI 10.1046/j.1471-4159.1999.721534.x; Peet DJ, 1998, CURR OPIN GENET DEV, V8, P571, DOI 10.1016/S0959-437X(98)80013-0; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Puglielli L, 2001, NAT CELL BIOL, V3, P905, DOI 10.1038/ncb1001-905; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Singaraja RR, 2002, J CLIN INVEST, V110, P35, DOI 10.1172/JCI200215748; Sun Y, 2003, J BIOL CHEM, V278, P5813, DOI 10.1074/jbc.M208687200; Tall AR, 2000, NAT MED, V6, P1104, DOI 10.1038/80433; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; VAUGHAN AM, 2003, IN PRESS J LIPID RES; Wang L, 2002, P NATL ACAD SCI USA, V99, P13878, DOI 10.1073/pnas.172510899; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Whitney KD, 2002, MOL ENDOCRINOL, V16, P1378, DOI 10.1210/me.16.6.1378; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Wolozin B, 2001, P NATL ACAD SCI USA, V98, P5371, DOI 10.1073/pnas.101123198	40	154	163	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27688	27694		10.1074/jbc.M300760200	http://dx.doi.org/10.1074/jbc.M300760200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12754201	hybrid			2022-12-25	WOS:000184242700046
J	Takahashi, T; Konno, T; Muto, A; Himeno, H				Takahashi, T; Konno, T; Muto, A; Himeno, H			Various effects of paromomycin on tmRNA-directed trans-translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI TMRNA; TRANSFER-MESSENGER-RNA; 30S RIBOSOMAL-SUBUNIT; ELONGATION-FACTOR TU; PROTEIN-SYNTHESIS INHIBITORS; 10SA RNA; BACILLUS-SUBTILIS; IN-VITRO; AMINOGLYCOSIDE ANTIBIOTICS; MYCOPLASMA-CAPRICOLUM	trans-Translation is an unusual translation in which tmRNA plays a dual function as a tRNA and an mRNA to relieve the stalled translation on the ribosome. In this study, we examined the effects of an aminoglycoside antibiotic, paromomycin, on several tmRNA-related events in vitro. The results of a chemical footprinting study indicated that paromomycin molecules bind tmRNA at G(332)/G(333) in the tRNA domain and A(316) in the middle of the long helix between tRNA and mRNA domains. Paromomycin bound at G(332)/G(333) inhibited aminoacylation, and the inhibition was suppressed by the addition of SmpB, a tmRNA-binding protein. It was also found that paromomycin causes a shift of the translation resuming point on tmRNA by -1. The effect on initiation shift was canceled by a mutation at the paromomycin-binding site in 16 S rRNA but not by mutations in tmRNA. A high concentration of paromomycin inhibited trans-translation, whereas it enhanced the initiation-shifted trans-translation when SmpB was exogenously added or a mutation was introduced at 333. The effect of paromomycin on trans-translation differs substantially from that on canonical translation, in which it induces miscoding by modulating the A site of the decoding helix of the small subunit RNA of the ribosome.	Hirosaki Univ, Fac Agr & Life Sci, Dept Biochem & Biotechnol, Hirosaki, Aomori 0368561, Japan; Hirosaki Univ, Fac Sci, Dept Biol, Hirosaki, Aomori 0368561, Japan	Hirosaki University; Hirosaki University	Himeno, H (corresponding author), Hirosaki Univ, Fac Agr & Life Sci, Dept Biochem & Biotechnol, Hirosaki, Aomori 0368561, Japan.	himeno@cc.hirosaki-u.ac.jp	Himeno, Hyouta/E-8703-2010					Abo T, 2002, GENES CELLS, V7, P629, DOI 10.1046/j.1365-2443.2002.00549.x; Abo T, 2000, EMBO J, V19, P3762, DOI 10.1093/emboj/19.14.3762; Asai T, 1999, P NATL ACAD SCI USA, V96, P1971, DOI 10.1073/pnas.96.5.1971; Barends S, 2000, BIOCHEMISTRY-US, V39, P2652, DOI 10.1021/bi992439d; Barends S, 2001, J MOL BIOL, V314, P9, DOI 10.1006/jmbi.2001.5114; BROSIUS J, 1981, PLASMID, V6, P112, DOI 10.1016/0147-619X(81)90058-5; Carter AP, 2000, NATURE, V407, P340, DOI 10.1038/35030019; Corvaisier S, 2003, J BIOL CHEM, V278, P14788, DOI 10.1074/jbc.M212830200; de la Cruz J, 2001, RNA, V7, P1708; Felden B, 1997, RNA, V3, P89; Felden B, 1998, EMBO J, V17, P3188, DOI 10.1093/emboj/17.11.3188; Fujihara A, 2002, GENES CELLS, V7, P343, DOI 10.1046/j.1365-2443.2002.00523.x; GRISEMIRON L, 1981, BIOCHIM BIOPHYS ACTA, V656, P103, DOI 10.1016/0005-2787(81)90032-0; Hanawa-Suetsugu K, 2002, NUCLEIC ACIDS RES, V30, P1620, DOI 10.1093/nar/30.7.1620; Hanawa-Suetsugu K, 2001, NUCLEIC ACIDS RES, V29, P4663, DOI 10.1093/nar/29.22.4663; Hickerson RP, 1998, J MOL BIOL, V279, P577, DOI 10.1006/jmbi.1998.1813; Himeno H, 1997, J MOL BIOL, V268, P803, DOI 10.1006/jmbi.1997.1011; Hirokawa G, 2002, EMBO J, V21, P2272, DOI 10.1093/emboj/21.9.2272; Huang CH, 2000, EMBO J, V19, P1098, DOI 10.1093/emboj/19.5.1098; Ito K, 2002, FEBS LETT, V516, P245, DOI 10.1016/S0014-5793(02)02561-9; Jerinic O, 2000, J MOL BIOL, V304, P707, DOI 10.1006/jmbi.2000.4269; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Karzai AW, 1999, EMBO J, V18, P3793, DOI 10.1093/emboj/18.13.3793; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Knudsen B, 2001, NUCLEIC ACIDS RES, V29, P171, DOI 10.1093/nar/29.1.171; Komine Y, 1996, J BIOCHEM-TOKYO, V119, P463; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; Lee S, 2001, RNA, V7, P999, DOI 10.1017/S1355838201010342; MARTIN R, 1989, MOL GEN GENET, V217, P411, DOI 10.1007/BF02464911; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; Mehta R, 2002, ANTIMICROB AGENTS CH, V46, P1546, DOI 10.1128/AAC.46.5.1546-1549.2002; Mikkelsen NE, 1999, P NATL ACAD SCI USA, V96, P6155, DOI 10.1073/pnas.96.11.6155; Mikkelsen NE, 2001, NAT STRUCT BIOL, V8, P510, DOI 10.1038/88569; Miyaguchi H, 1996, NUCLEIC ACIDS RES, V24, P3700, DOI 10.1093/nar/24.19.3700; Muto A, 2000, GENES CELLS, V5, P627, DOI 10.1046/j.1365-2443.2000.00356.x; Muto A, 1996, BIOCHIMIE, V78, P985, DOI 10.1016/S0300-9084(97)86721-1; Muto A, 1998, TRENDS BIOCHEM SCI, V23, P25, DOI 10.1016/S0968-0004(97)01159-6; Nameki N, 1999, NUCLEIC ACIDS RES, V27, P3667, DOI 10.1093/nar/27.18.3667; Nameki N, 2000, FEBS LETT, V470, P345, DOI 10.1016/S0014-5793(00)01349-1; Nameki N, 1999, J MOL BIOL, V286, P733, DOI 10.1006/jmbi.1998.2487; Nameki N, 1999, J MOL BIOL, V289, P1, DOI 10.1006/jmbi.1999.2754; OBA T, 1991, P NATL ACAD SCI USA, V88, P921, DOI 10.1073/pnas.88.3.921; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; Recht MI, 1999, EMBO J, V18, P3133, DOI 10.1093/emboj/18.11.3133; Recht MI, 1999, J MOL BIOL, V286, P33, DOI 10.1006/jmbi.1998.2446; Recht MI, 1996, J MOL BIOL, V262, P421, DOI 10.1006/jmbi.1996.0526; Recht MI, 2001, ANTIMICROB AGENTS CH, V45, P2414, DOI 10.1128/AAC.45.9.2414-2419.2001; Roche ED, 1999, EMBO J, V18, P4579, DOI 10.1093/emboj/18.16.4579; Roche ED, 2001, J BIOL CHEM, V276, P28509, DOI 10.1074/jbc.M103864200; Rogers J, 1996, J MOL BIOL, V259, P916, DOI 10.1006/jmbi.1996.0369; Rudinger-Thirion J, 1999, RNA, V5, P989, DOI 10.1017/S135583829999101X; STAGE TK, 1995, RNA, V1, P95; Stagg SM, 2001, J MOL BIOL, V309, P727, DOI 10.1006/jmbi.2001.4632; STERN S, 1988, METHOD ENZYMOL, V164, P481; Tadaki T, 1996, FEBS LETT, V399, P223, DOI 10.1016/S0014-5793(96)01330-0; Tamura K, 1991, J Mol Recognit, V4, P129, DOI 10.1002/jmr.300040404; Thompson J, 2002, J MOL BIOL, V322, P273, DOI 10.1016/S0022-2836(02)00784-2; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; USHIDA C, 1994, NUCLEIC ACIDS RES, V22, P3392, DOI 10.1093/nar/22.16.3392; VONAHSEN U, 1991, NATURE, V353, P368, DOI 10.1038/353368a0; Williams KP, 1999, EMBO J, V18, P5423, DOI 10.1093/emboj/18.19.5423; Williams KP, 1996, RNA, V2, P1306; Williams KP, 2002, NUCLEIC ACIDS RES, V30, P179, DOI 10.1093/nar/30.1.179; Wower IK, 2000, EMBO J, V19, P6612, DOI 10.1093/emboj/19.23.6612; Wower J, 2002, BIOCHEMISTRY-US, V41, P8826, DOI 10.1021/bi0201365; Zvereva MI, 2001, J BIOL CHEM, V276, P47702, DOI 10.1074/jbc.M106786200; Zwieb C, 2001, BIOCHEMISTRY-US, V40, P9587, DOI 10.1021/bi010443v	67	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27672	27680		10.1074/jbc.M211724200	http://dx.doi.org/10.1074/jbc.M211724200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12754221	hybrid			2022-12-25	WOS:000184242700044
J	He, HJ; Kole, S; Kwon, YK; Crow, MT; Bernier, M				He, HJ; Kole, S; Kwon, YK; Crow, MT; Bernier, M			Interaction of filamin A with the insulin receptor alters insulin-dependent activation of the mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSING RECEPTOR; ACTIN CYTOSKELETON; LIPID RAFTS; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; MEMBRANE DOMAINS; TARGETS FILAMIN; TERMINAL TAIL; CROSS-LINKING; GROWTH-FACTOR	The biological actions of insulin are associated with a rapid reorganization of the actin cytoskeleton within cells in culture. Even though this event requires the participation of actin-binding proteins, the effect of filamin A (FLNa) on insulin-mediated signaling events is still unknown. We report here that human melanoma M2 cells lacking FLNa expression exhibited normal insulin receptor (IR) signaling, whereas FLNa-expressing A7 cells were unable to elicit insulin-dependent Shc tyrosine phosphorylation and p42/44 MAPK activation despite no significant defect in IR-stimulated phosphorylation of insulin receptor substrate-1 or activation of the phosphatidylinositol 3-kinase/AKT cascade. Insulin-dependent translocation of Shc, SOS1, and MAPK to lipid raft microdomains was markedly attenuated by FLNa expression. Coimmunoprecipitation experiments and in vitro binding assays demonstrated that FLNa binds constitutively to IR and that neither insulin nor depolymerization of actin by cytochalasin D affected this interaction. The colocalization of endogenous FLNa with IR was detected at the surface of HepG2 cells. Ectopic expression of a C-terminal fragment of FLNa ( FLNaCT) in HepG2 cells blocked the endogenous IR-FLNa interaction and potentiated insulin-stimulated MAPK phosphorylation and transactivation of Elk-1 compared with vector-transfected cells. Expression of FLNaCT had no major effect on insulin-induced phosphorylation of the IR, insulin receptor substrate-1, or AKT, but it elicited changes in actin cytoskeletal structure and ruffle formation in HepG2 cells. Taken together, these results indicate that FLNa interacts constitutively with the IR to exert an inhibitory tone along the MAPK activation pathway.	NIA, Diabet Sect, Clin Invest Lab, NIH, Baltimore, MD 21224 USA; NIA, Vasc Studies Unit, Cardiovasc Sci Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Bernier, M (corresponding author), NIA, Diabet Sect, Clin Invest Lab, NIH, 5600 Nathan Shock Dr,Box 23, Baltimore, MD 21224 USA.	Bernierm@vax.grc.nia.nih.gov	Bernier, Michel/AAO-3983-2021; Bernier, Michel/Y-7139-2019	Bernier, Michel/0000-0002-5948-368X; 	NATIONAL INSTITUTE ON AGING [Z01AG000882] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Awata H, 2001, J BIOL CHEM, V276, P34871, DOI 10.1074/jbc.M100775200; Bellanger JM, 2000, NAT CELL BIOL, V2, P888, DOI 10.1038/35046533; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chen H, 1998, ENDOCRINOLOGY, V139, P4147, DOI 10.1210/en.139.10.4147; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Dyson JM, 2001, J CELL BIOL, V155, P1065, DOI 10.1083/jcb.200104005; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200; Garant MJ, 2000, BIOCHEMISTRY-US, V39, P7178, DOI 10.1021/bi992947n; Goldmann WH, 2001, CELL BIOL INT, V25, P805, DOI 10.1006/cbir.2000.0710; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Hjalm G, 2001, J BIOL CHEM, V276, P34880, DOI 10.1074/jbc.M100784200; Khayat ZA, 2000, J CELL SCI, V113, P279; LAEMMLI UK, 1970, NATURE, V227, P685; Lin RW, 2001, P NATL ACAD SCI USA, V98, P5258, DOI 10.1073/pnas.011538198; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; Ohta Y, 1996, J BIOL CHEM, V271, P11858, DOI 10.1074/jbc.271.20.11858; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; OKKENHAUG K, 2001, SCI STKE; Ozanne DM, 2000, MOL ENDOCRINOL, V14, P1618, DOI 10.1210/me.14.10.1618; Plyte S, 2000, ONCOGENE, V19, P1529, DOI 10.1038/sj.onc.1203451; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Rodgers W, 2001, EXP CELL RES, V267, P173, DOI 10.1006/excr.2001.5253; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Sasaki A, 2001, J BIOL CHEM, V276, P17871, DOI 10.1074/jbc.M008422200; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Seck T, 2003, J BIOL CHEM, V278, P10408, DOI 10.1074/jbc.M209655200; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Takenawa T, 2001, BBA-MOL CELL BIOL L, V1533, P190, DOI 10.1016/S1388-1981(01)00165-2; Tsakiridis T, 1999, MICROSC RES TECHNIQ, V47, P79, DOI 10.1002/(SICI)1097-0029(19991015)47:2<79::AID-JEMT1>3.0.CO;2-S; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; Vainio S, 2002, EMBO REP, V3, P95, DOI 10.1093/embo-reports/kvf010; Valensin S, 2002, EUR J IMMUNOL, V32, P435, DOI 10.1002/1521-4141(200202)32:2<435::AID-IMMU435>3.0.CO;2-H; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; White MF, 1998, RECENT PROG HORM RES, V53, P119; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zajchowski LD, 2002, EUR J BIOCHEM, V269, P737, DOI 10.1046/j.0014-2956.2001.02715.x	47	53	57	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27096	27104		10.1074/jbc.M301003200	http://dx.doi.org/10.1074/jbc.M301003200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12734206	hybrid			2022-12-25	WOS:000184155700103
J	He, ZQ; Cho, YY; Liu, GM; Ma, WY; Bode, AM; Dong, ZG				He, ZQ; Cho, YY; Liu, GM; Ma, WY; Bode, AM; Dong, ZG			p38 mitogen-activated protein kinase regulation of JB6 Cl41 cell transformation promoted by epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED PHOSPHORYLATION; EPITHELIAL-CELLS; AP-1 ACTIVITY; HISTONE H3; C-MYC; MAPK; PATHWAY; JNK; EXPRESSION; INHIBITION	The relationship between cell transformation and p38 MAP kinase, a major mitogen-activated protein ( MAP) kinase pathway converting signals of various extracellular stimuli into expression of specific target genes through activation of transcription factors, still remains unclear. The aim of the present study was to investigate the role of the p38 MAP kinase pathway in epidermal growth factor (EGF)-induced cell transformation in JB6 cells. Our data show that a dominant negative mutant of p38 MAP (DN-p38) kinase inhibits EGF-promoted JB6 C141 cell transformation and that SB202190, an inhibitor of p38 MAP kinase, also inhibits JB6 C141 cell transformation in a dose-dependent manner. Moreover, our results show that DN-p38 MAP kinase inhibits the phosphorylation of EGF-stimulated activating transcription factor-2 (ATF-2) and signal transducer and activator of transcription 1 (STAT1). Additionally, DN-p38 MAP kinase inhibits EGF-induced phosphorylation of c-Myc (Thr(58)/Ser(62)). Gel shift assays indicate that DN-p38 MAP kinase inhibits EGF-induced activator protein-1 (AP-1) DNA binding in a dose-dependent manner. These results show that p38 MAP kinase plays a key role in the regulation of EGF-induced cell transformation in JB6 cells through regulation of phosphorylation of p38 MAP kinase and activation of its target genes in phosphorylation, c-Myc cell transformation-related genes, and AP-1 binding ability.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.		Cho, Yong-Yeon/AAD-4263-2020	Cho, Yong-Yeon/0000-0003-1107-2651	NCI NIH HHS [CA77646, CA88961, CA81064] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077646, R37CA081064, R01CA081064, P01CA088961] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMOUSTAFA AE, 1992, ONCOGENE, V7, P1667; Antonyak MA, 2002, ONCOGENE, V21, P5038, DOI 10.1038/sj.onc.1205593; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; BARRETT J, 1992, MOL CELL BIOL, V12, P3130, DOI 10.1128/MCB.12.7.3130; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Bode AM, 2001, CANCER RES, V61, P850; Calaf G, 2001, INT J RADIAT BIOL, V77, P31, DOI 10.1080/095530001453096; Caruso JA, 2001, MUTAT RES-FUND MOL M, V473, P85, DOI 10.1016/S0027-5107(00)00140-8; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; Ding M, 1999, J BIOL CHEM, V274, P30611, DOI 10.1074/jbc.274.43.30611; DONG Z, 2002, SCI STKE; Dong ZG, 1997, J BIOL CHEM, V272, P9962; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; Eriksson M, 2002, J BIOL CHEM, V277, P15992, DOI 10.1074/jbc.M107340200; Fan MY, 2001, DRUG RESIST UPDATE, V4, P253, DOI 10.1054/drup.2001.0214; Greenberg AK, 2002, AM J RESP CELL MOL, V26, P558, DOI 10.1165/ajrcmb.26.5.4689; Harper SJ, 2001, CELL SIGNAL, V13, P299, DOI 10.1016/S0898-6568(01)00148-6; Harris VK, 2000, J BIOL CHEM, V275, P10802, DOI 10.1074/jbc.275.15.10802; Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357-4310(99)01544-0; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Kaminska B, 2000, ACTA NEUROBIOL EXP, V60, P395; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Liu GM, 2002, J BIOL CHEM, V277, P8810, DOI 10.1074/jbc.M110477200; Liu GM, 2001, P NATL ACAD SCI USA, V98, P7510, DOI 10.1073/pnas.131195198; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; New LG, 2001, J CELL BIOCHEM, V83, P585, DOI 10.1002/jcb.1253; Nomura M, 2001, J BIOL CHEM, V276, P46624, DOI 10.1074/jbc.M107897200; Nomura M, 2001, J BIOL CHEM, V276, P25558, DOI 10.1074/jbc.M101164200; Okano J, 2001, J BIOL CHEM, V276, P19555, DOI 10.1074/jbc.M011164200; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; Papatsoris AG, 2001, TRENDS MOL MED, V7, P288, DOI 10.1016/S1471-4914(01)02015-9; Poselova T V, 1998, Tsitologiia, V40, P1074; Qi XM, 2002, J BIOL CHEM, V277, P25884, DOI 10.1074/jbc.M203039200; Sanyal S, 2002, NATURE, V416, P870, DOI 10.1038/416870a; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; WHITMARSH AJ, 1999, SCI STKE; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Ye JP, 1996, MOL CELL BIOL, V16, P157; Yu CY, 2002, ONCOGENE, V21, P3949, DOI 10.1038/sj.onc.1205499; Yuen MF, 2001, CANCER, V91, P106, DOI 10.1002/1097-0142(20010101)91:1<106::AID-CNCR14>3.0.CO;2-2; Zhong SP, 2000, J BIOL CHEM, V275, P20980, DOI 10.1074/jbc.M909934199; Zhong SP, 2001, J BIOL CHEM, V276, P12932, DOI 10.1074/jbc.M010931200; Zoumpourlis V, 2000, ONCOGENE, V19, P4011, DOI 10.1038/sj.onc.1203732	49	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26435	26442		10.1074/jbc.M303859200	http://dx.doi.org/10.1074/jbc.M303859200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12748197	hybrid			2022-12-25	WOS:000184155700020
J	Leppanen, A; Yago, T; Otto, VI; McEver, RP; Cummings, RD				Leppanen, A; Yago, T; Otto, VI; McEver, RP; Cummings, RD			Model glycosulfopeptides from P-selectin glycoprotein ligand-1 require tyrosine sulfation and a core 2-branched O-glycan to bind to L-selectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL LIGAND; LEUKOCYTE ACCUMULATION; HYDRODYNAMIC SHEAR; MOLECULAR-BASIS; AMINO-TERMINUS; LEWIS-X; PSGL-1; IDENTIFICATION; ADHESION; CELLS	L-selectin expressed on leukocytes is involved in lymphocyte homing to secondary lymphoid organs and leukocyte recruitment into inflamed tissue. L-selectin binds to the sulfated sialyl Lewis x (6-sulfo-sLe(x)) epitope present on O-glycans of various glycoproteins in high endothelial venules. In addition, L-selectin interacts with the dimeric mucin P-selectin glycoprotein ligand-1 (PSGL-1) expressed on leukocytes. PSGL-1 lacks 6-sulfo-sLe(x) but contains sulfated tyrosine residues (Tyr-SO3) at positions 46, 48, and 51 and sLe(x) in a core 2-based O-glycan (C2-O-sLe(x)) on Thr at position 57. The role of tyrosine sulfation and core 2 O-glycans in binding of PSGL-1 to L-selectin is not well defined. Here, we show that L-selectin binds to a glycosulfopeptide (GSP-6) modeled after the extreme N terminus of human PSGL-1, containing three Tyr-SO3 and a nearby Thr modified with C2-O-sLe(x). Leukocytes roll on immobilized GSP-6 in an L-selectin-dependent manner, and rolling is dependent on Tyr-SO3 and C2-O-sLe(x) on GSP-6. The dissociation constant for binding of L-selectin to GSP-6, as measured by equilibrium gel filtration, is similar to5 muM. Binding is dependent on Tyr-SO3 residues as well as the sialic acid and fucose residues of C2-O-sLe(x). Binding to an isomeric glycosulfopeptide containing three Tyr-SO3 residues and a core 1-based O-glycan expressing sLe(x) was reduced by similar to90%. All three Tyr-SO3 residues of GSP-6 are required for high affinity binding to L-selectin. Low affinity binding to mono- and disulfated GSPs is largely independent of the position of the Tyr-SO3 residues, except for some binding preference for an isomer sulfated on both Tyr-48 and -51. These results demonstrate that L-selectin binds with high affinity to the N-terminal region of PSGL-1 through cooperative interactions with three sulfated tyrosine residues and an appropriately positioned C2-O-sLe(x) O-glycan.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation	Cummings, RD (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, 975 NE 10th St,BRC417, Oklahoma City, OK 73104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048075] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 65631] Funding Source: Medline; NIAID NIH HHS [AI48075] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aeed PA, 1998, GLYCOCONJUGATE J, V15, P975, DOI 10.1023/A:1006985825141; AKERS GK, 1973, METHOD ENZYMOL, V27, P441; Andre P, 2000, P NATL ACAD SCI USA, V97, P3400, DOI 10.1073/pnas.040569797; BAUMHUETER S, 1994, BLOOD, V84, P2554; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; Bernimoulin MP, 2003, J BIOL CHEM, V278, P37, DOI 10.1074/jbc.M204360200; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CARLSSON SR, 1986, J BIOL CHEM, V261, P2787; Cummings RD, 1999, BRAZ J MED BIOL RES, V32, P519, DOI 10.1590/S0100-879X1999000500004; DELUCA M, 1995, J BIOL CHEM, V270, P26734, DOI 10.1074/jbc.270.45.26734; Ellies LG, 1998, IMMUNITY, V9, P881, DOI 10.1016/S1074-7613(00)80653-6; Eriksson EE, 2001, J EXP MED, V194, P205, DOI 10.1084/jem.194.2.205; Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0; Guyer DA, 1996, BLOOD, V88, P2415, DOI 10.1182/blood.V88.7.2415.bloodjournal8872415; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; Hemmerich S, 2000, GLYCOBIOLOGY, V10, P849, DOI 10.1093/glycob/10.9.849; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; IMAI Y, 1993, GLYCOCONJUGATE J, V10, P34, DOI 10.1007/BF00731184; IMAI Y, 1993, NATURE, V361, P555; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; Kanamori A, 2002, J BIOL CHEM, V277, P32578, DOI 10.1074/jbc.M204400200; Koenig A, 1997, GLYCOBIOLOGY, V7, P79, DOI 10.1093/glycob/7.1.79; Lee JK, 2003, GLYCOBIOLOGY, V13, P245, DOI 10.1093/glycob/cwg018; Leppanen A, 2002, J BIOL CHEM, V277, P39749, DOI 10.1074/jbc.M206281200; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; Liu W, 1998, J BIOL CHEM, V273, P7078, DOI 10.1074/jbc.273.12.7078; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; Mitoma J, 2003, J BIOL CHEM, V278, P9953, DOI 10.1074/jbc.M212756200; Moll T, 1999, METH MOL B, V96, P77; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; Nicholson MW, 1998, J BIOL CHEM, V273, P763, DOI 10.1074/jbc.273.2.763; Ohmori K, 2000, BIOCHEM BIOPH RES CO, V278, P90, DOI 10.1006/bbrc.2000.3768; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; Ramachandran V, 1999, P NATL ACAD SCI USA, V96, P13771, DOI 10.1073/pnas.96.24.13771; Rosen SD, 1999, AM J PATHOL, V155, P1013, DOI 10.1016/S0002-9440(10)65201-7; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Sassetti C, 2000, J BIOL CHEM, V275, P9001, DOI 10.1074/jbc.275.12.9001; Sassetti C, 1998, J EXP MED, V187, P1965, DOI 10.1084/jem.187.12.1965; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; Tu LL, 1996, J IMMUNOL, V157, P3995; Uchimura K, 2002, J BIOL CHEM, V277, P3979, DOI 10.1074/jbc.M106587200; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Yago T, 2002, J CELL BIOL, V158, P787, DOI 10.1083/jcb.200204041; Yeh JC, 2001, CELL, V105, P957, DOI 10.1016/S0092-8674(01)00394-4; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	54	84	93	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26391	26400		10.1074/jbc.M303551200	http://dx.doi.org/10.1074/jbc.M303551200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12736247	hybrid			2022-12-25	WOS:000184155700015
J	Gibson, N; McAlister-Henn, L				Gibson, N; McAlister-Henn, L			Physical and genetic interactions of cytosolic malate dehydrogenase with other gluconeogenic enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE FRUCTOSE-1,6-BISPHOSPHATASE; PROTEIN-PROTEIN INTERACTIONS; GLUCOSE-INDUCED DEGRADATION; CITRATE SYNTHASE; FUSION PROTEIN; CATABOLITE INACTIVATION; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; MDH2 ISOZYME; YEAST	A truncated form (DeltanMDH2) of yeast cytosolic malate dehydrogenase (MDH2) lacking 12 residues on the amino terminus was found to be inadequate for gluconeogenic function in vivo because the mutant enzyme fails to restore growth of a Deltamdh2 strain on minimal medium with ethanol or acetate as the carbon source. The DeltanMDH2 enzyme was also previously found to be refractory to the rapid glucose-induced inactivation and degradation observed for authentic MDH2. In contrast, kinetic properties measured for purified forms of MDH2 and DeltanMDH2 enzymes are very similar. Yeast two-hybrid assays indicate weak interactions between MDH2 and yeast phosphoenolpyruvate carboxykinase (PCK1) and between MDH2 and fructose-1,6-bisphosphatase (FBP1). These interactions are not observed for DeltanMDH2, suggesting that differences in cellular function between authentic and truncated forms of MDH2 may be related to their ability to interact with other gluconeogenic enzymes. Additional evidence was obtained for interaction of MDH2 with PCK1 using Hummel-Dreyer gel filtration chromatography, and for interactions of MDH2 with PCK1 and with FBP1 using surface plasmon resonance. Experiments with the latter technique demonstrated a much lower affinity for interaction of DeltanMDH2 with PCK1 and no interaction between DeltanMDH2 and FBP1. These results suggest that the interactions of MDH2 with other gluconeogenic enzymes are dependent on the amino terminus of the enzyme, and that these interactions are important for gluconeogenic function in vivo.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	McAlister-Henn, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.				NCRR NIH HHS [1S10RR15883] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015883] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Beeckmans S, 1999, METHODS, V19, P278, DOI 10.1006/meth.1999.0857; BIGL M, 1994, BIOL CHEM H-S, V375, P153, DOI 10.1515/bchm3.1994.375.3.153; BOTSTEIN D, 1979, GENE, V8, P12; CHAPMAN C, 1968, BIOCHEM J, V107, P455, DOI 10.1042/bj1070455; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; CUPP JR, 1991, J BIOL CHEM, V266, P22199; Elcock AH, 1996, BIOCHEMISTRY-US, V35, P12652, DOI 10.1021/bi9614747; ENTIAN KD, 1988, FEBS LETT, V236, P195, DOI 10.1016/0014-5793(88)80313-2; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FUNAYAMA S, 1979, ARCH BIOCHEM BIOPHYS, V197, P170, DOI 10.1016/0003-9861(79)90233-9; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HALL MD, 1992, J MOL BIOL, V226, P867, DOI 10.1016/0022-2836(92)90637-Y; Hammerle M, 1998, J BIOL CHEM, V273, P25000, DOI 10.1074/jbc.273.39.25000; HANSEN RJ, 1976, ANAL BIOCHEM, V74, P178; HOLZER H, 1976, TRENDS BIOCHEM SCI, V1, P178, DOI 10.1016/S0968-0004(76)80018-7; Horak J, 2002, J BIOL CHEM, V277, P8248, DOI 10.1074/jbc.M107255200; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; James P, 1996, GENETICS, V144, P1425; KIM KS, 1986, MOL CELL BIOL, V6, P1936, DOI 10.1128/MCB.6.6.1936; KRAUTWURST H, 1995, BIOCHEMISTRY-US, V34, P6382, DOI 10.1021/bi00019a017; LINDBLADH C, 1994, BIOCHEMISTRY-US, V33, P11692, DOI 10.1021/bi00205a004; McAlister-Henn L, 1999, METHODS, V19, P330, DOI 10.1006/meth.1999.0860; MCALISTERHENN L, 1995, J BIOL CHEM, V270, P21220, DOI 10.1074/jbc.270.36.21220; McCammon MT, 1996, GENETICS, V144, P57; Miller J.H., 1972, EXPT MOL GENETICS; MINARD KI, 1994, ARCH BIOCHEM BIOPHYS, V315, P302, DOI 10.1006/abbi.1994.1504; MINARD KI, 1992, J BIOL CHEM, V267, P17458; MINARD KI, 1991, MOL CELL BIOL, V11, P370, DOI 10.1128/MCB.11.1.370; Morgunov I, 1998, J BIOL CHEM, V273, P29540, DOI 10.1074/jbc.273.45.29540; Ovadi J, 2000, INT REV CYTOL, V192, P255; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; RITTENHOUSE J, 1987, J BIOL CHEM, V262, P10114; RODERICK SL, 1986, J BIOL CHEM, V261, P9461; SCHORK SM, 1995, J BIOL CHEM, V270, P26446, DOI 10.1074/jbc.270.44.26446; Shatalin K, 1999, BIOCHEMISTRY-US, V38, P881, DOI 10.1021/bi982195h; SIKORSKI RS, 1989, GENETICS, V122, P19; Skerra A, 1999, BIOMOL ENG, V16, P79, DOI 10.1016/S1050-3862(99)00033-9; Small WC, 1998, J BACTERIOL, V180, P4051, DOI 10.1128/JB.180.16.4051-4055.1998; Srere P. A., 1972, ENERGY METABOLISM RE, P79; STEFFAN JS, 1992, J BIOL CHEM, V267, P24708; THOMPSON LM, 1989, J BIOL CHEM, V264, P12091; THOMPSON LM, 1988, BIOCHEMISTRY-US, V27, P8393, DOI 10.1021/bi00422a015; VANROERMUND CWT, 1995, EMBO J, V14, P3480, DOI 10.1002/j.1460-2075.1995.tb07354.x; Velot C, 2000, J BIOL CHEM, V275, P12926, DOI 10.1074/jbc.275.17.12926; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; WITT I, 1966, BIOCHIM BIOPHYS ACTA, V128, P63, DOI 10.1016/0926-6593(66)90142-1	48	20	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25628	25636		10.1074/jbc.M213231200	http://dx.doi.org/10.1074/jbc.M213231200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730240	hybrid			2022-12-25	WOS:000183920200045
J	Wang, XS; Phelan, SA; Forsman-Semb, K; Taylor, EF; Petros, C; Brown, A; Lerner, CP; Paigen, B				Wang, XS; Phelan, SA; Forsman-Semb, K; Taylor, EF; Petros, C; Brown, A; Lerner, CP; Paigen, B			Mice with targeted mutation of peroxiredoxin 6 develop normally but are susceptible to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR GLUTATHIONE-PEROXIDASE; ONE-CONSERVED CYSTEINE; MAMMALIAN PEROXIREDOXIN; CRYSTAL-STRUCTURE; 1-CYS PEROXIREDOXIN; SPECTROPHOTOMETRIC METHOD; THIOREDOXIN PEROXIDASE; SUPEROXIDE-DISMUTASE; 2-CYS PEROXIREDOXIN; ANGSTROM RESOLUTION	Reactive oxygen species, especially hydrogen peroxide, are important in cellular signal transduction. However, excessive amounts of these species damage tissues and cells by oxidizing virtually all important biomolecules. Peroxiredoxin 6 (PRDX6) ( also called antioxidant protein 2, or AOP2) is a novel peroxiredoxin family member whose function in vivo is unknown. Through immunohistochemistry, we have determined that the PRDX6 protein was widely expressed in every tissue examined, most abundantly in epithelial cells. It was found in cytosol, but not in membranes, organelles, and nuclei fractions. Prdx6 mRNA was also expressed in every tissue examined. The widespread expression of Prdx6 suggested that its functions were quite important. To determine these functions, we generated Prdx6-targeted mutant (Prdx6(-/-)) mice, confirmed the gene disruption by Southern blots, PCR, RT-PCR, Western blots, and immunohistochemistry, and compared the effects of paraquat, hydrogen peroxide, and t-butyl hydroperoxide on Prdx6(-/-) and wild-type (Prdx6(+/+)) macrophages, and of paraquat on Prdx6(-/-) and Prdx6(+/+) mice. Prdx6(-/-) macrophages had higher hydrogen peroxide levels, and lower survival rates; Prdx6(-/-) mice had significantly lower survival rates, more severe tissue damage, and higher protein oxidation levels. Additionally, there were no differences in the mRNA expression levels of other peroxiredoxins, glutathione peroxidases, catalase, superoxide dismutases, thioredoxins, and glutaredoxins between normal Prdx6(-/-) and Prdx6(-/-) mice and those injected with paraquat. Our study provides in vivo evidence that PRDX6 is a unique non-redundant antioxidant that functions independently of other peroxiredoxins and antioxidant proteins.	Jackson Lab, Bar Harbor, ME 04609 USA; Fairfield Univ, Dept Biol, Fairfield, CT 06430 USA; AstraZeneca R&D Molndal, S-43183 Molndal, Sweden	Jackson Laboratory; Fairfield University; AstraZeneca	Paigen, B (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.				NATIONAL CANCER INSTITUTE [P30CA034196] Funding Source: NIH RePORTER; NCI NIH HHS [CA34196] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alphey MS, 2000, J MOL BIOL, V300, P903, DOI 10.1006/jmbi.2000.3881; BUS JS, 1974, BIOCHEM BIOPH RES CO, V58, P749, DOI 10.1016/S0006-291X(74)80481-X; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; Chae HZ, 1999, DIABETES RES CLIN PR, V45, P101, DOI 10.1016/S0168-8227(99)00037-6; Chen JW, 2000, J BIOL CHEM, V275, P28421, DOI 10.1074/jbc.M005073200; Cheng WH, 1998, J NUTR, V128, P1070, DOI 10.1093/jn/128.7.1070; Cheng WH, 1999, J NUTR, V129, P1951, DOI 10.1093/jn/129.11.1951; Cheng WH, 1999, FASEB J, V13, P1467, DOI 10.1096/fasebj.13.11.1467; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; Curtin JF, 2002, J IMMUNOL METHODS, V265, P49, DOI 10.1016/S0022-1759(02)00070-4; Declercq JP, 2001, J MOL BIOL, V311, P751, DOI 10.1006/jmbi.2001.4853; Fisher AB, 1999, J BIOL CHEM, V274, P21326, DOI 10.1074/jbc.274.30.21326; Frank S, 1997, ONCOGENE, V14, P915, DOI 10.1038/sj.onc.1200905; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Iakoubova OA, 1997, GENOMICS, V42, P474, DOI 10.1006/geno.1997.4762; ISHII T, 1993, J BIOL CHEM, V268, P18633; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; JOHANSSON LH, 1988, ANAL BIOCHEM, V174, P331, DOI 10.1016/0003-2697(88)90554-4; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KAWAI S, 1994, J BIOCHEM-TOKYO, V115, P641, DOI 10.1093/oxfordjournals.jbchem.a124388; Knoops B, 1999, J BIOL CHEM, V274, P30451, DOI 10.1074/jbc.274.43.30451; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; Lee TH, 2000, BIOCHEM BIOPH RES CO, V270, P356, DOI 10.1006/bbrc.2000.2430; Lyu MS, 1999, MAMM GENOME, V10, P1017, DOI 10.1007/s003359901150; Manevich Y, 2002, P NATL ACAD SCI USA, V99, P11599, DOI 10.1073/pnas.182384499; Matsumoto A, 1999, FEBS LETT, V443, P246, DOI 10.1016/S0014-5793(98)01736-0; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Munz B, 1997, BIOCHEM J, V326, P579, DOI 10.1042/bj3260579; NEBOT C, 1993, ANAL BIOCHEM, V214, P442, DOI 10.1006/abio.1993.1521; Okado-Matsumoto A, 2000, J BIOCHEM, V127, P493, DOI 10.1093/oxfordjournals.jbchem.a022632; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Pak JH, 2002, J BIOL CHEM, V277, P49927, DOI 10.1074/jbc.M204222200; Pedrajas JR, 2000, J BIOL CHEM, V275, P16296, DOI 10.1074/jbc.275.21.16296; Phelan SA, 1998, GENOMICS, V54, P132, DOI 10.1006/geno.1998.5568; PROSPERI MT, 1994, GENOMICS, V19, P236, DOI 10.1006/geno.1994.1053; REZNICK AZ, 1994, METHOD ENZYMOL, V233, P357; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Schroder E, 2000, STRUCTURE, V8, P605, DOI 10.1016/S0969-2126(00)00147-7; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; SHAU HG, 1994, IMMUNOGENETICS, V40, P129; Stadtman ER, 1998, DRUG METAB REV, V30, P225, DOI 10.3109/03602539808996310; Stuhlmeier KM, 2003, EUR J BIOCHEM, V270, P334, DOI 10.1046/j.1432-1033.2003.03393.x; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; TSUJI K, 1995, BIOCHEM J, V307, P377, DOI 10.1042/bj3070377; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197; Wood ZA, 2002, BIOCHEMISTRY-US, V41, P5493, DOI 10.1021/bi012173m; YAMAMOTO T, 1989, GENE, V80, P337; Yamashita H, 1999, J BIOL CHEM, V274, P29897, DOI 10.1074/jbc.274.42.29897; [No title captured]	52	263	287	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25179	25190		10.1074/jbc.M302706200	http://dx.doi.org/10.1074/jbc.M302706200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12732627	hybrid			2022-12-25	WOS:000183824800113
J	Pei, HP; Yordy, JS; Leng, QX; Zhao, QH; Watson, DK; Li, RZ				Pei, HP; Yordy, JS; Leng, QX; Zhao, QH; Watson, DK; Li, RZ			EAPII interacts with ETS1 and modulates its transcriptional function	ONCOGENE			English	Article						ETS1; EAPII; transcriptional control; migration	LONG TERMINAL REPEAT; NF-KAPPA-B; MATRIX METALLOPROTEINASE-1; HEPATOCELLULAR-CARCINOMA; PROTEIN INTERACTIONS; TERNARY COMPLEXES; ENDOTHELIAL-CELLS; FAMILY PROTEINS; EXPRESSION; PROMOTER	Ets proteins constitute a family of conserved sequence-specific DNA-binding proteins and function as transcription factors. ETS1 plays important roles in differentiation, lymphoid cell development, invasiveness and angiogenesis. Such diverse roles of ETS1 are likely to be dependent on its associated proteins. A yeast two-hybrid screen was conducted and here we describe a novel ETS1 interacting protein designated as ETS1-associated protein II (EAPII). EAPII protein interacts with ETS1 and other Ets proteins (ETS2 and FLI1) both in vitro and in vivo. Indirect immunofluorescence demonstrated that EAPII is predominately localized to the nucleus of mammalian cells. EAPII negatively modulates ETS1 transcriptional activity and attenuates synergistic transactivation by ETS1 and AP-1. Significantly, re-expression of EAPII inhibits the migration of epithelial cancer cells, but does not affect cell viability. Therefore, EAPII is a novel ETS1 modulator that regulates specific aspects of the ETS1 functions.	Med Univ S Carolina, Hollings Canc Ctr, Lab Canc Genom, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Li, RZ (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Lab Canc Genom, Room 315,86 Jonathan Lucas St, Charleston, SC 29425 USA.				NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA78582] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Chen ZQ, 1997, CANCER RES, V57, P2013; Davidson B, 2001, CLIN CANCER RES, V7, P551; de Nigris F, 2001, CANCER RES, V61, P2267; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; FISHER RJ, 1991, ONCOGENE, V6, P2249; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; GHYSDAEL J, 1997, ETS FAMILY TRANSCRIP; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Gri G, 1998, J BIOL CHEM, V273, P6431, DOI 10.1074/jbc.273.11.6431; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HOLZMEISTER J, 1993, BIOCHEM BIOPH RES CO, V197, P1229, DOI 10.1006/bbrc.1993.2608; Ito Y, 2000, AM J CLIN PATHOL, V114, P719, DOI 10.1309/RAVV-8NM1-CJB7-GJFR; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; KOIZUMI S, 1990, ONCOGENE, V5, P675; KRAMER B, 1995, J BIOL CHEM, V270, P6577; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Maroulakou IG, 2000, ONCOGENE, V19, P6432, DOI 10.1038/sj.onc.1204039; Narayan VA, 1997, J BIOL CHEM, V272, P7801, DOI 10.1074/jbc.272.12.7801; Nimer S, 1996, BLOOD, V88, P66, DOI 10.1182/blood.V88.1.66.bloodjournal88166; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Ozaki I, 2000, CANCER RES, V60, P6519; Pype S, 2000, J BIOL CHEM, V275, P18586, DOI 10.1074/jbc.M000531200; Remy P, 2000, ONCOGENE, V19, P6417, DOI 10.1038/sj.onc.1204044; Rutter JL, 1998, CANCER RES, V58, P5321; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Sementchenko VI, 1998, ONCOGENE, V17, P2883, DOI 10.1038/sj.onc.1202220; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; Verger A, 2002, BIOESSAYS, V24, P362, DOI 10.1002/bies.10068; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 2002, ENCY CANC, V2, P751; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Wheat W, 1999, MOL CELL BIOL, V19, P2231; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9	41	56	59	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2699	2709		10.1038/sj.onc.1206374	http://dx.doi.org/10.1038/sj.onc.1206374			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743594				2022-12-25	WOS:000182569300001
J	Iijima, Y; Nagai, T; Mizukami, M; Matsuura, K; Ogura, T; Wada, H; Toko, H; Akazawa, H; Takano, H; Nakaya, H; Komuro, I				Iijima, Y; Nagai, T; Mizukami, M; Matsuura, K; Ogura, T; Wada, H; Toko, H; Akazawa, H; Takano, H; Nakaya, H; Komuro, I			Beating is necessary for transdifferentiation of skeletal muscle-derived cells into cardiomyocytes	FASEB JOURNAL			English	Article						stem cells; mechanical stress; transdifferentiation	NATRIURETIC-FACTOR GENE; CARDIAC TROPONIN-T; STEM-CELLS; PERFORMANCE; EXPRESSION; MYOCYTES; TRANSPLANTATION; IDENTIFICATION; TRANSCRIPTION; DYSTROPHIN	Cell transplantation could be a potential therapy for heart damage. Skeletal myoblasts have been expected to be a good cell source for autologous transplantation; however, the safety and efficacy of their transplantation are still controversial. Recent studies have revealed that skeletal muscle possesses the stem cell population that is distinct from myoblasts. To elucidate whether skeletal muscle stem cells can transdifferentiate into cardiomyocytes, we cocultured skeletal muscle cells isolated from transgenic mice expressing green fluorescent protein with cardiomyocytes of neonatal rats. Skeletal muscle-derived cells expressed cardiac-specific proteins such as cardiac troponin T and atrial natriuretic peptide as well as cardiac-enriched transcription factors such as Nkx2E (formerly called Csx/Nkx2.5) and GATA4 by coculture with cardiomyocytes. Skeletal muscle-derived cells also expressed cadherin and connexin 43 at the junctions with neighboring cardiomyocytes. Cardiomyocyte-like action potentials were recorded from beating skeletal muscle-derived cells. Treatment of nifedipine or culture in Ca2+-free media suppressed contraction of cardiomyocytes and inhibited skeletal muscle cells to express cardiac-specific proteins. Cyclic stretch completely restored this inhibitory effect. These results suggest that some part of skeletal muscle cells can transdifferentiate into cardiomyocytes and that direct cell-to-cell contact and contraction of neighboring cardiomyocytes are important for the transdifferentiation.	Chiba Univ, Grad Sch Med, Dept Pharmacol, Chiba, Japan; Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chiba, Japan	Chiba University; Chiba University	Komuro, I (corresponding author), Chiba Univ, Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	komuro-tky@umin.ac.jp		Akazawa, Hiroshi/0000-0002-3574-9607				Aikawa R, 2002, HYPERTENSION, V39, P233, DOI 10.1161/hy0202.102699; Altman GH, 2001, FASEB J, V15, P270, DOI 10.1096/fj.01-0656fje; ARGENTIN S, 1994, MOL CELL BIOL, V14, P777, DOI 10.1128/MCB.14.1.777; Atkins BZ, 1999, J HEART LUNG TRANSPL, V18, P1173, DOI 10.1016/S1053-2498(99)00096-0; Carlson F.D., 1974, MUSCLE PHYSL, VVolume 53; EVANS SM, 1994, MOL CELL BIOL, V14, P4269, DOI 10.1128/MCB.14.6.4269; Frey N, 2000, NAT MED, V6, P1221, DOI 10.1038/81321; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Hutcheson KA, 2000, CELL TRANSPLANT, V9, P359, DOI 10.1177/096368970000900307; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Jain M, 2001, CIRCULATION, V103, P1920; Kawada H, 2001, BLOOD, V98, P2008, DOI 10.1182/blood.V98.7.2008; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; McKinney-Freeman SL, 2002, P NATL ACAD SCI USA, V99, P1341, DOI 10.1073/pnas.032438799; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Pouzet B, 2001, CIRCULATION, V104, pI223; Qu-Petersen ZQ, 2002, J CELL BIOL, V157, P851, DOI 10.1083/jcb.200108150; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; Reinecke H, 2000, J CELL BIOL, V149, P731, DOI 10.1083/jcb.149.3.731; Reinecke H, 2002, J MOL CELL CARDIOL, V34, P241, DOI 10.1006/jmcc.2001.1507; SAGGIN L, 1990, DEVELOPMENT, V110, P547; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; SIMPSON P, 1982, CIRC RES, V50, P101, DOI 10.1161/01.RES.50.1.101; Taigen T, 2000, P NATL ACAD SCI USA, V97, P1196, DOI 10.1073/pnas.97.3.1196; Tatsumi R, 2001, EXP CELL RES, V267, P107, DOI 10.1006/excr.2001.5252; Taylor DA, 1998, NAT MED, V4, P929, DOI 10.1038/nm0898-929; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Torrente Y, 2001, J CELL BIOL, V152, P335, DOI 10.1083/jcb.152.2.335; Wang Q, 2000, CIRC RES, V86, P478, DOI 10.1161/01.RES.86.4.478; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221; YAMAZAKI T, 1995, CIRC RES, V77, P258, DOI 10.1161/01.RES.77.2.258; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; ZELLER R, 1987, GENE DEV, V1, P693, DOI 10.1101/gad.1.7.693; Zou YZ, 2002, ENDOCR J, V49, P1, DOI 10.1507/endocrj.49.1	36	64	73	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1361	+		10.1096/fj.02-1048fje	http://dx.doi.org/10.1096/fj.02-1048fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738802				2022-12-25	WOS:000183165000026
J	Jendrossek, V; Muller, I; Eibl, H; Belka, C				Jendrossek, V; Muller, I; Eibl, H; Belka, C			Intracellular mediators of erucylphosphocholine-induced apoptosis	ONCOGENE			English	Article						apoptosis; erucylphosphocholine; caspases; mitochondria; Bcl-2; FADD	DRUG-INDUCED APOPTOSIS; HEMATOPOIETIC PROGENITOR CELLS; RADIATION-INDUCED APOPTOSIS; BREAST-CANCER PATIENTS; HUMAN CARCINOMA-CELLS; HUMAN LEUKEMIC-CELLS; ETHER LIPID ANALOGS; PROTEIN-KINASE-C; CYTOCHROME-C; CASPASE ACTIVATION	Induction of apoptosis contributes to the cytotoxic action of the intravenously applicable alkylphosphocholine erucylphosphocholine (ErPC). To define molecular requirements for ErPC-induced apoptosis, activation of caspases-8, -9 and -3 and cleavage of the caspase-3 substrates PARP and ICAD were tested in normal Jurkat T cells, Jurkat cells resistant to death receptor (CD95 or TNFalpha-related apoptosis inducing ligand (TRAIL)-induced apoptosis, Jurkat cells lacking caspase-8 or Fas-associated death domain (FADD) Jurkat cells expressing a dominant-negative caspase-9 or overexpressing Bcl-2 as well as BJAB B-lymphoma cells expressing a dominant-negative FADD (FADD-DN). ErPC induced a time- and dose-dependent apoptotic cell death in Jurkat and BJAB cells, which was characterized by breakdown of the phosphatidylserine asymmetry, depolarization of the mitochondrial membrane potential, release of cytochrome c, activation of caspases-9, -8 and -3, cleavage of PARP and ICAD, as well as chromatin condensation. ErPC-induced apoptosis was independent from CD95-receptor signaling and FADD since CD95- and TRAIL-resistant, caspase-8- and FADD-negative Jurkat cells, as well as BJAB cells expressing FADD-DN were sensitive to ErPC-induced apoptosis. In contrast, inhibition of caspase-9 and overexpression of Bcl-2 significantly reduced ErPC-induced caspase activation and apoptosis. Thus, ErPC triggers apoptosis via a Bcl-2-dependent mitochondrial but death receptor-independent pathway.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Max Planck Inst Biophys Chem, D-37075 Gottingen, Germany	Eberhard Karls University of Tubingen; Max Planck Society	Jendrossek, V (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.		Jendrossek, Verena/AAH-4967-2019	Jendrossek, Verena/0000-0003-1058-2107				Belka C, 2002, INT J RADIAT BIOL, V78, P643, DOI 10.1080/09553000210137680; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; BERGER MR, 1993, J CANCER RES CLIN, V119, P541, DOI 10.1007/BF01686464; BERGGREN MI, 1993, CANCER RES, V53, P4297; BERGMANN J, 1994, ANTICANCER RES, V14, P1549; Berkovic D, 1995, EUR J CANCER, V31A, P2080, DOI 10.1016/0959-8049(95)00350-9; Berkovic D, 1997, RADIOTHER ONCOL, V43, P293, DOI 10.1016/S0167-8140(97)01909-9; Berkovic D, 2001, EUR J CANCER, V37, P503, DOI 10.1016/S0959-8049(00)00394-4; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cabaner C, 1999, BRIT J PHARMACOL, V127, P813, DOI 10.1038/sj.bjp.0702606; Chen M, 2002, APOPTOSIS, V7, P313, DOI 10.1023/A:1016167228059; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CINEK T, 1995, IMMUNOGENETICS, V41, P110, DOI 10.1007/BF00182321; Clive S, 1999, CANCER CHEMOTH PHARM, V44, pS29, DOI 10.1007/s002800051114; Cuvillier O, 1999, BLOOD, V94, P3583, DOI 10.1182/blood.V94.10.3583.422k31_3583_3592; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Engelmann J, 1996, ANTICANCER RES, V16, P1429; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Erdlenbruch B, 1999, CANCER CHEMOTH PHARM, V44, P484, DOI 10.1007/s002800051122; Ergezinger K, 1999, ANTICANCER RES, V19, P3213; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Friesen C, 1997, LEUKEMIA, V11, P1833, DOI 10.1038/sj.leu.2400827; Fulda S, 1997, CANCER RES, V57, P4956; Gajate C, 2000, INT J CANCER, V85, P674, DOI 10.1002/(SICI)1097-0215(20000301)85:5<674::AID-IJC13>3.0.CO;2-Z; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Gajate C, 1998, MOL PHARMACOL, V53, P602, DOI 10.1124/mol.53.4.602; Georgieva MC, 2002, CANCER LETT, V182, P163, DOI 10.1016/S0304-3835(02)00088-5; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Huang HW, 1999, BIOPHYS J, V77, P1489, DOI 10.1016/S0006-3495(99)76996-1; Jendrossek V, 2001, ANTICANCER RES, V21, P3389; Jendrossek V, 1999, INT J ONCOL, V14, P15; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Konstantinov SM, 1998, CANCER CHEMOTH PHARM, V41, P210; Konstantinov SM, 1999, CANCER LETT, V144, P153, DOI 10.1016/S0304-3835(99)00219-0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li XY, 2001, CANCER RES, V61, P1699; Lucas L, 2001, ONCOGENE, V20, P1110, DOI 10.1038/sj.onc.1204216; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matzke A, 2001, EUR J CELL BIOL, V80, P1, DOI 10.1078/0171-9335-00130; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; MIYASHITA T, 1993, BLOOD, V81, P151; Mollinedo F, 1997, CANCER RES, V57, P1320; MOLLINEDO F, 1994, BIOCHEM J, V302, P325, DOI 10.1042/bj3020325; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Nomura Y, 2000, LEUKEMIA, V14, P299, DOI 10.1038/sj.leu.2401649; NOSEDA A, 1989, EXP MOL PATHOL, V50, P69, DOI 10.1016/0014-4800(89)90057-9; NOSEDA A, 1988, CANCER RES, V48, P1788; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Raisova M, 2002, FEBS LETT, V516, P47, DOI 10.1016/S0014-5793(02)02472-9; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Rudner J, 2001, J CELL SCI, V114, P4161; Rudner J, 2001, INT J RADIAT BIOL, V77, P1, DOI 10.1080/095530001453069; Ruiter GA, 2001, INT J RADIAT ONCOL, V49, P415, DOI 10.1016/S0360-3016(00)01476-0; Ruiter GA, 1999, CANCER RES, V59, P2457; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Smorenburg CH, 2000, ANTI-CANCER DRUG, V11, P825, DOI 10.1097/00001813-200011000-00006; STEKAR J, 1995, EUR J CANCER, V31A, P372, DOI 10.1016/0959-8049(94)00495-Q; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; UNGER C, 1992, PROG EXP TUMOR RES, V34, P153; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; VEHMEYER K, 1992, EXP HEMATOL, V20, P1; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VERWEIJ J, 1992, J CANCER RES CLIN, V118, P606, DOI 10.1007/BF01211805; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; ZHENG B, 1990, CANCER RES, V50, P3025; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	81	57	57	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2621	2632		10.1038/sj.onc.1206355	http://dx.doi.org/10.1038/sj.onc.1206355			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730676				2022-12-25	WOS:000182569000010
J	Ahn, JS; Whitby, MC				Ahn, JS; Whitby, MC			The role of the SAP motif in promoting Holliday junction binding and resolution by SpCCE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-WAY DNA JUNCTION; BACTERIOPHAGE-T7 ENDONUCLEASE-I; RESOLVING ENZYME CCE1; ESCHERICHIA-COLI; SCHIZOSACCHAROMYCES-POMBE; REPLICATION FORKS; BRANCH MIGRATION; SACCHAROMYCES-CEREVISIAE; SEQUENCE SPECIFICITY; MITOCHONDRIAL-DNA	Holliday junctions are four-way branched DNA structures that are formed during recombination and by replication fork regression. Their processing depends on helicases that catalyze junction branch migration, and endonucleases that resolve the junction into nicked linear DNAs. Here we have investigated the role of a DNA binding motif called SAP in binding and resolving Holliday junctions by the fission yeast mitochondrial resolvase SpCCE1. Mutation or partial/complete deletion of the SAP motif dramatically impairs the ability of SpCCE1 to resolve Holliday junctions in a heterologous in vivo system. These mutant proteins retain the ability to recognize the junction structure and to distort it upon binding. However, once formed the mutant protein-junction complexes are relatively unstable and dissociate much faster than wild-type complexes. We show that binding stability is necessary for efficient junction resolution, and that this may be due in part to a requirement for maintaining the junction in an open conformation so that it can branch migrate to cleavable sites.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford	Whitby, MC (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.			Whitby, Matthew/0000-0003-0951-3374				Aravind L, 2000, NUCLEIC ACIDS RES, V28, P3417, DOI 10.1093/nar/28.18.3417; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; BENNETT RJ, 1995, J MOL BIOL, V252, P213, DOI 10.1006/jmbi.1995.0489; Ceschini S, 2001, EMBO J, V20, P6601, DOI 10.1093/emboj/20.23.6601; Chan SN, 1997, J BIOL CHEM, V272, P14873, DOI 10.1074/jbc.272.23.14873; Chan SN, 1998, NUCLEIC ACIDS RES, V26, P1560, DOI 10.1093/nar/26.7.1560; CHOU CH, 1992, J EXP MED, V175, P1677, DOI 10.1084/jem.175.6.1677; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Declais AC, 2000, J MOL BIOL, V296, P421, DOI 10.1006/jmbi.1999.3479; Doe CL, 2000, MOL GEN GENET, V263, P889, DOI 10.1007/s004380000256; DUCKETT DR, 1995, J MOL BIOL, V246, P95, DOI 10.1006/jmbi.1994.0069; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; FACKELMAYER FO, 1994, EUR J BIOCHEM, V221, P749, DOI 10.1111/j.1432-1033.1994.tb18788.x; FACKELMAYER FO, 1994, BIOCHEMISTRY-US, V33, P10416, DOI 10.1021/bi00200a024; Fogg JM, 1999, BIOCHEMISTRY-US, V38, P11349, DOI 10.1021/bi990926n; Giraud-Panis MJE, 1998, J MOL BIOL, V278, P117, DOI 10.1006/jmbi.1998.1681; Gohring F, 1997, EMBO J, V16, P7361, DOI 10.1093/emboj/16.24.7361; Ho PS, 2001, CURR OPIN STRUC BIOL, V11, P302, DOI 10.1016/S0959-440X(00)00219-0; JOHNSON RD, 1993, J MOL BIOL, V229, P812, DOI 10.1006/jmbi.1993.1087; Kipp M, 2000, MOL CELL BIOL, V20, P7480, DOI 10.1128/MCB.20.20.7480-7489.2000; KLEFF S, 1992, EMBO J, V11, P699, DOI 10.1002/j.1460-2075.1992.tb05102.x; LANE D, 1992, MICROBIOL REV, V56, P509, DOI 10.1128/MMBR.56.4.509-528.1992; Lilley DMJ, 2001, NAT REV MOL CELL BIO, V2, P433, DOI 10.1038/35073057x; LOCKSHON D, 1995, CELL, V81, P947, DOI 10.1016/0092-8674(95)90014-4; Mahdi AA, 1996, J MOL BIOL, V257, P561, DOI 10.1006/jmbi.1996.0185; MANDAL TN, 1993, J BACTERIOL, V175, P4325, DOI 10.1128/JB.175.14.4325-4334.1993; McGlynn P, 2000, CELL, V101, P35, DOI 10.1016/S0092-8674(00)80621-2; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; PANYUTIN IG, 1995, EMBO J, V14, P1819, DOI 10.1002/j.1460-2075.1995.tb07170.x; PICKSLEY SM, 1990, J MOL BIOL, V212, P723, DOI 10.1016/0022-2836(90)90233-C; Pohler JRG, 1996, J MOL BIOL, V260, P678; Postow L, 2001, J BIOL CHEM, V276, P2790, DOI 10.1074/jbc.M006736200; Robu ME, 2001, P NATL ACAD SCI USA, V98, P8211, DOI 10.1073/pnas.131022698; Schofield MJ, 1998, BIOCHEMISTRY-US, V37, P7733, DOI 10.1021/bi980399s; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; SHAH R, 1994, CELL, V79, P853, DOI 10.1016/0092-8674(94)90074-4; Sharples GJ, 2001, MOL MICROBIOL, V39, P823, DOI 10.1046/j.1365-2958.2001.02284.x; Shinohara A, 1999, MUTAT RES-DNA REPAIR, V435, P13, DOI 10.1016/S0921-8777(99)00033-6; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; van Gool AJ, 1998, EMBO J, V17, P1838, DOI 10.1093/emboj/17.6.1838; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; WANG JS, 1994, FEBS LETT, V351, P219, DOI 10.1016/0014-5793(94)00863-9; Whitby MC, 1997, J MOL BIOL, V272, P509, DOI 10.1006/jmbi.1997.1286; Whitby MC, 1996, J MOL BIOL, V264, P878, DOI 10.1006/jmbi.1996.0684; Whitby MC, 2001, J MOL BIOL, V306, P703, DOI 10.1006/jmbi.2000.4407; Whitby MC, 1998, J BIOL CHEM, V273, P35063, DOI 10.1074/jbc.273.52.35063; White MF, 1998, NUCLEIC ACIDS RES, V26, P5609, DOI 10.1093/nar/26.24.5609; White MF, 1996, J MOL BIOL, V257, P330, DOI 10.1006/jmbi.1996.0166; White MF, 1997, MOL CELL BIOL, V17, P6465, DOI 10.1128/MCB.17.11.6465; White MF, 1997, J MOL BIOL, V266, P122, DOI 10.1006/jmbi.1996.0795	50	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29121	29129		10.1074/jbc.M302314200	http://dx.doi.org/10.1074/jbc.M302314200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12748193	hybrid			2022-12-25	WOS:000184421100096
J	Elorza, A; Penela, P; Sarnago, S; Mayor, F				Elorza, A; Penela, P; Sarnago, S; Mayor, F			MAPK-dependent degradation of G protein-coupled receptor kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASES; SRC TYROSINE KINASE; BETA-ARRESTIN; MEDIATED ENDOCYTOSIS; PROTEASOME PATHWAY; 2 GRK2; C-SRC; PHOSPHORYLATION; ACTIVATION; DESENSITIZATION	G protein-coupled receptor kinase 2 (GRK2) is a key modulator of G protein-coupled receptors (GPCR). Altered expression of GRK2 has been described to occur during pathological conditions characterized by impaired GPCR signaling. We have reported recently that GRK2 is rapidly degraded by the proteasome pathway and that beta-arrestin function and Src-mediated phosphorylation are involved in targeting GRK2 for proteolysis. In this report, we show that phosphorylation of GRK2 by MAPK also triggers GRK2 turnover by the proteasome pathway. Modulation of MAPK activation alters the degradation of transfected or endogenous GRK2, and a GRK2 mutant that mimics phosphorylation by MAPK shows an enhanced degradation rate, thus indicating a direct effect of MAPK on GRK2 turnover. Interestingly, MAPK-mediated modulation of wild-type GRK2 stability requires beta-arrestin function and is facilitated by previous phosphorylation of GRK2 on tyrosine residues by c-Src. Consistent with an important physiological role, interfering with this GRK2 degradation process results in altered GPCR responsiveness. Our data suggest that both c-Src and MAPK-mediated phosphorylation would contribute to modulate GRK2 degradation, and put forward the existence of new feedback mechanisms connecting MAPK cascades and GPCR signaling.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain; Univ Autonoma Madrid, Dept Biol Mol, CSIC, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)	Mayor, F (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain.		Mayor, Federico/N-7644-2016	Mayor Menendez, Federico/0000-0003-1434-8449				Aragay AM, 1998, FEBS LETT, V430, P37, DOI 10.1016/S0014-5793(98)00495-5; Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; Delmas C, 2001, J BIOL CHEM, V276, P34958, DOI 10.1074/jbc.M101714200; Eckhart AD, 2002, MOL PHARMACOL, V61, P749, DOI 10.1124/mol.61.4.749; Elorza A, 2000, MOL PHARMACOL, V57, P778, DOI 10.1124/mol.57.4.778; Esch RK, 2002, P NATL ACAD SCI USA, V99, P9160, DOI 10.1073/pnas.142034399; Feldman RD, 2002, MOL PHARMACOL, V61, P707, DOI 10.1124/mol.61.4.707; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Freedman NJ, 2002, J BIOL CHEM, V277, P48261, DOI 10.1074/jbc.M204431200; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gros R, 1997, J CLIN INVEST, V99, P2087, DOI 10.1172/JCI119381; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Lombardi MS, 2002, CRIT REV IMMUNOL, V22, P141; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDonald PH, 2001, CELL SIGNAL, V13, P683, DOI 10.1016/S0898-6568(01)00203-0; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; PAO CS, 2002, SCI STKE; Penela P, 1998, J BIOL CHEM, V273, P35238, DOI 10.1074/jbc.273.52.35238; Penela P, 2001, EMBO J, V20, P5129, DOI 10.1093/emboj/20.18.5129; PENELA P, 2003, IN PRESS CELL SIGNAL; Penn RB, 2000, TRENDS CARDIOVAS MED, V10, P81, DOI 10.1016/S1050-1738(00)00053-0; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Ruiz-Gomez A, 2000, J BIOL CHEM, V275, P29724, DOI 10.1074/jbc.M001864200; Sarnago S, 1999, J BIOL CHEM, V274, P34411, DOI 10.1074/jbc.274.48.34411; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Tang T, 2002, J BIOL CHEM, V277, P18365, DOI 10.1074/jbc.M109812200; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; Whistler JL, 1999, J BIOL CHEM, V274, P24575, DOI 10.1074/jbc.274.35.24575; Yehia G, 2001, J BIOL CHEM, V276, P35272, DOI 10.1074/jbc.M105404200	41	67	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29164	29173		10.1074/jbc.M304314200	http://dx.doi.org/10.1074/jbc.M304314200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12738776	hybrid			2022-12-25	WOS:000184421100101
J	Funakoshi-Tago, M; Sonoda, Y; Tanaka, S; Hashimoto, K; Tago, K; Tominaga, S; Kasahara, T				Funakoshi-Tago, M; Sonoda, Y; Tanaka, S; Hashimoto, K; Tago, K; Tominaga, S; Kasahara, T			Tumor necrosis factor-induced nuclear factor kappa B activation is impaired in focal adhesion kinase-deficient fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED SIGNAL-TRANSDUCTION; N-TERMINAL KINASE; TYROSINE PHOSPHORYLATION; PROTEIN-KINASE; CELL-MIGRATION; TNF RECEPTOR; GROWTH-FACTOR; INDUCED APOPTOSIS; IKK ACTIVATION; C-JUN	Focal adhesion kinase (FAK) is widely involved in important cellular functions such as proliferation, migration, and survival, although its roles in immune and inflammatory responses have yet to be explored. We demonstrate a critical role for FAK in the tumor necrosis factor (TNF)-induced activation of nuclear factor (NF)-kappaB, using FAK-deficient (FAK-/-) embryonic fibroblasts. Interestingly, TNF-induced interleukin (IL)-6 production was nearly abolished in FAK -/- fibroblasts, whereas a normal level of production was obtained in FAK -/- or FAK +/+ fibroblasts. FAK deficiency did not affect the three types of mitogen-activated protein kinases, ERK, JNK, and p38. Similarly, TNF-induced activation of activator protein 1 or NF-IL-6 was not impaired in FAK -/- cells. Of note, TNF-induced NF-kappaB DNA binding activity and activation of IkappaB kinases (IKKs) were markedly impaired in FAK -/- cells, whereas the expression of TNF receptor I or other signaling molecules such as receptor-interacting protein (RIP), tumor necrosis factor receptor-associated factor 2 (TRAF2), IKKalpha, IKKbeta, and IKKgamma was unchanged. Also, TNF-induced association of FAK with RIP and subsequent association of RIP with TRAF2 were not observed, resulting in a failure of RIP to recruit the IKK complex in FAK -/- cells. The reintroduction of wild type FAK into FAK -/- cells restored the interaction of RIP with TRAF2 and the IKK complex and allowed recovery of NF-kappaB activation and subsequent IL-6 production. Thus, we propose a novel role for FAK in the NF-kappaB activation pathway leading to the production of cytokines.	Kyoritsu Coll Pharmaceut Sci, Dept Biochem, Minato Ku, Tokyo 1058512, Japan; Jichi Med Sch, Dept Biochem, Minami Kawachi, Tochigi 3290433, Japan	Jichi Medical University	Kasahara, T (corresponding author), Kyoritsu Coll Pharmaceut Sci, Dept Biochem, Minato Ku, 1-5-30 Shibakoen, Tokyo 1058512, Japan.							ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901; Corredor J, 2003, AM J PHYSIOL-CELL PH, V284, pC953, DOI 10.1152/ajpcell.00309.2002; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Devin A, 2001, MOL CELL BIOL, V21, P3986, DOI 10.1128/MCB.21.12.3986-3994.2001; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Funakoshi M, 2001, INT IMMUNOPHARMACOL, V1, P595, DOI 10.1016/S1567-5769(00)00035-7; Funakoshi M, 2001, BIOCHEM BIOPH RES CO, V283, P248, DOI 10.1006/bbrc.2001.4759; FURUTA Y, 1995, ONCOGENE, V11, P1989; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Ilic D, 1997, J CELL SCI, V110, P401; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kasahara T, 2002, ANTIOXID REDOX SIGN, V4, P491, DOI 10.1089/15230860260196290; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rozengurt E, 1997, ESSAYS BIOCHEM, V32, P73; Sakurai S, 2002, BIOCHEM BIOPH RES CO, V293, P174, DOI 10.1016/S0006-291X(02)00192-4; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tuyt LML, 1999, J IMMUNOL, V162, P4893; Ueki K, 1998, FEBS LETT, V432, P197, DOI 10.1016/S0014-5793(98)00862-X; Yamamoto D, 2003, CELL SIGNAL, V15, P575, DOI 10.1016/S0898-6568(02)00142-0; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zhang LF, 2002, CARCINOGENESIS, V23, P1251, DOI 10.1093/carcin/23.7.1251; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	54	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29359	29365		10.1074/jbc.M213115200	http://dx.doi.org/10.1074/jbc.M213115200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12748169	hybrid			2022-12-25	WOS:000184421100122
J	Martina, JA; Moriyama, K; Bonifacino, JS				Martina, JA; Moriyama, K; Bonifacino, JS			BLOC-3, a protein complex containing the Hermansky-Pudlak syndrome gene products HPS1 and HPS4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AP-3 ADAPTER COMPLEX; STORAGE POOL DEFICIENCY; PALE EAR EP; BETA-3A SUBUNIT; LIGHT-EAR; MOUSE; MUTATION; HOMOLOG; TRAFFICKING; BIOGENESIS	The Hermansky-Pudlak syndrome (HPS) is a genetic disorder characterized by defective lysosome-related organelles. HPS results from mutations in either one of six human genes named HPS1 to HPS6, most of which encode proteins of unknown function. Here we report that the human HPS1 and HPS4 proteins are part of a complex named BLOC-3 ( for biogenesis of lysosome-related organelles complex 3). Co-immunoprecipitation experiments demonstrated that epitope-tagged and endogenous HPS1 and HPS4 proteins assemble with each other in vivo. The HPS1 . HPS4 complex is predominantly cytosolic, with a small amount being peripherally associated with membranes. Size exclusion chromatography and sedimentation velocity analyses of the cytosolic fraction indicate that HPS1 and HPS4 form a moderately asymmetric protein complex with a molecular mass of similar to 175 kDa. HPS4-deficient fibroblasts from light ear mice display normal distribution and trafficking of the lysosomal membrane protein, Lamp-2, in contrast to fibroblasts from AP-3-deficient pearl mice (HPS2), which exhibit increased trafficking of this lysosomal protein via the plasma membrane. Similarly, light ear fibroblasts display an apparently normal accumulation of Zn2+ in intracellular vesicles, unlike pearl fibroblasts, which exhibit a decreased intracellular Zn2+ storage. Taken together, these observations demonstrate that the HPS1 and HPS4 proteins are components of a cytosolic complex that is involved in the biogenesis of lysosomal-related organelles by a mechanism distinct from that operated by AP-3 complex.	NICHD, Metab Branch, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Bonifacino, JS (corresponding author), NICHD, Metab Branch, Cell Biol & Metab Branch, NIH, Bldg 18T,Rm 101, Bethesda, MD 20892 USA.	juan@helix.nih.gov	Martina, Jose A/C-2772-2013	Martina, Jose/0000-0001-5814-8807; Bonifacino, Juan S./0000-0002-5673-6370	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001607] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001607] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anikster Y, 2001, NAT GENET, V28, P376, DOI 10.1038/ng576; Bonifacino J. S., 1998, CURRENT PROTOCOLS CE; BROWN JA, 1985, J CELL BIOL, V100, P1894, DOI 10.1083/jcb.100.6.1894; Ciciotte SL, 2003, BLOOD, V101, P4402, DOI 10.1182/blood-2003-01-0020; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; Dell'Angelica EC, 2000, J BIOL CHEM, V275, P1300, DOI 10.1074/jbc.275.2.1300; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; DellAngelica EC, 1997, J BIOL CHEM, V272, P15078, DOI 10.1074/jbc.272.24.15078; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Detter JC, 2000, P NATL ACAD SCI USA, V97, P4144, DOI 10.1073/pnas.080517697; Falcon-Perez JM, 2002, J BIOL CHEM, V277, P28191, DOI 10.1074/jbc.M204011200; Feng GH, 1997, HUM MOL GENET, V6, P793, DOI 10.1093/hmg/6.5.793; Feng LJ, 1999, HUM MOL GENET, V8, P323, DOI 10.1093/hmg/8.2.323; Gardner JM, 1997, P NATL ACAD SCI USA, V94, P9238, DOI 10.1073/pnas.94.17.9238; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Huang LP, 1999, NAT GENET, V23, P329, DOI 10.1038/15507; Huizing M, 2001, MOL BIOL CELL, V12, P2075, DOI 10.1091/mbc.12.7.2075; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; Le Borgne R, 1998, J BIOL CHEM, V273, P29451, DOI 10.1074/jbc.273.45.29451; Le Borgne R, 2001, J CELL SCI, V114, P2831; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; MARKS MS, 1998, CURRENT PROTOCOLS CE; Martina JA, 2001, J CELL BIOL, V153, P1111, DOI 10.1083/jcb.153.5.1111; MEISLER M, 1980, AM J PATHOL, V101, P581; MEISLER MH, 1984, J HERED, V75, P103, DOI 10.1093/oxfordjournals.jhered.a109881; Moriyama K, 2002, TRAFFIC, V3, P666, DOI 10.1034/j.1600-0854.2002.30908.x; Nguyen T, 2002, J INVEST DERMATOL, V119, P1156, DOI 10.1046/j.1523-1747.2002.19535.x; Oh J, 2000, HUM MOL GENET, V9, P375, DOI 10.1093/hmg/9.3.375; Oh J, 1996, NAT GENET, V14, P300, DOI 10.1038/ng1196-300; Reusch U, 2002, TRAFFIC, V3, P752, DOI 10.1034/j.1600-0854.2002.31007.x; Sato TK, 2000, MOL CELL, V6, P661, DOI 10.1016/S1097-2765(00)00064-2; Seals DF, 2000, P NATL ACAD SCI USA, V97, P9402, DOI 10.1073/pnas.97.17.9402; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; Suzuki T, 2003, P NATL ACAD SCI USA, V100, P1146, DOI 10.1073/pnas.0237292100; Suzuki T, 2002, NAT GENET, V30, P321, DOI 10.1038/ng835; Suzuki T, 2001, GENOMICS, V78, P30, DOI 10.1006/geno.2001.6644; Swank RT, 1998, PIGM CELL RES, V11, P60, DOI 10.1111/j.1600-0749.1998.tb00713.x; Ward Diane McVey, 2002, Current Molecular Medicine (Hilversum), V2, P469, DOI 10.2174/1566524023362339; Yang W, 2000, J CELL SCI, V113, P4077; ZALEWSKI PD, 1993, BIOCHEM J, V296, P403, DOI 10.1042/bj2960403; Zhang Q, 2003, NAT GENET, V33, P145, DOI 10.1038/ng1087; Zhang Q, 2002, HUM MOL GENET, V11, P697, DOI 10.1093/hmg/11.6.697; Zhen LJ, 1999, BLOOD, V94, P146, DOI 10.1182/blood.V94.1.146.413k39_146_155	45	86	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29376	29384		10.1074/jbc.M301294200	http://dx.doi.org/10.1074/jbc.M301294200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12756248	hybrid			2022-12-25	WOS:000184421100124
J	Beebe, JA; Wiepz, GJ; Guadarrama, AG; Bertics, PJ; Burke, TJ				Beebe, JA; Wiepz, GJ; Guadarrama, AG; Bertics, PJ; Burke, TJ			A carboxyl-terminal mutation of the epidermal growth factor receptor alters tyrosine kinase activity and substrate specificity as measured by a fluorescence polarization assay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE C-GAMMA; SELF-PHOSPHORYLATION; AUTOPHOSPHORYLATION SITES; EGF RECEPTOR; HUMAN GLIOBLASTOMAS; ACTIVATION; PROTEIN; SHC; EXPRESSION; BINDING	The expression of certain COOH-terminal truncation mutants of the epidermal growth factor receptor ( EGFR) can lead to cell transformation, and with ligand stimulation, a broader spectrum of phosphorylated proteins appears compared with EGF-treated cells expressing wild-type EGFR. Accordingly, it has been proposed that elements within the COOH terminus may determine substrate specificity of the EGFR tyrosine kinase (Decker, S. J., Alexander, C., and Habib, T. ( 1992) J. Biol. Chem. 267, 1104 - 1108; Walton, G. M., Chen, W. S., Rosenfeld, M. G., and Gill, G. N. ( 1990) J. Biol. Chem. 265, 1750 - 1754). To address this hypothesis, we analyzed in vitro the steady-state kinetic parameters for phosphorylation of several substrates by both wild-type EGFR and an oncogenic EGFR mutant ( the ct1022 mutant) truncated at residue 1022. The substrates included: (i) a phospholipase C-gamma fragment ( residues 530 - 850); (ii) the 46-kDa isoform of the Shc adapter protein; (iii) a 13-residue peptide mimic for the region around the major autophosphorylation tyrosine and the Shc binding site ( the Y1173 peptide); (iv) a poly(Glu, Tyr) 4: 1 copolymer; and ( v) the 8-residue peptide, angiotensin II. Our data demonstrate that the steady-state kinetic parameters for the ct1022 mutant differ from those of the wild-type enzyme, and the differences are substrate-dependent. These results support the concept that this oncogenic truncation/mutation alters EGFR substrate specificity, rather than causing a general alteration of activity. We performed the experiments using a non-radioactive fluorescence polarization assay that quantifies the degree of phosphorylation of peptide as well as natural substrates. The results are consistent with those from the traditional [gamma-P-32] ATP/filtration assay.	PanVera, Madison, WI 53719 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Beebe, JA (corresponding author), PanVera, 501 Charmany Dr, Madison, WI 53719 USA.				NATIONAL CANCER INSTITUTE [R44CA080516] Funding Source: NIH RePORTER; NCI NIH HHS [1R44CA/GM80516-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allison R D, 1979, Methods Enzymol, V63, P3; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; Carpenter KA, 1998, EUR J BIOCHEM, V251, P448, DOI 10.1046/j.1432-1327.1998.2510448.x; CHECOVICH WJ, 1995, NATURE, V375, P254, DOI 10.1038/375254a0; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; Fenstermaker RA, 1998, ONCOGENE, V16, P3435, DOI 10.1038/sj.onc.1202156; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; FERSHT A, 1985, ENZYME STRUCTURE MEC, P153; Frederick L, 2000, CANCER RES, V60, P1383; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; HERTEL C, 1986, J BIOL CHEM, V261, P5974; Homann S, 2001, J BIOTECHNOL, V86, P51, DOI 10.1016/S0168-1656(00)00399-0; HUBLER L, 1992, BIOCHEM J, V281, P107, DOI 10.1042/bj2810107; Jan AY, 2000, BIOCHEMISTRY-US, V39, P9786, DOI 10.1021/bi9924922; Kargacin ME, 1997, AM J PHYSIOL-CELL PH, V273, pC1416; KIM JW, 1990, J BIOL CHEM, V265, P3940; Kim YN, 2000, J BIOL CHEM, V275, P7481, DOI 10.1074/jbc.275.11.7481; LAX I, 1985, EMBO J, V4, P3179, DOI 10.1002/j.1460-2075.1985.tb04062.x; Li J, 1999, J BIOL CHEM, V274, P11209, DOI 10.1074/jbc.274.16.11209; MAIHLE NJ, 1989, BIOCHIM BIOPHYS ACTA, V948, P287, DOI 10.1016/0304-419X(89)90003-6; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Nasir MS, 1999, COMB CHEM HIGH T SCR, V2, P177; Parker GJ, 2000, J BIOMOL SCREEN, V5, P77, DOI 10.1177/108705710000500204; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REIBSTEIN D, 1986, BIOCHEMISTRY-US, V25, P219, DOI 10.1021/bi00349a031; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SALOMON DS, 2001, SIGNAL, V2, P4; Sasaoka T, 1996, J BIOL CHEM, V271, P8338, DOI 10.1074/jbc.271.14.8338; Sherrill JM, 1999, BIOCHEMISTRY-US, V38, P3106, DOI 10.1021/bi982276d; SOLER C, 1994, ONCOGENE, V9, P2207; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WEBER W, 1984, J BIOL CHEM, V259, P4631; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wells A., 2000, SIGNAL, V1, P4; Wikstrand CJ, 2000, EXPER OPIN THER TAR, V4, P497; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	39	9	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26810	26816		10.1074/jbc.M301397200	http://dx.doi.org/10.1074/jbc.M301397200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12746449	hybrid			2022-12-25	WOS:000184155700067
J	Ge, WW; Leystra-Lantz, C; Wen, WY; Strong, MJ				Ge, WW; Leystra-Lantz, C; Wen, WY; Strong, MJ			Selective loss of trans-acting instability determinants of neurofilament mRNA in amyotrophic lateral sclerosis spinal cord	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR-NEURON DISEASE; HEAVY GENE; DESTABILIZING ELEMENT; NF-H; EXPRESSION; LIGHT; MICE; OVEREXPRESSION; ACCUMULATION; P190RHOGEF	Neurofilament (NF) aggregates in motor neurons are a key neuropathological feature of amyotrophic lateral sclerosis (ALS). We have previously observed an alteration in the stoichiometry of NF subunit steady state mRNA levels in ALS spinal motor neurons using in situ hybridization and proposed that this led to aggregate formation. We have now examined the levels of NF mRNA in whole tissue homogenates of spinal cord using the RNase protection assay and real time reverse transcriptase-PCR and observed significant elevations of NF mRNA level in ALS. Compared with age-matched control, we observed a greater stability of heterogeneously expressed NFL mRNA in the presence of ALS spinal cord homogenates. Heat denaturing or protease K digestion of the control homogenates increased the stability of the NFL mRNA to levels observed in ALS homogenate. Increased NFL mRNA stability was also induced by increasing the percentage of ALS homogenate in an admixture of control and ALS homogenates. These observations suggest the presence of trans-acting NFL mRNA-destabilizing elements in control but not in ALS spinal cord homogenates. This was confirmed in gel retardation assays. We also observed that the destabilizing elements interact with the 3'-untranslated region of NFL mRNA. These findings suggest that the trans-acting NFL-destabilizing elements are selectively suppressed in ALS homogenates, resulting in an increased stability and level of NFL mRNA.	John P Robarts Res Inst, Cell Biol Res Grp, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Clin Neurol Sci, London, ON N6A 5A5, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Strong, MJ (corresponding author), Rm 7OF10,Univ Campus,339 Windermere Rd, London, ON N6A 5A5, Canada.	mstrong@uwo.ca	Strong, Michael J/H-9689-2012; Strong, Michael/AAU-5699-2020	Strong, Michael/0000-0003-1988-6262				AVERBACK P, 1981, ARCH PATHOL LAB MED, V105, P490; BERGERON C, 1994, J NEUROPATH EXP NEUR, V53, P221, DOI 10.1097/00005072-199405000-00002; BROOKS BR, 1994, J NEUROL SCI, V124, P96, DOI 10.1016/0022-510X(94)90191-0; Canete-Soler R, 1998, J BIOL CHEM, V273, P12655, DOI 10.1074/jbc.273.20.12655; Canete-Soler R, 2001, J BIOL CHEM, V276, P32046, DOI 10.1074/jbc.M104104200; CANETESOLER R, 1998, J BIOL CHEM, V273, P12651; CARPENTER S, 1968, NEUROLOGY, V18, P841, DOI 10.1212/WNL.18.9.841; CASHMAN NR, 1992, DEV DYNAM, V194, P209, DOI 10.1002/aja.1001940306; CATNETESOLER R, 2001, BRAIN RES, V867, P265; Chan SO, 1997, BRAIN RES, V775, P107, DOI 10.1016/S0006-8993(97)00834-2; Cookson MR, 1998, J NEUROCHEM, V70, P501; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; Couillard-Despres S, 1998, P NATL ACAD SCI USA, V95, P9626, DOI 10.1073/pnas.95.16.9626; Couillard-Despres S, 2000, NEUROBIOL DIS, V7, P462, DOI 10.1006/nbdi.2000.0296; DELISLE MB, 1984, J NEUROL SCI, V63, P241, DOI 10.1016/0022-510X(84)90199-0; DURRLEMAN S, 1989, NEUROLOGY, V39, P768, DOI 10.1212/WNL.39.6.768; Ge WW, 2002, J BIOL CHEM, V277, P42701, DOI 10.1074/jbc.M206635200; HARTMANN HA, 1992, MOL CHEM NEUROPATHOL, V17, P249, DOI 10.1007/BF03160014; JULIEN JP, 1995, NEUROBIOL AGING, V16, P487, DOI 10.1016/0197-4580(94)00169-2; Julien JP, 1998, BRAIN PATHOL, V8, P759, DOI 10.1111/j.1750-3639.1998.tb00199.x; Kirkcaldie MTK, 2002, J CHEM NEUROANAT, V24, P163, DOI 10.1016/S0891-0618(02)00043-1; KURE R, 1995, NEUROCHEM RES, V20, P833, DOI 10.1007/BF00969696; LEIGH PN, 1989, BRAIN, V112, P521, DOI 10.1093/brain/112.2.521; LILIENFELD DE, 1989, LANCET, V1, P710; MANETTO V, 1988, J NEUROPATH EXP NEUR, V47, P642, DOI 10.1097/00005072-198811000-00007; Meier J, 1999, J NEUROPATH EXP NEUR, V58, P1099, DOI 10.1097/00005072-199910000-00009; Menzies FM, 2002, J NEUROCHEM, V82, P1118, DOI 10.1046/j.1471-4159.2002.01045.x; MOSKOWITZ PF, 1995, MOL BRAIN RES, V30, P211, DOI 10.1016/0169-328X(95)00006-E; MUNOZ DG, 1988, J NEUROPATH EXP NEUR, V47, P9, DOI 10.1097/00005072-198801000-00002; MURAYAMA S, 1992, ACTA NEUROPATHOL, V83, P518, DOI 10.1007/BF00310029; SCHWARTZ ML, 1994, MOL BRAIN RES, V27, P215, DOI 10.1016/0169-328X(94)90003-5; STRONG M, 2003, IN PRESS AMYOTROPH L; VICKERS JC, 1992, NEUROSCIENCE, V49, P73, DOI 10.1016/0306-4522(92)90077-F; Williamson TL, 1998, P NATL ACAD SCI USA, V95, P9631, DOI 10.1073/pnas.95.16.9631; Wong NKY, 2000, J NEUROPATH EXP NEUR, V59, P972, DOI 10.1093/jnen/59.11.972; WONG PC, 1995, J CELL BIOL, V130, P1413, DOI 10.1083/jcb.130.6.1413; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L	37	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26558	26563		10.1074/jbc.M302886200	http://dx.doi.org/10.1074/jbc.M302886200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12730211	hybrid			2022-12-25	WOS:000184155700036
J	Steuber, J				Steuber, J			The C-terminally truncated NuoL subunit (ND5 homologue) of the Na+-dependent complex I from Escherichia coli transports Na+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; BOVINE HEART-MITOCHONDRIA; QUINONE OXIDOREDUCTASE; BINDING-SITES; KLEBSIELLA-PNEUMONIAE; TRANSLOCATING NADH; ANTIPORTER; MEMBRANE; GROWTH; OVERPRODUCTION	The NADH: quinone oxidoreductase ( complex I) from Escherichia coli acts as a primary Na+ pump. Expression of a C-terminally truncated version of the hydrophobic NuoL subunit (ND5 homologue) from E. coli complex I resulted in Na+-dependent growth inhibition of the E. coli host cells. Membrane vesicles containing the truncated NuoL subunit ( NuoL(N)) exhibited 2-4-fold higher Na+ uptake activity than control vesicles without NuoL(N). Respiratory proton transport into inverted vesicles containing NuoL(N) decreased upon addition of Na+, but was not affected by K+, indicating a Na+-dependent increase of proton permeability of membranes in the presence of NuoL(N). The His-tagged NuoL(N) protein was solubilized, enriched by affinity chromatography, and reconstituted into proteoliposomes. Reconstituted His(6)-NuoL(N) facilitated the uptake of Na+ into the proteoliposomes along a concentration gradient. This Na+ uptake was prevented by EIPA (5-(N-ethyl-N-isopropyl)amiloride), which acts as inhibitor against Na+/H+ antiporters.	ETH, Inst Mikrobiol, ETH Zentrum, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Steuber, J (corresponding author), ETH, Inst Mikrobiol, ETH Zentrum, Schmelzbergstr 7, CH-8092 Zurich, Switzerland.							Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Boffelli D, 1997, BIOCHEMISTRY-US, V36, P10784, DOI 10.1021/bi970625i; Bottcher B, 2002, J BIOL CHEM, V277, P17970, DOI 10.1074/jbc.M112357200; Chevallet M, 2003, BBA-BIOENERGETICS, V1557, P51, DOI 10.1016/S0005-2728(02)00398-5; Dimroth P, 2000, BBA-BIOENERGETICS, V1459, P506, DOI 10.1016/S0005-2728(00)00190-0; Drose S, 2002, BBA-BIOENERGETICS, V1556, P65, DOI 10.1016/S0005-2728(02)00307-9; Dupuis A, 2001, J BIOENERG BIOMEMBR, V33, P159, DOI 10.1023/A:1010770600418; EYA S, 1989, J BACTERIOL, V171, P6853, DOI 10.1128/jb.171.12.6853-6858.1989; FINEL M, 1992, BIOCHEMISTRY-US, V31, P11425, DOI 10.1021/bi00161a022; Fisher N, 2000, J MOL BIOL, V296, P1153, DOI 10.1006/jmbi.2000.3509; FRIEDRICH T, 1994, EUR J BIOCHEM, V219, P691, DOI 10.1111/j.1432-1033.1994.tb19985.x; Gemperli AC, 2003, P NATL ACAD SCI USA, V100, P839, DOI 10.1073/pnas.0237328100; Gemperli AC, 2002, J BIOL CHEM, V277, P33811, DOI 10.1074/jbc.M204860200; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; HAMAMOTO T, 1994, MOL MICROBIOL, V14, P939, DOI 10.1111/j.1365-2958.1994.tb01329.x; Hiramatsu T, 1998, J BACTERIOL, V180, P6642, DOI 10.1128/JB.180.24.6642-6648.1998; HOFHAUS G, 1995, MOL CELL BIOL, V15, P964; HOWELL N, 1993, AM J HUM GENET, V53, P959; HWANG DS, 1992, J BIOL CHEM, V267, P2209; Ito M, 2001, FEBS LETT, V496, P117, DOI 10.1016/S0014-5793(01)02417-6; Jockel P, 2000, BIOCHEMISTRY-US, V39, P2307, DOI 10.1021/bi992261v; KAIM G, 1993, EUR J BIOCHEM, V218, P937, DOI 10.1111/j.1432-1033.1993.tb18450.x; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; Mathiesen C, 2002, BBA-BIOENERGETICS, V1556, P121, DOI 10.1016/S0005-2728(02)00343-2; Nakamaru-Ogiso E, 2003, BIOCHEMISTRY-US, V42, P746, DOI 10.1021/bi0269660; Nakashima Y, 2002, J BIOENERG BIOMEMBR, V34, P11, DOI 10.1023/A:1013862502185; Padan E, 2001, BBA-BIOENERGETICS, V1505, P144, DOI 10.1016/S0005-2728(00)00284-X; Padan E., 1996, HDB BIOL PHYS, V2, P501; PINNER E, 1993, J BIOL CHEM, V268, P1729; PRUSS BM, 1994, J BACTERIOL, V176, P2143; REENSTRA WW, 1980, BIOCHEMISTRY-US, V19, P1, DOI 10.1021/bi00542a001; Saier MH, 2000, MICROBIOL MOL BIOL R, V64, P354, DOI 10.1128/MMBR.64.2.354-411.2000; Sazanov LA, 2000, BIOCHEMISTRY-US, V39, P7229, DOI 10.1021/bi000335t; Sazanov LA, 2000, J MOL BIOL, V302, P455, DOI 10.1006/jmbi.2000.4079; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHULTE U, 1994, BBA-BIOENERGETICS, V1187, P121, DOI 10.1016/0005-2728(94)90096-5; Schulz H, 1998, SCIENCE, V281, P1197, DOI 10.1126/science.281.5380.1197; Smeitink J, 2001, J BIOENERG BIOMEMBR, V33, P259, DOI 10.1023/A:1010743321800; Steuber J, 2000, MOL MICROBIOL, V35, P428, DOI 10.1046/j.1365-2958.2000.01712.x; Steuber J, 2001, J BIOENERG BIOMEMBR, V33, P179, DOI 10.1023/A:1010774701327; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; Ventura B, 2002, BBA-BIOENERGETICS, V1553, P249, DOI 10.1016/S0005-2728(01)00246-8; Wackwitz B, 1999, MOL GEN GENET, V262, P876, DOI 10.1007/s004380051153; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; Yagi T, 2001, J BIOENERG BIOMEMBR, V33, P233, DOI 10.1023/A:1010787004053; Yano T, 2001, J BIOENERG BIOMEMBR, V33, P213, DOI 10.1023/A:1010782903144	47	45	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26817	26822		10.1074/jbc.M301682200	http://dx.doi.org/10.1074/jbc.M301682200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12740360	hybrid			2022-12-25	WOS:000184155700068
J	Lawrence, A; Jones, CM; Wardman, P; Burkitt, MJ				Lawrence, A; Jones, CM; Wardman, P; Burkitt, MJ			Evidence for the role of a peroxidase compound I-type intermediate in the oxidation of glutathione, NADH, ascorbate, and dichlorofluorescin by cytochrome c/H2O2 - Implications for oxidative stress during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER REACTIONS; PROGRAMMED CELL-DEATH; HYDROGEN-PEROXIDE; FREE-RADICALS; LIPID-PEROXIDATION; PULSE-RADIOLYSIS; REDOX STATE; PROBE 2',7'-DICHLOROFLUORESCIN; REDUCTION POTENTIALS; BIOCHEMICAL SYSTEMS	The release of cytochrome c from mitochondria is a crucial step in apoptosis, resulting in the activation of the caspase proteases. A further consequence of cytochrome c release is the enhanced mitochondrial production of superoxide radicals (O-2(radical anion)), which are converted to hydrogen peroxide by manganese-superoxide dismutase. Recently, we showed that cytochrome c is a potent catalyst of 2', 7'-dichlorofluorescin oxidation to the fluorescent 2', 7'-dichlorofluorescein by these species, leading to the conclusion that 2', 7'-dichlorofluorescein fluorescence is a reflection of cytosolic cytochrome c concentration rather than "reactive oxygen species" levels ( Burkitt, M. J., and Wardman, P. ( 2001) Biochem. Biophys. Res. Commun. 282, 329 - 333). The oxidant generated from cytochrome c has so far not been identified. Several authors have suggested that the hydroxyl radical ((OH)-O-.) is generated, but others have discussed the possibility of a peroxidase compound I. By examining the effects of various antioxidants ( glutathione, ascorbate, and NADH) and " hydroxyl radical scavengers" ( ethanol and mannitol) on the rate of 2', 7'-dichlorofluorescin oxidation by cytochrome c, together with complementary EPR spin-trapping studies, we demonstrate that the hydroxyl radical is not generated. Instead, our findings suggest the formation of a peroxidase compound I-type intermediate, in which one oxidizing equivalent is present as an oxoferryl heme species and the other as the protein tyrosyl radical previously identified ( Barr, D. P., Gunther, M. R., Deterding, L. J., Tomer, K. B., and Mason, R. P. ( 1996) J. Biol. Chem. 271, 15498 - 15503). Competition studies involving spin traps indicated that the oxoferryl heme component is the active oxidant. These findings provide an improved understanding of the physicochemical basis of the redox changes that occur during apoptosis.	Mt Vernon Hosp, Gray Canc Inst, Northwood HA6 2JR, Middx, England	University of Oxford	Burkitt, MJ (corresponding author), Mt Vernon Hosp, Gray Canc Inst, POB 100, Northwood HA6 2JR, Middx, England.							Atlante A, 2000, J BIOL CHEM, V275, P37159, DOI 10.1074/jbc.M002361200; Barr DP, 1996, J BIOL CHEM, V271, P15498, DOI 10.1074/jbc.271.26.15498; Belcher R, 1970, QUANTITATIVE INORGAN; BELLOMO G, 1992, P NATL ACAD SCI USA, V89, P4412, DOI 10.1073/pnas.89.10.4412; BUETTNER GR, 1988, J BIOCHEM BIOPH METH, V16, P27, DOI 10.1016/0165-022X(88)90100-5; Buettner GR, 1996, RADIAT RES, V145, P532, DOI 10.2307/3579271; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; BURKITT MJ, 1993, FREE RADICAL RES COM, V18, P43, DOI 10.3109/10715769309149912; Burkitt MJ, 2001, BIOCHEM BIOPH RES CO, V282, P329, DOI 10.1006/bbrc.2001.4578; Bustamante J, 1997, ARCH BIOCHEM BIOPHYS, V337, P121, DOI 10.1006/abbi.1996.9754; BUXTON GV, 1988, J PHYS CHEM REF DATA, V17, P513, DOI 10.1063/1.555805; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CADENAS E, 1980, BIOCHEM J, V188, P577, DOI 10.1042/bj1880577; CADENAS E, 1980, FEBS LETT, V113, P141, DOI 10.1016/0014-5793(80)80577-1; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Carmody RJ, 2001, REDOX REP, V6, P77, DOI 10.1179/135100001101536085; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Clement JL, 2001, J CHEM SOC PERK T 2, P1463, DOI 10.1039/b103211a; DEPELIPPIS MR, 1989, BIOCHEMISTRY-US, V28, P4847; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; DUNFORD HB, 1987, FREE RADICAL BIO MED, V3, P405, DOI 10.1016/0891-5849(87)90019-0; EBERSON L, 1994, J CHEM SOC PERK T 2, P171, DOI 10.1039/p29940000171; EBERSON L, 1993, ACTA CHEM SCAND, V47, P1129, DOI 10.3891/acta.chem.scand.47-1129; Egawa T, 2000, J BIOL CHEM, V275, P34858, DOI 10.1074/jbc.M004026200; FABER RJ, 1967, J CHEM PHYS, V47, P2462, DOI 10.1063/1.1703331; FARRINGTON JA, 1980, BIOCHIM BIOPHYS ACTA, V590, P273, DOI 10.1016/0005-2728(80)90031-6; FERRI A, 1995, BIOCHEM MOL BIOL INT, V35, P691; FLINT DH, 1993, J BIOL CHEM, V268, P22369; Gogvadze V, 2001, J BIOL CHEM, V276, P19066, DOI 10.1074/jbc.M100614200; GOLDSTEIN S, 1995, FREE RADICAL BIO MED, V19, P505, DOI 10.1016/0891-5849(95)00034-U; Gunther MR, 1998, BIOCHEM J, V330, P1293; Gunther MR, 2000, FREE RADICAL BIO MED, V28, P709, DOI 10.1016/S0891-5849(00)00164-7; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Hampton MB, 2002, FEBS LETT, V517, P229, DOI 10.1016/S0014-5793(02)02629-7; Hampton MB, 1998, BIOFACTORS, V8, P1, DOI 10.1002/biof.5520080101; HAREL S, 1988, FREE RADICAL RES COM, V5, P21, DOI 10.3109/10715768809068555; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Higuchi Y, 2002, ARCH BIOCHEM BIOPHYS, V400, P133, DOI 10.1006/abbi.2002.2784; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Jones CM, 2002, FREE RADICAL BIO MED, V32, P982, DOI 10.1016/S0891-5849(02)00791-8; Jones CM, 2002, J CHEM SOC PERK T 2, P2044, DOI 10.1039/b207709b; Jones DP, 2000, FREE RADICAL BIO MED, V28, P625, DOI 10.1016/S0891-5849(99)00275-0; Kagan VE, 2002, J IMMUNOL, V169, P487, DOI 10.4049/jimmunol.169.1.487; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kirlin WG, 1999, FREE RADICAL BIO MED, V27, P1208, DOI 10.1016/S0891-5849(99)00145-8; Kooy NW, 1997, FREE RADICAL RES, V27, P245, DOI 10.3109/10715769709065763; LAND EJ, 1971, BIOCHIM BIOPHYS ACTA, V234, P34, DOI 10.1016/0005-2728(71)90126-5; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MASUI M, 1982, J CHEM SOC CHEM COMM, P879, DOI 10.1039/c39820000879; Meister A., 1983, FUNCTIONS GLUTATHION, P1; MUSCHEL RJ, 1995, CANCER RES, V55, P995; OHNISHI T, 1969, BIOCHIM BIOPHYS ACTA, V172, P357, DOI 10.1016/0005-2728(69)90132-7; Pan ZH, 1999, CELL DEATH DIFFER, V6, P683, DOI 10.1038/sj.cdd.4400544; Qian SY, 2002, BIOCHEM J, V363, P281, DOI 10.1042/0264-6021:3630281; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P118, DOI 10.1016/0003-9861(91)90172-F; Rose ML, 1999, CARCINOGENESIS, V20, P27, DOI 10.1093/carcin/20.1.27; ROST N, 1964, NATURE, V201, P185; Rota C, 1999, FREE RADICAL BIO MED, V27, P873, DOI 10.1016/S0891-5849(99)00137-9; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Samali A, 1999, BIOCHEM BIOPH RES CO, V255, P6, DOI 10.1006/bbrc.1998.0139; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Szaleczky E, 2000, J CLIN GASTROENTEROL, V30, P47, DOI 10.1097/00004836-200001000-00008; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Voehringer DW, 1999, FREE RADICAL BIO MED, V27, P945, DOI 10.1016/S0891-5849(99)00174-4; WAHLLANDER A, 1979, FEBS LETT, V97, P138, DOI 10.1016/0014-5793(79)80069-1; Ward Paul, 1995, P1; WARDMAN P, 1989, J PHYS CHEM REF DATA, V18, P1637, DOI 10.1063/1.555843; WEFERS H, 1983, EUR J BIOCHEM, V137, P29, DOI 10.1111/j.1432-1033.1983.tb07791.x; WILLSON RL, 1970, J CHEM SOC CHEM COMM, P1005, DOI 10.1039/c29700001005; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; ZHU H, 1994, ARCH TOXICOL, V68, P582, DOI 10.1007/s002040050118	79	139	142	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29410	29419		10.1074/jbc.M300054200	http://dx.doi.org/10.1074/jbc.M300054200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12748170	hybrid			2022-12-25	WOS:000184507000005
J	Li, JL; Xiang, B; Su, WJ; Zhang, XQ; Huang, YL; Ma, L				Li, JL; Xiang, B; Su, WJ; Zhang, XQ; Huang, YL; Ma, L			Agonist-induced formation of opioid receptor-G protein-coupled receptor kinase (GRK)-G beta gamma complex on membrane is required for GRK2 function in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACIDIC AMINO-ACIDS; PHOSPHORYLATION; ACTIVATION; IDENTIFICATION; MECHANISM; SUBUNITS; SITES	G protein-coupled receptor kinases (GRKs) catalyze agonist-induced receptor phosphorylation on the membrane and initiate receptor desensitization. Previous in vitro studies have shown that the binding of GRK to membrane-associated Gbetagamma subunits plays an important role in translocation of GRK2 from the cytoplasm to the plasma membrane. The current study investigated the role of the interaction of GRK2 with the activated delta-opioid receptor (DOR) and Gbetagamma subunits in the membrane translocation and function of GRK2 using intact human embryonic kidney 293 cells. Our results showed that agonist treatment induced GRK2 binding to DOR, GRK2 translocation to the plasma membrane, and DOR phosphorylation in cells expressing the wild-type DOR but not the mutant DOR lacking the carboxyl terminus, which contains all three GRK2 phosphorylation sites. DORs with the GRK2 phosphorylation sites modified (M3) or with the acidic residues flanking phosphorylation sites mutated (E355Q/D364N) failed to be phosphorylated in response to agonist stimulation. Agonist-induced GRK2 membrane translocation and GRK-receptor association were observed in cells expressing M3 but not E355Q/D364N. Moreover, over-expression of Gbetagamma subunits promoted GRK2 binding to DOR, whereas overexpression of transducin alpha or the carboxyl terminus of GRK2 blocked binding. Further study demonstrated that agonist stimulation induced the formation of a complex containing DOR, GRK2, and Gbetagamma subunits in the cell and that agonist-stimulated formation of this complex is essential for the stable localization of GRK2 on the membrane and for its catalytic activity in vivo.	Fudan Univ, Shanghai Med Coll, Natl Lab Med Neurobiol, Shanghai 200032, Peoples R China; Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China	Fudan University; Fudan University	Ma, L (corresponding author), Fudan Univ, Shanghai Med Coll, Natl Lab Med Neurobiol, Shanghai 200032, Peoples R China.	lanma@shmu.edu.cn	Ma, Lan/B-9295-2009; Zhang, Xiaoqing/O-3424-2017	Zhang, Xiaoqing/0000-0002-7405-1893; Li, Jiali/0000-0002-0039-3671; Ma, Lan/0000-0001-9034-5472				Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Cheng ZJ, 1997, NEUROREPORT, V8, P1913, DOI 10.1097/00001756-199705260-00024; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; Dhami GK, 2002, J BIOL CHEM, V277, P25266, DOI 10.1074/jbc.M203593200; Guo J, 2000, MOL PHARMACOL, V58, P1050, DOI 10.1124/mol.58.5.1050; HAGA K, 1994, J BIOL CHEM, V269, P12594; Hisatomi O, 1998, FEBS LETT, V424, P159, DOI 10.1016/S0014-5793(98)00162-8; INGLESE J, 1993, J BIOL CHEM, V268, P23735; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; KIM CM, 1993, J BIOL CHEM, V268, P15412; Lee KB, 2000, J BIOL CHEM, V275, P35767, DOI 10.1074/jbc.M002225200; Maestri-El Kouhen O, 2000, J BIOL CHEM, V275, P36659, DOI 10.1074/jbc.M006788200; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; PEI G, 1995, MOL PHARMACOL, V48, P173; Penn RB, 2000, TRENDS CARDIOVAS MED, V10, P81, DOI 10.1016/S1050-1738(00)00053-0; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Small KM, 2001, J BIOL CHEM, V276, P4917, DOI 10.1074/jbc.M008118200; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Xiang B, 2001, J BIOL CHEM, V276, P4709, DOI 10.1074/jbc.M006187200; Zhao J, 1997, BIOCHEM BIOPH RES CO, V238, P71, DOI 10.1006/bbrc.1997.7242	29	38	42	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30219	30226		10.1074/jbc.M302385200	http://dx.doi.org/10.1074/jbc.M302385200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12750365	hybrid			2022-12-25	WOS:000184507000102
J	Pearce, G; Ryan, CA				Pearce, G; Ryan, CA			Systemic signaling in tomato plants for defense against herbivores - Isolation and characterization of three novel defense-signaling glycopeptide hormones coded in a single precursor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASE-INHIBITOR; LEAVES; PURIFICATION; POLYPEPTIDE; RECEPTOR; INSECTS; PROLINE; POTATO	An 18-amino acid peptide in tomato leaves called systemin is a primary signal released at wound sites in response to herbivory that systemically signals the activation of defense genes throughout the plants. We report here the isolation of three hydroxyproline-rich glycopeptides from tomato leaves, of 20, 18, and 15 amino acids in length, that signal the activation of defense genes, similar to the activity of the systemin peptide. The three new peptides cause an alkalinization of suspension-cultured cells and induce the synthesis of defensive proteinase inhibitor proteins when supplied at fmol levels to young tomato plants through their cut stems. This suggests that they are part of the wound signaling of tomato plants that activates defense against herbivores and pathogens. Isolation of cDNAs coding for the tomato peptides revealed that they are all derived from the same pre-proprotein precursor that is systemically wound-inducible. The peptides are considered members of the functionally characterized systemin family of defense signals from plants that are synthesized both in wounded leaves and in distal, unwounded leaves in response to herbivory or other mechanical wounding. The precursor deduced from the cDNA exhibits a leader sequence, indicating that it is synthesized through the secretory pathway, where it is hydroxylated and glycosylated. The amino acid sequence of the precursor exhibited weak identity to the precursor of two hydroxyproline-rich defense signals recently found in tobacco, suggesting that the two pre-protein precursors have evolved from a common ancestral protein. The identification of hydroxyproline-rich glycoprotein systemins in tomato indicates that the initiation of wound signaling is more complex than previously thought and appears to involve multiple peptide signals.	Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA	Washington State University	Ryan, CA (corresponding author), Washington State Univ, Inst Biol Chem, 299 Clark Hall, Pullman, WA 99164 USA.							Constabel CP, 1998, PLANT MOL BIOL, V36, P55, DOI 10.1023/A:1005986004615; GREEN TR, 1972, SCIENCE, V175, P776, DOI 10.1126/science.175.4023.776; Hunziker A.T., 2001, GENERA SOLANACEAE; Kieliszewski MJ, 2001, PHYTOCHEMISTRY, V57, P319, DOI 10.1016/S0031-9422(01)00029-2; MCGURL B, 1992, SCIENCE, V255, P1570, DOI 10.1126/science.1549783; Meindl T, 1998, PLANT CELL, V10, P1561, DOI 10.1105/tpc.10.9.1561; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; PEARCE G, 1993, PLANT PHYSIOL, V102, P639, DOI 10.1104/pp.102.2.639; Pearce G, 2001, NATURE, V411, P817, DOI 10.1038/35081107; Pearce G, 2001, P NATL ACAD SCI USA, V98, P12843, DOI 10.1073/pnas.201416998; PEARCE G, 2003, IN PRESS P NATL ACAD; PLUNKETT G, 1982, ARCH BIOCHEM BIOPHYS, V213, P463, DOI 10.1016/0003-9861(82)90572-0; Reiersen H, 2001, TRENDS BIOCHEM SCI, V26, P679, DOI 10.1016/S0968-0004(01)01957-0; RYAN CA, 1967, ANAL BIOCHEM, V19, P434, DOI 10.1016/0003-2697(67)90233-3; RYAN CA, 1990, ANNU REV PHYTOPATHOL, V28, P425, DOI 10.1146/annurev.py.28.090190.002233; Scheer JM, 1999, PLANT CELL, V11, P1525, DOI 10.1105/tpc.11.8.1525; TOUMADJE A, 1995, J AM CHEM SOC, V117, P7023, DOI 10.1021/ja00131a034; TRAUTMAN R, 1971, IMMUNOCHEMISTRY, V8, P901, DOI 10.1016/0019-2791(71)90429-0; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; Zhang ZP, 1997, PLANTA, V203, P436, DOI 10.1007/s004250050211	20	109	120	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30044	30050		10.1074/jbc.M304159200	http://dx.doi.org/10.1074/jbc.M304159200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12748180	hybrid			2022-12-25	WOS:000184507000080
J	Salmon, K; Hung, SP; Mekjian, K; Baldi, P; Hatfield, GW; Gunsalus, RP				Salmon, K; Hung, SP; Mekjian, K; Baldi, P; Hatfield, GW; Gunsalus, RP			Global gene expression profiling in Escherichia coli K12 - The effects of oxygen availability and FNR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-DEHYDROGENASE COMPLEX; RESPONSIVE REGULATORY PROTEIN; PROTON-TRANSLOCATING NADH; COLI K-12; DEPENDENT REPRESSION; ELECTRON-ACCEPTORS; OPERON EXPRESSION; NDH GENE; PRODUCT; PROMOTER	The work presented here is a first step toward a long term goal of systems biology, the complete elucidation of the gene regulatory networks of a living organism. To this end, we have employed DNA microarray technology to identify genes involved in the regulatory networks that facilitate the transition of Escherichia coli cells from an aerobic to an anaerobic growth state. We also report the identification of a subset of these genes that are regulated by a global regulatory protein for anaerobic metabolism, FNR. Analysis of these data demonstrated that the expression of over one-third of the genes expressed during growth under aerobic conditions are altered when E. coli cells transition to an anaerobic growth state, and that the expression of 712 (49%) of these genes are either directly or indirectly modulated by FNR. The results presented here also suggest interactions between the FNR and the leucine-responsive regulatory protein (Lrp) regulatory networks. Because computational methods to analyze and interpret high dimensional DNA microarray data are still at an early stage, and because basic issues of data analysis are still being sorted out, much of the emphasis of this work is directed toward the development of methods to identify differentially expressed genes with a high level of confidence. In particular, we describe an approach for identifying gene expression patterns ( clusters) obtained from multiple perturbation experiments based on a subset of genes that exhibit high probability for differential expression values.	Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Sch Informat & Comp Sci, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Inst Genom & Bioinformat, Irvine, CA 92697 USA; Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Gunsalus, RP (corresponding author), Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.	gwhatfie@uci.edu; robg@microbio.ucla.edu			NIAID NIH HHS [AI21678] Funding Source: Medline; NIGMS NIH HHS [GM49694, GM55073, GM68903] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068903] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABAIBOU H, 1995, J BACTERIOL, V177, P7141, DOI 10.1128/jb.177.24.7141-7149.1995; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Baldi P., 2002, DNA MICROARRAYS GENE, P73; Baldi P, 2002, DNA MICROARRAYS GENE; BELL AI, 1990, MOL MICROBIOL, V4, P1753, DOI 10.1111/j.1365-2958.1990.tb00553.x; BIRKMANN A, 1987, MOL GEN GENET, V210, P535, DOI 10.1007/BF00327209; Blankenhorn D, 1999, J BACTERIOL, V181, P2209, DOI 10.1128/JB.181.7.2209-2216.1999; BONGAERTS J, 1995, MOL MICROBIOL, V16, P521, DOI 10.1111/j.1365-2958.1995.tb02416.x; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CASADO C, 1991, FEMS MICROBIOL LETT, V83, P153; CHANG YY, 1994, MOL MICROBIOL, V11, P1019, DOI 10.1111/j.1365-2958.1994.tb00380.x; COMPAN I, 1994, MOL MICROBIOL, V11, P955, DOI 10.1111/j.1365-2958.1994.tb00374.x; COTTER PA, 1990, J BACTERIOL, V172, P6333, DOI 10.1128/jb.172.11.6333-6338.1990; COTTER PA, 1989, J BACTERIOL, V171, P3817, DOI 10.1128/jb.171.7.3817-3823.1989; Cotter PA, 1997, MOL MICROBIOL, V25, P605, DOI 10.1046/j.1365-2958.1997.5031860.x; COTTER PA, 1992, FEMS MICROBIOL LETT, V91, P31; Cunningham L, 1998, FEMS MICROBIOL LETT, V169, P403, DOI 10.1111/j.1574-6968.1998.tb13347.x; DARWIN AJ, 1995, J BACTERIOL, V177, P3865, DOI 10.1128/jb.177.13.3865-3869.1995; EICHLER K, 1994, MOL MICROBIOL, V13, P775, DOI 10.1111/j.1365-2958.1994.tb00470.x; Ferrandez A, 1997, J BACTERIOL, V179, P2573, DOI 10.1128/jb.179.8.2573-2581.1997; GENNIS RB, 1996, ESCHERICHIA COLI SAL, V1, P217; Govantes F, 2000, MOL MICROBIOL, V37, P1456, DOI 10.1046/j.1365-2958.2000.02100.x; GREEN J, 1994, MOL MICROBIOL, V12, P433, DOI 10.1111/j.1365-2958.1994.tb01032.x; Guest John R., 1996, P317; Guest JR, 1997, MICROBIOL-SGM, V143, P457, DOI 10.1099/00221287-143-2-457; GUNSALUS RP, 1994, RES MICROBIOL, V145, P437, DOI 10.1016/0923-2508(94)90092-2; Hatfield GW, 2003, MOL MICROBIOL, V47, P871, DOI 10.1046/j.1365-2958.2003.03298.x; HIRSHFIELD IN, 1984, J BACTERIOL, V158, P615, DOI 10.1128/JB.158.2.615-620.1984; Hung SP, 2002, J BIOL CHEM, V277, P40309, DOI 10.1074/jbc.M204044200; IUCHI S, 1990, J BACTERIOL, V172, P6020, DOI 10.1128/jb.172.10.6020-6025.1990; Janausch IG, 1999, ARCH MICROBIOL, V172, P219, DOI 10.1007/s002030050763; JAYARAMAN PS, 1989, NUCLEIC ACIDS RES, V17, P135, DOI 10.1093/nar/17.1.135; JONES HM, 1987, J BACTERIOL, V169, P3340, DOI 10.1128/jb.169.7.3340-3349.1987; Kiley PJ, 1998, FEMS MICROBIOL REV, V22, P341, DOI 10.1111/j.1574-6976.1998.tb00375.x; LAMBDEN PR, 1976, J GEN MICROBIOL, V97, P145, DOI 10.1099/00221287-97-2-145; LEVEQUE F, 1991, J BACTERIOL, V173, P7903, DOI 10.1128/jb.173.24.7903-7910.1991; LIN R, 1992, J BACTERIOL, V174, P2779, DOI 10.1128/JB.174.9.2779-2784.1992; Long AD, 2001, J BIOL CHEM, V276, P19937, DOI 10.1074/jbc.M010192200; LYNCH AS, 1996, REGULATION GENE EXPR, P362; LYNCH AS, 1996, ESCHERICHIA COLI SAL, V1, P1526; Meng WM, 1997, MICROBIOL-SGM, V143, P1521, DOI 10.1099/00221287-143-5-1521; NEWMAN EB, 1996, ESCHERICHIA COLI SAL, V1, P1513; QUAIL MA, 1994, MOL MICROBIOL, V12, P95, DOI 10.1111/j.1365-2958.1994.tb00998.x; RAVNIKAR PD, 1987, J BACTERIOL, V169, P2611, DOI 10.1128/jb.169.6.2611-2617.1987; Rhee KY, 1996, J BIOL CHEM, V271, P26499, DOI 10.1074/jbc.271.43.26499; SHARROCKS AD, 1991, P ROY SOC B-BIOL SCI, V245, P219, DOI 10.1098/rspb.1991.0113; Soballe B, 1997, FEBS LETT, V414, P373, DOI 10.1016/S0014-5793(97)01041-7; SPIRO S, 1989, MOL MICROBIOL, V3, P601, DOI 10.1111/j.1365-2958.1989.tb00207.x; Tseng CP, 1996, J BACTERIOL, V178, P1094, DOI 10.1128/jb.178.4.1094-1098.1996; Tseng CP, 1997, FEMS MICROBIOL LETT, V157, P67, DOI 10.1016/S0378-1097(97)00455-2; WEIDNER U, 1993, J MOL BIOL, V233, P109, DOI 10.1006/jmbi.1993.1488; WOODS SA, 1988, BIOCHIM BIOPHYS ACTA, V954, P14, DOI 10.1016/0167-4838(88)90050-7; WU LF, 1986, BIOCHIMIE, V68, P167, DOI 10.1016/S0300-9084(86)81081-1	54	214	241	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29837	29855		10.1074/jbc.M213060200	http://dx.doi.org/10.1074/jbc.M213060200			19	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12754220	hybrid			2022-12-25	WOS:000184507000057
J	Ivanina, T; Rishal, I; Varon, D; Mullner, C; Frohnwieser-Steinecke, B; Schreibmayer, W; Dessauer, CW; Dascal, N				Ivanina, T; Rishal, I; Varon, D; Mullner, C; Frohnwieser-Steinecke, B; Schreibmayer, W; Dessauer, CW; Dascal, N			Mapping the G beta gamma-binding sites in GIRK1 and GIRK2 subunits of the G protein-activated K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING POTASSIUM CHANNELS; INWARD RECTIFIER; XENOPUS-OOCYTES; MOLECULAR-PROPERTIES; KINASE-C; I-KACH; IDENTIFICATION; EXPRESSION; BRAIN; G(BETA-GAMMA)	G protein-activated K+ channels (Kir3 or GIRK) are activated by direct binding of Gbetagamma. The binding sites of Gbetagamma in the ubiquitous GIRK1 (Kir3.1) subunit have not been unequivocally charted, and in the neuronal GIRK2 (Kir3.2) subunit the binding of Gbetagamma has not been studied. We verified and extended the map of Gbetagamma-binding sites in GIRK1 by using two approaches: direct binding of Gbetagamma to fragments of GIRK subunits (pull down), and competition of these fragments with the Galpha(i1) subunit for binding to Gbetagamma. We also mapped the Gbetagamma-binding sites in GIRK2. In both subunits, the N terminus binds Gbetagamma. In the C terminus, the Gbetagamma-binding sites in the two subunits are not identical; GIRK1, but not GIRK2, has a previously unrecognized Gbetagamma-interacting segments in the first half of the C terminus. The main C-terminal Gbetagamma-binding segment found in both subunits is located approximately between amino acids 320 and 409 (by GIRK1 count). Mutation of C-terminal leucines 262 or 333 in GIRK1, recognized previously as crucial for Gbetagamma regulation of the channel, and of the corresponding leucines 273 and 344 in GIRK2 dramatically altered the properties of K+ currents via GIRK1/GIRK2 channels expressed in Xenopus oocytes but did not appreciably reduce the binding of Gbetagamma to the corresponding fusion proteins, indicating that these residues are mainly important for the regulation of Gbetagamma-induced changes in channel gating rather than Gbetagamma binding.	Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Ramat Aviv, Israel; Graz Univ, Inst Med Phys & Biophys, A-8010 Graz, Austria; Univ Texas, Dept Integrat Biol & Pharmacol, Houston Med Sch, Houston, TX 77030 USA	Tel Aviv University; Sackler Faculty of Medicine; University of Graz; University of Texas System; University of Texas Health Science Center Houston	Dascal, N (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel.	dascaln@post.tau.ac.il	RISHAL, IDA/K-1691-2012; Dascal, Nathan/O-3915-2015; Dessauer, Carmen/N-6933-2018	Dascal, Nathan/0000-0002-5397-4146; Steinecker-Frohnwieser, Bibiane/0000-0001-6852-4466; Schreibmayer, Wolfgang/0000-0002-4631-7922; Dessauer, Carmen/0000-0003-1210-4280	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068493, R01GM060419] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM060419, GM60419, R01 GM060419-04, GM68493] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albsoul-Younes AM, 2001, J BIOL CHEM, V276, P12712, DOI 10.1074/jbc.M011231200; Bettahi H, 2002, J BIOL CHEM, V277, P48282, DOI 10.1074/jbc.M209599200; CASEY PJ, 1991, METHOD ENZYMOL, V195, P315; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Corey S, 2001, J BIOL CHEM, V276, P11409, DOI 10.1074/jbc.M100058200; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Doupnik CA, 1996, NEUROPHARMACOLOGY, V35, P923, DOI 10.1016/0028-3908(96)00125-6; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; He C, 1999, J BIOL CHEM, V274, P12517, DOI 10.1074/jbc.274.18.12517; He C, 2002, J BIOL CHEM, V277, P6088, DOI 10.1074/jbc.M104851200; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Inanobe A, 1995, BIOCHEM BIOPH RES CO, V217, P1238, DOI 10.1006/bbrc.1995.2901; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; Ivanina T, 2000, J BIOL CHEM, V275, P39846, DOI 10.1074/jbc.M005881200; Jan LY, 1997, J PHYSIOL-LONDON, V505, P267, DOI 10.1111/j.1469-7793.1997.267bb.x; Jelacic TM, 1999, J MEMBRANE BIOL, V169, P123, DOI 10.1007/s002329900524; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Krapivinsky G, 1998, J BIOL CHEM, V273, P16946, DOI 10.1074/jbc.273.27.16946; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; LEE E, 1994, METHOD ENZYMOL, V237, P146; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; Mirshahi T, 2002, J BIOL CHEM, V277, P36345, DOI 10.1074/jbc.M205359200; Mirshahi T, 2002, J BIOL CHEM, V277, P7348, DOI 10.1074/jbc.M109999200; Nishida M, 2002, CELL, V111, P957, DOI 10.1016/S0092-8674(02)01227-8; Peleg S, 2002, NEURON, V33, P87, DOI 10.1016/S0896-6273(01)00567-0; Petit-Jacques J, 1999, J GEN PHYSIOL, V114, P673, DOI 10.1085/jgp.114.5.673; Rishal I, 2003, J BIOL CHEM, V278, P3840, DOI 10.1074/jbc.C200605200; Robillard L, 2000, CELL SIGNAL, V12, P673, DOI 10.1016/S0898-6568(00)00118-2; Sadja R, 2002, P NATL ACAD SCI USA, V99, P10783, DOI 10.1073/pnas.162346199; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; Singer-Lahat D, 2000, PFLUG ARCH EUR J PHY, V440, P627, DOI 10.1007/s004240000341; Vorobiov D, 1998, PFLUG ARCH EUR J PHY, V436, P56, DOI 10.1007/s004240050604; Wang CR, 1997, PROTEIN SCI, V6, P2264; Yamada M, 1998, PHARMACOL REV, V50, P723; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0	43	59	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29174	29183		10.1074/jbc.M304518200	http://dx.doi.org/10.1074/jbc.M304518200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12743112	hybrid			2022-12-25	WOS:000184421100102
J	Matsuda, T; Suzuki, H; Oishi, I; Kani, S; Kuroda, Y; Komori, T; Sasaki, A; Watanabe, K; Minami, Y				Matsuda, T; Suzuki, H; Oishi, I; Kani, S; Kuroda, Y; Komori, T; Sasaki, A; Watanabe, K; Minami, Y			The receptor tyrosine kinase Ror2 associates with the melanoma-associated antigen (MAGE) family protein Dlxin-1 and regulates its intracellular distribution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRACHYDACTYLY TYPE-B; RECESSIVE ROBINOW-SYNDROME; P75 NEUROTROPHIN RECEPTOR; MOUSE DEVELOPMENT; INTERACTING PROTEIN; GROWTH SUPPRESSOR; NERVOUS-SYSTEM; CELL-DEATH; GENE; EXPRESSION	The mammalian Ror family receptor tyrosine kinases, Ror1 and Ror2, play crucial roles in developmental morphogenesis. Although the functions of Ror1 and Ror2 are redundant, Ror2 exhibits more specific functions during development. We show that when expressed in mammalian cells, Ror2, but not Ror1, associates with the melanoma-associated antigen (MAGE) family protein, Dlxin-1, which is known to bind to the homeodomain proteins Msx2 and Dlx5 and regulate their transcriptional functions. This association requires the cytoplasmic C-terminal region of Ror2, containing proline-rich and serine/threonine-rich domains, and the C-terminal necdin homology domain of Dlxin-1. Interestingly, the cytoplasmic C-terminal region of Ror2 is missing in patients with brachydactyly type B. Interestingly, transient expression and immunohistochemical analyses reveal that both Dlxin-1 and Msx2 are co-localized in the nuclei in the absence of Ror2. In the presence of Ror2, Dlxin-1 is colocalized with Ror2 at the membranous compartments and Msx2 is retained in the nuclei. It was also found that the majority of cellular Dlxin-1 is retained in the membrane fractions of wild-type but not Ror2(-/-) mouse embryonic fibroblasts. Furthermore, we show that transcriptional activity of Msx2, irrespective of Ror2 kinase activity, is regulated by ectopic expression of Ror2 using a reporter plasmid containing the WIP element. Thus, Ror2 sequesters Dlxin-1 in membranous compartments, thereby affecting the transcriptional function of Msx2.	Kobe Univ, Dept Genome Sci, Fac Med Sci, Grad Sch Med,Chuo Ku, Kobe, Hyogo 6500017, Japan; Kobe Univ, Dept Clin Mol Med, Fac Med Sci, Grad Sch Med,Chuo Ku, Kobe, Hyogo 6500017, Japan; Kobe Univ, Dept Oral & Maxillofacial Surg, Fac Med Sci, Grad Sch Med,Chuo Ku, Kobe, Hyogo 6500017, Japan; Natl Inst Longev Sci, Dept Geriatr Res, Aichi 4748522, Japan	Kobe University; Kobe University; Kobe University	Minami, Y (corresponding author), Kobe Univ, Dept Genome Sci, Fac Med Sci, Grad Sch Med,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.		Oishi, Isao/L-8639-2018; Watanabe, Ken/I-3960-2013	Oishi, Isao/0000-0003-3682-5349; Watanabe, Ken/0000-0003-0664-3915				Afzal AR, 2000, NAT GENET, V25, P419, DOI 10.1038/78107; Al-Shawi R, 2001, DEV GENES EVOL, V211, P161, DOI 10.1007/s004270100140; DeChiara TM, 2000, NAT GENET, V24, P271, DOI 10.1038/73488; Forrester WC, 1999, NATURE, V400, P881, DOI 10.1038/23722; Forrester WC, 2002, CELL MOL LIFE SCI, V59, P83, DOI 10.1007/s00018-002-8407-9; Hennuy B, 2000, ENDOCRINOLOGY, V141, P3821, DOI 10.1210/en.141.10.3821; IMAI Y, 1995, GENE, V160, P287, DOI 10.1016/0378-1119(94)00680-Q; Jordan BWM, 2001, J BIOL CHEM, V276, P39985, DOI 10.1074/jbc.C100171200; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V178, P291, DOI 10.1016/0006-291X(91)91812-Q; Masiakowski P, 1998, CURR BIOL, V8, pR407, DOI 10.1016/S0960-9822(98)70263-5; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; Masuda Y, 2001, J BIOL CHEM, V276, P5331, DOI 10.1074/jbc.M008590200; Matsuda T, 2001, MECH DEVELOP, V105, P153, DOI 10.1016/S0925-4773(01)00383-5; McKay SE, 2001, MOL CELL NEUROSCI, V17, P821, DOI 10.1006/mcne.2001.0977; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; MINAMI Y, 1991, J BIOL CHEM, V266, P9222; Nomi M, 2001, MOL CELL BIOL, V21, P8329, DOI 10.1128/MCB.21.24.8329-8335.2001; Oishi I, 1999, GENES CELLS, V4, P41, DOI 10.1046/j.1365-2443.1999.00234.x; Oishi I, 1997, J BIOL CHEM, V272, P11916, DOI 10.1074/jbc.272.18.11916; Oishi I, 1998, MECH DEVELOP, V71, P49, DOI 10.1016/S0925-4773(97)00200-1; Oldridge M, 2000, NAT GENET, V24, P275, DOI 10.1038/73495; Rehn M, 1998, TRENDS BIOCHEM SCI, V23, P415, DOI 10.1016/S0968-0004(98)01290-0; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; Salehi AH, 2002, J BIOL CHEM, V277, P48043, DOI 10.1074/jbc.M205324200; Sasaki A, 2002, J BIOL CHEM, V277, P22541, DOI 10.1074/jbc.M109728200; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schwabe GC, 2000, AM J HUM GENET, V67, P822, DOI 10.1086/303084; Takeuchi S, 2000, GENES CELLS, V5, P71, DOI 10.1046/j.1365-2443.2000.00300.x; Taniura H, 1999, J BIOL CHEM, V274, P16242, DOI 10.1074/jbc.274.23.16242; Taniura H, 1998, J BIOL CHEM, V273, P720, DOI 10.1074/jbc.273.2.720; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; van Bokhoven H, 2000, NAT GENET, V25, P423, DOI 10.1038/78113; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Wilkie AOM, 2000, NAT GENET, V24, P387, DOI 10.1038/74224; WILSON C, 1993, P NATL ACAD SCI USA, V90, P7109, DOI 10.1073/pnas.90.15.7109; Yoshikawa Y, 1997, DEV BIOL, V183, P234, DOI 10.1006/dbio.1997.8502; Zhang HL, 1997, MOL CELL BIOL, V17, P2920, DOI 10.1128/MCB.17.5.2920	38	57	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29057	29064		10.1074/jbc.M302199200	http://dx.doi.org/10.1074/jbc.M302199200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12754255	hybrid			2022-12-25	WOS:000184421100088
J	Meyers, MB; Fischer, A; Sun, YJ; Lopes, CMB; Rohacs, T; Nakamura, TY; Zhou, YY; Lee, PC; Altschuld, RA; McCune, SA; Coetzee, WA; Fishman, GI				Meyers, MB; Fischer, A; Sun, YJ; Lopes, CMB; Rohacs, T; Nakamura, TY; Zhou, YY; Lee, PC; Altschuld, RA; McCune, SA; Coetzee, WA; Fishman, GI			Sorcin regulates excitation-contraction coupling in the heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANT CELLS; CAUDATE-PUTAMEN NUCLEUS; CALCIUM-BINDING PROTEIN; CA2+-DEPENDENT INACTIVATION; CRYSTAL-STRUCTURE; CA2+ CHANNELS; ULTRASTRUCTURAL-LOCALIZATION; CA2+-SENSITIVE INACTIVATION; SARCOPLASMIC-RETICULUM; RYANODINE RECEPTORS	Sorcin is a penta-EF hand Ca2+-binding protein that associates with both cardiac ryanodine receptors and L-type Ca2+ channels and has been implicated in the regulation of intracellular Ca2+ cycling. To better define the function of sorcin, we characterized transgenic mice in which sorcin was overexpressed in the heart. Transgenic mice developed normally with no evidence of cardiac hypertrophy and no change in expression of other calcium regulatory proteins. In vivo hemodynamics revealed significant reductions in global indices of contraction and relaxation. Contractile abnormalities were also observed in isolated adult transgenic myocytes, along with significant depression of Ca2+ transient amplitudes. Whole cell I-Ca density and the time course of activation were normal in transgenic myocytes, but the rate of inactivation was significantly accelerated. These effects of sorcin on L-type Ca2+ currents were confirmed in Xenopus oocyte expression studies. Finally, we examined the expression of sorcin in normal and failing hearts from spontaneous hypertensive heart failure rats. In normal myocardium, sorcin extensively co-localized with ryanodine receptors at the Z-lines, whereas in myopathic hearts the degree of co-localization was markedly disrupted. Together, these data indicate that sorcin modulates intracellular Ca2+ cycling and Ca2+ influx pathways in the heart.	NYU, Sch Med, Dept Med, Div Cardiol, New York, NY 10016 USA; NYU, Sch Med, Dept Pediat, New York, NY 10016 USA; CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA; Ohio State Univ, Coll Med, Dept Med Biochem, Columbus, OH 43210 USA; Ohio State Univ, Dept Food Sci & Technol, Columbus, OH 43210 USA	New York University; New York University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Fishman, GI (corresponding author), NYU, Sch Med, Dept Med, Div Cardiol, 550 1st Ave,OBV A-615, New York, NY 10016 USA.	glenn.fishman@med.nyu.edu		Coetzee, William/0000-0003-1522-8326; Fishman, Glenn/0000-0002-2366-8527				Balaguru D, 1997, J MOL CELL CARDIOL, V29, P2747, DOI 10.1006/jmcc.1997.0509; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Bers Donald M., 2002, Basic Research in Cardiology, V97; Brownawell AM, 1997, J BIOL CHEM, V272, P22182, DOI 10.1074/jbc.272.35.22182; Chan KW, 1996, P NATL ACAD SCI USA, V93, P14193, DOI 10.1073/pnas.93.24.14193; Cleemann L, 1998, P NATL ACAD SCI USA, V95, P10984, DOI 10.1073/pnas.95.18.10984; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; Eisner DA, 2003, J PHYSIOL-LONDON, V546, P3, DOI 10.1113/jphysiol.2002.036756; Flucher BE, 1996, P NATL ACAD SCI USA, V93, P8101, DOI 10.1073/pnas.93.15.8101; Frank KF, 2002, BASIC RES CARDIOL S1, V97, pI72, DOI DOI 10.1007/S003950200033; Gomez AM, 1997, SCIENCE, V276, P800, DOI 10.1126/science.276.5313.800; Gracy KN, 1999, NEUROSCIENCE, V90, P107, DOI 10.1016/S0306-4522(98)00440-0; GULICK J, 1991, J BIOL CHEM, V266, P9180; Hasenfuss G, 1998, CARDIOVASC RES, V37, P279, DOI 10.1016/S0008-6363(97)00277-0; Herr C, 2001, MOL CELL BIOL, V21, P4119, DOI 10.1128/MCB.21.13.4119-4128.2001; Heubach JF, 2001, BRIT J PHARMACOL, V133, P73, DOI 10.1038/sj.bjp.0704045; Houser SR, 2000, J MOL CELL CARDIOL, V32, P1595, DOI 10.1006/jmcc.2000.1206; Ilari A, 2002, J MOL BIOL, V317, P447, DOI 10.1006/jmbi.2002.5417; Jia J, 2000, J MOL BIOL, V300, P1271, DOI 10.1006/jmbi.2000.3925; Jia J, 2001, STRUCTURE, V9, P267, DOI 10.1016/S0969-2126(01)00585-8; Kamp TJ, 2002, CIRC RES, V91, P451, DOI 10.1161/01.RES.0000035346.21625.4A; Kitaura Y, 1999, BIOCHEM BIOPH RES CO, V263, P68, DOI 10.1006/bbrc.1999.1189; Lokuta AJ, 1997, J BIOL CHEM, V272, P25333, DOI 10.1074/jbc.272.40.25333; Maki M, 1997, BIOCHEM J, V328, P718; Marx SO, 2002, BASIC RES CARDIOL S1, V97, pI49; MELLONI E, 1989, TRENDS NEUROSCI, V12, P438, DOI 10.1016/0166-2236(89)90093-3; MEYERS MB, 1987, BIOCHEM PHARMACOL, V36, P2373, DOI 10.1016/0006-2952(87)90606-X; Meyers MB, 1998, J BIOL CHEM, V273, P18930, DOI 10.1074/jbc.273.30.18930; MEYERS MB, 1995, J BIOL CHEM, V270, P26411, DOI 10.1074/jbc.270.44.26411; MEYERS MB, 1995, FEBS LETT, V357, P230, DOI 10.1016/0014-5793(94)01338-2; Mohiddin SA, 2002, CIRCULATION, V106, P319; Pack-Chung E, 2000, J BIOL CHEM, V275, P14440, DOI 10.1074/jbc.M909882199; Peterson BZ, 2000, BIOPHYS J, V78, P1906, DOI 10.1016/S0006-3495(00)76739-7; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Pickel VM, 1997, J COMP NEUROL, V386, P625, DOI 10.1002/(SICI)1096-9861(19971006)386:4<625::AID-CNE8>3.0.CO;2-4; Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; RINDT H, 1995, TRANSGENIC RES, V4, P397, DOI 10.1007/BF01973758; SANFORD J, 1991, J BIOL CHEM, V266, P9570; Soldatov NM, 1998, J BIOL CHEM, V273, P957, DOI 10.1074/jbc.273.2.957; VANDERBLIEK AM, 1986, EMBO J, V5, P3201, DOI 10.1002/j.1460-2075.1986.tb04630.x; Wolska BM, 1996, AM J PHYSIOL-HEART C, V271, pH1250, DOI 10.1152/ajpheart.1996.271.3.H1250; Xie XL, 2001, PROTEIN SCI, V10, P2419, DOI 10.1110/ps.ps.36701; Zamparelli C, 1997, FEBS LETT, V409, P1, DOI 10.1016/S0014-5793(97)00464-X; Zamparelli C, 2000, BIOCHEMISTRY-US, V39, P658, DOI 10.1021/bi991648v; Zhou JM, 1997, P NATL ACAD SCI USA, V94, P2301, DOI 10.1073/pnas.94.6.2301; Zhou YY, 1999, J PHYSIOL-LONDON, V521, P351, DOI 10.1111/j.1469-7793.1999.00351.x; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	49	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28865	28871		10.1074/jbc.M302009200	http://dx.doi.org/10.1074/jbc.M302009200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12754254	hybrid			2022-12-25	WOS:000184421100065
J	Raynal, BDE; Hardingham, TE; Sheehan, JK; Thornton, DJ				Raynal, BDE; Hardingham, TE; Sheehan, JK; Thornton, DJ			Calcium-dependent protein interactions in MUC5B provide reversible cross-links in salivary mucus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN TRACHEA INVITRO; HUMAN CERVICAL-MUCUS; CONFOCAL FLUORESCENCE RECOVERY; PORCINE SUBMAXILLARY MUCIN; VISCOELASTIC PROPERTIES; DIFFUSION; GEL; GLYCOPROTEINS; SECRETION; RHEOLOGY	The macromolecular organization within saliva was investigated by tracer diffusion measurements of fluorescent polystyrene microspheres by fluorescence recovery after photobleaching using a confocal microscope (confocal-FRAP). There was a concentration-dependent reduction in microsphere diffusion; this was much greater in the presence of calcium (10 mM) and was reduced by the addition of EGTA (10 mM). These effects on tracer diffusion showed that native saliva contained a macromolecular organization that was sensitive to free calcium concentrations. This was supported by a major increase in the weight average molecular weight of the high molecular weight mucin fraction in saliva (10-62 x 10(6)) and an increase in intrinsic viscosity of saliva (733 to 1203 ml/g) both caused by calcium. Analysis of the change in tracer diffusion in saliva showed a 20-fold increase in the apparent pore size (from 130 nm in 10 mM CaCl2 to 2600 nm in 10 mM EGTA at physiological concentration). The effect was specific for calcium and was unaffected by up to 2 M NaCl. The calcium binding activity was contained in a high buoyant density fraction of saliva excluded from Sepharose CL-2B. Calcium binding to this fraction gave an approximate K-d of 7 x 10(-6) M, and the binding was irreversibly destroyed by treatment with 6 M guanidinium chloride and by mild reduction, suggesting it to be to a protein site. This fraction of saliva was shown to contain MUC5B as the single major protein species by positive ion electrospray ionization-tandem mass spectrometry analysis. The results suggested that oligomeric MUC5B in saliva is assembled into much larger linear or branched assemblies through calcium-mediated protein cross-links.	Univ Manchester, Wellcome Trust, Ctr Cell Matrix Res, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Thornton, DJ (corresponding author), Univ Manchester, Wellcome Trust, Ctr Cell Matrix Res, Sch Biol Sci, 2-205 Stopford Bldg, Manchester M13 9PT, Lancs, England.			Thornton, David/0000-0001-7148-1970; raynal, Bertrand/0000-0001-5634-0408; Hardingham, Timothy/0000-0001-8271-6763				BEELEY JA, 1993, BIOCHEM SOC T, V21, P133, DOI 10.1042/bst0210133; Bromberg LE, 2000, BIOMACROMOLECULES, V1, P325, DOI 10.1021/bm005532m; CARLSTEDT I, 1985, ESSAYS BIOCHEM, V20, P40; CARLSTEDT I, 1983, BIOCHEM J, V211, P13, DOI 10.1042/bj2110013; CROWTHER RS, 1984, BIORHEOLOGY, V21, P253; De Gennes P.-G., 1979, SCALING CONCEPTS POL; DE SMEDT SC, 1994, MACROMOLECULES, V27, P141, DOI 10.1021/ma00079a021; FORSTNER JF, 1975, BIOCHIM BIOPHYS ACTA, V386, P283, DOI 10.1016/0005-2795(75)90270-6; FORSTNER JF, 1976, PEDIATR RES, V10, P609, DOI 10.1203/00006450-197606000-00009; GLANTZ PO, 1989, ACTA ODONTOL SCAND, V47, P7, DOI 10.3109/00016358909004794; Gribbon P, 1999, BIOPHYS J, V77, P2210, DOI 10.1016/S0006-3495(99)77061-X; Gribbon P, 1998, BIOPHYS J, V75, P1032, DOI 10.1016/S0006-3495(98)77592-7; Gribbon P, 2000, BIOCHEM J, V350, P329, DOI 10.1042/0264-6021:3500329; KUBITSCHECK U, 1994, BIOPHYS J, V67, P948, DOI 10.1016/S0006-3495(94)80596-X; Madsen F, 1998, J CONTROL RELEASE, V50, P167, DOI 10.1016/S0168-3659(97)00138-7; MARRIOTT C, 1979, BIORHEOLOGY, V16, P331; MCCULLAGH CM, 1995, BIOPOLYMERS, V35, P149, DOI 10.1002/bip.360350203; MIAN N, 1986, BIOCHIM BIOPHYS ACTA, V883, P486, DOI 10.1016/0304-4165(86)90288-6; MIAN N, 1986, BIOCHIM BIOPHYS ACTA, V883, P476, DOI 10.1016/0304-4165(86)90287-4; MIAN N, 1982, BIOCHEM J, V208, P425, DOI 10.1042/bj2080425; NORDBO H, 1984, SCAND J DENT RES, V92, P306; Offner GD, 1998, BIOCHEM BIOPH RES CO, V251, P350, DOI 10.1006/bbrc.1998.9469; PHILLIES GDJ, 1989, J PHYS CHEM-US, V93, P5029, DOI 10.1021/j100350a008; Raynal BDE, 2002, BIOCHEM J, V362, P289, DOI 10.1042/0264-6021:3620289; Rogunova MA, 1997, BIORHEOLOGY, V34, P295, DOI 10.1016/S0006-355X(98)00006-7; SALTZMAN WM, 1994, BIOPHYS J, V66, P508, DOI 10.1016/S0006-3495(94)80802-1; SELLERS LA, 1991, BIOCHIM BIOPHYS ACTA, V1115, P174, DOI 10.1016/0304-4165(91)90027-E; SHEEHAN JK, 1984, BIOCHEM J, V217, P93, DOI 10.1042/bj2170093; SHOGREN R, 1983, BIOPOLYMERS, V22, P1657, DOI 10.1002/bip.360220705; SMITH BF, 1989, GASTROENTEROLOGY, V97, P179, DOI 10.1016/0016-5085(89)91433-9; SOBY LM, 1990, BIOPOLYMERS, V29, P1359, DOI 10.1002/bip.360291004; STEINER CA, 1984, BIORHEOLOGY, V21, P235; Thornton DJ, 1999, GLYCOBIOLOGY, V9, P293, DOI 10.1093/glycob/9.3.293; THORNTON DJ, 1989, ANAL BIOCHEM, V182, P160, DOI 10.1016/0003-2697(89)90735-5; VARMA BK, 1990, BIOPOLYMERS, V29, P441, DOI 10.1002/bip.360290214; VEERMAN ECI, 1989, J BIOL BUCCALE, V17, P297; VERDUGO P, 1987, BIORHEOLOGY, V24, P625; VERDUGO P, 1990, ANNU REV PHYSIOL, V52, P157, DOI 10.1146/annurev.ph.52.030190.001105; Wickstrom C, 1998, BIOCHEM J, V334, P685, DOI 10.1042/bj3340685	39	109	120	2	49	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28703	28710		10.1074/jbc.M304632200	http://dx.doi.org/10.1074/jbc.M304632200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12756239	hybrid			2022-12-25	WOS:000184421100045
J	Ulmer, TS; Soelaiman, S; Li, SP; Klee, CB; Tang, WJ; Bax, A				Ulmer, TS; Soelaiman, S; Li, SP; Klee, CB; Tang, WJ; Bax, A			Calcium dependence of the interaction between calmodulin and anthrax edema factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLYL-CYCLASE; TARGET RECOGNITION; STRUCTURAL BASIS; CA2+ BINDING; ACTIVATION; TOXIN; NMR; PROTEINS; ASSIGNMENT; DIVERSITY	Edema factor (EF), a toxin from Bacillus anthracis ( anthrax), possesses adenylyl cyclase activity and requires the ubiquitous Ca2+- sensor calmodulin (CaM) for activity. CaM can exist in three major structural states: an apo state with no Ca2+ bound, a two Ca2+ state with its C-terminal domain Ca2+- loaded, and a four Ca2+ state in which the lower Ca2+ affinity N-terminal domain is also ligated. Here, the interaction of EF with the three Ca2+ states of CaM has been examined by NMR spectroscopy and changes in the Ca2+ affinity of CaM in the presence of EF have been determined by flow dialysis. Backbone chemical shift perturbations of CaM show that EF interacts weakly with the N-terminal domain of apoCaM. The C-terminal CaM domain only engages in the interaction upon Ca2+ ligation, rendering the overall interaction much tighter. In the presence of EF, the C-terminal domain binds Ca2+ with higher affinity, but loses binding cooperativity, whereas the N-terminal domain exhibits strongly reduced Ca2+ affinity. As judged by chemical shift differences, the N-terminal CaM domain remains bound to EF upon subsequent Ca2+ ligation. This Ca2+ dependence of the EF-CaM interaction differs from that observed for most other CaM targets, which normally interact only with the Ca2+- bound CaM domains and become active following the transition to the four Ca2+ state.	Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA	University of Chicago; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Klee, CB (corresponding author), Univ Chicago, Ben May Inst Canc Res, JFK T120,924 E 57th St, Chicago, IL 60637 USA.			Tang, Wei-Jen/0000-0002-8267-8995	NIGMS NIH HHS [GM62548, GM53459] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK029020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053459, R01GM062548] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Drum CL, 2002, NATURE, V415, P396, DOI 10.1038/415396a; Drum CL, 2000, J BIOL CHEM, V275, P36334, DOI 10.1074/jbc.M004778200; EDSALL JT, 1958, BIOPHYS CHEM, V1, P591; Evenas J, 1998, BIOCHEMISTRY-US, V37, P13744, DOI 10.1021/bi9806448; HAIECH J, 1981, BIOCHEMISTRY-US, V20, P3890, DOI 10.1021/bi00516a035; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; HUANG CY, 1981, P NATL ACAD SCI-BIOL, V78, P871, DOI 10.1073/pnas.78.2.871; IKURA M, 1990, BIOCHEM PHARMACOL, V40, P153; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; IKURA M, 1984, BIOCHEMISTRY-US, V23, P3124, DOI 10.1021/bi00309a003; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kumar P, 2002, INFECT IMMUN, V70, P4997, DOI 10.1128/IAI.70.9.4997-5007.2002; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; LINSE S, 1991, J BIOL CHEM, V266, P8050; Malmendal A, 1999, J MOL BIOL, V293, P883, DOI 10.1006/jmbi.1999.3188; Martell A. E., 1977, CRITICAL STABILITY C, V3; Mourez M, 2002, TRENDS MICROBIOL, V10, P287, DOI 10.1016/S0966-842X(02)02369-7; Nelson MR, 1998, BIOMETALS, V11, P297, DOI 10.1023/A:1009253808876; Pannifer AD, 2001, NATURE, V414, P229, DOI 10.1038/n35101998; Pervushin KV, 1998, J BIOMOL NMR, V12, P345, DOI 10.1023/A:1008268930690; Riek R, 2000, TRENDS BIOCHEM SCI, V25, P462, DOI 10.1016/S0968-0004(00)01665-0; Salzmann M, 1998, P NATL ACAD SCI USA, V95, P13585, DOI 10.1073/pnas.95.23.13585; Shen YQ, 2002, EMBO J, V21, P6721, DOI 10.1093/emboj/cdf681; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; TSIEN RY, 1984, TRENDS BIOCHEM SCI, V9, P263, DOI 10.1016/0968-0004(84)90160-9; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325	29	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29261	29266		10.1074/jbc.M302837200	http://dx.doi.org/10.1074/jbc.M302837200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12724328	hybrid			2022-12-25	WOS:000184421100111
J	Bartels, C; Urlaub, H; Luhrmann, R; Fabrizio, P				Bartels, C; Urlaub, H; Luhrmann, R; Fabrizio, P			Mutagenesis suggests several roles of Snu114p in pre- mRNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-G; SNRNP-SPECIFIC PROTEIN; U5 SNRNP; RIBOSOMAL TRANSLOCASE; U4/U6 RNA; CRYSTAL-STRUCTURE; U6 SNRNA; YEAST; HOMOLOG; GTP	Snu114p, a yeast U5 small nuclear ribonucleoprotein (snRNP) homologous to the ribosomal GTPase EF-2, was recently found to play a part in the dissociation of U4 small nuclear RNA (snRNA) from U6 snRNA. Here, we show that purified Snu114p binds GTP specifically. To test the possibility that binding and hydrolysis of GTP by Snu114p are required to stimulate the unwinding of U4 from U6, we produced several mutations of Snu114p. Residues whose mutations led to lethal phenotypes were all clustered in the P loop and in the guanine-ring binding sequence (NKXD) of the G domain, which in elongation factor-G is required for the binding and hydrolysis of GTP. An arginine residue in domain II, which in EF-G forms a salt bridge with a residue of the G domain, when mutated in Snu114p (R487E), led to a temperature-sensitive phenotype. The substitution D271N in the NKXD sequence is predicted to bind XTP instead of GTP. Spliceosomes containing this mutant, isolated by affinity chromatography after heat treatment, retained U4 snRNA paired with the U6 snRNA. U4 snRNA was released efficiently only when these arrested spliceosomes were reactivated by lowering the temperature in the presence of a mixture of ATP and XTP. Because non-hydrolyzable XTP analogues did not consent the release of U4, we conclude that the release requires hydrolysis of XTP. This suggests that Snu114p needs GTP to influence, directly or indirectly, the unwinding of U4 from U6. An additional role for Snu114p is also demonstrated: after growth of the D271N and R487E strains at high temperatures, we observed decreased levels of the U5 and the U4/U6.U5 snRNPs. This indicates that, before splicing, Snu114p plays a part in the assembly of both particles.	Max Planck Inst Biophys Chem, Dept Cellular Biochem, D-37077 Gottingen, Germany	Max Planck Society	Fabrizio, P (corresponding author), Max Planck Inst Biophys Chem, Dept Cellular Biochem, Fassberg 11, D-37077 Gottingen, Germany.	pfabriz1@gwdg.de						Achsel T, 1998, MOL CELL BIOL, V18, P6756, DOI 10.1128/MCB.18.11.6756; Aevarsson A, 1995, J MOL EVOL, V41, P1096; AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Ayadi L, 1997, RNA, V3, P197; Bartels C, 2002, EMBO REP, V3, P875, DOI 10.1093/embo-reports/kvf172; Bishop A, 2000, ANNU REV BIOPH BIOM, V29, P577, DOI 10.1146/annurev.biophys.29.1.577; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BROWN JD, 1992, EMBO J, V11, P3721, DOI 10.1002/j.1460-2075.1992.tb05457.x; Burge CB, 1999, RNA WORLD, P525; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; Dix I, 1998, RNA, V4, P1239, DOI 10.1017/S1355838298981109; Fabrizio P, 1997, EMBO J, V16, P4092, DOI 10.1093/emboj/16.13.4092; GOODY RS, 1991, TRENDS BIOCHEM SCI, V16, P327, DOI 10.1016/0968-0004(91)90134-H; GRABOWSKI PJ, 1986, SCIENCE, V233, P1294, DOI 10.1126/science.3638792; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; Kuhn AN, 1999, MOL CELL, V3, P65, DOI 10.1016/S1097-2765(00)80175-6; Laggerbauer B, 1996, NUCLEIC ACIDS RES, V24, P868, DOI 10.1093/nar/24.5.868; Laggerbauer B, 1998, P NATL ACAD SCI USA, V95, P4188, DOI 10.1073/pnas.95.8.4188; Lauber J, 1996, EMBO J, V15, P4001, DOI 10.1002/j.1460-2075.1996.tb00774.x; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; LIN RJ, 1985, J BIOL CHEM, V260, P4780; LINDAHL M, 1994, EMBO J, V13, P1249, DOI 10.1002/j.1460-2075.1994.tb06376.x; MURZIN AG, 1995, NAT STRUCT BIOL, V2, P25, DOI 10.1038/nsb0195-25; Nilsen TW, 1998, COLD SPRING HARBOR M, P279; Raghunathan PL, 1998, CURR BIOL, V8, P847, DOI 10.1016/S0960-9822(07)00345-4; RAMAKRISHNAN V, 1992, NATURE, V358, P768, DOI 10.1038/358768a0; Rodnina MV, 1997, NATURE, V385, P37, DOI 10.1038/385037a0; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; TARN WY, 1993, P NATL ACAD SCI USA, V90, P10821, DOI 10.1073/pnas.90.22.10821; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; van Nues RW, 2001, GENETICS, V157, P1451; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; Wang Y, 1998, CURR BIOL, V8, P441, DOI 10.1016/S0960-9822(98)70178-2; WEIJLAND A, 1994, BIOCHEMISTRY-US, V33, P10711, DOI 10.1021/bi00201a019; Xie J, 1998, EMBO J, V17, P2938, DOI 10.1093/emboj/17.10.2938	37	54	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28324	28334		10.1074/jbc.M303043200	http://dx.doi.org/10.1074/jbc.M303043200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12736260	Green Published, hybrid			2022-12-25	WOS:000184242700123
J	Boyd, GW; Doward, AI; Kirkness, EF; Millar, NS; Connolly, CN				Boyd, GW; Doward, AI; Kirkness, EF; Millar, NS; Connolly, CN			Cell surface expression of 5-hydroxytryptamine type 3 receptors is controlled by an endoplasmic reticulum retention signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; BETA-SUBUNITS; ER RETENTION; INTERSUBUNIT CONTACTS; 5-HT3 RECEPTORS; ALPHA-SUBUNITS; ION-CHANNEL; TRAFFICKING; IDENTIFICATION; EXPORT	Two subunits of the 5-hydroxytryptamine type 3 (5-HT(3)) have been identified (5-HT(3A) and 5-HT(3B)) that assemble into homomeric (5-HT(3A)) and heteromeric (5-HT(3A) + 5-HT(3B)) complexes. Unassembled 5-HT(3B) subunits are efficiently retained within the cell. In this study, we address the mechanism controlling the release of 5-HT(3B) from the endoplasmic reticulum (ER). An analysis of chimeric 5-HT(3A) receptor(R).5-HT(3B)R constructs suggests the presence of elements downstream of the first transmembrane domain of 5-HT(3B) subunits that inhibit cell surface expression. To investigate this possibility, truncated 5-HT(3B) subunits were constructed and assessed for their ability to access the cell surface in COS-7 and ts201 cells. Using this approach, we have identified the presence of an ER retention signal located within the first cytoplasmic loop between transmembrane domains I and II of 5-HT(3B). Transplantation of this signal (CRAR) into the homologous region of 5-HT(3A) results in the ER retention of this subunit until rescued by co-assembly with wild-type 5-HT(3A). The mutation of this ER retention signal in 5-HT(3B) (5-HT(3B)SGER) does not lead to cell surface expression, suggesting the presence of other signals or mechanisms to control the surface expression of 5-HT(3B)Rs. The generation of truncated 5-HT(3B)SGER constructs confirmed that the CRAR signal does play an important role in the ER retention of 5-HT(3B).	Univ Dundee, Ninewells Hosp & Med Sch, Dept Pharmacol & Neurosci, Dundee DD1 9SY, Scotland; UCL, Dept Pharmacol, Mol Pharmacol Lab, London WC1E 6BT, England; Inst Genom Res, Rockville, MD 20850 USA	University of Dundee; University of London; University College London; J. Craig Venter Institute	Connolly, CN (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Pharmacol & Neurosci, Dundee DD1 9SY, Scotland.	c.n.connolly@dundee.ac.uk		Connolly, Christopher/0000-0002-0445-8874				Andersson H, 1999, J BIOL CHEM, V274, P15080, DOI 10.1074/jbc.274.21.15080; Bollan K, 2003, J BIOL CHEM, V278, P4747, DOI 10.1074/jbc.M210229200; Bottomley MJ, 2001, CURR BIOL, V11, P1114, DOI 10.1016/S0960-9822(01)00317-7; Boyd GW, 2002, MOL CELL NEUROSCI, V21, P38, DOI 10.1006/mcne.2002.1160; Brown AM, 1998, J PHYSIOL-LONDON, V507, P653, DOI 10.1111/j.1469-7793.1998.653bs.x; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Cooper ST, 1999, J BIOL CHEM, V274, P27145, DOI 10.1074/jbc.274.38.27145; Cosson P, 1998, EMBO J, V17, P6863, DOI 10.1093/emboj/17.23.6863; Davies PA, 1999, NATURE, V397, P359, DOI 10.1038/16941; Dubin AE, 1999, J BIOL CHEM, V274, P30799, DOI 10.1074/jbc.274.43.30799; Ehya N, 2003, J NEUROCHEM, V84, P127, DOI 10.1046/j.1471-4159.2003.01509.x; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Fletcher S, 1998, TRENDS PHARMACOL SCI, V19, P212, DOI 10.1016/S0165-6147(98)01210-3; Girod A, 1999, NAT CELL BIOL, V1, P423, DOI 10.1038/15658; GREEN WN, 1995, TRENDS NEUROSCI, V18, P280, DOI 10.1016/0166-2236(95)93915-K; Greenshaw AJ, 1997, DRUGS, V53, P20, DOI 10.2165/00003495-199753010-00003; Greger IH, 2002, NEURON, V34, P759, DOI 10.1016/S0896-6273(02)00693-1; Harkness PC, 2002, J NEUROSCI, V22, P10172; HUSSY N, 1994, J PHYSIOL-LONDON, V481, P311, DOI 10.1113/jphysiol.1994.sp020441; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Keller SH, 2001, J BIOL CHEM, V276, P18384, DOI 10.1074/jbc.M100691200; KING FD, 1994, 5 HYDROXYTRYPTAMINE3; Klausberger T, 2000, J BIOL CHEM, V275, P8921, DOI 10.1074/jbc.275.12.8921; Klausberger T, 2001, J NEUROSCI, V21, P9124, DOI 10.1523/JNEUROSCI.21-23-09124.2001; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Macleod AD, 2000, J PAIN SYMPTOM MANAG, V20, P388, DOI 10.1016/S0885-3924(00)00205-0; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; Morales M, 2001, J COMP NEUROL, V438, P163, DOI 10.1002/cne.1307; Nishimura N, 1999, J BIOL CHEM, V274, P15937, DOI 10.1074/jbc.274.22.15937; Nufer O, 2002, J CELL SCI, V115, P619; PETERS JA, 1997, RECOMBINANT CELL SUR, P119; Sarto I, 2002, J BIOL CHEM, V277, P30656, DOI 10.1074/jbc.M203597200; Sarto I, 2002, NEUROPHARMACOLOGY, V43, P482, DOI 10.1016/S0028-3908(02)00160-0; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Taylor PM, 2000, J NEUROSCI, V20, P1297; Taylor PM, 1999, J NEUROSCI, V19, P6360; Votsmeier C, 2001, EMBO J, V20, P6742, DOI 10.1093/emboj/20.23.6742; YANG J, 1992, J PHYSIOL-LONDON, V448, P237, DOI 10.1113/jphysiol.1992.sp019039; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zerangue N, 2001, P NATL ACAD SCI USA, V98, P2431, DOI 10.1073/pnas.051630198	43	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27681	27687		10.1074/jbc.M304938200	http://dx.doi.org/10.1074/jbc.M304938200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12750374	hybrid			2022-12-25	WOS:000184242700045
J	Cheltsov, AV; Guida, WC; Ferreira, GC				Cheltsov, AV; Guida, WC; Ferreira, GC			Circular permutation of 5-aminolevulinate synthase - Effect on folding, conformational stability, and structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-AMINOLEVULINATE SYNTHASE; DIHYDROFOLATE-REDUCTASE; ESCHERICHIA-COLI; 8-AMINO-7-OXONONANOATE SYNTHASE; GUANIDINIUM CHLORIDE; SECONDARY STRUCTURE; PROTEIN; EQUILIBRIUM; TOPOLOGY; COFACTOR	The first and regulatory step of heme biosynthesis in mammals begins with the pyridoxal 5'-phosphate-dependent condensation reaction catalyzed by 5-aminolevulinate synthase. The enzyme functions as a homodimer with the two active sites at the dimer interface. Previous studies demonstrated that circular permutation of 5-aminolevulinate synthase does not prevent folding of the polypeptide chain into a structure amenable to binding of the pyridoxal 5'-phosphate cofactor and assembly of the two subunits into a functional enzyme. However, while maintaining a wild type-like three-dimensional structure, active, circularly permuted 5-aminolevulinate synthase variants possess different topologies. To assess whether the aminolevulinate synthase overall structure can be reached through alternative or multiple folding pathways, we investigated the guanidine hydrochloride-induced unfolding, conformational stability, and structure of active, circularly permuted variants in relation to those of the wild type enzyme using fluorescence, circular dichroism, activity, and size exclusion chromatography. Aminolevulinate synthase and circularly permuted variants folded reversibly; the equilibrium unfolding/refolding profiles were biphasic and, in all but one case, protein concentration-independent, indicating a unimolecular process with the presence of at least one stable intermediate. The formation of this intermediate was preceded by the disruption of the dimeric interface or dissociation of the dimer without significant change in the secondary structural content of the subunits. In contrast to the similar stabilities associated with the dimeric interface, the energy for the unfolding of the intermediate as well as the overall conformational stabilities varied among aminolevulinate synthase and variants. The unfolding of one functional permuted variant was protein concentration-dependent and had a potentially different folding mechanism. We propose that the order of the ALAS secondary structure elements does not determine the ability of the polypeptide chain to fold but does affect its folding mechanism.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Eckerd Coll, Dept Chem, St Petersburg, Russia	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Ferreira, GC (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	gferreir@hsc.usf.edu	Ferreira, Gloria C/A-4709-2012	Ferreira, Gloria C/0000-0001-9279-2217				Alexeev D, 1998, J MOL BIOL, V284, P401, DOI 10.1006/jmbi.1998.2086; Bettati S, 2000, J BIOL CHEM, V275, P40244, DOI 10.1074/jbc.M007015200; BISHOP DF, 1990, GENOMICS, V7, P207, DOI 10.1016/0888-7543(90)90542-3; BOTTOMLEY SS, 1995, J BIOENERG BIOMEMBR, V27, P161, DOI 10.1007/BF02110031; BOTTOMLEY SS, 1999, WINTROBES CLIN HEMAT, P1022; CAI K, 1995, J BIOL CHEM, V270, P19294, DOI 10.1074/jbc.270.33.19294; Chapeaurouge A, 2002, J BIOL CHEM, V277, P16478, DOI 10.1074/jbc.M105232200; Cheltsov AV, 2001, J BIOL CHEM, V276, P19141, DOI 10.1074/jbc.M100329200; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Cotter PD, 1999, BLOOD, V93, P1757, DOI 10.1182/blood.V93.5.1757.405a12_1757_1769; COTTER PD, 1992, GENOMICS, V13, P211, DOI 10.1016/0888-7543(92)90223-F; Eftink M. R., 1991, BIOPHYSICAL BIOCH AS, P1; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Fan YX, 1998, PROTEIN SCI, V7, P2631, DOI 10.1002/pro.5560071217; FANICAGA.M, 1973, EUR J BIOCHEM, V40, P19, DOI 10.1111/j.1432-1033.1973.tb03164.x; FERREIRA GC, 1993, PROTEIN SCI, V2, P1959, DOI 10.1002/pro.5560021117; FERREIRA GC, 1995, J BIOENERG BIOMEMBR, V27, P151, DOI 10.1007/BF02110030; FERREIRA GC, 1993, J BIOL CHEM, V268, P584; FERREIRA GC, 1995, PROTEIN SCI, V4, P1001; Ferreira GC., 1999, IRON METABOLISM, P15, DOI [10.1002/9783527613700.CH02., DOI 10.1002/9783527613700.CH02]; FIERKE CA, 1987, BIOCHEMISTRY-US, V26, P4085, DOI 10.1021/bi00387a052; GHELIS C, 1982, PROTEIN FOLDING, P223; Gokhale RS, 1999, BIOCHEMISTRY-US, V38, P423, DOI 10.1021/bi981087s; Gong J, 1998, BIOCHEMISTRY-US, V37, P3509, DOI 10.1021/bi9719298; Gsponer J, 2001, J MOL BIOL, V309, P285, DOI 10.1006/jmbi.2001.4552; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harigae H, 1999, BRIT J HAEMATOL, V106, P175, DOI 10.1046/j.1365-2141.1999.01479.x; Herbst R, 1997, J BIOL CHEM, V272, P7099, DOI 10.1074/jbc.272.11.7099; HUALA E, 1991, J BACTERIOL, V173, P382, DOI 10.1128/jb.173.1.382-390.1991; HUNTER GA, 1995, ANAL BIOCHEM, V226, P221, DOI 10.1006/abio.1995.1217; Hunter GA, 1999, BIOCHEMISTRY-US, V38, P3711, DOI 10.1021/bi982390w; Ionescu RM, 2000, BIOCHEMISTRY-US, V39, P9540, DOI 10.1021/bi000511y; IWAKURA M, 1995, J BIOCHEM, V117, P480, DOI 10.1093/oxfordjournals.jbchem.a124733; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kolossavary I, 1999, J COMPUT CHEM, V20, P1671, DOI 10.1002/(SICI)1096-987X(19991130)20:15<1671::AID-JCC7>3.0.CO;2-Y; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIEN LF, 1982, ENZYME, V28, P120; LONDON J, 1974, EUR J BIOCHEM, V47, P409, DOI 10.1111/j.1432-1033.1974.tb03707.x; MAUZERALL D, 1956, J BIOL CHEM, V219, P435; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; Nakajima O, 1999, EMBO J, V18, P6282, DOI 10.1093/emboj/18.22.6282; Pace C N, 1986, Methods Enzymol, V131, P266; REYES AM, 1993, J BIOL CHEM, V268, P22281; Rietveld AWM, 1998, BIOCHEMISTRY-US, V37, P933, DOI 10.1021/bi9721593; Sadlon TJ, 1999, INT J BIOCHEM CELL B, V31, P1153, DOI 10.1016/S1357-2725(99)00073-4; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Smith VF, 2001, PROTEIN SCI, V10, P116, DOI 10.1110/ps.26601; Tan DW, 1996, BIOCHEMISTRY-US, V35, P8934, DOI 10.1021/bi952918m; Tan DW, 1998, PROTEIN SCI, V7, P1208, DOI 10.1002/pro.5560070516; Tan DW, 1998, BIOCHEMISTRY-US, V37, P1478, DOI 10.1021/bi971928f; TANDON S, 1986, J BIOL CHEM, V261, P5615; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOUCHETTE NA, 1986, BIOCHEMISTRY-US, V25, P5445, DOI 10.1021/bi00367a015; VIGUERA AR, 1995, J MOL BIOL, V247, P670, DOI 10.1016/S0022-2836(05)80146-9; Viguera AR, 1996, NAT STRUCT BIOL, V3, P874, DOI 10.1038/nsb1096-874; Webster SP, 2000, BIOCHEMISTRY-US, V39, P516, DOI 10.1021/bi991620j; Westhead DR, 1999, PROTEIN SCI, V8, P897; Westhead DR, 1998, TRENDS BIOCHEM SCI, V23, P35, DOI 10.1016/S0968-0004(97)01161-4	61	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27945	27955		10.1074/jbc.M207011200	http://dx.doi.org/10.1074/jbc.M207011200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12736261	hybrid			2022-12-25	WOS:000184242700078
J	Kaji, T; Hachimura, S; Ise, W; Kaminogawa, S				Kaji, T; Hachimura, S; Ise, W; Kaminogawa, S			Proteome analysis reveals caspase activation in hyporesponsive CD4 T lymphocytes induced in vivo by the oral administration of antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TRANSGENIC MICE; CELL-RECEPTOR; ADAPTER PROTEIN; AUTOIMMUNE ENCEPHALOMYELITIS; PHOSPHOLIPASE C-GAMMA-1; TYROSINE PHOSPHORYLATION; NUCLEAR TRANSLOCATION; POLYACRYLAMIDE-GELS; MEDIATED ACTIVATION; ACTIVE SUPPRESSION	The oral administration of antigen can lead to systemic antigen-specific hyporesponsiveness, also known as oral tolerance. This phenomenon is a representative form of immune tolerance to exogenous antigen under physiological conditions. We have previously reported that long term feeding of dietary antigen to ovalbumin-specific T cell receptor (TCR) transgenic mice induced oral tolerance of peripheral T cells with impairment in their TCR-induced calcium-signaling pathway. In this study, we utilized two-dimensional electrophoresis to compare intracellular protein expression patterns of orally tolerant and unsensitized CD4 T cells. We detected 26 increased and 16 decreased protein spots and identified 35 of these by mass spectrometry. The results indicated that the expression of caspases was up-regulated and that the protein levels of intact proteins susceptible to caspase cleavage, such as Grb2-related adaptor downstream of Shc (GADS), were decreased in orally tolerant CD4 T cells. Western blotting experiments confirmed that expression of the active form of caspase-3 and the antiapoptotic factor, X-linked inhibitor of apoptosis, were both up-regulated in orally tolerant CD4 T cells, which were found to be nonapoptotic. We further demonstrated that orally tolerant CD4 T cells could not form normal TCR signaling complexes associated with GADS and showed down-regulated phospholipase C-gamma1 activation, which is likely to contribute to the impairment of TCR-induced calcium signaling. Our findings indicate that orally tolerant CD4 T cells up-regulate caspase activation and show decreased levels of caspase-targeted proteins, including TCR signaling-associated molecules, while up-regulating antiapoptotic factors, all of which appear to contribute to their unique tolerant characteristics.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 113, Japan; Nihon Univ, Coll Bioresource Sci, Dept Food Sci & Technol, Fujisawa, Kanagawa 2528510, Japan	University of Tokyo; Nihon University	Hachimura, S (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 113, Japan.							Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Alpan O, 2001, J IMMUNOL, V166, P4843, DOI 10.4049/jimmunol.166.8.4843; Anderson NL, 1998, ELECTROPHORESIS, V19, P1853, DOI 10.1002/elps.1150191103; Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; Asai K, 2002, J IMMUNOL, V169, P4723, DOI 10.4049/jimmunol.169.9.4723; BECKER JC, 1995, P NATL ACAD SCI USA, V92, P2375, DOI 10.1073/pnas.92.6.2375; Berggren K, 2000, ELECTROPHORESIS, V21, P2509, DOI 10.1002/1522-2683(20000701)21:12<2509::AID-ELPS2509>3.3.CO;2-0; Berry DM, 2001, ONCOGENE, V20, P1203, DOI 10.1038/sj.onc.1204218; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Chen YH, 1996, P NATL ACAD SCI USA, V93, P388, DOI 10.1073/pnas.93.1.388; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; Chen YHH, 1996, ANN NY ACAD SCI, V778, P111, DOI 10.1111/j.1749-6632.1996.tb21120.x; Datta R, 2000, J BIOL CHEM, V275, P31733, DOI 10.1074/jbc.M910231199; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; DUBOIS PM, 1994, EUR J IMMUNOL, V24, P348, DOI 10.1002/eji.1830240212; Faria AMC, 1999, ADV IMMUNOL, V73, P153, DOI 10.1016/S0065-2776(08)60787-7; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688; Garside P, 1996, AM J PATHOL, V149, P1971; GARSIDE P, 1995, J IMMUNOL, V154, P5649; Garside P, 2001, SEMIN IMMUNOL, V13, P177, DOI 10.1006/smim.2001.0310; Gavin MA, 2002, NAT IMMUNOL, V3, P33, DOI 10.1038/ni743; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Hanninen A, 2000, SCAND J IMMUNOL, V52, P217; HIRAHARA K, 1995, J IMMUNOL, V154, P6238; Kaji T, 2002, NITRIC OXIDE-BIOL CH, V6, P125, DOI 10.1006/niox.2001.0389; Kang B, 1999, IMMUNOBIOLOGY, V200, P264, DOI 10.1016/S0171-2985(99)80075-8; Kimura M, 2000, INT IMMUNOL, V12, P817, DOI 10.1093/intimm/12.6.817; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Lechner O, 2001, CURR BIOL, V11, P587, DOI 10.1016/S0960-9822(01)00160-9; Liu SK, 1998, ONCOGENE, V17, P3073, DOI 10.1038/sj.onc.1202337; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Liu SKW, 2001, ONCOGENE, V20, P6284, DOI 10.1038/sj.onc.1204771; Macian F, 2002, CELL, V109, P719, DOI 10.1016/S0092-8674(02)00767-5; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; Mann M, 2001, ANNU REV BIOCHEM, V70, P437, DOI 10.1146/annurev.biochem.70.1.437; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; MELAMED D, 1993, EUR J IMMUNOL, V23, P935, DOI 10.1002/eji.1830230426; MIGITA K, 1995, J IMMUNOL, V155, P5083; MIGITA K, 1994, EUR J IMMUNOL, V24, P2081, DOI 10.1002/eji.1830240922; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SATO T, 1994, EUR J IMMUNOL, V24, P1512, DOI 10.1002/eji.1830240708; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; Shen R, 2002, MOL CELL BIOL, V22, P3230, DOI 10.1128/MCB.22.10.3230-3236.2002; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; Strobel S, 2002, ANN NY ACAD SCI, V958, P47; Strober W, 1998, J CLIN IMMUNOL, V18, P1, DOI 10.1023/A:1023222003039; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thorstenson KM, 2001, J IMMUNOL, V167, P188, DOI 10.4049/jimmunol.167.1.188; Tsuji NM, 2001, IMMUNOLOGY, V103, P458, DOI 10.1046/j.1365-2567.2001.01265.x; Ura S, 2001, P NATL ACAD SCI USA, V98, P10148, DOI 10.1073/pnas.181161698; VanHouten N, 1996, J IMMUNOL, V157, P1337; Vaughan ATM, 2002, APOPTOSIS, V7, P173, DOI 10.1023/A:1014374717773; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WHITACRE CC, 1991, J IMMUNOL, V147, P2155; Wilhelm S, 1998, EUR J IMMUNOL, V28, P891, DOI 10.1002/(SICI)1521-4141(199803)28:03<891::AID-IMMU891>3.3.CO;2-O; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yankee TM, 2001, P NATL ACAD SCI USA, V98, P6789, DOI 10.1073/pnas.111158598; Yoshida T, 1997, CLIN IMMUNOL IMMUNOP, V82, P207, DOI 10.1006/clin.1996.4319; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhang XM, 2001, J IMMUNOL, V167, P4245, DOI 10.4049/jimmunol.167.8.4245	67	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27836	27843		10.1074/jbc.M212820200	http://dx.doi.org/10.1074/jbc.M212820200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12736267	hybrid			2022-12-25	WOS:000184242700065
J	Schepers, G; Wilson, M; Wilhelm, D; Koopman, P				Schepers, G; Wilson, M; Wilhelm, D; Koopman, P			SOX8 is expressed during testis differentiation in mice and synergizes with SF1 to activate the Amh promoter in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULLERIAN-INHIBITING SUBSTANCE; AUTOSOMAL SEX REVERSAL; II COLLAGEN; STEROIDOGENIC FACTOR-1; TRANSCRIPTION FACTORS; CAMPOMELIC DYSPLASIA; GENE; SRY; CHONDROGENESIS; MUTATIONS	Sox8 is a member of the Sox family of developmental transcription factor genes and is closely related to Sox9, a key gene in the testis determination pathway in mammals. Like Sox9, Sox8 is expressed in the developing mouse testis around the time of sex determination, suggesting that it might play a role in regulating the expression of testis-specific genes. An early step in male sex differentiation is the expression of anti-Mullerian hormone (AMH) in Sertoli cells. Expression of the Amh gene during sex differentiation requires the interaction of several transcription factors, including SF1, SOX9, GATA4, WT1, and DAX1. Here we show that SOX8 may also be involved in regulating the expression of Amh. Expression of Sox8 begins just prior to that of Amh at 12 days post coitum (dpc) in mouse testes and continues beyond 16 dpc in Sertoli cells. In vitro assays showed that SOX8 binds specifically to SOX binding sites within the Amh minimal promoter and, like SOX9, acts synergistically with SF1 through direct protein-protein interaction to enhance Amh expression, albeit at lower levels compared with SOX9. SOX8 and SOX9 appear to have arisen from a common ancestral gene and may have retained some common functions during sexual development. Our data provide the first evidence that SOX8 may partially compensate for the reduced SOX9 activity in campomelic dysplasia and substitute for Sox9 where Sox9 is either not expressed or expressed too late to be involved in sex determination or regulation of Amh expression.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia	University of Queensland	Koopman, P (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	p.koopman@imb.uq.edu.au	Koopman, Peter A/C-9416-2009; Wilhelm, Dagmar/B-6915-2009	Koopman, Peter A/0000-0001-6939-0914; Wilhelm, Dagmar/0000-0002-7757-4075; Wilson, Megan/0000-0003-3425-5071				Arango NA, 1999, CELL, V99, P409, DOI 10.1016/S0092-8674(00)81527-5; BEHRINGER RR, 1994, CELL, V79, P415, DOI 10.1016/0092-8674(94)90251-8; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bell KM, 2000, MECH DEVELOP, V94, P257, DOI 10.1016/S0925-4773(00)00296-3; Bowles J, 2000, DEV BIOL, V227, P239, DOI 10.1006/dbio.2000.9883; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; Bullejos M, 2001, DEV DYNAM, V221, P201, DOI 10.1002/dvdy.1134; Chiang EFL, 2001, DEV BIOL, V231, P149, DOI 10.1006/dbio.2000.0129; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; De Santa Barbara P, 1998, MOL CELL BIOL, V18, P6653, DOI 10.1128/MCB.18.11.6653; Downes M, 2001, TRENDS CARDIOVAS MED, V11, P318, DOI 10.1016/S1050-1738(01)00131-1; Force A, 1999, GENETICS, V151, P1531; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Harada S, 1999, J BONE MINER RES, V14, pS144; Hargrave M, 2000, METH MOL B, V123, P279; Hosking BM, 2001, GENE, V262, P239, DOI 10.1016/S0378-1119(00)00525-4; HOUSTON CS, 1983, AM J MED GENET, V15, P3, DOI 10.1002/ajmg.1320150103; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Kamachi Y, 1999, MOL CELL BIOL, V19, P107; Kanai Y, 1999, HUM MOL GENET, V8, P691, DOI 10.1093/hmg/8.4.691; Kent J, 1996, DEVELOPMENT, V122, P2813; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; Koopman P, 1999, CELL MOL LIFE SCI, V55, P839; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; McDowall S, 1999, J BIOL CHEM, V274, P24023, DOI 10.1074/jbc.274.34.24023; Morohashi K, 2000, ENDOCR RES, V26, P953, DOI 10.3109/07435800009048621; MUNSTERBERG A, 1991, DEVELOPMENT, V113, P613; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; Nishiguchi S, 1998, GENE DEV, V12, P776, DOI 10.1101/gad.12.6.776; Oreal E, 1998, DEV DYNAM, V212, P522, DOI 10.1002/(SICI)1097-0177(199808)212:4<522::AID-AJA5>3.0.CO;2-J; Peirano RI, 2000, NUCLEIC ACIDS RES, V28, P3047, DOI 10.1093/nar/28.16.3047; Schepers GE, 2000, NUCLEIC ACIDS RES, V28, P1473, DOI 10.1093/nar/28.6.1473; Schlierf B, 2002, NUCLEIC ACIDS RES, V30, P5509, DOI 10.1093/nar/gkf690; Shen JHC, 2002, MOL ENDOCRINOL, V16, P529, DOI 10.1210/me.16.3.529; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; Sock E, 2001, MOL CELL BIOL, V21, P6951, DOI 10.1128/MCB.21.20.6951-6959.2001; Tremblay JJ, 1999, MOL ENDOCRINOL, V13, P1388, DOI 10.1210/me.13.8.1388; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; UENO S, 1989, ENDOCRINOLOGY, V125, P1060, DOI 10.1210/endo-125-2-1060; Vidal VPI, 2001, NAT GENET, V28, P216, DOI 10.1038/90046; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Western PS, 1999, DEV DYNAM, V216, P411; Wilson M, 2002, CURR OPIN GENET DEV, V12, P441, DOI 10.1016/S0959-437X(02)00323-4; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15	46	133	136	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28101	28108		10.1074/jbc.M304067200	http://dx.doi.org/10.1074/jbc.M304067200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12732652	hybrid			2022-12-25	WOS:000184242700096
J	Sorkina, T; Doolen, S; Galperin, E; Zahniser, NR; Sorkin, A				Sorkina, T; Doolen, S; Galperin, E; Zahniser, NR; Sorkin, A			Oligomerization of dopamine transporters visualized in living cells by fluorescence resonance energy transfer microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT GABA TRANSPORTER-1; IN-VITRO MODEL; RADIATION INACTIVATION; SEROTONIN TRANSPORTER; XENOPUS OOCYTES; EARLY ENDOSOMES; PHORBOL ESTERS; PROTEIN; METHAMPHETAMINE; INTERNALIZATION	To examine the oligomeric state and trafficking of the dopamine transporter (DAT) in different compartments of living cells, human DAT was fused to yellow (YFP) or cyan fluorescent protein (CFP). YFP-DAT and CFP-DAT were transiently and stably expressed in porcine aortic endothelial (PAE) cells, human embryonic kidney (HEK) 293 cells, and an immortalized dopaminergic cell line 1RB(3)AN(27). Fluorescence microscopic imaging of cells co-expressing YFP-DAT and CFP-DAT revealed fluorescence resonance energy transfer (FRET) between CFP and YFP, which is consistent with an intermolecular interaction of DAT fusion proteins. FRET signals were detected between CFP- and YFP-DAT located at the plasma membrane and in intracellular membrane compartments. Phorbol esters or amphetamine induced the endocytosis of YFP/CFP-DAT to early and recycling endosomes, identified by Rab5, Rab11, Hrs and EEA.1 proteins. Interestingly, however, DAT was mainly excluded from Rab5- and Hrs-containing microdomains within the endosomes. The strongest FRET signals were measured in endosomes, indicative of efficient oligomerization of internalized DAT. The intermolecular DAT interactions were confirmed by co-immunoprecipitation. A DAT mutant that was retained in the endoplasmic reticulum (ER) after biosynthesis was used to show that DAT is oligomeric in the ER. Moreover, co-expression of an ER-retained DAT mutant and wild-type DAT resulted in the retention of wild-type DAT in the ER. These data suggest that DAT oligomers are formed in the ER and then are constitutively maintained both at the cell surface and during trafficking between the plasma membrane and endosomes.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Neurosci Program, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sorkin, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, 4200 E 9th Ave, Denver, CO 80262 USA.	alexander.sorkin@uchsc.edu		Galperin, Emilia/0000-0002-8743-026X; Sorkin, Alexander/0000-0002-4446-1920	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA014204] Funding Source: NIH RePORTER; NIDA NIH HHS [DA1505, DA14204] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BEGUINOT L, 1985, P NATL ACAD SCI USA, V82, P2774, DOI 10.1073/pnas.82.9.2774; BERGER SP, 1994, MOL PHARMACOL, V46, P726; Carneiro AM, 2002, J NEUROSCI, V22, P7045; Carvelli L, 2002, J NEUROCHEM, V81, P859, DOI 10.1046/j.1471-4159.2002.00892.x; Chang AS, 1998, BIOCHEM BIOPH RES CO, V249, P416, DOI 10.1006/bbrc.1998.9158; Clarkson ED, 1998, P NATL ACAD SCI USA, V95, P1265, DOI 10.1073/pnas.95.3.1265; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Doolen S, 2001, J PHARMACOL EXP THER, V296, P931; Fleckenstein AE, 1997, J PHARMACOL EXP THER, V282, P834; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Gu HH, 2001, MOL BIOL CELL, V12, P3797, DOI 10.1091/mbc.12.12.3797; Gulley JM, 2002, J NEUROCHEM, V83, P400, DOI 10.1046/j.1471-4159.2002.01133.x; Gulley JM, 2002, NEUROSCI LETT, V322, P165, DOI 10.1016/S0304-3940(02)00064-2; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; Kim S, 2000, J PHARMACOL EXP THER, V293, P625; Kitayama S, 1999, J BIOL CHEM, V274, P10731, DOI 10.1074/jbc.274.16.10731; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; Melikian HE, 1999, J NEUROSCI, V19, P7699; Metzger RR, 2000, J PHARMACOL EXP THER, V295, P1077; MILNER HE, 1994, BBA-BIOMEMBRANES, V1190, P185, DOI 10.1016/0005-2736(94)90051-5; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Sandoval V, 2001, J NEUROSCI, V21, P1413; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Scholze P, 2002, J BIOL CHEM, V277, P43682, DOI 10.1074/jbc.M205602200; Sonders MS, 1997, J NEUROSCI, V17, P960; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Stenmark H, 2001, GENOME BIOL, V2; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Zahniser NR, 2001, PHARMACOL THERAPEUT, V92, P21, DOI 10.1016/S0163-7258(01)00158-9; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	37	147	150	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28274	28283		10.1074/jbc.M210652200	http://dx.doi.org/10.1074/jbc.M210652200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12746456	hybrid			2022-12-25	WOS:000184242700118
J	Stalz, WD; Greie, JC; Deckers-Hebestreit, G; Altendorf, K				Stalz, WD; Greie, JC; Deckers-Hebestreit, G; Altendorf, K			Direct interaction of subunits a and b of the F-0 complex of Escherichia coli ATP synthase by forming an ab(2) subcomplex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; CROSS-LINKING; ADENOSINE-TRIPHOSPHATASE; MEMBRANE MOIETY; ROTARY MOTOR; C OLIGOMER; F1F0; RECONSTITUTION; ORGANIZATION; MECHANISM	The addition of a His(6) tag to the N terminus of subunit a of the F-0 complex of the Escherichia coli ATP synthase allowed the purification of an ab(2) subcomplex after solubilization of membranes with n-dodecyl-beta-D-maltoside and subsequent nickel-nitrilotriacetic acid affinity chromatography. After co-reconstitution of the ab(2) subcomplex with purified subunit c, passive proton translocation rates as well as coupled ATPase activities after binding of F-1 were measured that were comparable with those of wild type F-0. The interaction between subunits a and b, which has been shown to be stoichiometric and functional, is not triggered by any cross-linking reagent and therefore reflects subunit interactions occurring within the F-0 complex in vivo.	Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany	University Osnabruck	Deckers-Hebestreit, G (corresponding author), Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany.							ALTENDORF K, 1979, FUNCTION MOL ASPECTS, P53; ARIS JP, 1983, J BIOL CHEM, V258, P4599; Birkenhager R, 1999, EUR J BIOCHEM, V264, P385, DOI 10.1046/j.1432-1327.1999.00652.x; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Capaldi RA, 2002, TRENDS BIOCHEM SCI, V27, P154, DOI 10.1016/S0968-0004(01)02051-5; DMITRIEV OY, 1995, EUR J BIOCHEM, V233, P478, DOI 10.1111/j.1432-1033.1995.478_2.x; Dunn SD, 2000, J BIOENERG BIOMEMBR, V32, P347, DOI 10.1023/A:1005571818730; Fillingame RH, 2000, J EXP BIOL, V203, P9; Greie JC, 2000, J BIOENERG BIOMEMBR, V32, P357, DOI 10.1023/A:1005523902800; Greie JC, 2000, EUR J BIOCHEM, V267, P3040, DOI 10.1046/j.1432-1327.2000.01327.x; GREIE JC, 2001, MICROBIAL TRANSPORT, P23; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hutcheon ML, 2001, P NATL ACAD SCI USA, V98, P8519, DOI 10.1073/pnas.151236798; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jones PC, 2000, J BIOL CHEM, V275, P31340, DOI 10.1074/jbc.M003687200; Junge W, 1999, P NATL ACAD SCI USA, V96, P4735, DOI 10.1073/pnas.96.9.4735; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KUMAMOTO CA, 1986, J BIOL CHEM, V261, P37; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; McLachlin DT, 2000, J BIOL CHEM, V275, P17571, DOI 10.1074/jbc.M000375200; Meunier B, 1998, J MOL BIOL, V283, P727, DOI 10.1006/jmbi.1998.2132; MORIYAMA Y, 1991, J BIOL CHEM, V266, P22141; Neidhardt FC, 1990, PHYSL BACTERIAL CELL; OKAMOTO H, 1977, J BIOL CHEM, V252, P6125; SCHNEIDER E, 1984, P NATL ACAD SCI-BIOL, V81, P7279, DOI 10.1073/pnas.81.23.7279; SCHNEIDER E, 1982, EUR J BIOCHEM, V126, P149, DOI 10.1111/j.1432-1033.1982.tb06759.x; SCHNEIDER E, 1985, EMBO J, V4, P515, DOI 10.1002/j.1460-2075.1985.tb03658.x; SENIOR AE, 1979, BIOCHEM J, V180, P111, DOI 10.1042/bj1800111; SONE N, 1981, J BIOL CHEM, V256, P2873; STEFFENS K, 1984, EUR J BIOCHEM, V138, P617, DOI 10.1111/j.1432-1033.1984.tb07959.x; STEFFENS K, 1987, J BIOL CHEM, V262, P5866; VIK SB, 1994, J BIOL CHEM, V269, P30364; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908	34	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27068	27071		10.1074/jbc.M302027200	http://dx.doi.org/10.1074/jbc.M302027200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12724321	hybrid			2022-12-25	WOS:000184155700099
J	Thomas, CB; Scavetta, RD; Gumport, RI; Churchill, MEA				Thomas, CB; Scavetta, RD; Gumport, RI; Churchill, MEA			Structures of liganded and unliganded RsrI N6-adenine DNA methyltransferase - A distinct orientation for active cofactor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; HHAI METHYLTRANSFERASE; S-ADENOSYLMETHIONINE; CATALYTIC MECHANISM; METHYLATION; ENZYMES; ECORI; CRYSTALLOGRAPHY; PURIFICATION; CLONING	The structures of RsrI DNA methyltransferase (M. RsrI) bound to the substrate S-adenosyl-L-methionine (AdoMet), the product S-adenosyl-L-homocysteine (AdoHcy), the inhibitor sinefungin, as well as a mutant apo-enzyme have been determined by x-ray crystallography. Two distinct binding configurations were observed for the three ligands. The substrate AdoMet adopts a bent shape that directs the activated methyl group toward the active site near the catalytic DPPY motif. The product AdoHcy and the competitive inhibitor sinefungin bind with a straight conformation in which the amino acid moiety occupies a position near the activated methyl group in the AdoMet complex. Analysis of ligand binding in comparison with other DNA methyltransferases reveals a small, common subset of available conformations for the ligand. The structures of M. RsrI with the non-substrate ligands contained a bound chloride ion in the AdoMet carboxylate-binding pocket, explaining its inhibition by chloride salts. The L72P mutant of M. RsrI is the first DNA methyltransferase structure without bound ligand. With respect to the wild-type protein, it had a larger ligand-binding pocket and displayed movement of a loop (223 227) that is responsible for binding the ligand, which may account for the weaker affinity of the L72P mutant for AdoMet. These studies show the subtle changes in the tight specific interactions of substrate, product, and an inhibitor with M. RsrI and help explain how each displays its unique effect on the activity of the enzyme.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Coll Med, Urbana, IL 61801 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Churchill, MEA (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, 4200 E 9th Ave, Denver, CO 80262 USA.	mair.churchill@uchsc.edu	Churchill, Mair E. A./C-5549-2014	Churchill, Mair E. A./0000-0003-0862-235X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048660] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059456, T32GM007283, R01GM025621] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI048660] Funding Source: Medline; NIGMS NIH HHS [R01-GM25621, R01-GM59456, T32 GM07283, R01 GM059456] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brunger AT, 1997, METHOD ENZYMOL, V277, P366, DOI 10.1016/S0076-6879(97)77021-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bujnicki JM, 2001, ACTA BIOCHIM POL, V48, P969; Goedecke K, 2001, NAT STRUCT BIOL, V8, P121, DOI 10.1038/84104; Gong WM, 1997, NUCLEIC ACIDS RES, V25, P2702, DOI 10.1093/nar/25.14.2702; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HOFFMAN JL, 1986, BIOCHEMISTRY-US, V25, P4444, DOI 10.1021/bi00363a041; Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KASZUBSKA W, 1992, GENE, V118, P5, DOI 10.1016/0378-1119(92)90242-H; KASZUBSKA W, 1989, NUCLEIC ACIDS RES, V17, P10403, DOI 10.1093/nar/17.24.10403; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lindstrom WM, 2000, J BIOL CHEM, V275, P4912, DOI 10.1074/jbc.275.7.4912; Low DA, 2001, INFECT IMMUN, V69, P7197, DOI 10.1128/IAI.69.12.7197-7204.2001; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; Malygin EG, 1997, NUCLEIC ACIDS RES, V25, P4393, DOI 10.1093/nar/25.21.4393; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; O'Gara M, 1999, J MOL BIOL, V287, P201, DOI 10.1006/jmbi.1999.2608; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paulsen M, 2001, J PATHOL, V195, P97, DOI 10.1002/path.890; POGOLOTTI AL, 1988, J BIOL CHEM, V263, P7461; REICH NO, 1990, J BIOL CHEM, V265, P8966; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2933, DOI 10.1021/bi00225a029; Roberts RJ, 2003, NUCLEIC ACIDS RES, V31, P1805, DOI 10.1093/nar/gkg274; Scavetta R, 2000, NUCLEIC ACIDS RES, V28, P3950, DOI 10.1093/nar/28.20.3950; Schluckebier G, 1997, J MOL BIOL, V265, P56, DOI 10.1006/jmbi.1996.0711; Schubert HL, 2003, TRENDS BIOCHEM SCI, V28, P329, DOI 10.1016/S0968-0004(03)00090-2; Szegedi SS, 2000, NUCLEIC ACIDS RES, V28, P3962, DOI 10.1093/nar/28.20.3962; Szegedi SS, 2000, NUCLEIC ACIDS RES, V28, P3972, DOI 10.1093/nar/28.20.3972; Tran PH, 1998, STRUCT FOLD DES, V6, P1563, DOI 10.1016/S0969-2126(98)00154-3; Vilkaitis G, 2001, J BIOL CHEM, V276, P20924, DOI 10.1074/jbc.M101429200; WU JC, 1987, J BIOL CHEM, V262, P4778	34	17	17	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26094	26101		10.1074/jbc.M303751200	http://dx.doi.org/10.1074/jbc.M303751200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12732637	hybrid			2022-12-25	WOS:000183920200107
J	Peng, CH; Rich, ED; Thor, CA; Varnum, MD				Peng, CH; Rich, ED; Thor, CA; Varnum, MD			Functionally important calmodulin-binding sites in both NH2- and COOH-terminal regions of the cone photoreceptor cyclic nucleotide-gated channel CNGB3 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD PHOTORECEPTOR; ION CHANNELS; BETA-SUBUNIT; CATION CHANNEL; CALCIUM-CALMODULIN; OLFACTORY NEURONS; CHROMOSOMAL LOCALIZATION; MOLECULAR MECHANISM; ACTIVATED CHANNELS; LIGAND SENSITIVITY	Whereas an important aspect of sensory adaptation in rod photoreceptors and olfactory receptor neurons is thought to be the regulation of cyclic nucleotide-gated (CNG) channel activity by calcium-calmodulin (Ca2+-CaM), it is not clear that cone photoreceptor CNG channels are similarly modulated. Cone CNG channels are composed of at least two different subunit types, CNGA3 and CNGB3. We have investigated whether calmodulin modulates the activity of these channels by direct binding to the CNGB3 subunit. Heteromeric channels were formed by co-expression of human CNGB3 with human CNGA3 subunits in Xenopus oocytes; CNGB3 subunits conferred sensitivity to regulation by Ca2+-CaM, whereas CaM regulation of homomeric CNGA3 channels was not detected. To explore the mechanism underlying this regulation, we localized potential CaM-binding sites in both NH2- and COOH-terminal cytoplasmic domains of CNGB3 using gel-overlay and glutathione S-transferase pull-down assays. For both sites, binding of CaM depended on the presence of Ca2+. Individual deletions of either CaM-binding site in CNGB3 generated channels that remained sensitive to regulation by Ca2+-CaM, but deletion of both together resulted in heteromeric channels that were not modulated. Thus, both NH2- and COOH-terminal CaM-binding sites in CNGB3 are functionally important for regulation of recombinant cone CNG channels. These studies suggest a potential role for direct binding and unbinding of Ca2+-CaM to human CNGB3 during cone photoreceptor adaptation and recovery.	Washington State Univ, Dept Vet & Comparat Anat Pharmacol & Physiol, Pullman, WA 99164 USA; Washington State Univ, Program Neurosci, Pullman, WA 99164 USA	Washington State University; Washington State University	Varnum, MD (corresponding author), Washington State Univ, Dept Vet & Comparat Anat Pharmacol & Physiol, Pullman, WA 99164 USA.				NEI NIH HHS [EY12836] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012836] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Balasubramanian S, 1996, J MEMBRANE BIOL, V152, P13, DOI 10.1007/s002329900081; Bauer PJ, 1996, J PHYSIOL-LONDON, V494, P675, DOI 10.1113/jphysiol.1996.sp021523; Bonigk W, 1999, J NEUROSCI, V19, P5332; Bonigk W, 1996, J NEUROSCI, V16, P7458; BRADLEY J, 1994, P NATL ACAD SCI USA, V91, P8890, DOI 10.1073/pnas.91.19.8890; Bradley J, 2001, SCIENCE, V294, P2176, DOI 10.1126/science.1063415; Bradley J, 2001, SCIENCE, V294, P2095, DOI 10.1126/science.294.5549.2095; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; CHEN TY, 1994, P NATL ACAD SCI USA, V91, P11757, DOI 10.1073/pnas.91.24.11757; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117; Gerstner A, 2000, J NEUROSCI, V20, P1324; GORDON SE, 1992, NEURON, V9, P739, DOI 10.1016/0896-6273(92)90036-D; GORDON SE, 1995, J PHYSIOL-LONDON, V486, P533, DOI 10.1113/jphysiol.1995.sp020832; GORDON SE, 1995, NEURON, V14, P857, DOI 10.1016/0896-6273(95)90229-5; GOULDING EH, 1994, NATURE, V372, P369, DOI 10.1038/372369a0; Grunwald ME, 1999, P NATL ACAD SCI USA, V96, P13444, DOI 10.1073/pnas.96.23.13444; Grunwald ME, 1998, J BIOL CHEM, V273, P9148, DOI 10.1074/jbc.273.15.9148; Hackos DH, 1997, J GEN PHYSIOL, V110, P515, DOI 10.1085/jgp.110.5.515; Haeseleer F, 2002, BIOCHEM BIOPH RES CO, V290, P615, DOI 10.1006/bbrc.2001.6228; Haynes LW, 1997, VISUAL NEUROSCI, V14, P233, DOI 10.1017/S0952523800011378; HAYNES LW, 1992, J GEN PHYSIOL, V100, P783, DOI 10.1085/jgp.100.5.783; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; Ko GYP, 2001, NEURON, V29, P255, DOI 10.1016/S0896-6273(01)00195-7; Kohl S, 2000, HUM MOL GENET, V9, P2107, DOI 10.1093/hmg/9.14.2107; KORSCHEN HG, 1995, NEURON, V15, P627, DOI 10.1016/0896-6273(95)90151-5; Kramer RH, 2001, J EXP BIOL, V204, P2921; Kurahashi T, 1997, NATURE, V385, P725, DOI 10.1038/385725a0; Lee A, 2002, NAT NEUROSCI, V5, P210, DOI 10.1038/nn805; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LIMAN ER, 1994, NEURON, V13, P611, DOI 10.1016/0896-6273(94)90029-9; Liu DT, 1996, NEURON, V16, P983, DOI 10.1016/S0896-6273(00)80121-X; LIU MY, 1994, SCIENCE, V266, P1348, DOI 10.1126/science.266.5189.1348; Menini A, 1999, CURR OPIN NEUROBIOL, V9, P419, DOI 10.1016/S0959-4388(99)80063-4; Molday RS, 1996, CURR OPIN NEUROBIOL, V6, P445, DOI 10.1016/S0959-4388(96)80048-1; Molokanova E, 1997, J NEUROSCI, V17, P9068; Muller F, 1998, J NEUROSCI, V18, P164; Muller F, 2001, J PHYSIOL-LONDON, V532, P399, DOI 10.1111/j.1469-7793.2001.0399f.x; Munger SD, 2001, SCIENCE, V294, P2172, DOI 10.1126/science.1063224; Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2; Rebrik TI, 2000, J GEN PHYSIOL, V116, P521, DOI 10.1085/jgp.116.4.521; Rebrik TI, 1998, J GEN PHYSIOL, V112, P537, DOI 10.1085/jgp.112.5.537; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Richards MJ, 2000, BIOCHEMISTRY-US, V39, P14003, DOI 10.1021/bi001639i; Sautter A, 1998, P NATL ACAD SCI USA, V95, P4696, DOI 10.1073/pnas.95.8.4696; Sundin OH, 2000, NAT GENET, V25, P289, DOI 10.1038/77162; Trudeau MC, 2003, J BIOL CHEM, V278, P18705, DOI 10.1074/jbc.R300001200; Trudeau MC, 2002, P NATL ACAD SCI USA, V99, P8424, DOI 10.1073/pnas.122015999; Varnum MD, 1996, BIOPHYS J, V70, P2667, DOI 10.1016/S0006-3495(96)79836-3; Varnum MD, 1997, SCIENCE, V278, P110, DOI 10.1126/science.278.5335.110; VARNUM MD, 1995, NEURON, V15, P619, DOI 10.1016/0896-6273(95)90150-7; Warren R, 2002, ADV EXP MED BIOL, V514, P205; Weitz D, 1998, EMBO J, V17, P2273, DOI 10.1093/emboj/17.8.2273; Wissinger B, 1997, EUR J NEUROSCI, V9, P2512, DOI 10.1111/j.1460-9568.1997.tb01680.x; Yu WP, 1996, FEBS LETT, V393, P211, DOI 10.1016/0014-5793(96)00889-7; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315; Zufall F, 2000, CHEM SENSES, V25, P473, DOI 10.1093/chemse/25.4.473	61	40	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24617	24623		10.1074/jbc.M301699200	http://dx.doi.org/10.1074/jbc.M301699200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12730238	hybrid			2022-12-25	WOS:000183824800045
J	Chamond, N; Gregoire, C; Coatnoan, N; Rougeot, C; Freitas, LH; da Silveira, JF; Degrave, WM; Minoprio, P				Chamond, N; Gregoire, C; Coatnoan, N; Rougeot, C; Freitas, LH; da Silveira, JF; Degrave, WM; Minoprio, P			Biochemical characterization of proline racemases from the human protozoan parasite Trypanosoma cruzi and definition of putative protein signatures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-AMINO ACIDS; B-CELL MITOGEN; D-ASPARTATE; GENE-EXPRESSION; SERINE RACEMASE; MECHANISM; DIFFERENTIATION; BIOSYNTHESIS; PURIFICATION; GENERATION	Proline racemase catalyzes the interconversion Of L-and D-proline enantiomers and has to date been described in only two species. Originally found in the bacterium Clostridium sticklandii, it contains cysteine residues in the active site and does not require co-factors or other known coenzymes. We recently described the first eukaryotic amino acid (proline) racemase, after isolation and cloning of a gene from the pathogenic human parasite Trypanosoma cruzi. Although this enzyme is intracellularly located in replicative non-infective forms of T. cruzi, membrane-bound and secreted forms of the enzyme are present upon differentiation of the parasite into non-dividing infective forms. The secreted form of proline racemase is a potent host B-cell mitogen supporting parasite evasion of specific immune responses. Here we describe that the TcPRAC genes in T. cruzi encode functional intracellular or secreted versions of the enzyme exhibiting distinct kinetic properties that may be relevant for their relative catalytic efficiency. Although the K-m of the enzyme isoforms were of a similar order of magnitude (29 -75 mm), V-max varied between 2 x 10(-4) and 5.3 x 10(-5) mol of L-proline/s/0.125 muM of homodimeric recombinant protein. Studies with the enzyme-specific inhibitor and abrogation of enzymatic activity by site-directed mutagenesis of the active site Cys(330) residue reinforced the potential of proline racemase as a critical target for drug development against Chagas' disease. Finally, we propose a protein signature for proline racemases and suggest that the enzyme is present in several other pathogenic and nonpathogenic bacterial genomes of medical and agricultural interest, yet absent in mammalian host, suggesting that inhibition of proline racemases may have therapeutic potential.	Inst Pasteur, Dept Immunol, F-75724 Paris, France; Inst Pasteur, Dept Parasitol, F-75724 Paris, France; Escola Paulista Med, Unifesp, Dept Microbiol Immunol & Parasitol, BR-04023062 Sao Paulo, Brazil; Inst Oswaldo Cruz, Dept Biochem Mol Biol, BR-21045900 Rio De Janeiro, Brazil	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universidade Federal de Sao Paulo (UNIFESP); Fundacao Oswaldo Cruz	Minoprio, P (corresponding author), Inst Pasteur, Dept Immunol, 25 Rue Dr Roux, F-75724 Paris, France.	pmm@pasteur.fr	Degrave, Wim/B-4162-2009; Chamond, Nathalie/C-5907-2018; da Silveira, Jose Franco/F-5390-2012; Freitas-Junior, Lucio H/C-8677-2011	Freitas-Junior, Lucio H/0000-0002-8904-7897; Chamond, Nathalie/0000-0002-0518-2929; COATNOAN, Nicolas/0000-0003-4129-0019; Minoprio, Paola/0000-0002-1659-833X				ALBERY WJ, 1986, BIOCHEMISTRY-US, V25, P2572, DOI 10.1021/bi00357a043; Auerswald L, 1998, J EXP BIOL, V201, P2333; BOWMAN IBR, 1972, COMP BIOCH PARASITES; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; Burleigh BA, 1998, CURR OPIN MICROBIOL, V1, P461, DOI 10.1016/S1369-5274(98)80066-0; CANO MI, 1995, MOL BIOCHEM PARASIT, V71, P273, DOI 10.1016/0166-6851(95)00066-A; CARDINALE GJ, 1968, BIOCHEMISTRY-US, V7, P3970, DOI 10.1021/bi00851a026; CONTRERAS VT, 1985, MOL BIOCHEM PARASIT, V16, P315, DOI 10.1016/0166-6851(85)90073-8; CONTRERAS VT, 1985, MOL BIOCHEM PARASIT, V14, P83, DOI 10.1016/0166-6851(85)90108-2; DEISOLA ELD, 1981, J PARASITOL, V67, P53, DOI 10.2307/3280778; DEJONG MH, 1975, J BACTERIOL, V123, P824, DOI 10.1128/JB.123.3.824-827.1975; EVANS DA, 1972, J PROTOZOOL, V19, P686, DOI 10.1111/j.1550-7408.1972.tb03561.x; Fisher G H, 1998, EXS, V85, P109; FISHER LM, 1986, BIOCHEMISTRY-US, V25, P2529, DOI 10.1021/bi00357a037; Gao W, 2002, INT IMMUNOL, V14, P299, DOI 10.1093/intimm/14.3.299; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Janes BK, 1998, J BACTERIOL, V180, P563, DOI 10.1128/JB.180.3.563-570.1998; JANEWAY CA, 1970, FOLIA BIOL, V16, P156; KEENAN MV, 1974, BIOCHEM BIOPH RES CO, V57, P500, DOI 10.1016/0006-291X(74)90960-7; KLEINKAUF H, 1987, ANNU REV MICROBIOL, V41, P259, DOI 10.1146/annurev.mi.41.100187.001355; KRASSNER SM, 1972, J PROTOZOOL, V19, P682, DOI 10.1111/j.1550-7408.1972.tb03560.x; Lamzin VS, 1995, CURR OPIN STRUC BIOL, V5, P830, DOI 10.1016/0959-440X(95)80018-2; Manning-Cela R, 2002, INFECT IMMUN, V70, P4726, DOI 10.1128/IAI.70.8.4726-4728.2002; MARTIN D, 1992, EUR J PHARMACOL, V219, P59, DOI 10.1016/0014-2999(92)90580-W; MOZES E, 1993, SCIENCE, V261, P91, DOI 10.1126/science.8316860; Nagata Y, 1999, BBA-PROTEIN STRUCT M, V1435, P160, DOI 10.1016/S0167-4838(99)00208-3; Nagata Y, 1999, FEBS LETT, V454, P317, DOI 10.1016/S0014-5793(99)00840-6; Nagata Y, 1998, BBA-GEN SUBJECTS, V1379, P76, DOI 10.1016/S0304-4165(97)00084-6; NEIDLE A, 1990, LIFE SCI, V46, P1517, DOI 10.1016/0024-3205(90)90424-P; Oguri S, 1999, BBA-GEN SUBJECTS, V1472, P107, DOI 10.1016/S0304-4165(99)00110-5; Reina-San-Martin B, 2000, NAT MED, V6, P890, DOI 10.1038/78651; RUDNICK G, 1975, BIOCHEMISTRY-US, V14, P4515, DOI 10.1021/bi00691a028; SCHELL MJ, 1995, P NATL ACAD SCI USA, V92, P3948, DOI 10.1073/pnas.92.9.3948; Sela M, 1997, FASEB J, V11, P449; Shakibaei M, 1996, J EXP MED, V184, P1699, DOI 10.1084/jem.184.5.1699; Silber AM, 2002, J EUKARYOT MICROBIOL, V49, P441, DOI 10.1111/j.1550-7408.2002.tb00225.x; SOUTOPADRON T, 1989, EUR J CELL BIOL, V50, P272; SYLVESTER D, 1976, COMP BIOCHEM PHYS B, V55, P443, DOI 10.1016/0305-0491(76)90318-7; Thompson RJ, 1998, INFECT IMMUN, V66, P3552, DOI 10.1128/IAI.66.8.3552-3561.1998; VANHARREVELD A, 1980, J NEUROBIOL, V11, P519, DOI 10.1002/neu.480110603; Watanabe T, 1998, AMINO ACIDS, V14, P353, DOI 10.1007/BF01318854; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P13409, DOI 10.1073/pnas.96.23.13409; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P721, DOI 10.1073/pnas.96.2.721	43	56	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15484	15494		10.1074/jbc.M210830200	http://dx.doi.org/10.1074/jbc.M210830200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12735293	hybrid			2022-12-25	WOS:000182680000006
J	Grossin, L; Cournil-Henrionnet, C; Mir, LM; Liagre, B; Dumas, D; Etienne, S; Guingamp, C; Netter, P; Gillet, P				Grossin, L; Cournil-Henrionnet, C; Mir, LM; Liagre, B; Dumas, D; Etienne, S; Guingamp, C; Netter, P; Gillet, P			Direct gene transfer into rat articular cartilage by in vivo electroporation	FASEB JOURNAL			English	Article						electropermeabilization; in vivo gene transfer; electro gene therapy; GFP; patellar cartilage	VIRAL VECTORS; THERAPY	To establish a system for efficient direct in vivo gene targeting into rat joint, we have evaluated a strategy of gene transfer by means of the delivery of external electric pulses (EP) to the knee after intra-articular injection of a reporter gene (GFP). Rats were killed at various times after the electro gene-therapy to analyze GFP gene expression by immunohistochemistry. GFP staining was detected in the superficial, middle, and deep zones of the patellar cartilage at days 2 and 9, and thereafter only in the deep zone (months 1 and 2). The average percentage of GFP-positive cells was estimated at 30% both one and 2 months after the gene transfer. Moreover, no pathologic change caused by the EP was detected in the cartilage. The level and stability of the long-term GFP expression found in this study demonstrate the feasibility of a treatment of joint disorders (inflammatory or degenerative, focal or diffuse) using electric gene transfer.	Univ Nancy 1, Fac Med, CNRS, UMR 7561, F-54505 Vandoeuvre Les Nancy, France; Univ Nancy 1, Fac Med, CNRS, UMR Mecan & Ingn Cellulaire & Tissulaire 7563, F-54505 Vandoeuvre Les Nancy, France; Inst Gustave Roussy, CNRS, UMR Vectorol & Transfert Genes 8121, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Netter, P (corresponding author), Univ Nancy 1, Fac Med, CNRS, UMR 7561, Ave Foret Haye,BP184, F-54505 Vandoeuvre Les Nancy, France.	Patrick.Netter@medecine.uhp-nancy.fr	Dumas, Dominique DD/A-5633-2012; MIR, Lluis M/AAJ-9110-2020	GROSSIN, Laurent/0000-0001-6761-0936; Liagre, Bertrand/0000-0003-4148-2598; GILLET, Pierre/0000-0002-0598-7508; Christel, HENRIONNET/0000-0001-7484-0377; Cournil, Christel/0000-0002-4827-4276				Banga AK, 1998, TRENDS BIOTECHNOL, V16, P408, DOI 10.1016/S0167-7799(98)01238-4; Baragi VM, 1997, OSTEOARTHR CARTILAGE, V5, P275, DOI 10.1016/S1063-4584(97)80023-4; Dumas D, 2000, BIORHEOLOGY, V37, P165; Evans CH, 1999, ARTHRITIS RHEUM-US, V42, P1, DOI 10.1002/1529-0131(199901)42:1<1::AID-ANR1>3.0.CO;2-4; Gao JZ, 2001, TISSUE ENG, V7, P363, DOI 10.1089/10763270152436427; Goater J, 2000, J RHEUMATOL, V27, P983; Goomer RS, 2001, OSTEOARTHR CARTILAGE, V9, P248, DOI 10.1053/joca.2000.0382; Guingamp C, 1997, ARTHRITIS RHEUM, V40, P1670, DOI 10.1002/art.1780400917; Hong K, 2001, BIOMOL ENG, V18, P185, DOI 10.1016/S1389-0344(01)00100-9; Inoue T, 2001, NAT NEUROSCI, V4, P1156, DOI 10.1038/nn1101-1156; LIND L, 1989, DIABETES RES CLIN EX, V11, P141; Madry H, 2001, GENE THER, V8, P1443, DOI 10.1038/sj.gt.3301535; Mir LM, 1999, P NATL ACAD SCI USA, V96, P4262, DOI 10.1073/pnas.96.8.4262; MIR LM, 1998, CR ACAD SCI III-VIE, V1, P893; Muramatsu T, 1998, INT J MOL MED, V1, P55; Noth U, 2002, TISSUE ENG, V8, P131, DOI 10.1089/107632702753503126; Ohashi S, 2002, BIOCHEM BIOPH RES CO, V293, P1530, DOI 10.1016/S0006-291X(02)00386-8; Pelletier JP, 1999, OSTEOARTHR CARTILAGE, V7, P374, DOI 10.1053/joca.1998.0215; Robbins PD, 1998, PHARMACOL THERAPEUT, V80, P35, DOI 10.1016/S0163-7258(98)00020-5; Rols MP, 1998, NAT BIOTECHNOL, V16, P168, DOI 10.1038/nbt0298-168; Satkauskas S, 2002, MOL THER, V5, P133, DOI 10.1006/mthe.2002.0526; Spack EG, 2001, DRUG DISCOV TODAY, V6, P186, DOI 10.1016/S1359-6446(00)01633-0; Tomita T, 1997, ARTHRITIS RHEUM, V40, P901, DOI 10.1002/art.1780400518; VANDENBERG WB, 1982, RHEUMATOL INT, V1, P165, DOI 10.1007/BF00541171; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; Vervoordeldonk MJBM, 2001, BEST PRACT RES CL RH, V15, P771, DOI 10.1053/berh.2001.0193; Vicat JM, 2000, HUM GENE THER, V11, P909, DOI 10.1089/10430340050015518; Watrin A, 2001, RADIOLOGY, V219, P395, DOI 10.1148/radiology.219.2.r01ma32395; WOLF H, 1994, BIOPHYS J, V66, P524, DOI 10.1016/S0006-3495(94)80805-7	29	36	37	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					829	835		10.1096/fj.02-0518com	http://dx.doi.org/10.1096/fj.02-0518com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12724342				2022-12-25	WOS:000183165000009
J	Mani, K; Cheng, F; Havsmark, B; Jonsson, M; Belting, M; Fransson, LA				Mani, K; Cheng, F; Havsmark, B; Jonsson, M; Belting, M; Fransson, LA			Prion, amyloid beta-derived Cu(II) ions, or free Zn(II) ions support S-Nitroso-dependent autocleavage of glypican-1 heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-UNSUBSTITUTED GLUCOSAMINE; NITRIC-OXIDE; BINDING-SITES; PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; COPPER-BINDING; PROTEOGLYCAN; ENDOCYTOSIS; ACCUMULATION; DEGRADATION	Copper are generally bound to proteins, e. g. the prion and the amyloid beta proteins. We have previously shown that copper ions are required to nitrosylate thiol groups in the core protein of glypican-1, a heparan sulfate-substituted proteoglycan. When S-nitrosylated glypican-1 is then exposed to an appropriate reducing agent, such as ascorbate, nitric oxide is released and autocatalyzes deaminative cleavage of the glypican-1 heparan sulfate side chains at sites where the glucosamines are N-unsubstituted. These processes take place in a stepwise manner, whereas glypican-1 recycles via a caveolin-1-associated pathway where copper ions could be provided by the prion protein. Here we show, by using both biochemical and microscopic techniques, that ( a) the glypican-1 core protein binds copper(II) ions, reduces them to copper( I) when the thiols are nitrosylated and reoxidizes copper( I) to copper( II) when ascorbate releases nitric oxide; ( b) maximally S-nitrosylated glypican-1 can cleave its own heparan sulfate chains at all available sites in a nitroxyl ion-dependent reaction; ( c) free zinc( II) ions, which are redox inert, also support autocleavage of glypican-1 heparan sulfate, probably via transnitrosation, whereas they inhibit copper(II)-supported degradation; and (d) copper( II)-loaded but not zinc( II)-loaded prion protein or amyloid beta peptide support heparan sulfate degradation. As glypican-1 in prion null cells is poorly S-nitrosylated and as ectopic expression of cellular prion protein restores S-nitrosylation of glypican-1 in these cells, we propose that one function of the cellular prion protein is to deliver copper( II) for the S-nitrosylation of recycling glypican-1.	Lund Univ, Dept Cell & Mol Biol, Sect Cell & Matrix Biol, SE-22184 Lund, Sweden	Lund University	Fransson, LA (corresponding author), Lund Univ, Dept Cell & Mol Biol, Sect Cell & Matrix Biol, BMC C13, SE-22184 Lund, Sweden.	lars-ake.fransson@medkem.lu.se		Mani, Katrin/0000-0002-1821-0634; Belting, Mattias/0000-0003-1585-5434				Barbero P, 2002, J CELL BIOL, V156, P511, DOI 10.1083/jcb.200109030; Bartberger MD, 2002, P NATL ACAD SCI USA, V99, P10958, DOI 10.1073/pnas.162095599; Brimacombe DB, 1999, BIOCHEM J, V342, P605, DOI 10.1042/0264-6021:3420605; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Bush AI, 2002, P NATL ACAD SCI USA, V99, P7317, DOI 10.1073/pnas.122249699; BUSH AI, 1994, J BIOL CHEM, V269, P26618; Castillo GM, 1999, J NEUROCHEM, V72, P1681, DOI 10.1046/j.1471-4159.1999.721681.x; Caughey B, 2001, TRENDS BIOCHEM SCI, V26, P235, DOI 10.1016/S0968-0004(01)01792-3; Chen Y, 2002, BIOCHEMISTRY-US, V41, P8360, DOI 10.1021/bi020030+; Cheng F, 2002, J BIOL CHEM, V277, P44431, DOI 10.1074/jbc.M205241200; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; Ding K, 2002, J BIOL CHEM, V277, P33353, DOI 10.1074/jbc.M203383200; Ding K, 2001, J BIOL CHEM, V276, P46779, DOI 10.1074/jbc.M105419200; Ding K, 2001, J BIOL CHEM, V276, P3885, DOI 10.1074/jbc.M005238200; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712; Fransson LA, 2003, INT J BIOCHEM CELL B, V35, P125, DOI 10.1016/S1357-2725(02)00095-X; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; Gonzalez-Iglesias R, 2002, J MOL BIOL, V319, P527, DOI 10.1016/S0022-2836(02)00341-8; HORTON D, 1973, CARBOHYD RES, V30, P367, DOI 10.1016/S0008-6215(00)81823-6; Hughes MN, 1999, METHOD ENZYMOL, V301, P279; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; Jantzen PT, 2002, J NEUROSCI, V22, P2246, DOI 10.1523/JNEUROSCI.22-06-02246.2002; Kanu N, 2002, CURR BIOL, V12, P523, DOI 10.1016/S0960-9822(02)00722-4; Knipp M, 2003, J BIOL CHEM, V278, P3410, DOI 10.1074/jbc.M209088200; Lehmann S, 2002, CURR OPIN CHEM BIOL, V6, P187, DOI 10.1016/S1367-5931(02)00295-8; Leteux C, 2001, J BIOL CHEM, V276, P12539, DOI 10.1074/jbc.M010291200; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; Lindegren H, 2003, J NEUROSCI RES, V71, P291, DOI 10.1002/jnr.10473; Mani K, 2000, GLYCOBIOLOGY, V10, P577, DOI 10.1093/glycob/10.6.577; Martins VR, 2002, FEBS LETT, V512, P25, DOI 10.1016/S0014-5793(02)02291-3; Miura T, 2000, BIOCHEMISTRY-US, V39, P7024, DOI 10.1021/bi0002479; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Pan T, 2002, BIOCHEM J, V368, P81, DOI 10.1042/BJ20020773; Patel BN, 1997, J BIOL CHEM, V272, P20185, DOI 10.1074/jbc.272.32.20185; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Qin KF, 2002, J BIOL CHEM, V277, P1981, DOI 10.1074/jbc.M108744200; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; SHIVELY JE, 1970, BIOCHEMISTRY-US, V9, P33, DOI 10.1021/bi00803a005; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Simons A, 2002, BIOCHEMISTRY-US, V41, P9310, DOI 10.1021/bi0258647; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; SNOW AD, 1988, AM J PATHOL, V133, P456; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; Tkachenko E, 2002, J BIOL CHEM, V277, P19946, DOI 10.1074/jbc.M200841200; Tsuchida K, 2001, J BIOL CHEM, V276, P37155, DOI 10.1074/jbc.M105818200; Upchurch G R Jr, 2001, J Cardiovasc Pharmacol Ther, V6, P163, DOI 10.1177/107424840100600208; van Horssen J, 2002, NEUROBIOL AGING, V23, P537, DOI 10.1016/S0197-4580(02)00010-6; van Horssen J, 2001, ACTA NEUROPATHOL, V102, P604; Vilar RE, 1997, BIOCHEM J, V324, P473, DOI 10.1042/bj3240473; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Warner RG, 2002, J BIOL CHEM, V277, P18421, DOI 10.1074/jbc.M110406200; Westling C, 2002, J BIOL CHEM, V277, P49247, DOI 10.1074/jbc.M209139200	59	35	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38956	38965		10.1074/jbc.M300394200	http://dx.doi.org/10.1074/jbc.M300394200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12732622	hybrid			2022-12-25	WOS:000185575100106
J	Hyle, JW; Shaw, RJ; Reines, D				Hyle, JW; Shaw, RJ; Reines, D			Functional distinctions between IMP dehydrogenase genes in providing mycophenolate resistance and guanine prototrophy to yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; INOSINE MONOPHOSPHATE DEHYDROGENASE; TRANSCRIPTION ELONGATION MUTANTS; SACCHAROMYCES-CEREVISIAE GENOME; DOMINANT RETINITIS-PIGMENTOSA; IMMUNOSUPPRESSIVE DRUG; END-PRODUCTS; INHIBITION; ACID; IDENTIFICATION	IMP dehydrogenase (IMPDH) catalyzes the rate-limiting step in the de novo synthesis of GTP. Yeast with mutations in the transcription elongation machinery are sensitive to inhibitors of this enzyme such as 6-azauracil and mycophenolic acid, at least partly because of their inability to transcriptionally induce IMPDH. To understand the molecular basis of this drug-sensitive phenotype, we have dissected the expression and function of a four-gene family in yeast called IMD1 through IMD4. We show here that these family members are distinct, despite a high degree of amino acid identity between the proteins they encode. Extrachromosomal copies of IMD1, IMD3, or IMD4 could not rescue the drug-sensitive phenotype of IMD2 deletants. When overexpressed, IMD3 or IMD4 weakly compensated for deletion of IMD2. IMD1 is transcriptionally silent and bears critical amino acid substitutions compared with IMD2 that destroy its function, offering strong evidence that it is a pseudogene. The simultaneous deletion of all four IMD genes was lethal unless growth media were supplemented with guanine. This suggests that there are no other essential functions of the IMPDH homologs aside from IMP dehydrogenase activity. Although neither IMD3 nor IMD4 could confer drug resistance to cells lacking IMD2, either alone was sufficient to confer guanine prototrophy. The special function of IMD2 was provided by its ability to be transcriptionally induced and the probable intrinsic drug resistance of its enzymatic activity.	Emory Univ, Sch Med, Dept Biochem, Rollins Res Ctr, Atlanta, GA 30322 USA	Emory University	Reines, D (corresponding author), Emory Univ, Sch Med, Dept Biochem, Rollins Res Ctr, 1510 Clifton Rd,Rm 4023, Atlanta, GA 30322 USA.	dreines@emory.edu	excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243	NIGMS NIH HHS [GM46331, R01 GM046331] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046331] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; Barton AB, 1997, YEAST, V13, P1251; Bowne SJ, 2002, HUM MOL GENET, V11, P559, DOI 10.1093/hmg/11.5.559; Desmoucelles C, 2002, J BIOL CHEM, V277, P27036, DOI 10.1074/jbc.M111433200; Escobar-Henriques M, 2001, J BIOL CHEM, V276, P46237, DOI 10.1074/jbc.M103416200; Escobar-Henriques M, 2001, J BIOL CHEM, V276, P1523, DOI 10.1074/jbc.M007926200; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLESNE DA, 1991, MOL CELL BIOL, V11, P5417, DOI 10.1128/MCB.11.11.5417; Gu JJ, 1997, J BIOL CHEM, V272, P4458, DOI 10.1074/jbc.272.7.4458; Gu JJ, 2000, J CLIN INVEST, V106, P599, DOI 10.1172/JCI8669; Guetsova ML, 1997, GENETICS, V147, P383; Guetsova ML, 1999, J BACTERIOL, V181, P2984, DOI 10.1128/JB.181.9.2984-2986.1999; Harrison P, 2002, J MOL BIOL, V316, P409, DOI 10.1006/jmbi.2001.5343; Hedstrom L, 1999, CURR MED CHEM, V6, P545; HUBERT JC, 1983, EMBO J, V2, P2071, DOI 10.1002/j.1460-2075.1983.tb01702.x; JACKSON RC, 1975, NATURE, V256, P331, DOI 10.1038/256331a0; Kennan A, 2002, HUM MOL GENET, V11, P547, DOI 10.1093/hmg/11.5.547; Kerr KM, 1997, BIOCHEMISTRY-US, V36, P13365, DOI 10.1021/bi9714161; Lee SK, 2002, CELL, V109, P823, DOI 10.1016/S0092-8674(02)00795-X; Massingham T, 2001, BIOESSAYS, V23, P873, DOI 10.1002/bies.1128; NAGAI M, 1992, CANCER RES, V52, P258; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; Niedenthal R, 1999, YEAST, V15, P1775, DOI 10.1002/(SICI)1097-0061(199912)15:16<1775::AID-YEA496>3.3.CO;2-L; Prince VE, 2002, NAT REV GENET, V3, P827, DOI 10.1038/nrg928; REINES D, 2003, IN PRESS METHODS ENZ; SEOIGHE C, 1999, GENE, V23, P8253; Shaw RJ, 2001, J BIOL CHEM, V276, P32905, DOI 10.1074/jbc.M105075200; Shaw RJ, 2000, MOL CELL BIOL, V20, P7427, DOI 10.1128/MCB.20.20.7427-7437.2000; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sintchak MD, 1996, CELL, V85, P921, DOI 10.1016/S0092-8674(00)81275-1; SNYDER FF, 1995, PURINE PYRIMIDINE ME, V8, P725; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; Tham WH, 2002, ONCOGENE, V21, P512, DOI 10.1038/sj.onc.1205078; Wind M, 2000, BIOESSAYS, V22, P327, DOI 10.1002/(SICI)1521-1878(200004)22:4<327::AID-BIES3>3.0.CO;2-4; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Zhang RG, 1999, CURR MED CHEM, V6, P537	41	50	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28470	28478		10.1074/jbc.M303736200	http://dx.doi.org/10.1074/jbc.M303736200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12746440	Green Accepted, hybrid			2022-12-25	WOS:000184421100017
J	Pessler, F; Hernandez, N				Pessler, F; Hernandez, N			Flexible DNA binding of the BTB/POZ-domain protein FBI-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHORT TRANSCRIPTS; POZ DOMAIN; GENE-EXPRESSION; COMPLEX-FORMATION; INTERACTION MOTIF; HIV-1 INDUCER; BTB DOMAIN; SHORT RNAS; FAMILY; FLEXIBILITY	POZ-domain transcription factors are characterized by the presence of a protein-protein interaction domain called the POZ or BTB domain at their N terminus and zinc fingers at their C terminus. Despite the large number of POZ-domain transcription factors that have been identified to date and the significant insights that have been gained into their cellular functions, relatively little is known about their DNA binding properties. FBI-1 is a BTB/POZ-domain protein that has been shown to modulate HIV-1 Tat trans-activation and to repress transcription of some cellular genes. We have used various viral and cellular FBI-1 binding sites to characterize the interaction of a POZ-domain protein with DNA in detail. We find that FBI-1 binds to inverted sequence repeats downstream of the HIV-1 transcription start site. Remarkably, it binds efficiently to probes carrying these repeats in various orientations and spacings with no particular rotational alignment, indicating that its interaction with DNA is highly flexible. Indeed, FBI-1 binding sites in the adenovirus 2 major late promoter, the c-fos gene, and the c-myc P1 and P2 promoters reveal variously spaced direct, inverted, and everted sequence repeats with the consensus sequence G(A/G)GGG(T/ C)(C/T)(T/C)(C/T)for each repeat.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute	Pessler, F (corresponding author), Childrens Hosp Philadelphia, Div Rheumatol, 3516 Civ Ctr Blvd,1102 ARC, Philadelphia, PA 19104 USA.		Stangel, Martin/AAH-5345-2020	Hernandez, Nouria/0000-0003-1465-4585				Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Astier AL, 2003, BLOOD, V101, P1118, DOI 10.1182/blood-2002-05-1519; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; CAO XM, 1993, J BIOL CHEM, V268, P16949; CLEARY MA, 1995, MOL CELL BIOL, V15, P2090; Cleary MA, 1997, P NATL ACAD SCI USA, V94, P8450, DOI 10.1073/pnas.94.16.8450; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Daniel JM, 2002, NUCLEIC ACIDS RES, V30, P2911, DOI 10.1093/nar/gkf398; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; Espinas ML, 1999, J BIOL CHEM, V274, P16461, DOI 10.1074/jbc.274.23.16461; GALERA P, 1994, P NATL ACAD SCI USA, V91, P9372, DOI 10.1073/pnas.91.20.9372; Katsani KR, 1999, EMBO J, V18, P698, DOI 10.1093/emboj/18.3.698; Kobayashi A, 2000, MOL CELL BIOL, V20, P1733, DOI 10.1128/MCB.20.5.1733-1746.2000; Kukita A, 1999, BLOOD, V94, P1987, DOI 10.1182/blood.V94.6.1987.418k26_1987_1997; Lee DK, 2002, J BIOL CHEM, V277, P26761, DOI 10.1074/jbc.M202078200; Morrison DJ, 1999, NUCLEIC ACIDS RES, V27, P1251, DOI 10.1093/nar/27.5.1251; Pendergrast PS, 2002, MOL BIOL CELL, V13, P915, DOI 10.1091/mbc.01-08-0383; Pessler F, 1998, J BIOL CHEM, V273, P5375, DOI 10.1074/jbc.273.9.5375; Pessler F, 1997, MOL CELL BIOL, V17, P3786, DOI 10.1128/MCB.17.7.3786; PESSLER F, 1994, THESIS STATE U NEW Y; RATNASABAPATHY R, 1990, GENE DEV, V4, P2061, DOI 10.1101/gad.4.12a.2061; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; SHELDON M, 1993, MOL CELL BIOL, V13, P1251, DOI 10.1128/MCB.13.2.1251; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; Widom RL, 2001, MATRIX BIOL, V20, P451, DOI 10.1016/S0945-053X(01)00167-6; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	29	35	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29327	29335		10.1074/jbc.M302980200	http://dx.doi.org/10.1074/jbc.M302980200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12750370	hybrid			2022-12-25	WOS:000184421100118
J	Silver, DL; Wang, N; Vogel, S				Silver, DL; Wang, N; Vogel, S			Identification of small PDZK1-associated protein, DD96/MAP17, as a regulator of PDZK1 and plasma high density lipoprotein levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR SR-BI; PHOSPHOLIPID TRANSFER PROTEIN; DOMAIN-CONTAINING PROTEIN; SCAVENGER RECEPTOR; TARGETED MUTATION; HUMAN CARCINOMAS; HDL CHOLESTEROL; HEPATIC LIPASE; DEFICIENT MICE; A-I	Scavenger receptor class B, type I (SR-BI) is the high density lipoprotein (HDL) receptor essential for hepatic uptake of HDL cholesterol. SR-BI was shown to impact plasma HDL levels and be anti-atherogenic. Thus, the ability to regulate hepatic SR-BI may allow for the modulation of plasma HDL cholesterol and progression of atherosclerosis. However, regulation of SR-BI in liver is not well understood. Recently, the PDZ domain containing protein PDZK1 was shown to interact with SR-BI and may serve an essential role in SR-BI cell surface expression. Here we identify an in vivo PDZK1-interacting protein that we named small PDZK1-associated protein ( SPAP; also known as DD96/MAP17). Unexpectedly, we found that hepatic overexpression of SPAP in mice resulted in liver deficiency of PDZK1. The absence of PDZK1 in SPAP transgenic mice resulted in a deficiency of SR-BI in liver and markedly increased plasma HDL. Metabolic labeling experiments showed that the proteasome plays a role in the turnover of newly synthesized PDZK1, but that SPAP overexpression in liver increased PDZK1 turnover in an alternate, proteasome-independent pathway. Thus, SPAP may be an endogenous regulator of cellular PDZK1 levels by regulating PDZK1 turnover.	Columbia Univ Coll Phys & Surg, Dept Med, Div Mol Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Div Prevent Med, New York, NY 10032 USA	Columbia University; Columbia University	Silver, DL (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, Div Mol Med, P&S Rm 8-401,630 W 168th St, New York, NY 10032 USA.	dls51@columbia.edu		Silver, David/0000-0002-7289-9890				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Braun A, 2002, CIRC RES, V90, P270, DOI 10.1161/hh0302.104462; Connelly MA, 2001, BIOCHEMISTRY-US, V40, P5249, DOI 10.1021/bi002825r; Custer M, 1997, AM J PHYSIOL-RENAL, V273, pF801, DOI 10.1152/ajprenal.1997.273.5.F801; FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724; Gelman MS, 2002, J CLIN INVEST, V110, P1591, DOI 10.1172/JCI200216786; Gisler SM, 2001, J BIOL CHEM, V276, P9206, DOI 10.1074/jbc.M008745200; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Hauser H, 1998, BIOCHEMISTRY-US, V37, P17843, DOI 10.1021/bi982404y; HOMANICS GE, 1995, J BIOL CHEM, V270, P2974, DOI 10.1074/jbc.270.7.2974; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Huszar D, 2000, ARTERIOSCL THROM VAS, V20, P1068, DOI 10.1161/01.ATV.20.4.1068; Ikemoto M, 2000, P NATL ACAD SCI USA, V97, P6538, DOI 10.1073/pnas.100114397; Ishida T, 2003, J CLIN INVEST, V111, P347, DOI [10.1172/JCI200316306, 10.1172/JCI16306]; Jaye M, 1999, NAT GENET, V21, P424, DOI 10.1038/7766; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Jiang XC, 1996, J CLIN INVEST, V98, P2373, DOI 10.1172/JCI119050; Jin WJ, 2003, J CLIN INVEST, V111, P357, DOI [10.1172/JCI16146, 10.1172/JCI200316146]; Keppler D, 2000, SEMIN LIVER DIS, V20, P265, DOI 10.1055/s-2000-9391; Kikuchi S, 2002, NAT GENET, V31, P320, DOI 10.1038/ng905; Kocher O, 1998, LAB INVEST, V78, P117; Kocher O, 2003, MOL CELL BIOL, V23, P1175, DOI 10.1128/MCB.23.4.1175-1180.2003; Kocher O, 1996, AM J PATHOL, V149, P493; Kocher O, 1999, LAB INVEST, V79, P1161; Kocher O, 1995, CLIN CANCER RES, V1, P1209; Kozarsky KF, 2000, ARTERIOSCL THROM VAS, V20, P721, DOI 10.1161/01.ATV.20.3.721; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Mardones P, 2003, J BIOL CHEM, V278, P7884, DOI 10.1074/jbc.M211627200; Miettinen HE, 2001, J CLIN INVEST, V108, P1717, DOI 10.1172/JCI13288; Plump AS, 1997, J LIPID RES, V38, P1033; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Scott RO, 2002, J BIOL CHEM, V277, P22934, DOI 10.1074/jbc.M202434200; Silver DL, 2000, J CLIN INVEST, V105, P151, DOI 10.1172/JCI8087; Silver DL, 2002, J BIOL CHEM, V277, P34042, DOI 10.1074/jbc.M206584200; SIMONET WS, 1991, J BIOL CHEM, V266, P8651; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Ueda Y, 1999, J BIOL CHEM, V274, P7165, DOI 10.1074/jbc.274.11.7165; Uittenbogaard A, 2000, J BIOL CHEM, V275, P11278, DOI 10.1074/jbc.275.15.11278; Vaisman BL, 2001, J CLIN INVEST, V108, P303; WALSH A, 1989, J BIOL CHEM, V264, P6488; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Yuhanna IS, 2001, NAT MED, V7, P853, DOI 10.1038/89986	48	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28528	28532		10.1074/jbc.M304109200	http://dx.doi.org/10.1074/jbc.M304109200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12754212	hybrid			2022-12-25	WOS:000184421100024
J	Wang, X; Ryter, SW; Dai, CS; Tang, ZL; Watkins, SC; Yin, XM; Song, RP; Choi, AMK				Wang, X; Ryter, SW; Dai, CS; Tang, ZL; Watkins, SC; Yin, XM; Song, RP; Choi, AMK			Necrotic cell death in response to oxidant stress involves the activation of the apoptogenic caspase-8/Bid pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; INDUCED LUNG INJURY; INDUCED CONFORMATIONAL-CHANGE; APOPTOSIS-INDUCING FACTOR; OXYGEN-TOXICITY; MOUSE LUNG; HYPEROXIA; NECROSIS; BAX; MITOCHONDRIA	Human epithelial (A549) cells exposed to hyperoxia die by cellular necrosis. In the current study, we demonstrated the involvement of apoptogenic factors in epithelial cell necrosis in response to hyperoxia, including the formation of the Fas-related death-inducing signaling complex and initiation of mitochondria-dependent apoptotic pathways. We showed increased activation of both Bid and Bax in A549 cells subjected to hyperoxia. Bax activation involved a Bid-assisted conformational change. We discovered that the response to hyperoxia in vivo predominantly involved the activation of the Bid/ caspase-8 pathway without apparent increases in Bax expression. Disruption of the Bid pathway by gene deletion protected against cell death in vivo and in vitro. Likewise, inhibition of caspase-8 by Flip also protected against cell death. Taken together, we have demonstrated the involvement of apoptogenic factors in epithelial cell responses to hyperoxia, despite a final outcome of cellular necrosis. We have, for the first time, identified a predominant role for the caspase-8/Bid pathway in signaling associated with hyperoxic lung injury and cell death in vivo and in vitro.	Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Pathol, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Ctr Biol Imaging, Dept Cell Biol & Physiol, Sch Med, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Choi, AMK (corresponding author), Montefiore Univ Hosp, Dept Med, Div Pulm Allergy & Crit Care Med, 3459 5th Ave,628 NW, Pittsburgh, PA 15213 USA.		Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060234, R01HL055330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042365] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL55330, R01-HL60234] Funding Source: Medline; NIAID NIH HHS [R01-AI42365] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALISON MR, 1994, GUT, V35, P577, DOI 10.1136/gut.35.5.577; Allen CB, 1998, AM J PHYSIOL-LUNG C, V274, pL159, DOI 10.1152/ajplung.1998.274.1.L159; Barazzone C, 1998, AM J RESP CELL MOL, V19, P573, DOI 10.1165/ajrcmb.19.4.3173; Brady HJM, 1998, INT J BIOCHEM CELL B, V30, P647, DOI 10.1016/S1357-2725(98)00006-5; Budinger GRS, 2002, J BIOL CHEM, V277, P15654, DOI 10.1074/jbc.M109317200; Denecker G, 2001, CELL MOL LIFE SCI, V58, P356, DOI 10.1007/PL00000863; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Franek WR, 2001, J BIOL CHEM, V276, P569, DOI 10.1074/jbc.M004716200; Fujita M, 1998, INT ARCH ALLERGY IMM, V117, P202, DOI 10.1159/000024011; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; Horowitz S, 1999, CHEST, V116, p64S, DOI 10.1378/chest.116.suppl_1.64S; HOROWITZ S, 1997, LUNG GROWTH DEV, P577; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Kazzaz JA, 1996, J BIOL CHEM, V271, P15182, DOI 10.1074/jbc.271.25.15182; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MAJNO G, 1995, AM J PATHOL, V146, P3; Mantell LL, 2002, AM J PHYSIOL-LUNG C, V283, pL31, DOI 10.1152/ajplung.00037.2001; Mantell LL, 1999, ANN NY ACAD SCI, V887, P171, DOI 10.1111/j.1749-6632.1999.tb07931.x; Mantell LL, 2000, MOL GENET METAB, V71, P359, DOI 10.1006/mgme.2000.3046; McGrath SA, 1998, AM J RESP CELL MOL, V18, P179, DOI 10.1165/ajrcmb.18.2.2964m; McGrath-Morrow SA, 2001, AM J RESP CELL MOL, V25, P150, DOI 10.1165/ajrcmb.25.2.4362; Meilhac O, 1999, FASEB J, V13, P485, DOI 10.1096/fasebj.13.3.485; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; O'Reilly MA, 1998, AM J RESP CELL MOL, V19, P777, DOI 10.1165/ajrcmb.19.5.3200; O'Reilly MA, 1998, AM J RESP CELL MOL, V18, P43, DOI 10.1165/ajrcmb.18.1.2950m; O'Reilly MA, 2000, AM J PHYSIOL-LUNG C, V278, pL552, DOI 10.1152/ajplung.2000.278.3.L552; O'Reilly MA, 2001, AM J RESP CELL MOL, V24, P703, DOI 10.1165/ajrcmb.24.6.4355; O'Reilly MA, 2001, AM J PHYSIOL-LUNG C, V281, pL291, DOI 10.1152/ajplung.2001.281.2.L291; O'Reilly MA, 2000, LAB INVEST, V80, P1845, DOI 10.1038/labinvest.3780195; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Otterbein LE, 1998, AM J PHYSIOL-LUNG C, V275, pL14, DOI 10.1152/ajplung.1998.275.1.L14; Petrache I, 1999, AM J PHYSIOL-LUNG C, V277, pL589, DOI 10.1152/ajplung.1999.277.3.L589; Pryhuber GS, 2000, AM J PHYSIOL-LUNG C, V278, pL1082, DOI 10.1152/ajplung.2000.278.5.L1082; Raffray M, 1997, PHARMACOL THERAPEUT, V75, P153, DOI 10.1016/S0163-7258(97)00037-5; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Ward NS, 2000, AM J RESP CELL MOL, V22, P535, DOI 10.1165/ajrcmb.22.5.3808; WHITE C W, 1989, Biotherapy (Dordrecht), V1, P361, DOI 10.1007/BF02171012; Wu M, 2002, J BIOL CHEM, V277, P25617, DOI 10.1074/jbc.M202285200; Yin XM, 2000, CELL RES, V10, P161, DOI 10.1038/sj.cr.7290045	45	107	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29184	29191		10.1074/jbc.M301624200	http://dx.doi.org/10.1074/jbc.M301624200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12754217	hybrid			2022-12-25	WOS:000184421100103
J	Levesque, K; Zhao, YS; Cohen, RA				Levesque, K; Zhao, YS; Cohen, RA			Vpu exerts a positive effect on HIV-1 infectivity by down-modulating CD4 receptor molecules at the surface of HIV-1-producing cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN; CYTOPLASMIC DOMAIN; TYPE-1; PROTEIN; NEF; DEGRADATION; ACTIVATION; EXPRESSION; MEMBRANE	Human immunodeficiencey virus, type 1 (HIV-1) encodes three proteins, Nef, Vpu, and gp160, that down-modulate surface expression of the CD4 receptor during viral infection. In the present study, we have investigated the role of CD4 down-modulation in the HIV-1 infection cycle, primarily from the perspective of Vpu function. We report here that, like Nef, Vpu-mediated CD4 degradation modulates positively HIV-1 infectivity. Our data reveal that accumulation of CD4 at the cell surface of Vpu-deficient HIV-1-producing cells leads to an efficient recruitment of CD4 into virions and to an impairment of viral infectivity. This CD4-mediated inhibition of viral infectivity was not observed when a CD4 mutant unable to bind Env gp120 was used or when VSV-G glycoprotein was utilized to pseudotype viruses, suggesting that an interaction between CD4 and gp120 is required for interference. Indeed, protein analysis of Vpu-defective viral particles reveals that CD4 recruitment is associated with an increased formation of gp120-CD4 complexes at the virion surface. Interestingly, we did not detect any difference at the level of total virion-associated Env glycoproteins between wild-type and Vpu-defective virus, indicating that accumulation of CD4 at the cell surface and recruitment of CD4 into Vpu-defective HIV-1 particles exert a negative effect on viral infectivity, most likely by promoting the formation of nonfunctional gp120-CD4 complexes at the virion surface. Finally, we show that both Vpu- and Nef-induced CD4 down-modulation activities are required for production of fully infectious particles in CD4(+) T cell lines and primary cells, an observation that has clear implications for viral spread in vivo.	Univ Montreal, Dept Microbiol & Immunol, Lab Retrovirol Humaine, Montreal, PQ H3C 3J7, Canada; Achillion Pharmaceut Inc, New Haven, CT 06511 USA	Universite de Montreal	Cohen, RA (corresponding author), Univ Montreal, Dept Microbiol & Immunol, Lab Retrovirol Humaine, POB 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	eric.cohen@umontreal.ca						ABACIOGLU YH, 1994, AIDS RES HUM RETROV, V10, P371, DOI 10.1089/aid.1994.10.371; ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; AGUILARCORDOVA E, 1994, AIDS RES HUM RETROV, V10, P295, DOI 10.1089/aid.1994.10.295; AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; BENSON RE, 1993, J EXP MED, V177, P1561, DOI 10.1084/jem.177.6.1561; BOUR S, 1995, J VIROL, V69, P1510, DOI 10.1128/JVI.69.3.1510-1520.1995; Bour S, 1999, J BIOL CHEM, V274, P33800, DOI 10.1074/jbc.274.47.33800; Chen BK, 1996, J VIROL, V70, P6044, DOI 10.1128/JVI.70.9.6044-6053.1996; CHOWERS MY, 1995, VIROLOGY, V212, P451, DOI 10.1006/viro.1995.1502; COHEN EA, 1988, NATURE, V334, P532, DOI 10.1038/334532a0; Cortes MJ, 2002, J BIOL CHEM, V277, P1770, DOI 10.1074/jbc.M109807200; CRISE B, 1990, J VIROL, V64, P5585, DOI 10.1128/JVI.64.11.5585-5593.1990; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; Dickey C, 2000, DNA CELL BIOL, V19, P243, DOI 10.1089/104454900314519; Doms RW, 2000, GENE DEV, V14, P2677, DOI 10.1101/gad.833300; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; FRIBORG J, 1995, J ACQ IMMUN DEF SYND, V8, P10; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; Gratton S, 1996, J IMMUNOL, V157, P3305; Greenberg ME, 1997, EMBO J, V16, P6964, DOI 10.1093/emboj/16.23.6964; Gummuluru S, 2000, J VIROL, V74, P10882, DOI 10.1128/JVI.74.23.10882-10891.2000; HUET T, 1990, NATURE, V345, P356, DOI 10.1038/345356a0; KAWAMURA I, 1989, J VIROL, V63, P3748, DOI 10.1128/JVI.63.9.3748-3754.1989; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; Lama J, 1999, CURR BIOL, V9, P622, DOI 10.1016/S0960-9822(99)80284-X; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; MICELI MC, 1993, ADV IMMUNOL, V53, P59, DOI 10.1016/S0065-2776(08)60498-8; MOORE JP, 1990, AIDS, V4, P297, DOI 10.1097/00002030-199004000-00003; PALESE P, 1974, VIROLOGY, V61, P397, DOI 10.1016/0042-6822(74)90276-1; Piguet V, 1999, CELL, V97, P63, DOI 10.1016/S0092-8674(00)80715-1; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Ross TM, 1999, CURR BIOL, V9, P613, DOI 10.1016/S0960-9822(99)80283-8; ROWELL JF, 1995, J IMMUNOL, V155, P1818; SCHUBERT U, 1995, J VIROL, V69, P7699, DOI 10.1128/JVI.69.12.7699-7711.1995; Schubert U, 1998, J VIROL, V72, P2280, DOI 10.1128/JVI.72.3.2280-2288.1998; SCHWARTZ O, 1995, J VIROL, V69, P528, DOI 10.1128/JVI.69.1.528-533.1995; SCHWARTZ S, 1990, J VIROL, V64, P5448, DOI 10.1128/JVI.64.11.5448-5456.1990; STEVENSON M, 1988, CELL, V53, P483, DOI 10.1016/0092-8674(88)90168-7; STREBEL K, 1989, J VIROL, V63, P3784, DOI 10.1128/JVI.63.9.3784-3791.1989; TERWILLIGER EF, 1989, P NATL ACAD SCI USA, V86, P5163, DOI 10.1073/pnas.86.13.5163; WILLEY RL, 1992, J VIROL, V66, P226, DOI 10.1128/JVI.66.1.226-234.1992; WILLEY RL, 1992, J VIROL, V66, P7193, DOI 10.1128/JVI.66.12.7193-7200.1992; YAO XJ, 1995, VIROLOGY, V209, P615, DOI 10.1006/viro.1995.1293; Yao XJ, 1998, J VIROL, V72, P4686, DOI 10.1128/JVI.72.6.4686-4693.1998; YAO XJ, 1992, J VIROL, V66, P5119, DOI 10.1128/JVI.66.8.5119-5126.1992	45	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28346	28353		10.1074/jbc.M300327200	http://dx.doi.org/10.1074/jbc.M300327200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12746459	hybrid			2022-12-25	WOS:000184242700125
J	Vos, MD; Ellis, CA; Elam, C; Ulku, AS; Taylor, BJ; Clark, GJ				Vos, MD; Ellis, CA; Elam, C; Ulku, AS; Taylor, BJ; Clark, GJ			RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL; APOPTOSIS; PATHWAYS; GENE; PROTEIN; MOUSE	Ras proteins regulate a wide range of biological processes by interacting with a broad assortment of effector proteins. Although activated forms of Ras are frequently associated with oncogenesis, they may also provoke growth-antagonistic effects. These include senescence, cell cycle arrest, differentiation, and apoptosis. The mechanisms that underlie these growth-inhibitory activities are relatively poorly understood. Recently, two related novel Ras effectors, NORE1 and RASSF1, have been identified as mediators of apoptosis and cell cycle arrest. Both of these proteins exhibit many of the properties normally associated with tumor suppressors. We now identify a novel third member of this family, designated RASSF2. RASSF2 binds directly to K-Ras in a GTP-dependent manner via the Ras effector domain. However, RASSF2 only weakly interacts with H-Ras. Moreover, RASSF2 promotes apoptosis and cell cycle arrest and is frequently down-regulated in lung tumor cell lines. Thus, we identify RASSF2 as a new member of the RASSF1 family of Ras effectors/tumor suppressors that exhibits a specificity for interacting with K-Ras.	NCI, Dept Cell & Canc Biol, NIH, Rockville, MD 20850 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Clark, GJ (corresponding author), NCI, Dept Cell & Canc Biol, NIH, 9610 Med Ctr Dr, Rockville, MD 20850 USA.	gclark@mail.nih.gov			DIVISION OF CLINICAL SCIENCES - NCI [Z01SC010279, Z01SC010280] Funding Source: NIH RePORTER	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen CY, 1998, J BIOL CHEM, V273, P16700, DOI 10.1074/jbc.273.27.16700; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Clark GJ, 2000, CANC DRUG DISC DEV, V5, P213; CLARK GJ, 1993, GT PASES BIOL, P259; Comincini S, 2001, MAMM GENOME, V12, P150, DOI 10.1007/s003350010239; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Ellis CA, 2000, CELL SIGNAL, V12, P425, DOI 10.1016/S0898-6568(00)00084-X; Ellis CA, 2002, P NATL ACAD SCI USA, V99, P9876, DOI 10.1073/pnas.142193799; Fiordalisi JJ, 2001, METHOD ENZYMOL, V332, P3; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Rommel C, 1998, CURR OPIN GENET DEV, V8, P412, DOI 10.1016/S0959-437X(98)80111-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shao JY, 2000, J BIOL CHEM, V275, P22916, DOI 10.1074/jbc.M002235200; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Ward Y, 2001, MOL CELL BIOL, V21, P5958, DOI 10.1128/MCB.21.17.5958-5969.2001; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052	30	138	160	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28045	28051		10.1074/jbc.M300554200	http://dx.doi.org/10.1074/jbc.M300554200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12732644	Green Published, hybrid			2022-12-25	WOS:000184242700090
J	Gimenez, I; Forbush, B				Gimenez, I; Forbush, B			Short-term stimulation of the renal Na-K-Cl cotransporter (NKCC2) by vasopressin involves phosphorylation and membrane translocation of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THICK ASCENDING LIMB; HENLES LOOP; NA-K-2CL COTRANSPORTER; SURFACE EXPRESSION; ADENYLATE-CYCLASE; WATER TRANSPORT; COLLECTING DUCT; MOUSE; ACTIVATION; KIDNEY	Na-K-Cl cotransporter (NKCC2)-mediated sodium chloride reabsorption in the thick ascending limb is stimulated by the antidiuretic hormone vasopressin. We investigate the mechanisms underlying the short term activation of NKCC2 by vasopressin in vivo, finding that administration of a vasopressin analogue (deamino-Cys-D- Arg vasopressin) causes a 2-fold increase in mouse kidney NKCC2 phosphorylation, as detected with a phosphospecific antibody, R5. The subtissue localization of the activation is defined by immunofluorescence. In vasopressin-treated animals, a dramatic increase in R5 immunostaining is observed in the initial segment of the thick ascending limb located in the inner stripe of the outer medulla, the region with a higher sensitivity to vasopressin. Although a pool of NKCC2 is present in cytoplasmic vesicles, the distribution of the phosphorylated cotransporter seems to be restricted to the cell membrane compartment; morphometric analysis of electron microscope images demonstrates a 55% increase in NKCC2 molecules at the apical membrane, suggesting the administration of vasopressin induces trafficking of the cotransporter. Thus, the short term actions of vasopressin on the thick ascending limb cotransporter are mediated by both an effect on the translocation of the protein and an increase in phosphorylation of regulatory threonines in the amino terminus of NKCC2.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University	Gimenez, I (corresponding author), 333 Cedar St,Bldg SHM,Room B146, New Haven, CT 06520 USA.	ignacio.gimenez@yale.edu	Giménez, Ignacio/B-6322-2013	Giménez, Ignacio/0000-0002-6043-4869	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK017433] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK17433] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN F, 1976, KIDNEY INT, V9, P8, DOI 10.1038/ki.1976.2; Bailly C, 1998, KIDNEY INT, pS29; Bertuccio CA, 2002, AM J PHYSIOL-RENAL, V282, pF265, DOI 10.1152/ajprenal.00354.2000; BESSEGHIR K, 1986, AM J PHYSIOL, V251, pF271, DOI 10.1152/ajprenal.1986.251.2.F271; BURG MB, 1982, KIDNEY INT, V22, P454, DOI 10.1038/ki.1982.198; D'Andrea-Winslow L, 2001, J EXP BIOL, V204, P147; DAndrea L, 1996, J BIOL CHEM, V271, P28969, DOI 10.1074/jbc.271.46.28969; Darman RB, 2002, J BIOL CHEM, V277, P37542, DOI 10.1074/jbc.M206293200; DEROUFFIGNAC C, 1995, AM J PHYSIOL-REG I, V269, pR739, DOI 10.1152/ajpregu.1995.269.4.R739; Ecelbarger CA, 1996, AM J PHYSIOL-RENAL, V271, pF619, DOI 10.1152/ajprenal.1996.271.3.F619; Ecelbarger CA, 2001, EXP NEUROL, V171, P227, DOI 10.1006/exnr.2001.7775; Flemmer AW, 2002, J BIOL CHEM, V277, P37551, DOI 10.1074/jbc.M206294200; Gimenez I, 2002, J BIOL CHEM, V277, P8767, DOI 10.1074/jbc.C200021200; Gimenez Ignacio, 2000, Journal of the American Society of Nephrology, V11, p28A; HALL DA, 1980, J CLIN INVEST, V66, P792, DOI 10.1172/JCI109917; HEBERT SC, 1981, J MEMBRANE BIOL, V58, P1, DOI 10.1007/BF01871030; IMBERT M, 1975, PFLUG ARCH EUR J PHY, V357, P173, DOI 10.1007/BF00585973; Inoue T, 2001, CARDIOVASC RES, V51, P470, DOI 10.1016/S0008-6363(01)00248-6; Kaplan MR, 1996, KIDNEY INT, V49, P40, DOI 10.1038/ki.1996.6; Kaplan MR, 1996, J CLIN INVEST, V98, P723, DOI 10.1172/JCI118844; Kim GH, 1999, AM J PHYSIOL-RENAL, V276, pF96, DOI 10.1152/ajprenal.1999.276.1.F96; Lytle C, 1995, AM J PHYSIOL-CELL PH, V269, pC1496, DOI 10.1152/ajpcell.1995.269.6.C1496; Lytle C, 1997, J BIOL CHEM, V272, P15069, DOI 10.1074/jbc.272.24.15069; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Meade P, 2003, AM J PHYSIOL-RENAL, V284, pF1145, DOI 10.1152/ajprenal.00421.2002; MOLONY DA, 1987, AM J PHYSIOL, V252, pF177, DOI 10.1152/ajprenal.1987.252.1.F177; Nielsen S, 1998, AM J PHYSIOL-RENAL, V275, pF885, DOI 10.1152/ajprenal.1998.275.6.F885; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; NONOGUCHI H, 1995, J CLIN INVEST, V96, P1768, DOI 10.1172/JCI118222; REEVES WB, 1988, AM J PHYSIOL, V255, pF1145, DOI 10.1152/ajprenal.1988.255.6.F1145; RUGGLES BT, 1985, J CLIN ENDOCR METAB, V60, P914, DOI 10.1210/jcem-60-5-914; SASAKI S, 1980, PFLUG ARCH EUR J PHY, V383, P215, DOI 10.1007/BF00587521; Wang WD, 2002, AM J PHYSIOL-RENAL, V282, pF34, DOI 10.1152/ajprenal.0101.2001; Ward DT, 1999, ANNU REV PHYSIOL, V61, P683, DOI 10.1146/annurev.physiol.61.1.683; WITTNER M, 1988, PFLUG ARCH EUR J PHY, V412, P516, DOI 10.1007/BF00582541; WU MS, 1994, J MEMBRANE BIOL, V142, P323; Yang TX, 1996, AM J PHYSIOL-RENAL, V271, pF931, DOI 10.1152/ajprenal.1996.271.4.F931	37	165	166	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26946	26951		10.1074/jbc.M303435200	http://dx.doi.org/10.1074/jbc.M303435200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12732642	hybrid			2022-12-25	WOS:000184155700084
J	Shiba, T; Nishimura, D; Kawazoe, Y; Onodera, Y; Tsutsumi, K; Nakamura, R; Ohshiro, M				Shiba, T; Nishimura, D; Kawazoe, Y; Onodera, Y; Tsutsumi, K; Nakamura, R; Ohshiro, M			Modulation of mitogenic activity of fibroblast growth factors by inorganic polyphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RECEPTOR; BINDING; CELLS; KINASE; FGF	The proliferation of normal human fibroblast cells was enhanced by the addition of inorganic polyphosphate ( poly( P)) into culture media. The mitogenic activities of acidic fibroblast growth factor (FGF-1) and basic fibroblast growth factor (FGF-2) were also enhanced by poly( P). A physical interaction between poly( P) and FGF-2 was observed, and FGF-2 was both physically and functionally stabilized by poly( P). Furthermore, poly( P) facilitated the FGF-2 binding to its cell surface receptors. Because poly( P) is widely distributed in mammalian tissues, it may be a spontaneous modulator of FGFs.	Fujirebio Inc, Frontier Res Div, Tokyo 1920031, Japan; Hokkaido Univ, Grad Sch Engn, Div Mol Chem, Sapporo, Hokkaido 0608628, Japan	H.U. Group Holdings Inc; Hokkaido University	Shiba, T (corresponding author), Fujirebio Inc, Frontier Res Div, 51 Komiya, Tokyo 1920031, Japan.		Tsutsumi, Kaori/A-4039-2012					AHN KH, 1990, J BIOL CHEM, V265, P11734; Fannon M, 1996, J BIOL CHEM, V271, P17949, DOI 10.1074/jbc.271.30.17949; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kiefer M C, 1991, Growth Factors, V5, P115, DOI 10.3109/08977199109000276; KORNBERG A, 1995, J BACTERIOL, V177, P491, DOI 10.1128/jb.177.3.491-496.1995; Kulaev I, 1999, J BIOSCI BIOENG, V88, P111, DOI 10.1016/S1389-1723(99)80189-3; Kulaev IS, 1979, BIOCH INORGANIC POLY; Kuroda A, 2001, SCIENCE, V293, P705, DOI 10.1126/science.1061315; Leyhausen G, 1998, J BONE MINER RES, V13, P803, DOI 10.1359/jbmr.1998.13.5.803; MARSHALL NJ, 1995, GROWTH REGULAT, V5, P69; Naski M.C., 1998, FRONT BIOSCI-LANDMRK, V3, pd781, DOI [10.2741/a321, DOI 10.2741/A321]; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; Sambrook J., 2002, MOL CLONING LAB MANU; Schroder H C, 1999, Prog Mol Subcell Biol, V23, P45; SHIBA T, 2001, Patent No. 6333193; SOUTTOU B, 1994, CELL GROWTH DIFFER, V5, P615; Venkataraman G, 1999, P NATL ACAD SCI USA, V96, P1892, DOI 10.1073/pnas.96.5.1892; WOOD HG, 1988, ANNU REV BIOCHEM, V57, P235, DOI 10.1146/annurev.bi.57.070188.001315	23	106	111	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26788	26792		10.1074/jbc.M303468200	http://dx.doi.org/10.1074/jbc.M303468200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12740373	hybrid			2022-12-25	WOS:000184155700064
J	Bollenbach, TJ; Stern, DB				Bollenbach, TJ; Stern, DB			Secondary structures common to chloroplast mRNA 3 '-untranslated regions direct cleavage by CSP41, an endoribonuclease belonging to the short chain dehydrogenase/reductase superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' INVERTED REPEATS; SPINACH-CHLOROPLASTS; BINDING PROTEINS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; RIBONUCLEASE; DEGRADATION; RECOGNITION; COMPLEX; DOMAIN; MATURATION	CSP41 (chloroplast stem-loop-binding protein of 41 kDa), a chloroplast endonuclease belonging to the SDR superfamily, preferentially cleaves stem-loop-containing RNAs in vitro. This potentially directs it to the 3' ends of mature chloroplast mRNAs, which generally possess such structures. To understand the basis for this discrimination, the RNA elements directing CSP41 cleavage of petD RNA in vitro were dissected. Substrates containing fully base-paired stem-loops were optimal substrates, whereas deletion of part of the stem-loop decreased activity by 100-fold, and deletion of the distal arm of the stem-loop abolished cleavage, even in substrates containing the primary CSP41 cleavage site. Competition assays showed that the decrease in activity resulted from decreased affinity for the RNA by CSP41. Mutations of the residues at the scissile bond and mutations and deletions at the terminal loop of the stem had a moderate effect on activity but no effect on cleavage site specificity, suggesting that CSP41 has no sequence specificity. Titration of ethidium bromide into the assay decreased activity to a basal level of similar to18%, and introduction of a single base bulge into either arm of the stem-loop decreased cleavage at the primary cleavage site by up to 70%. This suggests that changing the structure of the helical stem has a mild effect on activity. Deletion analysis of CSP41 suggests that the specificity domain lies in the first 73 amino acids of the protein, a domain that also contains a putative dehydrogenase-like mononucleotide binding motif. These results are consistent with a broad role for CSP41 in the degradation of stem-loop-containing mRNAs.	Cornell Univ, Boyce Thompson Inst Plant Res, Ithaca, NY 14853 USA	Cornell University; Boyce Thompson Institute for Plant Research	Stern, DB (corresponding author), Cornell Univ, Boyce Thompson Inst Plant Res, Tower Rd, Ithaca, NY 14853 USA.	ds28@cornell.edu						Baginsky S, 2001, RNA, V7, P1464; Baker ME, 1998, BIOCHEM BIOPH RES CO, V248, P250, DOI 10.1006/bbrc.1998.8951; Bellamacina CR, 1996, FASEB J, V10, P1257, DOI 10.1096/fasebj.10.11.8836039; Bevilacqua PC, 1998, BIOCHEMISTRY-US, V37, P6303, DOI 10.1021/bi980113j; Calin-Jageman I, 2001, NUCLEIC ACIDS RES, V29, P1915, DOI 10.1093/nar/29.9.1915; CHEN HC, 1991, J BIOL CHEM, V266, P24205; CHEN HC, 1991, MOL CELL BIOL, V11, P4380, DOI 10.1128/MCB.11.9.4380; Elela SA, 1998, EMBO J, V17, P3738, DOI 10.1093/emboj/17.13.3738; Evguenieva-Hackenberg E, 2002, J BIOL CHEM, V277, P46145, DOI 10.1074/jbc.M208717200; Hayes R, 1996, EMBO J, V15, P1132, DOI 10.1002/j.1460-2075.1996.tb00451.x; Kallberg Y, 2002, PROTEIN SCI, V11, P636, DOI 10.1110/ps.26902; Klaff P, 1995, NUCLEIC ACIDS RES, V23, P4885, DOI 10.1093/nar/23.23.4885; Kudla J, 1996, EMBO J, V15, P7137, DOI 10.1002/j.1460-2075.1996.tb01105.x; Lebars I, 2001, EMBO J, V20, P7250, DOI 10.1093/emboj/20.24.7250; LOWMAN HB, 1986, J BIOL CHEM, V261, P5396; MCGRATH M, 1987, MOL PHARMACOL, V32, P600; Memon AR, 1996, PLANT MOL BIOL, V30, P1195, DOI 10.1007/BF00019552; Monde RA, 2000, BIOCHIMIE, V82, P573, DOI 10.1016/S0300-9084(00)00606-4; Nagel R, 2000, RNA, V6, P1142, DOI 10.1017/S1355838200000431; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; Nibbs RJB, 1997, J BIOL CHEM, V272, P32078, DOI 10.1074/jbc.272.51.32078; NICKELSEN J, 1993, PLANT J, V3, P537, DOI 10.1046/j.1365-313X.1993.03040537.x; Ramos A, 2000, EMBO J, V19, P997, DOI 10.1093/emboj/19.5.997; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; STERN DB, 1989, PLANT MOL BIOL, V13, P615, DOI 10.1007/BF00016017; STERN DB, 1989, J BIOL CHEM, V264, P18742; STERN DB, 1987, CELL, V51, P1145, DOI 10.1016/0092-8674(87)90600-3; TORGERSON PM, 1980, BIOCHEMISTRY-US, V19, P3957, DOI 10.1021/bi00558a010; UCHIDA T, 1967, J BIOCHEM-TOKYO, V61, P44, DOI 10.1093/oxfordjournals.jbchem.a128519; Yang JJ, 1996, PLANT CELL, V8, P1409, DOI 10.1105/tpc.8.8.1409; Yehudai-Resheff S, 2001, MOL CELL BIOL, V21, P5408, DOI 10.1128/MCB.21.16.5408-5416.2001	32	25	27	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25832	25838		10.1074/jbc.M303559200	http://dx.doi.org/10.1074/jbc.M303559200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12734190	hybrid			2022-12-25	WOS:000183920200071
J	Brown, CR; Liu, JJ; Hung, GC; Carter, D; Cui, DY; Chiang, HL				Brown, CR; Liu, JJ; Hung, GC; Carter, D; Cui, DY; Chiang, HL			The Vid vesicle to vacuole trafficking event requires components of the SNARE membrane fusion machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; SACCHAROMYCES-CEREVISIAE; PEROXISOME DEGRADATION; TRANSPORT PATHWAYS; DEFICIENT MUTANTS; SELECTIVE UPTAKE; T-SNARES; YEAST; AUTOPHAGY; COMPLEX	The key gluconeogenic enzyme fructose-1,6-bisphosphatase (FBPase) is targeted to Vid vesicles when glucose-starved cells are replenished with glucose. Vid vesicles then deliver FBPase to the vacuole for degradation. A modified alkaline phosphatase assay was developed to study the trafficking of Vid vesicles to the vacuole. For this assay, FBPase was fused with a truncated form of alkaline phosphatase. Under in vivo conditions, FBPase-Delta60Pho8p was targeted to the vacuole via Vid vesicles, and it exhibited Pep4p- and Vid24p-dependent alkaline phosphatase activation. Vid vesicle-vacuole targeting was reconstituted using Vid vesicles that contained FBPase-Delta60Pho8p. These vesicles were incubated with vacuoles in the presence of cytosol and an ATP-regenerating system. Under in vitro conditions, alkaline phosphatase was also activated in a Pep4p- and Vid24p-dependent manner. The GTPase Ypt7p was identified as an essential component in Vid vesicle-vacuole trafficking. Likewise, a number of v-SNAREs (Ykt6p, Nyv1p, Vti1p) and homotypic fusion vacuole protein sorting complex family members (Vps39p and Vps41p) were required for the proper function of Vid vesicles. In contrast, the t-SNARE Vam3p was a necessary vacuolar component. Vid vesicle-vacuole trafficking exhibits characteristics similar to heterotypic membrane fusion events.	Penn State Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Brown, CR (corresponding author), Penn State Coll Med, Dept Cellular & Mol Physiol, 500 Univ Dr, Hershey, PA 17033 USA.	crb13@psu.edu						Abeliovich H, 2001, MICROBIOL MOL BIOL R, V65, P463, DOI 10.1128/MMBR.65.3.463-479.2001; Antonin W, 2002, J BIOL CHEM, V277, P36449, DOI 10.1074/jbc.M204369200; Brown CR, 2001, J BIOL CHEM, V276, P48017, DOI 10.1074/jbc.M109222200; Brown CR, 2002, J CELL SCI, V115, P655; Brown CR, 2000, J CELL BIOL, V150, P65, DOI 10.1083/jcb.150.1.65; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; Chiang HL, 1996, J BIOL CHEM, V271, P9934, DOI 10.1074/jbc.271.17.9934; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; Chiang MC, 1998, J CELL BIOL, V140, P1347, DOI 10.1083/jcb.140.6.1347; Cuervo AM, 1998, J MOL MED-JMM, V76, P6, DOI 10.1007/s109-1998-8099-y; CUERVO AM, 1994, J BIOL CHEM, V269, P26374; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; Darsow T, 2001, MOL BIOL CELL, V12, P37, DOI 10.1091/mbc.12.1.37; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; Dulubova I, 2001, NAT STRUCT BIOL, V8, P258, DOI 10.1038/85012; Eitzen G, 2000, EMBO J, V19, P6713, DOI 10.1093/emboj/19.24.6713; George MD, 2000, MOL BIOL CELL, V11, P969, DOI 10.1091/mbc.11.3.969; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Haas Albert, 1995, Methods in Cell Science, V17, P283, DOI 10.1007/BF00986234; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; Hoffman M, 1996, GENETICS, V143, P1555; Huang PH, 1997, J CELL BIOL, V136, P803, DOI 10.1083/jcb.136.4.803; Hutchins MU, 1999, J CELL SCI, V112, P4079; JONES EW, 1991, J BIOL CHEM, V266, P7963; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kim J, 2001, J CELL BIOL, V153, P381, DOI 10.1083/jcb.153.2.381; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 1998, J BIOL CHEM, V273, P10807, DOI 10.1074/jbc.273.18.10807; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Lazar T, 1997, TRENDS BIOCHEM SCI, V22, P468, DOI 10.1016/S0968-0004(97)01150-X; Liou W, 1997, J CELL BIOL, V136, P61, DOI 10.1083/jcb.136.1.61; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Price A, 2000, J CELL BIOL, V148, P1231, DOI 10.1083/jcb.148.6.1231; Price A, 2000, J CELL BIOL, V148, P1223, DOI 10.1083/jcb.148.6.1223; Rehling P, 1999, NAT CELL BIOL, V1, P346, DOI 10.1038/14037; Sato K, 1998, SCIENCE, V281, P700, DOI 10.1126/science.281.5377.700; SCHIMMOLLER F, 1993, J CELL SCI, V106, P823; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 1998, CURR OPIN CELL BIOL, V10, P523, DOI 10.1016/S0955-0674(98)80068-9; Seals DF, 2000, P NATL ACAD SCI USA, V97, P9402, DOI 10.1073/pnas.97.17.9402; Shieh HL, 1998, J BIOL CHEM, V273, P3381, DOI 10.1074/jbc.273.6.3381; Shieh HL, 2001, J BIOL CHEM, V276, P10398, DOI 10.1074/jbc.M001767200; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; TERLECKY SR, 1993, J BIOL CHEM, V268, P23490; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; TUTTLE DL, 1995, J CELL SCI, V108, P25; Ungermann C, 1999, J CELL BIOL, V145, P1435, DOI 10.1083/jcb.145.7.1435; Ungermann C, 1998, EMBO J, V17, P3269, DOI 10.1093/emboj/17.12.3269; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Ungermann C, 2000, P NATL ACAD SCI USA, V97, P8889, DOI 10.1073/pnas.160269997; Vida T, 1999, J CELL BIOL, V146, P85; von Mollard GF, 1999, MOL BIOL CELL, V10, P1719, DOI 10.1091/mbc.10.6.1719; vonMollard GF, 1997, J CELL BIOL, V137, P1511, DOI 10.1083/jcb.137.7.1511; WICHMANN H, 1992, CELL, V71, P1131, DOI 10.1016/S0092-8674(05)80062-5; Wickner W, 2000, ANNU REV BIOCHEM, V69, P247, DOI 10.1146/annurev.biochem.69.1.247; Yuan WP, 1999, MOL BIOL CELL, V10, P1353, DOI 10.1091/mbc.10.5.1353	69	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25688	25699		10.1074/jbc.M210549200	http://dx.doi.org/10.1074/jbc.M210549200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730205	hybrid			2022-12-25	WOS:000183920200053
J	Hawrani, A; Dempsey, CE; Banfield, MJ; Scott, DJ; Clarke, AR; Kenny, B				Hawrani, A; Dempsey, CE; Banfield, MJ; Scott, DJ; Clarke, AR; Kenny, B			Effect of protein kinase A-mediated phosphorylation on the structure and association properties of the enteropathogenic Escherichia coli Tir virulence protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-CELLS; CONFORMATIONAL STABILITY; RECEPTOR MOLECULE; EPEC; INTIMIN; MEMBRANES; BINDING; NCK	Enteropathogenic Escherichia coli virulence is dependent on delivery of the translocated intimin receptor protein (Tir) into host cells. Tir phosphorylation on a single tyrosine (Tyr-474) is essential in mediating cytoskeletal rearrangement correlated with disease. Tir is also phosphorylated on other residues, with cAMP-dependent kinase (PKA) modification shown to play a role in Tir function. However, the mechanism by which nontyrosine phosphorylation affects Tir function remains unclear. In this study, analytical ultracentrifugation, SDS and native gel electrophoresis revealed that both Tir and its C-terminal domain ( residues 385 - 550 of Tir that include the PKA substrate sites) exist in an equilibrium of monomers, dimers, and in the case of Tir, higher oligomers. PKA phosphorylation ( 1: 300, PKA/C-Tir, mol/ mol) shifted the equilibrium of C-Tir, but not Tir, predominantly to the dimeric state, whereas, at 100-fold higher concentrations of PKA the phosphorylated C-Tir was largely monomeric. This monomeric state was also produced at the lower PKA concentration and physiological ionic strength. Phosphorylation-mediated effects were achieved without significant changes in secondary structure as determined by circular dichroism spectroscopy. The data presented indicate that PKA-mediated phosphorylation induces changes in the association properties of the C-terminal domain of Tir that may facilitate Tir-Tir interactions and subsequently C-Tirhost protein interactions in vivo.	Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, Bristol BS8 1TD, Avon, England; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol; University of Bristol	Kenny, B (corresponding author), Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, Bristol BS8 1TD, Avon, England.	B.Kenny@Bristol.ac.uk	Banfield, Mark/C-7453-2013	Banfield, Mark/0000-0001-8921-3835; Dempsey, Christopher/0000-0002-1933-7805; Scott, David/0000-0002-6726-2078; , Brendan/0000-0001-7455-360X				Campellone KG, 2002, MOL MICROBIOL, V43, P1227, DOI 10.1046/j.1365-2958.2002.02817.x; Delahay RM, 2002, MOL MICROBIOL, V45, P905, DOI 10.1046/j.1365-2958.2002.03083.x; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Goosney DL, 2000, CURR BIOL, V10, P735, DOI 10.1016/S0960-9822(00)00543-1; Gruenheid S, 2001, NAT CELL BIOL, V3, P856, DOI 10.1038/ncb0901-856; Hartland EL, 1999, MOL MICROBIOL, V32, P151, DOI 10.1046/j.1365-2958.1999.01338.x; Ide T, 2001, CELL MICROBIOL, V3, P669, DOI 10.1046/j.1462-5822.2001.00146.x; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Kaper JB, 1998, TRENDS MICROBIOL, V6, P169, DOI 10.1016/S0966-842X(98)01266-9; Kenny B, 1999, MOL MICROBIOL, V31, P1229, DOI 10.1046/j.1365-2958.1999.01265.x; Kenny B, 2002, MICROBIOL-SGM, V148, P1967, DOI 10.1099/00221287-148-7-1967; Kenny B, 2001, INFECT IMMUN, V69, P1444, DOI 10.1128/IAI.69.3.1444-1453.2001; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; Laue TM, 1999, ANNU REV BIOPH BIOM, V28, P75, DOI 10.1146/annurev.biophys.28.1.75; Lewis RJ, 2002, J MOL BIOL, V316, P235, DOI 10.1006/jmbi.2001.5331; Marches O, 2000, INFECT IMMUN, V68, P2171, DOI 10.1128/IAI.68.4.2171-2182.2000; Martin ME, 2000, J BIOL CHEM, V275, P19050, DOI 10.1074/jbc.275.25.19050; Nashar TO, 1996, P NATL ACAD SCI USA, V93, P226, DOI 10.1073/pnas.93.1.226; Nataro JP, 1998, CLIN MICROBIOL REV, V11, P403; NEET KE, 1994, PROTEIN SCI, V3, P2167, DOI 10.1002/pro.5560031202; PACE CN, 1990, TRENDS BIOCHEM SCI, V15, P14, DOI 10.1016/0968-0004(90)90124-T; PARKER MJ, 1995, J MOL BIOL, V253, P771, DOI 10.1006/jmbi.1995.0590; Schuck P, 2000, BIOPOLYMERS, V54, P328, DOI 10.1002/1097-0282(20001015)54:5<328::AID-BIP40>3.0.CO;2-P; Simons PC, 1998, BIOCHEM BIOPH RES CO, V253, P561, DOI 10.1006/bbrc.1998.9823; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; STANIFORTH RA, 1993, BIOCHEMISTRY-US, V32, P3842, DOI 10.1021/bi00066a003; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Vallance BA, 2000, P NATL ACAD SCI USA, V97, P8799, DOI 10.1073/pnas.97.16.8799; Warawa J, 2001, MOL MICROBIOL, V42, P1269, DOI 10.1046/j.1365-2958.2001.02693.x; Yu L, 2000, NATURE, V405, P1073, DOI 10.1038/35016618	30	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25839	25846		10.1074/jbc.M212409200	http://dx.doi.org/10.1074/jbc.M212409200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12738766	hybrid			2022-12-25	WOS:000183920200072
J	Stillman, TJ; Connolly, PP; Latimer, CL; Morland, AF; Quail, MA; Andrews, SC; Treffry, A; Guest, JR; Artymiuk, PJ; Harrison, PM				Stillman, TJ; Connolly, PP; Latimer, CL; Morland, AF; Quail, MA; Andrews, SC; Treffry, A; Guest, JR; Artymiuk, PJ; Harrison, PM			Insights into the effects on metal binding of the systematic substitution of five key glutamate ligands in the ferritin of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON STORAGE FUNCTION; HUMAN H-FERRITIN; CRYSTAL-STRUCTURE; RIBONUCLEOTIDE REDUCTASE; METHANE MONOOXYGENASE; ANGSTROM RESOLUTION; OXIDATION; PROTEIN; ECFTNA; MANGANESE	Ferritins are nearly ubiquitous iron storage proteins playing a fundamental role in iron metabolism. They are composed of 24 subunits forming a spherical protein shell encompassing a central iron storage cavity. The iron storage mechanism involves the initial binding and subsequent O-2-dependent oxidation of two Fe2+ ions located at sites A and B within the highly conserved dinuclear "ferroxidase center" in individual subunits. Unlike animal ferritins and the heme-containing bacterioferritins, the Escherichia coli ferritin possesses an additional iron-binding site (site C) located on the inner surface of the protein shell close to the ferroxidase center. We report the structures of five E. coli ferritin variants and their Fe3+ and Zn2+ (a redox-stable alternative for Fe2+) derivatives. Single carboxyl ligand replacements in sites A, B, and C gave unique effects on metal binding, which explain the observed changes in Fe2+ oxidation rates. Binding of Fe2+ at both A and B sites is clearly essential for rapid Fe2+ oxidation, and the linking of Fe-B(2+) to Fe-C(2+) enables the oxidation of three Fe2+ ions. The transient binding of Fe2+ at one of three newly observed Zn2+ sites may allow the oxidation of four Fe2+ by one dioxygen molecule.	Univ Sheffield, Krebs Inst, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Sanger Ctr, Cambridge CB10 1SA, England; Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England	University of Sheffield; Wellcome Trust Sanger Institute; University of Reading	Stillman, TJ (corresponding author), Univ Sheffield, Krebs Inst, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England.	t.stillman@sheffield.ac.uk	Quail, michael/ABE-6131-2020; Andrews, Simon C/H-4758-2019	Andrews, Simon C/0000-0003-4295-2686				Andrews SC, 1998, ADV MICROB PHYSIOL, V40, P281, DOI 10.1016/S0065-2911(08)60134-4; ATTA M, 1992, J BIOL CHEM, V267, P20682; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barynin VV, 2001, STRUCTURE, V9, P725, DOI 10.1016/S0969-2126(01)00628-1; BAUMINGER ER, 1991, P ROY SOC B-BIOL SCI, V244, P211, DOI 10.1098/rspb.1991.0073; BAUMINGER ER, 1991, BIOCHIM BIOPHYS ACTA, V1118, P48, DOI 10.1016/0167-4838(91)90440-B; Bauminger ER, 1999, BIOCHEMISTRY-US, V38, P7791, DOI 10.1021/bi990377l; Bauminger ER, 2000, INORG CHIM ACTA, V297, P171, DOI 10.1016/S0020-1693(99)00336-9; Bou-Abdallah F, 2002, J BIOL CHEM, V277, P37064, DOI 10.1074/jbc.M205712200; Chasteen ND, 1999, J STRUCT BIOL, V126, P182, DOI 10.1006/jsbi.1999.4118; CHENBARRETT Y, 1995, BIOCHEMISTRY-US, V34, P7847, DOI 10.1021/bi00024a008; deMare F, 1996, NAT STRUCT BIOL, V3, P539, DOI 10.1038/nsb0696-539; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FISCHBACH FA, 1969, J MOL BIOL, V39, P235, DOI 10.1016/0022-2836(69)90344-1; FROLOW F, 1994, NAT STRUCT BIOL, V1, P453, DOI 10.1038/nsb0794-453; Gallois B, 1997, J BIOL INORG CHEM, V2, P360, DOI 10.1007/s007750050143; Granier T, 2003, J BIOL INORG CHEM, V8, P105, DOI 10.1007/s00775-002-0389-4; Ha Y, 1999, J BIOL INORG CHEM, V4, P243, DOI 10.1007/s007750050310; Harrison PM, 1998, MET IONS BIOL SYST, V35, P435; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; HARRISON PM, 1999, IRON METABOLISM INOR, P227; HEMPSTEAD PD, 1994, FEBS LETT, V350, P258, DOI 10.1016/0014-5793(94)00781-0; Hempstead PD, 1997, J MOL BIOL, V268, P424, DOI 10.1006/jmbi.1997.0970; HUDSON AJ, 1993, EUR J BIOCHEM, V218, P985, DOI 10.1111/j.1432-1033.1993.tb18457.x; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LEBRUN NE, 1995, BIOCHEM J, V312, P385, DOI 10.1042/bj3120385; Lindqvist Y, 1996, EMBO J, V15, P4081, DOI 10.1002/j.1460-2075.1996.tb00783.x; Logan DT, 1996, STRUCTURE, V4, P1053, DOI 10.1016/S0969-2126(96)00112-8; MOORE GR, 1992, J INORG BIOCHEM, V47, P175, DOI 10.1016/0162-0134(92)84063-S; NORDLUND P, 1992, FEBS LETT, V307, P257, DOI 10.1016/0014-5793(92)80690-I; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; ROSENZWEIG AC, 1995, CHEM BIOL, V2, P409, DOI 10.1016/1074-5521(95)90222-8; Stillman TJ, 2001, J MOL BIOL, V307, P587, DOI 10.1006/jmbi.2001.4475; Treffry A, 1998, J BIOL INORG CHEM, V3, P682, DOI 10.1007/s007750050282; Treffry A, 1998, FEBS LETT, V432, P213, DOI 10.1016/S0014-5793(98)00867-9; TREFFRY A, 1995, BIOCHEMISTRY-US, V34, P15204, DOI 10.1021/bi00046a028; Treffry A, 1997, BIOCHEMISTRY-US, V36, P432, DOI 10.1021/bi961830l; TRIKHA J, 1995, J MOL BIOL, V248, P949, DOI 10.1006/jmbi.1995.0274; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Yang XK, 1998, BIOCHEMISTRY-US, V37, P9743, DOI 10.1021/bi973128a; Zhao GH, 2001, BIOCHEMISTRY-US, V40, P10832, DOI 10.1021/bi011052j; ZHAO Z, 1997, J CHEM SOC DA, V21, P3977	47	24	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26275	26286		10.1074/jbc.M207354200	http://dx.doi.org/10.1074/jbc.M207354200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730190	hybrid			2022-12-25	WOS:000183920200127
J	Sartori, AA; Jiricny, J				Sartori, AA; Jiricny, J			Enzymology of base excision repair in the hyperthermophilic archaeon Pyrobaculum aerophilum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-BETA; ENDONUCLEASE-IV; AEROPYRUM-PERNIX; AP SITES; URACIL; GLYCOSYLASE; SEQUENCE; REPLICATION; REQUIREMENT; PROTEINS	DNA of all living organisms is constantly modified by exogenous and endogenous reagents. The mutagenic threat of modifications such as methylation, oxidation, and hydrolytic deamination of DNA bases is counteracted by base excision repair (BER). This process is initiated by the action of one of several DNA glycosylases, which removes the aberrant base and thus initiates a cascade of events that involves scission of the DNA backbone, removal of the baseless sugar-phosphate residue, filling in of the resulting single nucleotide gap, and ligation of the remaining nick. We were interested to find out how the BER process functions in hyperthermophiles, organisms growing at temperatures around 100degreesC, where the rates of these spontaneous reactions are greatly accelerated. In our previous studies, we could show that the crenarchaeon Pyrobaculum aerophilum has at least three uracil-DNA glycosylases, Pa-UDGa, Pa-UDGb, and Pa-MIG, that can initiate the BER process by catalyzing the removal of uracil residues arising through the spontaneous deamination of cytosines. We now report that the genome of P. aerophilum encodes also the remaining functions necessary for BER and show that a system consisting of four P. aerophilum encoded enzymes, Pa-UDGb, AP endonuclease IV, DNA polymerase B2, and DNA ligase, can efficiently repair a G.U mispair in an oligonucleotide substrate to a G.C pair. Interestingly, the efficiency of the in vitro repair reaction was stimulated by Pa-PCNA1, the processivity clamp of DNA polymerases.	Univ Zurich, Inst Mol Canc Res, CH-8008 Zurich, Switzerland	University of Zurich	Jiricny, J (corresponding author), Univ Zurich, Inst Mol Canc Res, August Forel Str 7, CH-8008 Zurich, Switzerland.	jiricny@imr.unizh.ch	Sartori, Alessandro/AAK-7840-2021	Sartori, Alessandro/0000-0003-2770-0333				Bell SD, 1998, P NATL ACAD SCI USA, V95, P15218, DOI 10.1073/pnas.95.26.15218; Blanco L, 1995, METHOD ENZYMOL, V262, P283; Bogenhagen DF, 2001, PROG NUCLEIC ACID RE, V68, P257; Bohlke K, 2002, EXTREMOPHILES, V6, P1, DOI 10.1007/s007920100222; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; Cann IKO, 1999, J BACTERIOL, V181, P5984, DOI 10.1128/JB.181.19.5984-5992.1999; Cann IKO, 1999, GENETICS, V152, P1249; Daimon K, 2002, J BACTERIOL, V184, P687, DOI 10.1128/JB.184.3.687-694.2002; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dogliotti E, 2001, PROG NUCLEIC ACID RE, V68, P3; Edgell DR, 1997, J BACTERIOL, V179, P2632, DOI 10.1128/jb.179.8.2632-2640.1997; Fitz-Gibbon ST, 2002, P NATL ACAD SCI USA, V99, P984, DOI 10.1073/pnas.241636498; Fogg MJ, 2002, NAT STRUCT BIOL, V9, P922, DOI 10.1038/nsb867; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; GOFFIN C, 1987, NUCLEIC ACIDS RES, V15, P8755, DOI 10.1093/nar/15.21.8755; Haas BJ, 1999, J BACTERIOL, V181, P2834, DOI 10.1128/JB.181.9.2834-2839.1999; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; HUDEPOHL U, 1990, P NATL ACAD SCI USA, V87, P5851, DOI 10.1073/pnas.87.15.5851; Kahler M, 2000, J BACTERIOL, V182, P655, DOI 10.1128/JB.182.3.655-663.2000; KEELING PJ, 1995, P NATL ACAD SCI USA, V92, P5761, DOI 10.1073/pnas.92.13.5761; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Krokan HE, 2002, ONCOGENE, V21, P8935, DOI 10.1038/sj.onc.1205996; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LEVIN JD, 1991, J BIOL CHEM, V266, P22893; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Lindahl T, 2001, PROG NUCLEIC ACID RE, V68, pXVII; Martin IV, 2002, GENOME BIOL, V3; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Mol CD, 2000, MUTAT RES-DNA REPAIR, V460, P211, DOI 10.1016/S0921-8777(00)00028-8; Perler FB, 1996, ADV PROTEIN CHEM, V48, P377; Podlutsky AJ, 2001, EMBO J, V20, P1477, DOI 10.1093/emboj/20.6.1477; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; Reilly MS, 2002, FEMS MICROBIOL LETT, V208, P29, DOI 10.1016/S0378-1097(01)00575-4; SAMBROOK J, 1989, MOL CLONING, V2, P9; Sartori AA, 2002, EMBO J, V21, P3182, DOI 10.1093/emboj/cdf309; Sartori AA, 2001, J BIOL CHEM, V276, P29979, DOI 10.1074/jbc.M102985200; Scharer OD, 2001, BIOESSAYS, V23, P270, DOI 10.1002/1521-1878(200103)23:3<270::AID-BIES1037>3.0.CO;2-J; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Skorvaga M, 1998, P NATL ACAD SCI USA, V95, P6711, DOI 10.1073/pnas.95.12.6711; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Timson DJ, 2000, MUTAT RES-DNA REPAIR, V460, P301, DOI 10.1016/S0921-8777(00)00033-1; Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088; Yang HJ, 2000, J BACTERIOL, V182, P1272, DOI 10.1128/JB.182.5.1272-1279.2000; Yang HJ, 2002, J BIOL CHEM, V277, P22271, DOI 10.1074/jbc.M201820200; Yang HJ, 2001, NUCLEIC ACIDS RES, V29, P604, DOI 10.1093/nar/29.3.604	55	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24563	24576		10.1074/jbc.M302397200	http://dx.doi.org/10.1074/jbc.M302397200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12730226	hybrid, Green Accepted			2022-12-25	WOS:000183824800039
J	Colombo, R; Draetta, GF; Chiocca, S				Colombo, R; Draetta, GF; Chiocca, S			Modulation of p120(E4F) transcriptional activity by the Gam1 adenoviral early protein	ONCOGENE			English	Article						HDAC1; Gam1; adenoviral protein; P120(E4F) transcriptional activity	MOUSE HISTONE DEACETYLASE-1; FACTOR E4F; GENE; IDENTIFICATION; GROWTH; CELO; ARREST	Gam1, an early adenoviral CELO protein, is required for viral replication. Consistent with its ability to inhibit histone deacetylation by HDAC1, Gam1 activates transcription. In this report, we identify the cellular transcription factor p120(E4F) as a Gam1 interaction partner. p120(E4F) is a low-abundance transcription factor that represses the adenovirus E4 promoter. Here we demonstrate that p120(E4F) interacts with HDAC1 in vivo and in vitro, and that E4F-mediated transcriptional repression is alleviated by the HDAC inhibitor trichostatin A or by overexpressing Gam1. A mutant E4 promoter unresponsive to E4F-mediated transcriptional repression is also not stimulated by Gam1. Moreover, our cofractionation experiments demonstrate that p120(E4F), HDAC1 and Gam1 may be concomitantly present in protein complexes. We conclude that Gam1 activates E4-dependent transcription possibly by inactivating HDAC1.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO)	Chiocca, S (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.		Chiocca, Susanna/AAC-8863-2019; Chiocca, Susanna/K-5233-2016	Chiocca, Susanna/0000-0002-9721-0850	Telethon [E.0865] Funding Source: Medline	Telethon(Fondazione Telethon)		Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; Chiocca S, 1997, J VIROL, V71, P3168, DOI 10.1128/JVI.71.4.3168-3177.1997; Chiocca S, 1996, J VIROL, V70, P2939, DOI 10.1128/JVI.70.5.2939-2949.1996; Chiocca S, 2002, CURR BIOL, V12, P594, DOI 10.1016/S0960-9822(02)00720-0; Colombo R, 2002, EMBO REP, V3, P1062, DOI 10.1093/embo-reports/kvf213; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fajas L, 2001, MOL CELL BIOL, V21, P2956, DOI 10.1128/MCB.21.8.2956-2966.2001; Fajas L, 2000, P NATL ACAD SCI USA, V97, P7738, DOI 10.1073/pnas.130198397; Fernandes ER, 1997, MOL CELL BIOL, V17, P1890, DOI 10.1128/MCB.17.4.1890; Fernandes ER, 1998, MOL CELL BIOL, V18, P459, DOI 10.1128/MCB.18.1.459; FOGNANI C, 1993, EMBO J, V12, P4985, DOI 10.1002/j.1460-2075.1993.tb06192.x; Glotzer JB, 2000, NATURE, V407, P207, DOI 10.1038/35025102; Johnson CA, 1999, SEMIN CELL DEV BIOL, V10, P179, DOI 10.1006/scdb.1999.0299; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lehrmann H, 1999, J VIROL, V73, P6517, DOI 10.1128/JVI.73.8.6517-6525.1999; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; RIZOS H, 2002, J BIOL CHEM, V21, P21; Rooney RJ, 2001, CELL GROWTH DIFFER, V12, P505; Rooney RJ, 1998, MAMM GENOME, V9, P320, DOI 10.1007/s003359900758; Sandy P, 2000, ONCOGENE, V19, P188, DOI 10.1038/sj.onc.1203250; Taplick J, 2001, J MOL BIOL, V308, P27, DOI 10.1006/jmbi.2001.4569; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	26	10	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2541	2547		10.1038/sj.onc.1206379	http://dx.doi.org/10.1038/sj.onc.1206379			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730668				2022-12-25	WOS:000182569000001
J	Gokool, S				Gokool, S			sigma 1- and mu 1-adaptin homologues of Leishmania mexicana are required for parasite survival in the infected host	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; BOUND ACID-PHOSPHATASE; GPI-ANCHORED PROTEINS; VIRULENCE FACTOR; TRYPANOSOMATID PARASITES; GENE DELETION; CLATHRIN; EXPRESSION; COMPLEX; MICE	The sorting of membrane-bound proteins from the trans-Golgi network to lysosomal/endosomal compartments is achieved by preferential inclusion into clathrin-coated vesicles. Contained within the cytoplasmic domains of such proteins, specific sequence motifs have been identified ( tyrosine-based and/or di-leucine-based) that are essential for targeting and are recognized by a family of heterotetrameric adaptor complexes, which then recruit clathrin. These cytosolic protein complexes, which have been found in a wide variety of higher eukaryotic organisms, are essential for the development of multicellular organisms. In trypanosomatids, the adaptin-mediated sorting of proteins is largely uncharacterized. In order to identify components of the adaptor-complex machinery, this study reports the cloning and characterization of sigma1- and mu1-adaptin gene homologues from the eukaryotic protozoan parasite, Leishmania mexicana. Generation of sigma1- and mu1-adaptin gene deletion mutants shows that these promastigote parasites are viable in culture, but are unable to establish infection of macrophages or mice, indicating that adaptin function is crucial for pathogenesis in these unicellular organisms.	Max Planck Inst Biol, Abt Membranbiochem, D-72076 Tubingen, Germany	Max Planck Society	Gokool, S (corresponding author), Addenbrookes Hosp, Cambridge Inst Med Res, Wellcome Trust MRC Bldg,Box 139,Hills Rd, Cambridge CB2 2XY, England.							AHLE S, 1989, J BIOL CHEM, V264, P20089; ALEXANDER J, 1992, ADV PARASIT, V31, P175, DOI 10.1016/S0065-308X(08)60022-6; Benzel I, 2000, MOL BIOCHEM PARASIT, V111, P77, DOI 10.1016/S0166-6851(00)00306-6; Boehm M, 2002, GENE, V286, P175, DOI 10.1016/S0378-1119(02)00422-5; Boehm M, 2001, MOL BIOL CELL, V12, P2907, DOI 10.1091/mbc.12.10.2907; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Clayton C, 1998, MOL BIOCHEM PARASIT, V97, P221, DOI 10.1016/S0166-6851(98)00115-7; COULSON RMR, 1990, MOL BIOCHEM PARASIT, V40, P63, DOI 10.1016/0166-6851(90)90080-6; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; FREEDMAN DJ, 1993, MOL BIOCHEM PARASIT, V62, P37, DOI 10.1016/0166-6851(93)90175-W; Garami A, 2001, EMBO J, V20, P3657, DOI 10.1093/emboj/20.14.3657; Garami A, 2001, MOL CELL BIOL, V21, P8168, DOI 10.1128/MCB.21.23.8168-8183.2001; Harlow E., 1988, ANTIBODIES LAB MANUA; Hilley JD, 2000, MOL BIOL CELL, V11, P1183, DOI 10.1091/mbc.11.4.1183; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Huang KM, 1999, EMBO J, V18, P3897, DOI 10.1093/emboj/18.14.3897; Ilg T, 2000, PARASITOL TODAY, V16, P489, DOI 10.1016/S0169-4758(00)01791-9; Ilg T, 2001, J BIOL CHEM, V276, P4988, DOI 10.1074/jbc.M008030200; Ilg T, 2000, EMBO J, V19, P1953, DOI 10.1093/emboj/19.9.1953; Joshi PB, 2002, MOL BIOCHEM PARASIT, V120, P33, DOI 10.1016/S0166-6851(01)00432-7; Kelley RJ, 1999, MOL BIOCHEM PARASIT, V98, P17, DOI 10.1016/S0166-6851(98)00155-8; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; McConville MJ, 2002, MICROBIOL MOL BIOL R, V66, P122, DOI 10.1128/MMBR.66.1.122-154.2002; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L; Meyer C, 2000, EMBO J, V19, P2193, DOI 10.1093/emboj/19.10.2193; Misslitz A, 2000, MOL BIOCHEM PARASIT, V107, P251, DOI 10.1016/S0166-6851(00)00195-X; Morgan GW, 2002, TRENDS PARASITOL, V18, P540, DOI 10.1016/S1471-4922(02)02392-9; Mottram JC, 1996, P NATL ACAD SCI USA, V93, P6008, DOI 10.1073/pnas.93.12.6008; Overath P, 1997, TRENDS CELL BIOL, V7, P27, DOI 10.1016/S0962-8924(97)10046-0; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; PAGE LJ, 1995, J CELL BIOL, V131, P619, DOI 10.1083/jcb.131.3.619; PEARSE BMF, 1975, J MOL BIOL, V97, P93, DOI 10.1016/S0022-2836(75)80024-6; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; ROBINSON MS, 1993, J CELL BIOL, V123, P67, DOI 10.1083/jcb.123.1.67; Sambrook J., 2002, MOL CLONING LAB MANU; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; Shim J, 2000, MOL BIOL CELL, V11, P2743, DOI 10.1091/mbc.11.8.2743; Shim J, 2000, MOL CELLS, V10, P309; Spath GF, 2000, P NATL ACAD SCI USA, V97, P9258, DOI 10.1073/pnas.160257897; Turco SJ, 2001, TRENDS PARASITOL, V17, P223, DOI 10.1016/S1471-4922(01)01895-5; WEBSTER P, 1993, PARASITOL TODAY, V9, P201, DOI 10.1016/0169-4758(93)90008-4; Weise F, 2000, J CELL SCI, V113, P4587; Wiese M, 1996, MOL BIOCHEM PARASIT, V82, P153, DOI 10.1016/0166-6851(96)02729-6; Wiese M, 1998, EMBO J, V17, P2619, DOI 10.1093/emboj/17.9.2619; Zizioli D, 1999, J BIOL CHEM, V274, P5385, DOI 10.1074/jbc.274.9.5385	49	12	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29400	29409		10.1074/jbc.M304572200	http://dx.doi.org/10.1074/jbc.M304572200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12730207	hybrid			2022-12-25	WOS:000184507000004
J	Hossain, GS; van Thienen, JV; Werstuck, GH; Zhou, J; Sood, SK; Dickhout, JG; de Koning, ABL; Tang, D; Wu, DC; Falk, E; Poddar, R; Jacobsen, DW; Zhang, KZ; Kaufman, RJ; Austin, RC				Hossain, GS; van Thienen, JV; Werstuck, GH; Zhou, J; Sood, SK; Dickhout, JG; de Koning, ABL; Tang, D; Wu, DC; Falk, E; Poddar, R; Jacobsen, DW; Zhang, KZ; Kaufman, RJ; Austin, RC			TDAG51 is induced by homocysteine, promotes detachment-mediated programmed cell death, and contributes to the development of atherosclerosis in hyperhomocysteinemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; VASCULAR ENDOTHELIAL-CELLS; HYDROGEN-PEROXIDE; PROTEIN-SYNTHESIS; MAMMALIAN-CELLS; GENE-EXPRESSION; IN-VIVO; APOPTOSIS; ACTIVATION; KINASE	Hyperhomocysteinemia is an independent risk factor for cardiovascular disease and accelerates atherosclerosis in apoE(-/-) mice. Despite the observations that homocysteine causes endoplasmic reticulum (ER) stress and programmed cell death (PCD) in cultured human vascular endothelial cells, the cellular factors responsible for this effect and their relevance to atherogenesis have not been completely elucidated. We report here that homocysteine induces the expression of T-cell death-associated gene 51 (TDAG51), a member of the pleckstrin homology-related domain family, in cultured human vascular endothelial cells. This effect was observed for other ER stress-inducing agents, including dithiothreitol and tunicamycin. TDAG51 expression was attenuated in homozygous A/A mutant eukaryotic translation initiation factor 2alpha mouse embryonic fibroblasts treated with homocysteine or tunicamycin, suggesting that ER stress-induced phosphorylation of eukaryotic translation initiation factor 2alpha is required for TDAG51 transcriptional activation. Transient overexpression of TDAG51 elicited significant changes in cell morphology, decreased cell adhesion, and promoted detachment-mediated PCD. In support of these in vitro findings, TDAG51 expression was increased and correlated with PCD in the atherosclerotic lesions from apoE(-/-) mice fed hyperhomocysteinemic diets, compared with mice fed a control diet. Collectively, these findings provide evidence that TDAG51 is induced by homocysteine, promotes detachment-mediated PCD, and contributes to the development of atherosclerosis observed in hyperhomocysteinemia.	Henderson Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8V 1C3, Canada; Univ Aarhus, Aarhus Univ Hosp, Dept Cardiol, Aarhus, Denmark; Yale Univ, Sch Med, Dept Genet, Boyer Ctr Mol Med, New Haven, CT 06536 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Univ Michigan, Howard Hughes Med Inst, Dept Biol Chem, Med Ctr, Ann Arbor, MI 48109 USA	McMaster University; Aarhus University; Yale University; Cleveland Clinic Foundation; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Austin, RC (corresponding author), Henderson Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.		Falk, Erling/A-7475-2015; Tang, Damu/AAQ-1786-2021; Dickhout, Jeffrey/R-2606-2019	Falk, Erling/0000-0001-8566-9974; Tang, Damu/0000-0002-3282-9521; Zhang, Kezhong/0000-0002-6062-235X	NHLBI NIH HHS [R01HL52234] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052234] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Bachelder RE, 2001, J BIOL CHEM, V276, P34702, DOI 10.1074/jbc.M102806200; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Cai Y, 2000, BLOOD, V96, P2140, DOI 10.1182/blood.V96.6.2140.h8002140_2140_2148; Eikelboom JW, 1999, ANN INTERN MED, V131, P363, DOI 10.7326/0003-4819-131-5-199909070-00008; Frank D, 1999, MAMM GENOME, V10, P1150, DOI 10.1007/s003359901182; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; FUSTER V, 1994, CIRCULATION, V90, P2126, DOI 10.1161/01.CIR.90.4.2126; Gomes I, 1999, J NEUROCHEM, V73, P612, DOI 10.1046/j.1471-4159.1999.0730612.x; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hegyi L, 1996, J PATHOL, V180, P423, DOI 10.1002/(SICI)1096-9896(199612)180:4<423::AID-PATH677>3.0.CO;2-1; Hinz T, 2001, CELL SIGNAL, V13, P345, DOI 10.1016/S0898-6568(01)00141-3; Hladovec J, 1997, THROMB RES, V88, P361, DOI 10.1016/S0049-3848(97)00266-1; Hofmann MA, 2001, J CLIN INVEST, V107, P675, DOI 10.1172/JCI10588; Huang RFS, 2001, LIFE SCI, V68, P2799, DOI 10.1016/S0024-3205(01)01066-9; Ikeda J, 1997, BIOCHEM BIOPH RES CO, V230, P94, DOI 10.1006/bbrc.1996.5890; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; Jacobsen DW, 2000, ARTERIOSCL THROM VAS, V20, P1182, DOI 10.1161/01.ATV.20.5.1182; Jacobsen DW, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P425; Jakubowski H, 1997, J BIOL CHEM, V272, P1935; Kockx MM, 1996, ATHEROSCLEROSIS, V120, P115, DOI 10.1016/0021-9150(95)05691-2; Kokame K, 2000, J BIOL CHEM, V275, P32846, DOI 10.1074/jbc.M002063200; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Lee RT, 1997, ARTERIOSCL THROM VAS, V17, P1859, DOI 10.1161/01.ATV.17.10.1859; Ma K, 2002, J BIOL CHEM, V277, P18728, DOI 10.1074/jbc.M200903200; Malinow MR, 1999, CIRCULATION, V99, P178, DOI 10.1161/01.CIR.99.1.178; Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Neef R, 2002, CANCER RES, V62, P5920; Nonaka H, 2001, CIRCULATION, V104, P1165, DOI 10.1161/hc3601.093976; Outinen PA, 1998, BIOCHEM J, V332, P213, DOI 10.1042/bj3320213; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; Park CG, 1996, IMMUNITY, V4, P583, DOI 10.1016/S1074-7613(00)80484-7; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Reddy PH, 1997, GENOMICS, V46, P174, DOI 10.1006/geno.1997.5044; Rho J, 2001, MOL CELL BIOL, V21, P8365, DOI 10.1128/MCB.21.24.8365-8370.2001; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; Tedgui A, 2001, THROMB HAEMOSTASIS, V86, P420; Upchurch GR, 1997, J BIOL CHEM, V272, P17012, DOI 10.1074/jbc.272.27.17012; Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071; Zhang C, 2001, J BIOL CHEM, V276, P35867, DOI 10.1074/jbc.M100747200; Zhou J, 2001, ARTERIOSCL THROM VAS, V21, P1470, DOI 10.1161/hq0901.096582; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	50	172	186	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					30317	30327		10.1074/jbc.M212897200	http://dx.doi.org/10.1074/jbc.M212897200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12738777	hybrid			2022-12-25	WOS:000184507000112
J	Tarui, T; Andronicos, N; Czekay, RP; Mazar, AP; Bdeir, K; Parry, GC; Kuo, A; Loskutoff, DJ; Cines, DB; Takada, Y				Tarui, T; Andronicos, N; Czekay, RP; Mazar, AP; Bdeir, K; Parry, GC; Kuo, A; Loskutoff, DJ; Cines, DB; Takada, Y			Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR RECEPTOR; LIGAND-BINDING POCKET; AMINO-ACID-RESIDUES; CELL-MIGRATION; EXTRACELLULAR SEGMENT; CRYSTAL-STRUCTURE; HUMAN CARCINOMA; SUBUNIT; GROWTH; IDENTIFICATION	Urokinase-type plasminogen activator (uPA) induces cell adhesion and chemotactic movement. uPA signaling requires its binding to uPA receptor (uPAR/CD87), but how glycosylphosphatidylinositol-anchored uPAR mediates signaling is unclear. uPAR is a ligand for several integrins (e.g. alpha(5)beta(1)) and supports cell-cell interaction by binding to integrins on apposing cells ( in trans). We studied whether binding of uPAR to alpha(5)beta(1) in cis is involved in adhesion and migration of Chinese hamster ovary cells in response to immobilized uPA. This process was temperature-sensitive and required mitogen-activated protein kinase activation. Anti-uPAR antibody or depletion of uPAR blocked, whereas overexpression of uPAR enhanced, cell adhesion to uPA. Adhesion to uPA was also blocked by deletion of the growth factor domain (GFD) of uPA and by anti-GFD antibody, whereas neither the isolated uPA kringle nor serine protease domain supported adhesion directly. Interestingly, anti-alpha(5) antibody, RGD peptide, and function-blocking mutations in alpha(5)beta(1) blocked adhesion to uPA. uPA-induced cell migration also required GFD, uPAR, and alpha(5)beta(1), but alpha(5)beta(1) alone did not support uPA-induced adhesion and migration. Thus, binding of uPA causes uPAR to act as a ligand for alpha(5)beta(1) to induce cell adhesion, intracellular signaling, and cell migration. We demonstrated that uPA induced RGD-dependent binding of uPAR to alpha(5)beta(1) in solution. These results suggest that uPA-induced adhesion and migration of Chinese hamster ovary cells occurs as a consequence of ( a) uPA binding to uPAR through GFD, (b) the subsequent binding of a uPA . uPAR complex to alpha(5)beta(1) via uPAR, and ( c) signal transduction through alpha(5)beta(1).	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Attenuon LLC, San Diego, CA 92121 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Scripps Research Institute; University of Pennsylvania	Takada, Y (corresponding author), Scripps Res Inst, Dept Cell Biol, VB-6,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	takada@scripps.edu	Tarui, Takehiko/L-4778-2019; Andronicos, Nicholas/AAV-6282-2021	Tarui, Takehiko/0000-0002-2519-7052; Andronicos, Nicholas/0000-0001-5881-2296; takada, yoshikazu/0000-0001-5481-9589	NHLBI NIH HHS [HL60169] Funding Source: Medline; NIGMS NIH HHS [GM47157] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047157] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPELLA E, 1987, ANN NY ACAD SCI, V511, P192, DOI 10.1111/j.1749-6632.1987.tb36247.x; AXELROD JH, 1989, MOL CELL BIOL, V9, P2133, DOI 10.1128/MCB.9.5.2133; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; Bdeir K, 2000, J BIOL CHEM, V275, P28532, DOI 10.1074/jbc.M001595200; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117; FALCIONI R, 1988, CANCER RES, V48, P816; Fischer K, 1998, FEBS LETT, V438, P101, DOI 10.1016/S0014-5793(98)01279-4; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Gum R, 1998, ONCOGENE, V17, P213, DOI 10.1038/sj.onc.1201917; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; Irie A, 1997, P NATL ACAD SCI USA, V94, P7198, DOI 10.1073/pnas.94.14.7198; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; Kamata T, 1996, J BIOL CHEM, V271, P18610, DOI 10.1074/jbc.271.31.18610; Kamata T, 2001, J BIOL CHEM, V276, P44275, DOI 10.1074/jbc.M107021200; MIN HY, 1992, J IMMUNOL, V148, P3636; Mould AP, 1998, J BIOL CHEM, V273, P25664, DOI 10.1074/jbc.273.40.25664; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; ODEKON LE, 1992, J CELL PHYSIOL, V150, P258, DOI 10.1002/jcp.1041500206; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; Preissner KT, 2000, CURR OPIN CELL BIOL, V12, P621, DOI 10.1016/S0955-0674(00)00141-1; Puzon-McLaughlin W, 2000, J BIOL CHEM, V275, P7795, DOI 10.1074/jbc.275.11.7795; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Shliom O, 2000, J BIOL CHEM, V275, P24304, DOI 10.1074/jbc.M002024200; Simon DI, 2000, J BIOL CHEM, V275, P10228, DOI 10.1074/jbc.275.14.10228; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Tarui T, 2001, J BIOL CHEM, V276, P39562, DOI 10.1074/jbc.M101815200; Tarui T, 2001, J BIOL CHEM, V276, P3983, DOI 10.1074/jbc.M008220200; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; Wei Y, 2001, MOL BIOL CELL, V12, P2975, DOI 10.1091/mbc.12.10.2975; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Xue W, 1997, CANCER RES, V57, P1682; XUE W, 1994, J IMMUNOL, V152, P4630; Yebra M, 1999, EXP CELL RES, V250, P231, DOI 10.1006/excr.1999.4510; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345	42	64	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29863	29872		10.1074/jbc.M304694200	http://dx.doi.org/10.1074/jbc.M304694200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12754207	hybrid			2022-12-25	WOS:000184507000059
J	Dziak, R; Leishman, D; Radovic, M; Tye, BK; Yankulov, K				Dziak, R; Leishman, D; Radovic, M; Tye, BK; Yankulov, K			Evidence for a role of MCM (mini-chromosome maintenance)5 in transcriptional repression of sub-telomeric and Ty-proximal genes in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; MINICHROMOSOME MAINTENANCE; S-PHASE; NUCLEAR PROTEINS; IFN-GAMMA; YEAST; ACTIVATION; RETROTRANSPOSONS	The MCM (mini-chromosome maintenance) genes have a well established role in the initiation of DNA replication and in the elongation of replication forks in Saccharomyces cerevisiae. In this study we demonstrate elevated expression of sub-telomeric and Ty retrotransposon-proximal genes in two mcm5 strains. This pattern of up-regulated genes resembles the genome-wide association of MCM proteins to chromatin that was reported earlier. We link the altered gene expression in mcm5 strains to a reversal of telomere position effect (TPE) and to remodeling of sub-telomeric and Ty chromatin. We also show a suppression of the Ts phenotype of a mcm5 strain by the high copy expression of the TRA1 component of the chromatin-remodeling SAGA/ADA (SPT-ADA-GCN5 acetylase/ADAptor). We propose that MCM proteins mediate the establishment of silent chromatin domains around telomeres and Ty retrotransposons.	Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14583 USA	University of Guelph; Cornell University	Yankulov, K (corresponding author), Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada.	yankulov@uoguelph.ca		Yankulov, Krassimir/0000-0001-9440-9234				APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; BRADSHAW VA, 1989, MOL GEN GENET, V218, P465, DOI 10.1007/BF00332411; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; CHAN CSM, 1983, CELL, V33, P563, DOI 10.1016/0092-8674(83)90437-3; CHEN YR, 1992, P NATL ACAD SCI USA, V89, P10459, DOI 10.1073/pnas.89.21.10459; DaFonseca CJ, 2001, P NATL ACAD SCI USA, V98, P3034, DOI 10.1073/pnas.061487598; de Bruin D, 2000, MOL CELL BIOL, V20, P7991, DOI 10.1128/MCB.20.21.7991-8000.2000; Dillin A, 1997, GENETICS, V147, P1053; Ehrenhofer-Murray AE, 1999, GENETICS, V153, P1171; EHRENHOFERMURRAY AE, 1995, SCIENCE, V270, P1671, DOI 10.1126/science.270.5242.1671; Fox CA, 1997, SCIENCE, V276, P1547, DOI 10.1126/science.276.5318.1547; Gauthier L, 2002, GENETICS, V162, P1117; Gladden AB, 2003, J BIOL CHEM, V278, P9754, DOI 10.1074/jbc.M212088200; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HASSETT N, 1991, INTRO STAT; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; Holland L, 2002, EUR J BIOCHEM, V269, P5192, DOI 10.1046/j.1432-1033.2002.03224.x; Ishimi Y, 1996, J BIOL CHEM, V271, P24115, DOI 10.1074/jbc.271.39.24115; Ishimi Y, 1998, J BIOL CHEM, V273, P8369, DOI 10.1074/jbc.273.14.8369; Jiang YW, 2002, GENE DEV, V16, P467, DOI 10.1101/gad.923502; Kirchmaier AL, 2001, SCIENCE, V291, P646, DOI 10.1126/science.291.5504.646; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Labib K, 2001, CURR OPIN GENET DEV, V11, P64, DOI 10.1016/S0959-437X(00)00158-1; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Lau A, 2002, GENE DEV, V16, P2935, DOI 10.1101/gad.764102; Lei M, 2002, J BIOL CHEM, V277, P30824, DOI 10.1074/jbc.M201816200; Lei M, 1996, MOL CELL BIOL, V16, P5081; Lei M, 2001, J CELL SCI, V114, P1447; Li YC, 2001, SCIENCE, V291, P650, DOI 10.1126/science.291.5504.650; Liang DT, 1999, J CELL SCI, V112, P559; LOO S, 1994, SCIENCE, V264, P1768, DOI 10.1126/science.8209257; MAINE GT, 1984, GENETICS, V106, P365; Morillon A, 2002, MOL CELL BIOL, V22, P2078, DOI 10.1128/MCB.22.7.2078-2088.2002; Morillon S, 2000, MOL CELL BIOL, V20, P5766, DOI 10.1128/MCB.20.15.5766-5776.2000; NEWLON CS, 1993, CURR OPIN GENET DEV, V3, P752, DOI 10.1016/S0959-437X(05)80094-2; Raghuraman MK, 2001, SCIENCE, V294, P115, DOI 10.1126/science.294.5540.115; Ricci AR, 2002, MOL CELL BIOL, V22, P4033, DOI 10.1128/MCB.22.12.4033-4042.2002; Roy N, 2000, CURR BIOL, V10, P111, DOI 10.1016/S0960-9822(00)00298-0; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Staleva LS, 2001, MUTAT RES-FUND MOL M, V474, P93, DOI 10.1016/S0027-5107(00)00165-2; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Tham WH, 2002, ONCOGENE, V21, P512, DOI 10.1038/sj.onc.1205078; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Tye BK, 1999, METHODS, V18, P329, DOI 10.1006/meth.1999.0793; Wang Y, 2000, FEBS LETT, V484, P17, DOI 10.1016/S0014-5793(00)02117-7; Wyrick JJ, 2001, SCIENCE, V294, P2357, DOI 10.1126/science.1066101; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; Yankulov K, 1999, MOL CELL BIOL, V19, P6154; Young MR, 1997, MOL BIOL CELL, V8, P1587, DOI 10.1091/mbc.8.8.1587; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963	55	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27372	27381		10.1074/jbc.M301110200	http://dx.doi.org/10.1074/jbc.M301110200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12750362	hybrid			2022-12-25	WOS:000184242700007
J	Gummow, BM; Winnay, JN; Hammer, GD				Gummow, BM; Winnay, JN; Hammer, GD			Convergence of Wnt signaling and steroidogenic factor-1 (SF-1) on transcription of the rat inhibin alpha gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL HYPOPLASIA CONGENITA; SENSITIVE SEX REVERSAL; NUCLEAR RECEPTOR SF-1; MOUSE FTZ-F1 GENE; BETA-CATENIN; CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE; EPITHELIAL TRANSFORMATION; METANEPHRIC MESENCHYME; ANDROGEN RECEPTOR; DEVELOPING KIDNEY	The action of a variety of peptide hormones is critical for proper growth and differentiation of the urogenital ridge, which ultimately gives rise to the kidney, adrenal cortex, and gonad. One such class of peptides is the Wnt family of secreted glycoproteins that is classically involved in development of cell polarity and cell fate determination. Notably, alterations in Wnt-4 expression in mice and humans result in profound defects in urogenital ridge development, including dysregulation of kidney, gonadal, and adrenal growth. The nuclear receptor steroidogenic factor-1 (SF-1) has been implicated as a downstream effector of peptide hormone signaling during urogenital ridge development as evidenced by both the activation of SF-1-dependent transcription in the adrenal cortex by signaling molecules such as protein kinase A and by the adrenal and gonadal agenesis in mice with null mutations in SF-1. We hypothesized that Wnt-dependent signaling cascades regulate SF-1-dependent transcription of genes required for adreno-gonadal development. Specifically, the data demonstrate that beta-catenin synergizes with SF-1 to activate the alpha-inhibin promoter through formation of a transcriptional complex. The activation requires an intact SF-1 RE and is independent of TCF/Lef. These data support the recent observation that beta-catenin can participate in nuclear receptor-mediated transcriptional activation and extend the findings to the monomer binding class of orphan nuclear receptors.	Univ Michigan, Dept Internal Med, Div Endocrinol & Metab, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol & Integrat Physiol, Div Endocrinol & Metab, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Hammer, GD (corresponding author), Univ Michigan, Dept Internal Med, Div Endocrinol & Metab, 1150 W Med Ctr Dr,5560 MSRBII, Ann Arbor, MI 48109 USA.							Babu PS, 2002, ENDOCRINOLOGY, V143, P665, DOI 10.1210/en.143.2.665; BICSAK TA, 1986, ENDOCRINOLOGY, V119, P2711, DOI 10.1210/endo-119-6-2711; Borud B, 2002, MOL ENDOCRINOL, V16, P757, DOI 10.1210/me.16.4.757; Briggs MW, 2002, J BIOL CHEM, V277, P7453, DOI 10.1074/jbc.M104315200; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cho EA, 1998, MECH DEVELOP, V77, P9; Crawford PA, 1997, MOL ENDOCRINOL, V11, P1626, DOI 10.1210/me.11.11.1626; Crawford PA, 1998, MOL CELL BIOL, V18, P2949, DOI 10.1128/MCB.18.5.2949; Desclozeaux M, 2002, MOL CELL BIOL, V22, P7193, DOI 10.1128/MCB.22.20.7193-7203.2002; Dressel U, 1999, MOL CELL BIOL, V19, P3383; Feng ZM, 1998, MOL ENDOCRINOL, V12, P378, DOI 10.1210/me.12.3.378; Hammer GD, 1999, FRONT NEUROENDOCRIN, V20, P199, DOI 10.1006/frne.1999.0182; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Hanley NA, 2001, MOL ENDOCRINOL, V15, P57, DOI 10.1210/me.15.1.57; Heikkila M, 2002, ENDOCRINOLOGY, V143, P4358, DOI 10.1210/en.2002-220275; HSU SY, 1995, MOL ENDOCRINOL, V9, P1356, DOI 10.1210/me.9.10.1356; Hu MC, 2001, MOL ENDOCRINOL, V15, P812, DOI 10.1210/me.15.5.812; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; Ito M, 2000, MOL ENDOCRINOL, V14, P66, DOI 10.1210/me.14.1.66; Ito M, 1998, MOL ENDOCRINOL, V12, P290, DOI 10.1210/me.12.2.290; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; Jacob AL, 2001, J BIOL CHEM, V276, P37659, DOI 10.1074/jbc.M104427200; Jordan BK, 2001, AM J HUM GENET, V68, P1102, DOI 10.1086/320125; Kawabe K, 1999, MOL ENDOCRINOL, V13, P1267, DOI 10.1210/me.13.8.1267; Kispert A, 1998, DEVELOPMENT, V125, P4225; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Lako M, 1998, GENE, V219, P101, DOI 10.1016/S0378-1119(98)00393-X; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; Li LA, 1999, MOL ENDOCRINOL, V13, P1588, DOI 10.1210/me.13.9.1588; Lin YF, 2001, DEV DYNAM, V222, P26, DOI 10.1002/dvdy.1164; Liu Z, 1999, MOL CELL ENDOCRINOL, V153, P183, DOI 10.1016/S0303-7207(99)00036-2; LUO XR, 1995, MOL ENDOCRINOL, V9, P1233, DOI 10.1210/me.9.9.1233; MATZUK MM, 1994, P NATL ACAD SCI USA, V91, P8817, DOI 10.1073/pnas.91.19.8817; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MATZUK MM, 1994, SEMIN CANCER BIOL, V5, P37; Mizusaki H, 2003, MOL ENDOCRINOL, V17, P507, DOI 10.1210/me.2002-0362; Monte D, 1998, J BIOL CHEM, V273, P4585, DOI 10.1074/jbc.273.8.4585; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOROHASHI K, 1994, MOL ENDOCRINOL, V8, P643, DOI 10.1210/me.8.5.643; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; Mukherjee A, 1998, MOL ENDOCRINOL, V12, P785, DOI 10.1210/me.12.6.785; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Ou QL, 2001, MOL ENDOCRINOL, V15, P69, DOI 10.1210/me.15.1.69; Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200; PEI L, 1991, MOL ENDOCRINOL, V5, P521, DOI 10.1210/mend-5-4-521; Richards JS, 2002, RECENT PROG HORM RES, V57, P195, DOI 10.1210/rp.57.1.195; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; Sarkar D, 2000, ENDOCR J, V47, P63, DOI 10.1507/endocrj.47.63; Sewer MB, 2002, ENDOCRINOLOGY, V143, P1769, DOI 10.1210/en.143.5.1769; SHINODA K, 1995, DEV DYNAM, V204, P22, DOI 10.1002/aja.1002040104; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Sugawara T, 2001, ENDOCRINOLOGY, V142, P3570, DOI 10.1210/en.142.8.3570; SUZUKI T, 1987, MOL CELL ENDOCRINOL, V54, P185, DOI 10.1016/0303-7207(87)90156-0; Swank MW, 1999, NEUROREPORT, V10, P3685, DOI 10.1097/00001756-199911260-00041; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; Waterman MR, 1996, ENDOCR RES, V22, P615, DOI 10.1080/07435809609043755; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200	63	79	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26572	26579		10.1074/jbc.M212677200	http://dx.doi.org/10.1074/jbc.M212677200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12732619	hybrid			2022-12-25	WOS:000184155700038
J	Kravchenko, VV; Mathison, JC; Schwamborn, K; Mercurio, F; Ulevitch, RJ				Kravchenko, VV; Mathison, JC; Schwamborn, K; Mercurio, F; Ulevitch, RJ			IKKi/IKK epsilon plays a key role in integrating signals induced by pro-inflammatory stimuli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; COMPLEMENT COMPONENT C3; TRANSCRIPTION FACTORS; C/EBP-BETA; LIVER DEGENERATION; MICE LACKING; IKK-EPSILON; GENE; NF-IL6; EXPRESSION	We report that the product of the inducible gene encoding the kinase known as IKKi/IKKepsilon (IKKi) is required for expression of a group of genes up-regulated by pro-inflammatory stimuli such as bacterial endotoxin (lipopolysaccharide (LPS)). Here, using murine embryonic fibroblasts obtained from mice bearing deletions in IKK2, p65, and IKKi genes, we provide evidence to support a link between signaling through the NF-kappaB and CCAAA/enhancer-binding protein (C/EBP) pathways. This link includes an NF-kappaB-dependent regulation of C/EBPbeta and C/EBPdelta gene transcription and IKKi-mediated activation of C/EBP. Disruption of the NF-kappaB pathway results in the blockade of the inducible up-regulation of C/EBPbeta, C/EBPdelta, and IKKi genes. Cells lacking IKKi are normal in activation of the canonical NF-kappaB pathway but fail to induce C/EBPdelta activity and transcription of C/EBP and C/EBP-NF-kappaB target genes in response to LPS. In addition we show that, in response to LPS or tumor necrosis factor alpha, both beta and delta subunits of C/EBP interact with IKKi promoter, suggesting a feedback mechanism in the regulation of IKKi-dependent cellular processes. These data are among the first to provide insights into the biological function of IKKi.	Scripps Res Inst, La Jolla, CA 92037 USA; Celgene Res Div, San Diego, CA 92121 USA	Scripps Research Institute	Ulevitch, RJ (corresponding author), Scripps Res Inst, IMM-12,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Ulevitch, Richard J/Q-3393-2017	Schwamborn, Klaus/0000-0001-9702-6036				Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Baer M, 1998, BLOOD, V92, P4353, DOI 10.1182/blood.V92.11.4353.423k21_4353_4365; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Buck M, 2001, EMBO J, V20, P6712, DOI 10.1093/emboj/20.23.6712; Caivano M, 2001, J BIOL CHEM, V276, P48693, DOI 10.1074/jbc.M108282200; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Cardinaux JR, 2000, GLIA, V29, P91, DOI 10.1002/(SICI)1098-1136(20000101)29:1<91::AID-GLIA9>3.0.CO;2-I; Casola A, 2001, J VIROL, V75, P6428, DOI 10.1128/JVI.75.14.6428-6439.2001; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gitlin L, 2002, NATURE, V418, P430, DOI 10.1038/nature00873; Hogan TH, 2002, J NEUROVIROL, V8, P21, DOI 10.1080/13550280290167911; Hu HM, 1998, J IMMUNOL, V160, P2334; Ivanov VN, 2001, MOL CELL, V7, P517, DOI 10.1016/S1097-2765(01)00199-X; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; McKnight SL, 2001, CELL, V107, P259, DOI 10.1016/S0092-8674(01)00543-8; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; OHMORI Y, 1993, J BIOL CHEM, V268, P6677; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; POPE RM, 1994, J CLIN INVEST, V94, P1449, DOI 10.1172/JCI117482; Pratt JR, 2002, NAT MED, V8, P582, DOI 10.1038/nm0602-582; Rincon M, 2001, ONCOGENE, V20, P2490, DOI 10.1038/sj.onc.1204382; RUS HG, 1992, J IMMUNOL, V148, P928; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	50	101	110	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26612	26619		10.1074/jbc.M303001200	http://dx.doi.org/10.1074/jbc.M303001200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12736252	hybrid			2022-12-25	WOS:000184155700043
J	Liu, AG; Zhuang, ZY; Hoffman, PW; Bai, G				Liu, AG; Zhuang, ZY; Hoffman, PW; Bai, G			Functional analysis of the rat N-methyl-D-aspartate receptor 2A promoter - Multiple transcription start points, positive regulation by Sp factors, and translational regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT MESSENGER-RNA; GONADOTROPIN-RELEASING-HORMONE; NMDA RECEPTOR; GENE-EXPRESSION; CORE PROMOTER; CELL-DEATH; NR2A; REGION; BRAIN; MODULATION	N-Methyl-D-aspartate (NMDA) receptor subunit 2A (NR2A) is an important modulatory component of the NMDA subtype of glutamate receptors. To investigate the transcription mechanism of the NR2A gene, we cloned the 5'-flanking sequence from a rat genomic library. RNA mapping with rat brain RNA revealed two sets of major and several minor transcription start points in a single exon of 1140 bp. Reporter gene and mutation studies indicated that core promoter activity resided in exon 1, whereas the 5'-flanking sequence up to 1.5 kb showed no significant impact on promoter activity. Fragments containing minor transcription start points were able to drive a reporter gene in transfected cells and produce nascent RNAs in an in vitro transcription system. All fragments tested showed more promoter activity in dissociated neurons of the rat embryonic cerebrocortex and cell lines expressing NR2A mRNA than that in glial cultures and non-neuronal cells. Within exon 1 there are three GC-box elements that displayed distinct binding affinity to both Sp1- and Sp4-like factors. Overexpression of Sp1 or Sp4, but not Sp3, significantly increased the activity of the promoter containing these elements. Inclusion of exon 2 and 3 sequences, which contain five short open-reading frames, attenuated promoter-driven reporter activity more than 3-fold but attenuated the level of reporter mRNA less than 1.4-fold. Our results suggest that the core promoter of the rat NR2A gene requires exon 1, that Sp factors positively regulate this core promoter, and that a post-transcriptional mechanism may negatively regulate expression of the gene.	Univ Maryland, Sch Dent, Dept Oral & Craniofacial Biol Sci, Baltimore, MD 21201 USA; Univ Maryland, Program Neurosci, Baltimore, MD 21201 USA; Coll Notre Dame Maryland, Dept Biol, Baltimore, MD 21210 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Bai, G (corresponding author), Univ Maryland, Sch Dent, Dept Oral & Craniofacial Biol Sci, 666 W Baltimore St, Baltimore, MD 21201 USA.	GNB001@dental.umaryland.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038077] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38077] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Awobuluyi M., 1994, Society for Neuroscience Abstracts, V20, P237; Bai G, 1998, NEURON, V20, P363, DOI 10.1016/S0896-6273(00)80979-4; BAI G, 1991, J CELL PHYSIOL, V149, P414, DOI 10.1002/jcp.1041490309; Bai G, 1998, J BIOL CHEM, V273, P1086, DOI 10.1074/jbc.273.2.1086; BAI G, 1995, J BIOL CHEM, V270, P7737, DOI 10.1074/jbc.270.13.7737; BAI G, 1993, BIOCHIM BIOPHYS ACTA, V1152, P197, DOI 10.1016/0005-2736(93)90249-Y; BESSHO Y, 1994, NEURON, V12, P87, DOI 10.1016/0896-6273(94)90154-6; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; Chatterton JE, 2002, NATURE, V415, P793, DOI 10.1038/nature715; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Choi YB, 2000, NAT NEUROSCI, V3, P15, DOI 10.1038/71090; Conti F, 1996, GLIA, V17, P254, DOI 10.1002/(SICI)1098-1136(199607)17:3<254::AID-GLIA7>3.0.CO;2-0; Das M, 2001, PHYSIOL GENOMICS, V6, P57, DOI 10.1152/physiolgenomics.2001.6.2.57; Desai A, 2002, J BIOL CHEM, V277, P46374, DOI 10.1074/jbc.M203032200; Dingledine R, 1999, PHARMACOL REV, V51, P7; Dracheva S, 2001, AM J PSYCHIAT, V158, P1400, DOI 10.1176/appi.ajp.158.9.1400; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; Fayyazuddin A, 2000, NEURON, V25, P683, DOI 10.1016/S0896-6273(00)81070-3; Flint AC, 1997, J NEUROSCI, V17, P2469; Gore AC, 2002, J NEUROENDOCRINOL, V14, P300, DOI 10.1046/j.1365-2826.2002.00777.x; Gore AC, 2000, ENDOCRINOLOGY, V141, P4757, DOI 10.1210/en.141.12.4757; Grossman SD, 2000, J NEUROCHEM, V75, P174, DOI 10.1046/j.1471-4159.2000.0750174.x; Guilarte TR, 1998, BRAIN RES, V790, P98, DOI 10.1016/S0006-8993(98)00054-7; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hoffmann H, 2000, J NEUROCHEM, V75, P1590, DOI 10.1046/j.1471-4159.2000.0751590.x; Hsieh CY, 2002, DEV BRAIN RES, V133, P19, DOI 10.1016/S0165-3806(01)00314-5; ISHII T, 1993, J BIOL CHEM, V268, P2836; Kakeyama M, 2001, NEUROREPORT, V12, P4009, DOI 10.1097/00001756-200112210-00031; Khashnobish A, 1999, APPL MICROBIOL BIOT, V52, P191, DOI 10.1007/s002530051508; Kim HS, 2000, NEUROCHEM RES, V25, P1149, DOI 10.1023/A:1007634432095; Klein M, 1998, GENE, V208, P259, DOI 10.1016/S0378-1119(98)00005-5; Krainc D, 1998, J BIOL CHEM, V273, P26218, DOI 10.1074/jbc.273.40.26218; Krupp JJ, 1998, NEURON, V20, P317, DOI 10.1016/S0896-6273(00)80459-6; Kutach AK, 2000, MOL CELL BIOL, V20, P4754, DOI 10.1128/MCB.20.13.4754-4764.2000; LeGreves P, 1997, NEUROSCI LETT, V226, P61, DOI 10.1016/S0304-3940(97)00244-9; LIPTON SA, 1989, TRENDS NEUROSCI, V12, P265, DOI 10.1016/0166-2236(89)90026-X; Liu A, 2001, J BIOL CHEM, V276, P45372, DOI 10.1074/jbc.M105399200; Lopez T, 1997, FEBS LETT, V405, P245, DOI 10.1016/S0014-5793(97)00195-6; Matsuda K, 2002, MOL BRAIN RES, V100, P43, DOI 10.1016/S0169-328X(02)00173-0; Miki K, 2002, J NEUROPHYSIOL, V87, P750, DOI 10.1152/jn.00534.2001; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; Naraba H, 2002, J BIOL CHEM, V277, P28601, DOI 10.1074/jbc.M203618200; Naylor LH, 1999, BIOCHEM PHARMACOL, V58, P749, DOI 10.1016/S0006-2952(99)00096-9; Oh S, 2000, NEUROCHEM RES, V25, P1603, DOI 10.1023/A:1026618603795; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; PRATT GD, 1993, NEUROSCIENCE, V57, P307, DOI 10.1016/0306-4522(93)90064-M; Prediger EA, 2000, METH MOL B, V160, P495; Quinlan EM, 1999, P NATL ACAD SCI USA, V96, P12876, DOI 10.1073/pnas.96.22.12876; RAY WJ, 1993, BIOCHEM BIOPH RES CO, V197, P1475, DOI 10.1006/bbrc.1993.2643; Richter M, 2002, GENE, V295, P135, DOI 10.1016/S0378-1119(02)00833-8; Roopra A, 2001, Mol Interv, V1, P219; Rumpel S, 2000, NEUROREPORT, V11, P4021, DOI 10.1097/00001756-200012180-00024; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Schwartz M. L., 1996, Methods (Orlando), V10, P320, DOI 10.1006/meth.1996.0109; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Smale ST, 2001, GENE DEV, V15, P2503, DOI 10.1101/gad.937701; Small DL, 1998, NEUROSCI LETT, V252, P211, DOI 10.1016/S0304-3940(98)00587-4; Snell LD, 2001, J NEUROCHEM, V78, P396, DOI 10.1046/j.1471-4159.2001.00424.x; Sze CI, 2001, J NEUROL SCI, V182, P151, DOI 10.1016/S0022-510X(00)00467-6; Tanaka M, 2001, MOL BRAIN RES, V91, P81, DOI 10.1016/S0169-328X(01)00125-5; Twyman RM, 1997, J MOL NEUROSCI, V8, P63, DOI 10.1007/BF02736864; Vallano ML, 1996, J NEUROSCI, V16, P631; Weber JRM, 1997, J NEUROSCI, V17, P7583; Wood MW, 1996, J BIOL CHEM, V271, P8115, DOI 10.1074/jbc.271.14.8115; Zhou Q, 2000, NEUROSCI LETT, V291, P109, DOI 10.1016/S0304-3940(00)01406-3	68	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26423	26434		10.1074/jbc.M211165200	http://dx.doi.org/10.1074/jbc.M211165200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12746457	hybrid			2022-12-25	WOS:000184155700019
J	Jin, XP; Turcott, E; Englehardt, S; Mize, GJ; Morris, DR				Jin, XP; Turcott, E; Englehardt, S; Mize, GJ; Morris, DR			The two upstream open reading frames of oncogene mdm2 have different translational regulatory properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE DECARBOXYLASE; WILD-TYPE P53; MESSENGER-RNA; ENHANCED TRANSLATION; INITIATION; SEQUENCE; EXPRESSION; GENE; OVEREXPRESSION; INHIBITION	Few details are known of the mechanisms through which multiple upstream open reading frames (uORFs) interact to regulate translation in higher eukaryotes. The predominant transcript of oncogene mdm2 in normal human cells (L-mdm2) contains two upstream open reading frames in its 5' leader. Elimination of these two uORFs raises the translational efficiency of the transcript by over 10-fold in HeLa cells. The 5'-most uORF (uORF1) alone suppresses downstream translational activity by over 5-fold, whereas uORF2 contributes <2-fold to the inhibition by the intact leader. The different activities of the two uORFs do not depend on the nucleotide sequence surrounding the uORFs in the 5' leader, the order of the two uORFs in the 5' leader, or the occurrence of secondary structure or rare codons within the uORFs. Specific features of the amino acid sequence encoded by uORF1 contribute to its stronger suppressive activity, suggesting that it belongs to the class of "sequence-specific" uORFs. The weaker inhibitory activity inherent in uORF2 is potentiated by a suboptimal nucleotide context surrounding its initiator AUG. The occurrence of two uORFs with differing activities in both the human gene and the mouse orthologue suggests that this pair of elements may play a fundamental role in regulating expression of the mdm2 gene.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Morris, DR (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.	dmorris@u.washington.edu	Morris, David/G-4503-2011		NCI NIH HHS [CA71453] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brown CY, 1999, ONCOGENE, V18, P5631, DOI 10.1038/sj.onc.1202949; Cao JH, 1996, MOL CELL BIOL, V16, P7109; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; Daujat S, 2001, TRENDS GENET, V17, P459, DOI 10.1016/S0168-9525(01)02369-1; DEGNIN CR, 1993, J VIROL, V67, P5514, DOI 10.1128/JVI.67.9.5514-5521.1993; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; Geballe AP, 2000, COLD SPRING HARBOR M, V39, P595; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HILL JR, 1992, J BIOL CHEM, V267, P21886; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; JANG SK, 1990, ENZYME, V44, P292, DOI 10.1159/000468766; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, GENE EXPRESSION, V1, P111; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Landers JE, 1997, CANCER RES, V57, P3562; LANDERS JE, 1994, ONCOGENE, V9, P2745; Law GL, 2001, J BIOL CHEM, V276, P38036; Mendrysa SM, 2001, GENE, V264, P139, DOI 10.1016/S0378-1119(00)00589-8; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Mize GJ, 1998, J BIOL CHEM, V273, P32500, DOI 10.1074/jbc.273.49.32500; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; Raney A, 2002, J BIOL CHEM, V277, P5988, DOI 10.1074/jbc.M108375200; Richter, 1997, ANAL MRNA FORMATION, P305, DOI 10.1016/B978-012587545-5/50017-3; Ruan HJ, 1996, J BIOL CHEM, V271, P29576, DOI 10.1074/jbc.271.47.29576; RUAN HJ, 1994, J BIOL CHEM, V269, P17905; SONENBERG N, 1990, CURR TOP MICROBIOL, V161, P23; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Wang Z, 1998, MOL CELL BIOL, V18, P7528, DOI 10.1128/MCB.18.12.7528; Wang Z, 1999, J BIOL CHEM, V274, P37565, DOI 10.1074/jbc.274.53.37565; WATERHOUSE P, 1990, J BIOL CHEM, V265, P5585	35	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25716	25721		10.1074/jbc.M300316200	http://dx.doi.org/10.1074/jbc.M300316200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730202	hybrid			2022-12-25	WOS:000183920200056
J	Uruno, T; Liu, JL; Li, YS; Smith, N; Zhan, X				Uruno, T; Liu, JL; Li, YS; Smith, N; Zhan, X			Sequential interaction of actin-related proteins 2 and 3 (Arp2/3) complex with neural Wiscott-Aldrich syndrome protein (N-WASP) and cortactin during branched actin filament network formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHIGELLA-FLEXNERI; BINDING-PROTEIN; FAMILY PROTEINS; TYROSINE PHOSPHORYLATION; LISTERIA-MONOCYTOGENES; WASP/SCAR PROTEINS; DYNAMIC ACTIN; BARBED ENDS; MYOSIN-I; ACTIVATION	The WASP and cortactin families constitute two distinct classes of Arp2/3 modulators in mammalian cells. Physical and functional interactions among the Arp2/3 complex, VCA (a functional domain of N-WASP), and cortactin were examined under conditions that were with or without actin polymerization. In the absence of actin, cortactin binds significantly weaker to the Arp2/3 complex than VCA. At concentrations of VCA 20-fold lower than cortactin, the association of cortactin with the Arp2/3 complex was nearly abolished. Analysis of the cells infected with Shigella demonstrated that N-WASP located at the tip of the bacterium, whereas cortactin accumulated in the comet tail. Interestingly, cortactin promotes Arp2/3 complex-mediated actin polymerization and actin branching in the presence of VCA at a saturating concentration, and cortactin acquired 20 nM affinity for the Arp2/3 complex during actin polymerization. The interaction of VCA with the Arp2/3 complex was reduced in the presence of both cortactin and actin. Moreover, VCA reduced its affinity for Arp2/3 complex at branching sites that were stabilized by phalloidin. These data imply a novel mechanism for the de novo assembly of a branched actin network that involves a coordinated sequential interaction of N-WASP and cortactin with the Arp2/3 complex.	Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Expt Pathol, Rockville, MD 20855 USA; George Washington Univ, Dept Anat & Cell Biol, Washington, DC 20037 USA	American Red Cross; George Washington University	Zhan, X (corresponding author), Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Expt Pathol, Rockville, MD 20855 USA.		Uruno, Takehito/AAF-7998-2019	Uruno, Takehito/0000-0002-2812-9645	NATIONAL CANCER INSTITUTE [R01CA091984] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052753] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA91984-01] Funding Source: Medline; NHLBI NIH HHS [R01HL52753-09] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amann KJ, 2001, NAT CELL BIOL, V3, P306, DOI 10.1038/35060104; Bailly M, 1999, J CELL BIOL, V145, P331, DOI 10.1083/jcb.145.2.331; Blanchoin L, 2000, CURR BIOL, V10, P1273, DOI 10.1016/S0960-9822(00)00749-1; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; Boeckers TM, 1999, J NEUROSCI, V19, P6506; Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; Boujemaa-Paterski R, 2001, BIOCHEMISTRY-US, V40, P11390, DOI 10.1021/bi010486b; DANCKER P, 1990, BIOCHIM BIOPHYS ACTA, V1035, P197, DOI 10.1016/0304-4165(90)90116-E; Dayel MJ, 2001, P NATL ACAD SCI USA, V98, P14871, DOI 10.1073/pnas.261419298; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Evangelista M, 2000, J CELL BIOL, V148, P353, DOI 10.1083/jcb.148.2.353; Frishknecht F, 2001, TRENDS CELL BIOL, V11, P30, DOI 10.1016/S0962-8924(00)01871-7; GOLDBERG MB, 1993, J BACTERIOL, V175, P2189, DOI 10.1128/JB.175.8.2189-2196.1993; Goode BL, 2001, J CELL BIOL, V153, P627, DOI 10.1083/jcb.153.3.627; Gouin E, 1999, J CELL SCI, V112, P1697; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Kaksonen M, 2000, J CELL SCI, V113, P4421; Katsube T, 1998, J BIOL CHEM, V273, P29672, DOI 10.1074/jbc.273.45.29672; Kinley AW, 2003, CURR BIOL, V13, P384, DOI 10.1016/S0960-9822(03)00107-6; KITAMURA D, 1995, BIOCHEM BIOPH RES CO, V208, P1137, DOI 10.1006/bbrc.1995.1452; Le Clainche C, 2001, J BIOL CHEM, V276, P46689, DOI 10.1074/jbc.C100476200; Lechler T, 2000, J CELL BIOL, V148, P363, DOI 10.1083/jcb.148.2.363; Lee WL, 2000, J CELL BIOL, V151, P789, DOI 10.1083/jcb.151.4.789; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 2000, J CELL BIOL, V148, P219, DOI 10.1083/jcb.148.2.219; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Mizutani K, 2002, CANCER RES, V62, P669; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Mullins RD, 1997, J CELL BIOL, V136, P331, DOI 10.1083/jcb.136.2.331; Ohoka Y, 1998, GENES CELLS, V3, P603, DOI 10.1046/j.1365-2443.1998.00216.x; Pantaloni D, 2000, NAT CELL BIOL, V2, P385, DOI 10.1038/35017011; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; Suetsugu S, 1999, BIOCHEM BIOPH RES CO, V260, P296, DOI 10.1006/bbrc.1999.0894; Suzuki T, 1998, EMBO J, V17, P2767, DOI 10.1093/emboj/17.10.2767; Takenawa T, 2001, J CELL SCI, V114, P1801; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Uruno T, 2003, BIOCHEM J, V371, P485, DOI 10.1042/BJ20021791; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Volkmann N, 2001, SCIENCE, V293, P2456, DOI 10.1126/science.1063025; Weaver AM, 2002, CURR BIOL, V12, P1270, DOI 10.1016/S0960-9822(02)01035-7; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Weed SA, 1998, J CELL SCI, V111, P2433; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; Welch MD, 1997, J CELL BIOL, V138, P375, DOI 10.1083/jcb.138.2.375; Welch MD, 2002, ANNU REV CELL DEV BI, V18, P247, DOI 10.1146/annurev.cellbio.18.040202.112133; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Yamaguchi H, 2000, P NATL ACAD SCI USA, V97, P12631, DOI 10.1073/pnas.190351397; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7; Zalevsky J, 2001, CURR BIOL, V11, P1903, DOI 10.1016/S0960-9822(01)00603-0; Zalevsky J, 2001, J BIOL CHEM, V276, P3468, DOI 10.1074/jbc.M006407200; Zettl M, 2001, NAT CELL BIOL, V3, pE74, DOI 10.1038/35060152; ZHAN X, 1993, J BIOL CHEM, V268, P24427	67	71	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26086	26093		10.1074/jbc.M301997200	http://dx.doi.org/10.1074/jbc.M301997200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12732638	hybrid			2022-12-25	WOS:000183920200106
J	Abe, I; Sano, Y; Takahashi, Y; Noguchi, H				Abe, I; Sano, Y; Takahashi, Y; Noguchi, H			Site-directed mutagenesis of benzalacetone synthase - The role of PHE215 in plant type III polyketide synthases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHALCONE SYNTHASE; ENZYMATIC FORMATION; AROMATIC POLYKETIDE; CATALYTIC CYSTEINE; STILBENE; PURIFICATION; SUBSTRATE; HISTIDINE; MECHANISM; COENZYME	Benzalacetone synthase (BAS) and chalcone synthase (CHS) are plant-specific type III polyketide synthases (PKSs) that share similar to70% amino acid sequence identity. BAS catalyzes a one-step decarboxylative condensation of 4-coumaroyl-CoA with malonyl-CoA to produce a diketide benzalacetone, whereas CHS performs sequential condensations with three malonyl-CoA to generate a tetraketide chalcone. A homology model suggested that BAS has the same overall fold as CHS with cavity volume almost as large as that of CHS. One of the most characteristic features is that Rheum palmatum BAS lacks active site Phe-215; the residues (LF)-L-214 conserved in type III PKSs are uniquely replaced by IL. Our observation that the BAS I214L/L215F mutant exhibited chalcone-forming activity in a pH-dependent manner supported a hypothesis that the absence of Phe-215 in BAS accounts for the interruption of the polyketide chain elongation at the diketide stage. On the other hand, Phe-215 mutants of Scutellaria baicalensis CHS (L214I/F215L, F215W, F215Y, F215S, F215A, F215H, and F215C) afforded increased levels of truncated products; however, none of them generated benzalacetone. These results confirmed the critical role of Phe-215 in the polyketide formation reactions and provided structural basis for understanding the structure-function relationship of the plant type III PKSs.	Univ Shizuoka, Sch Pharmaceut Sci, Shizuoka 4228526, Japan; Univ Shizuoka, 21st Century COE Program, Shizuoka 4228526, Japan	University of Shizuoka; University of Shizuoka	Abe, I (corresponding author), Univ Shizuoka, Sch Pharmaceut Sci, 52-1 Yada, Shizuoka 4228526, Japan.	abei@ys7.u-shizuoka-ken.ac.jp	Abe, Ikuro/E-4449-2010	Abe, Ikuro/0000-0002-3640-888X				Abe I, 2001, EUR J BIOCHEM, V268, P3354, DOI 10.1046/j.1432-1327.2001.02255.x; Abe I, 2003, ORG LETT, V5, P1277, DOI 10.1021/ol0300165; Abe I, 2002, ORG LETT, V4, P3623, DOI 10.1021/ol0201409; Abe I, 2000, J AM CHEM SOC, V122, P11242, DOI 10.1021/ja0027113; Akiyama T, 1999, EUR J BIOCHEM, V263, P834, DOI 10.1046/j.1432-1327.1999.00562.x; Austin MB, 2003, NAT PROD REP, V20, P79, DOI 10.1039/b100917f; BorejszaWysocki W, 1996, PLANT PHYSIOL, V110, P791, DOI 10.1104/pp.110.3.791; Eckermann S, 1998, NATURE, V396, P387, DOI 10.1038/24652; Ferrer JL, 1999, NAT STRUCT BIOL, V6, P775, DOI 10.1038/11553; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Jez JM, 2002, P NATL ACAD SCI USA, V99, P5319, DOI 10.1073/pnas.082590499; Jez JM, 2000, CHEM BIOL, V7, P919, DOI 10.1016/S1074-5521(00)00041-7; Jez JM, 2000, J BIOL CHEM, V275, P39640, DOI 10.1074/jbc.M008569200; Jez JM, 2001, BIOCHEMISTRY-US, V40, P14829, DOI 10.1021/bi015621z; Jez JM, 2000, BIOCHEMISTRY-US, V39, P890, DOI 10.1021/bi991489f; KREUZALER F, 1975, ARCH BIOCHEM BIOPHYS, V169, P84, DOI 10.1016/0003-9861(75)90319-7; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; Lukacin R, 1999, FEBS LETT, V448, P135, DOI 10.1016/S0014-5793(99)00355-5; Lukacin R, 2001, FEBS LETT, V508, P413, DOI 10.1016/S0014-5793(01)03061-7; Morita H, 2001, EUR J BIOCHEM, V268, P3759, DOI 10.1046/j.1432-1327.2001.02289.x; Morita H, 2000, BIOCHEM BIOPH RES CO, V279, P190, DOI 10.1006/bbrc.2000.3920; SCHOPPNER A, 1984, J BIOL CHEM, V259, P6806; Schroder J, 1997, TRENDS PLANT SCI, V2, P373, DOI 10.1016/S1360-1385(97)01104-7; SCHRODER J, 1999, COMPREHENSIVE NATURA, V2, P749; SILVERMAN RB, 2000, ORGANIC CHEM ENZYME, P321; STOCKIGT J, 1975, Z NATURFORSCH C, V30, P352; Suh DY, 2000, BIOCHEM J, V350, P229, DOI 10.1042/0264-6021:3500229; Suh DY, 2000, BIOCHEM BIOPH RES CO, V275, P725, DOI 10.1006/bbrc.2000.3368; TROPF S, 1995, J BIOL CHEM, V270, P7922, DOI 10.1074/jbc.270.14.7922	29	56	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25218	25226		10.1074/jbc.M303276200	http://dx.doi.org/10.1074/jbc.M303276200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12724310	hybrid			2022-12-25	WOS:000183824800116
J	Loeser, RF; Forsyth, CB; Samarel, AM; Im, HJ				Loeser, RF; Forsyth, CB; Samarel, AM; Im, HJ			Fibronectin fragment activation of proline-rich tyrosine kinase PYK2 mediates integrin signals regulating collagenase-3 expression by human chondrocytes through a protein kinase C-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; HUMAN ARTICULAR CHONDROCYTES; N-TERMINAL KINASE; CELL-ADHESION; DIFFERENTIAL REGULATION; GENE-EXPRESSION; PHOSPHOLIPASE-C; ANGIOTENSIN-II; SYNOVIAL-FLUID; SMOOTH-MUSCLE	Fibronectin fragments (FN-f), including the 110-kDa fragment that binds the alpha(5)beta(1) integrin, stimulate collagenase-3 (MMP-13) production and cartilage destruction. In the present study, treatment of chondrocytes with the 110-kDa FN-f or an activating antibody to the alpha(5)beta(1) integrin was found to increase tyrosine autophosphorylation (Tyr-402) of the proline-rich tyrosine kinase-2 (PYK2) without significant change in autophosphorylation (Tyr-397) of focal adhesion kinase (FAK). The tyrosine kinase inhibitor tyrphostin A9, shown previously to block a PYK2-dependent pathway, blocked the FN-f-stimulated increase in MMP-13, whereas tyrphostin A25 did not. FN-f-stimulated PYK2 phosphorylation and MMP-13 production was also blocked by reducing intracellular calcium levels. Adenovirally mediated overexpression of wild type but not mutant PYK2 resulted in increased MMP-13 production. The protein kinase C (PKC) activator phorbol 12-myristate 13-acetate stimulated PYK2 phosphorylation and MMP-13 production. MMP-13 expression stimulated by either phorbol 12-myristate 13-acetate or FN-f was blocked by PKC inhibitors including the PKCdelta inhibitor rottlerin. Furthermore, PKCdelta translocation from cytosol to membrane was noted within 5 min of stimulation with FN-f. Immortalized human chondrocytes, transiently transfected with MMP-13 promoter-luciferase reporter constructs, showed increased promoter activity after FN-f treatment that was inhibited by co-transfection with either of two dominant negative mutants of PYK2 (Y402F and K457A). No inhibition was seen after co-transfection with wild type PYK2, a dominant negative of FAK ( FRNK) or empty vector plasmid. FN-f-stimulated MMP-13 promoter activity was also inhibited by chemical inhibitors of ERK, JNK, and p38 mitogen-activated protein ( MAP) kinases or by co-transfection of dominant negative MAP kinase mutant constructs. These studies have identified a novel pathway for the MAP kinase regulation of MMP-13 production which involves FN-f stimulation of the alpha(5)beta(1) integrin and activation of the nonreceptor tyrosine kinase PYK2 by PKC, most likely PKCdelta.	Rush Presbyterian St Lukes Med Ctr, Dept Internal Med, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Biochem, Chicago, IL 60612 USA; Loyola Univ, Cardiovasc Inst, Maywood, IL 60153 USA	Rush University; Rush University; Loyola University Chicago	Loeser, RF (corresponding author), Rush Presbyterian St Lukes Med Ctr, Dept Internal Med, 1725 W Harrison,Ste 1017, Chicago, IL 60612 USA.		Samarel, Allen/Q-9810-2019	Samarel, Allen/0000-0001-8765-9884	NHLBI NIH HHS [HL63711, R01 HL063711] Funding Source: Medline; NIAMS NIH HHS [AR49003, P50 AR039239, R01 AR049003, R37 AR049003, R01 AR053220-04, P50-AR39239, R01 AR053220] Funding Source: Medline; BLRD VA [I01 BX002647] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR049003, P50AR039239, R01AR053220, R01AR049003] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002647] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); BLRD VA; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Veterans Affairs(US Department of Veterans Affairs)		AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Billinghurst RC, 1997, J CLIN INVEST, V99, P1534, DOI 10.1172/JCI119316; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; DEAN DD, 1989, J CLIN INVEST, V84, P678, DOI 10.1172/JCI114215; Forsyth CB, 2002, ARTHRITIS RHEUM, V46, P2368, DOI 10.1002/art.10502; Frank GD, 2002, MOL ENDOCRINOL, V16, P367, DOI 10.1210/me.16.2.367; Fuortes M, 1999, J CLIN INVEST, V104, P327, DOI 10.1172/JCI6018; Gemba T, 2002, J BIOL CHEM, V277, P907, DOI 10.1074/jbc.M109690200; Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Homandberg GA, 1998, OSTEOARTHR CARTILAGE, V6, P231, DOI 10.1053/joca.1998.0116; HOMANDBERG GA, 1992, J BIOL CHEM, V267, P3597; HOMANDBERG GA, 1999, FRONT BIOSCI, V4, P713; Jin G, 2000, J ORTHOPAED RES, V18, P899, DOI 10.1002/jor.1100180608; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Loeser RF, 2000, OSTEOARTHR CARTILAGE, V8, P96, DOI 10.1053/joca.1999.0277; Melendez J, 2002, J BIOL CHEM, V277, P45203, DOI 10.1074/jbc.M204886200; Mengshol JA, 2000, ARTHRITIS RHEUM, V43, P801, DOI 10.1002/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-4; Mengshol JA, 2001, NUCLEIC ACIDS RES, V29, P4361, DOI 10.1093/nar/29.21.4361; Muehleman C, 1997, OSTEOARTHR CARTILAGE, V5, P23, DOI 10.1016/S1063-4584(97)80029-5; Neuhold LA, 2001, J CLIN INVEST, V107, P35, DOI 10.1172/JCI10564; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Rocic P, 2001, J BIOL CHEM, V276, P21902, DOI 10.1074/jbc.M101684200; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Sein TT, 2000, ONCOGENE, V19, P5539, DOI 10.1038/sj.onc.1203932; Shlopov BV, 2000, ARTHRITIS RHEUM-US, V43, P195, DOI 10.1002/1529-0131(200001)43:1<195::AID-ANR24>3.0.CO;2-G; Shlopov BV, 1997, ARTHRITIS RHEUM-US, V40, P2065, DOI 10.1002/art.1780401120; Shum JKS, 2002, J BIOL CHEM, V277, P42830, DOI 10.1074/jbc.M205094200; Sorokin A, 2001, J BIOL CHEM, V276, P21521, DOI 10.1074/jbc.M008869200; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Thomas B, 2002, BIOCHEM J, V362, P367, DOI 10.1042/0264-6021:3620367; Tsuda T, 1997, BIOCHEMISTRY-US, V36, P16328, DOI 10.1021/bi971448o; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; Wu SS, 2002, AM J PHYSIOL-CELL PH, V282, pC1432, DOI 10.1152/ajpcell.00323.2001; Wu W, 2002, ARTHRITIS RHEUM, V46, P2087, DOI 10.1002/art.10428; XIE DL, 1992, J RHEUMATOL, V19, P1448; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zhang YY, 2002, BIOCHEM BIOPH RES CO, V290, P1123, DOI 10.1006/bbrc.2001.6321; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	45	110	110	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24577	24585		10.1074/jbc.M304530200	http://dx.doi.org/10.1074/jbc.M304530200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12730223	Green Accepted, hybrid			2022-12-25	WOS:000183824800040
J	Elkabetz, Y; Kerem, A; Tencer, L; Winitz, D; Kopito, RR; Bar-Nun, S				Elkabetz, Y; Kerem, A; Tencer, L; Winitz, D; Kopito, RR; Bar-Nun, S			Immunoglobulin light chains dictate vesicular transport-dependent and -independent routes for IgM degradation by the ubiquitin-proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER QUALITY-CONTROL; ENDOPLASMIC-RETICULUM; HEAVY-CHAIN; B-LYMPHOCYTES; BINDING-PROTEIN; SECRETORY IGM; IN-VIVO; EXPRESSION; RECEPTOR; OCCURS	Degradation of IgM mu heavy chains in light chain-negative pre-B cells is independent of vesicular transport, as is evident by its insensitivity to brefeldin A or cell permeabilization. Conversely, by the same criteria, degradation of the secretory mus heavy chain in light chain-expressing B cells depends on vesicular transport. To investigate whether the presence of conventional light chains or the developmental stage of the B-lymphocytes dictates the degradative route taken by mu, we express in 70Z/3 pre-B cells either lambda ectopically or kappa by lipopolysaccharides-stimulated differentiation into B cells and show their assembly with mu heavy chains. The resulting sensitivity of mu degradation to brefeldin A and cell permeabilization demonstrates that conventional light chains, a hallmark of B cell differentiation, are necessary and sufficient to divert mu from a vesicular transport-independent to a vesicular transport-dependent degradative route. Although both routes converge at the ubiquitin-proteasome degradation pathway, only in light chain-expressing cells is vesicular transport a prerequisite for mu ubiquitination.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Tel Aviv University; Stanford University	Bar-Nun, S (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel.	sbnun@post.tau.ac.il						ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; AMITAY R, 1991, J BIOL CHEM, V266, P12568; AMITAY R, 1992, J BIOL CHEM, V267, P20694; Ausubel FM, 2001, CURRENT PROTOCOLS MO, V3; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Bornemann KD, 1997, J IMMUNOL, V158, P2551; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Brouns GS, 1996, J BIOL CHEM, V271, P19272, DOI 10.1074/jbc.271.32.19272; Caldwell SR, 2001, J BIOL CHEM, V276, P23296, DOI 10.1074/jbc.M102962200; Chillaron J, 2000, MOL BIOL CELL, V11, P217, DOI 10.1091/mbc.11.1.217; ELROYSTEIN O, 1990, P NATL ACAD SCI USA, V87, P6743, DOI 10.1073/pnas.87.17.6743; Fu LW, 2003, J CELL BIOL, V160, P157, DOI 10.1083/jcb.200210086; Greenfield JJA, 1999, J CELL SCI, V112, P1477; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hampton RY, 2002, ANNU REV CELL DEV BI, V18, P345, DOI 10.1146/annurev.cellbio.18.032002.131219; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Haynes CM, 2002, J CELL BIOL, V158, P91, DOI 10.1083/jcb.200201053; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; Ho SC, 2000, J IMMUNOL, V164, P4713, DOI 10.4049/jimmunol.164.9.4713; KALOFF CR, 1995, IMMUNITY, V2, P629, DOI 10.1016/1074-7613(95)90007-1; Karasuyama H, 1996, ADV IMMUNOL, V63, P1, DOI 10.1016/S0065-2776(08)60853-6; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Lassoued K, 1996, J EXP MED, V183, P421, DOI 10.1084/jem.183.2.421; LASSOUED K, 1993, CELL, V73, P73, DOI 10.1016/0092-8674(93)90161-I; Mancini R, 2000, FASEB J, V14, P769, DOI 10.1096/fasebj.14.5.769; MELCHERS F, 1994, ANNU REV IMMUNOL, V12, P209, DOI 10.1146/annurev.immunol.12.1.209; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NISHIMOTO N, 1991, P NATL ACAD SCI USA, V88, P6284, DOI 10.1073/pnas.88.14.6284; O'Hare T, 1999, J IMMUNOL, V163, P11; PAIGE CJ, 1978, J IMMUNOL, V121, P641; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; RABINOVICH E, 1993, J BIOL CHEM, V268, P24145; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Ravid T, 2000, J BIOL CHEM, V275, P35840, DOI 10.1074/jbc.M004793200; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SHACHAR I, 1992, J BIOL CHEM, V267, P24241; Vanhove M, 2001, IMMUNITY, V15, P105, DOI 10.1016/S1074-7613(01)00163-7; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wilhovsky S, 2000, MOL BIOL CELL, V11, P1697, DOI 10.1091/mbc.11.5.1697; Winitz D, 1996, J BIOL CHEM, V271, P27645, DOI 10.1074/jbc.271.44.27645; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043; Zhou MY, 1999, MOL CELL, V4, P925, DOI 10.1016/S1097-2765(00)80222-1; Zuber C, 2001, P NATL ACAD SCI USA, V98, P10710, DOI 10.1073/pnas.191359198; Zuber C, 2000, MOL BIOL CELL, V11, P4227, DOI 10.1091/mbc.11.12.4227	51	23	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18922	18929		10.1074/jbc.M208730200	http://dx.doi.org/10.1074/jbc.M208730200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12754269	hybrid			2022-12-25	WOS:000182932200028
J	Kovalchuk, AL; Kim, JS; Janz, S				Kovalchuk, AL; Kim, JS; Janz, S			E mu/S mu transposition into Myc is sometimes a precursor for T(12;15) translocation in mouse B cells	ONCOGENE			English	Article						genetic transposition; immunoglobulin heavy-chain locus; intronic heavy-chain enhancer; immunoglobulin switch region; chromosomal translocation	CLASS-SWITCH RECOMBINATION; HEAVY-CHAIN GENE; VISIBLE CHROMOSOMAL TRANSLOCATIONS; C-MYC; MURINE PLASMACYTOMA; MULTIPLE-MYELOMA; ABERRANT REARRANGEMENT; IMMUNOGLOBULIN; REGION; ENHANCER	Misguided immunoglobulin (Ig) class switch recombination (CSR) has been implicated in the origin of Myc-activating chromosomal translocations, T(12;15), in BALB/c mouse plasmacytomas (PCTs). CSR has also been involved in the progression of T(12;15); for example, the approximation of Myc to the 3'-Calpha enhancer. This study provides evidence for an additional mechanism by which aberrant CSR may facilitate T(12;15): transposition of Ig heavy-chain (IgH) sequences to Myc. Five IgH transposons containing the intronic heavy-chain enhancer, Emu, and a truncated switch mu region, Smu, were found in the first intron of Myc in lymph node cells of IL-6 transgenic BALB/c mice. In two cases Emu/Smu transposition primed Myc to get involved in apparent trans-chromosomal CSR to Cgamma1, presumably leading to T(12;15). Translocations preceded by Emu/Smu transposition can sometimes be distinguished from de novo translocations by molecular fingerprints in translocation breakpoint regions (Ig switch region [S] inversions and unusual gene orders in composite S regions). The presence of such fingerprints in some PCTs suggests that the tumors sometimes evolve from transposition-bearing precursors. We propose that Emu/Smu transposition to Myc may facilitate plasmacytomagenesis by sensitizing Myc to undergo T(12;15) translocation. T(12;15), in turn, juxtaposes Myc to the 3'-Calpha enhancer, which appears to be required for deregulating Myc in a manner that is conducive to PCT development.	NCI, Genet Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Janz, S (corresponding author), NCI, Genet Lab, Ctr Canc Res, NIH, Bldg 37,Room 2B10, Bethesda, MD 20892 USA.			Kovalchuk, Alexander/0000-0003-2761-0442	DIVISION OF BASIC SCIENCES - NCI [Z01BC010024] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUILERA RJ, 1985, EMBO J, V4, P3689, DOI 10.1002/j.1460-2075.1985.tb04136.x; AXELSON H, 1991, ONCOGENE, V6, P2263; Bakkus MHC, 2001, LEUKEMIA, V15, P1127, DOI 10.1038/sj.leu.2402164; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Chaganti SR, 1998, GENE CHROMOSOME CANC, V23, P328, DOI 10.1002/(SICI)1098-2264(199812)23:4<328::AID-GCC8>3.0.CO;2-M; Chen C, 1995, IMMUNITY, V3, P747, DOI 10.1016/1074-7613(95)90064-0; CORCORAN LM, 1985, CELL, V40, P71, DOI 10.1016/0092-8674(85)90310-1; Crossen PE, 1998, LEUKEMIA LYMPHOMA, V31, P559, DOI 10.3109/10428199809057615; DUNNICK W, 1993, NUCLEIC ACIDS RES, V21, P365, DOI 10.1093/nar/21.3.365; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; FAHRLANDER PD, 1985, P NATL ACAD SCI USA, V82, P3746, DOI 10.1073/pnas.82.11.3746; Gabrea A, 1999, MOL CELL, V3, P119, DOI 10.1016/S1097-2765(00)80180-X; Geltinger C, 1996, GENE EXPRESSION, V6, P113; GERSTEIN RM, 1990, CELL, V63, P537, DOI 10.1016/0092-8674(90)90450-S; GREENBERG R, 1982, NUCLEIC ACIDS RES, V10, P7751, DOI 10.1093/nar/10.23.7751; HORTNAGEL K, 1995, ONCOGENE, V10, P1393; JANZ S, 1993, P NATL ACAD SCI USA, V90, P7361, DOI 10.1073/pnas.90.15.7361; Janz S, 1995, Curr Top Microbiol Immunol, V194, P373; Kovalchuk AL, 2000, LEUKEMIA, V14, P1127, DOI 10.1038/sj.leu.2401767; Kovalchuk AL, 1997, ONCOGENE, V15, P2369, DOI 10.1038/sj.onc.1201409; Kovalchuk AL, 2000, LEUKEMIA, V14, P909, DOI 10.1038/sj.leu.2401676; Kovalchuk AL, 2002, P NATL ACAD SCI USA, V99, P1509, DOI 10.1073/pnas.022643999; Kovalchuk AL, 2001, GENE CHROMOSOME CANC, V30, P283, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1094>3.0.CO;2-I; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; LAFFAN M, 1992, J CLIN INVEST, V90, P2299, DOI 10.1172/JCI116117; Lee CG, 1998, CURR BIOL, V8, P227, DOI 10.1016/S0960-9822(98)70087-9; Luby TM, 2001, J EXP MED, V193, P159, DOI 10.1084/jem.193.2.159; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; Muller JR, 1996, CANCER RES, V56, P419; Muller JR, 1997, BLOOD, V89, P291, DOI 10.1182/blood.V89.1.291.291_291_296; MULLER JR, 1995, CANCER RES, V55, P5012; MULLER JR, 1994, P NATL ACAD SCI USA, V91, P12066, DOI 10.1073/pnas.91.25.12066; MURAMATSU M, 2000, CELL, DOI UNSP 102553; Nardini E, 2000, BLOOD, V95, P1032, DOI 10.1182/blood.V95.3.1032.003k38_1032_1038; OHNO S, 1989, ONCOGENE, V4, P1513; OHNO S, 1991, INT J CANCER, V49, P102, DOI 10.1002/ijc.2910490119; Papavasiliou FN, 2000, NATURE, V408, P216, DOI 10.1038/35041599; Papavasiliou FN, 2002, CELL, V109, pS35, DOI 10.1016/S0092-8674(02)00706-7; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; PEAR WS, 1986, IMMUNOGENETICS, P23393; POTTER M, 1992, CARCINOGENESIS, V13, P1681, DOI 10.1093/carcin/13.10.1681; Pratt G, 2001, BRIT J HAEMATOL, V112, P388, DOI 10.1046/j.1365-2141.2001.02588.x; Proffitt J, 1999, LEUKEMIA, V13, P1100, DOI 10.1038/sj.leu.2401465; RAYNAL MC, 1989, P NATL ACAD SCI USA, V86, P8024, DOI 10.1073/pnas.86.20.8024; Roschke V, 1997, ONCOGENE, V14, P3011, DOI 10.1038/sj.onc.1201156; SHAPIRO MA, 1987, MOL CELL BIOL, V7, P4130, DOI 10.1128/MCB.7.11.4130; SHAUGHNESSY JD, 1993, ONCOGENE, V8, P3111; SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232; Vaandrager JW, 2000, BLOOD, V96, P1947, DOI 10.1182/blood.V96.5.1947.h8001947_1947_1952; VANNESS BG, 1983, NATURE, V301, P425, DOI 10.1038/301425a0; Willis TG, 2000, BLOOD, V96, P808, DOI 10.1182/blood.V96.3.808.015k30_808_822; ZHANG K, 1995, J IMMUNOL, V154, P2237	53	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2842	2850		10.1038/sj.onc.1206345	http://dx.doi.org/10.1038/sj.onc.1206345			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743607				2022-12-25	WOS:000182569300015
J	Zhang, XP; Graham, SH; Kochanek, PM; Marion, DW; Nathaniel, PD; Watkins, SC; Clark, RSB				Zhang, XP; Graham, SH; Kochanek, PM; Marion, DW; Nathaniel, PD; Watkins, SC; Clark, RSB			Caspase-8 expression and proteolysis in human brain after severe head injury	FASEB JOURNAL			English	Article						apoptosis; cysteine protease; Fas; programmed cell death; traumatic brain injury	TUMOR-NECROSIS-FACTOR; CEREBROSPINAL-FLUID; NEURONAL APOPTOSIS; FAS LIGAND; CELL-DEATH; SIGNALING COMPLEX; ACTIVATION; MICE; CONTUSIONS; INDUCTION	Programmed cell death involves a complex and interrelated cascade of cysteine proteases termed caspases that are synthesized as inactive zymogens, which are proteolytically processed to active enzymes. Caspase-8 is an initiator caspase that becomes activated when Fas death receptor-Fas ligand (FasL) coupling on the cell surface leads to coalescence of a "death complex" perpetuating the programmed cell death cascade. In this study, brain tissue samples removed from adult patients during the surgical management of severe intracranial hypertension after traumatic brain injury (TBI; n=17) were compared with postmortem control brain tissue samples (n=6). Caspase-8 mRNA was measured by semiquantitative reverse transcription and polymerase chain reaction, and caspase-8 protein was examined by Western blot and immunocytochemistry. Fas and FasL were also examined using Western blot. Caspase-8 mRNA and protein were increased in TBI patients vs. controls, and caspase-8 protein was predominately expressed in neurons. Proteolysis of caspase-8 to 20-kDa fragments was seen only in TBI patients. Fas was also increased after TBI vs. control and was associated with relative levels of caspase-8, supporting formation of a death complex. These data identify additional steps in the programmed cell death cascade involving Fas death receptors and caspase-8 after TBI in humans.	Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Safar Ctr Resuscitat Res, Dept Neurol, Pittsburgh, PA USA; Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA USA; Safar Ctr Resuscitat Res, Dept Neurol Surg, Pittsburgh, PA USA; Safar Ctr Resuscitat Res, Dept Cell Biol & Physiol, Pittsburgh, PA USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA USA; VA Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System	Clark, RSB (corresponding author), Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	clarkrs@ccm.upmc.edu	Marion, Donald/AAR-5749-2021; Watkins, Simon/ABG-2590-2021; Kochanek, Patrick M/D-2371-2015	Watkins, Simon/0000-0003-4092-1552; Kochanek, Patrick M/0000-0002-2627-913X				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Buki A, 2000, J NEUROSCI, V20, P2825; Cheema ZF, 1999, J NEUROSCI, V19, P1754; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; Henshall DC, 2001, NEUROBIOL DIS, V8, P568, DOI 10.1006/nbdi.2001.0415; HOLMIN S, 2000, J NEUROSURG, V92; Jin KL, 2001, J CEREBR BLOOD F MET, V21, P1411, DOI 10.1097/00004647-200112000-00005; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Lenzlinger PM, 2002, J NEUROIMMUNOL, V122, P167, DOI 10.1016/S0165-5728(01)00466-0; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Qiu JH, 2002, J NEUROSCI, V22, P3504; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; SEIDBERG N, 2002, IN PRESS J NEUROCHEM; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x	33	45	51	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1367	+		10.1096/fj.02-1067fje	http://dx.doi.org/10.1096/fj.02-1067fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738800				2022-12-25	WOS:000183165000027
J	Alon, T; Friedman, JM; Socci, ND				Alon, T; Friedman, JM; Socci, ND			Cytokine-induced patterns of gene expression in skeletal muscle tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FATTY-ACID OXIDATION; FACTOR-ALPHA; INSULIN-RESISTANCE; ADIPOSE-TISSUE; BODY-WEIGHT; TNF-ALPHA; PROTEIN LOSS; FOOD-INTAKE; OBESE GENE	Tumor necrosis factor alpha (TNF-alpha) and other cytokines induce a state of negative energy balance leading to the breakdown of skeletal muscle. Leptin, another member of the cytokine superfamily, also induces a state of negative energy balance but does not alter lean body mass. The transcription profile of skeletal muscle was compared in animals treated with TNF-alpha or leptin or in animals pair-fed over a 7-day time course using 11,000-gene microarrays (Affymetrix, Santa Clara, CA). Ten clusters of skeletal muscle genes were identified, each of which showed significantly different expression between TNF-alpha treatment and pair feeding. Studies comparing leptin treatment and pair feeding revealed that both activate nearly identical programs of gene expression in skeletal muscle. These data indicate that the effects of leptin on skeletal muscle are markedly different from those of TNF-alpha and that the effects of leptin on skeletal muscle can be largely ascribed to its anorectic effects. Subtle differences between leptin and pair feeding were evident only after 7 days of treatment. In general, pair feeding altered gene expression after the 7-day treatment, whereas leptin did not. The effects of TNF-alpha on skeletal muscle are distinct from those of pair feeding, a result consistent with its known catabolic effects on this tissue. Analyses of the data from food-restricted animals also identified a set of transcriptional changes associated with this state. Further studies of many newly identified leptin-, TNF-alpha-, and starvation-regulated genes and the apparent coordinate regulation of these clusters may reveal important insights into the different effects of cytokines on skeletal muscle.	Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, Dept Mol Genet, New York, NY 10021 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	Howard Hughes Medical Institute; Rockefeller University; Rockefeller University; Yeshiva University; Albert Einstein College of Medicine	Friedman, JM (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA.				NIDDK NIH HHS [R01DK41096] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041096] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attaix D, 1997, MOL BIOL REP, V24, P95, DOI 10.1023/A:1006806103675; Ausubel F., 1999, CURRENT PROTOCOLS MO; Bedard S, 1997, BIOCHEM J, V325, P487, DOI 10.1042/bj3250487; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Ceddia RB, 2001, FRONT BIOSCI-LANDMRK, V6, pD90, DOI 10.2741/ceddia; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Dandona P, 1998, J CLIN ENDOCR METAB, V83, P2907, DOI 10.1210/jc.83.8.2907; Dawson-Saunders B., 1994, BASIC CLIN BIOSTATIS; Duda R. O., 1973, PATTERN CLASSIFICATI; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; GARCIAMARTINEZ C, 1993, FEBS LETT, V323, P211, DOI 10.1016/0014-5793(93)81341-V; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; HARTIGAN JA, 1975, CLUSTERING ALGORITHM, V351; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; JAIN AK, 1978, ALGORITHMS CLUSTERIN; Jucker BM, 1999, AM J PHYSIOL-ENDOC M, V277, pE505, DOI 10.1152/ajpendo.1999.277.3.E505; Kelley DE, 1999, AM J PHYSIOL-ENDOC M, V277, pE1130; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; Kohonen T., 1997, SELF ORGANIZING MAPS; Li YP, 1998, FASEB J, V12, P871, DOI 10.1096/fasebj.12.10.871; Li YP, 2001, CURR OPIN RHEUMATOL, V13, P483, DOI 10.1097/00002281-200111000-00005; Llovera M, 1997, BIOCHEM BIOPH RES CO, V230, P238, DOI 10.1006/bbrc.1996.5827; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Masaki T, 1999, BBA-MOL CELL BIOL L, V1436, P585, DOI 10.1016/S0005-2760(98)00173-8; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Muoio DM, 1997, DIABETES, V46, P1360, DOI 10.2337/diabetes.46.8.1360; Pan DA, 1997, DIABETES, V46, P983, DOI 10.2337/diabetes.46.6.983; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Peraldi P, 1998, MOL CELL BIOCHEM, V182, P169, DOI 10.1023/A:1006865715292; PLATASALAMAN CR, 1988, BRAIN RES, V448, P106, DOI 10.1016/0006-8993(88)91106-7; Rasmussen BB, 1999, ANNU REV NUTR, V19, P463, DOI 10.1146/annurev.nutr.19.1.463; Reid MB, 2001, RESP RES, V2, P269, DOI 10.1186/rr67; Saghizadeh M, 1996, J CLIN INVEST, V97, P1111, DOI 10.1172/JCI118504; Sambrook J., 2002, MOL CLONING LAB MANU; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; SOCHER SH, 1988, J EXP MED, V167, P1957, DOI 10.1084/jem.167.6.1957; Soukas A, 2000, GENE DEV, V14, P963; Tisdale MJ, 2000, SCIENCE, V289, P2293, DOI 10.1126/science.289.5488.2293; TRACEY KJ, 1988, J EXP MED, V167, P1211, DOI 10.1084/jem.167.3.1211; Zahorska-Markiewicz B, 2000, INT J OBESITY, V24, P1392, DOI 10.1038/sj.ijo.0801398	42	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32324	32334		10.1074/jbc.M300972200	http://dx.doi.org/10.1074/jbc.M300972200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12750389	hybrid			2022-12-25	WOS:000184782100110
J	Damblon, C; Jensen, M; Ababou, A; Barsukov, I; Papamicael, C; Schofield, CJ; Olsen, L; Bauer, R; Roberts, GCK				Damblon, C; Jensen, M; Ababou, A; Barsukov, I; Papamicael, C; Schofield, CJ; Olsen, L; Bauer, R; Roberts, GCK			The inhibitor thiomandelic acid binds to both metal ions in metallo-beta-lactamase and induces positive cooperativity in metal binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERTURBED-ANGULAR-CORRELATION; BACILLUS-CEREUS; CRYSTAL-STRUCTURE; COORDINATION GEOMETRY; BACTEROIDES-FRAGILIS; PSEUDOMONAS-AERUGINOSA; CADMIUM; SITE; PROTEINS; PURIFICATION	Thiomandelic acid is a simple, broad spectrum, and reasonably potent inhibitor of metallo-beta-lactamases, enzymes that mediate resistance to beta-lactam antibiotics. We report studies by NMR and perturbed angular correlation (PAC) spectroscopy of the mode of binding of the R and S enantiomers of thiomandelic acid, focusing on their interaction with the two metal ions in cadmium-substituted Bacillus cereus metallo-beta-lactamase. The Cd-113 resonances are specifically assigned to the metals in the two individual sites on the protein by using Cd-113- edited H-1 NMR spectra. Each enantiomer of thiomandelate produces large downfield shifts of both Cd-113 resonances and changes in the PAC spectra, which indicate that they bind such that the thiol of the inhibitor bridges between the two metals. For R-thiomandelate, this is unambiguously confirmed by the observation of scalar coupling between Halpha of the inhibitor and both cadmium ions. The NMR and PAC spectra reveal that the two chiral forms of the inhibitor differ in the details of their coordination geometry. The complex with R-thiomandelate, but not that with the S-enantiomer, shows evidence in the PAC spectra of a dynamic process in the nanosecond time regime, the possible nature of which is discussed. The thiomandelate complex of the mononuclear enzyme can be detected only at low metal to enzyme stoichiometry; the relative populations of mononuclear and binuclear enzyme as a function of cadmium concentration provide clear evidence for positive cooperativity in metal ion binding in the presence of the inhibitor, in contrast to the negative cooperativity observed in the free enzyme.	Univ Leicester, Biol NMR Ctr, Dept Biochem, Leicester LE1 9HN, Leics, England; Royal Vet & Agr Univ, Dept Math & Phys, DK-1871 Frederiksberg C, Denmark; Dyson Perrins Lab, Oxford OX1 3QY, England; Oxford Ctr Mol Sci, Oxford OX1 3QY, England	University of Leicester; University of Copenhagen; University of Oxford; University of Oxford	Roberts, GCK (corresponding author), Univ Leicester, Biol NMR Ctr, Dept Biochem, POB 138,Univ Rd, Leicester LE1 9HN, Leics, England.	gcr@le.ac.uk	Olsen, Lars/AAY-8278-2020; Olsen, Lars/C-9706-2010; Jensen, Mikael/I-8358-2012	Jensen, Mikael/0000-0002-9109-2187; Olsen, Lars/0000-0002-7607-7130; Schofield, Christopher/0000-0002-0290-6565; Roberts, Gordon/0000-0001-6200-1373				Baleja JD, 1997, J BIOMOL NMR, V10, P397, DOI 10.1023/A:1018332327565; Bauer R, 1997, J AM CHEM SOC, V119, P157, DOI 10.1021/ja962499w; BAUER R, 1988, HYPERFINE INTERACT, V39, P203, DOI 10.1007/BF02394319; Bauer R, 1997, BIOCHEMISTRY-US, V36, P11514, DOI 10.1021/bi970936t; BAUER R, 1985, Q REV BIOPHYS, V18, P1, DOI 10.1017/S0033583500004972; Bounaga S, 1998, BIOCHEM J, V331, P703, DOI 10.1042/bj3310703; Carfi A, 1998, ACTA CRYSTALLOGR D, V54, P47, DOI 10.1107/S090744499700927X; Carfi A, 1998, ACTA CRYSTALLOGR D, V54, P313, DOI 10.1107/S0907444997010627; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Concha NO, 1997, PROTEIN SCI, V6, P2671; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Concha NO, 2000, BIOCHEMISTRY-US, V39, P4288, DOI 10.1021/bi992569m; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Crowder MW, 1998, ANTIMICROB AGENTS CH, V42, P921, DOI 10.1128/AAC.42.4.921; Damblon C, 1999, J AM CHEM SOC, V121, P11575, DOI 10.1021/ja992896h; de Seny D, 2001, J BIOL CHEM, V276, P45065, DOI 10.1074/jbc.M106447200; Dixon SL, 1997, J CHEM PHYS, V107, P879, DOI 10.1063/1.474386; Fabiane SM, 1998, BIOCHEMISTRY-US, V37, P12404, DOI 10.1021/bi980506i; Fitzgerald PMD, 1998, BIOCHEMISTRY-US, V37, P6791, DOI 10.1021/bi9730339; FRERE JM, 1995, MOL MICROBIOL, V16, P385, DOI 10.1111/j.1365-2958.1995.tb02404.x; Galleni M, 2001, ANTIMICROB AGENTS CH, V45, P660, DOI 10.1128/AAC.45.3.660-663.2001; Gogonea V, 1999, J PHYS CHEM A, V103, P5171, DOI 10.1021/jp990266w; Hanessian S, 2001, J COMPUT AID MOL DES, V15, P873, DOI 10.1023/A:1014356529909; Hemmingsen L, 1996, EUR J BIOCHEM, V241, P546, DOI 10.1111/j.1432-1033.1996.00546.x; Hemmingsen L, 2001, J AM CHEM SOC, V123, P10329, DOI 10.1021/ja0112240; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; KUWABARA S, 1967, BIOCHEM J, V103, pC27, DOI 10.1042/bj1030027C; Laraki N, 1999, ANTIMICROB AGENTS CH, V43, P902, DOI 10.1128/AAC.43.4.902; MCCOY MA, 1993, J MAGN RESON SER A, V101, P122, DOI 10.1006/jmra.1993.1021; Mollard C, 2001, J BIOL CHEM, V276, P45015, DOI 10.1074/jbc.M107054200; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Orellano EG, 1998, BIOCHEMISTRY-US, V37, P10173, DOI 10.1021/bi980309j; Paul-Soto R, 1999, BIOCHEMISTRY-US, V38, P16500, DOI 10.1021/bi9911381; Paul-Soto R, 1999, J BIOL CHEM, V274, P13242, DOI 10.1074/jbc.274.19.13242; PAYNE DJ, 1993, J MED MICROBIOL, V39, P93, DOI 10.1099/00222615-39-2-93; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Toney JH, 1998, CHEM BIOL, V5, P185, DOI 10.1016/S1074-5521(98)90632-9; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Wang ZG, 1998, J BIOL CHEM, V273, P22402, DOI 10.1074/jbc.273.35.22402; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Wommer S, 2002, J BIOL CHEM, V277, P24142, DOI 10.1074/jbc.M202467200	41	41	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29240	29251		10.1074/jbc.M301562200	http://dx.doi.org/10.1074/jbc.M301562200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12724330	Green Published, hybrid			2022-12-25	WOS:000184421100109
J	Ito, T; Niwa, J; Hishikawa, N; Ishigaki, S; Doyu, M; Sobue, G				Ito, T; Niwa, J; Hishikawa, N; Ishigaki, S; Doyu, M; Sobue, G			Dorfin localizes to Lewy bodies and ubiquitylates synphilin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; HUMAN ALPHA-SYNUCLEIN; SPORADIC PARKINSONS-DISEASE; NEURODEGENERATIVE DISORDERS; PROTEASOMAL FUNCTION; DROSOPHILA MODEL; BODY FORMATION; WILD-TYPE; BRAIN; MICE	Parkinson's disease (PD) is a neurodegenerative disease characterized by loss of nigra dopaminergic neurons. Lewy bodies (LBs) are a characteristic neuronal inclusion in PD brains. In this study, we report that Dorfin, a RING finger-type ubiquityl ligase for mutant superoxide dismutase-1, was localized with ubiquitin in LBs. Recently, synphilin-1 was identified to associate with alpha-synuclein and to be a major component of LBs. We found that overexpression of synphilin-1 in cultured cells led to the formation of large juxtanuclear inclusions, but showed no cytotoxicity. Dorfin colocalized in these large inclusions with ubiquitin and proteasomal components. In contrast to full-length synphilin-1, overexpression of the central portion of synphilin-1, including ankyrin-like repeats, a coiled-coil domain, and an ATP/GTP-binding domain, predominantly led to the formation of small punctate aggregates scattered throughout the cytoplasm and showed cytotoxic effects. Dorfin and ubiquitin did not localize in these small aggregates. Overexpression of the N or C terminus of synphilin-1 did not lead to the formation of any aggregates. Dorfin physically bound and ubiquitylated synphilin-1 through its central portion, but did not ubiquitylate wild-type or mutant alpha-synuclein. These results suggest that the central domain of synphilin-1 has an important role in the formation of aggregates and cytotoxicity and that Dorfin may be involved in the pathogenic process of PD and LB formation by ubiquitylation of synphilin-1.	Nagoya Univ, Dept Neurol, Grad Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University	Sobue, G (corresponding author), Nagoya Univ, Dept Neurol, Grad Sch Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	sobueg@med.nagoya-u.ac.jp	ISHIGAKI, Shinsuke/I-7305-2014	Ishigaki, Shinsuke/0000-0002-9555-0659				Ardley HC, 2001, J BIOL CHEM, V276, P19640, DOI 10.1074/jbc.M011028200; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Baba M, 1998, AM J PATHOL, V152, P879; Braak H, 1999, NEUROSCI LETT, V265, P67, DOI 10.1016/S0304-3940(99)00208-6; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Furukawa Y, 2002, ANN NEUROL, V51, P779, DOI 10.1002/ana.10207; Gearhart DA, 2002, NEUROSCI RES, V44, P255, DOI 10.1016/S0168-0102(02)00133-5; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Hishikawa N, 2001, NEUROPATH APPL NEURO, V27, P362, DOI 10.1046/j.1365-2990.2001.00345.x; Ii K, 1997, J NEUROPATH EXP NEUR, V56, P125, DOI 10.1097/00005072-199702000-00002; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Iwatsubo T, 1996, AM J PATHOL, V148, P1517; Kahle PJ, 2001, AM J PATHOL, V159, P2215, DOI 10.1016/S0002-9440(10)63072-6; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; Kawamata H, 2001, J NEUROCHEM, V77, P929, DOI 10.1046/j.1471-4159.2001.00301.x; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d; Lee G, 2002, J NEUROCHEM, V83, P346, DOI 10.1046/j.1471-4159.2002.01136.x; Lee HJ, 2002, J BIOL CHEM, V277, P48976, DOI 10.1074/jbc.M208192200; Lee M, 2001, J NEUROCHEM, V76, P998, DOI 10.1046/j.1471-4159.2001.00149.x; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; Marin I, 2002, MOL BIOL EVOL, V19, P2039, DOI 10.1093/oxfordjournals.molbev.a004029; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McKeith IG, 2000, ANN NY ACAD SCI, V920, P1; McNaught KSP, 2001, NEUROSCI LETT, V297, P191, DOI 10.1016/S0304-3940(00)01701-8; McNaught KSP, 2001, NAT REV NEUROSCI, V2, P589, DOI 10.1038/35086067; Mezey E, 1998, NAT MED, V4, P755, DOI 10.1038/nm0798-755; Morett E, 1999, TRENDS BIOCHEM SCI, V24, P229, DOI 10.1016/S0968-0004(99)01381-X; Moynihan TP, 1999, J BIOL CHEM, V274, P30963, DOI 10.1074/jbc.274.43.30963; Neystat M, 2002, NEUROSCI LETT, V325, P119, DOI 10.1016/S0304-3940(02)00253-7; Niwa J, 2002, J BIOL CHEM, V277, P36793, DOI 10.1074/jbc.M206559200; Niwa J, 2001, BIOCHEM BIOPH RES CO, V281, P706, DOI 10.1006/bbrc.2001.4414; O'Farrell C, 2001, MOL BRAIN RES, V97, P94, DOI 10.1016/S0169-328X(01)00292-3; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ribeiro CS, 2002, J BIOL CHEM, V277, P23927, DOI 10.1074/jbc.M201115200; Schlossmacher MG, 2002, AM J PATHOL, V160, P1655, DOI 10.1016/S0002-9440(10)61113-3; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Takahashi H, 2001, NEUROPATHOLOGY, V21, P315, DOI 10.1046/j.1440-1789.2001.00403.x; Valente EM, 2002, ANN NEUROL, V51, P14, DOI 10.1002/ana.10053; Valente EM, 2001, AM J HUM GENET, V68, P895, DOI 10.1086/319522; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; Wakabayashi K, 2000, ANN NEUROL, V47, P521, DOI 10.1002/1531-8249(200004)47:4<521::AID-ANA18>3.3.CO;2-2; Wakabayashi K, 2002, ACTA NEUROPATHOL, V103, P209, DOI 10.1007/s004010100451; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	61	63	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29106	29114		10.1074/jbc.M302763200	http://dx.doi.org/10.1074/jbc.M302763200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12750386	hybrid			2022-12-25	WOS:000184421100094
J	Kim, YS; Lee, JY; Son, MY; Park, W; Bae, YS				Kim, YS; Lee, JY; Son, MY; Park, W; Bae, YS			Phosphorylation of threonine 10 on CKBBP1/SAG/ROC2/Rbx2 by protein kinase CKII promotes the degradation of I kappa B alpha and p27(Kip1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; UBIQUITIN LIGASE; CASEIN KINASE-2; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; CK2; PROTEOLYSIS; EXPRESSION; COMPLEX; TUMORS	In eukaryotic cells, protein kinase CKII is required for progression through the cell division cycle. We recently reported that CKBBP1/SAG/ROC2/Rbx2 associates with the beta-subunit of CKII and is phosphorylated by purified CKII in the presence of ATP in vitro. In this report, we demonstrate that CKBBP1 is efficiently phosphorylated in vitro by purified CKII in the presence of GTP and by heparin-sensitive protein kinase in HeLa cell extract. Mutational analysis indicates that CKII phosphorylates threonine at residue 10 within CKBBP1. Furthermore, CKBBP1 is phosphorylated in vivo and threonine to alanine mutation at residue 10 abrogates the phosphorylation of CKBBP1 observed in vivo, indicating that CKII is a major kinase that is responsible for in vivo phosphorylation of CKBBP1. As compared with the wild-type CKBBP1 or CKBBP1(T10E) ( in which threonine 10 is replaced by glutamate), overexpression of nonphosphorylatable CKBBP1 (CKBBP1T10A) results in accumulation of IkappaBalpha and p27(Kip1). Experiments using proteasome inhibitor MG132 and CKII inhibitor 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole suggest that the accumulation of IkappaBalpha and p27(Kip1) results primarily from the reduction of proteasomal degradation in cells expressing CKBBP1T10A, and that CKII-mediated CKBBP1 phosphorylation is required for efficient degradation of IkappaBalpha and p27(Kip1). Overexpression of CKBBP1T10A in HeLa cells suppresses cell proliferation and causes accumulation of G(1)/G(0) peak of the cell cycle. Taken together, our results indicate that CKII may control IkappaBalpha and p27(Kip1) degradation and thereby G(1)/S phase transition through the phosphorylation of threonine 10 within CKBBP1.	Kyungpook Natl Univ, Dept Biochem, Coll Nat Sci, Taegu 702701, South Korea; Kyungpook Natl Univ, Dept Microbiol, Coll Nat Sci, Taegu 702701, South Korea	Kyungpook National University; Kyungpook National University	Bae, YS (corresponding author), Kyungpook Natl Univ, Dept Biochem, Coll Nat Sci, Taegu 702701, South Korea.	ysbae@knu.ac.kr		Bae, Young-Seuk/0000-0002-5520-4444				ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Block K, 2001, J BIOL CHEM, V276, P41049, DOI 10.1074/jbc.M106453200; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; DAYAMAKIN M, 1994, CANCER RES, V54, P2262; Duan HJ, 1999, MOL CELL BIOL, V19, P3145; Faust RA, 1996, CANCER LETT, V101, P31, DOI 10.1016/0304-3835(96)04110-9; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; GIETZ RD, 1995, J BIOL CHEM, V270, P13017, DOI 10.1074/jbc.270.22.13017; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; JAKOBI R, 1992, J BIOL CHEM, V267, P23894; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kim MS, 1998, MOL CELLS, V8, P43; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; LIN WJ, 1991, J BIOL CHEM, V266, P5664; Lorenz P, 1999, FEBS LETT, V448, P283, DOI 10.1016/S0014-5793(99)00388-9; LORENZ P, 1993, J BIOL CHEM, V268, P2733; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; Niefind K, 1998, EMBO J, V17, P2451, DOI 10.1093/emboj/17.9.2451; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; Seger D, 1998, J BIOL CHEM, V273, P24805, DOI 10.1074/jbc.273.38.24805; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SERRANO L, 1987, J CELL BIOL, V105, P1731, DOI 10.1083/jcb.105.4.1731; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Son MY, 1999, BIOCHEM BIOPH RES CO, V263, P743, DOI 10.1006/bbrc.1999.1460; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; Sun Y, 2001, ANTIOXID REDOX SIGN, V3, P635, DOI 10.1089/15230860152542989; Swaroop M, 2000, ONCOGENE, V19, P2855, DOI 10.1038/sj.onc.1203635; SWEENEY HL, 1994, P NATL ACAD SCI USA, V91, P1490, DOI 10.1073/pnas.91.4.1490; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; ZANDOMENI RO, 1989, BIOCHEM J, V262, P469, DOI 10.1042/bj2620469	43	13	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28462	28469		10.1074/jbc.M302584200	http://dx.doi.org/10.1074/jbc.M302584200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12748192	hybrid			2022-12-25	WOS:000184421100016
J	Zhang, LY; Wu, GS; Tate, CG; Lookene, A; Olivecrona, G				Zhang, LY; Wu, GS; Tate, CG; Lookene, A; Olivecrona, G			Calreticulin promotes folding/dimerization of human lipoprotein lipase expressed in insect cells (Sf21)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED BROWN ADIPOCYTES; HORMONE-SENSITIVE LIPASE; LARGE-SCALE PURIFICATION; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONES; LINKED GLYCOSYLATION; HEPATIC LIPASE; ADIPOSE-TISSUE; SECRETION; PROTEIN	Lipoprotein lipase (LPL) is a non-covalent, homodimeric, N-glycosylated enzyme important for metabolism of blood lipids. LPL is regulated by yet unknown post-translational events affecting the levels of active dimers. On co-expression of LPL with human molecular chaperones, we found that calreticulin had the most pronounced effects on LPL activity, but calnexin was also effective. Calreticulin caused a 9-fold increase in active LPL, amounting to about 50% of the expressed LPL protein. The total expression of LPL protein was increased less than 20%, and the secretion rates for active and inactive LPL were not significantly changed by the chaperone. Thus, the main effect was an increased specific activity of LPL both in cells and media. Chromatography on heparin-Sepharose and sucrose density gradient centrifugation demonstrated that most of the inactive LPL was monomeric and that calreticulin promoted formation of active dimers. Higher oligomers of inactive LPL were present in cell extracts, but only monomers and dimers were secreted to the medium. Interaction between LPL and calreticulin was demonstrated, and the effect of the chaperone was prevented by castanospermine, an inhibitor of N-glycan glucose trimming. Our data indicate an important role of endoplasmic reticulum-based chaperones for the folding/dimerization of LPL.	Umea Univ, Dept Med Biosci, SE-90187 Umea, Sweden; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Tallinn Univ Technol, Dept Gene Technol, EE-19086 Tallinn, Estonia	Umea University; MRC Laboratory Molecular Biology; Tallinn University of Technology	Olivecrona, G (corresponding author), Umea Univ, Dept Med Biosci, Bldg 6M,3rd Floor, SE-90187 Umea, Sweden.	Gunilla.Olivecrona@medbio.umu.se		Tate, Christopher/0000-0002-2008-9183				Ben-Zeev O, 2002, J BIOL CHEM, V277, P10727, DOI 10.1074/jbc.M108128200; BENGTSSONOLIVECRONA G, 1991, METHOD ENZYMOL, V197, P345; BENZEEV O, 1992, J BIOL CHEM, V267, P6219; BENZEEV O, 1994, J LIPID RES, V35, P1511; Bergo M, 1996, BIOCHEM J, V313, P893, DOI 10.1042/bj3130893; Boedeker JC, 1999, J LIPID RES, V40, P1627; BOURDI M, 1995, ARCH BIOCHEM BIOPHYS, V323, P397, DOI 10.1006/abbi.1995.0060; Briquet-Laugier V, 1999, J LIPID RES, V40, P2044; BUSCA R, 1995, J LIPID RES, V36, P939; CLARKE AR, 1983, BIOCHIM BIOPHYS ACTA, V747, P130, DOI 10.1016/0167-4838(83)90131-0; Contreras JA, 1998, PROTEIN EXPRES PURIF, V12, P93, DOI 10.1006/prep.1997.0821; Dhahbi JM, 1997, J NUTR, V127, P1758, DOI 10.1093/jn/127.9.1758; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P4570; Doolittle MH, 1998, J LIPID RES, V39, P934; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; Fisher RM, 2003, ATHEROSCLEROSIS, V166, P243, DOI 10.1016/S0021-9150(02)00337-4; Goldberg IJ, 2001, FRONT BIOSCI-LANDMRK, V6, pD388, DOI 10.2741/Goldberg; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HARTL FU, 1995, CURR OPIN STRUC BIOL, V5, P92; HIDE WA, 1992, J LIPID RES, V33, P167; Holm C, 1997, METHOD ENZYMOL, V284, P272; HSU TA, 1994, PROTEIN EXPRES PURIF, V5, P595, DOI 10.1006/prep.1994.1082; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; IVERIUS PH, 1971, BIOCHEM J, V124, P677, DOI 10.1042/bj1240677; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; Kobayashi Y, 2002, EUR J BIOCHEM, V269, P4701, DOI 10.1046/j.1432-1033.2002.03179.x; KRAPP A, 1995, J LIPID RES, V36, P2362; Lookene A, 1997, J BIOL CHEM, V272, P766, DOI 10.1074/jbc.272.2.766; Lookene A, 1996, BIOCHEMISTRY-US, V35, P12155, DOI 10.1021/bi960008e; Malide D, 2001, MOL BIOL CELL, V12, P101, DOI 10.1091/mbc.12.1.101; MASUNO H, 1991, BIOCHEM J, V277, P801, DOI 10.1042/bj2770801; MASUNO H, 1990, J BIOL CHEM, V265, P1628; MASUNO H, 1992, J LIPID RES, V33, P1343; Miranda EA, 1997, BRAZ J MED BIOL RES, V30, P923, DOI 10.1590/S0100-879X1997000800002; OLIVECRONA T, 1987, J BIOL CHEM, V262, P10748; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; Park JW, 1996, BIOCHEM J, V317, P125, DOI 10.1042/bj3170125; Preiss-Landl K, 2002, CURR OPIN LIPIDOL, V13, P471, DOI 10.1097/00041433-200210000-00002; Roderick HL, 1997, FEBS LETT, V405, P181, DOI 10.1016/S0014-5793(97)00183-X; Roth J, 2002, HISTOCHEM CELL BIOL, V117, P159, DOI 10.1007/s00418-001-0365-z; SAKAYAMA K, 1992, BIOCHIM BIOPHYS ACTA, V1127, P153, DOI 10.1016/0005-2760(92)90271-V; SEMB H, 1989, J BIOL CHEM, V264, P4195; SEMB H, 1986, BIOCHIM BIOPHYS ACTA, V878, P330, DOI 10.1016/0005-2760(86)90240-7; SEMENKOVICH CF, 1990, J BIOL CHEM, V265, P5429; Tate CG, 1999, J BIOL CHEM, V274, P17551, DOI 10.1074/jbc.274.25.17551; THIRSTRUP K, 1993, FEBS LETT, V327, P79, DOI 10.1016/0014-5793(93)81044-Z; VANNIER C, 1989, J BIOL CHEM, V264, P13206; VANNIER C, 1985, J BIOL CHEM, V260, P4424; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; Wong H, 2002, J LIPID RES, V43, P993, DOI 10.1194/jlr.R200007-JLR200; Wu GS, 2003, J BIOL CHEM, V278, P11925, DOI 10.1074/jbc.M212736200; ZAIDAN H, 1985, PEDIATR RES, V19, P23, DOI 10.1203/00006450-198501000-00007	53	55	61	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29344	29351		10.1074/jbc.M300455200	http://dx.doi.org/10.1074/jbc.M300455200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12740382	hybrid			2022-12-25	WOS:000184421100120
J	Campanale, N; Nickel, C; Daubenberger, CA; Wehlan, DA; Gorman, JJ; Klonis, N; Becker, K; Tilley, L				Campanale, N; Nickel, C; Daubenberger, CA; Wehlan, DA; Gorman, JJ; Klonis, N; Becker, K; Tilley, L			Identification and characterization of heme-interacting proteins in the malaria parasite, Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; HISTIDINE-RICH PROTEIN-2; INFECTED ERYTHROCYTES; THIOREDOXIN SYSTEM; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; CROSS-LINKING; REDUCTASE; CHLOROQUINE; HEMOGLOBIN; INHIBITION	The degradation of hemoglobin by the malaria parasite, Plasmodium falciparum, produces free ferriprotoporphyrin IX ( FP) as a toxic by-product. In the presence of FP-binding drugs such as chloroquine, FP detoxification is inhibited, and the build-up of free FP is thought to be a key mechanism in parasite killing. In an effort to identify parasite proteins that might interact preferentially with FP, we have used a mass spectrometry approach. Proteins that bind to FP immobilized on agarose include P. falciparum glyceraldehyde-3-phosphate dehydrogenase (PfGAPDH), P. falciparum glutathione reductase (PfGR), and P. falciparum protein disulfide isomerase. To examine the potential consequences of FP binding, we have examined the ability of FP to inhibit the activities of GAPDH and GR from P. falciparum and other sources. FP inhibits the enzymic activity of PfGAPDH with a K-i value of 0.2 muM, whereas red blood cell GAPDH is much less sensitive. By contrast, PfGR is more resistant to FP inhibition (K-i > 25 muM) than its human counterpart. We also examined the ability of FP to inhibit the activities of the additional antioxidant enzymes, P. falciparum thioredoxin reductase, which exhibits a K-i value of 1 muM, and P. falciparum glutaredoxin, which shows more moderate sensitivity to FP. The exquisite sensitivity of PfGAPDH to FP may indicate that the glycolytic pathway of the parasite is particularly susceptible to modulation by FP stress. Inhibition of this pathway may drive flux through the pentose phosphate pathway ensuring sufficient production of reducing equivalents to counteract the oxidative stress induced by FP build-up.	La Trobe Univ, Dept Biochem, Melbourne, Vic 3086, Australia; La Trobe Univ, Cooperat Res Ctr Diagnost, Melbourne, Vic 3086, Australia; Univ Giessen, Interdisciplinary Res Ctr, D-35392 Giessen, Germany; Swiss Trop Inst, CH-4002 Basel, Switzerland; CSIRO, Div Hlth Sci & Nutr, Parkville, Vic 3052, Australia	La Trobe University; La Trobe University; Justus Liebig University Giessen; University of Basel; Swiss Tropical & Public Health Institute; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Tilley, L (corresponding author), La Trobe Univ, Dept Biochem, Melbourne, Vic 3086, Australia.	L.Tilley@LaTrobe.edu.au	Tilley, Leann/AAU-5281-2020	Tilley, Leann/0000-0001-9910-0199; Daubenberger, Claudia/0000-0001-7136-0642				AFT RL, 1985, LIFE SCI, V36, P2153, DOI 10.1016/0024-3205(85)90312-1; ALIN P, 1985, FEBS LETT, V179, P267, DOI 10.1016/0014-5793(85)80532-9; ATAMNA H, 1994, MOL BIOCHEM PARASIT, V67, P79, DOI 10.1016/0166-6851(94)90098-1; Becker K, 2003, EUR J BIOCHEM, V270, P1057, DOI 10.1046/j.1432-1033.2003.03495.x; Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; Bruns CM, 1999, J MOL BIOL, V288, P427, DOI 10.1006/jmbi.1999.2697; CHOU AC, 1980, BIOCHEMISTRY-US, V19, P1543, DOI 10.1021/bi00549a600; Daubenberger CA, 2000, GENE, V246, P255, DOI 10.1016/S0378-1119(00)00069-X; Egan TJ, 2002, BIOCHEM J, V365, P343, DOI 10.1042/BJ20020793; Egan TJ, 1997, J INORG BIOCHEM, V68, P137, DOI 10.1016/S0162-0134(97)00086-X; Eggleson KK, 1999, J BIOL CHEM, V274, P32411, DOI 10.1074/jbc.274.45.32411; Famin O, 2003, PARASITE, V10, P39, DOI 10.1051/parasite/2003101p39; Farber PM, 1998, FEBS LETT, V422, P311, DOI 10.1016/S0014-5793(98)00031-3; FERDINAND W, 1964, BIOCHEM J, V92, P578, DOI 10.1042/bj0920578; Florenta I, 2000, FEBS LETT, V484, P246, DOI 10.1016/S0014-5793(00)02170-0; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Ginsburg H, 1998, BIOCHEM PHARMACOL, V56, P1305, DOI 10.1016/S0006-2952(98)00184-1; Gorman JJ, 1996, RAPID COMMUN MASS SP, V10, P529, DOI 10.1002/(SICI)1097-0231(19960331)10:5<529::AID-RCM522>3.0.CO;2-9; HAHN JE, 1982, J BIOL CHEM, V257, P934; Harwaldt P, 2002, BIOL CHEM, V383, P821, DOI 10.1515/BC.2002.086; Holmgren A, 2000, ANTIOXID REDOX SIGN, V2, P811, DOI 10.1089/ars.2000.2.4-811; Kang XS, 1999, BIOCHEMISTRY-US, V38, P15944, DOI 10.1021/bi9919089; Kanzok SM, 2001, SCIENCE, V291, P643, DOI 10.1126/science.291.5504.643; Kanzok SM, 2002, METHOD ENZYMOL, V347, P370; Kanzok SM, 2000, J BIOL CHEM, V275, P40180, DOI 10.1074/jbc.M007633200; Karnezis T, 2002, J BACTERIOL, V184, P4114, DOI 10.1128/JB.184.15.4114-4123.2002; Kawazu S, 2001, MOL BIOCHEM PARASIT, V116, P73, DOI 10.1016/S0166-6851(01)00308-5; KINDT JT, 1992, J BIOL CHEM, V267, P8739; Krnajski Z, 2002, J BIOL CHEM, V277, P25970, DOI 10.1074/jbc.M203539200; LaGreca N, 1997, MOL BIOCHEM PARASIT, V89, P283, DOI 10.1016/S0166-6851(97)00134-5; Lew VL, 2003, BLOOD, V101, P4189, DOI 10.1182/blood-2002-08-2654; Liebau E, 2002, MOL BIOCHEM PARASIT, V124, P85, DOI 10.1016/S0166-6851(02)00160-3; Lopaticki S, 1998, J MASS SPECTROM, V33, P950, DOI 10.1002/(SICI)1096-9888(199810)33:10<950::AID-JMS704>3.3.CO;2-1; Loria P, 1999, BIOCHEM J, V339, P363, DOI 10.1042/0264-6021:3390363; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; Mashima R, 2002, J BIOL CHEM, V277, P14514, DOI 10.1074/jbc.M109386200; Meshnick SR, 2002, INT J PARASITOL, V32, P1655, DOI 10.1016/S0020-7519(02)00194-7; NORDHOFF A, 1993, BIOCHEMISTRY-US, V32, P4060, DOI 10.1021/bi00066a029; Olliaro PL, 2001, TRENDS PARASITOL, V17, P122, DOI 10.1016/S1471-4922(00)01838-9; Padgett CM, 1997, AM J PHYSIOL-CELL PH, V272, pC99, DOI 10.1152/ajpcell.1997.272.1.C99; Papalexis V, 2001, MOL BIOCHEM PARASIT, V115, P77, DOI 10.1016/S0166-6851(01)00271-7; Posner GH, 2001, TRENDS PARASITOL, V17, P266, DOI 10.1016/S1471-4922(01)02001-3; Rahlfs S, 2002, CELL MOL LIFE SCI, V59, P1024, DOI 10.1007/s00018-002-8484-9; Rahlfs S, 2001, J BIOL CHEM, V276, P37133, DOI 10.1074/jbc.M105524200; Rahlfs S, 2001, EUR J BIOCHEM, V268, P1404, DOI 10.1046/j.1432-1327.2001.02005.x; ROTH E, 1990, BLOOD CELLS, V16, P453; SCHIRMER M, 1999, FLAVINS FLAVOPROTEIN, V13, P857; SCHIRMER RH, 1995, ANGEW CHEM INT EDIT, V34, P141, DOI 10.1002/anie.199501411; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; Tilley L, 2001, INFEC DIS S, P87; TSUTSUI K, 1986, METHOD ENZYMOL, V123, P331; YAYON A, 1983, J PROTOZOOL, V30, P642, DOI 10.1111/j.1550-7408.1983.tb05336.x; Zhang JM, 1999, MOL BIOCHEM PARASIT, V99, P129, DOI 10.1016/S0166-6851(99)00008-0; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o	57	55	57	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27354	27361		10.1074/jbc.M303634200	http://dx.doi.org/10.1074/jbc.M303634200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12748176	hybrid			2022-12-25	WOS:000184242700005
J	Chen, J; Wersinger, C; Sidhu, A				Chen, J; Wersinger, C; Sidhu, A			Chronic stimulation of D1 dopamine receptors in human SK-N-MC neuroblastoma cells induces nitric-oxide synthase activation and cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; KAPPA-B; PROTEIN-KINASE; EXPRESSION; D-1; BINDING; TRANSCRIPTION; STRIATUM; PHOSPHORYLATION; DESENSITIZATION	Elevated synaptic levels of dopamine may induce striatal neurodegeneration in L-DOPA-unresponsive parkinsonism subtype of multiple system atrophy (MSA-P subtype), multiple system atrophy, and methamphetamine addiction. We examined the participation of dopamine and D1 dopamine receptors in the genesis of postsynaptic neurodegeneration. Chronic treatment of human SK-N-MC neuroblastoma cells with dopamine or H2O2 increased NO production and accelerated cytotoxicity, as indexed by enhanced nitrite levels and cell death. The antioxidant sodium metabisulfite or SCH 23390, a D1 dopamine receptor-selective antagonist, partially blocked dopamine effects but together ablated dopamine-mediated cytotoxicity, indicating the participation of both autoxidation and D1 receptor stimulation. Direct activation of D1 dopamine receptors with SKF R-38393 caused cytotoxicity, which was refractory to sodium metabisulfite. Dopamine and SKF R-38393 induced overexpression of the nitric-oxide synthase ( NOS) isoforms neuronal NOS, inducible NOS ( iNOS), and endothelial NOS in a protein kinase A-dependent manner. Functional studies showed that similar to 60% of total NOS activity was due to activation of iNOS. The NOS inhibitor N(G)-nitro-L-arginine methyl ester and genistein, wortmannin, or NF-kappaB SN50, inhibitors of protein tyrosine kinases phosphatidylinositol 3-kinase and NF-kappaB, respectively, reduced nitrite production by dopamine and SKF R-38393 but were less effective in attenuating H2O2-mediated effects. In rat striatal neurons, dopamine and SKF R-38393, but not H2O2, accelerated cell death through increased expression of neuronal NOS and iNOS but not endothelial NOS. These data demonstrate a novel pathway of dopamine-mediated postsynaptic oxidative stress and cell death through direct activation of NOS enzymes by D1 dopamine receptors and its associated signaling pathways.	Georgetown Univ, Dept Pediat, Lab Mol Neurochem, Washington, DC 20007 USA	Georgetown University	Sidhu, A (corresponding author), Georgetown Univ, Dept Pediat, Lab Mol Neurochem, Res Bldg,Rm W222,6970 Reservoir Rd NW, Washington, DC 20007 USA.	sidhua@georgetown.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041555, R01NS034914] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-41555, NS-34914] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Andringa G, 1999, BEHAV PHARMACOL, V10, P175, DOI 10.1097/00008877-199903000-00006; Andringa G, 1999, PSYCHOPHARMACOLOGY, V146, P328, DOI 10.1007/s002130051124; Ayata C, 1997, J NEUROSCI, V17, P6908; Bazzett T, 1997, BRAIN RES, V775, P229, DOI 10.1016/S0006-8993(97)00962-1; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BERTORELLO AM, 1990, NATURE, V347, P386, DOI 10.1038/347386a0; Bhat NR, 2002, J BIOL CHEM, V277, P29584, DOI 10.1074/jbc.M204994200; Bockelmann R, 2000, AMINO ACIDS, V19, P423, DOI 10.1007/s007260070021; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bredt DS, 1999, FREE RADICAL RES, V31, P577, DOI 10.1080/10715769900301161; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Calabresi P, 2000, PROG NEUROBIOL, V61, P231, DOI 10.1016/S0301-0082(99)00030-1; Chen NH, 1998, METHOD ENZYMOL, V296, P719; Coleman JW, 2002, CLIN EXP IMMUNOL, V129, P4, DOI 10.1046/j.1365-2249.2002.01918.x; DAWSON VL, 1994, NEUROPHARMACOLOGY, V33, P1425, DOI 10.1016/0028-3908(94)90045-0; Deckel AW, 2002, NEUROREPORT, V13, P707, DOI 10.1097/00001756-200204160-00034; Drago J, 1998, J NEUROSCI, V18, P9845; FariasEisner R, 1996, J BIOL CHEM, V271, P6144, DOI 10.1074/jbc.271.11.6144; FELDER CC, 1990, AM J PHYSIOL, V259, pF297, DOI 10.1152/ajprenal.1990.259.2.F297; FUJIHARA M, 1994, J IMMUNOL, V152, P1898; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; Ghorayeb I, 2000, MOVEMENT DISORD, V15, P531, DOI 10.1002/1531-8257(200005)15:3<531::AID-MDS1017>3.0.CO;2-C; Gudi T, 2000, ONCOGENE, V19, P6324, DOI 10.1038/sj.onc.1204007; Hantraye P, 1998, NUCL MED BIOL, V25, P721, DOI 10.1016/S0969-8051(98)00054-7; Horn TFW, 2002, FASEB J, V16, P1611, DOI 10.1096/fj.02-0126com; Imam SZ, 2001, ANN NY ACAD SCI, V939, P366; Jackson A, 2002, J NEUROCHEM, V82, P683, DOI 10.1046/j.1471-4159.2002.01001.x; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; JUN CD, 1994, J IMMUNOL, V153, P3684; Junn E, 2001, J NEUROCHEM, V78, P374, DOI 10.1046/j.1471-4159.2001.00425.x; Keinanen R, 1999, GENE, V234, P297, DOI 10.1016/S0378-1119(99)00196-1; Kim OJ, 2002, J NEUROSCI, V22, P5920; KIMURA K, 1995, J BIOL CHEM, V270, P14672, DOI 10.1074/jbc.270.24.14672; Kitazawa M, 2002, J PHARMACOL EXP THER, V302, P26, DOI 10.1124/jpet.302.1.26; Lecanu L, 1998, BRIT J PHARMACOL, V125, P584, DOI 10.1038/sj.bjp.0702119; Lecanu L, 1998, NEUROREPORT, V9, P559, DOI 10.1097/00001756-199802160-00032; Lee FJS, 1996, J BIOL CHEM, V271, P20885, DOI 10.1074/jbc.271.34.20885; Lewis MM, 1998, J PHARMACOL EXP THER, V286, P345; Luo YQ, 1999, MOL PHARMACOL, V56, P254, DOI 10.1124/mol.56.2.254; Nagatsu T, 2002, J NEURAL TRANSM, V109, P731, DOI 10.1007/s007020200061; Nagatsu T, 1999, CELL MOL NEUROBIOL, V19, P57, DOI 10.1023/A:1006912523846; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; Nishino H, 1996, J CHEM NEUROANAT, V10, P209, DOI 10.1016/0891-0618(96)00134-2; Paul A, 1997, BRIT J PHARMACOL, V120, P1439, DOI 10.1038/sj.bjp.0701070; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; PRISTUPA ZB, 1994, MOL PHARMACOL, V45, P125; Prou D, 2001, J CELL SCI, V114, P3517; Rao KMK, 2000, J TOXICOL ENV HEAL B, V3, P27, DOI 10.1080/109374000281131; Ruan J, 1996, J BIOL CHEM, V271, P22679, DOI 10.1074/jbc.271.37.22679; SIBLEY DR, 1999, ANN REV PHARM TOXICO, V288, P421; Sidhu A, 1997, J RECEPT SIGNAL TR R, V17, P777, DOI 10.3109/10799899709044285; Sidhu A, 1999, NEUROSCIENCE, V91, P537, DOI 10.1016/S0306-4522(98)00555-7; Sidhu A, 2000, INT J DEV NEUROSCI, V18, P669, DOI 10.1016/S0736-5748(00)00033-2; Sidhu A, 1997, J NEUROCHEM, V68, P187; Sidhu A, 1998, MOL NEUROBIOL, V16, P125, DOI 10.1007/BF02740640; SIDHU A, 1990, BIOCHEM BIOPH RES CO, V166, P574, DOI 10.1016/0006-291X(90)90847-G; Spencer JPE, 2002, J NEUROCHEM, V81, P122, DOI 10.1046/j.1471-4159.2002.00808.x; Spielewoy C, 2000, EUR J NEUROSCI, V12, P1827, DOI 10.1046/j.1460-9568.2000.00063.x; Steiner H, 2000, J NEUROSCI, V20, P5449, DOI 10.1523/JNEUROSCI.20-14-05449.2000; Stephans S, 1996, NEUROSCIENCE, V72, P593, DOI 10.1016/0306-4522(95)00587-0; UNDIE AS, 1994, J NEUROCHEM, V62, P2045; Wersinger C, 2001, AMINO ACIDS, V21, P91, DOI 10.1007/s007260170018; Wersinger Christophe, 2002, Current Drug Targets - Inflammation and Allergy, V1, P221, DOI 10.2174/1568010023344580; Whitehead RE, 2001, J NEUROCHEM, V76, P1242, DOI 10.1046/j.1471-4159.2001.00125.x; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; XIE QW, 1994, J BIOL CHEM, V269, P28500; Xie QW, 1997, J BIOL CHEM, V272, P14867, DOI 10.1074/jbc.272.23.14867; Yao LP, 1998, HYPERTENSION, V32, P1049, DOI 10.1161/01.HYP.32.6.1049; Yurochko AD, 1997, J VIROL, V71, P5051, DOI 10.1128/JVI.71.7.5051-5059.1997; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320	72	53	54	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28089	28100		10.1074/jbc.M303094200	http://dx.doi.org/10.1074/jbc.M303094200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12738794	hybrid			2022-12-25	WOS:000184242700095
J	Johansson, E; Bjornberg, O; Nyman, PO; Larsen, S				Johansson, E; Bjornberg, O; Nyman, PO; Larsen, S			Structure of the bifunctional dCTP deaminase-dUTPase from Methanocaldococcus jannaschii and its relation to other homotrimeric dUTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CYTIDINE DEAMINASE; VIRUS; PYROPHOSPHATASE; BINDING; RECOGNITION; URACIL; ENZYME; ERRORS	The bifunctional dCTP deaminase-dUTPase (DCD-DUT) from Methanocaldococcus jannaschii catalyzes the deamination of the cytosine moiety in dCTP and the hydrolysis of the triphosphate moiety forming dUMP, thereby preventing uracil from being incorporated into DNA. The crystal structure of DCD-DUT has been determined to 1.88-Angstrom resolution and represents the first known structure of an enzyme catalyzing dCTP deamination. The functional form of DCD-DUT is a homotrimer wherein the subunits are composed of a central distorted beta-barrel surrounded by two beta-sheets and four helices. The trimeric DCD-DUT shows structural similarity to trimeric dUTPases at the tertiary and quaternary levels. There are also additional structural elements in DCD-DUT compared with dUTPase because of a longer primary structure. Four of the five conserved sequence motifs that create the active sites in dUTPase are found in structurally equivalent positions in DCD-DUT. The last 25 C-terminal residues of the 204-residue-long DCD-DUT are not visible in the electron density map, but, analogous to dUTPases, the C terminus is probably ordered, closing the active site upon catalysis. Unlike other enzymes catalyzing the deamination of cytosine compounds, DCD-DUT is not exploiting an enzyme-bound metal ion such as zinc or iron for nucleophile generation. The active site contains two water molecules that are engaged in hydrogen bonds to the invariant residues Ser(118), Arg(122), Thr(130), and Glu(145). These water molecules are potential nucleophile candidates in the deamination reaction.	Univ Copenhagen, Dept Chem, Ctr Crystallog Studies, DK-2100 Copenhagen O, Denmark; Lund Univ, Dept Biochem, S-22100 Lund, Sweden	University of Copenhagen; Lund University	Larsen, S (corresponding author), Univ Copenhagen, Dept Chem, Ctr Crystallog Studies, Univ Pk 5, DK-2100 Copenhagen O, Denmark.	sine@ccs.ki.ku.dk	Larsen, Sine/A-4487-2017; Johansson, Eva/AAB-9003-2021	Larsen, Sine/0000-0003-3848-1789; Johansson, Eva/0000-0001-9330-5169				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BECK CF, 1975, J BIOL CHEM, V250, P609; Bergdoll M, 1997, STRUCTURE, V5, P391, DOI 10.1016/S0969-2126(97)00196-2; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; Bjornberg O, 2003, J BIOL CHEM, V278, P20667, DOI 10.1074/jbc.M213010200; Bjornberg O, 1996, J GEN VIROL, V77, P3107, DOI 10.1099/0022-1317-77-12-3107; CEDERGRENZEPPEZAUER ES, 1992, NATURE, V355, P740, DOI 10.1038/355740a0; Cerenius Y, 2000, J SYNCHROTRON RADIAT, V7, P203, DOI 10.1107/S0909049500005331; Dauter Z, 1999, J MOL BIOL, V285, P655, DOI 10.1006/jmbi.1998.2332; ELHAJJ HH, 1988, J BACTERIOL, V170, P1069, DOI 10.1128/jb.170.3.1069-1075.1988; GADSDEN MH, 1993, EMBO J, V12, P4425, DOI 10.1002/j.1460-2075.1993.tb06127.x; Gonzalez A, 2001, ACTA CRYSTALLOGR D, V57, P767, DOI 10.1107/S0907444901004255; Harris JM, 1999, J MOL BIOL, V288, P275, DOI 10.1006/jmbi.1999.2680; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Johansson E, 2002, BIOCHEMISTRY-US, V41, P2563, DOI 10.1021/bi011849a; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koonin EV, 1996, NUCLEIC ACIDS RES, V24, P2411, DOI 10.1093/nar/24.12.2411; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamzin V. S., 2001, INT TABLES CRYSTALLO, VF, P720; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li H, 2003, J BIOL CHEM, V278, P11100, DOI 10.1074/jbc.M212460200; MCGEOCH DJ, 1990, NUCLEIC ACIDS RES, V18, P4105, DOI 10.1093/nar/18.14.4105; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mol CD, 1996, STRUCTURE, V4, P1077, DOI 10.1016/S0969-2126(96)00114-1; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Neuhard J., 1996, ESCHERICHIA COLI SAL, V2nd, P580; Nord J, 2001, FEBS LETT, V492, P228, DOI 10.1016/S0014-5793(01)02257-8; Nord J, 2000, FEBS LETT, V472, P312, DOI 10.1016/S0014-5793(00)01453-8; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Persson R, 2001, CURR PROTEIN PEPT SC, V2, P287, DOI 10.2174/1389203013381035; Prangishvili D, 1998, J BIOL CHEM, V273, P6024, DOI 10.1074/jbc.273.11.6024; Prasad GS, 2000, ACTA CRYSTALLOGR D, V56, P1100, DOI 10.1107/S0907444900009197; STEAGALL WK, 1995, VIROLOGY, V210, P302, DOI 10.1006/viro.1995.1347; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1863, DOI 10.1107/S0907444999010033; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839	38	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27916	27922		10.1074/jbc.M304361200	http://dx.doi.org/10.1074/jbc.M304361200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12756253	hybrid			2022-12-25	WOS:000184242700074
J	Kock, J; Kann, M; Putz, G; Blum, HE; von Weizsacker, F				Kock, J; Kann, M; Putz, G; Blum, HE; von Weizsacker, F			Central role of a serine phosphorylation site within duck hepatitis B virus core protein for capsid trafficking and genome release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENVELOPE PROTEINS; KINASE ACTIVITY; DNA MATURATION; C-TERMINUS; HEPADNAVIRUS; REPLICATION; INFECTION; PARTICLES; BINDING; DOMAIN	Viral nucleocapsids compartmentalize and protect viral genomes during assembly while they mediate targeted genome release during viral infection. This dual role of the capsid in the viral life cycle must be tightly regulated to ensure efficient virus spread. Here, we used the duck hepatitis B virus ( DHBV) infection model to analyze the effects of capsid phosphorylation and hydrogen bond formation. The potential key phosphorylation site at serine 245 within the core protein, the building block of DHBV capsids, was substituted by alanine (S245A), aspartic acid (S245D) and asparagine (S245N), respectively. Mutant capsids were analyzed for replication competence, stability, nuclear transport, and infectivity. All mutants formed DHBV DNA-containing nucleocapsids. Wild-type and S245N but not S245A and S245D fully protected capsid-associated mature viral DNA from nuclease action. A negative ionic charge as contributed by phosphorylated serine or aspartic acid-supported nuclear localization of the viral capsid and generation of nuclear superhelical DNA. Finally, wildtype and S245D but not S245N virions were infectious in primary duck hepatocytes. These results suggest that hydrogen bonds formed by non-phosphorylated serine 245 stabilize the quarterny structure of DHBV nucleocapsids during viral assembly, while serine phosphorylation plays an important role in nuclear targeting and DNA release from capsids during viral infection.	Univ Freiburg, Dept Med 2, D-79106 Freiburg, Germany; Univ Giessen, Inst Med Virol, D-35392 Giessen, Germany	University of Freiburg; Justus Liebig University Giessen	von Weizsacker, F (corresponding author), Univ Freiburg, Dept Med 2, Hugstetter Str 55, D-79106 Freiburg, Germany.	weiz@ukl.uni-freiburg.de	Putz, Gerhard/AFP-9594-2022	Putz, Gerhard/0000-0002-0816-2018				ALBIN C, 1980, J VIROL, V34, P297, DOI 10.1128/JVI.34.1.297-302.1980; BEAMES B, 1993, VIROLOGY, V194, P597, DOI 10.1006/viro.1993.1299; Cartier C, 1999, J BIOL CHEM, V274, P19434, DOI 10.1074/jbc.274.27.19434; CONDREAY LD, 1990, J VIROL, V64, P3249, DOI 10.1128/JVI.64.7.3249-3258.1990; Daub H, 2002, J VIROL, V76, P8124, DOI 10.1128/JVI.76.16.8124-8137.2002; Duclos-Vallee JC, 1998, J GEN VIROL, V79, P1665, DOI 10.1099/0022-1317-79-7-1665; FEITELSON MA, 1982, J VIROL, V43, P741, DOI 10.1128/JVI.43.2.741-748.1982; GALLINA A, 1989, J VIROL, V63, P4645, DOI 10.1128/JVI.63.11.4645-4652.1989; GERLICH WH, 1982, J VIROL, V42, P761, DOI 10.1128/JVI.42.3.761-766.1982; HATTON T, 1992, J VIROL, V66, P5232, DOI 10.1128/JVI.66.9.5232-5241.1992; Kann M, 1999, J CELL BIOL, V145, P45, DOI 10.1083/jcb.145.1.45; KANN M, 1993, ARCH VIROL, P53; Kau JH, 1998, J VIROL, V72, P3796, DOI 10.1128/JVI.72.5.3796-3803.1998; Kock J, 1998, J VIROL, V72, P9116; Kock J, 2001, J VIROL, V75, P5084, DOI 10.1128/JVI.75.11.5084-5089.2001; LIAO W, 1995, J VIROL, V69, P1025, DOI 10.1128/JVI.69.2.1025-1029.1995; Mabit H, 2000, J VIROL, V74, P11472, DOI 10.1128/JVI.74.24.11472-11478.2000; Mabit H, 2001, J VIROL, V75, P1968, DOI 10.1128/JVI.75.4.1968-1977.2001; MASON WS, 1980, J VIROL, V36, P829, DOI 10.1128/JVI.36.3.829-836.1980; NASSAL M, 1992, J VIROL, V66, P4107, DOI 10.1128/JVI.66.7.4107-4116.1992; Nassal M, 1993, Trends Microbiol, V1, P221, DOI 10.1016/0966-842X(93)90136-F; PUGH J, 1989, J VIROL, V63, P1371, DOI 10.1128/JVI.63.3.1371-1376.1989; SCHLICHT HJ, 1989, J VIROL, V63, P2995, DOI 10.1128/JVI.63.7.2995-3000.1989; SCHLICHT HJ, 1987, J VIROL, V61, P2280, DOI 10.1128/JVI.61.7.2280-2285.1987; SCHLICHT HJ, 1989, CELL, V56, P85, DOI 10.1016/0092-8674(89)90986-0; Seeger C, 2000, MICROBIOL MOL BIOL R, V64, P51, DOI 10.1128/MMBR.64.1.51-68.2000; SUMMERS J, 1990, J VIROL, V64, P2819, DOI 10.1128/JVI.64.6.2819-2824.1990; SUMMERS J, 1991, J VIROL, V65, P1310, DOI 10.1128/JVI.65.3.1310-1317.1991; SUMMERS J, 1978, P NATL ACAD SCI USA, V75, P4533, DOI 10.1073/pnas.75.9.4533; TUTTLEMAN JS, 1986, J VIROL, V58, P17, DOI 10.1128/JVI.58.1.17-25.1986; WRIGHT TL, 1993, LANCET, V342, P1340, DOI 10.1016/0140-6736(93)92250-W; YU MS, 1991, J VIROL, V65, P2511, DOI 10.1128/JVI.65.5.2511-2517.1991; YU MS, 1994, J VIROL, V68, P2965, DOI 10.1128/JVI.68.5.2965-2969.1994; YU MS, 1994, J VIROL, V68, P4341, DOI 10.1128/JVI.68.7.4341-4348.1994; Zlotnick A, 1999, BIOCHEMISTRY-US, V38, P14644, DOI 10.1021/bi991611a	35	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28123	28129		10.1074/jbc.M300064200	http://dx.doi.org/10.1074/jbc.M300064200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12740387	hybrid			2022-12-25	WOS:000184242700099
J	Schwudke, D; Linscheid, M; Strauch, E; Appel, B; Zahringer, U; Moll, H; Muller, M; Brecker, L; Gronow, S; Lindner, B				Schwudke, D; Linscheid, M; Strauch, E; Appel, B; Zahringer, U; Moll, H; Muller, M; Brecker, L; Gronow, S; Lindner, B			The obligate predatory Bdellovibrio bacteriovorus possesses a neutral lipid A containing alpha-D-mannoses that replace phosphate residues - Similarities and differences between the lipid As and the lipopolysaccharides of the wild type strain B-bacteriovorus HD100 and its host-independent derivative HI100	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; INTRAPERIPLASMIC GROWTH; MONOCLONAL-ANTIBODIES; OUTER-MEMBRANE; FATTY-ACIDS; BACTERIAL; BDELLOVIBRIO-BACTERIOVORUS-109J; ENDOTOXIN; DIVERSITY; CELLS	Bdellovibrio bacteriovorus are predatory bacteria that penetrate Gram-negative bacteria and grow intraperiplasmically at the expense of the prey. It was suggested that B. bacteriovorus partially degrade and reutilize lipopolysaccharide (LPS) of the host, thus synthesizing an outer membrane containing structural elements of the prey. According to this hypothesis a host-independent mutant should possess a chemically different LPS. Therefore, the lipopolysaccharides of B. bacteriovorus HD100 and its host-independent derivative B. bacteriovorus HI100 were isolated and characterized by SDS-polyacrylamide gel electrophoresis, immunoblotting, and mass spectrometry. LPS of both strains were identified as smooth-form LPS with different repeating units. The lipid As were isolated after mild acid hydrolysis and their structures were determined by chemical analysis, by mass spectrometric methods, and by NMR spectroscopy. Both lipid As were characterized by an unusual chemical structure, consisting of a beta-(1-->6)-linked 2,3-diamino-2,3-dideoxy-D-glucopyranose disaccharide carrying six fatty acids that were all hydroxylated. Instead of phosphate groups substituting position O-1 of the reducing and O-4' of the nonreducing end alpha-D-mannopyranose residues were found in these lipid As. Thus, they represent the first lipid As completely missing negatively charged groups. A reduced endotoxic activity as determined by cytokine induction from human macrophages was shown for this novel structure. Only minor differences with respect to fatty acids were detected between the lipid As of the host-dependent wild type strain HD100 and for its host-independent derivative HI100. From the results of the detailed analysis it can be concluded that the wild type strain HD100 synthesizes an innate LPS.	Humboldt Univ, Dept Chem, D-12489 Berlin, Germany; Robert Koch Inst, Project Grp Biol Safety, D-13353 Berlin, Germany; Res Ctr Borstel, Ctr Med & Biosci, D-23845 Borstel, Germany	Humboldt University of Berlin; Robert Koch Institute; Forschungszentrum Borstel	Linscheid, M (corresponding author), Humboldt Univ, Dept Chem, Brook Taylor Str 2, D-12489 Berlin, Germany.	michael.linscheid@chemie.hu-berlin.de	Lindner, Buko/G-9731-2014; Schwudke, Dominik/B-3478-2013; Linscheid, Michael/ABB-7808-2020; Schwudke, Dominik/A-3472-2009; Linscheid, Michael W/D-2125-2009	Schwudke, Dominik/0000-0002-1379-9451; Linscheid, Michael W/0000-0002-8902-1734				ABRAM D, 1974, J BACTERIOL, V118, P663, DOI 10.1128/JB.118.2.663-680.1974; Alexander C, 2001, J ENDOTOXIN RES, V7, P167, DOI 10.1179/096805101101532675; Baer ML, 2000, INT J SYST EVOL MICR, V50, P219, DOI 10.1099/00207713-50-1-219; Barel G, 2001, ARCH MICROBIOL, V176, P211, DOI 10.1007/s002030100312; Bengoechea JA, 1998, MICROBIOL-UK, V144, P1517, DOI 10.1099/00221287-144-6-1517; BRADE L, 1987, INFECT IMMUN, V55, P462, DOI 10.1128/IAI.55.2.462-466.1987; Brandenburg K, 1997, BBA-BIOMEMBRANES, V1329, P183, DOI 10.1016/S0005-2736(97)00109-0; BRECKER L, 2003, IN PRESS CHEM PHYS L; BRYN K, 1982, J CHROMATOGR, V240, P405, DOI 10.1016/S0021-9673(00)99620-1; COTTER TW, 1992, J BACTERIOL, V174, P6018, DOI 10.1128/JB.174.19.6018-6024.1992; COVER WH, 1984, J BACTERIOL, V157, P385, DOI 10.1128/JB.157.2.385-390.1984; COVER WH, 1984, J BACTERIOL, V157, P391, DOI 10.1128/JB.157.2.391-397.1984; DIPADOVA FE, 1993, INFECT IMMUN, V61, P3863, DOI 10.1128/IAI.61.9.3863-3872.1993; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; GALLATI H, 1982, J CLIN CHEM CLIN BIO, V20, P907; GERWIG GJ, 1979, CARBOHYD RES, V77, P1, DOI 10.1016/S0008-6215(00)83788-X; GRAFE U, 1992, BIOCH ANTIBIOTIKA, P268; IBRAGIMOV FK, 1980, ZH MIKROB EPID IMMUN, P97; Janusch H, 2002, J ENDOTOXIN RES, V8, P343, DOI 10.1179/096805102125000678; Jurkevitch E, 2000, APPL ENVIRON MICROB, V66, P2365, DOI 10.1128/AEM.66.6.2365-2371.2000; KUENEN JG, 1975, J BACTERIOL, V121, P1145, DOI 10.1128/JB.121.3.1145-1157.1975; KUHN HM, 1992, INFECT IMMUN, V60, P2201, DOI 10.1128/IAI.60.6.2201-2210.1992; LAMBINA W, 1987, MIKROBIOLOGIYA, V56, P860; Mingeot-Leclercq MP, 1999, ANTIMICROB AGENTS CH, V43, P727, DOI 10.1128/AAC.43.4.727; NELSON DR, 1981, J BACTERIOL, V147, P860, DOI 10.1128/JB.147.3.860-868.1981; Plotz BM, 2000, J BIOL CHEM, V275, P11222, DOI 10.1074/jbc.275.15.11222; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; Ravenschlag K, 1999, APPL ENVIRON MICROB, V65, P3982; RICHARDSON IR, 1990, J APPL BACTERIOL, V69, P134, DOI 10.1111/j.1365-2672.1990.tb02921.x; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; RIETSCHEL ET, 1993, IMMUNOBIOLOGY, V187, P169, DOI 10.1016/S0171-2985(11)80338-4; ROSSON RA, 1979, J BACTERIOL, V140, P620, DOI 10.1128/JB.140.2.620-633.1979; Rund S, 1999, J BIOL CHEM, V274, P16819, DOI 10.1074/jbc.274.24.16819; Schromm AB, 2000, EUR J BIOCHEM, V267, P2008, DOI 10.1046/j.1432-1327.2000.01204.x; Schromm AB, 1998, J IMMUNOL, V161, P5464; Schwudke D, 2001, SYST APPL MICROBIOL, V24, P385, DOI 10.1078/0723-2020-00042; SEIDLER RJ, 1969, J BACTERIOL, V100, P769, DOI 10.1128/JB.100.2.769-785.1969; STEIN MA, 1992, J BACTERIOL, V174, P2858, DOI 10.1128/JB.174.9.2858-2864.1992; STOLP H, 1963, ANTON VAN LEE J M S, V29, P217, DOI 10.1007/BF02046064; TALLEY BG, 1987, J BACTERIOL, V169, P694, DOI 10.1128/jb.169.2.694-698.1987; THOMASHOW MF, 1978, J BACTERIOL, V135, P998, DOI 10.1128/JB.135.3.998-1007.1978; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; TUDOR JJ, 1990, J BACTERIOL, V172, P2421, DOI 10.1128/jb.172.5.2421-2426.1990; WOLLENWEBER HW, 1990, J MICROBIOL METH, V11, P195, DOI 10.1016/0167-7012(90)90056-C	45	75	79	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27502	27512		10.1074/jbc.M303012200	http://dx.doi.org/10.1074/jbc.M303012200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12743115	hybrid			2022-12-25	WOS:000184242700022
J	Hirashima, Y; Kobayashi, H; Suzuki, M; Tanaka, Y; Kanayama, N; Terao, T				Hirashima, Y; Kobayashi, H; Suzuki, M; Tanaka, Y; Kanayama, N; Terao, T			Transforming growth factor-beta 1 produced by ovarian cancer cell line HRA stimulates attachment and invasion through an up-regulation of plasminogen activator inhibitor type-1 in human peritoneal mesothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URINARY TRYPSIN-INHIBITOR; GROWTH-FACTOR-BETA; UROKINASE RECEPTOR; GENE-EXPRESSION; BREAST-CANCER; GASTRIC-CANCER; IN-VITRO; PROTEIN; ADHESION; TGF-BETA-1	The processes of ovarian cancer dissemination are characterized by altered local proteolysis, cellular proliferation, cell attachment, and invasion, suggesting that the urokinase-type plasminogen activator (uPA) and its specific inhibitor ( plasminogen activator inhibitor type-1 (PAI-1)) could be involved in the pathogenesis of peritoneal dissemination. We showed previously that expression of uPA and PAI-1 in the human ovarian cancer cell line HRA can be down-regulated by exogenous bikunin (bik), a Kunitz-type protease inhibitor, via suppression of transforming growth factor-beta1 (TGF-beta1) up-regulation and that overexpression of the bik gene can specifically suppress the in vivo growth and peritoneal dissemination of HRA cells in an animal model. We hypothesize that the plasminogen activator system in mesothelial cells can be modulated by HRA cells. To test this hypothesis, we used complementary techniques in mesothelial cells to determine whether uPA and PAI-1 expression are altered by exposure to culture media conditioned by HRA cells. Here we show the following: 1) that expression of PAI-1, but not uPA, was markedly induced by culture media conditioned by wild-type HRA cells but not by bik transfected clones; 2) that by antibody neutralization the effect appeared to be mediated by HRA cell-derived TGF-beta1; 3) that exogenous TGF-beta1 specifically enhanced PAI-1 up-regulation at the mRNA and protein level in mesothelial cells in a time- and concentration-dependent manner, mainly through MAPK-dependent activation mechanism; and 4) that mesothelial cell-derived PAI-1 may promote tumor invasion possibly by enhancing cell-cell interaction. This represents a novel pathway by which tumor cells can regulate the plasminogen activator system-dependent cellular responses in mesothelial cells that may contribute to formation of peritoneal dissemination of ovarian cancer.	Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Shizuoka 4313192, Japan	Hamamatsu University School of Medicine	Kobayashi, H (corresponding author), Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Handayama 1-20-1, Shizuoka 4313192, Japan.	hirokoba@hama-med.ac.jp						ANDREASEN PA, 1986, FEBS LETT, V209, P213, DOI 10.1016/0014-5793(86)81113-9; CATTERALL JB, 1994, CANCER LETT, V87, P199, DOI 10.1016/0304-3835(94)90223-2; Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com; Duffy MJ, 2002, CLIN CHEM, V48, P1194; DUMLER I, 1994, FEBS LETT, V343, P103, DOI 10.1016/0014-5793(94)80298-X; Falk P, 2000, SCAND J CLIN LAB INV, V60, P439, DOI 10.1080/003655100448419; Fishman DA, 1998, INVAS METAST, V18, P15, DOI 10.1159/000024495; Frey RS, 1997, CANCER RES, V57, P628; GARNER WL, 1993, J INVEST DERMATOL, V101, P875, DOI 10.1111/1523-1747.ep12371710; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; Harbeck N, 2000, INT J BIOL MARKER, V15, P79, DOI 10.1177/172460080001500115; Harbeck Nadia, 2002, Clin Breast Cancer, V3, P196, DOI 10.3816/CBC.2002.n.023; Hashizume K, 2002, ANTICANCER RES, V22, P1781; Hirashima Y, 2001, J BIOL CHEM, V276, P13650, DOI 10.1074/jbc.M009906200; Hung KY, 2001, KIDNEY INT, V60, P1249, DOI 10.1046/j.1523-1755.2001.00933.x; KIKUCHI Y, 1987, CANCER RES, V47, P592; KOBAYASHI H, 1995, BRIT J CANCER, V72, P1131, DOI 10.1038/bjc.1995.476; Kobayashi H, 2003, J BIOL CHEM, V278, P7790, DOI 10.1074/jbc.M210407200; Kobayashi H, 1998, BBA-PROTEIN STRUCT M, V1383, P253, DOI 10.1016/S0167-4838(97)00215-X; Kobayashi H, 2001, J BIOL CHEM, V276, P2015, DOI 10.1074/jbc.M007650200; Kondoh N, 1998, BRIT J CANCER, V78, P718, DOI 10.1038/bjc.1998.567; Kutz SM, 2001, J CELL SCI, V114, P3905; LIU GH, 1995, INT J CANCER, V60, P501, DOI 10.1002/ijc.2910600413; Massague J, 1996, CANCER SURV, V27, P41; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Mizutani K, 2000, SURG TODAY, V30, P614, DOI 10.1007/s005950070101; Nakashio T, 1997, INT J CANCER, V70, P612, DOI 10.1002/(SICI)1097-0215(19970304)70:5<612::AID-IJC20>3.3.CO;2-Y; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; PEPPER MS, 1990, CELL DIFFER DEV, V32, P319, DOI 10.1016/0922-3371(90)90046-Y; Planus E, 1997, J CELL SCI, V110, P1091; RABBANI SA, 1990, BIOCHEM BIOPH RES CO, V173, P1058, DOI 10.1016/S0006-291X(05)80893-9; Rodriguez GC, 2001, GYNECOL ONCOL, V80, P245, DOI 10.1006/gyno.2000.6042; Rougier JP, 1998, KIDNEY INT, V54, P87, DOI 10.1046/j.1523-1755.1998.00955.x; Rougier JP, 1997, KIDNEY INT, V51, P337, DOI 10.1038/ki.1997.42; Sandberg T, 1998, BIOL REPROD, V59, P759, DOI 10.1095/biolreprod59.4.759; SHETTY S, 1995, ANTISENSE RES DEV, V5, P307, DOI 10.1089/ard.1995.5.307; Sitter T, 1996, AM J PHYSIOL-REG I, V271, pR1256, DOI 10.1152/ajpregu.1996.271.5.R1256; STYLIANOU E, 1990, KIDNEY INT, V37, P1563, DOI 10.1038/ki.1990.150; Suzuki M, 2003, INT J CANCER, V104, P289, DOI 10.1002/ijc.10950; Tietze L, 1998, THROMB HAEMOSTASIS, V79, P362; van Rossen MEE, 2001, J PATHOL, V193, P530; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Zhang H, 2000, CLIN EXP METASTAS, V18, P343	45	57	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26793	26802		10.1074/jbc.M212187200	http://dx.doi.org/10.1074/jbc.M212187200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12743121	hybrid			2022-12-25	WOS:000184155700065
J	Pasternak, SH; Bagshaw, RD; Guiral, M; Zhang, SQ; Ackerley, CA; Pak, BJ; Callahan, JW; Mahuran, DJ				Pasternak, SH; Bagshaw, RD; Guiral, M; Zhang, SQ; Ackerley, CA; Pak, BJ; Callahan, JW; Mahuran, DJ			Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; BETA-PROTEIN; CELL-SURFACE; RAT-LIVER; A-BETA; SUBCELLULAR-LOCALIZATION; ENDOPLASMIC-RETICULUM; INTRAMEMBRANE PROTEOLYSIS; MISSENSE MUTATIONS; TERMINAL FRAGMENTS	Alzheimer's disease (AD) is caused by the cerebral deposition of beta-amyloid (Abeta), a 38-43-amino acid peptide derived by proteolytic cleavage of the amyloid precursor protein (APP). Initial studies indicated that final cleavage of APP by the gamma-secretase (a complex containing presenilin and nicastrin) to produce Abeta occurred in the endosomal/lysosomal system. However, other studies showing a predominant endoplasmic reticulum localization of the gamma-secretase proteins and a neutral pH optimum of in vitro gamma-secretase assays have challenged this conclusion. We have recently identified nicastrin as a major lysosomal membrane protein. In the present work, we use Western blotting and immunogold electron microscopy to demonstrate that significant amounts of mature nicastrin, presenilin-1, and APP are co-localized with lysosomal associated membrane protein-1 (cAMP-1) in the outer membranes of lysosomes. Furthermore, we demonstrate that these membranes contain an acidic gamma-secretase activity, which is immunoprecipitable with an antibody to nicastrin. These experiments establish APP, nicastrin, and presenilin-1 as resident lysosomal membrane proteins and indicate that gamma-secretase is a lysosomal protease. These data reassert the importance of the lysosomal/endosomal system in the generation of Abeta and suggest a role for lysosomes in the pathophysiology of AD.	Univ Toronto, Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Dept Pediat Lab Med, Toronto, ON M5G 1X8, Canada; Univ Toronto, Clinician Investigator Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Pathobiol & Lab Med, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1X8, Canada; Ciphergen Biosyst Inc, Fremont, CA 94555 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto	Mahuran, DJ (corresponding author), Univ Toronto, Hosp Sick Children, Res Inst, Rm 9146A Elm Wing,555 Univ Ave, Toronto, ON M5G 1X8, Canada.	hex@sickkids.ca	Bagshaw, Rick/B-7739-2009	Bagshaw, Rick/0000-0001-5013-4291				Andrews NW, 2000, TRENDS CELL BIOL, V10, P316, DOI 10.1016/S0962-8924(00)01794-3; Annaert W, 1999, TRENDS NEUROSCI, V22, P439, DOI 10.1016/S0166-2236(99)01455-1; Arawaka S, 2002, J NEUROCHEM, V83, P1065, DOI 10.1046/j.1471-4159.2002.01207.x; Bagshaw RD, 2003, BIOCHEM BIOPH RES CO, V300, P615, DOI 10.1016/S0006-291X(02)02865-6; Berezovska O, 2001, J BIOL CHEM, V276, P30018, DOI 10.1074/jbc.M008268200; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; BURNSIDE J, 1982, BIOCHEM J, V204, P525, DOI 10.1042/bj2040525; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; Chen FS, 2000, J BIOL CHEM, V275, P36794, DOI 10.1074/jbc.M006986200; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; D'Andrea MR, 2001, HISTOPATHOLOGY, V38, P120, DOI 10.1046/j.1365-2559.2001.01082.x; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Dewji NN, 1997, P NATL ACAD SCI USA, V94, P9926, DOI 10.1073/pnas.94.18.9926; Evin G, 2001, BIOCHEMISTRY-US, V40, P8359, DOI 10.1021/bi002770t; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Figueiredo-Pereira ME, 1999, J NEUROCHEM, V72, P1417, DOI 10.1046/j.1471-4159.1999.721417.x; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; Gough NR, 1999, J CELL SCI, V112, P4257; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; Hook VYH, 2002, J NEUROCHEM, V81, P237; Hou YM, 1996, AM J HUM GENET, V59, P52; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Ikin AF, 1996, J BIOL CHEM, V271, P31783, DOI 10.1074/jbc.271.50.31783; Jaiswal JK, 2002, J CELL BIOL, V159, P625, DOI 10.1083/jcb.200208154; Ji ZS, 2002, J BIOL CHEM, V277, P21821, DOI 10.1074/jbc.M112109200; Jung SS, 1999, NEUROREPORT, V10, P3875, DOI 10.1097/00001756-199912160-00028; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; KHAN MN, 1981, P NATL ACAD SCI-BIOL, V78, P4980, DOI 10.1073/pnas.78.8.4980; Kim SH, 2000, NEUROBIOL DIS, V7, P99, DOI 10.1006/nbdi.1999.0280; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; KNOPS J, 1995, J BIOL CHEM, V270, P2419, DOI 10.1074/jbc.270.6.2419; Koo EH, 1996, J CELL SCI, V109, P991; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lah JJ, 2000, MOL CELL NEUROSCI, V16, P111, DOI 10.1006/mcne.2000.0861; Lah JJ, 1997, J NEUROSCI, V17, P1971; LeBlanc AC, 1999, J NEUROCHEM, V72, P1832, DOI 10.1046/j.1471-4159.1999.0721832.x; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Mirnics ZK, 2002, BLOOD CELL MOL DIS, V28, P28, DOI 10.1006/bcmd.2002.0486; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Nixon RA, 2000, NEUROCHEM RES, V25, P1161, DOI 10.1023/A:1007675508413; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Robinson J., 1987, ENZYMATIC APPROACH S, P160; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Sadik G, 1999, INT J BIOCHEM CELL B, V31, P1327, DOI 10.1016/S1357-2725(99)00053-9; SchraderFischer G, 1996, BRAIN RES, V716, P91, DOI 10.1016/0006-8993(96)00002-9; SCHWAGERL AL, 1995, J NEUROCHEM, V64, P443; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Selkoe DJ, 2000, ANN NY ACAD SCI, V924, P17; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SIMAN R, 1993, J BIOL CHEM, V268, P16602; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Su Y, 2001, BRAIN RES, V893, P287, DOI 10.1016/S0006-8993(00)03322-9; Takahashi RH, 2002, AM J PATHOL, V161, P1869, DOI 10.1016/S0002-9440(10)64463-X; Taylor RS, 2000, ELECTROPHORESIS, V21, P3441, DOI 10.1002/1522-2683(20001001)21:16<3441::AID-ELPS3441>3.0.CO;2-G; TOMMASINI R, 1985, CAN J BIOCHEM CELL B, V63, P219, DOI 10.1139/o85-031; van der Spoel A, 1998, EMBO J, V17, P1588, DOI 10.1093/emboj/17.6.1588; Wang HY, 2002, NEUROBIOL AGING, V23, P213, DOI 10.1016/S0197-4580(01)00279-2; Waschuk SA, 2001, J BIOL CHEM, V276, P33561, DOI 10.1074/jbc.M103598200; Wattiaux R, 1996, BIOCHEM BIOPH RES CO, V220, P569, DOI 10.1006/bbrc.1996.0444; WATTIAUX R, 1967, NATURE, V216, P1132, DOI 10.1038/2161132a0; Wiltfang J, 2002, J NEUROCHEM, V81, P481, DOI 10.1046/j.1471-4159.2002.00818.x; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Yamazaki T, 1996, J CELL SCI, V109, P999; Yang AJ, 1998, J NEUROSCI RES, V52, P691, DOI 10.1002/(SICI)1097-4547(19980615)52:6<691::AID-JNR8>3.0.CO;2-3; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yip CM, 2001, BIOPHYS J, V80, P1359, DOI 10.1016/S0006-3495(01)76109-7; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436; Zhang LL, 2001, BIOCHEMISTRY-US, V40, P5049, DOI 10.1021/bi0028800	89	237	249	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26687	26694		10.1074/jbc.M304009200	http://dx.doi.org/10.1074/jbc.M304009200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12736250	hybrid			2022-12-25	WOS:000184155700051
J	Philipp, S; Strauss, B; Hirnet, D; Wissenbach, U; Mery, L; Flockerzi, V; Hoth, M				Philipp, S; Strauss, B; Hirnet, D; Wissenbach, U; Mery, L; Flockerzi, V; Hoth, M			TRPC3 mediates T-cell receptor-dependent calcium entry in human T-lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CAPACITATIVE CA2+ ENTRY; OPERATED CATION CHANNELS; STORE DEPLETION; HTRP3 CHANNELS; TRISPHOSPHATE RECEPTOR; POTENTIAL CHANNELS; ENDOTHELIAL-CELLS; B-LYMPHOCYTES; CRAC CHANNELS	Stimulation of the T-cell receptor (TCR) activates Ca2+ entry across the plasma membrane, which is a key triggering event for the T-cell-associated immune response. We show that TRPC3 channels are important for the TCR-dependent Ca2+ entry pathway. The TRPC3 gene was found to be damaged in human T-cell mutants defective in Ca2+ influx. Mutations of the TRPC3 gene were accompanied by changes of TRPC3 gene expression. Introduction of the complete human TRPC3 cDNA into those mutants rescued Ca2+ currents as well as TCR-dependent Ca2+ signals. Our data provide the initial step toward understanding the molecular nature of endogenous Ca2+ channels participating in T-cell activation and put forward TRPC3 as a new target for modulating the immune response.	Univ Saarland, Inst Expt & Klin Pharmakol & Toxikol, D-66421 Homburg, Germany; Univ Saarland, Inst Physiol, D-66421 Homburg, Germany	Saarland University; Saarland University	Philipp, S (corresponding author), Univ Saarland, Inst Expt & Klin Pharmakol & Toxikol, Gebaude 58, D-66421 Homburg, Germany.		Philipp, Stephan/AAR-7519-2020	Philipp, Stephan/0000-0003-1959-9167; Hoth, Markus/0000-0001-7080-4643				Barritt GJ, 1999, BIOCHEM J, V337, P153, DOI 10.1042/0264-6021:3370153; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Broad LM, 1999, J BIOL CHEM, V274, P32881, DOI 10.1074/jbc.274.46.32881; Cui J, 2002, J BIOL CHEM, V277, P47175, DOI 10.1074/jbc.M205870200; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Gamberucci A, 2002, BIOCHEM J, V364, P245, DOI 10.1042/bj3640245; Gebhart E, 2002, INT J ONCOL, V21, P887; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; HOTH M, 1995, PFLUG ARCH EUR J PHY, V430, P315, DOI 10.1007/BF00373905; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Hoth M, 2000, P NATL ACAD SCI USA, V97, P10607, DOI 10.1073/pnas.180143997; Hurst RS, 1998, FEBS LETT, V422, P333, DOI 10.1016/S0014-5793(98)00035-0; Kamouchi M, 1999, J PHYSIOL-LONDON, V518, P345, DOI 10.1111/j.1469-7793.1999.0345p.x; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; LEDEIST F, 1995, BLOOD, V85, P1053, DOI 10.1182/blood.V85.4.1053.bloodjournal8541053; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Luo DL, 2001, J BIOL CHEM, V276, P20186, DOI 10.1074/jbc.M100327200; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 2001, J BIOL CHEM, V276, P18888, DOI 10.1074/jbc.M100944200; McKay RR, 2000, BIOCHEM J, V351, P735, DOI 10.1042/0264-6021:3510735; Mignen O, 2001, J BIOL CHEM, V276, P35676, DOI 10.1074/jbc.M105626200; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Montell C., 2001, SCI STKE; Mori Y, 2002, J EXP MED, V195, P673, DOI 10.1084/jem.20011758; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PARTISETI M, 1994, J BIOL CHEM, V269, P32327; Patterson RL, 2002, CELL, V111, P529, DOI 10.1016/S0092-8674(02)01045-0; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Putney JW, 2001, J CELL SCI, V114, P2223; Sambrock J, 1989, MOL CLONING LAB MANU; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Singer AL, 2002, SCIENCE, V296, P1639, DOI 10.1126/science.1071551; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Thyagarajan B, 2001, J BIOL CHEM, V276, P48149, DOI 10.1074/jbc.M103977200; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Vazquez G, 2002, EMBO J, V21, P4531, DOI 10.1093/emboj/cdf467; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Wissenbach U, 2001, J BIOL CHEM, V276, P19461, DOI 10.1074/jbc.M009895200; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	58	109	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26629	26638		10.1074/jbc.M304044200	http://dx.doi.org/10.1074/jbc.M304044200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12736256	hybrid			2022-12-25	WOS:000184155700045
J	Walter, S; Schrempf, H				Walter, S; Schrempf, H			Oligomerization, membrane anchoring, and cellulose-binding characteristics of AbpS, a receptor-like Streptomyces protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MYCOBACTERIUM-TUBERCULOSIS; SURFACE-PROTEINS; TEICHOIC-ACIDS; COILED-COILS; IDENTIFICATION; LECTIN; GENE; PEPTIDOGLYCAN; COELICOLOR	Streptomyces reticuli produces a 34.6- kDa surface-anchored protein (AbpS) whose surface-exposed N terminus binds strongly to Avicel, a dominantly crystalline type of cellulose. The generation of a large set of mutated abpS-genes and the subsequent analysis of the corresponding proteins in vitro as well as in vivo in a Streptomyces host allow the assignment of the following characteristics for AbpS. (i) Amino acid residues participating directly in the cellulose-interaction are located at the N terminus. (ii) As ascertained by cross-linking experiments, AbpS forms homotetramers in its soluble as well as cellulose-bound form. (iii) The intermolecular assembly of four AbpS molecules is governed by two domains (including amino acids 60-110 and 161-212). Both domains possess large portions of alpha-helical regions in which hydrophobic amino acids are located on one side as known from coiled-coil proteins. (iv) The C-terminal part of AbpS comprising 35 amino acids contains a transmembrane domain. Due to the surface-exposed N terminus of AbpS and the presence of transmembrane helix the C terminus has to be situated in the cytoplasm of the S. reticuli hyphae. Thus AbpS connects the interior of the mycelia with the extracellular space and binds cellulose using a unique cellulose-binding module.	Univ Osnabruck, Fachbereich Biol Chem B, D-49069 Osnabruck, Germany	University Osnabruck	Walter, S (corresponding author), Univ Osnabruck, Fachbereich Biol Chem, Barbarastr 11, D-49069 Osnabruck, Germany.	Stefan.Walter@uni-osnabrueck.de						Alexander M., 1977, Introduction to soil microbiology.; Bayer EA, 1998, CURR OPIN STRUC BIOL, V8, P548, DOI 10.1016/S0959-440X(98)80143-7; BERDY J, 1980, PROCESS BIOCHEM, V15, P28; Berger R, 1998, J BACTERIOL, V180, P6396; Betzler M, 1997, MICROBIOL-SGM, V143, P1243, DOI 10.1099/00221287-143-4-1243; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Chandra NR, 1999, J MOL BIOL, V285, P1157, DOI 10.1006/jmbi.1998.2353; Deller MC, 2000, CURR OPIN STRUC BIOL, V10, P213, DOI 10.1016/S0959-440X(00)00072-5; Dijkstra AJ, 1996, J BACTERIOL, V178, P5555, DOI 10.1128/jb.178.19.5555-5562.1996; Elliot M, 1998, J BACTERIOL, V180, P1549, DOI 10.1128/JB.180.6.1549-1555.1998; Fagan PK, 2001, INFECT IMMUN, V69, P4851, DOI 10.1128/IAI.69.8.4851-4857.2001; Fernandez-Espla MD, 2000, APPL ENVIRON MICROB, V66, P4772, DOI 10.1128/AEM.66.11.4772-4778.2000; Fira D, 2001, J APPL MICROBIOL, V90, P123, DOI 10.1046/j.1365-2672.2001.01226.x; Flock JI, 1999, MOL MED TODAY, V5, P532, DOI 10.1016/S1357-4310(99)01597-X; Hammerschmidt S, 1999, INFECT IMMUN, V67, P1683; HESTER G, 1995, NAT STRUCT BIOL, V2, P472, DOI 10.1038/nsb0695-472; HODGES RS, 1981, J BIOL CHEM, V256, P1214; Hopwood D. A., 1985, GENETIC MANIPULATION; Horinouchi S, 1996, FEMS MICROBIOL LETT, V141, P1; Joh D, 1999, MATRIX BIOL, V18, P211, DOI 10.1016/S0945-053X(99)00025-6; Jung H, 1998, BIOCHEMISTRY-US, V37, P11083, DOI 10.1021/bi980684b; Kelemen GH, 1998, CURR OPIN MICROBIOL, V1, P656, DOI 10.1016/S1369-5274(98)80111-2; Kutzner H., 1981, PROKARYOTES HDB HABI, P2028; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lis H, 1998, CHEM REV, V98, P637, DOI 10.1021/cr940413g; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; Molinari G, 1999, CURR OPIN MICROBIOL, V2, P56, DOI 10.1016/S1369-5274(99)80010-1; Naumova IB, 2001, FEMS MICROBIOL REV, V25, P269, DOI 10.1016/S0168-6445(00)00064-4; NAUMOVA IB, 1980, ARCH MICROBIOL, V126, P71, DOI 10.1007/BF00421893; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; Peczynska-Czoch W., 1988, Actinomycetes in biotechnology., P219; Pethe K, 2001, NATURE, V412, P190, DOI 10.1038/35084083; Pethe K, 2001, MOL MICROBIOL, V39, P89, DOI 10.1046/j.1365-2958.2001.02206.x; PHILLIPS GN, 1981, P NATL ACAD SCI-BIOL, V78, P4689, DOI 10.1073/pnas.78.8.4689; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sauerborn MK, 1999, J MOL BIOL, V290, P185, DOI 10.1006/jmbi.1999.2862; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SCHLOCHTERMEIER A, 1992, APPL ENVIRON MICROB, V58, P3240, DOI 10.1128/AEM.58.10.3240-3248.1992; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; Scott June R., 1993, P53; Stephenson K, 1998, APPL ENVIRON MICROB, V64, P2875; Tillotson RD, 1998, MOL MICROBIOL, V30, P595, DOI 10.1046/j.1365-2958.1998.01093.x; Tormo J, 1996, EMBO J, V15, P5739, DOI 10.1002/j.1460-2075.1996.tb00960.x; VARA J, 1989, J BACTERIOL, V171, P5872, DOI 10.1128/jb.171.11.5872-5881.1989; WACHINGER G, 1989, APPL ENVIRON MICROB, V55, P2653, DOI 10.1128/AEM.55.10.2653-2657.1989; Walter S, 1996, APPL ENVIRON MICROB, V62, P1065, DOI 10.1128/AEM.62.3.1065-1069.1996; Walter S, 1999, APPL ENVIRON MICROB, V65, P886; Walter S, 1998, J BACTERIOL, V180, P1647, DOI 10.1128/JB.180.7.1647-1654.1998; WEST S, 1990, ANAL BIOCHEM, V190, P254, DOI 10.1016/0003-2697(90)90189-G; Wood SD, 1999, ACTA CRYSTALLOGR D, V55, P1264, DOI 10.1107/S0907444999005326; Zou PJ, 1999, MICROBIOL-SGM, V145, P549, DOI 10.1099/13500872-145-3-549	51	12	12	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26639	26647		10.1074/jbc.M212792200	http://dx.doi.org/10.1074/jbc.M212792200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12736266	hybrid			2022-12-25	WOS:000184155700046
J	Hosokawa, N; Tremblay, LO; You, ZP; Herscovics, A; Wada, I; Nagata, K				Hosokawa, N; Tremblay, LO; You, ZP; Herscovics, A; Wada, I; Nagata, K			Enhancement of endoplasmic reticulum (ER) degradation of misfolded null Hong Kong alpha(1)-antitrypsin by human ER mannosidase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN QUALITY-CONTROL; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; PROTEIN; BIOSYNTHESIS; YEAST; ALPHA-1,2-MANNOSIDASE; OLIGOSACCHARIDES; EXPRESSION; CALNEXIN	Misfolded glycoproteins synthesized in the endoplasmic reticulum (ER) are degraded by cytoplasmic proteasomes, a mechanism known as ERAD (ER-associated degradation). In the present study, we demonstrate that ERAD of the misfolded genetic variant-null Hong Kong alpha(1)-antitrypsin is enhanced by overexpression of the ER processing alpha1,2-mannosidase (ER ManI) in HEK 293 cells, indicating the importance of ER ManI in glycoprotein quality control. We showed previously that EDEM, an enzymatically inactive mannosidase homolog, interacts with misfolded alpha1-antitrypsin and accelerates its degradation (Hosokawa, N., Wada, I., Hasegawa, K., Yorihuzi, T., Tremblay, L. O., Herscovics, A., and Nagata, K. (2001) EMBO Rep. 2, 415-422). Herein we demonstrate a combined effect of ER ManI and EDEM on ERAD of misfolded alpha(1)-antitrypsin. We also show that misfolded alpha(1)-antitrypsin NHK contains labeled Glc(1)Man(9)GlcNAc and Man(5-9)GlcNAc released by endo-beta-N-acetylglucosaminidase H in pulse-chase experiments with [2-H-3] mannose. Overexpression of ER ManI greatly increases the formation of Man(8)GlcNAc, induces the formation of Glc(1)Man(8)GlcNAc and increases trimming to Man(5-7)GlcNAc. We propose a model whereby the misfolded glycoprotein interacts with ER ManI and with EDEM, before being recognized by downstream ERAD components. This detailed characterization of oligosaccharides associated with a misfolded glycoprotein raises the possibility that the carbohydrate recognition determinant triggering ERAD may not be restricted to Man(8)GlcNAc(2) isomer B as previous studies have suggested.	Kyoto Univ, Dept Mol & Cellular Biol, Inst Frontier Med Sci, Kyoto 6068397, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Saitama 3320012, Japan; McGill Univ, McGill Canc Ctr, Montreal, PQ HEG 1Y6, Canada; Sapporo Med Univ, Dept Biochem, Sapporo, Hokkaido 0608556, Japan	Kyoto University; Japan Science & Technology Agency (JST); McGill University; Sapporo Medical University	Hosokawa, N (corresponding author), Kyoto Univ, Dept Mol & Cellular Biol, Inst Frontier Med Sci, Kyoto 6068397, Japan.			Wada, Ikuo/0000-0001-5668-6994				Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Cabral CM, 2001, TRENDS BIOCHEM SCI, V26, P619, DOI 10.1016/S0968-0004(01)01942-9; COX DW, 1995, METABOLIC MOL BASES, P4125; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fagioli C, 2001, J BIOL CHEM, V276, P12885, DOI 10.1074/jbc.M009603200; Gonzalez DS, 1999, J BIOL CHEM, V274, P21375, DOI 10.1074/jbc.274.30.21375; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; Herscovics A, 2002, GLYCOBIOLOGY, V12, p14G; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Jakob CA, 2001, EMBO REP, V2, P423; Knop M, 1996, YEAST, V12, P1229, DOI 10.1002/(SICI)1097-0061(19960930)12:12<1229::AID-YEA15>3.0.CO;2-H; LE AQ, 1994, J BIOL CHEM, V269, P7514; Lipari F, 1999, BIOCHEMISTRY-US, V38, P1111, DOI 10.1021/bi981643i; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; MOORE SEH, 1994, J BIOL CHEM, V269, P12715; Nakatsukasa K, 2001, J BIOL CHEM, V276, P8635, DOI 10.1074/jbc.C100023200; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; ROMERO PA, 1985, BIOCHEM J, V226, P733, DOI 10.1042/bj2260733; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; SIFERS RN, 1988, J BIOL CHEM, V263, P7330; Tokunaga F, 2000, J BIOL CHEM, V275, P40757, DOI 10.1074/jbc.M001073200; Tremblay LO, 1999, GLYCOBIOLOGY, V9, P1073, DOI 10.1093/glycob/9.10.1073	26	165	169	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26287	26294		10.1074/jbc.M303395200	http://dx.doi.org/10.1074/jbc.M303395200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12736254	hybrid			2022-12-25	WOS:000183920200128
J	Matsuda, T; Berg, BJV; Bebenek, K; Osheroff, WP; Wilson, SH; Kunkel, TA				Matsuda, T; Berg, BJV; Bebenek, K; Osheroff, WP; Wilson, SH; Kunkel, TA			The base substitution fidelity of DNA polymerase beta-dependent single nucleotide base excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE LYASE ACTIVITY; CELL-EXTRACTS/; IN-VITRO; IOTA; IDENTIFICATION; ENZYME; SPECIFICITY; CORRECT; LAMBDA; GAMMA	Damaged DNA bases are removed from mammalian genomes by base excision repair (BER). Single nucleotide BER requires several enzymatic activities, including DNA polymerase and 5',2'-deoxyribose-5-phosphate lyase. Both activities are intrinsic to four human DNA polymerases whose base substitution error rate during gap-filling DNA synthesis varies by more than 10,000-fold. This suggests that BER fidelity could vary over a wide range in an enzyme dependent manner. To investigate this possibility, here we describe an assay to measure the fidelity of BER reactions reconstituted with purified enzymes. When human uracil DNA glycosylase, AP endonuclease, DNA polymerase beta, and DNA ligase 1 replace uracil opposite template A or G, base substitution error rates are less than or equal to0.3 to less than or equal to2.8 x 10(-4). BER error rates are higher when excess incorrect dNTPs are included in the reaction or when wild type DNA polymerase beta is replaced by DNA polymerase beta variants that fill single nucleotide gaps with lower fidelity. Under these conditions, the base substitution fidelity of polymerase beta-dependent BER is 3-8-fold higher than is single nucleotide gap filling by polymerase beta alone. Thus other proteins in the BER reaction may enhance the base substitution fidelity of DNA polymerase beta during single nucleotide BER.	NIEHS, Mol Genet Lab, NIH, DHHS, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Kunkel, TA (corresponding author), NIEHS, Mol Genet Lab, NIH, DHHS, POB 12233,111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.		Wilson, Samuel H/E-6644-2019; Kunkel, Thomas A./D-5088-2019	Wilson, Samuel H/0000-0002-1702-5293; Kunkel, Thomas A./0000-0002-9900-1788	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065046, Z01ES050158, ZIAES050158] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Beard WA, 2002, J BIOL CHEM, V277, P47393, DOI 10.1074/jbc.M210036200; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bebenek K, 2001, SCIENCE, V291, P2156, DOI 10.1126/science.1058386; Bennett SE, 2001, J BIOL CHEM, V276, P42588, DOI 10.1074/jbc.M106212200; Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8; Chou KM, 2002, NATURE, V415, P655, DOI 10.1038/415655a; Garcia-Diaz M, 2002, J BIOL CHEM, V277, P13184, DOI 10.1074/jbc.M111601200; Garcia-Diaz M, 2001, J BIOL CHEM, V276, P34659, DOI 10.1074/jbc.M106336200; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Kunkel TA, 2003, DNA REPAIR, V2, P135, DOI 10.1016/S1568-7864(02)00224-0; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Mazur DJ, 1999, J BIOL CHEM, V274, P19655, DOI 10.1074/jbc.274.28.19655; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; Osheroff WP, 1999, J BIOL CHEM, V274, P20749, DOI 10.1074/jbc.274.30.20749; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; Sanderson RJ, 1998, J BIOL CHEM, V273, P24822, DOI 10.1074/jbc.273.38.24822; Sanderson RJ, 2001, PROG NUCLEIC ACID RE, V68, P165; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Tissier A, 2000, GENE DEV, V14, P1642; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Wilson SH, 2000, COLD SPRING HARB SYM, V65, P143, DOI 10.1101/sqb.2000.65.143; Zhang YB, 2000, MOL CELL BIOL, V20, P7099, DOI 10.1128/MCB.20.19.7099-7108.2000	30	32	37	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25947	25951		10.1074/jbc.C300170200	http://dx.doi.org/10.1074/jbc.C300170200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12734201	hybrid			2022-12-25	WOS:000183920200087
J	Roman, LJ; McLain, J; Masters, BSS				Roman, LJ; McLain, J; Masters, BSS			Chimeric enzymes of cytochrome P450 oxidoreductase and neuronal nitric-oxide synthase reductase domain reveal structural and functional differences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOINHIBITORY CONTROL ELEMENT; ELECTRON FLOW-THROUGH; CALMODULIN-BINDING; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; FLAVIN DOMAIN; PHOSPHORYLATION; ISOFORMS; ACTIVATION; MODULATION	The nitric-oxide synthases (NOSs) are comprised of an oxygenase domain and a reductase domain bisected by a calmodulin (CaM) binding region. The NOS reductase domains share similar to60% sequence similarity with the cytochrome P450 oxidoreductase (CYPOR), which transfers electrons to microsomal cytochromes P450. The crystal structure of the neuronal NOS ( nNOS) connecting/FAD binding subdomains reveals that the structure of the nNOS-connecting subdomain diverges from that of CYPOR, implying different alignments of the flavins in the two enzymes. We created a series of chimeric enzymes between nNOS and CYPOR in which the FMN binding and the connecting/FAD binding subdomains are swapped. A chimera consisting of the nNOS heme domain and FMN binding subdomain and the CYPOR FAD binding subdomain catalyzed significantly increased rates of cytochrome c reduction in the absence of CaM and of NO synthesis in its presence. Cytochrome c reduction by this chimera was inhibited by CaM. Other chimeras consisting of the nNOS heme domain, the CYPOR FMN binding subdomain, and the nNOS FAD binding subdomain with or without the tail region also catalyzed cytochrome c reduction, were not modulated by CaM, and could not transfer electrons into the heme domain. A chimera consisting of the heme domain of nNOS and the reductase domain of CYPOR reduced cytochrome c and ferricyanide at rates 2-fold higher than that of native CYPOR, suggesting that the presence of the heme domain affected electron transfer through the reductase domain. These data demonstrate that the FMN subdomain of CYPOR cannot effectively substitute for that of nNOS, whereas the FAD subdomains are interchangeable. The differences among these chimeras most likely result from alterations in the alignment of the flavins within each enzyme construct.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Roman, LJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 79229 USA.				NHLBI NIH HHS [HL30050] Funding Source: Medline; NIGMS NIH HHS [GM52419] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030050, R37HL030050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052419] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; Chen PF, 2000, J BIOL CHEM, V275, P13155, DOI 10.1074/jbc.275.17.13155; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Craig DH, 2002, J BIOL CHEM, V277, P33987, DOI 10.1074/jbc.M203118200; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Lane P, 2002, J BIOL CHEM, V277, P19087, DOI 10.1074/jbc.M200258200; Martasek P, 1999, METHOD ENZYMOL, V301, P70; Masters B.S., 2000, NITRIC OXIDE BIOL PA, P91; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; Matsuda H, 1999, BBA-GEN SUBJECTS, V1473, P345, DOI 10.1016/S0304-4165(99)00193-2; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Miller RT, 1999, BIOCHEM BIOPH RES CO, V265, P184, DOI 10.1006/bbrc.1999.1643; Montgomery HJ, 2000, J BIOL CHEM, V275, P5052, DOI 10.1074/jbc.275.7.5052; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Pou S, 1999, J BIOL CHEM, V274, P9573, DOI 10.1074/jbc.274.14.9573; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Roman LJ, 2000, J BIOL CHEM, V275, P21914, DOI 10.1074/jbc.M002449200; Roman LJ, 2002, CHEM REV, V102, P1179, DOI 10.1021/cr000661e; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Sagami I, 2001, J BIOL CHEM, V276, P30036, DOI 10.1074/jbc.M104123200; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SHETA EA, 1994, J BIOL CHEM, V269, P15147; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Zhang J, 2001, J BIOL CHEM, V276, P37506, DOI 10.1074/jbc.M105503200; ZHANG MJ, 1994, BIOCHEMISTRY-US, V33, P1163, DOI 10.1021/bi00171a016	36	26	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25700	25707		10.1074/jbc.M212309200	http://dx.doi.org/10.1074/jbc.M212309200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730215	hybrid			2022-12-25	WOS:000183920200054
J	Beghini, A; Magnani, I; Roversi, G; Piepoli, T; Di Terlizzi, S; Moroni, RF; Pollo, B; Conti, AMF; Cowell, JK; Finocchiaro, G; Larizza, L				Beghini, A; Magnani, I; Roversi, G; Piepoli, T; Di Terlizzi, S; Moroni, RF; Pollo, B; Conti, AMF; Cowell, JK; Finocchiaro, G; Larizza, L			The neural progenitor-restricted isoform of the MARK4 gene in 19q13.2 is upregulated in human gliomas and overexpressed in a subset of glioblastoma cell lines	ONCOGENE			English	Article						glioma; MARK4; neural progenitor; upregulation and overexpression; intrachromosomal amplification; Wnt pathway	HUMAN-MALIGNANT GLIOMAS; EPIDERMAL-GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; TUMOR-SUPPRESSOR GENE; BRAIN-TUMORS; HUMAN ASTROCYTOMAS; FACTOR RECEPTOR; FRAGILE SITES; EXPRESSION; AMPLIFICATION	Alterations of 19q13 are frequently observed in glial neoplasms, suggesting that this region harbors at least one gene involved in gliomagenesis. Following our previous studies on structural 19q chromosome rearrangements in gliomas, we have undertaken a detailed FISH analysis of the breakpoints and identified a 19q13.2 intrachromosomal amplification of the MAP/microtubule affinity-regulating kinase 4 (MARK4) gene in three primary glioblastoma cell lines. Recent data suggest that this gene is involved in the Wnt-signating pathway. We observed that the expression of the alternatively spliced MARK4L isoform is upregulated in both fresh and cultured gliomas and overexpressed in all of the above three glioblastoma cell lines. Interestingly, we also found that MARK4L expression is restricted to undifferentiated neural progenitor cells or proliferating glial precursor cells, whereas its expression is downregulated during glial differentiation. Perturbation of expression using antisense oligonucleotides against MARK4 in glioblastoma cell tines, consistently induced a decreased proliferation of tumor cells. Taken together, these data show that MARK4, which is normally expressed in neural progenitors, is re-expressed in gliomas and may become a key target of intrachromosomal amplification upon 19q rearrangements.	Univ Milan, Dept Biol & Genet, I-20133 Milan, Italy; Ist Nazl Neurol Carlo Besta, I-20133 Milan, Italy; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	University of Milan; IRCCS Istituto Neurologico Besta; Roswell Park Cancer Institute	Beghini, A (corresponding author), Univ Milan, Dept Biol & Genet, Via Viotti 3-5, I-20133 Milan, Italy.	alessandro.beghini@unimi.it	Beghini, Alessandro/F-7306-2012; Finocchiaro, Gaetano/AAG-6791-2020; Pollo, Bianca/K-5347-2018	Pollo, Bianca/0000-0002-5523-4256; Cowell, John/0000-0002-2079-5950; Finocchiaro, Gaetano/0000-0003-3583-4040; Beghini, Alessandro/0000-0002-8234-3474; Moroni, Ramona Frida/0000-0002-0461-3213	NCI NIH HHS [CA76457] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076457] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLO MJ, 1995, INT J CANCER, V64, P207; BIGNER SH, 1988, CANCER RES, V48, P405; Chernova O, 1998, CANCER GENET CYTOGEN, V105, P60, DOI 10.1016/S0165-4608(97)00479-2; Chernova OB, 1998, ONCOGENE, V17, P2873, DOI 10.1038/sj.onc.1202481; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; ELAZOUZI M, 1989, P NATL ACAD SCI USA, V86, P7186, DOI 10.1073/pnas.86.18.7186; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; GUHA A, 1995, INT J CANCER, V60, P168, DOI 10.1002/ijc.2910600206; Hartmann C, 2002, CANCER RES, V62, P4100; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; HENSON JW, 1994, ANN NEUROL, V36, P714, DOI 10.1002/ana.410360505; Holland EC, 2001, NAT REV GENET, V2, P120, DOI 10.1038/35052535; JEN J, 1994, CANCER RES, V54, P6353; Kato T, 2001, NEOPLASIA, V3, P4, DOI 10.1038/sj.neo.7900132; Koch A, 2001, INT J CANCER, V93, P445, DOI 10.1002/ijc.1342; Lee JC, 2000, GLIA, V30, P105, DOI 10.1002/(SICI)1098-1136(200004)30:2<105::AID-GLIA1>3.0.CO;2-H; Louis DN, 2002, CANCER CELL, V1, P125, DOI 10.1016/S1535-6108(02)00040-5; Magnani I, 1999, CANCER GENET CYTOGEN, V110, P82, DOI 10.1016/S0165-4608(98)00190-3; MAGNANI I, 1994, CANCER GENET CYTOGEN, V75, P77, DOI 10.1016/0165-4608(94)90157-0; MARSDEN HB, 1983, INT J CANCER, V31, P439, DOI 10.1002/ijc.2910310408; Megason SG, 2002, DEVELOPMENT, V129, P2087; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Nagase T, 2001, DNA RES, V8, P85, DOI 10.1093/dnares/8.2.85; NOBEL M, 1997, J NEUROONCOL, V35, P193; PEREGO P, 1994, J CANCER RES CLIN, V120, P585, DOI 10.1007/BF01212812; REIFENBERGER G, 1995, CANCER RES, V55, P731; REIFENBERGER G, 1994, CANCER RES, V54, P4299; RITLAND SR, 1995, GENE CHROMOSOME CANC, V12, P277, DOI 10.1002/gcc.2870120407; Rosenberg JE, 1996, ONCOGENE, V13, P2483; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Sano T, 1999, CANCER RES, V59, P1820; Satoh J, 2000, NEUROPATHOLOGY, V20, P113, DOI 10.1046/j.1440-1789.2000.00293.x; SCHROCK E, 1994, AM J PATHOL, V144, P1203; Smith JS, 2000, GENE CHROMOSOME CANC, V29, P16, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1007>3.3.CO;2-9; SUTHERLAND GR, 1995, CURR OPIN GENET DEV, V5, P323, DOI 10.1016/0959-437X(95)80046-8; Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5; TAKAHASHI JA, 1992, J NEUROSURG, V76, P792, DOI 10.3171/jns.1992.76.5.0792; VONDEIMLING A, 1992, CANCER RES, V52, P4277; Vrieling H, 2001, NAT GENET, V28, P101, DOI 10.1038/88794; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Zurawel RH, 1998, CANCER RES, V58, P896	42	61	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2581	2591		10.1038/sj.onc.1206336	http://dx.doi.org/10.1038/sj.onc.1206336			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12735302				2022-12-25	WOS:000182569000006
J	Wagner, KD; Wagner, N; Wellmann, S; Schley, G; Bondke, A; Theres, H; Scholz, H				Wagner, KD; Wagner, N; Wellmann, S; Schley, G; Bondke, A; Theres, H; Scholz, H			Oxygen-regulated expression of the Wilms' tumor suppressor Wt1 involves hypoxia-inducible factor-1 (HIF-1)	FASEB JOURNAL			English	Article						gene regulation; promoter; electrophoretic mobility shift assay; immunohistochemistry; apoptosis	ENDOTHELIAL GROWTH-FACTOR; GENE WT1; TRANSCRIPTION FACTOR; KIDNEY DEVELOPMENT; FACTOR 1-ALPHA; SMOOTH-MUSCLE; PROTEIN; APOPTOSIS; BCL-2; QUANTIFICATION	The Wilms' tumor gene Wt1 is unique among tumor suppressors because of its requirement for the development of certain organs. We recently described de novo expression of Wt1 in myocardial blood vessels of ischemic rat hearts. The purpose of this study was to analyze the mechanism(s) of hypoxic/ischemic induction of Wt1. We show here that Wt1 mRNA and protein is up-regulated in the heart and kidneys of rats exposed to normobaric hypoxia (8% O-2). Ectopic Wt1 immunoreactivity was detected in renal tubules of hypoxic rats, which also expressed the antiapoptotic protein Bcl-2 and contained significantly fewer TUNEL-positive cells than in normoxic kidneys. Wt1 expression was enhanced in the osteosarcoma line U-2OS and in Reh lymphoblast cells that were grown either at 1% O-2 or in the presence of CoCl2 and desferrioxamine, respectively. The promoter of the Wt1 gene was capable of mediating expression of a luciferase reporter in response to hypoxia. We identified a hypoxia-responsive element in the Wt1 sequence that bound to hypoxia-inducible factor-1 (HIF-1) and was required for activation of the Wt1 promoter by CoCl2 and HIF-1. These findings demonstrate that Wt1 expression can be stimulated by hypoxia, which involves activation of the Wt1 promoter by HIF-1.	Humboldt Univ, Charite, Johannes Muller Inst Physiol, D-10117 Berlin, Germany; Humboldt Univ, Charite, Klin Padiat Schwerpunkt Onkol & Hamatol, D-10117 Berlin, Germany; Humboldt Univ, Charite, Innere Med Klin 1, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Scholz, H (corresponding author), Humboldt Univ, Charite, Johannes Muller Inst Physiol, Tucholskystr 2, D-10117 Berlin, Germany.	holger.scholz@charite.de	Wellmann, Sven/A-2771-2017; Wagner, Kay-Dietrich/E-6119-2016	Wagner, Kay-Dietrich/0000-0001-5483-7760; Wagner, Nicole/0000-0002-2746-0707; Schley, Gunnar/0000-0001-9929-5854				An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Beckwith JB, 1998, AM J MED GENET, V79, P268, DOI 10.1002/(SICI)1096-8628(19981002)79:4<268::AID-AJMG7>3.0.CO;2-I; Chien CT, 2000, TRANSPLANT P, V32, P1653, DOI 10.1016/S0041-1345(00)01434-2; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; Dettman RW, 1998, DEV BIOL, V193, P169, DOI 10.1006/dbio.1997.8801; Dong Z, 2001, J BIOL CHEM, V276, P18702, DOI 10.1074/jbc.M011774200; Englert C, 1995, P NATL ACAD SCI USA, V92, P11960, DOI 10.1073/pnas.92.26.11960; English MA, 1999, J BIOL CHEM, V274, P13258, DOI 10.1074/jbc.274.19.13258; Freeburg Paul B., 2001, Journal of the American Society of Nephrology, V12, p520A; GERALL AA, 1992, HDB BEHAVIORAL NEURO, V11, P1; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRUBB GR, 1994, LAB INVEST, V71, P472; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; HEWITT SM, 1995, CANCER RES, V55, P5386; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Karth J, 2000, J PEDIATR SURG, V35, P1749, DOI 10.1053/jpsu.2000.19241; KNUDSON AG, 1972, AM J HUM GENET, V24, P514; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Kreuzer KA, 2001, BRIT J HAEMATOL, V114, P313, DOI 10.1046/j.1365-2141.2001.02912.x; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Leuenroth SJ, 2000, SURGERY, V128, P171, DOI 10.1067/msy.2000.107609; LITTLE MH, 1992, ONCOGENE, V7, P635; MALIK KTA, 1994, FEBS LETT, V349, P75, DOI 10.1016/0014-5793(94)00642-3; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Moore AW, 1999, DEVELOPMENT, V126, P1845; MUNDLOS S, 1993, DEVELOPMENT, V119, P1329; NOVACK DV, 1994, AM J PATHOL, V145, P61; Peeters MPFMV, 1999, ANAT EMBRYOL, V199, P367, DOI 10.1007/s004290050235; Piret JP, 2002, BIOCHEM PHARMACOL, V64, P889, DOI 10.1016/S0006-2952(02)01155-3; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; Rosenberger C, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017223.49823.2A; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; Schedl A, 2000, CURR OPIN GENET DEV, V10, P543, DOI 10.1016/S0959-437X(00)00125-8; Scholz F, 1997, J SOLID STATE ELECTR, V1, P1, DOI 10.1007/s100080050017; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Wagner KD, 2002, FASEB J, V16, P1117, DOI 10.1096/fj.01-0986fje; Wagner KD, 2002, EMBO J, V21, P1398, DOI 10.1093/emboj/21.6.1398; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wellmann S, 2001, CLIN CHEM, V47, P654; Wenger RH, 1998, EUR J BIOCHEM, V253, P771, DOI 10.1046/j.1432-1327.1998.2530771.x; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev	44	83	85	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1364	+		10.1096/fj.02-1065fje	http://dx.doi.org/10.1096/fj.02-1065fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738801				2022-12-25	WOS:000183165000036
J	Janssen, E; Terzic, A; Wieringa, B; Dzeja, PP				Janssen, E; Terzic, A; Wieringa, B; Dzeja, PP			Impaired intracellular energetic communication in muscles from creatine kinase and adenylate kinase (M-CK/AK1) double knock-out mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTACT SKELETAL-MUSCLE; SENSITIVE K+ CHANNELS; FAST-TWITCH MUSCLE; CATALYZED PHOSPHOTRANSFER; PHOSPHORYL TRANSFER; MITOCHONDRIAL-FUNCTION; DEFICIENT MUSCLES/; P-31 NMR; HEART; COMPARTMENTATION	Previously we demonstrated that efficient coupling between cellular sites of ATP production and ATP utilization, required for optimal muscle performance, is mainly mediated by the combined activities of creatine kinase (CK)- and adenylate kinase (AK)-catalyzed phosphotransfer reactions. Herein, we show that simultaneous disruption of the genes for the cytosolic M-CK- and AK1 isoenzymes compromises intracellular energetic communication and severely reduces the cellular capability to maintain total ATP turnover under muscle functional load. M-CK/AK1 (MAK(=/=)) mutant skeletal muscle displayed aberrant ATP/ADP, ADP/AMP and ATP/GTP ratios, reduced intracellular phosphotransfer communication, and increased ATP supply capacity as assessed by O-18 labeling of [P-i] and [ATP]. An analysis of actomyosin complexes in vitro demonstrated that one of the consequences of M-CK and AK1 deficiency is hampered phosphoryl delivery to the actomyosin ATPase, resulting in a loss of contractile performance. These results suggest that MAK(=/=) muscles are energetically less efficient than wild-type muscles, but an apparent compensatory redistribution of high-energy phosphoryl flux through glycolytic and guanylate phosphotransfer pathways limited the overall energetic deficit. Thus, this study suggests a coordinated network of complementary enzymatic pathways that serve in the maintenance of energetic homeostasis and physiological efficiency.	Univ Nijmegen, Fac Med, Univ Med Ctr, Nijmegen Ctr Mol Life Sci,Dept Cell Biol, NL-6500 HB Nijmegen, Netherlands; Mayo Clin, Dept Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin, Dept Mol Pharmacol, Rochester, MN 55905 USA; Mayo Clin, Dept Expt Therapeut, Rochester, MN 55905 USA	Radboud University Nijmegen; Mayo Clinic; Mayo Clinic; Mayo Clinic	Wieringa, B (corresponding author), Univ Nijmegen, Fac Med, Univ Med Ctr, Nijmegen Ctr Mol Life Sci,Dept Cell Biol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	b.wieringa@ncmls.kun.nl	Wieringa, Berend/A-5346-2011	Wieringa, Berend/0000-0001-9192-8020	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064822] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64822] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham MR, 2002, J BIOL CHEM, V277, P24427, DOI 10.1074/jbc.M201777200; Askenasy N, 2002, AM J PHYSIOL-CELL PH, V282, pC338, DOI 10.1152/ajpcell.00404.2001; Atkinson DE, 1977, CELLULAR ENERGY META, DOI DOI 10.1016/C2009-0-03136-5; Bergeron R, 2001, AM J PHYSIOL-ENDOC M, V281, pE1340, DOI 10.1152/ajpendo.2001.281.6.E1340; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; BRDICZKA D, 1994, BBA-BIOENERGETICS, V1187, P264, DOI 10.1016/0005-2728(94)90124-4; Carrasco AJ, 2001, P NATL ACAD SCI USA, V98, P7623, DOI 10.1073/pnas.121038198; Chen GP, 2001, AM J PHYSIOL-CELL PH, V281, pC114, DOI 10.1152/ajpcell.2001.281.1.C114; Collavin L, 1999, ONCOGENE, V18, P5879, DOI 10.1038/sj.onc.1202970; Conley KE, 2001, J EXP BIOL, V204, P3189; de Groof AJC, 2001, FEBS LETT, V506, P73, DOI 10.1016/S0014-5793(01)02879-4; de Groof AJC, 2001, MUSCLE NERVE, V24, P1188, DOI 10.1002/mus.1131; DOLKEN G, 1975, HISTOCHEMISTRY, V43, P113, DOI 10.1007/BF00492440; Dzeja P P, 2000, Curr Cardiol Rep, V2, P212, DOI 10.1007/s11886-000-0071-9; Dzeja PP, 1996, J BIOL CHEM, V271, P12847, DOI 10.1074/jbc.271.22.12847; Dzeja PP, 1999, CIRC RES, V84, P1137, DOI 10.1161/01.RES.84.10.1137; Dzeja PP, 1998, MOL CELL BIOCHEM, V184, P169, DOI 10.1023/A:1006859632730; Dzeja PP, 1998, FASEB J, V12, P523, DOI 10.1096/fasebj.12.7.523; Dzeja PP, 2002, P NATL ACAD SCI USA, V99, P10156, DOI 10.1073/pnas.152259999; ElvirMairena JR, 1996, J BIOL CHEM, V271, P31903, DOI 10.1074/jbc.271.50.31903; Hochachka PW, 1999, P NATL ACAD SCI USA, V96, P12233, DOI 10.1073/pnas.96.22.12233; HONIG CR, 1968, AM J PHYSIOL, V214, P357, DOI 10.1152/ajplegacy.1968.214.2.357; Huser J, 2000, J PHYSIOL-LONDON, V524, P795, DOI 10.1111/j.1469-7793.2000.00795.x; Janssen E, 2000, EMBO J, V19, P6371, DOI 10.1093/emboj/19.23.6371; Janssen E, 2003, J BIOL CHEM, V278, P12937, DOI 10.1074/jbc.M211465200; JANSSEN E, 2003, IN PRESS MOL CELL BI; Kaasik A, 2001, CIRC RES, V89, P153, DOI 10.1161/hh1401.093440; KORGE P, 1995, SPORTS MED, V20, P215, DOI 10.2165/00007256-199520040-00002; Kraft T, 2000, J MUSCLE RES CELL M, V21, P691, DOI 10.1023/A:1005623002979; LaBella JJ, 1998, J APPL PHYSIOL, V84, P1166, DOI 10.1152/jappl.1998.84.4.1166; Lu Q, 1996, P NATL ACAD SCI USA, V93, P5720, DOI 10.1073/pnas.93.12.5720; Noda L, 1973, ENZYMES; OGorman E, 1996, BBA-BIOENERGETICS, V1276, P161, DOI 10.1016/0005-2728(96)00074-6; Ottaway J H, 1977, Curr Top Cell Regul, V12, P107; Parra J, 1997, FEBS LETT, V403, P279, DOI 10.1016/S0014-5793(97)00047-1; Pucar D, 2002, AM J PHYSIOL-HEART C, V283, pH776, DOI 10.1152/ajpheart.00116.2002; Pucar D, 2000, J BIOL CHEM, V275, P41424, DOI 10.1074/jbc.M007903200; Pucar D, 2001, J BIOL CHEM, V276, P44812, DOI 10.1074/jbc.M104425200; RAY NB, 1992, CURR TOP CELL REGUL, V33, P343; REDDY YS, 1976, CARDIOVASC RES, V10, P129, DOI 10.1093/cvr/10.1.129; ROSSI AM, 1990, J BIOL CHEM, V265, P5258; SAKO EY, 1988, J BIOL CHEM, V263, P10600; Saks V, 1998, MOL CELL BIOCHEM, V184, P291, DOI 10.1023/A:1006828106322; SAVABI F, 1994, MOL CELL BIOCHEM, V133, P145, DOI 10.1007/BF01267953; SAVABI F, 1986, BIOCHEM MED METAB B, V35, P227, DOI 10.1016/0885-4505(86)90078-2; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; Schlattner U, 2000, J BIOL CHEM, V275, P17314, DOI 10.1074/jbc.M001919200; Steeghs K, 1998, MOL CELL BIOCHEM, V184, P183, DOI 10.1023/A:1006811717709; Steeghs K, 1997, CELL, V89, P93, DOI 10.1016/S0092-8674(00)80186-5; Stolworthy TS, 2001, PROTEIN ENG, V14, P903, DOI 10.1093/protein/14.11.903; 't Zandt HJAI, 1999, NMR BIOMED, V12, P327, DOI 10.1002/(SICI)1099-1492(199910)12:6<327::AID-NBM570>3.0.CO;2-9; TANABE T, 1993, J BIOCHEM-TOKYO, V113, P200, DOI 10.1093/oxfordjournals.jbchem.a124026; Van Rompay AR, 1999, EUR J BIOCHEM, V261, P509, DOI 10.1046/j.1432-1327.1999.00294.x; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VEKSLER VI, 1995, J BIOL CHEM, V270, P19921, DOI 10.1074/jbc.270.34.19921; WALLIMANN T, 1983, J MUSCLE RES CELL M, V4, P429, DOI 10.1007/BF00711948; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WEGMANN G, 1992, J MUSCLE RES CELL M, V13, P420, DOI 10.1007/BF01738037; Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9; Yoneda T, 1998, MOL BRAIN RES, V62, P187, DOI 10.1016/S0169-328X(98)00249-6; ZELEZNIKAR RJ, 1990, J BIOL CHEM, V265, P300; ZELEZNIKAR RJ, 1991, J BIOL CHEM, V266, P15110; ZELEZNIKAR RJ, 1995, J BIOL CHEM, V270, P7311, DOI 10.1074/jbc.270.13.7311	65	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30441	30449		10.1074/jbc.M303150200	http://dx.doi.org/10.1074/jbc.M303150200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12730234	Green Published, hybrid			2022-12-25	WOS:000184658800007
J	Veal, EA; Ross, SJ; Malakasi, P; Peacock, E; Morgan, BA				Veal, EA; Ross, SJ; Malakasi, P; Peacock, E; Morgan, BA			Ybp1 is required for the hydrogen peroxide-induced oxidation of the Yap1 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; STRESS-RESPONSE; NUCLEAR EXPORT; AUTONOMOUS PLASMIDS; CANDIDA-ALBICANS; ESCHERICHIA-COLI; THIOL PEROXIDASE; GENE-EXPRESSION; PROTEINS	We describe the characterization of Ybp1, a novel protein, in Saccharomyces cerevisiae, that is required for the oxidative stress response to peroxides. Ybp1 is required for H2O2-induced expression of the antioxidant encoding gene TRX2. Our data indicate that the effects of Ybp1 are mediated through the Yap1 transcription factor. Indeed, Ybp1 forms a stress-induced complex with Yap1 in vivo and stimulates the nuclear accumulation of Yap1 in response to H2O2 but not in response to the thiol-oxidizing agent diamide. The H2O2-induced nuclear accumulation of Yap1 is regulated by the oxidation of specific cysteine residues and is dependent on the thiol peroxidase Gpx3. Our data suggest that Ybp1 is required for the H2O2-induced oxidation of Yap1 and acts in the same pathway as Gpx3. Consequently, Ybp1 represents a novel class of stress regulator of Yap1. These data have important implications for the regulation of protein oxidation and stress responses in eukaryotes.	Univ Newcastle Upon Tyne, Fac Med Sci, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Morgan, BA (corresponding author), Univ Newcastle Upon Tyne, Fac Med Sci, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Veal, Elizabeth/0000-0002-1152-5473				Alarco AM, 1999, J BACTERIOL, V181, P700, DOI 10.1128/JB.181.3.700-708.1999; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; Babior BM, 2000, AM J MED, V109, P33, DOI 10.1016/S0002-9343(00)00481-2; BARTEL PL, 1993, DEV PRACTICAL APPROA, P153; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Coleman ST, 1999, MOL CELL BIOL, V19, P8302; Craven RA, 1998, GENE, V221, P59, DOI 10.1016/S0378-1119(98)00434-X; Delaunay A, 2000, EMBO J, V19, P5157, DOI 10.1093/emboj/19.19.5157; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; Ferreira MCD, 2001, CURR GENET, V40, P27, DOI 10.1007/s002940100237; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Higgins VJ, 2002, YEAST, V19, P203, DOI 10.1002/yea.811; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Isoyama T, 2001, J BIOL CHEM, V276, P21863, DOI 10.1074/jbc.M009258200; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; James P, 1996, GENETICS, V144, P1425; Jamieson DJ, 1998, YEAST, V14, P1511, DOI 10.1002/(SICI)1097-0061(199812)14:16<1511::AID-YEA356>3.3.CO;2-J; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Kuge S, 2001, MOL CELL BIOL, V21, P6139, DOI 10.1128/MCB.21.18.6139-6150.2001; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; MORGAN BA, 1995, EMBO J, V14, P5679, DOI 10.1002/j.1460-2075.1995.tb00255.x; Morgan BA, 1997, EMBO J, V16, P1035, DOI 10.1093/emboj/16.5.1035; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; Ross SJ, 2000, MOL BIOL CELL, V11, P2631, DOI 10.1091/mbc.11.8.2631; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Sherman F., 1986, METHODS YEAST GENETI; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toone WM, 2001, ONCOGENE, V20, P2336, DOI 10.1038/sj.onc.1204384; Toone WM, 1999, CURR OPIN GENET DEV, V9, P55, DOI 10.1016/S0959-437X(99)80008-2; WEMMIE JA, 1997, J BIOL CHEM, V272, P7809; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Zhang XT, 2000, MOL MICROBIOL, V36, P618, DOI 10.1046/j.1365-2958.2000.01877.x; ZHAO LJ, 1993, GENE, V137, P345, DOI 10.1016/0378-1119(93)90032-X	43	113	126	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30896	30904		10.1074/jbc.M303542200	http://dx.doi.org/10.1074/jbc.M303542200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12743123	hybrid			2022-12-25	WOS:000184658800062
J	Jones, C; Hammer, RE; Li, WP; Cohen, JC; Hobbs, HH; Herz, J				Jones, C; Hammer, RE; Li, WP; Cohen, JC; Hobbs, HH; Herz, J			Normal sorting but defective endocytosis of the low density lipoprotein receptor in mice with autosomal recessive hypercholesterolemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LDL-RECEPTOR; APOLIPOPROTEIN-E; FAMILIAL HYPERCHOLESTEROLEMIA; HOMOLOGOUS RECOMBINATION; CYTOSOLIC ADAPTER; KNOCKOUT MICE; PROTEIN; GENE; DISRUPTION; MUTATIONS	Autosomal recessive hypercholesterolemia (ARH) is a genetic form of hypercholesterolemia that clinically resembles familial hypercholesterolemia (FH). As in FH, the rate of clearance of circulating low density lipoprotein (LDL) by the LDL receptor (LDLR) in the liver is markedly reduced in ARH. Unlike FH, LDL uptake in cultured fibroblasts from ARH patients is normal or only slightly impaired. The gene defective in ARH encodes a putative adaptor protein that has been implicated in linking the LDLR to the endocytic machinery. To determine the role of ARH in the liver, ARH-deficient mice were developed. Plasma levels of LDL-cholesterol were elevated in the chow-fed Arh(-/-) mice (83+/-8 mg/dl versus 68+/-8 mg/dl) but were lower than those of mice expressing no LDLR (Ldlr(-/-)) (197+/-8 mg/dl). Cholesterol feeding elevated plasma cholesterol levels in both strains. The fractional clearance rate of radiolabeled LDL was reduced to similar levels in the Arh(-/-) and Ldlr(-/-) mice, whereas the rate of removal of alpha2-macroglobulin by the LDLR-related protein, which also interacts with ARH, was unchanged. Immunolocalization studies revealed that a much greater proportion of immunodetectable LDLR, but not LDLR-related protein, was present on the sinusoidal surface of hepatocytes in the Arh(-/-) mice. Taken together, these results are consistent with ARH playing a critical and specific role in LDLR endocytosis in the liver.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Human Nutr, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Herz, J (corresponding author), 5323 Harry Hinnes Blvd, Dallas, TX 75390 USA.	Joachim.Herz@utsouthwestern.edu		Hammer, Robert E./0000-0001-5487-7551	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063762, P01HL020948, R37HL063762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043408] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948, R37 HL063762, HL63762] Funding Source: Medline; NINDS NIH HHS [NS43408] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arca M, 2002, LANCET, V359, P841, DOI 10.1016/S0140-6736(02)07955-2; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHOI SY, 1993, J BIOL CHEM, V268, P15804; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; Eden ER, 2002, J CLIN INVEST, V110, P1695, DOI 10.1172/JCI200216445; Forman-Kay JD, 1999, CURR OPIN STRUC BIOL, V9, P690, DOI 10.1016/S0959-440X(99)00031-7; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Garcia CK, 2001, SCIENCE, V292, P1394, DOI 10.1126/science.1060458; Garcia-Garcia A B, 2001, Hum Mutat, V18, P458, DOI 10.1002/humu.1218; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Goldstein JL, 2001, SCIENCE, V292, P1310, DOI 10.1126/science.1061815; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Gotthardt M, 2003, J BIOL CHEM, V278, P6059, DOI 10.1074/jbc.M211723200; He GC, 2002, J BIOL CHEM, V277, P44044, DOI 10.1074/jbc.M208539200; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Koivisto UM, 2001, CELL, V105, P575, DOI 10.1016/S0092-8674(01)00371-3; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; Li YH, 2001, J BIOL CHEM, V276, P18000, DOI 10.1074/jbc.M101589200; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Mishra SK, 2002, P NATL ACAD SCI USA, V99, P16099, DOI 10.1073/pnas.252630799; Morris SM, 2002, EMBO J, V21, P1555, DOI 10.1093/emboj/21.7.1555; Norman D, 1999, J CLIN INVEST, V104, P619, DOI 10.1172/JCI6677; OSONO Y, 1995, J CLIN INVEST, V95, P1124, DOI 10.1172/JCI117760; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Rodman JS, 2000, J CELL SCI, V113, P183; Rohlmann A, 1996, NAT BIOTECHNOL, V14, P1562, DOI 10.1038/nbt1196-1562; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; Sambrook J., 2001, MOL CLONING LAB MANU; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Stockinger W, 2002, EMBO J, V21, P4259, DOI 10.1093/emboj/cdf435; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Twisk J, 2000, J CLIN INVEST, V105, P521, DOI 10.1172/JCI8623; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1994, METHOD CELL BIOL, V43, P305; Wilund KR, 2002, HUM MOL GENET, V11, P3019, DOI 10.1093/hmg/11.24.3019; Yan KS, 2002, FEBS LETT, V513, P67, DOI 10.1016/S0014-5793(01)03305-1; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210; Zuliani G, 1999, ARTERIOSCL THROM VAS, V19, P802, DOI 10.1161/01.ATV.19.3.802; ZULIANI G, 1995, EUR J CLIN INVEST, V25, P322, DOI 10.1111/j.1365-2362.1995.tb01709.x	42	74	82	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29024	29030		10.1074/jbc.M304855200	http://dx.doi.org/10.1074/jbc.M304855200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12746448	hybrid			2022-12-25	WOS:000184421100084
J	Zhu, YM; Bradbury, DA; Pang, LH; Knox, AJ				Zhu, YM; Bradbury, DA; Pang, LH; Knox, AJ			Transcriptional regulation of interleukin (IL)-8 by bradykinin in human airway smooth muscle cells involves prostanoid-dependent activation of AP-1 and nuclear factor (NF)-IL-6 and prostanoid-independent activation of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-INDUCED SECRETION; PROTEIN-KINASE-C; CYCLOOXYGENASE-2 EXPRESSION; GENE-EXPRESSION; EOTAXIN RELEASE; PATHWAY; BETA(2)-AGONISTS; TRANSLOCATION; STIMULATION; MODULATION	Bradykinin (BK) is a potent neutrophil chemotractant, proinflammatory mediator, and angiogenic factor, which acts through G protein-coupled receptors (GPCRs). Here we studied the mechanisms involved in IL-8 generation by BK in human airway smooth muscle cells focusing on the transcription factors involved and role of endogenous prostanoids in transcription factor activation. Transfection experiments with wild-type IL-8 promoter constructs or constructs with NF-kappaB, AP-1, and NF-IL-6 binding site mutations suggested that all three transcription factors were necessary for optimal IL-8 expression. BK increased NF-kappaB, AP-1, and NF-IL-6 binding to the IL-8 promoter by electrophoretic mobility shift assay. NF-kappaB, the most important transcription factor in the current study, was translocated to the nucleus after BK stimulation. Indomethacin, a cyclooxygenase inhibitor, partially inhibited IL-8 release and the promoter binding of AP-1 and NF-IL-6, but not NF-kappaB. Furthermore, exogenous prostaglandin E-2 stimulated AP-1 and NF-IL-6 binding to the IL-8 promoter. The anti-inflammatory glucocorticoid dexamethasone inhibited NF-kappaB translocation and the promoter binding of NF-kappaB, AP-1, and NF-IL-6. These results are the first to delineate the transcription factors involved in BK induced IL-8 release. Transcriptional activation of the IL-8 promoter by BK involves the prostanoid-independent activation of NF-kappaB, and prostanoid-dependent activation of AP-1 and NF- IL-6 plays a key role in augmenting the response. Endogenous prostanoid generation in response to GPCR ligands such as BK may be an important mechanism whereby GPCRs signal to the nucleus to maximize the transcription of inflammatory response genes.	Univ Nottingham, Div Resp Med, Sch Med & Surg Sci, Nottingham NG5 1PB, England	University of Nottingham	Knox, AJ (corresponding author), City Hosp, Div Resp Med, Clin Sci Bldg,Hucknall Rd, Nottingham NG5 1PB, England.	alan.knox@nottingham.ac.uk		Knox, Alan/0000-0002-5906-4143				Ammit AJ, 2002, AM J RESP CELL MOL, V26, P465, DOI 10.1165/ajrcmb.26.4.4681; Ammit AJ, 2000, AM J RESP CELL MOL, V23, P794, DOI 10.1165/ajrcmb.23.6.4184; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BARNES PJ, 1992, THORAX, V47, P979, DOI 10.1136/thx.47.11.979; Bernier SG, 2000, J BIOL CHEM, V275, P30707, DOI 10.1074/jbc.M005116200; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Brasier AR, 1998, J BIOL CHEM, V273, P3551, DOI 10.1074/jbc.273.6.3551; Casola A, 2000, J IMMUNOL, V164, P5944, DOI 10.4049/jimmunol.164.11.5944; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Fong CY, 2000, AM J PHYSIOL-LUNG C, V279, pL201, DOI 10.1152/ajplung.2000.279.1.L201; Hayashi R, 1998, IMMUNOLOGY, V95, P507, DOI 10.1046/j.1365-2567.1998.00649.x; HONG SCL, 1976, J BIOL CHEM, V251, P5814; HU DE, 1993, INFLAMMATION, V17, P135, DOI 10.1007/BF00916100; Johnson SR, 1997, TRENDS PHARMACOL SCI, V18, P288, DOI 10.1016/S0165-6147(97)01092-4; Knox AJ, 2001, FASEB J, V15, P2480, DOI 10.1096/fj.01-0256com; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Lehmann T, 2002, J RHEUMATOL, V29, P787; Mombouli JV, 1999, J MOL CELL CARDIOL, V31, P61, DOI 10.1006/jmcc.1998.0844; Moore PE, 2002, AM J PHYSIOL-LUNG C, V282, pL847, DOI 10.1152/ajplung.00245.2001; Naraba H, 1998, FEBS LETT, V435, P96, DOI 10.1016/S0014-5793(98)01045-X; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; Pan ZXK, 1998, J IMMUNOL, V160, P3038; Pang LH, 1998, J IMMUNOL, V161, P2509; Pang LH, 2003, J IMMUNOL, V170, P1043, DOI 10.4049/jimmunol.170.2.1043; Pang LH, 2002, FASEB J, V16, P1435, DOI 10.1096/fj.02-0169fje; Pang LH, 1997, AM J PHYSIOL-LUNG C, V273, pL1132, DOI 10.1152/ajplung.1997.273.6.L1132; Pang LH, 2001, FASEB J, V15, P261, DOI 10.1096/fj.00-0103com; Pang LH, 2000, AM J RESP CELL MOL, V23, P79, DOI 10.1165/ajrcmb.23.1.3985; RAHMAN S, 1992, BIOCHIM BIOPHYS ACTA, V1135, P97, DOI 10.1016/0167-4889(92)90172-8; Shi CS, 2001, J BIOL CHEM, V276, P31845, DOI 10.1074/jbc.M101043200; TRIFILIEFF A, 1993, EUR RESPIR J, V6, P576; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200	32	59	63	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29366	29375		10.1074/jbc.M301785200	http://dx.doi.org/10.1074/jbc.M301785200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12748173	hybrid			2022-12-25	WOS:000184421100123
J	Marques, CA; Keil, U; Bonert, A; Steiner, B; Haass, C; Muller, WE; Eckert, A				Marques, CA; Keil, U; Bonert, A; Steiner, B; Haass, C; Muller, WE; Eckert, A			Neurotoxic mechanisms caused by the Alzheimer's disease-linked Swedish amyloid precursor protein mutation - Oxidative stress, caspases, and the JNK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; A-BETA PEPTIDE; TROPHIC FACTOR WITHDRAWAL; CYTOCHROME-C RELEASE; INDUCED CELL-DEATH; TRANSGENIC MICE; PC12 CELLS; NEURONAL APOPTOSIS; NERVOUS-SYSTEM; CYTOPLASMIC DOMAIN	Autosomal dominant forms of familial Alzheimer's disease (FAD) are caused by mutations of the amyloid precursor protein (APP) gene and by mutations of the genes encoding for presenilin 1 or presenilin 2. Simultaneously, evidence is provided that increased oxidative stress might play a crucial role in the rapid progression of the Swedish FAD. Here we investigated the effect of the Swedish double mutation (K670M/N671L) in the beta-amyloid precursor protein on oxidative stress-induced cell death mechanisms in PC12 cells. Western blot analysis and cleavage studies of caspase substrates revealed an elevated activity of the executor caspase 3 after treatment with hydrogen peroxide in cells containing the Swedish APP mutation. This elevated activity is the result of the enhanced activation of both intrinsic and extrinsic apoptosis pathways, including activation of caspase 2 and caspase 8. Furthermore, we observed an enhanced activation of JNK pathway and an attenuation of apoptosis by SP600125, a JNK inhibitor, through protection of mitochondrial dysfunction and reduction of caspase 9 activity. Our findings provide evidence that the massive neurodegeneration in early age of FAD patients could be a result of an increased vulnerability of neurons through activation of different apoptotic pathways as a consequence of elevated levels of oxidative stress.	Goethe Univ Frankfurt, Bioctr, Dept Pharmacol, D-60439 Frankfurt, Germany; Adolf Butenandt Inst, Dept Biochem, D-80336 Munich, Germany	Goethe University Frankfurt; University of Munich	Eckert, A (corresponding author), Goethe Univ Frankfurt, Bioctr, Dept Pharmacol, Bldg N260,Marie Curie Str 9, D-60439 Frankfurt, Germany.	A.Eckert@em.uni-frankfurt.de		Muller, Werner E.G./0000-0002-8223-3689; Marques, Celio/0000-0002-8438-2354; Eckert, Anne/0000-0002-9341-3669				Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bogdanovic N, 2001, DEMENT GERIATR COGN, V12, P364, DOI 10.1159/000051282; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Chishti MA, 2001, J BIOL CHEM, V276, P21562, DOI 10.1074/jbc.M100710200; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cotman CW, 1998, NEUROBIOL AGING, V19, pS29, DOI 10.1016/S0197-4580(98)00042-6; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Eckert A, 2001, J NEUROSCI RES, V64, P183, DOI 10.1002/jnr.1064; Eckert A, 2001, NEUROBIOL DIS, V8, P331, DOI 10.1006/nbdi.2000.0378; ECKERT A, IN PRESS BIOCH PHARM; Gau JT, 2002, AM J PATHOL, V160, P731, DOI 10.1016/S0002-9440(10)64893-6; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Ghahremani MH, 2002, J BIOL CHEM, V277, P35586, DOI 10.1074/jbc.M204362200; Gibson GE, 2002, FREE RADICAL BIO MED, V32, P1061, DOI 10.1016/S0891-5849(02)00802-X; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Gottlieb RA, 2002, METHODS, V26, P341, DOI 10.1016/S1046-2023(02)00040-3; Guo Q, 1997, J NEUROSCI, V17, P4212; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; HAASS C, 1994, J BIOL CHEM, V269, P17741; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Hartmann T, 1999, EUR ARCH PSY CLIN N, V249, P291, DOI 10.1007/s004060050102; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Ivins KJ, 1999, NEUROBIOL DIS, V6, P440, DOI 10.1006/nbdi.1999.0268; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Leutner S, 2000, NEUROSCI LETT, V292, P87, DOI 10.1016/S0304-3940(00)01449-X; Leutz S, 2002, J MOL NEUROSCI, V18, P189, DOI 10.1385/JMN:18:3:189; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Luth HJ, 2002, BRAIN RES, V953, P135, DOI 10.1016/S0006-8993(02)03280-8; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Matsuda S, 2001, J NEUROSCI, V21, P6597; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MESNER PW, 1995, J NEUROSCI, V15, P7357; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Rottkamp CA, 2001, FREE RADICAL BIO MED, V30, P447, DOI 10.1016/S0891-5849(00)00494-9; Sajithlal G, 2002, J BIOL CHEM, V277, P6888, DOI 10.1074/jbc.M107627200; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Savage MJ, 2002, J NEUROSCI, V22, P3376; Scheinfeld MH, 2002, J BIOL CHEM, V277, P3767, DOI 10.1074/jbc.M108357200; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Soreghan B, 2002, NEUROMOL MED, V1, P81; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Suzaki Y, 2002, J BIOL CHEM, V277, P9614, DOI 10.1074/jbc.M111790200; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tabner BJ, 2002, FREE RADICAL BIO MED, V32, P1076, DOI 10.1016/S0891-5849(02)00801-8; Tamagno E, 2002, NEUROBIOL DIS, V10, P279, DOI 10.1006/nbdi.2002.0515; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; Taru H, 2002, J BIOL CHEM, V277, P20070, DOI 10.1074/jbc.M108372200; Taru H, 2002, J BIOL CHEM, V277, P27567, DOI 10.1074/jbc.M203713200; Torok M, 2002, J BIOL CHEM, V277, P40810, DOI 10.1074/jbc.M205659200; Troy CM, 2001, J NEUROCHEM, V77, P157, DOI 10.1046/j.1471-4159.2001.00218.x; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; Troy CM, 2000, J NEUROSCI, V20, P1386; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; Wirths O, 2001, NEUROSCI LETT, V306, P116, DOI 10.1016/S0304-3940(01)01876-6; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yin KJ, 2002, J NEUROSCI, V22, P9764; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhao B, 1997, J NEUROSCI RES, V47, P253; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x	79	151	160	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28294	28302		10.1074/jbc.M212265200	http://dx.doi.org/10.1074/jbc.M212265200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12730216	hybrid			2022-12-25	WOS:000184242700120
J	Nakazawa, Y; Kamijo, T; Koike, K; Noda, T				Nakazawa, Y; Kamijo, T; Koike, K; Noda, T			ARF tumor suppressor induces mitochondria-dependent apoptosis by modulation of mitochondrial Bcl-2 family proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; P53-DEPENDENT APOPTOSIS; GENE-EXPRESSION; CELL-DEATH; IN-VIVO; P53; P19(ARF); GROWTH; BAX; COMPLEX	A tumor suppressor gene product, ARF, sensitizes cells to apoptosis in the presence of appropriate collateral signals. In this study, we analyzed the mechanism of ARF-dependent apoptosis and demonstrated that ARF induces mitochondria-dependent apoptosis in p53 wild-type, ARF/p16-null cells. We also found that ARF evokes cytochrome c release from mitochondria, decreases mitochondrial membrane potential, and activates procaspase-9 to induce apoptosis. Our findings suggest that this apoptotic cellular modulation is brought about by up-regulation of the proapoptotic Bcl-2 family proteins Bax and Bim and down-regulation of antiapoptotic Bcl-2 in mitochondrial fractions. Additionally, ARF seems to down-regulate Bcl-2 in a p53-dependent manner while up-regulating Bax/Bim via a p53-independent pathway.	Shinshu Univ, Sch Med, Dept Pediat, Nagano 3908621, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Toshima Ku, Tokyo 170, Japan; Tohoku Univ, Grad Sch Med, Dept Mol Genet, Sendai, Miyagi 9808575, Japan	Shinshu University; Japanese Foundation for Cancer Research; Tohoku University	Kamijo, T (corresponding author), Shinshu Univ, Sch Med, Dept Pediat, 3-1-1 Asahi, Nagano 3908621, Japan.	tkamijo@hsp.md.shinshu-u.ac.jp	Noda, Tetsuo/B-1667-2016					Aoki M, 1997, HEART VESSELS, P71; Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Butt AJ, 2000, J BIOL CHEM, V275, P39174, DOI 10.1074/jbc.M908888199; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Doi T, 1999, INT IMMUNOL, V11, P933, DOI 10.1093/intimm/11.6.933; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KAMIJO T, 1993, J BIOL CHEM, V268, P26452; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lu JB, 2001, CARCINOGENESIS, V22, P321, DOI 10.1093/carcin/22.2.321; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; QUELLE DE, 1995, CELL, V83, P993; RAFFELD M, 1987, CANCER RES, V47, P2537; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; Sherr CJ, 2000, CANCER RES, V60, P3689; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Zhan QM, 1999, ONCOGENE, V18, P297, DOI 10.1038/sj.onc.1202310; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	54	35	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27888	27895		10.1074/jbc.M300510200	http://dx.doi.org/10.1074/jbc.M300510200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12740365	hybrid			2022-12-25	WOS:000184242700070
J	Runge, S; Gram, C; Brauner-Osborne, H; Madsen, K; Knudsen, LB; Wulff, BS				Runge, S; Gram, C; Brauner-Osborne, H; Madsen, K; Knudsen, LB; Wulff, BS			Three distinct epitopes on the extracellular face of the glucagon receptor determine specificity for the glucagon amino terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2ND TRANSMEMBRANE HELIX; CONSTITUTIVE ACTIVATION; HORMONE RECEPTOR; LIGAND-BINDING; DISULFIDE BOND; DOMAIN; EXPRESSION; RESIDUES; SECRETIN; AGONIST	The glucagon and glucagon-like peptide-1 (GLP-1) receptors are homologous family B seven-transmembrane (7TM) G protein-coupled receptors, and they selectively recognize the homologous peptide hormones glucagon ( 29 amino acids) and GLP-1 (30-31 amino acids), respectively. The amino-terminal extracellular domain of the glucagon and GLP-1 receptors (140-150 amino acids) determines specificity for the carboxyl terminus of glucagon and GLP-1, respectively. In addition, the glucagon receptor core domain ( 7TM helices and connecting loops) strongly determines specificity for the glucagon amino terminus. Only 4 of 15 residues are divergent in the glucagon and GLP-1 amino termini; Ser(2), Gln(3), Tyr(10), and Lys(12) in glucagon and the corresponding Ala(8), Glu(9), Val(16), and Ser(18) in GLP-1. In this study, individual substitution of these four residues of glucagon with the corresponding residues of GLP-1 decreased the affinity and potency at the glucagon receptor relative to glucagon. Substitution of distinct segments of the glucagon receptor core domain with the corresponding segments of the GLP-1 receptor rescued the affinity and potency of specific glucagon analogs. Site-directed mutagenesis identified the Asp(385) --> Glu glucagon receptor mutant that specifically rescued Ala(2)-glucagon. The results show that three distinct epitopes of the glucagon receptor core domain determine specificity for the N terminus of glucagon. We suggest a glucagon receptor binding model in which the extracellular ends of TM2 and TM7 are close to and determine specificity for Gln(3) and Ser(2) of glucagon, respectively. Furthermore, the second extracellular loop and/or proximal segments of TM4 and/or TM5 are close to and determine specificity for Lys(12) of glucagon.	Novo Nordisk AS, Mol Pharmacol, DK-2760 Malov, Denmark; Pharmaceut Univ Denmark, Dept Med Chem, DK-2100 Copenhagen, Denmark; Novo Nordisk AS, Med Chem 4, DK-2760 Malov, Denmark; Novo Nordisk AS, Pharmacol Res 3, DK-2760 Malov, Denmark	Novo Nordisk; Novo Nordisk; Novo Nordisk	Wulff, BS (corresponding author), Novo Nordisk AS, Mol Pharmacol, Novo Nordisk Pk C9 S-27, DK-2760 Malov, Denmark.	bsw@novonordisk.com	Bräuner-Osborne, Hans/D-7260-2011	Bräuner-Osborne, Hans/0000-0001-9495-7388; Knudsen, Lotte Bjerre/0000-0002-2439-7116				ADELHORST K, 1994, J BIOL CHEM, V269, P6275; Bazarsuren A, 2002, BIOPHYS CHEM, V96, P305, DOI 10.1016/S0301-4622(02)00023-6; Boyd ND, 1996, P NATL ACAD SCI USA, V93, P433, DOI 10.1073/pnas.93.1.433; BRAUN W, 1983, J MOL BIOL, V169, P921, DOI 10.1016/S0022-2836(83)80143-0; Bremer AA, 2001, J BIOL CHEM, V276, P22857, DOI 10.1074/jbc.M100824200; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; Chang XQ, 2001, MAGN RESON CHEM, V39, P477, DOI 10.1002/mrc.880; Chorev M, 2002, RECEPTOR CHANNEL, V8, P219, DOI 10.1080/10606820213685; Cook JVF, 1997, ENDOCRINOLOGY, V138, P2800, DOI 10.1210/en.138.7.2800; de Maturana RL, 2003, J BIOL CHEM, V278, P10195, DOI 10.1074/jbc.M212147200; de Maturana RL, 2002, FEBS LETT, V530, P244, DOI 10.1016/S0014-5793(02)03492-0; Di Paolo E, 1998, FEBS LETT, V424, P207, DOI 10.1016/S0014-5793(98)00175-6; Dong MQ, 2000, J BIOL CHEM, V275, P26032, DOI 10.1074/jbc.M000612200; Frimurer TM, 1999, PROTEINS, V35, P375, DOI 10.1002/(SICI)1097-0134(19990601)35:4<375::AID-PROT1>3.0.CO;2-2; Gardella TJ, 1996, J BIOL CHEM, V271, P12820, DOI 10.1074/jbc.271.22.12820; Gaudin P, 1998, J BIOL CHEM, V273, P4990, DOI 10.1074/jbc.273.9.4990; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; Hjorth SA, 1998, MOL ENDOCRINOL, V12, P78, DOI 10.1210/mend.12.1.0045; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; Inooka H, 2001, NAT STRUCT BIOL, V8, P161, DOI 10.1038/84159; Knudsen SM, 1997, FEBS LETT, V412, P141, DOI 10.1016/S0014-5793(97)00714-X; LOK S, 1994, GENE, V140, P203, DOI 10.1016/0378-1119(94)90545-2; LOPEZ LC, 1984, MOL BIOL EVOL, V1, P335; MOJSOV S, 1986, J BIOL CHEM, V261, P1880; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Perret J, 2002, BIOCHEM J, V362, P389, DOI 10.1042/0264-6021:3620389; Perrin MH, 2001, J BIOL CHEM, V276, P31528, DOI 10.1074/jbc.M101838200; Plisetskaya EM, 1996, INT REV CYTOL, V168, P187, DOI 10.1016/S0074-7696(08)60885-2; ROBBERECHT P, 1992, EUR J BIOCHEM, V207, P239, DOI 10.1111/j.1432-1033.1992.tb17043.x; Runge S, 2003, BRIT J PHARMACOL, V138, P787, DOI 10.1038/sj.bjp.0705120; Schipani E, 1997, MOL ENDOCRINOL, V11, P851, DOI 10.1210/me.11.7.851; Solano RM, 2001, J BIOL CHEM, V276, P1084, DOI 10.1074/jbc.M007686200; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; THORENS B, 1993, DIABETES, V42, P1678, DOI 10.2337/diabetes.42.11.1678; UNSON CG, 1991, J BIOL CHEM, V266, P2763; Unson CG, 2002, BIOCHEMISTRY-US, V41, P11795, DOI 10.1021/bi025711j; Vertongen P, 2001, PEPTIDES, V22, P1363, DOI 10.1016/S0196-9781(01)00476-4; Xiao Q, 2000, J MOL ENDOCRINOL, V25, P321, DOI 10.1677/jme.0.0250321	38	69	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28005	28010		10.1074/jbc.M301085200	http://dx.doi.org/10.1074/jbc.M301085200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12724331	hybrid			2022-12-25	WOS:000184242700085
J	Seshadri, V; McArthur, AG; Sogin, ML; Adam, RD				Seshadri, V; McArthur, AG; Sogin, ML; Adam, RD			Giardia lamblia RNA polymerase II - Amanitin- resistant transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; UNUSUAL RIBOSOMAL-RNA; PROTEIN-CODING GENES; ALPHA-AMANITIN; SACCHAROMYCES-CEREVISIAE; STRUCTURAL BASIS; CELL VIABILITY; MESSENGER-RNA; SUBUNITS; SEQUENCE	Giardia lamblia is an early branching eukaryote, and although distinctly eukaryotic in its cell and molecular biology, transcription and translation in G. lamblia demonstrate important differences from these processes in higher eukaryotes. The cyclic octapeptide amanitin is a relatively selective inhibitor of eukaryotic RNA polymerase II (RNAP II) and is commonly used to study RNAP II transcription. Therefore, we measured the sensitivity of G. lamblia RNAP II transcription to alpha-amanitin and found that unlike most other eukaryotes, RNAP II transcription in Giardia is resistant to 1 mg/ml amanitin. In contrast, 50 mug/ml amanitin inhibits 85% of RNAP III transcription activity using leucyl-tRNA as a template. To better understand transcription in G. lamblia, we identified 10 of the 12 known eukaryotic rpb subunits, including all 10 subunits that are required for viability in Saccharomyces cerevisiae. The amanitin motif (amanitin binding site) of Rpb1 from G. lamblia has amino acid substitutions at six highly conserved sites that have been associated with amanitin resistance in other organisms. These observations of amanitin resistance of Giardia RNA polymerase II support previous proposals of the mechanism of amanitin resistance in other organisms and provide a molecular framework for the development of novel drugs with selective activity against G. lamblia.	Univ Arizona, Coll Med, Dept Microbiol & Immunol, Tucson, AZ 85724 USA; Univ Arizona, Coll Med, Dept Med, Tucson, AZ 85724 USA; Marine Biol Lab, Josephine Bay Paul Ctr Comprehens Mol Biol & Evol, Woods Hole, MA 02543 USA	University of Arizona; University of Arizona; Marine Biological Laboratory - Woods Hole	Adam, RD (corresponding author), Univ Arizona, Dept Immunol Microbiol, 1501 N Campbell, Tucson, AZ 85724 USA.	adamr@u.arizona.edu	Sogin, Mitchell/AAE-7186-2019	McArthur, Andrew/0000-0002-1142-3063	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051089, U01AI043273, R01AI043273] Funding Source: NIH RePORTER; NIAID NIH HHS [AI51089, AI43273] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAM RD, 1988, NUCLEIC ACIDS RES, V16, P4555, DOI 10.1093/nar/16.10.4555; ADAM RD, 1992, MOL CELL BIOL, V12, P1194, DOI 10.1128/MCB.12.3.1194; Adam RD, 2000, INT J PARASITOL, V30, P475, DOI 10.1016/S0020-7519(99)00191-5; Adam RD, 2001, CLIN MICROBIOL REV, V14, P447, DOI 10.1128/CMR.14.3.447-475.2001; AGGARWAL A, 1989, INFECT IMMUN, V57, P1305, DOI 10.1128/IAI.57.4.1305-1310.1989; BAILEY TL, 1994, P 2 INT C INT SYST M, P28; BAKER DA, 1988, NUCLEIC ACIDS RES, V16, P7177, DOI 10.1093/nar/16.14.7177; Bapteste E, 2002, P NATL ACAD SCI USA, V99, P1414, DOI 10.1073/pnas.032662799; BARTOLOMEI MS, 1995, MOL GEN GENET, V246, P778, DOI 10.1007/BF00290727; Briand JF, 2001, MOL CELL BIOL, V21, P6056, DOI 10.1128/MCB.21.17.6056-6065.2001; Bushnell DA, 2002, P NATL ACAD SCI USA, V99, P1218, DOI 10.1073/pnas.251664698; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; CROSSLEY R, 1983, J CELL SCI, V59, P81; EDLIND TD, 1987, NUCLEIC ACIDS RES, V15, P7889, DOI 10.1093/nar/15.19.7889; Elmendorf HG, 2001, MOL BIOCHEM PARASIT, V113, P157, DOI 10.1016/S0166-6851(01)00211-0; Elmendorf HG, 2001, NUCLEIC ACIDS RES, V29, P4674, DOI 10.1093/nar/29.22.4674; FURTERGRAVES EM, 1994, NUCLEIC ACIDS RES, V22, P4932, DOI 10.1093/nar/22.23.4932; FURTERGRAVES EM, 1991, MOL CELL BIOL, V11, P4121, DOI 10.1128/MCB.11.8.4121; Hatfield L, 1996, MOL CELL BIOL, V16, P5830; HOLBERTON DV, 1995, NUCLEIC ACIDS RES, V23, P2945, DOI 10.1093/nar/23.15.2945; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; HULL MW, 1995, GENE DEV, V9, P481, DOI 10.1101/gad.9.4.481; Ishihama A, 1998, CURR OPIN MICROBIOL, V1, P190; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; Kimura M, 2001, EUR J BIOCHEM, V268, P612, DOI 10.1046/j.1432-1327.2001.01911.x; Knodler LA, 1999, MOL MICROBIOL, V34, P327, DOI 10.1046/j.1365-2958.1999.01602.x; KOOTER JM, 1984, NUCLEIC ACIDS RES, V12, P9457, DOI 10.1093/nar/12.24.9457; LIOUTAS C, 1995, MOL BIOCHEM PARASIT, V73, P259, DOI 10.1016/0166-6851(95)00101-6; McArthur AG, 2000, FEMS MICROBIOL LETT, V189, P271, DOI 10.1111/j.1574-6968.2000.tb09242.x; MCKUNE K, 1993, YEAST, V9, P295, DOI 10.1002/yea.320090309; MCKUNE K, 1995, MOL CELL BIOL, V15, P6895; MOWATT MR, 1991, MOL BIOCHEM PARASIT, V49, P215, DOI 10.1016/0166-6851(91)90065-E; NASH TE, 1985, J INFECT DIS, V152, P64, DOI 10.1093/infdis/152.1.64; Nixon JEJ, 2002, P NATL ACAD SCI USA, V99, P3701, DOI 10.1073/pnas.042700299; Philippe H, 2000, CURR OPIN GENET DEV, V10, P596, DOI 10.1016/S0959-437X(00)00137-4; Philippe H, 2000, MOL BIOL EVOL, V17, P830, DOI 10.1093/oxfordjournals.molbev.a026362; Quon DVK, 1996, J MOL EVOL, V43, P253, DOI 10.1007/PL00006084; RUBTSOV PM, 1980, NUCLEIC ACIDS RES, V8, P5779, DOI 10.1093/nar/8.23.5779; Sakurai H, 1999, MOL CELL BIOL, V19, P7511; Sakurai H, 1997, GENE, V196, P165, DOI 10.1016/S0378-1119(97)00222-9; SMITH PD, 1982, INFECT IMMUN, V36, P714, DOI 10.1128/IAI.36.2.714-719.1982; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Sun CH, 1999, J BIOL CHEM, V274, P19699, DOI 10.1074/jbc.274.28.19699; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TUKEY RH, 1991, METHOD ENZYMOL, V206, P284; ULLU E, 1990, NUCLEIC ACIDS RES, V18, P3319, DOI 10.1093/nar/18.11.3319; Vanacova S, 2001, MOL BIOCHEM PARASIT, V115, P239, DOI 10.1016/S0166-6851(01)00294-8; WOYCHIK NA, 1990, TRENDS BIOCHEM SCI, V15, P347, DOI 10.1016/0968-0004(90)90074-L; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313; Yee J, 2000, J BIOL CHEM, V275, P11432, DOI 10.1074/jbc.275.15.11432; Yu DC, 1998, MOL BIOCHEM PARASIT, V96, P151, DOI 10.1016/S0166-6851(98)00126-1; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107	54	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27804	27810		10.1074/jbc.M303316200	http://dx.doi.org/10.1074/jbc.M303316200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12734189	hybrid			2022-12-25	WOS:000184242700061
J	Bravman, T; Belakhov, V; Solomon, D; Shoham, G; Henrissat, B; Baasov, T; Shoham, Y				Bravman, T; Belakhov, V; Solomon, D; Shoham, G; Henrissat, B; Baasov, T; Shoham, Y			Identification of the catalytic residues in family 52 glycoside hydrolase, a beta-xylosidase from Geobacillus stearothermophilus T-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-BASED CLASSIFICATION; DETAILED KINETIC-ANALYSIS; ACID-BASE CATALYST; ACID/BASE CATALYST; SULFOLOBUS-SOLFATARICUS; ASPERGILLUS-AWAMORI; MUTANT GLYCOSIDASES; MECHANISM; GLUCOSIDASE; MUTAGENESIS	beta-D-Xylosidases (EC 3.2.1.37) are exo-type glycoside hydrolases that hydrolyze short xylooligosaccharides to xylose units. The enzymatic hydrolysis of the glycosidic bond involves two carboxylic acid residues, and their identification, together with the stereochemistry of the reaction, provides crucial information on the catalytic mechanism. Two catalytic mutants of a beta-xylosidase from Geobacillus stearothermophilus T-6 were subjected to detailed kinetic analysis to verify their role in catalysis. The activity of the E335G mutant decreased similar to10(6) fold, and this activity was enhanced 10(3)-fold in the presence of external nucleophiles such as formate and azide, resulting in a xylosyl-azide product with an opposite anomeric configuration. These results are consistent with Glu(335) as the nucleophile in this retaining enzyme. The D495G mutant was subjected to detailed kinetic analysis using substrates bearing different leaving groups (pK(a)). The mutant exhibited 10(3)-fold reduction in activity, and the Bronsted plot of log(k(cat)) versus pK(a) revealed that deglycosylation is the rate-limiting step, indicating that this step was reduced by 10(3)-fold. The rates of the glycosylation step, as reflected by the specificity constant (k(cat)/K-m), were similar to those of the wild type enzyme for hydrolysis of substrates requiring little protonic assistance ( low pK(a)) but decreased 10(2)-fold for those that require strong acid catalysis ( high pK(a)). Furthermore, the pH dependence profile of the mutant enzyme revealed that acid catalysis is absent. Finally, the presence of azide significantly enhanced the mutant activity accompanied with the generation of a xylosyl-azide product with retained anomeric configuration. These results are consistent with Asp(495) acting as the acid-base in XynB2.	Technion Israel Inst Technol, Dept Chem, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Inst Catalysis & Technol, IL-32000 Haifa, Israel; Hebrew Univ Jerusalem, Dept Inorgan Chem, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Lab Struct Chem & Biol, IL-91904 Jerusalem, Israel; CNRS, UMR 6098, F-13402 Marseille 20, France; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France	Technion Israel Institute of Technology; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite	Baasov, T (corresponding author), Technion Israel Inst Technol, Dept Chem, IL-32000 Haifa, Israel.		Shoham, Yuval/M-4409-2013; Baasov, Timor/L-5173-2019; Henrissat, Bernard/J-2475-2012	Baasov, Timor/0000-0002-1427-2619; Henrissat, Bernard/0000-0002-3434-8588; Belakhov, Valery/0000-0003-1918-974X				Beg QK, 2001, APPL MICROBIOL BIOT, V56, P326, DOI 10.1007/s002530100704; Bravman T, 2001, FEBS LETT, V495, P115, DOI 10.1016/S0014-5793(01)02371-7; Bravman T, 2001, FEBS LETT, V495, P39, DOI 10.1016/S0014-5793(01)02360-2; Davies G. J., 1998, INCOMPREHENSIVE BIOL, P119; Fersht A., 1999, STRUCTURE MECH PROTE, P169; Galbe M, 2002, APPL MICROBIOL BIOT, V59, P618, DOI 10.1007/s00253-002-1058-9; HARRIS EMS, 1993, BIOCHEMISTRY-US, V32, P1618, DOI 10.1021/bi00057a028; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; Jahn M, 2003, ANGEW CHEM INT EDIT, V42, P352, DOI 10.1002/anie.200390114; KEMPTON JB, 1992, BIOCHEMISTRY-US, V31, P9961, DOI 10.1021/bi00156a015; Lawson SL, 1997, BIOCHEMISTRY-US, V36, P2257, DOI 10.1021/bi9620215; Leatherbarrow R.J., 2001, GRAFIT; Li YK, 2002, BIOCHEMISTRY-US, V41, P2751, DOI 10.1021/bi016049e; Ly HD, 1999, ANNU REV BIOCHEM, V68, P487, DOI 10.1146/annurev.biochem.68.1.487; Mackenzie LF, 1998, J AM CHEM SOC, V120, P5583, DOI 10.1021/ja980833d; MACLEOD AM, 1994, BIOCHEMISTRY-US, V33, P6371, DOI 10.1021/bi00186a042; MacLeod AM, 1996, BIOCHEMISTRY-US, V35, P13165, DOI 10.1021/bi9610616; MIKAMI B, 1994, BIOCHEMISTRY-US, V33, P7779, DOI 10.1021/bi00191a005; Moracci M, 1996, PROTEIN ENG, V9, P1191, DOI 10.1093/protein/9.12.1191; Moracci M, 1998, BIOCHEMISTRY-US, V37, P17262, DOI 10.1021/bi981855f; Nurizzo D, 2002, NAT STRUCT BIOL, V9, P665, DOI 10.1038/nsb835; Shallom D, 2003, CURR OPIN MICROBIOL, V6, P219, DOI 10.1016/S1369-5274(03)00056-0; Shallom D, 2002, FEBS LETT, V514, P163, DOI 10.1016/S0014-5793(02)02343-8; Shallom D, 2002, J BIOL CHEM, V277, P43667, DOI 10.1074/jbc.M208285200; SIERKS MR, 1990, PROTEIN ENG, V3, P193, DOI 10.1093/protein/3.3.193; Suurnakki A, 1997, Adv Biochem Eng Biotechnol, V57, P261; TOTSUKA A, 1994, EUR J BIOCHEM, V221, P649, DOI 10.1111/j.1432-1033.1994.tb18777.x; Vallmitjana M, 2001, BIOCHEMISTRY-US, V40, P5975, DOI 10.1021/bi002947j; Viladot JL, 1998, BIOCHEMISTRY-US, V37, P11332, DOI 10.1021/bi980586q; Vocadlo DJ, 2002, BIOCHEMISTRY-US, V41, P9736, DOI 10.1021/bi020078n; Vocadlo DJ, 1998, BIOCHEM J, V335, P449, DOI 10.1042/bj3350449; WANG Q, 1995, BIOCHEMISTRY-US, V34, P14554, DOI 10.1021/bi00044a034; WANG QP, 1994, J AM CHEM SOC, V116, P11594, DOI 10.1021/ja00104a060; Wolfenden R, 1998, J AM CHEM SOC, V120, P6814, DOI 10.1021/ja9813055; Zechel D. L., 1999, COMPREHENSIVE NATURA, V5, P279; Zechel DL, 2000, ACCOUNTS CHEM RES, V33, P11, DOI 10.1021/ar970172+; ZISER L, 1995, CARBOHYD RES, V274, P137, DOI 10.1016/0008-6215(95)00080-D	38	45	45	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26742	26749		10.1074/jbc.M304144200	http://dx.doi.org/10.1074/jbc.M304144200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12738774	hybrid			2022-12-25	WOS:000184155700058
J	Son, YJ; Hur, MK; Ryu, BJ; Park, SK; Damante, G; D'Elia, AV; Costa, ME; Ojeda, SR; Lee, BJ				Son, YJ; Hur, MK; Ryu, BJ; Park, SK; Damante, G; D'Elia, AV; Costa, ME; Ojeda, SR; Lee, BJ			TTF-1, a homeodomain-containing transcription factor, participates in the control of body fluid homeostasis by regulating angiotensinogen gene transcription in the rat subfornical organ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; MESSENGER-RNA; THYROGLOBULIN PROMOTER; VASOPRESSIN RELEASE; ACTIVATING ELEMENTS; PROXIMAL PROMOTER; NUCLEAR-PROTEIN; BLOOD-PRESSURE; LHRH NEURONS; BRAIN	In recent years, it has become increasingly evident that angiotensins synthesized in the brain contribute to regulating body fluid homeostasis. Although angiotensinogen, the unique angiotensin precursor, is produced in the brain, the factors that regulate its gene expression remain unknown. We recently found that TTF-1, a homeodomain-containing transcription factor essential for the development of the fetal diencephalon, is postnatally expressed in discrete areas of the hypothalamus. We now report that the subfornical organ, an important site of angiotensinogen synthesis, is an extrahypothalamic site of TTF-1 expression. Double in situ hybridization histochemistry demonstrated the presence of TTF-1 mRNA in angiotensinogen-producing cells of the rat subfornical organ. RNase protection assays showed that TTF-1 and angiotensinogen mRNA levels are simultaneously increased in the subfornical organ by water deprivation. The angiotensinogen promoter contains seven presumptive TTF-1 binding motifs, four of which are recognized by the TTF-1 homeodomain. In the C6 glioma cell line, TTF-1 transactivates the angiotensinogen promoter in a dose-dependent manner. This transactivation is abolished by deletion of the TTF-1 binding motif at -125. Intracranial administration of an antisense TTF-1 oligodeoxynucleotide decreased angiotensinogen mRNA in the subfornical organ and dramatically reduced the animal's water intake while increasing urine excretion. Moreover, plasma arginine vasopressin content was decreased by the same treatment. These results demonstrate a novel role for TTF-1 in the regulation of body fluid homeostasis, exerted via the transactivational control of angiotensinogen synthesis in the subfornical organ.	Univ Ulsan, Coll Nat Sci, Dept Biol Sci, Ulsan 680749, South Korea; Univ Ulsan, Coll Med, Dept Pediat, Ulsan 682060, South Korea; Univ Udine, Dept Biomed Sci & Technol, I-33100 Udine, Italy; Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Div Neurosci, Beaverton, OR 97006 USA	University of Ulsan; University of Ulsan; University of Udine; Oregon Health & Science University; Oregon National Primate Research Center	Lee, BJ (corresponding author), Univ Ulsan, Coll Nat Sci, Dept Biol Sci, Ulsan 680749, South Korea.	bjlee@mail.ulsan.ac.kr	Damante, Giuseppe/AAC-5200-2022	Damante, Giuseppe/0000-0003-2312-4009				ABDELAAL AE, 1974, CAN J PHYSIOL PHARM, V52, P1217, DOI 10.1139/y74-160; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Barth SW, 1999, MOL BRAIN RES, V64, P151, DOI 10.1016/S0169-328X(98)00308-8; Bourque CW, 1997, ANNU REV PHYSIOL, V59, P601, DOI 10.1146/annurev.physiol.59.1.601; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; Camargo LAD, 2000, BRAIN RES, V881, P176, DOI 10.1016/S0006-8993(00)02840-7; Choi EJ, 2000, MOL BRAIN RES, V80, P35, DOI 10.1016/S0169-328X(00)00116-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOUAF L, 1991, CELL TISSUE RES, V266, P553, DOI 10.1007/BF00318597; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; CLOUSTON W M, 1988, Genomics, V2, P240, DOI 10.1016/0888-7543(88)90008-0; Damante G, 1996, EMBO J, V15, P4992, DOI 10.1002/j.1460-2075.1996.tb00879.x; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; Dellmann HD, 1998, MICROSC RES TECHNIQ, V41, P85, DOI 10.1002/(SICI)1097-0029(19980415)41:2<85::AID-JEMT1>3.0.CO;2-P; EMDE KBD, 1995, J NEUROSCI, V15, P4223; FABBRO D, 1995, BIOCHEM BIOPH RES CO, V213, P781, DOI 10.1006/bbrc.1995.2198; FITTS DA, 1994, AM J PHYSIOL, V267, pR7, DOI 10.1152/ajpregu.1994.267.1.R7; Fitzsimons JT, 1998, PHYSIOL REV, V78, P583, DOI 10.1152/physrev.1998.78.3.583; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; Ha CM, 2000, MOL BRAIN RES, V78, P59, DOI 10.1016/S0169-328X(00)00070-X; HAINSWORTH R, 1991, PHYSIOL REV, V71, P617, DOI 10.1152/physrev.1991.71.3.617; IOVINO M, 1984, BRAIN RES, V322, P365, DOI 10.1016/0006-8993(84)90135-5; Jain S, 2002, J BIOL CHEM, V277, P36889, DOI 10.1074/jbc.M204732200; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; Jung H, 1998, BRAIN RES, V780, P218, DOI 10.1016/S0006-8993(97)01152-9; Kim MS, 2002, J BIOL CHEM, V277, P36863, DOI 10.1074/jbc.M206443200; Kim MS, 2001, BRAIN RES PROTOC, V7, P277, DOI 10.1016/S1385-299X(01)00078-2; KNEPEL W, 1982, BRAIN RES, V248, P180, DOI 10.1016/0006-8993(82)91161-1; KUHN R, 1991, MOL CELL BIOL, V11, P4642, DOI 10.1128/MCB.11.9.4642; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; Lee BJ, 2001, MOL CELL NEUROSCI, V17, P107, DOI 10.1006/mcne.2000.0933; LIND RW, 1984, BRAIN RES, V321, P209, DOI 10.1016/0006-8993(84)90174-4; LIPPOLDT A, 1993, NEUROSCI LETT, V150, P153, DOI 10.1016/0304-3940(93)90524-O; LIPPOLDT A, 1995, CLIN EXP HYPERTENS, V17, P251, DOI 10.3109/10641969509087069; Liu C, 2002, J BIOL CHEM, V277, P4519, DOI 10.1074/jbc.M107585200; Ma Ying Jun, 1996, Methods (Orlando), V10, P273, DOI 10.1006/meth.1996.0102; McKinley MJ, 2000, METHODS, V22, P219, DOI 10.1006/meth.2000.1073; MEISTER B, 1988, NEUROSCIENCE, V27, P607, DOI 10.1016/0306-4522(88)90292-8; Morishita R, 1996, HYPERTENSION, V27, P502, DOI 10.1161/01.HYP.27.3.502; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Nakamura K, 2001, DEV BRAIN RES, V130, P159, DOI 10.1016/S0165-3806(01)00226-7; Narayanan CS, 2000, MOL CELL BIOCHEM, V212, P81, DOI 10.1023/A:1007180322263; Narayanan CS, 1998, BIOCHEM BIOPH RES CO, V251, P388, DOI 10.1006/bbrc.1998.9430; NARUSE M, 1985, BRAIN RES, V333, P147, DOI 10.1016/0006-8993(85)90135-0; NIBU Y, 1994, J BIOL CHEM, V269, P28598; Nishii T, 1999, CIRC RES, V85, P257, DOI 10.1161/01.RES.85.3.257; OHKUBO H, 1986, J BIOL CHEM, V261, P319; Paxinos G, 1998, RAT BRAIN; Pellizzari L, 1999, BIOCHEM J, V337, P253, DOI 10.1042/0264-6021:3370253; PICKEL VM, 1986, J NEUROSCI, V6, P2457; Rage F, 1997, J NEUROSCI, V17, P9145; RON D, 1991, MOL CELL BIOL, V11, P2887, DOI 10.1128/MCB.11.5.2887; RUTZEL H, 1980, CELL TISSUE RES, V211, P117; SAAVEDRA JM, 1992, ENDOCR REV, V13, P329, DOI 10.1210/er.13.2.329; Sanvitto GL, 1997, AM J PHYSIOL-ENDOC M, V273, pE156, DOI 10.1152/ajpendo.1997.273.1.E156; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SIMPSON JB, 1975, BRAIN RES, V88, P154, DOI 10.1016/0006-8993(75)90965-8; TAMURA K, 1994, J CLIN INVEST, V93, P1370, DOI 10.1172/JCI117113; UNGER T, 1988, CIRCULATION, V77, P40; Weidenfeld J, 2002, J BIOL CHEM, V277, P21061, DOI 10.1074/jbc.M111702200; ZHAO YY, 1993, CELL MOL BIOL RES, V39, P727	62	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27043	27052		10.1074/jbc.M303157200	http://dx.doi.org/10.1074/jbc.M303157200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12730191	hybrid			2022-12-25	WOS:000184155700096
J	MacLeod, TJ; Kwon, M; Filipenko, NR; Waisman, DM				MacLeod, TJ; Kwon, M; Filipenko, NR; Waisman, DM			Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits - Characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL RECEPTOR; II TETRAMER; BINDING-PROTEINS; P11 SUBUNIT; T-PA; SURFACE; EXPRESSION; COMPLEX; CANCER; SITES	Annexin A2 (p36) is a highly alpha-helical molecule that consists of two opposing sides, a convex side that contains the phospholipid-binding sites and a concave side, which faces the extracellular milieu and contains multiple ligand-binding sites. The amino-terminal region of annexin A2 extends along the concave side of the protein and contains the binding site for the S100A10 (p11) subunit. The interaction of these subunits results in the formation of the heterotetrameric form of the protein, annexin A2-S100A10 heterotetramer (AIIt). To simulate the orientation of AIIt on the plasma membrane we bound AIIt to a phospholipid bilayer that was immobilized on a BIAcore biosensor chip. Surface plasmon resonance was used to observe in real time the molecular interactions between phospholipid-associated AIIt or its annexin A2 subunit and the ligands, tissue-type plasminogen activator (t-PA), plasminogen, and plasmin. AIIt bound t-PA (K-d = 0.68 muM), plasminogen (K-d = 0.11 muM), and plasmin (K-d = 75 nM) with moderate affinity. Contrary to previous reports, the phospholipid-associated annexin A2 subunit failed to bind t-PA or plasminogen but bound plasmin (K-d = 0.78 muM). The S100A10 subunit bound t-PA (K-d = 0.45 muM), plasminogen (K-d = 1.81 muM), and plasmin (K-d = 0.36 muM). Removal of the carboxyl-terminal lysines from the S100A10 subunit attenuated t-PA and plasminogen binding to AIIt. These results show that the carboxyl-terminal lysines of S100A10 form t-PA and plasminogen-binding sites. In contrast, annexin A2 and S100A10 contain distinct binding sites for plasmin.	Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary	Waisman, DM (corresponding author), Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	waisman@ucalgary.ca		Waisman, David/0000-0002-5097-9662	NCI NIH HHS [CA78639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andronicos NM, 2001, BRIT J CANCER, V85, P909, DOI 10.1054/bjoc.2001.2022; Balch C, 1997, EXP CELL RES, V237, P259, DOI 10.1006/excr.1997.3817; BLACKWOOD RA, 1990, BIOCHEM J, V266, P195, DOI 10.1042/bj2660195; Butler JE, 1997, IMMUNOL INVEST, V26, P39, DOI 10.3109/08820139709048914; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; Chetcuti A, 2001, CANCER RES, V61, P6331; Choi KS, 2003, FASEB J, V17, P235, DOI 10.1096/fj.02-0697com; Choi KS, 2001, J BIOL CHEM, V276, P25212, DOI 10.1074/jbc.M101426200; CHOI KS, 2003, IN PRESS ANNEXINS BI; Donato R., 1999, Cell Calcium, V26, P85, DOI 10.1054/ceca.1999.0079; Ellis V, 1996, J BIOL CHEM, V271, P14779, DOI 10.1074/jbc.271.25.14779; Erb EM, 2000, ANAL BIOCHEM, V280, P29, DOI 10.1006/abio.1999.4469; EVANS TC, 1994, BIOCHEMISTRY-US, V33, P13231, DOI 10.1021/bi00249a009; Falcone DJ, 2001, BLOOD, V97, P777, DOI 10.1182/blood.V97.3.777; Felez J, 1998, FIBRINOLYSIS PROTEOL, V12, P183, DOI 10.1016/S0268-9499(98)80012-X; FELEZ J, 1993, BLOOD, V82, P2433, DOI 10.1182/blood.V82.8.2433.bloodjournal8282433; Felez J, 1996, THROMB HAEMOSTASIS, V76, P577; FELEZ J, 1991, BLOOD, V78, P2318; FILIPENKO NR, 2003, IN PRESS ANNEXINS BI; Fitzpatrick SL, 2000, BIOCHEMISTRY-US, V39, P1021, DOI 10.1021/bi991411z; Fogg DK, 2002, BIOCHEMISTRY-US, V41, P4953, DOI 10.1021/bi012045y; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Girard C, 2002, EMBO J, V21, P4439, DOI 10.1093/emboj/cdf469; GLENNEY JR, 1985, FEBS LETT, V192, P79, DOI 10.1016/0014-5793(85)80047-8; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hajjar KA, 1996, J BIOL CHEM, V271, P21652, DOI 10.1074/jbc.271.35.21652; HARDER T, 1993, J CELL SCI, V104, P1109; Hawley SB, 2001, J BIOL CHEM, V276, P179, DOI 10.1074/jbc.M004919200; Kang HM, 1997, BIOCHEMISTRY-US, V36, P2041, DOI 10.1021/bi962569b; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; KHANNA NC, 1990, BIOCHEMISTRY-US, V29, P4852, DOI 10.1021/bi00472a015; KUBE E, 1992, J BIOL CHEM, V267, P14175; Kwon M, 2002, J BIOL CHEM, V277, P10903, DOI 10.1074/jbc.M111219200; Lambert O, 1997, J MOL BIOL, V272, P42, DOI 10.1006/jmbi.1997.1183; LEE SW, 1994, J BIOL CHEM, V269, P2411; Lewit-Bentley A, 2000, CELL BIOL INT, V24, P799, DOI 10.1006/cbir.2000.0629; Ma JX, 2000, J BIOL CHEM, V275, P12806, DOI 10.1074/jbc.275.17.12806; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; Norde W, 1998, BIOTECHNOL APPL BIOC, V28, P133; Norde W, 2000, J BIOTECHNOL, V79, P259, DOI 10.1016/S0168-1656(00)00242-X; Okuse K, 2002, NATURE, V417, P653, DOI 10.1038/nature00781; Puisieux A, 1996, BIOCHEM J, V313, P51, DOI 10.1042/bj3130051; Ranson M, 1998, BRIT J CANCER, V77, P1586, DOI 10.1038/bjc.1998.261; Rety S, 2000, STRUCTURE, V8, P175, DOI 10.1016/S0969-2126(00)00093-9; Rety S, 1999, NAT STRUCT BIOL, V6, P89; Roda O, 2003, J BIOL CHEM, V278, P5702, DOI 10.1074/jbc.M207605200; Saenko E, 2001, J CHROMATOGR A, V921, P49, DOI 10.1016/S0021-9673(01)00601-X; Seaton BA, 1998, BIOMETALS, V11, P399, DOI 10.1023/A:1009205925714; Siever DA, 1997, INT J BIOCHEM CELL B, V29, P1219, DOI 10.1016/S1357-2725(97)00057-5; SOPKOVADEOLIVEI.SJ, 2000, BIOCHIM BIOPHYS ACTA, V1498, P181; THIEL C, 1992, J CELL SCI, V103, P733; TRESSLER RJ, 1993, J CELL BIOCHEM, V53, P265, DOI 10.1002/jcb.240530311; Wu T, 1997, J BIOL CHEM, V272, P17145, DOI 10.1074/jbc.272.27.17145; YEATMAN TJ, 1993, CLIN EXP METASTAS, V11, P37, DOI 10.1007/BF00880064; Zobiack N, 2001, FEBS LETT, V500, P137, DOI 10.1016/S0014-5793(01)02604-7	56	103	110	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25577	25584		10.1074/jbc.M301017200	http://dx.doi.org/10.1074/jbc.M301017200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730231	hybrid			2022-12-25	WOS:000183920200039
J	Touret, N; Furuya, W; Forbes, J; Gros, P; Grinstein, S				Touret, N; Furuya, W; Forbes, J; Gros, P; Grinstein, S			Dynamic traffic through the recycling compartment couples the metal transporter Nramp2 (DMT1) with the transferrin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON TRANSPORTER; ACTIN CYTOSKELETON; SUBCELLULAR-LOCALIZATION; MEDIATED ENDOCYTOSIS; ION TRANSPORTER; DIETARY IRON; MK MICE; EXPRESSION; CELLS; GENE	Nramp2 (natural resistance-associated macrophage protein 2, also called DMT1 and Slc11a2) is a proton-dependent cation transporter, which plays a central role in iron homeostasis. To study the subcellular distribution and dynamics of the transporter, we generated a construct encoding the long splice variant of Nramp2 (isoform II) tagged with the hemagglutinin epitope on a predicted extracellular loop. Cells stably transfected with this construct revealed the presence of Nramp2 in both the plasma membrane and in an endomembrane compartment. By labeling the exofacial epitope with a pH-sensitive fluorescent indicator, we were able to establish that this variant of Nramp2 resides in a vesicular compartment with an acidic lumen (pH 6.2) and that acidification was maintained by vacuolar-type ATPases. Dual labeling experiments identified this compartment as sorting and recycling endosomes. Kinetic studies by surface labeling with I-125-labeled antibodies established that the fraction of endomembrane Nramp2 was approximately equal to that on the cell surface. The two components are in dynamic equilibrium: surface transporters are internalized continuously via a clathrin and dynamin-dependent process, whereas endosomal Nramp2 is recycled to the plasmalemma by a phosphatidylinositol 3-kinase-dependent exocytic process. Depletion of cholesterol had no discernible effect on Nramp2 internalization, suggesting that rafts or caveolae are not essential. Because the pH at the cell surface and in endosomes differs by greater than or equal to1 unit, the rates of transport of Nramp2 at the surface and in endomembrane compartments will differ drastically. Their subcellular colocalization and parallel trafficking suggest that Nramp2 and transferrin receptors are functionally coupled to effect pH-dependent iron uptake across the endosomal membrane.	Hosp Sick Children, Cell Biol Programme, Toronto, ON M5G 1X8, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University	Grinstein, S (corresponding author), Hosp Sick Children, Cell Biol Programme, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	sga@sickkids.ca			PHS HHS [1R01 A13523] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607; Burdo JR, 2001, J NEUROSCI RES, V66, P1198, DOI 10.1002/jnr.1256.abs; Canonne-Hergaux F, 2000, BLOOD, V96, P3964; Canonne-Hergaux F, 2001, BLOOD, V98, P3823, DOI 10.1182/blood.V98.13.3823; Canonne-Hergaux F, 2001, BLOOD, V97, P1138, DOI 10.1182/blood.V97.4.1138; Canonne-Hergaux F, 1999, BLOOD, V93, P4406, DOI 10.1182/blood.V93.12.4406.412k21_4406_4417; Canonne-Hergaux FS, 2002, KIDNEY INT, V62, P147, DOI 10.1046/j.1523-1755.2002.00405.x; Christensen EI, 2002, NAT REV MOL CELL BIO, V3, P258, DOI 10.1038/nrm778; Collins RF, 2002, J IMMUNOL, V169, P3250, DOI 10.4049/jimmunol.169.6.3250; Dayel MJ, 1999, BIOPHYS J, V76, P2843, DOI 10.1016/S0006-3495(99)77438-2; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; Ferguson CJ, 2001, AM J PHYSIOL-RENAL, V280, pF803, DOI 10.1152/ajprenal.2001.280.5.F803; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Ghio AJ, 2003, AM J PHYSIOL-LUNG C, V284, pL938, DOI 10.1152/ajplung.00225.2002; Gruenheid S, 1999, J EXP MED, V189, P831, DOI 10.1084/jem.189.5.831; GRUENHEID S, 1995, GENOMICS, V25, P514, DOI 10.1016/0888-7543(95)80053-O; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Gunshin H, 2001, FEBS LETT, V509, P309, DOI 10.1016/S0014-5793(01)03189-1; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Hubert N, 2002, P NATL ACAD SCI USA, V99, P12345, DOI 10.1073/pnas.192423399; Kozyraki R, 2001, P NATL ACAD SCI USA, V98, P12491, DOI 10.1073/pnas.211291398; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; Lee PL, 1998, BLOOD CELL MOL DIS, V24, P199, DOI 10.1006/bcmd.1998.0186; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Picard V, 2000, J BIOL CHEM, V275, P35738, DOI 10.1074/jbc.M005387200; Scott CC, 2002, J BIOL CHEM, V277, P12770, DOI 10.1074/jbc.M110399200; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647; Spiro DJ, 1996, MOL BIOL CELL, V7, P355, DOI 10.1091/mbc.7.3.355; Su MA, 1998, BLOOD, V92, P2157, DOI 10.1182/blood.V92.6.2157.418k16_2157_2163; Szaszi K, 2002, J BIOL CHEM, V277, P42623, DOI 10.1074/jbc.M206629200; Tabuchi M, 2002, MOL BIOL CELL, V13, P4371, DOI 10.1091/mbc.E02-03-0165; Tabuchi M, 2000, J BIOL CHEM, V275, P22220, DOI 10.1074/jbc.M001478200; Tallkvist J, 2001, TOXICOL LETT, V122, P171, DOI 10.1016/S0378-4274(01)00363-0; Tandy S, 2000, J BIOL CHEM, V275, P1023, DOI 10.1074/jbc.275.2.1023; Tchernitchko D, 2002, BIOCHEM J, V363, P449, DOI 10.1042/0264-6021:3630449; van Dam EM, 2002, MOL BIOL CELL, V13, P169, DOI 10.1091/mbc.01-07-0380; VIDAL S, 1995, MAMM GENOME, V6, P224, DOI 10.1007/BF00352405; Yeh KY, 2000, AM J PHYSIOL-GASTR L, V279, pG1070, DOI 10.1152/ajpgi.2000.279.5.G1070	43	87	90	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25548	25557		10.1074/jbc.M212374200	http://dx.doi.org/10.1074/jbc.M212374200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12724326	hybrid			2022-12-25	WOS:000183920200036
J	Mangiacasale, R; Pittoggi, C; Sciamanna, I; Careddu, A; Mattei, E; Lorenzini, R; Travaglini, L; Landriscina, M; Barone, C; Nervi, C; Lavia, P; Spadafora, C				Mangiacasale, R; Pittoggi, C; Sciamanna, I; Careddu, A; Mattei, E; Lorenzini, R; Travaglini, L; Landriscina, M; Barone, C; Nervi, C; Lavia, P; Spadafora, C			Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitor, reduces cell growth and promotes differentiation	ONCOGENE			English	Article						reverse transcriptase inhibitor; endogenous reverse transcriptase; proliferation; differentiation; transformation	EMBRYONAL CARCINOMA-CELLS; ENDOGENOUS RETROVIRAL SEQUENCES; TOXIC EPIDERMAL NECROLYSIS; DEPENDENT DNA POLYMERASE; F9 TERATOCARCINOMA CELLS; ACUTE MYELOID-LEUKEMIA; RETINOIC-ACID; PROMYELOCYTIC LEUKEMIA; HISTONE DEACETYLASE; LINE-1 RNA	Endogenous, nontelomeric reverse transcriptase (RT) is encoded by two classes of repeated elements: retrotransposons and endogenous retroviruses. Expression of RT-coding genes is generally repressed in differentiated nonpathological tissues, yet is active in the mammalian germ line, embryonic tissues and tumor cells. Nevirapine is a non-nucleoside RT inhibitor with a well-characterized inhibitory activity on RT enzymes of retroviral origin. Here, we show that nevirapine is also an effective inhibitor of the endogenous RT in murine and human cell lines. In addition, progenitor and transformed cells undergo a significant reduction in the rate of cell growth upon exposure to nevirapine. This is accompanied by the onset of differentiation, as depicted in F9 and C2C7 progenitor cells cultures in which nevirapine triggers the expression of differentiation-specific markers. Consistent with this, an extensive reprogramming of cell cycle gene expression was depicted in nevirapine-treated F9 cultures. Furthermore, nevirapine exposure rescued the differentiation block present in acute myeloid leukemia (AML) cell lines and primary blasts from two AML patients, as indicated by morphological, functional and immunophenotypic assays. The finding that an RT inhibitor can modulate cell proliferation and differentiation suggests that RT may represent a novel target in the development of therapeutical approaches to neoplasia.	Ist Super Sanita, I-00161 Rome, Italy; CNR, Inst Mol Biol & Pathol, Rome, Italy; Univ Siena, Dept Paediat Obstet & Reprod Med, I-53100 Siena, Italy; Univ Roma La Sapienza, Dept Med Histol & Embryol, Rome, Italy; Univ Cattolica Sacro Cuore, Med Oncol Unit, Rome, Italy	Istituto Superiore di Sanita (ISS); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); University of Siena; Sapienza University Rome; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Spadafora, C (corresponding author), Ist Super Sanita, Viale Regina Elena 299, I-00161 Rome, Italy.		Lavia, Patrizia/J-5793-2019; Landriscina, Matteo/K-1092-2016; Lavia, Patrizia/AAL-3982-2021; Travaglini, Lorena/AAA-6245-2020	Lavia, Patrizia/0000-0003-3310-6701; Spadafora, Corrado/0000-0001-9647-1410; Travaglini, Lorena/0000-0003-0142-6516; Landriscina, Matteo/0000-0003-0591-9799; NERVI, Clara/0000-0001-9341-0188; Spadafora, Corrado/0000-0002-5743-3224; Sciamanna, Ilaria/0000-0002-5629-6184				ASHWORTH A, 1990, EMBO J, V9, P1529, DOI 10.1002/j.1460-2075.1990.tb08271.x; Babich V, 1999, GENE, V239, P341, DOI 10.1016/S0378-1119(99)00391-1; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; Banerjee S, 2000, BBA-PROTEIN STRUCT M, V1480, P1, DOI 10.1016/S0167-4838(00)00080-7; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BROSIUS J, 1996, VIRUS GENES, V11, P163; Cattelan AM, 2001, J INFECTION, V43, P246, DOI 10.1053/jinf.2001.0902; Chou HK, 2000, BIOCHEM J, V348, P473, DOI 10.1042/0264-6021:3480473; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; DARROW AL, 1990, METHOD ENZYMOL, V190, P110; DERAGON JM, 1990, EMBO J, V9, P3363, DOI 10.1002/j.1460-2075.1990.tb07537.x; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Fagot JP, 2001, AIDS, V15, P1843, DOI 10.1097/00002030-200109280-00014; Ferrara FF, 2001, CANCER RES, V61, P2; Ferrigno O, 2001, NAT GENET, V28, P77, DOI 10.1038/ng0501-77; FEUCHTERMURTHY AE, 1993, NUCLEIC ACIDS RES, V21, P135, DOI 10.1093/nar/21.1.135; Friedlander A, 1999, CRIT REV ONCOGENESIS, V10, P129; Giordano R, 2000, J CELL BIOL, V148, P1107, DOI 10.1083/jcb.148.6.1107; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; ISLAM TC, 1993, J BIOL CHEM, V268, P3251; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kazazian HH, 1998, CURR OPIN GENET DEV, V8, P343, DOI 10.1016/S0959-437X(98)80092-0; KIESSLING AA, 1979, CANCER RES, V39, P2062; LANOTTE M, 1991, BLOOD, V77, P1080; Li Y, 1999, EXP CELL RES, V253, P372, DOI 10.1006/excr.1999.4664; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; MARTIN SL, 1993, MOL CELL BIOL, V13, P5383, DOI 10.1128/MCB.13.9.5383; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; MEDSTRAND P, 1993, J VIROL, V67, P6778, DOI 10.1128/JVI.67.11.6778-6787.1993; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; Mi S, 2000, NATURE, V403, P785, DOI 10.1038/35001608; Miki Y, 1998, J HUM GENET, V43, P77, DOI 10.1007/s100380050045; Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490; MWENDA JM, 1993, CELL MOL BIOL, V39, P317; Nekrutenko A, 2001, TRENDS GENET, V17, P619, DOI 10.1016/S0168-9525(01)02445-3; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; PACKER AI, 1993, DEV BIOL, V157, P281, DOI 10.1006/dbio.1993.1133; POZNANSKI AA, 1991, DEV BIOL, V143, P271, DOI 10.1016/0012-1606(91)90077-G; ROGERS MB, 1990, J CELL BIOL, V110, P1767, DOI 10.1083/jcb.110.5.1767; ROSS SA, 1994, J CELL PHYSIOL, V159, P263, DOI 10.1002/jcp.1041590210; SALGANIK RI, 1985, BIOCHEM BIOPH RES CO, V131, P492, DOI 10.1016/0006-291X(85)91829-7; Speek M, 2001, MOL CELL BIOL, V21, P1973, DOI 10.1128/MCB.21.6.1973-1985.2001; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; TEMIN HM, 1971, J NATL CANCER I, V46, P56; TING CN, 1992, GENE DEV, V6, P1457, DOI 10.1101/gad.6.8.1457; Tirelli U, 2001, EUR J CANCER, V37, P1320, DOI 10.1016/S0959-8049(01)00106-X; Tomilin NV, 1999, INT REV CYTOL, V186, P1; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; Whitelaw E, 2001, NAT GENET, V27, P361, DOI 10.1038/86850; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	57	93	100	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2750	2761		10.1038/sj.onc.1206354	http://dx.doi.org/10.1038/sj.onc.1206354			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12747369				2022-12-25	WOS:000182569300006
J	Teramoto, H; Malek, RL; Behbahani, B; Castellone, MD; Lee, NH; Gutkind, JS				Teramoto, H; Malek, RL; Behbahani, B; Castellone, MD; Lee, NH; Gutkind, JS			Identification of H-Ras, RhoA, Rac1 and Cdc42 responsive genes	ONCOGENE			English	Article						foci formation; small GTPases; microarray	GTP-BINDING PROTEINS; SIGNAL-TRANSDUCTION; CELLS; GTPASES; EXPRESSION; CANCER; TRANSFORMATION; TRANSCRIPTION; ACTIVATION; RECEPTOR	The superfamily of small GTP-binding proteins has expanded dramatically in recent years. The Ras family has long been associated with signaling pathways contributing to normal and aberrant cell growth, while Rho-related protein function is to integrate extracellular signals with specific targets regulating cell morphology, cell aggregation, tissue polarity, cell motility and cytokinesis. Recent findings suggest that certain Rho proteins, including RhoA, Rac1 and Cdc42, can also play a role in signal transduction to the nucleus and cell growth control. However, the nature of the genes regulated by Ras and Rho GTPases, as well as their contribution to their numerous biological effects is still largely unknown. To approach these questions, we investigated the global gene expression pattern induced by activated forms of H-Ras, RhoA, Rac1 and Cdc42 using cDNA microarrays comprising 19 117 unique elements. Using this approach, we identified 1184 genes that were up- or downregulated by at least twofold. Hierarchical cluster analysis revealed the existence of patterns of gene regulation both unique and common to H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL activation. For example, H-Ras V12 upregulated osteopontin and Akt 1, and H-Ras and RhoA stimulated cyclin G1, cyclin-dependent kinase 8, cyclin A2 and HMGI-C, while Rac1 QL and Cdc42 QL upregulated extracellular matrix and cell adhesion proteins such as alpha-actinin 4, procollagen type I and V and neuropilin. Furthermore, H-Ras V12 downregulated by >eightfold 52 genes compared to only three genes by RhoA QL, Rac1 QL and Cdc42 QL. These results provide key information to begin unraveling the complexity of the molecular mechanisms underlying the transforming potential of Ras and Rho proteins, as well as the numerous morphological and cell cycle effects induced by these small GTPases.	NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Inst Genom Res, Dept Funct Genom, Rockville, MD 20850 USA; George Washington Univ, Med Ctr, Dept Pharmacol, Washington, DC 20037 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); J. Craig Venter Institute; George Washington University	Gutkind, JS (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, 9000 Rockville Pike,Bldg 30,Room 212, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558, Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BOS JL, 1989, CANCER RES, V49, P4682; Brenner KA, 2000, ONCOGENE, V19, P3156, DOI 10.1038/sj.onc.1203626; Chen H, 1998, NAT NEUROSCI, V1, P436, DOI 10.1038/2154; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Fedele M, 1998, ONCOGENE, V17, P413, DOI 10.1038/sj.onc.1201952; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Liu CT, 2000, J BIOL CHEM, V275, P20315, DOI 10.1074/jbc.M909046199; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Malek RL, 2002, ONCOGENE, V21, P7256, DOI 10.1038/sj.onc.1205900; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PERONA R, 1993, ONCOGENE, V8, P1285; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Prasad MVVSV, 1999, ONCOGENE, V18, P1639, DOI 10.1038/sj.onc.1202461; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; YANG IV, 2002, GENOME BIOL, V3; Zentner MD, 2001, J BIOL CHEM, V276, P29805, DOI 10.1074/jbc.M103153200; Zhang J, 2001, CANCER LETT, V171, P215, DOI 10.1016/S0304-3835(01)00607-3	27	45	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2689	2697		10.1038/sj.onc.1206364	http://dx.doi.org/10.1038/sj.onc.1206364			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730683				2022-12-25	WOS:000182569000017
J	Catalano, S; Marsico, S; Giordano, C; Mauro, L; Rizza, P; Panno, ML; Ando, S				Catalano, S; Marsico, S; Giordano, C; Mauro, L; Rizza, P; Panno, ML; Ando, S			Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; HUMAN BREAST-CANCER; PROLIFERATIVE RESPONSE; ADIPOSE-TISSUE; GROWTH-FACTOR; IN-VITRO; C-JUN; RECEPTOR; IDENTIFICATION; ACTIVATION	Leptin, a product of adipocytes, is involved in the regulation of body weight and results strongly correlated to body fat content. An excess of fat mass represents a breast cancer risk factor particularly in postmenopausal women, where estrogen production by adipose tissue through its own aromatase activity stimulates tumor progression. Leptin stimulates estrogen production through the increase of aromatase expression and activity in human luteinized granulosa cells and adipose stromal cells. In the present study, we have examined the possible link that exists between leptin and breast cancer, focusing our attention on the direct effect of leptin on aromatase activity, which may enhance estrogen production and induce tumor cell growth stimulation. We have shown that leptin enhances aromatase mRNA expression, aromatase content, and its enzymatic activity in MCF-7. Aromatase expression appears to be regulated by tissue-specific promoter. It has been demonstrated that promoters II and 1.3 are the major promoters that drive aromatase expression in MCF-7. Transient transfection experiments using vector containing human aromatase promoters II and 1.3 sequence fused with luciferase reporter gene demonstrated that leptin is able to activate this promoter. In the presence of either mitogen-activated protein kinase inhibitor PD 98059 or ERK2 dominant negative as well as in the presence of STAT3 dominant negative, the stimulatory effects of leptin on aromatase promoter, enzymatic activity, and aromatase protein content were inhibited. Functional studies of mutagenesis and electrophoretic mobility shift assay revealed that the AP-1 motif is important in determining the up-regulatory effects induced by leptin on aromatase expression in MCF-7.	Univ Calabria, Dept Cell Biol, Fac Pharm, I-87030 Arcavacata di Rende CS, Italy; Univ Calabria, Ctr Sanitario, Fac Pharm, I-87030 Arcavacata di Rende CS, Italy; Univ Calabria, Dept Pharmacobiol, Fac Pharm, I-87030 Arcavacata di Rende CS, Italy; Univ Calabria, Dept Cell Biol, Fac Pharm, I-87030 Arcavacata di Rende CS, Italy	University of Calabria; University of Calabria; University of Calabria; University of Calabria	Ando, S (corresponding author), Univ Calabria, Dept Cell Biol, Fac Pharm, I-87030 Arcavacata di Rende CS, Italy.	sebastiano.ando@unical.it	MARSICO, Stefania/J-9938-2019	MARSICO, Stefania/0000-0003-1598-0526; GIORDANO, Cinzia/0000-0003-4969-0607; RIZZA, Pietro/0000-0002-1267-3910; CATALANO, Stefania/0000-0002-6352-9628				Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bannister AJ, 1995, ONCOGENE, V11, P2509; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bray GA, 2002, J NUTR, V132, p3451S, DOI 10.1093/jn/132.11.3451S; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Caro JF, 1996, DIABETES, V45, P1455, DOI 10.2337/diab.45.11.1455; Casabiell X, 1998, J CLIN ENDOCR METAB, V83, P2149, DOI 10.1210/jc.83.6.2149; Chen SA, 1998, FRONT BIOSCI-LANDMRK, V3, P922; CORBIN CJ, 1988, P NATL ACAD SCI USA, V85, P8948, DOI 10.1073/pnas.85.23.8948; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Darnell JE, 1996, RECENT PROG HORM RES, V51, P391; Dieudonne MN, 2002, BIOCHEM BIOPH RES CO, V293, P622, DOI 10.1016/S0006-291X(02)00205-X; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gottlicher M, 1997, MOL B INT U, P67; Hu X, 2002, J NATL CANCER I, V94, P1704, DOI 10.1093/jnci/94.22.1704; Islam MS, 1997, BIOCHEM BIOPH RES CO, V238, P851, DOI 10.1006/bbrc.1997.7399; Kitawaki J, 1999, MOL HUM REPROD, V5, P708, DOI 10.1093/molehr/5.8.708; Laud K, 1999, FEBS LETT, V463, P194, DOI 10.1016/S0014-5793(99)01616-6; Laud K, 2002, MOL CELL ENDOCRINOL, V188, P219, DOI 10.1016/S0303-7207(01)00678-5; LEPHART ED, 1991, METHOD ENZYMOL, V206, P477; Machinal-Quelin F, 2002, AM J PHYSIOL-CELL PH, V282, pC853, DOI 10.1152/ajpcell.00331.2001; Maehle BO, 1996, BREAST CANCER RES TR, V41, P123, DOI 10.1007/BF01807157; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Maggiolini M, 2001, MOL CELL ENDOCRINOL, V184, P163, DOI 10.1016/S0303-7207(01)00563-9; Magoffin D A, 1999, Ginekol Pol, V70, P1; Mantzoros CS, 1999, INT J CANCER, V80, P523, DOI 10.1002/(SICI)1097-0215(19990209)80:4<523::AID-IJC7>3.3.CO;2-3; Marttunen MB, 2000, MATURITAS, V35, P175, DOI 10.1016/S0378-5122(00)00121-3; O'Brien SN, 1999, BIOCHEM BIOPH RES CO, V259, P695, DOI 10.1006/bbrc.1999.0843; Ozet A, 2001, JPN J CLIN ONCOL, V31, P424, DOI 10.1093/jjco/hye097; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Reed MJ, 2001, CLIN ENDOCRINOL, V54, P563, DOI 10.1046/j.1365-2265.2001.01276.x; Rosenbaum M, 1996, J CLIN ENDOCR METAB, V81, P3424, DOI 10.1210/jc.81.9.3424; Schneider R, 2001, HORM METAB RES, V33, P1, DOI 10.1055/s-2001-12617; Shimizu H, 1997, J ENDOCRINOL, V154, P285, DOI 10.1677/joe.0.1540285; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; SIMPSON ER, 1994, ENDOCR REV, V15, P342, DOI 10.1210/er.15.3.342; Smith-Kirwin SM, 1998, J CLIN ENDOCR METAB, V83, P1810, DOI 10.1210/jc.83.5.1810; Stallmeyer B, 2001, J INVEST DERMATOL, V117, P98, DOI 10.1046/j.0022-202x.2001.01387.x; Stoll BA, 1998, BREAST CANCER RES TR, V49, P187, DOI 10.1023/A:1006003110909; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Tessitore L, 1999, 2ND BALKAN CONGRESS OF ONCOLOGY, P163; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; Tsuchiya T, 1999, EUR J PHARMACOL, V365, P273, DOI 10.1016/S0014-2999(98)00884-X; van den Brandt PA, 2000, AM J EPIDEMIOL, V152, P514, DOI 10.1093/aje/152.6.514; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yamashita T, 1998, BIOCHEM BIOPH RES CO, V246, P752, DOI 10.1006/bbrc.1998.8689; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhou DJ, 1996, J BIOL CHEM, V271, P15194, DOI 10.1074/jbc.271.25.15194	53	238	249	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28668	28676		10.1074/jbc.M301695200	http://dx.doi.org/10.1074/jbc.M301695200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12734209	hybrid			2022-12-25	WOS:000184421100041
J	Dobson, DE; Mengeling, BJ; Cilmi, S; Hickerson, S; Turco, SJ; Beverley, SM				Dobson, DE; Mengeling, BJ; Cilmi, S; Hickerson, S; Turco, SJ; Beverley, SM			Identification of genes encoding arabinosyltransferases (SCA) mediating developmental modifications of lipophosphoglycan required for sand fly transmission of Leishmania major	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOZOAN PARASITE LEISHMANIA; SURFACE LIPOPHOSPHOGLYCAN; TRANSFECTED LEISHMANIA; TRYPANOSOMA-BRUCEI; INFECTIVE STAGE; VIRULENCE GENES; PROMASTIGOTES; EXPRESSION; DONOVANI; VECTOR	At key steps in the infectious cycle pathogens must adhere to target cells, but at other times detachment is required for transmission. During sand fly infections by the protozoan parasite Leishmania major, binding of replicating promastigotes is mediated by galactosyl side chain (scGal) modifications of phosphoglycan repeats of the major surface adhesin, lipophosphoglycan (LPG). Release is mediated by arabinosyl (Ara) capping of LPG scbetaGal residues upon differentiation to the infective metacyclic stage. We used intraspecific polymorphisms of LPG structure to develop a genetic strategy leading to the identification of two genes (SCA1/2) mediating scAra capping. These LPG side chain beta1,2-arabinosyltransferases (scbetaAraTs) exhibit canonical glycosyltransferase motifs, and their overexpression leads to elevated microsomal scbetaAraT activity. Although the level of scAra caps is maximal in metacyclic parasites, scbetaAraT activity is maximal in log phase cells. Because quantitative immunolocalization studies suggest this is not mediated by sequestration of SCA scbetaAraTs away from the Golgi apparatus during log phase, regulation of activated Ara precursors may control LPG arabinosylation in vivo. The SCA genes define a new family of eukaryotic betaAraTs and represent novel developmentally regulated LPG-modifying activities identified in Leishmania.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Univ Kentucky, Med Ctr, Dept Biochem, Lexington, KY 40536 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Washington University (WUSTL); University of Kentucky; Harvard University; Harvard Medical School	Dobson, DE (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, 660 S Euclid Ave,Box 8230, St Louis, MO 63110 USA.			Beverley, Stephen/0000-0001-5319-0811				Al-Qahtani A, 1998, BIOCHEM J, V331, P521, DOI 10.1042/bj3310521; ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2; Beverley SM, 1998, TRENDS MICROBIOL, V6, P35, DOI 10.1016/S0966-842X(97)01180-3; Butcher BA, 1996, J BIOL CHEM, V271, P20573, DOI 10.1074/jbc.271.34.20573; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; Chakkalath HR, 2000, INFECT IMMUN, V68, P809, DOI 10.1128/IAI.68.2.809-814.2000; Cunningham ML, 2001, MOL BIOCHEM PARASIT, V113, P199, DOI 10.1016/S0166-6851(01)00213-4; Descoteaux A, 2002, EMBO J, V21, P4458, DOI 10.1093/emboj/cdf447; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; Dobson DE, 2003, J BIOL CHEM, V278, P15523, DOI 10.1074/jbc.M301568200; Duncan R, 2001, PARASITOL RES, V87, P897; Garraway LA, 1997, GENE, V198, P27, DOI 10.1016/S0378-1119(97)00288-6; Guerra-Giraidez C, 2002, J CELL SCI, V115, P2651; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Ilg T, 2001, MED MICROBIOL IMMUN, V190, P13, DOI 10.1007/s004300100071; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KELLEHER M, 1994, MOL BIOCHEM PARASIT, V66, P187, DOI 10.1016/0166-6851(94)90146-5; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; Mahoney AB, 1999, BIOCHEMISTRY-US, V38, P9813, DOI 10.1021/bi990741g; MCCONVILLE MJ, 1995, BIOCHEM J, V310, P807, DOI 10.1042/bj3100807; MCCONVILLE MJ, 1992, EMBO J, V11, P3593, DOI 10.1002/j.1460-2075.1992.tb05443.x; Mengeling BJ, 1999, ANAL BIOCHEM, V267, P227, DOI 10.1006/abio.1998.3011; Ng K, 1996, BIOCHEM J, V317, P247, DOI 10.1042/bj3170247; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; Pelletier I, 2002, J BIOL CHEM, V277, P17663, DOI 10.1074/jbc.M201562200; PIMENTA PFP, 1992, SCIENCE, V256, P1812, DOI 10.1126/science.1615326; PIMENTA PFP, 1991, EXP PARASITOL, V72, P191, DOI 10.1016/0014-4894(91)90137-L; PIMENTA PFP, 1994, P NATL ACAD SCI USA, V91, P9155, DOI 10.1073/pnas.91.19.9155; Roditi I, 2002, TRENDS MICROBIOL, V10, P128, DOI 10.1016/S0966-842X(02)02309-0; RYAN KA, 1993, GENE, V131, P145, DOI 10.1016/0378-1119(93)90684-U; RYAN KA, 1993, P NATL ACAD SCI USA, V90, P8609, DOI 10.1073/pnas.90.18.8609; Sacks D, 2001, ANNU REV MICROBIOL, V55, P453, DOI 10.1146/annurev.micro.55.1.453; SACKS DL, 1990, MOL BIOCHEM PARASIT, V42, P225, DOI 10.1016/0166-6851(90)90165-I; SACKS DL, 1992, INFECT AGENT DIS, V1, P200; SACKS DL, 1985, J IMMUNOL, V135, P564; SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528; Sacks DL, 2001, CELL MICROBIOL, V3, P189, DOI 10.1046/j.1462-5822.2001.00115.x; SACKS DL, 1995, J EXP MED, V181, P685, DOI 10.1084/jem.181.2.685; SACKS DL, 1987, J IMMUNOL, V139, P3099; SACKS DL, 1989, EXP PARASITOL, V69, P100, DOI 10.1016/0014-4894(89)90176-8; SCHNEIDER P, 1994, J BIOL CHEM, V269, P18332; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; TITUS RG, 1995, P NATL ACAD SCI USA, V92, P10267, DOI 10.1073/pnas.92.22.10267; TURCO SJ, 1991, MOL BIOCHEM PARASIT, V45, P91, DOI 10.1016/0166-6851(91)90030-A; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; WHITFIELD C, 1993, ADV MICROB PHYSIOL, V35, P135, DOI 10.1016/S0065-2911(08)60099-5; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945	48	29	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28840	28848		10.1074/jbc.M302728200	http://dx.doi.org/10.1074/jbc.M302728200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12750366	hybrid			2022-12-25	WOS:000184421100062
J	Doong, H; Rizzo, K; Fang, SY; Kulpa, V; Weissman, AM; Kohn, EC				Doong, H; Rizzo, K; Fang, SY; Kulpa, V; Weissman, AM; Kohn, EC			CAIR-1/BAG-3 abrogates heat shock protein-70 chaperone complex-mediated protein degradation - Accumulation of poly-ubiquitinated Hsp90 client proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; BCL-2-BINDING PROTEIN; INDUCED APOPTOSIS; BAG-1; RECEPTOR; CANCER; AKT; EXPRESSION; BINDING; HSP70	BAG family proteins are regulatory co-chaperones for heat shock protein (Hsp) 70. Hsp70 facilitates the removal of injured proteins by ubiquitin-mediated proteasomal degradation. This process can be driven by geldanamycin, an irreversible blocker of Hsp90. We hypothesize that CAIR-1/BAG-3 inhibits Hsp-mediated proteasomal degradation. Human breast cancer cells were engineered to overexpress either full-length CAIR-1 (FL), which binds Hsp70, or a BAG domain-deletion mutant (dBAG) that cannot bind Hsp70. FL overexpression prevented geldanamycin-mediated loss of total and phospho-Akt and other Hsp client proteins. dBAG provided no protection, indicating a requirement for Hsp70 binding. Ubiquitinated Akt accumulated in FL-expressing cells, mimicking the effect of lactacystin proteasomal inhibition, indicating that CAIR-1 inhibits proteasomal degradation distal to protein ubiquitination in a BAG domain-dependent manner. Protein protection in FL cells was generalizable to downstream Akt targets, GSK3beta, P70S6 kinase, CREB, and other Hsp client proteins, including Raf-1, cyclin-dependent kinase 4, and epidermal growth factor receptor. These findings suggest that Hsp70 is a chaperone driving a multiprotein degradation complex and that the inhibitory co-chaperone CAIR-1 functions distal to client ubiquitination. Furthermore, poly-ubiquitination is not sufficient for efficient proteasomal targeting of Hsp client proteins.	NCI, Mol Signaling Sect, Pathol Lab, NIH, Bethesda, MD 20892 USA; NCI, Regulat Prot Funct Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Doong, H (corresponding author), NCI, Mol Signaling Sect, Pathol Lab, NIH, 10 Ctr Dr,MSC 1500, Bethesda, MD 20892 USA.	ek1b@nih.gov	高, 雨莉/HGU-8187-2022; Fang, Shengyun/H-3802-2011	Fang, Shengyun/0000-0001-7280-5463	NATIONAL CANCER INSTITUTE [Z01SC009163, ZIASC009163] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antoku K, 2001, BIOCHEM BIOPH RES CO, V286, P1003, DOI 10.1006/bbrc.2001.5512; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bang OS, 2000, BIOCHEM BIOPH RES CO, V278, P306, DOI 10.1006/bbrc.2000.3805; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Brimmell M, 1999, BRIT J CANCER, V81, P1042, DOI 10.1038/sj.bjc.6690805; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; Doong H, 2000, ONCOGENE, V19, P4385, DOI 10.1038/sj.onc.1203797; ERDOS G, 1994, BIOCHEM BIOPH RES CO, V202, P476, DOI 10.1006/bbrc.1994.1953; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Gassler CS, 2001, J BIOL CHEM, V276, P32538, DOI 10.1074/jbc.M105328200; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kanelakis KC, 1999, J BIOL CHEM, V274, P34134, DOI 10.1074/jbc.274.48.34134; KIM SH, 1993, BIOCHEM BIOPH RES CO, V193, P759, DOI 10.1006/bbrc.1993.1690; Kudoh M, 2002, CANCER RES, V62, P1904; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lee JH, 1999, ONCOGENE, V18, P6183, DOI 10.1038/sj.onc.1203043; Liao Q, 2001, FEBS LETT, V503, P151, DOI 10.1016/S0014-5793(01)02728-4; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; McClellan AJ, 2001, NAT CELL BIOL, V3, pE51, DOI 10.1038/35055162; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Morimoto RI, 1998, NAT BIOTECHNOL, V16, P833, DOI 10.1038/nbt0998-833; Naishiro Y, 1999, ONCOGENE, V18, P3244, DOI 10.1038/sj.onc.1202661; Neckers L, 1999, INVEST NEW DRUG, V17, P361, DOI 10.1023/A:1006382320697; Nollen EAA, 2001, J BIOL CHEM, V276, P4677, DOI 10.1074/jbc.M009745200; Romano MF, 2003, CELL DEATH DIFFER, V10, P383, DOI 10.1038/sj.cdd.4401167; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schulte TW, 1998, CANCER CHEMOTH PHARM, V42, P273, DOI 10.1007/s002800050817; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; Supino-Rosin L, 2000, J BIOL CHEM, V275, P21850, DOI 10.1074/jbc.M001834200; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Tang SC, 1999, J CLIN ONCOL, V17, P1710, DOI 10.1200/JCO.1999.17.6.1710; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Thress K, 1998, EMBO J, V17, P6135, DOI 10.1093/emboj/17.21.6135; Wang Q, 2003, BIOCHEM BIOPH RES CO, V300, P253, DOI 10.1016/S0006-291X(02)02840-1; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yawata A, 1998, ONCOGENE, V16, P2681, DOI 10.1038/sj.onc.1201792	47	133	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28490	28500		10.1074/jbc.M209682200	http://dx.doi.org/10.1074/jbc.M209682200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12750378	hybrid			2022-12-25	WOS:000184421100019
J	Kondo, Y; Issa, JPJ				Kondo, Y; Issa, JPJ			Enrichment for histone H3 lysine 9 methylation at Alu repeats in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLORECTAL-CANCER; HUMAN COLON; IN-VIVO; GENE; PATTERNS; CHROMOSOMES; REPRESSION; SEQUENCES; PROTEIN; GENOME	The aim of this study was to identify in human cells common targets of histone H3 lysine 9 (H3-Lys(9)) methylation, a modification that is generally associated with gene silencing. After chromatin immunoprecipitation using an H3-Lys(9) methylated antibody, we cloned the recovered DNA and sequenced 47 independent clones. Of these, 38 clones (81%) contained repetitive elements, either short interspersed transposable element (SINE or Alu elements), long terminal repeat (LTR), long interspersed transposable element (LINE), or satellite region (ALR/Alpha) DNA, and three additional clones were near Alu elements. Further characterization of these repetitive elements revealed that 32 clones (68%) were Alu repeats, corresponding to both old Alu (23 clones) and young Alu (9 clones) subfamilies. Association of H3-Lys(9) methylation was confirmed by chromatin immunoprecipitation-PCR using conserved Alu primers. In addition, we randomly selected 5 Alu repeats from the recovered clones and confirmed association with H3-Lys(9) by PCR using primer sets flanking the Alu elements. Treatment with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine rapidly decreased the level of H3-Lys(9) methylation in the Alu elements, suggesting that H3-Lys(9) methylation may be related to the suppression of Alu elements through DNA methylation. Thus H3-Lys(9) methylation is enriched at human repetitive elements, particularly Alu elements, and may play a role in the suppression of recombination by these elements.	Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Issa, JPJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Unit 428,1515 Holcombe Blvd, Houston, TX 77030 USA.			Issa, Jean-Pierre/0000-0003-2258-5030	NCI NIH HHS [R33CA89837] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R33CA089837] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; Cohen DE, 2002, CURR OPIN GENET DEV, V12, P219, DOI 10.1016/S0959-437X(02)00289-7; Deininger PL, 2002, GENOME RES, V12, P1455, DOI 10.1101/gr.282402; ENGLANDER EW, 1993, J BIOL CHEM, V268, P19565; Fahrner JA, 2002, CANCER RES, V62, P7213; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Hakimi MA, 2002, NATURE, V418, P994, DOI 10.1038/nature01024; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Hata K, 1997, GENE, V189, P227, DOI 10.1016/S0378-1119(96)00856-6; HOWARD B H, 1990, New Biologist, V2, P759; Issa JP, 2000, ANN NY ACAD SCI, V910, P140; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kellum R, 2003, CURR TOP MICROBIOL, V274, P53; KOCHANEK S, 1995, FEBS LETT, V360, P115, DOI 10.1016/0014-5793(95)00068-K; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; MAGEWU AN, 1994, MOL CELL BIOL, V14, P4225, DOI 10.1128/MCB.14.6.4225; Mighell AJ, 1997, FEBS LETT, V417, P1, DOI 10.1016/S0014-5793(97)01259-3; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nguyen CT, 2002, CANCER RES, V62, P6456; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Shen L, 2003, GASTROENTEROLOGY, V124, P626, DOI 10.1053/gast.2003.50102; Turker MS, 1997, MUTAT RES-REV MUTAT, V386, P119, DOI 10.1016/S1383-5742(96)00048-8; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	30	93	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27658	27662		10.1074/jbc.M304072200	http://dx.doi.org/10.1074/jbc.M304072200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12724318	hybrid			2022-12-25	WOS:000184242700042
J	Hogg, RC; Hopping, G; Alewood, PF; Adams, DJ; Bertrand, D				Hogg, RC; Hopping, G; Alewood, PF; Adams, DJ; Bertrand, D			alpha-conotoxins PnIA and [A10L] PnIA stabilize different states of the alpha 7-L247T nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL ALPHA(7); CHANNEL DOMAIN; ALLOSTERIC TRANSITIONS; M2 DOMAIN; 5-HYDROXYTRYPTAMINE; SELECTIVITY; ANTAGONIST; MUTATIONS; SUBTYPES; AGONIST	The effects of the native alpha-conotoxin PnIA, its synthetic derivative [ A10L] PnIA and alanine scan derivatives of [ A10L] PnIA were investigated on chick wild type alpha7 and alpha7-L247T mutant nicotinic acetylcholine receptors (nAChRs) expressed in Xenopus oocytes. PnIA and [A10L] PnIA inhibited acetylcholine (ACh)-activated currents at wtalpha7 receptors with IC50 values of 349 and 168 nM, respectively. Rates of onset of inhibition were similar for PnIA and [ A10L] PnIA; however, the rate of recovery was slower for [ A10L] PnIA, indicating that the increased potency of [ A10L] PnIA at alpha7 receptors is conveyed by its slower rate of dissociation from the receptors. All the alanine mutants of [ A10L] PnIA inhibited ACh-activated currents at wtalpha7 receptors. Insertion of an alanine residue between position 5 and 13 and at position 15 significantly reduced the ability of [ A10L] PnIA to inhibit ACh-evoked currents. PnIA inhibited the non-desensitizing ACh-activated currents at alpha7-L247T receptors with an IC50 194 nM. In contrast, [ A10L] PnIA and the alanine mutants potentiated the ACh-activated current alpha7-L247T receptors and in addition [ A10L] PnIA acted as an agonist. PnIA stabilized the receptor in a state that is non-conducting in both the wild type and mutant receptors, whereas [ A10L] PnIA stabilized a state that is non-conducting in the wild type receptor and conducting in the alpha7-L247T mutant. These data indicate that the change of a single amino acid side-chain, at position 10, is sufficient to change the toxin specificity for receptor states in the alpha7-L247T mutant.	Ctr Med Univ Geneva, Dept Physiol, CH-1211 Geneva 4, Switzerland; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia	University of Geneva; University of Queensland	Hogg, RC (corresponding author), Ctr Med Univ Geneva, Dept Physiol, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	hogg1@etu.unige.ch	Adams, David John/K-3578-2019; Hopping, Gene G/A-5942-2012; Adams, David/J-9125-2014	Adams, David John/0000-0002-7030-2288; Adams, David/0000-0002-7030-2288; Alewood, Paul/0000-0001-7454-6522; Hopping, Gene/0000-0001-8409-1867				Adams DJ, 1999, DRUG DEVELOP RES, V46, P219; Arias HR, 2000, INT J BIOCHEM CELL B, V32, P1017, DOI 10.1016/S1357-2725(00)00051-0; BERTRAND D, 1993, P NATL ACAD SCI USA, V90, P6971, DOI 10.1073/pnas.90.15.6971; BERTRAND D, 1992, P NATL ACAD SCI USA, V89, P1261, DOI 10.1073/pnas.89.4.1261; Bertrand D, 1991, METHODS NEUROSCIENCE, V4, P174; Bertrand S, 1997, NEUROREPORT, V8, P3591, DOI 10.1097/00001756-199711100-00034; CHANGEUX JP, 1990, TRENDS PHARMACOL SCI, V11, P485, DOI 10.1016/0165-6147(90)90049-E; Edelstein SJ, 1996, BIOL CYBERN, V75, P361, DOI 10.1007/s004220050302; FAINZILBER M, 1994, BIOCHEMISTRY-US, V33, P9523, DOI 10.1021/bi00198a018; FILATOV GN, 1995, MOL PHARMACOL, V48, P379; Hogg RC, 1999, J BIOL CHEM, V274, P36559, DOI 10.1074/jbc.274.51.36559; Hu SH, 1996, STRUCTURE, V4, P417, DOI 10.1016/S0969-2126(96)00047-0; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; Luo S, 1999, BIOCHEMISTRY-US, V38, P14542, DOI 10.1021/bi991252j; McIntosh JM, 2001, TOXICON, V39, P1447, DOI 10.1016/S0041-0101(01)00145-3; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Palma E, 1996, J PHYSIOL-LONDON, V491, P151, DOI 10.1113/jphysiol.1996.sp021203; Palma E, 1997, P NATL ACAD SCI USA, V94, P1539, DOI 10.1073/pnas.94.4.1539; Palma E, 1996, P NATL ACAD SCI USA, V93, P11231, DOI 10.1073/pnas.93.20.11231; Palma E, 1997, P NATL ACAD SCI USA, V94, P9915, DOI 10.1073/pnas.94.18.9915; Quiram PA, 2000, J BIOL CHEM, V275, P4889, DOI 10.1074/jbc.275.7.4889; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180	24	55	56	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26908	26914		10.1074/jbc.M212628200	http://dx.doi.org/10.1074/jbc.M212628200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12746432	hybrid, Green Published			2022-12-25	WOS:000184155700079
J	Lian, Q; Szarka, SJ; Ng, KKS; Wong, SL				Lian, Q; Szarka, SJ; Ng, KKS; Wong, SL			Engineering of a staphylokinase-based fibrinolytic agent with antithrombotic activity and targeting capability toward thrombin-rich fibrin and plasma clots	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN ANTIBODY FRAGMENT; CORONARY-ARTERY PATENCY; HUMAN ALPHA-THROMBIN; N-TERMINAL REGION; RECOMBINANT STAPHYLOKINASE; BACILLUS-SUBTILIS; PLASMINOGEN-ACTIVATOR; SECRETORY PRODUCTION; GLYCOPROTEIN-IIB/IIIA; HIRUDIN	Current clinically approved thrombolytic agents have significant drawbacks including reocclusion and bleeding complications. To address these problems, a staphylokinase-based thrombolytic agent equipped with antithrombotic activity from hirudin was engineered. Because the N termini for both staphylokinase and hirudin are required for their activities, a Y-shaped molecule is generated using engineered coiled-coil sequences as the heterodimerization domain. This agent, designated HE-SAKK, was produced and assembled from Bacillus subtilis via secretion using an optimized co-cultivation approach. After a simple in vitro treatment to reshuffle the disulfide bonds of hirudin, both staphylokinase and hirudin in HE-SAKK showed biological activities comparable with their parent molecules. This agent was capable of targeting thrombin-rich fibrin clots and inhibiting clot-bound thrombin activity. The time required for lysing 50% of fibrin clot in the absence or presence of fibrinogen was shortened 21 and 30%, respectively, with HE-SAKK in comparison with staphylokinase. In plasma clot studies, the HE-SAKK concentration required to achieve a comparable 50% clot lysis time was at least 12 times less than that of staphylokinase. Therefore, HE-SAKK is a promising thrombolytic agent with the capability to target thrombin-rich fibrin clots and to minimize clot reformation during fibrinolysis.	Univ Calgary, Dept Biol Sci, Div Cellular Mol & Microbial Biol, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Biol Sci, Div Biochem, Calgary, AB T2N 1N4, Canada	University of Calgary; University of Calgary	Wong, SL (corresponding author), Univ Calgary, Dept Biol Sci, Div Cellular Mol & Microbial Biol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	slwong@ucalgary.ca		Ng, Kenneth K.S./0000-0001-7280-8445				Bajzar L, 2000, ARTERIOSCL THROM VAS, V20, P2511, DOI 10.1161/01.ATV.20.12.2511; BETZ A, 1992, BIOCHEMISTRY-US, V31, P4557, DOI 10.1021/bi00134a004; Bolhuis A, 1999, APPL ENVIRON MICROB, V65, P2934; Booth NA, 1999, BEST PRACT RES CL HA, V12, P423, DOI 10.1053/beha.1999.0034; CHANG JY, 1994, BIOCHEM J, V300, P643, DOI 10.1042/bj3000643; Collen D, 2000, CIRCULATION, V102, P1766; Collen D, 1997, CIRCULATION, V95, P463; Collen D, 1998, NAT MED, V4, P279, DOI 10.1038/nm0398-279; COLLEN D, 1993, CIRCULATION, V87, P1850, DOI 10.1161/01.CIR.87.6.1850; Collet JP, 2000, ARTERIOSCL THROM VAS, V20, P1354, DOI 10.1161/01.ATV.20.5.1354; COMPTON SJ, 1985, ANAL BIOCHEM, V151, P369, DOI 10.1016/0003-2697(85)90190-3; DODT J, 1988, FEBS LETT, V229, P87, DOI 10.1016/0014-5793(88)80803-2; Eccleston D, 1995, CORONARY ARTERY DIS, V6, P947; EISENBERG PR, 1991, FIBRINOLYSIS, V5, P217, DOI 10.1016/0268-9499(91)90003-M; EWALD GA, 1995, CIRCULATION, V91, P28, DOI 10.1161/01.CIR.91.1.28; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; FRANCIS CW, 1983, J LAB CLIN MED, V102, P220; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HALLING SM, 1977, BIOCHEMISTRY-US, V16, P2880, DOI 10.1021/bi00632a012; Heymans S, 2000, THROMB HAEMOSTASIS, V83, P666, DOI 10.1055/s-0037-1613889; Hodges RS, 1996, BIOCHEM CELL BIOL, V74, P133, DOI 10.1139/o96-015; Hoffmeister HM, 2001, THROMB RES, V103, pS51, DOI 10.1016/S0049-3848(01)00297-3; HUNT D, 1992, LANCET, V339, P753; JANG IK, 1989, CIRCULATION, V79, P920, DOI 10.1161/01.CIR.79.4.920; KUMAR R, 1994, THROMB HAEMOSTASIS, V72, P713; LAZAR JB, 1991, J BIOL CHEM, V266, P685; LEE CD, 1989, BLOOD, V73, P185; Lee KN, 2001, ANN NY ACAD SCI, V936, P335; LIJNEN HR, 1992, FIBRINOLYSIS, V6, P214, DOI 10.1016/0268-9499(92)90074-R; Margot P, 1996, MICROBIOL-UK, V142, P3437, DOI 10.1099/13500872-142-12-3437; MORRIS JP, 1983, BIOCHIM BIOPHYS ACTA, V744, P99, DOI 10.1016/0167-4838(83)90345-X; Ohman EM, 2001, CHEST, V119, p253S, DOI 10.1378/chest.119.1_suppl.253S; RAPOLD HJ, 1992, CIRCULATION, V85, P928, DOI 10.1161/01.CIR.85.3.928; Ryan EA, 1999, BIOPHYS J, V77, P2813, DOI 10.1016/S0006-3495(99)77113-4; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; SAKHAROV DV, 1995, CIRCULATION, V92, P1883, DOI 10.1161/01.CIR.92.7.1883; Sakharov DV, 1996, J BIOL CHEM, V271, P27912, DOI 10.1074/jbc.271.44.27912; SANDHU GS, 1992, BIOTECHNIQUES, V12, P14; Schlott B, 1998, J BIOL CHEM, V273, P22346, DOI 10.1074/jbc.273.35.22346; SILENCE K, 1993, BLOOD, V82, P1175, DOI 10.1182/blood.V82.4.1175.bloodjournal8241175; Syed S, 1997, BLOOD, V89, P3243, DOI 10.1182/blood.V89.9.3243; Szarka SJ, 1999, APPL ENVIRON MICROB, V65, P506; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Tripet B, 1996, PROTEIN ENG, V9, P1029, DOI 10.1093/protein/9.11.1029; van Zyl WB, 2000, THROMB RES, V98, P435, DOI 10.1016/S0049-3848(00)00204-8; Vanderschueren S, 1997, AM HEART J, V134, P213, DOI 10.1016/S0002-8703(97)70127-3; VANDERSCHUEREN S, 1995, CIRCULATION, V92, P2044, DOI 10.1161/01.CIR.92.8.2044; VANDEWERF F, 1990, LANCET, V336, P71; WALLACE A, 1989, BIOCHEMISTRY-US, V28, P10079, DOI 10.1021/bi00452a030; WANG LF, 1987, MOL GEN GENET, V207, P114, DOI 10.1007/BF00331498; Wirsching F, 2002, MOL GENET METAB, V75, P250, DOI 10.1006/mgme.2001.3292; Wirsching F, 1997, GENE, V204, P177, DOI 10.1016/S0378-1119(97)00540-4; WITTING JI, 1991, THROMB RES, V63, P473, DOI 10.1016/0049-3848(91)90235-O; WONG SL, 1986, J BACTERIOL, V168, P1005, DOI 10.1128/jb.168.2.1005-1009.1986; Wu SC, 2002, APPL ENVIRON MICROB, V68, P3261, DOI 10.1128/AEM.68.7.3261-3269.2002; Wu SC, 2002, PROTEIN EXPRES PURIF, V24, P348, DOI 10.1006/prep.2001.1582; Wu SC, 1998, J BACTERIOL, V180, P2830, DOI 10.1128/JB.180.11.2830-2835.1998; WU XC, 1991, J BACTERIOL, V173, P4952, DOI 10.1128/jb.173.16.4952-4958.1991; YANG WP, 1994, BIOCHEMISTRY-US, V33, P2306, DOI 10.1021/bi00174a043; YASUDA T, 1990, J AM COLL CARDIOL, V16, P714, DOI 10.1016/0735-1097(90)90364-U; YASUDA T, 1990, J AM COLL CARDIOL, V16, P1728, DOI 10.1016/0735-1097(90)90327-L; YE R, 1996, P INT S REC ADV BIOI, P160; Ye RQ, 1999, BIOTECHNOL BIOENG, V62, P87	63	32	37	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26677	26686		10.1074/jbc.M303241200	http://dx.doi.org/10.1074/jbc.M303241200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12736246	hybrid			2022-12-25	WOS:000184155700050
J	Lindhout, DA; Sykes, BD				Lindhout, DA; Sykes, BD			Structure and dynamics of the C-domain of human cardiac troponin C in complex with the inhibitory region of human cardiac troponin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; PROTEIN SECONDARY STRUCTURE; THIN FILAMENT PROTEINS; PULSED-FIELD GRADIENT; REGULATORY N-DOMAIN; SKELETAL-MUSCLE; CALCIUM-BINDING; IMPROVED SENSITIVITY; BIOLOGICAL-ACTIVITY; CRYSTAL-STRUCTURE	Cardiac troponin C is the Ca2+-dependent switch for heart muscle contraction. Troponin C is associated with various other proteins including troponin I and troponin T. The interaction between the subunits within the troponin complex is of critical importance in understanding contractility. Following a Ca2+ signal to begin contraction, the inhibitory region of troponin I comprising residues Thr(128)-Arg(147) relocates from its binding surface on actin to troponin C, triggering movement of troponin-tropomyosin within the thin filament and thereby freeing actin-binding site(s) for interactions with the myosin ATPase of the thick filament to generate the power stroke. The structure of calcium-saturated cardiac troponin C (C-domain) in complex with the inhibitory region of troponin I was determined using multinuclear and multidimensional nuclear magnetic resonance spectroscopy. The structure of this complex reveals that the inhibitory region adopts a helical conformation spanning residues Leu(134)-Lys(139), with a novel orientation between the E- and H-helices of troponin C, which is largely stabilized by electrostatic interactions. By using isotope labeling, we have studied the dynamics of the protein and peptide in the binary complex. The structure of this inhibited complex provides a framework for understanding into interactions within the troponin complex upon heart contraction.	Univ Alberta, Canadian Inst Hlth Res, Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	Institute for Work & Health; University of Alberta; University of Alberta	Sykes, BD (corresponding author), Univ Alberta, Canadian Inst Hlth Res, Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada.							ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; Brown LJ, 2002, P NATL ACAD SCI USA, V99, P12765, DOI 10.1073/pnas.202477399; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CACHIA PJ, 1983, BIOCHEMISTRY-US, V22, P4145, DOI 10.1021/bi00286a024; CAMPBELL AP, 1992, BIOCHIM BIOPHYS ACTA, V1160, P35, DOI 10.1016/0167-4838(92)90036-D; CAMPBELL AP, 1991, J MOL BIOL, V222, P405, DOI 10.1016/0022-2836(91)90219-V; Chandra M, 1997, BIOCHEMISTRY-US, V36, P13305, DOI 10.1021/bi9710129; Dargis R, 2002, J BIOL CHEM, V277, P34662, DOI 10.1074/jbc.C200419200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dvoretsky A, 2002, J BIOL CHEM, V277, P38565, DOI 10.1074/jbc.M205306200; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Finley N, 2000, J MOL CELL CARDIOL, V32, P1439, DOI 10.1006/jmcc.2000.1174; Gagne SM, 1997, BIOCHEMISTRY-US, V36, P4386, DOI 10.1021/bi963076+; Gagne SM, 1998, J MOL BIOL, V278, P667, DOI 10.1006/jmbi.1998.1723; GREASER ML, 1973, J BIOL CHEM, V248, P2125; HEAD JF, 1974, BIOCHEM J, V137, P145, DOI 10.1042/bj1370145; Heller WT, 2002, BIOCHEMISTRY-US, V41, P15654, DOI 10.1021/bi026687c; Hernandez G, 1999, BIOCHEMISTRY-US, V38, P6911, DOI 10.1021/bi990150q; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; Huth JR, 1997, PROTEIN SCI, V6, P2359; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; JOHNSON JD, 1979, J BIOL CHEM, V254, P3497; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; Li MX, 2000, BIOCHEMISTRY-US, V39, P8782, DOI 10.1021/bi000473i; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; LI MX, 1995, BIOCHEMISTRY-US, V34, P8330, DOI 10.1021/bi00026a014; Li Y, 2000, P NATL ACAD SCI USA, V97, P5140, DOI 10.1073/pnas.090098997; Lindhout DA, 2002, BIOCHEMISTRY-US, V41, P7267, DOI 10.1021/bi020100c; Luo Y, 2000, J MOL BIOL, V296, P899, DOI 10.1006/jmbi.1999.3495; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; McKay RT, 1998, BIOCHEMISTRY-US, V37, P12419, DOI 10.1021/bi9809019; Mercier P, 2003, BIOCHEMISTRY-US, V42, P4333, DOI 10.1021/bi027041n; Mercier P, 2000, BIOCHEMISTRY-US, V39, P2902, DOI 10.1021/bi992579n; Mercier P, 2001, BIOCHEMISTRY-US, V40, P10063, DOI 10.1021/bi010748+; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NGAI SM, 1994, J BIOL CHEM, V269, P2165; NGAI SM, 1992, J BIOL CHEM, V267, P15715; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ogura K, 1996, J BIOMOL NMR, V8, P492, DOI 10.1007/BF00228150; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; PEARLSTONE JR, 1985, CAN J BIOCHEM CELL B, V63, P212, DOI 10.1139/o85-030; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; Spyracopoulos L, 1998, BIOCHEMISTRY-US, V37, P18032, DOI 10.1021/bi9816960; Spyracopoulos L, 1997, BIOCHEMISTRY-US, V36, P12138, DOI 10.1021/bi971223d; Strynadka NCJ, 1997, J MOL BIOL, V273, P238, DOI 10.1006/jmbi.1997.1257; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; Takeda S, 2002, BIOPHYS J, V82, p170A; TALBOT JA, 1979, J BIOL CHEM, V254, P3720; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; Tripet B, 2002, J MOL BIOL, V323, P345, DOI 10.1016/S0022-2836(02)00883-5; Tung CS, 2000, PROTEIN SCI, V9, P1312; VALLINS WJ, 1990, FEBS LETT, V270, P57, DOI 10.1016/0014-5793(90)81234-F; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847; Wang X, 2002, J BIOL CHEM, V277, P31124, DOI 10.1074/jbc.M203896200; Wang X, 2001, J BIOL CHEM, V276, P25456, DOI 10.1074/jbc.M102418200; WISHART DS, 1994, COMPUT APPL BIOSCI, V10, P121; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	74	35	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27024	27034		10.1074/jbc.M302497200	http://dx.doi.org/10.1074/jbc.M302497200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12732641	hybrid			2022-12-25	WOS:000184155700094
J	Oberst, MD; Williams, CA; Dickson, RB; Johnson, MD; Lin, CY				Oberst, MD; Williams, CA; Dickson, RB; Johnson, MD; Lin, CY			The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; BREAST-CANCER CELLS; MICROARRAY ANALYSIS; LIGAND-BINDING; OVARIAN-CANCER; RECEPTOR; COMPLEX; GENES; LOCALIZATION; CLONING	The activation of matriptase requires proteolytic cleavage at a canonical activation motif that converts the enzyme from a one-chain zymogen to an active, two-chain protease. In this study, matriptase bearing a mutation in its catalytic triad was unable to undergo this activational cleavage, suggesting that the activating cleavage occurs via a transactivation mechanism where interaction between matriptase zymogen molecules leads to activation of the protease. Using additional point and deletion mutants, we showed that activation of matriptase requires proteolytic processing at Gly-149 in the SEA domain of the protease, glycosylation of the first CUB domain and the serine protease domain, and intact low density lipoprotein receptor class A domains. Its cognate inhibitor, hepatocyte growth factor activator inhibitor-1, may also participate in the activation of matriptase, based on the observation that matriptase activation did not occur when the protease was co-expressed with hepatocyte growth factor activator inhibitor-1 mutated in its low density lipoprotein receptor class A domain. These results suggest that besides matriptase catalytic activity, matriptase activation requires post-translational modification of the protease, intact noncatalytic domains, and its cognate inhibitor.	Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20057 USA	Georgetown University	Lin, CY (corresponding author), Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Dept Oncol, 3970 Reservoir Rd NW,Box 571469, Washington, DC 20057 USA.				NCI NIH HHS [2P50CA58155, 1R21CA80897] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R43CA058155, R21CA080897] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Benaud C, 2002, J BIOL CHEM, V277, P10539, DOI 10.1074/jbc.M109064200; Benaud C, 2001, EUR J BIOCHEM, V268, P1439, DOI 10.1046/j.1432-1327.2001.02016.x; Benaud CM, 2002, CLIN EXP METASTAS, V19, P639, DOI 10.1023/A:1020985632550; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; Comoglio PM, 2001, SEMIN CANCER BIOL, V11, P153, DOI 10.1006/scbi.2000.0366; ESSER V, 1988, J BIOL CHEM, V263, P13282; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; Ihara S, 2002, J BIOL CHEM, V277, P16960, DOI 10.1074/jbc.M200673200; Kang JY, 2003, CANCER RES, V63, P1101; KILPATRICK LM, 2002, BIOCH SOC M 678 LOND; Kim MG, 1999, IMMUNOGENETICS, V49, P420, DOI 10.1007/s002510050515; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Lin CY, 1997, J BIOL CHEM, V272, P9147; List K, 2002, ONCOGENE, V21, P3765, DOI 10.1038/sj.onc.1205502; Oberst M, 2001, AM J PATHOL, V158, P1301, DOI 10.1016/S0002-9440(10)64081-3; Oberst MD, 2002, CLIN CANCER RES, V8, P1101; OBERST MD, 2003, IN PRESS J HISTOCHEM; Satomi S, 2001, BIOCHEM BIOPH RES CO, V287, P995, DOI 10.1006/bbrc.2001.5686; Suzuki M, 2003, J BIOL CHEM, V278, P14640, DOI 10.1074/jbc.M300239200; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; Tanimoto H, 2001, TUMOR BIOL, V22, P104, DOI 10.1159/000050604; Thielens NM, 1999, IMMUNOPHARMACOLOGY, V42, P3, DOI 10.1016/S0162-3109(99)00019-3; Yamada K, 2000, GENE, V252, P209, DOI 10.1016/S0378-1119(00)00225-0; Zhang Y, 1998, CYTOGENET CELL GENET, V83, P56, DOI 10.1159/000015125	31	149	162	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26773	26779		10.1074/jbc.M304282200	http://dx.doi.org/10.1074/jbc.M304282200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12738778	hybrid			2022-12-25	WOS:000184155700062
J	Sturla, L; Rampal, R; Haltiwanger, RS; Fruscione, F; Etzioni, A; Tonetti, M				Sturla, L; Rampal, R; Haltiwanger, RS; Fruscione, F; Etzioni, A; Tonetti, M			Differential terminal fucosylation of N-linked glycans versus protein O-fucosylation in leukocyte adhesion deficiency type II (CDG IIc)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE REPEATS; GDP-FUCOSE; C-MANNOSYLATION; FRINGE; GLYCOSYLATION; TRANSFERASE; LIGAND; ROLES; O-FUCOSYL-TRANSFERASE-1; GLYCOSYLTRANSFERASE	LAD II/CDG IIc is a rare autosomal recessive disease characterized by a decreased expression of fucosylated antigens on cell surfaces that results in leukocyte adhesion deficiency and severe neurological and developmental abnormalities. Its molecular basis has been identified as a defect in the transporter of GDP-L-fucose into the Golgi lumen, which reduces the availability of the substrate for fucosyltransferases. During metabolic radiolabeling experiments using [H-3]fucose, LAD II fibroblasts incorporated significantly less radiolabel compared with control cells. However, fractionation and analysis of the different classes of glycans indicated that the decrease in [H-3]fucose incorporation is not generalized and is mainly confined to terminal fucosylation of N-linked oligosaccharides. In contrast, the total levels of protein O-fucosylation, including that observed in Notch protein, were unaffected. This finding demonstrates that the decrease in GDP-L-fucose levels in the fibroblast Golgi caused by the LAD II defect does not impair bulk protein O-fucosylation, but severely affects the bulk addition of fucose as a terminal modification of N-linked glycans. These data suggest that the severe clinical abnormalities including neurological and developmental ones observed in at least some of the LAD II patients may be related to alteration in recognition systems involving terminal fucose modifications of N-glycans and not be due to a defective O-fucosylation of proteins such as Notch.	Univ Genoa, Dept Expt Med, I-16132 Genoa, Italy; Ist Giannina Gaslini, I-16147 Genoa, Italy; SUNY Stony Brook, Inst Cell & Dev Biol, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Ctr Excellence Biomed Res, I-16132 Genoa, Italy; Technion Israel Inst Technol, Rambam Med Ctr, Meyer Children Hosp, Dept Pediat, IL-31096 Haifa, Israel; Technion Israel Inst Technol, B Rappaport Sch Med, IL-31096 Haifa, Israel	University of Genoa; University of Genoa; IRCCS Istituto Giannina Gaslini; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Tonetti, M (corresponding author), Univ Genoa, Dept Expt Med, Viale Benedetto 15,1, I-16132 Genoa, Italy.	tonetti@unige.it	TONETTI, MICHELA/AAF-3404-2021; fruscione, floriana/AAA-8747-2020; Tonetti, Michela/F-3039-2018	TONETTI, MICHELA/0000-0002-8829-7173; fruscione, floriana/0000-0002-4054-645X	NIGMS NIH HHS [GM61226, R01 GM061126, T32 GM008444] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061226, T32GM008444, R01GM061126] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JC, 2000, DEV DYNAM, V218, P280; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; BJOERN S, 1991, J BIOL CHEM, V266, P11051; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; de Peredo AG, 2002, MOL CELL PROTEOMICS, V1, P11, DOI 10.1074/mcp.M100011-MCP200; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; Etzioni A, 2002, AM J MED GENET, V110, P131, DOI 10.1002/ajmg.10423; Fukuda M, 1996, CANCER RES, V56, P2237; FUKUDA M, 1994, MOL GLYCOBIOLOGY, P163; Haltiwanger RS, 2002, BBA-GEN SUBJECTS, V1573, P328, DOI 10.1016/S0304-4165(02)00400-2; Haltiwanger RS, 2002, CURR OPIN STRUC BIOL, V12, P593, DOI 10.1016/S0959-440X(02)00371-8; HARDY MR, 1994, METHOD ENZYMOL, V230, P208; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; HARRIS RJ, 1992, J BIOL CHEM, V267, P5102; HARRIS RJ, 1991, BIOCHEMISTRY-US, V30, P2311, DOI 10.1021/bi00223a004; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; KENTZER EJ, 1990, BIOCHEM BIOPH RES CO, V171, P401, DOI 10.1016/0006-291X(90)91407-J; LIN AI, 1994, GLYCOBIOLOGY, V4, P895, DOI 10.1093/glycob/4.6.895; Listinsky JJ, 1998, AM J CLIN PATHOL, V110, P425; Lowe JB, 1997, KIDNEY INT, V51, P1418, DOI 10.1038/ki.1997.194; Lu FM, 1996, P NATL ACAD SCI USA, V93, P5663, DOI 10.1073/pnas.93.11.5663; Lubke T, 1999, J BIOL CHEM, V274, P25986, DOI 10.1074/jbc.274.37.25986; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/ng0501-73; Manzi AE, 2000, GLYCOBIOLOGY, V10, P669, DOI 10.1093/glycob/10.7.669; Moloney DJ, 1999, GLYCOBIOLOGY, V9, P679, DOI 10.1093/glycob/9.7.679; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; MURAMATSU T, 1993, GLYCOBIOLOGY, V3, P294; NISHIMURA H, 1992, J BIOL CHEM, V267, P17520; Okajima T, 2002, CELL, V111, P893, DOI 10.1016/S0092-8674(02)01114-5; Panin VM, 2002, J BIOL CHEM, V277, P29945, DOI 10.1074/jbc.M204445200; Puglielli L, 1999, J BIOL CHEM, V274, P35596, DOI 10.1074/jbc.274.50.35596; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; Schiffer SG, 2001, J BIOL CHEM, V276, P37769; Shao L, 2003, J BIOL CHEM, V278, P7775, DOI 10.1074/jbc.M212221200; Shao L, 2003, CELL MOL LIFE SCI, V60, P241, DOI 10.1007/s000180300019; Shi SL, 2003, P NATL ACAD SCI USA, V100, P5234, DOI 10.1073/pnas.0831126100; Smith PL, 2002, J CELL BIOL, V158, P801, DOI 10.1083/jcb.200203125; Staudacher E, 1999, BBA-GEN SUBJECTS, V1473, P216, DOI 10.1016/S0304-4165(99)00181-6; Sturla L, 2001, PEDIATR RES, V49, P537, DOI 10.1203/00006450-200104000-00016; Toma L, 1996, J BIOL CHEM, V271, P3897; Wang Y, 1998, J BIOL CHEM, V273, P8112, DOI 10.1074/jbc.273.14.8112; Wang Y, 2001, J BIOL CHEM, V276, P40338, DOI 10.1074/jbc.M107849200; Yan YT, 2002, MOL CELL BIOL, V22, P4439, DOI 10.1128/MCB.22.13.4439-4449.2002; Yurchenco P D, 1978, Methods Enzymol, V50, P175	46	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26727	26733		10.1074/jbc.M304068200	http://dx.doi.org/10.1074/jbc.M304068200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12738772	hybrid			2022-12-25	WOS:000184155700056
J	Jefferies, CA; Doyle, S; Brunner, C; Dunne, A; Brint, E; Wietek, C; Walch, E; Wirth, T; O'Neill, LAJ				Jefferies, CA; Doyle, S; Brunner, C; Dunne, A; Brint, E; Wietek, C; Walch, E; Wirth, T; O'Neill, LAJ			Bruton's tyrosine kinase is a toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappa B activation by toll-like receptor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC FAMILY KINASES; SIGNAL-TRANSDUCTION; ADAPTER MOLECULE; CELL RECEPTOR; X-CHROMOSOME; SH3 DOMAIN; PATHWAY; IMMUNODEFICIENCY; ALPHA; TIRAP	In this study we have identified members of the Toll-like receptor (TLR) family (namely, TLRs 4, 6, 8, and 9) as proteins to which the intracellular protein tyrosine kinase, Bruton's tyrosine kinase (Btk), binds. Detailed analysis of the interaction between Btk and TLR8 demonstrates that the presence of both Box 2 and 3 motifs in the Toll/interleukin-1 receptor domain was required for the interaction. Furthermore, co-immunoprecipitation experiments revealed that Btk can also interact with key proteins involved in TLR4 signal transduction, namely, MyD88, Mal (MyD88 adapter-like protein), and interleukin-1 receptor-associated kinase-1, but not TRAF-6. The ability of Btk to interact with TLR4 and Mal suggests a role for Btk in lipopolysaccharide (LPS) signal transduction. Stimulation of the human monocytic cell line THP-1 with LPS resulted in an increase in the level of tyrosine phosphorylation of Btk (indicative of activation). The autokinase activity of Btk was also stimulated after LPS stimulation. In addition, a dominant negative form of Btk inhibited TLR4-mediated activation of a nuclear factor kappaB (NFkappaB)-dependent reporter gene in HEK293 cells as well as LPS-induced activation of NFkappaB in the astrocytoma cell line U373 and the monocytic cell line RAW264.7. Further investigation revealed that the Btk-specific inhibitor, LFM-A13, inhibited the activation of NFkappaB by LPS in THP-1 cells. Our findings implicate Btk as a Toll/interleukin-1 receptor domain-binding protein that is important for NFkappaB activation by TLR4.	Univ Dublin Trinity Coll, Dept Biochem, Cytokine Res Grp, Dublin 2, Ireland; Univ Dublin Trinity Coll, Inst Biotechnol, Dublin 2, Ireland; Univ Ulm, Dept Physiol Chem, D-89081 Ulm, Germany	Trinity College Dublin; Trinity College Dublin; Ulm University	Jefferies, CA (corresponding author), Univ Dublin Trinity Coll, Dept Biochem, Cytokine Res Grp, Dublin 2, Ireland.	jefferca@tcd.ie	Brunner, Cornelia/H-8893-2018; Brunner, Cornelia/L-1291-2013; Wirth, Thomas/X-7172-2019; Jefferies, Caroline/AAI-1543-2021	Brunner, Cornelia/0000-0002-6456-5508; Jefferies, Caroline/0000-0002-8879-6722; Doyle, Sarah/0000-0002-6294-9380; Brint, Elizabeth/0000-0001-9214-149X; dunne, aisling/0000-0002-2342-9518; O'Neill, Luke/0000-0002-4333-2748				Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Baba Y, 1999, BLOOD, V93, P2003, DOI 10.1182/blood.V93.6.2003.406k13_2003_2012; Bajpai UD, 2000, J EXP MED, V191, P1735, DOI 10.1084/jem.191.10.1735; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; Guinamard R, 1997, SCAND J IMMUNOL, V45, P587, DOI 10.1046/j.1365-3083.1997.d01-447.x; Hagemann C, 1997, FEBS LETT, V403, P200, DOI 10.1016/S0014-5793(97)00011-2; Hata D, 1998, J EXP MED, V187, P1235, DOI 10.1084/jem.187.8.1235; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; HUBER B, 1979, EUR J IMMUNOL, V9, P827, DOI 10.1002/eji.1830091016; Inabe K, 2002, FEBS LETT, V514, P260, DOI 10.1016/S0014-5793(02)02375-X; Jefferies C., 2002, MOD ASP IMMUNOBIOL, V2, P169; Jefferies CA, 2000, J BIOL CHEM, V275, P3114, DOI 10.1074/jbc.275.5.3114; Kawakami Y, 1999, J LEUKOCYTE BIOL, V65, P286, DOI 10.1002/jlb.65.3.286; KOIKE M, 1995, INT IMMUNOL, V7, P21, DOI 10.1093/intimm/7.1.21; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; Mahajan S, 1999, J BIOL CHEM, V274, P9587, DOI 10.1074/jbc.274.14.9587; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; Mukhopadhyay S, 2002, J IMMUNOL, V168, P2914, DOI 10.4049/jimmunol.168.6.2914; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Orlicek SL, 1999, SHOCK, V12, P350, DOI 10.1097/00024382-199911000-00004; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; Petro JB, 2002, FEBS LETT, V532, P57, DOI 10.1016/S0014-5793(02)03623-2; Petro JB, 2001, J BIOL CHEM, V276, P1715, DOI 10.1074/jbc.M009137200; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Saijo K, 2002, J EXP MED, V195, P1647, DOI 10.1084/jem.20020408; SCHER I, 1982, ADV IMMUNOL, V33, P1, DOI 10.1016/S0065-2776(08)60834-2; Slack JL, 2000, J BIOL CHEM, V275, P4670, DOI 10.1074/jbc.275.7.4670; TSUKADA S, 1994, CURR OPIN IMMUNOL, V6, P623, DOI 10.1016/0952-7915(94)90151-1; Vihinen Mauno, 1997, Frontiers in Bioscience (online), V2, pD27; Wahl MI, 1997, P NATL ACAD SCI USA, V94, P11526, DOI 10.1073/pnas.94.21.11526; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182	39	232	288	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26258	26264		10.1074/jbc.M301484200	http://dx.doi.org/10.1074/jbc.M301484200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12724322	Green Published, hybrid			2022-12-25	WOS:000183920200125
J	Bubb, MR; Yarmola, EG; Gibson, BG; Southwick, FS				Bubb, MR; Yarmola, EG; Gibson, BG; Southwick, FS			Depolymerization of actin filaments by profilin - Effects of profilin on capping protein function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARBED-END; F-ACTIN; LISTERIA-MONOCYTOGENES; LIVING CELLS; IN-VITRO; POLYMERIZATION; PATHOGENESIS; NUCLEATION; COMPLEXES; MOTILITY	Profilin interacts with the barbed ends of actin filaments and is thought to facilitate in vivo actin polymerization. This conclusion is based primarily on in vitro kinetic experiments using relatively low concentrations of profilin (1-5 muM). However, the cell contains actin regulatory proteins with multiple profilin binding sites that potentially can attract millimolar concentrations of profilin to areas requiring rapid actin filament turnover. We have studied the effects of higher concentrations of profilin (10-100 muM) on actin monomer kinetics at the barbed end. Prior work indicated that profilin might augment actin filament depolymerization in this range of profilin concentration. At barbed-end saturating concentrations (final concentration, similar to40 muM), profilin accelerated the off-rate of actin monomers by a factor of four to six. Comparable concentrations of latrunculin had no detectable effect on the depolymerization rate, indicating that profilin-mediated acceleration was independent of monomer sequestration. Furthermore, we have found that high concentrations of profilin can successfully compete with CapG for the barbed end and uncap actin filaments, and a simple equilibrium model of competitive binding could explain these effects. In contrast, neither gelsolin nor CapZ could be dissociated from actin filaments under the same conditions. These differences in the ability of profilin to dissociate capping proteins may explain earlier in vivo data showing selective depolymerization of actin filaments after microinjection of profilin. The finding that profilin can uncap actin filaments was not previously appreciated, and this newly discovered function may have important implications for filament elongation as well as depolymerization.	Univ Florida, Dept Med, Coll Med, Gainesville, FL 32610 USA; Malcolm Randall Dept Vet Affairs Med Ctr, Res Serv, Gainesville, FL 32608 USA	State University System of Florida; University of Florida	Bubb, MR (corresponding author), Univ Florida, Dept Med, Coll Med, Box 100277, Gainesville, FL 32610 USA.				NIAID NIH HHS [R01 AI034276, R01-AI34276, R01 AI023262, R01-AI23262] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034276, R01AI023262] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABCOCK G, 1993, CELL MOTIL CYTOSKEL, V24, P179, DOI 10.1002/cm.970240305; Baum B, 2001, NAT CELL BIOL, V3, P883, DOI 10.1038/ncb1001-883; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; CAO LG, 1990, J CELL BIOL, V111, P1905, DOI 10.1083/jcb.111.5.1905; CAO LG, 1992, J CELL BIOL, V117, P1023, DOI 10.1083/jcb.117.5.1023; CASELLA JF, 1995, CELL MOTIL CYTOSKEL, V30, P164, DOI 10.1002/cm.970300208; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Cossart P, 2001, CURR OPIN IMMUNOL, V13, P96, DOI 10.1016/S0952-7915(00)00188-6; DABIRI GA, 1992, J BIOL CHEM, V267, P16545; DINUBILE MJ, 1995, MOL BIOL CELL, V6, P1659, DOI 10.1091/mbc.6.12.1659; Ermentrout GB, 1998, B MATH BIOL, V60, P477, DOI 10.1006/bulm.1997.0012; FINKEL T, 1994, P NATL ACAD SCI USA, V91, P1510, DOI 10.1073/pnas.91.4.1510; Gutsche-Perelroizen I, 1999, J BIOL CHEM, V274, P6234, DOI 10.1074/jbc.274.10.6234; Hajkova L, 1997, EXP CELL RES, V234, P66, DOI 10.1006/excr.1997.3607; HAUGWITZ M, 1994, CELL, V79, P303, DOI 10.1016/0092-8674(94)90199-6; Hopmann R, 2003, MOL BIOL CELL, V14, P118, DOI 10.1091/mbc.E02-05-0300; JANMEY PA, 1994, J BIOL CHEM, V269, P32503; JANMEY PA, 1986, J BIOL CHEM, V261, P8357; JANMEY PA, 1988, BIOCHEMISTRY-US, V27, P8218, DOI 10.1021/bi00421a035; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; Kang F, 1999, J BIOL CHEM, V274, P36963, DOI 10.1074/jbc.274.52.36963; Kinosian HJ, 2002, BIOCHEMISTRY-US, V41, P6734, DOI 10.1021/bi016083t; KINOSIAN HJ, 1993, BIOCHEMISTRY-US, V32, P12353, DOI 10.1021/bi00097a011; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAL AA, 1985, J BIOL CHEM, V260, P132; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; Moldovan NI, 1997, CURR BIOL, V7, P24, DOI 10.1016/S0960-9822(06)00024-8; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; Portnoy DA, 2002, J CELL BIOL, V158, P409, DOI 10.1083/jcb.200205009; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; Purich DL, 1997, BIOCHEM BIOPH RES CO, V231, P686, DOI 10.1006/bbrc.1997.6158; SANDERS MC, 1990, J CELL BIOL, V110, P359, DOI 10.1083/jcb.110.2.359; Sansonetti PJ, 2001, AM J PHYSIOL-GASTR L, V280, pG319, DOI 10.1152/ajpgi.2001.280.3.G319; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SELVE N, 1986, EUR J BIOCHEM, V155, P397, DOI 10.1111/j.1432-1033.1986.tb09504.x; SOUTHWICK FS, 1990, J CELL BIOL, V110, P1965, DOI 10.1083/jcb.110.6.1965; SOUTHWICK FS, 1995, J BIOL CHEM, V270, P45, DOI 10.1074/jbc.270.1.45; Suzuki T, 2001, INFECT IMMUN, V69, P5959, DOI 10.1128/IAI.69.10.5959-5966.2001; Teubner A, 1998, BIOCHEMISTRY-US, V37, P7532, DOI 10.1021/bi972176s; Yarmola EG, 2001, J BIOL CHEM, V276, P45555, DOI 10.1074/jbc.M105723200; YOUNG CL, 1990, BIOCHEMISTRY-US, V29, P2232, DOI 10.1021/bi00461a005; YOUNG CL, 1994, J BIOL CHEM, V269, P13997	44	56	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24629	24635		10.1074/jbc.M302796200	http://dx.doi.org/10.1074/jbc.M302796200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12730212	hybrid			2022-12-25	WOS:000183824800047
J	Chapple, JP; Cheetham, ME				Chapple, JP; Cheetham, ME			The chaperone environment at the cytoplasmic face of the endoplasmic reticulum can modulate rhodopsin processing and inclusion formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT RETINITIS-PIGMENTOSA; PROTEIN RP2; DNAJ; DEGRADATION; MUTATIONS; CFTR; LOCALIZATION; TERMINUS; HOMOLOG; BINDING	The human DnaJ (Hsp40) proteins HSJ1a and HSJ1b are type II DnaJ proteins with different C termini generated by alternate splicing. Both protein isoforms can regulate the ATPase activity and substrate binding of Hsp70. In this study, we have confirmed the neuronal expression of HSJ1a and HSJ1b proteins and localized their expression in human neural retina using isoform-specific antisera. HSJ1a and HSJ1b were enriched in photoreceptors, particularly the inner segments, but had different intracellular localization due to the prenylation of HSJ1b by a geranylgeranyl moiety. Because of their enrichment at the site of rhodopsin production, we investigated the effect of HSJ1 isoforms on the cellular processing of wild-type and mutant rhodopsin apoprotein in SK-N-SH cells. The expression of HSJ1b, but not HSJ1a, inhibited the normal cellular processing of wild-type rhodopsin-GFP, which co-localized with HSJ1b at the ER. HSJ1b expression also increased the incidence of inclusion formation by the wild-type protein. Both isoforms were recruited to mutant P23H rhodopsin inclusions, but only HSJ1b enhanced inclusion formation. Investigation of a prenylation-null mutant showed that the modulation of rhodopsin processing and inclusion formation was dependent on the correct subcellular targeting of HSJ1b to the cytosolic face of the ER. An Hsp70 interaction-null mutant of HSJ1b had the same effect as HSJ1b, suggesting that these phenomena were independent of Hsp70 and, furthermore, overexpression of Hsp70 with HSJ1b did not modulate the HSJ1b effect on inclusion formation, showing that Hsp70 was not limiting. The data provide evidence that cytoplasmic chaperones when targeted to the ER can influence the folding and processing of a GPCR and show that DnaJ protein function can be further specialized by alternative splicing and post-translational modification.	UCL, Div Pathol, Inst Ophthalmol, London EC1V 9EL, England	University of London; University College London	Cheetham, ME (corresponding author), UCL, Div Pathol, Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.	michael.cheetham@ucl.ac.uk	Cheetham, Michael/B-4672-2011	Cheetham, Michael/0000-0001-6429-654X; Chapple, Paul/0000-0003-1876-1505				ANUKANTH A, 1994, J BIOL CHEM, V269, P19738; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; Chapple JP, 2000, HUM MOL GENET, V9, P1919, DOI 10.1093/hmg/9.13.1919; Chapple JP, 2002, INVEST OPHTH VIS SCI, V43, P2015; Chapple JP, 2001, TRENDS MOL MED, V7, P414, DOI 10.1016/S1471-4914(01)02103-7; CHEETHAM ME, 1992, BIOCHEM J, V284, P469, DOI 10.1042/bj2840469; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; Cheetham ME, 1996, BIOCHEM J, V319, P103, DOI 10.1042/bj3190103; CHEETHAM ME, 1994, EUR J BIOCHEM, V226, P99, DOI 10.1111/j.1432-1033.1994.tb20030.x; Grayson C, 2002, HUM MOL GENET, V11, P3065, DOI 10.1093/hmg/11.24.3065; Illing ME, 2002, J BIOL CHEM, V277, P34150, DOI 10.1074/jbc.M204955200; Kanazawa M, 1997, J BIOCHEM-TOKYO, V121, P890; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; KOPITO RR, 1999, PHYSIOL REV, V79, P167; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Muchowskil PJ, 2002, NEURON, V35, P9, DOI 10.1016/S0896-6273(02)00761-4; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Rajan RS, 2001, P NATL ACAD SCI USA, V98, P13060, DOI 10.1073/pnas.181479798; ROOF DJ, 1994, INVEST OPHTH VIS SCI, V35, P4049; Saliba RS, 2002, J CELL SCI, V115, P2907; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1993, J BIOL CHEM, V268, P26645; SUNG CH, 1994, J NEUROSCI, V14, P5818; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Tam BM, 2000, J CELL BIOL, V151, P1369, DOI 10.1083/jcb.151.7.1369; van der Spuy J, 2002, HUM MOL GENET, V11, P823, DOI 10.1093/hmg/11.7.823; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303; ZHU JK, 1993, P NATL ACAD SCI USA, V90, P8557, DOI 10.1073/pnas.90.18.8557	35	85	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19087	19094		10.1074/jbc.M212349200	http://dx.doi.org/10.1074/jbc.M212349200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12754272	hybrid			2022-12-25	WOS:000182932200049
J	Zhang, YF; Homer, C; Edwards, SJ; Hananeia, L; Lasham, A; Royds, J; Sheard, P; Braithwaite, AW				Zhang, YF; Homer, C; Edwards, SJ; Hananeia, L; Lasham, A; Royds, J; Sheard, P; Braithwaite, AW			Nuclear localization of Y-box factor YB1 requires wild-type p53	ONCOGENE			English	Article						YB1; p53; nuclear localization	MDR1 GENE-EXPRESSION; BINDING-PROTEIN YB-1; TRANSCRIPTIONAL TARGET; MONOCLONAL-ANTIBODY; POTENTIAL MEDIATOR; CELL-PROLIFERATION; APOPTOSIS; DOMAIN; TRANSACTIVATION; ACTIVATION	Nuclear localization and high levels of the Y-box binding protein YB1 appear to be important indicators of drug resistance and tumor prognosis. YB1 also interacts with the p53 tumor suppressor protein. In this paper, we explore a role for p53 in the nuclear localization of YB1. We report that various genotoxic stresses induce nuclear localization of YB1 in a small proportion of treated cells, but only in cells with wild-type p53. We go on to show directly that functional p53 is required for YB1 to translocate to the nucleus. Tumor-associated p53 mutants however are attenuated for YB1 nuclear localization as are mutants mutated in the proline-rich domain of p53. These data link the DNA-damage response of p53 to YB1 nuclear translocation. In addition, we find that YB1 inhibits p53-induced cell death and its ability to transactivate promoters of genes involved in cell death signaling. Together these data suggest that some forms of p53 cause YB1 to accumulate in the nucleus, which in turn inhibits p53 activity. These results provide a possible explanation for the correlation of nuclear YB1 with drug resistance and poor prognosis in some tumor types, and for the first time implicate p53 in the process of nuclear translocation.	Univ Otago, Dunedin Sch Med, Dept Pathol, Dunedin, New Zealand; Genesis Res & Dev Corp Ltd, Auckland, New Zealand; Univ Otago, Sch Med Sci, Dept Physiol, Dunedin, New Zealand	University of Otago; University of Otago	Braithwaite, AW (corresponding author), Univ Otago, Dunedin Sch Med, Dept Pathol, Box 913, Dunedin, New Zealand.	antony.braithwaite@stonebow.otago.ac.nz		Edwards, Sara/0000-0002-3468-1217				Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Bissonnette N, 1997, BIOCHEM CELL BIOL, V75, P351, DOI 10.1139/bcb-75-4-351; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; Dix BR, 2000, CANCER RES, V60, P2666; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Holm PS, 2002, J BIOL CHEM, V277, P10427, DOI 10.1074/jbc.M106955200; JACKSON P, 1994, BIOCHEM BIOPH RES CO, V203, P133, DOI 10.1006/bbrc.1994.2159; Janz M, 2002, INT J CANCER, V97, P278, DOI 10.1002/ijc.1610; Kamura T, 1999, CANCER, V85, P2450, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; Lasham A, 2000, GENE, V252, P1, DOI 10.1016/S0378-1119(00)00220-1; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Mertens PR, 2002, J BIOL CHEM, V277, P24875, DOI 10.1074/jbc.M200445200; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; O'Carroll SJ, 2000, BIOTECHNIQUES, V28, P408, DOI 10.2144/00283bm03; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Prives C, 1999, J PATHOL, V187, P112; Robles AI, 2001, CANCER RES, V61, P6660; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Shibahara K, 2001, CLIN CANCER RES, V7, P3151; Shibao K, 1999, INT J CANCER, V83, P732; Sommerville J, 1999, BIOESSAYS, V21, P319, DOI 10.1002/(SICI)1521-1878(199904)21:4<319::AID-BIES8>3.3.CO;2-V; STEIN U, 2001, J BIOL CHEM, V21, P21; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; Vater CA, 1996, ONCOGENE, V13, P739; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	51	51	53	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2003	22	18					2782	2794		10.1038/sj.onc.1206357	http://dx.doi.org/10.1038/sj.onc.1206357			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743601				2022-12-25	WOS:000182569300009
J	Alisi, A; Giambartolomei, S; Cupelli, F; Merlo, P; Fontemaggi, G; Spaziani, A; Balsano, C				Alisi, A; Giambartolomei, S; Cupelli, F; Merlo, P; Fontemaggi, G; Spaziani, A; Balsano, C			Physical and functional interaction between HCV core protein and the different p73 isoforms	ONCOGENE			English	Article						HCV; core p53; p73; p21(WAF1/CIP1); HCC	HEPATITIS-C VIRUS; KAPPA-B ACTIVATION; HEPATOCELLULAR-CARCINOMA; TRANSCRIPTIONAL ACTIVITY; P53-RELATED PROTEIN; HUMAN HEPATOCYTES; RNA HELICASE; DNA-BINDING; P53; APOPTOSIS	Hepatitis C virus (HCV) core protein is a structural viral protein that packages the viral genomic RNA. In addition to this function, HCV core also modulates a number of cellular regulatory functions. In fact, HCV core protein has been found to modulate the expression of the cyclin-dependent inhibitor p21(WAF1/CIP1) and to promote both apoptosis and cell proliferation through its physical interaction with p53. Here, we studied the ability of HCV core to bind the p53-related p73 protein, its isoforms and its deletion mutants. We found that HCV core co-immunoprecipitated with p73 in HepG2 and SAOS-2 cells. Deletion mutational analysis of p73 indicates that the domain involved in HCV core binding is located between amino-acid residues 321-353. We also demonstrate that p73/core interaction results in the nuclear translocation of HCV core protein either in the presence of the p73 or or p73 beta tumor-suppressor proteins. In addition, the interaction with HCV core protein prevents p73 alpha, but not p73 beta dependent cell growth arrest in a p53-dependent manner. Our findings demonstrate that HCV core protein may directly influence the various p73 functions, thus playing a role in HCV pathogenesis.	Fdn Andrea Cesalpino, Med Clin 1, I-00161 Rome, Italy; Univ Aquila, Dip MISP, I-67100 Laquila, Italy; Regina Elena Inst Canc Res, I-00158 Rome, Italy	University of L'Aquila; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Balsano, C (corresponding author), Policlin Umberto 1, Med Clin 1, Viale Policlin 155, I-00161 Rome, Italy.		Balsano, Clara/AAK-9870-2020; Alisi, Anna/A-6469-2010; Merlo, Paola/K-5330-2014; Fontemaggi, Giulia/K-9702-2016	Balsano, Clara/0000-0002-9615-7031; Alisi, Anna/0000-0001-7241-6329; Merlo, Paola/0000-0003-0105-7044; Fontemaggi, Giulia/0000-0001-8332-8842				Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Basu A, 2002, VIROLOGY, V298, P53, DOI 10.1006/viro.2002.1460; Colombo M, 1999, J HEPATOL, V31, P25, DOI 10.1016/S0168-8278(99)80370-5; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Francesco R, 1999, J HEPATOL, V31, P47, DOI 10.1016/S0168-8278(99)80374-2; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Giambartolomei S, 2001, ONCOGENE, V20, P2606, DOI 10.1038/sj.onc.1204372; Hayashi J, 1999, INTERVIROLOGY, V42, P205, DOI 10.1159/000024962; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kaida A, 2000, ONCOGENE, V19, P827, DOI 10.1038/sj.onc.1203387; Koike K, 2002, ONCOLOGY-BASEL, V62, P29, DOI 10.1159/000048273; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Lu W, 1999, VIROLOGY, V264, P134, DOI 10.1006/viro.1999.9979; Maillard P, 2001, J VIROL, V75, P8240, DOI 10.1128/JVI.75.17.8240-8250.2001; Mamiya N, 1999, J BIOL CHEM, V274, P15751, DOI 10.1074/jbc.274.22.15751; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Otsuka M, 2000, J BIOL CHEM, V275, P34122, DOI 10.1074/jbc.M000578200; Park KJ, 2002, J BIOL CHEM, V277, P13122, DOI 10.1074/jbc.M111599200; Prabhu NS, 1998, INT J ONCOL, V13, P5; Ray RB, 1996, VIROLOGY, V226, P176, DOI 10.1006/viro.1996.0644; Ray RB, 1998, GENE, V208, P331, DOI 10.1016/S0378-1119(98)00030-4; Ray RB, 2000, VIROLOGY, V271, P197, DOI 10.1006/viro.2000.0295; Reichelt M, 1999, ARCH VIROL, V144, P621, DOI 10.1007/s007050050530; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shi ST, 2002, VIROLOGY, V292, P198, DOI 10.1006/viro.2001.1225; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Takamatsu Manabu, 2001, Kobe Journal of Medical Sciences, V47, P97; TANNAPFEL A, 1999, J NATL CANCER I, V79, P164; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Tsutsumi T, 2002, HEPATOLOGY, V35, P937, DOI 10.1053/jhep.2002.32470; Uchida M, 2002, HEPATOL RES, V22, P297, DOI 10.1016/S1386-6346(02)00005-0; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; Yamanaka T, 2002, BIOCHEM BIOPH RES CO, V294, P528, DOI 10.1016/S0006-291X(02)00508-9; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Zemel R, 2002, DIGEST DIS SCI, V47, P716, DOI 10.1023/A:1014767311799; Zeng YX, 1996, ONCOGENE, V12, P1557; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	45	50	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2573	2580		10.1038/sj.onc.1206333	http://dx.doi.org/10.1038/sj.onc.1206333			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730672				2022-12-25	WOS:000182569000005
J	He, Q; Montalbano, J; Corcoran, C; Jin, WX; Huang, Y; Sheikh, MS				He, Q; Montalbano, J; Corcoran, C; Jin, WX; Huang, Y; Sheikh, MS			Effect of Bax deficiency on death receptor 5 and mitochondrial pathways during endoplasmic reticulum calcium pool depletion-induced apoptosis	ONCOGENE			English	Article						thapsigargin; Apo2L/TRAIL; death receptor 5; caspases; Bax; cytochrome c	PROSTATE-CANCER CELLS; CYTOCHROME-C; RELEASE; THAPSIGARGIN; SULINDAC; CYTOSOL; LIGAND; AGENTS; COLON	Thapsigargin (TG), by inducing perturbations in cellular Ca2+ homeostasis, can induce apoptosis, but the molecular mechanisms remain to be fully elucidated. We have recently reported that TG-induced apoptosis appears to involve the DR5-dependent apoptotic pathway that cross talks with the mitochondrial pathway via TG-induced Bid cleavage. In this study, we have utilized Bax-proficient and -deficient HCT116 human colon cancer cells to investigate the effect of Bax deficiency on TG-induced apoptosis and TG regulation of the DR5 and mitochondrial pathways. Our results indicate that Bax-deficient cells are less sensitive to undergo apoptosis following TG treatment. Our results further demonstrate that TG-induced apoptosis is coupled with DR5 upregulation and caspases 8 and 3 activation, as well as Bid cleavage in both Bax-proficient and -deficient cells, although caspase 3 activation was reduced in Bax-deficient cells. TG also promoted the release of cytochrome c into cytosol and caspase 9 activation in Bax-proficient cells but not in Bax-deficient cells. These findings suggest that although Bax is not absolutely required for death receptor (DR)-dependent signals, it appears to be a key molecule in TG-regulated mitochondrial events. Bax-deficient cells were relatively more resistant to Apo2L/TRAIL than the Bax-proficient counterparts. However, the combination of Apo2L/TRAIL and TG was more effective in mediating apoptosis in both Bax-proficient. and -deficient cells and that was coupled with activation of caspases 8 and 3. Although both agents in combination also induced cytochrome c release into cytosol and caspase 9 activation in Bax-proficient cells, these events were abrogated in Bax-deficient cells. Our results thus suggest that the combination of Apo2L/TRAIL and TG appears to bypass the Bax deficiency-induced defects in the mitochondrial (intrinsic) pathway by engaging the DR5-dependent apoptotic signals (extrinsic pathway).	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Sheikh, MS (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA.				NATIONAL CANCER INSTITUTE [R21CA089043] Funding Source: NIH RePORTER; NCI NIH HHS [CA89043] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Boya P, 2002, CELL DEATH DIFFER, V9, P465, DOI 10.1038/sj.cdd.4401006; Burns TF, 2001, J BIOL CHEM, V276, P37879; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; FURUYA Y, 1994, CANCER RES, V54, P6167; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; He Q, 2002, ONCOGENE, V21, P2623, DOI 10.1038/sj.onc.1205345; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Huang Y, 2001, CANCER RES, V61, P6918; Jin ZY, 2002, CELL CYCLE, V1, P82, DOI 10.4161/cc.1.1.104; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kim BC, 2002, J BIOL CHEM, V277, P31381, DOI 10.1074/jbc.M203465200; Krebs J, 1998, BIOMETALS, V11, P375, DOI 10.1023/A:1009226316146; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Tombal B, 2002, CELL DEATH DIFFER, V9, P561, DOI 10.1038/sj.cdd.4400999; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang XD, 2001, GENE DEV, V15, P2922; Wertz IE, 2000, J BIOL CHEM, V275, P11470, DOI 10.1074/jbc.275.15.11470; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YANG E, 1996, BLOOD, V88, P368; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	32	32	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2674	2679		10.1038/sj.onc.1206363	http://dx.doi.org/10.1038/sj.onc.1206363			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730681				2022-12-25	WOS:000182569000015
J	Levine, L				Levine, L			Does the release of arachidonic acid from cells play a role in cancer chemoprevention?	FASEB JOURNAL			English	Article						AA; retinoid; COX-2; antioxidant	RAT-LIVER CELLS; MAMMARY CARCINOGENESIS; SYNTHETIC ANALOGS; EPITHELIAL-CELLS; COLON-CANCER; CYCLOOXYGENASE-2; PREVENTION; INHIBITION; RETINOIDS; GAMMA	COX-2 is overexpressed in cancer cells and has become a major target for cancer preventive drugs. NSAIDs, retinoids, antioxidants, and PPAR agonists, reported to be chemopreventive, suppress COX-2 synthesis. NSAIDs also have been shown to be chemopreventive independent of COX-2 activity. Common to all of these compounds is their ability to release arachidonic acid (AA) from rat liver cells in culture. Most of these compounds inhibit induced PGI(2) production. Vitamin D-3 and tamoxifen, however, not only stimulate the release of AA from cells: they amplify rather than inhibits induced COX activity. In view of the many activities attributable to AA, I propose that its release and accumulation could initiate molecular reactions that lead to apoptosis and eventually to suppression of cancer. Some drugs shown to release AA from cells and affect PGI(2) production e.g., thiazolidinediones and statins are widely used for conditions unrelated to cancer. In vivo studies could reveal whether they can also function as cancer preventive agents.	Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA	Brandeis University	Levine, L (corresponding author), Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA.	llevine@brandeis.edu						Brash AR, 2001, J CLIN INVEST, V107, P1339, DOI 10.1172/JCI13210; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951; Fujiki H, 2002, P JPN ACAD B-PHYS, V78, P263, DOI 10.2183/pjab.78.263; Guyton KZ, 2001, ANNU REV PHARMACOL, V41, P421, DOI 10.1146/annurev.pharmtox.41.1.421; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; Kelloff GJ, 2000, ADV CANCER RES, V78, P199; LEVINE L, 1978, NATURE, V276, P274, DOI 10.1038/276274a0; Levine L, 1998, CELL SIGNAL, V10, P653, DOI 10.1016/S0898-6568(98)00008-4; Levine L, 2002, PROSTAG LEUKOTR ESS, V67, P453, DOI 10.1054/plef.2002.0456; Levine L, 2001, PROSTAG LEUKOTR ESS, V65, P31, DOI 10.1054/plef.2001.0284; Levine L, 2000, PROSTAG LEUKOTR ESS, V63, P363, DOI 10.1054/plef.2000.0227; LEVINE L, 1986, MANUAL CLIN LABORATO, P685; LEVINE L, 1988, PROGR ALLERGY, V44, P1; Marnett LJ, 2002, ANNU REV PHARMACOL, V42, P55, DOI 10.1146/annurev.pharmtox.42.082301.164620; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mestre JR, 1997, CANCER RES, V57, P2890; Michaluart P, 1999, CANCER RES, V59, P2347; RAO CV, 1993, CANCER RES, V53, P4182; Rayyan Y, 2002, CANCER INVEST, V20, P1002, DOI 10.1081/CNV-120005917; Rioux N, 1998, CANCER RES, V58, P5354; Rockwell P, 2000, ARCH BIOCHEM BIOPHYS, V374, P325, DOI 10.1006/abbi.1999.1646; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; SPORN MB, 1976, FED PROC, V35, P1332; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; Suh N, 1999, CANCER RES, V59, P5671; THOMPSON HJ, 1995, J NATL CANCER I, V87, P1259; WHATLEY RE, 1994, J CLIN INVEST, V94, P1889, DOI 10.1172/JCI117539; YANG M, 1997, SCIENCE, V275, P218	31	20	24	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					800	802		10.1096/fj.02-0906hyp	http://dx.doi.org/10.1096/fj.02-0906hyp			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12724337				2022-12-25	WOS:000183165000004
J	Nebigil, CG; Etienne, N; Messaddeq, N; Maroteaux, L				Nebigil, CG; Etienne, N; Messaddeq, N; Maroteaux, L			Serotonin is a novel survival factor of cardiomyocytes: mitochondria as a target of 5-HT2B-receptor signaling	FASEB JOURNAL			English	Article						PI3 kinase; Akt; Gq; ERK; Bax	ADENINE-NUCLEOTIDE TRANSLOCATOR; NF-KAPPA-B; PERMEABILITY TRANSITION PORE; BCL-2 PROTEIN FAMILY; CARDIAC MYOCYTES; HEART-FAILURE; 2B RECEPTOR; PROMOTES SURVIVAL; CROSS-TALK; IN-VITRO	Identification of factors regulating cardiomyocyte survival and growth is important to understand the pathogenesis of congenital heart diseases. Little is known about the molecular mechanism of cardiac functions triggered by serotonin. The link between signaling circuitry of external stimuli and the mitochondrial apoptotic machinery is of wide interest in cardiac diseases. Using cultured cardiomyocytes and 5-hydroxytryptamine (5-HT)(2B)-receptor knockout mice as an animal model of dilated cardiomyopathy, for the first time we show that serotonin via the Gq-coupled 5-HT2B-receptor protect cardiomyocytes against serum deprivation-induced apoptosis as manifested by DNA fragmentation, nuclear chromatin condensation, and TUNEL labeling. Serotonin prevents cytochrome c release and caspase-9 and -3 activation after serum deprivation via cross-talks between phosphatidylinositol-3 kinase/Akt and extracellular signal-regulated kinase (ERK) 1/2 signaling pathways. Serotonin binding to 5-HT2B-receptor activates ERK kinases to inhibit Bax expression induced by serum deprivation. Serotonin via phosphatidylinositol-3 kinase/Akt can activate NF-kappaB that is required for the regulation of the mitochondrial adenine nucleotide translocator (ANT-1). Parallel to these observations, ultrastructural analysis in the 5-HT2B-receptor knockout mice heart revealed pronounced mitochondrial defects in addition to altered mitochondrial enzyme activities (cytochrome oxidase and succinate dehydrogenase) and ANT-1 and Bax expressions. These findings identify 5-HT as a novel survival factor targeting mitochondria in cardiomyocytes.	Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Maroteaux, L (corresponding author), Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, BP 10142, F-67404 Illkirch Graffenstaden, France.	lucm@igbmc.u-strasbg.fr	Maroteaux, Luc/H-4585-2019; Nebigil, Canan/AAK-7162-2021	Maroteaux, Luc/0000-0002-9499-8603; Nebigil, Canan/0000-0002-2035-5795				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Adams JW, 2001, ONCOGENE, V20, P1626, DOI 10.1038/sj.onc.1204275; Adams JW, 2000, CIRC RES, V87, P1180, DOI 10.1161/01.RES.87.12.1180; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.3.CO;2-S; Bratton SB, 2001, TRENDS PHARMACOL SCI, V22, P306, DOI 10.1016/S0165-6147(00)01718-1; Choi DS, 1997, DEVELOPMENT, V124, P1745; Communal C, 2002, P NATL ACAD SCI USA, V99, P6252, DOI 10.1073/pnas.092022999; Condorelli G, 2002, FASEB J, V16, P1732, DOI 10.1096/fj.02-0419com; Cook SA, 1999, EUR HEART J, V20, P1619, DOI 10.1053/euhj.1999.1548; Craig R, 2001, J BIOL CHEM, V276, P37621, DOI 10.1074/jbc.M103276200; De Windt LJ, 2000, CIRC RES, V86, P255, DOI 10.1161/01.RES.86.3.255; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P6400, DOI 10.1073/pnas.96.11.6400; Dorn GW, 1999, TRENDS CARDIOVAS MED, V9, P26, DOI 10.1016/S1050-1738(99)00004-3; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Frishman WH, 2000, ANN MED, V32, P195, DOI 10.3109/07853890008998827; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Gill C, 2002, FASEB J, V16, P135, DOI 10.1096/fj.01-0629com; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hoyer D, 2002, PHARMACOL BIOCHEM BE, V71, P533, DOI 10.1016/S0091-3057(01)00746-8; Huang HM, 2000, BLOOD, V96, P1764, DOI 10.1182/blood.V96.5.1764.h8001764_1764_1771; HUANG P, 1992, ANAL BIOCHEM, V207, P163, DOI 10.1016/0003-2697(92)90518-C; Iwai-Kanai E, 1999, CIRCULATION, V100, P305, DOI 10.1161/01.CIR.100.3.305; Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; KUBALAK S, 1996, METHODS MOL GENETICS, V8; Maddock HL, 2002, AM J PHYSIOL-HEART C, V283, pH1307, DOI 10.1152/ajpheart.00851.2001; Manivet P, 2000, J BIOL CHEM, V275, P9324, DOI 10.1074/jbc.275.13.9324; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Moretti A, 2002, P NATL ACAD SCI USA, V99, P11860, DOI 10.1073/pnas.182373099; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Narula J, 1999, P NATL ACAD SCI USA, V96, P8144, DOI 10.1073/pnas.96.14.8144; Narula J, 2000, CURR OPIN CARDIOL, V15, P183, DOI 10.1097/00001573-200005000-00011; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P9508, DOI 10.1073/pnas.97.17.9508; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P2591, DOI 10.1073/pnas.050282397; Nebigil CG, 2001, CIRCULATION, V103, P2973, DOI 10.1161/01.CIR.103.24.2973; Portman MA, 2000, MOL GENET METAB, V71, P445, DOI 10.1006/mgme.2000.3030; Reed JC, 1999, P NATL ACAD SCI USA, V96, P7614, DOI 10.1073/pnas.96.14.7614; Saito S, 2000, J BIOL CHEM, V275, P34528, DOI 10.1074/jbc.M002844200; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; Shi YG, 2001, NAT STRUCT BIOL, V8, P394, DOI 10.1038/87548; Tournois C, 1998, J BIOL CHEM, V273, P17498, DOI 10.1074/jbc.273.28.17498; Villalon CM, 1997, DRUG DISCOV TODAY, V2, P294, DOI 10.1016/S1359-6446(97)01055-6; von Harsdorf R, 1999, CIRC RES, V85, P128, DOI 10.1161/01.RES.85.2.128; von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934; Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zhu H, 2000, CELL DEATH DIFFER, V7, P773, DOI 10.1038/sj.cdd.4400721	56	113	120	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1373	+		10.1096/fj.02-1122fje	http://dx.doi.org/10.1096/fj.02-1122fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738797	Green Submitted			2022-12-25	WOS:000183165000031
J	Potolicchio, I; Santambrogio, L; Strominger, JL				Potolicchio, I; Santambrogio, L; Strominger, JL			Molecular interaction and enzymatic activity of macrophage migration inhibitory factor with immunorelevant peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II MOLECULES; HEAT-SHOCK PROTEINS; IMMATURE DENDRITIC CELLS; LYSOSOMAL THIOL REDUCTASE; MIF TAUTOMERASE ACTIVITY; RHEUMATOID-ARTHRITIS; CRYSTAL-STRUCTURE; MATRIX METALLOPROTEINASES; ANTIGEN PRESENTATION; DISULFIDE BONDS	Disulfide reduction is an important step in antigen processing for HLA class II restricted T cell responses. Migration inhibitory factor (MIF) is a member of the thioredoxin family and has been classically defined as a cytokine. Using enzyme-linked immunosorbent assay and CD analysis, here we describe the binding to MIF of two peptides, hepatitis B surface antigen (HBsAg) and insulin B (InsB) with high affinity for HLA class II allotypes, HLA-DP2 and HLA-DQ8, respectively. At neutral pH, cysteinylated InsB was a substrate for MIF thiol reductase activity, as assessed by mass spectroscopy/electrospray analysis. Finally, a biologically active form of MIF co-immunopurified with mature forms of HLA DP2/15, and a peptide derived from the HLA-DP beta1 helix could be used for affinity purification of MIF. The possibility that MIF participates in class II antigen presentation and/or as a chaperone is discussed.	Harvard Univ, Dept Mol Cell Biol, Cambridge, MA 02138 USA; Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA	Harvard University; Harvard University; Dana-Farber Cancer Institute	Strominger, JL (corresponding author), Harvard Univ, Dept Mol Cell Biol, Cambridge, MA 02138 USA.	ipotolic@mcb.harvard.edu; jlstrom@fas.harvard.edu			NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049524, R01AI048832] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47554] Funding Source: Medline; NIAID NIH HHS [AI-49524, AI-48832] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Accapezzato D, 1998, J IMMUNOL, V160, P5262; Angelini G, 2002, P NATL ACAD SCI USA, V99, P1491, DOI 10.1073/pnas.022630299; ANSORGE S, 1991, BIOMED BIOCHIM ACTA, V50, P799; Arunachalam B, 1998, J IMMUNOL, V160, P5797; Auger I, 1996, NAT MED, V2, P306, DOI 10.1038/nm0396-306; Auger I, 2002, ARTHRITIS RHEUM-US, V46, P929, DOI 10.1002/art.10214; Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Bendrat K, 1997, BIOCHEMISTRY-US, V36, P15356, DOI 10.1021/bi971153a; Bernhagen J, 1998, J MOL MED-JMM, V76, P151, DOI 10.1007/s001090050204; Brocke P, 2002, CURR OPIN IMMUNOL, V14, P22, DOI 10.1016/S0952-7915(01)00294-1; Calandra T, 1997, CRIT REV IMMUNOL, V17, P77, DOI 10.1615/CritRevImmunol.v17.i1.30; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; Chervonsky AV, 1998, P NATL ACAD SCI USA, V95, P10094, DOI 10.1073/pnas.95.17.10094; Chicz RM, 1997, J IMMUNOL, V159, P4935; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; COLLINS DS, 1991, J IMMUNOL, V147, P4054; de Jong YP, 2001, NAT IMMUNOL, V2, P1061, DOI 10.1038/ni720; Dios A, 2002, J MED CHEM, V45, P2410, DOI 10.1021/jm010534q; Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320; Engering A, 2001, INT IMMUNOL, V13, P127, DOI 10.1093/intimm/13.2.127; Fiebiger E, 2002, J EXP MED, V196, P1263, DOI 10.1084/jem.20020762; FOX BS, 1988, NATURE, V331, P538, DOI 10.1038/331538a0; GORGA JC, 1987, J BIOL CHEM, V262, P16087; Haque MA, 2002, J EXP MED, V195, P1267, DOI 10.1084/jem.20011853; Haque MA, 2001, J IMMUNOL, V166, P4543, DOI 10.4049/jimmunol.166.7.4543; JENSEN PE, 1991, J EXP MED, V174, P1121, DOI 10.1084/jem.174.5.1121; Kang SJ, 2002, EMBO J, V21, P1650, DOI 10.1093/emboj/21.7.1650; Kleemann R, 1998, J MOL BIOL, V280, P85, DOI 10.1006/jmbi.1998.1864; Kropshofer H, 2002, NAT IMMUNOL, V3, P61, DOI 10.1038/ni750; Lee KH, 2001, NAT IMMUNOL, V2, P501, DOI 10.1038/88694; Li ZH, 2002, CURR OPIN IMMUNOL, V14, P45, DOI 10.1016/S0952-7915(01)00297-7; Lubetsky JB, 1999, BIOCHEMISTRY-US, V38, P7346, DOI 10.1021/bi990306m; Lue HQ, 2002, MICROBES INFECT, V4, P449, DOI 10.1016/S1286-4579(02)01560-5; Malik P, 2000, J IMMUNOL METHODS, V234, P83, DOI 10.1016/S0022-1759(99)00201-X; Maric M, 2001, SCIENCE, V294, P1361, DOI 10.1126/science.1065500; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; Mischke R, 1997, FEBS LETT, V414, P226, DOI 10.1016/S0014-5793(97)01039-9; Mischke R, 1998, FEBS LETT, V427, P85, DOI 10.1016/S0014-5793(98)00400-1; Monji T, 1997, J IMMUNOL, V158, P3155; Mullen MM, 2002, MOL CELL, V9, P375, DOI 10.1016/S1097-2765(02)00465-3; Onodera S, 2000, J BIOL CHEM, V275, P444, DOI 10.1074/jbc.275.1.444; OSULLIVAN D, 1990, J IMMUNOL, V145, P1799; Parks WC, 2002, J CLIN INVEST, V110, P613, DOI 10.1172/JCI200216550; Phan UT, 2002, P NATL ACAD SCI USA, V99, P12298, DOI 10.1073/pnas.182430499; Potolicchio I, 1997, EUR J IMMUNOL, V27, P2741, DOI 10.1002/eji.1830271039; Potolicchio I, 1996, TRANSPLANTATION, V62, P1347, DOI 10.1097/00007890-199611150-00029; Potolicchio L, 1999, EUR J IMMUNOL, V29, P2140; RICHELDI L, 1993, SCIENCE, V262, P242, DOI 10.1126/science.8105536; Rosengren E, 1996, MOL MED, V2, P143, DOI 10.1007/BF03402210; Santambrogio L, 1999, P NATL ACAD SCI USA, V96, P15050, DOI 10.1073/pnas.96.26.15050; Santambrogio L, 1999, P NATL ACAD SCI USA, V96, P15056, DOI 10.1073/pnas.96.26.15056; Srivastava PK, 1998, IMMUNITY, V8, P657, DOI 10.1016/S1074-7613(00)80570-1; Sun HW, 1996, P NATL ACAD SCI USA, V93, P5191, DOI 10.1073/pnas.93.11.5191; Suzuki M, 1996, NAT STRUCT BIOL, V3, P259, DOI 10.1038/nsb0396-259; SUZUKI M, 1994, J MOL BIOL, V235, P1141, DOI 10.1006/jmbi.1994.1063; Taylor AB, 1999, BIOCHEMISTRY-US, V38, P7444, DOI 10.1021/bi9904048; Vacchino JF, 2001, J IMMUNOL, V166, P6680, DOI 10.4049/jimmunol.166.11.6680; Villadangos JA, 1999, IMMUNOL REV, V172, P109, DOI 10.1111/j.1600-065X.1999.tb01360.x; Wang XY, 2001, J IMMUNOL, V166, P490, DOI 10.4049/jimmunol.166.1.490; Zhang XN, 1999, BIOORG MED CHEM LETT, V9, P3193	62	30	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30889	30895		10.1074/jbc.M302854200	http://dx.doi.org/10.1074/jbc.M302854200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12740374	hybrid			2022-12-25	WOS:000184658800061
J	Abulencia, JP; Gaspard, R; Healy, ZR; Gaarde, WA; Quackenbush, J; Konstantopoulos, K				Abulencia, JP; Gaspard, R; Healy, ZR; Gaarde, WA; Quackenbush, J; Konstantopoulos, K			Shear-induced cyclooxygenase-2 via a JNK2/c-Jun-dependent pathway regulates prostaglandin receptor expression in chondrocytic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; NITRIC-OXIDE; IN-VITRO; TRANSCRIPTIONAL INDUCTION; ARTICULAR CHONDROCYTES; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; FLUID-FLOW	Using cDNA microarrays coupled with bioinformatics tools, we elucidated a signaling cascade regulating cyclooxygenase-2 (COX-2), a pivotal pro-inflammatory enzyme expressed in rheumatic and osteoarthritic, but not normal, cartilage. Exposure of T/C-28a2 chondrocytic cells to fluid shear results in co-regulation of c-Jun N-terminal kinase2 (JNK2), c-Jun, and COX-2 as well as concomitant downstream expression of prostaglandin receptors EP2 and EP3a1. JNK2 transcript inhibition abrogated shear-induced COX-2, EP2, and EP3a1 mRNA up-regulation as well as c-Jun phosphorylation. Functional knock-out experiments using an antisense c-Jun oligonucleotide revealed the abolition of shear-induced COX-2, EP2, and EP3a1, but not JNK2, transcripts. Moreover, inhibition of COX-2 activity eliminated mRNA upregulation of EP2 and EP3a1 induced by shear. Hence, a biochemical pathway exists wherein fluid shear activates COX-2, via a JNK2/c-Jun-dependent pathway, which in turn elicits downstream EP2 and EP3a1 mRNA synthesis.	Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; Inst Genom Res, Rockville, MD 20850 USA; ISIS Pharmaceut, Carlsbad, CA 92008 USA	Johns Hopkins University; J. Craig Venter Institute; Isis Pharmaceuticals Inc	Konstantopoulos, K (corresponding author), 3400 N Charles St, Baltimore, MD 21218 USA.		Konstantopoulos, Konstantinos/A-7045-2011	Abulencia, J. Patrick/0000-0003-0403-8295; Quackenbush, John/0000-0002-2702-5879				Amin AR, 1997, J CLIN INVEST, V99, P1231, DOI 10.1172/JCI119280; Baker BF, 1997, J BIOL CHEM, V272, P11994, DOI 10.1074/jbc.272.18.11994; Barrios-Rodiles M, 1998, J IMMUNOL, V161, P2441; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; Curtis CL, 2000, J BIOL CHEM, V275, P721, DOI 10.1074/jbc.275.2.721; DIAMOND SL, 1989, SCIENCE, V243, P1483, DOI 10.1126/science.2467379; DiBattista JA, 1997, J CELL BIOCHEM, V65, P408, DOI 10.1002/(SICI)1097-4644(19970601)65:3<408::AID-JCB10>3.3.CO;2-H; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; Hardy MM, 2002, ARTHRITIS RHEUM, V46, P1789, DOI 10.1002/art.10356; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Hung CT, 2000, J BIOMECH, V33, P73, DOI 10.1016/S0021-9290(99)00176-1; Inoue H, 2002, ARTERIOSCL THROM VAS, V22, P1415, DOI 10.1161/01.ATV.0000028816.13582.13; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kaarniranta K, 1998, P NATL ACAD SCI USA, V95, P2319, DOI 10.1073/pnas.95.5.2319; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KAWAGUCHI H, 1995, J CLIN INVEST, V96, P923, DOI 10.1172/JCI118140; Kokenyesi R, 2000, ARCH BIOCHEM BIOPHYS, V383, P79, DOI 10.1006/abbi.2000.2044; Kontrogianni-Konstantopoulos A, 2000, MOL BIOL CELL, V11, P3805, DOI 10.1091/mbc.11.11.3805; Lee MS, 2002, J ORTHOP RES, V20, P556, DOI 10.1016/S0736-0266(01)00149-8; Lowe GN, 1996, ENDOCRINOLOGY, V137, P2208, DOI 10.1210/en.137.6.2208; McCormick SM, 2000, ANN BIOMED ENG, V28, P824, DOI 10.1114/1.1289472; McCormick SM, 2001, P NATL ACAD SCI USA, V98, P8955, DOI 10.1073/pnas.171259298; McCoy JM, 2002, J CLIN INVEST, V110, P651, DOI 10.1172/JCI200215528; Miller C, 1998, J CELL BIOCHEM, V69, P392, DOI 10.1002/(SICI)1097-4644(19980615)69:4<392::AID-JCB2>3.3.CO;2-Z; Nasrallah R, 2001, AM J PHYSIOL-RENAL, V281, pF123, DOI 10.1152/ajprenal.2001.281.1.F123; Notoya K, 2000, J IMMUNOL, V165, P3402, DOI 10.4049/jimmunol.165.6.3402; Ogasawara A, 2001, J BIOL CHEM, V276, P7048, DOI 10.1074/jbc.M008070200; Sakai T, 2001, J BONE MINER RES, V16, P1272, DOI 10.1359/jbmr.2001.16.7.1272; Sales KJ, 2002, CANCER RES, V62, P424; Smith RL, 1995, J ORTHOPAED RES, V13, P824, DOI 10.1002/jor.1100130604; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Spencer AG, 1999, J BIOL CHEM, V274, P32936, DOI 10.1074/jbc.274.46.32936; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Weinreb M, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740127; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Xu XM, 1996, AM J PHYSIOL-CELL PH, V270, pC259, DOI 10.1152/ajpcell.1996.270.1.C259	40	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28388	28394		10.1074/jbc.M301378200	http://dx.doi.org/10.1074/jbc.M301378200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12743126	hybrid			2022-12-25	WOS:000184421100007
J	Lehman, JA; Calvo, V; Gomez-Cambronero, J				Lehman, JA; Calvo, V; Gomez-Cambronero, J			Mechanism of ribosomal p70S6 kinase activation by granulocyte macrophage colony-stimulating factor in neutrophils - Cooperation of a MEK-related, THR421/SER424 kinase and a rapamycin-sensitive, mTOR-related THR389 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S6 KINASE; MAMMALIAN TARGET; IN-VIVO; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASES; PHOSPHORYLATION; P70(S6K); CELLS; SITE; IDENTIFICATION	We report here for the first time the detection of the ribosomal p70S6 kinase (p70S6K) in a hematopoietic cell, the neutrophil, and the stimulation of its enzymatic activity by granulocyte macrophage colony-stimulating factor (GM-CSF). GM-CSF modified the V-max of the enzyme (from 7.2 to 20.5 pmol/min/mg) and induced a time- and dose-dependent phosphorylation on p70S6K residues Thr(389) and Thr(421)/Ser(424). The immunosuppressant macrolide rapamycin caused either a decrease in intensity of phospho-Thr(389) bands in Western blots, or as a downshift in the relative mobility of phospho-Thr(421)/ Ser(424) bands ( consistent with the loss of phosphate), but not both simultaneously. The immunosuppressant FK506 failed to inhibit p70S6K activation, but was able to rescue the rapamycin-induced downshift, pointing to a role for the mammalian target of rapamycin ( mTOR) kinase. Rapamycin also caused an inhibition (IC50 0.2 nM) of the in vitro enzymatic activity of p70S6K. However, the inhibition of activity was not complete, but only a 40 - 50%, indicating that neutrophil p70S6K activity has a rapamycin-resistant component. This component was totally inhibited by pre-incubating the cells with the mitogen-activated protein kinase ( MAPK) kinase (MEK) inhibitor PD-98059 prior to treatment with rapamycin. This indicated that a kinase from the MEK/ MAPK pathway also plays a role in p70S6K activation. Thus, GM-CSF causes the dual activation of a rapamycin-resistant, MAPK-related kinase, that targets Thr(421)/ Ser(424) S6K phosphorylation, and a rapamycin-sensitive, mTOR-related kinase, that targets Thr(389), both of which are needed in cooperation to achieve full activation of neutrophil p70S6K.	Wright State Univ, Sch Med, Dept Physiol & Biophys, Dayton, OH 45435 USA	University System of Ohio; Wright State University Dayton	Gomez-Cambronero, J (corresponding author), Wright State Univ, Sch Med, Dept Physiol & Biophys, 3640 Colonel Glenn Highway, Dayton, OH 45435 USA.	julian.cambronero@wright.edu	Calvo, Victor/L-5024-2014	Calvo, Victor/0000-0002-5913-7058; Gomez-Cambronero, Julian/0000-0002-7581-9227	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL056653, R01HL056653] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL056653] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHN NG, 1990, J BIOL CHEM, V265, P11487; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Avruch J, 2001, Prog Mol Subcell Biol, V26, P115; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Belham C, 2001, CURR BIOL, V11, P1155, DOI 10.1016/S0960-9822(01)00369-4; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CALVO V, 1994, EUR J IMMUNOL, V24, P2664, DOI 10.1002/eji.1830241115; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; Egger G, 2001, VIRCHOWS ARCH, V438, P394, DOI 10.1007/s004280000321; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; Erbay E, 2001, J BIOL CHEM, V276, P36079, DOI 10.1074/jbc.C100406200; Gardiner EM, 2002, CURR BIOL, V12, P2029, DOI 10.1016/S0960-9822(02)01334-9; GomezCambronero J, 1996, LIFE SCI, V59, P2099, DOI 10.1016/S0024-3205(96)00414-6; Gonzalez-Garcia A, 2002, J BIOL CHEM, V277, P1500, DOI 10.1074/jbc.M103808200; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Hayes AL, 1999, J BIOL CHEM, V274, P33455, DOI 10.1074/jbc.274.47.33455; Hunter MG, 2000, BLOOD, V95, P2132, DOI 10.1182/blood.V95.6.2132; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Joseph DE, 1996, J BIOL CHEM, V271, P13088, DOI 10.1074/jbc.271.22.13088; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1991, METHOD ENZYMOL, V200, P268; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lee-Fruman KK, 1999, ONCOGENE, V18, P5108, DOI 10.1038/sj.onc.1202894; Lehman JA, 2002, BIOCHEM BIOPH RES CO, V293, P463, DOI 10.1016/S0006-291X(02)00238-3; Lehman JA, 2001, AM J PHYSIOL-CELL PH, V280, pC183, DOI 10.1152/ajpcell.2001.280.1.C183; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NEMENOFF RA, 1988, J BIOL CHEM, V263, P19455; Patel S, 2002, J BIOL CHEM, V277, P9889, DOI 10.1074/jbc.M109870200; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Pellegatta F, 1998, J BIOL CHEM, V273, P27768, DOI 10.1074/jbc.273.43.27768; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; Romanelli A, 2002, J BIOL CHEM, V277, P40281, DOI 10.1074/jbc.M205168200; Saitoh M, 2002, J BIOL CHEM, V277, P20104, DOI 10.1074/jbc.M201745200; Salh B, 1998, J IMMUNOL, V161, P6947; Scheid MP, 1996, BIOCHEM CELL BIOL, V74, P595, DOI 10.1139/o96-064; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; SIEGMANN M, 1987, METHOD ENZYMOL, V146, P362; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Yamaguchi T, 1999, J BIOL CHEM, V274, P15575, DOI 10.1074/jbc.274.22.15575; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	56	72	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28130	28138		10.1074/jbc.M300376200	http://dx.doi.org/10.1074/jbc.M300376200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12740386	hybrid			2022-12-25	WOS:000184242700100
J	Pan, WJ; Arnone, M; Kendall, M; Grafstrom, RH; Seitz, SP; Wasserman, ZR; Albright, CF				Pan, WJ; Arnone, M; Kendall, M; Grafstrom, RH; Seitz, SP; Wasserman, ZR; Albright, CF			Identification of peptide substrates for human MMP-11 (stromelysin-3) using phage display	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; MATRIX; EXPRESSION; CANCER; METALLOPROTEINASES; DETERMINANTS; GELATINASE; INHIBITORS; SEQUENCES	The MMP-11 proteinase, also known as stromelysin-3, probably plays an important role in human cancer because MMP-11 is frequently overexpressed in human tumors and MMP-11 levels affect tumorogenesis in mice. Unlike other MMPs, however, human MMP-11 does not cleave extracellular matrix proteins, such as collagen, laminin, fibronectin, and elastin. To help identify physiologic MMP-11 substrates, a phage display library was used to find peptide substrates for MMP-11. One class of peptides containing 26 members had the consensus sequence A(A/Q)(N/A) down arrow (L/Y)(T/V/M/R)(R/K), where down arrow denotes the cleavage site. This consensus sequence was similar to that for other MMPs, which also cleave peptides containing Ala in position 3, Ala in position 1, and Leu/Tyr in position 1', but differed from most other MMP substrates in that proline was rarely found in position 3 and Asn was frequently found in position 1. A second class of peptides containing four members had the consensus sequence G(G/A)E down arrow LR. Although other MMPs also cleave peptides with these residues, other MMPs prefer proline at position 3 in this sequence. In vitro assays with MMP-11 and representative peptides from both classes yielded modest k(cat)/K-m values relative to values found for other MMPs with their preferred peptide substrates. These reactions also showed that peptides with proline in position 3 were poor substrates for MMP-11. A structural basis for the lower k(cat)/K-m values of human MMP-11, relative to other MMPs, and poor cleavage of position 3 proline substrates by MMP-11 is provided. Taken together, these findings explain why MMP-11 does not cleave most other MMP substrates and predict that MMP-11 has unique substrates that may contribute to human cancer.	Bristol Myers Squibb Pharmaceut Res Inst, Princeton, NJ 08534 USA	Bristol-Myers Squibb	Albright, CF (corresponding author), Stine Haskell Res Ctr, Incyte Pharmaceut, 1090 Elkton Rd, Newark, DE 19711 USA.	cAlbright@incyte.com	Grafström, Roland C/N-7217-2016					Ahmad A, 1998, AM J PATHOL, V152, P721; Bantan-Polak T, 2001, ANAL BIOCHEM, V297, P128, DOI 10.1006/abio.2001.5338; Basset P, 1997, CRIT REV ONCOL HEMAT, V26, P43, DOI 10.1016/S1040-8428(97)00010-3; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; Bode W, 2000, METH MOL B, V151, P45, DOI 10.1385/1-59259-046-2:045; Boulay A, 2001, CANCER RES, V61, P2189; Chenard MP, 1996, INT J CANCER, V69, P448, DOI 10.1002/(SICI)1097-0215(19961220)69:6<448::AID-IJC5>3.3.CO;2-4; Gall AL, 2001, J MOL BIOL, V307, P577, DOI 10.1006/jmbi.2001.4493; Kannan R, 1999, PROTEIN EXPRES PURIF, V16, P76, DOI 10.1006/prep.1999.1068; Kossakowska AE, 1996, BRIT J CANCER, V73, P1401, DOI 10.1038/bjc.1996.266; Kridel SJ, 2001, J BIOL CHEM, V276, P20572, DOI 10.1074/jbc.M100900200; Lang R, 2001, J MOL BIOL, V312, P731, DOI 10.1006/jmbi.2001.4954; Luo DC, 2002, J BIOL CHEM, V277, P25527, DOI 10.1074/jbc.M202494200; Manes S, 1997, J BIOL CHEM, V272, P25706, DOI 10.1074/jbc.272.41.25706; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; MCGEEHAN GM, 1994, J BIOL CHEM, V269, P32814; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Mucha A, 1998, J BIOL CHEM, V273, P2763, DOI 10.1074/jbc.273.5.2763; NAGASE H, 1994, J BIOL CHEM, V269, P20952; NOEL A, 1995, J BIOL CHEM, V270, P22866, DOI 10.1074/jbc.270.39.22866; Noel A, 2000, ONCOGENE, V19, P1605, DOI 10.1038/sj.onc.1203465; Ohkubo S, 1999, BIOCHEM BIOPH RES CO, V266, P308, DOI 10.1006/bbrc.1999.1816; Ohkubo S, 2001, COMB CHEM HIGH T SCR, V4, P573; PEI DQ, 1994, J BIOL CHEM, V269, P25849; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; ROUYER N, 1994, INVAS METAST, V14, P269; Shalinsky DR, 1999, ANN NY ACAD SCI, V878, P236, DOI 10.1111/j.1749-6632.1999.tb07689.x; Tetu B, 1998, HUM PATHOL, V29, P979, DOI 10.1016/S0046-8177(98)90204-0; Turk BE, 2001, NAT BIOTECHNOL, V19, P661, DOI 10.1038/90273; Velazquez-Campoy A, 2000, BIOCHEMISTRY-US, V39, P2201, DOI 10.1021/bi992399d; Woessner J.F., 2000, PROTEIN PROFILE SER	32	46	51	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27820	27827		10.1074/jbc.M304436200	http://dx.doi.org/10.1074/jbc.M304436200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12738779	hybrid			2022-12-25	WOS:000184242700063
J	Perron, A; Chen, ZG; Gingras, D; Dupre, DJ; Stankova, J; Rola-Pleszczynski, M				Perron, A; Chen, ZG; Gingras, D; Dupre, DJ; Stankova, J; Rola-Pleszczynski, M			Agonist-independent desensitization and internalization of the human platelet-activating factor receptor by coumermycin-gyrase B-induced dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; DELTA-OPIOID RECEPTOR; BINDS COUMARIN DRUGS; BETA(2)-ADRENERGIC RECEPTOR; SIGNAL-TRANSDUCTION; MUSCARINIC ACETYLCHOLINE; BETA-ARRESTINS; CELL-SURFACE; FACTOR PAF; PHOSPHORYLATION	Platelet-activating factor (PAF) is a phospholipid with potent and diverse physiological actions, particularly as a mediator of inflammation. We have reported previously that mutant G protein-coupled receptors (GPCRs) affect the functional properties of coexpressed wildtype human PAF receptor (hPAFR) ( Le Gouill, C., Parent, J. L., Caron, C. A., Gaudreau, R., Volkov, L., Rola-Pleszczynski, M., and Stankova, J. ( 1999) J. Biol. Chem. 274, 12548 - 12554). Increasing evidence suggests that dimerization of GPCRs may play an important role in the regulation of their biological activity. Additional data have also suggested that dimerization may be important in the subsequent internalization of the delta-opioid receptor. To investigate the specific role of dimerization in the internalization process of GPCRs, we generated a fusion protein of hPAFR and bacterial DNA gyrase B (GyrB), dimerized through the addition of coumermycin. We found that dimerization potentiates PAF-induced internalization of hPAFR-GyrB in Chinese hamster ovary cells stably expressing c-Myc-hPAFR-GyrB. Coumermycin-driven dimerization was also sufficient to induce an agonist-independent sequestration process in an arrestin- and clathrin-independent manner. Moreover, the protein kinase C inhibitors staurosporine and GF109203X blocked the coumermycin-induced desensitization of hPAFR-GyrB, suggesting the implication of protein kinase C in the molecular mechanism mediating the agonist-independent desensitization of the receptor. Taken together, these findings suggest a novel mechanism of GPCR desensitization and internalization triggered by dimerization.	Univ Sherbrooke, Fac Med, Dept Pediat, Div Immunol, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Rola-Pleszczynski, M (corresponding author), Univ Sherbrooke, Fac Med, Dept Pediat, Div Immunol, 3001 N 12th Ave, Sherbrooke, PQ J1H 5N4, Canada.		Dupre, Denis J/AAI-2631-2021; Chen, Zhangguo/AAW-2032-2021	Dupre, Denis J/0000-0001-6401-6157; Chen, Zhangguo/0000-0002-2741-0080				ALI H, 1994, J BIOL CHEM, V269, P24557; ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Barak LS, 1999, J BIOL CHEM, V274, P7565, DOI 10.1074/jbc.274.11.7565; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; BECK KA, 1991, J BIOL CHEM, V266, P4442; Bito H, 1997, ADV EXP MED BIOL, V400, P215; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; Chen ZG, 2002, J BIOL CHEM, V277, P7356, DOI 10.1074/jbc.M110058200; Chung HJ, 2000, J NEUROSCI, V20, P7258; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; EVANGELOU AM, 1994, PROSTAG LEUKOTR ESS, V50, P1, DOI 10.1016/0952-3278(94)90101-5; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; GILBERT EJ, 1994, MOL MICROBIOL, V12, P365, DOI 10.1111/j.1365-2958.1994.tb01026.x; Gilbert TL, 2001, BIOCHEMISTRY-US, V40, P3467, DOI 10.1021/bi001320y; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Hipkin RW, 2000, J BIOL CHEM, V275, P5591, DOI 10.1074/jbc.275.8.5591; IMAIZUMI TA, 1995, J INTERN MED, V238, P5, DOI 10.1111/j.1365-2796.1995.tb00894.x; Ishii I, 1998, J BIOL CHEM, V273, P9878, DOI 10.1074/jbc.273.16.9878; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Gouill C, 1999, J BIOL CHEM, V274, P12548, DOI 10.1074/jbc.274.18.12548; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LeGouill C, 1997, J BIOL CHEM, V272, P21289, DOI 10.1074/jbc.272.34.21289; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Lukashova V, 2001, J BIOL CHEM, V276, P24113, DOI 10.1074/jbc.M100720200; McConalogue K, 1999, J BIOL CHEM, V274, P16257, DOI 10.1074/jbc.274.23.16257; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; Parent JL, 1996, J BIOL CHEM, V271, P23298, DOI 10.1074/jbc.271.38.23298; Rodriguez-Frade JM, 1999, J CELL BIOL, V144, P755, DOI 10.1083/jcb.144.4.755; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; Snyder F., 1990, AM J PHYSIOL, V259, P697; STODDARD BL, 1992, COLD SPRING HARB SYM, V57, P1; Tsao P, 2000, CURR OPIN NEUROBIOL, V10, P365, DOI 10.1016/S0959-4388(00)00096-9; VazquezPrado J, 1997, J BIOL CHEM, V272, P27330, DOI 10.1074/jbc.272.43.27330; VENABLE ME, 1993, J LIPID RES, V34, P691; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; Walker JKL, 1999, J BIOL CHEM, V274, P31515, DOI 10.1074/jbc.274.44.31515; Werbonat Y, 2000, J BIOL CHEM, V275, P21969, DOI 10.1074/jbc.M001736200; Xiang B, 2001, J BIOL CHEM, V276, P4709, DOI 10.1074/jbc.M006187200; Zeng FY, 2000, NEUROPSYCHOPHARMACOL, V23, pS19, DOI 10.1016/S0893-133X(00)00146-9; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; Zhang ZX, 2001, J BIOL CHEM, V276, P5316, DOI 10.1074/jbc.M005958200	56	20	20	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27956	27965		10.1074/jbc.M212302200	http://dx.doi.org/10.1074/jbc.M212302200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12756251	hybrid			2022-12-25	WOS:000184242700079
J	Riggins, RB; Quilliam, LA; Bouton, AH				Riggins, RB; Quilliam, LA; Bouton, AH			Synergistic promotion of c-Src activation and cell migration by Cas and AND-34/BCAR3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; FOCAL ADHESION KINASE; CRK-ASSOCIATED SUBSTRATE; NUCLEOTIDE EXCHANGE ACTIVITY; SIGNALING COMPLEX-FORMATION; ADAPTER PROTEIN CAS; TYROSINE PHOSPHORYLATION; FAMILY KINASES; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX	The adapter molecule p130(Cas) (Cas) plays a role in cellular processes such as proliferation, survival, cell adhesion, and migration. The ability of Cas to promote migration has been shown to be dependent upon its carboxyl terminus, which contains a bipartite binding site for the protein tyrosine kinase c-Src (Src). The association between Src and Cas enhances Src kinase activity, and like Cas, Src plays an important role in cell proliferation and migration. In this study, we show that Src and Cas function cooperatively to promote cell migration in a manner that depends upon kinase-active Src. Another carboxyl-terminal binding partner of Cas, AND-34/BCAR3 (AND-34), functions synergistically with Cas to enhance Src activation and cell migration. The carboxyl-terminal guanine nucleotide exchange factor domain of AND-34, as well as the activity of its putative target Rap1, contribute to these events. A mechanism through which AND-34 may regulate Cas-dependent cell migration is suggested by the finding that Cas becomes redistributed from focal adhesions to lamellipodia located at the leading edge of AND-34 overexpressing cells. These data thus provide insight into how Cas and AND-34 may function together to stimulate Src signaling pathways and promote cell migration.	Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Ctr Canc, Charlottesville, VA 22908 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	University of Virginia; University of Virginia; Indiana University System; Indiana University-Purdue University Indianapolis	Bouton, AH (corresponding author), Univ Virginia Hlth Syst, Dept Microbiol, POB 800734, Charlottesville, VA 22908 USA.	ahb8y@virginia.edu	Riggins, Rebecca/GQH-4466-2022; Quilliam, Lawrence/Q-4987-2019; Quilliam, Lawrence/B-6447-2015	Riggins, Rebecca/0000-0002-1555-4431				Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Bouton AH, 1997, HYBRIDOMA, V16, P403, DOI 10.1089/hyb.1997.16.403; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Burnham MR, 1999, MOL CARCINOGEN, V26, P20, DOI 10.1002/(SICI)1098-2744(199909)26:1<20::AID-MC3>3.0.CO;2-M; Burnham MR, 1996, ONCOGENE, V12, P2467; Cai DP, 1999, J IMMUNOL, V163, P2104; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; Cary LA, 2002, MOL CELL BIOL, V22, P2427, DOI 10.1128/MCB.22.8.2427-2440.2002; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Gotoh T, 2000, J BIOL CHEM, V275, P30118, DOI 10.1074/jbc.M003074200; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Harte MT, 2000, BBA-MOL CELL RES, V1499, P34, DOI 10.1016/S0167-4889(00)00104-X; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; Huang JH, 2002, J BIOL CHEM, V277, P27265, DOI 10.1074/jbc.M203063200; Hubbard SR, 1999, NAT STRUCT BIOL, V6, P711, DOI 10.1038/11468; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kiyono M, 2000, J BIOL CHEM, V275, P5441, DOI 10.1074/jbc.275.8.5441; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Law SF, 1999, EXP CELL RES, V252, P224, DOI 10.1006/excr.1999.4609; Li LM, 2002, MOL CELL BIOL, V22, P1203, DOI 10.1128/MCB.22.4.1203-1217.2002; Lu YM, 1999, J BIOL CHEM, V274, P10047, DOI 10.1074/jbc.274.15.10047; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; McLeod S J, 2001, Int Rev Immunol, V20, P763, DOI 10.3109/08830180109045589; McLeod SJ, 2002, J IMMUNOL, V169, P1365, DOI 10.4049/jimmunol.169.3.1365; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; O'Neill GM, 2001, MOL CELL BIOL, V21, P5094, DOI 10.1128/MCB.21.15.5094-5108.2001; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PATCH LA, 1995, J CELL SCI, V108, P1371; Pellicena P, 2001, J BIOL CHEM, V276, P28190, DOI 10.1074/jbc.M100055200; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ruest PJ, 2001, MOL CELL BIOL, V21, P7641, DOI 10.1128/MCB.21.22.7641-7652.2001; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sakakibara A, 2002, J CELL SCI, V115, P4915, DOI 10.1242/jcs.00207; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Slack JK, 1999, J BIOL CHEM, V274, P27177, DOI 10.1074/jbc.274.38.27177; Suga K, 2001, FEBS LETT, V489, P249, DOI 10.1016/S0014-5793(00)02222-5; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; van Agthoven T, 1998, EMBO J, V17, P2799, DOI 10.1093/emboj/17.10.2799; van der Flier S, 2000, JNCI-J NATL CANCER I, V92, P120, DOI 10.1093/jnci/92.2.120; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; WILSON LK, 1990, ONCOGENE, V5, P1471; Xing LZ, 2000, MOL CELL BIOL, V20, P7363, DOI 10.1128/MCB.20.19.7363-7377.2000	79	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28264	28273		10.1074/jbc.M303535200	http://dx.doi.org/10.1074/jbc.M303535200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12740391	hybrid			2022-12-25	WOS:000184242700117
J	Torres, B; Porras, G; Garcia, JL; Diaz, E				Torres, B; Porras, G; Garcia, JL; Diaz, E			Regulation of the mhp cluster responsible for 3-(3-hydroxyphenyl)propionic acid degradation in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN ADP1; 4-HYDROXYPHENYLACETATE CATABOLIC PATHWAY; P-HYDROXYBENZOATE HYDROXYLASE; RHODOCOCCUS-OPACUS 1CP; TRANSCRIPTIONAL REGULATOR; PSEUDOMONAS-PUTIDA; ACINETOBACTER-CALCOACETICUS; MELILOTATE HYDROXYLASE; 3-PHENYLPROPIONIC ACID; POSITIVE REGULATOR	The mhp gene cluster from Escherichia coli constitutes a model system to study bacterial degradation of 3-(3-hydroxyphenyl) propionic acid (3HPP). In this work the regulation of the inducible mhp catabolic genes has been studied by genetic and biochemical approaches. The Pr and Pa promoters, which control the expression of the divergently transcribed mhpR regulatory gene and mhp catabolic genes, respectively, show a peculiar arrangement leading to transcripts that are complementary at their 5'-ends. By using Pr-lacZ and Pa-lacZ translational fusions and gel retardation assays, we have shown that the mhpR gene product behaves as a 3HPP-dependent activator of the Pa promoter, being the expression from Pr constitutive and MhpR-independent. DNase I footprinting experiments and mutational analysis mapped an MhpR-protected region, centered at position -58 with respect to the Pa transcription start site, which is indispensable for MhpR binding and in vivo activation of the Pa promoter. Superimposed in the specific MhpR-mediated regulation of the Pa promoter, we have observed a strict catabolite repression control carried out by the cAMP receptor protein (CRP) that allows expression of the mhp catabolic genes when the preferred carbon source (glucose) is not available and 3HPP is present in the medium. Gel retardation assays revealed that the specific activator, MhpR, is essential for the binding of the second activator, CRP, to the Pa promoter. Such peculiar synergistic transcription activation has not yet been observed in other aromatic catabolic pathways, and the MhpR activator becomes the first member of the IclR family of transcriptional regulators that is indispensable for recruiting CRP to the target promoter.	CSIC, Ctr Invest Biol, Dept Mol Microbiol, Madrid 28040, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Diaz, E (corresponding author), CSIC, Ctr Invest Biol, Dept Mol Microbiol, Ramiro Maeztu 9, Madrid 28040, Spain.		Diaz, Eduardo/F-8605-2016; Garcia Lopez, Jose Luis/G-9139-2015	Diaz, Eduardo/0000-0002-9731-6524; Garcia Lopez, Jose Luis/0000-0002-9238-2485				ANDREONI V, 1986, APPL ENVIRON MICROB, V52, P930, DOI 10.1128/AEM.52.4.930-934.1986; [Anonymous], 1996, ESCHERICHIA COLI SAL, P1325; Arai H, 1999, MICROBIOL-SGM, V145, P2813, DOI 10.1099/00221287-145-10-2813; Barnes MR, 1997, J BACTERIOL, V179, P6145, DOI 10.1128/jb.179.19.6145-6153.1997; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURLINGAME R, 1983, J BACTERIOL, V155, P424, DOI 10.1128/JB.155.1.424-426.1983; BURLINGAME RP, 1986, J BACTERIOL, V168, P55, DOI 10.1128/jb.168.1.55-64.1986; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; COULSON CB, 1959, CHEM IND-LONDON, P543; DAGLEY S, 1965, BIOCHEM J, V97, P643, DOI 10.1042/bj0970643; DELORENZO V, 1994, METHOD ENZYMOL, V235, P386; Diaz E, 1998, J BACTERIOL, V180, P2915; Diaz E, 2000, CURR OPIN BIOTECH, V11, P467, DOI 10.1016/S0958-1669(00)00126-9; Diaz E, 2001, MICROBIOL MOL BIOL R, V65, P523, DOI 10.1128/MMBR.65.4.523-569.2001; DIMARCO AA, 1994, J BACTERIOL, V176, P4277, DOI 10.1128/jb.176.14.4277-4284.1994; DIMARCO AA, 1993, J BACTERIOL, V175, P4499, DOI 10.1128/JB.175.14.4499-4506.1993; Eulberg D, 1998, ANTON LEEUW INT J G, V74, P71, DOI 10.1023/A:1001755928637; Eulberg D, 1998, J BACTERIOL, V180, P1072, DOI 10.1128/JB.180.5.1072-1081.1998; Ferrandez A, 2000, J BIOL CHEM, V275, P12214, DOI 10.1074/jbc.275.16.12214; Ferrandez A, 1998, J BIOL CHEM, V273, P25974, DOI 10.1074/jbc.273.40.25974; Ferrandez A, 1997, J BACTERIOL, V179, P2573, DOI 10.1128/jb.179.8.2573-2581.1997; Galan B, 2001, J BIOL CHEM, V276, P37060, DOI 10.1074/jbc.M103033200; Gerischer U, 1998, J BACTERIOL, V180, P1512, DOI 10.1128/JB.180.6.1512-1524.1998; Guo Z, 1999, MOL MICROBIOL, V32, P253, DOI 10.1046/j.1365-2958.1999.01342.x; Kimata K, 1997, P NATL ACAD SCI USA, V94, P12914, DOI 10.1073/pnas.94.24.12914; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; Kovarova K, 1997, APPL ENVIRON MICROB, V63, P2619; LEVY CC, 1967, J BIOL CHEM, V242, P747; Masai E, 2002, APPL ENVIRON MICROB, V68, P4416, DOI 10.1128/AEM.68.9.4416-4424.2002; Maxam A M, 1980, Methods Enzymol, V65, P499; McFall SM, 1998, GENE, V223, P257, DOI 10.1016/S0378-1119(98)00366-7; Miller J.H., 1972, EXPT MOL GENETICS; Parke D, 1997, FEMS MICROBIOL LETT, V146, P3, DOI 10.1016/S0378-1097(96)00382-5; PerezMartin J, 1996, GENE, V172, P81, DOI 10.1016/0378-1119(96)00193-X; Perna NT, 2001, NATURE, V409, P529, DOI 10.1038/35054089; Popp R, 2002, J BACTERIOL, V184, P1988, DOI 10.1128/JB.184.7.1988-1997.2002; Powell JAC, 1998, ANTON LEEUW INT J G, V74, P175, DOI 10.1023/A:1001784702230; Priefert H, 2001, APPL MICROBIOL BIOT, V56, P296, DOI 10.1007/s002530100687; Prieto MA, 1997, BIOCHEM BIOPH RES CO, V232, P759, DOI 10.1006/bbrc.1997.6368; ROMEROSTEINER S, 1994, J BACTERIOL, V176, P5771, DOI 10.1128/JB.176.18.5771-5779.1994; ROPER DI, 1993, MOL GEN GENET, V237, P241, DOI 10.1007/BF00282806; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Smith MA, 2003, APPL ENVIRON MICROB, V69, P524, DOI 10.1128/AEM.69.1.524-532.2003; Speicher David W., 1994, Methods (Orlando), V6, P262, DOI 10.1006/meth.1994.1028; STREM ST, 1998, P NATL ACAD SCI USA, V95, P9761; STRICKLAND S, 1973, J BIOL CHEM, V248, P2944; Trautwein G, 2001, J BACTERIOL, V183, P873, DOI 10.1128/JB.183.3.873-881.2001; Venturi V, 1998, MICROBIOL-SGM, V144, P965, DOI 10.1099/00221287-144-4-965; Wade JT, 2001, EMBO J, V20, P7160, DOI 10.1093/emboj/20.24.7160; Yamashita M, 1996, J BACTERIOL, V178, P2941, DOI 10.1128/jb.178.10.2941-2947.1996	51	31	35	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27575	27585		10.1074/jbc.M303245200	http://dx.doi.org/10.1074/jbc.M303245200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12748194	Green Published, hybrid			2022-12-25	WOS:000184242700032
J	Paternot, S; Coulonval, K; Dumont, JE; Roger, PP				Paternot, S; Coulonval, K; Dumont, JE; Roger, PP			Cyclic AMP-dependent phosphorylation of cyclin D3-bound CDK4 determines the passage through the cell cycle restriction point in thyroid epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RETINOBLASTOMA PROTEIN; PRIMARY CULTURE; INHIBITOR P27(KIP1); GROWTH-FACTOR; SUBCELLULAR-LOCALIZATION; G(1) PHASE; THR-160 PHOSPHORYLATION; ADENOSINE-MONOPHOSPHATE; MURINE FIBROBLASTS	According to current concepts, the cell cycle commitment after restriction ( R) point passage requires the sustained stimulation by mitogens of the synthesis of labile D-type cyclins, which associate with cyclin-dependent kinase (CDK) 4/6 to phosphorylate pRb family proteins and sequester the CDK inhibitor p27(kip1). In primary cultures of dogthyroid epithelial cells, the cAMP-dependent cell cycle induced by a sustained stimulation by thyrotropin or forskolin differs from growth factor mitogenic pathways, as cAMP does not upregulate D-type cyclins but increases p27 levels. Instead, cAMP induces the assembly of required cyclin D3-CDK4 complexes, which associate with nuclear p27. In this study, the arrest of forskolin stimulation rapidly slowed down the entry of dog thyrocytes into S phase and the phosphorylation of pRb family proteins. The pRb kinase activity, but not the formation, of the cyclin D3-CDK4-p27 complex was strongly reduced. Using two-dimensional gel electrophoresis, a phosphorylated form of CDK4 was separated. It appeared in response to forskolin and was bound to both cyclin D3 and p27, presumably reflecting the activating Thr-172 phosphorylation of CDK4. Upon forskolin withdrawal or after cycloheximide addition, this CDK4 phosphoform unexpectedly persisted in p27 complexes devoid of cyclin D3 but it disappeared from the more labile cyclin D3 complexes. These data demonstrate that the assembly of the cyclin D3-CDK4-p27 holoenzyme and the subsequent phosphorylation and activation of CDK4 depend on distinct cAMP actions. This provides a first example of a crucial regulation of CDK4 phosphorylation by a mitogenic cascade and a novel mechanism of cell cycle control at the R point.	Free Univ Brussels, IRIBHM, Inst Interdisciplinary Res, B-1070 Brussels, Belgium; Free Univ Brussels, Dept Prot Chem, Fac Med, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Roger, PP (corresponding author), Free Univ Brussels, IRIBHM, Inst Interdisciplinary Res, CAmpus Erasme,Bldg C,808 Route Lennik, B-1070 Brussels, Belgium.			Roger, Pierre/0000-0002-5812-1783				Bagui TK, 2000, MOL CELL BIOL, V20, P8748, DOI 10.1128/MCB.20.23.8748-8757.2000; BAPTIST M, 1993, J CELL SCI, V105, P69; Baptist M, 1996, J CELL PHYSIOL, V166, P256; BAPTIST M, 1995, EXP CELL RES, V221, P160, DOI 10.1006/excr.1995.1363; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bartkova J, 1996, INT J CANCER, V66, P732, DOI 10.1002/(SICI)1097-0215(19960611)66:6<732::AID-IJC4>3.0.CO;2-0; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Chiariello M, 2000, BIOCHEM J, V349, P869, DOI 10.1042/bj3490869; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Coulonval K, 1997, EXP CELL RES, V233, P395, DOI 10.1006/excr.1997.3582; DARBON JM, 1994, ONCOGENE, V9, P3127; Depoortere F, 1996, J CELL SCI, V109, P1759; Depoortere F, 1998, J CELL BIOL, V140, P1427, DOI 10.1083/jcb.140.6.1427; Depoortere F, 2000, MOL BIOL CELL, V11, P1061, DOI 10.1091/mbc.11.3.1061; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; Ekholm SV, 2001, MOL CELL BIOL, V21, P3256, DOI 10.1128/MCB.21.9.3256-3265.2001; Farkas T, 2002, J BIOL CHEM, V277, P26741, DOI 10.1074/jbc.M200381200; Garrett S, 2001, MOL CELL BIOL, V21, P88, DOI 10.1128/MCB.21.1.88-99.2001; Gorg A, 2000, ELECTROPHORESIS, V21, P1037, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1037::AID-ELPS1037>3.0.CO;2-V; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harper JW, 1998, GENE DEV, V12, P285, DOI 10.1101/gad.12.3.285; Jinno S, 1999, ONCOGENE, V18, P565, DOI 10.1038/sj.onc.1202347; Kaldis P, 2000, EUR J BIOCHEM, V267, P4213, DOI 10.1046/j.1432-1327.2000.01455.x; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kelly BL, 1998, P NATL ACAD SCI USA, V95, P2535, DOI 10.1073/pnas.95.5.2535; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Leng XH, 2002, MOL CELL BIOL, V22, P2242, DOI 10.1128/MCB.22.7.2242-2254.2002; Lents NH, 2002, J BIOL CHEM, V277, P47469, DOI 10.1074/jbc.M207425200; Liu J, 2000, MOL BIOL EVOL, V17, P1061, DOI 10.1093/oxfordjournals.molbev.a026387; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Murray AW, 2001, NATURE, V409, P844, DOI 10.1038/35057033; Nagahara H, 1999, P NATL ACAD SCI USA, V96, P14961, DOI 10.1073/pnas.96.26.14961; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Obaya AJ, 2002, J BIOL CHEM, V277, P31263, DOI 10.1074/jbc.M202528200; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Parry D, 1999, MOL CELL BIOL, V19, P1775; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Roger PP, 1997, EUR J ENDOCRINOL, V137, P579, DOI 10.1530/eje.0.1370579; ROGER PP, 1987, EXP CELL RES, V172, P282, DOI 10.1016/0014-4827(87)90387-9; Roger PP, 1999, EXP CELL RES, V252, P492, DOI 10.1006/excr.1999.4646; ROGER PP, 1987, J CELL PHYSIOL, V130, P58, DOI 10.1002/jcp.1041300110; Roger PP, 1995, VITAM HORM, V51, P59, DOI 10.1016/S0083-6729(08)61038-9; ROGER PP, 1983, FEBS LETT, V157, P323, DOI 10.1016/0014-5793(83)80569-9; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Skildum AJ, 2002, J BIOL CHEM, V277, P5145, DOI 10.1074/jbc.M109179200; Sugimoto M, 2002, ONCOGENE, V21, P8067, DOI 10.1038/sj.onc.1206019; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; Taules M, 1998, J BIOL CHEM, V273, P33279, DOI 10.1074/jbc.273.50.33279; Tsakraklides V, 2002, J BIOL CHEM, V277, P33482, DOI 10.1074/jbc.M205537200; Ukomadu C, 2003, J BIOL CHEM, V278, P4840, DOI 10.1074/jbc.M208658200; Van Keymeulen A, 1999, ONCOGENE, V18, P7351, DOI 10.1038/sj.onc.1203164; Van Keymeulen A, 2001, ENDOCRINOLOGY, V142, P1251, DOI 10.1210/en.142.3.1251; VANSANDE J, 1983, MOL CELL ENDOCRINOL, V29, P109, DOI 10.1016/0303-7207(83)90009-6; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0; Zhang XH, 2000, MOL BIOL CELL, V11, P2117, DOI 10.1091/mbc.11.6.2117	79	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26533	26540		10.1074/jbc.M302492200	http://dx.doi.org/10.1074/jbc.M302492200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12730225	hybrid			2022-12-25	WOS:000184155700033
J	Pruett, PS; Azzi, A; Clark, SA; Yousef, MS; Gattis, JL; Somasundaram, T; Ellington, WR; Chapman, MS				Pruett, PS; Azzi, A; Clark, SA; Yousef, MS; Gattis, JL; Somasundaram, T; Ellington, WR; Chapman, MS			The putative catalytic bases have, at most, an accessory role in the mechanism of arginine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL CREATINE-KINASE; STATE ANALOG COMPLEX; LIMULUS-POLYPHEMUS; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; REACTIVE CYSTEINE; ACTIVE-SITE; CRYSTALLOGRAPHY; CONSEQUENCES; EXPRESSION	Arginine kinase is a member of the phosphagen kinase family that includes creatine kinase and likely shares a common reaction mechanism in catalyzing the buffering of cellular ATP energy levels. Abstraction of a proton from the substrate guanidinium by a catalytic base has long been thought to be an early mechanistic step. The structure of arginine kinase as a transition state analog complex ( Zhou, G., Somasundaram, T., Blanc, E., Parthasarathy, G., Ellington, W. R., and Chapman, M. S. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 8449 - 8454) showed that Glu-225 and Glu-314 were the only potential catalytic residues contacting the phosphorylated nitrogen. In the present study, these residues were changed to Asp, Gln, and Val or Ala in several single and multisite mutant enzymes. These mutations had little impact on the substrate binding constants. The effect upon activity varied with reductions in k(cat) between 3000-fold and less than 2-fold. The retention of significant activity in some mutants contrasts with published studies of homologues and suggests that acid-base catalysis by these residues may enhance the rate but is not absolutely essential. Crystal structures of mutant enzymes E314D at 1.9 Angstrom and E225Q at 2.8 Angstrom resolution showed that the precise alignment of substrates is subtly distorted. Thus, pre-ordering of substrates might be just as important as acid-base chemistry, electrostatics, or other potential effects in the modest impact of these residues upon catalysis.	Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA; Florida State Univ, Dept Chem & Biochem, Tallahassee, FL 32306 USA; Florida State Univ, Dept Biol Sci, Tallahassee, FL 32306 USA	State University System of Florida; Florida State University; State University System of Florida; Florida State University; State University System of Florida; Florida State University	Chapman, MS (corresponding author), Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA.			Chapman, Michael/0000-0001-8525-8585; Somasundaram, Thayumanasamy/0000-0002-3629-5117; Yousef, Mohammad/0000-0003-0492-7658	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055837] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM55837] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLETHEN SL, 1972, ARCH BIOCHEM BIOPHYS, V149, P244, DOI 10.1016/0003-9861(72)90319-0; Bruice TC, 2002, ACCOUNTS CHEM RES, V35, P139, DOI 10.1021/ar0001665; Brunger AT, 1997, METHOD ENZYMOL, V277, P366, DOI 10.1016/S0076-6879(97)77021-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cantwell JS, 2001, BIOCHEMISTRY-US, V40, P3056, DOI 10.1021/bi0020980; COOK PF, 1981, BIOCHEMISTRY-US, V20, P1204, DOI 10.1021/bi00508a023; DAFFORN A, 1971, P NATL ACAD SCI USA, V68, P2463, DOI 10.1073/pnas.68.10.2463; DOUMEN C, 1990, J COMP PHYSIOL B, V160, P459, DOI 10.1007/BF01075678; Eder M, 1999, PROTEIN SCI, V8, P2258; Eder M, 2000, PROTEINS, V39, P216, DOI 10.1002/(SICI)1097-0134(20000515)39:3<216::AID-PROT40>3.0.CO;2-#; Eder M, 2000, J BIOL CHEM, V275, P27094; Ellington WR, 2001, ANNU REV PHYSIOL, V63, P289, DOI 10.1146/annurev.physiol.63.1.289; FritzWolf K, 1996, NATURE, V381, P341, DOI 10.1038/381341a0; FURTER R, 1993, BIOCHEMISTRY-US, V32, P7022, DOI 10.1021/bi00078a030; HANSEN DE, 1981, J BIOL CHEM, V256, P5967; JENCKS WP, 1974, BIOCHEM BIOPH RES CO, V57, P887, DOI 10.1016/0006-291X(74)90629-9; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P829, DOI 10.1107/S0907444996001783; Lahiri SD, 2002, BIOCHEMISTRY-US, V41, P13861, DOI 10.1021/bi026655p; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MAGGIO ET, 1977, J BIOL CHEM, V252, P1202; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; Otwinowski Z., 2001, INT TABLES CRYSTALLO, VF, P226; Rao JK, 1998, FEBS LETT, V439, P133; ROSALKI SB, 1967, J LAB CLIN MED, V69, P696; Schlattner U, 2000, BIOL CHEM, V381, P1063, DOI 10.1515/BC.2000.131; STRONG SJ, 1995, BBA-PROTEIN STRUCT M, V1246, P197, DOI 10.1016/0167-4838(94)00218-6; Strong SJ, 1996, COMP BIOCHEM PHYS B, V113, P809, DOI 10.1016/0305-0491(95)02104-3; Stroud RM, 1996, NAT STRUCT BIOL, V3, P567, DOI 10.1038/nsb0796-567; STURA E A, 1990, Methods (Orlando), V1, P38, DOI 10.1016/S1046-2023(05)80145-8; Tong L, 1997, METHOD ENZYMOL, V276, P594, DOI 10.1016/S0076-6879(97)76080-4; Wolfenden R, 1999, J AM CHEM SOC, V121, P7419, DOI 10.1021/ja991280p; Yousef MS, 2002, ACTA CRYSTALLOGR D, V58, P2009, DOI 10.1107/S0907444902014683; YOUSEF MS, 1932, PROTEIN SCI, V12, P103; Zhou GF, 1998, P NATL ACAD SCI USA, V95, P8449, DOI 10.1073/pnas.95.15.8449; Zhou GF, 1997, PROTEIN SCI, V6, P444	35	45	46	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26952	26957		10.1074/jbc.M212931200	http://dx.doi.org/10.1074/jbc.M212931200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12732621	hybrid			2022-12-25	WOS:000184155700085
J	Kino, T; Souvatzoglou, E; De Martino, MU; Tsopanomihalu, M; Wan, YH; Chrousos, GP				Kino, T; Souvatzoglou, E; De Martino, MU; Tsopanomihalu, M; Wan, YH; Chrousos, GP			Protein 14-3-3 sigma interacts with and favors cytoplasmic subcellular localization of the glucocorticoid receptor, acting as a negative regulator of the glucocorticoid signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; NUCLEAR EXPORT; 14-3-3 PROTEIN; BETA-ISOFORM; DNA-BINDING; PHOSPHORYLATION; 14-3-3-PROTEINS; TRAFFICKING; RAF-1; CALRETICULIN	The glucocorticoid receptor (GR) alpha interacts with the highly conserved 14-3-3 family proteins. The latter bind phosphorylated serine/threonine residues of "partner" molecules and influence many signal transduction events by altering their subcellular localization and/or protecting them from proteolysis. To examine the physiologic role of 14-3-3 on the glucocorticoid-signaling pathway, we studied the nucleocytoplasmic shuttling and transactivation properties of GRalpha in a cell line replete with or devoid of 14-3-3sigma. We found that endogenous 14-3-3sigma helped localize green fluorescent protein-fused GRalpha in the cytoplasm in the absence of ligand and potentiated its nuclear export after ligand withdrawal. 14-3-3sigma also suppressed the transcriptional activity of GRalpha on a glucocorticoid-responsive promoter. Disruption of the classic nuclear export signal of 14-3-3sigma inactivated its ability to influence the nucleocytoplasmic trafficking and transactivation activity of GRalpha, whereas introduction of a mutation inactivating the binding activity of 14-3-3sigma to some of its partner proteins did not. 14-3-3sigma bound the ligand-binding domain of GRalpha through its COOH-terminal portion, in a partially ligand-dependent fashion, while it did not interact with "ligand-binding domain" of GRbeta at all. These results suggest that 14-3-3sigma functions as a negative regulator in the glucocorticoid signaling pathway, possibly by shifting the subcellular localization/circulation of this receptor toward the cytoplasm through its nuclear export signal. Since 14-3-3 proteins play significant roles in numerous cellular activities, such as cell cycle progression, growth, differentiation, and apoptosis, these actions might indirectly influence the transcriptional activity of GRalpha. Conversely, through its 14-3-3 protein interactions, GRalpha may influence these processes.	NICHD, Pediat & Reprod Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NCI, Human Retrovirus Sect, Ctr Canc Res, NIH, Frederick, MD 21702 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Kino, T (corresponding author), NICHD, Pediat & Reprod Endocrinol Branch, NIH, Bldg 10,Rm 9D42,10 Ctr Dr,MSC 1583, Bethesda, MD 20892 USA.		tsopanomichalou, maria/H-3703-2019	tsopanomichalou, maria/0000-0002-1886-2376	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000615, ZIAHD008732, ZIAHD000618] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008732, Z01HD000618, Z01HD000615] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; Black BE, 2001, CURR BIOL, V11, P1749, DOI 10.1016/S0960-9822(01)00537-1; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; Craparo A, 1997, J BIOL CHEM, V272, P11663; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FINLEY RL, 1995, DNA CLONING EXPRESSI, P169; Fletcher TM, 2000, MOL CELL BIOL, V20, P6466, DOI 10.1128/MCB.20.17.6466-6475.2000; Frew IJ, 2002, MOL CELL BIOL, V22, P8155, DOI 10.1128/MCB.22.23.8155-8164.2002; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Hache RJG, 1999, J BIOL CHEM, V274, P1432, DOI 10.1074/jbc.274.3.1432; Holaska JM, 2002, MOL CELL BIOL, V22, P6286, DOI 10.1128/MCB.22.17.6286-6297.2002; Holaska JM, 2001, J CELL BIOL, V152, P127, DOI 10.1083/jcb.152.1.127; Itoh M, 2002, MOL ENDOCRINOL, V16, P2382, DOI 10.1210/me.2002-0144; Kino T, 2003, J BIOL CHEM, V278, P3023, DOI 10.1074/jbc.M209234200; Kino T, 2001, J ENDOCRINOL, V169, P437, DOI 10.1677/joe.0.1690437; Kino T, 2001, J CLIN ENDOCR METAB, V86, P5600, DOI 10.1210/jc.86.11.5600; Kino T, 2000, J STEROID BIOCHEM, V75, P283, DOI 10.1016/S0960-0760(00)00187-4; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Oakley RH, 1996, J BIOL CHEM, V271, P9550, DOI 10.1074/jbc.271.16.9550; Oakley RH, 1997, ENDOCRINOLOGY, V138, P5028, DOI 10.1210/en.138.11.5028; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Rosenquist M, 2000, J MOL EVOL, V51, P446, DOI 10.1007/s002390010107; Savory JGA, 1999, MOL CELL BIOL, V19, P1025; Tang YT, 1997, MOL BIOL CELL, V8, P795, DOI 10.1091/mbc.8.5.795; Vottero A, 1999, TRENDS ENDOCRIN MET, V10, P333, DOI 10.1016/S1043-2760(99)00179-4; Wakui H, 1997, J BIOL CHEM, V272, P8153, DOI 10.1074/jbc.272.13.8153; Widen C, 2000, J BIOL CHEM, V275, P39296, DOI 10.1074/jbc.M006943200; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	41	63	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25651	25656		10.1074/jbc.M302818200	http://dx.doi.org/10.1074/jbc.M302818200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730237	hybrid			2022-12-25	WOS:000183920200048
J	Mendoza, HM; Shen, LN; Botting, C; Lewis, A; Chen, JW; Ink, B; Hay, RT				Mendoza, HM; Shen, LN; Botting, C; Lewis, A; Chen, JW; Ink, B; Hay, RT			NEDP1, a highly conserved cysteine protease that deNEDDylates Cullins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIGASE; COP9 SIGNALOSOME; NEDD8 CONJUGATION; CRYSTAL-STRUCTURE; CELL-CYCLE; YEAST; CLEAVAGE; SCF; IDENTIFICATION; ISOPEPTIDASE	The ubiquitin-like protein NEDD8 is essential for activity of SCF-like ubiquitin ligase complexes. Here we identify and characterize NEDP1, a human NEDD8-specific protease. NEDP1 is highly conserved throughout evolution and equivalent proteins are present in yeast, plants, insects, and mammals. Bacterially expressed NEDP1 is capable of processing NEDD8 in vitro to expose the diglycine motif required for conjugation and can deconjugate NEDD8 from modified substrates. NEDP1 appears to be specific for NEDD8 as neither ubiquitin nor SUMO bearing COOH-terminal extensions are utilized as substrates. Inhibition studies and mutagenesis indicate that NEDP1 is a cysteine protease with sequence similarities to SUMO-specific proteases and the class of viral proteases typified by the adenovirus protease. In vivo NEDP1 deconjugates NEDD8 from a wide variety of substrates including the cullin component of SCF-like complexes. Thus NEDP1 is likely to play an important role in ubiquitin-mediated proteolysis by controlling the activity of SCF complexes.	Univ St Andrews, Sch Biol, Ctr Biomol Sci, St Andrews KY16 9AL, Fife, Scotland; Glaxo SmithKline, Med Res Ctr, Stevenage SG1 2NY, Herts, England; GlaxoSmithKline, Res Triangle Pk, NC 27709 USA	University of St Andrews; GlaxoSmithKline; GlaxoSmithKline	Hay, RT (corresponding author), Univ St Andrews, Sch Biol, Ctr Biomol Sci, St Andrews KY16 9AL, Fife, Scotland.		Hay, Ronald T/F-9338-2011; Hay, Ronald/S-3233-2019	Hay, Ronald T/0000-0001-7113-9024; Hay, Ronald/0000-0001-7113-9024				Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; Chen YZ, 2000, J BIOL CHEM, V275, P8929, DOI 10.1074/jbc.275.12.8929; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; del Pozo JC, 1999, P NATL ACAD SCI USA, V96, P15342, DOI 10.1073/pnas.96.26.15342; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Ding JZ, 1996, EMBO J, V15, P1778, DOI 10.1002/j.1460-2075.1996.tb00526.x; Furukawa M, 2000, MOL CELL BIOL, V20, P8185, DOI 10.1128/MCB.20.21.8185-8197.2000; Gong LM, 2000, J BIOL CHEM, V275, P14212, DOI 10.1074/jbc.275.19.14212; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hochstrasser M, 2002, SCIENCE, V298, P549, DOI 10.1126/science.1078097; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Nishida T, 2001, J BIOL CHEM, V276, P39060, DOI 10.1074/jbc.M103955200; Osaka F, 2000, EMBO J, V19, P3475, DOI 10.1093/emboj/19.13.3475; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Schwechheimer C, 2001, TRENDS CELL BIOL, V11, P420, DOI 10.1016/S0962-8924(01)02091-8; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Wada H, 1998, BIOCHEM BIOPH RES CO, V251, P688, DOI 10.1006/bbrc.1998.9532; Wada H, 1999, BIOCHEM BIOPH RES CO, V257, P100, DOI 10.1006/bbrc.1999.0339; Wada H, 1999, J BIOL CHEM, V274, P36025, DOI 10.1074/jbc.274.50.36025	29	146	150	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25637	25643		10.1074/jbc.M212948200	http://dx.doi.org/10.1074/jbc.M212948200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730221	hybrid			2022-12-25	WOS:000183920200046
J	Sakoda, H; Gotoh, Y; Katagiri, H; Kurokawa, M; Ono, H; Onishi, Y; Anai, M; Ogihara, T; Fujishiro, M; Fukushima, Y; Abe, M; Shojima, N; Kikuchi, M; Oka, Y; Hirai, H; Asano, T				Sakoda, H; Gotoh, Y; Katagiri, H; Kurokawa, M; Ono, H; Onishi, Y; Anai, M; Ogihara, T; Fujishiro, M; Fukushima, Y; Abe, M; Shojima, N; Kikuchi, M; Oka, Y; Hirai, H; Asano, T			Differing roles of Akt and serum- and glucocorticoid-regulated kinase in glucose metabolism, DNA synthesis, and oncogenic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; INDUCED INSULIN-RESISTANCE; NF-KAPPA-B; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CONSTITUTIVE ACTIVATION; 3T3-L1 ADIPOCYTES; INDUCIBLE KINASE; HOMOLOGY DOMAIN; TRANSLOCATION	Serum- and glucocorticoid-regulated kinase (SGK) is a serine kinase that has a catalytic domain homologous to that of Akt, but lacks the pleckstrin homology domain present in Akt. Akt reportedly plays a key role in various cellular actions, including glucose transport, glycogen synthesis, DNA synthesis, anti-apoptotic activity, and cell proliferation. In this study, we attempted to reveal the different roles of SGK and Akt by overexpressing active mutants of Akt and SGK. We found that adenovirus-mediated overexpression of myristoylated ( myr-) forms of Akt resulted in high glucose transport activity in 3T3-L1 adipocytes, phosphorylated glycogen synthase kinase-3 (GSK3) and enhanced glycogen synthase activity in hepatocytes, and the promotion of DNA synthesis in interleukin-3-dependent 32D cells. In addition, stable transfection of myr- Akt in NIH3T3 cells induced an oncogenic transformation in soft agar assays. The active mutant of SGK (D-SGK, substitution of Ser(422) with Asp) and myr- SGK were shown to phosphorylate GSK3 and to enhance glycogen synthase activity in hepatocytes in a manner very similar to that observed for myr- Akt. However, despite the comparable degree of GSK3 phosphorylation between myr- Akt and D-SGK or myr- SGK, D-SGK and myr- SGK failed to enhance glucose transport activity in 3T3-L1 cells, DNA synthesis in 32D cells, and oncogenic transformation in NIH3T3 cells. Therefore, the different roles of SGK and Akt cannot be attributed to ability or inability to translocate to the membrane thorough the pleckstrin homology domain, but rather must be attributable to differences in the relatively narrow substrate specificities of these kinases. In addition, our observations strongly suggest that phosphorylation of GSK3 is either not involved in or not sufficient for GLUT4 translocation, DNA synthesis, or oncogenic transformation. Thus, the identification of substrates selectively phosphorylated by Akt, but by not SGK, may provide clues to clarifying the pathway leading from Akt activation to these cellular activities.	Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, Tokyo 113, Japan; Asahi Life Fdn, Inst Adult Dis, Shinjuku Ku, Tokyo 116, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Dept Biol Mol, Bunkyo Ku, Tokyo 1130032, Japan; Tohoku Univ, Grad Sch Med, Dept Internal Med, Div Mol Metab & Diabet,Aoba Ku, Sendai, Miyagi 9808575, Japan	University of Tokyo; Asahi Life Foundation; University of Tokyo; Tohoku University	Asano, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.	asano-tky@umin.ac.jp	Onishi, Yukiko/AAU-9057-2021	Onishi, Yukiko/0000-0003-1180-5982				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Bhargava A, 2001, ENDOCRINOLOGY, V142, P1587, DOI 10.1210/en.142.4.1587; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brady MJ, 1999, J BIOL CHEM, V274, P27497, DOI 10.1074/jbc.274.39.27497; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Foster LJ, 2001, J BIOL CHEM, V276, P44212, DOI 10.1074/jbc.M102964200; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Glowacki J, 1998, CELL TRANSPLANT, V7, P319, DOI 10.1016/S0963-6897(98)00003-7; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; KAHN CR, 1993, HORM RES, V39, P93, DOI 10.1159/000182793; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kurokawa M, 1996, J BIOL CHEM, V271, P16870, DOI 10.1074/jbc.271.28.16870; Kurokawa M, 1998, BLOOD, V92, P4003, DOI 10.1182/blood.V92.11.4003.423a56_4003_4012; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Mizuno H, 2001, GENES CELLS, V6, P261, DOI 10.1046/j.1365-2443.2001.00418.x; Ogihara T, 2002, HYPERTENSION, V40, P872, DOI 10.1161/01.HYP.0000040262.48405.A8; Ozes ON, 1999, NATURE, V401, P82; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Sable CL, 1998, J BIOL CHEM, V273, P29600, DOI 10.1074/jbc.273.45.29600; Sakoda H, 2000, DIABETES, V49, P1700, DOI 10.2337/diabetes.49.10.1700; Sakoda H, 1999, DIABETES, V48, P1365, DOI 10.2337/diabetes.48.7.1365; Sakoda H, 2002, AM J PHYSIOL-ENDOC M, V282, pE1239, DOI 10.1152/ajpendo.00455.2001; Somervaille TCP, 2001, BLOOD, V98, P1374, DOI 10.1182/blood.V98.5.1374; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Verrey F, 1999, AM J PHYSIOL-RENAL, V277, pF319, DOI 10.1152/ajprenal.1999.277.3.F319; Virbasius JV, 2001, P NATL ACAD SCI USA, V98, P12908, DOI 10.1073/pnas.221352898; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang QH, 1999, MOL CELL BIOL, V19, P4008; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; Welch H, 1998, J BIOL CHEM, V273, P11248, DOI 10.1074/jbc.273.18.11248	49	105	110	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25802	25807		10.1074/jbc.M301127200	http://dx.doi.org/10.1074/jbc.M301127200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12734207	hybrid			2022-12-25	WOS:000183920200067
J	Watanabe, N; Wachi, S; Fujita, T				Watanabe, N; Wachi, S; Fujita, T			Identification and characterization of BCL-3-binding protein - Implications for transcription and DNA repair or recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANDIDATE PROTOONCOGENE BCL-3; KAPPA-B PROTEIN; MISMATCH REPAIR; TARGETED DISRUPTION; MICE DEFICIENT; CELL-SURVIVAL; EXPRESSION; ONCOPROTEIN; COACTIVATOR; HOMODIMERS	A putative oncogene bcl-3 was originally identified and cloned at the breakpoint in the recurring chromosome translocation t(14;19) found in some cases of B cell chronic lymphocytic leukemia. Studies of bcl-3-deficient mice demonstrated a critical role for bcl-3 in the development of a normal immune response and the formation of germinal centers in secondary lymphoid organs. However, the molecular mechanism that underlies B cell leukemogenesis and the knockout mouse phenotype remains unclear. Here we have identified and characterized BCL-3-binding protein (B3BP) as a protein interacting specifically with the bcl-3 gene product (BCL-3) by a yeast two-hybrid screen. We found that B3BP associates with not only BCL-3 but also p300/CBP histone acetyl-transferases. The N-terminal region of B3BP that contains the ATP-binding site is important for the interaction with BCL-3 and p300/CBP. Homology searches indicate that the ATP-binding region of B3BP, which contains a typical Walker-type ATP-binding P-loop, most resembles that of 2',3'-cyclic nucleotide 3'-phosphodiesterase of mammals and polynucleotide kinase of T4 bacteriophage. In fact B3BP shows intrinsic ATP binding and hydrolyzing activity. Furthermore, we demonstrated that B3BP is a 5'-polynucleotide kinase. We also found a small MutS-related domain, which is thought to be involved in the DNA repair or recombination reaction, in the C-terminal region of B3BP, and it shows nicking endonuclease activity. These observations might help to gain new insights into the function of BCL-3 and p300/CBP, especially the coupling of transcription with repair or recombination.	Tokyo Metropolitan Inst Med Sci, Dept Tumor Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan	Tokyo Metropolitan Institute of Medical Science	Fujita, T (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Tumor Cell Biol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	fujita@rinshoken.or.jp						AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; Boulton SJ, 2002, SCIENCE, V295, P127, DOI 10.1126/science.1065986; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Feng X, 2001, J BIOL CHEM, V276, P15066, DOI 10.1074/jbc.M011027200; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Franzoso G, 1997, IMMUNITY, V6, P479, DOI 10.1016/S1074-7613(00)80291-5; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Hasan S, 2001, NATURE, V410, P387, DOI 10.1038/35066610; Hildeman DA, 2002, CURR OPIN IMMUNOL, V14, P354, DOI 10.1016/S0952-7915(02)00335-7; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; Leadon SA, 1998, MUTAT RES-DNA REPAIR, V407, P177, DOI 10.1016/S0921-8777(98)00007-X; Malik HS, 2000, TRENDS BIOCHEM SCI, V25, P414, DOI 10.1016/S0968-0004(00)01623-6; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; Martin A, 2002, NAT REV IMMUNOL, V2, P605, DOI 10.1038/nri858; Michel F, 2001, EMBO J, V20, P6180, DOI 10.1093/emboj/20.22.6180; Mitchell TC, 2001, NAT IMMUNOL, V2, P397, DOI 10.1038/87692; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moreira D, 1999, TRENDS BIOCHEM SCI, V24, P298, DOI 10.1016/S0968-0004(99)01419-X; Murillas R, 2002, J BIOL CHEM, V277, P2897, DOI 10.1074/jbc.M110047200; Na SY, 1998, J BIOL CHEM, V273, P30933, DOI 10.1074/jbc.273.47.30933; Na SY, 1999, J BIOL CHEM, V274, P28491, DOI 10.1074/jbc.274.40.28491; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; Ong ST, 1998, ONCOGENE, V16, P2333, DOI 10.1038/sj.onc.1201771; Paxian S, 2002, GASTROENTEROLOGY, V122, P1853, DOI 10.1053/gast.2002.33651; Poljak L, 1999, J IMMUNOL, V163, P6581; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; Richard M, 1999, BLOOD, V93, P4318, DOI 10.1182/blood.V93.12.4318.412k09_4318_4327; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Schwarz EM, 1997, GENE DEV, V11, P187, DOI 10.1101/gad.11.2.187; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Suhara W, 2002, J BIOL CHEM, V277, P22304, DOI 10.1074/jbc.M200192200; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; Tini M, 2002, MOL CELL, V9, P265, DOI 10.1016/S1097-2765(02)00453-7; Wang LK, 2001, J BIOL CHEM, V276, P26868, DOI 10.1074/jbc.M103663200; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Zhang MY, 1998, BLOOD, V92, P1225, DOI 10.1182/blood.V92.4.1225.416k20_1225_1234	45	33	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26102	26110		10.1074/jbc.M303518200	http://dx.doi.org/10.1074/jbc.M303518200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730195	hybrid			2022-12-25	WOS:000183920200108
J	Yang, CC; Lin, HP; Chen, CS; Yang, YT; Tseng, PH; Rangnekar, VM; Chen, CS				Yang, CC; Lin, HP; Chen, CS; Yang, YT; Tseng, PH; Rangnekar, VM; Chen, CS			Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; TUMOR-SUPPRESSOR; CARCINOMA-CELLS; PHOSPHATIDYLINOSITOL 3'-KINASE; FREQUENT INACTIVATION; CASPASE ACTIVATION; SIGNALING PATHWAYS; INDUCED APOPTOSIS; GROWTH; OVEREXPRESSION	Among various molecular strategies by which prostate cancer cells evade apoptosis, phosphoinositide 3-kinase (PI3K)/Akt signaling represents a dominant survival pathway. However, different prostate cancer cell lines such as LNCaP and PC-3 display differential sensitivity to the apoptotic effect of PI3K inhibition in serum-free media, reflecting the heterogeneous nature of prostate cancer in apoptosis regulation. Whereas both cell lines are equally susceptible to LY294002-mediated Akt dephosphorylation, only LNCaP cells default to apoptosis, as evidenced by DNA fragmentation and cytochrome c release. In PC-3 cells, Akt deactivation does not lead to cytochrome c release, suggesting that the intermediary signaling pathway is short-circuited by an antiapoptotic factor. This study presents evidence that Bcl-xL overexpression provides a distinct survival mechanism that protects PC-3 cells from apoptotic signals emanating from PI3K inhibition. First, the Bcl-xL/ BAD ratio in PC-3 cells is at least an order of magnitude greater than that of LNCaP cells. Second, ectopic expression of Bcl-xL protects LNCaP cells against LY294002-induced apoptosis. Third, antisense down-regulation of Bcl-xL sensitizes PC-3 cells to the apoptotic effect of LY294002. The physiological relevance of this Bcl-xL-mediated survival mechanism is further underscored by the protective effect of serum on LY294002-induced cell death in LNCaP cells, which is correlated with a multifold increase in Bcl-xL expression. In contrast to Bcl-xL, Bcl-2 expression levels are similar in both cells lines, and do not respond to serum stimulation, suggesting that Bcl-2 may not play a physiological role in antagonizing apoptosis signals pertinent to BAD activation in prostate cancer cells.	Ohio State Univ, Coll Pharm, Div Med Chem & Pharmacognosy, Columbus, OH 43210 USA; Univ Kentucky, Dept Radiat Med, Lexington, KY 40536 USA	University System of Ohio; Ohio State University; University of Kentucky	Chen, CS (corresponding author), Ohio State Univ, Coll Pharm, Div Med Chem & Pharmacognosy, Parks Hall,Rm 336,500 W 12th Ave, Columbus, OH 43210 USA.	chen.844@osu.edu			NATIONAL CANCER INSTITUTE [R01CA094829] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053448] Funding Source: NIH RePORTER; NCI NIH HHS [CA94829] Funding Source: Medline; NIGMS NIH HHS [GM53448] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barton J, 2001, UROLOGY, V58, P114, DOI 10.1016/S0090-4295(01)01253-5; Beresford SA, 2001, J INTERF CYTOK RES, V21, P313, DOI 10.1089/107999001300177501; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cairns P, 1997, CANCER RES, V57, P4997; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carson JP, 1999, CANCER RES, V59, P1449; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; Ciardiello F, 2000, DRUGS, V60, P25, DOI 10.2165/00003495-200060001-00003; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davies MA, 1999, CANCER RES, V59, P2551; DEL PL, 1997, SCIENCE, V278, P687; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Herrmann JL, 1997, EXP CELL RES, V234, P442, DOI 10.1006/excr.1997.3653; Lebedeva I, 2000, CANCER RES, V60, P6052; Li XY, 2001, CANCER RES, V61, P1699; Lin JQ, 1999, CANCER RES, V59, P2891; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Okuma E, 2000, LEUKEMIA, V14, P612, DOI 10.1038/sj.leu.2401716; Page C, 2000, ANTICANCER RES, V20, P407; Pesche S, 1998, ONCOGENE, V16, P2879, DOI 10.1038/sj.onc.1202081; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RAFFO AJ, 1995, CANCER RES, V55, P4438; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Storz P, 2002, FRONT BIOSCI-LANDMRK, V7, pD886, DOI 10.2741/storz; Tang DG, 1998, CANCER RES, V58, P3466; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	37	53	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25872	25878		10.1074/jbc.M301744200	http://dx.doi.org/10.1074/jbc.M301744200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12738789	hybrid			2022-12-25	WOS:000183920200077
J	Helmers, J; Schmidt, D; Glavy, JS; Blobel, G; Schwartz, T				Helmers, J; Schmidt, D; Glavy, JS; Blobel, G; Schwartz, T			The beta-subunit of the protein-conducting channel of the endoplasmic reticulum functions as the guanine nucleotide exchange factor for the beta-subunit of the signal recognition particle receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; STRUCTURAL BASIS; GTP HYDROLYSIS; ALPHA-SUBUNIT; COMPLEX; TRANSLOCATION; RIBOSOME; MEMBRANE; TRANSPORT; DOMAIN	Cotranslational protein transport to the endoplasmic reticulum is controlled by the concerted interaction of three GTPases: the SRP54 subunit of the signal recognition particle (SRP) and the alpha- and beta-subunits of the SRP receptor (SR). SRbeta is related to ADP-ribosylation factor (ARF)-type GTPases, and the recently published crystal structure of SRbeta-GTP in complex with the binding domain of SRalpha suggested that SRbeta, like all ARF-type GTPases, requires a guanine nucleotide exchange factor (GEF) for function. Searching the sequence data base, we identified significant sequence similarity between the Sec7 domain of ARF-GEFs and the cytosolic domains of the beta-subunits of the two homologous heterotrimeric protein-conducting channels in yeast. Using a fluorescence nucleotide exchange assay, we show that the beta-subunits of the heterotrimeric protein-conducting channels function as the GEFs for SRbeta. Both the cytosolic domain of Sec61beta as well as the holo-Sec61beta, when part of the isolated trimeric Sec61p complex, function as the GEF for SRbeta, whereas the same Sec61beta, when part of the heptameric complex that facilitates posttranslational protein transport, is inactive as the GEF for SRbeta.	Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	Helmers, J (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, 1230 York Ave,Box 168, New York, NY 10021 USA.		Schwartz, Thomas/ABA-1770-2021; Schwartz, Thomas/K-9029-2017	Schwartz, Thomas/0000-0001-8012-1512; Schwartz, Thomas/0000-0001-8012-1512; Glavy, Joseph/0000-0003-3716-3965	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM020520] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32 GM020520] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bacher G, 1999, J CELL BIOL, V146, P723, DOI 10.1083/jcb.146.4.723; Bacher G, 1996, NATURE, V381, P248, DOI 10.1038/381248a0; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; Freymann DM, 1997, NATURE, V385, P361, DOI 10.1038/385361a0; Fulga TA, 2001, EMBO J, V20, P2338, DOI 10.1093/emboj/20.9.2338; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Kalies KU, 1998, J CELL BIOL, V141, P887, DOI 10.1083/jcb.141.4.887; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; MILLER JD, 1995, J CELL BIOL, V128, P273, DOI 10.1083/jcb.128.3.273; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; Montoya G, 1997, PROTEINS, V28, P285, DOI 10.1002/(SICI)1097-0134(199706)28:2<285::AID-PROT15>3.0.CO;2-E; Ogg SC, 1998, J CELL BIOL, V142, P341, DOI 10.1083/jcb.142.2.341; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; Rapiejko PJ, 1997, CELL, V89, P703, DOI 10.1016/S0092-8674(00)80253-6; Schwartz T, 2003, CELL, V112, P793, DOI 10.1016/S0092-8674(03)00161-2; Song WQ, 2000, CELL, V100, P333, DOI 10.1016/S0092-8674(00)80669-8; Toikkanen J, 1996, YEAST, V12, P425, DOI 10.1002/(SICI)1097-0061(199604)12:5<425::AID-YEA924>3.3.CO;2-2; Wittke S, 2002, MOL BIOL CELL, V13, P2223, DOI 10.1091/mbc.01-10-0518; YOUNG JC, 1995, J BIOL CHEM, V270, P15650, DOI 10.1074/jbc.270.26.15650	26	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23686	23690		10.1074/jbc.C300180200	http://dx.doi.org/10.1074/jbc.C300180200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12750387	hybrid			2022-12-25	WOS:000183638600061
J	Wang, QF; Cleaves, R; Kummalue, T; Nerlov, C; Friedman, AD				Wang, QF; Cleaves, R; Kummalue, T; Nerlov, C; Friedman, AD			Cell cycle inhibition mediated by the outer surface of the C/EBP alpha basic region is required but not sufficient for granulopoiesis	ONCOGENE			English	Article						C/EBP alpha; E2F; granulopoiesis; cell cycle; differentiation	ENHANCER-BINDING-PROTEIN; SERUM-ALBUMIN GENE; C-MYB; GRANULOCYTE DIFFERENTIATION; TRANSCRIPTIONAL ACTIVATION; MYELOID-LEUKEMIA; NUCLEAR-PROTEIN; GROWTH ARREST; PROLIFERATION; EXPRESSION	CCAAT/enhancer binding protein alpha (C/EBPalpha) transactivates target genes dependent upon DNA binding via its basic region-leucine zipper domain and slows G1 progression by interaction with E2F, cdk2, or cdk4. E2F interacts with the non-DNA-binding surface of the C/EBPalpha basic region and C/EBPa residues 1-70 are required for repressing E2F targets, while cdk2 and cdk4 bind residues 177-191. C/EBPalpha-ER induces the 32D c13 myeloblast cell line to differentiate to granulocytes. C/EBPalpha-ER variants incapable of binding DNA slowed G1, but did not induce early or late granulopoiesis, indicating that cell cycle inhibition as mediated by C/EBPalpha is not sufficient for differentiation. C/EBPalpha-ER variants lacking residues 1170 or residues 11-70 and 178-200 both slowed the G1 to S transition. C/EBPalpha(GZ)-ER, containing the GCN4 rather than the C/EBPalpha leucine zipper, also slowed G1. In contrast, C/EBPalpha(BRM2)-ER, carrying mutations in the outer surface of the basic region required for interaction with E2F, did not slow G1. C/EBPalpha:(BRM2)-ER induced early markers of granulopoiesis much less efficiently than C/EBPalpha-ER and did not direct terminal maturation. Inhibition of G1 progression using mimosine increased induction of late markers by G-CSF. Thus, both DNA binding and cell cycle arrest, mediated by opposite surfaces of the C/EBPalpha basic region, are required for granulopoiesis.	Johns Hopkins Univ, Div Pediat Oncol, Baltimore, MD 21231 USA; European Mol Biol Lab, I-00016 Monterotondo, Italy	Johns Hopkins University; European Molecular Biology Laboratory (EMBL)	Friedman, AD (corresponding author), Johns Hopkins Univ, Div Pediat Oncol, Canc Res Bldg,Room 253,1650 Orleans St, Baltimore, MD 21231 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062274] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL62274, HL62274] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; ANTONSON P, 1995, BIOCHEM BIOPH RES CO, V215, P105; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; Friedman AD, 2002, J CELL BIOCHEM, V86, P624, DOI 10.1002/jcb.10271; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; Muller C, 1999, P NATL ACAD SCI USA, V96, P7276, DOI 10.1073/pnas.96.13.7276; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; SCOTT LM, 1992, BLOOD, V80, P1725; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Strom DK, 1998, CELL GROWTH DIFFER, V9, P59; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Wang G, 2000, EXP CELL RES, V254, P64, DOI 10.1006/excr.1999.4743; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang QF, 2002, BLOOD, V99, P2776, DOI 10.1182/blood.V99.8.2776; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	43	41	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2548	2557		10.1038/sj.onc.1206360	http://dx.doi.org/10.1038/sj.onc.1206360			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730669				2022-12-25	WOS:000182569000002
J	Gronlund, H; Bergman, T; Sandstrom, K; Alvelius, G; Reininger, R; Verdino, P; Hauswirth, A; Liderot, K; Valent, P; Spitzauer, S; Keller, W; Valenta, R; van Hage-Hamsten, M				Gronlund, H; Bergman, T; Sandstrom, K; Alvelius, G; Reininger, R; Verdino, P; Hauswirth, A; Liderot, K; Valent, P; Spitzauer, S; Keller, W; Valenta, R; van Hage-Hamsten, M			Formation of disulfide bonds and homodimers of the major cat allergen Fel d 1 equivalent to the natural allergen by expression in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FEL-D-I; OVERLAPPING SYNTHETIC PEPTIDES; DOG-DANDER EXTRACTS; DOMESTIC CAT; MONOCLONAL-ANTIBODIES; SEQUENCE-ANALYSIS; CELL EPITOPES; HUMAN INSULIN; AMINO-ACID; C-PEPTIDE	Dander from the domestic cat (Felis domesticus) is one of the most common causes of IgE-mediated allergy. Attempts to produce tetrameric folded major allergen Fel d 1 by recombinant methods with structural features similar to the natural allergen have been only partially successful. In this study, a recombinant folded Fel d 1 with molecular and biological properties similar to the natural counterpart was produced. A synthetic gene coding for direct fusion of the Fel d 1 chain 2 N-terminally to chain 1 was constructed by overlapping oligonucleotides in PCR. Escherichia coli expression resulted in a non-covalently associated homodimer with an apparent molecular mass of 30 kDa defined by size exclusion chromatography. Furthermore, each 19,177-Da subunit displayed a disulfide pattern identical to that found in the natural Fel d 1, i.e. Cys(3)(1)-Cys(73)(2), Cys(44)(1)-Cys(48)(2), Cys(70)(1)-Cys(7)(2), as determined by electrospray mass spectrometry after tryptic digestion. Circular dichroism analysis showed identical folds of natural and recombinant Fel d 1. Furthermore, recombinant Fel d l reacted specifically with serum IgE, inducing expression of CD203c on basophils and lymphoproliferative responses in cat-allergic patients. The results show that the overall fold and immunological properties of the recombinant Fel d 1 are very similar to those of natural Fel d 1. Moreover, the recombinant Fel d 1 construct provides a tool for defining the three-dimensional structure of Fel d 1 and represents a reagent for diagnosis and allergen-specific immunotherapy of cat allergy.	Karolinska Inst, Allergy & Clin Immunol Unit, S-17176 Stockholm, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, S-17176 Stockholm, Sweden; Royal Inst Technol, Dept Biotechnol, S-10691 Stockholm, Sweden; Karl Franzens Univ Graz, Inst Chem, Div Struct Biol, A-8010 Graz, Austria; Univ Vienna, Vienna Gen Hosp, Dept Pathophysiol, A-1090 Vienna, Austria; Univ Vienna, Dept Internal Med, Div Hematol, A-1090 Vienna, Austria; Univ Vienna, Clin Inst Med & Chem Lab Diagnost, A-1090 Vienna, Austria	Karolinska Institutet; Karolinska Institutet; Royal Institute of Technology; University of Graz; University of Vienna; University of Vienna; University of Vienna	Gronlund, H (corresponding author), Karolinska Inst, Allergy & Clin Immunol Unit, S-17176 Stockholm, Sweden.		Test, Test/Y-7921-2019; Test, PV/U-9451-2019; Keller, Walter/AAW-1501-2021; Valent, Peter/B-8533-2016; Gamperl, Susi/V-2715-2019; van Hage, Marianne/A-9678-2017	Keller, Walter/0000-0002-2261-958X; Valent, Peter/0000-0003-0456-5095; Gamperl, Susi/0000-0003-0456-5095; van Hage, Marianne/0000-0003-3091-1596; Gronlund, Hans/0000-0003-4882-7624; Valenta, Rudolf/0000-0001-5944-3365				Ausubel FM, 1998, CURRENT PROTOCOLS MO; Batard T, 2000, J ALLERGY CLIN IMMUN, V106, P669, DOI 10.1067/mai.2000.110227; BEIER HM, 1968, BIOCHIM BIOPHYS ACTA, V160, P289, DOI 10.1016/0005-2795(68)90108-6; BOND JF, 1993, MOL IMMUNOL, V30, P1529, DOI 10.1016/0161-5890(93)90461-J; BROWN PR, 1984, INT ARCH ALLER A IMM, V74, P67, DOI 10.1159/000233518; CastellanosSerra LR, 1996, FEBS LETT, V378, P171, DOI 10.1016/0014-5793(95)01437-3; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Counsell CM, 1996, J ALLERGY CLIN IMMUN, V98, P884, DOI 10.1016/S0091-6749(96)80004-2; DEGROOT H, 1990, J ALLERGY CLIN IMMUN, V86, P107, DOI 10.1016/S0091-6749(05)80130-7; DELEAGE G, 1993, COMPUT APPL BIOSCI, V9, P197; DUFFORT OA, 1991, MOL IMMUNOL, V28, P301, DOI 10.1016/0161-5890(91)90141-6; GRIFFITH IJ, 1992, GENE, V113, P263, DOI 10.1016/0378-1119(92)90405-E; Hauswirth AW, 2002, J ALLERGY CLIN IMMUN, V110, P102, DOI 10.1067/mai.2002.125257; HEDLIN G, 1991, J ALLERGY CLIN IMMUN, V87, P955, DOI 10.1016/0091-6749(91)90417-M; Ichikawa K, 1999, CLIN EXP ALLERGY, V29, P754; Ichikawa K, 2001, INT ARCH ALLERGY IMM, V124, P55, DOI 10.1159/000053667; KEATING KM, 1995, MOL IMMUNOL, V32, P287, DOI 10.1016/0161-5890(94)00140-V; Kristensen AK, 1997, BIOL CHEM, V378, P899; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; LILJA G, 1989, J ALLERGY CLIN IMMUN, V83, P37, DOI 10.1016/0091-6749(89)90475-2; LOWENSTEIN H, 1985, ALLERGY, V40, P430, DOI 10.1111/j.1398-9995.1985.tb02682.x; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; Nilsson J, 1996, J BIOTECHNOL, V48, P241, DOI 10.1016/0168-1656(96)01514-3; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; Nygren P A, 1988, J Mol Recognit, V1, P69, DOI 10.1002/jmr.300010204; OHMAN JL, 1974, J IMMUNOL, V113, P1668; OHMAN JL, 1983, J ALLERGY CLIN IMMUN, V72, P288, DOI 10.1016/0091-6749(83)90033-7; OHMAN JL, 1977, J ALLERGY CLIN IMMUN, V60, P317, DOI 10.1016/0091-6749(77)90112-9; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Ring PC, 2000, CLIN EXP ALLERGY, V30, P1085; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Schmidt M, 1999, J BIOTECHNOL, V68, P71, DOI 10.1016/S0168-1656(98)00189-8; Scopes R. K, 1994, PROTEIN PURIFICATION, V3rd, DOI 10.1007/978-1-4757-2333-5; SINGH G, 1988, BIOCHIM BIOPHYS ACTA, V950, P329, DOI 10.1016/0167-4781(88)90129-7; SLUNT JB, 1995, J ALLERGY CLIN IMMUN, V95, P1221, DOI 10.1016/S0091-6749(95)70079-X; VAILES LD, 1994, J ALLERGY CLIN IMMUN, V93, P22, DOI 10.1016/0091-6749(94)90229-1; Vailes LD, 2002, J ALLERGY CLIN IMMUN, V110, P757, DOI 10.1067/mai.2002.129035; van Ree R, 1999, J ALLERGY CLIN IMMUN, V104, P1223, DOI 10.1016/S0091-6749(99)70017-5; VANMILLIGEN FJ, 1994, J ALLERGY CLIN IMMUN, V93, P34, DOI 10.1016/0091-6749(94)90230-5; VANMILLIGEN FJ, 1990, INT ARCH ALLER A IMM, V92, P375, DOI 10.1159/000235168; VANTHOF W, 1993, ALLERGY, V48, P255	42	69	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40144	40151		10.1074/jbc.M301416200	http://dx.doi.org/10.1074/jbc.M301416200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12732623	hybrid			2022-12-25	WOS:000185713800107
J	McKinney, MK; Cravatt, BF				McKinney, MK; Cravatt, BF			Evidence for distinct roles in catalysis for residues of the serine-serine-lysine catalytic triad of fatty acid amide hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-ASSISTED CATALYSIS; MOLECULAR CHARACTERIZATION; HUMAN ACETYLCHOLINESTERASE; NITRILE HYDRATASE; ENZYME; MECHANISM; CLONING; GENE; PURIFICATION; HYDROLYSIS	Fatty acid amide hydrolase ( FAAH) is a mammalian amidase signature enzyme that inactivates neuromodulatory fatty acid amides, including the endogenous cannabinoid anandamide and the sleep-inducing substance oleamide. The recent determination of the three-dimensional structures of FAAH and two distantly related bacterial amidase signature enzymes indicates that these enzymes employ an unusual serine-serine-lysine triad for catalysis ( Ser-241/Ser-217/Lys-142 in FAAH). Mutagenesis of each of the triad residues in FAAH has been shown to severely reduce amidase activity; however, how these residues contribute, both individually and in cooperation, to catalysis remains unclear. Here, through a combination of site-directed mutagenesis, enzyme kinetics, and chemical labeling experiments, we provide evidence that each FAAH triad residue plays a distinct role in catalysis. In particular, the mutation of Lys-142 to alanine indicates that this residue functions as both a base involved in the activation of the Ser-241 nucleophile and an acid that participates in the protonation of the substrate leaving group. This latter property appears to support the unusual ability of FAAH to hydrolyze amides and esters at equivalent rates. Interestingly, although structural evidence indicates that the impact of Lys-142 on catalysis probably occurs through the bridging Ser-217, the mutation of this latter residue to alanine impaired catalytic activity but left the amide/ ester hydrolysis ratios of FAAH intact. Collectively, these findings suggest that FAAH possesses a specialized active site structure dedicated to a mechanism for competitive amide and ester hydrolysis where nucleophile attack and leaving group protonation occur in a coordinated manner dependent on Lys-142.	Scripps Res Inst, Skaggs Inst Chem Biol, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, Dept Chem, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Cravatt, BF (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, Dept Cell Biol, La Jolla, CA 92037 USA.				NIDA NIH HHS [R01 DA013173-03, DA13173] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA013173] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BENDER ML, 1962, J AM CHEM SOC, V84, P2540, DOI 10.1021/ja00872a018; Boshoff HIM, 1998, J BACTERIOL, V180, P5809, DOI 10.1128/JB.180.22.5809-5814.1998; Bracey MH, 2002, SCIENCE, V298, P1793, DOI 10.1126/science.1076535; BRANDT KG, 1967, J BIOL CHEM, V242, P3973; CARTER P, 1991, BIOCHEMISTRY-US, V30, P6142, DOI 10.1021/bi00239a009; CARTER P, 1987, SCIENCE, V237, P394, DOI 10.1126/science.3299704; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; Chebrou H, 1996, BBA-PROTEIN STRUCT M, V1298, P285, DOI 10.1016/S0167-4838(96)00145-8; COREY DR, 1992, J AM CHEM SOC, V114, P1784, DOI 10.1021/ja00031a037; CRAIK CS, 1987, SCIENCE, V237, P909, DOI 10.1126/science.3303334; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; ETTINGER RA, 1995, ARCH BIOCHEM BIOPHYS, V316, P14, DOI 10.1006/abbi.1995.1003; FERSHT AR, 1971, J AM CHEM SOC, V93, P3505; Giang DK, 1997, P NATL ACAD SCI USA, V94, P2238, DOI 10.1073/pnas.94.6.2238; GOMI K, 1991, GENE, V108, P91, DOI 10.1016/0378-1119(91)90491-S; HASHIMOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1088, P225, DOI 10.1016/0167-4781(91)90058-T; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; KOBAYASHI M, 1993, EUR J BIOCHEM, V217, P327, DOI 10.1111/j.1432-1033.1993.tb18250.x; KOMIYAMA M, 1979, P NATL ACAD SCI USA, V76, P557, DOI 10.1073/pnas.76.2.557; Labahn J, 2002, J MOL BIOL, V322, P1053, DOI 10.1016/S0022-2836(02)00886-0; Lichtman AH, 2002, J PHARMACOL EXP THER, V302, P73, DOI 10.1124/jpet.302.1.73; MAYAUX JF, 1990, J BACTERIOL, V172, P6764, DOI 10.1128/jb.172.12.6764-6773.1990; Ordentlich A, 1998, J BIOL CHEM, V273, P19509, DOI 10.1074/jbc.273.31.19509; Ordentlich A, 1996, J BIOL CHEM, V271, P11953, DOI 10.1074/jbc.271.20.11953; Patricelli MP, 2000, J BIOL CHEM, V275, P19177, DOI 10.1074/jbc.M001607200; Patricelli MP, 1999, BIOCHEMISTRY-US, V38, P14125, DOI 10.1021/bi991876p; Patricelli MP, 1998, BIOCHEMISTRY-US, V37, P15177, DOI 10.1021/bi981733n; Patricelli MP, 1999, BIOCHEMISTRY-US, V38, P9804, DOI 10.1021/bi990637z; Patricelli MP, 2001, PROTEOMICS, V1, P1067, DOI 10.1002/1615-9861(200109)1:9<1067::AID-PROT1067>3.0.CO;2-4; Sako Y, 1996, INT J SYST BACTERIOL, V46, P1070, DOI 10.1099/00207713-46-4-1070; Shin S, 2002, EMBO J, V21, P2509, DOI 10.1093/emboj/21.11.2509; WALSH CT, 1979, ENZYMATIC REACTION M	34	119	122	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37393	37399		10.1074/jbc.M303922200	http://dx.doi.org/10.1074/jbc.M303922200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12734197	hybrid, Green Published			2022-12-25	WOS:000185437200050
J	Lohr, K; Moritz, C; Contente, A; Dobbelstein, M				Lohr, K; Moritz, C; Contente, A; Dobbelstein, M			p21/CDKN1A mediates negative regulation of transcription by p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; SUPPRESSOR PROTEIN P53; PROLINE-RICH DOMAIN; CELL-CYCLE ARREST; DNA-DAMAGE; TUMOR-SUPPRESSOR; RETINOBLASTOMA PROTEIN; DOWN-REGULATION; GENE-EXPRESSION; G(2) CHECKPOINT	The tumor suppressor p53 regulates transcription positively and negatively, depending on the target gene. Whereas p53 induces transcription through direct interaction with promoter DNA, the mechanism of p53-mediated transcriptional repression is less well understood. Early reports described the alleviation of p53-mediated repression by inhibitors of apoptosis, suggesting that negative regulation of transcription might occur only in conjunction with programmed cell death. More recently, it has been proposed that certain genes, such as survivin, are repressed by direct association of p53 with their promoters, followed by recruitment of a repressor complex. We show here that p53-mediated negative regulation of transcription could occur independently of apoptosis. In contrast, the amino-terminal transactivation domain of p53 was required for negative regulation of transcription. Similarly, the p53 homologue p73 diminished the expression of survivin and stathmin, depending on its transactivation domain. Mutation of the putative p53 binding site within the survivin promoter did not impair its repression. These observations raised the hypothesis that activation of an effector gene might be required for repression by p53. Strikingly, when the p53-inducible p21/CDKN1A gene was deleted, p53 no longer repressed any one among 11 genes that it downregulates otherwise. Most of these genes were also repressed by ectopic p21 in the absence of p53. Overexpressed c-Myc reduced the transcription of p21/CDKN1A and impaired p53-mediated repression but did not abolish repression by ectopic p21. Taken together, these results strongly suggest that increased expression of p21/CDKN1A is necessary and sufficient for the negative regulation of gene expression by p53.	Univ Marburg, Inst Virol, D-35037 Marburg, Germany	Philipps University Marburg	Dobbelstein, M (corresponding author), Univ Marburg, Inst Virol, Robert Koch Str 17, D-35037 Marburg, Germany.			Dobbelstein, Matthias/0000-0001-5052-3967				Ahn J, 1999, ONCOGENE, V18, P5954, DOI 10.1038/sj.onc.1202986; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Arizti P, 2000, MOL CELL BIOL, V20, P7450, DOI 10.1128/MCB.20.20.7450-7459.2000; Badie C, 2000, MOL CELL BIOL, V20, P2358, DOI 10.1128/MCB.20.7.2358-2366.2000; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 2000, GENE DEV, V14, P1584; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Cuconati A, 2002, J VIROL, V76, P4547, DOI 10.1128/JVI.76.9.4547-4558.2002; Damia G, 2001, J BIOL CHEM, V276, P10641, DOI 10.1074/jbc.M007178200; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Giodini A, 2002, CANCER RES, V62, P2462; Gottifredi V, 2001, MOL CELL BIOL, V21, P1066, DOI 10.1128/MCB.21.4.1066-1076.2001; Harris CC, 1996, CARCINOGENESIS, V17, P1187, DOI 10.1093/carcin/17.6.1187; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Johnsen JI, 2000, INT J CANCER, V88, P685, DOI 10.1002/1097-0215(20001201)88:5<685::AID-IJC1>3.0.CO;2-Z; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Koch P, 2001, CANCER RES, V61, P5941; Krause K, 2001, BIOCHEM BIOPH RES CO, V284, P743, DOI 10.1006/bbrc.2001.5040; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li BQ, 2001, J BIOL CHEM, V276, P29729, DOI 10.1074/jbc.M101167200; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; MacLachlan TK, 2000, J BIOL CHEM, V275, P31869, DOI 10.1074/jbc.M003338200; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Markey MP, 2002, CANCER RES, V62, P6587; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MULLER H, 2000, BIOCHIM BIOPHYS ACTA, V1470, P1; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Park M, 2000, CANCER RES, V60, P542; POLAGER S, 2002, J BIOL CHEM, V21, P21; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Roth J, 2000, ONCOGENE, V19, P1834, DOI 10.1038/sj.onc.1203500; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Troy CM, 1996, P NATL ACAD SCI USA, V93, P5635, DOI 10.1073/pnas.93.11.5635; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Vousden KH, 2002, CANCER CELL, V2, P351, DOI 10.1016/S1535-6108(02)00186-1; Weigel S, 2000, J VIROL, V74, P764, DOI 10.1128/JVI.74.2.764-772.2000; Wunderlich M, 2002, ONCOGENE, V21, P4414, DOI 10.1038/sj.onc.1205541; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; Zhao RB, 2000, GENE DEV, V14, P981; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	74	186	190	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32507	32516		10.1074/jbc.M212517200	http://dx.doi.org/10.1074/jbc.M212517200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12748190	hybrid			2022-12-25	WOS:000184901800006
J	Wong, CF; Barnes, LM; Dahler, AL; Smith, L; Serewko-Auret, MM; Popa, C; Abdul-Jabbar, I; Saunders, NA				Wong, CF; Barnes, LM; Dahler, AL; Smith, L; Serewko-Auret, MM; Popa, C; Abdul-Jabbar, I; Saunders, NA			E2F modulates keratinocyte squamous differentiation - Implications for E2F inhibition in squamous cell carcinoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; TRANSCRIPTION FACTOR E2F1; SKIN TUMOR-DEVELOPMENT; S-PHASE ENTRY; RETINOBLASTOMA PROTEIN; RETINOIC ACID; IN-VIVO; FUNCTIONAL-CHARACTERIZATION; TERMINAL DIFFERENTIATION; DEREGULATED EXPRESSION	E2F regulation is essential for normal cell cycle progression. Therefore, it is not surprising that squamous cell carcinoma cell lines (SCC) overexpress E2F1 and exhibit deregulated E2F activity when compared with normal keratinocytes. Indeed, deliberate E2F1 deregulation has been shown to induce hyperplasia and skin tumor formation. In this study, we report on a dual role for E2F as a mediator of keratinocyte proliferation and modulator of squamous differentiation. Overexpression of E2F isoforms in confluent primary keratinocyte cultures resulted in suppression of differentiation-associated markers. Moreover, we found that the DNA binding domain and the trans-activation domain of E2F1 are important in mediating suppression of differentiation. Use of a dominant/negative form of E2F1 ( E2F d/n) found that E2F inhibition alone is sufficient to suppress the activity of proliferation-associated markers but is not capable of inducing differentiation markers. However, if the E2F d/n is expressed in differentiated keratinocytes, differentiation marker activity is further induced, suggesting that E2F may act as a modulator of squamous differentiation. We therefore examined the effects of E2F d/n in a differentiation- insensitive SCC cell line. We found that treatment with the differentiating agent, 12-O-tetradecanoyl- phorbol-13-acetate (TPA), or expression of E2F d/n alone had no effect on differentiation markers. However, a combination of E2F d/n + TPA induced the expression of differentiation markers. Combined, these data indicate that E2F may play a key role in keratinocyte differentiation. These data also illustrate the unique potential of anti-E2F therapies in arresting proliferation and inducing differentiation of SCCs.	Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Epithelial Pathobiol Grp,Canc Biol Programme, Woolloongabba, Qld 4102, Australia; Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4067, Australia	University of Queensland; University of Queensland	Saunders, NA (corresponding author), Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Epithelial Pathobiol Grp,Canc Biol Programme, 4th Floor,Bldg 1,R Wing,Ipswich Rd, Woolloongabba, Qld 4102, Australia.		saunders, nicholas/AAJ-6101-2020; McTaggart, Jill/G-4696-2010	saunders, nicholas/0000-0002-2478-3420; McTaggart, Jill/0000-0002-9000-8529				ADAMS JC, 1988, J CELL BIOL, V107, P1927, DOI 10.1083/jcb.107.5.1927; ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; Apostolova MD, 2002, J BIOL CHEM, V277, P34471, DOI 10.1074/jbc.M205827200; BATES S, 1994, ONCOGENE, V9, P1633; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BUCK V, 1995, ONCOGENE, V11, P31; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Dahler AL, 1998, J CELL PHYSIOL, V177, P474, DOI 10.1002/(SICI)1097-4652(199812)177:3<474::AID-JCP10>3.3.CO;2-D; Dahler AL, 2001, J INVEST DERMATOL, V116, P266, DOI 10.1046/j.1523-1747.2001.01243.x; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Dicker AJ, 2000, EXP CELL RES, V258, P352, DOI 10.1006/excr.2000.4944; Dicker AJ, 2000, ONCOGENE, V19, P2887, DOI 10.1038/sj.onc.1203610; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; Gaubatz S, 2001, MOL CELL BIOL, V21, P1384, DOI 10.1128/MCB.21.4.1384-1392.2001; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V365, P468, DOI 10.1038/365468d0; Guy CT, 1996, MOL CELL BIOL, V16, P685; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; ITOH A, 1995, CELL MOL BIOL RES, V41, P147; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JETTEN AM, 1989, J INVEST DERMATOL, V93, P108, DOI 10.1111/1523-1747.ep12277374; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Jones SJ, 1997, J INVEST DERMATOL, V109, P187, DOI 10.1111/1523-1747.ep12319308; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KHANNA KK, 1995, ONCOGENE, V11, P609; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; LANE EB, 1985, ANN NY ACAD SCI, V455, P241, DOI 10.1111/j.1749-6632.1985.tb50415.x; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Mann MJ, 1999, LANCET, V354, P1493, DOI 10.1016/S0140-6736(99)09405-2; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Paramio JM, 2000, J BIOL CHEM, V275, P41219, DOI 10.1074/jbc.M004973200; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Popa C, 1999, BRIT J DERMATOL, V141, P460; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RIEGER M, 1988, J MOL BIOL, V204, P841, DOI 10.1016/0022-2836(88)90045-9; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Saunders, 1999, Expert Opin Investig Drugs, V8, P1611, DOI 10.1517/13543784.8.10.1611; Saunders NA, 1998, CANCER RES, V58, P1646; SAUNDERS NA, 1993, MOL ENDOCRINOL, V7, P387, DOI 10.1210/me.7.3.387; SAUNDERS NA, 1994, J BIOL CHEM, V269, P2016; SAUNDERS NA, 1993, BIOCHEM BIOPH RES CO, V197, P46, DOI 10.1006/bbrc.1993.2439; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000; WANG J, 1995, CELL GROWTH DIFFER, V6, P1299; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WOODWORTH CD, 1993, CELL GROWTH DIFFER, V4, P367; WU CL, 1995, MOL CELL BIOL, V15, P2536; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858; ZHANG YH, 1995, ONCOGENE, V10, P2085; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	69	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28516	28522		10.1074/jbc.M301246200	http://dx.doi.org/10.1074/jbc.M301246200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12754218	hybrid			2022-12-25	WOS:000184421100022
J	Danen-van Oorschot, AAAM; Zhang, YH; Leliveld, SR; Rohn, JL; Seelen, MCMJ; Bolk, MW; van Zon, A; Erkeland, SJ; Abrahams, JP; Mumberg, D; Noteborn, MHM				Danen-van Oorschot, AAAM; Zhang, YH; Leliveld, SR; Rohn, JL; Seelen, MCMJ; Bolk, MW; van Zon, A; Erkeland, SJ; Abrahams, JP; Mumberg, D; Noteborn, MHM			Importance of nuclear localization of apoptin for tumor-specific induction of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN ANEMIA VIRUS; CELL-DEATH; CASPASE ACTIVATION; MALIGNANT-CELLS; PROTEIN; SIGNAL; DOMAIN; EXPORT; BCL-2; IDENTIFICATION	The chicken anemia virus-derived protein Apoptin induces apoptosis specifically in human tumor and transformed cells and not in normal, untransformed cells. The cell killing activity correlates with a predominantly nuclear localization of Apoptin in tumor cells, whereas in normal cells, it is detected mainly in cytoplasmic structures. To explore the role of nuclear localization for Apoptin-induced cell death in tumor cells, we employed a mutagenesis strategy. First, we demonstrated that the C terminus of Apoptin contains a bipartite-type nuclear localization signal. Strikingly, further investigation showed that Apoptin contains two different domains that induce apoptosis independently, and for both domains, we found a strong correlation between localization and killing activity. Using inhibitors, we ruled out the involvement of de novo gene transcription and translation and further showed that Apoptin itself does not have any significant transcriptional repression activity, suggesting that Apoptin exerts its effects in the nucleus by some other method. To determine whether nuclear localization is sufficient to enable Apoptin to kill normal, untransformed cells, we expressed full-length Apoptin fused to a heterologous nuclear localization signal in these cells. However, despite its nuclear localization, no apoptosis was induced, which suggests that nuclear localization per se is not sufficient for Apoptin to become active. These studies increase our understanding of the molecular pathway of Apoptin and may also shed light on the mechanism of cellular transformation.	Leadd BV, NL-2300 RA Leiden, Netherlands; Leiden Univ, Dept Chem, NL-2333 CC Leiden, Netherlands; Leiden Univ, Med Ctr, NL-2300 RA Leiden, Netherlands; Schering AG, D-13342 Berlin, Germany	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Schering AG	Noteborn, MHM (corresponding author), Wassenaarseweg 72, NL-2333 AL Leiden, Netherlands.	m.noteborn@chem.leidenuniv.nl	Abrahams, Jan Pieter/AAE-4319-2020; Abrahams, Jan Pieter/G-7287-2016	Abrahams, Jan Pieter/0000-0001-8216-1868; Abrahams, Jan Pieter/0000-0001-8216-1868; Rohn, Jennifer/0000-0001-8766-6056; Erkeland, Stefan/0000-0002-1019-7957				Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; CAMPOS L, 1993, BLOOD, V81, P3091; COLLINS RJ, 1991, BRIT J CANCER, V64, P518, DOI 10.1038/bjc.1991.341; Danen-van Oorschot AAAM, 2000, J VIROL, V74, P7072, DOI 10.1128/JVI.74.15.7072-7078.2000; DanenVanOorschot AAAM, 1997, P NATL ACAD SCI USA, V94, P5843; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Garcia E, 1999, EMBO J, V18, P3404, DOI 10.1093/emboj/18.12.3404; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Kalkhoven E, 2002, MOL CELL BIOL, V22, P1961, DOI 10.1128/MCB.22.7.1961-1970.2002; KLEIN B, 1990, EXP CELL RES, V191, P256, DOI 10.1016/0014-4827(90)90012-Y; Lau JF, 2000, P NATL ACAD SCI USA, V97, P7278, DOI 10.1073/pnas.97.13.7278; Leliveld SR, 2003, J BIOL CHEM, V278, P9042, DOI 10.1074/jbc.M210803200; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Luo JC, 2001, ONCOGENE, V20, P1435, DOI 10.1038/sj.onc.1204228; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Noteborn Mathieu H. M., 2002, P275; NOTEBORN MHM, 1995, AVIAN PATHOL, V24, P11, DOI 10.1080/03079459508419046; NOTEBORN MHM, 1994, J VIROL, V68, P346, DOI 10.1128/JVI.68.1.346-351.1994; Noteborn MHM, 1998, MUTAT RES-FUND MOL M, V400, P447, DOI 10.1016/S0027-5107(98)00016-5; Oorschot AAAMD, 1999, LEUKEMIA, V13, pS75, DOI 10.1038/sj.leu.2401291; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Robert A, 2002, J CELL BIOL, V158, P519, DOI 10.1083/jcb.200201106; Rohn JL, 2002, J BIOL CHEM, V277, P50820, DOI 10.1074/jbc.M208557200; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; van der Eb A J, 1980, Methods Enzymol, V65, P826; WARING P, 1990, J BIOL CHEM, V265, P14476; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang YH, 1999, CANCER RES, V59, P3010; Zheng LX, 2001, J BIOL CHEM, V276, P31945, DOI 10.1074/jbc.M102799200; Zhuang SM, 1995, CARCINOGENESIS, V16, P2939, DOI 10.1093/carcin/16.12.2939; ZHUANG SM, 1995, LEUKEMIA, V9, pS118; ZHUANG SM, 1995, CANCER RES, V55, P486	42	119	123	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27729	27736		10.1074/jbc.M303114200	http://dx.doi.org/10.1074/jbc.M303114200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12754198	Green Published, hybrid			2022-12-25	WOS:000184242700051
J	Field, LS; Furukawa, Y; O'Halloran, TV; Culotta, VC				Field, LS; Furukawa, Y; O'Halloran, TV; Culotta, VC			Factors controlling the uptake of yeast copper/zinc superoxide dismutase into mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; BOVINE HEART-MITOCHONDRIA; C HEME LYASE; INTERMEMBRANE SPACE; CYTOCHROME-C; SACCHAROMYCES-CEREVISIAE; APOCYTOCHROME-C; CU,ZN-SUPEROXIDE DISMUTASE; TRANSGENIC MICE; MUTANT SOD1	We have previously shown that a fraction of yeast copper/zinc-superoxide dismutase (SOD1) and its copper chaperone CCS localize to the intermembrane space of mitochondria. In the present study, we have focused on the mechanism by which SOD1 is partitioned between cytosolic and mitochondrial pools. Using in vitro mitochondrial import assays, we show that only a very immature form of the SOD1 polypeptide that is apo for both copper and zinc can efficiently enter the mitochondria. Moreover, a conserved disulfide in SOD1 that is essential for activity must be reduced to facilitate mitochondrial uptake of SOD1. Once inside the mitochondria, SOD1 is converted to an active holo enzyme through the same post-translational modifications seen with cytosolic SOD1. The presence of high levels of CCS in the mitochondrial intermembrane space results in enhanced mitochondrial accumulation of SOD1, and this apparently involves CCS-mediated retention of SOD1 within mitochondria. This retention of SOD1 is not dependent on copper loading of the enzyme but does require protein-protein interactions at the heterodimerization interface of SOD1 and CCS as well as conserved cysteine residues in both molecules. A model for how CCS-mediated post-translational modification of SOD1 controls its partitioning between the mitochondria and cytosol will be presented.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem, Evanston, IL 60208 USA; Northwestern Univ, Dept Mol Biol, Evanston, IL 60208 USA; Northwestern Univ, Dept Cell Biol, Evanston, IL 60208 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Northwestern University; Northwestern University; Northwestern University; Northwestern University	Culotta, VC (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St,Rm 7032, Baltimore, MD 21205 USA.	vculotta@jhsph.edu	Furukawa, Yoshiaki/F-2871-2014; O'Halloran, Thomas/ABE-6125-2021	Furukawa, Yoshiaki/0000-0002-1918-372X; O'Halloran, Thomas/0000-0001-8732-5059	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM050016, R01GM054111, R01GM050016] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 54111, R01 GM054111, GM 50016] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERNETHY JL, 1974, J BIOL CHEM, V249, P7339; BERTINI I, 1994, EUR BIOPHYS J BIOPHY, V23, P167, DOI 10.1007/BF01007608; Bertini I, 1998, ADV INORG CHEM, V45, P127, DOI 10.1016/S0898-8838(08)60026-4; BORDO D, 1994, J MOL BIOL, V238, P366, DOI 10.1006/jmbi.1994.1298; BOVERIS A, 1975, FEBS LETT, V54, P311, DOI 10.1016/0014-5793(75)80928-8; CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169; CRAPO JD, 1992, P NATL ACAD SCI USA, V89, P10405, DOI 10.1073/pnas.89.21.10405; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DAUM G, 1982, J BIOL CHEM, V257, P3028; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Dhaliwal GK, 2000, NEUROREPORT, V11, P2507, DOI 10.1097/00001756-200008030-00032; Diekert K, 2001, EMBO J, V20, P5626, DOI 10.1093/emboj/20.20.5626; DUMONT ME, 1991, MOL CELL BIOL, V11, P5487, DOI 10.1128/MCB.11.11.5487; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; GELLER BL, 1982, J BIOL CHEM, V257, P8945; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GLICK BS, 1991, METHOD CELL BIOL, V34, P389; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HAKVOORT TBM, 1990, P NATL ACAD SCI USA, V87, P4996, DOI 10.1073/pnas.87.13.4996; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; Higgins CMJ, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-06-j0001.2002; Jaarsma D, 2000, NEUROBIOL DIS, V7, P623, DOI 10.1006/nbdi.2000.0299; Jaarsma D, 2001, ACTA NEUROPATHOL, V102, P293; Jung CW, 2002, J NEUROCHEM, V83, P535, DOI 10.1046/j.1471-4159.2002.01112.x; Kachur AV, 1999, FREE RADICAL RES, V31, P23, DOI 10.1080/10715769900300571; KELLER GA, 1991, P NATL ACAD SCI USA, V88, P7381, DOI 10.1073/pnas.88.16.7381; Kong JM, 1998, J NEUROSCI, V18, P3241; Lamb AL, 2001, NAT STRUCT BIOL, V8, P751, DOI 10.1038/nsb0901-751; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P1589, DOI 10.1021/bi992822i; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P14720, DOI 10.1021/bi002207a; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; Lyons TJ, 1998, J BIOL INORG CHEM, V3, P650, DOI 10.1007/s007750050279; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; Mattiazzi M, 2002, J BIOL CHEM, V277, P29626, DOI 10.1074/jbc.M203065200; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; Menzies FM, 2002, BRAIN, V125, P1522, DOI 10.1093/brain/awf167; Muller EGD, 1996, MOL BIOL CELL, V7, P1805, DOI 10.1091/mbc.7.11.1805; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; Okado-Matsumoto A, 2002, P NATL ACAD SCI USA, V99, P9010, DOI 10.1073/pnas.132260399; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Schmidt PJ, 2000, J BIOL CHEM, V275, P33771, DOI 10.1074/jbc.M006254200; Schmidt PJ, 1999, J BIOL CHEM, V274, P23719, DOI 10.1074/jbc.274.34.23719; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Sherman F., 1978, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; STEINER H, 1995, J BIOL CHEM, V270, P22842, DOI 10.1074/jbc.270.39.22842; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Zhang L, 1998, J BIOL CHEM, V273, P33972, DOI 10.1074/jbc.273.51.33972	53	179	184	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28052	28059		10.1074/jbc.M304296200	http://dx.doi.org/10.1074/jbc.M304296200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12748182	hybrid			2022-12-25	WOS:000184242700091
J	Tang, WN; Perry, SE				Tang, WN; Perry, SE			Binding site selection for the plant MADS domain protein AGL15 - An in vitro and in vivo study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX TRANSCRIPTION FACTORS; DNA-BINDING; ARABIDOPSIS; GENE; EXPRESSION; FAMILY; SPECIFICITIES; CONSTRUCTION; PROMOTERS; SEQUENCES	AGL15 (for AGAMOUS-like 15) is currently the only reported member of the plant MADS domain family of transcriptional regulators that preferentially accumulates during embryo development. Additionally, AGL15 is one of the more divergent members of the MADS domain family, including within the DNA-binding domain. Previous studies have shown that MADS domain proteins bind to DNA sequences with an overall consensus of CC(A/T)(6)GG (called a CArG motif). Nonetheless, different MADS domain proteins exhibit similar yet distinct binding site preferences that may be critical for differential gene regulation. To determine the consensus sequence preferentially bound by AGL15 in vitro, PCR-assisted binding site selection assays were performed. AGL15 was observed to prefer a CArG motif with a longer A/T-rich core and is to date the only plant MADS domain protein having such a preference. Next, the Arabidopsis genome data base was searched for genes containing AGL15 binding sites as candidates for direct regulation by AGL15. One gene, DTA4 (for Downstream Target of AGL15-4), was identified by this method, and then confirmed as a direct target of AGL15 in vivo.	Univ Kentucky, Dept Agron, Lexington, KY 40546 USA	University of Kentucky	Perry, SE (corresponding author), Univ Kentucky, Dept Agron, 1405 Vet Rd,307 Plant Sci Bldg, Lexington, KY 40546 USA.		Perry, Sharyn/M-9177-2013	Perry, Sharyn/0000-0002-3011-8240				Acton TB, 1997, MOL CELL BIOL, V17, P1881, DOI 10.1128/MCB.17.4.1881; Alvarez-Buylla ER, 2000, P NATL ACAD SCI USA, V97, P5328, DOI 10.1073/pnas.97.10.5328; ANDREW DJ, 1992, NEW BIOL, V4, P5; Ausubel FM, 1998, CURRENT PROTOCOLS MO; AXELOS M, 1989, MOL GEN GENET, V219, P106, DOI 10.1007/BF00261164; Campisi L, 1999, PLANT J, V17, P699, DOI 10.1046/j.1365-313X.1999.00409.x; CAREY M, 1999, TRANSCRIPTIONAL REGU, P291; Carr A, 1999, EMBO J, V18, P1598, DOI 10.1093/emboj/18.6.1598; DALRYMPLE MA, 1985, NUCLEIC ACIDS RES, V13, P7865, DOI 10.1093/nar/13.21.7865; Fernandez DE, 2000, PLANT CELL, V12, P183, DOI 10.1105/tpc.12.2.183; Gaudet J, 2002, SCIENCE, V295, P821, DOI 10.1126/science.1065175; HECK GR, 1995, PLANT CELL, V7, P1271, DOI 10.1105/tpc.7.8.1271; Huang H, 1996, PLANT CELL, V8, P81, DOI 10.1105/tpc.8.1.81; HUANG H, 1993, NUCLEIC ACIDS RES, V21, P4769, DOI 10.1093/nar/21.20.4769; Jack T, 2001, PLANT MOL BIOL, V46, P515, DOI 10.1023/A:1010689126632; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; Krizek BA, 1999, SEX PLANT REPROD, V12, P14, DOI 10.1007/s004970050167; Krizek BA, 1996, P NATL ACAD SCI USA, V93, P4063, DOI 10.1073/pnas.93.9.4063; Latchman DS, 2001, TRENDS BIOCHEM SCI, V26, P211, DOI 10.1016/S0968-0004(01)01812-6; Murphy EC, 2001, J MOL BIOL, V312, P481, DOI 10.1006/jmbi.2001.4977; Perry SE, 1996, PLANT CELL, V8, P1977, DOI 10.1105/tpc.8.11.1977; Perry SE, 1999, PLANT PHYSIOL, V120, P121, DOI 10.1104/pp.120.1.121; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; Riechmann JL, 1996, P NATL ACAD SCI USA, V93, P4793, DOI 10.1073/pnas.93.10.4793; Riechmann JL, 1997, BIOL CHEM, V378, P1079; SHIRAISHI H, 1993, PLANT J, V4, P385, DOI 10.1046/j.1365-313X.1993.04020385.x; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; SNUSTAD DP, 1992, PLANT CELL, V4, P549, DOI 10.1105/tpc.4.5.549; Theissen G, 1996, J MOL EVOL, V43, P484, DOI 10.1007/PL00006110; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VANCANNEYT G, 1990, MOL GEN GENET, V220, P245, DOI 10.1007/BF00260489; Wang H, 2002, PLANT J, V32, P831, DOI 10.1046/j.1365-313X.2002.01455.x; West AG, 1998, NUCLEIC ACIDS RES, V26, P5277, DOI 10.1093/nar/26.23.5277; West AG, 1997, MOL CELL BIOL, V17, P2876, DOI 10.1128/MCB.17.5.2876; West AG, 1999, J MOL BIOL, V286, P1311, DOI 10.1006/jmbi.1999.2576; Wilkins Thea A., 1996, P21; Yang YN, 2000, PLANT J, V22, P543, DOI 10.1046/j.1365-313x.2000.00760.x	37	96	114	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28154	28159		10.1074/jbc.M212976200	http://dx.doi.org/10.1074/jbc.M212976200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12743119	hybrid			2022-12-25	WOS:000184242700103
J	Wu, WD; Wang, XC; Zhang, WL; Reed, W; Samet, JM; Whang, YE; Ghio, AJ				Wu, WD; Wang, XC; Zhang, WL; Reed, W; Samet, JM; Whang, YE; Ghio, AJ			Zinc-induced PTEN protein degradation through the proteasome pathway in human airway epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PTEN; PHOSPHOINOSITIDE 3-KINASE; EGF-RECEPTOR; KINASE; GROWTH; PHOSPHORYLATION; ACTIVATION; PTEN/MMAC1; IDENTIFICATION; INVOLVEMENT	The tumor suppressor PTEN is a putative negative regulator of the phosphatidylinositol 3-kinase/Akt pathway. Exposure to Zn2+ ions induces Akt activation, suggesting that PTEN may be modulated in this process. Therefore, the effects of Zn2+ on PTEN were studied in human airway epithelial cells and rat lungs. Treatment with Zn2+ resulted in a significant reduction in levels of PTEN protein in a dose- and time-dependent fashion in a human airway epithelial cell line. This effect of Zn2+ was also observed in normal human airway epithelial cells in primary culture and in rat airway epithelium in vivo. Concomitantly, levels of PTEN mRNA were also significantly reduced by Zn2+ exposure. PTEN phosphatase activity evaluated by measuring Akt phosphorylation decreased after Zn2+ treatment. Pretreatment of the cells with a proteasome inhibitor significantly blocked zinc-induced reduction of PTEN protein as well as the increase in Akt phosphorylation, implicating the involvement of proteasome-mediated PTEN degradation. Further study revealed that Zn2+-induced ubiquitination of PTEN protein may mediate this process. A phosphatidylinositol 3-kinase inhibitor blocked PTEN degradation induced by Zn2+, suggesting that phosphatidylinositol 3-kinase may participate in the regulation of PTEN. However, both the proteasome inhibitor and phosphatidylinositol 3-kinase inhibitor failed to prevent significant down-regulation of PTEN mRNA expression in response to Zn2+. In summary, exposure to Zn2+ ions causes PTEN degradation and loss of function, which is mediated by an ubiquitin-associated proteolytic process in the airway epithelium.	Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Med, Chapel Hill, NC 27599 USA; US EPA, Human Studies Div, Natl Hlth Effects & Environm Res Lab, Off Res & Dev, Res Triangle Pk, NC 27711 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; United States Environmental Protection Agency	Wu, WD (corresponding author), Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27599 USA.	Weidong_Wu@med.unc.edu; Ghio.andy@epa.gov	Whang, Young/AAK-7435-2021	Whang, Young/0000-0002-1621-6661	NCI NIH HHS [CA85772] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA085772] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamson IYR, 2000, TOXICOL APPL PHARM, V166, P111, DOI 10.1006/taap.2000.8955; Adey NB, 2000, CANCER RES, V60, P35; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Barceloux DG, 1999, J TOXICOL-CLIN TOXIC, V37, P279, DOI 10.1081/CLT-100102426; Bruni P, 2000, ONCOGENE, V19, P3146, DOI 10.1038/sj.onc.1203633; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; DING JB, 1995, J BIOL CHEM, V270, P11684, DOI 10.1074/jbc.270.19.11684; Downes CP, 2001, BIOCHEM SOC T, V29, P846, DOI 10.1042/BST0290846; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Eng C, 1998, INT J ONCOL, V12, P701; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Kim S, 2000, J BIOL CHEM, V275, P25979, DOI 10.1074/jbc.M001975200; Kuschner WG, 1997, ENVIRON RES, V75, P7, DOI 10.1006/enrs.1997.3765; Kwak YG, 2003, J CLIN INVEST, V111, P1083, DOI 10.1172/JCI200316440; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Maret W, 2001, P NATL ACAD SCI USA, V98, P12325, DOI 10.1073/pnas.231481398; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Martin CJ, 1999, AM J IND MED, V35, P574, DOI 10.1002/(SICI)1097-0274(199906)35:6<574::AID-AJIM4>3.0.CO;2-L; Miller SJ, 2002, FEBS LETT, V528, P145, DOI 10.1016/S0014-5793(02)03274-X; Morimoto AM, 1999, ONCOGENE, V18, P1261, DOI 10.1038/sj.onc.1202441; Myers MP, 1997, AM J HUM GENET, V61, P1234, DOI 10.1086/301659; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Patel L, 2001, CURR BIOL, V11, P764, DOI 10.1016/S0960-9822(01)00225-1; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; REDDEL RR, 1988, CANCER RES, V48, P1904; Samet JM, 1999, AM J RESP CELL MOL, V21, P357, DOI 10.1165/ajrcmb.21.3.3656; Samet JM, 1998, AM J PHYSIOL-LUNG C, V275, pL551, DOI 10.1152/ajplung.1998.275.3.L551; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; Tamura M, 1999, CANCER RES, V59, P442; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Vazquez F, 2000, BBA-REV CANCER, V1470, pM21, DOI 10.1016/S0304-419X(99)00032-3; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; Waite KA, 2003, HUM MOL GENET, V12, P679, DOI 10.1093/hmg/ddg069; Wang XC, 2002, AM J PHYSIOL-LUNG C, V282, pL987, DOI 10.1152/ajplung.00253.2001; Wu WD, 2002, J BIOL CHEM, V277, P24252, DOI 10.1074/jbc.M200437200; Wu WD, 2002, AM J PHYSIOL-LUNG C, V282, pL1040, DOI 10.1152/ajplung.00390.2001; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yamada KM, 2001, J CELL SCI, V114, P2375; Yang FM, 2002, AM J PHYSIOL-LUNG C, V283, pL932, DOI 10.1152/ajplung.00114.2002	63	129	133	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28258	28263		10.1074/jbc.M303318200	http://dx.doi.org/10.1074/jbc.M303318200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12743124	Green Published, hybrid			2022-12-25	WOS:000184242700116
J	Wu, WWH; Molday, RS				Wu, WWH; Molday, RS			Defective discoidin domain structure, subunit assembly, and endoplasmic reticulum processing of retinoschisin are primary mechanisms responsible for X-linked retinoschisis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUVENILE RETINOSCHISIS; FACTOR-VIII; C2 DOMAIN; PROTEIN; PHOTORECEPTOR; EXPRESSION; GENE; MUTATIONS; SEQUENCE; FAMILY	Retinoschisin is a 24-kDa discoidin domain-containing protein that is secreted from photoreceptor and bipolar cells as a large disulfide-linked multisubunit complex. It functions as a cell adhesion protein to maintain the cellular organization and synaptic structure of the retina. Over 125 different mutations in the RS1 gene are associated with X-linked juvenile retinoschisis, the most common form of early onset macular degeneration in males. To identify molecular determinants important for retinoschisin structure and function and elucidate molecular and cellular mechanisms responsible for X-linked juvenile retinoschisis, we have analyzed the expression, protein folding, disulfide-linked subunit assembly, intracellular localization, and secretion of wild-type retinoschisin, 15 Cys-to-Ser variants and 12 disease-linked mutants. Our studies, together with molecular modeling of the discoidin domain, identify Cys residues involved in intramolecular and intermolecular disulfide bonds essential for protein folding and subunit assembly. We show that misfolding of the discoidin domain, defective disulfide-linked subunit assembly, and inability of retinoschisin to insert into the endoplasmic reticulum membrane as part of the protein secretion process are three primary mechanisms responsible for the loss in the function of retinoschisin as a cell adhesion protein and the pathogenesis of X-linked juvenile retinoschisis.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Molday, RS (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	molday@interchange.ubc.ca			NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER; NEI NIH HHS [EY 02422] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Baumgartner S, 1998, PROTEIN SCI, V7, P1626, DOI 10.1002/pro.5560070717; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brunner B, 1999, GENOME RES, V9, P437; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FORSIUS H, 1973, CAN J OPHTHALMOL, V8, P385; Fuentes-Prior P, 2002, CURR PROTEIN PEPT SC, V3, P313, DOI 10.2174/1389203023380639; Gehrig A, 1999, CLIN GENET, V55, P461, DOI 10.1034/j.1399-0004.1999.550611.x; Gehrig AE, 1999, MAMM GENOME, V10, P303, DOI 10.1007/s003359900991; George NDL, 1996, ARCH OPHTHALMOL-CHIC, V114, P274, DOI 10.1001/archopht.1996.01100130270007; Grayson C, 2000, HUM MOL GENET, V9, P1873, DOI 10.1093/hmg/9.12.1873; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hiriyanna KT, 1999, HUM MUTAT, V14, P423, DOI 10.1002/(SICI)1098-1004(199911)14:5<423::AID-HUMU8>3.0.CO;2-D; Kemball-Cook G, 1998, NUCLEIC ACIDS RES, V26, P216, DOI 10.1093/nar/26.1.216; Liu ML, 2000, BLOOD, V96, P979, DOI 10.1182/blood.V96.3.979.015k42a_979_987; Macedo-Ribeiro S, 1999, NATURE, V402, P434, DOI 10.1038/46594; Molday LL, 2001, INVEST OPHTH VIS SCI, V42, P816; MOLDAY LL, 1990, J BIOL CHEM, V265, P18690; PEACHEY NS, 1987, ARCH OPHTHALMOL-CHIC, V105, P513, DOI 10.1001/archopht.1987.01060040083038; POOLE S, 1981, J MOL BIOL, V153, P273, DOI 10.1016/0022-2836(81)90278-3; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; Reid SNM, 1999, GENE, V227, P257, DOI 10.1016/S0378-1119(98)00578-2; Sauer CG, 1997, NAT GENET, V17, P164, DOI 10.1038/ng1097-164; Sieving PA, 1998, OX MG MED G, P347; SIMPSON DL, 1974, BIOCHEMISTRY-US, V13, P3487, DOI 10.1021/bi00714a011; Vogel W, 1999, FASEB J, V13, pS77, DOI 10.1096/fasebj.13.9001.s77; Wang T, 2002, HUM MOL GENET, V11, P3097, DOI 10.1093/hmg/11.24.3097; Weber BHF, 2002, P NATL ACAD SCI USA, V99, P6222, DOI 10.1073/pnas.092528599	28	97	104	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28139	28146		10.1074/jbc.M302464200	http://dx.doi.org/10.1074/jbc.M302464200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12746437	hybrid			2022-12-25	WOS:000184242700101
J	Hock, MB; Brown, MA				Hock, MB; Brown, MA			Nuclear factor of activated T cells 2 transactivation in mast cells - A novel isoform-specific transactivation domain confers unique Fc epsilon RI responsiveness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; IL-4 GENE-TRANSCRIPTION; T-CELLS; NF-ATC; CYTOKINE PRODUCTION; INNATE IMMUNITY; PKC-THETA; CALCINEURIN; BINDING; LYMPHOCYTES	Murine nuclear factor of activated T cells (NFAT)2.alpha/beta differ by 42 and 28 unique amino-terminal amino acids and are differentially expressed. Both isoforms share conserved domains that regulate DNA-binding and subcellular localization. A genetic "one-hybrid" assay was used to define two distinct transactivation (TA) domains: in addition to a conserved TAD present in both isoforms, a second, novel TAD exists within the beta-specific amino terminus. Pharmacologic inhibitors Go6976 and rottlerin demonstrate that both conventional and novel protein kinase C (PKC) family members regulate endogenous mast cell NFAT activity, and NFAT2 TA. Overexpression of dominant active PKCtheta (which has been implicated in immune receptor signaling) induces NFAT2.alpha/beta TA. Mutations within the smallest PKCtheta-responsive transactivation domain demonstrate that the PKCtheta effect is at least partially indirect. Significantly, the beta-specific domain confers greater ability to TA in response to treatment with phorbol 12-myristate 13-acetate/ionomycin or lipopolysaccharide, and unique sensitivity to FcepsilonRI signaling. Accordingly, overexpression of NFAT2.beta results in significantly greater NFAT- and interleukin-4 reporter activity than NFAT2.alpha. These results suggest that whereas NFAT2 isoforms may share redundant DNA-binding preferences, there are specialized functional consequences of their isoform-specific domains.	Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Brown, MA (corresponding author), Northwestern Univ, Sch Med, Dept Microbiol & Immunol, Tarry Med Res Bldg,Rm 7-711,Mail Code S213,320 E, Chicago, IL 60611 USA.				NATIONAL CANCER INSTITUTE [R29CA047992, R01CA047992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008490] Funding Source: NIH RePORTER; NCI NIH HHS [CA047992] Funding Source: Medline; NIGMS NIH HHS [T32 GM008490] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altman A, 2000, IMMUNOL TODAY, V21, P567, DOI 10.1016/S0167-5699(00)01749-7; AUSUBEL FM, 2002, CURRENT PROTOCOLS MO; Barnes PJ, 1998, EUR RESPIR J, V12, P221, DOI 10.1183/09031936.98.12010221; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Boss V, 1996, J BIOL CHEM, V271, P10429, DOI 10.1074/jbc.271.18.10429; CASTIGLI E, 1993, J IMMUNOL, V150, P3284; Choi Y, 2000, J BIOL CHEM, V275, P15912, DOI 10.1074/jbc.275.21.15912; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Chuvpilo S, 1999, J IMMUNOL, V162, P7294; Chuvpilo S, 1999, IMMUNITY, V10, P261, DOI 10.1016/S1074-7613(00)80026-6; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; de Gregorio R, 2001, J BIOL CHEM, V276, P27003, DOI 10.1074/jbc.M100885200; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; Galli SJ, 1999, CURR OPIN IMMUNOL, V11, P53, DOI 10.1016/S0952-7915(99)80010-7; Garcia-Rodriguez C, 1998, J EXP MED, V187, P2031, DOI 10.1084/jem.187.12.2031; HAMA N, 1995, J EXP MED, V181, P1217, DOI 10.1084/jem.181.3.1217; Holla AD, 2002, CURR OPIN ALLERGY CL, V2, P141, DOI 10.1097/00130832-200204000-00010; Imamura R, 1998, J IMMUNOL, V161, P3455; Isakov N, 2002, ANNU REV IMMUNOL, V20, P761, DOI 10.1146/annurev.immunol.20.100301.064807; Ishizuka T, 1998, J IMMUNOL, V161, P3624; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; KEEGAN AD, 1991, EMBO J, V10, P3675, DOI 10.1002/j.1460-2075.1991.tb04935.x; Kiani A, 1997, IMMUNITY, V7, P849, DOI 10.1016/S1074-7613(00)80403-3; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lunderius C, 2000, EUR J IMMUNOL, V30, P3396, DOI 10.1002/1521-4141(2000012)30:12<3396::AID-IMMU3396>3.0.CO;2-O; Luo C, 1996, J EXP MED, V184, P141, DOI 10.1084/jem.184.1.141; Manninen A, 2001, J VIROL, V75, P3034, DOI 10.1128/JVI.75.6.3034-3037.2001; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Monick MM, 2000, J IMMUNOL, V165, P4632, DOI 10.4049/jimmunol.165.8.4632; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Monticelli S, 2002, EUR J IMMUNOL, V32, P2971, DOI 10.1002/1521-4141(2002010)32:10<2971::AID-IMMU2971>3.0.CO;2-G; MUSCH MW, 1985, BIOCHEM BIOPH RES CO, V126, P517, DOI 10.1016/0006-291X(85)90636-9; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; Park S, 2000, P NATL ACAD SCI USA, V97, P7130, DOI 10.1073/pnas.97.13.7130; Rainio EM, 2002, J IMMUNOL, V168, P1524, DOI 10.4049/jimmunol.168.4.1524; Ranger AM, 1998, IMMUNITY, V8, P125, DOI 10.1016/S1074-7613(00)80465-3; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; San-Antonio B, 2002, J BIOL CHEM, V277, P27073, DOI 10.1074/jbc.M106983200; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Sherman MA, 1999, J IMMUNOL, V162, P2820; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Supajatura V, 2002, J CLIN INVEST, V109, P1351, DOI 10.1172/JCI200214704; Szalay J, 2001, J HISTOCHEM CYTOCHEM, V49, P49, DOI 10.1177/002215540104900106; TARA D, 1995, J IMMUNOL, V154, P4592; Theoharides TC, 1996, INT J TISSUE REACT, V18, P1; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Villalba M, 1999, J IMMUNOL, V163, P5813; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1	58	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26695	26703		10.1074/jbc.M301007200	http://dx.doi.org/10.1074/jbc.M301007200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12738787	hybrid			2022-12-25	WOS:000184155700052
J	Jeong, SY; David, S				Jeong, SY; David, S			Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR-DISTRIBUTION; TRANSFERRIN RECEPTOR; MOUSE-BRAIN; GENE; EXPRESSION; MEMBRANE; ACERULOPLASMINEMIA; TRANSPORTER; MUTATION; FORM	Ceruloplasmin (Cp) is a ferroxidase that converts highly toxic ferrous iron to its non-toxic ferric form. A glycosylphosphatidylinositol (GPI)-anchored form of this enzyme is expressed by astrocytes in the mammalian central nervous system, whereas the secreted form is expressed by the liver and found in serum. Lack of this enzyme results in iron accumulation in the brain and neurodegeneration. Herein, we show using astrocytes purified from the central nervous system of Cp-null mice that GPI-Cp is essential for iron efflux and not involved in regulating iron influx. We also show that GPI-Cp colocalizes on the astrocyte cell surface with the divalent metal transporter IREG1 and is physically associated with IREG1. In addition, IREG1 alone is unable to efflux iron from astrocytes in the absence of GPI-Cp or secreted Cp. We also provide evidence that the divalent metal influx transporter DMT1 is expressed by astrocytes and is likely to mediate iron influx into these glial cells. The coordinated actions of GPI-Cp and IREG1 may be required for iron efflux from neural cells, and disruption of this balance could lead to iron accumulation in the central nervous system and neurodegeneration.	McGill Univ, Montreal Gen Hosp, Res Inst, Hlth Ctr,Ctr Res Neurosci, Montreal, PQ H3G 1A4, Canada	McGill University	David, S (corresponding author), 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.			Jeong, Suh Young/0000-0002-6376-7001				Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; Anderson GJ, 2002, INT J HEMATOL, V76, P203, DOI 10.1007/BF02982788; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Bradbury MWB, 1997, J NEUROCHEM, V69, P443; Burdo JR, 2003, BIOMETALS, V16, P63, DOI 10.1023/A:1020718718550; Dickinson TK, 1998, BRAIN RES, V801, P171, DOI 10.1016/S0006-8993(98)00575-7; DICKINSON TK, 1995, J COMP NEUROL, V355, P67, DOI 10.1002/cne.903550109; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; Fishman RA., 1992, CEREBROSPINAL FLUID; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812; Hellman NE, 2002, J BIOL CHEM, V277, P1375, DOI 10.1074/jbc.M109123200; Kim S, 1999, J BIOL CHEM, V274, P33035, DOI 10.1074/jbc.274.46.33035; Klomp LWJ, 1996, HUM MOL GENET, V5, P1989, DOI 10.1093/hmg/5.12.1989; Klomp LWJ, 1996, J CLIN INVEST, V98, P207, DOI 10.1172/JCI118768; KOOYMAN DL, 1995, SCIENCE, V269, P89, DOI 10.1126/science.7541557; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; McKie AT, 2001, SCIENCE, V291, P1755, DOI 10.1126/science.1057206; Mittal B, 2003, GLIA, V41, P337, DOI 10.1002/glia.10158; Miyajima H, 1998, NEUROLOGY, V51, P1188, DOI 10.1212/WNL.51.4.1188; MIYAJIMA H, 1987, NEUROLOGY, V37, P761, DOI 10.1212/WNL.37.5.761; OSAKI S, 1966, J BIOL CHEM, V241, P2746; Ousman SS, 2001, J NEUROSCI, V21, P4649, DOI 10.1523/JNEUROSCI.21-13-04649.2001; Patel BN, 2000, J BIOL CHEM, V275, P4305, DOI 10.1074/jbc.275.6.4305; Patel BN, 1997, J BIOL CHEM, V272, P20185, DOI 10.1074/jbc.272.32.20185; Patel BN, 2002, J NEUROSCI, V22, P6578; Qian ZM, 1999, EXP BRAIN RES, V129, P473, DOI 10.1007/s002210050916; Richardson DR, 1999, J LAB CLIN MED, V134, P454, DOI 10.1016/S0022-2143(99)90166-X; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267	36	302	316	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27144	27148		10.1074/jbc.M301988200	http://dx.doi.org/10.1074/jbc.M301988200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12743117	hybrid			2022-12-25	WOS:000184155700109
J	Motojima, F; Yoshida, M				Motojima, F; Yoshida, M			Discrimination of ATP, ADP, and AMPPNP by chaperonin GroEL - Hexokinase treatment revealed the exclusive role of ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE BINDING; PROTEIN; RELEASE; COMPLEX; INTERMEDIATE; MECHANISM; RESIDUES; CYCLE; CIS	The double ring chaperonin GroEL binds unfolded protein, ATP, and GroES to the same ring, generating the cis ternary complex in which folding occurs within the cavity capped by GroES ( cis folding). The functional role of ATP, however, remains unclear since several reports have indicated that ADP and AMPPNP (5'-adenylyl-beta,gamma-imidodiphosphate) are also able to support the formation of the cis ternary complex and the cis folding. To minimize the effect of contaminated ATP and adenylate kinase, we have included hexokinase plus glucose in the reaction mixtures and obtained new results. In ADP and AMPPNP, GroES bound quickly to GroEL but bound very slowly to the GroEL loaded with unfolded rhodanese or malate dehydrogenase. ADP was unable to support the formation of cis ternary complex and cis folding. AMPPNP supported cis folding of malate dehydrogenase to some extent but not cis folding of rhodanese. In the absence of hexokinase, apparent cis folding of rhodanese and malate dehydrogenase was observed in ADP and AMPPNP. Thus, the exclusive role of ATP in generation of the cis ternary complex is now evident.	Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan	Tokyo Institute of Technology	Yoshida, M (corresponding author), Tokyo Inst Technol, Chem Resources Lab, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.		Motojima, Fumihiro/J-2389-2014	Motojima, Fumihiro/0000-0003-4461-8673				BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; Burston SG, 1996, NATURE, V383, P96, DOI 10.1038/383096a0; Chaudhuri TK, 2001, CELL, V107, P235, DOI 10.1016/S0092-8674(01)00523-2; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Grallert H, 1998, J BIOL CHEM, V273, P33305, DOI 10.1074/jbc.273.50.33305; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; Makino Y, 1997, J BIOL CHEM, V272, P12468, DOI 10.1074/jbc.272.19.12468; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; Motojima F, 2000, BIOCHEM BIOPH RES CO, V267, P842, DOI 10.1006/bbrc.1999.2020; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7440, DOI 10.1021/bi00484a013; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1995, J BIOL CHEM, V270, P5388, DOI 10.1074/jbc.270.10.5388; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5	17	40	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26648	26654		10.1074/jbc.M300806200	http://dx.doi.org/10.1074/jbc.M300806200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12736270	hybrid			2022-12-25	WOS:000184155700047
J	Shen, YH; Godlewski, J; Zhu, J; Sathyanarayana, P; Leaner, V; Birrer, MJ; Rana, A; Tzivion, G				Shen, YH; Godlewski, J; Zhu, J; Sathyanarayana, P; Leaner, V; Birrer, MJ; Rana, A; Tzivion, G			Cross-talk between JNK/SAPK and ERK/MAPK pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIXED-LINEAGE KINASE; ACTIVATED PROTEIN-KINASE; C-JUN; MESANGIAL CELLS; DNA-SYNTHESIS; TNF-ALPHA; IDENTIFICATION; EXPRESSION; SCAFFOLD; BINDING	Mixed lineage kinases (MLKs) are a family of serine/threonine kinases that function in the SAPK signaling cascade. MLKs activate JNK/SAPK in vivo by directly phosphorylating and activating the JNK kinase SEK-1 (MKK4 and -7). Importantly, the MLK member MLK3/SPRK has been shown recently to be a direct target of ceramide and tumor necrosis factor-alpha (TNF-alpha) and to mediate the TNF-alpha and ceramide-induced JNK activation in Jurkat cells. Here we report that MLK3 can phosphorylate and activate MEK-1 directly in vitro and also can induce MEK phosphorylation on its activation sites in vivo in COS-7 cells. Surprisingly, this induction of MEK phosphorylation does not result in ERK activation in vivo. Rather, in cells expressing active MLK3, ERK becomes resistant to activation by growth factors and mitogens. This restriction in ERK activation requires MLK3 kinase activity, is independent of Raf activation, and is reversed by JNK pathway inhibition either at the level of SEK-1, JNK, or Jun. These results demonstrate that sustained JNK activation uncouples ERK activation from MEK in a manner requiring Jun-mediated gene transcription. This in turn points to the existence of a negative cross-talk relationship between the stress-activated JNK pathway and the mitogen-activated ERK pathway. Thus, our findings imply that some of the biological functions of JNK activators, such as TNF-alpha and ceramide, may be attributed to their ability to block cell responses to growth and survival factors acting through the ERK/MAPK pathway.	Texas A&M Univ Syst, Hlth Sci Ctr, Coll Med, Div Mol Cardiol,Cardiovasc Res Inst, Temple, TX 76504 USA; NCI, Cell & Canc Biol Dept, NIH, Rockville, MD 20850 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Tzivion, G (corresponding author), Texas A&M Univ, Cardiovasc Res Inst, HSC, 1901 S 1st St,Bldg 162, Temple, TX 76504 USA.		Tzivion, Guri/D-8954-2011; Godlewski, Jakub/U-4700-2019; shen, ying/HHS-5635-2022; Rana, Ajay/ABE-3739-2020	Rana, Ajay/0000-0003-0951-2566; Godlewski, Jakub/0000-0003-2122-9798	NIGMS NIH HHS [R01 GM 558385, R01 GM 067134] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067134] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Black EJ, 2002, ONCOGENE, V21, P6540, DOI 10.1038/sj.onc.1205851; Bock BC, 2000, J BIOL CHEM, V275, P14231, DOI 10.1074/jbc.275.19.14231; Bodner A, 2002, J NEUROCHEM, V82, P1424, DOI 10.1046/j.1471-4159.2002.01088.x; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Harris CA, 2002, J NEUROSCI, V22, P103, DOI 10.1523/JNEUROSCI.22-01-00103.2002; Hartkamp J, 1999, CANCER RES, V59, P2195; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; ING YL, 1994, ONCOGENE, V9, P1745; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Mielke K, 2002, MOL CELL NEUROSCI, V20, P211, DOI 10.1006/mcne.2002.1132; Murakata C, 2002, BIOORG MED CHEM LETT, V12, P147, DOI 10.1016/S0960-894X(01)00690-4; Parameswaran N, 2002, CELL PHYSIOL BIOCHEM, V12, P325, DOI 10.1159/000067902; Parameswaran N, 2002, MOL CELL BIOCHEM, V241, P37, DOI 10.1023/A:1020835106255; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Sathyanarayana P, 2002, MOL CELL, V10, P1527, DOI 10.1016/S1097-2765(02)00734-7; Stronach B, 2002, GENE DEV, V16, P377, DOI 10.1101/gad.953002; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Xu ZH, 2003, EMBO J, V22, P252, DOI 10.1093/emboj/cdg021; Yasuda J, 1999, MOL CELL BIOL, V19, P7245	33	166	169	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26715	26721		10.1074/jbc.M303264200	http://dx.doi.org/10.1074/jbc.M303264200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12738796	hybrid			2022-12-25	WOS:000184155700054
J	Nelsen, CJ; Rickheim, DG; Tucker, MM; McKenzie, TJ; Hansen, LK; Pestell, RG; Albrecht, JH				Nelsen, CJ; Rickheim, DG; Tucker, MM; McKenzie, TJ; Hansen, LK; Pestell, RG; Albrecht, JH			Amino acids regulate hepatocyte proliferation through modulation of cyclin D1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; LIVER-REGENERATION; S6 PHOSPHORYLATION; RNA LEVELS; GROWTH; TRANSLATION; PROGRESSION; G(1); RESTRICTION; ADENOVIRUS	The mechanisms by which amino acids regulate the cell cycle are not well characterized. In this study, we examined the control of hepatocyte proliferation by amino acids and protein intake. In short-term culture, hepatocytes demonstrated normal entry into S phase and cell cycle protein expression in the absence of essential amino acids. However, deprivation of a set of nonessential amino acids (NEAA) potently inhibited cell cycle progression and selectively down-regulated the expression of proliferation-control proteins. Notably, NEAA withdrawal after the mitogen restriction point still inhibited entry into S phase, suggesting that these amino acids regulate a distinct checkpoint. Cyclin D1, an important mediator of hepatocyte proliferation, was markedly inhibited at the transcriptional level by NEAA deprivation, and transfection with cyclin D1 ( but not cyclin E) overcame the cell cycle arrest. As previously shown, protein-deprived mice demonstrated impaired hepatocyte proliferation in vivo after 70% partial hepatectomy. The expression of cyclin D1 and downstream cell cycle proteins after partial hepatectomy was inhibited in these mice. Transfection with cyclin D1 in vivo triggered hepatocyte DNA synthesis and the expression of S phase proteins in the absence of dietary protein. Cyclin D1 also induced global protein synthesis in NEAA-deprived hepatocytes and promoted liver growth in vivo in the setting of protein deprivation. These results indicate that cyclin D1 is a key target of amino acid signaling in hepatocytes.	Hennepin Cty Med Ctr, Dept Gastroenterol, Minneapolis, MN 55415 USA; Minneapolis Med Res Fdn Inc, Minneapolis, MN 55404 USA; Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Georgetown Univ, Dept Oncol, Washington, DC 20057 USA	Hennepin County Medical Center; Minneapolis Medical Research Foundation; University of Minnesota System; University of Minnesota Twin Cities; Georgetown University	Albrecht, JH (corresponding author), Hennepin Cty Med Ctr, Div Gastroenterol 865B, 701 Pk Ave, Minneapolis, MN 55415 USA.	albre010@tc.umn.edu		Hansen, Linda/0000-0003-3651-0419	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [P50AT000009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054921] Funding Source: NIH RePORTER; NCCIH NIH HHS [P50 AT00009 - 04] Funding Source: Medline; NIDDK NIH HHS [DK54921] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Boylan JM, 2001, J BIOL CHEM, V276, P44457, DOI 10.1074/jbc.M103457200; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; Campo PA, 2002, CELL GROWTH DIFFER, V13, P409; DIEHL AM, 1991, SEMIN LIVER DIS, V11, P315, DOI 10.1055/s-2008-1040449; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; Fausto N, 2001, LIVER TRANSPLANT, V7, P835, DOI 10.1053/jlts.2001.27865; Hansen LK, 1999, J CELL SCI, V112, P2971; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Holecek M, 1999, NUTRITION, V15, P784, DOI 10.1016/S0899-9007(99)00158-6; HOUCK KA, 1985, IN VITRO CELL DEV B, V21, P121, DOI 10.1007/BF02620953; Ilan Y, 1999, SEMIN LIVER DIS, V19, P49, DOI 10.1055/s-2007-1007097; Kimball SR, 2002, J NUTR, V132, P883; Kopple JD, 2001, AM J KIDNEY DIS, V37, pS66, DOI 10.1053/ajkd.2001.20748; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Levy L, 2002, ANN NY ACAD SCI, V963, P21; Loyer P, 1996, J BIOL CHEM, V271, P11484, DOI 10.1074/jbc.271.19.11484; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; MEAD JE, 1990, CANCER RES, V50, P7023; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P884, DOI 10.1016/0006-291X(84)91173-2; Nelsen CJ, 2003, J BIOL CHEM, V278, P3656, DOI 10.1074/jbc.M209374200; Nelsen CJ, 2001, CANCER RES, V61, P8564; Nelsen CJ, 2001, ONCOGENE, V20, P1825, DOI 10.1038/sj.onc.1204248; Parviz F, 1998, J BACTERIOL, V180, P225, DOI 10.1128/JB.180.2.225-230.1998; Parviz F, 1998, J BACTERIOL, V180, P4508, DOI 10.1128/JB.180.17.4508-4515.1998; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; Prober DA, 2001, CURR OPIN GENET DEV, V11, P19, DOI 10.1016/S0959-437X(00)00151-9; Reeds PJ, 2002, CURR OPIN CLIN NUTR, V5, P43, DOI 10.1097/00075197-200201000-00008; Saitoh M, 2002, J BIOL CHEM, V277, P20104, DOI 10.1074/jbc.M201745200; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Shultz VD, 1999, TOXICOL APPL PHARM, V154, P84, DOI 10.1006/taap.1998.8555; Tapon N, 2001, CURR OPIN CELL BIOL, V13, P731, DOI 10.1016/S0955-0674(00)00284-2; TARAO K, 1994, CANCER, V73, P1149, DOI 10.1002/1097-0142(19940215)73:4<1149::AID-CNCR2820730405>3.0.CO;2-9; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; WALFORD RL, 1987, J NUTR, V117, P1650, DOI 10.1093/jn/117.10.1650; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178	41	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25853	25858		10.1074/jbc.M302360200	http://dx.doi.org/10.1074/jbc.M302360200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12736274	hybrid			2022-12-25	WOS:000183920200074
J	Schober, JM; Lau, LF; Ugarova, TP; Lam, SCT				Schober, JM; Lau, LF; Ugarova, TP; Lam, SCT			Identification of a novel integrin alpha(M)beta(2) binding site in CCN1 (CYR61), a matricellular protein expressed in healing wounds and atherosclerotic lesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE GROWTH-FACTOR; IMMEDIATE-EARLY GENE; HUMAN SKIN FIBROBLASTS; HEPARAN-SULFATE PROTEOGLYCANS; ENDOTHELIAL-CELL ADHESION; INTERCELLULAR-ADHESION; TERMINAL DOMAIN; LIGAND-BINDING; GAMMA-CHAIN; ALPHA(V)BETA(3)	CCN1 (cysteine-rich 61) and CCN2 ( connective tissue growth factor) are growth factor-inducible immediate-early gene products found in atherosclerotic lesions, restenosed blood vessels, and healing cutaneous wounds. Both CCN proteins have been shown to support cell adhesion and induce cell migration through interaction with integrin receptors. Recently, we have identified integrin alpha(M)beta(2) as the major adhesion receptor mediating monocyte adhesion to CCN1 and CCN2 and have shown that the alpha(M)I domain binds specifically to both proteins. In the present study, we demonstrated that activated monocytes adhered to a synthetic peptide ( CCN1-H2, SS-VKKYRPKYCGS) derived from a conserved region within the CCN1 C-terminal domain, and this process was blocked by the anti-alpha(M) monoclonal antibody 2LPM19c. Consistently, a glutathione S-transferase (GST) fusion protein containing the alpha(M)I domain (GST-alpha(M)I) bound to immobilized CCN1-H2 as well as to the corresponding H2 sequence in CCN2 (CCN2-H2, TSVKTYRAKFCGV). By contrast, a scrambled CCN1-H2 peptide and an 18-residue peptide derived from an adjacent sequence of CCN1-H2 failed to support monocyte adhesion or alpha(M)I domain binding. To confirm that the CCN1-H2 sequence within the CCN1 protein mediates alpha(M)beta(2) interaction, we developed an anti-peptide antibody against CCN1-H2 and showed that it specifically blocked GST-alpha(M)I binding to intact CCN1. Collectively, these results identify the H2 sequence in CCN1 and CCN2 as a novel integrin alpha(M)beta(2) binding motif that bears no apparent homology to any alpha(M)beta(2) binding sequence reported to date.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60612 USA; Cleveland Clin Fdn, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cleveland Clinic Foundation	Lam, SCT (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, M-C 868,835 S Wolcott Ave, Chicago, IL 60612 USA.	sclam@uic.edu		Lau, Lester/0000-0002-4364-2914	NATIONAL CANCER INSTITUTE [R01CA046565] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041793, R01HL063199, R29HL041793] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA046565, CA-46565, R01 CA046565-14, CA-80080] Funding Source: Medline; NHLBI NIH HHS [HL-41793, HL-07829, HL-63199] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Chen CC, 2001, J BIOL CHEM, V276, P47329, DOI 10.1074/jbc.M107666200; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; CONNOLLY DT, 1986, ANAL BIOCHEM, V152, P136, DOI 10.1016/0003-2697(86)90131-4; Grzeszkiewicz TM, 2002, ENDOCRINOLOGY, V143, P1441, DOI 10.1210/en.143.4.1441; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; Hilfiker A, 2002, CIRCULATION, V106, P254, DOI 10.1161/01.CIR.0000021426.87274.62; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; IUPAC-IUB commission on biochemical nomenclature, 1968, J BIOL CHEM, V243, P3557; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Koivunen E, 2001, J CELL BIOL, V153, P905, DOI 10.1083/jcb.153.5.905; Latinkic BV, 2001, ENDOCRINOLOGY, V142, P2549, DOI 10.1210/en.142.6.2549; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; LI R, 1995, J CELL BIOL, V129, P1143, DOI 10.1083/jcb.129.4.1143; LI R, 1993, J BIOL CHEM, V268, P17513; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; Mesri M, 1998, J BIOL CHEM, V273, P744, DOI 10.1074/jbc.273.2.744; Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709-8720.2002; Moyano JV, 1999, J BIOL CHEM, V274, P135, DOI 10.1074/jbc.274.1.135; Nielsen PK, 2001, J BIOL CHEM, V276, P10906, DOI 10.1074/jbc.M008743200; Oemar BS, 1997, ARTERIOSCL THROM VAS, V17, P1483, DOI 10.1161/01.ATV.17.8.1483; Oemar BS, 1997, CIRCULATION, V95, P831; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Schober JM, 2002, BLOOD, V99, P4457, DOI 10.1182/blood.V99.12.4457; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Ugarova TP, 1998, J BIOL CHEM, V273, P22519, DOI 10.1074/jbc.273.35.22519; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; Wu KJ, 2000, INT J MOL MED, V6, P433; Yakubenko VP, 2002, J BIOL CHEM, V277, P48635, DOI 10.1074/jbc.M208877200; Yakubenko VP, 2001, J BIOL CHEM, V276, P13995, DOI 10.1074/jbc.M010174200	39	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25808	25815		10.1074/jbc.M301534200	http://dx.doi.org/10.1074/jbc.M301534200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12736251	hybrid			2022-12-25	WOS:000183920200068
J	Zhao, KH; Chai, XM; Marmorstein, R				Zhao, KH; Chai, XM; Marmorstein, R			Structure of a Sir2 substrate, Alba, reveals a mechanism for deacetylation-induced enhancement of DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN PROTEIN; CRYSTAL-STRUCTURE; REFINEMENT; ARCHAEAL; SYSTEM; P53	The targeted acetylation status of histones and several other transcriptional regulatory proteins plays an important role in gene expression, although the mechanism for this is not well understood. As a model to understand how targeted acetylation may effect transcription, we determined the x-ray crystal structure of the chromatin protein Alba from Archaeoglobus fulgidus, a substrate for the Sir2 protein that deacetylates it at lysine 11 to promote DNA binding by Alba. The structure reveals a dimer of dimers in which the dimer-dimer interface is stabilized by several conserved hydrophobic residues as well as the lysine 11 target of Sir2. We show that, in solution, the mutation of these hydrophobic residues or lysine 11 disrupts dimer-dimer formation and decreases DNA-binding affinity. We propose that the in vivo deacetylation of lysine 11 of archaeal Alba by Sir2 promotes protein oligomerization for optimal DNA binding. Implications for the mechanism by which histone acetylation modulates gene expression are discussed.	Univ Penn, Wistar Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Chem, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania	Marmorstein, R (corresponding author), Univ Penn, Wistar Inst, Philadelphia, PA 19104 USA.	marmor@wistar.upenn.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060293] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60293, GM52880] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bell SD, 2002, SCIENCE, V296, P148, DOI 10.1126/science.1070506; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Grant PA, 2001, GENOME BIOL, V2; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; LURZ R, 1986, EMBO J, V5, P3715, DOI 10.1002/j.1460-2075.1986.tb04705.x; Marmorstein R, 2001, NAT REV MOL CELL BIO, V2, P422, DOI 10.1038/35073047; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Papworth C.B., 1996, STRATEGIES, V9, P3, DOI DOI 10.1080/08924562.1996.11000299; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Schreiber SL, 2002, CELL, V111, P771, DOI 10.1016/S0092-8674(02)01196-0; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wardleworth BN, 2002, EMBO J, V21, P4654, DOI 10.1093/emboj/cdf465; White MF, 2002, TRENDS GENET, V18, P621, DOI 10.1016/S0168-9525(02)02808-1; Xue H, 2000, J BACTERIOL, V182, P3929, DOI 10.1128/JB.182.14.3929-3933.2000	27	51	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26071	26077		10.1074/jbc.M303666200	http://dx.doi.org/10.1074/jbc.M303666200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730210	hybrid			2022-12-25	WOS:000183920200104
J	Javelaud, D; Laboureau, J; Gabison, E; Verrecchia, F; Mauviel, A				Javelaud, D; Laboureau, J; Gabison, E; Verrecchia, F; Mauviel, A			Disruption of basal JNK activity differentially affects key fibroblast functions important for wound healing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; N-TERMINAL KINASE; COLLAGEN-MATRIX CONTRACTION; PRO-INFLAMMATORY CYTOKINES; HUMAN LUNG FIBROBLASTS; C-JUN; MAP KINASES; SIGNAL-TRANSDUCTION; DEPENDENT PATHWAY; GENE-EXPRESSION	We used both a gene knockout approach and pharmacologic modulation to study the implication of the JNK pathway in regulating fibroblast motility, capacity to contract mechanically unloaded collagen gels, and type I collagen gene expression in vitro. These parameters, which are important for tissue repair, are positively regulated by transforming growth factor (TGF)-beta, a cytokine viewed as playing a master role during wound healing. We demonstrate that basal JNK activity is critical for fibroblast motility because ( a) mouse embryo jnk(-/-) fibroblasts exhibit significantly lower ability to close mechanically induced cell layer wounds than their wild-type (wt) counterparts, and (b) wound closure by human dermal fibroblasts is dramatically impaired by the specific JNK inhibitor SP600125. junAA fibroblasts, in which amino acids Ser(63) and Ser(73) of c-Jun are replaced by two Ala residues so that c-Jun cannot be phosphorylated by JNK, also exhibited impaired motility, suggesting that c-Jun phosphorylation by JNK is critical for fibroblast migration. In sharp contrast to their lesser motility on plastic, jnk(-/-) and junAA fibroblasts contracted free-floating, mechanically unloaded, collagen lattices markedly faster than wt fibroblasts. Furthermore, basal mRNA steady-state levels for types I and III collagen genes were similar in jnk(-/-) and wt fibroblasts. Likewise, overexpression of a dominant-negative mutant form of MKK4 in dermal fibroblasts did not affect collagen expression. We also demonstrate that basal JNK activity does not affect either TGF-beta-induced collagen gene expression or lattice contraction, whereas on the other hand, the blockage of motility initiated by JNK inhibition cannot be overcome by TGF-beta. Together these results demonstrate discrete, yet significant and highly specific, regulation of fibroblast functions important for wound healing by basal JNK activity.	Univ Paris 07, INSERM, U532,Hop St Louis, Inst Rech Peau, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Mauviel, A (corresponding author), Univ Paris 07, INSERM, U532,Hop St Louis, Inst Rech Peau, Pavillon Bazin,1 Ave Claude Vellefaux, F-75475 Paris 10, France.		MAUVIEL, Alain/F-6251-2013; Javelaud, Delphine/B-1129-2019; Verrecchia, Franck/G-5535-2018	Javelaud, Delphine/0000-0002-7674-7739; Verrecchia, Franck/0000-0003-4920-2554; Mauviel, Alain/0000-0002-0438-2793				Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; CHU ML, 1985, J BIOL CHEM, V260, P4357; CHU ML, 1985, J BIOL CHEM, V260, P2315; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Grinnell F, 2000, TRENDS CELL BIOL, V10, P362, DOI 10.1016/S0962-8924(00)01802-X; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Hashimoto S, 2001, J ALLERGY CLIN IMMUN, V107, P1001, DOI 10.1067/mai.2001.114702; Hashimoto S, 2001, AM J RESP CRIT CARE, V163, P152, DOI 10.1164/ajrccm.163.1.2005069; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Lee DJ, 2000, EXP CELL RES, V257, P190, DOI 10.1006/excr.2000.4866; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; OKane S, 1997, INT J BIOCHEM CELL B, V29, P63, DOI 10.1016/S1357-2725(96)00120-3; POSTLETHWAITE AE, 1987, J EXP MED, V165, P251, DOI 10.1084/jem.165.1.251; Reed MJ, 2001, MECH AGEING DEV, V122, P1203, DOI 10.1016/S0047-6374(01)00260-3; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Rosenfeldt H, 1998, MOL CELL BIOL, V18, P2659, DOI 10.1128/MCB.18.5.2659; Rosenfeldt H, 2000, J BIOL CHEM, V275, P3088, DOI 10.1074/jbc.275.5.3088; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Schramek H, 2002, NEWS PHYSIOL SCI, V17, P62, DOI 10.1152/nips.01365.2001; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Verrecchia F, 2003, J BIOL CHEM, V278, P1585, DOI 10.1074/jbc.M206927200; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; WHITMARSH AJ, 1999, SCI STKE; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004	31	99	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24624	24628		10.1074/jbc.M301942200	http://dx.doi.org/10.1074/jbc.M301942200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12730213	hybrid			2022-12-25	WOS:000183824800046
J	Verderio, EAM; Telci, D; Okoye, A; Melino, G; Griffin, M				Verderio, EAM; Telci, D; Okoye, A; Melino, G; Griffin, M			A novel RGD-independent cell adhesion pathway mediated by fibronectin-bound tissue transglutaminase rescues cells from anoikis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 FIBROBLASTS; EXTRACELLULAR-MATRIX; INTEGRIN-BINDING; HEPARIN-BINDING; CROSS-LINKING; V REGION; APOPTOSIS; EXPRESSION; ENZYME; DOMAIN	Specific association of tissue transglutaminase (tTG) with matrix fibronectin (FN) results in the formation of an extracellular complex (tTG-FN) with distinct adhesive and pro-survival characteristics. tTG-FN supports RGD-independent cell adhesion of different cell types and the formation of distinctive RhoA-dependent focal adhesions following inhibition of integrin function by competitive RGD peptides and function blocking anti-integrin antibodies alpha(5)beta(1). Association of tTG with its binding site on the 70-kDa amino-terminal FN fragment does not support this cell adhesion process, which seems to involve the entire FN molecule. RGD-independent cell adhesion to tTG-FN does not require transamidating activity, is mediated by the binding of tTG to cell-surface heparan sulfate chains, is dependent on the function of protein kinase Calpha, and leads to activation of the cell survival focal adhesion kinase. The tTG-FN complex can maintain cell viability of tTG-null mouse dermal fibroblasts when apoptosis is induced by inhibition of RGD-dependent adhesion (anoikis), suggesting an extracellular survival role for tTG. We propose a novel RGD-independent cell adhesion mechanism that promotes cell survival when the antiapoptotic role mediated by RGD-dependent integrin function is reduced as in tissue injury, which is consistent with the externalization and binding of tTG to fibronectin following cell damage/stress.	Nottingham Trent Univ, Dept Life Sci, Nottingham NG11 8NS, England; Univ Roma Tor Vergata, Dept Expt & Biochem Sci, I-00133 Rome, Italy; Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	Nottingham Trent University; University of Rome Tor Vergata; University of Leicester	Griffin, M (corresponding author), Nottingham Trent Univ, Dept Life Sci, Clifton Lane, Nottingham NG11 8NS, England.	martin.griffin@ntu.ac.uk	Telci, Dilek/N-5053-2019; Telci, Dilek/B-5880-2017; Verderio, Elisabetta/H-2789-2016	Telci, Dilek/0000-0002-2793-6533; Telci, Dilek/0000-0002-2793-6533; Verderio, Elisabetta/0000-0001-9153-8997; Griffin, Martin/0000-0003-3824-306X				Aeschlimann D, 2000, CONNECT TISSUE RES, V41, P1, DOI 10.3109/03008200009005638; Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; Balklava Z, 2002, J BIOL CHEM, V277, P16567, DOI 10.1074/jbc.M109836200; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; BERGAMINI CM, 1993, BIOCHEM J, V291, P37, DOI 10.1042/bj2910037; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; Davis GE, 2000, AM J PATHOL, V156, P1489, DOI 10.1016/S0002-9440(10)65020-1; De Laurenzi V, 2001, MOL CELL BIOL, V21, P148, DOI 10.1128/MCB.21.1.148-155.2001; DEDHAR S, 1987, J CELL BIOL, V104, P585, DOI 10.1083/jcb.104.3.585; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gaudry CA, 1999, J BIOL CHEM, V274, P30707, DOI 10.1074/jbc.274.43.30707; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; Gronthos S, 1997, J BONE MINER RES, V12, P1189, DOI 10.1359/jbmr.1997.12.8.1189; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Haroon ZA, 1999, FASEB J, V13, P1787, DOI 10.1096/fasebj.13.13.1787; HASEGAWA G, 2002, MINERVA BIOTECNOLOGI, V14, P192; Heath DJ, 2002, BIOMATERIALS, V23, P1519, DOI 10.1016/S0142-9612(01)00282-4; Heath DJ, 2001, J BONE MINER RES, V16, P1477, DOI 10.1359/jbmr.2001.16.8.1477; Hocking DC, 2000, J BIOL CHEM, V275, P10673, DOI 10.1074/jbc.275.14.10673; Humphries MJ, 2000, TRENDS PHARMACOL SCI, V21, P29, DOI 10.1016/S0165-6147(99)01410-8; JEONG J, 2001, BIOCHEM J, V356, P231; JEONG JM, 1995, J BIOL CHEM, V270, P5654, DOI 10.1074/jbc.270.10.5654; Johnson TS, 1999, J AM SOC NEPHROL, V10, P2146; Jones RA, 1997, J CELL SCI, V110, P2461; Kapila YL, 1999, J BIOL CHEM, V274, P30906, DOI 10.1074/jbc.274.43.30906; Leblanc A, 1999, PROTEIN EXPRES PURIF, V17, P89, DOI 10.1006/prep.1999.1107; LEMOSY EK, 1992, J BIOL CHEM, V267, P7880; Liu SP, 2002, P NATL ACAD SCI USA, V99, P2743, DOI 10.1073/pnas.042454899; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Madden HL, 2000, AM J RESP CRIT CARE, V162, P1553, DOI 10.1164/ajrccm.162.4.2001015; Melino G, 1997, J NEURO-ONCOL, V31, P65, DOI 10.1023/A:1005733430435; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Pereira M, 2002, J CELL SCI, V115, P609; RADEK JT, 1993, P NATL ACAD SCI USA, V90, P3152, DOI 10.1073/pnas.90.8.3152; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Sechler JL, 2000, J CELL SCI, V113, P1491; Sechler JL, 1998, J BIOL CHEM, V273, P25533, DOI 10.1074/jbc.273.40.25533; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; Takahashi H, 2000, J BIOL CHEM, V275, P23589, DOI 10.1074/jbc.M003526200; UPCHURCH HF, 1991, J CELL PHYSIOL, V149, P375, DOI 10.1002/jcp.1041490304; Verderio E, 1999, J HISTOCHEM CYTOCHEM, V47, P1417, DOI 10.1177/002215549904701108; Verderio E, 1998, EXP CELL RES, V239, P119, DOI 10.1006/excr.1997.3874; Verderio E, 2001, J BIOMED MATER RES, V54, P294, DOI 10.1002/1097-4636(200102)54:2<294::AID-JBM17>3.0.CO;2-Q; Woods A, 2001, CURR OPIN CELL BIOL, V13, P578, DOI 10.1016/S0955-0674(00)00254-4	48	107	111	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42604	42614		10.1074/jbc.M303303200	http://dx.doi.org/10.1074/jbc.M303303200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12732629	Green Accepted, Green Submitted, hybrid			2022-12-25	WOS:000185989500126
J	McHugh, JP; Rodriguez-Quinones, F; Abdul-Tehrani, H; Svistunenko, DA; Poole, RK; Cooper, CE; Andrews, SC				McHugh, JP; Rodriguez-Quinones, F; Abdul-Tehrani, H; Svistunenko, DA; Poole, RK; Cooper, CE; Andrews, SC			Global iron-dependent gene regulation in Escherichia coli - A new mechanism for iron homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRIC UPTAKE REGULATOR; GRAM-NEGATIVE BACTERIA; FUR REGULON; PSEUDOMONAS-AERUGINOSA; SALMONELLA-TYPHIMURIUM; EXPRESSION ANALYSIS; ELECTRON-TRANSPORT; OXIDASE COMPLEX; IDENTIFICATION; PROTEIN	Organisms generally respond to iron deficiency by increasing their capacity to take up iron and by consuming intracellular iron stores. Escherichia coli, in which iron metabolism is particularly well understood, contains at least 7 iron-acquisition systems encoded by 35 iron-repressed genes. This Fe-dependent repression is mediated by a transcriptional repressor, Fur ( ferric uptake regulation), which also controls genes involved in other processes such as iron storage, the Tricarboxylic Acid Cycle, pathogenicity, and redox-stress resistance. Our macroarray-based global analysis of iron- and Fur-dependent gene expression in E. coli has revealed several novel Fur-repressed genes likely to specify at least three additional iron- transport pathways. Interestingly, a large group of energy metabolism genes was found to be iron and Fur induced. Many of these genes encode iron- rich respiratory complexes. This iron- and Fur-dependent regulation appears to represent a novel iron-homeostatic mechanism whereby the synthesis of many iron- containing proteins is repressed under iron- restricted conditions. This mechanism thus accounts for the low iron contents of fur mutants and explains how E. coli can modulate its iron requirements. Analysis of Fe-55-labeled E. coli proteins revealed a marked decrease in iron- protein composition for the fur mutant, and visible and EPR spectroscopy showed major reductions in cytochrome b and d levels, and in iron- sulfur cluster contents for the chelator-treated wild-type and/or fur mutant, correlating well with the array and quantitative RT-PCR data. In combination, the results provide compelling evidence for the regulation of intracellular iron consumption by the Fe2+-Fur complex.	Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Univ Essex, Dept Biol Sci, Colchester CO4 3SQ, Essex, England	University of Reading; University of Sheffield; University of Essex	Andrews, SC (corresponding author), Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England.		Cooper, Chris/AAK-9729-2020; Andrews, Simon C/H-4758-2019	Cooper, Chris/0000-0003-0381-3990; Andrews, Simon C/0000-0003-4295-2686; Svistunenko, Dimitri/0000-0001-8060-2738				Abdul-Tehrani H, 1999, J BACTERIOL, V181, P1415, DOI 10.1128/JB.181.5.1415-1428.1999; Andrews SC, 1998, ADV MICROB PHYSIOL, V40, P281, DOI 10.1016/S0065-2911(08)60134-4; Baichoo N, 2002, MOL MICROBIOL, V45, P1613, DOI 10.1046/j.1365-2958.2002.03113.x; BOLGIANO B, 1991, BIOCHEM J, V274, P723, DOI 10.1042/bj2740723; CAMMACK R, 1993, METHOD ENZYMOL, V227, P353, DOI 10.1016/0076-6879(93)27014-8; COTTER PA, 1992, FEMS MICROBIOL LETT, V100, P227, DOI 10.1111/j.1574-6968.1992.tb05708.x; Earhart C.F., 1996, ESCHERICHIA COLI SAL, V2nd ed., P1075; Eitinger T, 2000, ARCH MICROBIOL, V173, P1, DOI 10.1007/s002030050001; Gennis R. B., 1996, ESCHERICHIA COLI SAL, P217; GRUER MJ, 1994, MICROBIOL-SGM, V140, P2531, DOI 10.1099/00221287-140-10-2531; GUERINOT ML, 1994, ANNU REV MICROBIOL, V48, P743, DOI 10.1146/annurev.mi.48.100194.003523; HANTKE K, 1981, MOL GEN GENET, V182, P288, DOI 10.1007/BF00269672; Hantke K, 2001, CURR OPIN MICROBIOL, V4, P172, DOI 10.1016/S1369-5274(00)00184-3; HANTKE K, 1990, FEMS MICROBIOL LETT, V67, P5, DOI 10.1111/j.1574-6968.1990.tb13826.x; JONES CW, 1966, BIOCHIM BIOPHYS ACTA, V113, P467, DOI 10.1016/S0926-6593(66)80005-X; Jordan A, 1996, MOL MICROBIOL, V19, P777, DOI 10.1046/j.1365-2958.1996.424950.x; Kalnenieks U, 1998, FEMS MICROBIOL LETT, V168, P91; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; KITA K, 1984, J BIOL CHEM, V259, P3369; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Masse E, 2002, P NATL ACAD SCI USA, V99, P4620, DOI 10.1073/pnas.032066599; NIEDERHOFFER EC, 1990, J BACTERIOL, V172, P1930, DOI 10.1128/jb.172.4.1930-1938.1990; Ochsner UA, 2002, MOL MICROBIOL, V45, P1277, DOI 10.1046/j.1365-2958.2002.03084.x; Ochsner UA, 1996, P NATL ACAD SCI USA, V93, P4409, DOI 10.1073/pnas.93.9.4409; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; Panina EM, 2001, NUCLEIC ACIDS RES, V29, P5195, DOI 10.1093/nar/29.24.5195; PARK SJ, 1995, J BACTERIOL, V177, P6255, DOI 10.1128/jb.177.21.6255-6262.1995; PARK SJ, 1995, MOL MICROBIOL, V15, P473, DOI 10.1111/j.1365-2958.1995.tb02261.x; Patzer SI, 1999, J BACTERIOL, V181, P3307, DOI 10.1128/JB.181.10.3307-3309.1999; Paustian ML, 2001, INFECT IMMUN, V69, P4109, DOI 10.1128/IAI.69.6.4109-4115.2001; PHILLIPSJONES MK, 1993, J MOL BIOL, V233, P1, DOI 10.1006/jmbi.1993.1479; Quail MA, 1996, BIOCHEM BIOPH RES CO, V229, P635, DOI 10.1006/bbrc.1996.1856; RAINNIE DJ, 1973, J GEN MICROBIOL, V77, P339, DOI 10.1099/00221287-77-2-339; Robison K, 1998, J MOL BIOL, V284, P241, DOI 10.1006/jmbi.1998.2160; Sambrook J., 2002, MOL CLONING LAB MANU; SPIRO S, 1990, FEMS MICROBIOL LETT, V75, P399, DOI 10.1016/0378-1097(90)90690-R; Stanley NR, 2001, J BACTERIOL, V183, P139, DOI 10.1128/JB.183.1.139-144.2001; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; STOJILJKOVIC I, 1994, J MOL BIOL, V236, P531, DOI 10.1006/jmbi.1994.1163; STOJILJKOVIC I, 1992, EMBO J, V11, P4359, DOI 10.1002/j.1460-2075.1992.tb05535.x; Thompson DK, 2002, APPL ENVIRON MICROB, V68, P881, DOI 10.1128/AEM.68.2.881-892.2002; TOUATI D, 1988, J BACTERIOL, V170, P2511, DOI 10.1128/jb.170.6.2511-2520.1988; Tseng CP, 1997, FEMS MICROBIOL LETT, V157, P67, DOI 10.1016/S0378-1097(97)00455-2; TSOLIS RM, 1995, J BACTERIOL, V177, P4628, DOI 10.1128/jb.177.16.4628-4637.1995; Vassinova N, 2000, MICROBIOL-SGM, V146, P3171, DOI 10.1099/00221287-146-12-3171; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	46	373	385	3	62	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29478	29486		10.1074/jbc.M303381200	http://dx.doi.org/10.1074/jbc.M303381200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12746439	hybrid			2022-12-25	WOS:000184507000012
J	Bertrand, C; Bergounioux, C; Domenichini, S; Delarue, M; Zhou, DX				Bertrand, C; Bergounioux, C; Domenichini, S; Delarue, M; Zhou, DX			Arabidopsis histone acetyltransferase AtGCN5 regulates the floral meristem activity through the WUSCHEL/AGAMOUS pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE REGULATION; ACETYLATION; TRANSCRIPTION; EXPRESSION; COMPLEXES; DEACETYLATION; BROMODOMAIN; PROTEINS; WUSCHEL; ROLES	Histone acetyltransferases, which are able to acetylate histone and non-histone proteins, play important roles in gene regulation. Many histone acetyltransferases are related to yeast Gcn5, a component of two transcription regulatory complexes SAGA and ADA. In this work, by characterizing a mutation in the Arabidopsis GCN5 gene (AtGCN5) we studied the regulatory function of this gene in controlling floral meristem activity. We show that in addition to pleiotropic effects on plant development, this mutation also leads to the production of terminal flowers. The flowers show homeotic transformations of petals into stamens and sepals into filamentous structures and produce ectopic carpels. The phenotypes correlate to an expansion of the expression domains within floral meristems of the key regulatory genes WUSCHEL (WUS) and AGAMOUS (AG). These results suggest that AtGCN5 is required to regulate the floral meristem activity through the WUS/AG pathway. This study brings new elements on the elucidation of specific developmental pathways regulated by AtGCN5 and on the control mechanism of meristem regulatory gene expression.	Univ Paris 11, Inst Biotechnol Plantes, CNRS, UMR 8618, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Zhou, DX (corresponding author), Univ Paris 11, Inst Biotechnol Plantes, CNRS, UMR 8618, Bat 425, F-91405 Orsay, France.	zhou@ibp.u-psud.fr		Bertrand, Claire/0000-0001-5595-0677; Zhou, Dao-Xiu/0000-0002-1540-0598; DOMENICHINI, Severine/0000-0002-5997-2694				BOWMAN JL, 1991, PLANT CELL, V3, P749, DOI 10.1105/tpc.3.8.749; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; Deyholos MK, 2000, PLANT CELL, V12, P1799, DOI 10.1105/tpc.12.10.1799; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Gross-Hardt R, 2002, GENE DEV, V16, P1129, DOI 10.1101/gad.225202; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Lenhard M, 2001, CELL, V105, P805, DOI 10.1016/S0092-8674(01)00390-7; Lohmann JU, 2001, CELL, V105, P793, DOI 10.1016/S0092-8674(01)00384-1; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; Lusser A, 2001, TRENDS PLANT SCI, V6, P59, DOI 10.1016/S1360-1385(00)01839-2; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; Mayer KFX, 1998, CELL, V95, P805, DOI 10.1016/S0092-8674(00)81703-1; Mizukami Y, 1997, PLANT CELL, V9, P393, DOI 10.1105/tpc.9.3.393; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Pollard KJ, 1998, BIOESSAYS, V20, P771, DOI 10.1002/(SICI)1521-1878(199809)20:9<771::AID-BIES10>3.0.CO;2-V; Ricci AR, 2002, MOL CELL BIOL, V22, P4033, DOI 10.1128/MCB.22.12.4033-4042.2002; SAKAI H, 1995, NATURE, V378, P199, DOI 10.1038/378199a0; Saleh A, 1997, J BIOL CHEM, V272, P5571, DOI 10.1074/jbc.272.9.5571; Sheldon LA, 2001, J BIOL CHEM, V276, P32423, DOI 10.1074/jbc.C100315200; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Stockinger EJ, 2001, NUCLEIC ACIDS RES, V29, P1524, DOI 10.1093/nar/29.7.1524; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tian L, 2001, P NATL ACAD SCI USA, V98, P200, DOI 10.1073/pnas.011347998; Vlachonasios KE, 2003, PLANT CELL, V15, P626, DOI 10.1105/tpc.007922; Winston F, 1999, NAT STRUCT BIOL, V6, P601, DOI 10.1038/10640; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9	35	117	132	3	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28246	28251		10.1074/jbc.M302787200	http://dx.doi.org/10.1074/jbc.M302787200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12740375	hybrid			2022-12-25	WOS:000184242700114
J	Sasaki, A; Hata, K; Suzuki, S; Sawada, M; Wada, T; Yamaguchi, K; Obinata, M; Tateno, H; Suzuki, H; Miyagi, T				Sasaki, A; Hata, K; Suzuki, S; Sawada, M; Wada, T; Yamaguchi, K; Obinata, M; Tateno, H; Suzuki, H; Miyagi, T			Overexpression of plasma membrane-associated sialidase attenuates insulin signaling in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GANGLIOSIDE SIALIDASE; SKELETAL-MUSCLE; DIFFERENTIAL EXPRESSION; RECEPTOR SUBSTRATE-1; MOLECULAR-CLONING; ADAPTER PROTEIN; LIPID RAFTS; RAT; RESISTANCE; CELLS	Plasma membrane-associated sialidase is a key enzyme for ganglioside hydrolysis, thereby playing crucial roles in regulation of cell surface functions. Here we demonstrate that mice overexpressing the human ortholog (NEU3) develop diabetic phenotype by 18-22 weeks associated with hyperinsulinemia, islet hyperplasia, and increased beta-cell mass. As compared with the wild type, insulin-stimulated phosphorylation of the insulin receptor (IR) and insulin receptor substrate I was significantly reduced, and activities of phosphatidylinositol 3-kinase and glycogen synthase were low in transgenic muscle. IR phosphorylation was already attenuated in the younger mice before manifestation of hyperglycemia. Transient transfection of NEU3 into 3T3-L1 adipocytes and L6 myocytes caused a significant decrease in IR signaling. In response to insulin, NEU3 was found to undergo tyrosine phosphorylation and subsequent association with the Grb2 protein, thus being activated and causing negative regulation of insulin signaling. In fact, accumulation of GM1 and GM2, the possible sialidase products in transgenic tissues, caused inhibition of IR phosphorylation in vitro, and blocking of association with Grb2 resulted in reversion of impaired insulin signaling in L6 cells. The data indicate that NEU3 indeed participates in the control of insulin signaling, probably via modulation of gangliosides and interaction with Grb2, and that the mice can serve as a valuable model for human insulin-resistant diabetes.	Miyagi Prefectural Canc Ctr, Res Inst, Div Biochem, Natori, Miyagi 9811293, Japan; Miyagi Prefectural Canc Ctr, Res Inst, Div Pathol, Natori, Miyagi 9811293, Japan; Miyagi Prefectural Canc Ctr, Dept Internal Med, Natori, Miyagi 9811293, Japan; Tohoku Univ, Sch Med, Dept Mol Metab & Diabet, Sendai, Miyagi 9808574, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Cell Biol, Sendai, Miyagi 9808575, Japan	Tohoku University; Tohoku University	Miyagi, T (corresponding author), Miyagi Prefectural Canc Ctr, Res Inst, Div Biochem, 47-1 Nodayama,Medeshima Shiode, Natori, Miyagi 9811293, Japan.							CHIEN JL, 1983, J BIOL CHEM, V258, P727; CLARK JB, 1983, P SOC EXP BIOL MED, V173, P68; COHENFORTERRE L, 1990, BIOCHEM PHARMACOL, V40, P507, DOI 10.1016/0006-2952(90)90549-Z; Czech MP, 2000, NATURE, V407, P147, DOI 10.1038/35025183; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; DUBLER RE, 1985, ARCH BIOCHEM BIOPHYS, V236, P119, DOI 10.1016/0003-9861(85)90611-3; FUJITAYAMAGUCHI Y, 1985, BIOCHEM BIOPH RES CO, V129, P739, DOI 10.1016/0006-291X(85)91954-0; Goldstein BJ, 2000, J BIOL CHEM, V275, P4283, DOI 10.1074/jbc.275.6.4283; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; Hakomori SI, 1998, ANN NY ACAD SCI, V845, P1, DOI 10.1111/j.1749-6632.1998.tb09657.x; Hasegawa T, 2001, BIOCHEM BIOPH RES CO, V280, P726, DOI 10.1006/bbrc.2000.4186; Hasegawa T, 2000, J BIOL CHEM, V275, P8007, DOI 10.1074/jbc.275.11.8007; Hata K, 1998, J BIOCHEM-TOKYO, V123, P899; HAYES GR, 1986, J BIOL CHEM, V261, P2791; JONES DH, 1991, BIOTECHNIQUES, V10, P62; Kakugawa Y, 2002, P NATL ACAD SCI USA, V99, P10718, DOI 10.1073/pnas.152597199; Kalka D, 2001, BIOCHEM BIOPH RES CO, V283, P989, DOI 10.1006/bbrc.2001.4864; Kopitz J, 1997, EUR J BIOCHEM, V248, P527, DOI 10.1111/j.1432-1033.1997.00527.x; Kopitz J, 1996, GLYCOBIOLOGY, V6, P367, DOI 10.1093/glycob/6.3.367; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Misasi R, 1997, DIABETES METAB REV, V13, P163, DOI 10.1002/(SICI)1099-0895(199709)13:3<163::AID-DMR189>3.0.CO;2-Z; MIYAGI T, 1990, J BIOCHEM-TOKYO, V107, P787, DOI 10.1093/oxfordjournals.jbchem.a123126; Miyagi T, 1999, J BIOL CHEM, V274, P5004, DOI 10.1074/jbc.274.8.5004; MIYAGI T, 1979, CANCER RES, V39, P2779; Monti E, 2000, BIOCHEM J, V349, P343, DOI 10.1042/0264-6021:3490343; NAKAMURA K, 1988, J BIOCHEM-TOKYO, V103, P201, DOI 10.1093/oxfordjournals.jbchem.a122232; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NOJIRI H, 1991, J BIOL CHEM, V266, P4531; Patti ME, 1999, DIABETES, V48, P1562, DOI 10.2337/diabetes.48.8.1562; Rellier N, 1999, LIFE SCI, V64, P1571, DOI 10.1016/S0024-3205(99)00094-6; SALHANICK AI, 1988, AM J PHYSIOL, V255, P173; SAYESKI PP, 1994, GENE, V140, P289, DOI 10.1016/0378-1119(94)90560-6; Tagami S, 2002, J BIOL CHEM, V277, P3085, DOI 10.1074/jbc.M103705200; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; TSURUOKA T, 1993, J BIOL CHEM, V268, P2211; Venerando B, 2002, BLOOD, V99, P1064, DOI 10.1182/blood.V99.3.1064; Wada T, 1999, BIOCHEM BIOPH RES CO, V261, P21, DOI 10.1006/bbrc.1999.0973; Wang Y, 2002, J BIOL CHEM, V277, P26252, DOI 10.1074/jbc.M110515200; WISE LS, 1979, J BIOL CHEM, V254, P273; Wu G, 1998, ANN NY ACAD SCI, V845, P126, DOI 10.1111/j.1749-6632.1998.tb09666.x; Yamashita T, 2003, P NATL ACAD SCI USA, V100, P3445, DOI 10.1073/pnas.0635898100; Yates AJ, 1998, ANN NY ACAD SCI, V845, P57, DOI 10.1111/j.1749-6632.1998.tb09662.x	44	95	104	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27896	27902		10.1074/jbc.M212200200	http://dx.doi.org/10.1074/jbc.M212200200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12730204	hybrid			2022-12-25	WOS:000184242700071
J	Janas, E; Hofacker, M; Chen, M; Gompf, S; van der Does, C; Tampe, R				Janas, E; Hofacker, M; Chen, M; Gompf, S; van der Does, C; Tampe, R			The ATP hydrolysis cycle of the nucleotide-binding domain of the mitochondrial ATP-binding cassette transporter Mdl1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; ABC TRANSPORTER; ESCHERICHIA-COLI; HISTIDINE PERMEASE; CRYSTAL-STRUCTURE; CATALYTIC CYCLE; SALMONELLA-TYPHIMURIUM; PEPTIDE-BINDING; MOTOR DOMAIN; ACTIVE-SITE	The ABC transporter Mdl1p, a structural and functional homologue of the transporter associated with antigen processing ( TAP) plays an important role in intracellular peptide transport from the mitochondrial matrix of Saccharomyces cerevisiae. To characterize the ATP hydrolysis cycle of Mdl1p, the nucleotide-binding domain (NBD) was overexpressed in Escherichia coli and purified to homogeneity. The isolated NBD was active in ATP binding and hydrolysis with a turnover of 25 ATP per minute and a K-m of 0.6 mM and did not show cooperativity in ATPase activity. However, the ATPase activity was non-linearly dependent on protein concentration ( Hill coefficient of 1.7), indicating that the functional state is a dimer. Dimeric catalytic transition states could be trapped either by incubation with orthovanadate or beryllium fluoride, or by mutagenesis of the NBD. The nucleotide composition of trapped intermediate states was determined using [alpha-P-32] ATP and [gamma-P-32] ATP. Three different dimeric intermediate states were isolated, containing either two ATPs, one ATP and one ADP, or two ADPs. Based on these experiments, it was shown that: (i) ATP binding to two NBDs induces dimerization, (ii) in all isolated dimeric states, two nucleotides are present, (iii) phosphate can dissociate from the dimer, (iv) both nucleotides are hydrolyzed, and ( v) hydrolysis occurs in a sequential mode. Based on these data, we propose a processive-clamp model for the catalytic cycle in which association and dissociation of the NBDs depends on the status of bound nucleotides.	Univ Frankfurt, Bioctr, Inst Biochem, D-60439 Frankfurt, Germany	Goethe University Frankfurt	Tampe, R (corresponding author), Univ Frankfurt, Bioctr, Inst Biochem, Marie Curie Str 9, D-60439 Frankfurt, Germany.		Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160				Annereau JP, 2003, BIOCHEM J, V371, P451, DOI 10.1042/BJ20021318; Arnold I, 2002, BBA-MOL CELL RES, V1592, P89, DOI 10.1016/S0167-4889(02)00267-7; Booth CL, 2000, BIOCHEMISTRY-US, V39, P5518, DOI 10.1021/bi992931x; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; CHEN M, 2003, J BIOL CHEM; Davidson AL, 1996, J BIOL CHEM, V271, P4858; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; Gorbulev S, 2001, P NATL ACAD SCI USA, V98, P3732, DOI 10.1073/pnas.061467898; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Karpowich N, 2001, STRUCTURE, V9, P571, DOI 10.1016/S0969-2126(01)00617-7; Kennedy KA, 1999, J BIOL CHEM, V274, P6259, DOI 10.1074/jbc.274.10.6259; Kerr ID, 2002, BBA-BIOMEMBRANES, V1561, P47, DOI 10.1016/S0304-4157(01)00008-9; Lankat-Buttgereit B, 2002, PHYSIOL REV, V82, P187, DOI 10.1152/physrev.00025.2001; Liu PQ, 1999, J BIOL CHEM, V274, P18310, DOI 10.1074/jbc.274.26.18310; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; MORBACH S, 1993, J BIOL CHEM, V268, P18617; Neumann L, 2002, J MOL BIOL, V324, P965, DOI 10.1016/S0022-2836(02)01148-8; Nikaido H, 2002, P NATL ACAD SCI USA, V99, P9609, DOI 10.1073/pnas.162375699; Nikaido K, 1999, J BIOL CHEM, V274, P26727, DOI 10.1074/jbc.274.38.26727; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; Sauna ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/bi026626e; Schmitt L, 2002, CURR OPIN STRUC BIOL, V12, P754, DOI 10.1016/S0959-440X(02)00399-8; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; Sharma S, 2000, J BACTERIOL, V182, P6570, DOI 10.1128/JB.182.23.6570-6576.2000; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P14138, DOI 10.1021/bi001128w; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; WALKER JE, 1982, NATURE, V298, P867, DOI 10.1038/298867a0; Young L, 2001, SCIENCE, V291, P2135, DOI 10.1126/science.1056957; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200	42	149	149	3	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26862	26869		10.1074/jbc.M301227200	http://dx.doi.org/10.1074/jbc.M301227200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12746444	hybrid			2022-12-25	WOS:000184155700074
J	Marz, KE; Lauer, JM; Hanson, PI				Marz, KE; Lauer, JM; Hanson, PI			Defining the SNARE complex binding surface of alpha-SNAP - Implications for SNARE complex disassembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL-ELECTROPHORESIS; CRYSTAL-STRUCTURE; MEMBRANE-FUSION; CORE COMPLEX; SYNAPTIC EXOCYTOSIS; IN-VITRO; PROTEINS; NSF; TRANSPORT; GOLGI	N-Ethylmaleimide-sensitive factor (NSF) and its adaptor protein alpha-soluble NSF attachment protein (alpha-SNAP) sustain membrane trafficking by disassembling soluble NSF attachment protein receptor ( SNARE) complexes that form during membrane fusion. To better understand the role of alpha-SNAP in this process, we used site-directed mutagenesis to identify residues in alpha-SNAP that interact with SNARE complexes. We find that mutations in charged residues distributed over a concave surface formed by the N-terminal nine alpha-helices of alpha-SNAP affect its ability to bind synaptic SNARE complex and promote its disassembly by NSF. Replacing basic residues on this surface with alanines reduced SNARE complex binding and disassembly, whereas replacing acidic residues with alanines enhanced alpha-SNAP efficacy in both assays. These findings show that the ability of NSF to take apart SNARE complexes depends upon electrostatic interactions between alpha-SNAP and the acidic surface of the SNARE complex and provide insight into how NSF and alpha-SNAP work together to drive disassembly.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Hanson, PI (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave,Box 8228, St Louis, MO 63110 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038058] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38058] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Antonin W, 2000, J NEUROSCI, V20, P5724, DOI 10.1523/JNEUROSCI.20-15-05724.2000; Antonin W, 2002, NAT STRUCT BIOL, V9, P107, DOI 10.1038/nsb746; Antonin W, 2000, EMBO J, V19, P6453, DOI 10.1093/emboj/19.23.6453; Barnard RJO, 1996, MOL BIOL CELL, V7, P693, DOI 10.1091/mbc.7.5.693; Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; Berggren KN, 2001, PROTEOMICS, V1, P54, DOI 10.1002/1615-9861(200101)1:1<54::AID-PROT54>3.3.CO;2-X; Chen XC, 2002, NEURON, V33, P397, DOI 10.1016/S0896-6273(02)00583-4; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; Ernst JA, 2003, J BIOL CHEM, V278, P8630, DOI 10.1074/jbc.M211889200; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Gmachl MJS, 2001, J BIOL CHEM, V276, P18178, DOI 10.1074/jbc.M101513200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HANSON PI, 1995, J BIOL CHEM, V270, P16055; HARTLEY RW, 1993, BIOCHEMISTRY-US, V32, P5978, DOI 10.1021/bi00074a008; Hay JC, 2001, EXP CELL RES, V271, P10, DOI 10.1006/excr.2001.5368; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; Hirling H, 1996, P NATL ACAD SCI USA, V93, P11945, DOI 10.1073/pnas.93.21.11945; Hohl TM, 1998, MOL CELL, V2, P539, DOI 10.1016/S1097-2765(00)80153-7; Itin C, 1997, J BIOL CHEM, V272, P27737, DOI 10.1074/jbc.272.44.27737; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Mallard F, 2002, J CELL BIOL, V156, P653, DOI 10.1083/jcb.200110081; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; Pabst S, 2000, J BIOL CHEM, V275, P19808, DOI 10.1074/jbc.M002571200; Paek I, 1997, J CELL BIOL, V137, P1017, DOI 10.1083/jcb.137.5.1017; Prekeris R, 1999, MOL BIOL CELL, V10, P3891, DOI 10.1091/mbc.10.11.3891; Rice LM, 1999, MOL CELL, V4, P85, DOI 10.1016/S1097-2765(00)80190-2; Rossi G, 1997, J BIOL CHEM, V272, P16610, DOI 10.1074/jbc.272.26.16610; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Scales SJ, 2001, P NATL ACAD SCI USA, V98, P14262, DOI 10.1073/pnas.251547598; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHREIBER G, 1993, BIOCHEMISTRY-US, V32, P5145, DOI 10.1021/bi00070a025; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Steinberg TH, 1996, ANAL BIOCHEM, V239, P223, DOI 10.1006/abio.1996.0319; Subramaniam VN, 1997, J BIOL CHEM, V272, P25441, DOI 10.1074/jbc.272.41.25441; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Wang L, 2000, J BIOL CHEM, V275, P22862, DOI 10.1074/jbc.M001447200; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; Wimmer C, 2001, J BIOL CHEM, V276, P29091, DOI 10.1074/jbc.M011292200; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3; Xu DL, 2000, J BIOL CHEM, V275, P39631, DOI 10.1074/jbc.M007684200	47	59	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27000	27008		10.1074/jbc.M302003200	http://dx.doi.org/10.1074/jbc.M302003200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12730228	hybrid			2022-12-25	WOS:000184155700091
J	Mulder, J; Poland, M; Gebbink, MFBG; Calafat, J; Moolenaar, WH; Kranenburg, O				Mulder, J; Poland, M; Gebbink, MFBG; Calafat, J; Moolenaar, WH; Kranenburg, O			p116(Rip) is a novel filamentous actin-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; LYSOPHOSPHATIDIC ACID; EXCHANGE FACTOR; ARP2/3 COMPLEX; CYTOSKELETON; INHIBITION; BRAIN; ORGANIZATION; ACTIVATION; DYNAMICS	p116(Rip) is a ubiquitously expressed protein that was originally identified as a putative binding partner of RhoA in a yeast two-hybrid screen. Overexpression of p116(Rip) in neuroblastoma cells inhibits RhoA-mediated cell contraction induced by lysophosphatidic acid (LPA); so far, however, the function of p116(Rip) is unknown. Here we report that p116(Rip) localizes to filamentous actin (F-actin)-rich structures, including stress fibers and cortical microfilaments, in both serum-deprived and LPA-stimulated cells, with the N terminus ( residues 1-382) dictating cytoskeletal localization. In addition, p116(Rip) is found in the nucleus. Direct interaction or colocalization with RhoA was not detected. We find that p116(Rip) binds tightly to F-actin (K-d similar to 0.5 muM) via its N-terminal region, while immunoprecipitation assays show that p116(Rip) is complexed to both F-actin and myosin-II. Purified p116(Rip) and the F-actin-binding region can bundle F-actin in vitro, as shown by electron microscopy. When overexpressed in NIH3T3 cells, p116(Rip) disrupts stress fibers and promotes formation of dendrite-like extensions through its N-terminal actin-binding domain; furthermore, overexpressed p116(Rip) inhibits growth factor-induced lamellipodia formation. Our results indicate that p116(Rip) is an F-actin-binding protein with in vitro bundling activity and in vivo capability of disassembling the actomyosin-based cytoskeleton.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Moolenaar, WH (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	w.moolenaar@nki.nl	Kranenburg, Onno/K-4115-2015	Kranenburg, Onno/0000-0002-2112-4390				Ayscough KR, 1998, CURR OPIN CELL BIOL, V10, P102, DOI 10.1016/S0955-0674(98)80092-6; Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; Brouns MR, 2001, NAT CELL BIOL, V3, P361, DOI 10.1038/35070042; Thomas David D, 2002, Results Probl Cell Differ, V36, P7; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Friederich E, 1999, J BIOL CHEM, V274, P26751, DOI 10.1074/jbc.274.38.26751; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; ISHIKAWA R, 1994, J BIOL CHEM, V269, P29928; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; Janmey PA, 2001, P NATL ACAD SCI USA, V98, P14745, DOI 10.1073/pnas.011601598; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Lappalainen P, 1998, MOL BIOL CELL, V9, P1951, DOI 10.1091/mbc.9.8.1951; Lee SH, 2001, ONCOGENE, V20, P6700, DOI 10.1038/sj.onc.1204683; Mattila PK, 2003, J BIOL CHEM, V278, P8452, DOI 10.1074/jbc.M212113200; McCann RO, 1997, P NATL ACAD SCI USA, V94, P5679, DOI 10.1073/pnas.94.11.5679; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Oliver CJ, 2002, MOL CELL BIOL, V22, P4690, DOI 10.1128/MCB.22.13.4690-4701.2002; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; Ridley AJ, 1999, NAT CELL BIOL, V1, pE64, DOI 10.1038/11034; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Sasaki Y, 1996, J NEUROCHEM, V66, P980; Seipel K, 2001, J CELL SCI, V114, P389; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Tang JX, 1996, J BIOL CHEM, V271, P8556, DOI 10.1074/jbc.271.15.8556; Van Troys M, 1999, BBA-MOL CELL RES, V1448, P323, DOI 10.1016/S0167-4889(98)00152-9; vanHam SM, 1997, CURR BIOL, V7, P950, DOI 10.1016/S0960-9822(06)00414-3; Vartiainen M, 2000, MOL CELL BIOL, V20, P1772, DOI 10.1128/MCB.20.5.1772-1783.2000; Wear MA, 2000, CURR BIOL, V10, pR891, DOI 10.1016/S0960-9822(00)00845-9; Yao LB, 1999, J BIOL CHEM, V274, P19752, DOI 10.1074/jbc.274.28.19752; Zondag GCM, 1996, J CELL BIOL, V134, P1513, DOI 10.1083/jcb.134.6.1513	33	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27216	27223		10.1074/jbc.M302399200	http://dx.doi.org/10.1074/jbc.M302399200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12732640	hybrid			2022-12-25	WOS:000184155700117
J	Nowotny, M; Spiechowicz, M; Jastrzebska, B; Filipek, A; Kitagawa, K; Kuznicki, J				Nowotny, M; Spiechowicz, M; Jastrzebska, B; Filipek, A; Kitagawa, K; Kuznicki, J			Calcium-regulated interaction of Sgt1 with S100A6 (calcyclin) and other S100 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN LIGASE COMPLEX; KAPPA-B-ALPHA; EF-HAND TYPE; BINDING-PROTEINS; BETA-CATENIN; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; MOLECULAR-CLONING; FUNCTIONAL ROLES; ANNEXIN-II; EXPRESSION	S100A6 (calcyclin), a small calcium-binding protein from the S100 family, interacts with several target proteins in a calcium-regulated manner. One target is Calcyclin-Binding Protein/Siah-1-Interacting Protein (CacyBP/SIP), a component of a novel pathway of beta-catenin ubiquitination. A recently discovered yeast homolog of CacyBP/SIP, Sgt1, associates with Skp1 and regulates its function in the Skp1/Cullin1/F-box complex ubiquitin ligase and in kinetochore complexes. S100A6-binding domain of CacyBP/SIP is in its C-terminal region, where the homology between CacyBP/SIP and Sgt1 is the greatest. Therefore, we hypothesized that Sgt1, through its C-terminal region, interacts with S100A6. We tested this hypothesis by performing affinity chromatography and chemical cross-linking experiments. Our results showed that Sgt1 binds to S100A6 in a calcium-regulated manner and that the S100A6-binding domain in Sgt1 is comprised of 71 C-terminal residues. Moreover, S100A6 does not influence Skp1-Sgt1 binding, a result suggesting that separate Sgt1 domains are responsible for interactions with S100A6 and Skp1. Sgt1 binds not only to S100A6 but also to S100B and S100P, other members of the S100 family. The interaction between S100A6 and Sgt1 is likely to be physiologically relevant because both proteins were co-immunoprecipitated from HEp-2 cell line extract using monoclonal anti-S100A6 antibody. Phosphorylation of the S100A6-binding domain of Sgt1 by casein kinase II was inhibited by S100A6, a result suggesting that the role of S100A6 binding is to regulate the phosphorylation of Sgt1. These findings suggest that protein ubiquitination via Sgt1-dependent pathway can be regulated by S100 proteins.	M Nencki Inst Expt Biol, PL-02093 Warsaw, Poland; St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA; Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; St Jude Children's Research Hospital; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej	Kuznicki, J (corresponding author), M Nencki Inst Expt Biol, 3 Pasteur St, PL-02093 Warsaw, Poland.	jacek@iimcb.gov.pl	Kuznicki, Jacek/AAW-9239-2020	Kuznicki, Jacek/0000-0001-6486-0657; Filipek, Anna/0000-0001-9484-9555	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barker N, 2000, BIOESSAYS, V22, P961; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bronckart Y, 2001, HISTOL HISTOPATHOL, V16, P707, DOI 10.14670/HH-16.707; CALABRETTA B, 1986, P NATL ACAD SCI USA, V83, P1495, DOI 10.1073/pnas.83.5.1495; CALABRETTA B, 1986, J BIOL CHEM, V261, P2628; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; FILIPEK A, 1995, INT J BIOCHEM CELL B, V27, P1123, DOI 10.1016/1357-2725(95)00096-8; Filipek A, 1998, J NEUROCHEM, V70, P1793, DOI 10.1046/j.1471-4159.1998.70051793.x; FILIPEK A, 1991, EUR J BIOCHEM, V195, P795, DOI 10.1111/j.1432-1033.1991.tb15768.x; Filipek A, 1996, BIOCHEM J, V320, P585, DOI 10.1042/bj3200585; Filipek A, 2002, J BIOL CHEM, V277, P21103, DOI 10.1074/jbc.M111010200; Filipek A, 2002, J BIOL CHEM, V277, P28848, DOI 10.1074/jbc.M203602200; Gray WM, 2002, CURR BIOL, V12, pR352, DOI 10.1016/S0960-9822(02)00857-6; Jastrzebska B, 2000, J HISTOCHEM CYTOCHEM, V48, P1195, DOI 10.1177/002215540004800903; Kitagawa K, 1999, MOL CELL, V4, P21, DOI 10.1016/S1097-2765(00)80184-7; Komatsu K, 2002, ONCOLOGY-BASEL, V63, P192, DOI 10.1159/000063812; Komatsu K, 2000, BRIT J CANCER, V83, P769, DOI 10.1054/bjoc.2000.1356; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; Kriajevska M, 2002, J BIOL CHEM, V277, P5229, DOI 10.1074/jbc.M110976200; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; MINAMI H, 1992, FEBS LETT, V305, P217, DOI 10.1016/0014-5793(92)80671-3; Ng RWM, 1998, FEBS LETT, V438, P183, DOI 10.1016/S0014-5793(98)01299-X; Nowotny M, 2000, J BIOL CHEM, V275, P31178, DOI 10.1074/jbc.M001622200; OKAZAKI K, 1994, J BIOL CHEM, V269, P6149; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Stulik J, 2000, EUR J CANCER, V36, P1050, DOI 10.1016/S0959-8049(00)00043-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THORDARSON G, 1991, ENDOCRINOLOGY, V129, P1257, DOI 10.1210/endo-129-3-1257; WETERMAN MAJ, 1992, CANCER RES, V52, P1291; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; ZENG FY, 1993, INT J BIOCHEM, V25, P1019, DOI 10.1016/0020-711X(93)90116-V	34	61	70	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26923	26928		10.1074/jbc.M211518200	http://dx.doi.org/10.1074/jbc.M211518200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12746458	hybrid			2022-12-25	WOS:000184155700081
J	Cai, DS; Dhe-Paganon, S; Melendez, PA; Lee, JS; Shoelson, SE				Cai, DS; Dhe-Paganon, S; Melendez, PA; Lee, JS; Shoelson, SE			Two new substrates in insulin signaling, IRS5/DOK4 and IRS6/DOK5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; DOCKING PROTEIN; NEGATIVE REGULATION; PTB DOMAIN; DOK-R; FAMILY; IRS-1; ACTIVATION; P62(DOK); GROWTH	We have identified two new human genes that encode proteins with tandem pleckstrin homology-phosphotyrosine binding (PH-PTB) domains at their amino termini. Because the other known PH-PTB proteins ( insulin receptor substrates: IRS-1, IRS-2, IRS-3, and IRS-4, and the downstream of kinases: DOK-1, DOK-2, and DOK-3) are substrates of insulin and insulin-like growth factor (IGF)-1 receptors, we asked whether these new proteins, termed IRS5/DOK4 and IRS6/DOK5, might also have roles in insulin and IGF-1 signaling. Northern analyses indicate that IRS5/DOK4 is ubiquitously expressed but most abundant in kidney and liver. IRS6/DOK5 expression is highest in skeletal muscle. Both proteins are tyrosine-phosphorylated in response to insulin and IGF-1 in transfected cells, although the kinetics differ. Insulin receptor-phosphorylated IRS5/DOK4 associates with RasGAP, Crk, Src, and Fyn, but not phosphatidylinositol 3-kinase p85, Grb2, SHP-2, Nck, or phospholipase Cgamma Src homology 2 domains, and activates MAPK in cells. IRS6/DOK5 neither associates with these Src homology 2 domains nor activates MAPK. IRS5/DOK4 and IRS6/DOK5 represent two new signaling proteins with potential roles in insulin and IGF-1 action.	Joslin Diabet Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Shoelson, SE (corresponding author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.	Steven.Shoelson@joslin.harvard.edu	Lee, Jongsoon/AAG-1674-2020	Lee, Jongsoon/0000-0002-0891-5059	NIDDK NIH HHS [R01 DK43123, F32 DK61187, DK36836] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, F32DK061187, R01DK043123] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Burks DJ, 2000, NATURE, V407, P377, DOI 10.1038/35030105; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Ceresa BP, 1998, MOL CELL BIOCHEM, V182, P23, DOI 10.1023/A:1006819008507; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; Cong F, 1999, MOL CELL BIOL, V19, P8314; Dhe-Paganon S, 1999, P NATL ACAD SCI USA, V96, P8378, DOI 10.1073/pnas.96.15.8378; Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Fantin VR, 2000, AM J PHYSIOL-ENDOC M, V278, pE127, DOI 10.1152/ajpendo.2000.278.1.E127; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032; Jones N, 1999, CURR BIOL, V9, P1057, DOI 10.1016/S0960-9822(99)80458-8; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lemay S, 2000, MOL CELL BIOL, V20, P2743, DOI 10.1128/MCB.20.8.2743-2754.2000; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SHISHEVA A, 1994, ENDOCRINOLOGY, V134, P507, DOI 10.1210/en.134.1.507; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Songyang Z, 2001, J BIOL CHEM, V276, P2459, DOI 10.1074/jbc.M005504200; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wick MJ, 2001, J BIOL CHEM, V276, P42843, DOI 10.1074/jbc.M102116200; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; YAMADA K, 1992, J BIOL CHEM, V267, P12452; Yamanashi Y, 2000, GENE DEV, V14, P11; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	36	139	145	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25323	25330		10.1074/jbc.M212430200	http://dx.doi.org/10.1074/jbc.M212430200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730241	Green Published, hybrid			2022-12-25	WOS:000183920200010
J	Valks, DM; Kemp, TJ; Clerk, A				Valks, DM; Kemp, TJ; Clerk, A			Regulation of Bcl-xL expression by H2O2 in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; OXIDATIVE STRESS; KINASE CASCADE; CELL-DEATH; APOPTOSIS; PROMOTER; INITIATION; ISCHEMIA; CARDIOMYOCYTES; TRANSLATION	Oxidative stress promotes cardiac myocyte apoptosis through the mitochondrial death pathway. Since Bcl-2 family proteins are key regulators of apoptosis, we examined the effects of H2O2 on the expression of principal Bcl-2 family proteins (Bcl-2, Bcl-xL, Bax, Bad) in neonatal rat cardiac myocytes. Protein expression was assessed by immunoblotting. Bcl-2, Bax, and Bad were all down-regulated in myocytes exposed to 0.2 mM H2O2, a concentration that induces apoptosis. In contrast, although Bcl-xL levels initially declined, the protein was re-expressed from 4-6 h. Bcl-xL mRNA was up-regulated from 2 to 4 h in neonatal rat or mouse cardiac myocytes exposed to H2O2, consistent with the re-expression of protein. Four different untranslated first exons have been identified for the Bcl-x gene (exons 1, 1B, 1C, and 1D, where exon 1 is the most proximal and exon 1D the most distal to the coding region). All were detected in mouse or rat neonatal cardiac myocytes, but exon 1D was not expressed in adult mouse hearts. In neonatal mouse or rat cardiac myocytes, H2O2 induced the expression of exons 1B, 1C, and 1D, but not exon 1. These data demonstrate that the Bcl-x gene is selectively responsive to oxidative stress, and the response is mediated through distal promoter regions.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst Div, Cardiac Med Sect, London SW7 2AZ, England	Imperial College London	Clerk, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst Div, Cardiac Med Sect, Flowers Bldg,Armstrong Rd, London SW7 2AZ, England.	a.clerk@imperial.ac.uk		Clerk, Angela/0000-0002-5658-0708				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Antonsson B, 2001, CELL TISSUE RES, V306, P347, DOI 10.1007/s00441-001-0472-0; Becker LB, 1999, AM J PHYSIOL-HEART C, V277, pH2240, DOI 10.1152/ajpheart.1999.277.6.H2240; BOGOYEVITCH MA, 1995, BIOCHEM J, V309, P437, DOI 10.1042/bj3090437; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chen QM, 2000, ARCH BIOCHEM BIOPHYS, V373, P242, DOI 10.1006/abbi.1999.1558; Chen ZY, 2001, AM J PHYSIOL-HEART C, V280, pH2313, DOI 10.1152/ajpheart.2001.280.5.H2313; CLERK A, 1995, AM J PHYSIOL-HEART C, V269, pH1087, DOI 10.1152/ajpheart.1995.269.3.H1087; Clerk A, 2002, BIOCHEM J, V368, P101, DOI 10.1042/BJ20021083; Cook SA, 1999, CIRC RES, V85, P940; FERRARI R, 1998, EUR HEART J, V19, P2; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Kang PM, 2000, CIRC RES, V87, P118, DOI 10.1161/01.RES.87.2.118; Kirshenbaum LA, 1997, CIRCULATION, V96, P1580, DOI 10.1161/01.CIR.96.5.1580; MacCarthy-Morrogh L, 2000, ONCOGENE, V19, P5534, DOI 10.1038/sj.onc.1203949; Martinez-Salas E, 2001, J GEN VIROL, V82, P973, DOI 10.1099/0022-1317-82-5-973; Pecci A, 2001, J BIOL CHEM, V276, P21062, DOI 10.1074/jbc.M008665200; Pedersen SK, 2002, BIOCHEM J, V363, P37, DOI 10.1042/0264-6021:3630037; Pham FH, 2001, ADV ENZYME REGUL, V41, P73, DOI 10.1016/S0065-2571(00)00007-8; Pham FH, 2000, CIRC RES, V86, P1252, DOI 10.1161/01.RES.86.12.1252; Shiraiwa N, 1996, J BIOL CHEM, V271, P13258, DOI 10.1074/jbc.271.22.13258; Siwik DA, 1999, CIRC RES, V85, P147, DOI 10.1161/01.RES.85.2.147; Tian CX, 2003, BLOOD, V101, P2235, DOI 10.1182/blood-2002-04-1217; Valen G, 1998, FREE RADICAL RES, V29, P235, DOI 10.1080/10715769800300271; VandenHoek TL, 1997, J MOL CELL CARDIOL, V29, P2571, DOI 10.1006/jmcc.1997.0497; von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934; Yang XF, 1997, IMMUNITY, V7, P629, DOI 10.1016/S1074-7613(00)80384-2; Ytrehus K, 1995, CARDIOVASC RES, V30, P1033, DOI 10.1016/0008-6363(95)00182-4	29	40	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25542	25547		10.1074/jbc.M303760200	http://dx.doi.org/10.1074/jbc.M303760200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12721309	hybrid			2022-12-25	WOS:000183920200035
J	Watrin, E; Cubizolles, F; Osborne, HB; Le Guellec, K; Legagneux, V				Watrin, E; Cubizolles, F; Osborne, HB; Le Guellec, K; Legagneux, V			Expression and functional dynamics of the XCAP-D2 condensin subunit in Xenopus laevis oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC CHROMOSOME CONDENSATION; TOPOISOMERASE-II; CYTOPLASMIC POLYADENYLATION; CHROMATID SEGREGATION; PROTEIN COMPLEXES; DNA-REPLICATION; 13S CONDENSIN; EGG EXTRACTS; IN-VITRO; MITOSIS	The 13 S condensin complex plays a crucial role in the condensation and segregation of the two sets of chromosomes during mitosis in vivo as well as in cell-free extracts. This complex, conserved from yeast to human, contains a heterodimer of structural maintenance of chromosome (SMC) family proteins and three additional non-SMC subunits. We have investigated the expression of the non-SMC condensin component XCAP-D2 in Xenopus laevis oocytes. When studied during meiotic maturation, XCAP-D2 starts to accumulate at the time of germinal vesicle breakdown and reaches its maximal amount in metaphase II oocytes. This accumulation is specifically blocked by injection of antisense oligonucleotides. XCAP-D2 antisense- injected oocytes progress normally through meiosis until metaphase II. At this stage, however, chromosomes exhibit architecture defaults, and resolution of sister chromatids is impaired. Surprisingly, in mitotic extracts made from XCAP-D2 knocked-down oocytes, sperm chromatin normally condenses into compacted chromosomes, whereas the amounts of both free and chromosome-bound XCAP-D2 are markedly reduced. This apparent discrepancy is discussed in light of current knowledge on chromosome dynamics.	Univ Rennes 1, Fac Med, CNRS, UMR 6061, F-35043 Rennes, France	Centre National de la Recherche Scientifique (CNRS); Universite de Rennes	Legagneux, V (corresponding author), Univ Rennes 1, Fac Med, CNRS, UMR 6061, 2 Ave Leon Bernard, F-35043 Rennes, France.		Legagneux, Vincent/I-3409-2015	Legagneux, Vincent/0000-0002-1417-6678; watrin, erwan/0000-0002-4582-6493; Cubizolles, Fabien/0000-0002-9822-4074				ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; Andresson T, 1998, EMBO J, V17, P5627, DOI 10.1093/emboj/17.19.5627; Ball AR, 2002, MOL CELL BIOL, V22, P5769, DOI 10.1128/MCB.22.16.5769-5781.2002; Bhalla N, 2002, MOL BIOL CELL, V13, P632, DOI 10.1091/mbc.01-05-0264; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; Bomar J, 2002, J CELL SCI, V115, P2931; Cubizolles F, 1998, J CELL BIOL, V143, P1437, DOI 10.1083/jcb.143.6.1437; Cuvier O, 2003, J CELL BIOL, V160, P645, DOI 10.1083/jcb.200209023; de la Barre AE, 2000, EMBO J, V19, P379, DOI 10.1093/emboj/19.3.379; de Moor CH, 1999, EMBO J, V18, P2294, DOI 10.1093/emboj/18.8.2294; Eide T, 2002, EMBO REP, V3, P426, DOI 10.1093/embo-reports/kvf089; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Hagstrom KA, 2002, GENE DEV, V16, P729, DOI 10.1101/gad.968302; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; Hirano T, 2002, GENE DEV, V16, P399, DOI 10.1101/gad.955102; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HUTCHISON CJ, 1988, DEVELOPMENT, V103, P553; HUTCHISON CJ, 1987, EMBO J, V6, P2003, DOI 10.1002/j.1460-2075.1987.tb02464.x; Kaitna S, 2002, CURR BIOL, V12, P798, DOI 10.1016/S0960-9822(02)00820-5; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Kimura K, 2000, P NATL ACAD SCI USA, V97, P11972, DOI 10.1073/pnas.220326097; Lavoie BD, 2002, J CELL BIOL, V156, P805, DOI 10.1083/jcb.200109056; Lavoie BD, 2000, MOL BIOL CELL, V11, P1293, DOI 10.1091/mbc.11.4.1293; Lieb JD, 1998, CELL, V92, P265, DOI 10.1016/S0092-8674(00)80920-4; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Lupo R, 2001, MOL CELL, V7, P127, DOI 10.1016/S1097-2765(01)00161-7; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; Richter JD, 1999, MICROBIOL MOL BIOL R, V63, P446, DOI 10.1128/MMBR.63.2.446-456.1999; Roghi C, 1998, J CELL SCI, V111, P557; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; Steffensen S, 2001, CURR BIOL, V11, P295, DOI 10.1016/S0960-9822(01)00096-3; Sutani T, 1999, GENE DEV, V13, P2271, DOI 10.1101/gad.13.17.2271; Uhlmann F, 2001, CURR BIOL, V11, pR384, DOI 10.1016/S0960-9822(01)00214-7	38	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25708	25715		10.1074/jbc.M300192200	http://dx.doi.org/10.1074/jbc.M300192200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730203	hybrid			2022-12-25	WOS:000183920200055
J	Yamagishi, K; Suzuki, K; Imai, K; Mochizuki, H; Morikawa, K; Kyogashima, M; Kimata, K; Watanabe, H				Yamagishi, K; Suzuki, K; Imai, K; Mochizuki, H; Morikawa, K; Kyogashima, M; Kimata, K; Watanabe, H			Purification, characterization, and molecular cloning of a novel keratan sulfate hydrolase, endo-beta-N-acetylglucosaminidase, from Bacillus circulans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEANUT AGGLUTININ; DEFICIENT MICE; CELL-ADHESION; SIALYL-LEX; E-SELECTIN; GALACTOSIDASE; LIGANDS; PROTEOGLYCAN	Keratan sulfate (KS) is degraded by various enzymes including endo-beta-galactosidase, keratanase, and keratanase II, which are used for the structural analysis of KS. We purified a novel KS hydrolase, endo-beta-N-acetylglucosaminidase, from the cell pellet and conditioned medium of Bacillus circulans, by sequential chromatography using DE52 and phenyl-Sepharose columns with similar to63- and 180-fold purity and 58 and 12.5% recovery, respectively. Like keratanase II of Bacillus sp. Ks36, the enzyme, designated Bc keratanase II, hydrolyzed KS between the 4GlcNAcbeta1-3Gal1 structure (endo-beta-N-acetylglucosaminidase), but not hyaluronan, heparan sulfate, heparin, and chondroitin sulfate C, demonstrating a strict specificity to KS. The enzyme digested shark cartilage KS to disaccharides and tetrasaccharides and bovine cornea KS to hexasaccharide, indicating that it prefers highly sulfated KS. Distinct from keratanase II of strain Ks36, the enzyme digested shark cartilage KS at an optimal temperature of 55 degreesC. Based on partial peptide sequencing of the enzyme, we molecularly cloned the gene, which encodes a protein with a predicted molecular mass of similar to200 kDa. From the deduced protein sequence, Bc keratanase II contained a domain at the C terminus, homologous to the S-layer-like domain of pullulanase from Thermoanaerobacterium thermosulfurigenes and endoxylanase from Thermoanaerobacterium saccharolyticum, and a carbohydrate-binding domain, which may serve to specifically recognize KS chains. A full-length recombinant enzyme showed keratanase II activity. These results may prove useful for the structural analysis of KS toward achieving an understanding of its function.	Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan; Seikagaku Corp, Cent Res Labs, Tokyo 2070021, Japan	Aichi Medical University; Seikagaku Corporation	Watanabe, H (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan.			Watanabe, Hideto/0000-0001-5291-0696				Ameye L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0848com; ARAI M, 1992, BIOCHIM BIOPHYS ACTA, V1117, P60, DOI 10.1016/0304-4165(92)90163-O; Badcock G, 1999, CANCER RES, V59, P4715; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BROWN GM, 1995, GLYCOBIOLOGY, V5, P311, DOI 10.1093/glycob/5.3.311; FUKUDA MN, 1976, J BIOL CHEM, V251, P6218; Funderburgh JL, 2000, GLYCOBIOLOGY, V10, P951, DOI 10.1093/glycob/10.10.951; Hemming FJ, 1998, HISTOCHEM CELL BIOL, V110, P189, DOI 10.1007/s004180050281; HIRANO S, 1971, BIOCHEM BIOPH RES CO, V44, P1371, DOI 10.1016/S0006-291X(71)80237-1; Jepsen KJ, 2002, J BIOL CHEM, V277, P35532, DOI 10.1074/jbc.M205398200; Kariya Y, 2000, J BIOL CHEM, V275, P25949, DOI 10.1074/jbc.M004140200; KITAMIKADO M, 1981, J BIOL CHEM, V256, P3906; NAKAZAWA K, 1975, J BIOL CHEM, V250, P912; Nakazawa K., 1989, KERATAN SULPHATE CHE, P99; NELSON RM, 1993, J CLIN INVEST, V91, P1157, DOI 10.1172/JCI116275; OAKLEY RA, 1991, DEV BIOL, V147, P187, DOI 10.1016/S0012-1606(05)80017-X; PARK JT, 1949, J BIOL CHEM, V181, P149; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; Plaas AHK, 2001, GLYCOBIOLOGY, V11, P779, DOI 10.1093/glycob/11.10.779; Pratta MA, 2000, J BIOL CHEM, V275, P39096, DOI 10.1074/jbc.M006201200; Schakel K, 2002, IMMUNITY, V17, P289, DOI 10.1016/S1074-7613(02)00393-X; SCUDDER P, 1983, BIOCHEM J, V213, P485, DOI 10.1042/bj2130485	23	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25766	25772		10.1074/jbc.M212183200	http://dx.doi.org/10.1074/jbc.M212183200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12732618	hybrid			2022-12-25	WOS:000183920200063
J	Lang, SE; Hearing, P				Lang, SE; Hearing, P			The adenovirus E1A oncoprotein recruits the cellular TRRAP/GCN5 histone acetyltransferase complex	ONCOGENE			English	Article						E1A; GCN5; TRRAP; HAT	C-MYC; TRANSCRIPTIONAL ACTIVATION; ESSENTIAL COFACTOR; CBP; TRANSFORMATION; P300; PROTEINS; PROMOTER; PCAF; E2F1	The adenovirus E1A oncoprotein stimulates cell growth and inhibits differentiation by deregulating the normal transcription program via interaction with positive and negative cellular effectors. E1A associates with transcriptional regulatory complexes containing p400 and TRRAP involved in chromatin remodeling and decondensation. TRRAP is a component of three distinct human histone acetyltransferase (HAT) complexes: the TIP60 complex and complexes containing GCN5 or PCAF. We demonstrate here that E1A binds a TRRAP complex that contains the GCN5 acetyltransferase during a normal adenovirus infection. E1A binds GCN5 and TRRAP in vivo early after virus infection. E1A is associated with significant HAT activity in vitro that is partly attributable to GCN5. E1A represses c-Myc- and E2F-1-directed transcriptional activation in vivo by sequestering GCN5 and/or TRRAP. Our results demonstrate that E1A distinctly binds TRRAP/GCN5, p300/CBP and PCAF HAT complexes. Through interactions with multiple HAT complexes, E1A may deregulate cellular transcription programs and facilitate infection by recruiting functional HAT coactivators to viral and cellular promoter regions.	SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hearing, P (corresponding author), SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.				NATIONAL CANCER INSTITUTE [T32CA009176, P01CA028146] Funding Source: NIH RePORTER; NCI NIH HHS [CA09176, CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chan HM, 2001, J CELL SCI, V114, P2363; Deleu L, 2001, ONCOGENE, V20, P8270, DOI 10.1038/sj.onc.1205159; Fax P, 2000, J BIOL CHEM, V275, P40554, DOI 10.1074/jbc.M004626200; Fax P, 2000, J BIOL CHEM, V275, P8911, DOI 10.1074/jbc.275.12.8911; Flinn EM, 2002, J BIOL CHEM, V277, P23399, DOI 10.1074/jbc.M201704200; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Kulesza CA, 2002, ONCOGENE, V21, P1411, DOI 10.1038/sj.onc.1205201; Lang SE, 2001, J BIOL CHEM, V276, P32627, DOI 10.1074/jbc.M102067200; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Shuen M, 2002, J BIOL CHEM, V277, P30844, DOI 10.1074/jbc.M201877200; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WONG HK, 1994, J VIROL, V68, P4910, DOI 10.1128/JVI.68.8.4910-4920.1994	29	70	73	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2836	2841		10.1038/sj.onc.1206376	http://dx.doi.org/10.1038/sj.onc.1206376			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743606				2022-12-25	WOS:000182569300014
J	Rezende, LF; Willcox, S; Griffith, JD; Richardson, CC				Rezende, LF; Willcox, S; Griffith, JD; Richardson, CC			A single-stranded DNA-binding protein of bacteriophage T7 defective in DNA annealing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RAD52 PROTEIN; GENE 2.5 PROTEIN; CARBOXYL-TERMINAL DOMAIN; ESCHERICHIA-COLI; PROMOTES RENATURATION; BRANCH MIGRATION; BETA-PROTEIN; RECOMBINATION; REPLICATION; HELICASE	The annealing of complementary strands of DNA is a vital step during the process of DNA replication, recombination, and repair. In bacteriophage T7-infected cells, the product of viral gene 2.5, a single-stranded DNA-binding protein, performs this function. We have identified a single amino acid residue in gene 2.5 protein, arginine 82, that is critical for its DNA annealing activity. Expression of gene 2.5 harboring this mutation does not complement the growth of a T7 bacteriophage lacking gene 2.5. Purified gene 2.5 protein-R82C binds single-stranded DNA with a greater affinity than the wildtype protein but does not mediate annealing of complementary strands of DNA. A carboxyl-terminal-deleted protein, gene 2.5 protein-Delta26C, binds even more tightly to single-stranded DNA than does gene 2.5 protein-R82C, but it anneals homologous strands of DNA as well as does the wild-type protein. The altered protein forms dimers and interacts with T7 DNA polymerase comparable with the wild-type protein. Gene 2.5 protein-R82C condenses single-stranded M13 DNA in a manner similar to wild-type protein when viewed by electron microscopy.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Univ N Carolina, Lineberger Comprehens Canc Res Ctr, Chapel Hill, NC 27599 USA	Harvard University; Harvard Medical School; University of North Carolina; University of North Carolina Chapel Hill	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.				NIGMS NIH HHS [GM54397-39] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054397] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ARAKI H, 1981, MOL GEN GENET, V183, P66, DOI 10.1007/BF00270140; ARAKI H, 1981, VIROLOGY, V111, P509, DOI 10.1016/0042-6822(81)90353-6; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CHRISTIANSEN C, 1977, J MOL BIOL, V115, P441, DOI 10.1016/0022-2836(77)90164-4; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; HALL SD, 1993, J BACTERIOL, V175, P277, DOI 10.1128/JB.175.1.277-287.1993; Hollis T, 2001, P NATL ACAD SCI USA, V98, P9557, DOI 10.1073/pnas.171317698; Hyland EM, 2003, J BIOL CHEM, V278, P7247, DOI 10.1074/jbc.M210605200; Iyer LM, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-8; Kagawa W, 2002, MOL CELL, V10, P359, DOI 10.1016/S1097-2765(02)00587-7; KIM YT, 1994, J BIOL CHEM, V269, P5270; KIM YT, 1992, J BIOL CHEM, V267, P15032; KIM YT, 1992, J BIOL CHEM, V267, P15022; KIM YT, 1993, P NATL ACAD SCI USA, V90, P10173, DOI 10.1073/pnas.90.21.10173; KMIEC E, 1981, J BIOL CHEM, V256, P2636; Kong DC, 1997, J BIOL CHEM, V272, P8380; Kong DC, 1996, EMBO J, V15, P2010, DOI 10.1002/j.1460-2075.1996.tb00552.x; Kong DC, 1998, J BIOL CHEM, V273, P6556, DOI 10.1074/jbc.273.11.6556; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KRUGER DH, 1981, MICROBIOL REV, V45, P9; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; NAKAI H, 1988, J BIOL CHEM, V263, P9831; Passy SI, 1999, P NATL ACAD SCI USA, V96, P4279, DOI 10.1073/pnas.96.8.4279; POTEETE AR, 1983, J MOL BIOL, V171, P401, DOI 10.1016/0022-2836(83)90037-2; Reddy G, 1997, MUTAT RES-FUND MOL M, V377, P53, DOI 10.1016/S0027-5107(97)00057-2; REUBEN RC, 1973, P NATL ACAD SCI USA, V70, P1846, DOI 10.1073/pnas.70.6.1846; Rezende LF, 2002, J BIOL CHEM, V277, P50643, DOI 10.1074/jbc.M207359200; SCHERZINGER E, 1973, MOL GEN GENET, V123, P247, DOI 10.1007/BF00271243; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Singleton MR, 2002, P NATL ACAD SCI USA, V99, P13492, DOI 10.1073/pnas.212449899; Stasiak AZ, 2000, CURR BIOL, V10, P337, DOI 10.1016/S0960-9822(00)00385-7; Tabor S., 1996, Richardson, Method for Nucleic Acid Hybridization Using Single-stranded DNA Binding Protein, Patent No. 5534407; Van Dyck E, 1998, J MOL BIOL, V284, P1027, DOI 10.1006/jmbi.1998.2203; WHITE JH, 1986, THESIS HARVARD U; Yu M, 2001, J BACTERIOL, V183, P1862, DOI 10.1128/JB.183.6.1862-1869.2001	40	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29098	29105		10.1074/jbc.M303374200	http://dx.doi.org/10.1074/jbc.M303374200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12748198	hybrid, Green Published			2022-12-25	WOS:000184421100093
J	Wong, NK; Easton, RL; Panico, M; Sutton-Smith, M; Morrison, JC; Lattanzio, FA; Morris, HR; Clark, GF; Dell, A; Patankar, MS				Wong, NK; Easton, RL; Panico, M; Sutton-Smith, M; Morrison, JC; Lattanzio, FA; Morris, HR; Clark, GF; Dell, A; Patankar, MS			Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; C-TYPE LECTIN; DC-SIGN; MONOCLONAL-ANTIBODY; EXTRACELLULAR SUPERSTRUCTURE; IMMUNE-RESPONSES; CANCER ANTIGEN; GLYCOPHORIN-A; CA-125 GENE; CLASS-I	CA125 is a mucin commonly employed as a diagnostic marker for epithelial ovarian cancer. Induction of humoral responses to CA125 leads to increased survival times in patients with this form of cancer, suggesting a potential role for this mucin in tumor progression. In this study, oligosaccharides linked to CA125 derived from the human ovarian tumor cell line OVCAR-3 were subjected to rigorous biophysical analysis. Sequencing of the O-glycans indicates the presence of both core type 1 and type 2 glycans. An unusual feature is the expression of branched core 1 antennae in the core type 2 glycans. CA125 is also N-glycosylated, expressing primarily high mannose and complex bisecting type N-linked glycans. High mannose type glycans include Man(5)-Man(9)GlcNAc(2). The predominant N-glycans are the biantennary, triantennary, and tetraantennary bisecting type oligosaccharides. Remarkably, the N-glycosylation profiles of CA125 and the envelope glycoprotein gp120 ( derived from H9 lymphoblastoid cells chronically infected with HIV-1) are very similar. The CA125-associated N-glycans have also recently been implicated in crucial recognition events involved in both the innate and adaptive arms of the cell-mediated immune response. CA125 may therefore induce specific immunomodulatory effects by employing its carbohydrate sequences as functional groups, thereby promoting tumor progression. Immunotherapy directed against CA125 may attenuate these immunosuppressive effects, leading to the prolonged survival of patients with this extremely serious form of cancer.	Eastern Virginia Med Sch, Dept Physiol Sci, Norfolk, VA 23501 USA; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AY, England; M SCAN Mass Spectrometry Res & Training Ctr, Ascot SL5 7PZ, Berks, England	Eastern Virginia Medical School; Imperial College London	Patankar, MS (corresponding author), Eastern Virginia Med Sch, Dept Physiol Sci, Norfolk, VA 23501 USA.	clarkgf@evms.edu; a.dell@ic.ac.uk; pantankms@evmsmail.evms.edu	Wong, Nyet-Kui/E-6927-2010		NICHD NIH HHS [R01HD 35652] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035652] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; ANDERSON DJ, 1982, J IMMUNOL, V129, P452; Barber LD, 1996, J IMMUNOL, V156, P3275; BAST RC, 1983, NEW ENGL J MED, V309, P883, DOI 10.1056/NEJM198310133091503; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BISCHOF P, 1993, EUR J OBSTET GYN R B, V49, P93, DOI 10.1016/0028-2243(93)90131-U; CHALABI S, 2002, J BIOL CHEM, V12, P12; CHRISTMAS SE, 1990, IMMUNOLOGY, V71, P182; Clark GF, 1997, MOL HUM REPROD, V3, P985, DOI 10.1093/molehr/3.11.985; Clark GF, 2001, CELLS TISSUES ORGANS, V168, P113, DOI 10.1159/000016812; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; DAVIS HM, 1986, CANCER RES, V46, P6143; DELL A, 1994, METHOD ENZYMOL, V230, P108; DELL A, 1993, GLYCOBIOLOGY PRACTIC, P187; DOHR GA, 1987, J IMMUNOL, V138, P3766; Easton RL, 2000, J BIOL CHEM, V275, P21928, DOI 10.1074/jbc.M001534200; ELOUAGARI K, 1995, J BIOL CHEM, V270, P26970; FERGUSON A, 1985, BRIT J CANCER, V52, P551, DOI 10.1038/bjc.1985.227; Garrido F, 2001, ADV CANCER RES, V83, P117, DOI 10.1016/S0065-230X(01)83005-0; GARRIDO F, 1993, IMMUNOL TODAY, V14, P491, DOI 10.1016/0167-5699(93)90264-L; GARRIDO F, 1976, NATURE, V261, P705, DOI 10.1038/261705a0; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; HANISCH FG, 1988, CARBOHYD RES, V178, P29, DOI 10.1016/0008-6215(88)80100-9; Haslam SM, 1996, J BIOL CHEM, V271, P30561, DOI 10.1074/jbc.271.48.30561; IRIMURA T, 1981, BIOCHEMISTRY-US, V20, P560, DOI 10.1021/bi00506a018; JACOBS IJ, 1988, BRIT J OBSTET GYNAEC, V95, P1190, DOI 10.1111/j.1471-0528.1988.tb06798.x; Karre K, 2002, SCAND J IMMUNOL, V55, P221, DOI 10.1046/j.1365-3083.2002.01053.x; KORNFELD R, 1971, J BIOL CHEM, V246, P3259; Lee YS, 2002, EXP MOL MED, V34, P18, DOI 10.1038/emm.2002.3; Lloyd KO, 1997, INT J CANCER, V71, P842, DOI 10.1002/(SICI)1097-0215(19970529)71:5<842::AID-IJC24>3.0.CO;2-8; Maggino T, 2000, EUR J GYNAECOL ONCOL, V21, P64; MERKLE RK, 1987, METHOD ENZYMOL, V138, P232; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; MIZUOCHI T, 1990, J BIOL CHEM, V265, P8519; NAGATA A, 1991, TUMOR BIOL, V12, P279, DOI 10.1159/000217716; NILOFF JM, 1984, OBSTET GYNECOL, V64, P703; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; O'Brien TJ, 2002, TUMOR BIOL, V23, P154, DOI 10.1159/000064032; O'Brien TJ, 2001, TUMOR BIOL, V22, P348, DOI 10.1159/000050638; Patankar MS, 1997, MOL HUM REPROD, V3, P501, DOI 10.1093/molehr/3.6.501; Schultes BC, 1998, CANCER IMMUNOL IMMUN, V46, P201, DOI 10.1007/s002620050479; Taniguchi N, 1999, BBA-MOL BASIS DIS, V1455, P287, DOI 10.1016/S0925-4439(99)00066-6; Van Die I, 2002, GLYCOBIOLOGY, V12, P641; Wagner U, 1997, HYBRIDOMA, V16, P33, DOI 10.1089/hyb.1997.16.33; Wagner U, 2001, CLIN CANCER RES, V7, P1154; WARNER TG, 1985, J BIOL CHEM, V260, P6194; Yang XP, 2000, CANCER RES, V60, P3313; Yin BWT, 2001, J BIOL CHEM, V276, P27371, DOI 10.1074/jbc.M103554200	49	167	180	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28619	28634		10.1074/jbc.M302741200	http://dx.doi.org/10.1074/jbc.M302741200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12734200	hybrid			2022-12-25	WOS:000184421100036
J	Abaza, A; Soleilhac, JM; Westendorf, J; Piel, M; Crevel, I; Roux, A; Pirollet, F				Abaza, A; Soleilhac, JM; Westendorf, J; Piel, M; Crevel, I; Roux, A; Pirollet, F			M phase phosphoprotein 1 is a human plus-end-directed kinesin-related protein required for cytokinesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTROMERE-ASSOCIATED KINESIN; MICROTUBULE DYNAMICS; MITOTIC SPINDLE; CRYSTAL-STRUCTURE; MOTOR DOMAIN; CELL-CYCLE; RNA INTERFERENCE; KINASE; IDENTIFICATION; PHOSPHORYLATION	The human M phase phosphoprotein 1 (MPP1), previously identified through a screening of a subset of proteins specifically phosphorylated at the G(2)/M transition (Matsumoto-Taniura, N., Pirollet, F., Monroe, R., Gerace, L., and Westendorf, J. M. (1996) Mol. Biol. Cell 7, 1455 1469), is characterized as a plus-end-directed kinesin-related protein. Recombinant MPP1 exhibits in vitro microtubule-binding and microtubule-bundling properties as well as microtubule-stimulated ATPase activity. In gliding experiments using polarity-marked microtubules, MPP1 is a slow molecular motor that moves toward the microtubule plus-end at a 0.07 mum/s speed. In cycling cells, MPP1 localizes mainly to the nuclei in interphase. During mitosis, MPP1 is diffuse throughout the cytoplasm in metaphase and subsequently localizes to the midzone to further concentrate on the midbody. MPP1 suppression by RNA interference induces failure of cell division late in cytokinesis. We conclude that MPP1 is a new mitotic molecular motor required for completion of cytokinesis.	CEA, Lab Cytosquelette, Dept Reponse & Dynam Cellulaires, INSERM,U366, F-38054 Grenoble 9, France; Inst Curie, CNRS, UMR 144, Sect Rech, F-75248 Paris 05, France; Marie Curie Res Inst, Oxted RH8 0TL, England; Inst Curie, Sect Rech, CNRS, UMR 168, F-75248 Paris 05, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie	Pirollet, F (corresponding author), CEA, Lab Cytosquelette, Dept Reponse & Dynam Cellulaires, INSERM,U366, 17 Rue Martyrs, F-38054 Grenoble 9, France.	fpirollet@cea.fr	Pirollet, Fabienne/L-3088-2013; Roux, Aurelien/AAU-1262-2021; Roux, Aurelien R/G-9541-2013	Roux, Aurelien R/0000-0002-6088-0711; Soleilhac, jean-marc/0000-0001-8072-8496				Adams RR, 1998, GENE DEV, V12, P1483, DOI 10.1101/gad.12.10.1483; Andersen SSL, 1999, BIOESSAYS, V21, P53, DOI 10.1002/(SICI)1521-1878(199901)21:1<53::AID-BIES7>3.0.CO;2-L; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Boman AL, 1999, CELL MOTIL CYTOSKEL, V44, P119, DOI 10.1002/(SICI)1097-0169(199910)44:2<119::AID-CM4>3.3.CO;2-3; Burke B, 2002, NAT REV MOL CELL BIO, V3, P487, DOI 10.1038/nrm860; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Chevrier V, 2002, J CELL BIOL, V157, P807, DOI 10.1083/jcb.200203034; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Condreay JP, 1999, P NATL ACAD SCI USA, V96, P127, DOI 10.1073/pnas.96.1.127; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DAVIS FM, 1987, MOL REGULATION NUCLE, P259; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; DUSTIN P, 1984, MICROTUBULES, P8; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Endow SA, 1999, NAT CELL BIOL, V1, pE163, DOI 10.1038/14113; Fontijn RD, 2001, MOL CELL BIOL, V21, P2944, DOI 10.1128/MCB.21.8.2944-2955.2001; Fritzler MJ, 2000, J INVEST MED, V48, P28; Glotzer M, 2001, ANNU REV CELL DEV BI, V17, P351, DOI 10.1146/annurev.cellbio.17.1.351; Gradin HM, 1997, MOL CELL BIOL, V17, P3459, DOI 10.1128/MCB.17.6.3459; Harborth J, 2001, J CELL SCI, V114, P4557; Heald R, 2000, NAT CELL BIOL, V2, pE11, DOI 10.1038/71394; Hill E, 2000, EMBO J, V19, P5711, DOI 10.1093/emboj/19.21.5711; Hirokawa N, 1998, CURR OPIN CELL BIOL, V10, P60, DOI 10.1016/S0955-0674(98)80087-2; Hirose K, 2001, J BIOL CHEM, V276, P5821, DOI 10.1074/jbc.M007252200; HUANG TG, 1994, J BIOL CHEM, V269, P16493; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; Jantsch-Plunger V, 2000, J CELL BIOL, V149, P1391, DOI 10.1083/jcb.149.7.1391; Kamimoto T, 2001, J BIOL CHEM, V276, P37520, DOI 10.1074/jbc.M106207200; Kapoor TM, 1999, P NATL ACAD SCI USA, V96, P9106, DOI 10.1073/pnas.96.16.9106; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; KURIYAMA R, 1994, J CELL SCI, V107, P3485; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; LOCKHART A, 1995, J MOL BIOL, V249, P763, DOI 10.1006/jmbi.1995.0335; Lowe M, 2000, J CELL BIOL, V149, P341, DOI 10.1083/jcb.149.2.341; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mackay AM, 1998, J CELL BIOL, V140, P991, DOI 10.1083/jcb.140.5.991; Maney T, 1998, J CELL BIOL, V142, P787, DOI 10.1083/jcb.142.3.787; Martineau-Thuillier S, 1998, CHROMOSOMA, V107, P461, DOI 10.1007/s004120050330; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; Matuliene J, 2002, MOL BIOL CELL, V13, P1832, DOI 10.1091/mbc.01-10-0504; McNally FJ, 1996, CURR OPIN CELL BIOL, V8, P23, DOI 10.1016/S0955-0674(96)80044-5; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; Mollinari C, 2002, J CELL BIOL, V157, P1175, DOI 10.1083/jcb.200111052; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; O'Farrell PH, 2001, TRENDS CELL BIOL, V11, P512, DOI 10.1016/S0962-8924(01)02142-0; Ookata K, 1997, BIOCHEMISTRY-US, V36, P15873, DOI 10.1021/bi971251w; OOKATA K, 1995, J CELL BIOL, V128, P849, DOI 10.1083/jcb.128.5.849; PATURLELAFANECHERE L, 1994, J CELL SCI, V107, P1529; PIROLLET F, 1987, EMBO J, V6, P3247, DOI 10.1002/j.1460-2075.1987.tb02642.x; Raich WB, 1998, MOL BIOL CELL, V9, P2037, DOI 10.1091/mbc.9.8.2037; Robinson DN, 2000, TRENDS CELL BIOL, V10, P228, DOI 10.1016/S0962-8924(00)01747-5; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Savino TM, 2001, J CELL BIOL, V153, P1097, DOI 10.1083/jcb.153.5.1097; Severson AF, 2000, CURR BIOL, V10, P1162, DOI 10.1016/S0960-9822(00)00715-6; Somma MP, 2002, MOL BIOL CELL, V13, P2448, DOI 10.1091/mbc.01-12-0589; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; Valiron O, 2001, CELL MOL LIFE SCI, V58, P2069, DOI 10.1007/PL00000837; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; Wade RH, 2002, STRUCTURE, V10, P1329, DOI 10.1016/S0969-2126(02)00854-7; Wade RH, 2000, NAT STRUCT BIOL, V7, P456, DOI 10.1038/75850; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; Wheatley SP, 1996, J CELL BIOL, V135, P981, DOI 10.1083/jcb.135.4.981; Wiemann S, 2001, GENOME RES, V11, P422, DOI 10.1101/gr.GR1547R; Woehlke G, 2000, NAT REV MOL CELL BIO, V1, P50, DOI 10.1038/35036069; WORDEMAN L, 1995, J CELL BIOL, V128, P95, DOI 10.1083/jcb.128.1.95; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0; ZHU XL, 1995, MOL CELL BIOL, V15, P5017	79	72	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27844	27852		10.1074/jbc.M304522200	http://dx.doi.org/10.1074/jbc.M304522200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12740395	Green Submitted, Green Accepted, hybrid			2022-12-25	WOS:000184242700066
J	Chen, L; Yang, LK; Rezaie, AR				Chen, L; Yang, LK; Rezaie, AR			Proexosite-1 on prothrombin is a factor Va-dependent recognition site for the prothrombinase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; PRO-ARG CHLOROMETHYLKETONE; ACTIVATED PROTEIN-C; FACTOR-XA; EXOSITE-I; PROTEOLYTIC FORMATION; ALLOSTERIC LINKAGE; BLOOD-COAGULATION; CRYSTAL-STRUCTURE; MOLECULAR-BASIS	Although the contribution of basic residues of exosite-1 to the catalytic function of thrombin has been studied extensively, their role in the specificity of prothrombin recognition by factor Xa in the prothrombinase complex (factor Xa, factor Va, phosphatidylcholine/phosphatidylserine vesicles, and Ca2+) has not been examined. In this study, we prepared several mutants of prethrombin-1 (prothrombin lacking Gla and Kringle-1 domains) in which basic residues of this site (Arg(35), Lys(36), Arg(67), Lys(70), Arg(73), Arg(75), and Arg(77) in chymotrypsinogen numbering) were individually substituted with a Glu. Following expression in mammalian cells and purification to homogeneity, these mutants were characterized with respect to their ability to function as zymogens for both factor Xa and the prothrombinase complex. Factor Xa by itself exhibited similar catalytic activity toward both the wild type and mutant substrates; however, its activity in the prothrombinase complex toward most of mutants was severely impaired. Further kinetic studies in the presence of Tyr(63)-sulfated hirudin-(54-65) peptide suggested that although the peptide inhibits the prothrombinase activation of the wild type zymogen with a K-D of 0.5-0.7 muM, it is ineffective in inhibiting the activation of mutant zymogens (K-D = 2-30 muM). These results suggest that basic residues of proexosite-1 on prothrombin are factor Va-dependent recognition sites for factor Xa in the prothrombinase complex.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Rezaie, AR (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068571] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68571] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16428, DOI 10.1074/jbc.M001254200; Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; BAKKER HM, 1994, J BIOL CHEM, V269, P20662; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, PROTEIN SCI, V1, P426; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; BUSCH C, 1982, LAB INVEST, V47, P498; CASTELLINO FJ, 1995, TRENDS CARDIOVAS MED, V5, P55, DOI 10.1016/1050-1738(94)00031-X; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dharmawardana KR, 1999, J BIOL CHEM, V274, P18635, DOI 10.1074/jbc.274.26.18635; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; ESMON CT, 1993, ANNU REV CELL BIOL, V9, P1; ESMON CT, 1974, J BIOL CHEM, V249, P7791; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P1; FENTON JW, 1995, THROMB HAEMOSTASIS, V74, P493; Fredenburgh JC, 1997, J BIOL CHEM, V272, P25493, DOI 10.1074/jbc.272.41.25493; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HORTIN GL, 1990, BLOOD, V76, P946; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P3319, DOI 10.1021/bi9623993; KUROSAWA S, 1987, J BIOL CHEM, V262, P2206; LENTZ SR, 1993, J BIOL CHEM, V268, P15312; LIU LW, 1991, J BIOL CHEM, V266, P16977; LIU LW, 1991, J BIOL CHEM, V266, P23632; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; Myles T, 2002, BLOOD, V100, P2820, DOI 10.1182/blood-2002-03-0843; Myles T, 2001, J BIOL CHEM, V276, P25143, DOI 10.1074/jbc.M011324200; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; PEI G, 1993, J BIOL CHEM, V268, P3226; PITTMAN DD, 1994, BIOCHEMISTRY-US, V33, P6952, DOI 10.1021/bi00188a026; Rezaie AR, 2000, BIOCHEMISTRY-US, V39, P1817, DOI 10.1021/bi992006a; Rezaie AR, 1997, BIOCHEMISTRY-US, V36, P7437, DOI 10.1021/bi962965u; Rezaie AR, 1998, PROTEIN SCI, V7, P349; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; Rezaie AR, 2001, BBA-GEN SUBJECTS, V1528, P167, DOI 10.1016/S0304-4165(01)00189-1; ROSING J, 1980, J BIOL CHEM, V255, P274; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; TRACY PB, 1983, J BIOL CHEM, V258, P7264; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; Verhamme IM, 2002, J BIOL CHEM, V277, P6788, DOI 10.1074/jbc.M110257200; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; YE J, 1992, J BIOL CHEM, V267, P11023	46	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27564	27569		10.1074/jbc.M302707200	http://dx.doi.org/10.1074/jbc.M302707200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12750382	hybrid			2022-12-25	WOS:000184242700030
J	Elzaouk, L; Leimbacher, W; Turri, M; Ledermann, B; Burki, K; Blau, N; Thony, B				Elzaouk, L; Leimbacher, W; Turri, M; Ledermann, B; Burki, K; Blau, N; Thony, B			Dwarfism and low insulin-like growth factor-1 due to dopamine depletion in Pts(-/-) mice rescued by feeding neurotransmitter precursors and H-4-biopterin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP CYCLOHYDROLASE-I; DIHYDROPTERIDINE REDUCTASE DEFICIENCY; FEEDBACK REGULATORY PROTEIN; 6-PYRUVOYLTETRAHYDROPTERIN SYNTHASE; TETRAHYDROBIOPTERIN DEFICIENCY; BIOPTERIN METABOLISM; FOOD-INTAKE; GENE CAUSE; HYPERPHENYLALANINEMIA; MUTATIONS	The tetrahydrobiopterin (BH4) cofactor is essential for the biosynthesis of catecholamines and serotonin and for nitric-oxide synthase (NOS). Alterations in BH4 metabolism are observed in various neurological and psychiatric diseases, and mutations in one of the human metabolic genes causes hyperphenylalaninemia and/or monoamine neurotransmitter deficiency. We report on a knockout mouse for the Pts gene, which codes for a BH4-biosynthetic enzyme. Homozygous Pts(-/-) mice developed with normal morphology but died after birth. Upon daily oral administration of BH4 and neurotransmitter precursors the Pts(-/-) mice eventually survived. However, at sexual maturity (6 weeks) the mice had only one-third of the normal body weight and were sexually immature. Biochemical analysis revealed no hyperphenylalaninemia, normal brain NOS activity, and almost normal serotonin levels, but brain dopamine was 3% of normal. Low dopamine leads to impaired food consumption as reflected by the severe growth deficiency and a 7-fold reduced serum insulin-like growth factor-1 (IGF-1). This is the first link shown between 6-pyruvoyltetrahydropterin synthase- or BH4-biosynthetic activity and IGF-1.	Univ Zurich, Div Clin Chem & Biochem, Dept Pediat, CH-8032 Zurich, Switzerland; Univ Zurich, Div Anim Facil, CH-8032 Zurich, Switzerland	University of Zurich; University of Zurich	Thony, B (corresponding author), Univ Zurich, Div Clin Chem & Biochem, Dept Pediat, Steinwiesstr 75, CH-8032 Zurich, Switzerland.			Thony, Beat/0000-0002-8420-4769; Blau, Nenad/0000-0003-4347-3230				Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Bartke A, 2000, RES PRO CEL, V29, P181; BLAU N, 1992, PEDIATR RES, V32, P726, DOI 10.1203/00006450-199212000-00021; Blau N, 1997, CHEMISTRY AND BIOLOGY OF PTERIDINES AND FOLATES 1997, P719; BLAU N, 1985, J CLIN CHEM CLIN BIO, V23, P169; Blau N, 1999, J INHERIT METAB DIS, V22, P216, DOI 10.1023/A:1005584627797; BLAU N, 2002, PHYS GUIDE LAB DIAGN, P89; Blau N., 1993, PTERIDINES, V4, P1; Blau N., 2001, METABOLIC MOL BASIS, P1725; Bonafe L, 2001, CLIN CHEM, V47, P477; Bonafe L, 2001, AM J HUM GENET, V69, P269, DOI 10.1086/321970; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brand MP, 1996, J NEUROCHEM, V66, P1150; CURTIUS HC, 1991, TECHNIQUES DIAGNOSTI, P377; DHONDT JL, 1982, CLIN CHIM ACTA, V121, P33, DOI 10.1016/0009-8981(82)90207-8; Fitzpatrick PF, 1999, ANNU REV BIOCHEM, V68, P355, DOI 10.1146/annurev.biochem.68.1.355; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; Heales SJR, 1999, J INHERIT METAB DIS, V22, P221, DOI 10.1023/A:1005540828706; KLATT P, 1994, J BIOL CHEM, V269, P13861; LEDLEY FD, 1987, J BIOL CHEM, V262, P2228; Maita N, 2002, P NATL ACAD SCI USA, V99, P1212, DOI 10.1073/pnas.022646999; Meguid MM, 2000, NUTRITION, V16, P843, DOI 10.1016/S0899-9007(00)00449-4; Milstien S, 1996, J BIOL CHEM, V271, P19743, DOI 10.1074/jbc.271.33.19743; OPPLIGER T, 1995, J BIOL CHEM, V270, P29498, DOI 10.1074/jbc.270.49.29498; Oz OK, 2001, J STEROID BIOCHEM, V79, P49, DOI 10.1016/S0960-0760(01)00130-3; Pardridge WM, 1998, J NEUROCHEM, V70, P1781; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; Scherer-Oppliger T, 1999, J BIOL CHEM, V274, P31341, DOI 10.1074/jbc.274.44.31341; SCRIVER CR, 1994, ANNU REV GENET, V28, P141; SHAPER NL, 1994, J BIOL CHEM, V269, P25165; SMITH I, 1985, LANCET, V1, P818; Sumi-Ichinose C, 2001, J BIOL CHEM, V276, P41150, DOI 10.1074/jbc.M102237200; Szczypka MS, 1999, P NATL ACAD SCI USA, V96, P12138, DOI 10.1073/pnas.96.21.12138; Szczypka MS, 2000, NAT GENET, V25, P102, DOI 10.1038/75484; Szczypka MS, 1999, NEURON, V22, P167, DOI 10.1016/S0896-6273(00)80688-1; Thony B, 1997, HUM MUTAT, V10, P11; Thony B, 2000, BIOCHEM J, V347, P1, DOI 10.1042/0264-6021:3470001; Thony B, 1998, HUM GENET, V103, P162, DOI 10.1007/s004390050800; Thony B, 1998, AM J HUM GENET, V62, P1302, DOI 10.1086/301887; Tiefenbacher CP, 2001, AM J PHYSIOL-HEART C, V280, pH2484, DOI 10.1152/ajpheart.2001.280.6.H2484; Trefz FK, 2001, EUR J PEDIATR, V160, P315, DOI 10.1007/PL00008436; Turri MO, 1998, BIOL CHEM, V379, P1441; Underwood LE, 1996, J PEDIATR ENDOCR MET, V9, P303; Wellman PJ, 2000, NUTRITION, V16, P837, DOI 10.1016/S0899-9007(00)00415-9; Zhou QY, 1995, CELL, V83, P1197, DOI 10.1016/0092-8674(95)90145-0; Zorzi G, 2002, J NEUROCHEM, V80, P362, DOI 10.1046/j.0022-3042.2001.00710.x	46	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28303	28311		10.1074/jbc.M303986200	http://dx.doi.org/10.1074/jbc.M303986200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12734191	hybrid, Green Accepted			2022-12-25	WOS:000184242700121
J	Widlak, P; Lanuszewska, J; Cary, RB; Garrard, WT				Widlak, P; Lanuszewska, J; Cary, RB; Garrard, WT			Subunit structures and stoichiometries of human DNA fragmentation factor proteins before and after induction of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-ACTIVATED DNASE; CHROMATIN CONDENSATION; ENDONUCLEASE-G; MOLECULAR-CLONING; CELL-DEATH; NAKED DNA; ICAD-L; NUCLEASE; INHIBITOR; CLEAVAGE	DNA fragmentation factor (DFF) is one of the major endonucleases responsible for internucleosomal DNA cleavage during apoptosis. Understanding the regulatory checkpoints involved in safeguarding non-apoptotic cells against accidental activation of this nuclease is as important as elucidating its activation mechanisms during apoptosis. Here we address these issues by determining DFF native subunit structures and stoichiometries in human cells before and after induction of apoptosis using the technique of native pore-exclusion limit electrophoresis in combination with Western analyses. For comparison, we employed similar techniques with recombinant proteins in conjunction with atomic force microscopy. Before induction of apoptosis, the expression of DFF subunits varied widely among the cell types studied, and the chaperone/inhibitor subunits DFF45 and DFF35 unexpectedly existed primarily as monomers in vast excess of the latent nuclease subunit, DFF40, which was stoichiometrically associated with DFF45 to form heterodimers. DFF35 was exclusively cytoplasmic as a monomer. Nuclease activation upon caspase-3 cleavage of DFF45/DFF35 was accompanied by DFF40 homo-oligomer formation, with a tetramer being the smallest unit. Interestingly, intact DFF45 can inhibit nuclease activity by associating with these homooligomers without mediating their disassembly. We conclude that DFF nuclease is regulated by multiple pre- and post-activation fail-safe steps.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Ctr Oncol, Dept Expt & Clin Radiobiol, PL-44100 Gliwice, Poland; Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87545 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; United States Department of Energy (DOE); Los Alamos National Laboratory	Garrard, WT (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	william.garrad@utsouthwestern.edu	Widlak, Piotr/AAL-8075-2021	Widlak, Piotr/0000-0001-5099-4726	NIGMS NIH HHS [GMR01-59809] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059809] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Betti CJ, 2001, CANCER RES, V61, P4550; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Chen DX, 2000, J BIOL CHEM, V275, P38508, DOI 10.1074/jbc.M003906200; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; Durrieu F, 2000, CURR BIOL, V10, P923, DOI 10.1016/S0960-9822(00)00620-5; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Gu JJ, 1999, J BIOL CHEM, V274, P20759, DOI 10.1074/jbc.274.30.20759; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kawane K, 1999, CELL DEATH DIFFER, V6, P745, DOI 10.1038/sj.cdd.4400547; Kawane K, 2003, NAT IMMUNOL, V4, P138, DOI 10.1038/ni881; Korn C, 2002, NUCLEIC ACIDS RES, V30, P1325, DOI 10.1093/nar/30.6.1325; Lechardeur D, 2000, J CELL BIOL, V150, P321, DOI 10.1083/jcb.150.2.321; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li TK, 1999, GENE DEV, V13, P1553, DOI 10.1101/gad.13.12.1553; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lugovskoy AA, 1999, CELL, V99, P747, DOI 10.1016/S0092-8674(00)81672-4; McCarty JS, 1999, BIOCHEM BIOPH RES CO, V264, P181, DOI 10.1006/bbrc.1999.1498; McCarty JS, 1999, BIOCHEM BIOPH RES CO, V264, P176, DOI 10.1006/bbrc.1999.1497; McIlroy D, 2000, GENE DEV, V14, P549; Meiss G, 2001, NUCLEIC ACIDS RES, V29, P3901, DOI 10.1093/nar/29.19.3901; Mitamura S, 1998, BIOCHEM BIOPH RES CO, V243, P480, DOI 10.1006/bbrc.1998.8122; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; Nagase H, 2003, CELL DEATH DIFFER, V10, P142, DOI 10.1038/sj.cdd.4401139; Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Napirei M, 2000, NAT GENET, V25, P177, DOI 10.1038/76032; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Oliveri M, 2001, EUR J IMMUNOL, V31, P743, DOI 10.1002/1521-4141(200103)31:3<743::AID-IMMU743>3.0.CO;2-9; PAINE PL, 1983, J CELL BIOL, V97, P1240, DOI 10.1083/jcb.97.4.1240; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Roulston D, 1998, BLOOD, V92, P2879, DOI 10.1182/blood.V92.8.2879.420k22_2879_2885; Sabol SL, 1998, BIOCHEM BIOPH RES CO, V253, P151, DOI 10.1006/bbrc.1998.9770; Sakahira H, 2002, J BIOL CHEM, V277, P3364, DOI 10.1074/jbc.M110071200; Sakahira H, 1999, J BIOL CHEM, V274, P15740, DOI 10.1074/jbc.274.22.15740; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sakahira H, 1999, CURR BIOL, V9, P543, DOI 10.1016/S0960-9822(99)80240-1; Samejima K, 2000, EXP CELL RES, V255, P314, DOI 10.1006/excr.2000.4801; Samejima K, 1998, EXP CELL RES, V243, P453, DOI 10.1006/excr.1998.4212; Samejima K, 2001, J BIOL CHEM, V276, P45427, DOI 10.1074/jbc.M108844200; Slane JM, 2000, BRAIN RES, V867, P70, DOI 10.1016/S0006-8993(00)02258-7; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Toh SY, 1998, BIOCHEM BIOPH RES CO, V250, P598, DOI 10.1006/bbrc.1998.9369; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Wang XD, 2001, GENE DEV, V15, P2922; Widlak P, 2000, CELL MOL BIOL LETT, V5, P373; Widlak P, 2000, J BIOL CHEM, V275, P8226, DOI 10.1074/jbc.275.11.8226; Widlak P, 2001, J BIOL CHEM, V276, P48404, DOI 10.1074/jbc.M108461200; Widlak P, 2002, J BIOL CHEM, V277, P21683, DOI 10.1074/jbc.M201027200; Widlak P, 2001, MOL CELL BIOCHEM, V218, P125, DOI 10.1023/A:1007231822086; Wohrl W, 1999, BIOCHEM BIOPH RES CO, V254, P552, DOI 10.1006/bbrc.1998.9982; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yang Y, 2003, METHODS, V29, P175, DOI 10.1016/S1046-2023(02)00308-0; Yasutomo K, 2001, NAT GENET, V28, P313, DOI 10.1038/91070; Zhang JH, 1999, J BIOL CHEM, V274, P37450, DOI 10.1074/jbc.274.52.37450; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480; Zhang JH, 2000, BIOCHEM BIOPH RES CO, V274, P225, DOI 10.1006/bbrc.2000.3122; Zhang SM, 2002, MATH FINANC, V12, P89, DOI 10.1111/1467-9965.00006	66	36	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26915	26922		10.1074/jbc.M303807200	http://dx.doi.org/10.1074/jbc.M303807200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12748178	hybrid			2022-12-25	WOS:000184155700080
J	Williams, S; Bledsoe, RK; Collins, JL; Boggs, S; Lambert, MH; Miller, AB; Moore, J; McKee, DD; Moore, L; Nichols, J; Parks, D; Watson, M; Wisely, B; Willson, TM				Williams, S; Bledsoe, RK; Collins, JL; Boggs, S; Lambert, MH; Miller, AB; Moore, J; McKee, DD; Moore, L; Nichols, J; Parks, D; Watson, M; Wisely, B; Willson, TM			X-ray crystal structure of the liver X receptor beta ligand binding domain - Regulation by a histidine-tryptophan switch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION-PI INTERACTIONS; NUCLEAR-RECEPTOR; CHOLESTEROL EFFLUX; GENE-EXPRESSION; LXR; ACID; ACTIVATION; COACTIVATOR; RECOGNITION; OXYSTEROLS	The x-ray crystal structures of the human liver X receptor beta ligand binding domain complexed to sterol and nonsterol agonists revealed a perpendicular histidine-tryptophan switch that holds the receptor in its active conformation. Hydrogen bonding interactions with the ligand act to position the His-435 imidazole ring against the Trp-457 indole ring, allowing an electrostatic interaction that holds the AF2 helix in the active position. The neutral oxysterol 24( S), 25-epoxycholesterol accepts a hydrogen bond from His-435 that positions the imidazole ring of the histidine above the pyrrole ring of the tryptophan. In contrast, the acidic T0901317 hydroxyl group makes a shorter hydrogen bond with His-435 that pulls the imidazole over the electron-rich benzene ring of the tryptophan, possibly strengthening the electrostatic interaction. Point mutagenesis of Trp-457 supports the observation that the ligand-histidine-tryptophan coupling is different between the two ligands. The lipophilic liver X receptor ligand-binding pocket is larger than the corresponding steroid hormone receptors, which allows T0901317 to adopt two distinct conformations. These results provide a molecular basis for liver X receptor activation by a wide range of endogenous neutral and acidic ligands.	GlaxoSmithKline, Discovery Res, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline	Williams, S (corresponding author), GlaxoSmithKline, Discovery Res, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.	shawn.p.williams@gsk.com	feinstein, doug/M-9414-2019; ID, IMCACAT/D-5867-2014	Williams, Shawn/0000-0001-8311-2638				Beene DL, 2002, BIOCHEMISTRY-US, V41, P10262, DOI 10.1021/bi020266d; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Kallen JA, 2002, STRUCTURE, V10, P1697, DOI 10.1016/S0969-2126(02)00912-7; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; Mecozzi S, 1996, P NATL ACAD SCI USA, V93, P10566, DOI 10.1073/pnas.93.20.10566; Mi LZ, 2003, MOL CELL, V11, P1093, DOI 10.1016/S1097-2765(03)00112-6; Murray JS, 2000, INT J QUANTUM CHEM, V80, P1216, DOI 10.1002/1097-461X(2000)80:6<1216::AID-QUA8>3.0.CO;2-U; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Okada A, 2001, BIOCHEMISTRY-US, V40, P6053, DOI 10.1021/bi0028441; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Song C, 2000, ENDOCRINOLOGY, V141, P4180, DOI 10.1210/en.141.11.4180; SPENCER TA, 1994, ACCOUNTS CHEM RES, V27, P83, DOI 10.1021/ar00039a004; Spencer TA, 2000, J ORG CHEM, V65, P1919, DOI 10.1021/jo991370c; Spencer TA, 2001, J MED CHEM, V44, P886, DOI 10.1021/jm0004749; Steiner T, 2002, ANGEW CHEM INT EDIT, V41, P48, DOI 10.1002/1521-3773(20020104)41:1<48::AID-ANIE48>3.0.CO;2-U; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762; Weatherman RV, 1999, ANNU REV BIOCHEM, V68, P559, DOI 10.1146/annurev.biochem.68.1.559; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Zhang Z, 2001, J LIPID RES, V42, P649	35	175	182	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27138	27143		10.1074/jbc.M302260200	http://dx.doi.org/10.1074/jbc.M302260200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12736258	hybrid			2022-12-25	WOS:000184155700108
J	Carnevale, KA; Cathcart, MK				Carnevale, KA; Cathcart, MK			Protein kinase C beta is required for human monocyte chemotaxis to MCP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SIGNAL-TRANSDUCTION PATHWAYS; ENDOTHELIAL-CELLS; GENE-EXPRESSION; GROWTH-FACTOR; RESPIRATORY BURST; TRANSENDOTHELIAL MIGRATION; CHEMOATTRACTANT PROTEIN-1; ACTIVATING-FACTOR; LIPID OXIDATION	Monocyte chemoattractant protein 1 (MCP-1) is important in attracting monocytes to sites of inflammation. Using predominantly pharmacological approaches, prior studies have indicated that serine/ threonine kinases are involved in the MCP-1-induced signaling pathways. We report here that there is substantial inhibition of MCP-1-stimulated chemotaxis of human monocytes treated with inhibitors selective for the subset of serine/ threonine kinases, protein kinase C (PKC). Selective inhibitors of PKC such as GF109203X and Calphostin C both caused similar to80% inhibition of chemotaxis. Because these pharmacological inhibitors do not specifically inhibit individual PKC isoforms, we chose to use antisense oligodeoxyribonucleotides (ODN) to specifically reduce PKC isoform expression, first by inhibiting expression of the conventional PKC family, and next by using specific antisense ODN for PKCalpha and PKCbeta. Conventional PKC-antisense ODN treatment completely and significantly inhibited monocyte chemotaxis to MCP-1, whereas sense-control ODN caused no significant inhibition. PKCbeta-antisense ODN caused 89.2% inhibition of chemotaxis at its highest dose. In contrast, PKCbeta-sense ODN and PKCalpha-antisense and -sense ODN were without effect. Further studies evaluating the calcium response that is triggered upon MCP-1 interaction with its receptor, CCR2, indicate that this response is not altered by antisense or sense ODN treatment, thus supporting our hypothesis that PKCbeta is critical for post-receptor signal transduction downstream of the immediate calcium signal. These data contribute to our developing understanding of the signal transduction pathways involved in the chemotactic response of human monocytes to MCP-1 and uniquely identify the requirement for the PKCbeta isoform in this important process.	Cleveland Clin Fdn, Dept Cell Biol NC10, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Cathcart, MK (corresponding author), Cleveland Clin Fdn, Dept Cell Biol NC10, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061971] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61971] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELMANNGRILL BC, 1989, EUR J CELL BIOL, V50, P128; Akiba S, 2002, BIOCHEM PHARMACOL, V63, P1969, DOI 10.1016/S0006-2952(02)00988-7; BADOLATO R, 1995, J IMMUNOL, V155, P4004; Bae YS, 1999, J LEUKOCYTE BIOL, V66, P915, DOI 10.1002/jlb.66.6.915; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; Cambien B, 2001, BLOOD, V97, P359, DOI 10.1182/blood.V97.2.359; Carnevale KA, 2001, J IMMUNOL, V167, P3414, DOI 10.4049/jimmunol.167.6.3414; CATHCART MK, 1989, J IMMUNOL, V142, P1963; CATHCART MK, 1985, J LEUKOCYTE BIOL, V38, P341, DOI 10.1002/jlb.38.2.341; COLOTTA F, 1992, J IMMUNOL, V148, P760; DAI YL, 1994, J LEUKOCYTE BIOL, V56, P776, DOI 10.1002/jlb.56.6.776; DAVIET I, 1990, FEBS LETT, V259, P315, DOI 10.1016/0014-5793(90)80035-H; Entschladen F, 2000, CELL IMMUNOL, V199, P104, DOI 10.1006/cimm.1999.1605; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; Fine JS, 2001, INFLAMMATION, V25, P61, DOI 10.1023/A:1007152903135; Geng WD, 2001, J CELL PHYSIOL, V189, P216, DOI 10.1002/jcp.10019; GRAVES DT, 1989, SCIENCE, V245, P1490, DOI 10.1126/science.2781291; HALL DJ, 1989, J CELL PHYSIOL, V141, P154, DOI 10.1002/jcp.1041410123; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; JIANG YL, 1990, J BIOL CHEM, V265, P18318; Kahler CM, 2001, INT IMMUNOPHARMACOL, V1, P1351, DOI 10.1016/S1567-5769(01)00067-4; LASKIN DL, 1987, J LEUKOCYTE BIOL, V41, P474, DOI 10.1002/jlb.41.6.474; Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306; Li Q, 1999, J BIOL CHEM, V274, P3764, DOI 10.1074/jbc.274.6.3764; LI Q, 1994, J BIOL CHEM, V269, P17508; LOCATI M, 1994, J BIOL CHEM, V269, P4746; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Marumo T, 1999, DIABETES, V48, P1131, DOI 10.2337/diabetes.48.5.1131; Michaelson JE, 2002, AM J PHYSIOL-LUNG C, V282, pL291, DOI 10.1152/ajplung.00445.2000; Mine S, 2002, ATHEROSCLEROSIS, V160, P281, DOI 10.1016/S0021-9150(01)00582-2; MYERS MA, 1985, J IMMUNOL, V135, P3411; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Okazaki J, 2000, SURGERY, V128, P192, DOI 10.1067/msy.2000.108062; PIKE MC, 1986, BLOOD, V67, P909; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROLLINS BJ, 1990, AM J PATHOL, V136, P1229; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; ROLLINS BJ, 1991, BLOOD, V78, P1112; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Schratzberger P, 1996, NEUROSCI LETT, V214, P208, DOI 10.1016/0304-3940(96)12947-5; Schweickart VL, 2000, J BIOL CHEM, V275, P9550, DOI 10.1074/jbc.275.13.9550; SHYY YJ, 1993, BIOCHEM BIOPH RES CO, V192, P693, DOI 10.1006/bbrc.1993.1470; SICA A, 1990, J IMMUNOL, V144, P3034; SOZZANI S, 1994, J IMMUNOL, V152, P3615; SOZZANI S, 1993, J IMMUNOL, V150, P1544; SOZZANI S, 1991, J IMMUNOL, V147, P2215; SOZZANI S, 1995, J LEUKOCYTE BIOL, V57, P788, DOI 10.1002/jlb.57.5.788; SPUDICH A, 1992, CELL MOTIL CYTOSKEL, V22, P250, DOI 10.1002/cm.970220405; Steer SA, 2002, AM J PHYSIOL-CELL PH, V283, pC1621, DOI 10.1152/ajpcell.00109.2002; STRIETER RM, 1989, BIOCHEM BIOPH RES CO, V162, P694, DOI 10.1016/0006-291X(89)92366-8; Szalay J, 2001, J HISTOCHEM CYTOCHEM, V49, P49, DOI 10.1177/002215540104900106; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRUETT AP, 1988, P NATL ACAD SCI USA, V85, P1549, DOI 10.1073/pnas.85.5.1549; Turner SJ, 1998, J BIOL CHEM, V273, P25987, DOI 10.1074/jbc.273.40.25987; VALENTE AJ, 1988, BIOCHEMISTRY-US, V27, P4162, DOI 10.1021/bi00411a039; Volkov Y, 1998, J IMMUNOL, V161, P6487; Xiao YQ, 1998, EUR J PHARMACOL, V360, P195, DOI 10.1016/S0014-2999(98)00681-5; Yen HH, 1997, J LEUKOCYTE BIOL, V61, P529, DOI 10.1002/jlb.61.4.529; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3	63	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25317	25322		10.1074/jbc.M304182200	http://dx.doi.org/10.1074/jbc.M304182200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12724308	hybrid			2022-12-25	WOS:000183920200009
J	Francis, E; Wang, N; Parag, H; Halaban, R; Hebert, DN				Francis, E; Wang, N; Parag, H; Halaban, R; Hebert, DN			Tyrosinase maturation and oligomerization in the endoplasmic reticulum require a melanocyte-specific factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-BASIS; MISFOLDED GLYCOPROTEINS; INFLUENZA HEMAGGLUTININ; DHICA OXIDASE; CALNEXIN; DEGRADATION; PROTEIN; PIGMENTATION; RETENTION; TRANSPORT	Tyrosinase is a glycoprotein responsible for the synthesis of melanin in melanocytes. A large number of mutations have been identified in tyrosinase, with many leading to its misfolding, endoplasmic reticulum (ER) retention, and degradation. Here we describe the folding and maturation of human tyrosinase (TYR) using an in vitro translation system coupled with ER-derived microsomes or with semipermeabilized cells, as an intact ER source. TYR remained misfolded as determined by its sensitivity to trypsin digestion and its persistent interaction with the ER resident lectin chaperones calnexin and calreticulin when produced in ER-derived microsomes or nonmelanocytic semipermeabilized cells. However, when TYR was translocated into semipermeabilized melanocytes, chaperone interactions were transient, maturation progressed to a trypsin-resistant state, and a TYR homodimer was formed. The use of semipermeabilized mouse melanocytes defective for tyrosinase or other melanocyte-specific proteins as the ER source indicated that proper TYR maturation and oligomerization were greatly aided by the presence of wild type tyrosinase and tyrosinase-related protein 1. These findings suggested that oligomerization is a step in proper TYR maturation within the ER that requires melanocyte-specific factors.	Univ Massachusetts, Dept Biochem & Mol Biol, Mol & Cellular Biol Program, Amherst, MA 01003 USA; Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA	University of Massachusetts System; University of Massachusetts Amherst; Yale University	Hebert, DN (corresponding author), Univ Massachusetts, Dept Biochem & Mol Biol, Mol & Cellular Biol Program, Amherst, MA 01003 USA.	dhebert@biochem.umass.edu			NCI NIH HHS [CA44542, CA79864] Funding Source: Medline; NIAMS NIH HHS [AR41942] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA044542, R01CA044542, R01CA079864] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041942] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Berson JF, 2000, J BIOL CHEM, V275, P12281, DOI 10.1074/jbc.275.16.12281; Boissy RE, 1998, EXP DERMATOL, V7, P198, DOI 10.1111/j.1600-0625.1998.tb00324.x; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; BOUCHARD B, 1989, J EXP MED, V169, P2029, DOI 10.1084/jem.169.6.2029; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; Branza-Nichita N, 1999, BIOCHEM BIOPH RES CO, V261, P720, DOI 10.1006/bbrc.1999.1030; Cannon KS, 1996, J BIOL CHEM, V271, P14280, DOI 10.1074/jbc.271.24.14280; Chen K, 2002, MOL BIOL CELL, V13, P1953, DOI 10.1091/mbc.02-02-0022; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; Daniels R, 2003, MOL CELL, V11, P79, DOI 10.1016/S1097-2765(02)00821-3; HALABAN R, 1990, P NATL ACAD SCI USA, V87, P4809, DOI 10.1073/pnas.87.12.4809; Halaban R, 2000, P NATL ACAD SCI USA, V97, P5889, DOI 10.1073/pnas.97.11.5889; Halaban R, 2002, J INVEST DERMATOL, V119, P481, DOI 10.1046/j.1523-1747.2002.01824.x; Halaban R, 2002, J BIOL CHEM, V277, P14821, DOI 10.1074/jbc.M111497200; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; Halaban R, 2001, J BIOL CHEM, V276, P11933, DOI 10.1074/jbc.M008703200; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; JACKSON IJ, 1990, GENETICS, V126, P451; Jimenez-Cervantes C, 1998, BIOCHEM BIOPH RES CO, V253, P761, DOI 10.1006/bbrc.1998.9817; KOBAYASHI T, 1994, EMBO J, V13, P5818, DOI 10.1002/j.1460-2075.1994.tb06925.x; Kobayashi T, 1998, J BIOL CHEM, V273, P31801, DOI 10.1074/jbc.273.48.31801; LERNER AB, 1949, J BIOL CHEM, V178, P185; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Oetting WS, 1999, HUM MUTAT, V13, P99, DOI 10.1002/(SICI)1098-1004(1999)13:2<99::AID-HUMU2>3.3.CO;2-3; OETTING WS, 1998, PIGMENTARY SYSTEM PH, P231; ORLOW SJ, 1994, J INVEST DERMATOL, V103, P196, DOI 10.1111/1523-1747.ep12392743; Petrescu SM, 1997, J BIOL CHEM, V272, P15796, DOI 10.1074/jbc.272.25.15796; Potterf SB, 1998, BIOCHEM BIOPH RES CO, V248, P795, DOI 10.1006/bbrc.1998.9019; Puri N, 2000, J INVEST DERMATOL, V115, P607, DOI 10.1046/j.1523-1747.2000.00108.x; Schnell DJ, 2003, CELL, V112, P491, DOI 10.1016/S0092-8674(03)00110-7; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Sviderskaya EV, 1997, J INVEST DERMATOL, V108, P30, DOI 10.1111/1523-1747.ep12285621; TAKAHASHI H, 1992, J INVEST DERMATOL, V98, P481, DOI 10.1111/1523-1747.ep12499862; TATU U, 1995, EMBO J, V14, P1340, DOI 10.1002/j.1460-2075.1995.tb07120.x; Toyofuku K, 2002, PIGM CELL RES, V15, P217, DOI 10.1034/j.1600-0749.2002.02007.x; Toyofuku K, 2001, BIOCHEM J, V355, P259, DOI 10.1042/0264-6021:3550259; Ujvari A, 2001, J BIOL CHEM, V276, P5924, DOI 10.1074/jbc.M009203200; Wilson CM, 2000, J BIOL CHEM, V275, P21224, DOI 10.1074/jbc.M000567200; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679; WINDER AJ, 1993, J CELL SCI, V106, P153; ZDARSKY E, 1990, GENETICS, V126, P443	47	25	26	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25607	25617		10.1074/jbc.M303411200	http://dx.doi.org/10.1074/jbc.M303411200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12724309	hybrid, Green Submitted			2022-12-25	WOS:000183920200043
J	Wedel, BJ; Vazquez, G; McKay, RR; Bird, GS; Putney, JW				Wedel, BJ; Vazquez, G; McKay, RR; Bird, GS; Putney, JW			A calmodulin/inositol 1,4,5-trisphosphate (IP3) receptor-binding region targets TRPC3 to the plasma membrane in a calmodulin/IP3 receptor-independent process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULUM RETENTION SIGNAL; OPERATED HTRP3 CHANNELS; ENDOPLASMIC-RETICULUM; C-TERMINUS; CATION CHANNELS; SPLICE VARIANTS; MOLECULAR-BASIS; CA2+ ENTRY; TRAFFICKING; PROTEIN	Conformational coupling with the inositol 1,4,5-trisphosphate (IP3) receptor has been suggested as a possible mechanism of activation of TRPC3 channels and a region in the C terminus of TRPC3 has been shown to interact with the IP3 receptor as well as calmodulin (calmodulin/IP3 receptor-binding (CIRB) region). Here we show that internal deletion of 20 amino acids corresponding to the highly conserved CIRB region results in the loss of diacylglycerol and agonist-mediated channel activation in HEK293 cells. By using confocal microscopy to examine the cellular localization of Topaz fluorescent protein fusion constructs, we demonstrate that this loss in activity is caused by faulty targeting of CIRB-deleted mutants to intracellular compartments. Wild type TRPC3 and mutants lacking a C-terminal predicted coiled coil region downstream of CIRB were targeted to the plasma membrane correctly in HEK293 cells and exhibited TRPC3-mediated calcium entry in response to agonist activation. Mutation of conserved YQ and MKR motifs to alanine within the CIRB region in TRPC3-Topaz, which would be expected to interfere with IP3 receptor and/or calmodulin binding, had no effect on channel function or targeting. Additionally, TRPC3 targets to the plasma membrane of DT40 cells lacking all three IP3 receptors and forms functional ion channels. These findings indicate that the previously identified CIRB region of TRPC3 is involved in its targeting to the plasma membrane by a mechanism that does not involve interaction with IP3 receptors.	NIEHS, Lab Signal Transduct, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Putney, JW (corresponding author), NIEHS, Lab Signal Transduct, NIH, Dept Hlth & Human Serv, POB 12233, Res Triangle Pk, NC 27709 USA.	Putney@niehs.nih.gov	Putney, James W/F-7247-2019; Bird, Gary/AAI-8186-2021	Putney, James W/0000-0002-3379-4789; Bird, Gary/0000-0003-1389-8748	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090087, ZIAES090087] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Broad LM, 1999, J PHYSIOL-LONDON, V517, P121, DOI 10.1111/j.1469-7793.1999.0121z.x; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; Cai ZQ, 1999, J BIOL CHEM, V274, P28557, DOI 10.1074/jbc.274.40.28557; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Engelke M, 2002, FEBS LETT, V523, P193, DOI 10.1016/S0014-5793(02)02971-X; Estacion M, 2001, J PHYSIOL-LONDON, V530, P1, DOI 10.1111/j.1469-7793.2001.0001m.x; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Hubner CA, 2002, HUM MOL GENET, V11, P2435, DOI 10.1093/hmg/11.20.2435; Joiner WJ, 2001, J BIOL CHEM, V276, P37980; Jung S, 2003, J BIOL CHEM, V278, P3562, DOI 10.1074/jbc.M211484200; Kazanietz MG, 2002, MOL PHARMACOL, V61, P759, DOI 10.1124/mol.61.4.759; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Kupershmidt S, 2002, J BIOL CHEM, V277, P27442, DOI 10.1074/jbc.M112375200; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Margeta-Mitrovic M, 2002, METHODS, V27, P311, DOI 10.1016/S1046-2023(02)00088-9; McKay RR, 2000, BIOCHEM J, V351, P735, DOI 10.1042/0264-6021:3510735; Mery L, 2001, FEBS LETT, V487, P377, DOI 10.1016/S0014-5793(00)02362-0; Montell C., 2001, SCI STKE; Saimi Y, 2002, ANNU REV PHYSIOL, V64, P289, DOI 10.1146/annurev.physiol.64.100301.111649; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Sencer S, 2001, J BIOL CHEM, V276, P38237; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Singh BB, 2000, J BIOL CHEM, V275, P36483, DOI 10.1074/jbc.C000529200; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; Trebak M, 2003, CELL CALCIUM, V33, P451, DOI 10.1016/S0143-4160(03)00056-3; Trebak M, 2003, J BIOL CHEM, V278, P16244, DOI 10.1074/jbc.M300544200; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Trost C, 2001, BIOCHEM J, V355, P663, DOI 10.1042/bj3550663; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Vazquez G, 2003, J BIOL CHEM, V278, P21649, DOI 10.1074/jbc.M302162200; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhang L, 2001, J BIOL CHEM, V276, P13331, DOI 10.1074/jbc.M008914200; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; Zuhlke RD, 2000, J BIOL CHEM, V275, P21121, DOI 10.1074/jbc.M002986200	46	66	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25758	25765		10.1074/jbc.M303890200	http://dx.doi.org/10.1074/jbc.M303890200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730194	hybrid			2022-12-25	WOS:000183920200062
J	Adamson, J; Morgan, EA; Beesley, C; Meil, YQ; Foster, CS; Fujii, H; Rudland, PS; Smith, PH; Ke, YQ				Adamson, J; Morgan, EA; Beesley, C; Meil, YQ; Foster, CS; Fujii, H; Rudland, PS; Smith, PH; Ke, YQ			High-level expression of cutaneous fatty acid-binding protein in prostatic carcinomas and its effect on tumorigenicity	ONCOGENE			English	Article						C-FABP; prostate cancer; antisense transcript; DNA transfection; tumorigenicity	ENDOTHELIAL GROWTH-FACTOR; TRANSITIONAL-CELL CARCINOMAS; DIFFERENTIAL GENE-EXPRESSION; MESSENGER-RNA; TUMOR-CELLS; RECEPTOR; RAT; METASTASIS; DISPLAY; CANCER	The expression of cutaneous fatty acid-binding protein (C-FABP) in prostate tissues was examined by immunohistochemistry. Among the 76 cases, all seven (100%) normal tissues were unstained. Of the 35 benign prostatic hyperplasia (BPH), 25 (71.4%) specimens were unstained and 10 (28.6%) were stained positively. For the 34 prostatic carcinomas, the C-FABP expression was remarkably increased: 25 (73.5%) samples stained positively, and only nine (26.5%) were unstained. Transfection of a vector expressing an antisense C-FABP transcript into the PC-3M prostatic cancer cells yielded two transfectant lines: PC-3M-CFABP-1 and PC-3M-CFABP-3, producing, respectively, a 3.8- and a 6.9-fold reduction in C-FABP levels. Comparing with the control transfectants, the in vitro invasiveness of both PC-3M-CFABP-1 and PC-3M-CFABP-3 was significantly reduced. When tested in nude mouse, the average size of tumours produced by PC-3M-CFABP-1 and by PC-3M-CFABP-3 was reduced by 2.9- and 4.2-fold respectively, in comparison with that of tumours produced by the control transfectants. Analysis showed that the decreased vascular endothelial growth factor (VEGF) and microvessel densities in the tumours were associated with the reduced C-FABP. These data show that C-FABP is increased in prostatic carcinoma cells and suppression of its expression can significantly inhibit the tumorigenicity, probably by reducing the expression of VEGF.	Univ Liverpool, Fac Med, Dept Pathol, Mol Pathol Lab, Liverpool L69 3BX, Merseyside, England; Niigata Univ, Sch Med, Dept Biochem, Niigata 951, Japan; Univ Liverpool, Sch Biol Sci, Liverpool L69 3BX, Merseyside, England	University of Liverpool; Niigata University; University of Liverpool	Ke, YQ (corresponding author), Univ Liverpool, Fac Med, Dept Pathol, Mol Pathol Lab, Liverpool L69 3BX, Merseyside, England.							ALBINI A, 1987, CANCER RES, V47, P3239; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; Celis A, 1999, ELECTROPHORESIS, V20, P355, DOI 10.1002/(SICI)1522-2683(19990201)20:2<355::AID-ELPS355>3.0.CO;2-N; Celis JE, 1996, CANCER RES, V56, P4782; Chen HJ, 2000, BRIT J CANCER, V82, P1694; Chen HJ, 1997, ONCOGENE, V14, P1581, DOI 10.1038/sj.onc.1200993; Deshmukh N, 1997, BRIT J UROL, V80, P869, DOI 10.1046/j.1464-410X.1997.00479.x; Foster CS, 1999, BJU INT, V83, P171; Foster CS, 2002, J PATHOL, V197, P551, DOI 10.1002/path.1194; Glatz JFC, 1997, PROSTAG LEUKOTR ESS, V57, P1, DOI 10.1016/S0952-3278(97)90484-1; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; Jackson MW, 2002, CANCER RES, V62, P854; JANIK P, 1975, CANCER RES, V35, P3698; Jing C, 2000, CANCER RES, V60, P2390; Jing C, 2002, JNCI-J NATL CANCER I, V94, P482; Jing C, 2001, CANCER RES, V61, P4357; Jing C, 2000, ANAL BIOCHEM, V287, P334, DOI 10.1006/abio.2000.4864; Kaighn M E, 1978, Natl Cancer Inst Monogr, P17; Ke Y, 1998, BRIT J CANCER, V77, P287, DOI 10.1038/bjc.1998.45; KE YQ, 1993, J CELL SCI, V106, P135; Ke YQ, 1997, INT J CANCER, V71, P832, DOI 10.1002/(SICI)1097-0215(19970529)71:5<832::AID-IJC22>3.0.CO;2-8; Ke YQ, 1999, ANAL BIOCHEM, V269, P201, DOI 10.1006/abio.1999.4014; Ke YQ, 1999, NUCLEIC ACIDS RES, V27, P912, DOI 10.1093/nar/27.3.912; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; Landers J, 1999, COLON LAT AM HIST R, V8, P1; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MADSEN P, 1992, J INVEST DERMATOL, V99, P299, DOI 10.1111/1523-1747.ep12616641; Masood R, 2001, BLOOD, V98, P1904, DOI 10.1182/blood.V98.6.1904; Masouye I, 1997, CIRC RES, V81, P297, DOI 10.1161/01.RES.81.3.297; Ostergaard M, 1997, CANCER RES, V57, P4111; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sinha P, 1999, ELECTROPHORESIS, V20, P2952, DOI 10.1002/(SICI)1522-2683(19991001)20:14<2952::AID-ELPS2952>3.0.CO;2-H; Smith P, 1998, FEBS LETT, V423, P19, DOI 10.1016/S0014-5793(98)00050-7; Soker S, 2001, AM J PATHOL, V159, P651, DOI 10.1016/S0002-9440(10)61736-1; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; STORCH J, 1990, J BIOL CHEM, V265, P7827; Veikkola T, 2000, CANCER RES, V60, P203; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; Watanabe R, 1997, J DERMATOL SCI, V16, P17, DOI 10.1016/S0923-1811(97)00615-4; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Yamakawa K, 2000, BIOCHEM BIOPH RES CO, V271, P571, DOI 10.1006/bbrc.2000.2665	42	88	92	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2739	2749		10.1038/sj.onc.1206341	http://dx.doi.org/10.1038/sj.onc.1206341			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743598				2022-12-25	WOS:000182569300005
J	Kinoshita, I; Leaner, V; Katabami, M; Manzano, RG; Dent, P; Sabichi, A; Birrer, MJ				Kinoshita, I; Leaner, V; Katabami, M; Manzano, RG; Dent, P; Sabichi, A; Birrer, MJ			Identification of cJun-responsive genes in Rat-1a cells using multiple techniques: increased expression of stathmin is necessary for cJun-mediated anchorage-independent growth	ONCOGENE			English	Article						c-jun; transformation; microarray; AP-1	LEUKOCYTE INTEGRIN GENE; V-JUN; C-JUN; TRANSCRIPTION FACTOR; TISSUE INHIBITOR; CANCER-CELLS; PHOSPHOPROTEIN STATHMIN; SIGNAL TRANSDUCTION; GALECTIN-3 GENE; DOWN-REGULATION	cJun is a major component of the transcription factor AP-1 and mediates a diverse set of biologic properties including proliferation, differentiation, and apoptosis. To identify cJun-responsive genes, we inducibly expressed cJun in Rat-1a cells and observed two distinct phenotypes: changes in cellular morphology with adherent growth and anchorage-independent growth. The biologic effects of cJun were entirely reversible demonstrating that they require the continued presence of cJun. To determine the genes, which mediate the biologic effects of cJun, we employed multiple methods including differential gene analysis, suppression subtractive hybridization, and cDNA microarrays. We identified 38 cJun-responsive genes including three uncharacterized genes under adherent and/or nonadherent conditions. Half of the known 36 genes were cytoskeleton- and adhesion-related genes, suggesting a major role of cJun in the regulation of the genes related to cell morphology. As proof of the principle that this approach could identify genes whose upregulation was necessary for nonadherent growth, we investigated one gene, stathmin whose upregulation by cJun was observed only under these conditions. Although overexpression of stathmin did not result in nonadherent growth, inhibition of stathmin protein expression by antisense oligonucleotides in cJun-induced Rat-1a cells prevented nonadherent growth. These results suggest that stathmin plays an essential role in anchorage-independent growth by cJun and may be a potential target for specific inhibitors for AP-1-dependent processes involved in carcinogenesis.	NCI, Cell & Canc Biol Dept, Ctr Canc Res, Rockville, MD 20850 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Virginia Commonwealth University	Birrer, MJ (corresponding author), NCI, Cell & Canc Biol Dept, Ctr Canc Res, Rockville, MD 20850 USA.	birrerm@bprb.nci.nih.gov		Gonzalez Manzano, Ramon/0000-0003-2266-6965				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Arthur JSC, 1998, BBA-PROTEIN STRUCT M, V1388, P247, DOI 10.1016/S0167-4838(98)00166-6; Bader AG, 2001, ONCOGENE, V20, P7524, DOI 10.1038/sj.onc.1204938; Bader AG, 2000, VIROLOGY, V270, P98, DOI 10.1006/viro.2000.0222; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Balogh A, 1996, EXP CELL RES, V224, P8, DOI 10.1006/excr.1996.0106; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BERGERS G, 1994, EMBO J, V13, P1176, DOI 10.1002/j.1460-2075.1994.tb06367.x; Bieche I, 1998, BRIT J CANCER, V78, P701, DOI 10.1038/bjc.1998.565; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRASELMANN S, 1992, J CELL SCI, P97; BRATTSAND G, 1993, LEUKEMIA, V7, P569; BROWN PH, 1993, ONCOGENE, V8, P877; CERVELLA P, 1993, J BIOL CHEM, V268, P5148; Clark IM, 1997, BIOCHEM J, V324, P611, DOI 10.1042/bj3240611; Clark W, 2000, MOL CELL BIOL, V20, P2529, DOI 10.1128/MCB.20.7.2529-2542.2000; COOPER HL, 1991, J IMMUNOL, V146, P3689; COOPER HL, 1990, J IMMUNOL, V145, P1205; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DiPaolo G, 1996, J CELL BIOL, V133, P1383, DOI 10.1083/jcb.133.6.1383; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DOYE V, 1992, DIFFERENTIATION, V50, P89, DOI 10.1111/j.1432-0436.1992.tb00489.x; Fey MF, 1996, BBA-GENE STRUCT EXPR, V1306, P160, DOI 10.1016/0167-4781(95)00238-3; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gao MH, 1996, CANCER RES, V56, P4229; Gaudin JC, 1997, GLYCOBIOLOGY, V7, P1089, DOI 10.1093/glycob/7.8.1089; GHOSH PK, 1993, ONCOGENE, V8, P2869; Goller ME, 1998, ONCOGENE, V16, P2945, DOI 10.1038/sj.onc.1201819; GSCHWENDT M, 1989, FEBS LETT, V257, P357, DOI 10.1016/0014-5793(89)81571-6; Hadman M, 1998, ONCOGENE, V16, P655, DOI 10.1038/sj.onc.1201574; HAILAT N, 1990, ONCOGENE, V5, P1615; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; Hartl M, 2001, P NATL ACAD SCI USA, V98, P13601, DOI 10.1073/pnas.241451198; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Hosoya H, 1996, CELL STRUCT FUNCT, V21, P237, DOI 10.1247/csf.21.237; Howell B, 1999, J CELL SCI, V112, P3713; Jaworski J, 1999, J BIOL CHEM, V274, P28106, DOI 10.1074/jbc.274.40.28106; Johnston IMP, 2000, ONCOGENE, V19, P5348, DOI 10.1038/sj.onc.1203927; Kadrofske MM, 1998, ARCH BIOCHEM BIOPHYS, V349, P7, DOI 10.1006/abbi.1997.0447; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KATAI H, 1992, MOL CELL BIOCHEM, V118, P119; KOLCH W, 1993, ONCOGENE, V8, P361; KOPPEL J, 1993, FEBS LETT, V331, P65, DOI 10.1016/0014-5793(93)80298-9; Koski C, 1999, J BIOL CHEM, V274, P32619, DOI 10.1074/jbc.274.46.32619; Larsson N, 1999, J CELL BIOL, V146, P1289, DOI 10.1083/jcb.146.6.1289; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Loo DT, 1998, J BIOL CHEM, V273, P23304, DOI 10.1074/jbc.273.36.23304; LOPEZCABRERA M, 1993, J BIOL CHEM, V268, P1187; LopezRodriguez C, 1996, J IMMUNOL, V156, P3780; Lorenzi MV, 1999, ONCOGENE, V18, P4742, DOI 10.1038/sj.onc.1202851; LUO XN, 1994, J BIOL CHEM, V269, P10312; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; MAZZONE A, 1995, HAEMATOLOGICA, V80, P161; MELHEM RF, 1991, BIOCHEM BIOPH RES CO, V179, P1649, DOI 10.1016/0006-291X(91)91764-4; MELHEM RF, 1991, J BIOL CHEM, V266, P17747; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MISTRY S, 1995, CELL MOL BIOL RES, V41, P103; Mistry SJ, 1999, ANTICANCER RES, V19, P573; Morgan RO, 1995, J MOL EVOL, V41, P979; Noti JD, 1996, MOL IMMUNOL, V33, P115, DOI 10.1016/0161-5890(95)00140-9; NYLANDER K, 1995, HISTOCHEM J, V27, P155; OSEIFRIMPONG J, 1994, MOL CARCINOGEN, V10, P72, DOI 10.1002/mc.2940100204; PHILIPS N, 1995, J BIOL CHEM, V270, P9313, DOI 10.1074/jbc.270.16.9313; PRIETO J, 1994, CELL IMMUNOL, V156, P191, DOI 10.1006/cimm.1994.1164; RAPP UR, 1994, ONCOGENE, V9, P3493; Rodier A, 1999, EXP CELL RES, V249, P337, DOI 10.1006/excr.1999.4486; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Sabichi AL, 1998, J NATL CANCER I, V90, P597, DOI 10.1093/jnci/90.8.597; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SAWADA R, 1993, J BIOL CHEM, V268, P9014; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SCHUBART UK, 1992, DIFFERENTIATION, V51, P21, DOI 10.1111/j.1432-0436.1992.tb00676.x; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; SOBEL A, 1989, J BIOL CHEM, V264, P3765; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; Solito E, 1998, CELL GROWTH DIFFER, V9, P327; Spink BC, 1998, J CELL BIOCHEM, V70, P289, DOI 10.1002/(SICI)1097-4644(19980901)70:3<289::AID-JCB1>3.3.CO;2-H; Szabo E, 1998, CELL GROWTH DIFFER, V9, P475; Tang WM, 1996, J BIOL CHEM, V271, P28324, DOI 10.1074/jbc.271.45.28324; Tiwari B, 1998, DNA CELL BIOL, V17, P957, DOI 10.1089/dna.1998.17.957; Watsuji T, 1997, BIOCHEM BIOPH RES CO, V234, P769, DOI 10.1006/bbrc.1997.6705; Weinstein J, 1998, MOL GENET METAB, V64, P52, DOI 10.1006/mgme.1998.2698; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Xie JP, 1998, GENOMICS, V54, P338, DOI 10.1006/geno.1998.5583; Yet SF, 1998, J BIOL CHEM, V273, P10530, DOI 10.1074/jbc.273.17.10530	94	33	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2003	22	18					2710	2722		10.1038/sj.onc.1206371	http://dx.doi.org/10.1038/sj.onc.1206371			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743595				2022-12-25	WOS:000182569300002
J	Flynn, CR; Komalavilas, P; Tessier, D; Thresher, J; Niederkofler, EE; Dreiza, CM; Nelson, RW; Panitch, A; Joshi, L; Brophy, CM				Flynn, CR; Komalavilas, P; Tessier, D; Thresher, J; Niederkofler, EE; Dreiza, CM; Nelson, RW; Panitch, A; Joshi, L; Brophy, CM			Transduction of biologically active motifs of the small heat shock-related protein, HSP20, leads to relaxation of vascular smooth muscle	FASEB JOURNAL			English	Article						protein transduction; mass spectrometric immunoassay (MSIA) phospho-peptide analogs	SIGNAL-TRANSDUCTION; RAT SKELETAL; IN-VIVO; PHOSPHORYLATION; DELIVERY; INSULIN; INHIBITION; SERINE-16; ARTERY; P20	Activation of cyclic nucleotide-dependent signaling pathways leads to phosphorylation of the small heat shock-related protein, HSP20, on serine 16, and relaxation of vascular smooth muscle. In this study, we used an enhanced protein transduction domain (PTD) sequence to deliver HSP20 phosphopeptide analogs into porcine coronary artery. The transduction of phosphoHSP20 analogs led to dose-dependent relaxation of coronary artery smooth muscle. Peptides containing the protein transduction domain coupled to a random orientation of the same amino acids did not. Direct fluorescence microscopy of arterial rings incubated with fluorescein isothiocyanate (FITC)-PTD or FITC-PTD-HSP20 peptides showed a diffuse peptide uptake. Mass spectrometric immunoassays (MSIAs) of smooth muscle homogenates were used to determine whether the phosphopeptide analogs affected the phosphorylation of endogenous HSP20. Treatment with the phosphodiesterase inhibitor papaverine led to a mass shift of 80 Da. However, there was no mass shift of HSP20 in muscles treated with phosphoHSP20 analogs. This suggests that the PTD-phosphoHSP20 peptide alone is sufficient to inhibit force maintenance and likely has a direct effect on the target of phosphorylated HSP20. These results suggest that transduction of phosphopeptide analogs of HSP20 directly alters physiological responses of intact muscles. The data also support a direct role for phosphorylated HSP20 in mediating vasorelaxation.	Arizona State Univ, Dept Bioengn, Tempe, AZ 85287 USA; Carl T Hayden Vet Affairs Med Ctr, Phoenix, AZ USA; Mayo Clin Jacksonville, Dept Surg, Scottsdale, AZ 85259 USA; Arizona State Univ, Dept Kinesiol, Tempe, AZ 85287 USA; Intrins Bioprobes Inc, Tempe, AZ 85281 USA; Arizona State Univ, Dept Plant Biol, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; Mayo Clinic; Mayo Clinic Phoenix; Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Brophy, CM (corresponding author), Arizona State Univ, Dept Bioengn, Tempe, AZ 85287 USA.	colleen.brophy@asu.edu	Panitch, Alyssa/F-4413-2012; Flynn, Charles/M-3895-2015	Flynn, Charles/0000-0002-3749-0598; Joshi, Lokesh/0000-0002-3612-0747				Beall A, 1999, J BIOL CHEM, V274, P11344, DOI 10.1074/jbc.274.16.11344; Beall AC, 1997, J BIOL CHEM, V272, P11283; BERGH CM, 1995, AM J PHYSIOL-HEART C, V268, pH202, DOI 10.1152/ajpheart.1995.268.1.H202; Brophy CM, 1997, BIOL REPROD, V57, P1354, DOI 10.1095/biolreprod57.6.1354; Brophy CM, 2000, AM J PHYSIOL-HEART C, V278, pH991, DOI 10.1152/ajpheart.2000.278.3.H991; Brophy CM, 1999, J VASC SURG, V29, P326, DOI 10.1016/S0741-5214(99)70385-X; Brophy CM, 1999, J BIOL CHEM, V274, P6324, DOI 10.1074/jbc.274.10.6324; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; DOGRUEL D, 1995, ANAL CHEM, V67, P4343, DOI 10.1021/ac00119a022; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Fuchs LC, 2000, AM J PHYSIOL-REG I, V279, pR492, DOI 10.1152/ajpregu.2000.279.2.R492; Ho A, 2001, CANCER RES, V61, P474; Jerius H, 1999, J VASC SURG, V29, P678, DOI 10.1016/S0741-5214(99)70314-9; KATO K, 1994, J BIOL CHEM, V269, P15302; Knoepp L, 2000, J VASC SURG, V31, P343, DOI 10.1016/S0741-5214(00)90164-2; Pipkin W, 2003, CIRCULATION, V107, P469, DOI 10.1161/01.CIR.0000044386.27444.5A; Rembold CM, 2001, J APPL PHYSIOL, V91, P1460, DOI 10.1152/jappl.2001.91.3.1460; Rembold CM, 2000, J PHYSIOL-LONDON, V524, P865, DOI 10.1111/j.1469-7793.2000.00865.x; Sandu OA, 2001, J APPL PHYSIOL, V91, P1475, DOI 10.1152/jappl.2001.91.3.1475; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Tubbs KA, 2001, ANAL BIOCHEM, V289, P26, DOI 10.1006/abio.2000.4921; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Wang Y, 1999, BIOCHEM J, V344, P971, DOI 10.1042/0264-6021:3440971; Wang Y, 1999, FEBS LETT, V462, P25, DOI 10.1016/S0014-5793(99)01496-9; Woodrum DA, 1999, AM J PHYSIOL-HEART C, V277, pH931, DOI 10.1152/ajpheart.1999.277.3.H931	27	53	57	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1358	+		10.1096/fj.02-1028fje	http://dx.doi.org/10.1096/fj.02-1028fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738803				2022-12-25	WOS:000183165000025
J	Lee, CGL; Ren, JW; Cheong, ISY; Ban, KHK; Ooi, LLPJ; Tan, SY; Kan, A; Nuchprayoon, I; Jin, RX; Lee, KH; Choti, M; Lee, LA				Lee, CGL; Ren, JW; Cheong, ISY; Ban, KHK; Ooi, LLPJ; Tan, SY; Kan, A; Nuchprayoon, I; Jin, RX; Lee, KH; Choti, M; Lee, LA			Expression of the FAT 10 gene is highly upregulated in hepatocellular carcinoma and other gastrointestinal and gynecological cancers	ONCOGENE			English	Article						diubiquitin; FAT10; ubiquitin-like modifier (UBL); hepatocellular carcinoma; gastrointestinal cancers	UBIQUITIN-LIKE PROTEIN; SPINDLE ASSEMBLY CHECKPOINT; MAD2; IDENTIFICATION; CELLS; DEGRADATION; PROTECTION; APOPTOSIS; ANAPHASE; COMPLEX	The ubiquitin-like modifier (UBL) family has recently generated much interest in the scientific community, as it is implicated to play important regulatory roles via novel protein-protein modification. FAT10 (diubiquitin) belongs to this family of proteins, comprising two ubiquitin-like moieties fused in tandem, and has been implicated to be involved in the maintenance of spindle integrity during mitosis. As FAT10 may play a role in the regulation of genomic stability, we examined if there is an association between FAT10 expression and hepatocellular carcinoma (HCC) or other cancers. Northern blot analyses revealed upregulation of FAT10 expression in the tumors of 90% of HCC patients. In situ hybridization as well as immunohistochemistry utilizing anti-FAT10 antibodies localized highest FAT10 expression in the nucleus of HCC hepatocytes rather than the surrounding immune and non-HCC cells. FAT10 expression was also found to be highly upregulated in other cancers of the gastrointestinal tract and female reproductive system. In conclusion, we demonstrated upregulation of FAT10 expression in various gastrointestinal and gynecological cancers. Its overexpression is unrelated to the general increase in protein synthesis or a general immune/inflammatory response to cancer. Rather, FAT10 may modulate tumorigenesis through its reported interaction with the MAD2 spindle-assembly checkpoint protein.	Natl Canc Ctr, Div Med Sci, Lab 5, Singapore 169610, Singapore; Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore; Johns Hopkins Singapore, Singapore, Singapore; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21218 USA; Natl Canc Ctr, Dept Surg Oncol, Singapore, Singapore; Singapore Gen Hosp, Dept Surg, Singapore 0316, Singapore; Tan Tock Seng Hosp, Dept Pathol & Lab Med, Singapore, Singapore; Chulalongkorn Univ, Fac Med, Dept Pediat, Bangkok 10330, Thailand; Natl Univ Singapore Hosp, Dept Med, Singapore 117548, Singapore; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21218 USA	National Cancer Centre Singapore (NCCS); National University of Singapore; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; National Cancer Centre Singapore (NCCS); Singapore General Hospital; Tan Tock Seng Hospital; Chulalongkorn University; National University of Singapore; Johns Hopkins University	Lee, CGL (corresponding author), Natl Canc Ctr, Div Med Sci, Lab 5, Level 6,11 Hosp Dr, Singapore 169610, Singapore.	bchleec@nus.edu.sg	Ooi, London Lucien/AGK-1395-2022; Ban, Kenneth/A-1243-2012; Lee, Caroline G/M-8918-2019	Ban, Kenneth/0000-0001-7165-8713; Lee, Caroline G/0000-0002-4323-3635; Tan, Soo-Yong/0000-0002-6348-2823; Cheong, Ian/0000-0002-3062-6878; Nuchprayoon, Issarang/0000-0002-4014-5082				Bates EFM, 1997, EUR J IMMUNOL, V27, P2471, DOI 10.1002/eji.1830271002; Biggins S, 1996, J CELL BIOL, V133, P1331, DOI 10.1083/jcb.133.6.1331; Biggins S, 2001, GENETICS, V159, P453; Boddy MN, 1996, ONCOGENE, V13, P971; Braissant O, 1998, BIOCHEMICA, V1, P10; Fan WF, 1996, IMMUNOGENETICS, V44, P97, DOI 10.1007/s002510050095; Gemma A, 2001, LUNG CANCER-J IASLC, V32, P289, DOI 10.1016/S0169-5002(00)00223-3; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Hooi SC, 1997, MOL BRAIN RES, V51, P15, DOI 10.1016/S0169-328X(97)00191-5; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Iwanaga Y, 2002, J BIOL CHEM, V277, P31005, DOI 10.1074/jbc.M110666200; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; KOMMINOTH P, 1992, HISTOCHEMISTRY, V98, P217, DOI 10.1007/BF00271035; Lee CGL, 2000, FASEB J, V14, P516, DOI 10.1096/fasebj.14.3.516; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Okura T, 1996, J IMMUNOL, V157, P4277; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Raasi S, 2001, J BIOL CHEM, V276, P35334, DOI 10.1074/jbc.M105139200; Raasi S, 1999, EUR J IMMUNOL, V29, P4030, DOI 10.1002/(SICI)1521-4141(199912)29:12<4030::AID-IMMU4030>3.0.CO;2-Y; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Wang XH, 2000, CARCINOGENESIS, V21, P2293, DOI 10.1093/carcin/21.12.2293	29	138	157	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2592	2603		10.1038/sj.onc.1206337	http://dx.doi.org/10.1038/sj.onc.1206337			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730673				2022-12-25	WOS:000182569000007
J	Cher, CDN; Armugam, A; Lachumanan, R; Coghlan, MW; Jeyaseelan, K				Cher, CDN; Armugam, A; Lachumanan, R; Coghlan, MW; Jeyaseelan, K			Pulmonary inflammation and edema induced by phospholipase A2 - Global gene analysis and effects on aquaporins and Na+/K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FLUID TRANSPORT; MOUSE LUNG; A(2); EXPRESSION; CLEARANCE; VENOM	Victims of snakebite quickly succumb to severe respiratory failure, which can be fatal if left untreated. One of the most toxic components of snake venom is phospholipase A(2) (PLA(2); EC 3.1.1.4). PLA(2) isolated from the elapid, Naja sputatrix, induced pulmonary inflammation and edema when administered intravenously and intratracheally to rats. Analysis of pulmonary gene expression profiles using oligonucleotide microarrays revealed 60 genes whose expression was altered by at least 3-fold in response to intratracheal instillation of PLA(2) for 3 h as compared with controls. In addition to genes encoding cytokines and chemokines responsible for inflammatory processes, the Na+/ K+-ATPase gene has been found to be involved in edema formation. Real-time PCR, Western blot, and immunohistochemical analyses confirmed that the expression of AQP1 and AQP5 mRNAs and proteins was decreased. Besides providing an experimental model for studies on the pathophysiology of the lung, this investigation yields a clue to the mechanisms by which endogenous PLA(2)s could mediate inflammation in conditions such as allergy and rheumatoid arthritis.	Natl Univ Singapore, Fac Med, Dept Biochem, Singapore 117597, Singapore; Res Instruments Pte Ltd, Singapore S139944, Singapore; Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Parkville, Vic 3052, Australia	National University of Singapore; Florey Institute of Neuroscience & Mental Health; University of Melbourne	Jeyaseelan, K (corresponding author), Natl Univ Singapore, Fac Med, Dept Biochem, 8 Med Dr, Singapore 117597, Singapore.	bchjeya@nus.edu.sg		Armugam, Arunmozhiarasi/0000-0002-6064-1980				Abroug E, 2001, INTENS CARE MED, V27, P800, DOI 10.1007/s001340100928; Agrawal PN, 2001, NEUROL INDIA, V49, P25; Ali SA, 2000, TOXICON, V38, P687, DOI 10.1016/S0041-0101(99)00184-1; Armugam A, 1997, TOXICON, V35, P27, DOI 10.1016/S0041-0101(96)00071-2; Britt A, 1997, AM J EMERG MED, V15, P529, DOI 10.1016/S0735-6757(97)90202-3; CHANG CC, 1979, SNAKE VENOMS, P159; Chu J, 2002, AM J RESP CRIT CARE, V166, P9, DOI 10.1164/rccm.2108138; Costa EP, 2002, INFLAMMATION, V26, P13, DOI 10.1023/A:1014465611487; Crandall ED, 2001, AM J RESP CRIT CARE, V163, P1021, DOI 10.1164/ajrccm.163.4.2006116; Dematte JE, 2000, INTENS CARE MED, V26, P477, DOI 10.1007/s001340051186; Dennis EA, 1983, ENZYMES, P307; Dinarello CA, 2000, NEW ENGL J MED, V343, P732, DOI 10.1056/NEJM200009073431011; EDELSON JD, 1991, AM REV RESPIR DIS, V143, P1102, DOI 10.1164/ajrccm/143.5_Pt_1.1102; ETEMADI AH, 1980, BIOCHIM BIOPHYS ACTA, V604, P423; Factor P, 2001, CELL MOL BIOL, V47, P347; FERRER X, 1992, COMP BIOCHEM PHYS C, V102, P325, DOI 10.1016/0742-8413(92)90119-R; FLETCHER JE, 1997, VENOM PHOSPHOLIPASES, P428; FRAENKELCONRAT H, 1983, J TOXICOL-TOXIN REV, V1, P205; Freund V, 2002, EUR RESPIR J, V20, P458, DOI 10.1183/09031936.02.00269202; GOLD BS, 2002, NEW ENGL J MED, V347, P356; GUNTHER P, 2002, AM J RESP CRIT CARE, V166, P818; Harris J.B., 1991, P91; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; HIRATA F, 1980, SCIENCE, V209, P1082, DOI 10.1126/science.6157192; HORISBERGER JD, 1994, NA K ATPASE STRUCTUR, P11; HOWARD BD, 1982, TRENDS PHARMACOL SCI, V3, P167, DOI 10.1016/0165-6147(82)91072-0; HOWARDJONES N, 1985, WHO CHRON, V39, P51; Ingbar DH, 1998, LUNG BIOL HEALTH DIS, V116, P477; Jeyaseelan K, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.12.e58; Johnson MD, 2002, P NATL ACAD SCI USA, V99, P1966, DOI 10.1073/pnas.042689399; Johnston H, 2000, PLACENTA, V21, P88, DOI 10.1053/plac.1999.0445; King LS, 2002, P NATL ACAD SCI USA, V99, P1059, DOI 10.1073/pnas.022626499; KINI RM, 1997, VENOM PHOSPHOLIPASE, P7; Kips JC, 2001, EUR RESPIR J, V18, p24S, DOI 10.1183/09031936.01.00229601; KREBS JJR, 1982, J BIOENERG BIOMEMBR, V14, P141, DOI 10.1007/BF00745016; LEE CY, 1971, NEUROPOISONS, P21; Loghmani F, 2002, INFLAMMATION, V26, P73, DOI 10.1023/A:1014884127573; Ma TH, 2000, J CLIN INVEST, V105, P93, DOI 10.1172/JCI8258; Mandal AK, 2001, FASEB J, V15, P1834, DOI 10.1096/fj.00-0831fje; MATO JM, 1983, BIOCHEM J, V213, P1; Matthay MA, 2000, CLIN CHEST MED, V21, P477, DOI 10.1016/S0272-5231(05)70160-X; Menten P, 2002, CYTOKINE GROWTH F R, V13, P455, DOI 10.1016/S1359-6101(02)00045-X; NAIR X, 1993, INFLAMMATION, V17, P205, DOI 10.1007/BF00916106; Newton R, 1996, LIFE SCI, V60, P67, DOI 10.1016/S0024-3205(96)00590-5; Nielsen S, 1997, AM J PHYSIOL-CELL PH, V273, pC1549, DOI 10.1152/ajpcell.1997.273.5.C1549; ROELOFSEN B, 1982, J TOXICOL-TOXIN REV, V1, P87, DOI 10.3109/15569548209016468; Rosenberg P., 1986, NATURAL TOXINS ANIMA, P129; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Song YL, 2001, J GEN PHYSIOL, V117, P573, DOI 10.1085/jgp.117.6.573; Stocker K., 1990, P33; Sznajder JI, 2002, J APPL PHYSIOL, V93, P1860, DOI 10.1152/japplphysiol.00022.2002; TAN NH, 1982, BIOCHIM BIOPHYS ACTA, V719, P599, DOI 10.1016/0304-4165(82)90250-1; Tithof PK, 1998, J IMMUNOL, V160, P953; Towne JE, 2000, AM J RESP CELL MOL, V22, P34, DOI 10.1165/ajrcmb.22.1.3818; Towne JE, 2001, J BIOL CHEM, V276, P18657, DOI 10.1074/jbc.M100322200; VERHEIJ HM, 1996, PHOSPHOLIPASES CLIN, P3; YANG CC, 1994, J TOXICOL-TOXIN REV, V13, P125, DOI 10.3109/15569549409089958; Yedgar S, 2000, BBA-MOL CELL BIOL L, V1488, P182, DOI 10.1016/S1388-1981(00)00120-7	58	29	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31352	31360		10.1074/jbc.M302446200	http://dx.doi.org/10.1074/jbc.M302446200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12746451	hybrid			2022-12-25	WOS:000184658800117
J	Norager, S; Arent, S; Bjornberg, O; Ottosen, M; Lo Leggio, L; Jensen, KF; Larsen, S				Norager, S; Arent, S; Bjornberg, O; Ottosen, M; Lo Leggio, L; Jensen, KF; Larsen, S			Lactococcus lactis dihydroorotate dehydrogenase A mutants reveal important facets of the enzymatic function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; CRYSTAL-STRUCTURE; PROTEIN MODELS; MECHANISM; IDENTIFICATION; MUTAGENESIS; LEFLUNOMIDE; INHIBITORS; REFINEMENT; PYRK	Dihydroorotate dehydrogenases (DHODs) are flavoenzymes catalyzing the oxidation of (S)-dihydroorotate to orotate in the biosynthesis of UMP, the precursor of all other pyrimidine nucleotides. On the basis of sequence, DHODs can be divided into two classes, class 1, further divided in subclasses 1A and 1B, and class 2. This division corresponds to differences in cellular location and the nature of the electron acceptor. Herein we report a study of Lactococcus lactis DHODA, a representative of the class 1A enzymes. Based on the DHODA structure we selected seven residues that are highly conserved between both main classes of DHODs as well as three residues representing surface charges close to the active site for site-directed mutagenesis. The availability of both kinetic and structural data on the mutant enzymes allowed us to define the roles individual structural segments play in catalysis. We have also structurally proven the presence of an open active site loop in DHODA and obtained information about the interactions that control movements of loops around the active site. Furthermore, in one mutant structure we observed differences between the two monomers of the dimer, confirming an apparent asymmetry between the two substrate binding sites that was indicated by the kinetic results.	Univ Copenhagen, Ctr Crystallog Studies, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Dept Biol Chem, DK-1307 Copenhagen, Denmark	University of Copenhagen; University of Copenhagen	Larsen, S (corresponding author), European Synchrotron Radiat Facil, BP 220, F-38043 Grenoble, France.		Larsen, Sine/A-4487-2017; Leggio, Leila Lo/B-4287-2015	Larsen, Sine/0000-0003-3848-1789; Leggio, Leila Lo/0000-0002-5135-0882				Andersen PS, 1996, J BACTERIOL, V178, P5005, DOI 10.1128/jb.178.16.5005-5012.1996; Bjornberg O, 1999, BIOCHEMISTRY-US, V38, P2899, DOI 10.1021/bi982352c; Bjornberg O, 1997, BIOCHEMISTRY-US, V36, P16197, DOI 10.1021/bi971628y; BJORNBERG O, 2001, ARCH BIOCH BIOPHYS; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Davis JP, 1996, BIOCHEMISTRY-US, V35, P1270, DOI 10.1021/bi952168g; Davis JP, 1997, BIOCHEM PHARMACOL, V54, P459, DOI 10.1016/S0006-2952(97)00197-4; DEFREES SA, 1988, BIOCHEM PHARMACOL, V37, P3807, DOI 10.1016/0006-2952(88)90060-3; Fraaije MW, 2000, TRENDS BIOCHEM SCI, V25, P126, DOI 10.1016/S0968-0004(99)01533-9; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; HINES V, 1989, BIOCHEMISTRY-US, V28, P1222, DOI 10.1021/bi00429a040; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Knecht W, 2000, FEBS LETT, V467, P27, DOI 10.1016/S0014-5793(00)01117-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu SP, 2000, STRUCT FOLD DES, V8, P25, DOI 10.1016/S0969-2126(00)00077-0; Loffler M, 1998, ADV EXP MED BIOL, V431, P507; Marcinkeviciene J, 1999, BIOCHEMISTRY-US, V38, P13129, DOI 10.1021/bi990674q; MASSEY V, 1991, FLAVINS FLAVOPROTEIN, P60; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nielsen FS, 1996, PROTEIN SCI, V5, P852; Nielsen FS, 1996, J BIOL CHEM, V271, P29359, DOI 10.1074/jbc.271.46.29359; Norager S, 2002, STRUCTURE, V10, P1211, DOI 10.1016/S0969-2126(02)00831-6; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palfey BA, 2001, BIOCHEMISTRY-US, V40, P4381, DOI 10.1021/bi0025666; PASCAL RA, 1984, BIOCHEMISTRY-US, V23, P2745, DOI 10.1021/bi00307a033; Rowland P, 1997, STRUCTURE, V5, P239, DOI 10.1016/S0969-2126(97)00182-2; Rowland P, 1998, PROTEIN SCI, V7, P1269, DOI 10.1002/pro.5560070601; Rowland P, 2000, STRUCTURE, V8, P1227, DOI 10.1016/S0969-2126(00)00530-X; Ruckemann K, 1998, J BIOL CHEM, V273, P21682, DOI 10.1074/jbc.273.34.21682; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5	34	28	28	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28812	28822		10.1074/jbc.M303767200	http://dx.doi.org/10.1074/jbc.M303767200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12732650	hybrid			2022-12-25	WOS:000184421100059
J	Matsugami, A; Okuizumi, T; Uesugi, S; Katahira, M				Matsugami, A; Okuizumi, T; Uesugi, S; Katahira, M			Intramolecular higher order packing of parallel quadruplexes comprising a G : G : G : G tetrad and a G(: A): G(: A): G(: A): G heptad of GGA triplet repeat DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN RECEPTOR GENE; TRINUCLEOTIDE REPEAT; TELOMERIC DNA; EXPRESSION; RICH; NMR; SEQUENCES; MICROSATELLITES; CONFORMATION; EXPANSION	GGA triplet repeats are widely dispersed throughout eukaryotic genomes and are frequently located within biologically important regions such as gene regulatory regions and recombination hot spot sites. We determined the structure of d(GGA)(4) (12-mer) under physiological conditions and founded the formation of an intramolecular parallel quadruplex for the first time. Later, a similar architecture to that of the intramolecular parallel quadruplex was found for a telomere DNA in the crystalline state. Here, we have determined the structure of d(GGA)(8) (24-mer) under physiological conditions. Two intramolecular parallel quadruplexes comprising a G: G: G: G tetrad and a G(: A): G(: A): G(: A): G heptad are formed in d(GGA)(8). These quadruplexes are packed in a tail-to-tail manner. This is the first demonstration of the intramolecular higher order packing of quadruplexes at atomic resolution. K+ ions, but not Na+ ones, are critically required for the formation of this unique structure. The elucidated structure suggests the mechanisms underlying the biological events related to the GGA triplet repeat. Furthermore, in the light of the structure, the mode of the higher order packing of the telomere DNA is discussed.	Yokohama Natl Univ, Grad Sch Environm & Informat Sci, Dept Environm & Nat Sci, Hodohaya Ku, Yokohama, Kanagawa 2408501, Japan; RIKEN, Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan	Yokohama National University; RIKEN	Katahira, M (corresponding author), Yokohama Natl Univ, Grad Sch Environm & Informat Sci, Dept Environm & Nat Sci, Hodohaya Ku, 79-7 Tokiwadai, Yokohama, Kanagawa 2408501, Japan.							Aoki T, 1997, J MOL BIOL, V267, P229, DOI 10.1006/jmbi.1997.0890; BALAGURUMOORTHY P, 1992, NUCLEIC ACIDS RES, V20, P4061, DOI 10.1093/nar/20.15.4061; BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bowater RP, 2001, PROG NUCLEIC ACID RE, V66, P159; Brunger A.T., 1993, X PLOR VERSION 3 1 S; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Catasti P, 1999, GENETICA, V106, P15, DOI 10.1023/A:1003716509180; Catasti P, 1996, J MOL BIOL, V264, P534, DOI 10.1006/jmbi.1996.0659; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DERRY JMJ, 1995, GENOMICS, V29, P471, DOI 10.1006/geno.1995.9979; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; HEARNE CM, 1992, TRENDS GENET, V8, P288, DOI 10.1016/0168-9525(92)90256-4; HELLER M, 1985, MOL CELL BIOL, V5, P457, DOI 10.1128/MCB.5.3.457; HIRAO I, 1994, NUCLEIC ACIDS RES, V22, P576, DOI 10.1093/nar/22.4.576; HIRSCH MR, 1990, MOL CELL BIOL, V10, P1959, DOI 10.1128/MCB.10.5.1959; HOFFMANLIEBERMANN B, 1986, MOL CELL BIOL, V6, P3632, DOI 10.1128/MCB.6.11.3632; Huertas D, 1996, BIOCHEMISTRY-US, V35, P13125, DOI 10.1021/bi961020+; Katahira R, 1998, NUCLEIC ACIDS RES, V26, P744, DOI 10.1093/nar/26.3.744; Kettani A, 2000, J MOL BIOL, V297, P627, DOI 10.1006/jmbi.2000.3524; Kettani A, 1999, STRUCTURE, V7, P803, DOI 10.1016/S0969-2126(99)80104-X; KOCH KS, 1995, NUCLEIC ACIDS RES, V23, P1098, DOI 10.1093/nar/23.7.1098; LI Y, 1991, P NATL ACAD SCI USA, V88, P26, DOI 10.1073/pnas.88.1.26; Liu H, 2002, J MOL BIOL, V322, P955, DOI 10.1016/S0022-2836(02)00876-8; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; Matsugami A, 2001, J MOL BIOL, V313, P255, DOI 10.1006/jmbi.2001.5047; Mishima Y, 1997, J BIOL CHEM, V272, P26578, DOI 10.1074/jbc.272.42.26578; Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; Saenger W, 1983, PRINCIPLES NUCL ACID; SANTOS RA, 1989, BIOCHEMISTRY-US, V28, P9372, DOI 10.1021/bi00450a018; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; Smith JS, 2000, BIOCHEMISTRY-US, V39, P5642, DOI 10.1021/bi992712b; SUBDQUIST WI, 1989, NATURE, V342, P825; Usdin K, 1998, NUCLEIC ACIDS RES, V26, P4078, DOI 10.1093/nar/26.17.4078; Varani G, 1996, PROG NUCL MAG RES SP, V29, P51, DOI 10.1016/0079-6565(96)01028-X; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; Wuthrich K, 1986, NMR PROTEINS NUCL AC	40	86	87	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28147	28153		10.1074/jbc.M303694200	http://dx.doi.org/10.1074/jbc.M303694200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12748183	hybrid			2022-12-25	WOS:000184242700102
J	Couturier, C; Jockers, R				Couturier, C; Jockers, R			Activation of the leptin receptor by a ligand-induced conformational change of constitutive receptor dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; REVERSES INSULIN-RESISTANCE; TYROSINE-PHOSPHATASE 1B; EPIDERMAL GROWTH-FACTOR; ERYTHROPOIETIN RECEPTOR; OB-R; EXTRACELLULAR DOMAIN; CELL-SURFACE; INDEPENDENT DIMERIZATION; CRYSTAL-STRUCTURE	Binding of leptin to the leptin receptor is crucial for body weight and bone mass regulation in mammals. Leptin receptors were shown to exist as dimers, but the role of dimerization in receptor activation remains unknown. Using a quantitative Bioluminescence Resonance Energy Transfer approach, we show here in living cells that similar to60% of the leptin receptor exists as constitutive dimers at physiological expression levels in the absence of leptin. No further increase in leptin receptor dimerization was detected in the presence of leptin. Importantly, in cells expressing the short leptin receptor isoform, leptin promoted a robust enhancement of energy transfer signals that reflect specific conformational changes of pre-existing leptin receptor dimers and that may be used as read-out in screening assays for leptin receptor ligands. Both leptin receptor dimerization and the leptin-induced energy transfer were Janus kinase 2-independent. Taken together, our data support a receptor activation model based on ligand-induced conformational changes rather than ligand-induced dimerization.	Univ Paris 05, CNRS 8104, INSERM,U567, Dept Cell Biol, F-75014 Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Jockers, R (corresponding author), Univ Paris 05, CNRS 8104, INSERM,U567, Dept Cell Biol, 22 Rue Mechain, F-75014 Paris, France.		Jockers, Ralf/Q-2100-2019; Couturier, Cyril/ABG-9063-2020; Jockers, Ralf/P-2272-2017; Couturier, Cyril CC/I-3020-2016	Jockers, Ralf/0000-0002-4354-1750; Jockers, Ralf/0000-0002-4354-1750; 				Aritomi M, 1999, NATURE, V401, P713, DOI 10.1038/44394; Ayoub MA, 2002, J BIOL CHEM, V277, P21522, DOI 10.1074/jbc.M200729200; Barr VA, 1999, J BIOL CHEM, V274, P21416, DOI 10.1074/jbc.274.30.21416; Bjorbaek C, 2000, J BIOL CHEM, V275, P40649, DOI 10.1074/jbc.M007577200; Boute N, 2001, MOL PHARMACOL, V60, P640; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Constantinescu SN, 2001, MOL CELL, V7, P377, DOI 10.1016/S1097-2765(01)00185-X; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; Cook WS, 2002, DEV CELL, V2, P385, DOI 10.1016/S1534-5807(02)00158-2; Devos R, 1997, J BIOL CHEM, V272, P18304, DOI 10.1074/jbc.272.29.18304; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; Fong TM, 1998, MOL PHARMACOL, V53, P234, DOI 10.1124/mol.53.2.234; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Ge HF, 2002, J BIOL CHEM, V277, P45898, DOI 10.1074/jbc.M205825200; Gent J, 2002, P NATL ACAD SCI USA, V99, P9858, DOI 10.1073/pnas.152294299; Ghilardi N, 1997, MOL ENDOCRINOL, V11, P393, DOI 10.1210/me.11.4.393; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Haniu M, 1998, J BIOL CHEM, V273, P28691, DOI 10.1074/jbc.273.44.28691; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Jockers R, 1998, ENDOCRINOLOGY, V139, P2676, DOI 10.1210/en.139.6.2676; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Lundin A, 2000, BBA-MOL CELL RES, V1499, P130, DOI 10.1016/S0167-4889(00)00114-2; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Nakashima K, 1997, FEBS LETT, V403, P79, DOI 10.1016/S0014-5793(97)00013-6; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Oral EA, 2002, NEW ENGL J MED, V346, P570, DOI 10.1056/NEJMoa012437; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Petersen KF, 2002, J CLIN INVEST, V109, P1345, DOI [10.1172/JCI0215001, 10.1172/JCI200215001]; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rosenblum CI, 1998, MOL CELL ENDOCRINOL, V143, P117, DOI 10.1016/S0303-7207(98)00129-4; Sato M, 2002, NAT BIOTECHNOL, V20, P287, DOI 10.1038/nbt0302-287; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Sweeney G, 2002, CELL SIGNAL, V14, P655, DOI 10.1016/S0898-6568(02)00006-2; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; White DW, 1997, J BIOL CHEM, V272, P4065, DOI 10.1074/jbc.272.7.4065; White DW, 1999, J CELL BIOCHEM, V73, P278, DOI 10.1002/(SICI)1097-4644(19990501)73:2<278::AID-JCB13>3.0.CO;2-W; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151	45	98	105	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26604	26611		10.1074/jbc.M302002200	http://dx.doi.org/10.1074/jbc.M302002200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12734179	hybrid			2022-12-25	WOS:000184155700042
J	Gual, P; Gonzalez, T; Gremeaux, T; Barres, R; Le Marchand-Brustel, Y; Tanti, JF				Gual, P; Gonzalez, T; Gremeaux, T; Barres, R; Le Marchand-Brustel, Y; Tanti, JF			Hyperosmotic stress inhibits insulin receptor substrate-1 function by distinct mechanisms in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; STIMULATED GLUCOSE-TRANSPORT; GROWTH-FACTOR-I; GLUT4 TRANSLOCATION; OSMOTIC-STRESS; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; SERINE/THREONINE PHOSPHORYLATION; SERINE PHOSPHORYLATION; SIGNALING PATHWAYS	In 3T3-L1 adipocytes, hyperosmotic stress was found to inhibit insulin signaling, leading to an insulin-resistant state. We show here that, despite normal activation of insulin receptor, hyperosmotic stress inhibits both tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) and IRS-1-associated phosphoinositide 3 (PI 3)kinase activity in response to physiological insulin concentrations. Insulin-induced membrane ruffling, which is dependent on PI 3-kinase activation, was also markedly reduced. These inhibitory effects were associated with an increase in IRS-1 Ser(307) phosphorylation. Furthermore, the mammalian target of rapamycin ( mTOR) inhibitor rapamycin prevented the osmotic shock-induced phosphorylation of IRS-1 on Ser(307). The inhibition of mTOR completely reversed the inhibitory effect of hyperosmotic stress on insulin-induced IRS-1 tyrosine phosphorylation and PI 3-kinase activation. In addition, prolonged osmotic stress enhanced the degradation of IRS proteins through a rapamycin-insensitive pathway and a proteasome-independent process. These data support evidence of new mechanisms involved in osmotic stress-induced cellular insulin resistance. Short-term osmotic stress induces the phosphorylation of IRS-1 on Ser(307) by an mTOR-dependent pathway. This, in turn, leads to a decrease in early proximal signaling events induced by physiological insulin concentrations. On the other hand, prolonged osmotic stress alters IRS-1 function by inducing its degradation, which could contribute to the down-regulation of insulin action.	INSERM, U568, F-06107 Nice 02, France; Fac Med, Inst Federatif Rech 50, F-06107 Nice 02, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Tanti, JF (corresponding author), INSERM, U568, Ave Valombrose, F-06107 Nice 02, France.	tanti@unice.fr	Gual, Philippe/P-9833-2019; BARRES, Romain/N-2501-2016; Gual, Philippe/M-8787-2017	Gual, Philippe/0000-0001-7393-8356; BARRES, Romain/0000-0002-0158-519X; Gual, Philippe/0000-0001-7393-8356; Tanti, Jean-Francois/0000-0003-1782-1318; Gonzalez, Teresa/0000-0001-7558-6833				Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Berg CE, 2002, BIOCHEM BIOPH RES CO, V293, P1021, DOI 10.1016/S0006-291X(02)00333-9; Burks DJ, 1997, J BIOL CHEM, V272, P27716, DOI 10.1074/jbc.272.44.27716; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Chen D, 1999, MOL CELL BIOL, V19, P4684; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; DAHL SV, 1991, BIOCHEM J, V278, P771, DOI 10.1042/bj2780771; Desai BN, 2002, P NATL ACAD SCI USA, V99, P4319, DOI 10.1073/pnas.261702698; Dong LQ, 2000, P NATL ACAD SCI USA, V97, P5089, DOI 10.1073/pnas.090491897; Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; Gual P, 2002, J BIOL CHEM, V277, P43980, DOI 10.1074/jbc.M203042200; Gual P, 2002, DIABETOLOGIA, V45, pA69; Hartman ME, 2001, BIOCHEM BIOPH RES CO, V280, P776, DOI 10.1006/bbrc.2000.4214; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; HEYDRICK SJ, 1993, J CLIN INVEST, V91, P1358, DOI 10.1172/JCI116337; Janez A, 2000, J BIOL CHEM, V275, P26870; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; KOMJATI M, 1988, BIOCHEM MED METAB B, V39, P312, DOI 10.1016/0885-4505(88)90091-6; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Kozma SC, 2002, BIOESSAYS, V24, P65, DOI 10.1002/bies.10031; Lewis A, 2002, AM J PHYSIOL-CELL PH, V282, pC271, DOI 10.1152/ajpcell.00427.2001; Liu J, 2002, MOL CELL BIOL, V22, P3599, DOI 10.1128/MCB.22.11.3599-3609.2002; Mamay CL, 2003, ONCOGENE, V22, P602, DOI 10.1038/sj.onc.1206186; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Martin SS, 1996, ENDOCRINOLOGY, V137, P5045, DOI 10.1210/en.137.11.5045; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Parrott LA, 1999, J BIOL CHEM, V274, P24731, DOI 10.1074/jbc.274.35.24731; Pederson TM, 2001, DIABETES, V50, P24, DOI 10.2337/diabetes.50.1.24; Ricort JM, 1997, J BIOL CHEM, V272, P19814, DOI 10.1074/jbc.272.32.19814; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Rui LY, 2001, J BIOL CHEM, V276, P40362, DOI 10.1074/jbc.M105332200; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; Takano T, 2001, MOL CELL BIOL, V21, P5050, DOI 10.1128/MCB.21.15.5050-5062.2001; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Vollenweider P, 1997, ENDOCRINOLOGY, V138, P4941, DOI 10.1210/en.138.11.4941; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002	52	62	64	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26550	26557		10.1074/jbc.M212273200	http://dx.doi.org/10.1074/jbc.M212273200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12730242	hybrid			2022-12-25	WOS:000184155700035
J	St-Pierre, J; Lin, J; Krauss, S; Tarr, PT; Yang, RJ; Newgard, CB; Spiegelman, BM				St-Pierre, J; Lin, J; Krauss, S; Tarr, PT; Yang, RJ; Newgard, CB; Spiegelman, BM			Bioenergetic analysis of peroxisome proliferator-activated receptor gamma coactivators 1 alpha and 1 beta (PGC-1 alpha and PGC-1 beta) in muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL INNER MEMBRANE; UNCOUPLING PROTEIN HOMOLOG; PROTON LEAK; INDUCIBLE COACTIVATOR; METABOLIC DEPRESSION; LIVER-MITOCHONDRIA; THYROID-HORMONE; MAMMALIAN-CELLS; THERMOGENESIS; RESPIRATION	Peroxisome proliferator-activated receptor gamma coactivator (PGC)-1alpha is a coactivator of nuclear receptors and other transcription factors that regulates several components of energy metabolism, particularly certain aspects of adaptive thermogenesis in brown fat and skeletal muscle, hepatic gluconeogenesis, and fiber type switching in skeletal muscle. PGC-1alpha has been shown to induce mitochondrial biogenesis when expressed in muscle cells, and preliminary analysis has suggested that this molecule may specifically increase the fraction of uncoupled versus coupled respiration. In this paper, we have performed detailed bioenergetic analyses of the function of PGC-1alpha and its homolog PGC-1beta in muscle cells by monitoring simultaneously oxygen consumption and membrane potential. Cells expressing PGC-1alpha or PGC-1beta display higher proton leak rates at any given membrane potential than control cells. However, cells expressing PGC-1alpha have a higher proportion of their mitochondrial respiration linked to proton leak than cells expressing PGC-1beta. Although these two proteins cause a similar increase in the expression of many mitochondrial genes, PGC-1beta preferentially induces certain genes involved in the removal of reactive oxygen species, recently recognized as activators of uncoupling proteins. Together, these data indicate that PGC-1alpha and PGC-1beta profoundly alter mitochondrial metabolism and suggest that these proteins are likely to play different physiological functions.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol, Boston, MA 02115 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Sarah W Stedman Ctr Nutr Studies, Durham, NC 27710 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Duke University	Spiegelman, BM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 1 Jimmy Fund Way,SM958, Boston, MA 02115 USA.	bruce_spiegelman@dfci.harvard.edu	St-Pierre, Julie/AGB-3651-2022	St-Pierre, Julie/0000-0002-2815-7099	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK054477, R01DK054477] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54477] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersson U, 2001, MOL CELL BIOL, V21, P3738, DOI 10.1128/MCB.21.11.3738-3749.2001; [Anonymous], 1979, STEREOLOGICAL METHOD; Argyropoulos G, 2002, J APPL PHYSIOL, V92, P2187, DOI 10.1152/japplphysiol.00994.2001; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Bishop T, 2002, AM J PHYSIOL-REG I, V282, pR372, DOI 10.1152/ajpregu.00401.2001; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; BRAND MD, 1991, BIOCHEM J, V275, P81, DOI 10.1042/bj2750081; BRAND MD, 1995, MEASUREMENT MITOCHON, P39; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; HAFNER RP, 1988, EUR J BIOCHEM, V178, P511, DOI 10.1111/j.1432-1033.1988.tb14477.x; HAFNER RP, 1989, FEBS LETT, V248, P175, DOI 10.1016/0014-5793(89)80455-7; HARPER ME, 1993, J BIOL CHEM, V268, P14850; HARPER ME, 1993, BIOCHEM SOC T, V21, P785, DOI 10.1042/bst0210785; HENNING RH, 1994, BRIT J PHARMACOL, V111, P459, DOI 10.1111/j.1476-5381.1994.tb14758.x; Krauss S, 2002, P NATL ACAD SCI USA, V99, P118, DOI 10.1073/pnas.012410699; Kressler D, 2002, J BIOL CHEM, V277, P13918, DOI 10.1074/jbc.M201134200; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200; Nedergaard J, 2003, EXP PHYSIOL, V88, P65, DOI 10.1113/eph8802502; NOBES CD, 1990, J BIOL CHEM, V265, P12903; PORTER RK, 1993, NATURE, V362, P628, DOI 10.1038/362628a0; PORTER RK, 1995, AM J PHYSIOL-REG I, V269, pR1213, DOI 10.1152/ajpregu.1995.269.5.R1213; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; REYNAFARJE B, 1985, ANAL BIOCHEM, V145, P406, DOI 10.1016/0003-2697(85)90381-1; Rolfe DFS, 1997, PHYSIOL REV, V77, P731, DOI 10.1152/physrev.1997.77.3.731; St-Pierre J, 2000, J EXP BIOL, V203, P1469; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	35	444	471	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26597	26603		10.1074/jbc.M301850200	http://dx.doi.org/10.1074/jbc.M301850200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12734177	hybrid, Green Published			2022-12-25	WOS:000184155700041
J	Tucholski, J; Johnson, GVW				Tucholski, J; Johnson, GVW			Tissue transglutaminase directly regulates adenylyl cyclase resulting in enhanced cAMP-response element-binding protein (CREB) activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUNTINGTONS-DISEASE BRAIN; CROSS-LINKING ENZYMES; NERVE GROWTH-FACTOR; CYCLIC-AMP; ALZHEIMERS-DISEASE; RETINOIC ACID; TRANSCRIPTIONAL REGULATION; GENE-TRANSCRIPTION; NEURITE RETRACTION; NEURONAL SURVIVAL	Tissue transglutaminase (tTG) is present in the human nervous system and is predominantly localized to neurons. Treatment of human neuroblastoma SH-SY5Y cells with retinoic acid results in increased tTG expression, which is both necessary and sufficient for differentiation. The goal of the present study was to determine whether tTG modulates the activation of the cyclic AMP-response element (CRE)-binding protein, CREB, an event that likely plays a central role in the differentiation of SH-SY5Y cells. SH-SY5Y cells stably transfected with active wild type tTG, tTG without transamidating activity (C277S), an antisense tTG construct that depleted the endogenous levels of tTG, or vector only were used for the study. Treatment with forskolin, an adenylyl cyclase activator, increased that activation-associated phosphorylation of CREB, which was prolonged by tTG overexpression. CRE-reporter gene activity was also significantly elevated in the tTG cells compared with the other cells. The enhancement of CREB phosphorylation/activation in the tTG cells is likely due to the fact that tTG significantly potentiates cAMP production, and our findings indicate that tTG enhances adenylyl cyclase activity by modulating the conformation state of adenylyl cyclase. This is the first study to provide evidence of the mechanism by which tTG may contribute to neuronal differentiation.	Univ Alabama, Dept Psychiat, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Johnson, GVW (corresponding author), Univ Alabama, Dept Psychiat, 1720 7th Ave S,SC1061, Birmingham, AL 35294 USA.		Johnson, Gail V.W./K-4723-2012	Johnson, Gail V.W./0000-0003-3464-0404	NIA NIH HHS [AG12396] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012396] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Antoni FA, 2000, FRONT NEUROENDOCRIN, V21, P103, DOI 10.1006/frne.1999.0193; Appelt DM, 1996, J HISTOCHEM CYTOCHEM, V44, P1421, DOI 10.1177/44.12.8985134; BAROVSKY K, 1985, MOL PHARMACOL, V28, P502; BURNS DL, 1982, J BIOL CHEM, V257, P32; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P4155, DOI 10.1073/pnas.75.9.4155; CHAKRABORTY G, 1987, J NEUROCHEM, V48, P669, DOI 10.1111/j.1471-4159.1987.tb05567.x; Ciani E, 2002, J BIOL CHEM, V277, P49896, DOI 10.1074/jbc.M206177200; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; Festoff BW, 2001, INT REV CYTOL, V211, P153, DOI 10.1016/S0074-7696(01)11018-1; FRIEDRICH P, 1991, NEUROSCIENCE, V43, P331, DOI 10.1016/0306-4522(91)90297-2; Gentile V, 1997, BBA-MOL CELL RES, V1357, P115, DOI 10.1016/S0167-4889(97)00024-4; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Goodman RH, 2000, GENE DEV, V14, P1553; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; HAND D, 1993, J NEUROCHEM, V61, P1064, DOI 10.1111/j.1471-4159.1993.tb03621.x; Hanson MG, 1998, J NEUROSCI, V18, P7361; Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/BJ20021698; Johnson GVW, 1997, BRAIN RES, V751, P323, DOI 10.1016/S0006-8993(96)01431-X; Karpuj MV, 1999, P NATL ACAD SCI USA, V96, P7388, DOI 10.1073/pnas.96.13.7388; Kim SY, 1999, J BIOL CHEM, V274, P30715, DOI 10.1074/jbc.274.43.30715; Lai TS, 1998, J BIOL CHEM, V273, P1776, DOI 10.1074/jbc.273.3.1776; Lai TS, 1996, J BIOL CHEM, V271, P31191, DOI 10.1074/jbc.271.49.31191; Lesort M, 1999, J NEUROCHEM, V73, P2018; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; LI XH, 1995, J NEUROCHEM, V64, P1107; Lonze BE, 2002, NEURON, V34, P371, DOI 10.1016/S0896-6273(02)00686-4; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Mahoney SA, 2000, NEUROSCIENCE, V101, P141, DOI 10.1016/S0306-4522(00)00324-9; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; MENA MA, 1995, J NEUROCHEM, V65, P2612; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NORTHUP JK, 1980, P NATL ACAD SCI-BIOL, V77, P6516, DOI 10.1073/pnas.77.11.6516; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; PAHLMAN S, 1984, CELL DIFFER DEV, V14, P135, DOI 10.1016/0045-6039(84)90038-1; PASTUSZKO A, 1986, J NEUROCHEM, V46, P499, DOI 10.1111/j.1471-4159.1986.tb12996.x; PERRY MJM, 1993, INT J DEV NEUROSCI, V11, P325, DOI 10.1016/0736-5748(93)90004-W; Pham TA, 1999, NEURON, V22, P63, DOI 10.1016/S0896-6273(00)80679-0; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; Sanchez S, 2001, J NEUROCHEM, V78, P468, DOI 10.1046/j.1471-4159.2001.00453.x; Sayas CL, 1999, J BIOL CHEM, V274, P37046, DOI 10.1074/jbc.274.52.37046; Schwartz JH, 2001, P NATL ACAD SCI USA, V98, P13482, DOI 10.1073/pnas.251533998; SEAMON KB, 1981, J CYCLIC NUCL PROT, V7, P201; SELINGER Z, 1981, ADV CYCLIC NUCL PROT, V14, P15; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Singh US, 2003, J BIOL CHEM, V278, P391, DOI 10.1074/jbc.M206361200; Snider WD, 2002, NEURON, V35, P13, DOI 10.1016/S0896-6273(02)00762-6; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tucholski J, 2002, J NEUROCHEM, V81, P780, DOI 10.1046/j.1471-4159.2002.00859.x; Tucholski J, 2001, NEUROSCIENCE, V102, P481, DOI 10.1016/S0306-4522(00)00482-6; WACHTEL H, 1982, PSYCHOPHARMACOLOGY, V77, P309, DOI 10.1007/BF00432761; Walton MR, 2000, TRENDS NEUROSCI, V23, P48, DOI 10.1016/S0166-2236(99)01500-3; Zhang JW, 1998, J BIOL CHEM, V273, P2288, DOI 10.1074/jbc.273.4.2288	59	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26838	26843		10.1074/jbc.M303683200	http://dx.doi.org/10.1074/jbc.M303683200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12743114	hybrid			2022-12-25	WOS:000184155700071
J	Wang, WG; Yang, XL; de Silanes, IL; Carling, D; Gorospe, M				Wang, WG; Yang, XL; de Silanes, IL; Carling, D; Gorospe, M			Increased AMP : ATP ratio and AMP-activated protein kinase activity during cellular senescence linked to reduced HuR function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH ELEMENT; RNA-BINDING PROTEIN; MESSENGER-RNA; SIGNALING PATHWAYS; OXIDATIVE STRESS; ELAV PROTEIN; IN-VIVO; TRANSCRIPTION; DEGRADATION; EXPRESSION	Cytoplasmic export of the RNA-binding protein HuR, a process that critically regulates its function, was recently shown to be inhibited by the AMP-activated protein kinase ( AMPK). In the present investigation, treatment of human fibroblasts with AMPK activators such as 5-amino-imidazole-4-carboxamide riboside, antimycin A, and sodium azide inhibited cell growth and lowered the expression of proliferative genes. As anticipated, AMPK activation also decreased both the cytoplasmic HuR levels and the association of HuR with target radiolabeled transcripts encoding such proliferative genes. HuR function was previously shown to be implicated in the maintenance of a "young cell" phenotype in models of replicative cellular senescence. We therefore postulated that AMPK activation in human fibroblasts might contribute to the implementation of the senescence phenotype through mechanisms that included a reduction in HuR cytoplasmic presence. Indeed, AMP: ATP ratios were 2 -3-fold higher in senescent fibroblasts compared with young fibroblasts. Accordingly, in vitro senescence was accompanied by a marked elevation in AMPK activity. Evidence that increased AMPK activity directly contributed to the implementation of the senescent phenotype was obtained through two experimental approaches. First, use of AMPK activators triggered senescence characteristics in fibroblasts, such as the acquisition of senescence-associated beta-galactosidase (beta-gal) activity and increased p16(INK4a) expression. Second, infection of cells with an adenoviral vector that expresses active AMPK increased senescence-associated beta-gal activity, whereas infection with an adenovirus that expresses dominant-negative AMPK decreased senescence-associated beta-gal activity. Together, our results indicate that AMPK activation can cause premature fibroblast senescence through mechanisms that likely involve reduced HuR function.	NIA, LCMB, IRP, NIH, Baltimore, MD 21224 USA; Imperial Coll Sch Med, MRC, Ctr Clin Sci, London W12 0NN, England	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Imperial College London	Gorospe, M (corresponding author), NIA, LCMB, IRP, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	myriam-gorospe@nih.gov	Carling, David/F-1943-2014; Lopez de Silanes, Isabel/K-4962-2015	Carling, David/0000-0002-2316-1830; Lopez de Silanes, Isabel/0000-0001-6762-9792	NATIONAL INSTITUTE ON AGING [Z01AG000511, ZIAAG000511] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Atasoy U, 1998, J CELL SCI, V111, P3145; Barthel A, 2002, ENDOCRINOLOGY, V143, P3183, DOI 10.1210/endo.143.8.8792; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; CHAPMAN ML, 1981, BIOCHEM BIOPH RES CO, V98, P303, DOI 10.1016/0006-291X(81)91903-3; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Cheung PCF, 2000, BIOCHEM J, V346, P659, DOI 10.1042/0264-6021:3460659; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Gorospe M, 1996, MOL CELL BIOL, V16, P762; GOROSPE M, 1994, J BIOL CHEM, V269, P11845; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hardie DG, 2000, METH MOL B, V99, P63; Hardie DG, 1999, BIOCHEM SOC SYMP, P13; Holbrook NJ, 2002, BIOCHEM PHARMACOL, V64, P999, DOI 10.1016/S0006-2952(02)01169-3; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; Joseph B, 1998, J BIOL CHEM, V273, P20511, DOI 10.1074/jbc.273.32.20511; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; Lee HC, 2001, BIOGERONTOLOGY, V2, P231, DOI 10.1023/A:1013270512172; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; MALTER JS, 1991, J BIOL CHEM, V266, P3167; Miquel J, 2002, ANN NY ACAD SCI, V959, P508, DOI 10.1111/j.1749-6632.2002.tb02120.x; MYER VE, 1995, RNA, V1, P171; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Ryazanov AG, 2002, MECH AGEING DEV, V123, P207, DOI 10.1016/S0047-6374(01)00337-2; Stapleton D, 1997, FEBS LETT, V409, P452, DOI 10.1016/S0014-5793(97)00569-3; Wang W, 2002, MOL CELL BIOL, V22, P3425, DOI 10.1128/MCB.22.10.3425-3436.2002; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wang WG, 2001, MOL CELL BIOL, V21, P5889, DOI 10.1128/MCB.21.17.5889-5898.2001; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; Yang WB, 2001, J BIOL CHEM, V276, P38341, DOI 10.1074/jbc.C100316200; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zheng DH, 2001, J APPL PHYSIOL, V91, P1073, DOI 10.1152/jappl.2001.91.3.1073	44	224	232	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27016	27023		10.1074/jbc.M300318200	http://dx.doi.org/10.1074/jbc.M300318200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12730239	hybrid			2022-12-25	WOS:000184155700093
J	Gao, HH; Sumanaweera, N; Bailer, SM; Stochaj, U				Gao, HH; Sumanaweera, N; Bailer, SM; Stochaj, U			Nuclear accumulation of the small GTPase Gsp1p depends on nucleoporins Nup133p, Rat2p/Nup120p, Nup85p, Nic96p, and the Acetyl-CoA carboxylase Acc1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE COMPLEX; NUCLEOCYTOPLASMIC TRANSPORT; SACCHAROMYCES-CEREVISIAE; CONDITIONAL ALLELE; PROTEIN IMPORT; RNA; RAN; LOCALIZATION; ARCHITECTURE; EXPORT	The small GTPase Ran/Gsp1p plays an essential role in nuclear trafficking of macromolecules, as Ran/Gsp1p regulates many transport processes across the nuclear pore complex ( NPC). To determine the role of nucleoporins in the generation of the nucleocytoplasmic Gsp1p concentration gradient, mutations in various nucleoporin genes were analyzed in the yeast Saccharomyces cerevisiae. We show that the nucleoporins Nup133p, Rat2p/Nup120p, Nup85p, Nic96p, and the enzyme acetylCoA carboxylase (MTR7) control the distribution and cellular concentration of Gsp1p. At the restrictive temperature the reporter protein GFP-Gsp1p, which is too large to diffuse across the nuclear envelope, fails to concentrate in nuclei of nup133Delta, rat2-1, nup85Delta, nic96DeltaC, and mtr7-1 cells, demonstrating that GFP-Gsp1p nuclear import is deficient. In addition, the concentration of Gsp1p is severely reduced in mutants nup133Delta and mtr7-1 under these conditions. We have now identified the molecular mechanisms that contribute to the dissipation of the Gsp1p concentration gradient in these mutants. Loss of the Gsp1p gradient in nup133Delta and rat2-1 can be explained by reduced binding of the Gsp1p nuclear carrier Ntf2p to NPCs. Likewise, nup85Delta cells that mislocalize GFP-Gsp1p at the permissive as well as non-permissive temperature have a diminished association of Ntf2p-GFP with nuclear envelopes under both conditions. Moreover, under restrictive conditions Prp20p, the guanine nucleotide exchange factor for Gsp1p, mislocalizes to the cytoplasm in nup85Delta, nic96DeltaC, and mtr7-1 cells, thereby contributing to a collapse of the Gsp1p gradient. Taken together, components of the NPC subcomplex containing Rat2p/Nup120p, Nup133p, and Nup85p, in addition to proteins Nic96p and Mtr7p, are shown to be crucial for the formation of a nucleocytoplasmic Gsp1p gradient.	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada; Univ Saarland, D-66421 Homburg, Germany	McGill University; Saarland University	Stochaj, U (corresponding author), McGill Univ, Dept Physiol, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	ursula.stochaj@mcgill.ca	stochaj, ursula/AAC-1865-2021					Aitchison JD, 1995, J CELL BIOL, V131, P1659, DOI 10.1083/jcb.131.6.1659; Allen NPC, 2002, MOL CELL PROTEOMICS, V1, P930, DOI 10.1074/mcp.T200012-MCP200; Bailer SM, 2000, J BIOL CHEM, V275, P23540, DOI 10.1074/jbc.M001963200; Bailer SM, 2001, MOL CELL BIOL, V21, P7944, DOI 10.1128/MCB.21.23.7944-7955.2001; Barth W, 1996, BIOCHEM CELL BIOL, V74, P363, DOI 10.1139/o96-039; Belgareh N, 2001, J CELL BIOL, V154, P1147, DOI 10.1083/jcb.200101081; Belgareh N, 1998, MOL BIOL CELL, V9, P3475, DOI 10.1091/mbc.9.12.3475; Bucci M, 1997, J CELL BIOL, V136, P1185, DOI 10.1083/jcb.136.6.1185; Clarkson WD, 1996, J MOL BIOL, V263, P517, DOI 10.1006/jmbi.1996.0594; Czubryt MP, 2000, J CELL BIOL, V148, P7, DOI 10.1083/jcb.148.1.7; Del Priore V, 1997, J CELL SCI, V110, P2987; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; Fahrenkrog B, 1998, J CELL BIOL, V143, P577, DOI 10.1083/jcb.143.3.577; Goldstein AL, 1996, MOL BIOL CELL, V7, P917, DOI 10.1091/mbc.7.6.917; GORSCH LC, 1995, J CELL BIOL, V129, P939, DOI 10.1083/jcb.129.4.939; GRANDI P, 1993, EMBO J, V12, P3061, DOI 10.1002/j.1460-2075.1993.tb05975.x; GRANDI P, 1995, J CELL BIOL, V130, P1263, DOI 10.1083/jcb.130.6.1263; GRANDI P, 1995, EMBO J, V14, P76, DOI 10.1002/j.1460-2075.1995.tb06977.x; Grosshans H, 2001, J CELL BIOL, V153, P745, DOI 10.1083/jcb.153.4.745; Heath CV, 1995, J CELL BIOL, V131, P1677, DOI 10.1083/jcb.131.6.1677; Ho AK, 2000, MOL CELL BIOL, V20, P5736, DOI 10.1128/MCB.20.15.5736-5748.2000; Hurt E, 1999, J CELL BIOL, V144, P389, DOI 10.1083/jcb.144.3.389; HURWITZ ME, 1995, J CELL BIOL, V130, P1275, DOI 10.1083/jcb.130.6.1275; Kunzler M, 2001, J CELL SCI, V114, P3233; Lutzmann M, 2002, EMBO J, V21, P387, DOI 10.1093/emboj/21.3.387; Mosammaparast N, 2001, J CELL BIOL, V153, P251, DOI 10.1083/jcb.153.2.251; Moy TI, 1999, GENE DEV, V13, P2118, DOI 10.1101/gad.13.16.2118; NEHRBASS U, 1993, EUR J CELL BIOL, V62, P1; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; Nemergut ME, 2001, SCIENCE, V292, P1540, DOI 10.1126/science.292.5521.1540; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; PEMBERTON LF, 1995, P NATL ACAD SCI USA, V92, P1187, DOI 10.1073/pnas.92.4.1187; Rabut G, 2001, CURR BIOL, V11, pR551, DOI 10.1016/S0960-9822(01)00340-2; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; SCHLENSTEDT G, 1993, J CELL BIOL, V123, P785, DOI 10.1083/jcb.123.4.785; Schneiter R, 1996, MOL CELL BIOL, V16, P7161; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; Siniossoglou S, 2000, J CELL BIOL, V149, P41, DOI 10.1083/jcb.149.1.41; Smith A, 1998, CURR BIOL, V8, P1403, DOI 10.1016/S0960-9822(98)00023-2; Steggerda SM, 2000, MOL BIOL CELL, V11, P703, DOI 10.1091/mbc.11.2.703; Stewart M, 2001, FEBS LETT, V498, P145, DOI 10.1016/S0014-5793(01)02489-9; Stochaj U, 1999, BIOESSAYS, V21, P579, DOI 10.1002/(SICI)1521-1878(199907)21:7<579::AID-BIES6>3.0.CO;2-E; Stochaj U, 1998, BIOCHEM J, V330, P421, DOI 10.1042/bj3300421; STOCHAJ U, 2000, FASEB J, DOI DOI 10.1096/FJ.99-99-0751FJE; Traglia HM, 1996, P NATL ACAD SCI USA, V93, P7667, DOI 10.1073/pnas.93.15.7667; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; Yang Q, 1998, MOL CELL, V1, P223, DOI 10.1016/S1097-2765(00)80023-4	50	19	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25331	25340		10.1074/jbc.M301607200	http://dx.doi.org/10.1074/jbc.M301607200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12730220	hybrid			2022-12-25	WOS:000183920200011
J	Pozidis, C; Chalkiadaki, A; Gomez-Serrano, A; Stahlberg, H; Brown, I; Tampakaki, AP; Lustig, A; Sianidis, G; Politou, AS; Engel, A; Panopoulos, NJ; Mansfield, J; Pugsley, AP; Karamanou, S; Economou, A				Pozidis, C; Chalkiadaki, A; Gomez-Serrano, A; Stahlberg, H; Brown, I; Tampakaki, AP; Lustig, A; Sianidis, G; Politou, AS; Engel, A; Panopoulos, NJ; Mansfield, J; Pugsley, AP; Karamanou, S; Economou, A			Type III protein translocase - Hrcn is a peripheral membrane ATPase that is activated by oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAGELLAR EXPORT APPARATUS; SYRINGAE PV PHASEOLICOLA; SALMONELLA-TYPHIMURIUM; NEEDLE COMPLEX; HRP PILUS; MOLECULAR CHARACTERIZATION; SUPRAMOLECULAR STRUCTURE; F0F1 ATPASE; SECRETION; COMPONENTS	Type III protein secretion (TTS) is catalyzed by translocases that span both membranes of Gram-negative bacteria. A hydrophilic TTS component homologous to F-1/V-1-ATPases is ubiquitous and essential for secretion. We show that hrcN encodes the putative TTS ATPase of Pseudomonas syringae pathovar phaseolicola and that HrcN is a peripheral protein that assembles in clusters at the membrane. A decahistidinyl HrcN derivative was overexpressed in Escherichia coli and purified to homogeneity in a folded state. Hydrodynamic analysis, cross-linking, and electron microscopy revealed four distinct HrcN forms: I, 48 kDa ( monomer); II, similar to300 kDa ( putative hexamer); III, 575 kDa ( dodecamer); and IV, similar to3.5 MDa. Form III is the predominant form of HrcN at the membrane, and its ATPase activity is dramatically stimulated (> 700-fold) over the basal activity of Form I. We propose that TTS ATPases catalyze protein translocation as activated homo-oligomers at the plasma membrane.	FORTH, Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Crete, Greece; Univ Crete, Dept Biol, GR-71110 Iraklion, Crete, Greece; Univ Basel, Biozentrum, ME Mueller Inst Struct Biol, CH-4056 Basel, Switzerland; Univ London, Imperial Coll Wye, Dept Biol Sci, Ashford TN25 5AH, Kent, England; Univ Ioannina, Sch Med, Biol Chem Lab, GR-45110 Ioannina, Greece; Inst Pasteur, CNRS, FRE 2364, Mol Genet Unit, F-75724 Paris 15, France	Foundation for Research & Technology - Hellas (FORTH); University of Crete; University of Basel; Imperial College London; University of London; University of Ioannina; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Economou, A (corresponding author), FORTH, Inst Mol Biol & Biotechnol, POB 1527, GR-71110 Iraklion, Crete, Greece.	aeconomo@imbb.forth.gr	Stahlberg, Henning/H-1868-2011; Economou, Anastassios/P-8292-2017; Tampakaki, Anastasia/ABF-8966-2021; Karamanou, Spyridoula/H-7485-2018	Stahlberg, Henning/0000-0002-1185-4592; Economou, Anastassios/0000-0002-1770-507X; Tampakaki, Anastasia/0000-0003-4439-0920; Karamanou, Spyridoula/0000-0002-8803-1404; Pozidis, Charalambos/0000-0001-7467-1980				Alfano JR, 2000, P NATL ACAD SCI USA, V97, P4856, DOI 10.1073/pnas.97.9.4856; Auvray F, 2002, J MOL BIOL, V318, P941, DOI 10.1016/S0022-2836(02)00172-9; Blocker A, 2001, MOL MICROBIOL, V39, P652, DOI 10.1046/j.1365-2958.2001.02200.x; Bogdanove AJ, 1996, J BACTERIOL, V178, P1720, DOI 10.1128/jb.178.6.1720-1730.1996; Brown IR, 2001, MOL PLANT MICROBE IN, V14, P394, DOI 10.1094/MPMI.2001.14.3.394; CHANG CN, 1979, P NATL ACAD SCI USA, V76, P1251, DOI 10.1073/pnas.76.3.1251; Cornelis GR, 2000, ANNU REV MICROBIOL, V54, P735, DOI 10.1146/annurev.micro.54.1.735; Dalal S, 2001, CELL, V104, P5, DOI 10.1016/S0092-8674(01)00186-6; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; DREYFUS G, 1993, J BACTERIOL, V175, P3131, DOI 10.1128/JB.175.10.3131-3138.1993; Economou A, 2002, MOL MEMBR BIOL, V19, P159, DOI 10.1080/09687680210152609; EICHELBERG K, 1994, J BACTERIOL, V176, P4501, DOI 10.1128/JB.176.15.4501-4510.1994; Fan F, 1996, J BIOL CHEM, V271, P31981, DOI 10.1074/jbc.271.50.31981; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; GROMETELHANAN Z, 1992, J BIOENERG BIOMEMBR, V24, P447, DOI 10.1007/BF00762361; HUYNH TV, 1989, SCIENCE, V245, P1374, DOI 10.1126/science.2781284; Jackson MW, 2000, FEMS MICROBIOL LETT, V186, P85, DOI 10.1111/j.1574-6968.2000.tb09086.x; Jin QL, 2001, SCIENCE, V294, P2556, DOI 10.1126/science.1066397; KAGAWA Y, 1992, J BIOENERG BIOMEMBR, V24, P441, DOI 10.1007/BF00762360; Kane PM, 2000, FEBS LETT, V469, P137, DOI 10.1016/S0014-5793(00)01265-5; Karamanou S, 1999, MOL MICROBIOL, V34, P1133, DOI 10.1046/j.1365-2958.1999.01686.x; Katayama E, 1996, J MOL BIOL, V255, P458, DOI 10.1006/jmbi.1996.0038; Kimbrough TG, 2000, P NATL ACAD SCI USA, V97, P11008, DOI 10.1073/pnas.200209497; KING EO, 1954, J LAB CLIN MED, V44, P301; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; Kubori T, 2000, P NATL ACAD SCI USA, V97, P10225, DOI 10.1073/pnas.170128997; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Li CM, 2002, EMBO J, V21, P1909, DOI 10.1093/emboj/21.8.1909; LIDELL MC, 1994, MOL PLANT MICROBE IN, V7, P488, DOI 10.1094/MPMI-7-0488; Macnab RM, 1999, J BACTERIOL, V181, P7149, DOI 10.1128/JB.181.23.7149-7153.1999; MANSFIELD J, 1994, MOL PLANT MICROBE IN, V7, P726, DOI 10.1094/MPMI-7-0726; Minamino T, 2000, MOL MICROBIOL, V37, P1494, DOI 10.1046/j.1365-2958.2000.02106.x; Minamino T, 2001, J MOL BIOL, V312, P1027, DOI 10.1006/jmbi.2001.5000; Minamino T, 2000, MOL MICROBIOL, V35, P1052, DOI 10.1046/j.1365-2958.2000.01771.x; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; Plano GV, 2001, MOL MICROBIOL, V40, P284, DOI 10.1046/j.1365-2958.2001.02354.x; POSSOT O, 1994, MOL MICROBIOL, V12, P287, DOI 10.1111/j.1365-2958.1994.tb01017.x; Puri N, 1997, MOL PLANT MICROBE IN, V10, P247, DOI 10.1094/MPMI.1997.10.2.247; RAHME LG, 1991, J BACTERIOL, V173, P575, DOI 10.1128/jb.173.2.575-586.1991; Rossier O, 2000, MOL MICROBIOL, V38, P828, DOI 10.1046/j.1365-2958.2000.02173.x; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Sekiya K, 2001, P NATL ACAD SCI USA, V98, P11638, DOI 10.1073/pnas.191378598; Sianidis G, 2001, EMBO J, V20, P961, DOI 10.1093/emboj/20.5.961; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Tamano K, 2000, EMBO J, V19, P3876, DOI 10.1093/emboj/19.15.3876; Tanese N, 1997, METHODS, V12, P224, DOI 10.1006/meth.1997.0475; WOESTYN S, 1994, J BACTERIOL, V176, P1561, DOI 10.1128/jb.176.6.1561-1569.1994; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	48	63	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25816	25824		10.1074/jbc.M301903200	http://dx.doi.org/10.1074/jbc.M301903200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12734178	hybrid			2022-12-25	WOS:000183920200069
J	Sanishvili, R; Yakunin, AF; Laskowski, RA; Skarina, T; Evdokimova, E; Doherty-Kirby, A; Lajoie, GA; Thornton, JM; Arrowsmith, CH; Savchenko, A; Joachimiak, A; Edwards, AM				Sanishvili, R; Yakunin, AF; Laskowski, RA; Skarina, T; Evdokimova, E; Doherty-Kirby, A; Lajoie, GA; Thornton, JM; Arrowsmith, CH; Savchenko, A; Joachimiak, A; Edwards, AM			Integrating structure, bioinformatics, and enzymology to discover function - BioH, a new carboxylesterase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SPHAERICUS; BIOTIN BIOSYNTHESIS; PROTEIN; ESTERASE; CLONING; CONSERVATION; REFINEMENT; PIMELATE; GENOMICS; PATHWAY	Structural proteomics projects are generating three-dimensional structures of novel, uncharacterized proteins at an increasing rate. However, structure alone is often insufficient to deduce the specific biochemical function of a protein. Here we determined the function for a protein using a strategy that integrates structural and bioinformatics data with parallel experimental screening for enzymatic activity. BioH is involved in biotin biosynthesis in Escherichia coli and had no previously known biochemical function. The crystal structure of BioH was determined at 1.7 Angstrom resolution. An automated procedure was used to compare the structure of BioH with structural templates from a variety of different enzyme active sites. This screen identified a catalytic triad (Ser(82), His(235), and Asp(207)) with a configuration similar to that of the catalytic triad of hydrolases. Analysis of BioH with a panel of hydrolase assays revealed a carboxylesterase activity with a preference for short acyl chain substrates. The combined use of structural bioinformatics with experimental screens for detecting enzyme activity could greatly enhance the rate at which function is determined from structure.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Argonne Natl Lab, Biosci Div, Argonne, IL 60439 USA; Clin Genom Cent Proteom, Univ Hlth Network, Toronto, ON M5G 1L7, Canada; European Bioinformat Inst, Cambridge CB10 1SD, England; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	University of Toronto; United States Department of Energy (DOE); Argonne National Laboratory; University of Toronto; University Toronto Affiliates; University Health Network Toronto; European Molecular Biology Laboratory (EMBL); Western University (University of Western Ontario)	Edwards, AM (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.		Yakunin, Alexander/J-1519-2014	Yakunin, Alexander/0000-0003-0813-6490; Thornton, Janet/0000-0003-0824-4096; Arrowsmith, Cheryl/0000-0002-4971-3250; Edwards, Aled/0000-0002-4782-6016; Laskowski, Roman/0000-0001-5528-0087	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062414] Funding Source: NIH RePORTER; NIGMS NIH HHS [P50 GM062414-02, P50 GM062414, GM 62414] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Baldet P, 1997, METHOD ENZYMOL, V279, P327; BARKER DF, 1980, J BACTERIOL, V143, P789, DOI 10.1128/JB.143.2.789-800.1980; Berge R K, 1981, Methods Enzymol, V71 Pt C, P234; Bienvenue DL, 2002, J BIOL INORG CHEM, V7, P129, DOI 10.1007/s007750100280; Bower S, 1996, J BACTERIOL, V178, P4122, DOI 10.1128/jb.178.14.4122-4130.1996; BRONNER WM, 1972, J BIOL CHEM, V247, P3123; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DEMOLL E, 1996, ESCHERICHIA COLI SAL, P704; Evans G, 2001, J APPL CRYSTALLOGR, V34, P82, DOI 10.1107/S0021889800014655; Gan ZB, 1999, ANAL BIOCHEM, V268, P151, DOI 10.1006/abio.1998.3053; GLOECKLER R, 1990, GENE, V87, P63, DOI 10.1016/0378-1119(90)90496-E; GOLD AM, 1965, BIOCHEMISTRY-US, V4, P897, DOI 10.1021/bi00881a016; IFUKU O, 1994, EUR J BIOCHEM, V220, P585, DOI 10.1111/j.1432-1033.1994.tb18659.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kanaya S, 1998, BIOCHEM J, V332, P75, DOI 10.1042/bj3320075; KUO MH, 1961, BIOCHIM BIOPHYS ACTA, V54, P101, DOI 10.1016/0006-3002(61)90942-8; Lee YL, 1997, BIOCHEM BIOPH RES CO, V231, P452, DOI 10.1006/bbrc.1997.5797; Lemoine Y, 1996, MOL MICROBIOL, V19, P645, DOI 10.1046/j.1365-2958.1996.t01-4-442924.x; LEZIUS A, 1963, BIOCHEM Z, V336, P510; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAGGERT J, 1991, J BIOL CHEM, V266, P11044; NIXON M, 1979, ANAL BIOCHEM, V97, P403, DOI 10.1016/0003-2697(79)90093-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PELLETIER I, 1995, MICROBIOL-SGM, V141, P459, DOI 10.1099/13500872-141-2-459; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Rodionov DA, 2002, GENOME RES, V12, P1507, DOI 10.1101/gr.314502; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; SANYAL I, 1994, J AM CHEM SOC, V116, P2637, DOI 10.1021/ja00085a061; Schrag JD, 1997, STRUCTURE, V5, P187, DOI 10.1016/S0969-2126(97)00178-0; Stevens RC, 2001, SCIENCE, V294, P89, DOI 10.1126/science.1066011; Tomczyk NH, 2002, FEBS LETT, V513, P299, DOI 10.1016/S0014-5793(02)02342-6; VORDERWULBECKE T, 1992, ENZYME MICROB TECH, V14, P631, DOI 10.1016/0141-0229(92)90038-P; Wallace AC, 1997, PROTEIN SCI, V6, P2308; Westbrook EM, 1997, METHOD ENZYMOL, V276, P244, DOI 10.1016/S0076-6879(97)76063-4; Zarembinski TI, 1998, P NATL ACAD SCI USA, V95, P15189, DOI 10.1073/pnas.95.26.15189; Zhang RG, 2001, STRUCTURE, V9, P1095, DOI 10.1016/S0969-2126(01)00675-X	38	97	104	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26039	26045		10.1074/jbc.M303867200	http://dx.doi.org/10.1074/jbc.M303867200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12732651	Green Submitted, Green Accepted, hybrid			2022-12-25	WOS:000183920200100
J	Tureci, O; Bian, HJ; Nestle, FO; Raddrizzani, L; Rosinski, JA; Tassis, A; Hilton, H; Walstead, M; Sahin, U; Hammer, J				Tureci, O; Bian, HJ; Nestle, FO; Raddrizzani, L; Rosinski, JA; Tassis, A; Hilton, H; Walstead, M; Sahin, U; Hammer, J			Cascades of transcriptional induction during dendritic cell maturation revealed by genome-wide expression analysis	FASEB JOURNAL			English	Article						DC; B cells; apoptotic death	CLUSTERIN GENE-EXPRESSION; T-CELLS; TNF-RECEPTOR; B-CELLS; IN-VIVO; APOPTOSIS; VACCINATION; CHEMOKINES; RESISTANCE; IMMATURE	Dendritic cells (DC) are central regulators of immunity. Signal-induced maturation of DCs is assumed to be the starting point for specific immune responses. To further understand this process, we analyzed the alteration of transcript profiles along the time course of CD40 ligand-induced maturation of human myeloid DCs by Affymetrix GeneChip(R) microarrays covering >6800 genes. Besides rediscovery of genes already described as associated with DC maturation proving reliability of the methods used, we identified clusterin as novel maturation marker. Looking across the time course, we observed synchronized kinetics of distinct functional groups of molecules whose temporal coregulation underscores known cellular events during dendritic cell maturation. For example, an early-peaking wave of inflammatory chemokines was followed by a sustained increase of constitutive chemokines and accompanied by slow but continuous induction of survival proteins. After an immediate but transient induction of cytokine-responsive transcripts, there was an increased expression of a group of genes involved in not only the regulation of cytokine effects, but also of transcription in general. Our results demonstrate that microarray studies along time courses combined with real-time PCR not only discover new marker molecules with functional implications, but also dissect the molecular kinetics of biological processes identifying complex pathways of regulation.	Univ Mainz, Med Klin & Poliklin 3, Dept Internal Med 3, D-55131 Mainz, Germany; Hoffmann La Roche Inc, Genom & Informat Sci, Nutley, NJ 07110 USA; Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland; Affymetrix, Santa Clara, CA USA	Johannes Gutenberg University of Mainz; Roche Holding; University of Zurich; University Zurich Hospital; Affymetrix	Tureci, O (corresponding author), Univ Mainz, Med Klin & Poliklin 3, Dept Internal Med 3, Obere Zahlbacherstr 63, D-55131 Mainz, Germany.	Tureci@mail.uni-mainz.de	Sahin, Ugur/L-4818-2017	Sahin, Ugur/0000-0003-0363-1564				Aicher A, 1999, J IMMUNOL, V163, P5786; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; ASHANASY D, 1999, J IMMUNOL, V163, P5503; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bjorck P, 1997, INT IMMUNOL, V9, P365, DOI 10.1093/intimm/9.3.365; Cyster JG, 1999, J EXP MED, V189, P447, DOI 10.1084/jem.189.3.447; Dhodapkar MV, 2002, BLOOD, V100, P174, DOI 10.1182/blood.V100.1.174; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; FRENCH LE, 1994, J CLIN INVEST, V93, P877, DOI 10.1172/JCI117043; Granucci F, 2001, NAT IMMUNOL, V2, P882, DOI 10.1038/ni0901-882; Gupta S, 1998, J IMMUNOL, V161, P5997; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; Hartgers FC, 2000, IMMUNOL TODAY, V21, P542, DOI 10.1016/S0167-5699(00)01736-9; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Josien R, 2000, J EXP MED, V191, P495, DOI 10.1084/jem.191.3.495; Koch-Brandt C, 1996, Prog Mol Subcell Biol, V16, P130; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Morse MA, 1999, CANCER RES, V59, P56; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Nestle FO, 2001, NAT MED, V7, P761, DOI 10.1038/89863; Perlman H, 1999, J EXP MED, V190, P1679, DOI 10.1084/jem.190.11.1679; Poon S, 2000, BIOCHEMISTRY-US, V39, P15953, DOI 10.1021/bi002189x; ROSENBERG ME, 1995, INT J BIOCHEM CELL B, V27, P633, DOI 10.1016/1357-2725(95)00027-M; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; Sozzani S, 1998, J IMMUNOL, V161, P1083; Steinman RM, 2001, INT J CANCER, V94, P459, DOI 10.1002/ijc.1503; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; vanKooten C, 1997, CURR OPIN IMMUNOL, V9, P330, DOI 10.1016/S0952-7915(97)80078-7; Viard I, 1999, J INVEST DERMATOL, V112, P290, DOI 10.1046/j.1523-1747.1999.00531.x; Wellmann A, 2000, BLOOD, V96, P398; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yamagata T, 1996, MOL CELL BIOL, V16, P1283	34	72	73	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					836	847		10.1096/fj.02-0724com	http://dx.doi.org/10.1096/fj.02-0724com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12724343				2022-12-25	WOS:000183165000010
J	Ikezawa, N; Tanaka, M; Nagayoshi, M; Shinkyo, R; Sakaki, T; Inouye, K; Sato, F				Ikezawa, N; Tanaka, M; Nagayoshi, M; Shinkyo, R; Sakaki, T; Inouye, K; Sato, F			Molecular cloning and characterization of CYP719, a methylenedioxy bridge-forming enzyme that belongs to a novel P450 family, from cultured Coptis japonica cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST NADPH-CYTOCHROME-P450 REDUCTASE; ADENOSYL-L-METHIONINE; SACCHAROMYCES-CEREVISIAE; ALKALOID BIOSYNTHESIS; BERBERINE SYNTHESIS; EXPRESSION; MONOOXYGENASE; COLUMBAMINE; METHYLTRANSFERASE; NORCOCLAURINE	Two cytochrome P450 (P450) cDNAs involved in the biosynthesis of berberine, an antimicrobial benzylisoquinoline alkaloid, were isolated from cultured Coptis japonica cells and characterized. A sequence analysis showed that one C. japonica P450 ( designated CYP719) belonged to a novel P450 family. Further, heterologous expression in yeast confirmed that it had the same activity as a methylenedioxy bridge-forming enzyme ( canadine synthase), which catalyzes the conversion of (S)-tetrahydrocolumbamine ((S)-THC) to (S)-tetrahydroberberine ((S)-THB, (S)-canadine). The other P450 ( designated CYP80B2) showed high homology to California poppy (S)-N-methylcoclaurine-3'-hydroxylase (CYP80B1), which converts (S)-N-methylcoclaurine to (S)-3'-hydroxy-N-methylcoclaurine. Recombinant CYP719 showed typical P450 properties as well as high substrate affinity and specificity for (S)-THC. (S)S-coulerine was not a substrate of CYP719, indicating that some other P450, e.g. (S)-cheilanthifoline synthase, is needed in (S)-stylopine biosynthesis. All of the berberine biosynthetic genes, including CYP719 and CYP80B2, were highly expressed in selected cultured C. japonica cells and moderately expressed in root, which suggests coordinated regulation of the expression of biosynthetic genes.	Kyoto Univ, Div Integrated Life Sci, Grad Sch Biostudies, Kyoto 6068502, Japan; Kyoto Univ, Div Appl Life Sci, Grad Sch Agr, Kyoto 6068502, Japan; Kyoto Univ, Div Food Sci & Biotechnol, Grad Sch Agr, Kyoto 6068502, Japan	Kyoto University; Kyoto University; Kyoto University	Sato, F (corresponding author), Kyoto Univ, Div Integrated Life Sci, Grad Sch Biostudies, Kyoto 6068502, Japan.		Sato, Fumihiko/C-1078-2011; Shinkyo, Raku/HIK-2997-2022	Sato, Fumihiko/0000-0001-9497-4452; 				BAUER W, 1991, PHYTOCHEMISTRY, V30, P2953, DOI 10.1016/S0031-9422(00)98230-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAVA MP, 1965, LLOYD, V28, P73; CAVA MP, 1967, J ORG CHEM, V32, P1640, DOI 10.1021/jo01280a087; Chapple C, 1998, ANNU REV PLANT PHYS, V49, P311, DOI 10.1146/annurev.arplant.49.1.311; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Choi KB, 2002, J BIOL CHEM, V277, P830, DOI 10.1074/jbc.M106405200; FUJIWARA H, 1993, PHYTOCHEMISTRY, V34, P949, DOI 10.1016/S0031-9422(00)90692-7; Gotoh O., 1989, FRONTIERS BIOTRANSFO, V1, P195; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LINDENMAYER A, 1964, BIOCHIM BIOPHYS ACTA, V93, P445, DOI 10.1016/0304-4165(64)90329-0; LOEFFLER S, 1990, PHYTOCHEMISTRY, V29, P3499, DOI 10.1016/0031-9422(90)85264-G; Morishige T, 2000, J BIOL CHEM, V275, P23398, DOI 10.1074/jbc.M002439200; Morishige T, 2002, EUR J BIOCHEM, V269, P5659, DOI 10.1046/j.1432-1033.2002.03275.x; MURAKAMI H, 1990, J BIOCHEM, V108, P859, DOI 10.1093/oxfordjournals.jbchem.a123293; MUTO N, 1987, BIOCHEM BIOPH RES CO, V146, P487, DOI 10.1016/0006-291X(87)90555-9; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; OEDA K, 1985, DNA-J MOLEC CELL BIO, V4, P203, DOI 10.1089/dna.1985.4.203; OMURA T, 1964, J BIOL CHEM, V239, P2379; Pauli HH, 1998, PLANT J, V13, P793, DOI 10.1046/j.1365-313X.1998.00085.x; RUEFFER M, 1994, PHYTOCHEMISTRY, V36, P1219, DOI 10.1016/S0031-9422(00)89640-5; RUEFFER M, 1985, TETRAHEDRON LETT, V26, P201, DOI 10.1016/S0040-4039(00)61879-8; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAKAKI T, 1990, DNA CELL BIOL, V9, P603, DOI 10.1089/dna.1990.9.603; SAKAKI T, 1992, J BIOL CHEM, V267, P16497; Sambrook J., 2002, MOL CLONING LAB MANU; SATO F, 1993, PHYTOCHEMISTRY, V32, P659, DOI 10.1016/S0031-9422(00)95151-3; SATO F, 1994, EUR J BIOCHEM, V225, P125, DOI 10.1111/j.1432-1033.1994.00125.x; SATO F, 1984, PHYTOCHEMISTRY, V23, P281, DOI 10.1016/S0031-9422(00)80318-0; Sato F, 2001, P NATL ACAD SCI USA, V98, P367, DOI 10.1073/pnas.011526398; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; TAKESHITA N, 1995, PLANT CELL PHYSIOL, V36, P29; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; YAMADA Y, 1985, PHYTOCHEMISTRY, V24, P63, DOI 10.1016/S0031-9422(00)80807-9	36	140	163	2	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38557	38565		10.1074/jbc.M302470200	http://dx.doi.org/10.1074/jbc.M302470200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12732624	hybrid			2022-12-25	WOS:000185575100058
J	Stahelin, RV; Long, F; Peter, BJ; Murray, D; De Camilli, P; McMahon, HT; Cho, W				Stahelin, RV; Long, F; Peter, BJ; Murray, D; De Camilli, P; McMahon, HT; Cho, W			Contrasting membrane interaction mechanisms of AP180 N-terminal homology (ANTH) and epsin N-terminal homology (ENTH) domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); SURFACE-PLASMON RESONANCE; KINASE-C-ALPHA; CLATHRIN-MEDIATED ENDOCYTOSIS; PROTEIN INTERACTIONS; DIFFERENTIAL ROLES; BINDING RESIDUES; MONOLAYERS; CURVATURE; DYNAMIN	Epsin and AP180/CALM are endocytotic accessory proteins that have been implicated in the formation of clathrin-coated pits. Both proteins have phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2)-binding domains in their N termini, but these domains are structurally and functionally different. To understand the basis of their distinct properties, we measured the PtdIns(4,5)P-2-dependent membrane binding of the epsin N-terminal homology (ENTH) domain and the AP180 N-terminal homology (ANTH) domain by means of surface plasmon resonance and monolayer penetration techniques and also calculated the effect of PtdIns(4,5)P-2 on the electrostatic potential of these domains. PtdIns(4,5)P-2 enhances the electrostatic membrane association of both domains; however, PtdIns(4,5)P-2 binding exerts distinct effects on their membrane dissociation. Specifically, PtdIns(4,5)P-2 induces the membrane penetration of the N-terminal alpha-helix of the ENTH domain, which slows the membrane dissociation of the domain and triggers the membrane deformation. These results provide the biophysical explanation for the membrane bending activity of epsin and its ENTH domain.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Cornell Univ, Dept Microbiol & Immunol, Weill Med Coll, New York, NY 10021 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; MRC Laboratory Molecular Biology; Cornell University; Yale University; Howard Hughes Medical Institute; Yale University	Cho, W (corresponding author), Univ Illinois, Dept Chem, M-C 111,845 W taylor St, Chicago, IL 60607 USA.		Peter, Brian/AAZ-7323-2020; Stahelin, Robert/L-3567-2019	Stahelin, Robert/0000-0001-5443-7863	NIGMS NIH HHS [GM53987, GM66147, GM52598] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052598, R01GM066147, R01GM053987] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANANTHARAMAIAH GM, 1985, J BIOL CHEM, V260, P248; Ball A, 1999, P NATL ACAD SCI USA, V96, P6637, DOI 10.1073/pnas.96.12.6637; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; BLUME A, 1979, BIOCHIM BIOPHYS ACTA, V557, P32, DOI 10.1016/0005-2736(79)90087-7; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; Cremona O, 2001, J CELL SCI, V114, P1041; De Camilli P, 2002, FEBS LETT, V513, P11, DOI 10.1016/S0014-5793(01)03306-3; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Frazier AA, 2002, BIOCHEMISTRY-US, V41, P6282, DOI 10.1021/bi0160821; Higgins MK, 2002, TRENDS BIOCHEM SCI, V27, P257, DOI 10.1016/S0968-0004(02)02089-3; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Huttner WB, 2002, TRENDS CELL BIOL, V12, P155, DOI 10.1016/S0962-8924(02)02252-3; Itoh T, 2002, CELL SIGNAL, V14, P733, DOI 10.1016/S0898-6568(02)00028-1; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Kates M., 1986, TECHNIQUES LIPIDOLOG, P114; Kay BK, 1999, PROTEIN SCI, V8, P435; KELLER RCA, 1992, BIOCHEMISTRY-US, V31, P1672, DOI 10.1021/bi00121a014; KOSHIBA S, 2001, J STRUCT FUNCT GENOM, V0002; Lichtenbergova L, 1998, BIOCHEMISTRY-US, V37, P14128, DOI 10.1021/bi980888s; Lohi O, 2002, FEBS LETT, V513, P19, DOI 10.1016/S0014-5793(01)03287-2; Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Nalefski EA, 1998, BIOCHEMISTRY-US, V37, P17642, DOI 10.1021/bi982372e; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nossal R, 2001, TRAFFIC, V2, P138, DOI 10.1034/j.1600-0854.2001.020208.x; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; Stahelin RV, 2003, J BIOL CHEM, V278, P14469, DOI 10.1074/jbc.M212579200; Stahelin RV, 2002, J BIOL CHEM, V277, P26379, DOI 10.1074/jbc.M201106200; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Stahelin RV, 2001, BIOCHEM J, V359, P679, DOI 10.1042/0264-6021:3590679; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; VERGER R, 1982, CHEM PHYS LIPIDS, V30, P189, DOI 10.1016/0009-3084(82)90052-4; WALD JH, 1990, J BIOL CHEM, V265, P20037	47	142	144	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28993	28999		10.1074/jbc.M302865200	http://dx.doi.org/10.1074/jbc.M302865200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12740367	Green Submitted, hybrid			2022-12-25	WOS:000184421100080
J	Gao, GH; Simpson, L				Gao, GH; Simpson, L			Is the Trypanosoma brucei REL1 RNA ligase specific for U-deletion RNA editing, and is the REL2 RNA ligase specific for U-insertion editing?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEISHMANIA-TARENTOLAE MITOCHONDRIA; PRECURSOR MESSENGER-RNA; BLOOD-STREAM-FORM; KINETOPLASTID MITOCHONDRIA; IN-VITRO; BAND IV; COMPLEX; MECHANISM; GENE; INTERFERENCE	It was shown previously that the REL1 mitochondrial RNA ligase in Trypanosoma brucei was a vital gene and disruption affected RNA editing in vivo, whereas the REL2 RNA ligase gene could be down-regulated with no effect on cell growth or on RNA editing. We performed down-regulation of REL1 in procyclic T. brucei (midgut insect forms) by RNA interference and found a 40-50% inhibition of Cyb editing, which has only U-insertions, as well as a similar inhibition of ND7 editing, which has both U-insertions and U-deletions. In addition, both U-insertion and U-deletion in vitro pre-cleaved editing were inhibited to similar extents. We also found little if any effect of REL1 down-regulation on the sedimentation coefficient or abundance of the RNA ligase-containing L-complex (Aphasizhev, R., Aphasizheva, I., Nelson, R. E., Gao, G., Simpson, A. M., Kang, X., Falick, A. M., Sbicego, S., and Simpson, L. (2003) EMBO J. 22, 913-924), suggesting that the inhibition of both insertion and deletion editing was not due to a disruption of the L-complex. Together with the evidence that down-regulation of REL2 has no effect on cell growth or on RNA editing in vivo or in vitro, these data suggest that the REL1 RNA ligase may be active in vivo in both U-insertion and U-deletion editing. The in vivo biological role of REL2 remains obscure.	Univ Calif Los Angeles, MacDonald Res Labs 6780, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Simpson, L (corresponding author), Univ Calif Los Angeles, MacDonald Res Labs 6780, Howard Hughes Med Inst, 675 Charles Young Dr S, Los Angeles, CA 90095 USA.							Alfonzo JD, 1997, NUCLEIC ACIDS RES, V25, P3751, DOI 10.1093/nar/25.19.3751; Aphasizhev R, 2003, EMBO J, V22, P913, DOI 10.1093/emboj/cdg083; Aphasizhev R, 2002, CELL, V108, P637, DOI 10.1016/S0092-8674(02)00647-5; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; Carrillo R, 2001, MOL BIOCHEM PARASIT, V113, P175, DOI 10.1016/S0166-6851(00)00385-6; CARRUTHERS VB, 1992, P NATL ACAD SCI USA, V89, P8818, DOI 10.1073/pnas.89.18.8818; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cruz-Reyes J, 1998, MOL CELL, V1, P401, DOI 10.1016/S1097-2765(00)80040-4; Cruz-Reyes J, 2002, MOL CELL BIOL, V22, P4652, DOI 10.1128/MCB.22.13.4652-4660.2002; CruzReyes J, 1996, P NATL ACAD SCI USA, V93, P8901, DOI 10.1073/pnas.93.17.8901; Drozdz M, 2002, EMBO J, V21, P1791, DOI 10.1093/emboj/21.7.1791; Estevez AM, 1999, MOL BIOCHEM PARASIT, V100, P5, DOI 10.1016/S0166-6851(99)00024-9; Huang CE, 2001, EMBO J, V20, P4694, DOI 10.1093/emboj/20.17.4694; Kable ML, 1996, SCIENCE, V273, P1189, DOI 10.1126/science.273.5279.1189; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; McManus MT, 2001, RNA, V7, P167, DOI 10.1017/S1355838201002072; Panigrahi AK, 2001, MOL CELL BIOL, V21, P380, DOI 10.1128/MCB.21.2.380-389.2001; Peris M, 1997, MOL BIOCHEM PARASIT, V85, P9, DOI 10.1016/S0166-6851(96)02795-8; Rusche LN, 2001, MOL CELL BIOL, V21, P979, DOI 10.1128/MCB.21.4.979-989.2001; Schnaufer A, 2001, SCIENCE, V291, P2159, DOI 10.1126/science.1058655; SEIWERT SD, 1994, SCIENCE, V266, P114, DOI 10.1126/science.7524149; Seiwert SD, 1996, CELL, V84, P831, DOI 10.1016/S0092-8674(00)81062-4; Simpson L, 2000, P NATL ACAD SCI USA, V97, P6986, DOI 10.1073/pnas.97.13.6986; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200	24	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27570	27574		10.1074/jbc.M303317200	http://dx.doi.org/10.1074/jbc.M303317200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12748175	hybrid			2022-12-25	WOS:000184242700031
J	Sheng, Y; Tsai-Morris, CH; Dufau, ML				Sheng, Y; Tsai-Morris, CH; Dufau, ML			Cell-specific and hormone-regulated expression of gonadotropinregulated testicular RNA helicase gene (GRTH/Ddx25) resulting from alternative utilization of translation initiation codons in the rat testis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALE GERM-CELLS; MESSENGER-RNA; LEYDIG-CELLS; PROTEIN; SPERMATOGENESIS; BINDING; FAMILY; VASA	Gonadotropin-regulated testicular RNA helicase (GRTH) is a novel DEAD-box protein with ATPase and RNA helicase activities. GRTH gene transcription is stimulated by human chorionic gonadotropin (hCG) via cyclic AMP-induced androgen formation in testicular Leydig cells. In this study, immunocytochemical and Western analyses identified GRTH as a developmentally regulated protein in Leydig cells and in germ cells (pachytene spermatocytes and round spermatids) of the rat testis. Three ATGs with the potential for generation of multiple protein species were identified. Germ cells primarily utilized the 1st ATG codon (+1) and contained major proteins of 61/56 kDa, whereas Leydig cells utilized preferentially the 2nd ATG codon (+343) with expression of 48/43 kDa species. A 3rd ATG was weakly utilized and yielded a 33-kDa protein only in germ cells. The increase in GRTH 43-kDa protein in Leydig cells caused by hCG treatment was prevented by the androgen receptor antagonist, flutamide. In round spermatids, hCG caused a significant decrease of 61 kDa species and an induction 48/43 kDa species, whereas no changes were observed in pachytene spermatocytes. Reversal of this hormone-induced switch of expression by flutamide indicated a role of androgen in utilization of the 2nd ATG. These studies have demonstrated a cell-specific and hormone-dependent alternative usage of ATG codons in the testis. They have also revealed that the androgen-dependent transcription of GRTH expression in Leydig cells is accompanied by a marked increase of 43-kDa species. The findings indicate that expression of GRTH proteins is regulated by gonadotropin/androgen at the translational level.	NICHD, Sect Mol Endocrinol, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dufau, ML (corresponding author), NICHD, Sect Mol Endocrinol, Endocrinol & Reprod Res Branch, NIH, Bldg 49,Rm 6A-36,49 Convent Dr,MSC 4510, Bethesda, MD 20892 USA.			Tsai Morris, Chon Hwa/0000-0002-8113-0979	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000150] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000150] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AQUILANO DR, 1984, ENDOCRINOLOGY, V114, P499, DOI 10.1210/endo-114-2-499; Babik JM, 1999, J IMMUNOL, V162, P4069; BUCCI LR, 1986, BIOL REPROD, V34, P195, DOI 10.1095/biolreprod34.1.195; Byrd MP, 2002, MOL CELL BIOL, V22, P4499, DOI 10.1128/MCB.22.13.4499-4511.2002; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Dufau ML, 2001, J STEROID BIOCHEM, V76, P187, DOI 10.1016/S0960-0760(01)00051-6; GEE SL, 1994, GENE, V140, P171, DOI 10.1016/0378-1119(94)90541-X; ICHIHARA I, 1993, CELL TISSUE RES, V271, P241, DOI 10.1007/BF00318610; LEBLOND CP, 1952, ANN NY ACAD SCI, V55, P548, DOI 10.1111/j.1749-6632.1952.tb26576.x; LEMAIRE L, 1993, LIFE SCI, V52, P917, DOI 10.1016/0024-3205(93)90526-9; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; McLachlan RI, 2002, RECENT PROG HORM RES, V57, P149, DOI 10.1210/rp.57.1.149; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; SANDHU H, 1995, BIOCHEM BIOPH RES CO, V214, P632, DOI 10.1006/bbrc.1995.2333; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; Schmitt C, 1999, EMBO J, V18, P4332, DOI 10.1093/emboj/18.15.4332; Styhler S, 1998, DEVELOPMENT, V125, P1569; Tanaka SS, 2000, GENE DEV, V14, P841; Tang PZ, 1999, J BIOL CHEM, V274, P37932, DOI 10.1074/jbc.274.53.37932; Tang PZ, 2001, P NATL ACAD SCI USA, V98, P6581, DOI 10.1073/pnas.121046998; VORNBERGER W, 1994, ENDOCRINOLOGY, V134, P2307, DOI 10.1210/en.134.5.2307	22	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27796	27803		10.1074/jbc.M302411200	http://dx.doi.org/10.1074/jbc.M302411200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12734186	hybrid			2022-12-25	WOS:000184242700060
J	Ling, L; Zhu, T; Lobie, PE				Ling, L; Zhu, T; Lobie, PE			Src-CrkII-C3G-dependent activation of Rap1 switches growth hormone-stimulated p44/42 MAP kinase and JNK/SAPK activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; DEPENDENT RAL ACTIVATION; JUN NH2-TERMINAL KINASE; C-JUN; PROTEIN-KINASE; DISSOCIATION STIMULATOR; CELL-ADHESION; R-RAS; TYROSINE PHOSPHORYLATION; EFFECTOR MOLECULES	We demonstrate here that growth hormone (GH) stimulates the activation of Rap1 and Rap2 in NIH-3T3 cells. Full activation of Rap1 and Rap2 by GH necessitated the combined activity of both JAK2 and c-Src kinases, although c-Src was predominantly required. GH-stimulated Rap1 and Rap2 activity was also demonstrated to be CrkII-C3G-dependent. GH stimulated the tyrosine phosphorylation of C3G, which again required the combined activity of JAK2 and c-Src. C3G tyrosine residue 504 was required for GH-stimulated Rap activation. Activated Rap1 inhibited GH-stimulated activation of RalA and subsequent GH-stimulated p44/42 MAP kinase activity and Elk-1-mediated transcription. In addition, we demonstrated that C3G-Rap1 mediated CrkII enhancement of GH-stimulated JNK/SAPK activity. We have therefore identified a linear JAK2-independent pathway switching GH-stimulated p44/42 MAP kinase and JNK/SAPK activities.	Inst Mol & Cell Biol, Singapore 117609, Singapore; Natl Univ Singapore, Dept Med, Singapore 119074, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Lobie, PE (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.							ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; Arai A, 2001, J BIOL CHEM, V276, P10453, DOI 10.1074/jbc.M004627200; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BERGAD PL, 1995, J BIOL CHEM, V270, P24903, DOI 10.1074/jbc.270.42.24903; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; BOS JL, 1989, CANCER RES, V49, P4682; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; Carter-Su C, 1998, RECENT PROG HORM RES, V53, P61; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Dehez S, 2002, CELL GROWTH DIFFER, V13, P375; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Diakonova M, 2002, J BIOL CHEM, V277, P10669, DOI 10.1074/jbc.M111138200; EDEN S, 1979, ENDOCRINOLOGY, V105, P555, DOI 10.1210/endo-105-2-555; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Fukunaga K, 2000, J BIOL CHEM, V275, P5208, DOI 10.1074/jbc.275.7.5208; Gaur S, 1996, AM J PHYSIOL-CELL PH, V270, pC1485, DOI 10.1152/ajpcell.1996.270.5.C1485; Goh ELK, 2000, J BIOL CHEM, V275, P17683, DOI 10.1074/jbc.M001972200; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Kawajiri A, 2000, BIOCHEM BIOPH RES CO, V273, P712, DOI 10.1006/bbrc.2000.3002; Kirsch KH, 1998, J BIOL CHEM, V273, P25673, DOI 10.1074/jbc.273.40.25673; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; Lekmine F, 2002, BIOCHEM BIOPH RES CO, V291, P744, DOI 10.1006/bbrc.2002.6516; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Li LM, 2002, MOL CELL BIOL, V22, P1203, DOI 10.1128/MCB.22.4.1203-1217.2002; Linnemann T, 2002, J BIOL CHEM, V277, P7831, DOI 10.1074/jbc.M110800200; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Matsubara K, 1999, ONCOGENE, V18, P1303, DOI 10.1038/sj.onc.1202425; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; Michelitch M, 1996, CURR BIOL, V6, P446, DOI 10.1016/S0960-9822(02)00512-2; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; Nancy V, 1999, J BIOL CHEM, V274, P8737, DOI 10.1074/jbc.274.13.8737; Ohba Y, 2000, MOL CELL BIOL, V20, P6074, DOI 10.1128/MCB.20.16.6074-6083.2000; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; Palsson EM, 2000, J BIOL CHEM, V275, P7818, DOI 10.1074/jbc.275.11.7818; PIZON V, 1988, ONCOGENE, V3, P201; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; Rui LY, 2000, MOL CELL BIOL, V20, P3168, DOI 10.1128/MCB.20.9.3168-3177.2000; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TANNENBAUM GS, 1976, ENDOCRINOLOGY, V98, P562, DOI 10.1210/endo-98-3-562; Torti M, 1999, J CELL BIOCHEM, V75, P675, DOI 10.1002/(SICI)1097-4644(19991215)75:4<675::AID-JCB13>3.0.CO;2-M; Vanderkuur JA, 1997, ENDOCRINOLOGY, V138, P4301, DOI 10.1210/en.138.10.4301; WIESER RJ, 1990, ENVIRON HEALTH PERSP, V88, P251, DOI 10.2307/3431085; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; Xing LZ, 2000, MOL CELL BIOL, V20, P7363, DOI 10.1128/MCB.20.19.7363-7377.2000; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhai B, 2001, BIOCHEM BIOPH RES CO, V286, P61, DOI 10.1006/bbrc.2001.5348; Zhu T, 2000, J BIOL CHEM, V275, P2103, DOI 10.1074/jbc.275.3.2103; Zhu T, 2002, J BIOL CHEM, V277, P45592, DOI 10.1074/jbc.M201385200; Zhu T, 2001, CELL SIGNAL, V13, P599, DOI 10.1016/S0898-6568(01)00186-3; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864; Zhu T, 1998, J BIOL CHEM, V273, P10682, DOI 10.1074/jbc.273.17.10682; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	77	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27301	27311		10.1074/jbc.M302516200	http://dx.doi.org/10.1074/jbc.M302516200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12734187	hybrid			2022-12-25	WOS:000184155700127
J	Lybarger, L; Yu, YYL; Miley, MJ; Fremont, DH; Myers, N; Primeau, T; Truscott, SM; Connolly, JM; Hansen, TH				Lybarger, L; Yu, YYL; Miley, MJ; Fremont, DH; Myers, N; Primeau, T; Truscott, SM; Connolly, JM; Hansen, TH			Enhanced immune presentation of a single-chain major histocompatibility complex class I molecule engineered to optimize linkage of a C-terminally extended peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; T-CELLS; ANTIGEN PRESENTATION; 3-DIMENSIONAL STRUCTURE; HEAVY-CHAIN; MONOCLONAL-ANTIBODIES; LOADING COMPLEX; LYMPHOCYTES-T; BINDING; RECOGNITION	Major histocompatibility complex class I molecules can be expressed as single polypeptides wherein the antigenic peptide, beta(2)-microglobulin, and heavy chain are attached by flexible linkers. These molecules, single-chain trimers (SCTs), are remarkably stable at the cell surface compared with native (noncovalently attached) class I molecules. In this study, we used a structure-based approach to engineer an F pocket variant SCT of the murine class I molecule K-b that presents the SIINFEKL epitope of ovalbumin. Mutation of heavy chain residue Tyr(84) (Y84A) in the SCT resulted in enhanced serological and cytolytic CD8 T cell recognition of the covalently linked peptide due to better accommodation of the linker extending from the C terminus of the peptide. These SCTs exhibit significant cell-surface stability, which we hypothesize is rendered by their ability to continuously and efficiently rebind the covalently attached peptide. In addition, we demonstrate that SCT technology can be applied to tetramer construction using recombinant SCTs expressed in Escherichia coli. SCT-based tetramers could have applications for the enumeration of T and natural killer cells that recognize peptide . class I complexes prone to dissociation.	Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Hansen, TH (corresponding author), Washington Univ, Sch Med, Dept Genet, POB 8232,660 S Euclid Ave, St Louis, MO 63110 USA.			Fremont, Daved/0000-0002-8544-2689	NCI NIH HHS [CA86803-04] Funding Source: Medline; NIAID NIH HHS [AI19687, AI27568, T32AI07163, AI42793] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007163, R21AI042793, R01AI042793, R01AI027568, R01AI019687] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahn K, 1997, IMMUNITY, V6, P613, DOI 10.1016/S1074-7613(00)80349-0; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; BOUVIER M, 1994, SCIENCE, V265, P398, DOI 10.1126/science.8023162; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; Chung DH, 1999, J IMMUNOL, V163, P3699; COLLINS EJ, 1995, P NATL ACAD SCI USA, V92, P1218, DOI 10.1073/pnas.92.4.1218; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; Cresswell P, 2000, TRAFFIC, V1, P301, DOI 10.1034/j.1600-0854.2000.010402.x; Dela Cruz CS, 2000, INT IMMUNOL, V12, P1293, DOI 10.1093/intimm/12.9.1293; Fremont DH, 2002, J EXP MED, V195, P1043, DOI 10.1084/jem.20011971; Fremont DH, 1996, SCIENCE, V272, P1001, DOI 10.1126/science.272.5264.1001; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; FRUH K, 1995, NATURE, V375, P415, DOI 10.1038/375415a0; Greten TF, 2002, J IMMUNOL METHODS, V271, P125, DOI 10.1016/S0022-1759(02)00346-0; HAMMERLING GJ, 1982, P NATL ACAD SCI-BIOL, V79, P4737, DOI 10.1073/pnas.79.15.4737; Harris MR, 2001, INT IMMUNOL, V13, P1275, DOI 10.1093/intimm/13.10.1275; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Hornell TMC, 2001, J IMMUNOL, V167, P4207, DOI 10.4049/jimmunol.167.8.4207; Ignatowicz L, 1996, CELL, V84, P521, DOI 10.1016/S0092-8674(00)81028-4; JAULIN C, 1992, INT IMMUNOL, V4, P943; JOYCE S, 1994, P NATL ACAD SCI USA, V91, P4145, DOI 10.1073/pnas.91.10.4145; Kersh GJ, 2001, J IMMUNOL, V166, P3345, DOI 10.4049/jimmunol.166.5.3345; KOZONO H, 1994, NATURE, V369, P151, DOI 10.1038/369151a0; KOZONO H, 1995, IMMUNITY, V3, P187, DOI 10.1016/1074-7613(95)90088-8; LATRON F, 1992, SCIENCE, V257, P964, DOI 10.1126/science.1380181; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; Lybarger L, 2003, IMMUNITY, V18, P121, DOI 10.1016/S1074-7613(02)00509-5; Lybarger L, 2001, J IMMUNOL, V167, P2097, DOI 10.4049/jimmunol.167.4.2097; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MAGE MG, 1992, P NATL ACAD SCI USA, V89, P10658, DOI 10.1073/pnas.89.22.10658; Maile R, 2001, J IMMUNOL, V167, P3708, DOI 10.4049/jimmunol.167.7.3708; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; Messaoudi I, 1999, J IMMUNOL, V163, P3286; MOTTEZ E, 1995, J EXP MED, V181, P493, DOI 10.1084/jem.181.2.493; Myers NB, 2000, J IMMUNOL, V165, P5656, DOI 10.4049/jimmunol.165.10.5656; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; Toshitani K, 1996, P NATL ACAD SCI USA, V93, P236, DOI 10.1073/pnas.93.1.236; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; Udaka K, 1996, J IMMUNOL, V157, P670; Uger RA, 1998, J IMMUNOL, V160, P1598; Uger RA, 1999, J IMMUNOL, V162, P6024; URBAN RG, 1994, P NATL ACAD SCI USA, V91, P1534, DOI 10.1073/pnas.91.4.1534; VEST HN, 2001, EUR J IMMUNOL, V31, P32; White J, 1999, J IMMUNOL, V162, P2671; Williams A, 2002, TISSUE ANTIGENS, V59, P3, DOI 10.1034/j.1399-0039.2002.590103.x; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; Yewdell JW, 2002, NAT IMMUNOL, V3, P1019, DOI 10.1038/ni1102-1019; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1; Yu YYL, 1999, INT IMMUNOL, V11, P1897, DOI 10.1093/intimm/11.12.1897; Yu YYL, 2002, J IMMUNOL, V168, P3145, DOI 10.4049/jimmunol.168.7.3145	52	43	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27105	27111		10.1074/jbc.M303716200	http://dx.doi.org/10.1074/jbc.M303716200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12732632	hybrid			2022-12-25	WOS:000184155700104
J	Misra, I; Wang, CZ; Miziorko, HM				Misra, I; Wang, CZ; Miziorko, HM			The influence of conserved aromatic residues in 3-hydroxy-3-methylglutaryl-CoA synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-S-ENZYME; MAGNETIC-RESONANCE SPECTROSCOPY; COENZYME-A SYNTHASE; REACTION INTERMEDIATE; CRYSTAL-STRUCTURE; ACETOACETYL-COA; SITE; LIVER; ACETYLCHOLINESTERASE; IDENTIFICATION	In order to evaluate the potential contribution of conserved aromatic residues to the hydrophobic active site of 3-hydroxy-3-methylglutaryl-CoA synthase, site-directed mutagenesis was employed to produce Y130L, Y163L, F204L, Y225L, Y346L, and Y376L proteins. Each mutant protein was expressed at levels comparable with wild-type enzyme and was isolated in highly purified form. Initial kinetic characterization indicated that F204L exhibits a substantial (>300-fold) decrease in catalytic rate (k(cat)). Upon modification with the mechanism-based inhibitor, 3-chloropropionyl-CoA, or in formation of a stable binary complex with acetoacetyl-CoA, F204L exhibits binding stoichiometries comparable with wild-type enzyme, suggesting substantial retention of active site integrity. Y130L and Y376L exhibit inflated values (80- and 40-fold, respectively) for the Km for acetyl-CoA in the acetyl-CoA hydrolysis partial reaction; these mutants also exhibit an order of magnitude decrease in k(cat). Formation of the acetyl-S-enzyme reaction intermediate by Y130L, F204L, and Y376L proceeds slowly in comparison with wild-type enzyme. However, solvent exchange into the thioester carbonyl oxygen of these acetyl-S-enzyme intermediates is not slow in comparison with previous observations for D159A and D203A mutants, which also exhibit slow acetyl-S-enzyme formation. The magnitude of the differential isotope shift upon exchange of (H2O)-O-18 into [C-13] acetyl-S-enzyme suggests a polarization of the thioester carbonyl and a reduction in bond order. Such an effect may substantially contribute to the upfield C-13 NMR shift observed for [C-13]acetyl-S-enzyme. The influence on acetyl-S-enzyme formation, as well as observed k(cat) ( F204L) and Km (Y130L; Y376L) effects, implicate these invariant residues as part of the catalytic site. Substitution of phenylalanine (Y130F, Y376F) instead of leucine at residues 130 and 376 diminishes the effects on catalytic rate and substrate affinity observed for Y130L and Y376L, underscoring the influence of aromatic side chains near the active site.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Miziorko, HM (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.				NIDDK NIH HHS [DK21491] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021491, R01DK021491] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barak D, 2002, BIOCHEMISTRY-US, V41, P8245, DOI 10.1021/bi020143t; Bell AF, 2001, BIOCHEMISTRY-US, V40, P1725, DOI 10.1021/bi001733z; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPOBASSO N, 2002, KEYST S STRUCT GEN G; Chun KY, 2000, BIOCHEMISTRY-US, V39, P14670, DOI 10.1021/bi001805m; Chun KY, 2000, J BIOL CHEM, V275, P17946, DOI 10.1074/jbc.M909725199; CLINKENBEARD KD, 1975, J BIOL CHEM, V250, P3108; Davies C, 2000, STRUCTURE, V8, P185, DOI 10.1016/S0969-2126(00)00094-0; DEREWENDA ZS, 1995, J MOL BIOL, V252, P248, DOI 10.1006/jmbi.1995.0492; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hegardt FG, 1999, BIOCHEM J, V338, P569, DOI 10.1042/0264-6021:3380569; HERSH LB, 1967, J BIOL CHEM, V242, P3468; Holden HM, 2001, ACCOUNTS CHEM RES, V34, P145, DOI 10.1021/ar000053l; Misra I, 1996, BIOCHEMISTRY-US, V35, P9610, DOI 10.1021/bi9605797; MISRA I, 1993, J BIOL CHEM, V268, P12129; Miura R, 1996, J BIOCHEM-TOKYO, V119, P512; MIZIORKO HM, 1977, J BIOL CHEM, V252, P1414; MIZIORKO HM, 1975, J BIOL CHEM, V250, P5768; MIZIORKO HM, 1985, J BIOL CHEM, V260, P3513; MIZIORKO HM, 1985, BIOCHEMISTRY-US, V24, P3174, DOI 10.1021/bi00334a015; Ordentlich A, 1998, J BIOL CHEM, V273, P19509, DOI 10.1074/jbc.273.31.19509; Qiu XY, 1999, J BIOL CHEM, V274, P36465, DOI 10.1074/jbc.274.51.36465; RISLEY JM, 1980, J AM CHEM SOC, V102, P4609, DOI 10.1021/ja00534a007; SIMON EJ, 1953, J AM CHEM SOC, V75, P2520, DOI 10.1021/ja01106a522; Vinarov D, 1999, J AM CHEM SOC, V121, P270, DOI 10.1021/ja983511i; Vinarov DA, 2000, BIOCHEMISTRY-US, V39, P3360, DOI 10.1021/bi9922897; VOLLMER SH, 1988, BIOCHEMISTRY-US, V27, P4288, DOI 10.1021/bi00412a014	27	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26443	26449		10.1074/jbc.M300244200	http://dx.doi.org/10.1074/jbc.M300244200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12743118	hybrid			2022-12-25	WOS:000184155700021
J	Orr, WC; Mockett, RJ; Benes, JJ; Sohal, RS				Orr, WC; Mockett, RJ; Benes, JJ; Sohal, RS			Effects of overexpression of copper-zinc and manganese superoxide dismutases, catalase, and thioredoxin reductase genes on longevity in Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIFE-SPAN; TRANSGENIC DROSOPHILA; OXIDATIVE STRESS; GLUTATHIONE-REDUCTASE; MOTOR-NEURONS; EXPRESSION; RESISTANCE; EXTENDS; SOD; MECHANISMS	The overexpression of antioxidative enzymes such as CuZn-superoxide dismutase (SOD), Mn-SOD, and catalase has previously been reported to extend life span in transgenic flies (Drosophila melanogaster). The purpose of this study was to determine whether life-extending effects persist if the recipient control strains of flies are relatively long-lived. Accordingly, the life spans of large numbers of replicate control and overexpressor lines were determined in two long-lived genetic backgrounds involving a combined total of >90,000 flies. Significant increases in the activities of both CuZn-SOD and catalase had no beneficial effect on survivorship in relatively long-lived y w mutant flies and were associated with slightly decreased life spans in wild type flies of the Oregon-R strain. The introduction of additional transgenes encoding Mn-SOD or thioredoxin reductase in the same genetic background also failed to cause life span extension. In conjunction with data from earlier studies, the results show that increasing the activities of these major antioxidative enzymes above wild type levels does not decrease the rate of aging in long-lived strains of Drosophila, although there may be some effect in relatively short-lived strains.	Univ So Calif, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA	University of Southern California; Southern Methodist University	Sohal, RS (corresponding author), Univ So Calif, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA.				NATIONAL INSTITUTE ON AGING [R01AG007657] Funding Source: NIH RePORTER; NIA NIH HHS [R01AG7657] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Elia AJ, 1999, FREE RADICAL BIO MED, V26, P1332, DOI 10.1016/S0891-5849(98)00333-5; GELLER BL, 1983, ANAL BIOCHEM, V128, P86, DOI 10.1016/0003-2697(83)90348-2; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Huang TT, 2000, J GERONTOL A-BIOL, V55, pB5; Kanzok SM, 2001, SCIENCE, V291, P643, DOI 10.1126/science.291.5504.643; KIM I, 1993, AM J PUBLIC HEALTH, V83, P546, DOI 10.2105/AJPH.83.4.546; Klichko VI, 1999, NEUROBIOL AGING, V20, P537, DOI 10.1016/S0197-4580(99)00090-1; LEDVINA M, 1980, EXP GERONTOL, V15, P67, DOI 10.1016/0531-5565(80)90076-5; Luck H., 1974, ESTIMATION CATALASE, V885; Mockett RJ, 1999, FASEB J, V13, P1733, DOI 10.1096/fasebj.13.13.1733; Mockett RJ, 1999, ARCH BIOCHEM BIOPHYS, V371, P260, DOI 10.1006/abbi.1999.1460; Mockett RJ, 2003, P NATL ACAD SCI USA, V100, P301, DOI 10.1073/pnas.0136976100; Mockett RJ, 2003, FREE RADICAL BIO MED, V34, P207, DOI 10.1016/S0891-5849(02)01190-5; Mockett RJ, 2002, METHOD ENZYMOL, V349, P287, DOI 10.1016/S0076-6879(02)49343-3; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; ORR WC, 1992, ARCH BIOCHEM BIOPHYS, V297, P35, DOI 10.1016/0003-9861(92)90637-C; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; ORR WC, 1993, ARCH BIOCHEM BIOPHYS, V301, P34, DOI 10.1006/abbi.1993.1111; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; Pletcher SD, 2002, CURR BIOL, V12, P712, DOI 10.1016/S0960-9822(02)00808-4; REVEILLAUD I, 1991, MOL CELL BIOL, V11, P632, DOI 10.1128/MCB.11.2.632; SETO NOL, 1990, P NATL ACAD SCI USA, V87, P4270, DOI 10.1073/pnas.87.11.4270; Sohal RS, 2002, FREE RADICAL BIO MED, V33, P575, DOI 10.1016/S0891-5849(02)00886-9; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; Sun JT, 2002, GENETICS, V161, P661; Sun JT, 1999, MOL CELL BIOL, V19, P216; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; Tatar M, 1999, AM NAT, V154, pS67, DOI 10.1086/303284; Tower J, 1996, BIOESSAYS, V18, P799, DOI 10.1002/bies.950181006; Zar JH., 1999, BIOSTAT ANAL	30	143	164	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26418	26422		10.1074/jbc.M303095200	http://dx.doi.org/10.1074/jbc.M303095200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12743125	hybrid			2022-12-25	WOS:000184155700018
J	Lee, WS; Ngo-Anh, TJ; Bruening-Wright, A; Maylie, J; Adelman, JP				Lee, WS; Ngo-Anh, TJ; Bruening-Wright, A; Maylie, J; Adelman, JP			Small conductance Ca2+-activated K+ channels and calmodulin - Cell surface expression and gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-DEPENDENT INACTIVATION; POTASSIUM CHANNELS; PLASMA-MEMBRANE; MODULATION; PEPTIDE; HYPERPOLARIZATIONS; TRAFFICKING; SUPPORTS; SUBUNIT; COMPLEX	Small conductance Ca2+-activated K+ channels (SK channels) are heteromeric complexes of pore-forming alpha subunits and constitutively bound calmodulin (CaM). The binding of CaM is mediated in part by the electrostatic interaction between residues Arg-464 and Lys-467 of SK2 and Glu-84 and Glu-87 of CaM. Heterologous expression of the double charge reversal in SK2, SK2 R464E/K467E (SK2:64/67), did not yield detectable surface expression or channel activity in whole cell or inside-out patch recordings. Coexpression of SK2:64/67 with wild type CaM or CaM1,2,3,4, a mutant lacking the ability to bind Ca2+, rescued surface expression. In patches from cells coexpressing SK2:64/67 and wild type CaM, currents were recorded immediately following excision into Ca2+-containing solution but disappeared within minutes after excision or immediately upon exposure to Ca2+-free solution and were not reactivated upon reapplication of Ca2+-containing solution. Channel activity was restored by application of purified recombinant Ca2+-CaM or exposure to Ca2+-free CaM followed by application of Ca2+-containing solution. Coexpression of the double charge reversal E84R/E87K in CaM (CaM:84/87) with SK2:64/67 reconstituted stable Ca2+-dependent channel activity that was not lost with exposure to Ca2+-free solution. Therefore, Ca2+-independent interactions with CaM are required for surface expression of SK channels, whereas the constitutive association between the two channel subunits is not an essential requirement for gating.	Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Adelman, JP (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	adelman@ohsu.edu	Lee, Cynthia Wei-Sheng/A-8654-2010	Lee, Cynthia Wei-Sheng/0000-0002-9783-8031				ALGER BE, 1980, SCIENCE, V210, P1122, DOI 10.1126/science.7444438; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; Deschenes I, 2002, CIRC RES, V90, pE49, DOI 10.1161/01.RES.0000012502.92751.E6; Doughty JM, 1999, AM J PHYSIOL-HEART C, V276, pH1107, DOI 10.1152/ajpheart.1999.276.3.H1107; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; Hamilton SL, 2000, ANTIOXID REDOX SIGN, V2, P41, DOI 10.1089/ars.2000.2.1-41; Herrera GM, 2000, AM J PHYSIOL-REG I, V279, pR60, DOI 10.1152/ajpregu.2000.279.1.R60; Hirschberg B, 1998, J GEN PHYSIOL, V111, P565, DOI 10.1085/jgp.111.4.565; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Joiner WJ, 2001, J BIOL CHEM, V276, P37980; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; Kasri NN, 2002, BBA-PROTEINS PROTEOM, V1600, P19; Keen JE, 1999, J NEUROSCI, V19, P8830, DOI 10.1523/JNEUROSCI.19-20-08830.1999; Khawaled R, 1999, PFLUG ARCH EUR J PHY, V438, P314, DOI 10.1007/s004240050915; KLEVIT RE, 1985, BIOCHEMISTRY-US, V24, P8152, DOI 10.1021/bi00348a047; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; LAMERS JMJ, 1983, CELL CALCIUM, V4, P281, DOI 10.1016/0143-4160(83)90005-2; LANCASTER B, 1987, J PHYSIOL-LONDON, V389, P187, DOI 10.1113/jphysiol.1987.sp016653; MADISON DV, 1984, J PHYSIOL-LONDON, V354, P319, DOI 10.1113/jphysiol.1984.sp015378; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Molday RS, 1996, CURR OPIN NEUROBIOL, V6, P445, DOI 10.1016/S0959-4388(96)80048-1; Mori M, 2000, BIOCHEMISTRY-US, V39, P1316, DOI 10.1021/bi9912600; Murphy ME, 1995, J PHYSIOL-LONDON, V489, P723, DOI 10.1113/jphysiol.1995.sp021086; Palfi A, 2002, LIFE SCI, V70, P2829, DOI 10.1016/S0024-3205(02)01544-8; Palfi A, 1999, J HISTOCHEM CYTOCHEM, V47, P583, DOI 10.1177/002215549904700502; Persechini A, 2002, TRENDS CARDIOVAS MED, V12, P32, DOI 10.1016/S1050-1738(01)00144-X; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200; Saimi Y, 2002, ANNU REV PHYSIOL, V64, P289, DOI 10.1146/annurev.physiol.64.100301.111649; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; SKENE JHP, 1990, NEUROSCI RES, pS112; Stocker M, 1999, P NATL ACAD SCI USA, V96, P4662, DOI 10.1073/pnas.96.8.4662; Toutenhoofd SL, 2000, CELL CALCIUM, V28, P83, DOI 10.1054/ceca.2000.0136; TSE A, 1995, PFLUG ARCH EUR J PHY, V430, P645, DOI 10.1007/BF00386158; TSE A, 1992, SCIENCE, V255, P462, DOI 10.1126/science.1734523; Varnum MD, 1997, SCIENCE, V278, P110, DOI 10.1126/science.278.5335.110; Verkade P, 1997, NEUROSCIENCE, V79, P1207, DOI 10.1016/S0306-4522(97)00041-9; Wen H, 2002, J NEUROSCI, V22, P7991, DOI 10.1523/jneurosci.22-18-07991.2002; Wissmann R, 2002, J BIOL CHEM, V277, P4558, DOI 10.1074/jbc.M109240200; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Yus-Najera E, 2002, J BIOL CHEM, V277, P28545, DOI 10.1074/jbc.M204130200; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	47	80	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25940	25946		10.1074/jbc.M302091200	http://dx.doi.org/10.1074/jbc.M302091200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12734181	hybrid			2022-12-25	WOS:000183920200086
J	Sagi, Y; Khan, S; Eisenbach, M				Sagi, Y; Khan, S; Eisenbach, M			Binding of the chemotaxis response regulator CheY to the isolated, intact switch complex of the bacterial flagellar motor - Lack of cooperativity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MS RING COMPLEX; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; PHOSPHATASE-ACTIVITY; PROTEIN CHEY; BASAL BODY; IN-VIVO; C-RING; PHOSPHORYLATION; ROTATION	In bacteria, the chemotactic signal is greatly amplified between the chemotaxis receptors and the flagellar motor. In Escherichia coli, part of this amplification occurs at the flagellar switch. However, it is not known whether the amplification results from cooperativity of CheY binding to the switch or from a postbinding step. To address this question, we purified the intact switch complex ( constituting the switch proteins FliG, FliM, and FliN and the scaffolding protein FliF) in quantities sufficient for biochemical work and used it to investigate whether the binding of CheY to the switch complex is cooperative. As a negative control, we used complexes of switchless basal bodies, formed from the proteins FliF and FliG and similarly isolated. Using double-labeling centrifugation assays for binding, we found that CheY binds to the isolated, intact switch complex in a phosphorylation-dependent manner. We observed no significant phosphorylation-dependent binding to the negative control of the switchless basal body. The dissociation constant for the binding between the switch complex and phosphorylated CheY ( CheY similar to P) was 4.0 +/- 1.1 muM, well in line with the published range of CheY similar to P concentrations to which the flagellar motor is responsive. Furthermore, the binding was not cooperative ( Hill coefficient similar to 1). This lack of CheY similar to P-switch complex binding cooperativity, taken together with earlier in vivo studies suggesting that the dependence of the rotational state of the motor on the fraction of occupied sites at the switch is sigmoidal and very steep (Bren, A., and Eisenbach, M. ( 2001) J. Mol. Biol. 312, 699 - 709), indicates that the chemotactic signal is amplified within the switch, subsequent to the CheY similar to P binding.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Mol Biol Consortium, Chicago, IL 60612 USA	Weizmann Institute of Science	Eisenbach, M (corresponding author), Weizmann Inst Sci, Dept Biol Chem, POB 26, IL-76100 Rehovot, Israel.			Khan, Shahid/0000-0002-0361-6068; Eisenbach, Michael/0000-0001-9048-4720	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036936] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; Alon U, 1998, EMBO J, V17, P4238, DOI 10.1093/emboj/17.15.4238; Ames P, 2002, P NATL ACAD SCI USA, V99, P7060, DOI 10.1073/pnas.092071899; Blat Y, 1998, J MOL BIOL, V284, P1191, DOI 10.1006/jmbi.1998.2224; Blat Y, 1996, J BIOL CHEM, V271, P1232, DOI 10.1074/jbc.271.2.1232; Bourret RB, 2002, J BIOL CHEM, V277, P9625, DOI 10.1074/jbc.R100066200; Bray D, 2002, P NATL ACAD SCI USA, V99, P7, DOI 10.1073/pnas.022641699; Bray D, 1998, NATURE, V393, P85, DOI 10.1038/30018; Bren A, 1998, J MOL BIOL, V278, P507, DOI 10.1006/jmbi.1998.1730; Bren A, 2001, J MOL BIOL, V312, P699, DOI 10.1006/jmbi.2001.4992; Bren A, 2000, J BACTERIOL, V182, P6865, DOI 10.1128/JB.182.24.6865-6873.2000; Cluzel P, 2000, SCIENCE, V287, P1652, DOI 10.1126/science.287.5458.1652; Duke TAJ, 1999, P NATL ACAD SCI USA, V96, P10104, DOI 10.1073/pnas.96.18.10104; Duke TAJ, 2001, J MOL BIOL, V308, P541, DOI 10.1006/jmbi.2001.4610; EISENBACH M, 1990, MOL MICROBIOL, V4, P161, DOI 10.1111/j.1365-2958.1990.tb00584.x; Eisenbach M, 1998, CURR BIOL, V8, pR444, DOI 10.1016/S0960-9822(98)70288-X; FRANCIS NR, 1994, J MOL BIOL, V235, P1261, DOI 10.1006/jmbi.1994.1079; Jasuja R, 1999, P NATL ACAD SCI USA, V96, P11346, DOI 10.1073/pnas.96.20.11346; KAISER AD, 1960, J MOL BIOL, V2, P392, DOI 10.1016/S0022-2836(60)80050-2; Khan S, 2000, CURR BIOL, V10, P927, DOI 10.1016/S0960-9822(00)00629-1; Kim SH, 2002, P NATL ACAD SCI USA, V99, P11611, DOI 10.1073/pnas.132376499; Kubori T, 1997, J BACTERIOL, V179, P813, DOI 10.1128/jb.179.3.813-817.1997; KUO SC, 1989, J BACTERIOL, V171, P6279, DOI 10.1128/jb.171.11.6279-6287.1989; LARSEN SH, 1974, NATURE, V249, P74, DOI 10.1038/249074a0; LI JY, 1995, BIOCHEMISTRY-US, V34, P14626, DOI 10.1021/bi00045a003; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; Lux R, 2000, J MOL BIOL, V298, P577, DOI 10.1006/jmbi.2000.3703; Macnab R., 1996, ESCHERICHIA COLI SAL, V2nd ed, P119; MACNAB RM, 1995, 2 COMPONENT SIGNAL T, P181; Marykwas DL, 1996, J MOL BIOL, V256, P564, DOI 10.1006/jmbi.1996.0109; McEvoy MM, 1999, J MOL BIOL, V289, P1423, DOI 10.1006/jmbi.1999.2830; OOSAWA K, 1994, J BACTERIOL, V176, P3683, DOI 10.1128/JB.176.12.3683-3691.1994; Scharf BE, 1998, P NATL ACAD SCI USA, V95, P201, DOI 10.1073/pnas.95.1.201; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SEGALL JE, 1986, P NATL ACAD SCI USA, V83, P8987, DOI 10.1073/pnas.83.23.8987; Silversmith RE, 1999, TRENDS MICROBIOL, V7, P16, DOI 10.1016/S0966-842X(98)01409-7; Sourjik V, 2002, P NATL ACAD SCI USA, V99, P12669, DOI 10.1073/pnas.192463199; Spiro PA, 1997, P NATL ACAD SCI USA, V94, P7263, DOI 10.1073/pnas.94.14.7263; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Thomas DR, 1999, P NATL ACAD SCI USA, V96, P10134, DOI 10.1073/pnas.96.18.10134; UENO T, 1992, J MOL BIOL, V227, P672, DOI 10.1016/0022-2836(92)90216-7; WELCH M, 1994, BIOCHEMISTRY-US, V33, P10470, DOI 10.1021/bi00200a031; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8787, DOI 10.1073/pnas.90.19.8787; Young HS, 2003, BIOPHYS J, V84, P571, DOI [10.1016/s0006-3495(03)74877-2, 10.1016/S0006-3495(03)74877-2]; ZAMENHOF PJ, 1972, J BACTERIOL, V110, P171, DOI 10.1128/JB.110.1.171-178.1972; ZHAO RB, 1995, J MOL BIOL, V251, P400, DOI 10.1006/jmbi.1995.0443; Zhao RB, 1996, J BACTERIOL, V178, P258, DOI 10.1128/jb.178.1.258-265.1996; Zhao RH, 1996, J MOL BIOL, V261, P195, DOI 10.1006/jmbi.1996.0452	48	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25867	25871		10.1074/jbc.M303201200	http://dx.doi.org/10.1074/jbc.M303201200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12736245	hybrid			2022-12-25	WOS:000183920200076
J	Iyer, SPN; Hart, GW				Iyer, SPN; Hart, GW			Roles of the tetratricopeptide repeat domain in O-GlcNAc transferase targeting and protein substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED N-ACETYLGLUCOSAMINE; RNA-POLYMERASE-II; CYTOSOLIC PROTEINS; CYTOPLASMIC GLYCOSYLATION; TRANSCRIPTION FACTORS; TERMINAL DOMAIN; NUCLEAR; CLONING; IDENTIFICATION; LOCALIZATION	The abundant and dynamic post-translational modification of nuclear and cytosolic proteins by beta-O-linked N-acetylglucosamine (O-GlcNAc) is catalyzed by O-Glc-NAc-transferase (OGT). Recently, we reported the identification of a novel family of OGT-interacting proteins (OIPs) that interact strongly with the tetratricopeptide repeat (TPR) domain of OGT (Iyer, S. P., Akimoto, Y., and Hart, G. W. ( 2003) J. Biol. Chem. 278, 5399-5409). Members of this family are modified by O-GlcNAc and are excellent substrates of OGT. Here, we further investigated the role of the TPR domain in the O-GlcNAcylation of OIP106, one of the members of this OIP family. Using N-terminal deletions, we first identified the region of OIP106 that binds OGT, termed the OGT-interacting domain (OID). Deletion analysis indicated that TPRs 2-6 of OGT interact with the OID of OIP106. The apparent K-m of OGT for the OID of OIP106 is 3.35 muM. Unlike small peptide substrates, glycosylation of the OID was dependent upon its interaction with the first 6 TPRs of OGT. Furthermore, the isolated TPR domain of OGT competitively inhibited glycosylation of the OID protein, but did not inhibit glycosylation of a 12-amino acid casein kinase II peptide substrate, providing kinetic evidence for the role of the TPR domain as a protein substrate docking site. Additionally, both the OID of OIP106 and nucleoporin p62 competed with each other for glycosylation by OGT. These studies support the model that the catalytic subunit of OGT achieves both high specificity and a remarkable diversity of substrates by complexing with a variety of targeting proteins via its TPR protein-protein interaction domains.	Johns Hopkins Univ, Dept Biol Chem, Sch Med, Baltimore, MD 21205 USA; Univ Alabama, Grad Program, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	Johns Hopkins University; University of Alabama System; University of Alabama Birmingham	Hart, GW (corresponding author), Johns Hopkins Univ, Dept Biol Chem, Sch Med, 401 Hunterian Bldg,725 N Wolfe St, Baltimore, MD 21205 USA.			Hart, Gerald/0000-0001-7812-4351	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD013563, R01HD013563] Funding Source: NIH RePORTER; NICHD NIH HHS [HD13563] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Beck M, 2002, J BIOL CHEM, V277, P30079, DOI 10.1074/jbc.M200438200; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; CHOU TY, 1995, P NATL ACAD SCI USA, V92, P4417, DOI 10.1073/pnas.92.10.4417; Chung JJ, 2002, TRENDS CELL BIOL, V12, P146, DOI 10.1016/S0962-8924(01)02241-3; Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132; Comer FI, 2001, BIOCHEMISTRY-US, V40, P7845, DOI 10.1021/bi0027480; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; DONG DLY, 1993, J BIOL CHEM, V268, P16679; DONG DLY, 1994, J BIOL CHEM, V269, P19321; Gao Y, 2001, J BIOL CHEM, V276, P9838, DOI 10.1074/jbc.M010420200; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Hanover JA, 2001, FASEB J, V15, P1865, DOI 10.1096/fj.01-0094rev; HART GW, 1995, ADV EXP MED BIOL, V376, P115; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; HOLT GD, 1987, J BIOL CHEM, V262, P14847; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; IYER SP, 2002, HDB GLYCOSYLTRANSFER, V21, P158; Iyer SPN, 2003, J BIOL CHEM, V278, P5399, DOI 10.1074/jbc.M209384200; Iyer SPN, 2003, BIOCHEMISTRY-US, V42, P2493, DOI 10.1021/bi020685a; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Kreppel LK, 1999, J BIOL CHEM, V274, P32015, DOI 10.1074/jbc.274.45.32015; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; KREPPEL LK, 1999, THESIS J HOPKISN U B; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; Lefebvre T, 2001, BIOCHEM J, V360, P179, DOI 10.1042/0264-6021:3600179; Love DC, 2003, J CELL SCI, V116, P647, DOI 10.1242/jcs.00246; Lubas WA, 2000, J BIOL CHEM, V275, P10983, DOI 10.1074/jbc.275.15.10983; Lubas WA, 1997, J BIOL CHEM, V272, P9316; Medina L, 1998, GLYCOBIOLOGY, V8, P383, DOI 10.1093/glycob/8.4.383; MEIKRANTZ W, 1991, J CELL SCI, V98, P303; Nolte D, 2002, MAMM GENOME, V13, P62, DOI 10.1007/s00335-001-2108-9; REASON AJ, 1992, J BIOL CHEM, V267, P16911; Roquemore EP, 1996, BIOCHEMISTRY-US, V35, P3578, DOI 10.1021/bi951918j; Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; Wells L, 2002, J BIOL CHEM, V277, P1755, DOI 10.1074/jbc.M109656200; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3	41	136	154	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24608	24616		10.1074/jbc.M300036200	http://dx.doi.org/10.1074/jbc.M300036200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12724313	hybrid			2022-12-25	WOS:000183824800044
J	Mahboubi, K; Kirkiles-Smith, NC; Karras, J; Pober, JS				Mahboubi, K; Kirkiles-Smith, NC; Karras, J; Pober, JS			Desensitization of signaling by oncostatin M in human vascular cells involves cytoplasmic Tyr residue 759 in gp130 but is not mediated by either Src homology 2 domain-containing tyrosine phosphatase 2 or suppressor of cytokine signaling 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-INHIBITORY FACTOR; HUMAN-ENDOTHELIAL-CELLS; DISTINCT MECHANISMS; NEGATIVE REGULATION; TRANSDUCER GP130; GLYCOPROTEIN 130; FACTOR-RECEPTOR; DOWN-REGULATION; HEPATIC CELLS; ACTIVATION	Oncostatin M (OnM) signals through cell surface receptors, which utilize the gp130 subunit. In cultured human umbilical vein endothelial cells (HUVEC), OnM transiently elevates mRNA encoding for suppressor of cytokine signaling-3 (SOCS-3). By 1 h of OnM treatment, HUVEC become refractory to the restimulation by OnM, measured as failure to reinduce SOCS-3 mRNA. OnM-induced desensitization also prevents responses to other gp130-signaling cytokines (e.g. leukemia inhibitory factor and interleukin 11). OnM treatment does not affect gp130 expression levels and desensitizes signaling mediated by a transduced chimeric receptor containing extracellular domains of platelet-derived growth factor receptor-beta (PDGFRbeta) and the cytoplasmic region of gp130. Interestingly, a chimeric PDGFRbeta-gp130 mutant receptor, in which intracellular Tyr residue 759 of gp130 is replaced by a Phe residue, mediates prolonged signaling and is not cross-desensitized by OnM. Phospho-Tyr(759) is the binding site for both SOCS-3 and for Src homology domain 2-containing tyrosine phosphatase 2 (SHP-2). In human aortic smooth muscle cells, neither prevention of SOCS-3 protein induction, using STAT3 or SOCS-3 antisense, nor prevention of SHP-2 expression, also with antisense, ablates desensitization. These data suggest that desensitization of vascular cells to OnM is mediated in trans and involves Tyr residue 759 in gp130 but is not mediated by either SOCS-3 or SHP-2, the only two proteins currently known to bind to gp130 at this site.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Interdept Program Vasc Biol & Transplantat, New Haven, CT 06510 USA; ISIS Pharmaceut, Mol & Cellular Pharmacol, Carlsbad, CA 92008 USA	Yale University; Isis Pharmaceuticals Inc	Pober, JS (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Interdept Program Vasc Biol & Transplantat, Room 454,295 Congress Ave, New Haven, CT 06510 USA.				NHLBI NIH HHS [HL36003, F32-HL10275] Funding Source: Medline; PHS HHS [62188] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036003, F32HL010275, R37HL036003] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Anhuf D, 2000, J IMMUNOL, V165, P2535, DOI 10.4049/jimmunol.165.5.2535; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Blanchard F, 2001, J BIOL CHEM, V276, P47038, DOI 10.1074/jbc.M107971200; Bravo J, 2000, EMBO J, V19, P2399, DOI 10.1093/emboj/19.11.2399; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; Hermanns HM, 1999, J IMMUNOL, V163, P6651; Hermanns HM, 2000, J BIOL CHEM, V275, P40742, DOI 10.1074/jbc.M005408200; Kaur N, 2002, CELL SIGNAL, V14, P419, DOI 10.1016/S0898-6568(01)00280-7; Kim H, 1999, MOL CELL BIOL, V19, P5326; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Magrangeas F, 2001, EUR CYTOKINE NETW, V12, P309; Magrangeas F, 2001, BIOCHEM J, V353, P223, DOI 10.1042/0264-6021:3530223; Mahboubi K, 2002, J BIOL CHEM, V277, P8012, DOI 10.1074/jbc.M107542200; Mahboubi K, 2000, J IMMUNOL, V164, P3837, DOI 10.4049/jimmunol.164.7.3837; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Paul C, 2000, EUR J BIOCHEM, V267, P5849, DOI 10.1046/j.1432-1327.2000.01395.x; Qiu BS, 1996, DIGEST DIS SCI, V41, P1625, DOI 10.1007/BF02087911; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Schoenwaelder SM, 2000, CURR BIOL, V10, P1523, DOI 10.1016/S0960-9822(00)00831-9; Siewert E, 1999, EUR J BIOCHEM, V265, P251, DOI 10.1046/j.1432-1327.1999.00719.x; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Stein-Gerlach M, 1998, INT J BIOCHEM CELL B, V30, P559, DOI 10.1016/S1357-2725(98)00002-8; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Terstegen L, 2000, J BIOL CHEM, V275, P18810, DOI 10.1074/jbc.M904148199; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; Trepicchio WL, 1996, J IMMUNOL, V157, P3627; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wallace PM, 1999, J IMMUNOL, V162, P5547; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Zheng L, 2000, J IMMUNOL, V164, P4665, DOI 10.4049/jimmunol.164.9.4665	37	18	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25014	25023		10.1074/jbc.M211867200	http://dx.doi.org/10.1074/jbc.M211867200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12724316	hybrid			2022-12-25	WOS:000183824800094
J	Pristovsek, P; Sengupta, K; Lohr, F; Schafer, B; von Trebra, MW; Ruterjans, H; Bernhard, F				Pristovsek, P; Sengupta, K; Lohr, F; Schafer, B; von Trebra, MW; Ruterjans, H; Bernhard, F			Structural analysis of the DNA-binding domain of the Erwinia amylovora RcsB protein and its interaction with the RcsAB box	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENITRIFICANS CYTOCHROME C(552); ESCHERICHIA-COLI K-12; FUNCTIONAL DOMAIN; CAPSULE SYNTHESIS; EXOPOLYSACCHARIDE BIOSYNTHESIS; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; SALMONELLA-TYPHI; VI-ANTIGEN; REGULATOR	The transcriptional regulator RcsB interacts with other coactivators to control the expression of biosynthetic operons in enterobacteria. While in a heterodimer complex with the regulator RcsA the RcsAB box consensus is recognized, DNA binding sites for RcsB without RcsA have also been identified. The conformation of RcsB might therefore be modulated upon interaction with various coactivators, resulting in the recognition of different DNA targets. We report the solution structure of the C-terminal DNA-binding domain of the RcsB protein from Erwinia amylovora spanning amino acid residues 129-215 solved by heteronuclear magnetic resonance (NMR) spectroscopy. The C-terminal domain is composed of four alpha-helices where two central helices form a helix-turn-helix motif similar to the structures of the regulatory proteins GerE, NarL, and TraR. Amino acid residues involved in the RcsA independent DNA binding of RcsB were identified by titration studies with a RcsAB box consensus fragment. Data obtained from NMR spectroscopy together with surface plasmon resonance measurements demonstrate that the RcsAB box is specifically recognized by the RcsAB heterodimer as well as by RcsB alone. However, the binding constant of RcsB alone at target promoters from Escherichia coli, E. amylovora, and Pantoea stewartii was approximately 1 order of magnitude higher compared with that of the RcsAB heterodimer. We present evidence that the obvious role of RcsA is not to alter the DNA binding specificity of RcsB but to stabilize RcsB-DNA complexes.	Goethe Univ Frankfurt, Inst Biophys Chem, D-60439 Frankfurt, Germany; Natl Inst Chem, Kem Inst, SI-1001 Ljubljana, Slovenia; Free Univ Berlin, Inst Kristallog, D-14195 Berlin, Germany	Goethe University Frankfurt; National Institute of Chemistry - Slovenia; Free University of Berlin	Bernhard, F (corresponding author), Goethe Univ Frankfurt, Inst Biophys Chem, Marie Curie Str 9, D-60439 Frankfurt, Germany.	fbern@bpc.uni-frankfurt.de		Wehland, Markus/0000-0002-8160-859X; Bernhard, Frank/0000-0002-4860-1783; Pristovsek, Primoz/0000-0002-2304-1791				Arricau N, 1998, MOL MICROBIOL, V29, P835, DOI 10.1046/j.1365-2958.1998.00976.x; Baikalov I, 1996, BIOCHEMISTRY-US, V35, P11053, DOI 10.1021/bi960919o; BERNHARD F, 1990, MOL PLANT MICROBE IN, V3, P429, DOI 10.1094/MPMI-3-429; BRILL JA, 1988, J BACTERIOL, V170, P2599, DOI 10.1128/jb.170.6.2599-2611.1988; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Carballes F, 1999, MOL MICROBIOL, V34, P442, DOI 10.1046/j.1365-2958.1999.01605.x; Clarke DJ, 1997, MOL MICROBIOL, V25, P933, DOI 10.1111/j.1365-2958.1997.mmi528.x; Clavel T, 1996, MOL MICROBIOL, V19, P19, DOI 10.1046/j.1365-2958.1996.343880.x; Davalos-Garcia M, 2001, J BACTERIOL, V183, P5870, DOI 10.1128/JB.183.20.5870-5876.2001; Ducros VMA, 2001, J MOL BIOL, V306, P759, DOI 10.1006/jmbi.2001.4443; Ebel W, 1999, J BACTERIOL, V181, P577, DOI 10.1128/JB.181.2.577-584.1999; GERVAIS FG, 1992, J BACTERIOL, V174, P8016, DOI 10.1128/JB.174.24.8016-8022.1992; GERVAIS FG, 1992, J BACTERIOL, V174, P3964, DOI 10.1128/jb.174.12.3964-3971.1992; GOTTESMAN S, 1995, 2 COMPONENT SIGNAL T, P253; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HENIKOFF SJC, 1990, METHOD ENZYMOL, V183, P111; KAHN D, 1991, MOL MICROBIOL, V5, P987, DOI 10.1111/j.1365-2958.1991.tb00774.x; KAY LE, 1989, J MAGN RESON, V84, P72, DOI 10.1016/0022-2364(89)90006-1; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Kelley WL, 1997, MOL MICROBIOL, V25, P913, DOI 10.1111/j.1365-2958.1997.mmi527.x; Kelm O, 1997, MOL GEN GENET, V256, P72, DOI 10.1007/s004380050547; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lucke C, 2000, J BIOMOL NMR, V18, P365, DOI 10.1023/A:1026722523546; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miller J.H., 1972, EXPT MOL GENETICS; Pristovsek P, 2000, J BIOMOL NMR, V16, P353, DOI 10.1023/A:1008389023103; Pristovsek P, 2002, J COMPUT CHEM, V23, P335, DOI 10.1002/jcc.10011; Pristovsek P, 2000, EUR J BIOCHEM, V267, P4205, DOI 10.1046/j.1432-1327.2000.01456.x; Reincke B, 2001, BIOCHEMISTRY-US, V40, P12312, DOI 10.1021/bi010615o; Sambrock J, 1989, MOL CLONING LAB MANU; SCHLEUCHER J, 1993, ANGEW CHEM INT EDIT, V32, P1489, DOI 10.1002/anie.199314891; Sledjeski DD, 1996, J BACTERIOL, V178, P1204, DOI 10.1128/jb.178.4.1204-1206.1996; STOUT V, 1990, J BACTERIOL, V172, P659, DOI 10.1128/jb.172.2.659-669.1990; Takeda S, 2001, MOL MICROBIOL, V40, P440, DOI 10.1046/j.1365-2958.2001.02393.x; Vannini A, 2002, EMBO J, V21, P4393, DOI 10.1093/emboj/cdf459; Virlogeux I, 1996, J BACTERIOL, V178, P1691, DOI 10.1128/jb.178.6.1691-1698.1996; VUISTER GW, 1992, J MAGN RESON, V98, P428, DOI 10.1016/0022-2364(92)90144-V; Wehland M, 1999, J BIOL CHEM, V274, P3300, DOI 10.1074/jbc.274.6.3300; Wehland M, 2000, J BIOL CHEM, V275, P7013, DOI 10.1074/jbc.275.10.7013; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zhang RG, 2002, NATURE, V417, P971, DOI 10.1038/nature00833; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	45	50	55	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17752	17759		10.1074/jbc.M301328200	http://dx.doi.org/10.1074/jbc.M301328200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12740396	hybrid			2022-12-25	WOS:000182838300022
J	Cardoso, I; Merlini, G; Saraiva, MJ				Cardoso, I; Merlini, G; Saraiva, MJ			4 '-iodo-4 '-Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters	FASEB JOURNAL			English	Article						familial amyloidotic polyneuropathy; transthyretin; I-DOX; tetracyclines; amyloid disruption	CARDIAC TOXICITY; POLYNEUROPATHY; CARDIOTOXICITY; INHIBITION; DEPOSITION; RECEPTOR	Transthyretin Leu55Pro is one of the most aggressive mutations in familial amyloidotic polyneuropathy, an autosomal dominant disorder characterized by extracellular deposition of fibrillar amyloid protein. This variant has the ability to form fibrils in vitro under physiological conditions (PBS, pH 7.4). We studied by transmission electron microscopy the effect of the drug 4'-iodo-4'-deoxydoxorubicin (I-DOX) on the in vitro assembly of TTR Leu55Pro fibrils by following fibril growth over a 15 day period. Our results showed that I-DOX at a concentration of 10(-5) M/100 mug fibrils does not inhibit fibril formation in up to 10 days since fibrils identical to the ones present in the untreated sample were observed. However, after 15 days of treatment, only round particles, resembling soluble native TTR, were observed. We also tested the ability of tetracyclines and nitrophenols to interfere with amyloid fibril formation for 17 days; the group of compounds tested showed fibril disruption activity to different extents: doxycycline and 2,4-dinitrophenol resulted in complete disaggregation of fibrils. The species generated upon I-DOX and tetracyclines treatments were nontoxic, as revealed by the lack of significant caspase-3 activation on a Schwannoma cell line, making them potential therapeutic drugs in TTR-related and other amyloidosis.	Univ Porto, IBMC, Amyloid Unit, P-4150180 Oporto, Portugal; Univ Porto, ICBAS, P-4150180 Oporto, Portugal; Policlin San Matteo, IRCCS, Univ Hosp, Biotechnol Res Labs, Pavia, Italy; Univ Pavia, Dept Biochem, I-27100 Pavia, Italy	Universidade do Porto; Universidade do Porto; IRCCS Fondazione San Matteo; University of Pavia; University of Pavia	Saraiva, MJ (corresponding author), Univ Porto, IBMC, Amyloid Unit, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.	mjsaraiv@ibmc.up.pt	Cardoso, Isabel/K-3903-2013; Merlini, Giampaolo/A-3817-2008; Saraiva, Maria João/K-3907-2013	Cardoso, Isabel/0000-0003-2472-7055; Merlini, Giampaolo/0000-0001-7680-3254; Saraiva, Maria João/0000-0002-3360-6899				Almeida MR, 1997, ENDOCRINE, V6, P309, DOI 10.1007/BF02820508; Bendeck MP, 2002, AM J PATHOL, V160, P1089, DOI 10.1016/S0002-9440(10)64929-2; Cardoso I, 2002, J MOL BIOL, V317, P683, DOI 10.1006/jmbi.2002.5441; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; COIMBRA A, 1971, BRAIN, V94, P199, DOI 10.1093/brain/94.2.199; DANESI R, 1990, CANCER CHEMOTH PHARM, V26, P403, DOI 10.1007/BF02994089; De Felice FG, 2001, FASEB J, V15, P1297, DOI 10.1096/fj.00-0676fje; Forloni G, 2001, FEBS LETT, V487, P404, DOI 10.1016/S0014-5793(00)02380-2; FURUYA H, 1991, BIOCHEMISTRY-US, V30, P2415, DOI 10.1021/bi00223a017; Gertz MA, 2002, AMYLOID, V9, P24, DOI 10.3109/13506120209072441; GIANNI L, 1995, BLOOD, V86, P855; Howlett DR, 1999, BIOCHEM J, V343, P419, DOI 10.1042/0264-6021:3430419; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERLINI G, 1995, P NATL ACAD SCI USA, V92, P2959, DOI 10.1073/pnas.92.7.2959; Merlini G, 1999, BLOOD, V93, P1112, DOI 10.1182/blood.V93.3.1112; MROSS K, 1990, EUR J CLIN PHARMACOL, V39, P507; Palha JA, 2000, AM J PATHOL, V156, P1919, DOI 10.1016/S0002-9440(10)65065-1; PODESTA A, 1994, TOXICOL PATHOL, V22, P68, DOI 10.1177/019262339402200109; Saraiva MJM, 2001, FEBS LETT, V498, P201, DOI 10.1016/S0014-5793(01)02480-2; Sebastiao MP, 2000, BIOCHEM J, V351, P273, DOI 10.1042/0264-6021:3510273; Sousa MM, 2001, AM J PATHOL, V159, P1993; Sousa MM, 2001, J NEUROSCI, V21, P7576, DOI 10.1523/JNEUROSCI.21-19-07576.2001; Sousa MM, 2000, LAB INVEST, V80, P1101, DOI 10.1038/labinvest.3780116; Suhr OB, 2000, LIVER TRANSPLANT, V6, P263, DOI 10.1053/lv.2000.6145; Tagliavini F, 2000, J MOL BIOL, V300, P1309, DOI 10.1006/jmbi.2000.3840; VILLANI F, 1991, EUR J CANCER, V27, P1601, DOI 10.1016/0277-5379(91)90423-B; VILLANI F, 1988, INVEST NEW DRUG, V6, P173; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	29	97	102	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					803	809		10.1096/fj.02-0764com	http://dx.doi.org/10.1096/fj.02-0764com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12724338				2022-12-25	WOS:000183165000005
J	Dyer, DH; Lovell, S; Thoden, JB; Holden, HM; Rayment, I; Lan, Q				Dyer, DH; Lovell, S; Thoden, JB; Holden, HM; Rayment, I; Lan, Q			The structural determination of an insect sterol carrier protein-2 with a ligand-bound C16 fatty acid at 1.35-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEINS; ACYL-COENZYME; HELIOTHIS-ZEA; LIPID-BINDING; CHOLESTEROL; GENE; SEQUENCE; PROGRAM; STIMULATION; METABOLISM	Yellow fever mosquito sterol carrier protein (SCP-2) is known to bind to cholesterol. We report here the three-dimensional structure of the complex of SCP-2 from Aedes aegypti with a C16 fatty acid to 1.35-Angstrom resolution. The protein fold is exceedingly similar to the human and rabbit proteins, which consist of a five-stranded beta-sheet that exhibits strand order 3-2-1-4-5 with an accompanying layer of four alpha-helices that cover the beta-sheet. A large cavity exists at the interface of the layer alpha-helices and the beta-sheet, which serves as the fatty acid binding site. The carboxylate moiety of the fatty acid is coordinated by a short loop that connects the first alpha-helix to the first beta-strand, whereas the acyl chain extends deep into the interior of the protein. Interestingly, the orientation of the fatty acid is opposite to the observed orientation for Triton X-100 in the SCP-2-like domain from the peroxisomal multifunctional enzyme (Haapalainen, A. M., van Aalten, D. M., Merilainen, G., Jalonen, J. E., Pirila, P., Wierenga, R. K., Hiltunen, J. K., and Glumoff, T. (2001) J. Mol. Biol. 313, 1127-1138). The present study suggests that the binding pocket in the SCP-2 family of proteins may exhibit conformational flexibility to allow coordination of a variety of lipids.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Entomol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Rayment, I (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	Ivan_Rayment@biochem.wisc.edu; qlan@entomology.wisc.edu	rayment, ivan/A-2720-2008	rayment, ivan/0000-0001-9279-7835	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035186] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35168] Funding Source: Medline; NIAMS NIH HHS [AR-35186] Funding Source: Medline; NIGMS NIH HHS [GM35332] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baum CL, 1997, J BIOL CHEM, V272, P6490, DOI 10.1074/jbc.272.10.6490; BEYDON P, 1987, ARCH INSECT BIOCHEM, V5, P139, DOI 10.1002/arch.940050208; Chakravarty S, 2002, J BIOL CHEM, V277, P31345, DOI 10.1074/jbc.M201373200; CHANDERBHAN R, 1982, J BIOL CHEM, V257, P8928; Choinowski T, 2000, BIOCHEMISTRY-US, V39, P1897, DOI 10.1021/bi992742e; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CLAYTON RB, 1964, J LIPID RES, V5, P3; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; COLLES SM, 1995, LIPIDS, V30, P795, DOI 10.1007/BF02533954; DWIVEDI AK, 1982, ENTOMON, V7, P411; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P9, DOI 10.1016/S0167-4838(00)00148-5; Frolov A, 1996, J BIOL CHEM, V271, P31878, DOI 10.1074/jbc.271.50.31878; Fuchs M, 2001, J BIOL CHEM, V276, P48058, DOI 10.1074/jbc.M106732200; Gallegos AM, 2001, PROG LIPID RES, V40, P498, DOI 10.1016/S0163-7827(01)00015-7; Garcia FL, 2000, J MOL BIOL, V295, P595, DOI 10.1006/jmbi.1999.3355; Haapalainen AM, 2001, J MOL BIOL, V313, P1127, DOI 10.1006/jmbi.2001.5084; Huang H, 2002, BIOCHEMISTRY-US, V41, P12149, DOI 10.1021/bi0260536; Jouni ZE, 2002, ARCH INSECT BIOCHEM, V49, P167, DOI 10.1002/arch.10017; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kitamura T, 1996, DEV GROWTH DIFFER, V38, P373; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krebs KC, 2003, INSECT MOL BIOL, V12, P51, DOI 10.1046/j.1365-2583.2003.00386.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lo Conte L, 2000, NUCLEIC ACIDS RES, V28, P257, DOI 10.1093/nar/28.1.257; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nes WD, 1997, LIPIDS, V32, P1317, DOI 10.1007/s11745-006-0170-5; NODA H, 1979, J INSECT PHYSIOL, V25, P443, DOI 10.1016/0022-1910(79)90012-X; RITTER KS, 1981, J INSECT PHYSIOL, V27, P175, DOI 10.1016/0022-1910(81)90125-6; Roussel A., 1991, SILICON GRAPHICS GEO, V86; Schroeder F, 2003, BIOCHEMISTRY-US, V42, P3189, DOI 10.1021/bi026904+; Schroeder F, 2000, J BIOL CHEM, V275, P25547, DOI 10.1074/jbc.M000431200; Seedorf U, 2000, BBA-MOL CELL BIOL L, V1486, P45, DOI 10.1016/S1388-1981(00)00047-0; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; SPATES GE, 1988, J INSECT PHYSIOL, V34, P1055, DOI 10.1016/0022-1910(88)90205-3; Thompson J, 1999, MOL CELL BIOCHEM, V192, P9, DOI 10.1023/A:1006806616963; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tronrud DE, 1997, METHOD ENZYMOL, V277, P306, DOI 10.1016/S0076-6879(97)77017-4; VANNOORT M, 1988, BIOCHEM BIOPH RES CO, V154, P60, DOI 10.1016/0006-291X(88)90649-3; XU TS, 1991, J BIOL CHEM, V266, P6801; Zdobnov EM, 2002, SCIENCE, V298, P149, DOI 10.1126/science.1077061; Zimmerman AW, 2002, CELL MOL LIFE SCI, V59, P1096, DOI 10.1007/s00018-002-8490-y	42	83	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39085	39091		10.1074/jbc.M306214200	http://dx.doi.org/10.1074/jbc.M306214200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12754195	hybrid			2022-12-25	WOS:000185575100122
